PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Guicciardi, ME; Gores, GJ				Guicciardi, Maria Eugenia; Gores, Gregory J.			Life and death by death receptors	FASEB JOURNAL			English	Review						Fas/CD95/APO1; TNF; TRAIL; Bcl-2 family; caspases; MAP kinases	NF-KAPPA-B; APOPTOSIS-INDUCING LIGAND; TRAIL-INDUCED APOPTOSIS; NECROSIS-FACTOR RECEPTOR; FAS-MEDIATED APOPTOSIS; DOMAIN KINASE RIP; CELL-DEATH; TNF-RECEPTOR; LIVER-REGENERATION; CASPASE ACTIVATION	Death receptors are members of the tumor necrosis factor receptor superfamily characterized by a cytoplasmic region known as the "death domain" that enables the receptors to initiate cytotoxic signals when engaged by cognate ligands. Binding to the ligand results in receptor aggregation and recruitment of adaptor proteins, which, in turn, initiates a proteolytic cascade by recruiting and activating initiator caspases 8 and 10. Death receptors were once thought to primarily induce cytotoxic signaling cascades. However, recent data indicate that they initiate multiple signaling pathways, unveiling a number of nonapoptosis-related functions, including regulation of cell proliferation and differentiation, chemokine production, inflammatory responses, and tumor-promoting activities. These noncytotoxic cascades are not simply a manifestation of inhibiting proapoptotic pathways but are intrinsically regulated by adaptor protein and receptor internalization processes. Insights into these various death receptor signaling pathways provide new therapeutic strategies targeting these receptors in pathophysiological processes.-Guicciardi, M. E., Gores, G. J. Life and death by death receptors. FASEB J. 23, 1625-1637 (2009)	[Guicciardi, Maria Eugenia; Gores, Gregory J.] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu			U.S. National Institutes of Health [DK63947]; Mayo Foundation, Rochester, Minnesota, USA; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063947] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation, Rochester, Minnesota, USA; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the U.S. National Institutes of Health (DK63947 to G.J.G.) and the Mayo Foundation, Rochester, Minnesota, USA.	Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Algeciras-Schimnich A, 2003, FEBS LETT, V546, P185, DOI 10.1016/S0014-5793(03)00558-1; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bodmer JL, 2000, J BIOL CHEM, V275, P20632, DOI 10.1074/jbc.M909721199; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CASCINO I, 1995, J IMMUNOL, V154, P2706; Chakrabandhu K, 2008, CELL DEATH DIFFER, V15, P1824, DOI 10.1038/cdd.2008.115; Chakrabandhu K, 2007, EMBO J, V26, P209, DOI 10.1038/sj.emboj.7601456; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chao Y, 2005, PLOS BIOL, V3, P1079, DOI 10.1371/journal.pbio.0030183; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Dohrman A, 2005, J IMMUNOL, V175, P311, DOI 10.4049/jimmunol.175.1.311; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Eramo A, 2004, EUR J IMMUNOL, V34, P1930, DOI 10.1002/eji.200324786; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Feig C, 2007, EMBO J, V26, P221, DOI 10.1038/sj.emboj.7601460; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Finnberg N, 2008, J CLIN INVEST, V118, P111, DOI 10.1172/JCI29900; Frank S, 1999, BIOCHEM BIOPH RES CO, V257, P454, DOI 10.1006/bbrc.1999.0493; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Gores GJ, 2001, HEPATOLOGY, V34, P3, DOI 10.1053/jhep.2001.25173; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Grosse-Wilde A, 2008, CANCER RES, V68, P6035, DOI 10.1158/0008-5472.CAN-08-0078; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Guicciardi ME, 2007, AM J PHYSIOL-GASTR L, V292, pG1337, DOI 10.1152/ajpgi.00497.2006; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hayakawa Y, 2004, J IMMUNOL, V172, P123, DOI 10.4049/jimmunol.172.1.123; Henkler F, 2005, J CELL BIOL, V168, P1087, DOI 10.1083/jcb.200501048; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hong F, 2000, BIOCHEM BIOPH RES CO, V279, P974, DOI 10.1006/bbrc.2000.4044; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Inoue H, 2002, LAB INVEST, V82, P1111, DOI 10.1097/01.LAB.0000027838.69455.39; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Jackson LN, 2008, AM J PHYSIOL-GASTR L, V294, pG1401, DOI 10.1152/ajpgi.00062.2008; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kim YS, 2002, HEPATOLOGY, V36, P1498, DOI 10.1053/jhep.2002.36942; Kleber S, 2008, CANCER CELL, V13, P235, DOI 10.1016/j.ccr.2008.02.003; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Koyama S, 2002, J CANCER RES CLIN, V128, P73, DOI 10.1007/s004320100292; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lancaster JM, 2003, CLIN CANCER RES, V9, P762; Lavrik IN, 2008, J BIOL CHEM, V283, P26401, DOI 10.1074/jbc.M800823200; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; Lee TJ, 2006, BIOCHEM BIOPH RES CO, V351, P1024, DOI 10.1016/j.bbrc.2006.10.163; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Legembre P, 2006, J IMMUNOL, V176, P716, DOI 10.4049/jimmunol.176.2.716; Legembre P, 2004, CELL CYCLE, V3, P1235, DOI 10.4161/cc.3.10.1194; Legembre P, 2004, EMBO REP, V5, P1084, DOI 10.1038/sj.embor.7400280; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Meylan E, 2005, TRENDS BIOCHEM SCI, V30, P151, DOI 10.1016/j.tibs.2005.01.003; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Milhas D, 2005, J BIOL CHEM, V280, P19836, DOI 10.1074/jbc.M414358200; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; Neumeyer J, 2006, EXP CELL RES, V312, P2142, DOI 10.1016/j.yexcr.2006.03.014; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; O'Donnell MA, 2007, CURR BIOL, V17, P418, DOI 10.1016/j.cub.2007.01.027; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Peter ME, 2005, BBA-REV CANCER, V1755, P25, DOI 10.1016/j.bbcan.2005.01.001; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Reinehr R, 2008, GASTROENTEROLOGY, V134, P1494, DOI 10.1053/j.gastro.2008.02.021; Riccioni R, 2005, HAEMATOLOGICA, V90, P612; Rieger J, 1999, ACTA NEUROPATHOL, V97, P1, DOI 10.1007/s004010050948; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schneider-Brachert W, 2006, J CLIN INVEST, V116, P2901, DOI 10.1172/JCI23771; Secchiero P, 2004, NEOPLASIA, V6, P364, DOI 10.1593/neo.03421; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shudo K, 2001, EUR J IMMUNOL, V31, P2504, DOI 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Siegel RM, 2004, J CELL BIOL, V167, P735, DOI 10.1083/jcb.200406101; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Trabzuni D, 2000, BIOCHEM J, V350, P505, DOI 10.1042/0264-6021:3500505; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Tzung SP, 1997, AM J PATHOL, V150, P1985; VAN AD, 1996, SCIENCE, V274, P787; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zhao SR, 1999, BRIT J HAEMATOL, V106, P827, DOI 10.1046/j.1365-2141.1999.01630.x	141	428	449	0	48	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1625	1637		10.1096/fj.08-111005	http://dx.doi.org/10.1096/fj.08-111005			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19141537	Green Published			2022-12-28	WOS:000266652400002
J	Mookerjee, I; Hewitson, TD; Halls, ML; Summers, RJ; Mathai, ML; Bathgate, RAD; Tregear, GW; Samuel, CS				Mookerjee, Ishanee; Hewitson, Tim D.; Halls, Michelle L.; Summers, Roger J.; Mathai, Michael L.; Bathgate, Ross A. D.; Tregear, Geoffrey W.; Samuel, Chrishan S.			Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2	FASEB JOURNAL			English	Article						tubulointerstitial fibrosis; transforming growth factor-beta 1; alpha-smooth muscle actin; cell signaling	INTERSTITIAL FIBROSIS; MEDIATED MECHANISM; ENDOTHELIAL-CELLS; IN-VITRO; TUBULOINTERSTITIAL FIBROSIS; FIBROBLAST PROLIFERATION; ENDOGENOUS RELAXIN; FAMILY PEPTIDES; GROWTH-FACTOR; COLLAGEN	The hormone relaxin inhibits renal myofibroblast differentiation by interfering with TGF-beta 1/Smad2 signaling. However, the pathways involved in the relaxin-TGF-beta 1/Smad2 interaction remain unknown. This study investigated the signaling mechanisms by which human gene-2 (H2) relaxin regulates myofibroblast differentiation in vitro by examining its effects on mixed populations of fibroblasts and myofibroblasts propagated from injured rat kidneys. Cultures containing similar to 60-70% myofibroblasts were used to determine which relaxin receptors, G-proteins, and signaling pathways were involved in the H2 relaxin-mediated regulation of alpha-smooth muscle actin (alpha-SMA; a marker of myofibroblast differentiation). H2 relaxin only inhibited alpha-SMA immunostaining and collagen concentration in the presence of relaxin family peptide receptor 1 (RXFP1). H2 relaxin also induced a transient rise in cAMP in the presence of G(i/o) inhibition, and a sustained increase in extracellular signal-regulated kinase (ERK)-1/2 phosphorylation. Furthermore, inhibition of neuronal nitric oxide synthase (nNOS), NO, and cGMP significantly blocked the inhibitory effects of relaxin on alpha-SMA and Smad2 phosphorylation, while the NO inhibitor, L-nitroarginine methyl ester (hydrochloride) (L-NAME) significantly blocked the inhibitory actions of relaxin on collagen concentration in vivo. These findings suggest that relaxin signals through RXFP1, and a nNOS-NO-cGMP-dependent pathway to inhibit Smad2 phosphorylation and interfere with TGF-beta 1-mediated renal myofibroblast differentiation and collagen production.- Mookerjee, I., Hewitson, T. D., Halls, M. L., Summers, R. J., Mathai, M. L., Bathgate, R. A. D., Tregear, G. W., Samuel, C. S. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 23, 1219-1229 (2009)	[Mookerjee, Ishanee; Mathai, Michael L.; Bathgate, Ross A. D.; Tregear, Geoffrey W.; Samuel, Chrishan S.] Univ Melbourne, Howard Florey Inst, Parkville, Vic 3010, Australia; [Mookerjee, Ishanee; Bathgate, Ross A. D.; Tregear, Geoffrey W.; Samuel, Chrishan S.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; [Hewitson, Tim D.] Univ Melbourne, Dept Nephrol, Royal Melbourne Hosp, Parkville, Vic 3010, Australia; [Hewitson, Tim D.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Parkville, Vic 3010, Australia; [Halls, Michelle L.; Summers, Roger J.] Monash Univ, Dept Pharmacol, Clayton, Vic 3800, Australia; [Mathai, Michael L.] Victoria Univ, Sch Biomed & Hlth Sci, Melbourne, Vic 8001, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; Monash University; Victoria University	Samuel, CS (corresponding author), Univ Melbourne, Howard Florey Inst, Parkville, Vic 3010, Australia.	chrishan.samuel@florey.edu.au	Bathgate, Ross/ABE-6471-2020; Summers, Roger J/F-6351-2011	Bathgate, Ross/0000-0001-6301-861X; Summers, Roger J/0000-0002-8367-4056; Hewitson, Tim/0000-0002-1994-2423; Halls, Michelle/0000-0001-8555-8959				Baccari MC, 2007, AM J PHYSIOL-REG I, V293, pR662, DOI 10.1152/ajpregu.00214.2007; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; BANISACCHI T, 1995, BRIT J PHARMACOL, V116, P1589, DOI 10.1111/j.1476-5381.1995.tb16377.x; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Boffa JJ, 1999, CIRCULATION, V100, P1901, DOI 10.1161/01.CIR.100.18.1901; Conrad KP, 2004, J SOC GYNECOL INVEST, V11, P438, DOI 10.1016/j.jsgi.2004.05.002; Danielson LA, 2000, AM J PHYSIOL-REG I, V279, pR1298, DOI 10.1152/ajpregu.2000.279.4.R1298; Darby IA, 2007, INT REV CYTOL, V257, P143, DOI 10.1016/S0074-7696(07)57004-X; Diamond JR, 1998, SEMIN NEPHROL, V18, P594; Eddy AA, 2000, PEDIATR NEPHROL, V15, P290, DOI 10.1007/s004670000461; Erikson MS, 2001, RELAXIN 2000, P373; Fu P, 2006, J ENDOCRINOL, V189, P397, DOI 10.1677/joe.1.06697; GALLOP PM, 1975, PHYSIOL REV, V55, P418, DOI 10.1152/physrev.1975.55.3.418; Garber SL, 2003, AM J NEPHROL, V23, P8, DOI 10.1159/000066302; Garber SL, 2001, KIDNEY INT, V59, P876, DOI 10.1046/j.1523-1755.2001.059003876.x; Halls ML, 2006, MOL PHARMACOL, V70, P214, DOI 10.1124/mol.105.021691; Halls ML, 2005, J PHARMACOL EXP THER, V313, P677, DOI 10.1124/jpet.104.080655; Heeg MHJ, 2005, KIDNEY INT, V68, P96, DOI 10.1111/j.1523-1755.2005.00384.x; Hewitson TD, 2002, J LAB CLIN MED, V140, P199, DOI 10.1067/mlc.2002.126828; Hewitson TD, 1998, J AM SOC NEPHROL, V9, P632; Hewitson TD, 2007, ENDOCRINOLOGY, V148, P660, DOI 10.1210/en.2006-0814; Krotova K, 2006, BRIT J PHARMACOL, V148, P732, DOI 10.1038/sj.bjp.0706777; Lekgabe ED, 2005, HYPERTENSION, V46, P412, DOI 10.1161/01.HYP.0000171930.00697.2f; Liu YH, 2004, AM J PHYSIOL-RENAL, V287, pF7, DOI 10.1152/ajprenal.00451.2003; Masini E, 1997, ENDOCRINOLOGY, V138, P4713, DOI 10.1210/en.138.11.4713; Masini E, 2004, ENDOCRINOLOGY, V145, P1106, DOI 10.1210/en.2003-0833; Masterson R, 2004, NEPHROL DIAL TRANSPL, V19, P544, DOI 10.1093/ndt/gfg598; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Mookerjee I, 2006, ENDOCRINOLOGY, V147, P754, DOI 10.1210/en.2005-1006; Naqvi T, 2005, ARTHRITIS RES THER, V7, pR1, DOI 10.1186/ar1451; Nistri S, 2003, FASEB J, V17, P2109, DOI 10.1096/fj.03-0216fje; Nistri Silvia, 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P101, DOI 10.2174/187152507780363179; Ortiz PA, 2003, AM J PHYSIOL-REG I, V284, pR628, DOI 10.1152/ajpregu.00401.2002; Palejwala S, 1998, ENDOCRINOLOGY, V139, P1208, DOI 10.1210/en.139.3.1208; Parsell DA, 1996, J BIOL CHEM, V271, P27936, DOI 10.1074/jbc.271.44.27936; RODEMANN HP, 1990, P SOC EXP BIOL MED, V195, P57; Samuel CS, 2007, CELL MOL LIFE SCI, V64, P1539, DOI 10.1007/s00018-007-6543-y; Samuel CS, 2006, PHARMACOL THERAPEUT, V112, P529, DOI 10.1016/j.pharmthera.2005.05.012; Samuel CS, 2004, ENDOCRINOLOGY, V145, P4125, DOI 10.1210/en.2004-0209; Samuel CS, 2005, ANN NY ACAD SCI, V1041, P173, DOI 10.1196/annals.1282.025; Samuel CS, 1996, ENDOCRINOLOGY, V137, P3884, DOI 10.1210/en.137.9.3884; Saura M, 2005, CIRC RES, V97, P1115, DOI 10.1161/01.RES.0000191538.76771.66; Szabo AJ, 2003, KIDNEY INT, V64, P1765, DOI 10.1046/j.1523-1755.2003.00260.x; Taguchi M, 2000, MOL HUM REPROD, V6, P185, DOI 10.1093/molehr/6.2.185; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; Unemori EN, 1996, J CLIN INVEST, V98, P2739, DOI 10.1172/JCI119099; Winbanks CE, 2007, INT J BIOCHEM CELL B, V39, P206, DOI 10.1016/j.biocel.2006.08.004; Zeisberg M, 2004, NEPHROL DIAL TRANSPL, V19, P759, DOI 10.1093/ndt/gfh060	48	109	112	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1219	1229		10.1096/fj.08-120857	http://dx.doi.org/10.1096/fj.08-120857			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19073841				2022-12-28	WOS:000266651600026
J	Wendler, CC; Busovsky-McNeal, M; Ghatpande, S; Kalinowski, A; Russell, KS; Rivkees, SA				Wendler, Christopher C.; Busovsky-McNeal, Melissa; Ghatpande, Satish; Kalinowski, April; Russell, Kerry S.; Rivkees, Scott A.			Embryonic caffeine exposure induces adverse effects in adulthood	FASEB JOURNAL			English	Article						hypoxia-inducible factor 1 alpha; cardiac; heart development; echocardiography	PLASMA ADENOSINE CONCENTRATION; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR EXPRESSION; HEART; RISK; PROTECTION; ONTOGENY	The purpose of this study was to determine both the short-term effects on cardiac development and embryo growth and the long-term effects on cardiac function and body composition of in utero caffeine exposure. Pregnant mice (C57BL/6) were exposed to hypoxia (10% O-2) or room air from embryonic days (E) 8.5-10.5, and treated with caffeine (20 mg/kg, i.p.) or vehicle (normal saline, 0.9% NaCl). This caffeine dose results in a circulating level that is equivalent to 2 cups of coffee in humans. Hypoxic exposure acutely reduced embryonic growth by 30%. Exposure to a single dose of caffeine inhibited cardiac ventricular development by 53% in hypoxia and 37% in room air. Caffeine exposure resulted in inhibition of hypoxia-induced HIF1 alpha protein expression in embryos by 40%. When offspring from dams treated with a single dose of caffeine were studied in adulthood, we observed that caffeine treatment alone resulted in a decrease in cardiac function of 38%, as assessed by echocardiography. We also observed a 20% increase in body fat with male mice exposed to caffeine. Caffeine was dissolved in normal saline, so it was used as a control. Room air controls were used to compare to the hypoxic mice. Exposure to a single dose of caffeine during embryogenesis results in both short-term effects on cardiac development and long-term effects on cardiac function.-Wendler, C. C., Busovsky-McNeal, M., Ghatpande, S., Kalinowski, A., Russell, K. S., Rivkees, S. A. Embryonic caffeine exposure induces adverse effects in adulthood. FASEB J. 23, 1272-1278 (2009)	[Wendler, Christopher C.; Busovsky-McNeal, Melissa; Ghatpande, Satish; Rivkees, Scott A.] Yale Univ, Sch Med, Dept Pediat, Yale Child Hlth Res Ctr,Sect Dev Endocrinol & Bio, New Haven, CT 06520 USA; [Kalinowski, April; Russell, Kerry S.] Yale Univ, Sch Med, Div Cardiovasc Med, New Haven, CT 06520 USA	Yale University; Yale University	Wendler, CC (corresponding author), Yale Univ, Sch Med, Dept Pediat, Yale Child Hlth Res Ctr,Sect Dev Endocrinol & Bio, 464 Congress Ave, New Haven, CT 06520 USA.	christopher.wendler@yale.edu			U. S. National Institutes of Health (NIH) [R01HL58442, U24 DK-76169]; March of Dimes; Charles H. Hood Foundation; Yale Diabetes Endocrinology Research Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK076169] Funding Source: NIH RePORTER	U. S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); Charles H. Hood Foundation; Yale Diabetes Endocrinology Research Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U. S. National Institutes of Health (NIH) grant R01HL58442 (S. A. R), the March of Dimes (S. A. R.), the Charles H. Hood Foundation (S. G.) and the Yale Diabetes Endocrinology Research Center (C. C. W.). We thank Dr. Gerald Shulman, Varman Samuel, and David Frederick of the Yale Mouse Metabolic Phenotyping Center, which is supported by NIH grant U24 DK-76169. We also thank Sarah Renzi and Ryan Poulsen for their technical assistance.	Browne ML, 2006, EPIDEMIOLOGY, V17, P324, DOI 10.1097/01.ede.0000208476.36988.44; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; Cnattingius S, 2003, FOOD CHEM TOXICOL, V41, P1202, DOI 10.1016/S0278-6915(03)00103-0; Cnattingius S, 2000, NEW ENGL J MED, V343, P1839, DOI 10.1056/NEJM200012213432503; Daly JW, 2007, CELL MOL LIFE SCI, V64, P2153, DOI 10.1007/s00018-007-7051-9; De Ponti C, 2007, J LEUKOCYTE BIOL, V82, P392, DOI 10.1189/jlb.0107060; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x; GOLDING J, 1995, EARLY HUM DEV, V43, P1, DOI 10.1016/0378-3782(95)01660-U; Higdon JV, 2006, CRIT REV FOOD SCI, V46, P101, DOI 10.1080/10408390500400009; Ijzerman A. P., 1997, P129; Jacoby JJ, 2003, P NATL ACAD SCI USA, V100, P12929, DOI 10.1073/pnas.2134694100; KOOS BJ, 1994, AM J PHYSIOL, V266, pR215, DOI 10.1152/ajpregu.1994.266.1.R215; KOOS BJ, 1994, J APPL PHYSIOL, V77, P2734, DOI 10.1152/jappl.1994.77.6.2734; Lankford AR, 2006, AM J PHYSIOL-HEART C, V290, pH1469, DOI 10.1152/ajpheart.00181.2005; Lukac R, 2006, J VIS COMMUN IMAGE R, V17, P1, DOI 10.1016/j.jvcir.2005.08.007; Merighi S, 2005, NEOPLASIA, V7, P894, DOI 10.1593/neo.05334; Merighi S, 2007, MOL PHARMACOL, V72, P395, DOI 10.1124/mol.106.032920; Merighi S, 2006, BIOCHEM PHARMACOL, V72, P19, DOI 10.1016/j.bcp.2006.03.020; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Porter GA, 2001, AM J PHYSIOL-REG I, V281, pR401, DOI 10.1152/ajpregu.2001.281.2.R401; Rivkees SA, 1999, J BIOL CHEM, V274, P14204, DOI 10.1074/jbc.274.20.14204; RIVKEES SA, 1995, DEV BRAIN RES, V89, P202, DOI 10.1016/0165-3806(95)00120-3; Schulte G, 2004, ACTA PHYSIOL SCAND, V182, P133, DOI 10.1111/j.1365-201X.2004.01350.x; SEMENIUK C, 2007, WETLANDS ECOL CONSER, V1, P1; Signorello LB, 2001, OBSTET GYNECOL, V98, P1059, DOI 10.1016/S0029-7844(01)01575-7; Simon DK, 2008, CLIN NEUROPHARMACOL, V31, P189, DOI 10.1097/WNF.0b013e31815a3f03; Simon MC, 2008, ANNU REV PHYSIOL, V70, P51, DOI 10.1146/annurev.physiol.70.113006.100526; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Turner CP, 2003, P NATL ACAD SCI USA, V100, P11718, DOI 10.1073/pnas.1931975100; Wendler CC, 2007, P NATL ACAD SCI USA, V104, P9697, DOI 10.1073/pnas.0703557104; Weng XP, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.10.803; YONEYAMA Y, 1994, AM J OBSTET GYNECOL, V170, P684, DOI 10.1016/S0002-9378(94)70248-9; YONEYAMA Y, 1994, AM J OBSTET GYNECOL, V171, P701, DOI 10.1016/0002-9378(94)90085-X	35	30	34	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1272	1278		10.1096/fj.08-124941	http://dx.doi.org/10.1096/fj.08-124941			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19088180	Green Published			2022-12-28	WOS:000266651600031
J	Makowski, L; Noland, RC; Koves, TR; Xing, WB; Ilkayeva, OR; Muehlbauer, MJ; Stevens, RD; Muoio, DM				Makowski, Liza; Noland, Robert C.; Koves, Timothy R.; Xing, Weibing; Ilkayeva, Olga R.; Muehlbauer, Michael J.; Stevens, Robert D.; Muoio, Deborah M.			Metabolic profiling of PPAR alpha(-/-) mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation	FASEB JOURNAL			English	Article						beta-oxidation; metabolomics; liver; skeletal muscle; acylcarnitine; organic acid; starvation	ACTIVATED-RECEPTOR-ALPHA; ACYL-COA DEHYDROGENASE; PPAR-ALPHA; SKELETAL-MUSCLE; GENE-EXPRESSION; ACETYLTRANSFERASE ACTIVITY; HEMODIALYSIS-PATIENTS; SARCOPENIC OBESITY; INSULIN-RESISTANCE; MASS-SPECTROMETRY	Peroxisome proliferator-activated receptor-alpha (PPAR alpha) is a master transcriptional regulator of beta-oxidation and a prominent target of hypolipidemic drugs. To gain deeper insights into the systemic consequences of impaired fat catabolism, we used quantitative, mass spectrometry-based metabolic profiling to investigate the fed-to-fasted transition in PPAR alpha(+/+) and PPAR alpha(-/-) mice. Compared to PPAR alpha(+/+) animals, acylcarnitine profiles of PPAR alpha(-/-) mice revealed 2- to 4-fold accumulation of long-chain species in the plasma, whereas short-chain species were reduced by as much as 69% in plasma, liver, and skeletal muscle. These results reflect a metabolic bottleneck downstream of carnitine palmitoyltransferase-1, a mitochondrial enzyme that catalyzes the first step in beta-oxidation. Organic and amino acid profiles of starved PPAR alpha(-/-) mice suggested compromised citric acid cycle flux, enhanced urea cycle activity, and increased amino acid catabolism. PPAR alpha(-/-) mice had 40-50% lower plasma and tissue levels of free carnitine, corresponding with diminished hepatic expression of genes involved in carnitine biosynthesis and transport. One week of oral carnitine supplementation conferred partial metabolic recovery in the PPAR alpha(-/-) mice. In summary, comprehensive metabolic profiling revealed novel biomarkers of defective fat oxidation, while also highlighting the potential value of supplemental carnitine as a therapy and diagnostic tool for metabolic disorders.-Makowski, L., Noland, R. C., Koves, T. R., Xing, W., Ilkayeva, O. R., Muehlbauer, M. J., Stevens, R. D., Muoio, D. M. Metabolic profiling of PPAR alpha(-/-) mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB J. 23, 586-604 (2009)	[Makowski, Liza; Noland, Robert C.; Koves, Timothy R.; Xing, Weibing; Ilkayeva, Olga R.; Muehlbauer, Michael J.; Stevens, Robert D.; Muoio, Deborah M.] Duke Univ, Sch Med, Div Metab Endocrinol & Nutr, Durham, NC USA; [Koves, Timothy R.] Duke Univ, Sch Med, Dept Med, Div Geriatr, Durham, NC 27706 USA; [Muoio, Deborah M.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC 27706 USA; [Makowski, Liza; Noland, Robert C.; Koves, Timothy R.; Xing, Weibing; Ilkayeva, Olga R.; Muehlbauer, Michael J.; Stevens, Robert D.; Muoio, Deborah M.] Duke Univ, Sch Med, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27706 USA	Duke University; Duke University; Duke University; Duke University	Muoio, DM (corresponding author), 4321 Med Pk Dr,Ste 200, Durham, NC 27704 USA.	muoio@duke.edu	Koves, Tim/I-4806-2012; Muoio, Debbie Marie/E-1147-2012; Makowski, Liza/B-8062-2012; Noland, Robert/N-1982-2017	Koves, Tim/0000-0001-8763-5866; Noland, Robert/0000-0001-5543-3450; Makowski, Liza/0000-0002-5337-8037; Muoio, Deborah/0000-0003-3760-9277	National Institutes of Health [P30-AG028716, K99-AA017376-01, F32-DK080609]; American Diabetes Association; John A. Hartford Duke Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK080609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K99AA017376] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); John A. Hartford Duke Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank Barbara Abbott (National Institute of Environmental Health Sciences, Raleigh, NC, USA) for sharing her mouse colony and Chris Newgard for his thoughtful evaluation of this article. We thank the dedicated staff of the Metabolomics and Biomarker Core of the Sarah W. Stedman Nutrition and Metabolism Center. This work was supported by National Institutes of Health grants P30-AG028716 (D.M.M.), K99-AA017376-01 (L. M.), and F32-DK080609 ( R. N.); the American Diabetes Association ( D. M. M.); and a John A. Hartford Duke Center for Excellence award (T. R. K).	An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Anderson SR, 2008, METABOLISM, V57, P347, DOI 10.1016/j.metabol.2007.10.009; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; AOYAMA T, 1993, BIOCHEM BIOPH RES CO, V191, P1369, DOI 10.1006/bbrc.1993.1368; Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; Asai T, 2006, CARDIOVASC RES, V70, P566, DOI 10.1016/j.cardiores.2006.02.005; Atherton HJ, 2008, FEBS LETT, V582, P1661, DOI 10.1016/j.febslet.2008.04.020; Atherton HJ, 2006, PHYSIOL GENOMICS, V27, P178, DOI 10.1152/physiolgenomics.00060.2006; Barton BE, 2001, IMMUNOL RES, V23, P41, DOI 10.1385/IR:23:1:41; BHUIYAN AKMJ, 1988, BIOCHEM J, V253, P337, DOI 10.1042/bj2530337; Biolo G, 2008, NEPHROL DIAL TRANSPL, V23, P991, DOI 10.1093/ndt/gfm664; Blaak EE, 2004, P NUTR SOC, V63, P323, DOI 10.1079/PNS2004361; BLUMBERG D, 1995, METABOLISM, V44, P145, DOI 10.1016/0026-0495(95)90255-4; Cahill GF, 2006, ANNU REV NUTR, V26, P1, DOI 10.1146/annurev.nutr.26.061505.111258; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Edgar AD, 1998, TOXICOL LETT, V98, P13, DOI 10.1016/S0378-4274(98)00042-3; Finck BN, 2002, J MOL CELL CARDIOL, V34, P1249, DOI 10.1006/jmcc.2002.2061; GIOVENALI P, 1994, KIDNEY INT, V46, P1616, DOI 10.1038/ki.1994.460; Gloerich J, 2005, J LIPID RES, V46, P716, DOI 10.1194/jlr.M400337-JLR200; Grarnignano G, 2006, NUTRITION, V22, P136, DOI 10.1016/j.nut.2005.06.003; Hardy OT, 2007, MOL ENDOCRINOL, V21, P765, DOI 10.1210/me.2006-0411; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Jensen MV, 2006, J BIOL CHEM, V281, P22342, DOI 10.1074/jbc.M604350200; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE1130; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; Kersten S, 2001, FASEB J, V15, P1971, DOI 10.1096/fj.01-0147com; Koch A, 2008, EXP BIOL MED, V233, P356, DOI 10.3181/0706-RM-168; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Lee SST, 1996, ANN NY ACAD SCI, V804, P524, DOI 10.1111/j.1749-6632.1996.tb18642.x; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Mansouri RM, 2008, ENDOCRINOLOGY, V149, P3215, DOI 10.1210/en.2007-1339; MOODY DE, 1974, RES COMMUN CHEM PATH, V9, P501; Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Murakami K, 2007, EUR J PHARMACOL, V561, P206, DOI 10.1016/j.ejphar.2006.12.037; Owen KQ, 2001, J ANIM SCI, V79, P3104; Park SW, 2007, DIABETES CARE, V30, P1507, DOI 10.2337/dc06-2537; Patsouris D, 2006, ENDOCRINOLOGY, V147, P1508, DOI 10.1210/en.2005-1132; PAUL HS, 1986, AM J PHYSIOL, V251, pE311, DOI 10.1152/ajpendo.1986.251.3.E311; Pedersen BK, 2003, SCAND J MED SCI SPOR, V13, P56, DOI 10.1034/j.1600-0838.2003.20218.x; Power RA, 2007, DIABETOLOGIA, V50, P824, DOI 10.1007/s00125-007-0605-4; Primassin S, 2008, PEDIATR RES, V63, P632, DOI 10.1203/PDR.0b013e31816ff6f0; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; Ringseis R, 2007, PHARMACOL RES, V56, P175, DOI 10.1016/j.phrs.2007.06.001; Roubenoff R, 2000, ANN NY ACAD SCI, V904, P553; Satapati S, 2008, DIABETES, V57, P2012, DOI 10.2337/db08-0226; Sayer AA, 2007, QJM-INT J MED, V100, P707, DOI 10.1093/qjmed/hcm095; Schrager MA, 2007, J APPL PHYSIOL, V102, P919, DOI 10.1152/japplphysiol.00627.2006; SEMENIUK C, 2007, WETLANDS ECOL CONSER, V1, P1; Sheikh K, 2007, AM J PHYSIOL-ENDOC M, V292, pE1157, DOI 10.1152/ajpendo.00254.2006; SIAMI G, 1991, NEPHRON, V57, P306, DOI 10.1159/000186280; Siddiq A, 2007, NEUROCHEM RES, V32, P931, DOI 10.1007/s11064-006-9268-7; Smeets PJH, 2008, CARDIOVASC RES, V78, P79, DOI 10.1093/cvr/cvn001; Steiber AL, 2004, CLIN NUTR, V23, P27, DOI 10.1016/S0261-5614(03)00085-2; Stevens RD, 2000, CLIN CHEM, V46, P727; Thyfault John P, 2006, J Cardiometab Syndr, V1, P184, DOI 10.1111/j.1559-4564.2006.05629.x; Thyfault JP, 2007, AM J PHYSIOL-CELL PH, V292, pC729, DOI 10.1152/ajpcell.00311.2006; TURNBULL DM, 1984, NEW ENGL J MED, V311, P1232, DOI 10.1056/NEJM198411083111906; Van Vlies N, 2005, BIOCHEM J, V387, P185, DOI 10.1042/BJ20041489; van Vlies N, 2007, BBA-BIOENERGETICS, V1767, P1134, DOI 10.1016/j.bbabio.2007.07.001; Vary TC, 2007, J NUTR, V137, P1835, DOI 10.1093/jn/137.8.1835; Vaz FM, 2002, BIOCHEM J, V361, P417, DOI 10.1042/0264-6021:3610417; Villareal DT, 2004, OBES RES, V12, P913, DOI 10.1038/oby.2004.111; Xu J, 2004, ENDOCRINOLOGY, V145, P1087, DOI 10.1210/en.2003-1173; Xu J, 2002, J BIOL CHEM, V277, P50237, DOI 10.1074/jbc.M201208200; Zambon A, 2006, ARTERIOSCL THROM VAS, V26, P977, DOI 10.1161/01.ATV.0000204327.96431.9a	69	87	90	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					586	604		10.1096/fj.08-119420	http://dx.doi.org/10.1096/fj.08-119420			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18945875	Green Published			2022-12-28	WOS:000262892900030
J	Snider, AJ; Kawamori, T; Bradshaw, SG; Orr, KA; Gilkeson, GS; Hannun, YA; Obeid, LM				Snider, Ashley J.; Kawamori, Toshihiko; Bradshaw, Sarah G.; Orr, K. Alexa; Gilkeson, Gary S.; Hannun, Yusuf A.; Obeid, Lina M.			A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis	FASEB JOURNAL			English	Article						sphingosine-1-phosphate; tumor necrosis factor alpha; cyclooxygenase-2; inflammation; ceramide	TUMOR-NECROSIS-FACTOR; TNF-ALPHA; LYMPHOCYTE EGRESS; COLON CARCINOGENESIS; ENDOTHELIAL-CELLS; COX-2 INHIBITOR; 1-PHOSPHATE; MIGRATION; RECEPTOR; MICE	The bioactive lipid sphingosine-1-phosphate (S1P) is emerging as an important mediator of immune and inflammatory responses. S1P formation is catalyzed by sphingosine kinase (SK), of which the SK1 isoenzyme is activated by tumor necrosis alpha (TNF-alpha). SK1 has been shown to be required for mediating TNF-alpha inflammatory responses in cells, including induction of cyclooxygenase 2 (COX-2). Because TNF-alpha and COX-2 are increased in patients with inflammatory bowel disease (IBD), we investigated the role of SK1 in a murine model of colitis. SK1(-/-) mice treated with dextran sulfate sodium (DSS) had significantly less blood loss, weight loss, colon shortening, colon histological damage, and splenomegaly than did wild-type (WT) mice. In addition, SK1(-/-) mice had no systemic inflammatory response. Moreover, WT but not SK1(-/-) mice treated with dextran sulfate sodium had significant increases in blood S1P levels, colon SK1 message and activity, and colon neutrophilic infiltrate. Unlike WT mice, SK1(-/-) mice failed to show colonic COX-2 induction despite an exaggerated TNF-alpha response; thus implicating for the first time SK1 in TNF-alpha-mediated COX-2 induction in vivo. Inhibition of SK1 may prove to be a valuable therapeutic target by inhibiting systemic and local inflammation in IBD.-Snider, A. J., Kawamori, T., Bradshaw, S. G., Orr, K. A., Gilkeson, G. S., Hannun, Y. A., Obeid, L. M. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J. 23, 143-152 (2009)	[Snider, Ashley J.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Kawamori, Toshihiko] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Orr, K. Alexa] Med Univ S Carolina, Dept Mol & Cellular Biol & Pathobiol, Charleston, SC 29425 USA; [Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Bradshaw, Sarah G.; Gilkeson, Gary S.; Obeid, Lina M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,MSC 779, Charleston, SC 29425 USA.	obeidl@musc.edu	Kawamori, Toshihiko/G-7636-2012	obeid, lina/0000-0002-0734-0847	U.S. National Institutes of Health (NIH) [GM062887, C06 RR018823]; Veterans Affairs (VA) Merit Award; American College of Rheumatology Research and Education Foundation's; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs (VA) Merit Award(US Department of Veterans Affairs); American College of Rheumatology Research and Education Foundation's; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by U.S. National Institutes of Health (NIH) grant GM062887 and a Veterans Affairs (VA) Merit Award (L.M.O.) and by the American College of Rheumatology Research and Education Foundation's Within Our Reach: Finding a Cure for Arthritis campaign (G.S.G.). Lipid analysis was conducted by the Lipidomics Core at MUSC and was supported by NIH grant C06 RR018823. We thank Dr. Richard Proia (NIDDK, Bethesda, MD, USA) for supplying the SK1<SUP>-/-</SUP> mice; George Washington, DeAnna Baker, Samer Maalouf, and Tatsuya Kaneshiro for technical help; Margaret H. Romano and the Core Histology Laboratory for their technical assistance; Chris Clarke for careful examination of the manuscript; and Kathy Wiita-Fisk for her administrative assistance.	Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Billich A, 2005, CELL SIGNAL, V17, P1203, DOI 10.1016/j.cellsig.2004.12.005; BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0; Chiba K, 2006, CELL MOL IMMUNOL, V3, P11; Cuzzocrea S, 2001, EUR J PHARMACOL, V431, P91, DOI 10.1016/S0014-2999(01)01403-0; Daniel C, 2007, MOL IMMUNOL, V44, P3305, DOI 10.1016/j.molimm.2007.02.026; Daniel C, 2007, J IMMUNOL, V178, P2458, DOI 10.4049/jimmunol.178.4.2458; De Palma C, 2006, ARTERIOSCL THROM VAS, V26, P99, DOI 10.1161/01.ATV.0000194074.59584.42; Eigenbrod S, 2006, IMMUNOL INVEST, V35, P149, DOI 10.1080/08820130600616490; Gonzalez-Juanatey C, 2005, ATHEROSCLEROSIS, V181, P209, DOI 10.1016/j.atherosclerosis.2005.02.031; Hendel J, 1997, AM J GASTROENTEROL, V92, P1170; Inoue T., 2008, Inflammopharmacology, V16, P36, DOI 10.1007/s10787-006-1543-3; Johnson KR, 2005, J HISTOCHEM CYTOCHEM, V53, P1159, DOI 10.1369/jhc.4A6606.2005; Kaneider NC, 2002, BIOCHEM BIOPH RES CO, V297, P806, DOI 10.1016/S0006-291X(02)02304-5; Kawa S, 1997, FEBS LETT, V420, P196, DOI 10.1016/S0014-5793(97)01516-0; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kohno H, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-46; Kohno T, 2008, GENES CELLS, V13, P747, DOI 10.1111/j.1365-2443.2008.01202.x; Lee C, 1998, VISUAL NEUROSCI, V15, P27, DOI 10.1017/S0952523898146151; Lin CI, 2006, J CELL BIOCHEM, V99, P1216, DOI 10.1002/jcb.20963; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Maines LW, 2008, DIGEST DIS SCI, V53, P997, DOI 10.1007/s10620-007-0133-6; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Martin AR, 2005, INFLAMM RES, V54, P145, DOI 10.1007/s00011-004-1337-2; Martino A, 2007, J BIOSCIENCES, V32, P1207, DOI 10.1007/s12038-007-0122-0; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; OLSON AD, 1993, J PEDIATR GASTR NUTR, V16, P241, DOI 10.1097/00005176-199304000-00003; Osterman Mark T, 2007, Curr Treat Options Gastroenterol, V10, P195, DOI 10.1007/s11938-007-0013-3; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Rogler G, 1998, WORLD J SURG, V22, P382, DOI 10.1007/s002689900401; Rosen H, 2003, IMMUNOL REV, V195, P160, DOI 10.1034/j.1600-065X.2003.00068.x; Sarkar S, 2005, FEBS LETT, V579, P5313, DOI 10.1016/j.febslet.2005.08.055; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Suzuki R, 2006, CARCINOGENESIS, V27, P162, DOI 10.1093/carcin/bgi205; Tsubouchi R, 2006, DIGESTION, V74, P91, DOI 10.1159/000097657; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Vlasenko LP, 2005, J IMMUNOL, V174, P6456, DOI 10.4049/jimmunol.174.10.6456; von Wenckstern H, 2006, ARCH IMMUNOL THER EX, V54, P239, DOI 10.1007/s00005-006-0028-9; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Zemann B, 2007, IMMUNOL LETT, V109, P56, DOI 10.1016/j.imlet.2007.01.001; Zhi L, 2006, J CELL PHYSIOL, V208, P109, DOI 10.1002/jcp.20646; zu Heringdorf DM, 2007, BBA-BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026	52	152	161	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					143	152		10.1096/fj.08-118109	http://dx.doi.org/10.1096/fj.08-118109			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18815359	Green Published			2022-12-28	WOS:000262095500017
J	Tan, LD; Sarkis, PTN; Wang, T; Tian, CJ; Yu, XF				Tan, Lindi; Sarkis, Phuong Thi Nguyen; Wang, Tao; Tian, Chunjuan; Yu, Xiao-Fang			Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1	FASEB JOURNAL			English	Article						Vif; L1; virus; antiviral; evolution; G to A hypermutation	VIRUS TYPE-1 VIF; E3 UBIQUITIN LIGASE; ANTIRETROVIRAL FACTOR; FAMILY PROTEINS; URACIL-DNA; L1 RETROTRANSPOSITION; ADAPTIVE EVOLUTION; AID/APOBEC FAMILY; POTENT INHIBITOR; ENZYME APOBEC3G	Human cytidine deaminase apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3) proteins have been classified as either Z1- or Z2-type cytidine deaminases on the basis of phylogenetic analysis of their catalytic domains. Despite the identification of a number of Z1-type domain-containing cytidine deaminases, only one copy of Z2-type cytidine deaminase has been detected in each of the mammalian species evaluated thus far. Z1-type human APOBEC3 proteins are known to exhibit broad activities against diverse retroelements. However, the potential role of the only human Z2-type cytidine deaminase, APOBEC3H (A3H), in the restriction of retroelements has not yet been fully characterized. Here, we demonstrate that human A3H is a potent inhibitor of non-LTR LINE-1 transposition. Interestingly, it was also as efficient as A3G in inhibiting Alu retrotransposition, despite its poor association with Alu RNA. We have further demonstrated, for the first time, that human APOBEC3DE is also a potent inhibitor of Alu retrotransposition. Variants of A3H have divergent antiviral activities against HIV-1-Vif-deficient viruses. Unlike the anti-HIV-1 cytidine deaminases A3G and A3F, A3H is moderately regulated by interferons. These observations suggest that human Z2-type cytidine deaminase A3H variants have varying intrinsic abilities to restrict retroelements and that various APOBEC3 proteins may have evolved distinct inhibitory mechanisms against retroelements.-Tan, L., Sarkis, P. T. N., Wang, T., Tian, C., Yu, X.-F. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J. 23, 279-287 (2009)	[Tan, Lindi; Sarkis, Phuong Thi Nguyen; Wang, Tao; Tian, Chunjuan; Yu, Xiao-Fang] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Yu, Xiao-Fang] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Zhejiang University	Yu, XF (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.	xfyu@jhsph.edu			NIAID NIH HHS [R01 AI062644-05, R21 AI071769, R56 AI062644, AI071769, R01 AI062644, AI062644] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI071769, R56AI062644, R01AI062644] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		*APPL BIOS, 1997, ABI PRISM 7700 SEQ D, V2, P11; Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125; Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2006, P NATL ACAD SCI USA, V103, P8780, DOI 10.1073/pnas.0603313103; Bonvin M, 2006, HEPATOLOGY, V43, P1364, DOI 10.1002/hep.21187; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Chen H, 2006, CURR BIOL, V16, P480, DOI 10.1016/j.cub.2006.01.031; Chiu YL, 2006, P NATL ACAD SCI USA, V103, P15588, DOI 10.1073/pnas.0604524103; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Dang Y, 2008, J BIOL CHEM, V283, P11606, DOI 10.1074/jbc.M707586200; Dang Y, 2006, J VIROL, V80, P10522, DOI 10.1128/JVI.01123-06; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Doehle BP, 2005, VIROLOGY, V339, P281, DOI 10.1016/j.virol.2005.06.005; Esnault C, 2006, NUCLEIC ACIDS RES, V34, P1522, DOI 10.1093/nar/gkl054; Esnault C, 2005, NATURE, V433, P430, DOI 10.1038/nature03238; Goff SP, 2004, MOL CELL, V16, P849, DOI 10.1016/j.molcel.2004.12.001; Guo F, 2006, J VIROL, V80, P11710, DOI 10.1128/JVI.01038-06; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2004, NAT REV IMMUNOL, V4, P868, DOI 10.1038/nri1489; He ZW, 2008, J MOL BIOL, V381, P1000, DOI 10.1016/j.jmb.2008.06.061; Hulme AE, 2007, GENE, V390, P199, DOI 10.1016/j.gene.2006.08.032; Kaiser SM, 2006, J VIROL, V80, P875, DOI 10.1128/JVI.80.2.875-882.2006; Kinomoto M, 2007, NUCLEIC ACIDS RES, V35, P2955, DOI 10.1093/nar/gkm181; Kobayashi M, 2004, J VIROL, V78, P8238, DOI 10.1128/JVI.78.15.8238-8244.2004; Kremer M, 2005, VIROLOGY, V337, P175, DOI 10.1016/j.virol.2005.04.006; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Langlois MA, 2005, NUCLEIC ACIDS RES, V33, P1913, DOI 10.1093/nar/gki343; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Luo K, 2005, P NATL ACAD SCI USA, V102, P11444, DOI 10.1073/pnas.0502440102; Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004; Luo K, 2007, J VIROL, V81, P7238, DOI 10.1128/JVI.02584-06; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mbisa JL, 2007, J VIROL, V81, P7099, DOI 10.1128/JVI.00272-07; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Mehle A, 2006, J BIOL CHEM, V281, P17259, DOI 10.1074/jbc.M602413200; Miyagij E, 2007, J VIROL, V81, P13346, DOI 10.1128/JVI.01361-07; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Muckenfuss H, 2006, J BIOL CHEM, V281, P22161, DOI 10.1074/jbc.M601716200; Navarro F, 2004, CURR OPIN IMMUNOL, V16, P477, DOI 10.1016/j.coi.2004.05.006; Niewiadomska AM, 2007, J VIROL, V81, P9577, DOI 10.1128/JVI.02800-06; Noguchi C, 2005, HEPATOLOGY, V41, P626, DOI 10.1002/hep.20580; OhAinle M, 2006, J VIROL, V80, P3853, DOI 10.1128/JVI.80.8.3853-3862.2006; Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418; Peng G, 2006, J EXP MED, V203, P41, DOI 10.1084/jem.20051512; Rogozin IB, 2005, CELL CYCLE, V4, P1281, DOI 10.4161/cc.4.9.1994; Rose KM, 2004, J BIOL CHEM, V279, P41744, DOI 10.1074/jbc.M406760200; Rosler C, 2004, SCIENCE, V305, p1403A, DOI 10.1126/science.1100464; Russell RA, 2007, J VIROL, V81, P8201, DOI 10.1128/JVI.00395-07; Sarkis PTN, 2006, J IMMUNOL, V177, P4530, DOI 10.4049/jimmunol.177.7.4530; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; Schrofelbauer B, 2005, J VIROL, V79, P10978, DOI 10.1128/JVI.79.17.10978-10987.2005; Schrofelbauer B, 2006, J VIROL, V80, P5984, DOI 10.1128/JVI.00388-06; Schumacher AJ, 2005, P NATL ACAD SCI USA, V102, P9854, DOI 10.1073/pnas.0501694102; Schumacher AJ, 2008, J VIROL, V82, P2652, DOI 10.1128/JVI.02391-07; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Shirakawa K, 2006, VIROLOGY, V344, P263, DOI 10.1016/j.virol.2005.10.028; Simon B, 2005, SURVEILL SOC, V3, P1; Stenglein MD, 2006, J BIOL CHEM, V281, P16837, DOI 10.1074/jbc.M602367200; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Suspene R, 2004, NUCLEIC ACIDS RES, V32, P2421, DOI 10.1093/nar/gkh554; Tanaka Y, 2006, BIOCHEM BIOPH RES CO, V341, P314, DOI 10.1016/j.bbrc.2005.12.192; Tian CJ, 2006, J VIROL, V80, P3112, DOI 10.1128/JVI.80.6.3112-3115.2006; Turelli P, 2005, SCIENCE, V307, P1061, DOI 10.1126/science.1105964; Turelli P, 2004, J BIOL CHEM, V279, P43371, DOI 10.1074/jbc.C400334200; Turelli P, 2004, SCIENCE, V305, p1403B; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Xiao ZX, 2007, FASEB J, V21, P217, DOI 10.1096/fj.06-6773com; Xiao ZX, 2006, VIROLOGY, V349, P290, DOI 10.1016/j.virol.2006.02.002; Yang B, 2007, J BIOL CHEM, V282, P11667, DOI 10.1074/jbc.M606864200; Ying SC, 2007, ACTA BIOCH BIOPH SIN, V39, P297, DOI 10.1111/j.1745-7270.2007.00275.x; Yu Q, 2004, J BIOL CHEM, V279, P53379, DOI 10.1074/jbc.M408802200; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	85	65	66	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					279	287		10.1096/fj.07-088781	http://dx.doi.org/10.1096/fj.07-088781			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18827027	Green Published			2022-12-28	WOS:000262095500030
J	Quistorff, B; Secher, NH; Van Lieshout, JJ				Quistorff, Bjorn; Secher, Niels H.; Van Lieshout, Johannes J.			Lactate fuels the human brain during exercise	FASEB JOURNAL			English	Review						energy metabolism; glucose; oxygen	CEREBRAL-BLOOD-FLOW; SKELETAL-MUSCLE; GLUCOSE CONSUMPTION; PROLONGED EXERCISE; ENERGY-METABOLISM; MAXIMAL EXERCISE; RATIO; ACCUMULATION; GLYCOGEN; VELOCITY	The human brain releases a small amount of lactate at rest, and even an increase in arterial blood lactate during anesthesia does not provoke a net cerebral lactate uptake. However, during cerebral activation associated with exercise involving a marked increase in plasma lactate, the brain takes up lactate in proportion to the arterial concentration. Cerebral lactate uptake, together with glucose uptake, is larger than the uptake accounted for by the concomitant O-2 uptake, as reflected by the decrease in cerebral metabolic ratio (CMR) [the cerebral molar uptake ratio O-2/(glucose + 1/2 lactate)] from a resting value of 6 to < 2. The CMR also decreases when plasma lactate is not increased, as during prolonged exercise, cerebral activation associated with mental activity, or exposure to a stressful situation. The CMR decrease is prevented with combined beta(1) and beta(2)-adrenergic receptor blockade but not with beta(1)-adrenergic blockade alone. Also, CMR decreases in response to epinephrine, suggesting that a beta(2)-adrenergic receptor mechanism enhances glucose and perhaps lactate transport across the blood-brain barrier. The pattern of CMR decrease under various forms of brain activation suggests that lactate may partially replace glucose as a substrate for oxidation. Thus, the notion of the human brain as an obligatory glucose consumer is not without exceptions.	[Quistorff, Bjorn] Univ Copenhagen, Rigshosp, Fac Hlth Sci, Dept Biomed Sci, DK-2100 Copenhagen, Denmark; [Secher, Niels H.] Univ Copenhagen, Rigshosp, Fac Hlth Sci, Dept Anesthesiol, DK-2100 Copenhagen, Denmark; [Secher, Niels H.] Univ Copenhagen, Rigshosp, Fac Hlth Sci, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; [Van Lieshout, Johannes J.] Univ Amsterdam, Acad Med Ctr, Ctr Heart Failure Res, Lab Clin Cardiovasc Physiol, NL-1100 DE Amsterdam, Netherlands	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam	Van Lieshout, JJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Med Care Unit, Room F7-205,Box 22700, NL-1100 DE Amsterdam, Netherlands.	j.j.vanlieshout@amc.uva.nl	van Lieshout, Johannes J/B-6674-2011; Van Lieshout, Johannes/P-5499-2019	van Lieshout, Johannes J/0000-0002-3646-2122; Van Lieshout, Johannes/0000-0002-3646-2122				ASTRAND PO, 1964, J APPL PHYSIOL, V19, P268, DOI 10.1152/jappl.1964.19.2.268; Barros LF, 2007, GLIA, V55, P1222, DOI 10.1002/glia.20375; Brooks GA, 2000, MED SCI SPORT EXER, V32, P790, DOI 10.1097/00005768-200004000-00011; Cori CF, 1931, PHYSIOL REV, V11, P143, DOI 10.1152/physrev.1931.11.2.143; Dalsgaard MK, 2007, J CEREBR BLOOD F MET, V27, P1137, DOI 10.1038/sj.jcbfm.9600426; Dalsgaard MK, 2004, AM J PHYSIOL-REG I, V287, pR534, DOI 10.1152/ajpregu.00256.2004; Dalsgaard MK, 2004, EXP PHYSIOL, V89, P271, DOI 10.1113/expphysiol.2003.026922; Dalsgaard MK, 2004, J PHYSIOL-LONDON, V554, P571, DOI 10.1113/jphysiol.2003.055053; Dalsgaard MK, 2002, J PHYSIOL-LONDON, V540, P681, DOI 10.1113/jphysiol.2001.013062; Dienel GA, 2004, AM J PHYSIOL-REG I, V287, pR519, DOI 10.1152/ajpregu.00377.2004; FEDDERSEN K, 1986, ANN THORAC SURG, V41, P395, DOI 10.1016/S0003-4975(10)62694-X; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; GARDINER M, 1982, J CEREBR BLOOD F MET, V2, P429, DOI 10.1038/jcbfm.1982.49; GJEDDE A, 1981, J NEUROCHEM, V37, P807, DOI 10.1111/j.1471-4159.1981.tb04465.x; Gonzalez-Alonso J, 2004, J PHYSIOL-LONDON, V557, P331, DOI 10.1113/jphysiol.2004.060574; GREENHAFF PL, 1994, AM J PHYSIOL, V266, pE725, DOI 10.1152/ajpendo.1994.266.5.E725; Hasselbalch SG, 1996, AM J PHYSIOL-ENDOC M, V270, pE746, DOI 10.1152/ajpendo.1996.270.5.E746; Hellstrom G, 1996, J APPL PHYSIOL, V81, P413, DOI 10.1152/jappl.1996.81.1.413; Ide K, 1999, J APPL PHYSIOL, V87, P1604, DOI 10.1152/jappl.1999.87.5.1604; Ide K, 2000, J PHYSIOL-LONDON, V522, P159, DOI 10.1111/j.1469-7793.2000.t01-2-00159.xm; JORGENSEN LG, 1992, J APPL PHYSIOL, V73, P1825, DOI 10.1152/jappl.1992.73.5.1825; JORGENSEN LG, 1992, J APPL PHYSIOL, V72, P1123, DOI 10.1152/jappl.1992.72.3.1123; KARLSSON J, 1971, J APPL PHYSIOL, V31, P203, DOI 10.1152/jappl.1971.31.2.203; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; Kemppainen J, 2005, J PHYSIOL-LONDON, V568, P323, DOI 10.1113/jphysiol.2005.091355; Lambert G W, 1998, Adv Pharmacol, V42, P364; Lambert GW, 1996, J HYPERTENS, V14, P951; LARSEN TS, 2008, J PHYSL, P2807; Madsen PL, 1999, J CEREBR BLOOD F MET, V19, P393, DOI 10.1097/00004647-199904000-00005; Madsen PL, 1999, PROG NEUROBIOL, V58, P541, DOI 10.1016/S0301-0082(98)00093-8; Mintun MA, 2004, P NATL ACAD SCI USA, V101, P659, DOI 10.1073/pnas.0307457100; Nielsen HB, 2007, J APPL PHYSIOL, V103, P1227, DOI 10.1152/japplphysiol.00027.2007; Nielsen HB, 1999, AM J PHYSIOL-HEART C, V277, pH1045, DOI 10.1152/ajpheart.1999.277.3.H1045; Nielsen HB, 2002, J APPL PHYSIOL, V92, P1677, DOI 10.1152/japplphysiol.00028.2001; NORBERG K, 1975, ACTA PHYSIOL SCAND, V95, P301, DOI 10.1111/j.1748-1716.1975.tb10054.x; Nybo L, 2005, J PHYSIOL-LONDON, V563, P285, DOI 10.1113/jphysiol.2004.075838; Nybo L, 2002, J PHYSIOL-LONDON, V542, P991, DOI 10.1113/jphysiol.2002.022285; Nybo L, 2002, J PHYSIOL-LONDON, V545, P697, DOI 10.1113/jphysiol.2002.030023; Pellerin L, 2005, MOL NEUROBIOL, V32, P59, DOI 10.1385/MN:32:1:059; Pere P, 2000, LIVER TRANSPLANT, V6, P471, DOI 10.1053/jlts.2000.8186; RASMUSSEN P, 2008, FASEB J, V22, pIB96; Rasmussen P, 2006, J APPL PHYSIOL, V101, P1406, DOI 10.1152/japplphysiol.00423.2006; Schurr A, 2008, J PHYSIOL-LONDON, V586, P2665, DOI 10.1113/jphysiol.2008.155416; Secher NH, 2008, J APPL PHYSIOL, V104, P306, DOI 10.1152/japplphysiol.00853.2007; SECHER NH, 1977, ACTA PHYSIOL SCAND, V100, P288, DOI 10.1111/j.1748-1716.1977.tb05952.x; Shearer J, 2000, AM J PHYSIOL-ENDOC M, V278, pE177, DOI 10.1152/ajpendo.2000.278.1.E177; Siesjo B K, 1982, Ciba Found Symp, V87, P77, DOI 10.1002/9780470720691.ch5; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Steensberg A, 2006, BRAIN BEHAV IMMUN, V20, P585, DOI 10.1016/j.bbi.2006.03.002; van Lieshout JJ, 2003, J APPL PHYSIOL, V94, P833, DOI 10.1152/japplphysiol.00260.2002; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; Volianitis S, 2008, J PHYSIOL-LONDON, V586, P107, DOI 10.1113/jphysiol.2007.142273	53	140	141	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3443	3449		10.1096/fj.08-106104	http://dx.doi.org/10.1096/fj.08-106104			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18653766				2022-12-28	WOS:000259642600006
J	French, JP; Hamilton, KL; Quindry, JC; Lee, Y; Upchurch, PA; Powers, SK				French, Joel P.; Hamilton, Karyn L.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.			Exercise-induced protection against myocardial apoptosis and necrosis: MnSOD, calcium-handling proteins, and calpain	FASEB JOURNAL			English	Article						ischemia; reperfusion; antioxidant	ISCHEMIA-REPERFUSION INJURY; OXYGEN-FREE-RADICALS; VITAMIN-E; ISCHEMIA/REPERFUSION INJURY; INDUCED CARDIOPROTECTION; CARDIAC MYOCYTES; RAT-HEART; CA2+; PERFORMANCE; TOLERANCE	Exercise provides protection against myocardial ischemia-reperfusion (IR) injury. Understanding the mechanisms of this protection may lead to new interventions for the prevention and/or treatment of heart disease. Although presently these mechanisms are not well understood, reports suggest that manganese superoxide dismutase (MnSOD) and calpain may be critical mediators of this protection. We hypothesized that an exercise-induced increase in MnSOD would provide cardioprotection by attenuating IR-induced oxidative modification to critical Ca2+-handling proteins, thereby decreasing calpain-mediated cleavage of these and other proteins attenuating cardiomyocyte death. After IR, myocardial apoptosis and infarct size were significantly reduced in hearts of exercised animals compared with sedentary controls. In addition, exercise prevented IR-induced calpain activation as well as the oxidative modification and calpain-mediated degradation of myocardial Ca2+-handling proteins (L-type Ca2+ channels, phospholamban, and sarcoplasmic/endoplasmic reticulum calcium ATPase). Further, IR-induced activation of proapoptotic proteins was attenuated in exercised animals. Importantly, prevention of the exercise-induced increase in MnSOD activity via antisense oligonucleotides greatly attenuated the cardioprotection conferred by exercise. These results suggest that MnSOD provides cardioprotection by attenuating IR-induced oxidation and calpain-mediated degradation of myocardial Ca2+-handling proteins, thereby preventing myocardial apoptosis and necrosis.	[French, Joel P.; Hamilton, Karyn L.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.] Univ Florida, Ctr Exercise Sci, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA; [French, Joel P.; Hamilton, Karyn L.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.] Univ Florida, Dept Physiol & Physiol Genom, Gainesville, FL USA; [French, Joel P.; Hamilton, Karyn L.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.] Univ Minnesota, Dept Med, Div Cardiol, Minneapolis, MN 55455 USA; [French, Joel P.; Hamilton, Karyn L.] Colorado State Univ, Dept Hlth & Exercise Sci, Ft Collins, CO 80523 USA; [French, Joel P.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.] Appalachian State Univ, Dept Hlth Leisure & Exercise Sci, Boone, NC 28608 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Minnesota System; University of Minnesota Twin Cities; Colorado State University; University of North Carolina; Appalachian State University	French, JP (corresponding author), Univ Minnesota, Dept Med, Div Cardiol, MMC 508 Mayo,420 Delaware St SE, Minneapolis, MN 55455 USA.	frenc147@umn.edu	Quindry, John/E-8476-2011; Lee, Youngil/AAX-2787-2021	Lee, Youngil/0000-0003-3819-2469				Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Baines CP, 2005, J MOL CELL CARDIOL, V38, P47, DOI 10.1016/j.yjmcc.2004.11.004; Bajaj G, 2006, BIOCHEM BIOPH RES CO, V345, P1558, DOI 10.1016/j.bbrc.2006.05.059; Bognar Z, 2006, FREE RADICAL BIO MED, V41, P835, DOI 10.1016/j.freeradbiomed.2006.06.004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; COETZEE WA, 1992, J MOL CELL CARDIOL, V24, P651, DOI 10.1016/0022-2828(92)91049-B; COETZEE WA, 1994, AM J PHYSIOL, V266, pH909, DOI 10.1152/ajpheart.1994.266.3.H909; Coombes JS, 2000, ACTA PHYSIOL SCAND, V169, P261, DOI 10.1046/j.1365-201x.2000.00740.x; Coombes JS, 2000, INT J VITAM NUTR RES, V70, P293, DOI 10.1024/0300-9831.70.6.293; Coombes JS, 2000, AM J PHYSIOL-REG I, V279, pR2149, DOI 10.1152/ajpregu.2000.279.6.R2149; Demirel HA, 2001, J APPL PHYSIOL, V91, P2205, DOI 10.1152/jappl.2001.91.5.2205; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; French JP, 2006, AM J PHYSIOL-HEART C, V290, pH128, DOI 10.1152/ajpheart.00739.2005; Galvez AS, 2007, CIRC RES, V100, P1071, DOI 10.1161/01.RES.0000261938.28365.11; Garg S, 2005, J MOL CELL CARDIOL, V38, P73, DOI 10.1016/j.yjmcc.2004.11.006; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guerra L, 1996, BRIT J PHARMACOL, V118, P1278, DOI 10.1111/j.1476-5381.1996.tb15534.x; Hamilton KL, 2004, FREE RADICAL BIO MED, V37, P1360, DOI 10.1016/j.freeradbiomed.2004.07.025; Hamilton KL, 2001, AM J PHYSIOL-HEART C, V281, pH1346, DOI 10.1152/ajpheart.2001.281.3.H1346; Hamilton KL, 2003, FREE RADICAL BIO MED, V34, P800, DOI 10.1016/S0891-5849(02)01431-4; Jin ZQ, 2005, AM J PHYSIOL-HEART C, V288, pH2986, DOI 10.1152/ajpheart.01144.2004; KANEKO M, 1989, AM J PHYSIOL, V256, pH368, DOI 10.1152/ajpheart.1989.256.2.H368; KATO M, 1988, MOL CELL BIOCHEM, V83, P15; Kim HD, 2003, J KOREAN MED SCI, V18, P337, DOI 10.3346/jkms.2003.18.3.337; KIM MS, 1987, AM J PHYSIOL, V252, pH252, DOI 10.1152/ajpheart.1987.252.2.H252; Kim SJ, 2001, CIRC RES, V89, P831, DOI 10.1161/hh2101.098547; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; LAWLER JM, 1993, MED SCI SPORT EXER, V25, P1259; Lebedeva I, 2001, ANNU REV PHARMACOL, V41, P403, DOI 10.1146/annurev.pharmtox.41.1.403; Lennon SL, 2004, ACTA PHYSIOL SCAND, V182, P161, DOI 10.1111/j.1365-201X.2004.01346.x; Lennon SL, 2004, AM J PHYSIOL-HEART C, V287, pH975, DOI 10.1152/ajpheart.01208.2003; Lennon SL, 2004, J APPL PHYSIOL, V96, P1299, DOI 10.1152/japplphysiol.00920.2003; Logue SE, 2005, J MOL CELL CARDIOL, V38, P21, DOI 10.1016/j.yjmcc.2004.11.009; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; Node K, 1997, CIRCULATION, V96, P1257, DOI 10.1161/01.CIR.96.4.1257; Powers SK, 1998, AM J PHYSIOL-REG I, V275, pR1468, DOI 10.1152/ajpregu.1998.275.5.R1468; Quindry J, 2005, EXP GERONTOL, V40, P416, DOI 10.1016/j.exger.2005.03.010; Regula KA, 2005, J MOL CELL CARDIOL, V38, P3, DOI 10.1016/j.yjmcc.2004.11.003; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; SUZUKI YJ, 1992, AM J PHYSIOL, V262, pH114, DOI 10.1152/ajpheart.1992.262.1.H114; Taylor RP, 2003, CARDIOVASC RES, V58, P575, DOI 10.1016/S0008-6363(03)00285-2; Thierry AR, 2003, CURR OPIN MOL THER, V5, P133; Tokube K, 1998, PFLUG ARCH EUR J PHY, V437, P155, DOI 10.1007/s004240050760; Trumbeckaite S, 2003, BIOCHEM PHARMACOL, V65, P911, DOI 10.1016/S0006-2952(02)01610-6; Wu YL, 1998, TRENDS CARDIOVAS MED, V8, P312, DOI 10.1016/S1050-1738(98)00023-1; Yamashita N, 1999, J EXP MED, V189, P1699, DOI 10.1084/jem.189.11.1699; Yoshikawa Y, 2005, AM J PHYSIOL-HEART C, V288, pH1690, DOI 10.1152/ajpheart.00666.2004; Zima AV, 2006, CARDIOVASC RES, V71, P310, DOI 10.1016/j.cardiores.2006.02.019; ZOLOTARJOVA N, 1994, BBA-BIOMEMBRANES, V1192, P125, DOI 10.1016/0005-2736(94)90152-X	53	96	101	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2862	2871		10.1096/fj.07-102541	http://dx.doi.org/10.1096/fj.07-102541			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18417547	Green Published			2022-12-28	WOS:000258089300026
J	Doengi, M; Deitmer, JW; Lohr, C				Doengi, Michael; Deitmer, Joachim W.; Lohr, Christian			New evidence for purinergic signaling in the olfactory bulb: A(2A) and P2Y(1) receptors mediate intracellular calcium release in astrocytes	FASEB JOURNAL			English	Article						neuron-glia interaction; adenosine triphosphate	CULTURED CORTICAL ASTROCYTES; RAT CEREBELLAR ASTROCYTES; RETINAL GLIAL-CELLS; GATED ION CHANNELS; DORSAL SPINAL-CORD; ADENOSINE RECEPTORS; NEURONAL-ACTIVITY; HIPPOCAMPAL ASTROCYTES; SYNAPTIC-TRANSMISSION; GLOMERULAR FORMATION	Purinergic receptors play a key role in neuron-glia and glia-neuron interactions. In the present study, we have recorded cytosolic Ca2+ responses using confocal imaging in astrocytes of acute olfactory bulb slices from mice (postnatal days 3-8). By application of agonists and antagonists, we identified two types of receptors, P2Y(1) and A(2A), that mediated Ca2+ responses attributable to Ca2+ release from intracellular stores in the astrocytes. Both receptor types were activated by application of ATP and ADP; however, when enzymatic ATP degradation was suppressed by the alkaline phosphatase inhibitor levamisole, ATP only activated MRS2179-sensitive P2Y(1) but not ZM241385-sensitive A(2A) receptors. The dose-response curve for A(2A) receptors activated by adenosine revealed an EC50 of 0.3 mu M, one order of magnitude smaller than the EC50 of 5 mu M determined for P2Y(1) receptors activated by ADP. Electrical stimulation of the olfactory nerve in the presence of glutamate receptor blockers to suppress excitation of postsynaptic neurons evoked Ca2+ responses in most of the astrocytes, which were inhibited by blocking both P2Y(1) and A(2A) receptors. Our results indicate that olfactory nerve terminals release not only glutamate, but also ATP, which activates P2Y(1) receptors and, after degradation of ATP to adenosine, A(2A) receptors in astrocytes.	[Doengi, Michael; Deitmer, Joachim W.; Lohr, Christian] Univ Kaiserslautern, Abt Allgemeine Zool, D-67653 Kaiserslautern, Germany	University of Kaiserslautern	Lohr, C (corresponding author), Univ Kaiserslautern, Abt Allgemeine Zool, POB 3049, D-67653 Kaiserslautern, Germany.	clohr@biologie.uni-kl.de	Lohr, Christian/F-2968-2011	Lohr, Christian/0000-0001-6518-6422				Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Alloisio S, 2004, BRIT J PHARMACOL, V141, P935, DOI 10.1038/sj.bjp.0705707; Alloisio S, 2006, MOL PHARMACOL, V69, P1975, DOI 10.1124/mol.105.020164; Amadio S, 2006, NEUROSCIENCE, V141, P1171, DOI 10.1016/j.neuroscience.2006.05.058; Bailey MS, 1999, J COMP NEUROL, V415, P423; Beck A, 2004, CELL CALCIUM, V35, P47, DOI 10.1016/S0143-4160(03)00171-4; Bernstein M, 1998, NEUROPHARMACOLOGY, V37, P169, DOI 10.1016/S0028-3908(98)00012-4; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Butt AM, 2006, GLIA, V54, P666, DOI 10.1002/glia.20424; Dallwig R, 2000, CELL CALCIUM, V28, P247, DOI 10.1054/ceca.2000.0153; Deitmer JW, 2006, CEREBELLUM, V5, P49, DOI 10.1080/14734220500497456; DEITMER JW, 2007, ASTROCYTE P IN PRESS; Fam SR, 2000, J NEUROSCI, V20, P2800; Fiacco TA, 2006, GLIA, V54, P676, DOI 10.1002/glia.20396; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Hartel K, 2007, CELL CALCIUM, V42, P271, DOI 10.1016/j.ceca.2006.12.004; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; JAN DD, 2005, J NEUROSCI, V25, P2917, DOI DOI 10.1523/JNEUR0SCI.5042-04.2005; Johansson B, 1997, NEUROSCIENCE, V80, P1187, DOI 10.1016/S0306-4522(97)00143-7; Jung S, 2000, J PHYSIOL-LONDON, V527, P549, DOI 10.1111/j.1469-7793.2000.00549.x; Kanjhan R, 1999, J COMP NEUROL, V407, P11; Kirischuk S, 1995, J NEUROSCI, V15, P7861; Kozlov AS, 2006, P NATL ACAD SCI USA, V103, P10058, DOI 10.1073/pnas.0603741103; Llaudet E, 2005, ANAL CHEM, V77, P3267, DOI 10.1021/ac048106q; Nasu-Tada K, 2005, GLIA, V52, P98, DOI 10.1002/glia.20224; Newman EA, 2005, J NEUROSCI, V25, P5502, DOI 10.1523/JNEUROSCI.1354-05.2005; Newman EA, 2004, GLIA, V47, P268, DOI 10.1002/glia.20030; Newman EA, 1997, SCIENCE, V275, P844, DOI 10.1126/science.275.5301.844; Pilitsis JG, 1998, BRAIN RES, V798, P294, DOI 10.1016/S0006-8993(98)00430-2; PORTER JT, 1995, J NEUROCHEM, V65, P1515, DOI 10.1046/j.1471-4159.1995.65041515.x; Prediger RDS, 2005, NEUROBIOL AGING, V26, P957, DOI 10.1016/j.neurobiolaging.2004.08.012; Rieger A, 2007, GLIA, V55, P352, DOI 10.1002/glia.20460; Rousse I, 2006, GLIA, V54, P691, DOI 10.1002/glia.20388; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; Scemes E, 2006, GLIA, V54, P716, DOI 10.1002/glia.20374; Simon J, 1997, NEUROPHARMACOLOGY, V36, P1243, DOI 10.1016/S0028-3908(97)00124-X; Singaravelu K, 2006, CELL CALCIUM, V39, P143, DOI 10.1016/j.ceca.2005.10.001; Singaravelu K, 2006, J NEUROSCI, V26, P9579, DOI 10.1523/JNEUROSCI.2604-06.2006; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; Treloar HB, 1999, J COMP NEUROL, V413, P289; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; Volterra A, 2004, GLIA, V47, P249, DOI 10.1002/glia.20080; von Kugelgen I, 2006, PHARMACOL THERAPEUT, V110, P415, DOI 10.1016/j.pharmthera.2005.08.014; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; Weissman TA, 2004, NEURON, V43, P647, DOI 10.1016/j.neuron.2004.08.015; White PJ, 2003, MOL PHARMACOL, V63, P1356, DOI 10.1124/mol.63.6.1356; Yuan Q, 2006, J NEUROPHYSIOL, V95, P3097, DOI 10.1152/jn.00001.2006; Zhang FL, 2002, J PHARMACOL EXP THER, V301, P705, DOI 10.1124/jpet.301.2.705; Zhu YZ, 2001, J NEUROCHEM, V77, P530, DOI 10.1046/j.1471-4159.2001.00241.x; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	52	48	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2368	2378		10.1096/fj.07-101782	http://dx.doi.org/10.1096/fj.07-101782			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18310463				2022-12-28	WOS:000257292500029
J	Huang, MC; Liao, JJ; Bonasera, S; Longo, DL; Goetzl, EJ				Huang, Mei-Chuan; Liao, Jia-Jun; Bonasera, Stephen; Longo, Dan L.; Goetzl, Edward J.			Nuclear factor-kappa B-dependent reversal of aging-induced alterations in T cell cytokines	FASEB JOURNAL			English	Article						immunosenescence; inflammation; autoimmunity; phytochemicals	IMMUNE RISK PHENOTYPE; CUTTING EDGE; LATE-LIFE; ACTIVATION; AGE; INTERLEUKIN-18; LYMPHOCYTES; INHIBITION; EXPRESSION; ALPHA	Immunosenescence is characterized by decreases in protective immune responses and increases in inflammation and autoimmunity. The T helper (Th) 17 subset of cluster-of-differentiation (CD) 4 T cells, which is identified by its generation of interleukin (IL)-17, is implicated in autoimmune pathogenesis. To elucidate immunosenescent changes in Th17 cell cytokines, splenic CD4 T cells from 22-to 24-month-old (old) mice and 6-to 10-wk-old (young) mice were incubated on anti-CD3 plus anti-CD28 (anti-T cell antigen receptor) antibodies. After 96 h, T cells of old C57BL/6 and CBA mice generated up to 20-fold more IL-17 and up to 3-fold more IL-6 than those of young mice; T cells of young mice generated up to 5-fold more IL-21 than those of old mice; and no difference was found for IFN-gamma. At 24 h, cytokine mRNA levels paralleled 96 h cytokine concentrations. Naive CD4 T cells from old mice incubated on anti-T cell antigen receptor antibodies with transforming growth factor-beta, IL-1, IL-6, and IL-23 to induce de novo differentiation of Th17 cells had more IL-17 mRNA and produced more IL-17 than those of young mice. BAY11-7082 and the phytochemicals triptolide and butein suppressed nuclear concentrations of nuclear factor-kappa B and secreted levels of IL-17, IL-21, and IFN-gamma in parallel, with greater potency in Th17 cells from young than old mice. Pharmacological correction of altered generation of Th17 cell cytokines in immunosenescence represents a novel therapeutic approach to aging-induced inflammatory diseases.	[Huang, Mei-Chuan; Liao, Jia-Jun; Bonasera, Stephen; Goetzl, Edward J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Longo, Dan L.] NIA, NIH, Baltimore, MD 21224 USA	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, Room UB8B,533 Parnassus 4th Ave, San Francisco, CA 94143 USA.	edward.goetzl@ucsf.edu	Longo, Dan L./F-6022-2011	Bonasera, Stephen/0000-0001-6808-2821	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG026043] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [R0-1 HL31809] Funding Source: Medline; NIA NIH HHS [R21 AG026043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agrawal A, 2007, J IMMUNOL, V178, P6912, DOI 10.4049/jimmunol.178.11.6912; Barker BR, 2007, J IMMUNOL, V179, P3596, DOI 10.4049/jimmunol.179.6.3596; Chan MA, 1999, PHYTOTHER RES, V13, P464, DOI 10.1002/(SICI)1099-1573(199909)13:6&lt;464::AID-PTR483&gt;3.0.CO;2-4; Dai R, 2007, J IMMUNOL, V179, P1776, DOI 10.4049/jimmunol.179.3.1776; Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S; Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood-2004-07-2599; Frayling TM, 2007, J GERONTOL A-BIOL, V62, P73, DOI 10.1093/gerona/62.1.73; Gangemi S, 2003, EXP GERONTOL, V38, P669, DOI 10.1016/S0531-5565(03)00061-5; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Haynes L, 2005, IMMUNOL REV, V205, P220, DOI 10.1111/j.0105-2896.2005.00255.x; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liao JJ, 2007, J IMMUNOL, V178, P5425, DOI 10.4049/jimmunol.178.9.5425; Liu H, 2000, ACTA PHARMACOL SIN, V21, P782; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; LONGO DL, 2003, FUNDAMENTAL IMMUNOLO, P1043; Lustgarten J, 2004, J IMMUNOL, V173, P4510, DOI 10.4049/jimmunol.173.7.4510; Marko MG, 2007, J IMMUNOL, V178, P1443, DOI 10.4049/jimmunol.178.3.1443; McDonald DR, 2007, J ALLERGY CLIN IMMUN, V120, P900, DOI 10.1016/j.jaci.2007.08.035; NAGELKERKEN L, 1991, EUR J IMMUNOL, V21, P273, DOI 10.1002/eji.1830210206; Nishioka T, 2006, J IMMUNOL, V176, P6586, DOI 10.4049/jimmunol.176.11.6586; Pandey MK, 2007, J BIOL CHEM, V282, P17340, DOI 10.1074/jbc.M700890200; Pawelec G, 2006, EXP GERONTOL, V41, P1239, DOI 10.1016/j.exger.2006.09.005; Pelletier M, 2007, THESCIENTIFICWORLDJO, V7, P1715, DOI 10.1100/tsw.2007.275; Ponnappan S, 2004, EXP GERONTOL, V39, P559, DOI 10.1016/j.exger.2003.12.012; Puel A, 2004, CURR OPIN IMMUNOL, V16, P34, DOI 10.1016/j.coi.2003.11.013; Rea IM, 1999, EXP GERONTOL, V34, P79, DOI 10.1016/S0531-5565(98)00058-8; Sharma S, 2006, J IMMUNOL, V177, P8348, DOI 10.4049/jimmunol.177.12.8348; Shibata W, 2007, J IMMUNOL, V179, P2681, DOI 10.4049/jimmunol.179.5.2681; Tanaka A, 2007, J INVEST DERMATOL, V127, P855, DOI 10.1038/sj.jid.5700603; Timm JA, 1999, J IMMUNOL, V162, P711; Trebilcock GU, 1996, GERONTOLOGY, V42, P137, DOI 10.1159/000213785; Trebilcock GU, 1998, MECH AGEING DEV, V102, P149, DOI 10.1016/S0047-6374(97)00160-7; Wikby A, 2005, J GERONTOL A-BIOL, V60, P556, DOI 10.1093/gerona/60.5.556; Wikby A, 2006, MECH AGEING DEV, V127, P695, DOI 10.1016/j.mad.2006.04.003; Zhao L, 2007, J LEUKOCYTE BIOL, V81, P1386, DOI 10.1189/jlb.0506364	38	54	58	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2142	2150		10.1096/fj.07-103721	http://dx.doi.org/10.1096/fj.07-103721			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18267981				2022-12-28	WOS:000257292500006
J	Lau, T; Horschitz, S; Berger, S; Bartsch, D; Schloss, P				Lau, Thorsten; Horschitz, Sandra; Berger, Stefan; Bartsch, Dusan; Schloss, Patrick			Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons	FASEB JOURNAL			English	Article						depression; citalopram; confocal microscopy	DOWN-REGULATION; NOREPINEPHRINE TRANSPORTER; DOPAMINE TRANSPORTER; PROTEIN-KINASE; MESSENGER-RNA; EXPRESSION; BINDING; TRAFFICKING; RECEPTORS; INCREASES	A deficiency of serotonergic signaling is thought to be involved in the etiology of depression. Thus, drugs blocking the reuptake of serotonin back into the neurons are widely used in treatment of this disease; however, their delayed effect in remission of patients suggests that the clinical response does not rely on simple serotonin uptake inhibition but may include further regulatory mechanisms. We have analyzed cellular serotonin transporter (SERT) expression on exposure to the selective serotonin reuptake inhibitor citalopram in serotonergic neurons expressing the native SERT allele in its natural surroundings. Biotinylation of SERT-expressing HEK293 cells, as well as confocal microscopy analysis in these cells and in serotonergic neurons, revealed that exposure to citalopram time dependently reduces the amount of cell surface-expressed SERT. Furthermore, in serotonergic neurons, longer exposure to citalopram not only caused an internalization of SERT proteins from the cell surface but also induced a redistribution of SERT from neurite extensions into the soma. This process was reversible on drug removal. Microarray analysis performed on citalopram-treated serotonergic neurons revealed that antidepressant treatment does not alter SERT mRNA expression, suggesting that SERT trafficking from and to the cell membrane is regulated on the posttranscriptional level.	[Lau, Thorsten; Horschitz, Sandra; Schloss, Patrick] Cent Inst Mental Hlth, Biochem Lab, D-68159 Mannheim, Germany; [Berger, Stefan; Bartsch, Dusan] Cent Inst Mental Hlth, Dept Mol Biol, D-68159 Mannheim, Germany	Central Institute of Mental Health; Central Institute of Mental Health	Schloss, P (corresponding author), Cent Inst Mental Hlth, Biochem Lab, J5, D-68159 Mannheim, Germany.	patrick.schloss@zi-mannheim.de						Adell A, 2002, BRAIN RES REV, V39, P154, DOI 10.1016/S0165-0173(02)00182-0; Benmansour S, 2002, J NEUROSCI, V22, P6766; Benmansour S, 1999, J NEUROSCI, V19, P10494; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; BLAKELY RD, 1994, J EXP BIOL, V196, P263; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Cannon DM, 2006, BIOL PSYCHIAT, V60, P207, DOI 10.1016/j.biopsych.2006.05.005; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Coyle JT, 2003, NEURON, V38, P157, DOI 10.1016/S0896-6273(03)00195-8; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; De-Miguel FF, 2005, CELL MOL NEUROBIOL, V25, P297, DOI 10.1007/s10571-005-3061-z; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; Glatz K, 2003, J NEUROCHEM, V86, P1072, DOI 10.1046/j.1471-4159.2003.01944.x; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Horschitz S, 2003, J NEUROCHEM, V86, P958, DOI 10.1046/j.1471-4159.2003.01899.x; Horschitz S, 2001, NEUROREPORT, V12, P2181, DOI 10.1097/00001756-200107200-00027; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jayanthi LD, 2005, AAPS J, V7, pE728, DOI 10.1208/aapsj070373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau T, 2006, NEUROREPORT, V17, P975, DOI 10.1097/01.wnr.0000223395.66951.01; Little KY, 2006, J PSYCHIATR NEUROSCI, V31, P333; Little KY, 2002, MOL PHARMACOL, V61, P436, DOI 10.1124/mol.61.2.436; Mamounas LA, 2000, J NEUROSCI, V20, P771, DOI 10.1523/JNEUROSCI.20-02-00771.2000; Mash DC, 2000, J CHEM NEUROANAT, V20, P271, DOI 10.1016/S0891-0618(00)00102-2; MELTZER H, 1989, BRIT J PSYCHIAT, V155, P25, DOI 10.1192/S0007125000291733; Millan MJ, 2006, PHARMACOL THERAPEUT, V110, P135, DOI 10.1016/j.pharmthera.2005.11.006; Miner LH, 2006, J NEUROSCI, V26, P1571, DOI 10.1523/JNEUROSCI.4450-05.2006; Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186; Muller HK, 2006, J BIOL CHEM, V281, P28901, DOI 10.1074/jbc.M602848200; Nemeroff CB, 1998, BIOL PSYCHIAT, V44, P517; Nibuya M, 1996, J NEUROSCI, V16, P2365; OVERO KF, 1982, PROG NEURO-PSYCHOPH, V6, P311, DOI 10.1016/S0278-5846(82)80181-4; PINEYRO G, 1994, J NEUROSCI, V14, P3036; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Ressler KJ, 2000, DEPRESS ANXIETY, V12, P2, DOI 10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.3.CO;2-W; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; Scanlon SM, 2001, BIOCHEMISTRY-US, V40, P10507, DOI 10.1021/bi010730z; Schloss P, 1998, J PSYCHOPHARMACOL, V12, P115, DOI 10.1177/026988119801200201; Schloss P, 2004, PHARMACOL THERAPEUT, V102, P47, DOI 10.1016/j.pharmthera.2004.02.001; SCHLOSS P, 1995, BIOCHEMISTRY-US, V34, P12590, DOI 10.1021/bi00039a014; Sur C, 1996, NEUROSCIENCE, V73, P217, DOI 10.1016/0306-4522(96)00030-9; Sur C, 1996, EUR J NEUROSCI, V8, P2753, DOI 10.1111/j.1460-9568.1996.tb01570.x; Thakker DR, 2005, MOL PSYCHIATR, V10, P782, DOI 10.1038/sj.mp.4001687; TROJANOWSKI JQ, 1982, BRAIN RES, V231, P33, DOI 10.1016/0006-8993(82)90005-1; WAN XCS, 1982, BRAIN RES, V243, P215, DOI 10.1016/0006-8993(82)90244-X; Willins DL, 1998, ANN NY ACAD SCI, V861, P121, DOI 10.1111/j.1749-6632.1998.tb10182.x; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zavosh A, 1999, BRAIN RES BULL, V49, P291, DOI 10.1016/S0361-9230(99)00063-5; Zhu MY, 1998, J NEUROCHEM, V70, P1547; Zhu MY, 1997, J NEUROCHEM, V68, P134	52	38	38	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1702	1714		10.1096/fj.07-095471	http://dx.doi.org/10.1096/fj.07-095471			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18216289				2022-12-28	WOS:000256352700011
J	Schmidt, RL; Trejo, TR; Plummer, TB; Platt, JL; Tang, AH				Schmidt, Rebecca L.; Trejo, Theodore R.; Plummer, Timothy B.; Platt, Jeffrey L.; Tang, Amy H.			Infection-induced proteolvsis of PGRP-LC controls the IMD activation and melanization cascades in	FASEB JOURNAL			English	Article						innate immunity; host defense; IAM signaling pathway; antimicrobial peptide	PEPTIDOGLYCAN-RECOGNITION PROTEIN; OUTER-MEMBRANE PROTEASE; GRAM-POSITIVE BACTERIA; DROSOPHILA IMMUNE-RESPONSE; TOLL-LIKE RECEPTORS; ESCHERICHIA-COLI; PATTERN-RECOGNITION; HOST-DEFENSE; INNATE IMMUNITY; MATRIX METALLOPROTEINASES	The Drosophila immune deficiency (IMD) pathway, homologous to the mammalian tumor necrosis factor (TNF-alpha) signaling pathway, initiates antimicrobial peptide (AMP) production in response to infection by grain-negative bacteria. A membrane-spanning peptidoglycan recognition protein, PGRP-LC, functions as the receptor for the IMD pathway. This receptor is activated via pattern recognition and binding of monomeric peptidoglycan (DAP-type PGN) through the PGRP ectodomain. In this article, we show that the receptor PGRP-LC is down-regulated in response to Salmonella/Escherichia coli infection but is not affected by Staphylococcus infection in vivo, and an ectodomain-deleted PGRP-LC lacking the PGRP domain is an active receptor. We show that the receptor PGRP-LC regulates and integrates two host defense systems: the AMP production and melanization. A working model is proposed in which pathogen invasion and tissue dairnage may be monitored through the receptor integrity of PGRP-LC after host and pathogen are engaged via pattern recognition. The irreversible cleavage or down-regulation of PGRP-LC may provide an additional cue for the host to distinguish pathogenic microbes from nonpathogenic ones and to subsequently activate multiple host defense systems in Drosophila, thereby effectively combating bacterial infection and initiating tissue repair.-Schmidt, R. L., Trejo, T. R., Plummer, T. B., Platt, J. L., Tang, AH. Infection-induced proteolysis of PGRP-LC controls the IMD activation and melanization cascades in Drosophila.	[Schmidt, Rebecca L.; Tang, Amy H.] Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Trejo, Theodore R.; Plummer, Timothy B.; Platt, Jeffrey L.; Tang, Amy H.] Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Dept Surg, Rochester, MN 55905 USA; [Platt, Jeffrey L.] Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Dept Immunol, Rochester, MN 55905 USA; [Platt, Jeffrey L.] Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Dept Pediat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Tang, AH (corresponding author), Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Dept Biochem & Mol Biol, 200 1st St SW,Med Sci 2-85, Rochester, MN 55905 USA.	tang.amy@mayo.edu	Platt, Jeffrey/AHB-0480-2022; Tang, Amy/L-3226-2016	Platt, Jeffrey/0000-0002-4915-0419; Tang, Amy/0000-0002-5772-2878	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069922] Funding Source: NIH RePORTER; NIAID NIH HHS [AI53733] Funding Source: Medline; NIGMS NIH HHS [GM69922] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Asha H, 2003, GENETICS, V163, P203; Ashida Masaaki, 1998, P135; Basset A, 2000, P NATL ACAD SCI USA, V97, P3376, DOI 10.1073/pnas.070357597; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bidla G, 2005, DEV COMP IMMUNOL, V29, P669, DOI 10.1016/j.dci.2004.11.007; Bischoff V, 2004, NAT IMMUNOL, V5, P1175, DOI 10.1038/ni1123; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; Chang CI, 2005, P NATL ACAD SCI USA, V102, P10279, DOI 10.1073/pnas.0504547102; Chaput C, 2007, MICROBES INFECT, V9, P637, DOI 10.1016/j.micinf.2007.01.022; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; Choe KM, 2005, P NATL ACAD SCI USA, V102, P1122, DOI 10.1073/pnas.0404952102; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Coughlin SR, 2003, J CLIN INVEST, V111, P25, DOI 10.1172/JCI200317564; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dziarski R, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-232; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Garver LS, 2006, P NATL ACAD SCI USA, V103, P660, DOI 10.1073/pnas.0506182103; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Goto A, 2003, DEV BIOL, V264, P582, DOI 10.1016/j.ydbio.2003.06.001; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Gottar M, 2006, CELL, V127, P1425, DOI 10.1016/j.cell.2006.10.046; Gram H.C, 1884, FORTSCHRITTE MIKROCH, V2, P185; Green C, 2000, GENETICS, V156, P1117; Guina T, 2000, J BACTERIOL, V182, P4077, DOI 10.1128/JB.182.14.4077-4086.2000; Hashimoto C, 2003, DEV CELL, V5, P945, DOI 10.1016/S1534-5807(03)00338-1; Hu XD, 2004, P NATL ACAD SCI USA, V101, P9369, DOI 10.1073/pnas.0307062101; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Jang IH, 2006, DEV CELL, V10, P45, DOI 10.1016/j.devcel.2005.11.013; Johnson GB, 2003, TRENDS IMMUNOL, V24, P19, DOI 10.1016/S1471-4906(02)00014-5; Kambris Z, 2006, CURR BIOL, V16, P808, DOI 10.1016/j.cub.2006.03.020; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Kaneko T, 2006, NAT IMMUNOL, V7, P715, DOI 10.1038/ni1356; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kramer RA, 2002, EUR J BIOCHEM, V269, P1746, DOI 10.1046/j.1432-1327.2002.02820.x; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; LACKIE AM, 1988, ADV INSECT PHYSL, V21, P1; Leclerc V, 2004, IMMUNOL REV, V198, P59, DOI 10.1111/j.0105-2896.2004.0130.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; LUNDRIGAN MD, 1992, FEMS MICROBIOL LETT, V97, P51; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; McCarter JD, 2004, J BACTERIOL, V186, P5919, DOI 10.1128/JB.186.17.5919-5925.2004; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2005, P NATL ACAD SCI USA, V102, P6455, DOI 10.1073/pnas.0407559102; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Royet J, 2005, CURR OPIN IMMUNOL, V17, P11, DOI 10.1016/j.coi.2004.12.002; Ryan KJ., 2004, SHERRIS MED MICROBIO; Sansonetti PJ, 2006, NAT IMMUNOL, V7, P1237, DOI 10.1038/ni1420; Sansonetti PJ, 2004, NAT REV IMMUNOL, V4, P953, DOI 10.1038/nri1499; SODEINDE OA, 1992, SCIENCE, V258, P1004, DOI 10.1126/science.1439793; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Steiner H, 2004, IMMUNOL REV, V198, P83, DOI 10.1111/j.0105-2896.2004.0120.x; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stumpe S, 1998, J BACTERIOL, V180, P4002, DOI 10.1128/JB.180.15.4002-4006.1998; Takehana A, 2004, EMBO J, V23, P4690, DOI 10.1038/sj.emboj.7600466; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; TANG AH, 1995, J BIOL CHEM, V270, P13819, DOI 10.1074/jbc.270.23.13819; Tang AH, 2007, J LEUKOCYTE BIOL, V82, P282, DOI 10.1189/jlb.1206752; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; Theopold U, 2002, CELL MOL LIFE SCI, V59, P363, DOI 10.1007/s00018-002-8428-4; Tingvall TO, 2001, EMBO REP, V2, P239; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Ulvatne H, 2002, J ANTIMICROB CHEMOTH, V50, P461, DOI 10.1093/jac/dkf156; Volanakis JE, 1998, HUMAN COMPLEMENT SYS, V20, P9, DOI DOI 10.1201/B14212-3; Wang LH, 2006, EMBO J, V25, P5005, DOI 10.1038/sj.emboj.7601363; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601	85	48	52	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2008	22	3					918	929		10.1096/fj.06-7907com	http://dx.doi.org/10.1096/fj.06-7907com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	276LQ	18308747				2022-12-28	WOS:000254143700030
J	Lanner, JT; Bruton, JD; Assefaw-Redda, Y; Andronache, Z; Zhang, SJ; Severa, D; Zhang, ZB; Melzer, W; Zhang, SL; Katz, A; Westerblad, H				Lanner, Johanna T.; Bruton, Joseph D.; Assefaw-Redda, Yohannes; Andronache, Zoita; Zhang, Shi-Jin; Severa, Denise; Zhang, Zhi-Bin; Melzer, Werner; Zhang, Shi-Li; Katz, Abram; Westerblad, Hakan			Knockdown of TRPC3 with siRNA coupled to carbon nanotubes results in decreased insulin-mediated glucose uptake in adult skeletal muscle cells	FASEB JOURNAL			English	Article						Ca(2+); sarcolemma; transverse tubules; near-membrane Ca(2+); colocalization	PROTEIN-KINASE-C; STIMULATED GLUT4 TRANSLOCATION; CATION CHANNELS; TRANSVERSE TUBULES; PLASMA-MEMBRANE; CALCIUM SENSOR; VESICLE FUSION; SLOW-TWITCH; CA2+ INFLUX; ACTIVATION	The involvement of Ca(2+) in the insulin-mediated signaling cascade, resulting in glucose uptake in skeletal muscle, is uncertain. Here, we test the hypothesis that Ca(2+) influx through canonical transient receptor potential 3 (TRPC3) channels modulates insulin-mediated glucose uptake in adult skeletal muscle. Experiments were performed on adult skeletal muscle cells of wild-type (WT) and obese, insulin-resistant ob/ob mice. Application of the diacylglycerol analog 1-oleyl-2-acetyl-sn-glycerol (OAG) induced a nonselective cation current, which was inhibited by the addition of anti-TRPC3 antibody in the patch pipette and smaller in ob/ob than in WT cells. Knockdown of TRPC3, using a novel technique based on small interfering RNA (siRNA) coupled to functionalized carbon nanotubes, resulted in pronounced (similar to 70%) decreases in OAG-induced Ca(2+) influx and insulin-mediated glucose uptake. TRPC3 and the insulin-sensitive glucose transporter 4 (GLUT4) coimmunoprecipitated, and immunofluorescence staining showed that they were colocalized in the proximity of the transverse tubular system, which is the predominant site of insulin-mediated glucose transport in skeletal muscle. In conclusion, our results indicate that TRPC3 interacts functionally and physically with GLUT4, and Ca(2+) influx through TRPC3 modulates insulin-mediated glucose uptake. Thus, TRPC3 is a potential target for treatment of insulin-resistant conditions.-Lanner, J. T., Bruton, J. D., Assefaw-Redda, Y., Andronache, Z., Zhang, S.- J., Severa, D., Zhang, Z.- B., Melzer, W., Zhang, S.-L., Katz, A., Westerblad, H. Knockdown of TRPC3 with siRNA coupled to carbon nanotubes results in decreased insulin-mediated glucose uptake in adult skeletal muscle cells. FASEB J. 23, 1728-1738 (2009)	[Lanner, Johanna T.; Bruton, Joseph D.; Zhang, Shi-Jin; Severa, Denise; Katz, Abram; Westerblad, Hakan] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; [Assefaw-Redda, Yohannes; Zhang, Zhi-Bin; Zhang, Shi-Li] Royal Inst Technol, Sch Informat & Commun Technol, Stockholm, Sweden; [Andronache, Zoita; Melzer, Werner] Univ Ulm, Inst Angew Physiol, Ulm, Germany	Karolinska Institutet; Royal Institute of Technology; Ulm University	Lanner, JT (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden.	lanner@bcm.tmc.edu	Tuluc, Petronel/C-2527-2011; Zhang, Zhibin/H-4917-2016; Katz, Abram/AAL-2244-2020	Lanner, Johanna/0000-0002-1222-9473; Bruton, Joseph/0000-0002-6985-099X; Westerblad, Hakan/0000-0002-8180-3029	Swedish Research Council; Biovitrum Partner Fund; Swedish Diabetes Foundation; Karolinska Institutet, Tornspiran; Lars Hierta Memorial Fund	Swedish Research Council(Swedish Research CouncilEuropean Commission); Biovitrum Partner Fund; Swedish Diabetes Foundation; Karolinska Institutet, Tornspiran; Lars Hierta Memorial Fund	We thank Margareta Forsgren, Katrin Bergdahl, Kerstin Larsson, and Christina Sorving for the assistance with RT-PCR analysis. The present study was supported by the Swedish Research Council, the Biovitrum Partner Fund, the Swedish Diabetes Foundation, funds at the Karolinska Institutet, Tornspiran, and the Lars Hierta Memorial Fund.	Albert AP, 2006, J PHYSIOL-LONDON, V571, P361, DOI 10.1113/jphysiol.2005.102780; Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x; Baylor SM, 2003, J PHYSIOL-LONDON, V551, P125, DOI 10.1113/jphysiol.2003.041608; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; Bruton JD, 2001, ACTA PHYSIOL SCAND, V171, P259, DOI 10.1046/j.1365-201x.2001.00828.x; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Cheatham B, 2000, TRENDS ENDOCRIN MET, V11, P356, DOI 10.1016/S1043-2760(00)00308-8; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; Dugani CB, 2005, EMBO REP, V6, P1137, DOI 10.1038/sj.embor.7400584; Dumortier H, 2006, NANO LETT, V6, P1522, DOI 10.1021/nl061160x; Fauconnier J, 2007, CARDIOVASC RES, V73, P376, DOI 10.1016/j.cardiores.2006.10.018; Foster LJ, 2000, AM J PHYSIOL-CELL PH, V279, pC877, DOI 10.1152/ajpcell.2000.279.4.C877; HANDBERG A, 1990, DIABETOLOGIA, V33, P625, DOI 10.1007/BF00400207; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; Inoue G, 1999, P NATL ACAD SCI USA, V96, P14919, DOI 10.1073/pnas.96.26.14919; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kam NWS, 2005, J AM CHEM SOC, V127, P12492, DOI 10.1021/ja053962k; Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Khan AH, 2001, J BIOL CHEM, V276, P4063, DOI 10.1074/jbc.M007419200; Kostarelos K, 2007, NAT NANOTECHNOL, V2, P108, DOI 10.1038/nnano.2006.209; Kraegen EW, 2006, AM J PHYSIOL-ENDOC M, V290, pE471, DOI 10.1152/ajpendo.00316.2005; Kruger J, 2008, NEUROMUSCULAR DISORD, V18, P501, DOI 10.1016/j.nmd.2008.04.003; Kubis HP, 2003, AM J PHYSIOL-CELL PH, V285, pC56, DOI 10.1152/ajpcell.00377.2002; Kwan HY, 2006, J CELL PHYSIOL, V207, P315, DOI 10.1002/jcp.20567; Lanner JT, 2008, CURR OPIN PHARMACOL, V8, P339, DOI 10.1016/j.coph.2008.01.006; Lanner JT, 2006, DIABETES, V55, P2077, DOI 10.2337/db05-1613; Lauritzen HPMM, 2006, DIABETES, V55, P1300, DOI 10.2337/db05-1216; Lee EH, 2006, J BIOL CHEM, V281, P10042, DOI 10.1074/jbc.M600981200; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Li YY, 2007, BIOCHEM BIOPH RES CO, V362, P658, DOI 10.1016/j.bbrc.2007.08.023; LIN S, 1978, P NATL ACAD SCI USA, V75, P329, DOI 10.1073/pnas.75.1.329; Liu YW, 1997, AM J PHYSIOL-CELL PH, V273, pC1915, DOI 10.1152/ajpcell.1997.273.6.C1915; Liu Z, 2007, NAT NANOTECHNOL, V2, P47, DOI 10.1038/nnano.2006.170; LUND S, 1994, AM J PHYSIOL, V267, pE461, DOI 10.1152/ajpendo.1994.267.3.E461; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUNOZ P, 1995, BIOCHEM J, V312, P393, DOI 10.1042/bj3120393; Okada S, 2007, BIOCHEM BIOPH RES CO, V356, P102, DOI 10.1016/j.bbrc.2007.02.095; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Plant TD, 2005, N-S ARCH PHARMACOL, V371, P266, DOI 10.1007/s00210-005-1055-5; Plant TD, 2003, CELL CALCIUM, V33, P441, DOI 10.1016/S0143-4160(03)00055-1; Pramfalk C, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-7; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Sapru MK, 2002, J NEUROSCI METH, V114, P99, DOI 10.1016/S0165-0270(01)00518-0; Schneggenburger R, 2005, CURR OPIN NEUROBIOL, V15, P266, DOI 10.1016/j.conb.2005.05.006; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Smyth JT, 2006, J BIOL CHEM, V281, P11712, DOI 10.1074/jbc.M510541200; Trebak M, 2005, MOL PHARMACOL, V67, P558, DOI 10.1124/mol.104.007252; Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143-4160(03)00056-3; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; Yoshihara M, 2003, CURR OPIN NEUROBIOL, V13, P315, DOI 10.1016/S0959-4388(03)00063-1; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhang YH, 2003, CIRC RES, V92, P765, DOI 10.1161/01.RES.0000065920.64121.FC	69	47	50	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2009	23	6					1728	1738		10.1096/fj.08-116814	http://dx.doi.org/10.1096/fj.08-116814			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19141536				2022-12-28	WOS:000266652400013
J	Li, HQ; Randall, WR; Du, SJ				Li, Huiqing; Randall, William R.; Du, Shao-Jun			skNAC (skeletal Naca), a muscle-specific isoform of Naca (nascent polypeptide-associated complex alpha), is required for myofibril organization	FASEB JOURNAL			English	Article						thick filament; myofibrillogenesis; myosin; sarcomere	TRANSCRIPTION FACTOR; ZEBRAFISH EMBRYOS; SH3 DOMAIN; CARDIAC MYOFIBRILLOGENESIS; SELECTIVE REMOVAL; ELASTIC FILAMENTS; PROTEIN; GENE; EXPRESSION; SEQUENCE	Myofibrillogenesis, the precise assembly of sarcomeric proteins into the highly organized sarcomeres, is essential for muscle cell differentiation and function. Myofibrillogenesis requires proper folding and assembly of newly synthesized sarcomeric proteins. sknac (skeletal naca) is an alternatively spliced isoform of naca, which encodes the nascent polypeptide-associated complex alpha polypeptide that binds to newly synthesized polypeptides emerging from the ribosome. sknac is specifically expressed in skeletal and cardiac muscles. However, little is known about the function of skNAC in muscle development in vivo. To determine skNAC function, we have isolated and characterized the sknac gene from zebrafish. Zebrafish sknac cDNA differs from naca by containing an extra large exon that encodes 815 aa. Knockdown of sknac expression by antisense oligos resulted in zebrafish embryos with skeletal muscle defects. The sknac-knockdown embryos showed a paralyzed phenotype with little muscle contraction. In contrast, injection of a control oligo had no effect. Immunostaining and histological analyses revealed that sknac-knockdown embryos contained disorganized thick and thin filaments. Western blot analysis revealed that myosin protein levels were significantly reduced. Collectively, these results demonstrate that skNAC plays a vital role in myofibril assembly and function during muscle cell differentiation.-Li, H., Randall, W. R., Du, S.-J. skNAC (skeletal Naca), a muscle-specific isoform of Naca (nascent polypeptide-associated complex alpha), is required for myofibril organization in zebrafish embryo. FASEB J. 23, 1988-2000 (2009)	[Li, Huiqing; Du, Shao-Jun] Univ Maryland, Inst Biotechnol, Ctr Marine Biotechnol, Baltimore, MD 21202 USA; [Randall, William R.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21202 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Du, SJ (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Marine Biotechnol, 701 E Pratt St, Baltimore, MD 21202 USA.	dus@umbi.umd.edu		du, Jim/0000-0001-9227-4153	University of Maryland Biotechnology Institute; U.S.-Israel Binational Agricultural Research and Development (BARD) Fund [IS-3703-05]	University of Maryland Biotechnology Institute; U.S.-Israel Binational Agricultural Research and Development (BARD) Fund	We thank Becky Petre and Elena Bernick for editing. This research was supported by a University of Maryland Biotechnology Institute intercenter collaboration grant and by research grant IS-3703-05 from the U.S.-Israel Binational Agricultural Research and Development (BARD) Fund.	Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; DENG JM, 1995, TRANSGENIC RES, V4, P264, DOI 10.1007/BF01969120; Du SJ, 2008, P NATL ACAD SCI USA, V105, P554, DOI 10.1073/pnas.0707330105; Du SJ, 2006, DEV DYNAM, V235, P3306, DOI 10.1002/dvdy.20984; Du SJ, 2001, DEV DYNAM, V222, P655, DOI 10.1002/dvdy.1219; Du SJ, 1997, J CELL BIOL, V139, P145, DOI 10.1083/jcb.139.1.145; Etard C, 2007, DEV BIOL, V308, P133, DOI 10.1016/j.ydbio.2007.05.014; FUNATSU T, 1993, J CELL BIOL, V120, P711, DOI 10.1083/jcb.120.3.711; FUNATSU T, 1990, J CELL BIOL, V110, P53, DOI 10.1083/jcb.110.1.53; Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866; HANDEL SE, 1991, CELL TISSUE RES, V263, P419, DOI 10.1007/BF00327276; Hawkins TA, 2008, DEVELOPMENT, V135, P1147, DOI 10.1242/dev.018150; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; KOMIYAMA M, 1993, DEV DYNAM, V196, P291, DOI 10.1002/aja.1001960412; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; Liu L, 2008, J BIOL CHEM, V283, P13185, DOI 10.1074/jbc.M800757200; Lopez S, 2005, J CELL SCI, V118, P1595, DOI 10.1242/jcs.02295; Moreau A, 1998, MOL CELL BIOL, V18, P1312, DOI 10.1128/MCB.18.3.1312; Munz B, 1999, J BIOL CHEM, V274, P13305, DOI 10.1074/jbc.274.19.13305; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Raeker MO, 2006, DEV DYNAM, V235, P2018, DOI 10.1002/dvdy.20812; Robu ME, 2007, PLOS GENET, V3, P787, DOI 10.1371/journal.pgen.0030078; Roy S, 2001, GENE DEV, V15, P1563, DOI 10.1101/gad.195801; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sanger JW, 2002, CLIN ORTHOP RELAT R, pS153, DOI 10.1097/01.blo.0000031973.69509.21; Schoenauer R, 2005, J MOL BIOL, V349, P367, DOI 10.1016/j.jmb.2005.03.055; SHI XM, 1995, GENE, V165, P199, DOI 10.1016/0378-1119(95)00577-S; Sims RJ, 2002, J BIOL CHEM, V277, P26524, DOI 10.1074/jbc.M204121200; Srikakulam R, 2004, J CELL SCI, V117, P641, DOI 10.1242/jcs.00899; Tan XG, 2006, P NATL ACAD SCI USA, V103, P2713, DOI 10.1073/pnas.0509503103; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; Wang QH, 2007, PROTEIN SCI, V16, P189, DOI 10.1110/ps.062496807; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WANG SM, 1988, J CELL BIOL, V107, P1075, DOI 10.1083/jcb.107.3.1075; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Yotov WV, 1996, GENE DEV, V10, P1763, DOI 10.1101/gad.10.14.1763; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	39	18	19	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1988	2000		10.1096/fj.08-125542	http://dx.doi.org/10.1096/fj.08-125542			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19211926				2022-12-28	WOS:000266652400037
J	Ziemba, SE; Menard, SL; McCabe, MJ; Rosenspire, AJ				Ziemba, Stamatina E.; Menard, Sherri L.; McCabe, Michael J., Jr.; Rosenspire, Allen J.			T-cell receptor signaling is mediated by transient Lck activity, which is inhibited by inorganic mercury	FASEB JOURNAL			English	Article						Hg2+; ZAP-70; lymphocyte; signal transduction	TYROSINE PROTEIN-KINASE; INDUCED AUTOIMMUNITY; SH2 DOMAIN; ACTIVATION; PHOSPHORYLATION; ZAP-70; MECHANISM; LAT; TCR; TRANSDUCTION	Genetically susceptible rodents exposed to low nontoxic levels of inorganic mercury (Hg2+) develop idiosyncratic autoimmune disease associated with defective T-cell function. However, the molecular mechanisms underlying this phenomenon remain mostly unexplained. Brief exposure of T cells to micromolar concentrations of Hg2+ leads to physiologically relevant nontoxic cellular mercury burdens, and as we have previously reported, attenuates T-cell receptor (TCR) signal strength by similar to 50%. We have found this to be the result of an inadequate activation of the tyrosine kinase ZAP-70, which is hypophosphorylated following TCR stimulation in Hg2+ burdened cells when compared to untreated controls. In T cells, ZAP-70 phosphorylation is dependent on lymphocyte-specific protein tyrosine kinase (Lck) activity, which in turn is either positively or negatively regulated by the phosphorylation of specific Lck tyrosine residues. In particular, the general belief is that Lck is negatively regulated by phosphorylation of tyrosine 192 (Y192). We now demonstrate by Western blotting that, in Jurkat T cells, TCR signal transduction (and ZAP-70 phosphorylation) was positively associated with a rapid transient phosphorylation of Y192, which was inhibited in cells that were briefly (5 min) exposed to 5 mu M Hg2+. Thus, Hg2+ inhibits a critical activating role played by Lck Y192 during the most proximal events of the TCR-induced cell signaling.-Ziemba, S. E., Menard, S. L., McCabe, Jr., M. J., Rosenspire, A.J.T-cell receptor signaling is mediated by transient Lck activity, which is inhibited by inorganic mercury. FASEB J. 23, 1663-1671 (2009)	[Ziemba, Stamatina E.; Menard, Sherri L.; Rosenspire, Allen J.] Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA; [McCabe, Michael J., Jr.] Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY USA	Wayne State University; University of Rochester	Rosenspire, AJ (corresponding author), Wayne State Univ, Sch Med, Dept Immunol & Microbiol, 221 Lande Res Bldg, Detroit, MI 48201 USA.	arosenspire@wayne.edu			NIH [ES11000, ES12403, ES01247]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012403, R01ES011000, P30ES001247] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by NIH grants ES11000, ES12403 and ES01247.	Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; Akhand AA, 1998, J CELL BIOCHEM, V71, P243, DOI 10.1002/(SICI)1097-4644(19981101)71:2<243::AID-JCB9>3.0.CO;2-V; Bagenstose LM, 1998, J IMMUNOL, V160, P1612; Bernier J, 1995, ENVIRON HEALTH PERSP, V103, P23, DOI 10.2307/3432720; BOLLAG AG, 1991, PROTEIN METHODS; Bommhardt U, 2000, J IMMUNOL, V164, P2326, DOI 10.4049/jimmunol.164.5.2326; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdicka T, 2005, MOL CELL BIOL, V25, P4924, DOI 10.1128/MCB.25.12.4924-4933.2005; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; Daniels MA, 2006, NATURE, V444, P724, DOI 10.1038/nature05269; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FRANKLIN RA, 1994, J CLIN INVEST, V93, P2134, DOI 10.1172/JCI117209; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Hansson M, 2004, SCAND J IMMUNOL, V59, P469, DOI 10.1111/j.0300-9475.2004.01415.x; Havarinasab S, 2005, AUTOIMMUN REV, V4, P270, DOI 10.1016/j.autrev.2004.12.001; Holdorf AD, 2002, NAT IMMUNOL, V3, P259, DOI 10.1038/ni761; Hong R, 1999, MUTAT RES-FUND MOL M, V428, P109, DOI 10.1016/S1383-5742(99)00038-1; Hu H, 1999, IMMUNOLOGY, V96, P348; Huang YP, 2004, J BIOL CHEM, V279, P28827, DOI 10.1074/jbc.R400012200; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kazantzis G, 2002, Med Lav, V93, P139; KEVORKIAN J, 1972, AM J PUBLIC HEALTH N, V62, P504, DOI 10.2105/AJPH.62.4.504; Kishimoto H, 2000, CLIN IMMUNOL, V95, pS3, DOI 10.1006/clim.1999.4818; LoGrasso PV, 1996, P NATL ACAD SCI USA, V93, P12165, DOI 10.1073/pnas.93.22.12165; Lysechko TL, 2005, J IMMUNOL, V174, P7807, DOI 10.4049/jimmunol.174.12.7807; Mattingly RR, 2001, TOXICOL APPL PHARM, V176, P162, DOI 10.1006/taap.2001.9272; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Parashar A, 1999, FREE RADICAL BIO MED, V26, P227, DOI 10.1016/S0891-5849(98)00169-5; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Pitcher LA, 2003, J IMMUNOL, V171, P845, DOI 10.4049/jimmunol.171.2.845; RAHMAN SMJ, 1993, FEBS LETT, V317, P35, DOI 10.1016/0014-5793(93)81486-J; SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5; SOULA M, 1993, J BIOL CHEM, V268, P27420; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zheng Y, 2003, J IMMUNOL, V171, P1596, DOI 10.4049/jimmunol.171.3.1596; Ziemba SE, 2006, TOXICOL SCI, V89, P145, DOI 10.1093/toxsci/kfj029	45	12	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1663	1671		10.1096/fj.08-117283	http://dx.doi.org/10.1096/fj.08-117283			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19168706	Green Published			2022-12-28	WOS:000266652400006
J	Bascove, M; Huin-Schohn, C; Gueguinou, N; Tschirhart, E; Frippiat, JP				Bascove, Matthieu; Huin-Schohn, Cecile; Gueguinou, Nathan; Tschirhart, Eric; Frippiat, Jean-Pol			Spaceflight-associated changes in immunoglobulin VH gene expression in the amphibian Pleurodeles waltl	FASEB JOURNAL			English	Article						microgravity; B lymphocytes; selection; immune response; antibodies	GAMMA-IRRADIATION; LEUKOCYTE SUBSETS; HEAVY-CHAIN; STRESS; MOUSE; MICROGRAVITY; SENSITIVITY; ANTIBODIES; PHYSIOLOGY; POSITION	Understanding why the immune system is depressed during spaceflight is of obvious importance for future human deep-space missions, such as the foreseen missions to Mars. However, little is known about the effects of these flights on humoral immunity. We previously immunized adult Pleurodeles waltl (urodele amphibian) onboard the Mir space station and showed that heavy-chain variable (VH) domains of specific IgM antibodies are encoded by genes belonging to the VHII and VHVI families. We have now determined how these animals use their individual VHII and VHVI genes by screening IgM heavy-chain cDNA libraries and by quantifying IgM heavy-chain transcripts encoded by these genes. Results were compared with those obtained using control animals immunized on Earth under the same conditions as onboard Mir. Our experiments revealed an increase in the expression of IgM heavy-chain mRNAs encoded by the VHII and VHVI. C genes and a strong decrease in the expression of IgM heavy-chain mRNAs encoded by the VHVI. A and VHVI. B genes in spaceflight animals. Consequently, different heavy-chain mRNAs are expressed by spaceflight animals, demonstrating that this environment affects the humoral response. These observations may be due to a change in B-cell selection under spaceflight conditions. Bascove, M., Huin-Schohn, C., Gueguinou, N., Tschirhart, E., Frippiat, J.-P. Spaceflight-associated changes in immunoglobulin VH gene expression in the amphibian Pleurodeles waltl. FASEB J. 23, 1607-1615 (2009)	[Bascove, Matthieu; Huin-Schohn, Cecile; Gueguinou, Nathan; Frippiat, Jean-Pol] Nancy Univ, EA 3442, Lab Expt Biol & Immunol, Dev & Immunogenet Grp, F-54506 Vandoeuvre Les Nancy, France; [Huin-Schohn, Cecile; Tschirhart, Eric] Univ Luxembourg, Life Sci Res Unit, Luxembourg, Luxembourg	Universite de Lorraine; University of Luxembourg	Frippiat, JP (corresponding author), Nancy Univ, EA 3442, Lab Expt Biol & Immunol, Dev & Immunogenet Grp, Blvd Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	jean-pol.frippiat@scbiol.uhp-nancy.fr		Frippiat, Jean-Pol/0000-0002-4027-6269	Centre National d'Etudes Spatiales; European Space Agency; Ministere de l'Enseignement Superieur et de la Recherche; Nancy-University; Lorraine Region; University of Luxembourg	Centre National d'Etudes Spatiales(Centre National D'etudes Spatiales); European Space Agency(European Space AgencyEuropean Commission); Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); Nancy-University; Lorraine Region(Region Grand-Est); University of Luxembourg	We thank the French cosmonaut J.-P. Haignere for performing the Genesis experiment onboard the Mir space station, N. Touche for helpful discussions, the Centre National d'Etudes Spatiales, the European Space Agency, the Ministere de l'Enseignement Superieur et de la Recherche, Nancy-University, the Lorraine Region, and the University of Luxembourg for their financial support. M. B. is supported by the Ministere de l'Enseignement Superieur et de la Recherche, and C.H.-S. is supported by the Ministry of Culture, Higher Education, and Research of Luxembourg.	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ALLEBBAN Z, 1994, J LEUKOCYTE BIOL, V55, P209, DOI 10.1002/jlb.55.2.209; BAILLY S, 1973, CR ACAD SCI D NAT, V276, P1867; BENNETT MF, 1983, J COMP PHYSIOL, V153, P81, DOI 10.1007/BF00610345; BIRNSTEIN VJ, 1983, J MOL EVOL, V18, P73; Borchers AT, 2002, NUTRITION, V18, P889, DOI 10.1016/S0899-9007(02)00913-9; Bouic PJD, 1999, INT J SPORTS MED, V20, P258, DOI 10.1055/s-2007-971127; Boxio R, 2005, J APPL PHYSIOL, V98, P905, DOI 10.1152/japplphysiol.00957.2004; BRODEUR PH, 1984, EUR J IMMUNOL, V14, P922, DOI 10.1002/eji.1830141012; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; Cogoli-Greuter M., 2004, GRAV SPACE BIO B, V17, P27; Collis AVJ, 2003, J MOL BIOL, V325, P337, DOI 10.1016/S0022-2836(02)01222-6; Courtade M, 2001, INT J RADIAT BIOL, V77, P587, DOI 10.1080/09553000110034621; Dournon C, 2003, ADV SPACE B, V9, P101, DOI 10.1016/S1569-2574(03)09005-1; Frippiat C, 2001, IMMUNOGENETICS, V52, P264; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Glaser R, 2000, PSYCHOSOM MED, V62, P804, DOI 10.1097/00006842-200011000-00010; GOULD CL, 1987, AVIAT SPACE ENVIR MD, V58, P983; Gridley DS, 2008, IN VIVO, V22, P159; Gridley DS, 2002, IMMUNOL LETT, V80, P55, DOI 10.1016/S0165-2478(01)00306-6; GROVE DS, 1995, EXP CELL RES, V219, P102, DOI 10.1006/excr.1995.1210; Heppener M, 2008, EMBO REP, V9, pS4, DOI 10.1038/embor.2008.98; Jacobs H, 2001, CURR OPIN IMMUNOL, V13, P208, DOI 10.1016/S0952-7915(00)00206-5; Kimzey SL, 1977, BIOMEDICAL RESULTS S, P248; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KONSTANTINOVA IV, 1993, J LEUKOCYTE BIOL, V54, P189, DOI 10.1002/jlb.54.3.189; Lefranc MP, 1999, HUM GENET, V104, P361, DOI 10.1007/s004390050969; Morey-Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001; O'Donnell PM, 2009, STRESS, V12, P82, DOI 10.1080/10253890802049269; Pecaut MJ, 2006, RADIAT RES, V165, P68, DOI 10.1667/RR3493.1; Pecaut MJ, 2003, J APPL PHYSIOL, V94, P2085, DOI 10.1152/japplphysiol.01052.2002; Pecaut MJ, 2001, IN VIVO, V15, P195; Schaerlinger B, 2008, DEV COMP IMMUNOL, V32, P908, DOI 10.1016/j.dci.2008.01.001; Schaerlinger B, 2008, MOL IMMUNOL, V45, P776, DOI 10.1016/j.molimm.2007.06.356; Sonnenfeld G, 2002, NUTRITION, V18, P899, DOI 10.1016/S0899-9007(02)00903-6; SONNENFELD G, 1992, J APPL PHYSIOL, V73, pS191, DOI 10.1152/jappl.1992.73.2.S191; Sonnenfeld Gerald, 2003, Rev Environ Health, V18, P1; Stowe RP, 1999, J LEUKOCYTE BIOL, V65, P179, DOI 10.1002/jlb.65.2.179; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Vernikos J, 1996, BIOESSAYS, V18, P1029, DOI 10.1002/bies.950181215; Veynachter L, 2002, SCAND J LAB ANIM SCI, V29, P100; VOSS EW, 1984, SCIENCE, V225, P214, DOI 10.1126/science.6729476; WILSON M, 1992, EMBO J, V11, P4337, DOI 10.1002/j.1460-2075.1992.tb05533.x; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102	46	32	34	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1607	1615		10.1096/fj.08-121327	http://dx.doi.org/10.1096/fj.08-121327			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19141535				2022-12-28	WOS:000266651700035
J	Venkatesan, N; Barre, L; Magdalou, J; Mainard, D; Netter, P; Fournel-Gigleux, S; Ouzzine, M				Venkatesan, Narayanan; Barre, Lydia; Magdalou, Jacques; Mainard, Didier; Netter, Patrick; Fournel-Gigleux, Sylvie; Ouzzine, Mohamed			Modulation of xylosyltransferase I expression provides a mechanism regulating glycosaminoglycan chain synthesis during cartilage destruction and repair	FASEB JOURNAL			English	Article						glycosyltransferases; proteoglycans; regulation; gene silencing	GROWTH-FACTOR-BETA; CAENORHABDITIS-ELEGANS; THERAPEUTIC STRATEGIES; PROTEOGLYCAN SYNTHESIS; RHEUMATOID-ARTHRITIS; ARTICULAR-CARTILAGE; PROTEIN-KINASE; KEY ENZYME; CROSS-TALK; TGF-BETA	Osteoarthritis and rheumatoid arthritis are characterized by loss of proteoglycans (PGs) and their glycosaminoglycan (GAG) chains that are essential for cartilage function. Here, we investigated the role of glycosyltransferases (GTs) responsible for PG-GAG chain assembly during joint cartilage destruction and repair processes. At various times after antigen-induced arthritis (AIA) and papain-induced cartilage repair in rats, PG synthesis and deposition, expression of GTs, and GAG chain composition were analyzed. Our data showed that expression of the GT xylosyltransferase I (XT-I) gene initiating PG-GAG chain synthesis was significantly reduced in AIA rat cartilage and was associated with a decrease in PG synthesis. Interestingly, interleukin-1 beta, the main proinflammatory cytokine incriminated in joint diseases, down-regulated the XT-I gene expression with a concomitant decrease in PG synthesis in rat cartilage explants ex vivo. However, cartilage from papain-injected rat knees showed up-regulation of XT-I gene expression and increased PG synthesis at early stages of cartilage repair, a process associated with up-regulation of TGF-beta 1 gene expression and mediated by p38 mitogen-activated protein kinase activation. Consistently, silencing of XT-I expression by intraarticular injection of XT-I shRNA in rat knees prevented cartilage repair by decreasing PG synthesis and content. These findings show that GTs play a key role in the loss of PG-GAGs in joint diseases and identify novel targets for stimulating cartilage repair.-Venkatesan, N., Barre, L., Magdalou, J., Mainard, D., Netter, P., Fournel-Gigleux, S., Ouzzine, M. Modulation of xylosyltransferase I expression provides a mechanism regulating glycosaminoglycan chain synthesis during cartilage destruction and repair. FASEB J. 23, 813-822 (2009)	[Venkatesan, Narayanan; Barre, Lydia; Magdalou, Jacques; Mainard, Didier; Netter, Patrick; Fournel-Gigleux, Sylvie; Ouzzine, Mohamed] Univ Nancy 1, CNRS, UMR 7561, Fac Med, F-54505 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Ouzzine, M (corresponding author), Univ Nancy 1, CNRS, UMR 7561, Fac Med, BP 184, F-54505 Vandoeuvre Les Nancy, France.	ouzzine@medecine.uhp-nancy.fr	Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950	Institut National de la Sante et de la Recherche Medicale; Agence Nationale de la Recherche (ANR) [BLAN08-3_313970]; Ligue Regionale contre le Cancer; Contrat de Programme de Recherche Clinique; Programme Hospitalier de Recherche Clinique Centre Hospitalier Universitaire Nancy	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Ligue Regionale contre le Cancer(Ligue nationale contre le cancer); Contrat de Programme de Recherche Clinique; Programme Hospitalier de Recherche Clinique Centre Hospitalier Universitaire Nancy	This work was supported by the Programme National de Recherches sur les Maladies Osteo-Articulaire from the Institut National de la Sante et de la Recherche Medicale, The Agence Nationale de la Recherche (ANR BLAN08-3_313970), the Ligue Regionale contre le Cancer, the Contrat de Programme de Recherche Clinique, and the Programme Hospitalier de Recherche Clinique Centre Hospitalier Universitaire Nancy. We thank Pr. M. W. H. Coughtrie for critical reading of the manuscript.	Barre L, 2006, FASEB J, V20, P1692, DOI 10.1096/fj.05-5073fje; Blom AB, 2007, CURR DRUG TARGETS, V8, P283, DOI 10.2174/138945007779940179; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; Calabro A, 2000, GLYCOBIOLOGY, V10, P283, DOI 10.1093/glycob/10.3.283; CSSZABO G, 1995, ARTHRITIS RHEUM, V38, P660, DOI 10.1002/art.1780380514; Davidson ENB, 2007, OSTEOARTHR CARTILAGE, V15, P597, DOI 10.1016/j.joca.2007.02.005; Dinarello CA, 2004, CURR OPIN PHARMACOL, V4, P378, DOI 10.1016/j.coph.2004.03.010; Feldmann M, 2001, CURR DIRECT AUTOIMMU, V3, P188; Firestein G.S, 1997, TXB RHEUMATOLOGY, P851; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; Gouze JN, 2001, ARTHRITIS RHEUM, V44, P351, DOI 10.1002/1529-0131(200102)44:2<351::AID-ANR53>3.3.CO;2-D; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Koenders MI, 2005, AM J PATHOL, V167, P141, DOI 10.1016/S0002-9440(10)62961-6; Little CB, 2007, J CLIN INVEST, V117, P1627, DOI 10.1172/JCI30765; LOO FA, 1992, J RHEUMATOL, V19, P348; Lubberts E, 1999, J IMMUNOL, V163, P4546; MANKIN HJ, 1971, J CLIN INVEST, V50, P1712, DOI 10.1172/JCI106660; Martel-Pelletier J, 2001, BEST PRACT RES CL RH, V15, P805, DOI 10.1053/berh.2001.0195; Poole AR, 2007, OSTEOARTHR DIAGN MED, V4, P27; Prante C, 2007, J BIOL CHEM, V282, P26441, DOI 10.1074/jbc.M702299200; Roughley PJ, 2006, EUR CELLS MATER, V12, P92, DOI 10.22203/eCM.v012a11; Saklatvala J, 2007, CURR DRUG TARGETS, V8, P305, DOI 10.2174/138945007779940115; SANDY JD, 1984, ARTHRITIS RHEUM, V27, P388, DOI 10.1002/art.1780270405; SCHWARTZ ER, 1981, ARTHRITIS RHEUM-US, V24, P1528, DOI 10.1002/art.1780241212; Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109; Studer RK, 2005, J ORTHOP RES, V23, P454, DOI 10.1016/j.orthres.2004.08.012; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; THOMPSON RC, 1979, J BONE JOINT SURG AM, V61, P407, DOI 10.2106/00004623-197961030-00017; Tuli R, 2003, J BIOL CHEM, V278, P41227, DOI 10.1074/jbc.M305312200; vanderKraan PM, 1997, J RHEUMATOL, V24, P543; Venkatesan N, 2004, P NATL ACAD SCI USA, V101, P18087, DOI 10.1073/pnas.0404504102; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; YOSHINO S, 1995, CELL IMMUNOL, V163, P55, DOI 10.1006/cimm.1995.1098	33	24	24	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					813	822		10.1096/fj.08-118166	http://dx.doi.org/10.1096/fj.08-118166			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19001053				2022-12-28	WOS:000265506300017
J	Pawlak, J; Mackessy, SP; Sixberry, NM; Stura, EA; Le Du, MH; Menez, R; Foo, CS; Menez, A; Nirthanan, S; Kini, RM				Pawlak, Joanna; Mackessy, Stephen P.; Sixberry, Nicole M.; Stura, Enrico A.; Le Du, Marie Helene; Menez, Renee; Foo, Chun Shin; Menez, Andre; Nirthanan, Selvanayagam; Kini, R. Manjunatha			Irditoxin, a novel covalently linked heterodimeric three-finger toxin with high taxon-specific neurotoxicity	FASEB JOURNAL			English	Article						postsynaptic neurotoxin; acetylcholine receptor; neuromuscular junction; snake venom	NICOTINIC ACETYLCHOLINE-RECEPTORS; CRYSTAL-STRUCTURE; MOLECULAR EVOLUTION; BUNGARUS-CANDIDUS; COLUBRID SNAKES; COBRA VENOM; EXPRESSION; CLONING; COMPLEX; IDENTIFICATION	A novel heterodimeric three-finger neurotoxin, irditoxin, was isolated from venom of the brown treesnake Boiga irregularis (Colubridae). Irditoxin subunit amino acid sequences were determined by Edman degradation and cDNA sequencing. The crystal structure revealed two subunits with a three-finger protein fold, typical for "nonconventional" toxins such as denmotoxin, bucandin, and candoxin. This is the first colubrid three-finger toxin dimer, covalently connected via an interchain disulfide bond. Irditoxin showed taxon-specific lethality toward birds and lizards and was nontoxic toward mice. It produced a potent neuromuscular blockade at the avian neuromuscular junction (IC50 = 10 nM), comparable to alpha-bungarotoxin, but was three orders of magnitude less effective at the mammalian neuromuscular junction. Covalently linked heterodimeric three-finger toxins found in colubrid venoms constitute a new class of venom peptides, which may be a useful source of new neurobiology probes and therapeutic leads. - Pawlak, J., Mackessy, S. P., Sixberry, N. M., Stura, E. A., Le Du, M. H., Menez, R., Foo, C. S., Menez, A., Nirthanan, S., Kini, R. M. Irditoxin, a novel covalently linked heterodimeric three-finger toxin with high taxon-specific neurotoxicity. FASEB J. 23, 534-545 (2009)	[Kini, R. Manjunatha] Natl Univ Singapore, Dept Biol Sci, Fac Sci, Prot Sci Lab, Singapore 117543, Singapore; [Mackessy, Stephen P.; Sixberry, Nicole M.] Univ No Colorado, Sch Biol Sci, Greeley, CO 80639 USA; [Stura, Enrico A.; Le Du, Marie Helene; Menez, Renee; Menez, Andre] CEA, Dept Ingn & Etud Prot, Gif Sur Yvette, France; [Foo, Chun Shin; Nirthanan, Selvanayagam] Natl Inst Neurosci, Neuropharmacol & Lead Discovery Lab, Singapore, Singapore; [Kini, R. Manjunatha] Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	National University of Singapore; University of Northern Colorado; CEA; UDICE-French Research Universities; Universite Paris Saclay; National Neuroscience Institute (NNI); Virginia Commonwealth University	Kini, RM (corresponding author), Natl Univ Singapore, Dept Biol Sci, Fac Sci, Prot Sci Lab, Sci Dr 4, Singapore 117543, Singapore.	dbskinim@nus.edu.sg	Mackessy, Stephen/GPT-0793-2022; Kini, Manjunatha/H-8029-2012; Nirthanan, Selvanayagam/ABI-4281-2020; Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; Kini, Manjunatha/0000-0002-6100-3251; Mackessy, Stephen/0000-0003-4515-2545; Nirthanan, S. Niru/0000-0001-9888-8447	Biomedical Research Council (BMRC), Agency for Science and Technology, Singapore [01/1/21/18/072, 07/1/21/19/490, 06/1/33/19/481]; U.S. Geological Service Biological Resources Division [00CRAG0014]	Biomedical Research Council (BMRC), Agency for Science and Technology, Singapore(Agency for Science Technology & Research (A*STAR)); U.S. Geological Service Biological Resources Division	This manuscript is dedicated to the memory of our esteemed colleague and friend, Professor A. Menez. We thank W. H. Heyborne for assistance during purification and toxicity assays; F. Qualls and C. Terrell for assistance in obtaining snakes from Guam, and the Guam Department of Natural Resources for export permits for brown treesnakes; C. Fruchart-Gaillard, D. Servent and other employees of DIEP (CEA) for their counsel and invaluable help. This work was supported by research grants from the Biomedical Research Council (BMRC), Agency for Science and Technology, Singapore, to R.M.K. (BMRC grants 01/1/21/18/072 and 07/1/21/19/490) and S.N. (BMRC grant 06/1/33/19/481) and from the U.S. Geological Service Biological Resources Division to S.P.M. (grant 00CRAG0014).	Afifiyan F, 1998, TOXICON, V36, P1871, DOI 10.1016/S0041-0101(98)00108-1; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; Arredondo J, 2006, J CELL PHYSIOL, V208, P238, DOI 10.1002/jcp.20661; Banerjee Y, 2005, J BIOL CHEM, V280, P42601, DOI 10.1074/jbc.M508987200; BARCHAN D, 1992, P NATL ACAD SCI USA, V89, P7717, DOI 10.1073/pnas.89.16.7717; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Chiappinelli VA, 1996, TOXICON, V34, P1243, DOI 10.1016/S0041-0101(96)00110-9; Chimienti F, 2003, HUM MOL GENET, V12, P3017, DOI 10.1093/hmg/ddg320; Daltry JC, 1996, NATURE, V379, P537, DOI 10.1038/379537a0; Dellisanti CD, 2007, NAT NEUROSCI, V10, P953, DOI 10.1038/nn1942; DEWAN JC, 1994, BIOCHEMISTRY-US, V33, P13147, DOI 10.1021/bi00248a026; DUFTON MJ, 1988, PHARMACOL THERAPEUT, V36, P1, DOI 10.1016/0163-7258(88)90111-8; Endo T., 1991, P165; Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899; Fry BG, 2003, J MOL EVOL, V57, P446, DOI 10.1007/s00239-003-2497-3; Fry BG, 2003, RAPID COMMUN MASS SP, V17, P2047, DOI 10.1002/rcm.1148; Fry BG, 2003, J MOL EVOL, V57, P110, DOI 10.1007/s00239-003-2461-2; Fry BG, 2008, MOL CELL PROTEOMICS, V7, P215, DOI 10.1074/mcp.M700094-MCP200; Hill RE, 2000, TOXICON, V38, P1663, DOI 10.1016/S0041-0101(00)00091-X; Hill RE, 1997, TOXICON, V35, P671, DOI 10.1016/S0041-0101(96)00174-2; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Ibanez-Tallon I, 2002, NEURON, V33, P893, DOI 10.1016/S0896-6273(02)00632-3; Junqueira-de-Azevedo ILM, 2006, GENETICS, V173, P877, DOI 10.1534/genetics.106.056515; Kini RM, 2002, CLIN EXP PHARMACOL P, V29, P815, DOI 10.1046/j.1440-1681.2002.03725.x; Lewis RJ, 2003, NAT REV DRUG DISCOV, V2, P790, DOI 10.1038/nrd1197; Mackessy SP, 2006, TOXICON, V47, P537, DOI 10.1016/j.toxicon.2006.01.007; Mackessy SP, 2002, J TOXICOL-TOXIN REV, V21, P43, DOI 10.1081/TXR-120004741; MENEZ A, 1980, BIOCHEMISTRY-US, V19, P4166, DOI 10.1021/bi00559a005; MENEZ A, 1984, J PHYSIOLOGY PARIS, V79, P196; Miwa JM, 1999, NEURON, V23, P105, DOI 10.1016/S0896-6273(00)80757-6; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nirthanan S, 2003, TOXICON, V41, P397, DOI 10.1016/S0041-0101(02)00388-4; Nirthanan S, 2002, J BIOL CHEM, V277, P17811, DOI 10.1074/jbc.M111152200; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; Osipov AV, 2008, J BIOL CHEM, V283, P14571, DOI 10.1074/jbc.M802085200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pahari S, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-175; Pahari S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-115; Pawlak J, 2006, J BIOL CHEM, V281, P29030, DOI 10.1074/jbc.M605850200; Pawlak J, 2006, TOXICON, V48, P278, DOI 10.1016/j.toxicon.2006.05.013; Poh SL, 2002, EUR J BIOCHEM, V269, P4247, DOI 10.1046/j.1432-1033.2002.03113.x; Rajagopalan N, 2007, FASEB J, V21, P3685, DOI 10.1096/fj.07-8658com; Ricciardi A, 2000, J BIOL CHEM, V275, P18302, DOI 10.1074/jbc.275.24.18302; SMITH LA, 1990, J TOXICOL-TOXIN REV, V9, P243, DOI 10.3109/15569549009033116; TAMIYA T, 1985, BIOCHIMIE, V67, P185, DOI 10.1016/S0300-9084(85)80046-8; Teixeira-Clerc F, 2002, J BIOL CHEM, V277, P25741, DOI 10.1074/jbc.M200534200; Torres AM, 2001, BIOCHEM J, V360, P539, DOI 10.1042/0264-6021:3600539; VON HG, 1986, NUCLEIC ACIDS RES, V14, P4683	49	140	144	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					534	545		10.1096/fj.08-113555	http://dx.doi.org/10.1096/fj.08-113555			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18952712				2022-12-28	WOS:000262892900025
J	Fan, CY; Huang, CC; Chiu, WC; Lai, CC; Liou, GG; Li, HC; Chou, MY				Fan, Chia-Yu; Huang, Chuan-Chuan; Chiu, Wei-Chun; Lai, Chun-Chieh; Liou, Gunn-Guang; Li, Hsiu-Chuan; Chou, Min-Yuan			Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold	FASEB JOURNAL			English	Article						phage-display; single-chain antibody; EGFR; CD3	TRIPLE-HELIX FORMATION; SINGLE-CHAIN; ANTIBODY; ANTI-CD3; AFFINITY; ANTIGEN; HYDROXYPROLINE; TRANSITION; NUCLEATION; THERAPY	A class of multivalent protein binders was designed to overcome the limitations of low-affinity therapeutic antibodies. These binders, termed "collabodies," use a triplex-forming collagen-like peptide to drive the trimerization of a heterologous target-binding domain. Different forms of collabody, consisting of the human single-chain variable fragment ( scFv) fused to either the N or C terminus of the collagen-like peptide scaffold (Gly-Pro-Pro) 10, were stably expressed as soluble secretory proteins in mammalian cells. The collabody consisting of scFv fused to the N terminus of collagen scaffold is present as a homotrimer, whereas it exhibited a mixture of trimer and interchain disulfide-bonded hexamer when cysteine residues were introduced and flanked the scaffold. The collagenous motif in collabody is prolyl-hydroxylated, with remarkable thermal and serum stabilities. The collabody erb_scFvCol bound to the extracellular domain of epidermal growth factor receptor with a binding strength similar to 20- and 1000-fold stronger than the bivalent and monovalent counterparts, respectively. The trimeric collagen scaffold does not compromise the functionality of the binding moieties of parental immunoglobulin G (IgG); therefore, it could be applied to fuse other protein molecules to acquire significantly improved targeting-binding strengths.-Fan, C.-Y., Huang, C.-C., Chiu, W.-C., Lai, C.-C., Liou, G.-G., Li, H.-C., and Chou, M.-Y. Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold. FASEB J. 22, 3795-3804 (2008)	[Fan, Chia-Yu; Huang, Chuan-Chuan; Chiu, Wei-Chun; Li, Hsiu-Chuan; Chou, Min-Yuan] Ind Technol Res Inst, Biomed Engn Res Labs, Hsinchu 310, Taiwan; [Lai, Chun-Chieh; Liou, Gunn-Guang] Natl Hlth Res Inst, Div Mol & Genom Med, Taipei, Taiwan	Industrial Technology Research Institute - Taiwan; National Health Research Institutes - Taiwan	Chou, MY (corresponding author), Ind Technol Res Inst, Biomed Engn Res Labs, Bldg 53,195,Sec 4,Chung Hsing Rd, Hsinchu 310, Taiwan.	minyuanc@itri.org.tw	Liou, Gan-Guang/E-3976-2010; Liou, Gunn‐Guang/AAI-9787-2020		Ministry of Economic Affairs [7301XS5410]	Ministry of Economic Affairs	We thank Tsan-Lin Hu for conducting the pharmacokinetic analysis. This work was funded by the Ministry of Economic Affairs, grant 7301XS5410.	Adair John R., 1994, Human Antibodies and Hybridomas, V5, P41; Arakawa F, 1996, J BIOCHEM, V120, P657; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962; Boudko S, 2002, J MOL BIOL, V317, P459, DOI 10.1006/jmbi.2002.5439; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOPRA RK, 1982, P NATL ACAD SCI-BIOL, V79, P7180, DOI 10.1073/pnas.79.23.7180; Chou MY, 2002, GENOMICS, V79, P395, DOI 10.1006/geno.2002.6712; Cole MS, 1997, J IMMUNOL, V159, P3613; de Wildt RMT, 2000, NAT BIOTECHNOL, V18, P989, DOI 10.1038/79494; DUBEL S, 1995, J IMMUNOL METHODS, V178, P201, DOI 10.1016/0022-1759(94)00257-W; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; Frank S, 2003, J BIOL CHEM, V278, P7747, DOI 10.1074/jbc.C200698200; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; Graversen JH, 2000, J BIOL CHEM, V275, P37390, DOI 10.1074/jbc.M004873200; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Kabat EA, 1991, SEQUENCES PROTEINS I; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Li HC, 2005, BIOCHEM BIOPH RES CO, V336, P375, DOI 10.1016/j.bbrc.2005.08.018; Li J, 2006, INT IMMUNOPHARMACOL, V6, P880, DOI 10.1016/j.intimp.2005.12.009; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; Mazzorana M, 2001, J BIOL CHEM, V276, P27989, DOI 10.1074/jbc.M101633200; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; Rheinnecker M, 1996, J IMMUNOL, V157, P2989; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; ROSENBLO.J, 1973, ARCH BIOCHEM BIOPHYS, V158, P478, DOI 10.1016/0003-9861(73)90539-0; Silverman J, 2005, NAT BIOTECHNOL, V23, P1556, DOI 10.1038/nbt1166; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	31	40	45	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3795	3804		10.1096/fj.08-111484	http://dx.doi.org/10.1096/fj.08-111484			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18635738				2022-12-28	WOS:000260503000008
J	Sveinbjornsson, B; Rasmuson, A; Baryawno, N; Wan, M; Pettersen, I; Ponthan, F; Orrego, A; Haeggstrom, JZ; Johnsen, JI; Kogner, P				Sveinbjornsson, Baldur; Rasmuson, Agnes; Baryawno, Ninib; Wan, Min; Pettersen, Ingvild; Ponthan, Frida; Orrego, Abiel; Haeggstrom, Jesper Z.; Johnsen, John I.; Kogner, Per			Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy	FASEB JOURNAL			English	Article						eicosanoids; 5-lipoxygenase; apoptosis	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INTESTINAL EPITHELIAL-CELLS; GROWTH IN-VIVO; 5-LIPOXYGENASE-ACTIVATING PROTEIN; ARACHIDONIC-ACID; MULTIDRUG-RESISTANCE; INDUCE APOPTOSIS; PROSTATE-CANCER; C-4 SYNTHASE; LIPOXYGENASE	The metabolism of arachidonic acid by the cyclooxygenase (COX) or lipoxygenase (LO) pathways generates eicosanoids that have been implicated in the pathogenesis of a variety of human diseases, including cancer. In this study, we examined the expression and significance of components within the 5-LO pathway in human neuroblastoma, an embryonal tumor of the sympathetic nervous system. High expression of 5-LO, 5-LO-activating protein (FLAP), leukotriene A(4) hydrolase, leukotriene C-4 synthase, and leukotriene receptors was detected in a majority of primary neuroblastoma tumors and all cell lines investigated. Expression of 5-LO and FLAP was evident in tumor cells but not in nonmalignant adrenal medulla where neuroblastomas typically arise. Moreover, neuroblastoma cells produce leukotrienes, and stimulation of neuroblastoma cells with leukotrienes increased neuroblastoma cell viability. Inhibitors of 5-LO (AA-861), FLAP (MK- 886), or the leukotriene receptor antagonist montelukast inhibited neuroblastoma cell growth by induction of G(1)-cell cycle arrest and apoptosis. Similarly, specific 5-LO and leukotriene receptor silencing by small interfering RNA decreased neuroblastoma cell growth. These findings provide new insights into the pathobiology of neuroblastoma, and the use of leukotriene pathway inhibitors as a novel adjuvant therapy for children with neuroblastoma warrants further consideration.	[Sveinbjornsson, Baldur; Rasmuson, Agnes; Baryawno, Ninib; Ponthan, Frida; Johnsen, John I.; Kogner, Per] Karolinska Inst, Childhood Canc Res Unit, Dept Woman & Child Hlth, Stockholm, Sweden; [Wan, Min; Haeggstrom, Jesper Z.] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden; [Orrego, Abiel] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden; [Sveinbjornsson, Baldur; Pettersen, Ingvild] Univ Tromso, Fac Med, Dept Cell Biol & Histol, Tromso, Norway; [Ponthan, Frida] Univ Newcastle Upon Tyne, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; UiT The Arctic University of Tromso; Newcastle University - UK	Sveinbjornsson, B (corresponding author), Karolinska Hosp, Childhood Canc Res Unit, Astrid Lindgren Childrens Hosp, Q6 05, S-17176 Stockholm, Sweden.	baldur.sveinbjornsson@ki.se		Baryawno, Ninib/0000-0001-8211-8368; Kogner, Per/0000-0002-2202-9694; Johnsen, John Inge/0000-0003-1277-812X; Baryawno, Ninib/0000-0001-6054-4163	Swedish Research Council; Swedish Children Cancer Foundation; Swedish Cancer Society; Stockholm Cancer Society (Sweden); Wenner-Gren Foundation (Stockholm, Sweden); EC FP6 [LSHM-CT-2004-005033]; Aakre Foundation (University of Tromso, Tromso, Norway)	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Children Cancer Foundation; Swedish Cancer Society(Swedish Cancer Society); Stockholm Cancer Society (Sweden); Wenner-Gren Foundation (Stockholm, Sweden); EC FP6(European CommissionEuropean Commission Joint Research Centre); Aakre Foundation (University of Tromso, Tromso, Norway)	We thank Lotta Elfman, Anja Pedersen, and Roy Lysaa for technical assistance. This work was supported by the Swedish Research Council, the Swedish Children Cancer Foundation, the Swedish Cancer Society, the Stockholm Cancer Society (Sweden), the Wenner-Gren Foundation (Stockholm, Sweden), EC FP6 (LSHM-CT-2004-005033), and the Aakre Foundation (University of Tromso, Tromso, Norway).	Abel F, 2005, EUR J CANCER, V41, P635, DOI 10.1016/j.ejca.2004.12.021; ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BOADO RJ, 1992, P NATL ACAD SCI USA, V89, P9044, DOI 10.1073/pnas.89.19.9044; Bogatcheva NV, 2005, MICROVASC RES, V69, P107, DOI 10.1016/j.mvr.2005.01.007; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chen XX, 2003, J NATL CANCER I, V95, P1053, DOI 10.1093/jnci/95.14.1053; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Goodman JE, 2004, CARCINOGENESIS, V25, P2467, DOI 10.1093/carcin/bgh260; Gunning WT, 2002, CANCER RES, V62, P4199; Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F; Hennig R, 2005, CANCER RES, V65, P6011, DOI 10.1158/0008-5472.CAN-04-4090; Hennig R, 2004, CANCER LETT, V210, P41, DOI 10.1016/j.canlet.2004.02.023; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; HIRAI A, 1985, PROSTAGLANDINS, V30, P749, DOI 10.1016/0090-6980(85)90005-X; Hoque A, 2005, CARCINOGENESIS, V26, P785, DOI 10.1093/carcin/bgi026; IZUMI T, 1986, BIOCHEM BIOPH RES CO, V135, P139, DOI 10.1016/0006-291X(86)90953-8; JANSSENTIMMEN U, 1995, P NATL ACAD SCI USA, V92, P6966, DOI 10.1073/pnas.92.15.6966; Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P125, DOI 10.1016/j.plefa.2005.10.005; Johnsen JI, 2005, CANCER LETT, V228, P195, DOI 10.1016/j.canlet.2005.01.058; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; JONES DB, 1987, J ENDOCRINOL, V112, P253, DOI 10.1677/joe.0.1120253; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Knorr B, 2006, J CLIN PHARMACOL, V46, P620, DOI 10.1177/0091270006288324; Lam BK, 2003, PROSTAG LEUKOTR ESS, V69, P111, DOI 10.1016/S0952-3278(03)00071-1; Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039; Luo M, 2003, HISTOL HISTOPATHOL, V18, P587, DOI 10.14670/HH-18.587; Maeba S, 2005, ANN ALLERG ASTHMA IM, V94, P670, DOI 10.1016/S1081-1206(10)61326-9; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; Matsuyama M, 2007, ONCOL REP, V18, P99; Migoya E, 2004, J CLIN PHARMACOL, V44, P487, DOI 10.1177/0091270004264970; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Nie DT, 2004, SEMIN THROMB HEMOST, V30, P119; Norris MD, 2005, MOL CANCER THER, V4, P547, DOI 10.1158/1535-7163.MCT-04-0161; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; OMURA M, 1990, PROSTAG LEUKOTR ESS, V40, P93, DOI 10.1016/0952-3278(90)90150-J; PALMBLAD J, 1981, BLOOD, V58, P658; Paruchuri S, 2005, J BIOL CHEM, V280, P13538, DOI 10.1074/jbc.M409811200; Paruchuri S, 2003, J BIOL CHEM, V278, P45577, DOI 10.1074/jbc.M302881200; Paruchuri S, 2002, J CELL SCI, V115, P1883; Peaston AE, 2001, BRIT J CANCER, V85, P1564, DOI 10.1054/bjoc.2001.2144; Pettersen I, 2002, BIOCHEM BIOPH RES CO, V296, P671, DOI 10.1016/S0006-291X(02)00916-6; Ponthan F, 2003, INT J CANCER, V104, P418, DOI 10.1002/ijc.10954; Ponthan F, 2007, CLIN CANCER RES, V13, P1036, DOI 10.1158/1078-0432.CCR-06-1908; Ramires R, 2004, BIOCHEM BIOPH RES CO, V324, P815, DOI 10.1016/j.bbrc.2004.09.125; Reid G, 2003, P NATL ACAD SCI USA, V100, P9244, DOI 10.1073/pnas.1033060100; Reynolds LM, 2001, NEUROSCI LETT, V309, P193, DOI 10.1016/S0304-3940(01)02071-7; Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Schroder O, 2005, CELL MOL LIFE SCI, V62, P87, DOI 10.1007/s00018-004-4366-7; Tager AM, 2003, PROSTAG LEUKOTR ESS, V69, P123, DOI 10.1016/S0952-3278(03)00073-5; Tong WG, 2002, MOL CANCER THER, V1, P929; Uz T, 2001, EUR J PHARMACOL, V418, P15, DOI 10.1016/S0014-2999(01)00924-4; van Rossum GSAT, 2002, CELL MOL LIFE SCI, V59, P181, DOI 10.1007/s00018-002-8414-x; Wada K, 2006, FASEB J, V20, P1785, DOI 10.1096/fj.06-5809com; Zhi HY, 2003, INT J CANCER, V106, P327, DOI 10.1002/ijc.11225	64	56	59	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2008	22	10					3525	3536		10.1096/fj.07-103457	http://dx.doi.org/10.1096/fj.07-103457			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18591367				2022-12-28	WOS:000259642600015
J	Valente, P; Garcia-Sanz, N; Gomis, A; Fernandez-Carvajal, A; Fernandez-Ballester, G; Viana, F; Belmonte, C; Ferrer-Montiel, A				Valente, Pierluigi; Garcia-Sanz, Nuria; Gomis, Ana; Fernandez-Carvajal, Asia; Fernandez-Ballester, Gregorio; Viana, Felix; Belmonte, Carlos; Ferrer-Montiel, Antonio			Identification of molecular determinants of channel gating in the transient receptor potential box of vanilloid receptor I	FASEB JOURNAL			English	Article						structure-function; thermoreceptor; functional coupling; nociceptor; sensory transduction; oligomerization	TRP CHANNELS; CAPSAICIN-RECEPTOR; VOLTAGE SENSOR; COLD RECEPTOR; PAIN PATHWAY; ACTIVATION; HEAT; DOMAIN; THERMOSENSATION; DESENSITIZATION	Transient receptor potential vanilloid receptor subtype I (TRPV1) is an ion channel gated by physical and chemical stimuli that belongs to the TRPV protein family. TRPV receptors contain a highly conserved, 6-mer segment near the channel gate, known as the TRP box, whose function remains unknown. Here, we performed an alanine scanning mutagenesis of the TRP box of TRPV1 (IWKLQR) and found that mutation of this motif affected channel gating by raising the free energy of channel activation. Functional characterization of TRPV1 mutants showed that substitution of I696, W697, and R701 by alanine severely affected voltage- and heat-dependent activation and notably reduced the capsaicin responsiveness and tachyphylaxia, while mutation of K698, L699, and Q700 had minor effects. In addition, mutation of I696 to alanine promoted a strong outward rectification at negative membrane potentials, and slowed the kinetics of channel activation. Taken together, our findings suggest that modification of I696, W697, and R701 to alanine altered channel function by affecting events downstream of the initial stimuli-sensing step and imply that inter-subunit interactions within the TRP box play an important role in TRPV1 gating.	[Valente, Pierluigi; Garcia-Sanz, Nuria; Fernandez-Carvajal, Asia; Fernandez-Ballester, Gregorio; Ferrer-Montiel, Antonio] Univ Miguel Hernandez, Inst Mol & Cellular Biol, Alicante 03202, Spain; [Gomis, Ana; Viana, Felix; Belmonte, Carlos] Univ Miguel Hernandez, Consejo Super Invest Cient, Inst Neurociencias Alicante, Alicante 03202, Spain	Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, Inst Mol & Cellular Biol, Av Univ S-N, Alicante 03202, Spain.	aferrer@umh.es	Valente, Pierluigi/AAF-2802-2021; Gomis, Ana/S-1854-2017; Viana, Felix/U-8533-2017; Ferrer-Montiel, Antonio/C-3072-2015; Carvajal, Asia Fernandez/G-8877-2015	Gomis, Ana/0000-0003-4651-7673; Viana, Felix/0000-0003-1439-949X; Ferrer-Montiel, Antonio/0000-0002-2973-6607; Fernandez-Carvajal, Asia/0000-0003-2741-1427	Spanish Ministry of Education and Science (MEC) [SAF2006-2580, BFU2005-03986]; Fundacion Ramon Areces; Generalitat Valenciana [GV-ACOMP06/202, GV05/076]	Spanish Ministry of Education and Science (MEC)(Spanish Government); Fundacion Ramon Areces; Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission)	We thank Drs. Rosa Planells and Marco Caprini for critically reading the manuscript; and Reme Torres for cDNA and cRNA preparation, oocyte injection, and manipulation. We are indebted to Dr. Davis Julius (University of California, San Francisco, CA, USA) for the cDNA encoding rat TRPV1. This work was supported by grants from the Spanish Ministry of Education and Science (MEC) (SAF2006-2580 to A.F.-M. and BFU2005-03986 to A.G.), the Fundacion Ramon Areces (to A.F.-M), and the Generalitat Valenciana (GV-ACOMP06/202 to A.F-M. and GV05/076 to A.G.).	Arniges M, 2006, J BIOL CHEM, V281, P1580, DOI 10.1074/jbc.M511456200; Bandell M, 2006, NAT NEUROSCI, V9, P493, DOI 10.1038/nn1665; Brauchi S, 2006, J NEUROSCI, V26, P4835, DOI 10.1523/JNEUROSCI.5080-05.2006; Brauchi S, 2004, P NATL ACAD SCI USA, V101, P15494, DOI 10.1073/pnas.0406773101; Brauchi S, 2007, P NATL ACAD SCI USA, V104, P10246, DOI 10.1073/pnas.0703420104; Caprini M, 2005, J BIOL CHEM, V280, P18253, DOI 10.1074/jbc.M413389200; Caprini M, 2001, J BIOL CHEM, V276, P21070, DOI 10.1074/jbc.M100487200; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chang Q, 2004, J BIOL CHEM, V279, P54304, DOI 10.1074/jbc.M406222200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; Garcia-Sanz N, 2004, J NEUROSCI, V24, P5307, DOI 10.1523/JNEUROSCI.0202-04.2004; Garcia-Sanz N, 2007, J NEUROSCI, V27, P11641, DOI 10.1523/JNEUROSCI.2457-07.2007; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Lishko PV, 2007, NEURON, V54, P905, DOI 10.1016/j.neuron.2007.05.027; Liu BY, 2003, BIOPHYS J, V85, P2988, DOI 10.1016/S0006-3495(03)74719-5; Matta JA, 2007, J PHYSIOL-LONDON, V585, P469, DOI 10.1113/jphysiol.2007.144287; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Nilius B, 2005, J PHYSIOL-LONDON, V567, P35, DOI 10.1113/jphysiol.2005.088377; Novakova-Tousova K, 2007, NEUROSCIENCE, V149, P144, DOI 10.1016/j.neuroscience.2007.07.039; Planells-Cases R, 2005, PFLUG ARCH EUR J PHY, V451, P151, DOI 10.1007/s00424-005-1423-5; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Rohacs T, 2007, PFLUG ARCH EUR J PHY, V455, P157, DOI 10.1007/s00424-007-0275-6; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Vlachova V, 2003, J NEUROSCI, V23, P1340, DOI 10.1523/JNEUROSCI.23-04-01340.2003; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Voets T, 2007, J PHYSIOL-LONDON, V582, P939, DOI 10.1113/jphysiol.2007.132522; Voets T, 2007, NAT CHEM BIOL, V3, P174, DOI 10.1038/nchembio862; Wang T, 2005, J CELL BIOL, V171, P685, DOI 10.1083/jcb.200508030; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882	39	70	72	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3298	3309		10.1096/fj.08-107425	http://dx.doi.org/10.1096/fj.08-107425			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18559878	Green Submitted			2022-12-28	WOS:000258761300022
J	Yeang, CH; McCormick, F; Levine, A				Yeang, Chen-Hsiang; McCormick, Frank; Levine, Arnold			Combinatorial patterns of somatic gene mutations in cancer	FASEB JOURNAL			English	Review						cell cycle control; Ras pathway; Wnt pathway; P53 pathway; Igf; Akt pathway; TGF beta; pathway	GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR; TANDEM DUPLICATION; BETA-CATENIN; CELL; KINASE; INHIBITION; PATHWAY; P53; TUMORIGENESIS	Cancer is a complex process in which the abnormalities of many genes appear to be involved. The combinatorial patterns of gene mutations may reveal the functional relations between genes and pathways in tumorigenesis as well as identify targets for treatment. We examined the patterns of somatic mutations of cancers from Catalog of Somatic Mutations in Cancer ( COSMIC), a large-scale database curated by the Wellcome Trust Sanger Institute. The frequently mutated genes are well-known oncogenes and tumor suppressors that are involved in generic processes of cell- cycle control, signal transduction, and stress responses. These "signatures" of gene mutations are heterogeneous when the cancers from different tissues are compared. Mutations in genes functioning in different pathways can occur in the same cancer (i. e., co-occur), whereas those in genes functioning in the same pathway are rarely mutated in the same sample. This observation supports the view of tumorigenesis as derived from a process like Darwinian evolution. However, certain combinatorial mutational patterns violate these simple rules and demonstrate tissue-specific variations. For instance, mutations of genes in the Ras and Wnt pathways tend to co-occur in the large intestine but are mutually exclusive in cancers of the pancreas. The relationships between mutations in different samples of a cancer can also reveal the temporal orders of mutational events. In addition, the observed mutational patterns suggest candidates of new cosequencing targets that can either reveal novel patterns or validate the predictions deduced from existing patterns. These combinatorial mutational patterns provide guiding information for the ongoing cancer genome projects. Yeang, C-H., McCormick, F., Levine, A. Combinatorial patterns of somatic gene mutations in cancer.	[Yeang, Chen-Hsiang; Levine, Arnold] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; [McCormick, Frank] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [McCormick, Frank] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Institute for Advanced Study - USA; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Yeang, CH (corresponding author), Inst Adv Study, Simons Ctr Syst Biol, 1 Einstein Dr, Princeton, NJ 08540 USA.	chyeang@ias.edu	Yeang, Chen-Hsiang/AAP-2962-2021					Abraham SC, 2002, AM J PATHOL, V160, P1361, DOI 10.1016/S0002-9440(10)62563-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Chan RJ, 2007, BLOOD, V109, P862, DOI 10.1182/blood-2006-07-028829; Christiansen DH, 2005, LEUKEMIA, V19, P2232, DOI 10.1038/sj.leu.2404009; Ciesielski MJ, 2000, ONCOGENE, V19, P810, DOI 10.1038/sj.onc.1203409; Diaz R, 2005, INT J CANCER, V113, P241, DOI 10.1002/ijc.20563; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; HERMAN JG, 1995, CANCER RES, V55, P4525; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ji HB, 2006, P NATL ACAD SCI USA, V103, P7817, DOI 10.1073/pnas.0510284103; KAHN S, 1987, ANTICANCER RES, V7, P639; King RD, 2004, NATURE, V427, P247, DOI 10.1038/nature02236; Kiyoi H, 2006, METH MOLEC MED, V125, P189; Ku JL, 2002, CELL TISSUE RES, V308, P205, DOI 10.1007/s00441-001-0510-y; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakao M, 1996, LEUKEMIA, V10, P1911; NC I, CANC GEN ATL; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140-6736(07)60780-6; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sonobe M, 2005, BRIT J CANCER, V93, P355, DOI 10.1038/sj.bjc.6602707; To MD, 2006, NAT GENET, V38, P926, DOI 10.1038/ng1836; TOYOOKA M, 1995, CANCER RES, V55, P3165; Tsao H, 2000, CANCER RES, V60, P1800; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; *WELLC TRUST SANG, CANC CELL LIN PROJ; Wellcome Trust Sanger Institute, CANC GEN PROJ; Yeang CH, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-r62	54	185	191	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2605	2622		10.1096/fj.08-108985	http://dx.doi.org/10.1096/fj.08-108985			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18434431				2022-12-28	WOS:000258089300002
J	Cushing, MC; Mariner, PD; Liao, JT; Sims, EA; Anseth, KS				Cushing, Melinda C.; Mariner, Peter D.; Liao, Jo-Tsu; Sims, Evan A.; Anseth, Kristi S.			Fibroblast growth factor represses Smad-mediated myofibroblast activation in aortic valvular interstitial cells	FASEB JOURNAL			English	Article						transforming growth factor-beta 1; heart disease; alpha-smooth muscle actin; cell signaling	SMOOTH MUSCLE ACTIN; TGF-BETA; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; TRANSFORMING GROWTH-FACTOR-BETA-1; VALVE STENOSIS; TISSUE-REPAIR; PHENOTYPE; EXPRESSION; INDUCTION	This study aimed to identify signaling pathways that oppose connective tissue fibrosis in the aortic valve. Using valvular interstitial cells (VICs) isolated from porcine aortic valve leaflets, we show that basic fibroblast growth factor (FGF-2) effectively blocks transforming growth factor-beta 1 (TGF-beta 1)-mediated myofibroblast activation. FGF-2 prevents the induction of alpha-smooth muscle actin (alpha SMA) expression and the exit of VICs from the cell cycle, both of which are hallmarks of myofibroblast activation. By blocking the activity of the Smad transcription factors that serve as the downstream nuclear effectors of TGF-beta 1, FGF-2 treatment inhibits fibrosis in VICs. Using an exogenous Smad-responsive transcriptional promoter reporter, we show that Smad activity is repressed by FGF-2, likely an effect of the fact that FGF-2 treatment prevents the nuclear localization of Smads in these cells. This appears to be a direct effect of FGF signaling through mitogen-activated protein kinase (MAPK) cascades as the treatment of VICs with the MAPK/ extracellular regulated kinase (MEK) inhibitor U0126 acted to induce fibrosis and blocked the ability of FGF-2 to inhibit TGF-beta 1 signaling. Furthermore, FGF-2 treatment of VICs blocks the development of pathological contractile and calcifying phenotypes, suggesting that these pathways may be utilized in the engineering of effective treatments for valvular disease.	[Cushing, Melinda C.; Mariner, Peter D.; Liao, Jo-Tsu; Sims, Evan A.; Anseth, Kristi S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA; [Mariner, Peter D.; Anseth, Kristi S.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Anseth, KS (corresponding author), Univ Colorado, Dept Chem & Biol Engn, ECCH 111,UCB 424, Boulder, CO 80309 USA.	kristi.anseth@colorado.edu			Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [R01 HL089260-01A1, R01 HL089260, R01 HL089260-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089260] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Badid C, 2000, HISTOL HISTOPATHOL, V15, P269, DOI 10.14670/HH-15.269; Cushing MC, 2005, MATRIX BIOL, V24, P428, DOI 10.1016/j.matbio.2005.06.007; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Doukas J, 2002, MOL THER, V5, P517, DOI 10.1006/mthe.2002.0579; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Greenberg RS, 2006, FASEB J, V20, P1006, DOI 10.1096/fj.05-4838fje; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Jian B, 2003, ANN THORAC SURG, V75, P457, DOI 10.1016/S0003-4975(02)04312-6; JOHNSON CM, 1987, J MOL CELL CARDIOL, V19, P1185, DOI 10.1016/S0022-2828(87)80529-1; Kaden JJ, 2005, INT J MOL MED, V16, P869; Kaden JJ, 2005, CARDIOVASC PATHOL, V14, P80, DOI 10.1016/j.carpath.2005.01.002; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Maltseva O, 2001, INVEST OPHTH VIS SCI, V42, P2490; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2003, GENE DEV, V17, P2993, DOI 10.1101/gad.1167003; Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g; Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426; Merryman WD, 2006, J BIOMECH, V39, P88, DOI 10.1016/j.jbiomech.2004.11.008; Mohler ER, 1999, J HEART VALVE DIS, V8, P254; Papetti M, 2003, INVEST OPHTH VIS SCI, V44, P4994, DOI 10.1167/iovs.03-0291; Rabkin E, 2001, CIRCULATION, V104, P2525, DOI 10.1161/hc4601.099489; Rabkin-Aikawa E, 2004, J HEART VALVE DIS, V13, P841; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; Sato M, 2003, CELL STRUCT FUNCT, V28, P105; Schiller M, 2004, J DERMATOL SCI, V35, P83, DOI 10.1016/j.jdermsci.2003.12.006; SCOTTBURDEN T, 1989, J CELL PHYSIOL, V141, P267, DOI 10.1002/jcp.1041410206; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Tamaoki M, 2005, AM J PATHOL, V167, P71, DOI 10.1016/S0002-9440(10)62954-9; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Walker GA, 2004, CIRC RES, V95, P253, DOI 10.1161/01.RES.0000136520.07995.aa; Wells RG, 2000, AM J PHYSIOL-GASTR L, V279, pG845, DOI 10.1152/ajpgi.2000.279.5.G845; Yang JW, 2003, AM J PATHOL, V163, P621, DOI 10.1016/S0002-9440(10)63689-9; Yata Y, 2002, HEPATOLOGY, V35, P1022, DOI 10.1053/jhep.2002.32673; Yu L, 2002, CURR OPIN PHARMACOL, V2, P177, DOI 10.1016/S1471-4892(02)00144-3	40	101	111	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1769	1777		10.1096/fj.07-087627	http://dx.doi.org/10.1096/fj.07-087627			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18218921	Green Published			2022-12-28	WOS:000256352700017
J	Xu, XR; Gammon, MD; Zeisel, SH; Lee, YL; Wetmur, JG; Teitelbaum, SL; Bradshaw, PT; Neugut, AI; Santella, RM; Chen, J				Xu, Xinran; Gammon, Marilie D.; Zeisel, Steven H.; Lee, Yin Leng; Wetmur, James G.; Teitelbaum, Susan L.; Bradshaw, Patrick T.; Neugut, Alfred I.; Santella, Regina M.; Chen, Jia			Choline metabolism and risk of breast cancer in a population-based study	FASEB JOURNAL			English	Article						methyl diet; methylation; genetic polymorphism; phosphatidylethanolamine N-methyltransferase; choline dehydrogenase; betaine-homocysteine methyltransferase	DIETARY REQUIREMENTS	Choline is an essential nutrient required for methyl group metabolism, but its role in carcinogenesis and tumor progression is not well understood. By utilizing a population-based study of 1508 cases and 1556 controls, we investigated the associations of dietary intake of choline and two related micronutrients, methionine and betaine, and risk of breast cancer. The highest quintile of choline consumption was associated with a lower risk of breast cancer [odds ratio (OR): 0.76; 95% confidence interval (CI): 0.58-1.00] compared with the lowest quintile. Two putatively functional single nucleotide polymorphisms of choline-metabolizing genes, PEMT -774G > C (rs12325817) and CHDH +432G > T (rs12676), were also found be related to breast cancer risk. Compared with the PEMT GG genotype, the variant CC genotype was associated with an increased risk of breast cancer (OR: 1.30; 95% CI: 1.01-1.67). The CHDH minor T allele was also associated with an increased risk (OR: 1.19; 95% CI: 1.00-1.41) compared with the major G allele. The BHMT rs3733890 polymorphism was also examined but was found not to be associated with breast cancer risk. We observed a significant interaction between dietary betaine intake and the PEMT rs7926 polymorphism (P-interaction = 0.04). Our findings suggest that choline metabolism may play an important role in breast cancer etiology.	[Xu, Xinran; Lee, Yin Leng; Teitelbaum, Susan L.; Chen, Jia] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA; [Wetmur, James G.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Wetmur, James G.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA; [Chen, Jia] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; [Gammon, Marilie D.; Bradshaw, Patrick T.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA; [Zeisel, Steven H.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, New York, NY USA; [Neugut, Alfred I.] Columbia Univ, Dept Med, New York, NY USA; [Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Columbia University; Columbia University; Columbia University	Chen, J (corresponding author), Mt Sinai Sch Med, Dept Community & Prevent Med, Box 1043,1 Gustave L Levy Pl, New York, NY 10029 USA.	jia.chen@mssm.edu	Bradshaw, Patrick/AAJ-7529-2021	Bradshaw, Patrick/0000-0001-7761-3129; Xu, Xinran/0000-0001-6435-8181	NCI NIH HHS [UO1CA/ES66572, U01 CA066572, CA109753, UO1CA66572, R01 CA109753] Funding Source: Medline; NCRR NIH HHS [M01 RR000046-461213, M01 RR000046] Funding Source: Medline; NIDDK NIH HHS [R01 DK055865, R01 DK055865-07, DK56350, P30 DK056350-08, DK55865, P30 DK056350] Funding Source: Medline; NIEHS NIH HHS [P30ES09089, P30 ES010126, P30 ES009089, P30ES10126, ES10126, P30 ES010126-089008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109753, U01CA066572] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, P30ES009089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; DALMEIJER GW, 2007, EUR J CLIN NUTR; Fischer LM, 2007, AM J CLIN NUTR, V85, P1275; Fischer LM, 2005, J NUTR, V135, P826, DOI 10.1093/jn/135.4.826; NEWBERNE PM, 1986, ANNU REV NUTR, V6, P407, DOI 10.1146/annurev.nu.06.070186.002203; Potischman N, 1997, CANCER CAUSE CONTROL, V8, P713, DOI 10.1023/A:1018475203820; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; Tsujiuchi T, 1999, JPN J CANCER RES, V90, P909, DOI 10.1111/j.1349-7006.1999.tb00834.x; Yates AA, 1998, J AM DIET ASSOC, V98, P699, DOI 10.1016/S0002-8223(98)00160-6; ZEISEL SH, 1995, J NUTR, V125, P3049; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156	11	92	95	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2045	2052		10.1096/fj.07-101279	http://dx.doi.org/10.1096/fj.07-101279			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230680	Green Submitted, Green Accepted			2022-12-28	WOS:000256352700043
J	Hiroi, YK; Guo, ZM; Li, YX; Beggs, AH; Liao, JK				Hiroi, Yukio; Guo, Zhongmin; Li, Yuxin; Beggs, Alan H.; Liao, James K.			Dynamic regulation of endothelial NOS mediated by competitive interaction with alpha-actinin-4 and calmodulin	FASEB JOURNAL			English	Article						endothelium; nitric oxide; ionophore	NITRIC-OXIDE SYNTHASE; PROTEIN-PROTEIN INTERACTIONS; ALPHA-ACTININ; S-NITROSYLATION; PLASMALEMMAL CAVEOLAE; BINDING; CELLS; PHOSPHORYLATION; ACTIVATION; RECEPTOR	Alpha-actinins are critical components of the actin cytoskeleton. Here we show that alpha-actinins serve an other important biological function by binding to and competitively inhibiting calcium-dependent activation of endothelial NOS (eNOS). alpha-actinin-2 was found to associate with eNOS in a yeast two-hybrid. screen. In vascular endothelial cells, which only express alpha-actinin-1 and 4, alpha-actinin-4 interacted and colocalized with eNOS. Addition of alpha-actinin-4 directly inhibited eNOS recombinant protein, and overexpression of alpha-actinin-4 inhibited eNOS activity in eNOS-transfected COS-7 cells and bovine aortic endothelial cells (BAECs). In contrast, knockdown of alpha-actinin-4 by siRNA increased eNOS activity in BAECs. The alpha-actinin-4-binding site on eNOS was mapped to a central region comprising the calmodulin-binding domain, and the eNOS-binding site on alpha-actinin-4 was mapped to the fourth spectrin-like rod domain, R4. Treatment of endothelial cells with a calcium ionophore, A23187, decreased alpha-actinin-4-eNOS interaction, leading to translocation of alpha-actinin-4 from plasma membrane to cytoplasm. Indeed, addition of calmodulin displaced alpha-actinin-4 binding to eNOS and increased eNOS activity. These findings indicate that eNOS activity in vascular endothelial cells is tonically and dynamically regulated by competitive interaction with alpha-actinin-4 and calmodulin.	[Hiroi, Yukio; Guo, Zhongmin; Li, Yuxin; Liao, James K.] Brigham & Womens Hosp, Boston, MA 02139 USA; [Beggs, Alan H.] Harvard Univ, Sch Med, Program Genom, Childrens Hosp Boston, Boston, MA USA; [Beggs, Alan H.] Harvard Univ, Sch Med, Div Genet, Childrens Hosp Boston, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Liao, JK (corresponding author), Brigham & Womens Hosp, 65 Landsdowne St,Room 275, Boston, MA 02139 USA.	jliao@rics.bwh.harvard.edu	Li, yuxin/GSD-1668-2022; li, yu/HGL-9518-2022; li, Yu/HCI-9086-2022	Beggs, Alan/0000-0001-8818-0568	NHLBI NIH HHS [R01 HL080187, R01 HL052233-10, R01 HL052233-12, R01 HL052233, R01 HL080187-03, R01 HL070274-05, R01 HL080187-01A1, R01 HL070274, R01 HL052233-11, R01 HL070274-03, HL052233, R01 HL080187-02, R01 HL070274-04] Funding Source: Medline; NIAMS NIH HHS [R01 AR044345-10, R01 AR044345-11, R01 AR044345, AR044345] Funding Source: Medline; NIDDK NIH HHS [R01 DK062729-04, R01 DK062729-05, R01 DK062729] Funding Source: Medline; NINDS NIH HHS [P50 NS010828, P50 NS010828-310036, P50 NS010828-320036, P50 NS010828-300036] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070274, R01HL080187, R01HL052233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS010828] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araki N, 2000, J CELL SCI, V113, P3329; Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Chakraborty S, 2006, J BIOL CHEM, V281, P35070, DOI 10.1074/jbc.M602474200; CHANDLER L, 1998, YOUNG EXCEPTIONAL CH, V1, P14; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Djinovic-Carugo K, 2002, FEBS LETT, V513, P119, DOI 10.1016/S0014-5793(01)03304-X; Dudzinski DM, 2006, ANNU REV PHARMACOL, V46, P235, DOI 10.1146/annurev.pharmtox.44.101802.121844; Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Forstermann U, 2006, CIRCULATION, V113, P1708, DOI 10.1161/CIRCULATIONAHA.105.602532; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Iwakiri Y, 2006, P NATL ACAD SCI USA, V103, P19777, DOI 10.1073/pnas.0605907103; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Laufs U, 1997, J BIOL CHEM, V272, P31725, DOI 10.1074/jbc.272.50.31725; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; Nedvetsky PI, 2002, P NATL ACAD SCI USA, V99, P16510, DOI 10.1073/pnas.262701999; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; Prabhakar P, 2000, J BIOL CHEM, V275, P19416, DOI 10.1074/jbc.M001952200; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; Razani B, 2001, J BIOL CHEM, V276, P38121; Sessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Sonveaux P, 2004, CIRC RES, V95, P154, DOI 10.1161/01.RES.0000136344.27825.72; Sun JX, 2002, P NATL ACAD SCI USA, V99, P13108, DOI 10.1073/pnas.202260999; Takada F, 2001, P NATL ACAD SCI USA, V98, P1595, DOI 10.1073/pnas.041609698; Tang JH, 2001, J MOL BIOL, V310, P845, DOI 10.1006/jmbi.2001.4789; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; Zhang Q, 2006, ARTERIOSCL THROM VAS, V26, P1015, DOI 10.1161/01.ATV.0000216044.49494.c4	39	6	6	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1450	1457		10.1096/fj.07-9309com	http://dx.doi.org/10.1096/fj.07-9309com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18180332	Green Accepted			2022-12-28	WOS:000255898700017
J	Keely, S; Glover, LE; MacManus, CF; Campbell, EL; Scully, MM; Furuta, GT; Colgan, SP				Keely, Simon; Glover, Louise E.; MacManus, Christopher F.; Campbell, Eric L.; Scully, Melanie M.; Furuta, Glenn T.; Colgan, Sean P.			Selective induction of integrin beta 1 by hypoxia-inducible factor: implications for wound healing	FASEB JOURNAL			English	Article						inflammation; Crohn's disease; restitution; transcription; gene promoter	COLLAGEN GEL CONTRACTION; INTESTINAL EPITHELIUM; EXTRACELLULAR-MATRIX; MURINE MODEL; FACTOR-I; EXPRESSION; OXYGEN; INFLAMMATION; ANGIOGENESIS; HIF-1	Because of localized vascular damage and increased tissue oxygen demand, wound healing occurs in a relatively hypoxic microenvironment. These features are particularly relevant to wound healing and fibrosis in chronic inflammatory conditions, such as Crohn's disease and ulcerative colitis. In these studies, we sought to identify the contribution of hypoxia to mechanisms of wound repair in a model of the intestinal submucosa. Initial studies revealed that hypoxia promotes wound healing, as modeled by an increase in intestinal fibroblast-mediated collagen gel contraction. Guided by results from transcriptional profiling, we identified the selective induction of fibroblast integrin beta 1 (ITGB1) by hypoxia. Further analysis revealed that hypoxia, as well as pharmacological activators of hypoxia-inducible factor (HIF), induce fibroblast beta 1 integrin mRNA, protein, and function by as much as 4-fold. Cloning and analysis of the beta 1 integrin gene promoter revealed a 10 +/- 0.8-fold increase in promoter activity in response to hypoxia, and subsequent studies identified a functional DNA binding region for HIF in the ITGB1 gene promoter. Mutational analysis of the HIF binding site within the ITGB1 promoter resulted in a significant loss of ITGB1 hypoxia-inducibility. As proof of principle, studies in a murine model of colitis revealed a correlation between colitic disease severity and tissue ITGB1 expression (R-2=0.80). Taken together, these results demonstrate that hypoxia induces fibroblast ITGB1 expression and function by transcriptional mechanisms dependent on HIF.-Keely, S., Glover, L. E., MacManus, C. F., Campbell, E. L., Scully, M. M., Furuta, G. T., Colgan, S. P. Selective induction of integrin beta 1 by hypoxia-inducible factor: implications for wound healing. FASEB J. 23, 1338-1346 (2009)	[Colgan, Sean P.] Univ Colorado Denver, Mucosal Inflammat Program, Div Gastroenterol & Hepatol, Dept Med,Hlth Sci Ctr,Sch Med, Aurora, CO 80045 USA; [Furuta, Glenn T.] Univ Colorado Denver, Sch Med, Dept Pediat Gastroenterol Hepatol & Nutr, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Colgan, SP (corresponding author), Univ Colorado Denver, Mucosal Inflammat Program, Div Gastroenterol & Hepatol, Dept Med,Hlth Sci Ctr,Sch Med, 12700 E 19th Ave,MS B-146, Aurora, CO 80045 USA.	sean.colgan@uchsc.edu	Campbell, Eric/N-5357-2015; Keely, Simon/AAV-9973-2020	Campbell, Eric/0000-0003-0744-6577; Keely, Simon/0000-0002-1248-9590; Glover, Louise/0000-0001-9056-1810	U.S. National Institutes of Health [HL60569, DK50189, DE DE13499]; Crohn's and Colitis Foundation of America; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050189, R01DK050189, R29DK050189] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by U.S. National Institutes of Health grants HL60569, DK50189, and DE DE13499 and by a grant and research fellowship from the Crohn's and Colitis Foundation of America. The authors acknowledge the generous gift of FG4497 from Fibrogen Corp.	Albina JE, 2001, AM J PHYSIOL-CELL PH, V281, pC1971, DOI 10.1152/ajpcell.2001.281.6.C1971; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; Boirivant M, 1998, J EXP MED, V188, P1929, DOI 10.1084/jem.188.10.1929; Carlson TR, 2008, DEVELOPMENT, V135, P2193, DOI 10.1242/dev.016378; Chen CP, 2005, J CLIN ENDOCR METAB, V90, P1083, DOI 10.1210/jc.2004-0803; Colgan SP, 1996, J EXP MED, V184, P1003, DOI 10.1084/jem.184.3.1003; Comerford KM, 2002, CANCER RES, V62, P3387; Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; Eckes B, 2006, J INVEST DERM SYMP P, V11, P66, DOI 10.1038/sj.jidsymp.5650003; Elson DA, 2000, CANCER RES, V60, P6189; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Grinnell F, 2002, EXP CELL RES, V273, P248, DOI 10.1006/excr.2001.5445; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; Haddad JJ, 2003, CRIT CARE, V7, P47, DOI 10.1186/cc1840; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Imaizumi F, 2004, TISSUE ENG, V10, P657, DOI 10.1089/1076327041348329; Jones RG, 2006, J CELL BIOL, V175, P505, DOI 10.1083/jcb.200602160; Kan C, 2003, J DERMATOL SCI, V32, P75, DOI 10.1016/S0923-1811(03)00032-X; Karhausen J, 2005, CELL CYCLE, V4, P256; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; Krieglstein CF, 2002, J CLIN INVEST, V110, P1773, DOI 10.1172/JCI200215256; Laughlin KM, 1996, J PHARMACOL EXP THER, V277, P1049; Lawrance IC, 2001, INFLAMM BOWEL DIS, V7, P226, DOI 10.1097/00054725-200108000-00008; Lotz MM, 1997, AM J PATHOL, V150, P747; Louis NA, 2005, FASEB J, V19, P950, DOI 10.1096/fj.04-3251com; Louis NA, 2008, J IMMUNOL, V180, P4246, DOI 10.4049/jimmunol.180.6.4246; Louis NA, 2006, J CELL BIOCHEM, V99, P1616, DOI 10.1002/jcb.20947; Mace KA, 2007, WOUND REPAIR REGEN, V15, P636, DOI 10.1111/j.1524-475X.2007.00278.x; Maclachlan T, 2005, INT J RADIAT BIOL, V81, P567, DOI 10.1080/09553000500211091; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Meissner U, 2003, PHARMACOLOGY, V69, P74, DOI 10.1159/000072359; Montandon D, 1977, Clin Plast Surg, V4, P325; MOORE R, 1989, AM J PHYSIOL, V257, pG274, DOI 10.1152/ajpgi.1989.257.2.G274; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; Ngo P, 2006, METH MOL B, V341, P103; OLSON AD, 1993, DIGEST DIS SCI, V38, P388, DOI 10.1007/BF01316489; Papakonstantinou E, 2003, CYTOKINE, V24, P25, DOI 10.1016/S1043-4666(03)00253-9; Phillips JA, 2005, EXP CELL RES, V310, P79, DOI 10.1016/j.yexcr.2005.03.039; RIIKONEN T, 1995, J BIOL CHEM, V270, P376, DOI 10.1074/jbc.270.1.376; Robinson A, 2008, GASTROENTEROLOGY, V134, P145, DOI 10.1053/j.gastro.2007.09.033; Saadi S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0690hyp; SEMENIUK C, 2007, WETLANDS ECOL CONSER, V1, P1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Steinbrech DS, 1999, J SURG RES, V84, P127, DOI 10.1006/jsre.1999.5627; STEMME S, 1992, ARTERIOSCLER THROMB, V12, P206, DOI 10.1161/01.ATV.12.2.206; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Tandara AA, 2004, WORLD J SURG, V28, P294, DOI 10.1007/s00268-003-7400-2; Taylor CT, 2007, J MOL MED, V85, P1295, DOI 10.1007/s00109-007-0277-z; Turner CE, 2000, J CELL SCI, V113, P4139; Van Assche G, 2004, INFLAMM BOWEL DIS, V10, P55, DOI 10.1097/00054725-200401000-00009; Zhang QX, 2008, J INVEST DERMATOL, V128, P2102, DOI 10.1038/jid.2008.53; Zinkernagel AS, 2007, J MOL MED, V85, P1339, DOI 10.1007/s00109-007-0282-2; ZUTTER MM, 1990, AM J PATHOL, V137, P113	59	77	78	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1338	1346		10.1096/fj.08-125344	http://dx.doi.org/10.1096/fj.08-125344			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19103643	Green Published			2022-12-28	WOS:000266651700010
J	Piconi, S; Trabattoni, D; Luraghi, C; Perilli, E; Borelli, M; Pacei, M; Rizzardini, G; Lattuada, A; Bray, DH; Catalano, M; Sparaco, A; Clerici, M				Piconi, Stefania; Trabattoni, Daria; Luraghi, Cristina; Perilli, Edoardo; Borelli, Manuela; Pacei, Michela; Rizzardini, Giuliano; Lattuada, Antonella; Bray, Dorothy H.; Catalano, Mariella; Sparaco, Antonella; Clerici, Mario			Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intima-media thickness	FASEB JOURNAL			English	Article						leukocyte activation; inflammation; T lymphocytes; ultrasound measurement	TOLL-LIKE RECEPTOR-4; ATHEROSCLEROTIC LESIONS; MONOCYTE ADHESION; INFLAMMATION; MACROPHAGES; PROGRESSION; CD36; IDENTIFICATION; POLYMORPHISMS; MECHANISMS	Several cohort studies reported a relation of cardiovascular events and periodontal disease. In particular, Porphyromonas gingivalis is associated with the development of atherosclerotic plaques. We verified in a longitudinal study whether inflammation biomarkers, endothelial adhesion molecules, leukocyte activation markers, and intima-media thickness could be beneficially modified by periodontal treatment alone. Thirty-five otherwise healthy individuals affected by mild to moderate parodontopathy were enrolled in the study. Echo-Doppler cardiography of the carotid artery, fluorescence-activated cell sorting analyses on lymphocytes and monocytes, and plasma inflammatory indices were evaluated at baseline and at multiple time points after the periodontal treatment. Results showed that inflammation biomarkers were abnormally increased at baseline. Periodontal treatment resulted in a significant reduction of the total oral bacterial load that was associated with a significant amelioration of inflammation biomarkers and of adhesion and activation proteins. Notably, intima-media thickness was significantly diminished after treatment. Inflammatory alterations associated with the genesis of atherosclerotic plaques are detected in otherwise healthy individuals affected by parodontopathy and are positively influenced by periodontal treatment. Reduction of oral bacterial load results in a modification of an anatomical parameter directly responsible for atherosclerosis. These results shed light on the pathogenesis of atherosclerosis and could have practical implications for public health.-Piconi, S., Trabattoni, D., Luraghi, C., Perilli, E., Borelli, M., Pacei, M., Rizzardini, G., Lattuada, A., Bray, D. H., Catalano, M., Sparaco, A., Clerici, M. Treatment of periodontal disease results in improvements of endothelial dysfunction and reduction of the carotid intima-media thickness. FASEB J. 23, 1196-1204 (2009)	[Clerici, Mario] Univ Milan, Dept Biomed Sci & Technol, I-20090 Milan, Italy; [Piconi, Stefania; Rizzardini, Giuliano] Hosp Luigi Sacco, Infect Dis Unit, Milan, Italy; [Luraghi, Cristina; Sparaco, Antonella] Hosp Luigi Sacco, Odontoiatr Unit, Milan, Italy; [Perilli, Edoardo; Catalano, Mariella] Hosp Luigi Sacco, Res Ctr Vasc Dis & Angiol Unit, Milan, Italy; [Lattuada, Antonella] Hosp Luigi Sacco, Haematol Unit, Milan, Italy; [Bray, Dorothy H.] Immunoclin Ltd, London, England; [Clerici, Mario] Ist Ricovero & Cura Carattere Sci, Don C Gnocchi Fdn, Milan, Italy	University of Milan; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Fondazione Don Carlo Gnocchi Onlus	Clerici, M (corresponding author), Univ Milan, Dept Biomed Sci & Technol, Via Flli Cervi 93, I-20090 Milan, Italy.	mario.clerici@unimi.it	Catalano, Mariella/F-2708-2017; Trabattoni, Daria/G-7424-2012	Catalano, Mariella/0000-0002-8355-0344; Trabattoni, Daria/0000-0001-9535-3359; Clerici, Mario/0000-0001-5920-6191	Istituto Superiore di Sanita'; European Commission (EC); Japan Health Science Foundation,; Italian Ministry of Health; progetto Fondo Italiano Ricerca di Base RETI; Rete Italiana Chimica Farmaceutica CHEM-PRO-FARMA-NET	Istituto Superiore di Sanita'; European Commission (EC)(European CommissionEuropean Commission Joint Research Centre); Japan Health Science Foundation,; Italian Ministry of Health(Ministry of Health, Italy); progetto Fondo Italiano Ricerca di Base RETI; Rete Italiana Chimica Farmaceutica CHEM-PRO-FARMA-NET	This study was supported by grants from the Istituto Superiore di Sanita' "Programma Nazionale di Ricerca sull' AIDS," the AIDS Vaccine Integrated Project European Commission (EC) WP6 Projects, the nGIN EC FP7 Project, the Japan Health Science Foundation, 2007 Ricerca Finalizzata (Italian Ministry of Health), 2007 Ricerca Corrente (Italian Ministry of Health) and progetto Fondo Italiano Ricerca di Base RETI, Rete Italiana Chimica Farmaceutica CHEM-PRO-FARMA-NET (RBPR05NWWC). We are grateful to Gaba International AG and to Nadia Berto, RN, and Simona Pranzo for excellent technical support.	Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Armitage G C, 2000, Oral Dis, V6, P335, DOI 10.1111/j.1601-0825.2000.tb00126.x; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455; D'Aiuto F, 2005, J DENT RES, V84, P269, DOI 10.1177/154405910508400312; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; Elkind MSV, 2006, SEMIN NEUROL, V26, P88, DOI 10.1055/s-2006-933312; Elter JR, 2006, AM HEART J, V151, DOI 10.1016/j.ahj.2005.10.002; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Fiehn NE, 2005, J PERIODONTOL, V76, P731, DOI 10.1902/jop.2005.76.5.731; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Giacona MB, 2004, FEMS MICROBIOL LETT, V241, P95, DOI 10.1016/j.femsle.2004.10.009; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Haase R, 2003, J IMMUNOL, V171, P4294, DOI 10.4049/jimmunol.171.8.4294; Hajishengallis George, 2002, Ann Periodontol, V7, P72, DOI 10.1902/annals.2002.7.1.72; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Haraszthy VI, 2000, J PERIODONTOL, V71, P1554, DOI 10.1902/jop.2000.71.10.1554; Harokopakis E, 2006, J IMMUNOL, V176, P7645, DOI 10.4049/jimmunol.176.12.7645; Harris N, 1997, J EXP MED, V185, P177, DOI 10.1084/jem.185.1.177; Jain A, 2003, INFECT IMMUN, V71, P6012, DOI 10.1128/IAI.71.10.6012-6018.2003; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kozarov EV, 2005, ARTERIOSCL THROM VAS, V25, pE17, DOI 10.1161/01.ATV.0000155018.67835.1a; Kuchibhotla S, 2008, CARDIOVASC RES, V78, P185, DOI 10.1093/cvr/cvm093; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lalla E, 2003, ARTERIOSCL THROM VAS, V23, P1405, DOI 10.1161/01.ATV.0000082462.26258.FE; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Mercanoglu F, 2004, J PERIODONTOL, V75, P1694, DOI 10.1902/jop.2004.75.12.1694; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Papapanou P N, 1996, Ann Periodontol, V1, P1, DOI 10.1902/annals.1996.1.1.1; Papapanou PN, 2007, J CLIN PERIODONTOL, V34, P736, DOI 10.1111/j.1600-051X.2007.01113.x; Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; Roth GA, 2007, ATHEROSCLEROSIS, V190, P271, DOI 10.1016/j.atherosclerosis.2006.03.018; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; Schillinger T, 2006, STROKE, V37, P2271, DOI 10.1161/01.STR.0000236495.82545.2e; Stelzel M, 2002, J PERIODONTOL, V73, P868, DOI 10.1902/jop.2002.73.8.868; Tonetti MS, 2007, NEW ENGL J MED, V356, P911, DOI 10.1056/NEJMoa063186; Triantafilou M, 2007, CELL MICROBIOL, V9, P2030, DOI 10.1111/j.1462-5822.2007.00935.x; Xu XH, 2001, CIRCULATION, V104, P3103, DOI 10.1161/hc5001.100631	47	108	117	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1196	1204		10.1096/fj.08-119578	http://dx.doi.org/10.1096/fj.08-119578			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19074511				2022-12-28	WOS:000266651600024
J	Sun, J; Ramnath, RD; Tamizhselvi, R; Bhatia, M				Sun, Jia; Ramnath, Raina Devi; Tamizhselvi, Ramasamy; Bhatia, Madhav			Role of protein kinase C and phosphoinositide 3-kinase-Akt in substance P-induced proinflammatory pathways in mouse macrophages	FASEB JOURNAL			English	Article						neuroimmunoregulation; neuropeptides; leukocytes; inflammation; signaling kinases	NF-KAPPA-B; OXIDE SYNTHASE EXPRESSION; PANCREATIC ACINAR-CELLS; NITRIC-OXIDE; LUNG INJURY; PKC-DELTA; POLYMICROBIAL SEPSIS; NEGATIVE REGULATION; PHOSPHATIDYLINOSITOL 3-KINASE; ALVEOLAR MACROPHAGES	Neuropeptide modulation of immune cell function is an important mechanism of neuroimmune intersystem crosstalk. Substance P (SP) is one such key neuropeptide involved. In this study, we investigated the yet unexplored cellular mechanisms of SP-mediated inflammatory responses in macrophages using a mouse macrophage-like cell line RAW 264.7 and isolated peritoneal macrophages. We found that the conventional PKC alpha and novel PKC delta and epsilon were selectively activated by SP via its primary neurokinin-1 receptor (NK-1R) on the cells. Activation of these PKC isoforms mediated the activation of downstream extracellular signal-regulated kinase-1/2 (ERK1/2) and the transcription factor NF-kappa B, which drove the transcription of inducible chemokines in macrophages. Additionally, phosphoinositide 3-kinase (PI3K)-Akt was also activated by SP/NK-1R in macrophages. Inhibition of PI3K-Akt pathway attenuated ERK1/2 and NF-kappa B activation, suggesting it also played a part in SP-induced cellular inflammatory response. Kinetic analysis indicated that PKC isoforms induced early ERK1/2 activation, while PI3K-Akt contributed to the pathway at later time points. It was further demonstrated that PKC and PI3K-Akt were activated independent of each other. Collectively, our results suggest that SP/NK-1R activates two convergent proinflammatory signaling pathways, PKCs and PI3K-Akt, resulting in ERK1/2 and NF-kappa B activation and chemokine production in mouse macrophages.-Sun, J., Ramnath, R. D., Tamizhselvi, R., Bhatia, M. Role of protein kinase C and phosphoinositide 3-kinase-Akt in substance P-induced proinflammatory pathways in mouse macrophages. FASEB J. 23, 997-1010 (2009)	[Bhatia, Madhav] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol,Cardiovasc Biol Res Grp, Cardiovasc Biol Res Programme,Ctr Life Sci, Singapore 117456, Singapore	National University of Singapore	Bhatia, M (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol,Cardiovasc Biol Res Grp, Cardiovasc Biol Res Programme,Ctr Life Sci, 28 Med Dr, Singapore 117456, Singapore.	mbhatia@nus.edu.sg	Ramnath, Raina/AAO-1180-2020	Ramnath, Raina/0000-0001-8472-5081; Ramasamy, Tamizhselvi/0000-0002-8945-6308	National Medical Research Council [R-184-000-156213]; Life Sciences Institute of National University [R-184-000-074-712]	National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Life Sciences Institute of National University	This work was supported by National Medical Research Council grant R-184-000-156213 and Life Sciences Institute of National University of Singapore Cardiovascular Biology Program grant R-184-000-074-712. We thank Mr. Akhil Kumar Hegde Rama for reading and commenting on the manuscript. We also thank Ms. Mei Leng Shoon for technical support.	Bardelli C, 2005, BRIT J PHARMACOL, V145, P385, DOI 10.1038/sj.bjp.0706198; Basu JM, 2006, ANTIMICROB AGENTS CH, V50, P1788, DOI [10.1128/AAC.50.5.1788-1797.2006, 10.1128/AAC.50.5.1768-1797.2006]; Bhatia M, 2006, AM J PHYSIOL-LUNG C, V291, pL896, DOI 10.1152/ajplung.00053.2006; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Cao Y, 2007, AM J PATHOL, V170, P1521, DOI 10.2353/ajpath.2007.061149; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Chow JYC, 2008, AM J PHYSIOL-GASTR L, V294, pG899, DOI 10.1152/ajpgi.00411.2007; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489; Grimsholm O, 2007, ANN NY ACAD SCI, V1110, P525, DOI 10.1196/annals.1423.056; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; Hegde A, 2007, J LEUKOCYTE BIOL, V82, P678, DOI 10.1189/jlb.0407217; Holden NS, 2008, CELL SIGNAL, V20, P1338, DOI 10.1016/j.cellsig.2008.03.001; Kanchanapoo J, 2007, AM J PHYSIOL-CELL PH, V293, pC1851, DOI 10.1152/ajpcell.00194.2007; Kao SJ, 2005, IMMUNOLOGY, V115, P366, DOI 10.1111/j.1365-2567.2005.02160.x; Karimi K, 2004, EUR J PHARMACOL, V489, P49, DOI 10.1016/j.ejphar.2004.03.003; Koon HW, 2005, J PHARMACOL EXP THER, V314, P1393, DOI 10.1124/jpet.105.088013; Lau HY, 2005, BIOCHEM BIOPH RES CO, V327, P509, DOI 10.1016/j.bbrc.2004.12.030; Lee MC, 2008, J LEUKOCYTE BIOL, V84, P835, DOI 10.1189/jlb.1007691; Luyendyk JP, 2008, J IMMUNOL, V180, P4218, DOI 10.4049/jimmunol.180.6.4218; Martin M, 2003, J IMMUNOL, V171, P717, DOI 10.4049/jimmunol.171.2.717; Ng SW, 2008, J LEUKOCYTE BIOL, V83, P288, DOI 10.1189/jlb.0807575; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pengal RA, 2006, MOL IMMUNOL, V43, P1557, DOI 10.1016/j.molimm.2005.09.022; Puneet P, 2006, J IMMUNOL, V176, P3813, DOI 10.4049/jimmunol.176.6.3813; Ramnath RD, 2008, AM J PHYSIOL-CELL PH, V294, pC683, DOI 10.1152/ajpcell.00360.2007; Sapna S, 2007, CELL BIOL INT, V31, P856, DOI 10.1016/j.cellbi.2007.01.031; Satoh A, 2004, AM J PHYSIOL-GASTR L, V287, pG582, DOI 10.1152/ajpgi.00087.2004; Schechtman D, 2002, METHOD ENZYMOL, V345, P470; Sebastian C, 2008, J IMMUNOL, V180, P5898, DOI 10.4049/jimmunol.180.9.5898; Smith MV, 2007, J BONE JOINT SURG AM, V89A, P1019, DOI 10.2106/JBJS.F.00615; Soltoff SP, 2007, TRENDS PHARMACOL SCI, V28, P453, DOI 10.1016/j.tips.2007.07.003; Sud N, 2008, AM J PHYSIOL-LUNG C, V294, pL582, DOI 10.1152/ajplung.00353.2007; Sun J, 2008, AM J PHYSIOL-CELL PH, V294, pC1586, DOI 10.1152/ajpcell.00129.2008; Sun J, 2007, AM J PHYSIOL-CELL PH, V293, pC696, DOI 10.1152/ajpcell.00060.2007; Sun J, 2007, AM J PHYSIOL-GASTR L, V292, pG143, DOI 10.1152/ajpgi.00271.2006; Thrower EC, 2008, AM J PHYSIOL-GASTR L, V294, pG1344, DOI 10.1152/ajpgi.00020.2008; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Tsukamoto K, 2008, J IMMUNOL, V180, P2054, DOI 10.4049/jimmunol.180.4.2054; Ward SG, 2003, CURR OPIN PHARMACOL, V3, P426, DOI 10.1016/S1471-4892(03)00078-X; Xu J, 2008, AM J PHYSIOL-LUNG C, V295, pL162, DOI 10.1152/ajplung.00282.2007; Yaraee R, 2007, INT IMMUNOPHARMACOL, V7, P135, DOI 10.1016/j.intimp.2006.09.001; Yoo JK, 2005, J IMMUNOL, V175, P8280, DOI 10.4049/jimmunol.175.12.8280; Zhang H, 2008, AM J RESP CELL MOL, V38, P483, DOI 10.1165/rcmb.2007-0260OC; Zhang HL, 2007, J IMMUNOL, V179, P4153, DOI 10.4049/jimmunol.179.6.4153; Zhang Y, 2006, CURR DRUG TARGETS, V7, P1011, DOI 10.2174/138945006778019363	52	40	41	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					997	1010		10.1096/fj.08-121756	http://dx.doi.org/10.1096/fj.08-121756			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19029199				2022-12-28	WOS:000266651600004
J	Wang, Y; Meriin, AB; Zaarur, N; Romanova, NV; Chernoff, YO; Costello, CE; Sherman, MY				Wang, Yan; Meriin, Anatoli B.; Zaarur, Nava; Romanova, Nina V.; Chernoff, Yury O.; Costello, Catherine E.; Sherman, Michael Y.			Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery	FASEB JOURNAL			English	Article						polyglutamine; aggregation; VCP; 14-3-3 protein; neurodegeneration; misfolding	ENDOPLASMIC-RETICULUM MEMBRANE; NEURODEGENERATIVE DISEASES; POLYGLUTAMINE AGGREGATION; HUNTINGTONS-DISEASE; MISFOLDED PROTEINS; ALPHA-SYNUCLEIN; BODY FORMATION; MALLORY BODY; DEGRADATION; UBIQUITIN	In mammalian cells, abnormal proteins that escape proteasome-dependent degradation form small aggregates that can be transported into a centrosome-associated structure, called an aggresome. Here we demonstrate that in yeast a single aggregate formed by the huntingtin exon 1 with an expanded polyglutamine domain (103QP) represents a bona fide aggresome that colocalizes with the spindle pole body (the yeast centrosome) in a microtubule-dependent fashion. Since a polypeptide lacking the proline-rich region (P-region) of huntingtin (103Q) cannot form aggresomes, this domain serves as an aggresome-targeting signal. Coexpression of 103Q with 25QP, a soluble polypeptide that also carries the P-region, led to the recruitment of 103Q to the aggresome via formation of hetero-oligomers, indicating the aggresome targeting in trans. To identify additional factors involved in aggresome formation and targeting, we purified 103QP aggresomes and 103Q aggregates and identified the associated proteins using mass spectrometry. Among the aggresome-associated proteins we identified, Cdc48 (VCP/p97) and its cofactors, Ufd1 and Nlp4, were shown genetically to be essential for aggresome formation. The 14-3-3 protein, Bmh1, was also found to be critical for aggresome targeting. Its interaction with the huntingtin fragment and its role in aggresome formation required the huntingtin N-terminal N17 domain, adjacent to the polyQ domain. Accordingly, the huntingtin N17 domain, along with the P-region, plays a role in aggresome targeting. We also present direct genetic evidence for the protective role of aggresomes by demonstrating genetically that aggresome targeting of polyglutamine polypeptides relieves their toxicity. - Wang, Y., Meriin, A. B., Zaarur, N., Romanova, N. V., Chernoff, Y. O., Costello, C. E., Sherman, M. Y. Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. FASEB J. 23, 451-463 (2009)	[Wang, Yan; Meriin, Anatoli B.; Zaarur, Nava; Costello, Catherine E.; Sherman, Michael Y.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Romanova, Nina V.; Chernoff, Yury O.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; [Romanova, Nina V.; Chernoff, Yury O.] Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA 30332 USA	Boston University; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Sherman, MY (corresponding author), 715 Albany St,K323, Boston, MA 02118 USA.	sherma1@bu.edu	Romanova, Nina V/F-9852-2014; Chernoff, Yury O/J-2833-2014	Romanova, Nina V/0000-0003-4177-2712; Costello, Catherine/0000-0003-1594-5122; Meriin, Anatoli/0000-0003-0087-814X; Sherman, Michael/0000-0003-3345-073X; Chernoff, Yury/0000-0002-8934-9051	U.S. National Institutes of Health [R01 NS047705, P41 RR10888, S10 RR15942, R01GM58763]; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015942, P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047705] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by U.S. National Institutes of Health grants R01 NS047705 (to M.Y.S.), P41 RR10888 and S10 RR15942 (to C.E.C.), and R01GM58763 (to Y.O.C.). We are grateful to Dr. Martin Duennwald (Boston Biomedical Research Institute, Boston, MA, USA) for very helpful suggestions and insights.	Ardley HC, 2004, J NEUROCHEM, V90, P379, DOI 10.1111/j.1471-4159.2004.02485.x; Bar-Nun S, 2005, CURR TOP MICROBIOL, V300, P95; Bardag-Gorce F, 2004, EXP MOL PATHOL, V76, P9, DOI 10.1016/j.yexmp.2003.08.006; Burnett BG, 2005, P NATL ACAD SCI USA, V102, P4330, DOI 10.1073/pnas.0407252102; Cheeseman IM, 2004, CURR BIOL, V14, pR70, DOI 10.1016/j.cub.2003.12.048; Corboy Michael J., 2005, V301, P305; Dehay B, 2006, J BIOL CHEM, V281, P35608, DOI 10.1074/jbc.M605558200; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Duennwald ML, 2006, P NATL ACAD SCI USA, V103, P11045, DOI 10.1073/pnas.0604547103; Duennwald ML, 2006, P NATL ACAD SCI USA, V103, P11051, DOI 10.1073/pnas.0604548103; Erjavec N, 2007, GENE DEV, V21, P2410, DOI 10.1101/gad.439307; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fortun J, 2003, J NEUROSCI, V23, P10672; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gokhale KC, 2005, J BIOL CHEM, V280, P22809, DOI 10.1074/jbc.M500390200; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Heir R, 2006, EMBO REP, V7, P1252, DOI 10.1038/sj.embor.7400823; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaltenbach LS, 2007, PLOS GENET, V3, P689, DOI 10.1371/journal.pgen.0030082; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kobayashi T, 2007, GENES CELLS, V12, P889, DOI 10.1111/j.1365-2443.2007.01099.x; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; McNaught KSP, 2002, EUR J NEUROSCI, V16, P2136, DOI 10.1046/j.1460-9568.2002.02301.x; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Meriin AB, 2001, J CELL BIOL, V153, P851, DOI 10.1083/jcb.153.4.851; Meriin AB, 2007, FASEB J, V21, P1915, DOI 10.1096/fj.06-6878com; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x; Nowis D, 2006, EXP CELL RES, V312, P2921, DOI 10.1016/j.yexcr.2006.05.013; Olzmann JA, 2008, CURR MED CHEM, V15, P47; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Preisinger E, 1999, PHILOS T ROY SOC B, V354, P1029, DOI 10.1098/rstb.1999.0455; Riley NE, 2002, EXP MOL PATHOL, V72, P17, DOI 10.1006/exmp.2001.2413; Rujano MA, 2006, PLOS BIOL, V4, P2325, DOI 10.1371/journal.pbio.0040417; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shirakashi Y, 2006, ACTA NEUROPATHOL, V112, P681, DOI 10.1007/s00401-006-0132-2; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Stumptner C, 2002, HEPATOLOGY, V35, P1053, DOI 10.1053/jhep.2002.32674; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wang Y, 2007, PRION, V1, P128, DOI 10.4161/pri.1.2.4440; Weissmann C, 2002, ACTA NEUROBIOL EXP, V62, P153; Wigley WC, 1999, J CELL BIOL, V145, P481; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Wojcik C, 1996, EUR J CELL BIOL, V71, P311; Wojcik C, 2006, MOL BIOL CELL, V17, P4606, DOI 10.1091/mbc.E06-05-0432; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Yang H, 2005, NEUROREPORT, V16, P1117, DOI 10.1097/00001756-200507130-00017; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Zaarur N, 2008, J BIOL CHEM, V283, P27575, DOI 10.1074/jbc.M802216200; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o; Zubarev R, 2007, MOL CELL PROTEOMICS, V6, P377, DOI 10.1074/mcp.M600380-MCP200	60	109	111	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					451	463		10.1096/fj.08-117614	http://dx.doi.org/10.1096/fj.08-117614			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18854435	Green Published			2022-12-28	WOS:000262892900017
J	Vikman, J; Jimenez-Feltstrom, J; Nyman, P; Thelin, J; Eliasson, L				Vikman, Jenny; Jimenez-Feltstrom, Javier; Nyman, Per; Thelin, Johan; Eliasson, Lena			Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol	FASEB JOURNAL			English	Article						Ca2+; exocytosis; SNAP-25; methyl-beta-cyclodextrin	LIPID RAFTS; CA2+ CHANNELS; SNARE PROTEINS; ALPHA-CELLS; FUSION PORE; PC12 CELLS; EXOCYTOSIS; GRANULES; RELEASE; SNAP-25	Cholesterol-rich clusters of SNARE (soluble NSF attachment protein receptor) proteins have been implicated as being important for exocytosis. Here we demonstrate the significance of cholesterol for normal biphasic insulin secretion in mouse beta cells by removal of cholesterol from the plasma membrane using methyl-beta-cyclodextrin (MBCD). Maximal inhibition of insulin secretion in static incubations was achieved using 0.1 mM MBCD. In in situ pancreatic perfusion measurements, both first and second phase insulin secretions were reduced by similar to 50% (P<0.05). This was accompanied by a reduced number of docked large dense core vesicles (LDCVs) (similar to 40%; P<0.01) and a reduced exocytotic response (>50%; P<0.01). Further, subcellular fractionations demonstrated movement of the synaptosomal protein of 25 kDa (SNAP-25) from the plasma membrane to the cytosol after MBCD treatment. The inhibitory actions of MBCD were counteracted by subsequent addition of cholesterol. We hypothesize that desorption of cholesterol leads to the disturbance of a basic exocytotic mechanism partly due to migration of SNAP-25, and we conclude that insulin secretion is highly sensitive to changes in plasma membrane cholesterol.-Vikman, J., Jimenez-Feltstrom, J., Nyman, P., Thelin, J., Eliasson, L. Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. FASEB J. 23, 58-67 (2009)	[Vikman, Jenny; Jimenez-Feltstrom, Javier; Nyman, Per; Thelin, Johan; Eliasson, Lena] Lund Univ, Ctr Diabet, Dept Clin Sci Malmo, Unit Islet Cell Exocytosis,Clin Res Ctr, S-20502 Malmo, Sweden	Lund University	Vikman, J (corresponding author), Lund Univ, Ctr Diabet, Dept Clin Sci Malmo, Unit Islet Cell Exocytosis,Clin Res Ctr, CRC 91-11,UMAS Entrance 72, S-20502 Malmo, Sweden.	jenny.vikman@med.lu.se	Eliasson, Lena/E-9294-2012	Eliasson, Lena/0000-0002-6467-5029; Thelin, Johan/0000-0002-6101-4946; Vikman, Jenny/0000-0001-5082-8867	Swedish Research Council [13147]; EU-Biosim; European Foundation for the Study of Diabetes; Novo Nordisk Foundation; Albert Pahlssons Foundation; Svenska Sallskapet for Medicinsk Forskning; Swedish Diabetes Association; Diabetes Program at Lund University; Thurings Foundation; Royal Physiografic Society in Lund; Crafoord Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); EU-Biosim; European Foundation for the Study of Diabetes; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Albert Pahlssons Foundation; Svenska Sallskapet for Medicinsk Forskning; Swedish Diabetes Association; Diabetes Program at Lund University; Thurings Foundation; Royal Physiografic Society in Lund(Royal Society of London); Crafoord Foundation	We thank Kristina Borglid and Britt-Marie Nilsson for expert technical assistance and Dr. Dina Speidel for valuable discussion. This work was supported by the Swedish Research Council (13147), EU-Biosim, the European Foundation for the Study of Diabetes, the Novo Nordisk Foundation, the Albert Pahlssons Foundation, the Svenska Sallskapet for Medicinsk Forskning, the Swedish Diabetes Association, the Diabetes Program at Lund University, the Thurings Foundation, the Royal Physiografic Society in Lund, and the Crafoord Foundation. L.E. is employed by the Lund University Diabetes Centre.	AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; Barg S, 2002, DIABETES, V51, pS74, DOI 10.2337/diabetes.51.2007.S74; Barg S, 2001, BIOPHYS J, V81, P3308, DOI 10.1016/S0006-3495(01)75964-4; Barg S, 2000, DIABETES, V49, P1500, DOI 10.2337/diabetes.49.9.1500; BONNEVIENIELSEN V, 1981, DIABETES, V30, P424, DOI 10.2337/diabetes.30.5.424; Braun M, 2007, J GEN PHYSIOL, V129, P221, DOI 10.1085/jgp.200609658; CERASI E, 1992, INSULIN MOL BIOL PAT; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Cho WJ, 2007, CELL BIOL INT, V31, P1301, DOI 10.1016/j.cellbi.2007.06.011; Churchward MA, 2005, J CELL SCI, V118, P4833, DOI 10.1242/jcs.02601; Dotta F, 1998, ENDOCRINOLOGY, V139, P316, DOI 10.1210/en.139.1.316; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Gonelle-Gispert C, 2000, J CELL SCI, V113, P3197; Gopel SO, 2000, J PHYSIOL-LONDON, V528, P509, DOI 10.1111/j.1469-7793.2000.00509.x; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; HOSKER JP, 1989, METABOLISM, V38, P767, DOI 10.1016/0026-0495(89)90064-4; Ji JZ, 2002, DIABETES, V51, P1425, DOI 10.2337/diabetes.51.5.1425; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Lang T, 2007, J PHYSIOL-LONDON, V585, P693, DOI 10.1113/jphysiol.2007.134346; MacDonald PE, 2006, CELL METAB, V4, P283, DOI 10.1016/j.cmet.2006.08.011; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Ohara-Imaizumi M, 2004, DIABETOLOGIA, V47, P2200, DOI 10.1007/s00125-004-1579-0; Ohara-Imaizumi M, 2004, J BIOL CHEM, V279, P8403, DOI 10.1074/jbc.M308954200; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; Olofsson CS, 2002, PFLUG ARCH EUR J PHY, V444, P43, DOI 10.1007/s00424-002-0781-5; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Resh MD, 2004, SUB CELL BIOCHEM, V37, P217; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Salaun C, 2005, J BIOL CHEM, V280, P1236, DOI 10.1074/jbc.M410674200; Takahashi N, 2004, J CELL BIOL, V165, P255, DOI 10.1083/jcb.200312033; Vikman J, 2003, BIOCHEM SOC T, V31, P842, DOI 10.1042/BST0310842; Vikman J, 2006, J MOL ENDOCRINOL, V36, P503, DOI 10.1677/jme.1.01978; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; Xia FZ, 2007, ENDOCRINOLOGY, V148, P2157, DOI 10.1210/en.2006-1296; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200	42	63	65	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					58	67		10.1096/fj.08-105734	http://dx.doi.org/10.1096/fj.08-105734			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18806218				2022-12-28	WOS:000262095500008
J	De Feyter, HM; Lenaers, E; Houten, SM; Schrauwen, P; Hesselink, MK; Wanders, RJA; Nicolay, K; Prompers, JJ				De Feyter, Henk M.; Lenaers, Ellen; Houten, Sander M.; Schrauwen, Patrick; Hesselink, Matthijs K.; Wanders, Ronald J. A.; Nicolay, Klaas; Prompers, Jeanine J.			Increased intramyocellular lipid content but normal skeletal muscle mitochondrial oxidative capacity throughout the pathogenesis of type 2 diabetes	FASEB JOURNAL			English	Article						rat; NMR spectroscopy; In vivo NMR; insulin resistance; PCr recovery	INSULIN-RESISTANCE; GLUCOSE-HOMEOSTASIS; ZUCKER RATS; FATTY RATS; FIBER TYPE; DYSFUNCTION; OBESITY; HUMANS; DIET; SPECTROSCOPY	Currently inherited or acquired skeletal muscle mitochondrial dysfunction is linked to dysregulated fatty acid metabolism, resulting in increased levels of intramyocellular lipids (IMCLs) and lipid intermediates, inducing insulin resistance. The present study aimed to clarify the order of changes in IMCL levels and skeletal muscle mitochondrial function during the development of type 2 diabetes in Zucker diabetic fatty (ZDF) rats. IMCL levels and skeletal muscle oxidative capacity were determined in vivo, using localized H-1 magnetic resonance spectroscopy (MRS) and dynamic P-31 MRS, respectively. In parallel, in vitro activities were measured from enzymes involved in fatty acid oxidation, the tricarboxylic acid cycle and the electron transport chain. Fa/fa ZDF rats were studied at 3 different ages corresponding to different stages of type 2 diabetes, whereas fa/+ rats served as controls. Fa/fa ZDF rats had higher IMCL contents than controls throughout the duration of the study. In vivo muscle oxidative capacity was not different in fa/fa animals compared to controls, and in vitro enzyme activity data suggested improved functionality of enzymes involved in fat oxidation in type 2 diabetic animals. Accordingly, we can conclude that in the ZDF rat model, type 2 diabetes develops in the absence of skeletal muscle mitochondrial dysfunction. -De Feyter, H. M., Lenaers, E., Houten, S. M., Schrauwen, P., Hesselink, M. K., Wanders, R. J. A., Nicolay, K., Prompers, J. J. Increased intramyocellular lipid content but normal skeletal muscle mitochondrial oxidative capacity throughout the pathogenesis of type 2 diabetes. FASEB J. 22, 3947-3955 (2008)	[De Feyter, Henk M.; Nicolay, Klaas; Prompers, Jeanine J.] Eindhoven Univ Technol, Biomed NMR, Dept Biomed Engn, NL-5600 MB Eindhoven, Netherlands; [Lenaers, Ellen; Hesselink, Matthijs K.] Maastricht Univ, Dept Human Movement Sci, Nutr & Toxicol Res Inst, Maastricht, Netherlands; [Schrauwen, Patrick] Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst, Maastricht, Netherlands; [Houten, Sander M.; Wanders, Ronald J. A.] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands	Eindhoven University of Technology; Maastricht University; Maastricht University; University of Amsterdam; Academic Medical Center Amsterdam	De Feyter, HM (corresponding author), Yale Univ, MRRC, TAC N 136,300 Cedar St,POB 208043, New Haven, CT 06520 USA.	henk.defeyter@yale.edu	Houten, Sander/Y-3599-2019; De Feyter, Henk/B-8107-2008; Nicolay, Klaas/F-4192-2010	Houten, Sander/0000-0002-6167-9147; De Feyter, Henk/0000-0001-6111-0316; Nicolay, Klaas/0000-0002-4179-616X; schrauwen, patrick/0000-0002-0973-847X; Prompers, Jeanine/0000-0002-4756-4474	VIDI [917.66.359]	VIDI(Netherlands Organization for Scientific Research (NWO))	We express our appreciation to Stephan Majoor and Larry de Graaf for their assistance with the in vivo experiments and for technical support, respectively. We thank Jos P. N. Ruiter for technical assistance with the enzyme assays and Robin A. de Graaf for help with the implementation of the LASER pulse sequence. M. K. H. is supported by a VIDI grant for innovative research (917.66.359).	Befroy DE, 2007, DIABETES, V56, P1376, DOI 10.2337/db06-0783; Bonnard C, 2008, J CLIN INVEST, V118, P789, DOI 10.1172/JCI32601; BOSKA M, 1994, MAGN RESON MED, V32, P1, DOI 10.1002/mrm.1910320102; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; Chanseaume E, 2007, OBESITY, V15, P50, DOI 10.1038/oby.2007.511; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; De Feyter HMML, 2006, MAGN RESON MED, V56, P19, DOI 10.1002/mrm.20924; de Graaf RA, 1998, MAGNET RESON MED, V40, P690, DOI 10.1002/mrm.1910400508; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Dobbins RL, 2001, DIABETES, V50, P123, DOI 10.2337/diabetes.50.1.123; Etgen GJ, 2000, METABOLISM, V49, P684, DOI 10.1016/S0026-0495(00)80049-9; Garwood M, 2001, J MAGN RESON, V153, P155, DOI 10.1006/jmre.2001.2340; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Handschin C, 2007, J CLIN INVEST, V117, P3463, DOI 10.1172/JCI31785; He J, 2001, DIABETES, V50, P817, DOI 10.2337/diabetes.50.4.817; Hoeks J, 2008, FEBS LETT, V582, P510, DOI 10.1016/j.febslet.2008.01.013; Iossa S, 2002, INT J OBESITY, V26, P65, DOI 10.1038/sj.ijo.0801844; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; KLEIN M, 1994, AM J PHYSIOL, V266, pE410, DOI 10.1152/ajpendo.1994.266.3.E410; Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123; Kuhlmann J, 2003, DIABETES, V52, P138, DOI 10.2337/diabetes.52.1.138; Kulhmann J, 2005, MAGN RESON MED, V53, P1275, DOI 10.1002/mrm.20501; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; Lionetti L, 2007, INT J OBESITY, V31, P1596, DOI 10.1038/sj.ijo.0803636; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Petersen KF, 2006, AM J MED, V119, p10S, DOI 10.1016/j.amjmed.2006.01.009; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047; QUISTORFF B, 1993, BIOCHEM J, V291, P681, DOI 10.1042/bj2910681; Rabol R, 2006, APPL PHYSIOL NUTR ME, V31, P675, DOI 10.1139/h06-071; Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8; Roden M, 2005, INT J OBESITY, V29, pS111, DOI 10.1038/sj.ijo.0803102; Sanderson AL, 1996, CLIN SCI, V91, P691, DOI 10.1042/cs0910691; Schrauwen-Hinderling VB, 2007, DIABETOLOGIA, V50, P113, DOI 10.1007/s00125-006-0475-1; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; Taylor D J, 1983, Mol Biol Med, V1, P77; TAYLOR DJ, 1986, MAGNET RESON MED, V3, P44, DOI 10.1002/mrm.1910030107; Turner N, 2007, DIABETES, V56, P2085, DOI 10.2337/db07-0093; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Wanders RJA, 1999, J INHERIT METAB DIS, V22, P442, DOI 10.1023/A:1005504223140; Wredenberg A, 2006, BIOCHEM BIOPH RES CO, V350, P202, DOI 10.1016/j.bbrc.2006.09.029; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhang DY, 2007, P NATL ACAD SCI USA, V104, P17075, DOI 10.1073/pnas.0707060104	51	59	60	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3947	3955		10.1096/fj.08-112318	http://dx.doi.org/10.1096/fj.08-112318			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18653763	Green Submitted			2022-12-28	WOS:000260503000023
J	Saresella, M; Marventano, I; Longhi, R; Lissoni, F; Trabattoni, D; Mendozzi, L; Caputo, D; Clerici, M				Saresella, Marina; Marventano, Ivana; Longhi, Renato; Lissoni, Francesca; Trabattoni, Daria; Mendozzi, Laura; Caputo, Domenico; Clerici, Mario			CD4+CD25+FoxP3+PD1 - regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy	FASEB JOURNAL			English	Article						immunology; T lymphocytes; glatiramer acetate; copaxone; neurology	GLATIRAMER ACETATE COPAXONE; CENTRAL-NERVOUS-SYSTEM; SUPPRESSIVE FUNCTION; TH2 CELLS; MYELIN; FOXP3; EXPRESSION; TOLERANCE; DYSFUNCTION; PROGRESSION	The intracellular expression of the programmed death receptor 1 (PD1) identifies a subset of naive T-reg cells with enhanced suppressive ability; antigen stimulation results in the surface expression of PD1. Because the role of T-reg impairments in multiple sclerosis (MS) is still contradictory, we analyzed naive PD1- and PD1+T-reg cells in peripheral blood and cerebrospinal fluid (CSF) of relapsing-remitting multiple sclerosis (RR-MS) patients and of healthy control subjects. Results showed that 1) CSF PD1-T-reg cells were significantly augmented in MS patients; 2) PD1-Treg g cells were significantly increased in the peripheral blood of patients with stable disease (SMS) compared to those with acute (AMS) disease, and in patients responding to glatiramer acetate (COPA) compared to AMS- and COPA-unresponsive patients; and 3) PD1+ T-reg cells were similar in CSF and peripheral blood of all groups analyzed. PD1-T-reg cells were not increased in the peripheral blood of interferon-beta (IFN beta)-responsive patients, but the suppressive ability of T-reg cells was significantly higher in SMS and in COPA- or IFN beta-responsive compared to AMS- and COPA-unresponsive individuals. The data herein suggest that PD1-T-reg cells play a pivotal role in MS and offer a biological explanation for disease relapse and for the mechanism associated with response to COPA and IFN beta.	[Clerici, Mario] Univ Milan, Dept Biomed Sci & Technol, I-20090 Milan, Italy; [Saresella, Marina; Marventano, Ivana; Clerici, Mario] IRCCS, Lab Mol Med & Biotechnol, Don C Gnocchi ONLUS Fdn, Milan, Italy; [Mendozzi, Laura; Caputo, Domenico] IRCCS, Multiple Sclerosis Unit, Don C Gnocchi ONLUS Fdn, Milan, Italy; [Longhi, Renato] CNR, ICRM, I-20133 Milan, Italy; [Lissoni, Francesca; Trabattoni, Daria] DISP LITA Vialba, Milan, Italy	University of Milan; IRCCS Fondazione Don Carlo Gnocchi Onlus; IRCCS Fondazione Don Carlo Gnocchi Onlus; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR)	Clerici, M (corresponding author), Univ Milan, Dept Biomed Sci & Technol, Via Fratelli Cervi 93, I-20090 Milan, Italy.	mario.clerici@unimi.it	Saresella, Marina/G-7810-2012; Trabattoni, Daria/G-7424-2012	Saresella, Marina/0000-0002-2295-3043; Trabattoni, Daria/0000-0001-9535-3359; Clerici, Mario/0000-0001-5920-6191; Mendozzi, Laura/0000-0001-7394-4588; Marventano, Ivana/0000-0001-8111-3522	Japan Health Science Foundation; 2007 Ricerca Finalizzata (Italian Ministry of Health); 2007 Ricerca Corrente (Italian Ministry of Health); Rete Italiana Chimica Farmaceutica; CHEM-PROFARMA-NET [RBPR05NWWC]	Japan Health Science Foundation; 2007 Ricerca Finalizzata (Italian Ministry of Health)(Ministry of Health, Italy); 2007 Ricerca Corrente (Italian Ministry of Health)(Ministry of Health, Italy); Rete Italiana Chimica Farmaceutica; CHEM-PROFARMA-NET	This study was supported by grants from the Istituto Superiore di Sanita "Programma Nazionale di Ricerca sull' AIDS," the EMPRO and AVIP EC WP6 projects, the Japan Health Science Foundation, 2007 Ricerca Finalizzata (Italian Ministry of Health), 2007 Ricerca Corrente (Italian Ministry of Health), and project FIRB RETI, Rete Italiana Chimica Farmaceutica, CHEM-PROFARMA-NET (RBPR05NWWC). M.C. designed research and wrote the paper; M.S designed and performed research; I.M. analyzed results and drew figures; and R.L., F.L., D.T., L.M., and D.C. performed research. The authors declare no competing financial interests.	Aharoni R, 2000, P NATL ACAD SCI USA, V97, P11472, DOI 10.1073/pnas.97.21.11472; Aharoni R, 2002, J NEUROIMMUNOL, V126, P58, DOI 10.1016/S0165-5728(02)00053-X; Aharoni R, 2007, IMMUNOL LETT, V112, P110, DOI 10.1016/j.imlet.2007.07.009; Arnon R, 2004, P NATL ACAD SCI USA, V101, P14593, DOI 10.1073/pnas.0404887101; Blanco Y, 2006, NEUROSCI LETT, V406, P270, DOI 10.1016/j.neulet.2006.07.043; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; Crispin JC, 2003, J AUTOIMMUN, V21, P273, DOI 10.1016/S0896-8411(03)00121-5; de Kleer IM, 2004, J IMMUNOL, V172, P6435, DOI 10.4049/jimmunol.172.10.6435; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Feger U, 2007, CLIN EXP IMMUNOL, V147, P412, DOI 10.1111/j.1365-2249.2006.03271.x; Fehervari Z, 2004, J CLIN INVEST, V114, P1209, DOI 10.1172/JCI200434495; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Friese MA, 2007, BRAIN, V130, P2755, DOI 10.1093/brain/awm246; Haas J, 2005, EUR J IMMUNOL, V35, P3343, DOI 10.1002/eji.200526065; Haas J, 2007, J IMMUNOL, V179, P1322, DOI 10.4049/jimmunol.179.2.1322; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hori S, 2003, ADV IMMUNOL, V81, P331, DOI 10.1016/S0065-2776(03)81008-8; Huan J, 2005, J NEUROSCI RES, V81, P45, DOI 10.1002/jnr.20522; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Karandikar NJ, 2002, J CLIN INVEST, V109, P641, DOI 10.1172/JCI200214380; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605; Kumar M, 2006, J NEUROIMMUNOL, V180, P178, DOI 10.1016/j.jneuroim.2006.08.003; Kuniyasu Y, 2000, INT IMMUNOL, V12, P1145, DOI 10.1093/intimm/12.8.1145; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Magri G, 2005, VACCINE, V23, P2862, DOI 10.1016/j.vaccine.2004.11.067; MARTIN R, 1990, J IMMUNOL, V145, P540; Miller SD, 2007, ANN NY ACAD SCI, V1103, P179, DOI 10.1196/annals.1394.023; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; Piccirillo CA, 2004, TRENDS IMMUNOL, V25, P374, DOI 10.1016/j.it.2004.04.009; Putheti P, 2003, J NEUROIMMUNOL, V144, P125, DOI 10.1016/j.jneuroim.2003.08.001; Putheti P, 2004, J CLIN IMMUNOL, V24, P155, DOI 10.1023/B:JOCI.0000019780.93817.82; Raimondi G, 2006, J IMMUNOL, V176, P2808, DOI 10.4049/jimmunol.176.5.2808; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Sansom DM, 2006, IMMUNOL REV, V212, P131, DOI 10.1111/j.0105-2896.2006.00419.x; Sela M, 2006, REJUV RES, V9, P126, DOI 10.1089/rej.2006.9.126; Steinman L, 2001, J EXP MED, V194, pF27, DOI 10.1084/jem.194.5.F27; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143; Tennakoon DK, 2006, J IMMUNOL, V176, P7119, DOI 10.4049/jimmunol.176.11.7119; THOMPSON AJ, 1991, ANN NEUROL, V29, P53, DOI 10.1002/ana.410290111; Valenzuela RM, 2007, MULT SCLER J, V13, P754, DOI 10.1177/1352458506074510; Venken K, 2008, IMMUNOLOGY, V123, P79, DOI 10.1111/j.1365-2567.2007.02690.x; Venken K, 2007, J IMMUNOL METHODS, V322, P1, DOI 10.1016/j.jim.2007.01.025; Venken K, 2006, J NEUROSCI RES, V83, P1432, DOI 10.1002/jnr.20852; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579	53	55	60	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3500	3508		10.1096/fj.08-110650	http://dx.doi.org/10.1096/fj.08-110650			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18587005				2022-12-28	WOS:000259642600012
J	Qian, H; Robertson, AP; Powell-Coffman, JA; Martin, RJ				Qian, Hai; Robertson, Alan P.; Powell-Coffman, Jo Anne; Martin, Richard J.			Levamisole resistance resolved at the single-channel level in Caenorhabditis elegans	FASEB JOURNAL			English	Article						resistance; LEV-10; LEV-8; LEV-1; nAChR	ACETYLCHOLINE-RECEPTOR; GENE ENCODES; IDENTIFICATION; ACTIVATION; MUSCLE	Sydney Brenner promoted Caenorhabditis elegans as a model organism, and subsequent investigations pursued resistance to the nicotinic anthelmintic drug levamisole in C. elegans at a genetic level. These studies have advanced our understanding of genes associated with neuromuscular transmission and resistance to the antinematodal drug. In lev-8 and lev-1 mutant C. elegans, levamisole resistance is associated with reductions in levamisole-activated whole muscle cell currents. Although lev-8 and lev- 1 are known to code for nicotinic acetylcholine receptor (nAChR) subunits, an explanation for why these currents get smaller is not available. In wild-type adults, nAChRs aggregate at neuromuscular junctions and are not accessible for single-channel recording. Here we describe a use of LEV-10 knockouts, in which aggregation is lost, to make in situ recordings of nAChR channel currents. Our observations provide an explanation for levamisole resistance produced by LEV-8 and LEV-1 mutants at the single-channel level.	[Qian, Hai; Robertson, Alan P.; Martin, Richard J.] Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA; [Powell-Coffman, Jo Anne] Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA	Iowa State University; Iowa State University	Martin, RJ (corresponding author), Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA.	rjmartin@iastate.edu	/A-1783-2011	/0000-0003-2422-1847; Powell-Coffman, Jo Anne/0000-0001-9164-7499	National Institute of Allergy and Infectious Diseases [R01 AI047194]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047194] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Drs. Jean-Louis Bessereau and Thomas Boulin for providing mutant strains, primers and advice and Dr. Janet Richmond for encouragement and for showing us the dissection method. The project was supported by grant R01 AI047194 from the National Institute of Allergy and Infectious Diseases to R.J.M. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.	Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; BRENNER S, 1974, GENETICS, V77, P71; Culetto E, 2004, J BIOL CHEM, V279, P42476, DOI 10.1074/jbc.M404370200; Fleming JT, 1997, J NEUROSCI, V17, P5843; Gally C, 2004, NATURE, V431, P578, DOI 10.1038/nature02893; Gottschalk A, 2005, EMBO J, V24, P2566, DOI 10.1038/sj.emboj.7600741; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Levandoski MM, 2005, INT J PARASITOL, V35, P925, DOI 10.1016/j.ijpara.2005.03.007; LEWIS JA, 1980, GENETICS, V95, P905; LEWIS JA, 1980, NEUROSCIENCE, V5, P967, DOI 10.1016/0306-4522(80)90180-3; Prichard RK, 2007, PARASITOLOGY, V134, P1087, DOI 10.1017/S003118200700008X; Qian H, 2006, FASEB J, V20, P2606, DOI 10.1096/fj.06-6264fje; Rayes D, 2007, MOL PHARMACOL, V71, P1407, DOI 10.1124/mol.106.033514; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Robertson AP, 1999, FASEB J, V13, P749, DOI 10.1096/fasebj.13.6.749; ROBERTSON SJ, 1993, BRIT J PHARMACOL, V108, P170, DOI 10.1111/j.1476-5381.1993.tb13458.x; ROBERTSON SJ, 1993, PESTIC SCI, V37, P293, DOI 10.1002/ps.2780370310; Towers PR, 2005, J NEUROCHEM, V93, P1, DOI 10.1111/j.1471-4159.2004.02951.x; WHITE JG, 1983, COLD SPRING HARB SYM, V48, P633, DOI 10.1101/SQB.1983.048.01.067; Williams DC, 2005, GENETICS, V169, P1779, DOI 10.1534/genetics.104.038265; Wolstenholme AJ, 2004, TRENDS PARASITOL, V20, P469, DOI 10.1016/j.pt.2004.07.010	21	54	61	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3247	3254		10.1096/fj.08-110502	http://dx.doi.org/10.1096/fj.08-110502			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18519804	Green Published			2022-12-28	WOS:000258761300017
J	Grubb, DR; Vasilevski, O; Huynh, H; Woodcock, EA				Grubb, David R.; Vasilevski, Oliver; Huynh, Huy; Woodcock, Elizabeth A.			The extreme C-terminal region of phospholipase C beta 1 determines subcellular localization and function; the "b" splice variant mediates alpha(1)-adrenergic receptor responses in cardiomyocytes	FASEB JOURNAL			English	Article						proline-rich domain; Gq; PLC; myristoylated peptides; signaling specificity	MYOCARDIAL HYPERTROPHY; CARDIAC-HYPERTROPHY; BETA ISOZYMES; G-PROTEINS; 2 FORMS; ACTIVATION; CELLS; RHO; G-ALPHA(Q); C-BETA(1)	Phospholipase C beta 1 (PLC beta 1) exists as two splice variants, PLC beta 1a (150 kDa) and PLC beta 1b (140 kDa), which differ only in their C-terminal sequences of 64 and 31 amino acids, respectively. The 3 C-terminal amino acid residues of PLC beta 1a comprise a PDZ-interacting domain, whereas the PLC beta 1b sequence has no PDZ- interacting domain but contains unique proline-rich domain 5 residues from the C terminus. PLC beta 1a is localized in the cytoplasm, whereas PLC beta 1b targets to the sarcolemma and is enriched in caveolae. Deletion of 3 amino acids from the C terminus of PLC beta 1b did not alter its sarcolemmal localization, but deletion of the entire unique 31 amino acid sequence caused cytosolic localization. A myristoylated 10 amino acid peptide from the C terminus of PLC beta 1b selectively dissociated N-terminally GFP-tagged PLC beta 1b from the sarcolemma and inhibited PLC responses to alpha 1-adrenergic agonists, with a half maximal effective concentration of 12 +/- 1.6 mu M (mean +/- SE, n = 3). A similar peptide from PLC beta 1a was without effect at concentrations below 100 mu M. Thus, the extreme C-terminal sequences of the PLC beta 1 splice variants determine localization and, thus, function. In cardiomyocytes, responses initiated by alpha(1)-adrenergic receptor activation involve only PLC beta 1b, and the selective targeting of this splice variant to the sarcolemma provides a potential therapeutic target to reduce hypertrophy, apoptosis, and arrhythmias.	[Grubb, David R.; Vasilevski, Oliver; Huynh, Huy; Woodcock, Elizabeth A.] Baker Heart Res Inst, Cellular Biochem Lab, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute	Woodcock, EA (corresponding author), Baker Heart Res Inst, Cellular Biochem Lab, POB 6792,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	liz.woodcock@baker.edu.au						Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Arthur JF, 2001, J BIOL CHEM, V276, P37341, DOI 10.1074/jbc.M106572200; Bahk YY, 1998, BBA-LIPID LIPID MET, V1389, P76, DOI 10.1016/S0005-2760(97)00128-8; BAHK YY, 1994, J BIOL CHEM, V269, P8240; BRISTOL JA, 1994, TRENDS ENDOCRIN MET, V5, P402, DOI 10.1016/1043-2760(95)92522-K; Bush EW, 2006, J BIOL CHEM, V281, P33487, DOI 10.1074/jbc.M605536200; Cai Y, 2005, ONCOGENE, V24, P4293, DOI 10.1038/sj.onc.1208593; CannonCarlson S, 1997, ANAL BIOCHEM, V246, P146, DOI 10.1006/abio.1997.2002; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Dowal L, 2006, J BIOL CHEM, V281, P23999, DOI 10.1074/jbc.M512330200; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Fiume R, 2005, J BIOL CHEM, V280, P24221, DOI 10.1074/jbc.M411833200; Gonzales ML, 2006, J CELL BIOCHEM, V97, P252, DOI 10.1002/jcb.20655; Illenberger D, 2003, J BIOL CHEM, V278, P3006, DOI 10.1074/jbc.M208282200; Jezyk MR, 2006, NAT STRUCT MOL BIOL, V13, P1135, DOI 10.1038/nsmb1175; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Kim MJ, 1998, J BIOL CHEM, V273, P3618, DOI 10.1074/jbc.273.6.3618; Morris JB, 2006, J MOL CELL CARDIOL, V41, P17, DOI 10.1016/j.yjmcc.2006.03.011; Morris JB, 2004, J BIOL CHEM, V279, P8740, DOI 10.1074/jbc.M310012200; Onohara N, 2006, EMBO J, V25, P5305, DOI 10.1038/sj.emboj.7601417; Putney JW, 2007, BIOCHEM SOC SYMP, V74, P37, DOI 10.1042/BSS2007c04; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Saunders CM, 2007, BIOCHEM SOC SYMP, V74, P23, DOI 10.1042/BSS2007c03; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; Schnabel P, 2000, BIOCHEM BIOPH RES CO, V275, P1, DOI 10.1006/bbrc.2000.3255; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P16586, DOI 10.1073/pnas.0606894103; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Sun LS, 2007, PLATELETS, V18, P217, DOI 10.1080/09537100601016133; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; Zhang W, 2006, J BIOL CHEM, V281, P5811, DOI 10.1074/jbc.M507871200	38	36	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2768	2774		10.1096/fj.07-102558	http://dx.doi.org/10.1096/fj.07-102558			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18390926				2022-12-28	WOS:000258089300017
J	Kowalczuk, S; Broer, A; Tietze, N; Vanslambrouck, JM; Rasko, JEJ; Broer, S				Kowalczuk, Sonja; Broeer, Angelika; Tietze, Nadine; Vanslambrouck, Jessica M.; Rasko, John E. J.; Broeer, Stefan			A protein complex in the brush-border membrane explains a Hartnup disorder allele	FASEB JOURNAL			English	Article						amino acid transport; angiotensin-converting enzyme 2; epithelial transport	AMINO-ACID TRANSPORTERS; ANGIOTENSIN-CONVERTING ENZYME-2; XENOPUS-LAEVIS OOCYTES; PROLINE TRANSPORTER; MOLECULAR-CLONING; SYSTEM; FAMILY; EXPRESSION; COLLECTRIN; INTESTINE	Protein absorption in the intestine is mediated by proteases and brush-border peptidases together with peptide and amino acid transporters. Neutral amino acids are generated by a variety of aminopeptidases and carboxypeptidases and are subsequently taken up by the amino acid transporter B(0)AT1 (SLC6A19), which is mutated in Hartnup disorder. Coexpression of B(0)AT1 together with the brush-border carboxypeptidase angiotensin-converting enzyme 2 (ACE2) in Xenopus laevis oocytes led to a dramatic increase of transporter expression at the oocyte surface. Other members of the SLC6 family were not stimulated by coexpression with ACE2. Addition of a peptide containing a carboxyterminal leucine residue to ACE2- and B(0)AT1-coexpressing oocytes caused inward currents due to Na(+)-leucine cotransport, demonstrating the formation of a metabolic complex. Coexpression of the Hartnup disorder causing mutation B(0)AT1(R240Q) showed reduced interaction with ACE2 and its renal paralogue collectrin. This would result in reduced surface expression in both kidney and intestine, thereby explaining the onset of the disorder in individuals carrying this mutation.	[Vanslambrouck, Jessica M.; Rasko, John E. J.] Univ Sydney, Centenary Inst Canc Med & Cell Biol, Gene & Stem Cell Therapy Program, Camperdown, NSW, Australia; [Vanslambrouck, Jessica M.; Rasko, John E. J.] Royal Prince Alfred Hosp, Sydney Canc Ctr, Camperdown, NSW 2050, Australia; [Kowalczuk, Sonja; Broeer, Angelika; Tietze, Nadine; Broeer, Stefan] Australian Natl Univ, Sch Biochem & Mol Biol, Canberra, ACT 0200, Australia	University of Sydney; Centenary Institute; University of Sydney; Australian National University	Broer, S (corresponding author), Australian Natl Univ, Sch Biochem & Mol Biol, Linnaeus Way 41, Canberra, ACT 0200, Australia.	stefan.broeer@anu.edu.au	Rasko, John EJ/F-5754-2013; Broer, Stefan/A-1286-2008	Broer, Stefan/0000-0002-8040-1634; rasko, John/0000-0003-2975-807X				AZMANOV DN, 2008, HUM MUTAT IN PRESS; BAI JPF, 1994, PHARMACEUT RES, V11, P897, DOI 10.1023/A:1018946228432; Biber J, 2007, NAT PROTOC, V2, P1356, DOI 10.1038/nprot.2007.156; Bohmer C, 2005, BIOCHEM J, V389, P745; Broer A, 2006, BIOCHEM J, V393, P421, DOI 10.1042/BJ20051273; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; Broer S, 1997, J BIOL CHEM, V272, P30096, DOI 10.1074/jbc.272.48.30096; Broer S, 2008, PHYSIOL REV, V88, P249, DOI 10.1152/physrev.00018.2006; Broer Stefan, 2003, Methods Mol Biol, V227, P245, DOI 10.1385/1-59259-387-9:245; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Daniel H, 2004, ANNU REV PHYSIOL, V66, P361, DOI 10.1146/annurev.physiol.66.032102.144149; Danilczyk U, 2006, NATURE, V444, P1088, DOI 10.1038/nature05475; ELION EA, 2007, CURRENT PROTOCOLS IM; Guy JL, 2003, BIOCHEMISTRY-US, V42, P13185, DOI 10.1021/bi035268s; HILLMAN RE, 1986, PEDIATR RES, V20, pA265; Kleta R, 2004, NAT GENET, V36, P999, DOI 10.1038/ng1405; Kowalczuk S, 2005, BIOCHEM J, V386, P417, DOI 10.1042/BJ20050100; Lambert DW, 2008, BIOCHEM PHARMACOL, V75, P781, DOI 10.1016/j.bcp.2007.08.012; Malakauskas SM, 2007, AM J PHYSIOL-RENAL, V292, pF533, DOI 10.1152/ajprenal.00325.2006; Matthews D. M., 1991, PROTEIN ABSORPTION; O'Mara M, 2006, J MEMBRANE BIOL, V213, P111, DOI 10.1007/s00232-006-0879-3; Oudit GY, 2006, AM J PATHOL, V168, P1808, DOI 10.2353/ajpath.2006.051091; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SCRIVER CR, 1987, AM J HUM GENET, V40, P401; Seow HF, 2004, NAT GENET, V36, P1003, DOI 10.1038/ng1406; Takanaga H, 2005, BIOCHEM BIOPH RES CO, V337, P892, DOI 10.1016/j.bbrc.2005.09.128; Takanaga H, 2005, J BIOL CHEM, V280, P8974, DOI 10.1074/jbc.M413027200; Turner AJ, 2002, CAN J PHYSIOL PHARM, V80, P346, DOI 10.1139/Y02-021; Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Wilson MC, 2005, J BIOL CHEM, V280, P27213, DOI 10.1074/jbc.M411950200; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; [No title captured]	34	129	138	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2880	2887		10.1096/fj.08-107300	http://dx.doi.org/10.1096/fj.08-107300			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18424768				2022-12-28	WOS:000258089300028
J	Williams, SA; Stanley, P				Williams, Suzannah A.; Stanley, Pamela			Mouse fertility is enhanced by oocyte-specific loss of core 1-derived O-glycans	FASEB JOURNAL			English	Article						multiple-oocyte follicles; T-synthase; ovulation rate	FOLLICLE-STIMULATING-HORMONE; INCREASED OVULATION RATE; GROWTH-DIFFERENTIATION FACTOR-9; ZONA-PELLUCIDA; FEMALE MICE; TRANSGENIC MICE; POLYOVULAR FOLLICLES; NEONATAL EXPOSURE; OVARIAN-FOLLICLE; RECEPTOR	Regulation of the number of eggs ovulated by different mammalian species remains poorly understood. Here we show that oocyte-specific deletion at the primary follicle stage of core 1 beta 1,3-galactosyl-transferase (T-synthase; generates core 1-derived O-glycans), leads to a sustained increase in fertility. T-syn mutant females ovulated 30-50% more eggs and had a sustained increase in litter size compared to controls. Ovarian weights and follicle numbers were greater in mutants, but follicular apoptosis was not decreased. The number of follicles entering the growing pool was unaltered, but 3-wk mutants ovulated fewer eggs, suggesting that increased fertility results from prolonged follicle development. T-syn mutant ovaries also contained numerous multiple-oocyte follicles (MOFs) that appeared to form by adjacent, predominantly preantral, follicles joining-a new mechanism for MOF generation. Ovulation of multiple eggs from MOFs was not the reason for increased fertility based on ovulated egg and corpora lutea numbers. Thus, the absence of T- synthase caused modified follicular development, leading to the maturation and ovulation of more follicles, to MOF formation at late stages of folliculogenesis, and to increased fertility. These results identify novel roles for glycoproteins from the oocyte as suppressors of fertility and regulators of follicular integrity in the mouse.	[Williams, Suzannah A.; Stanley, Pamela] Albert Einstein Coll Med, Dept Cell Biol, New York, NY 10461 USA	Yeshiva University	Stanley, P (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, New York, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747; Williams, Suzannah/0000-0003-1798-976X	NATIONAL CANCER INSTITUTE [R01CA030645] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA030645-26, R01 CA030645-27, R01 CA030645-25A1, R01 CA030645] Funding Source: Medline; PHS HHS [P01 13330, NCI R01 30645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alfieri JA, 2003, J CELL SCI, V116, P2149, DOI 10.1242/jcs.00430; Barnett KR, 2006, HUM REPROD UPDATE, V12, P537, DOI 10.1093/humupd/dml022; Boja ES, 2003, J BIOL CHEM, V278, P34189, DOI 10.1074/jbc.M304026200; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; Danilovich N, 2000, ENDOCRINOLOGY, V141, P4295, DOI 10.1210/en.141.11.4295; Danilovich N, 2002, BIOL REPROD, V67, P361, DOI 10.1095/biolreprod67.2.361; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Durlinger ALL, 1999, ENDOCRINOLOGY, V140, P5789, DOI 10.1210/en.140.12.5789; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; Galloway SM, 2000, NAT GENET, V25, P279, DOI 10.1038/77033; Hahn KL, 2005, DEVELOPMENT, V132, P817, DOI 10.1242/dev.01601; Hanrahan JP, 2004, BIOL REPROD, V70, P900, DOI 10.1095/biolreprod.103.023093; Hsu SY, 1996, ENDOCRINOLOGY, V137, P4837, DOI 10.1210/en.137.11.4837; IGUCHI T, 1988, BIOL REPROD, V39, P689, DOI 10.1095/biolreprod39.3.689; IGUCHI T, 1986, TERATOLOGY, V34, P29, DOI 10.1002/tera.1420340105; Irving-Rodgers HF, 2006, SEMIN REPROD MED, V24, P195, DOI 10.1055/s-2006-948549; Jefferson W, 2006, BIOL REPROD, V74, P161, DOI 10.1095/biolreprod.105.045724; Jefferson WN, 2002, BIOL REPROD, V67, P1285, DOI 10.1095/biolreprod67.4.1285; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; Kipp JL, 2007, ENDOCRINOLOGY, V148, P1968, DOI 10.1210/en.2006-1083; Kumar TR, 1999, MOL ENDOCRINOL, V13, P851, DOI 10.1210/me.13.6.851; Lan ZJ, 2003, EMBO J, V22, P4070, DOI 10.1093/emboj/cdg405; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Lu LC, 2006, METHOD ENZYMOL, V417, P127, DOI 10.1016/S0076-6879(06)17010-X; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; McMullen ML, 2001, ENDOCRINOLOGY, V142, P5005, DOI 10.1210/en.142.11.5005; Mulsant P, 2001, P NATL ACAD SCI USA, V98, P5104, DOI 10.1073/pnas.091577598; NAAR EM, 1991, BIOL REPROD, V45, P178, DOI 10.1095/biolreprod45.1.178; NAGDAS SK, 1994, BIOL REPROD, V51, P262, DOI 10.1095/biolreprod51.2.262; Patsoula E, 2001, REPRODUCTION, V121, P455, DOI 10.1530/rep.0.1210455; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555; Pepling ME, 2001, DEV BIOL, V234, P339, DOI 10.1006/dbio.2001.0269; PHILPOTT CC, 1987, DEV BIOL, V121, P568, DOI 10.1016/0012-1606(87)90192-8; Racki WJ, 2006, DEVELOPMENT, V133, P4527, DOI 10.1242/dev.02651; Roby KF, 1999, BIOL REPROD, V61, P1616, DOI 10.1095/biolreprod61.6.1616; Shi SL, 2004, MOL CELL BIOL, V24, P9920, DOI 10.1128/MCB.24.22.9920-9929.2004; Slot KA, 2006, REPRODUCTION, V131, P525, DOI 10.1530/rep.1.00946; Souza CJH, 2001, J ENDOCRINOL, V169, pR1, DOI 10.1677/joe.0.169R001; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Thomas AD, 2001, REPRODUCTION, V122, P537, DOI 10.1530/reprod/122.4.537; Wassarman PM, 1997, P ROY SOC B-BIOL SCI, V264, P323, DOI 10.1098/rspb.1997.0046; Williams SA, 2007, J CELL SCI, V120, P1341, DOI 10.1242/jcs.004291; Wilson T, 2001, BIOL REPROD, V64, P1225, DOI 10.1095/biolreprod64.4.1225; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Yang YZ, 2003, BIOL REPROD, V69, P1294, DOI 10.1095/biolreprod.103.015610; Yu RN, 1998, NAT GENET, V20, P353, DOI 10.1038/3822	50	33	33	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2273	2284		10.1096/fj.07-101709	http://dx.doi.org/10.1096/fj.07-101709			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18276833	Green Accepted			2022-12-28	WOS:000257292500020
J	Chappell, AE; Bunz, M; Smoll, E; Dong, H; Lytle, C; Barrett, KE; McCole, DF				Chappell, Alfred E.; Bunz, Michael; Smoll, Eric; Dong, Hui; Lytle, Christian; Barrett, Kim E.; McCole, Declan F.			Hydrogen peroxide inhibits Ca2+-dependent chloride secretion across colonic epithelial cells via distinct kinase signaling pathways and ion transport proteins	FASEB JOURNAL			English	Article						reactive oxygen species; PI3-kinase; MAP kinases; NKCC1	EPIDERMAL-GROWTH-FACTOR; INFLAMMATORY-BOWEL-DISEASE; K-CL COTRANSPORTER; REACTIVE OXYGEN METABOLITES; FACTOR RECEPTOR; ELECTROLYTE TRANSPORT; FREE-RADICALS; TYROSINE PHOSPHORYLATION; INTESTINAL PERMEABILITY; ULCERATIVE-COLITIS	Reactive oxygen species (ROS) are key mediators in a number of inflammatory conditions, including inflammatory bowel disease (IBD). ROS, including hydrogen peroxide (H2O2), modulate intestinal epithelial ion transport and are believed to contribute to IBD-associated diarrhea. Intestinal crypt fluid secretion, driven by electrogenic Cl- secretion, hydrates and sterilizes the crypt, thus reducing bacterial adherence. Here, we show that pathophysiological concentrations of H2O2 inhibit Ca2+-dependent Cl- secretion across T-84 colonic epithelial cells by elevating cytosolic Ca2+, which contributes to activation of two distinct signaling pathways. One involves recruitment of the Ca2+-responsive kinases, Src and Pyk-2, as well as extracellular signal-regulated kinase (ERK). A separate pathway recruits p38 MAP kinase and phosphoinositide 3-kinase (PI3-K) signaling. The ion transport response to Ca2+-dependent stimuli is mediated in part by K+ efflux through basolateral K+ channels and Cl- uptake by the Na+-K+-2Cl(-) cotransporter, NKCC1. We demonstrate that H2O2 inhibits Ca2+-dependent basolateral K+ efflux and also inhibits NKCC1 activity independently of inhibitory effects on apical Cl- conductance. Thus, we have demonstrated that H2O2 inhibits Ca2+-dependent Cl- secretion through multiple negative regulatory signaling pathways and inhibition of specific ion transporters. These findings increase our understanding of mechanisms by which inflammation disturbs intestinal epithelial function and contributes to intestinal pathophysiology.	[Chappell, Alfred E.; Bunz, Michael; Smoll, Eric; Dong, Hui; Barrett, Kim E.; McCole, Declan F.] Univ Calif San Diego, Dept Med, Div Gastroenterol, Sch Med, La Jolla, CA 92093 USA; [Lytle, Christian] Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of California System; University of California San Diego; University of California System; University of California Riverside	McCole, DF (corresponding author), Univ Calif San Diego, Dept Med, Div Gastroenterol, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dmccole@ucsd.edu	McCole, Declan/AAL-2454-2020; Lytle, Christian/X-2836-2019; Barrett, Kim Elaine/AAE-7762-2019; Barrett, Kim/AAE-2794-2022	Lytle, Christian/0000-0001-5442-1546; Barrett, Kim Elaine/0000-0002-6704-998X; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305, T32DK007202] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK007202, DK-28305, R01 DK028305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGERON C, 1984, CANCER RES, V44, P3961; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Banan A, 2000, FREE RADICAL BIO MED, V28, P727, DOI 10.1016/S0891-5849(00)00160-X; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; Basuroy S, 2006, BIOCHEM J, V393, P69, DOI 10.1042/BJ20050959; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; Choudhary S, 2001, DIGEST DIS SCI, V46, P2222, DOI 10.1023/A:1011975218006; Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8; Cooke HJ, 1998, NEWS PHYSIOL SCI, V13, P269; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Del Castillo IC, 2005, AM J PHYSIOL-CELL PH, V289, pC1332, DOI 10.1152/ajpcell.00580.2004; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dong H, 2005, AM J PHYSIOL-GASTR L, V288, pG457, DOI 10.1152/ajpgi.00381.2004; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; Duvall MD, 1998, AM J PHYSIOL-CELL PH, V275, pC1313, DOI 10.1152/ajpcell.1998.275.5.C1313; Forsyth CB, 2007, J PHARMACOL EXP THER, V321, P84, DOI 10.1124/jpet.106.113019; GAGINELLA TS, 1995, GASTROENTEROLOGY, V109, P2019, DOI 10.1016/0016-5085(95)90772-6; Gassler N, 2001, AM J PHYSIOL-GASTR L, V281, pG216, DOI 10.1152/ajpgi.2001.281.1.G216; Gonzalez A, 2006, NEUROCHEM RES, V31, P741, DOI 10.1007/s11064-006-9078-y; Granados MP, 2006, BIOCHEM CELL BIOL, V84, P39, DOI 10.1139/O05-150; Greig E, 2000, ANN NY ACAD SCI, V915, P327; GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2; GRISHAM MB, 1990, INFLAMMATION, V14, P531, DOI 10.1007/BF00914274; GRISHAM MB, 1992, ANN NY ACAD SCI, V664, P103, DOI 10.1111/j.1749-6632.1992.tb39753.x; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARRIS ML, 1992, PHARMACOL THERAPEUT, V53, P375, DOI 10.1016/0163-7258(92)90057-7; Hirota CL, 2006, BRIT J PHARMACOL, V149, P463, DOI 10.1038/sj.bjp.0706889; Holmes EW, 1998, DIGEST DIS SCI, V43, P1088, DOI 10.1023/A:1018899222258; KACHUR JF, 1995, INFLAMMATION, V19, P245, DOI 10.1007/BF01534465; KACHUR JF, 1995, INFLAMMATION, V19, P717, DOI 10.1007/BF01534574; KARAYALCIN SS, 1990, J CLIN INVEST, V86, P60, DOI 10.1172/JCI114715; KEELY SJ, 1995, EUR J PHARMACOL, V279, P203, DOI 10.1016/0014-2999(95)00156-F; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2003, AM J PHYSIOL-CELL PH, V284, pC339, DOI 10.1152/ajpcell.00144.2002; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KESHAVARZIAN A, 1992, DIGEST DIS SCI, V37, P1866; Kim YM, 2007, J PROTEOME RES, V6, P593, DOI 10.1021/pr060326s; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P, P541; Kruidenier L, 2003, J PATHOL, V201, P17, DOI 10.1002/path.1408; LihBrody L, 1996, DIGEST DIS SCI, V41, P2078, DOI 10.1007/BF02093613; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1997, J BIOL CHEM, V272, P15069, DOI 10.1074/jbc.272.24.15069; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; McCole DF, 2007, J BIOL CHEM, V282, P13303, DOI 10.1074/jbc.M700424200; McCole DF, 1997, BIOCHEM PHARMACOL, V54, P1133, DOI 10.1016/S0006-2952(97)00266-9; McCole DF, 2005, GASTROENTEROLOGY, V129, P591, DOI 10.1053/j.gastro.2005.06.004; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; NGUYEN TD, 1994, BIOCHEM PHARMACOL, V47, P403, DOI 10.1016/0006-2952(94)90032-9; Ohashi T, 2006, J PHARMACOL EXP THER, V318, P296, DOI 10.1124/jpet.106.102541; OWEN NE, 1985, J BIOL CHEM, V260, P1445; Oz HS, 2005, J NUTR BIOCHEM, V16, P297, DOI 10.1016/j.jnutbio.2004.09.007; Pavlick KP, 2002, FREE RADICAL BIO MED, V33, P311, DOI 10.1016/S0891-5849(02)00853-5; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Perez A, 2007, AM J PHYSIOL-LUNG C, V292, pL383, DOI 10.1152/ajplung.00403.2005; RADI R, 1991, J BIOL CHEM, V266, P4244; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; Resta-Lenert S, 2002, GASTROENTEROLOGY, V122, P1070, DOI 10.1053/gast.2002.32372; REYNOLDS A, J PHYSL, V582, P507; SANDLE GI, 1990, GASTROENTEROLOGY, V99, P97, DOI 10.1016/0016-5085(90)91235-X; Schmitz H, 2000, ANN NY ACAD SCI, V915, P312; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shiratsuchi H, 2005, AM J PHYSIOL-CELL PH, V288, pC1083, DOI 10.1152/ajpcell.00543.2004; Smith AJ, 2006, FASEB J, V20, P2486, DOI 10.1096/fj.06-6391com; Soderholm JD, 2002, GUT, V50, P307, DOI 10.1136/gut.50.3.307; TAMAI H, 1991, J PHARMACOL EXP THER, V257, P887; TAMAI H, 1992, J CLIN INVEST, V89, P301, DOI 10.1172/JCI115576; TEST ST, 1984, J BIOL CHEM, V259, P399; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; Walker J, 2003, AM J PHYSIOL-GASTR L, V285, pG850, DOI 10.1152/ajpgi.00077.2003; WATSON AJM, 1994, GUT, V35, P1575, DOI 10.1136/gut.35.11.1575; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Zheng Y, 2005, REDOX REP, V10, P29, DOI 10.1179/135100005X21660	75	14	14	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2023	2036		10.1096/fj.07-099697	http://dx.doi.org/10.1096/fj.07-099697			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18211955	Green Accepted			2022-12-28	WOS:000256352700041
J	Chew, EH; Lu, J; Bradshaw, TD; Holmgren, A				Chew, Eng-Hui; Lu, Jun; Bradshaw, Tracey D.; Holmgren, Arne			Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity	FASEB JOURNAL			English	Article						Michael acceptors; anticancer agents; antitumor mechanism of action; selenocysteine	EARLY EMBRYONIC LETHALITY; MAMMALIAN THIOREDOXIN; GLUTATHIONE-REDUCTASE; ANTICANCER ACTIVITY; THERAPEUTIC AGENTS; INDUCED APOPTOSIS; ESCHERICHIA-COLI; LUNG-CARCINOMA; CANCER-THERAPY; HUMAN PLACENTA	Novel heteroaromatic-substituted 4-hydroxycyclohexa2,5-dienones (quinols) demonstrate potent in vitro antiproliferative activity and in vivo antitumor activity in tumor xenografts. The mechanism of action of these promising novel anticancer agents, however, remains to be fully elucidated. The thioredoxin (Trx) system comprising Trx, thioredoxin reductase (TrxR), and NADPH participates in a broad range of cellular functions involved in cell survival and proliferation. Accumulating evidence has indicated that the selenocysteine-containing mammalian TrxR is a valid molecular target for development of novel cancer therapeutics. In this study, we demonstrate that structural analogs containing a quinol pharmacophore inhibited TrxR with potencies correlated with their antiproliferative and cytotoxic efficacies. Benzenesulfonyl-6F-indole-substituted quinol (compound 6) irreversibly inhibited TrxR most strongly with a half-maximal inhibitory concentration of 2.7 mu M after 1 h of incubation with recombinant rat TrxR. The inhibition was shown to be concentration-, time-, and NADPH-dependent and mediated through a direct quinol attack on the penultimate C-terminal selenocysteine residue. Moreover, TrxR activity in lysates of HCT 116 cells treated with apoptosis-inducing doses of quinols was significantly reduced. From the results obtained, we propose that TrxR inhibition is a critical cellular event that contributes to the proapoptotic effects of quinols.	[Chew, Eng-Hui; Lu, Jun; Holmgren, Arne] Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden; [Bradshaw, Tracey D.] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England	Karolinska Institutet; University of Nottingham	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden.	arne.holmgren@ki.se	Chew, Eng Hui/D-8975-2016; Lu, Jun/E-9701-2017	Chew, Eng Hui/0000-0002-2615-8987; Lu, Jun/0000-0002-1699-8835				Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; ARNER ES, 2000, CURRENT PROTOCOLS S, V5, DOI UNSP 7.4.1-7.4.14; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Becker K, 2001, J MED CHEM, V44, P2784, DOI 10.1021/jm001014i; Berggren M, 1996, ANTICANCER RES, V16, P3459; Berry JM, 2005, J MED CHEM, V48, P639, DOI 10.1021/jm040859h; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; Bradshaw TD, 2005, CANCER RES, V65, P3911, DOI 10.1158/0008-5472.CAN-04-4141; Cassidy PB, 2006, CARCINOGENESIS, V27, P2538, DOI 10.1093/carcin/bgl111; Cenas N, 2004, J BIOL CHEM, V279, P2583, DOI 10.1074/jbc.M310292200; Chew EH, 2006, BIOCHEM BIOPH RES CO, V346, P242, DOI 10.1016/j.bbrc.2006.05.106; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; Fritz-Wolf K, 2007, J MOL BIOL, V370, P116, DOI 10.1016/j.jmb.2007.04.044; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; Hashemy SI, 2006, J BIOL CHEM, V281, P10691, DOI 10.1074/jbc.M511373200; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Kahlos K, 2001, INT J CANCER, V95, P198, DOI 10.1002/1097-0215(20010520)95:3<198::AID-IJC1034>3.0.CO;2-F; Kim SJ, 2005, CLIN CANCER RES, V11, P8425, DOI 10.1158/1078-0432.CCR-05-0449; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Lion CJ, 2006, BIOORG MED CHEM LETT, V16, P5005, DOI 10.1016/j.bmcl.2006.07.072; Lu J, 2006, CANCER RES, V66, P4410, DOI 10.1158/0008-5472.CAN-05-3310; Lu J, 2007, P NATL ACAD SCI USA, V104, P12288, DOI 10.1073/pnas.0701549104; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; McCarroll AJ, 2007, J MED CHEM, V50, P1707, DOI 10.1021/jm061163m; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Novoselov SV, 2003, PROTEIN SCI, V12, P372, DOI 10.1110/ps.0226503; Raffel J, 2003, J LAB CLIN MED, V142, P46, DOI 10.1016/S0022-2143(03)00068-4; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Soini Y, 2001, CLIN CANCER RES, V7, P1750; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Urig S, 2006, SEMIN CANCER BIOL, V16, P452, DOI 10.1016/j.semcancer.2006.09.004; Papp LV, 2007, ANTIOXID REDOX SIGN, V9, P775, DOI 10.1089/ars.2007.1528; Wang XF, 2007, TOXICOL APPL PHARM, V218, P88, DOI 10.1016/j.taap.2006.10.029; Wells G, 2003, J MED CHEM, V46, P532, DOI 10.1021/jm020984y; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; Yoo MH, 2006, J BIOL CHEM, V281, P13005, DOI 10.1074/jbc.C600012200; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	61	48	51	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2072	2083		10.1096/fj.07-101477	http://dx.doi.org/10.1096/fj.07-101477			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18180330				2022-12-28	WOS:000256352700046
J	De Franceschi, L; Platt, OS; Malpeli, G; Janin, A; Scarpa, A; Leboeuf, C; Beuzard, Y; Payen, E; Brugnara, C				De Franceschi, Lucia; Platt, Orah S.; Malpeli, Giorgio; Janin, Anne; Scarpa, Aldo; Leboeuf, Christophe; Beuzard, Yves; Payen, Emmanuel; Brugnara, Carlo			Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice	FASEB JOURNAL			English	Article						inflammatory response; lung injury; vascular remodeling; hypoxia; endothelin-1	ACUTE CHEST SYNDROME; ACUTE LUNG INJURY; SMOOTH-MUSCLE-CELLS; NITRIC-OXIDE; PROSTACYCLIN ANALOGS; ENDOTHELIN ANTAGONISM; PLASMA ENDOTHELIN-1; PROSTAGLANDIN E-2; TISSUE FACTOR; UP-REGULATION	Pulmonary arterial hypertension (PAH) is one of the leading causes of morbidity and mortality in adult patients with sickle cell disease (SCD). Here, we developed a model to study the early stage of PAH in SCD. We exposed wild-type and transgenic sickle cell SAD (Hbbs/Hbbs) mice to hypoxia (8% O-2) for 7 days. Prolonged hypoxia in SAD mice only induced 1) increased neutrophil count in both bronchoalveoal lavage (BAL) and peripheral circulation; 2) increased BAL IL1 beta, IL10, IL6, and TNF-alpha; and 3) up-regulation of the genes endothelin-1, cyclo-oxygenase-2, angiotensin-converting-enzyme, and IL-1 beta, suggesting that amplified inflammatory response and activation of the endothelin-1 system may contribute to the early phase of PAH in SCD. Since phosphodiesterases (PDEs) are involved in pulmonary vascular tone regulation, we evaluated gene expression of phosphodiesterase-4 (PDE-4) isoforms and of PDE-1, -2, -3, -7, -8, which are the main cyclic-adenosine-monophosphate hydrolyzing enzymes. In SAD mouse lungs, prolonged hypoxia significantly increased PDE-4 and -1 gene expressions. The PDE-4 inhibitor, rolipram, prevented the hypoxia-induced PDE-4 and -1 gene up-regulation and interfered with the development of PAH, most likely through modulation of both vascular tone and inflammatory factors. This finding supports a possible therapeutic use of PDEs inhibitors in the earlier phases of PAH in SCD.	[De Franceschi, Lucia] Univ Verona, Policlin GB Rossi, Sect Internal Med, Dept Clin & Expt Med, I-37134 Verona, Italy; [Malpeli, Giorgio; Scarpa, Aldo] Univ Verona, Sect Anat Pathol, Dept Pathol, I-37134 Verona, Italy; [Platt, Orah S.] Harvard Univ, Childrens Hosp, Sch Med, Lab Med, Boston, MA 02115 USA; [Platt, Orah S.] Harvard Univ, Childrens Hosp, Sch Med, Pathol Lab, Boston, MA 02115 USA; [Janin, Anne; Leboeuf, Christophe] Hop St Louis, INSERM 02 20, Pathol Lab, Paris, France; [Beuzard, Yves; Payen, Emmanuel] Hop St Louis, INSERM, Lab Gene Therapy & Hematol Dis, U 733, Paris, France	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	De Franceschi, L (corresponding author), Univ Verona, Policlin GB Rossi, Sect Internal Med, Dept Clin & Expt Med, Ple L Scuro 10, I-37134 Verona, Italy.	lucia.defranceschi@univr.it	Brugnara, Carlo/A-8041-2010; DE FRANCESCHI, Lucia/AAB-8652-2022; Leboeuf, christophe/H-4583-2012; Payen, Emmanuel/S-5357-2018; scarpa, aldo/K-6832-2016	Brugnara, Carlo/0000-0001-8192-8713; DE FRANCESCHI, Lucia/0000-0001-7093-777X; Leboeuf, christophe/0000-0002-6537-0550; Payen, Emmanuel/0000-0002-1329-2327; scarpa, aldo/0000-0003-1678-739X; Malpeli, Giorgio/0000-0002-2996-2903	NIDDK NIH HHS [DK504221] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ariga M, 2004, J IMMUNOL, V173, P7531, DOI 10.4049/jimmunol.173.12.7531; BALLAS SK, 1992, BLOOD, V79, P2154, DOI 10.1182/blood.V79.8.2154.2154; Ben Driss A, 2000, CIRCULATION, V101, P2764, DOI 10.1161/01.CIR.101.23.2764; Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; Bleiweis MS, 1999, ANN THORAC SURG, V67, P194, DOI 10.1016/S0003-4975(98)01310-1; Bowers R, 2004, AM J RESP CRIT CARE, V169, P764, DOI 10.1164/rccm.200301-147OC; Budhiraja R, 2004, CIRCULATION, V109, P159, DOI 10.1161/01.CIR.0000102381.57477.50; Castro O, 2003, BLOOD, V101, P1257, DOI 10.1182/blood-2002-03-0948; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Conran N, 2004, AM J HEMATOL, V76, P343, DOI 10.1002/ajh.20129; Corbel M, 2002, J PHARMACOL EXP THER, V301, P258, DOI 10.1124/jpet.301.1.258; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; de Franceschi L, 2003, BLOOD, V102, P1087, DOI 10.1182/blood-2002-07-2135; de Moraes VLG, 1998, BRIT J PHARMACOL, V123, P631; Derchi G, 2005, ANN NY ACAD SCI, V1054, P471, DOI 10.1196/annals.1345.070; Derchi G, 2005, HAEMATOLOGICA, V90, P452; Dorfmuller P, 2003, EUR RESPIR J, V22, P358, DOI 10.1183/09031936.03.00038903; Dorfmuller P, 2002, AM J RESP CRIT CARE, V165, P534, DOI 10.1164/rccm.2012112; El-Haroun H, 2004, CIRC RES, V94, P353, DOI 10.1161/01.RES.0000111801.48626.F4; Fartoukh M, 1998, CHEST, V114, p50S, DOI 10.1378/chest.114.1_Supplement.50S; Fike CD, 2005, J APPL PHYSIOL, V99, P670, DOI 10.1152/japplphysiol.01337.2004; Finsnes F, 1997, AM J RESP CRIT CARE, V155, P1404, DOI 10.1164/ajrccm.155.4.9105086; Finsnes F, 2001, AM J PHYSIOL-LUNG C, V280, pL659, DOI 10.1152/ajplung.2001.280.4.L659; Frid MG, 2006, AM J PATHOL, V168, P659, DOI 10.2353/ajpath.2006.050599; FULTON RM, 1952, BRIT HEART J, V14, P413; Gale DD, 2003, PULM PHARMACOL THER, V16, P97, DOI 10.1016/S1094-5539(02)00175-X; Gamanuma M, 2003, CELL SIGNAL, V15, P565, DOI 10.1016/S0898-6568(02)00146-8; Geraci MW, 1999, J CLIN INVEST, V103, P1509, DOI 10.1172/JCI5911; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Gomez-Alamillo C, 2003, HYPERTENSION, V42, P831, DOI 10.1161/01.HYP.0000088854.04562.DA; Graido-Gonzalez E, 1998, BLOOD, V92, P2551, DOI 10.1182/blood.V92.7.2551.2551_2551_2555; Hagen M, 2007, AM J PHYSIOL-LUNG C, V292, pL1473, DOI 10.1152/ajplung.00197.2006; Hammerman SI, 1997, AM J RESP CRIT CARE, V156, P280, DOI 10.1164/ajrccm.156.1.9611085; Haque AK, 2002, HUM PATHOL, V33, P1037, DOI 10.1053/hupa.2002.128059; HAYNES J, 1992, AM J PHYSIOL, V262, pH511, DOI 10.1152/ajpheart.1992.262.2.H511; Hoshikawa Y, 2001, AM J RESP CRIT CARE, V164, P314, DOI 10.1164/ajrccm.164.2.2010150; Hsu LL, 2007, BLOOD, V109, P3088, DOI 10.1182/blood-2006-08-039438; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Humbert M, 1998, CHEST, V114, p80S, DOI 10.1378/chest.114.1_Supplement.80S; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Kato GJ, 2005, BRIT J HAEMATOL, V130, P943, DOI 10.1111/j.1365-2141.2005.05701.x; Kaur K, 2000, ANN INTERN MED, V132, P165, DOI 10.7326/0003-4819-132-2-200001180-00019; Kim D, 2001, CIRCULATION, V104, P2338, DOI 10.1161/hc4401.098432; Lam CF, 2005, AM J PHYSIOL-HEART C, V289, pH2334, DOI 10.1152/ajpheart.00375.2005; Langleben D, 1999, CIRCULATION, V99, P3266, DOI 10.1161/01.CIR.99.25.3266; Levi M, 2001, CIRCULATION, V103, P2014; Machado RF, 2005, BRIT J HAEMATOL, V130, P445, DOI 10.1111/j.1365-2141.2005.05625.x; Machado RF, 2005, BRIT J HAEMATOL, V129, P449, DOI 10.1111/j.1365-2141.2005.05432.x; Merkus D, 2007, J PHYSIOL-LONDON, V580, P907, DOI 10.1113/jphysiol.2006.127118; Miotla JM, 1998, AM J RESP CELL MOL, V18, P411, DOI 10.1165/ajrcmb.18.3.2913; Omori K, 2007, CIRC RES, V100, P309, DOI 10.1161/01.RES.0000256354.95791.f1; Palmer LA, 2007, J CLIN INVEST, V117, P2592, DOI 10.1172/JCI29444; Phillips PG, 2005, AM J PHYSIOL-LUNG C, V288, pL103, DOI 10.1152/ajplung.00095.2004; Platt OS, 2000, NEW ENGL J MED, V342, P1904, DOI 10.1056/NEJM200006223422510; PLATT OS, 1994, NEW ENGL J MED, V330, P783, DOI 10.1056/NEJM199403173301110; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Pritchard KA, 2004, AM J PHYSIOL-LUNG C, V286, pL705, DOI 10.1152/ajplung.00288.2002; RABE KF, 1994, AM J PHYSIOL, V266, pL536, DOI 10.1152/ajplung.1994.266.5.L536; Rybicki AC, 1998, BLOOD, V92, P2594, DOI 10.1182/blood.V92.7.2594.2594_2594_2596; Said SI, 2006, AM J PHYSIOL-LUNG C, V291, pL547, DOI 10.1152/ajplung.00546.2005; Santing RE, 2001, EUR J PHARMACOL, V429, P335, DOI 10.1016/S0014-2999(01)01333-4; Schermuly RT, 2001, AM J RESP CRIT CARE, V164, P1694, DOI 10.1164/ajrccm.164.9.2105060; Sheares KKK, 2004, AM J PHYSIOL-LUNG C, V287, pL919, DOI 10.1152/ajplung.00012.2004; Solovey A, 2004, BLOOD, V104, P840, DOI 10.1182/blood-2003-10-3719; Solovey A, 1998, J CLIN INVEST, V101, P1899, DOI 10.1172/JCI1932; Solovey AA, 2001, BLOOD, V97, P1937, DOI 10.1182/blood.V97.7.1937; Steinbauer M, 2000, SHOCK, V14, P163, DOI 10.1097/00024382-200014020-00015; Steinberg MH, 1999, NEW ENGL J MED, V340, P1021, DOI 10.1056/NEJM199904013401307; Stenmark KR, 2006, CIRC RES, V99, P675, DOI 10.1161/01.RES.0000243584.45145.3f; Strukova S, 2006, FRONT BIOSCI-LANDMRK, V11, P59, DOI 10.2741/1780; Stuart MJ, 1999, BLOOD, V94, P1555, DOI 10.1182/blood.V94.5.1555.417k36_1555_1560; Tang HF, 2005, AM J RESP CRIT CARE, V171, P823, DOI 10.1164/rccm.200406-771OC; Tharaux PL, 2005, NEPHROL DIAL TRANSPL, V20, P2408, DOI 10.1093/ndt/gfi111; Toward TJ, 2004, AM J RESP CRIT CARE, V169, P227, DOI 10.1164/rccm.200211-1372OC; TRUDEL M, 1994, BLOOD, V84, P3189; Tuder RM, 2002, AM J RESP CELL MOL, V26, P171, DOI 10.1165/ajrcmb.26.2.f230; Tuder RM, 2007, CLIN CHEST MED, V28, P23, DOI 10.1016/j.ccm.2006.11.010; TURNER CR, 1993, CIRC SHOCK, V39, P237; Vichinsky EP, 2004, NEW ENGL J MED, V350, P857, DOI 10.1056/NEJMp038250; Villagra J, 2007, BLOOD, V110, P2166, DOI 10.1182/blood-2006-12-061697; Voelkel NF, 1998, CHEST, V114, p225S, DOI 10.1378/chest.114.3_Supplement.225S; Wagner RS, 1997, J PHARMACOL EXP THER, V282, P1650; Wang HC, 2007, J MOL BIOL, V371, P302, DOI 10.1016/j.jmb.2007.05.060; Werdehoff SG, 1998, AM J HEMATOL, V58, P195, DOI 10.1002/(SICI)1096-8652(199807)58:3<195::AID-AJH6>3.0.CO;2-M; Wood KC, 2006, FREE RADICAL BIO MED, V40, P1443, DOI 10.1016/j.freeradbiomed.2005.12.015; Wort SJ, 2002, MOL PHARMACOL, V62, P1147, DOI 10.1124/mol.62.5.1147; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117	88	23	23	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1849	1860		10.1096/fj.07-098921	http://dx.doi.org/10.1096/fj.07-098921			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18245171				2022-12-28	WOS:000256352700025
J	Puissant, A; Grosso, S; Jacquel, A; Belhacene, N; Colosetti, P; Cassuto, JP; Auberger, P				Puissant, Alexandre; Grosso, Sebastien; Jacquel, Arnaud; Belhacene, Nathalie; Colosetti, Pascal; Cassuto, Jill-Patrice; Auberger, Patrick			Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol	FASEB JOURNAL			English	Article						caspase-dependent cell death; caspase-independent cell death; anticancer therapy; BCR-ABL inhibitors	TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; ACTIVATED PROTEIN-KINASE; SMALL-INTERFERING-RNA; BCR-ABL; ERYTHROID-DIFFERENTIATION; INDUCED APOPTOSIS; BLAST-CRISIS; K562 CELLS; PHILADELPHIA-CHROMOSOME	Imatinib is successfully used in the treatment of chronic myelogenous leukemia (CML), and the main mechanisms of resistance in refractory patients are now partially understood. In the present study, we investigated the mechanism of action of resveratrol in imatinib-sensitive (IM-S) and -resistant (IM-R) CML cell lines. Resveratrol induced loss of viability and apoptosis in IM-S and IM-R in a time- and dose-dependent fashion. Inhibition of cell viability was detected for concentrations of resveratrol as low as 5 mu M, and the IC50 values for viability, clonogenic assays, apoptosis, and erythroid differentiation were in the 10-25 mu M range. The effect of imatinib and resveratrol was additive in IM-S but not in IM-R clones in which the resveratrol effect was already maximal. The effect of resveratrol on apoptosis was partially rescued by zVAD-fmk, suggesting a caspase-independent contribution. Resveratrol action was independent of BCR-ABL expression and phosphorylation, and in agreement was additive to BCR-ABL silencing. Finally, phytoalexin inhibited the growth of BaF3 cells expressing mutant BCR-ABL proteins found in resistant patients, including the multiresistant T315I mutation. Our findings show that resveratrol induces apoptosis, caspase-independent death, and differentiation that collectively contribute to the specific elimination of CML cells. Resveratrol should provide therapeutic benefits in IM-R patients and in other hematopoietic malignancies.	[Puissant, Alexandre; Grosso, Sebastien; Jacquel, Arnaud; Belhacene, Nathalie; Colosetti, Pascal; Auberger, Patrick] Fac Med Nice, INSERM, U526, F-06107 Nice 2, France; [Puissant, Alexandre; Grosso, Sebastien; Jacquel, Arnaud; Belhacene, Nathalie; Colosetti, Pascal; Auberger, Patrick] Univ Nice Sophia Antipolis, Sophia Antipolis, France; [Cassuto, Jill-Patrice] Ctr Hosp Univ, Serv Hematol Clin, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Auberger, P (corresponding author), Fac Med Nice, INSERM, U526, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Colosetti, Pascal/ABH-4585-2020; Jacquel, Arnaud/AAJ-4760-2021; Jacquel, Arnaud/O-1928-2017; PUISSANT, ALEXANDRE/O-9575-2016; AUBERGER, Patrick/G-1491-2013; Puissant, Alexandre/AAF-3875-2021	Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; PUISSANT, ALEXANDRE/0000-0002-3997-9282; AUBERGER, Patrick/0000-0002-2481-8275; Puissant, Alexandre/0000-0002-3997-9282				Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025; Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gao XH, 2002, J NUTR, V132, P2076, DOI 10.1093/jn/132.7.2076; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Horvath Z, 2006, EXP HEMATOL, V34, P1377, DOI 10.1016/j.exphem.2006.05.018; Jacquel A, 2007, ONCOGENE, V26, P2445, DOI 10.1038/sj.onc.1210034; Jacquel A, 2006, ONCOGENE, V25, P781, DOI 10.1038/sj.onc.1209119; Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje; Kawano T, 2004, MOL CELL BIOCHEM, V258, P25, DOI 10.1023/B:MCBI.0000012830.96393.b9; Kohmura K, 2004, J CELL PHYSIOL, V198, P370, DOI 10.1002/jcp.10426; Koschmieder S, 2005, BLOOD, V105, P324, DOI 10.1182/blood-2003-12-4369; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Luzi C, 2004, BIOCHEM PHARMACOL, V68, P2019, DOI 10.1016/j.bcp.2004.07.002; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mahon FX, 2003, BLOOD, V101, P2368, DOI 10.1182/blood.V101.6.2368; Morotti A, 2006, AM J HEMATOL, V81, P938, DOI 10.1002/ajh.20732; Neering SJ, 2007, BLOOD, V110, P2578, DOI 10.1182/blood-2007-02-073031; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Park CE, 2007, EXP MOL MED, V39, P222, DOI 10.1038/emm.2007.25; Rangatia J, 2006, LEUKEMIA, V20, P68, DOI 10.1038/sj.leu.2403999; Ren RB, 2002, ONCOGENE, V21, P8629, DOI 10.1038/sj.onc.1206090; Rodrigue CM, 2001, BRIT J HAEMATOL, V113, P500, DOI 10.1046/j.1365-2141.2001.02746.x; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; Shen M, 2006, VASC PHARMACOL, V45, P122, DOI 10.1016/j.vph.2006.04.002; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Tsan MF, 2002, LEUKEMIA LYMPHOMA, V43, P983, DOI 10.1080/10428190290021669; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Zang MW, 2006, DIABETES, V55, P2180, DOI 10.2337/db05-1188	42	59	63	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1894	1904		10.1096/fj.07-101394	http://dx.doi.org/10.1096/fj.07-101394			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18245170				2022-12-28	WOS:000256352700029
J	Sanders, RJ; Ofman, R; Dacremont, G; Wanders, RJA; Kemp, S				Sanders, Robert-Jan; Ofman, Rob; Dacremont, Georges; Wanders, Ronald J. A.; Kemp, Stephan			Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids	FASEB JOURNAL			English	Article						X-linked adrenoleukodystrophy; cytochrome P450; Sjogren-Larson syndrome; ALDH3A2	X-LINKED ADRENOLEUKODYSTROPHY; SJOGREN-LARSSON-SYNDROME; ALDEHYDE DEHYDROGENASE; RAT-LIVER; GENE; FAMILY; IDENTIFICATION; OXIDOREDUCTASE; LOCALIZATION; FIBROBLASTS	Very-long-chain fatty acids (VLCFAs) have long been known to be degraded exclusively in peroxisomes via beta-oxidation. A defect in peroxisomal beta-oxidation results in elevated levels of VLCFAs and is associated with the most frequent inherited disorder of the central nervous system white matter, X-linked adrenoleukodystrophy. Recently, we demonstrated that VLCFAs can also undergo omega-oxidation, which may provide an alternative route for the breakdown of VLCFAs. The omega-oxidation of VLCFA is initiated by CYP4F2 and CYP4F3B, which produce omega-hydroxy-VLCFAs. In this article, we characterized the enzymes involved in the formation of very-long-chain dicarboxylic acids from omega-hydroxy-VLCFAs. We demonstrate that very-long-chain dicarboxylic acids are produced via two independent pathways. The first is mediated by an as yet unidentified, microsomal NAD(+)-dependent alcohol dehydrogenase and fatty aldehyde dehydrogenase, which is encoded by the ALDH3A2 gene and is deficient in patients with Sjogren-Larsson syndrome. The second pathway involves the NADPH-dependent hydroxylation of omega-hydroxy-VLCFAs by CYP4F2, CYP4F3B, or CYP4F3A. Enzyme kinetic studies show that oxidation of omega-hydroxy-VLCFAs occurs predominantly via the NAD(+)-dependent route. Overall, our data demonstrate that in humans all enzymes are present for the complete conversion of VLCFAs to their corresponding very-long-chain dicarboxylic acids.	[Sanders, Robert-Jan; Ofman, Rob; Wanders, Ronald J. A.; Kemp, Stephan] Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, Dept Pediat,Emma Childrens Hosp & Clin Chem, NL-1105 AZ Amsterdam, Netherlands; [Dacremont, Georges] Univ Ghent, Dept Pediat, B-9000 Ghent, Belgium	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Ghent University	Kemp, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, Dept Pediat,Emma Childrens Hosp & Clin Chem, Room F0-224,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	s.kemp@amc.uva.nl	Kemp, Stephan/A-3935-2008	Kemp, Stephan/0000-0003-2023-064X				Bezman L, 2001, ANN NEUROL, V49, P512, DOI 10.1002/ana.101; DeLaurenzi V, 1996, NAT GENET, V12, P52; Doerflinger N, 1998, HUM GENE THER, V9, P1025, DOI 10.1089/hum.1998.9.7-1025; Dubois-Dalcq M, 1999, TRENDS NEUROSCI, V22, P4, DOI 10.1016/S0166-2236(98)01319-8; Ferdinandusse S, 2004, J LIPID RES, V45, P1104, DOI 10.1194/jlr.M300512-JLR200; Fouquet F, 1997, NEUROBIOL DIS, V3, P271, DOI 10.1006/nbdi.1997.0127; HO JK, 1995, J CLIN INVEST, V96, P1455, DOI 10.1172/JCI118182; HSU LC, 1994, GENE, V151, P285, DOI 10.1016/0378-1119(94)90672-6; HSU LC, 1995, ADV EXP MED BIOL, V372, P159; Hsu MH, 2007, J BIOL CHEM, V282, P5225, DOI 10.1074/jbc.M608176200; Jansen GA, 1999, BBA-MOL CELL BIOL L, V1440, P176, DOI 10.1016/S1388-1981(99)00126-2; Kelson TL, 1997, BBA-GEN SUBJECTS, V1335, P99, DOI 10.1016/S0304-4165(96)00126-2; Kemp S, 1998, NAT MED, V4, P1261, DOI 10.1038/3242; KUNDU RK, 1991, J CLIN INVEST, V88, P1865, DOI 10.1172/JCI115508; LEE T, 1979, J BIOL CHEM, V254, P2892; LINDAHL R, 1979, BIOCHEM J, V183, P55, DOI 10.1042/bj1830055; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; MOSER HW, 1981, NEUROLOGY, V31, P1241, DOI 10.1212/WNL.31.10.1241; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Nguyen X, 1999, AM J PHYSIOL-REG I, V276, pR1691; Peters C, 2004, BLOOD, V104, P881, DOI 10.1182/blood-2003-10-3402; RIZZO WB, 1991, J CLIN INVEST, V88, P1643, DOI 10.1172/JCI115478; RIZZO WB, 1989, NEUROLOGY, V39, P1415, DOI 10.1212/WNL.39.11.1415; ROBBINS KC, 1968, ARCH BIOCHEM BIOPHYS, V123, P531, DOI 10.1016/0003-9861(68)90174-4; ROCCHICCIOLI F, 1986, PEDIATR RES, V20, P62, DOI 10.1203/00006450-198601000-00018; Sanders RJ, 2006, J BIOL CHEM, V281, P13180, DOI 10.1074/jbc.M513481200; Sanders RJ, 2005, J LIPID RES, V46, P1001, DOI 10.1194/jlr.M400510-JLR200; SINGH I, 1984, PEDIATR RES, V18, P286, DOI 10.1203/00006450-198403000-00016; Singh I, 1998, NEW ENGL J MED, V339, P702, DOI 10.1056/NEJM199809033391012; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Valianpour F, 2003, MOL GENET METAB, V79, P189, DOI 10.1016/S1096-7192(03)00098-2; Vasiliou Vasilis, 2005, Human Genomics, V2, P138; WAKABAYASHI K, 1963, BIOCHIM BIOPHYS ACTA, V70, P132, DOI 10.1016/0006-3002(63)90733-9; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 2004, MOL GENET METAB, V83, P16, DOI 10.1016/j.ymgme.2004.08.016; Wanders RJA, 2007, PFLUG ARCH EUR J PHY, V453, P719, DOI 10.1007/s00424-006-0142-x; Willemsen MAAP, 2001, BRAIN, V124, P1426, DOI 10.1093/brain/124.7.1426; WOLVETANG EJ, 1990, BIOCHIM BIOPHYS ACTA, V1035, P6, DOI 10.1016/0304-4165(90)90166-T; Xu FY, 2004, J PHARMACOL EXP THER, V308, P887, DOI 10.1124/jpet.103.059626; ZORZANO A, 1990, GEN PHARMACOL, V21, P697, DOI 10.1016/0306-3623(90)91020-R	40	39	50	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2064	2071		10.1096/fj.07-099150	http://dx.doi.org/10.1096/fj.07-099150			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18182499	Green Published			2022-12-28	WOS:000256352700045
J	Mellberg, S; Dimberg, A; Bahram, F; Hayashi, M; Rennel, E; Ameur, A; Westholm, JO; Larsson, E; Lindahl, P; Cross, MJ; Claesson-Welsh, L				Mellberg, Sofie; Dimberg, Anna; Bahram, Fuad; Hayashi, Makoto; Rennel, Emma; Ameur, Adam; Westholm, Jakub Orzechowski; Larsson, Erik; Lindahl, Per; Cross, Michael J.; Claesson-Welsh, Lena			Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis	FASEB JOURNAL			English	Article						angiogenesis; gene expression; PTPRB; HPTP beta; signal transduction	GENE-EXPRESSION; TIP-CELLS; ANGIOGENESIS; DIFFERENTIATION; ADRENOMEDULLIN; VASCULOGENESIS; IDENTIFICATION; RECEPTOR-2	To define molecular events accompanying formation of the 3-dimensional (3D) vascular tube, we have characterized gene expression during vascular endothelial growth factor (VEGF)-induced tubular morphogenesis of endothelial cells. Microarray analyses were performed comparing gene induction in growth-arrested, tube-forming endothelial cells harvested from 3D collagen cultures to that in proliferating endothelial cells cultured on fibronectin. Differentially expressed genes were clustered and analyzed for specific endothelial expression through publicly available datasets. We validated the contribution of one of the identified genes, vascular endothelial protein tyrosine phosphatase (VE-PTP), to endothelial morphogenesis. Silencing of VE-PTP expression was accompanied by increased VEGF receptor-2 (VEGFR2) tyrosine phosphorylation and activation of downstream signaling pathways. The increased VEGFR2 activity promoted endothelial cell cycle progression, overcoming the G(0)/G(1) arrest associated with organization into tubular structures in the 3D cultures. Proximity ligation showed close association between VEGFR2 and VE-PTP in resting cells. Activation of VEGFR2 by VEGF led to rapid loss of association, which was resumed with time in parallel with decreased receptor activity. In conclusion, we have identified genes, which may serve critical functions in formation of the vascular tube. One of these, VE-PTP, regulates VEGFR2 activity thereby modulating the VEGF-response during angiogenesis.-Mellberg, S., Dimberg, A., Bahram, F., Hayashi, M., Rennel, E., Ameur, A., Westholm, J. O., Larsson, E., Lindahl, P., Cross, M. J., Claesson-Welsh, L. Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis. FASEB J. 23, 1490-1502 (2009)	[Mellberg, Sofie; Dimberg, Anna; Bahram, Fuad; Hayashi, Makoto; Rennel, Emma; Cross, Michael J.; Claesson-Welsh, Lena] Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Uppsala, Sweden; [Ameur, Adam; Westholm, Jakub Orzechowski] Uppsala Univ, Biomed Ctr, Linnaeus Ctr Bioinformat, Uppsala, Sweden; [Larsson, Erik; Lindahl, Per] Sahlgrens Univ Hosp, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden	Uppsala University; Uppsala University; Sahlgrenska University Hospital	Rennel, E (corresponding author), Univ Bristol, Preclin Vet Sch, Dept Physiol & Pharmacol, Microvasc Res Labs, Southwell St, Bristol BS2 8EJ, Avon, England.	lena.welsh@genpat.uu.se	Ameur, Adam/E-6207-2011; Larsson Lekholm, Erik/AHE-0932-2022; Larsson Lekholm, Erik/HDM-8032-2022	Ameur, Adam/0000-0001-6085-6749; Larsson Lekholm, Erik/0000-0003-1400-0119; Larsson Lekholm, Erik/0000-0003-1400-0119; Dimberg, Anna/0000-0003-4422-9125; Westholm, Jakub/0000-0002-6849-6220	Swedish Cancer Society [4734-B03-02XBB, 3820-B04-09XAC]; Swedish Research Council [K2005-32X-12552-08A]; Novo Nordisk foundation; Svenska Lakarsallskapet for medicinsk forskning; Association for International Cancer Research [04-069]	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Novo Nordisk foundation(Novo Nordisk FoundationNovocure Limited); Svenska Lakarsallskapet for medicinsk forskning; Association for International Cancer Research	This study was supported by grants to M.J.C. (Swedish Cancer Society project 4734-B03-02XBB) and to L. C.-W. (Swedish Cancer Society project 3820-B04-09XAC, Swedish Research Council project K2005-32X-12552-08A, and the Novo Nordisk foundation). A. D. was supported by Svenska Lakarsallskapet for medicinsk forskning and by a grant to L. C.-W. from the Association for International Cancer Research (04-069).	ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Ameur A, 2006, BIOINFORMATICS, V22, P1024, DOI 10.1093/bioinformatics/btl036; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baumer S, 2006, BLOOD, V107, P4754, DOI 10.1182/blood-2006-01-0141; Bell SE, 2001, J CELL SCI, V114, P2755; Bohman S, 2005, J BIOL CHEM, V280, P42397, DOI 10.1074/jbc.M506724200; Cavallaro U, 2006, EXP CELL RES, V312, P659, DOI 10.1016/j.yexcr.2005.09.019; Chabot C, 2009, MOL CELL BIOL, V29, P241, DOI 10.1128/MCB.01374-08; Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841; Dominguez MG, 2007, P NATL ACAD SCI USA, V104, P3243, DOI 10.1073/pnas.0611510104; Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002; Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992; Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; Gerritsen ME, 2003, MICROCIRCULATION, V10, P63, DOI 10.1038/sj.mn.7800170; Glesne DA, 2006, CANCER RES, V66, P4030, DOI 10.1158/0008-5472.CAN-05-3294; Hahn CN, 2005, PHYSIOL GENOMICS, V22, P57, DOI 10.1152/physiolgenomics.00278.2004; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Ho M, 2003, PHYSIOL GENOMICS, V13, P249, DOI 10.1152/physiolgenomics.00186.2002; Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Ichikawa-Shindo Y, 2008, J CLIN INVEST, V118, P29, DOI 10.1172/JCI33022; Ishimitsu T, 2006, PHARMACOL THERAPEUT, V111, P909, DOI 10.1016/j.pharmthera.2006.02.004; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kappert K, 2005, CARDIOVASC RES, V65, P587, DOI 10.1016/j.cardiores.2004.08.016; Matsumoto T, 2008, ARTERIOSCL THROM VAS, V28, P2123, DOI 10.1161/ATVBAHA.108.169128; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Niemela H, 2005, BLOOD, V106, P3405, DOI 10.1182/blood-2005-01-0254; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; PORTER CW, 1991, CANCER RES, V51, P3715; Saal LH, 2002, GENOME BIOL, V3; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; VINDELOV LL, 1983, CYTOMETRY, V3, P317, DOI 10.1002/cyto.990030502; Wallgard E, 2008, ARTERIOSCL THROM VAS, V28, P1469, DOI 10.1161/ATVBAHA.108.165738; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	43	80	88	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1490	1502		10.1096/fj.08-123810	http://dx.doi.org/10.1096/fj.08-123810			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19136612				2022-12-28	WOS:000266651700025
J	Michlewska, S; Dransfield, I; Megson, IL; Rossi, AG				Michlewska, Sylwia; Dransfield, Ian; Megson, Ian L.; Rossi, Adriano G.			Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents: key role for TNF-alpha	FASEB JOURNAL			English	Article						efferocytosis; interleukin-10; glucocorticoids; soluble TNF-receptors	NF-KAPPA-B; RHEUMATOID-ARTHRITIS; IN-VITRO; PROINFLAMMATORY CYTOKINES; THERAPEUTIC TARGET; AGING NEUTROPHILS; CELLS; RESOLUTION; CLEARANCE; KINASE	Apoptosis of inflammatory cells and their subsequent clearance (efferocytosis) by macrophages (M phi s) are key mechanisms orchestrating successful resolution of inflammation. Although the powerful proinflammatory agents lipopolysaccharide (LPS) and tumor necrosis factor alpha (TNF-alpha) influence rates of inflammatory cell apoptosis, little is known about their effects on efferocytosis. We have demonstrated that LPS and TNF-alpha potently inhibit efferocytosis of neutrophils by monocyte-derived M phi s. Inhibition was both concentration and time dependent, although the effect of TNF-alpha was more rapid. We have found that soluble TNF receptor-I attenuated LPS inhibition of phagocytosis, indicating that TNF-alpha production is critical. Inhibition of efferocytosis by LPS was found to be positively associated with M phi production of TNF-alpha, but negatively with interleukin-10 (IL-10) release. A critical role for IL-10 in the regulation of phagocytosis was suggested by 2 important findings: LPS inhibition was observed more rapidly in the presence of an antihuman IL-10 receptor-alpha antibody, and efferocytosis by IL-10-deficient M phi s was markedly reduced compared to wild-type M phi s. Furthermore, exogenous IL-10 and glucocorticoids reversed inhibitory effects of LPS on efferocytosis via suppression of TNF-alpha production. We suggest that efferocytosis is regulated in an autocrine manner by pro-and anti-inflammatory mediators, and the inflammatory milieu determines whether inflammation successfully resolves.-Michlewska, S., Dransfield, I., Megson, I. L., Rossi, A. G. Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of proinflammatory and anti-inflammatory agents: key role for TNF-alpha. FASEB J. 23, 844-854 (2009)	[Michlewska, Sylwia; Dransfield, Ian; Megson, Ian L.; Rossi, Adriano G.] Univ Edinburgh, Sch Med, Queens Med Res Inst, MRC Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Michlewska, S (corresponding author), Univ Edinburgh, Sch Med, Queens Med Res Inst, MRC Ctr Inflammat Res, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	s.michlewska@sms.ed.ac.uk	Megson, Ian L/K-2195-2012; Poubelle, Patrice E/G-6537-2013	Megson, Ian L/0000-0001-8287-2459; Dransfield, Ian/0000-0001-5848-7059	Medical Research Council [G0601481] Funding Source: Medline; MRC [G0601481] Funding Source: UKRI; Medical Research Council [G9900991B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; BRENNAN FM, 1989, LANCET, V2, P244; Charles P, 1999, J IMMUNOL, V163, P1521; Clark IA, 2007, CYTOKINE GROWTH F R, V18, P335, DOI 10.1016/j.cytogfr.2007.04.002; DE WMR, 1991, J EXP MED, V174, P1209; Denys A, 2002, J IMMUNOL, V168, P4837, DOI 10.4049/jimmunol.168.10.4837; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fan H, 2003, CYTOKINE, V22, P126, DOI 10.1016/S1043-4666(03)00122-4; Feldmann M, 2005, J AUTOIMMUN, V25, P26, DOI 10.1016/j.jaut.2005.09.006; FELDMANN M, 1994, CIRC SHOCK, V43, P179; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Feldmann M, 1996, J INFLAMM, V47, P90; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Hart SP, 2004, J IMMUNOL, V172, P1882, DOI 10.4049/jimmunol.172.3.1882; Jersmann HPA, 2003, CYTOM PART A, V51A, P7, DOI 10.1002/cyto.a.10005; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Liu YQ, 1999, J IMMUNOL, V162, P3639; MAINI RN, 1995, CLIN EXP IMMUNOL, V101, P207; Mazzon E, 2008, AM J PHYSIOL-GASTR L, V294, pG1268, DOI 10.1152/ajpgi.00014.2008; McColl A, 2007, THESCIENTIFICWORLDJO, V7, P1165, DOI 10.1100/tsw.2007.224; McPhillips K, 2007, J IMMUNOL, V178, P8117, DOI 10.4049/jimmunol.178.12.8117; Michlewska S, 2007, AUTOIMMUNITY, V40, P267, DOI 10.1080/08916930701357208; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Ogden CA, 2005, J IMMUNOL, V174, P3015, DOI 10.4049/jimmunol.174.5.3015; REN Y, 1995, J IMMUNOL, V154, P2366; Ren Y, 2008, J IMMUNOL, V180, P4978, DOI 10.4049/jimmunol.180.7.4978; Rossi AG, 2006, NAT MED, V12, P1056, DOI 10.1038/nm1468; Rossi AG, 1998, J IMMUNOL, V160, P3562; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Ward C, 2005, EUR J IMMUNOL, V35, P2728, DOI 10.1002/eji.200425561; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Xu W, 2006, BLOOD, V107, P4930, DOI 10.1182/blood-2005-10-4144	41	148	152	2	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					844	854		10.1096/fj.08-121228	http://dx.doi.org/10.1096/fj.08-121228			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18971259	Green Submitted			2022-12-28	WOS:000265506300020
J	Brunner, S; Winogradow, J; Huber, BC; Zaruba, MM; Fischer, R; David, R; Assmann, G; Herbach, N; Wanke, R; Mueller-Hoecker, J; Franz, WM				Brunner, Stefan; Winogradow, Janina; Huber, Bruno C.; Zaruba, Marc-Michael; Fischer, Rebekka; David, Robert; Assmann, Gerald; Herbach, Nadja; Wanke, Ruediger; Mueller-Hoecker, Josef; Franz, Wolfgang-Michael			Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis	FASEB JOURNAL			English	Article						EPO; cytokines; stem cell mobilization and homing	COLONY-STIMULATING FACTOR; IMPROVES CARDIAC-FUNCTION; ENDOTHELIAL GROWTH-FACTOR; HEMATOPOIETIC STEM-CELLS; REPERFUSION INJURY; HEART; NEOVASCULARIZATION; MOBILIZATION; REGENERATION; EXPRESSION	Mobilization of bone marrow-derived stem cells (BMCs) was shown to have protective effects after myocardial infarction (MI). However, the classical mobilizing agent, granulocyte-colony stimulating factor (G-CSF) relapsed after revealing an impaired homing capacity. In the search for superior cytokines, erythropoietin (EPO) appears to be a promising agent. Therefore, we analyzed in a murine model of surgically induced MI the influence of EPO treatment on survival and functional parameters as well as BMC mobilization, homing, and effect on resident cardiac stem cells (CSCs). Human EPO was injected intraperitoneally after ligation of the left anterior descendens (LAD) for 3 days with a total dose of 5000 IU/kg 6 and 30 days after MI, and pressure volume relationships were investigated in vivo. Cardiac tissues were analyzed by histology. To show the effect on BMCs and CSCs, FACS analyses were performed. Homing factors were analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and ELISA. EPO-treated animals showed a significant improvement of survival post-MI (62 vs. 36%). At days 6 and 30, all hemodynamic parameters associated with attenuated remodeling, enhanced neovascularization, and diminished apoptotic cells in the peri-infarct area were improved. BMC subpopulations (CD31(+), c-kit(+), and Sca-1(+) cells) were mobilized, and homing of Sca-1(+) and CXCR4(+) BMCs toward an SDF-1 gradient into the ischemic myocardium was enhanced. However, there was no beneficial effect on CSCs. We have shown that EPO application after MI shows cardioprotective effects. This may be explained by mobilization of BMCs, which are homing via the CXCR-4/SDF-1 axis. However, EPO has no beneficial effects on resident CSCs. Therefore, new treatment regimes using EPO together with other agents may combine complementary beneficial effects preventing ischemic cardiomyopathy. - Brunner, S., Winogradow, J., Huber, B. C., Zaruba, M.-M., Fischer, R., David, R., Assmann, G., Herbach, N., Wanke, R., Mueller-Hoecker, J., Franz, W.-M. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J. 23, 351-361 (2009)	[Brunner, Stefan; Winogradow, Janina; Huber, Bruno C.; Zaruba, Marc-Michael; Fischer, Rebekka; David, Robert; Franz, Wolfgang-Michael] Univ Munich, Klinikum Grosshadern, Dept Med 1, Med Klin & Poliklin 1, D-81377 Munich, Germany; [Assmann, Gerald; Mueller-Hoecker, Josef] Univ Munich, Inst Pathol, D-81377 Munich, Germany; [Herbach, Nadja; Wanke, Ruediger] Univ Munich, Inst Vet Pathol, D-81377 Munich, Germany	University of Munich; University of Munich; University of Munich	Franz, WM (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Med 1, Med Klin & Poliklin 1, Marchioninistr 15, D-81377 Munich, Germany.	wolfgang.franz@med.uni-muenchen.de	Zaruba, Marc-Michael/AAI-8571-2020	Zaruba, Marc-Michael/0000-0003-1074-5463; Wanke, Rudiger/0000-0002-0153-224X; Herbach, Nadja/0000-0001-5893-0356	Ludwig-Maximilians-University (Munich, Germany); Dr. Helmut Legerlotz-Stiftung (Munich, Germany)	Ludwig-Maximilians-University (Munich, Germany); Dr. Helmut Legerlotz-Stiftung (Munich, Germany)	We thank Judith Arcifa and Barbara Markieton for excellent technical assistance. Fritz-Bender-Stiftung provided funding to R. F. and B. M. Additional financial support was provided by the FoFoLe program of the Ludwig-Maximilians-University (Munich, Germany) and by the Dr. Helmut Legerlotz-Stiftung (Munich, Germany).	Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Bahlmann FH, 2004, BLOOD, V103, P921, DOI 10.1182/blood-2003-04-1284; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Brunner S, 2008, EXP HEMATOL, V36, P695, DOI 10.1016/j.exphem.2008.01.011; Bullard AJ, 2005, BASIC RES CARDIOL, V100, P397, DOI 10.1007/s00395-005-0537-4; Cai ZQ, 2004, CIRCULATION, V109, P2050, DOI 10.1161/01.CIR.0000127954.98131.23; Deindl E, 2006, FASEB J, V20, P956, DOI 10.1096/fj.05-4763fje; Engelmann MG, 2006, J AM COLL CARDIOL, V48, P1712, DOI 10.1016/j.jacc.2006.07.044; Engelmann MG, 2006, CURR OPIN MOL THER, V8, P396; Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019; Freedman A, 1997, BLOOD, V90, P4996, DOI 10.1182/blood.V90.12.4996.4996_4996_5001; Hanlon PR, 2005, FASEB J, V19, P1323, DOI 10.1096/fj.04-3545fje; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223; Ho QT, 2007, INT J BIOCHEM CELL B, V39, P1349, DOI 10.1016/j.biocel.2007.04.010; Honold J, 2006, ARTERIOSCL THROM VAS, V26, P2238, DOI 10.1161/01.ATV.0000240248.55172.dd; Jaquet K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/mvre.2002.2426; Lips DJ, 2004, BASIC RES CARDIOL, V99, P351, DOI 10.1007/s00395-004-0476-5; Lipsic E, 2006, CARDIOVASC DRUG THER, V20, P135, DOI 10.1007/s10557-006-7680-5; Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90; Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200; Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nakano M, 2007, CIRC RES, V100, P662, DOI 10.1161/01.RES.0000260179.43672.fe; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Parsa CJ, 2004, J BIOL CHEM, V279, P20655, DOI 10.1074/jbc.M314099200; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Prass K, 2003, STROKE, V34, P1981, DOI 10.1161/01.STR.0000080381.76409.B2; Schachinger V, 2004, J AM COLL CARDIOL, V44, P1690, DOI 10.1016/j.jacc.2004.08.014; Schuster MD, 2004, AM J PHYSIOL-HEART C, V287, pH525, DOI 10.1152/ajpheart.00058.2004; Shi Y, 2004, BASIC RES CARDIOL, V99, P173, DOI 10.1007/s00395-004-0455-x; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; van der Meer P, 2005, J AM COLL CARDIOL, V46, P125, DOI 10.1016/j.jacc.2005.03.044; van Os R, 1998, BLOOD, V92, P1950, DOI 10.1182/blood.V92.6.1950.418k21_1950_1956; Wang XH, 2006, STEM CELLS, V24, P1779, DOI 10.1634/stemcells.2005-0386; Westenbrink BD, 2007, EUR HEART J, V28, P2018, DOI 10.1093/eurheartj/ehm177; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; Zaruba MM, 2008, CARDIOVASC RES, V77, P722, DOI 10.1093/cvr/cvm080; Zohlnhofer D, 2006, JAMA-J AM MED ASSOC, V295, P1003, DOI 10.1001/jama.295.9.1003	45	70	82	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					351	361		10.1096/fj.08-109462	http://dx.doi.org/10.1096/fj.08-109462			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18827024				2022-12-28	WOS:000262892900007
J	Henderson, GC; Dhatariya, K; Ford, GC; Klaus, KA; Basu, R; Rizza, RA; Jensen, MD; Khosla, S; O'Brien, P; Nair, KS				Henderson, Gregory C.; Dhatariya, Ketan; Ford, G. Charles; Klaus, Katherine A.; Basu, Rita; Rizza, Robert A.; Jensen, Michael D.; Khosla, Sundeep; O'Brien, Peter; Nair, K. Sreekumaran			Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements	FASEB JOURNAL			English	Article						proteolysis; remodeling; aging; sexual dimorphism	RANDOMIZED CONTROLLED-TRIAL; AMINO-ACID KINETICS; SKELETAL-MUSCLE; RESISTANCE EXERCISE; ELDERLY-MEN; WHOLE-BODY; DEHYDROEPIANDROSTERONE SULFATE; ANABOLIC RESPONSE; GROWTH-HORMONE; HEALTHY-YOUNG	We investigated age and sex effects and determined whether androgen replacement in elderly individuals (>= 60 yr) could augment protein synthesis. Thirty young men and 32 young women (18-31 yr) were studied once, whereas 87 elderly men were studied before and after 1 yr of treatment with 5 mg/day testosterone (T), 75 mg/day dehydroepiandrosterone (DHEA), or placebo (P); and 57 elderly women were studied before and after 1 yr of treatment with 50 mg/day DHEA or P. [N-15] Phenylalanine and [H-2(4)] tyrosine tracers were infused, with measurements in plasma and vastus lateralis muscle. Whole-body protein synthesis per fat-free mass and muscle protein fractional synthesis rate (FSR) were lower in elderly than in young individuals (P<0.001), not significantly affected by hormone treatments, and higher in women than in men (P<0.0001), with no sex x age interaction. In regression analyses, peak O-2 consumption (VO2peak), resting energy expenditure (REE), and sex were independently associated with muscle FSR, as were VO2peak, REE, and interactions of sex with insulin-like growth factor-II and insulin for whole-body protein synthesis. Women maintain higher protein synthesis than men across the lifespan as rates decline in both sexes, and neither full replacement of DHEA (in elderly men and women) nor partial replacement of bioavailable T (in elderly men) is able to amend the age-related declines. Henderson, G. C., Dhatariya, K., Ford, G. C., Klaus, K. A., Basu, R., Rizza, R. A., Jensen, M. D., Khosla, S., O'Brien, P., Nair, K. S. Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. FASEB J. 23, 631-641 (2009)	[Henderson, Gregory C.; Dhatariya, Ketan; Ford, G. Charles; Klaus, Katherine A.; Basu, Rita; Rizza, Robert A.; Jensen, Michael D.; Khosla, Sundeep; O'Brien, Peter; Nair, K. Sreekumaran] Mayo Clin, Div Endocrinol, Rochester, MN 55905 USA	Mayo Clinic	Nair, KS (corresponding author), Mayo Clin, Div Endocrinol, 200 1st St SW,5-194 Joseph, Rochester, MN 55905 USA.	nair.sree@mayo.edu	Khosla, Sundeep/AAE-6170-2020	Khosla, Sundeep/0000-0002-2936-4372	National Institute of Health [P01 AG14283, R01 AG09531, UL1-RR-024150-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009531] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank the study participants for their time and compliance with the protocol. We also thank Traci Hammer for coordinating studies and Barbara Norby, Jean Feehan, and Laurie Wahlstrom for nursing support. We thank Peggy Helwig, Dawn Morse, and members of the Chemical Core Laboratory for technical assistance, Scott Przybelski for statistical support, and members of the General Clinical Research Center nursing and dietetic staff. This work was supported by National Institute of Health grants P01 AG14283, R01 AG09531, and UL1-RR-024150-01. The authors had no conflicts of interest.	Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; Basu R, 2006, DIABETES, V55, P2001, DOI 10.2337/db05-1692; Bhasin S, 2005, J CLIN ENDOCR METAB, V90, P678, DOI 10.1210/jc.2004-1184; Bhasin S, 2001, AM J PHYSIOL-ENDOC M, V281, pE1172, DOI 10.1152/ajpendo.2001.281.6.E1172; Brodsky IG, 1996, J CLIN ENDOCR METAB, V81, P3469, DOI 10.1210/jc.81.10.3469; Burt MG, 2008, J CLIN ENDOCR METAB, V93, P688, DOI 10.1210/jc.2007-2333; CARLSTROM K, 1988, MATURITAS, V10, P297, DOI 10.1016/0378-5122(88)90065-5; Chow LS, 2006, AM J PHYSIOL-ENDOC M, V291, pE729, DOI 10.1152/ajpendo.00003.2006; Christiansen JJ, 2005, EUR J ENDOCRINOL, V152, P77, DOI 10.1530/eje.1.01810; *COMM ASS NEED CLI, 2004, TEST AG CLIN RES DIR, P1; Dalla Man C, 2005, AM J PHYSIOL-ENDOC M, V289, pE954, DOI 10.1152/ajpendo.00076.2005; Dhatariya KK, 2003, MAYO CLIN PROC, V78, P1257, DOI 10.4065/78.10.1257; Ferrando AA, 2003, J CLIN ENDOCR METAB, V88, P358, DOI 10.1210/jc.2002-021041; Ferrando AA, 1998, AM J PHYSIOL-ENDOC M, V275, pE864; Ferrini RL, 1998, AM J EPIDEMIOL, V147, P750; FORBES GB, 1985, METABOLISM, V34, P571, DOI 10.1016/0026-0495(85)90196-9; Fujita S, 2007, AM J PHYSIOL-ENDOC M, V292, pE77, DOI 10.1152/ajpendo.00173.2006; Giannoulis MG, 2008, J CLIN ENDOCR METAB, V93, P3066, DOI 10.1210/jc.2007-2695; GRIGGS RC, 1989, J APPL PHYSIOL, V66, P498, DOI 10.1152/jappl.1989.66.1.498; Guillet C, 2004, FASEB J, V18, P1586, DOI 10.1096/fj.03-1341fje; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Hasten DL, 2000, AM J PHYSIOL-ENDOC M, V278, pE620, DOI 10.1152/ajpendo.2000.278.4.E620; HEYMSFIELD SB, 1990, AM J CLIN NUTR, V52, P214, DOI 10.1093/ajcn/52.2.214; Jahn LA, 1999, J CLIN ENDOCR METAB, V84, P1007, DOI 10.1210/jc.84.3.1007; Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266; Lang CH, 2003, ENDOCRINOLOGY, V144, P3922, DOI 10.1210/en.2002-0192; MATTHEWS DE, 1980, AM J PHYSIOL, V238, pE473, DOI 10.1152/ajpendo.1980.238.5.E473; Meek SE, 1998, DIABETES, V47, P1824, DOI 10.2337/diabetes.47.12.1824; Nair KS, 2006, NEW ENGL J MED, V355, P1647, DOI 10.1056/NEJMoa054629; NAIR KS, 1995, J CLIN INVEST, V95, P2926, DOI 10.1172/JCI118000; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; Parise G, 2001, J APPL PHYSIOL, V91, P1041, DOI 10.1152/jappl.2001.91.3.1041; PIRKE KM, 1973, ACTA ENDOCRINOL-COP, V74, P792, DOI 10.1530/acta.0.0740792; Prestwood KM, 2003, JAMA-J AM MED ASSOC, V290, P1042, DOI 10.1001/jama.290.8.1042; Proctor DN, 1999, AM J PHYSIOL-ENDOC M, V277, pE489, DOI 10.1152/ajpendo.1999.277.3.E489; Rasmussen BB, 2006, FASEB J, V20, P768, DOI 10.1096/fj.05-4607fje; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Short KR, 2004, AM J PHYSIOL-ENDOC M, V286, pE92, DOI 10.1152/ajpendo.00366.2003; Smith GI, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001875; Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P2647, DOI 10.1210/jc.84.8.2647; Symons TB, 2007, AM J CLIN NUTR, V86, P451, DOI 10.1093/ajcn/86.2.451; URBAN RJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE820, DOI 10.1152/ajpendo.1995.269.5.E820; Volpi E, 2001, JAMA-J AM MED ASSOC, V286, P1206, DOI 10.1001/jama.286.10.1206; Volpi E, 1999, AM J PHYSIOL-ENDOC M, V277, pE513, DOI 10.1152/ajpendo.1999.277.3.E513; WELLE S, 1993, AM J PHYSIOL, V264, pE693, DOI 10.1152/ajpendo.1993.264.5.E693; WELLE S, 1995, AM J PHYSIOL-ENDOC M, V268, pE422, DOI 10.1152/ajpendo.1995.268.3.E422; WELLE S, 1990, J CLIN ENDOCR METAB, V71, P1259, DOI 10.1210/jcem-71-5-1259; Yarasheski KE, 1999, AM J PHYSIOL-ENDOC M, V277, pE118, DOI 10.1152/ajpendo.1999.277.1.E118; YARASHESKI KE, 1993, AM J PHYSIOL, V265, pE210, DOI 10.1152/ajpendo.1993.265.2.E210; Yen SSC, 1995, ANN NY ACAD SCI, V774, P128, DOI 10.1111/j.1749-6632.1995.tb17377.x	50	70	70	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					631	641		10.1096/fj.08-117200	http://dx.doi.org/10.1096/fj.08-117200			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18827019	Green Published			2022-12-28	WOS:000262892900034
J	Sheldon, H; Andre, M; Legg, JA; Heal, P; Herbert, JM; Sainson, R; Sharma, AS; Kitajewski, JK; Heath, VL; Bicknell, R				Sheldon, Helen; Andre, Maud; Legg, John A.; Heal, Paul; Herbert, John M.; Sainson, Richard; Sharma, Anshula S.; Kitajewski, Jan K.; Heath, Victoria L.; Bicknell, Roy			Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors	FASEB JOURNAL			English	Article						roundabouts; angiogenesis; cell signaling	ROUNDABOUT RECEPTOR; N-WASP; GUIDANCE RECEPTORS; TUMOR ANGIOGENESIS; MAGIC ROUNDABOUT; SLIT; COMPLEX; MIDLINE; MIGRATION; PROTEIN	This study aimed to further elucidate the function of Roundabout proteins in endothelium. We show that both Robo1 and Robo4 are present in human umbilical vein endothelial cells (HUVECs) and have knocked expression down using small interfering RNA (siRNA) technology. Roundabout knockout endothelial cells were then studied in a variety of in vitro assays. We also performed a yeast 2-hybrid analysis using the intracellular domain of Robo4 as bait to identify interacting proteins and downstream signaling. Both Robo1 and Robo4 siRNA knockdown and transfection of Robo4-green fluorescent protein inhibited endothelial cell movement and disrupted tube formation on Matrigel. Consistent with a role in regulating cell movement, yeast 2-hybrid and glutathione-S-transferase pulldown analyses show Robo4 binding to a Wiskott-Aldrich syndrome protein (WASP), neural Wiskott-Aldrich syndrome protein, and WASP-interacting protein actin-nucleating complex. We have further shown that Robo1 forms a heterodimeric complex with Robo4, and that transfection of Robo4GFP into HUVECs induces filopodia formation. We finally show using Robo1 knockdown cells that Robo1 is essential for Robo4-mediated filopodia induction. Our results favor a model whereby Slit2 binding to a Robo1/Robo4 heterodimer activates actin nucleation-promoting factors to promote endothelial cell migration. - Sheldon, H., Andre, M., Legg, J. A., Heal, P., Herbert, J. M., Sainson, R., Sharma, A. S., Kitajewski, J. K., Heath, V. L., Bicknell, R. Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors. FASEB J. 23, 513-522 (2009)	[Bicknell, Roy] Univ Birmingham, Sch Med, Inst Biomed Res, Canc Res UK,Angiogenesis Grp, Birmingham B15 2TT, W Midlands, England; [Sheldon, Helen; Andre, Maud; Heal, Paul; Bicknell, Roy] Univ Oxford, Inst Mol Med, Mol Angiogenesis Grp, Canc Res UK, Oxford, England; [Sainson, Richard] Univ Oxford, Inst Mol Med, Growth Factor Grp, Canc Res UK, Oxford, England; [Sharma, Anshula S.; Kitajewski, Jan K.] Columbia Univ, Dept Pathol & OB GYN, New York, NY USA	Cancer Research UK; University of Birmingham; Cancer Research UK; University of Oxford; Cancer Research UK; University of Oxford; Columbia University	Bicknell, R (corresponding author), Univ Birmingham, Sch Med, Inst Biomed Res, Canc Res UK,Angiogenesis Grp, Birmingham B15 2TT, W Midlands, England.	r.bicknell@bham.ac.uk	Xiao, Yang/B-5668-2012	Sheldon, Helen/0000-0002-0945-5496; Bicknell, Roy/0000-0002-0941-8919	Cancer Research UK [A6766]; European Union [FP6 LSHC-CT-2003-503233]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062454] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); European Union(European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by Cancer Research UK grant A6766 and European Union FP6 LSHC-CT-2003-503233 grant "STROMA." We thank Laura M. Machesky and Guillaume Bompard for the WASP and NWASP constructs. H. S., M. A., and J.A.L. contributed equally to the work. They designed and performed research and helped write the paper. P. H. designed and performed the modified Boyden chamber assay. J.M.H. carried out the bioinformatics analysis of the yeast 2-hybrid experiments. A.S.N. made recombinant adenoviruses (vital new reagents). J.K.K. advised on the design of experiments. V. L. H. assisted with some experiments and helped write the paper. R. B. conceived and supervised the entire project, including the writing of the paper.	Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bedell VM, 2005, P NATL ACAD SCI USA, V102, P6373, DOI 10.1073/pnas.0408318102; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Herbert JMJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-153; Hivert B, 2002, MOL CELL NEUROSCI, V21, P534, DOI 10.1006/mcne.2002.1193; Hohenester E, 2006, BIOCHEM SOC T, V34, P418, DOI 10.1042/BST0340418; Howitt JA, 2004, EMBO J, V23, P4406, DOI 10.1038/sj.emboj.7600446; Hu HL, 2005, P NATL ACAD SCI USA, V102, P4613, DOI 10.1073/pnas.0409325102; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Kaus S, 2006, J BIOL CHEM, V281, P11347, DOI 10.1074/jbc.M508853200; Kessels MM, 2006, J BIOL CHEM, V281, P13285, DOI 10.1074/jbc.M510226200; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Legg JA, 2008, ANGIOGENESIS, V11, P13, DOI 10.1007/s10456-008-9100-x; Lundstrom A, 2004, GENE DEV, V18, P2161, DOI 10.1101/gad.310204; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Millard TH, 2003, CELL MOTIL CYTOSKEL, V54, P81, DOI 10.1002/cm.10087; Milligan ED, 2001, J NEUROSCI, V21, P2808, DOI 10.1523/JNEUROSCI.21-08-02808.2001; Morlot C, 2007, P NATL ACAD SCI USA, V104, P14923, DOI 10.1073/pnas.0705310104; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Sabatier C, 2004, CELL, V117, P157, DOI 10.1016/S0092-8674(04)00303-4; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Suchting S, 2004, FASEB J, V18, P121, DOI 10.1096/fj.04-1991fje; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X	31	93	102	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					513	522		10.1096/fj.07-098269	http://dx.doi.org/10.1096/fj.07-098269			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18948384	Green Published			2022-12-28	WOS:000262892900023
J	Attur, MG; Palmer, GD; Al-Mussawir, HE; Dave, M; Teixeira, CC; Rifkin, DB; Appleton, CTG; Beier, F; Abramson, SB				Attur, Mukundan G.; Palmer, Glyn D.; Al-Mussawir, Hayf E.; Dave, Mandar; Teixeira, Cristina C.; Rifkin, Daniel B.; Appleton, C. Thomas G.; Beier, Frank; Abramson, Steven B.			F-spondin, a neuroregulatory protein, is up-regulated in osteoarthritis and regulates cartilage metabolism via TGF-beta activation	FASEB JOURNAL			English	Article						extracellular matrix; chondrocyte regulation; prostaglandin	GROWTH-FACTOR-BETA; CHONDROCYTE DIFFERENTIATION; ARTICULAR-CARTILAGE; GENE-EXPRESSION; THROMBOSPONDIN-1; DEGRADATION; MECHANISMS; RECEPTOR; CELLS; MODEL	In osteoarthritis (OA) articular chondrocytes undergo phenotypic changes culminating in the progressive loss of cartilage from the joint surface. The molecular mechanisms underlying these changes are poorly understood. Here we report enhanced (similar to 7-fold) expression of F-spondin, a neuronal extracellular matrix glycoprotein, in human OA cartilage (P<0.005). OA-specific up-regulation of F-spondin was also demonstrated in rat knee cartilage following surgical menisectomy. F-spondin treatment of OA cartilage explants caused a 2-fold increase in levels of the active form of TGF-beta 1 (P<0.01) and a 10-fold induction of PGE2 (P<0.005) in culture supernatants. PGE2 induction was found to be dependent on TGF-beta and the thrombospondin domain of the F-spondin molecule. F-spondin addition to cartilage explant cultures also caused a 4-fold increase in collagen degradation (P<0.05) and a modest reduction in proteoglycan synthesis (similar to 20%; P<0.05), which were both TGF-beta and PGE2 dependent. F-spondin treatment also led to increased secretion and activation of MMP-13 (P<0.05). Together these studies identify F-spondin as a novel protein in OA cartilage, where it may act in situ at lesional areas to activate latent TGF-beta and induce cartilage degradation via pathways that involve production of PGE2.-Attur, M. G., Palmer, G. D., Al-Mussawir, H. E., Dave, M., Teixeira, C. C., Rifkin, D. B., Appleton, C. T. G., Beier, F., Abramson, S. B. F-spondin, a neuroregulatory protein, is up-regulated in osteoarthritis and regulates cartilage metabolism via TGF-beta activation. FASEB J. 23, 79-89 (2009)	[Attur, Mukundan G.; Palmer, Glyn D.; Al-Mussawir, Hayf E.; Dave, Mandar; Abramson, Steven B.] NYU, Hosp Joint Dis, Div Rheumatol, Sch Med, New York, NY 10003 USA; [Teixeira, Cristina C.] NYU, Dept Basic Sci & Craniofacial Biol, Coll Dent, New York, NY 10003 USA; [Rifkin, Daniel B.] NYU, Dept Cell Biol, Sch Med, New York, NY 10003 USA; [Appleton, C. Thomas G.; Beier, Frank] Univ Western Ontario, CIHR Grp Skeletal Dev & Remodeling, Schulich Sch Med & Dent, London, ON, Canada	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; New York University; Western University (University of Western Ontario)	Abramson, SB (corresponding author), NYU, Hosp Joint Dis, Div Rheumatol, Sch Med, 301 E 17th St, New York, NY 10003 USA.	stevenb.abramson@nyumc.org	Appleton, Tom/E-3145-2016; Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013; Attur, Mukundan/O-1578-2019	Appleton, Tom/0000-0001-7148-0767; Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537; Attur, Mukundan/0000-0001-7080-8118; Abramson, Steven/0000-0002-0668-6344	U.S. National Institutes of Health [CA034282]; William and Linda Steere Foundation; Joseph and Sophia Abeles Foundation; NATIONAL CANCER INSTITUTE [R01CA034282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054817, T32AR007176] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); William and Linda Steere Foundation; Joseph and Sophia Abeles Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Jyoti Patel (Division of Rheumatology, Hospital for Joint Diseases, New York, NY, USA) for her help with harvesting cartilage. This work is supported in part by U.S. National Institutes of Health grant CA034282 (D.B.R.). The authors also thank the William and Linda Steere Foundation and the Joseph and Sophia Abeles Foundation for their generous support.	ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Aigner T, 1999, ARTHRITIS RHEUM, V42, P1443, DOI 10.1002/1529-0131(199907)42:7<1443::AID-ANR18>3.0.CO;2-A; Aigner T, 2007, CURR DRUG TARGETS, V8, P377, DOI 10.2174/138945007779940052; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; AMIN AR, 1995, J EXP MED, V182, P2097, DOI 10.1084/jem.182.6.2097; Appleton CTG, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2120; Attur M. G., 2002, Current Issues in Molecular Biology, V4, P129; Attur MG, 2001, ARTHRITIS RHEUM-US, V44, P578, DOI 10.1002/1529-0131(200103)44:3<578::AID-ANR106>3.3.CO;2-Z; Attur M, 2006, ARTHRITIS RHEUM, V54, pS93; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; Burstyn-Cohen T, 1999, NEURON, V23, P233, DOI 10.1016/S0896-6273(00)80776-X; Dabovic B, 2002, J CELL BIOL, V156, P227, DOI 10.1083/jcb.200111080; Davidson ENB, 2007, OSTEOARTHR CARTILAGE, V15, P597, DOI 10.1016/j.joca.2007.02.005; Debby-Brafman A, 1999, NEURON, V22, P475, DOI 10.1016/S0896-6273(00)80703-5; Goldring MB, 2007, J CELL PHYSIOL, V213, P626, DOI 10.1002/jcp.21258; Goldring SR, 2004, CLIN ORTHOP RELAT R, pS27, DOI 10.1097/01.blo.0000144854.66565.8f; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LAFEBER FPJG, 1993, BRIT J RHEUMATOL, V32, P281; LIPPIELLO L, 1977, J CLIN INVEST, V59, P593, DOI 10.1172/JCI108676; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loeser RF, 2006, ARTHRITIS RHEUM-US, V54, P1357, DOI 10.1002/art.21813; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Martel-Pelletier Johanne, 1999, Frontiers in Bioscience, V4, pd694, DOI 10.2741/Martel; Mi Z, 2003, ARTHRITIS RES THER, V5, pR132, DOI 10.1186/ar745; Mix KS, 2007, J BIOL CHEM, V282, P9492, DOI 10.1074/jbc.M608327200; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Orito Keisuke, 2003, J Orthop Sci, V8, P294, DOI 10.1007/s10776-003-0647-6; PALMER GD, 2007, OSTEOARTHR CARTILAGE, V15, pC95; Quintavalla J, 2005, J CELL PHYSIOL, V204, P560, DOI 10.1002/jcp.20345; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541; Tardif G, 2001, J RHEUMATOL, V28, P1631; Tchetina EV, 2006, AM J PATHOL, V168, P131, DOI 10.2353/ajpath.2006.050369; Tchetina EV, 2005, J RHEUMATOL, V32, P876; Tzarfati-Majar V, 2001, P NATL ACAD SCI USA, V98, P4722, DOI 10.1073/pnas.081062398; Uchino M, 2000, CLIN ORTHOP RELAT R, P119; van Beuningen HM, 2000, OSTEOARTHR CARTILAGE, V8, P25, DOI 10.1053/joca.1999.0267; Verdier MP, 2005, RHEUMATOL INT, V25, P118, DOI 10.1007/s00296-003-0409-x; Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35	40	43	46	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					79	89		10.1096/fj.08-114363	http://dx.doi.org/10.1096/fj.08-114363			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18780763	Green Published			2022-12-28	WOS:000262095500010
J	Canugovi, C; Samaranayake, M; Bhagwat, AS				Canugovi, Chandrika; Samaranayake, Mala; Bhagwat, Ashok S.			Transcriptional pausing and stalling causes multiple clustered mutations by human activation-induced deaminase	FASEB JOURNAL			English	Article						hypermutations; antibody maturation; cytosine deamination; uracils in DNA	INDUCED CYTIDINE DEAMINASE; SINGLE-STRANDED-DNA; T7 RNA-POLYMERASE; CLASS SWITCH RECOMBINATION; SOMATIC HYPERMUTATION; ESCHERICHIA-COLI; R-LOOPS; NONTRANSCRIBED STRAND; CYTOSINE DEAMINATION; ELONGATION COMPLEX	Transcription of the rearranged immunoglobulin gene and expression of the enzyme activation-induced deaminase (AID) are essential for somatic hypermutations of this gene during antibody maturation. While AID acts as a single-strand DNA-cytosine deaminase creating U . G mispairs that lead to mutations, the role played by transcription in this process is less clear. We have used in vitro transcription of the kan gene by the T7 RNA polymerase (RNAP) in the presence of AID and a genetic reversion assay for kanamycin-resistance to investigate the causes of multiple clustered mutations (MCMs) during somatic hypermutations. We find that, depending on transcription conditions, AID can cause single-base substitutions or MCMs. When wild-type RNAP is used for transcription at physiologically relevant concentrations of ribonucleoside triphosphates (NTPs), few MCMs are found. In contrast, slowing the rate of elongation by reducing the NTP concentration or using a mutant RNAP increases several-fold the percent of revertants containing MCMs. Arresting the elongation complexes by a quick removal of NTPs leads to formation of RNA-DNA hybrids (R-loops). Treatment of these structures with AID results in a high percentage of Kan(R) revertants with MCMs. Furthermore, selecting for transcription elongation complexes stalled near the codon that suffers mutations during acquisition of kanamycin-resistance results in an overwhelming majority of revertants with MCMs. These results show that if RNAP II pauses or stalls during transcription of immunoglobulin gene, AID is likely to promote MCMs. As changes in physiological conditions such as occurrence of certain DNA primary or secondary structures or DNA adducts are known to cause transcriptional pausing and stalling in mammalian cells, this process may cause MCMs during somatic hypermutation.-Canugovi, C., Samaranayake, M., Bhagwat, A. S. Transcriptional pausing and stalling causes multiple clustered mutations by human activation-induced deaminase. FASEB J. 23, 34-44 (2009)	[Canugovi, Chandrika; Samaranayake, Mala; Bhagwat, Ashok S.] Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Wayne State University	Bhagwat, AS (corresponding author), Wayne State Univ, Dept Chem, 443 Chem, Detroit, MI 48202 USA.	axb@chem.wayne.edu	Bhagwat, Ashok/ABA-3861-2020; Bhagwat, Ashok/AAU-4186-2021	Bhagwat, Ashok/0000-0003-1188-0579	U.S. National Institutes of Health [GM 57200, CA 97899]; NATIONAL CANCER INSTITUTE [R21CA097899, R33CA097899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057200] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the U.S. National Institutes of Health (GM 57200 and CA 97899).	Bachl J, 2001, J IMMUNOL, V166, P5051, DOI 10.4049/jimmunol.166.8.5051; Beletskii A, 1996, P NATL ACAD SCI USA, V93, P13919, DOI 10.1073/pnas.93.24.13919; Beletskii A, 2000, J MOL BIOL, V300, P1057, DOI 10.1006/jmbi.2000.3944; Besmer E, 2006, MOL CELL BIOL, V26, P4378, DOI 10.1128/MCB.02375-05; Bhagwat AS, 2004, DNA REPAIR, V3, P85, DOI 10.1016/j.dnarep.2003.09.008; BONNER G, 1994, J BIOL CHEM, V269, P25120; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; Borukhov S, 2005, MOL MICROBIOL, V55, P1315, DOI 10.1111/j.1365-2958.2004.04481.x; Bransteitter R, 2004, J BIOL CHEM, V279, P51612, DOI 10.1074/jbc.M408135200; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Coker HA, 2007, DNA REPAIR, V6, P235, DOI 10.1016/j.dnarep.2006.10.001; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Duquette ML, 2004, GENE DEV, V18, P1618, DOI 10.1101/gad.1200804; GALLANT J, 1969, J BIOL CHEM, V244, P3125; Garibyan L, 2003, DNA REPAIR, V2, P593, DOI 10.1016/S1568-7864(03)00024-7; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; Huang FT, 2007, MOL CELL BIOL, V27, P5921, DOI 10.1128/MCB.00702-07; Klix N, 1998, EUR J IMMUNOL, V28, P317, DOI 10.1002/(SICI)1521-4141(199801)28:01&lt;317::AID-IMMU317&gt;3.0.CO;2-S; Landick R, 2006, BIOCHEM SOC T, V34, P1062, DOI 10.1042/BST0341062; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Lutsenko E, 1999, J BIOL CHEM, V274, P31034, DOI 10.1074/jbc.274.43.31034; Martomo SA, 2005, J IMMUNOL, V174, P7787, DOI 10.4049/jimmunol.174.12.7787; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; Mizuta R, 2003, J BIOL CHEM, V278, P4431, DOI 10.1074/jbc.M209262200; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Perlot T, 2008, P NATL ACAD SCI USA, V105, P3843, DOI 10.1073/pnas.0712291105; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Pham P, 2007, DNA REPAIR, V6, P689, DOI 10.1016/j.dnarep.2007.01.001; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; REABAN ME, 1994, J BIOL CHEM, V269, P21850; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Ronai D, 2007, J EXP MED, V204, P181, DOI 10.1084/jem.20062032; Samaranayake M, 2006, CHEM REV, V106, P700, DOI 10.1021/cr040496t; Shen HM, 2005, MOL CELL BIOL, V25, P10815, DOI 10.1128/MCB.25.24.10815-10821.2005; Shen HM, 2006, J IMMUNOL, V177, P5386, DOI 10.4049/jimmunol.177.8.5386; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Shilatifard A, 2004, BBA-GENE STRUCT EXPR, V1677, P79, DOI 10.1016/j.bbaexp.2003.11.013; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Sohn YH, 2005, P NATL ACAD SCI USA, V102, P75, DOI 10.1073/pnas.0406581101; Storb U, 1996, CURR OPIN IMMUNOL, V8, P206, DOI 10.1016/S0952-7915(96)80059-8; Storb U, 1998, J EXP MED, V188, P689, DOI 10.1084/jem.188.4.689; Storb U, 1998, IMMUNOL REV, V162, P153; Winter DB, 1998, P NATL ACAD SCI USA, V95, P6953, DOI 10.1073/pnas.95.12.6953; WYSZYNSKI M, 1994, P NATL ACAD SCI USA, V91, P1574, DOI 10.1073/pnas.91.4.1574; Xue KM, 2006, J EXP MED, V203, P2085, DOI 10.1084/jem.20061067; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Yu KF, 2005, MOL CELL BIOL, V25, P1730, DOI 10.1128/MCB.25.5.1730-1736.2005; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919	54	34	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					34	44		10.1096/fj.08-115352	http://dx.doi.org/10.1096/fj.08-115352			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18772346	Green Published			2022-12-28	WOS:000262095500006
J	Zhang, JH; Cao, RH; Zhang, Y; Jia, TH; Cao, YH; Wahlberg, E				Zhang, Junhang; Cao, Renhai; Zhang, Yun; Jia, Tanghong; Cao, Yihai; Wahlberg, Eric			Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability	FASEB JOURNAL			English	Article						neovascularization; ischemia; growth factor; receptor	ENDOTHELIAL GROWTH-FACTOR; THERAPEUTIC ANGIOGENESIS; MACULAR DEGENERATION; RANIBIZUMAB; ISCHEMIA; PROTEIN; CANCER; GENE	Preclinical and clinical evaluations of individual proangiogenic/arteriogenic factors for the treatment of ischemic myocardium and skeletal muscle have produced unfulfilled promises. The establishment of functional and stable arterial vascular networks may require combinations of different angiogenic and arteriogenic factors. Using in vivo angiogenesis and ischemic hind-limb animal models, we have compared the angiogenic and therapeutic activities of fibroblast growth factor 2 (FGF-2) in combinations with PDGF-AA and PDGF-AB, two members of the platelet-derived growth factor (PDGF) family, with distinct receptor binding patterns. We show that both PDGF-AA/FGF-2 and PDGF-AB/FGF-2 in combinations synergistically induce angiogenesis in the mouse cornea. FGF-2 upregulates PDGFR-alpha and -beta expression levels in the newly formed blood vessels. Interestingly, PDGF-AB/FGF-2, but not PDGF-AA/ FGF-2, is able to stabilize the newly formed vasculature by recruiting pericytes, and an anti-PDGFR-beta neutralizing antibody significantly blocks PDGF-AB/FGF-2-induced vessel stability. These findings demonstrate that PDGFR-beta receptor is essential for vascular stability. Similarly, PDGF-AB/FGF-2 significantly induces stable collateral growth in the rat ischemic hind limb. The high number of collaterals induced by PDGF-AB/FGF-2 leads to dramatic improvement of the paw's skin perfusion. Immunohistochemical analysis of the treated skeletal muscles confirms that a combination of PDGF-AB and FGF-2 significantly induces arteriogenesis in the ischemic tissue. A combination of PDGF-AB and FGF-2 would be optimal proangiogenic agents for the treatment of ischemic diseases.-Zhang, J., Cao, R., Zhang, Y., Jia, T., Cao, Y., Wahlberg, E. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J. 23, 153-163 (2009)	[Cao, Renhai; Cao, Yihai] Karolinska Inst, Lab Angiogenesis Res, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden; [Zhang, Junhang; Wahlberg, Eric] Karolinska Inst, Div Vasc Surg, Dept Mol Med & Surg, SE-17177 Stockholm, Sweden; [Zhang, Yun] Shandong Univ, Qilu Hosp, Jinan 250100, Shandong, Peoples R China; [Jia, Tanghong] Shandong Univ, Clin Med Coll, Jinan 250100, Shandong, Peoples R China; [Zhang, Junhang] China Med Univ, Dept Dev Biol, Liaoning Canc Hosp & Inst, Shenyang, Peoples R China	Karolinska Institutet; Karolinska Institutet; Shandong University; Shandong University; China Medical University	Cao, YH (corresponding author), Karolinska Inst, Lab Angiogenesis Res Microbiol Tumor & Cell Biol, Nobels Vag 16, SE-17177 Stockholm, Sweden.	yihai.cao@ki.se; eric.wahlberg@ki.se			China State Scholarship (Beijing, China); National Basic Research Program of China [2006CB503803]; National Natural Science Foundation of China [30428005]; Swedish Heart and Lung Foundation (Stockholm, Sweden); EU [STRP 013811]; Angiotargeting [504743]; Soderberg Foundation (Stockholm, Sweden); Swedish Medical Research Council (Stockholm, Sweden)	China State Scholarship (Beijing, China); National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Swedish Heart and Lung Foundation (Stockholm, Sweden)(Swedish Heart-Lung Foundation); EU(European Commission); Angiotargeting; Soderberg Foundation (Stockholm, Sweden); Swedish Medical Research Council (Stockholm, Sweden)(Swedish Medical Research Council (SMRC))	We thank Dr. Ebba Brakenhielm for performing the in situ hybridization studies. This study was supported by grants from China State Scholarship (Beijing, China), the National Basic Research Program of China (2006CB503803), the National Natural Science Foundation of China (30428005), the Swedish Heart and Lung Foundation (Stockholm, Sweden), the EU integrated project of VascuPlug (contract STRP 013811) and Angiotargeting (contract 504743), the Soderberg Foundation (Stockholm, Sweden), and the Swedish Medical Research Council (Stockholm, Sweden).	ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; Arbiser JL, 2007, J CLIN INVEST, V117, P2762, DOI 10.1172/JCI33190; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Carmeliet P, 2000, CIRC RES, V87, P176, DOI 10.1161/01.RES.87.3.176; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chen RR, 2007, PHARM RES, V24, P258, DOI 10.1007/s11095-006-9173-4; Crosby JR, 1998, NAT GENET, V18, P385, DOI 10.1038/ng0498-385; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; KITAMI Y, 1995, J CLIN INVEST, V96, P558, DOI 10.1172/JCI118068; KUMAR S, 1983, LANCET, V2, P364; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lu HX, 2007, P NATL ACAD SCI USA, V104, P12140, DOI 10.1073/pnas.0704966104; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Simons M, 2005, CIRCULATION, V111, P1556, DOI 10.1161/01.CIR.0000159345.00591.8F; Simons M, 2003, NAT REV DRUG DISCOV, V2, P863, DOI 10.1038/nrd1226; Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191; Toyota E, 2005, CIRCULATION, V112, P2108, DOI 10.1161/CIRCULATIONAHA.104.526954; Vale PR, 2000, CIRCULATION, V102, P965, DOI 10.1161/01.CIR.102.9.965; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	21	119	122	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					153	163		10.1096/fj.08-113860	http://dx.doi.org/10.1096/fj.08-113860			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18827023				2022-12-28	WOS:000262095500018
J	Schmieder, AH; Caruthers, SD; Zhang, H; Williams, TA; Robertson, JD; Wickline, SA; Lanza, GM				Schmieder, Anne H.; Caruthers, Shelton D.; Zhang, Huiying; Williams, Todd A.; Robertson, J. David; Wickline, Samuel A.; Lanza, Gregory M.			Three-dimensional MR mapping of angiogenesis with alpha(5)beta(1)(alpha(v)beta(3))-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model	FASEB JOURNAL			English	Article						magnetic resonance imaging; fumagillin; cancer; molecular imaging; antiangiogenic	VX-2 RABBIT TUMORS; IN-VIVO; BREAST-CANCER; INTEGRIN ALPHA(5)BETA(1); INHIBITOR TNP-470; CONTRAST AGENT; PHASE-I; ALPHA(V)BETA(3); AG-013736; ANTIBODY	Our objectives were 1) to characterize angiogenesis in the MDA-MB-435 xenograft mouse model with three-dimensional (3D) MR molecular imaging using alpha(5)beta(1)(RGD)- or irrelevant RGS-targeted paramagnetic nanoparticles and 2) to use MR molecular imaging to assess the antiangiogenic effectiveness of alpha(5)beta(1)(alpha(v)beta(3))- vs. alpha(v)beta(3)-targeted fumagillin (50 mu g/kg) nanoparticles. Tumor-bearing mice were imaged with MR before and after administration of either alpha(5)beta(1)(RGD) or irrelevant RGS-paramagnetic nanoparticles. In experiment 2, mice received saline or alpha(5)beta(1)(alpha(v)beta(3))- or alpha(v)beta(3)-targeted fumagillin nanoparticles on days 7, 11, 15, and 19 posttumor implant. On day 22, MRI was performed using alpha(5)beta(1)(alpha(v)beta(3))-targeted paramagnetic nanoparticles to monitor the antiangiogenic response. 3D reconstructions of alpha(5)beta(1)(RGD)-signal enhancement revealed a sparse, asymmetrical pattern of angiogenesis along the tumor periphery, which occupied < 2.0% tumor surface area. alpha(5)beta(1)-targeted rhodamine nanoparticles colocalized with FITC-lectin corroborated the peripheral neovascular signal. alpha(5)beta(1)(alpha(v)beta(3))-fumagillin nanoparticles decreased neovasculature to negligible levels relative to control; alpha(v)beta(3)-targeted fumagillin nanoparticles were less effective (P > 0.05). Reduction of angiogenesis in MDA-MB-435 tumors from low to negligible levels did not decrease tumor volume. MR molecular imaging may be useful for characterizing tumors with sparse neovasculature that are unlikely to have a reduced growth response to targeted antiangiogenic therapy.	[Schmieder, Anne H.; Caruthers, Shelton D.; Zhang, Huiying; Williams, Todd A.; Wickline, Samuel A.; Lanza, Gregory M.] Washington Univ, Sch Med, St Louis, MO 63108 USA; [Caruthers, Shelton D.] Philips Healthcare, Andover, MA USA; [Robertson, J. David] Univ Missouri Res Reactor, Columbia, MO USA	Washington University (WUSTL); Philips; Philips Healthcare; University of Missouri System; University of Missouri Columbia	Lanza, GM (corresponding author), Washington Univ, Sch Med, Campus Box 8215,4320 Forest Pk Ave, St Louis, MO 63108 USA.	greg@cvu.wustl.edu		Robertson, John/0000-0002-6675-8469	National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Biomedical Imaging and BioEngineering [HL-78631, HL-73646, CA-119342]; NATIONAL CANCER INSTITUTE [U54CA119342, U54CA136398] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073646, R01HL078631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059302] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Biomedical Imaging and BioEngineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Kereos, Inc. for the gift of the peptidomimetic integrin antagonists, Grace Hu for assistance with formulation chemistry, and John S. Allen and Cordelia Caradine for support of the animal studies. A.H.S., T.W., H.Z., S.A.W., and G. L. are supported by the National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Biomedical Imaging and BioEngineering (HL-78631, HL-73646, and CA-119342); and Philips Healthcare. S.A.W. and G.M.L. are scientific cofounders of Kereos, Inc. S.D.C. is employed by Philips Healthcare.	Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bhargava P, 1999, CLIN CANCER RES, V5, P1989; Boudreau NJ, 2004, J BIOL CHEM, V279, P4862, DOI 10.1074/jbc.M305190200; Cai WB, 2006, CANCER RES, V66, P9673, DOI 10.1158/0008-5472.CAN-06-1480; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Castronovo V, 1996, EUR J CANCER, V32A, P2520, DOI 10.1016/S0959-8049(96)00388-7; Chen XY, 2004, BIOCONJUGATE CHEM, V15, P41, DOI 10.1021/bc0300403; Cue D, 2000, P NATL ACAD SCI USA, V97, P2858, DOI 10.1073/pnas.050587897; Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330; Flacke S, 2001, CIRCULATION, V104, P1280, DOI 10.1161/hc3601.094303; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Frias JC, 2004, J AM CHEM SOC, V126, P16316, DOI 10.1021/ja044911a; Giles FJ, 2006, LEUKEMIA RES, V30, P801, DOI 10.1016/j.leukres.2005.10.024; Harris TD, 2003, CANCER BIOTHER RADIO, V18, P627, DOI 10.1089/108497803322287727; Holig P, 2004, PROTEIN ENG DES SEL, V17, P433, DOI 10.1093/protein/gzh055; Hu G, 2007, INT J CANCER, V120, P1951, DOI 10.1002/ijc.22581; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; Hylton N, 2006, J CLIN ONCOL, V24, P3293, DOI 10.1200/JCO.2006.06.8080; Izzedine H, 2007, AM J KIDNEY DIS, V50, P203, DOI 10.1053/j.ajkd.2007.04.025; Janssen M, 2004, CANCER BIOTHER RADIO, V19, P399, DOI 10.1089/cbr.2004.19.399; Jayson GC, 2002, J NATL CANCER I, V94, P1484, DOI 10.1093/jnci/94.19.1484; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Kong G, 2000, CANCER RES, V60, P4440; Konno H, 1996, CANCER-AM CANCER SOC, V77, P1736; Kudelka AP, 1998, NEW ENGL J MED, V338, P991, DOI 10.1056/NEJM199804023381412; Leach MO, 2005, BRIT J CANCER, V92, P1599, DOI 10.1038/sj.bjc.6602550; Li LY, 2004, INT J RADIAT ONCOL, V58, P1215, DOI 10.1016/j.ijrobp.2003.10.057; Liu G, 2005, J CLIN ONCOL, V23, P5464, DOI 10.1200/JCO.2005.04.143; Liu S, 2007, BIOCONJUGATE CHEM, V18, P438, DOI 10.1021/bc0603081; Logothetis CJ, 2001, CLIN CANCER RES, V7, P1198; Meoli DF, 2004, J CLIN INVEST, V113, P1684, DOI 10.1172/JCI200420352; Mulder WJM, 2005, FASEB J, V19, P2008, DOI 10.1096/fj.05-4145fje; Offodile R, 1999, TUMORI, V85, P51, DOI 10.1177/030089169908500111; Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3; Sadeghi MM, 2004, CIRCULATION, V110, P84, DOI 10.1161/01.CIR.0000133319.84326.70; Schmieder AH, 2005, MAGN RESON MED, V53, P621, DOI 10.1002/mrm.20391; Shusterman S, 2001, CLIN CANCER RES, V7, P977; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; Weissleder R, 2001, BIOCONJUGATE CHEM, V12, P213, DOI 10.1021/bc000091p; Wilmes LJ, 2007, MAGN RESON IMAGING, V25, P319, DOI 10.1016/j.mri.2006.09.041; Winter PM, 2008, FASEB J, V22, P2758, DOI 10.1096/fj.07-103929; Winter PM, 2006, ARTERIOSCL THROM VAS, V26, P2103, DOI 10.1161/01.ATV.0000235724.11299.76; Winter PM, 2003, CANCER RES, V63, P5838; Zakarija A, 2005, CURR OPIN ONCOL, V17, P578, DOI 10.1097/01.cco.0000183672.15133.ab; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zitzmann S, 2002, CANCER RES, V62, P5139	49	104	105	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4179	4189		10.1096/fj.08-112060	http://dx.doi.org/10.1096/fj.08-112060			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18697838	Green Published			2022-12-28	WOS:000261254800017
J	Csoka, B; Himer, L; Selmeczy, Z; Vizi, ES; Pacher, P; Ledent, C; Deitch, EA; Spolarics, Z; Nemeth, ZH; Hasko, G				Csoka, Balazs; Himer, Leondra; Selmeczy, Zsolt; Vizi, E. Sylvester; Pacher, Pal; Ledent, Catherine; Deitch, Edwin A.; Spolarics, Zoltan; Nemeth, Zoltan H.; Hasko, Gyoergy			Adenosine A(2A) receptor activation inhibits T helper 1 and T helper 2 cell development and effector function	FASEB JOURNAL			English	Article						autoimmunity; allergy; inflammation; rheumatoid arthritis; spleen and lymph nodes	ADENOSINE A(2A) RECEPTORS; HUMAN DENDRITIC CELLS; T-CELLS; EXTRACELLULAR ADENOSINE; POSTTRANSCRIPTIONAL MECHANISM; HUMAN NEUTROPHILS; HUMAN EOSINOPHILS; EXPRESSION; INFLAMMATION; MICE	Adenosine is an immunosuppressive nucleoside, and adenosine AA receptors inhibit T-cell activation. We investigated the role of A(2A) receptors in regulating T helper (Th)1- and Th2-cell development and effector function. A(2A)-receptor stimulation suppressed the development of Tell receptor (TCR) -stimulated naive T cells into both Th1 and Th2 cells, as indicated by decreased IFN-gamma production by cells developed under Th1-skewing conditions and decreased interleukin (IL)-4, IL-5, and IL-10 production by cells developed under Th2-skewing conditions. Using A(2A) receptor-deficient mice, we demonstrate that A(2A) receptor activation inhibits Th1- and Th2-cell development by decreasing the proliferation and IL,2 production of naive T cells, irrespective of whether the cells are expanded under Th1- or Th2-skewing environment. Using in vivo established Th1 and Th2 cells, we further demonstrate the nonselective nature of A(2A) receptor-mediated immunosuppressive effects, because A(2A) receptor activation decreased IFN-gamma and IL-4 secretion and mRNA level of TCR-stimulated effector Th1 and Th2 cells, respectively. A(2A) receptor mRNA expression in both Th1 and Th2 effector cells increased following TCR stimulation. In summary, these data demonstrate that A(2A) receptor activation has strong inhibitory actions during early developmental, as well as late effector, stages of Th1- and Th2-cell responses.	[Csoka, Balazs; Deitch, Edwin A.; Spolarics, Zoltan; Nemeth, Zoltan H.; Hasko, Gyoergy] Univ Med & Dent New Jersey, Dept Surg, New Jersey Med Sch, Newark, NJ 07103 USA; [Himer, Leondra; Selmeczy, Zsolt; Vizi, E. Sylvester; Hasko, Gyoergy] Hungarian Acad Sci, Inst Expt Med, Dept Pharmacol, Budapest, Hungary; [Pacher, Pal] NIAAA, Sect Oxidat Stress Tissue Injury, Lab Physiol Studies, NIH, Bethesda, MD USA; [Ledent, Catherine] Univ Libre Bruxelles, Inst Rech Interdisciplinaire Biol Humaine & Nucl, Brussels, Belgium; [Nemeth, Zoltan H.] Morristown Mem Hosp, Dept Surg, Morristown, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Universite Libre de Bruxelles; Atlantic Health System	Hasko, G (corresponding author), Univ Med & Dent New Jersey, Dept Surg, New Jersey Med Sch, 185 S Orange Ave,Univ Hts, Newark, NJ 07103 USA.	haskoge@umdnj.edu	Pacher, Pal/B-6378-2008	Pacher, Pal/0000-0001-7036-8108; Csoka, Balazs/0000-0002-7562-1130	U.S. National Institutes of Health (NIH) [R01 GM66189]; National Institute on Alchol Abuse and Alcoholism; Hungarian Research Fund OTKA [T 049537]; Hungarian National RD Programme [1A/036/2004]; NATIONAL CANCER INSTITUTE [R01CA163739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000375] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Alchol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Hungarian Research Fund OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Hungarian National RD Programme; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported by U.S. National Institutes of Health (NIH) grant R01 GM66189 and the Intramural Research Program of NIH, National Institute on Alchol Abuse and Alcoholism, as well as Hungarian Research Fund OTKA (T 049537) and Hungarian National R&D Programme 1A/036/2004.	Apasov S, 2000, BLOOD, V95, P3859; Armstrong JM, 2001, BIOCHEM J, V354, P123, DOI 10.1042/0264-6021:3540123; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Blackburn MR, 2003, TRENDS PHARMACOL SCI, V24, P66, DOI 10.1016/S0165-6147(02)00045-7; Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; Desai A, 2005, MOL PHARMACOL, V67, P1406, DOI 10.1124/mol.104.007807; Eltzschig HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066; Erdmann AA, 2005, BLOOD, V105, P4707, DOI 10.1182/blood-2004-04-1407; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Fortin A, 2006, J LEUKOCYTE BIOL, V79, P574, DOI 10.1189/jlb.0505249; Fozard JR, 2003, CURR OPIN PHARMACOL, V3, P264, DOI 10.1016/S1471-4892(03)00039-0; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Harish A, 2003, INT J ONCOL, V23, P1245; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; Hasko G, 2007, PHARMACOL THERAPEUT, V113, P264, DOI 10.1016/j.pharmthera.2006.08.003; Hua XY, 2007, J EXP MED, V204, P117, DOI 10.1084/jem.20061372; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Knight D, 1997, J LEUKOCYTE BIOL, V62, P465, DOI 10.1002/jlb.62.4.465; Kobie JJ, 2006, J IMMUNOL, V177, P6780, DOI 10.4049/jimmunol.177.10.6780; Kohno Y, 1996, BLOOD, V88, P3569, DOI 10.1182/blood.V88.9.3569.bloodjournal8893569; Koshiba M, 1999, MOL PHARMACOL, V55, P614; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Lappas CM, 2006, J EXP MED, V203, P2639, DOI 10.1084/jem.20061097; Ledent C, 1997, NATURE, V388, P674, DOI 10.1038/41771; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Naganuma M, 2006, J IMMUNOL, V177, P2765, DOI 10.4049/jimmunol.177.5.2765; Nemeth ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/jimmunol.175.12.8260; Nemeth ZH, 2007, FASEB J, V21, P2379, DOI 10.1096/fj.07-8213com; Nemeth ZH, 2006, J IMMUNOL, V176, P5616, DOI 10.4049/jimmunol.176.9.5616; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Panther E, 2003, BLOOD, V101, P3985, DOI 10.1182/blood-2002-07-2113; Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com; Ralevic V, 1998, PHARMACOL REV, V50, P413; Raskovalova T, 2005, J IMMUNOL, V175, P4383, DOI 10.4049/jimmunol.175.7.4383; Rogachev B, 2006, KIDNEY INT, V70, P675, DOI 10.1038/sj.ki.5001609; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Sullivan GW, 1999, J INFECT DIS, V180, P1550, DOI 10.1086/315084; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Williams BA, 1997, EXP CELL RES, V233, P187, DOI 10.1006/excr.1997.3530; Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646; Zhang H, 2004, J IMMUNOL, V173, P932, DOI 10.4049/jimmunol.173.2.932; Zhong HY, 2006, AM J RESP CELL MOL, V35, P587, DOI 10.1165/rcmb.2005-0476OC	49	130	132	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2008	22	10					3491	3499		10.1096/fj.08-107458	http://dx.doi.org/10.1096/fj.08-107458			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18625677	Green Published			2022-12-28	WOS:000259642600011
J	van Houwelingen, AH; Weathington, NM; Verweij, V; Blalock, JE; Nijkamp, FP; Folkerts, G				van Houwelingen, Anneke H.; Weathington, Nathaniel M.; Verweij, Vivienne; Blalock, J. Edwin; Nijkamp, Frans P.; Folkerts, Gert			Induction of lung emphysema is prevented by L-arginine-threonine-arginine	FASEB JOURNAL			English	Article						collagen breakdown; COPD; chemotaxis; neutrophil; inflammation	OBSTRUCTIVE PULMONARY-DISEASE; NEUTROPHIL CHEMOATTRACTANT; PEPTIDE; INFLAMMATION; EXPRESSION; PROLINE; SPUTUM	In patients with chronic obstructive pulmonary disease (COPD), an inflammatory process is ongoing in the lungs, with concomitant damage of the alveolar structures and loss of airway function. In this inflammatory process, extracellular matrix degradation is observed. During this lung matrix degradation, small peptide fragments consisting of proline and glycine repeats generated from collagen fibers are liberated from the matrix by matrix metalloproteinases. Chemotactic activities of these collagen-derived peptides such as N-acetyl-proline-glycine-proline (PGP) via CXCR1 and CXCR2 have been reported. We show here that PGP induces neutrophil migration in vivo, which is dose dependent. Moreover, PGP is involved in the development of emphysema-like changes in the airways. The complementary peptide, L-arginine-threonine-arginine (RTR), has been shown to bind to PGP sequences and inhibit neutrophil infiltration. We show that RTR impedes both PGP- and interleukin-8-induced chemotaxis in vitro. In vivo, RTR prevents both migration and activation of neutrophils induced by PGP. Furthermore, RTR completely inhibits PGP- induced lung emphysema, assessed by changes in alveolar enlargement and right ventricular hypertrophy. In conclusion, these data indicate that collagen breakdown products, especially PGP, are important in the pathogenesis of COPD and that PGP antagonism via RTR ameliorates lung emphysema.	[van Houwelingen, Anneke H.; Verweij, Vivienne; Nijkamp, Frans P.; Folkerts, Gert] Univ Utrecht, Fac Sci, Dept Pharmaceut Sci, Div Pharmacol & Pathophysiol, NL-3508 TB Utrecht, Netherlands; [Weathington, Nathaniel M.; Blalock, J. Edwin] Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	Utrecht University; University of Alabama System; University of Alabama Birmingham	van Houwelingen, AH (corresponding author), Univ Utrecht, Fac Sci, Dept Pharmaceut Sci, Div Pharmacol & Pathophysiol, POB 800 82, NL-3508 TB Utrecht, Netherlands.	a.h.vanhouwelingen@uu.nl	Verweij, Vivienne G.M/F-8447-2016	Blalock, J. Edwin/0000-0001-5303-8123	U. S. National Institute of Health [HL077783, HL090999, ES013874-03]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077783, R01HL090999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F30ES013874] Funding Source: NIH RePORTER	U. S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The work was supported by U. S. National Institute of Health grants HL077783, HL090999, and ES013874-03.	Babusyte A, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-81; Baraldo S, 2004, THORAX, V59, P308, DOI 10.1136/thx.2003.012146; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; BATTAGLIA S, 2006, J CLIN PATHOL ON AUG, pE1; Beeh KM, 2003, CHEST, V123, P1240, DOI 10.1378/chest.123.4.1240; Chapman KR, 2006, EUR RESPIR J, V27, P188, DOI 10.1183/09031936.06.00024505; Churg A, 2002, AM J RESP CELL MOL, V27, P368, DOI 10.1165/rcmb.4791; Culpitt SV, 2005, RESP MED, V99, P703, DOI 10.1016/j.rmed.2004.10.022; Gaggar A, 2008, J IMMUNOL, V180, P5662, DOI 10.4049/jimmunol.180.8.5662; Haddox JL, 2001, INVEST OPHTH VIS SCI, V42, P2769; Haddox JL, 1999, INVEST OPHTH VIS SCI, V40, P2427; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Imai K, 2001, AM J RESP CRIT CARE, V163, P786, DOI 10.1164/ajrccm.163.3.2001073; Malik M, 2007, J IMMUNOL, V178, P1013, DOI 10.4049/jimmunol.178.2.1013; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; PFISTER RR, 1995, INVEST OPHTH VIS SCI, V36, P1306; Pfister RR, 2000, CORNEA, V19, P384, DOI 10.1097/00003226-200005000-00025; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Weathington NM, 2006, NAT MED, V12, P317, DOI 10.1038/nm1361	19	56	56	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3403	3408		10.1096/fj.07-096230	http://dx.doi.org/10.1096/fj.07-096230			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18556462	Green Published			2022-12-28	WOS:000258761300032
J	Hart, ML; Henn, M; Koehler, D; Kloor, D; Mittelbronn, M; Gorzolla, IC; Stahl, GL; Eltzschig, HK				Hart, Melanie L.; Henn, Martina; Koehler, David; Kloor, Doris; Mittelbronn, Michel; Gorzolla, Iris C.; Stahl, Gregory L.; Eltzschig, Holger K.			Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury	FASEB JOURNAL			English	Article						CD73; adenosine receptor; hypoxia; HIF; hypoxia-inducible factor	HYPOXIA-INDUCIBLE FACTOR; ECTO-5'-NUCLEOTIDASE CD73; ADENOSINE RECEPTORS; ISCHEMIA/REPERFUSION INJURY; LYMPHOCYTE BINDING; COMPLEMENT PATHWAY; ENDOTHELIAL-CELLS; ADENYLATE-CYCLASE; TISSUE PROTECTION; EPITHELIA	Extracellular adenosine has been implicated as an innate antiinflammatory metabolite, particularly during conditions of limited oxygen availability such as ischemia. Because extracellular adenosine generation is primarily produced via phosphohydrolysis from its precursor molecule adenosine-monophosphate (AMP) through the enzyme ecto-5 '-nucleotidase (CD73), we examined the contribution of CD73-dependent adenosine production in modulation of intestinal ischemia-reperfusion (IR) injury. Following transcriptional and translational profiling of intestinal tissue that revealed a prominent induction of murine CD73, we next determined the role of CD73 in protection against intestinal IR injury. Interestingly, pharmacological inhibition or targeted gene deletion of CD73 significantly enhanced not only local intestinal injury, but also secondary organ injury, following IR as measured by intestinal and lung myeloperoxidase, aspartate and alanine aminotransferase, interleukin (IL)-1, IL-6, and histological injury. To confirm the role of CD73 in intestinal adenosine production, we measured adenosine tissue levels and found that they were increased with IR injury. In contrast, CD73-deficient (cd73(-/-)) mice had lower adenosine levels at baseline and no increase with IR injury. Finally, reconstitution of cd73(-/-) mice or treatment of wild- type mice with soluble 5 '-nucleotidase was associated with significantly lower levels of injury. These data reveal a previously unrecognized role of CD73 in attenuating intestinal IR-mediated injury.	[Hart, Melanie L.; Henn, Martina; Koehler, David; Gorzolla, Iris C.; Eltzschig, Holger K.] Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Ctr Inflammat & Hypoxia, D-72074 Tubingen, Germany; [Hart, Melanie L.; Stahl, Gregory L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Expt Therapeut & Reperfus Injury,Dept Anesthe, Boston, MA 02115 USA; [Mittelbronn, Michel] Univ Tubingen Hosp, Inst Brain Res, D-72074 Tubingen, Germany; [Kloor, Doris] Univ Tubingen, Dept Pharmacol & Toxicol, Tubingen, Germany; [Eltzschig, Holger K.] Univ Colorado, Hlth Sci Ctr, Dept Anesthesiol, Mucosal Inflammat Program, Denver, CO USA	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hart, ML (corresponding author), Univ Tubingen Hosp, Dept Anesthesiol & Intens Care Med, Ctr Inflammat & Hypoxia, Wilhelmstr 56, D-72074 Tubingen, Germany.	melaniehar@googlemail.com; holger.eltzschig@uchsc.edu		Stahl, Gregory/0000-0002-4805-8119; Mittelbronn, Michel/0000-0002-2998-052X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052886, R56HL056086, R01HL056086, R29HL052886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191, R01DE017821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK067782] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL056086, HL-56086, R56 HL056086, HL-52886, R01 HL052886] Funding Source: Medline; NIDCR NIH HHS [DE-16191, P50 DE016191, DE-17821, R01 DE017821] Funding Source: Medline; NIDDK NIH HHS [DK-067782, F32 DK067782] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Airas L, 2000, J IMMUNOL, V165, P5411, DOI 10.4049/jimmunol.165.10.5411; Airas L, 1997, J CELL BIOL, V136, P421, DOI 10.1083/jcb.136.2.421; AIRAS L, 1995, J EXP MED, V182, P1603, DOI 10.1084/jem.182.5.1603; Asfaha S, 2001, AM J PHYSIOL-GASTR L, V281, pG635, DOI 10.1152/ajpgi.2001.281.3.G635; Bourdi M, 2002, BIOCHEM BIOPH RES CO, V294, P225, DOI 10.1016/S0006-291X(02)00466-7; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; CHIU CJ, 1970, ARCH SURG-CHICAGO, V101, P478; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127; Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697; Eltzschig HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066; Eltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Eltzschig HK, 2006, CIRC RES, V99, P1100, DOI 10.1161/01.RES.0000250174.31269.70; Eltzschig HK, 2006, METH MOL B, V341, P73; Freeman SL, 2004, GUT, V53, P214, DOI 10.1136/gut.2003.023895; Grenz A, 2007, J AM SOC NEPHROL, V18, P833, DOI 10.1681/ASN.2006101141; GRISHAM MB, 1989, AM J PHYSIOL, V257, pH1334, DOI 10.1152/ajpheart.1989.257.5.H1334; Guckelberger O, 2004, THROMB HAEMOSTASIS, V91, P576, DOI 10.1160/TH03-06-0373; Hart ML, 2005, J IMMUNOL, V174, P6373, DOI 10.4049/jimmunol.174.10.6373; KAMINSKI PM, 1989, CIRC RES, V65, P426, DOI 10.1161/01.RES.65.2.426; KAMINSKI PM, 1992, CIRC RES, V71, P720, DOI 10.1161/01.RES.71.3.720; KAMINSKI PM, 1990, CIRC RES, V66, P1713, DOI 10.1161/01.RES.66.6.1713; Kolachala V, 2005, J BIOL CHEM, V280, P4048, DOI 10.1074/jbc.M409577200; Koury J, 2004, SHOCK, V22, P270, DOI 10.1097/01.shk.0000135256.67441.3f; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; Linden J, 2005, MOL PHARMACOL, V67, P1385, DOI 10.1124/mol.105.011783; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Luippold G, 1999, J CHROMATOGR B, V724, P231, DOI 10.1016/S0378-4347(98)00580-5; MADARA JL, 1993, J CLIN INVEST, V91, P2320, DOI 10.1172/JCI116462; Mallick IH, 2004, DIGEST DIS SCI, V49, P1359, DOI 10.1023/B:DDAS.0000042232.98927.91; Maxwell PH, 2005, EXP PHYSIOL, V90, P791, DOI 10.1113/expphysiol.2005.030924; McCallion K, 2004, CRIT CARE MED, V32, P273, DOI 10.1097/01.CCM.0000098026.12020.45; Naganuma M, 2006, J IMMUNOL, V177, P2765, DOI 10.4049/jimmunol.177.5.2765; Niemela J, 2004, J IMMUNOL, V172, P1646, DOI 10.4049/jimmunol.172.3.1646; Ozacmak VH, 2007, EUR J PHARMACOL, V562, P138, DOI 10.1016/j.ejphar.2007.01.061; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; PARKOS CA, 1994, J AM SOC NEPHROL, V5, P138; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Sitkovsky MV, 2003, BIOCHEM PHARMACOL, V65, P493, DOI 10.1016/S0006-2952(02)01548-4; Stahl GL, 2003, AM J PATHOL, V162, P449, DOI 10.1016/S0002-9440(10)63839-4; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; STROHMEIER GR, 1995, J BIOL CHEM, V270, P2387, DOI 10.1074/jbc.270.5.2387; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Tendler David A, 2003, Semin Gastrointest Dis, V14, P66; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; TURNAGE RH, 1994, SHOCK, V1, P408, DOI 10.1097/00024382-199406000-00003; Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259; Zhao H, 2002, J APPL PHYSIOL, V93, P338, DOI 10.1152/japplphysiol.00159.2002	51	83	84	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2784	2797		10.1096/fj.07-103911	http://dx.doi.org/10.1096/fj.07-103911			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18353866	Green Published			2022-12-28	WOS:000258089300019
J	Deshpande, DA; Theriot, BS; Penn, RB; Walker, JKL				Deshpande, Deepak A.; Theriot, Barbara S.; Penn, Raymond B.; Walker, Julia K. L.			beta-arrestins specifically constrain beta 2-adrenergic receptor signaling and function in airway smooth muscle	FASEB JOURNAL			English	Article							PROTEIN-COUPLED RECEPTORS; ADRENERGIC-RECEPTOR; ASTHMA; KINASE; MICE; DESENSITIZATION; SALMETEROL; AGONIST; HYPERREACTIVITY; PHOSPHORYLATION	Chronic use of inhaled beta-agonists by asthmatics is associated with a loss of bronchoprotective effect and deterioration of asthma control. Beta-agonistpromoted desensitization of airway smooth muscle beta-2-adrenergic receptors, mediated by G protein-coupled receptor kinases and arrestins, is presumed to underlie these effects, but such a mechanism has never been demonstrated. Using in vitro, ex vivo, and in vivo murine models, we demonstrate that beta-arrestin-2 gene ablation augments beta-agonist-mediated airway smooth muscle relaxation, while augmenting beta-agonist-stimulated cyclic adenosine monophosphate production. In cultures of human airway smooth muscle, small interfering RNA-mediated knockdown of arrestins also augments beta-agonist-stimulated cyclic adenosine monophosphate production. Interestingly, signaling and function mediated by m2/m3 muscarinic acetylcholine receptors or prostaglandin E-2 receptors were not affected by either beta-arrestin-2 knockout or arrestin knockdown. Thus, arrestins are selective regulators of beta-2-adrenergic receptor signaling and function in airway smooth muscle. These results and our previous findings, which demonstrate a role for arrestins in the development of allergic inflammation in the lung, identify arrestins as potentially important therapeutic targets for obstructive airway diseases.	[Deshpande, Deepak A.; Penn, Raymond B.] WFUHSC, Ctr Human Genom, Winston Salem, NC 27157 USA; [Deshpande, Deepak A.; Penn, Raymond B.] WFUHSC, Dept Internal Med, Winston Salem, NC 27157 USA; [Theriot, Barbara S.; Walker, Julia K. L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University	Penn, RB (corresponding author), WFUHSC, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rpenn@wfubmc.edu; walke082@mc.duke.edu	Walker, Julia/R-7585-2017		NHLBI NIH HHS [R01 HL084123, HL-58506, R01 HL093103, R01 HL058506, HL-084123, R29 HL058506, K99 HL-087560, K99 HL087560] Funding Source: Medline; NIAID NIH HHS [R01 AI059755, AI059755] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058506, R01HL084123, K99HL087560, R01HL058506, R01HL093103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059755] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aaronson DW, 2006, J ALLERGY CLIN IMMUN, V117, P40, DOI 10.1016/j.jaci.2005.08.060; Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; Billington CK, 2005, BIOCHEMISTRY-US, V44, P14595, DOI 10.1021/bi0510734; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; Deshpande DA, 2007, FASEB J, V21, P2335, DOI 10.1096/fj.06-8060com; Deshpande DA, 2006, CELL SIGNAL, V18, P2105, DOI 10.1016/j.cellsig.2006.04.008; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; GAVETT SH, 1993, AM J PHYSIOL, V265, pL493, DOI 10.1152/ajplung.1993.265.5.L493; Guo MH, 2005, BIOCHEMISTRY-US, V44, P13771, DOI 10.1021/bi051255y; HOSEY MM, 1995, LIFE SCI, V56, P951; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Jackson CM, 2004, DRUG SAFETY, V27, P243, DOI 10.2165/00002018-200427040-00003; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2002, J CELL SCI, V115, P455; Mak JCW, 2002, BRIT J PHARMACOL, V135, P987, DOI 10.1038/sj.bjp.0704545; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; PENN RB, 1998, HDB PHYSL, P125; Peters SP, 1999, AM J MED, V107, P283; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Struckmann N, 2003, MOL PHARMACOL, V64, P1444, DOI 10.1124/mol.64.6.1444; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; Walker JKL, 1999, AM J PHYSIOL-REG I, V276, pR1214, DOI 10.1152/ajpregu.1999.276.4.R1214; Walker JKL, 2003, J CLIN INVEST, V112, P566, DOI 10.1172/JCI200317265; WIDDOP S, 1993, AM J RESP CELL MOL, V9, P541, DOI 10.1165/ajrcmb/9.5.541	35	71	74	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2134	2141		10.1096/fj.07-102459	http://dx.doi.org/10.1096/fj.07-102459			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18337459	Green Accepted			2022-12-28	WOS:000257292500005
J	Membrez, M; Blancher, F; Jaquet, M; Bibiloni, R; Cani, PD; Burcelin, RG; Corthesy, I; Mace, K; Chou, CJ				Membrez, Mathieu; Blancher, Florence; Jaquet, Muriel; Bibiloni, Rodrigo; Cani, Patrice D.; Burcelin, Remy G.; Corthesy, Irene; Mace, Katherine; Chou, Chieh Jason			Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice	FASEB JOURNAL			English	Article						lipopolysaccharide; hepatic steatosis; liver glycogen; TNF-alpha	INDUCED INSULIN-RESISTANCE; TYROSINE KINASE-ACTIVITY; TOLL-LIKE RECEPTORS; MOLECULAR ANALYSIS; OBESITY; DIVERSITY; IMPROVES; ALPHA; OXYTETRACYCLINE; ENDOTOXEMIA	Recent data suggest that the gut microbiota plays a significant role in fat accumulation. However, it is not clear whether gut microbiota is involved in the pathophysiology of type 2 diabetes. To assess this issue, we modulated gut microbiota via antibiotics administration in two different mouse models with insulin resistance. Results from dose-determination studies showed that a combination of norfloxacin and ampicillin, at a dose of 1g/L, maximally suppressed the numbers of cecal aerobic and anaerobic bacteria in ob/ob mice. After a 2-wk intervention with the antibiotic combination, both ob/ob and diet-induced obese and insulin-resistant mice showed a significant improvement in fasting glycemia and oral glucose tolerance. The improved glycemic control was independent of food intake or adiposity because pair-fed ob/ob mice were as glucose intolerant as the control ob/ob mice. Reduced liver triglycerides and increased liver glycogen correlated with improved glucose tolerance in the treated mice. Concomitant reduction of plasma lipopolysaccharides and increase of adiponectin further supported the antidiabetic effects of the antibiotic treatment in ob/ob mice. In summary, modulation of gut microbiota ameliorated glucose tolerance of mice by altering the expression of hepatic and intestinal genes involved in inflammation and metabolism, and by changing the hormonal, inflammatory, and metabolic status of the host.	[Membrez, Mathieu; Blancher, Florence; Jaquet, Muriel; Bibiloni, Rodrigo; Corthesy, Irene; Mace, Katherine; Chou, Chieh Jason] Nestle Res Ctr, CH-1000 Lausanne, Switzerland; [Cani, Patrice D.] Catholic Univ Louvain, Unit Pharmacokinet Metab Nutr & Toxicol, Brussels, Belgium; [Burcelin, Remy G.] INSERM, Inst Mol Med Rangueil 12 MR, U858, IFR31, Toulouse, France	Nestle SA; Universite Catholique Louvain; Institut National de la Sante et de la Recherche Medicale (Inserm)	Chou, CJ (corresponding author), Nestle Res Ctr, POB 44, CH-1000 Lausanne, Switzerland.	chieh-jason.chou@rdls.nestle.com	burcelin, remy/M-6013-2014; D., Cani Patrice/M-8055-2016	D., Cani Patrice/0000-0003-2040-2448				Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Begin-Heck N, 1974, Biochem J, V142, P465; Bik EM, 2006, P NATL ACAD SCI USA, V103, P732, DOI 10.1073/pnas.0506655103; BLANDIZZI C, 1991, EUR J PHARMACOL, V201, P35, DOI 10.1016/0014-2999(91)90319-L; Blaut M, 2007, J NUTR, V137, p751S, DOI 10.1093/jn/137.3.751S; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Chou CJ, 2002, J BIOL CHEM, V277, P24484, DOI 10.1074/jbc.M202449200; DALPESCOTT M, 1982, DIABETES, V31, P53, DOI 10.2337/diabetes.31.1.53; DUBUC PU, 1978, DIABETOLOGIA, V14, P129, DOI 10.1007/BF01263451; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Hill MJ, 1997, EUR J CANCER PREV, V6, pS43, DOI 10.1097/00008469-199703001-00009; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; LEVINE M, 1921, B IOWA STATE COLLEGE, V62; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Murray P.R., 2003, MANUAL CLIN MICROBIO, V8th; Paster BJ, 2001, J BACTERIOL, V183, P3770, DOI 10.1128/JB.183.12.3770-3783.2001; Pei ZH, 2004, P NATL ACAD SCI USA, V101, P4250, DOI 10.1073/pnas.0306398101; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Schumann A, 2005, PHYSIOL GENOMICS, V23, P235, DOI 10.1152/physiolgenomics.00057.2005; Scougall KT, 2003, J MOL ENDOCRINOL, V30, P331, DOI 10.1677/jme.0.0300331; Solga SF, 2003, J HEPATOL, V38, P681, DOI 10.1016/S0168-8278(03)00097-7; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; VAN SCHOTHORST M., 1966, ZENTRALBL VETERINARMED REIHE B, V13, P273; VIRKAMAKI A, 1994, ENDOCRINOLOGY, V134, P2072, DOI 10.1210/en.134.5.2072; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zunkler BJ, 2006, TOXICOLOGY, V228, P239, DOI 10.1016/j.tox.2006.09.002	40	363	397	1	61	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2416	2426		10.1096/fj.07-102723	http://dx.doi.org/10.1096/fj.07-102723			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18326786				2022-12-28	WOS:000257292500033
J	Lane, JR; Henderson, D; Powney, B; Wise, A; Rees, S; Daniels, D; Plumpton, C; Kinghorn, I; Milligan, G				Lane, J. Robert; Henderson, David; Powney, Ben; Wise, Alan; Rees, Stephen; Daniels, Dion; Plumpton, Chris; Kinghorn, Ian; Milligan, Graeme			Antibodies that identify only the active conformation of G(i) family G protein alpha subunits	FASEB JOURNAL			English	Article						G protein-coupled receptor; ligand screening	NUCLEOTIDE-BINDING PROTEIN-G0; HETEROTRIMERIC G-PROTEIN; MONOCLONAL-ANTIBODIES; COUPLED RECEPTORS; CRYSTAL-STRUCTURE; ADENYLATE-CYCLASE; GTPASE ACTIVITY; ACTIVATION; INHIBITION; ASSAY	Production of antisera able to recognize individual heterotrimeric G protein alpha subunits resulted in rapid expansion of information on their distribution and function. However, no antibodies that specifically recognize the active state have been available. Four-way primary screening of 763 hybridomas generated from mice immunized with guanosine 5'-O-(3-thio)triphosphate-loaded G alpha(i1) and isolated using an automated robotic colony picker identified three antibodies that interacted with the constitutively active, Q(204)L, mutant but neither the constitutively inactive, G(203)A, mutant nor wild-type G alpha(i1). This profile extended to other closely related G(i) family G proteins but not to the less closely related G alpha(s) and G alpha(q)/G alpha(11) families. Each antibody was, however, also able to identify wild-type, GDP-bound Gi family G proteins in the presence of fluoroaluminate, which mimics the presence of the terminal phosphate of GTP and hence generates an active/transition state conformation. Stimulation of cells coexpressing a wild-type G alpha(i) subunit and the dopamine D2 receptor with the agonist ligand norapomorphine also allowed these conformationally selective antibodies to bind the G protein. Such reagents allow the specific identification of activated G proteins in a native environment and may allow the development of label-free screening assays for G protein-coupled receptor-mediated activation of G(i) family G proteins.	[Lane, J. Robert; Henderson, David; Milligan, Graeme] Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; [Powney, Ben; Wise, Alan; Rees, Stephen; Daniels, Dion] GlaxoSmithKline Res & Dev Ltd, Screening & Compound Profiling, Harlow, Essex, England; [Plumpton, Chris; Kinghorn, Ian] GlaxoSmithKline Res & Dev Ltd, Biol Reagents & Assay Dev, Med Res Ctr, Stevenage, Herts, England	University of Glasgow; GlaxoSmithKline; GlaxoSmithKline	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Lane, J. Robert/0000-0002-7361-7875	Biotechnology and Biological Sciences Research Council Funding Source: Medline; Medical Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ADIE EJ, 1992, BIOCHEM J, V285, P529, DOI 10.1042/bj2850529; Bynum J, 1999, HYBRIDOMA, V18, P407, DOI 10.1089/hyb.1999.18.407; DAVIS JM, 1982, J IMMUNOL METHODS, V50, P161, DOI 10.1016/0022-1759(82)90222-8; Ferrer M, 2003, ASSAY DRUG DEV TECHN, V1, P261, DOI 10.1089/15406580360545071; Frang H, 2003, ASSAY DRUG DEV TECHN, V1, P275, DOI 10.1089/15406580360545080; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; Gupta A, 2007, J BIOL CHEM, V282, P5116, DOI 10.1074/jbc.M609254200; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Jacoby E, 2006, CHEMMEDCHEM, V1, P760, DOI 10.1002/cmdc.200600134; Jameson EE, 2005, J BIOL CHEM, V280, P7712, DOI 10.1074/jbc.M413810200; Jameson EE, 2007, ANAL CHEM, V79, P1158, DOI 10.1021/ac061099g; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; Kilpatrick KE, 1997, HYBRIDOMA, V16, P381, DOI 10.1089/hyb.1997.16.381; Kostenis E, 2005, TRENDS PHARMACOL SCI, V26, P595, DOI 10.1016/j.tips.2005.09.007; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lane JR, 2007, MOL PHARMACOL, V71, P1349, DOI 10.1124/mol.106.032722; MAILLEUX P, 1992, NEUROSCIENCE, V51, P311, DOI 10.1016/0306-4522(92)90317-U; Mancia F, 2007, P NATL ACAD SCI USA, V104, P4303, DOI 10.1073/pnas.0700301104; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; Milligan G, 2006, BRIT J PHARMACOL, V147, pS46, DOI 10.1038/sj.bjp.0706405; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MULLANEY I, 1990, J NEUROCHEM, V55, P1890, DOI 10.1111/j.1471-4159.1990.tb05773.x; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Rios C, 2006, BRIT J PHARMACOL, V148, P387, DOI 10.1038/sj.bjp.0706757; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943	36	13	13	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1924	1932		10.1096/fj.07-100388	http://dx.doi.org/10.1096/fj.07-100388			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18199696				2022-12-28	WOS:000256352700032
J	Roesli, C; Mumprecht, V; Neri, D; Detmar, M				Roesli, Christoph; Mumprecht, Viviane; Neri, Dario; Detmar, Michael			Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping	FASEB JOURNAL			English	Article						angiogenesis; lymphangiogenesis; endothelium; proteomics; membrane proteins	LYMPHATIC ENDOTHELIAL-CELLS; PROMOTES TUMOR-METASTASIS; MEMBRANE-PROTEINS; IN-VIVO; LYMPHANGIOGENESIS; DISEASE; GROWTH; INDUCTION; BIOTINYLATION; ANGIOGENESIS	The formation of blood vessels (angiogenesis) and of lymphatic vessels (lymphangiogenesis) actively contributes to cancer progression and inflammation. Thus, there has been a quest for identifying the molecular mechanisms that control lymphatic and blood vessel formation and function. Membrane and extracellular matrix proteins can serve as suitable targets for imaging and/or therapeutic targeting; however, conventional proteomic technologies often fail to identify them systematically due to insolubility in water and low abundance of membrane proteins. To circumvent this problem, we applied a gel-free proteomics methodology termed two-dimensional peptide mapping (2DPM) to cultured blood vascular (BECs) and lymphatic (LECs) endothelial cells. 2D-PM comprises biotinylation of surface-accessible proteins, their selective enrichment, separation by HPLC, and analysis by mass spectrometry. We identified 184 proteins that were specifically or predominantly expressed by LECs and 185 proteins specifically expressed by BECs, whereas 377 additional proteins were equally detected in both cell types. For representative proteins, the differential, lineage-specific expression was confirmed by Western analyses of cultured cells and by differential immunofluorescence analyses of tissue samples. Our results identify the surface-accessible, vascular lineage-specific proteome, and they also reveal 2D-PM as a powerful technology for the large-scale screening of lineage-specific protein expression.	[Roesli, Christoph; Mumprecht, Viviane; Neri, Dario; Detmar, Michael] ETH, Swiss Fed Inst Technol, Inst Pharmaceut Sci, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Detmar, M (corresponding author), ETH, Swiss Fed Inst Technol, Inst Pharmaceut Sci, Wolfgang Pauli Str 10,HCI H303, CH-8093 Zurich, Switzerland.	michael.detmar@pharma.ethz.ch	Neri, Dario/P-4368-2016; Roesli, Christoph/B-9527-2018	Neri, Dario/0000-0001-5234-7370; Roesli, Christoph/0000-0001-6182-5020	NCI NIH HHS [CA-69184, CA-92644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092644, R01CA069184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Bruneel A, 2003, PROTEOMICS, V3, P714, DOI 10.1002/pmic.200300409; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132; Cueni LN, 2006, J INVEST DERMATOL, V126, P2167, DOI 10.1038/sj.jid.5700464; Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hong YK, 2004, NAT GENET, V36, P683, DOI 10.1038/ng1383; JOHNSON RS, 1987, ANAL CHEM, V59, P2621, DOI 10.1021/ac00148a019; Kajiya K, 2005, EMBO J, V24, P2885, DOI 10.1038/sj.emboj.7600763; Karsan A, 2005, MOL CELL PROTEOMICS, V4, P191, DOI 10.1074/mcp.M400152-MCP200; Kerjaschki D, 2006, NAT MED, V12, P230, DOI 10.1038/nm1340; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Nasdala I, 2002, J BIOL CHEM, V277, P16294, DOI 10.1074/jbc.M111999200; Neri D, 2005, NAT REV CANCER, V5, P436, DOI 10.1038/nrc1627; Ogura Y, 2005, LIFE SCI, V77, P2804, DOI 10.1016/j.lfs.2005.05.028; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; Oliver G, 2004, NAT REV IMMUNOL, V4, P35, DOI 10.1038/nri1258; Olsen CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-43; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Peitsch WK, 2005, J INVEST DERMATOL, V125, P761, DOI 10.1111/j.0022-202X.2005.23793.x; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399; Roesli C, 2006, CURR OPIN CHEM BIOL, V10, P35, DOI 10.1016/j.cbpa.2005.12.017; Rybak JN, 2005, NAT METHODS, V2, P291, DOI 10.1038/NMETH745; Sanchez J.-C, 2004, BIOMEDICAL APPL PROT; Scheurer SB, 2005, PROTEOMICS, V5, P2718, DOI 10.1002/pmic.200401163; Shin JW, 2006, MOL BIOL CELL, V17, P576, DOI 10.1091/mbc.E05-04-0368; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stevens TJ, 2000, PROTEINS, V39, P417, DOI 10.1002/(SICI)1097-0134(20000601)39:4<417::AID-PROT140>3.0.CO;2-Y; Tobler NE, 2006, J LEUKOCYTE BIOL, V80, P691, DOI 10.1189/jlb.1105653	38	30	31	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1933	1944		10.1096/fj.07-100529	http://dx.doi.org/10.1096/fj.07-100529			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18180333				2022-12-28	WOS:000256352700033
J	Conn, PM; Parkert, JV				Conn, P. Michael; Parkert, James V.			The animal research war	FASEB JOURNAL			English	Editorial Material									[Conn, P. Michael] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center	Conn, PM (corresponding author), Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, 505 NW 185th Ave, Beaverton, OR 97006 USA.	connm@ohsu.edu	Beversdorf, David Q./M-2786-2016	Beversdorf, David Q./0000-0002-0298-0634					0	7	7	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1294	1295		10.1096/fj.08-0502ufm	http://dx.doi.org/10.1096/fj.08-0502ufm			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18450645				2022-12-28	WOS:000255898700002
J	Langlois, MJ; Roy, SAB; Auclair, BA; Jones, C; Boudreau, F; Carrier, JC; Rivard, N; Perreault, N				Langlois, Marie-Josee; Roy, Sebastien A. B.; Auclair, Benoit A.; Jones, Christine; Boudreau, Francois; Carrier, Julie C.; Rivard, Nathalie; Perreault, Nathalie			Epithelial phosphatase and tensin homolog regulates intestinal architecture and secretory cell commitment and acts as a modifier gene in neoplasia	FASEB JOURNAL			English	Article						phosphatidylinositol 3-kinase; Akt; beta-catenin; cell fate; organomegaly; differentiation	CYCLIN D1; ENTEROENDOCRINE CELLS; COLORECTAL-CANCER; TUMOR SUPPRESSION; STEM-CELLS; PTEN; DIFFERENTIATION; EXPRESSION; MOUSE; MICE	Phosphatase and tensin homolog (PTEN), a negative regulator of the phosphatidylinositol 3-kinase/Akt pathway, is one of the most frequently mutated/deleted tumor suppressor genes in human cancers. The aim of this study was to gain insight into the role played by PTEN in intestinal homeostasis and epithelial cell function. Using the Cre/loxP system, we have generated a mouse with a conditional intestinal epithelial Pten deficiency. Pten mutant mice and controls were sacrificed for histology, immunofluorescence, Western blot, and quantitative polymerase chain reaction analysis. Our results show that loss of epithelial Pten leads to an intestinalomegaly associated with an increase in epithelial cell proliferation. Histological analysis demonstrated significant perturbation of the crypt-villus architecture, a marked increase in goblet cells and a decrease in enteroendocrine cells, suggesting a role for Pten in the commitment of the multipotential-secretory precursor cell. Loss of epithelial Pten does not result in induction of nuclear beta-catenin protein levels, nor is it sufficient to promote tumorigenesis initiation. However, it severely enhances intestinal tumor load in Apc(Min/+) mice, in which c-Myc is already deregulated. These results reveal an unknown function for Pten signaling in the commitment of multipotential-secretory progenitor cells and suggest that epithelial Pten functions as a modifier gene in intestinal neoplasia.-Langlois, M.- J., Roy, S. A. B., Auclair, B. A., Jones, C., Boudreau, F., Carrier, J. C., Rivard, N., Perreault, N. Epithelial phosphatase and tensin homolog regulates intestinal architecture and secretory cell commitment and acts as a modifier gene in neoplasia. FASEB J. 23, 1835-1844 (2009)	[Langlois, Marie-Josee; Roy, Sebastien A. B.; Auclair, Benoit A.; Jones, Christine; Boudreau, Francois; Rivard, Nathalie; Perreault, Nathalie] Univ Sherbrooke, Fac Med & Sci Sante, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada; [Langlois, Marie-Josee; Roy, Sebastien A. B.; Auclair, Benoit A.; Jones, Christine; Boudreau, Francois; Carrier, Julie C.; Rivard, Nathalie; Perreault, Nathalie] Univ Sherbrooke, Canadian Inst Hlth Res, Team Digest Epithelium, Sherbrooke, PQ J1H 5N4, Canada; [Carrier, Julie C.] Univ Sherbrooke, Fac Med & Sci Sante, Dept Med, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; Institute for Work & Health; University of Sherbrooke; University of Sherbrooke	Perreault, N (corresponding author), Univ Sherbrooke, Fac Med & Sci Sante, Dept Anat & Biol Cellulaire, 3001 12E Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	nathalie.perreault@usherbrooke.ca			Canadian Institutes of Health Research (CIHR) [MOP-84327, MT-14405, CTP-82942]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This research was supported by the Canadian Institutes of Health Research (CIHR) (MOP-84327 to N.P. and MT-14405 to N.R.) and a CIHR team grant (CTP-82942). N.P., N.R., F.B., and J.C. are members of the Fonds de la Recherche en Sante du Quebec (FRSQ)-funded Centre de Recherche Clinique Etienne Lebel. N.P., F.B., and J.C. are scholars from the FRSQ. N.R. is the recipient of a Canadian Research Chair in Signaling and Digestive Physiopathology. M.-J.L. is the recipient of a Natural Sciences and Engineering Research Council of Canada fellowship. The authors thank Elizabeth Herring for critical reading of the manuscript, M.P. Garand and S. Lamarre for help with statistical analysis, and Dr. Deborah L. Gumucio (University of Michigan, Ann Arbor, MI, USA) for providing the 12.4-kbVilCre transgenic line used in the study.	Abubaker J, 2008, ONCOGENE, V27, P3539, DOI 10.1038/sj.onc.1211013; Auclair BA, 2007, GASTROENTEROLOGY, V133, P887, DOI 10.1053/j.gastro.2007.06.066; Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Boulanger J, 2005, J BIOL CHEM, V280, P18095, DOI 10.1074/jbc.M502184200; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Clarke AR, 2006, ONCOGENE, V25, P7512, DOI 10.1038/sj.onc.1210065; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Duchesne C, 2003, J BIOL CHEM, V278, P14274, DOI 10.1074/jbc.M300425200; Goessling W, 2006, GASTROENTEROL CLIN N, V35, P713, DOI 10.1016/j.gtc.2006.07.006; Hardwick JC, 2008, NAT REV CANCER, V8, P806, DOI 10.1038/nrc2467; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lee CS, 2002, GENE DEV, V16, P1488, DOI 10.1101/gad.985002; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Lopez-Diaz L, 2007, DEV BIOL, V309, P298, DOI 10.1016/j.ydbio.2007.07.015; Lu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001237; Madison BB, 2005, DEVELOPMENT, V132, P279, DOI 10.1242/dev.01576; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; MENARD D, 1985, GASTROENTEROLOGY, V88, P691, DOI 10.1016/0016-5085(85)90139-8; Menard D, 2006, CELL SIGNALING AND GROWTH FACTORS IN DEVELOPMENT: FROM MOLECULES TO ORGANOGENESIS, P755; Munkholm P, 2003, ALIMENT PHARM THER, V18, P1, DOI 10.1046/j.1365-2036.18.s2.2.x; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; Perreault N, 2005, GENE DEV, V19, P311, DOI 10.1101/gad.1260605; Perreault N, 2001, J BIOL CHEM, V276, P43328, DOI 10.1074/jbc.M104366200; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Scoville DH, 2008, GASTROENTEROLOGY, V134, P849, DOI 10.1053/j.gastro.2008.01.079; Shao J, 2007, CARCINOGENESIS, V28, P2476, DOI 10.1093/carcin/bgm186; Shroyer NF, 2007, GASTROENTEROLOGY, V133, P1035, DOI 10.1053/j.gastro.2007.07.018; STEIN ED, 1989, J NUTR, V119, P1973, DOI 10.1093/jn/119.12.1973; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Vagefi Parsia A, 2005, Clin Colorectal Cancer, V4, P313, DOI 10.3816/CCC.2005.n.003; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; Varnat F, 2006, GASTROENTEROLOGY, V131, P538, DOI 10.1053/j.gastro.2006.05.004; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986	47	29	31	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1835	1844		10.1096/fj.08-123125	http://dx.doi.org/10.1096/fj.08-123125			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19168705				2022-12-28	WOS:000266652400024
J	Matalon, S; Shrestha, K; Kirk, M; Waldheuser, S; McDonald, B; Smith, K; Gao, ZQ; Belaaouaj, A; Crouch, EC				Matalon, Sadis; Shrestha, Kedar; Kirk, Marion; Waldheuser, Stephanie; McDonald, Barbara; Smith, Kelly; Gao, Zhiqian; Belaaouaj, Abderrazzak; Crouch, Erika C.			Modification of surfactant protein D by reactive oxygen-nitrogen intermediates is accompanied by loss of aggregating activity, in vitro and in vivo	FASEB JOURNAL			English	Article						collectin; covalent cross-linking; free radicals; nitrogen dioxide; peroxynitrite	RESPIRATORY-DISTRESS-SYNDROME; NITRIC-OXIDE; TYROSINE NITRATION; SP-A; BACTERIAL LIPOPOLYSACCHARIDES; CARBOHYDRATE-RECOGNITION; BRONCHOALVEOLAR LAVAGE; KLEBSIELLA-PNEUMONIAE; ALVEOLAR MACROPHAGES; HYDROGEN-PEROXIDE	Surfactant protein D (SP-D) is an important effector of innate immunity. We have previously shown that SP-D accumulates at sites of acute bacterial infection and neutrophil infiltration, a setting associated with the release of reactive species such as peroxynitrite. Incubation of native SP-D or trimeric SP-D lectin domains (NCRDs) with peroxynitrite resulted in nitration and nondisulfide cross-linking. Modifications were blocked by peroxynitrite scavengers or pH inactivation of peroxynitrite, and mass spectroscopy confirmed nitration of conserved tyrosine residues within the C-terminal neck and lectin domains. Mutant NCRDs lacking one or more of the tyrosines allowed us to demonstrate preferential nitration of Tyr314 and the formation of Tyr228-dependent cross-links. Although there was no effect of peroxynitrite or tyrosine mutations on lectin activity, incubation of SP-D dodecamers or murine lavage with peroxynitrite decreased the SP-D-dependent aggregation of lipopolysaccharide-coated beads, supporting our hypothesis that defective aggregation results from abnormal cross-linking. We also observed nitration, cross-linking of SP-D, and a significant decrease in SP-D-dependent aggregating activity in the lavage of mice acutely exposed to nitrogen dioxide. Thus, modification of SP-D by reactive oxygen-nitrogen species could contribute to alterations in the structure and function of SP-D at sites of inflammation in vivo.-Matalon, S., Shrestha, K., Kirk, M., Waldheuser, S., McDonald, B., Smith, K., Gao, Z., Belaaouaj, A., Crouch, E. C. Modification of surfactant protein D by reactive oxygen-nitrogen intermediates is accompanied by loss of aggregating activity, in vitro and in vivo. FASEB J. 23, 1415-1430 (2009)	[Waldheuser, Stephanie; McDonald, Barbara; Smith, Kelly; Crouch, Erika C.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Matalon, Sadis; Shrestha, Kedar; Gao, Zhiqian] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL USA; [Matalon, Sadis] Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL USA; [Kirk, Marion] Univ Alabama Birmingham, Sch Med, Ctr Comprehens Canc, Mass Spectrometry Facil, Birmingham, AL USA; [Kirk, Marion] Univ Alabama Birmingham, Sch Publ Hlth, Ctr Comprehens Canc, Mass Spectrometry Facil, Birmingham, AL USA; [Belaaouaj, Abderrazzak] INSERM, UMRS 514, Reims, France	Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Institut National de la Sante et de la Recherche Medicale (Inserm)	Crouch, EC (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid, St Louis, MO 63110 USA.	crouch@path.wustl.edu	Bentaher, Abderrazzaq/M-4424-2017; A, Bentaher/F-6531-2018	A, Bentaher/0000-0001-6001-5456	U.S. National Institutes of Health [HL-44015, HL-29594, UO1ES015676, HL075540, HL311197]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075540, R01HL044015, P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES015676] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Sharmin Sheikh and Bruce Linders for technical assistance, and Janet North for administrative support. We thank Dr. Edward Postlethwait and his lab for performing the nitrogen dioxide exposures. We also thank German Fierro Perez for work performed early in the course of this investigation. The studies were supported by U.S. National Institutes of Health grants HL-44015 and HL-29594 (E.C.C.) and UO1ES015676, HL075540, and HL311197 (S.M.).	BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; COCHRANE CG, 1983, J CLIN INVEST, V71, P754, DOI 10.1172/JCI110823; Crouch E, 2005, J BIOL CHEM, V280, P17046, DOI 10.1074/jbc.M413932200; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; Crouch E C, 2000, Respir Res, V1, P93; Crouch E, 2007, BIOCHEMISTRY-US, V46, P5160, DOI 10.1021/bi700037x; Crouch E, 2006, J BIOL CHEM, V281, P18008, DOI 10.1074/jbc.M601749200; Davis IC, 2002, FREE RADICAL BIO MED, V33, P1703, DOI 10.1016/S0891-5849(02)01170-X; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Gole MD, 2000, AM J PHYSIOL-LUNG C, V278, pL961, DOI 10.1152/ajplung.2000.278.5.L961; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; Greis KD, 1996, ARCH BIOCHEM BIOPHYS, V335, P396, DOI 10.1006/abbi.1996.0522; Griese M, 2003, BBA-MOL BASIS DIS, V1638, P157, DOI 10.1016/S0925-4439(03)00063-2; Guo CJ, 2008, PLOS BIOL, V6, P2414, DOI 10.1371/journal.pbio.0060266; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL281, DOI 10.1152/ajplung.1996.270.2.L281; HADDAD IY, 1994, AM J PHYSIOL, V267, pL242, DOI 10.1152/ajplung.1994.267.3.L242; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; Herbein JF, 2001, AM J PHYSIOL-LUNG C, V281, pL268, DOI 10.1152/ajplung.2001.281.1.L268; Hirche TO, 2004, J BIOL CHEM, V279, P27688, DOI 10.1074/jbc.M402936200; Honda Y, 1996, CHEST, V109, P1006, DOI 10.1378/chest.109.4.1006; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; Kishore U, 2006, MOL IMMUNOL, V43, P1293, DOI 10.1016/j.molimm.2005.08.004; Kishore U, 2001, Results Probl Cell Differ, V33, P225; Kovacs H, 2002, J BIOMOL NMR, V24, P89, DOI 10.1023/A:1020980006628; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; Matalon S, 1996, AM J PHYSIOL-LUNG C, V270, pL273, DOI 10.1152/ajplung.1996.270.2.L273; Ofek I, 2001, INFECT IMMUN, V69, P24, DOI 10.1128/IAI.69.1.24-33.2001; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479, DOI 10.1164/ajrccm.155.2.9032182; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Sahly H, 2002, J IMMUNOL, V169, P3267, DOI 10.4049/jimmunol.169.6.3267; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Starosta V, 2006, FREE RADICAL RES, V40, P419, DOI 10.1080/10715760600571248; SZNAJDER JI, 1989, CHEST, V96, P606, DOI 10.1378/chest.96.3.606; van Rozendaal BAWM, 1999, BBA-MOL BASIS DIS, V1454, P261, DOI 10.1016/S0925-4439(99)00042-3; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Velsor LW, 1997, AM J PHYSIOL-LUNG C, V273, pL1265, DOI 10.1152/ajplung.1997.273.6.L1265; von Bredow C, 2003, LUNG, V181, P79, DOI 10.1007/s00408-003-1008-z; Wang H, 2008, BIOCHEMISTRY-US, V47, P710, DOI 10.1021/bi7020553; Whitsett JA, 2005, BIOL NEONATE, V88, P175, DOI 10.1159/000087580; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Zhu S, 2001, AM J RESP CRIT CARE, V163, P166, DOI 10.1164/ajrccm.163.1.2005068; Zhu S, 1998, AM J PHYSIOL-LUNG C, V275, pL1031, DOI 10.1152/ajplung.1998.275.6.L1031; Zhu S, 1996, ARCH BIOCHEM BIOPHYS, V333, P282, DOI 10.1006/abbi.1996.0392; Zhu S, 2000, AM J PHYSIOL-LUNG C, V278, pL1025, DOI 10.1152/ajplung.2000.278.5.L1025	52	48	49	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1415	1430		10.1096/fj.08-120568	http://dx.doi.org/10.1096/fj.08-120568			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19126597	Green Published			2022-12-28	WOS:000266651700018
J	Telgmann, R; Dordelmann, C; Brand, E; Nicaud, V; Hagedorn, C; Pavenstadt, H; Cambien, F; Tiret, L; Paul, M; Brand-Herrmann, SM				Telgmann, Ralph; Doerdelmann, Corinna; Brand, Eva; Nicaud, Viviane; Hagedorn, Claudia; Pavenstaedt, Hermann; Cambien, Francois; Tiret, Laurence; Paul, Martin; Brand-Herrmann, Stefan-Martin			Molecular genetic analysis of a human insulin-like growth factor 1 promoter P1 variation	FASEB JOURNAL			English	Article						gene expression; hypertension; bandshift assay; reporter gene; transcription factor; functional analysis	SMOOTH-MUSCLE-CELLS; POSTNATAL BODY GROWTH; FACTOR-I; BINDING-PROTEIN; IGF-I; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; MESSENGER-RNA; RECEPTOR GENE; EXPRESSION	Insulin-like growth factor 1 (IGF1) exerts important endocrine and paracrine functions in the cardiovascular system. We identified the common variant -1411C>T in the IGF1 upstream promoter P1, located within several overlapping transcription factor binding sites. Using transient transfection assays, we identified this site as a functional enhancer. The T allele-carrying enhancer, compared with the C allelic portion, exerts significantly reduced or even abrogated activity, respectively, in SaOs-2 and HepG2 (all P<0.0001) as well as in differentiated THP-1 macrophages. Electrophoretic mobility shift assay and subsequent supershift experiments in HepG2 identified c-Jun as the binding partner exclusively to the T allele, whereas CCAAT/enhancer-binding protein delta and interferon consensus site-binding protein/interferon-regulating factor 8 interacted only with the C allelic promoter portion. Furthermore, genotyping in a case-control study for essential hypertension (n=745 hypertensive patients; n=769 normotensive control subjects) for this variant revealed an odds ratio for hypertension of 0.73 (95% confidence interval 0.58-0.91, P=0.006) associated with the T allele, and normotensive subjects carrying the protective T allele displayed a significant decrease in diastolic (P=0.036) and systolic (P=0.024) blood pressure levels. We here report detection of a functional enhancer module in the upstream IGF1 promoter region, which might play a key role in local IGF1 bioavailability. Whether -1411C>T is also associated with other IGF1-related disease phenotypes should be evaluated further in population studies.-Telgmann, R., Dordelmann, C., Brand, E., Nicaud, V., Hagedorn, C., Pavenstadt, H., Cambien, F., Tiret, L., Paul, M., Brand-Herrmann, S.-M. Molecular genetic analysis of a human insulin growth factor 1 promoter P1 variation. FASEB J. 23, 1303-1313 (2009)	[Telgmann, Ralph; Doerdelmann, Corinna; Hagedorn, Claudia; Brand-Herrmann, Stefan-Martin] Univ Munster, Leibniz Inst Arteriosclerosis Res, Dept Mol Genet Cardiovasc Dis, D-48149 Munster, Germany; [Brand, Eva; Pavenstaedt, Hermann] Univ Hosp Munster, Munster, Germany; [Nicaud, Viviane; Cambien, Francois; Tiret, Laurence] INSERM, UMR S 525, Paris, France; [Paul, Martin] Maastricht Univ, Fac Hlth Med & Life Sci, Maastricht, Netherlands	University of Munster; University of Munster; Institut National de la Sante et de la Recherche Medicale (Inserm); Maastricht University	Brand-Herrmann, SM (corresponding author), Univ Munster, Leibniz Inst Arteriosclerosis Res, Dept Mol Genet Cardiovasc Dis, Domagkstr 3, D-48149 Munster, Germany.	brandher@uni-muenster.de	Paul, Martin/K-5425-2015; Cambien, Francois/AAP-9751-2020	Hagedorn, Claudia/0000-0001-7010-4807	German Ministry for Education and Science (BMBF); BMBF [0313040C]; Deutsche Forschungsgemeinschaft [Br1589/8-1]; European Union [FP6-2005-LIFESCIHEALTH-6]; Integrating Genomics; Clinical Research and Care in Hypertension; InGenious HyperCare proposal [037093]; ICT [FP7-ICT-2007-2, 224635]; VPH2-Virtual Pathological Heart of the Virtual Physiological Human	German Ministry for Education and Science (BMBF)(Federal Ministry of Education & Research (BMBF)); BMBF(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Union(European Commission); Integrating Genomics; Clinical Research and Care in Hypertension; InGenious HyperCare proposal(European Commission); ICT; VPH2-Virtual Pathological Heart of the Virtual Physiological Human	This work was supported by grants from the German Ministry for Education and Science (BMBF) to M. P. in the context of the National Genome Research Network (NGFN) for Cardiovascular Disease and to E. B., S. M. B. H., and R. T. in the context of the BioProfile-Project BMBF 0313040C. S. M. B. H. and M. P. are participants in Deutsche Forschungsgemeinschaft grant "Graduierten-Kolleg 754, Myokardiale Genexpression und Funktion, Myokardhypertrophie." E. B. was supported by a Heisenberg professorship from the Deutsche Forschungsgemeinschaft (Br1589/8-1). This study was also supported by grants from the European Union Project Network of Excellence, FP6-2005-LIFESCIHEALTH-6, Integrating Genomics, Clinical Research and Care in Hypertension, InGenious HyperCare proposal 037093 to E. B. and S. M. B. H. (supported R. T.), an ICT in the FP7-ICT-2007-2, project 224635, and VPH2-Virtual Pathological Heart of the Virtual Physiological Human to S. M. B.	BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BRISSENDEN JE, 1984, NATURE, V310, P781, DOI 10.1038/310781a0; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Conti E, 2004, CIRCULATION, V110, P2260, DOI 10.1161/01.CIR.0000144309.87183.FB; Dehoux M, 2007, AM J PHYSIOL-ENDOC M, V292, pE145, DOI 10.1152/ajpendo.00085.2006; Dordelmann C, 2008, J BIOL CHEM, V283, P24382, DOI 10.1074/jbc.M802198200; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; Egecioglu E, 2007, AM J PHYSIOL-ENDOC M, V292, pE1418, DOI 10.1152/ajpendo.00335.2006; Gillespie CM, 1997, J ENDOCRINOL, V155, P351, DOI 10.1677/joe.0.1550351; Grabe Niels, 2002, In Silico Biology, V2, pS1; Herrmann SM, 1998, HUM MOL GENET, V7, P1277, DOI 10.1093/hmg/7.8.1277; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Izhar U, 2000, CORONARY ARTERY DIS, V11, P69, DOI 10.1097/00019501-200002000-00012; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; Katoh M, 2002, INT J MOL MED, V10, P221; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; Klover P, 2007, ENDOCRINOLOGY, V148, P1489, DOI 10.1210/en.2006-1431; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Mittanck DW, 1997, MOL CELL ENDOCRINOL, V126, P153, DOI 10.1016/S0303-7207(96)03979-2; Muller C, 2000, J Renin Angiotensin Aldosterone Syst, V1, P273, DOI 10.3317/jraas.2000.042; Nagy Z, 1999, J AM SOC NEPHROL, V10, P1709; Okura Y, 2001, J MOL CELL CARDIOL, V33, P1777, DOI 10.1006/jmcc.2001.1441; Patel VA, 2001, CIRC RES, V88, P895, DOI 10.1161/hh0901.090305; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Telgmann R, 2003, BIOL REPROD, V68, P1015, DOI 10.1095/biolreprod.102.008961; Tiret L, 1998, J HYPERTENS, V16, P37, DOI 10.1097/00004872-199816010-00007; TOBIN G, 1990, MOL ENDOCRINOL, V4, P1914, DOI 10.1210/mend-4-12-1914; TRICOLI JV, 1984, NATURE, V310, P784, DOI 10.1038/310784a0; TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78; Umayahara Y, 2002, J BIOL CHEM, V277, P15261, DOI 10.1074/jbc.M110827200; WU HY, 1994, DIABETES, V43, P1027, DOI 10.2337/diabetes.43.8.1027; Wynes MW, 2005, AM J PHYSIOL-LUNG C, V288, pL1089, DOI 10.1152/ajplung.00352.2004	36	17	17	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1303	1313		10.1096/fj.08-116863	http://dx.doi.org/10.1096/fj.08-116863			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19103645				2022-12-28	WOS:000266651700007
J	Bisaglia, M; Mammi, S; Bubacco, L				Bisaglia, Marco; Mammi, Stefano; Bubacco, Luigi			Structural insights on physiological functions and pathological effects of alpha-synuclein	FASEB JOURNAL			English	Review						Parkinson's disease; structural analysis; membranes; fibrils; oligomers	NATIVELY UNFOLDED PROTEINS; DISEASE-LINKED MUTATIONS; CHAPERONE-LIKE ACTIVITY; A-BETA COMPONENT; PARKINSONS-DISEASE; SECONDARY STRUCTURE; ALZHEIMERS-DISEASE; LEWY BODIES; CONFORMATIONAL PROPERTIES; MEMBRANE INTERACTIONS	alpha-Synuclein is an intrinsically unfolded protein that can adopt a partially helical structure when it interacts with different lipid membranes. Its pathological relevance is linked to its involvement in several neurodegenerative disorders including Parkinson's disease, Alzheimer's disease, and dementia with Lewy bodies. Typical of such ailments is the presence of alpha-synuclein aggregates in a beta-structure that can be soluble or precipitate. This review focuses on the structural knowledge acquired in recent years on the various conformations accessible to alpha-synuclein and to its pathologically relevant mutants. Furthermore, the role of the different variables of the chemical environments that govern the equilibria among the accessible conformations is also reviewed. The hypotheses that rationalize the relevance of the individual structural features and conformations for the physiological function of the protein or for its purported pathological role are described and compared. - Bisaglia, M., Mammi, S., Bubacco, L. Structural insights on physiological functions and pathological effects of alpha-synuclein. FASEB J. 23, 329-340 (2009)	[Bisaglia, Marco; Bubacco, Luigi] Univ Padua, Dept Biol, I-35121 Padua, Italy; [Mammi, Stefano] Univ Padua, Dept Chem Sci, I-35121 Padua, Italy	University of Padua; University of Padua	Bubacco, L (corresponding author), Univ Padua, Dept Biol, Via U Bassi 58B, I-35121 Padua, Italy.	luigi.bubacco@unipd.it	Bubacco, Luigi/B-5602-2012	Bubacco, Luigi/0000-0001-7927-9208	Italian Ministry of Education, University and Research (PRIN and FIRB)	Italian Ministry of Education, University and Research (PRIN and FIRB)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN))	We are very grateful to Dr. Mark R. Cookson for providing valuable comments on the manuscript. We are very grateful to Dr. Francesco Valle and Prof. Bruno Samori for kindly providing AFM images of alpha syn oligomers and fibrils. This work was supported by grants from the Italian Ministry of Education, University and Research (PRIN and FIRB).	Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Ahn BH, 2002, J BIOL CHEM, V277, P12334, DOI 10.1074/jbc.M110414200; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Bertoncini CW, 2005, J BIOL CHEM, V280, P30649, DOI 10.1074/jbc.C500288200; Bisaglia M, 2005, BIOCHEMISTRY-US, V44, P329, DOI 10.1021/bi048448q; Bisaglia M, 2006, BIOPOLYMERS, V84, P310, DOI 10.1002/bip.20440; Bisaglia M, 2006, PROTEIN SCI, V15, P1408, DOI 10.1110/ps.052048706; Bodles AM, 2001, J NEUROCHEM, V78, P384, DOI 10.1046/j.1471-4159.2001.00408.x; Bortolus M, 2008, J AM CHEM SOC, V130, P6690, DOI 10.1021/ja8010429; Bussell R, 2005, PROTEIN SCI, V14, P862, DOI 10.1110/ps.041255905; Bussell R, 2004, BIOCHEMISTRY-US, V43, P4810, DOI 10.1021/bi036135+; Bussell R, 2003, J MOL BIOL, V329, P763, DOI 10.1016/S0022-2836(03)00520-5; Bussell R, 2001, J BIOL CHEM, V276, P45996, DOI 10.1074/jbc.M106777200; Cabin DE, 2002, J NEUROSCI, V22, P8797; Celej MS, 2008, BIOPHYS J, V94, P4867, DOI 10.1529/biophysj.107.125211; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Chen M, 2007, J BIOL CHEM, V282, P24970, DOI 10.1074/jbc.M700368200; Choi W, 2004, FEBS LETT, V576, P363, DOI 10.1016/j.febslet.2004.09.038; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Croke RL, 2008, PROTEIN SCI, V17, P1434, DOI 10.1110/ps.033803.107; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dedmon MM, 2005, J AM CHEM SOC, V127, P476, DOI 10.1021/ja044834j; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Dev KK, 2003, NEUROPHARMACOLOGY, V45, P14, DOI 10.1016/S0028-3908(03)00140-0; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Drescher M, 2008, J AM CHEM SOC, V130, P7796, DOI 10.1021/ja801594s; Dusa A, 2006, BIOCHEMISTRY-US, V45, P2752, DOI 10.1021/bi051426z; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Fink AL, 2006, ACCOUNTS CHEM RES, V39, P628, DOI 10.1021/ar050073t; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Fredenburg RA, 2007, BIOCHEMISTRY-US, V46, P7107, DOI 10.1021/bi7000246; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Georgieva ER, 2008, J AM CHEM SOC, V130, P12856, DOI 10.1021/ja804517m; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Golovko MY, 2007, J NEUROCHEM, V101, P201, DOI 10.1111/j.1471-4159.2006.04357.x; Golovko MY, 2006, BIOCHEMISTRY-US, V45, P6956, DOI 10.1021/bi0600289; Golovko MY, 2005, BIOCHEMISTRY-US, V44, P8251, DOI 10.1021/bi0502137; Gomez-Tortosa E, 2001, ACTA NEUROPATHOL, V101, P36; HANSEN L, 1990, NEUROLOGY, V40, P1; Heise H, 2005, P NATL ACAD SCI USA, V102, P15871, DOI 10.1073/pnas.0506109102; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jeannotte AM, 2007, EUR J NEUROSCI, V26, P1509, DOI 10.1111/j.1460-9568.2007.05757.x; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kim HY, 2007, CHEMBIOCHEM, V8, P1671, DOI 10.1002/cbic.200700366; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Kim YS, 2006, J MOL BIOL, V360, P386, DOI 10.1016/j.jmb.2006.05.004; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kubo S, 2005, J BIOL CHEM, V280, P31664, DOI 10.1074/jbc.M504894200; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee JC, 2004, P NATL ACAD SCI USA, V101, P16466, DOI 10.1073/pnas.0407307101; Lee JC, 2005, J AM CHEM SOC, V127, P16388, DOI 10.1021/ja0561901; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Liu SM, 2004, EMBO J, V23, P4506, DOI 10.1038/sj.emboj.7600451; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; Luk KC, 2007, BIOCHEMISTRY-US, V46, P12522, DOI 10.1021/bi701128c; Madine J, 2008, J AM CHEM SOC, V130, P7873, DOI 10.1021/ja075356q; Maiti NC, 2004, J AM CHEM SOC, V126, P2399, DOI 10.1021/ja0356176; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; McNulty BC, 2006, J MOL BIOL, V355, P893, DOI 10.1016/j.jmb.2005.11.033; Mihajlovic M, 2008, PROTEINS, V70, P761, DOI 10.1002/prot.21558; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Murray IVJ, 2003, BIOCHEMISTRY-US, V42, P8530, DOI 10.1021/bi027363r; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; PAPPOLLA MA, 1986, ARCH PATHOL LAB MED, V110, P1160; Park SM, 2002, BIOCHEMISTRY-US, V41, P4137, DOI 10.1021/bi015961k; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; de Laureto PP, 2006, BIOCHEMISTRY-US, V45, P11523, DOI 10.1021/bi052614s; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ramakrishnan M, 2003, BIOCHEMISTRY-US, V42, P12919, DOI 10.1021/bi035048e; Rao JN, 2008, BIOCHEMISTRY-US, V47, P4651, DOI 10.1021/bi8002378; Rhoades E, 2006, BIOPHYS J, V90, P4692, DOI 10.1529/biophysj.105.079251; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Sandal M, 2008, PLOS BIOL, V6, P99, DOI 10.1371/journal.pbio.0060006; Scherzer CR, 2003, HUM MOL GENET, V12, P2457, DOI 10.1093/hmg/ddg265; SEGREST JP, 1992, J LIPID RES, V33, P141; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Stockl M, 2008, J MOL BIOL, V375, P1394, DOI 10.1016/j.jmb.2007.11.051; Tamamizu-Kato S, 2006, BIOCHEMISTRY-US, V45, P10947, DOI 10.1021/bi060939i; Tao-Cheng JH, 2006, NEUROSCIENCE, V141, P1217, DOI 10.1016/j.neuroscience.2006.04.061; Tehranian R, 2006, J NEUROCHEM, V99, P1188, DOI 10.1111/j.1471-4159.2006.04146.x; Thirunavukkuarasu S, 2008, J MOL BIOL, V378, P1064, DOI 10.1016/j.jmb.2008.03.034; Tompa P, 2005, FEBS LETT, V579, P3346, DOI 10.1016/j.febslet.2005.03.072; Tompkins MM, 1997, AM J PATHOL, V150, P119; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Ulmer TS, 2005, J BIOL CHEM, V280, P43179, DOI 10.1074/jbc.M507624200; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Uversky VN, 2007, J NEUROCHEM, V103, P17, DOI 10.1111/j.1471-4159.2007.04764.x; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Vilar M, 2008, P NATL ACAD SCI USA, V105, P8637, DOI 10.1073/pnas.0712179105; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wersinger C, 2003, NEUROSCI LETT, V340, P189, DOI 10.1016/S0304-3940(03)00097-1; Wersinger C, 2003, FASEB J, V17, P2151, DOI 10.1096/fj.03-0152fje; Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Woods WS, 2007, J BIOL CHEM, V282, P34555, DOI 10.1074/jbc.M705283200; Wright JA, 2008, J NEUROSCI RES, V86, P496, DOI 10.1002/jnr.21461; Wu KP, 2008, J MOL BIOL, V378, P1104, DOI 10.1016/j.jmb.2008.03.017; Yavich L, 2004, J NEUROSCI, V24, P11165, DOI 10.1523/JNEUROSCI.2559-04.2004; Zakharov SD, 2007, BIOCHEMISTRY-US, V46, P14369, DOI 10.1021/bi701275p; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhou Y, 2004, J BIOL CHEM, V279, P39155, DOI 10.1074/jbc.M405456200; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200; Zhu M, 2003, J BIOL CHEM, V278, P40186, DOI 10.1074/jbc.M305326200	126	111	114	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					329	340		10.1096/fj.08-119784	http://dx.doi.org/10.1096/fj.08-119784			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18948383				2022-12-28	WOS:000262892900005
J	Palm-Apergi, C; Lorents, A; Padari, K; Pooga, M; Hallbrink, M				Palm-Apergi, Caroline; Lorents, Annely; Padari, Kart; Pooga, Margus; Hallbrink, Mattias			The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake	FASEB JOURNAL			English	Article						protein transduction domains; perforin; granzyme B; granulysin; cellular wound healing	TAT PEPTIDE; MECHANISM; EXOCYTOSIS; PLASMA; LYSOSOMES; CALCIUM; MODEL; MACROPINOCYTOSIS; TRANSLOCATION; DEGRADATION	Although cell-penetrating peptides are able to deliver cargo into cells, their uptake mechanism is still not fully understood and needs to be elucidated to improve their delivery efficiency. Herein, we present evidence of a new mechanism involved in uptake, the membrane repair response. Recent studies have suggested that there might be a direct penetration of peptides in parallel with different forms of endocytosis. The direct penetration of hydrophilic peptides through the hydrophobic plasma membrane, however, is highly controversial. Three proteins involved in target cell apoptosis-perforin, granulysin, and granzymes-share many features common in uptake of cell-penetrating peptides (e. g., they bind proteoglycans). During perforin uptake, the protein activates the membrane repair response, a resealing mechanism triggered in cells with injured plasma membrane, because of extracellular calcium influx. On activation of the membrane repair response, internal vesicles are mobilized to the site of the disrupted plasma membrane, resealing it within seconds. In this study, we have used flow cytometry, fluorescence, and electron microscopy, together with high-performance liquid chromatography and mass spectrometry, to present evidence that the membrane repair response is able to mask damages caused during cell-penetrating peptide uptake, thus preventing leakage of endogenous molecules out of the cell.-Palm-Apergi, C., Lorents, A., Padari, K., Pooga, M., and Hallbrink, M. The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J. 23, 214-223 (2009)	[Palm-Apergi, Caroline; Hallbrink, Mattias] Stockholm Univ, Dept Neurochem, Arrhenius Labs, S-10691 Stockholm, Sweden; [Lorents, Annely; Padari, Kart; Pooga, Margus] Univ Tartu, Inst Mol & Cell Biol, EE-50090 Tartu, Estonia; [Lorents, Annely; Padari, Kart; Pooga, Margus] Estonian Bioctr, Tartu, Estonia	Stockholm University; University of Tartu; Estonian Biocentre	Palm-Apergi, C (corresponding author), Stockholm Univ, Dept Neurochem, Arrhenius Labs, S-10691 Stockholm, Sweden.	caroline@neurochem.su.se	Pooga, Margus/A-8575-2011	Pooga, Margus/0000-0003-4532-4087; Lorents, Annely/0000-0002-2823-5202; Palm Apergi, Caroline/0000-0003-2236-2099	Jeansson foundation; Estonian Science Foundation [ETF7058]	Jeansson foundation; Estonian Science Foundation	This work was supported by the Jeansson foundation and Estonian Science Foundation (ETF7058). We thank M. Kure for the expert help in electron microscopy experiments.	Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; Bird CH, 2005, MOL CELL BIOL, V25, P7854, DOI 10.1128/MCB.25.17.7854-7867.2005; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Deshayes S, 2004, BIOCHEMISTRY-US, V43, P7698, DOI 10.1021/bi049298m; Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s; Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x; Ernst WA, 2000, J IMMUNOL, V165, P7102, DOI 10.4049/jimmunol.165.12.7102; Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808; Gerbal-Chaloin S, 2007, BIOL CELL, V99, P223, DOI 10.1042/BC20060123; Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4; Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105; Howl J, 2003, CHEMBIOCHEM, V4, P1312, DOI 10.1002/cbic.200300694; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Johansson HJ, 2008, MOL THER, V16, P115, DOI 10.1038/sj.mt.6300346; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Keefe D, 2005, IMMUNITY, V23, P249, DOI 10.1016/j.immuni.2005.08.001; Kim JS, 1999, TRANSPLANTATION, V68, P938, DOI 10.1097/00007890-199910150-00007; Li Q, 2005, ANTIMICROB AGENTS CH, V49, P388, DOI 10.1128/AAC.49.1.388-397.2005; LIU CC, 1995, IMMUNOL TODAY, V16, P194, DOI 10.1016/0167-5699(95)80121-9; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; McNeil PL, 2002, J CELL SCI, V115, P873; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824; Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8; Padari K, 2005, BIOCONJUGATE CHEM, V16, P1399, DOI 10.1021/bc050125z; Palm C, 2007, BBA-BIOMEMBRANES, V1768, P1769, DOI 10.1016/j.bbamem.2007.03.029; Palm C, 2006, PEPTIDES, V27, P1710, DOI 10.1016/j.peptides.2006.01.006; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Saar K, 2005, ANAL BIOCHEM, V345, P55, DOI 10.1016/j.ab.2005.07.033; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Togo T, 1999, J CELL SCI, V112, P719; Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com; Yandek LE, 2007, BIOPHYS J, V92, P2434, DOI 10.1529/biophysj.106.100198; Zhang ZJ, 2007, NAT CELL BIOL, V9, P945, DOI 10.1038/ncb1620	35	89	100	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2009	23	1					214	223		10.1096/fj.08-110254	http://dx.doi.org/10.1096/fj.08-110254			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18787109				2022-12-28	WOS:000262095500024
J	Albiston, AL; Morton, CJ; Ng, HL; Pham, V; Yeatman, HR; Ye, S; Fernando, RN; De Bundel, D; Ascher, DB; Mendelsohn, FAO; Parker, MW; Chai, SY				Albiston, Anthony L.; Morton, Craig J.; Ng, Hooi Ling; Pham, Vi; Yeatman, Holly R.; Ye, Siying; Fernando, Ruani N.; De Bundel, Dimitri; Ascher, David B.; Mendelsohn, Frederick A. O.; Parker, Michael W.; Chai, Siew Yeen			Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase	FASEB JOURNAL			English	Article						facilitation of memory; drug development; virtual screening; homology model; glucose uptake	ANGIOTENSIN-IV BINDING; RECEPTOR SUBTYPE; AT(4) RECEPTOR; PASSIVE-AVOIDANCE; MEMBRANE AMINOPEPTIDASE; DRUG DISCOVERY; POTENTIAL ROLE; WATER MAZE; MEMORY; GLUCOSE	Approximately one-quarter of people over the age of 65 are estimated to suffer some form of cognitive impairment, underscoring the need for effective cognitive-enhancing agents. Insulin-regulated aminopeptidase (IRAP) is potentially an innovative target for the development of cognitive enhancers, as its peptide inhibitors exhibit memory-enhancing effects in both normal and memory-impaired rodents. Using a homology model of the catalytic domain of IRAP and virtual screening, we have identified a class of nonpeptide, small-molecule inhibitors of IRAP. Structure-based computational development of an initial "hit" resulted in the identification of two divergent families of compounds. Subsequent medicinal chemistry performed on the highest affinity compound produced inhibitors with nanomolar affinities (K-i 20-700 nM) for IRAP. In vivo efficacy of one of these inhibitors was demonstrated in rats with an acute dose (1 nmol in 1 mu l) administered into the lateral ventricles, improving performance in both spatial working and recognition memory paradigms. We have identified a family of specific IRAP inhibitors that is biologically active which will be useful both in understanding the physiological role of IRAP and potentially in the development of clinically useful cognitive enhancers. Notably, this study also provides unequivocal proof of principal that inhibition of IRAP results in memory enhancement.	[Albiston, Anthony L.; Pham, Vi; Yeatman, Holly R.; Ye, Siying; Fernando, Ruani N.; De Bundel, Dimitri; Mendelsohn, Frederick A. O.; Chai, Siew Yeen] Univ Melbourne, Howard Florey Inst, Florey Neurosci Inst, Parkville, Vic 3010, Australia; [Parker, Michael W.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3010, Australia; [Chai, Siew Yeen] Univ Melbourne, Ctr Neurosci, Parkville, Vic 3010, Australia; [Morton, Craig J.; Ng, Hooi Ling; Ascher, David B.; Parker, Michael W.] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; University of Melbourne; St. Vincent's Institute of Medical Research	Chai, SY (corresponding author), Univ Melbourne, Howard Florey Inst, Florey Neurosci Inst, Parkville, Vic 3010, Australia.	sychai@florey.edu.au	Ye, Siying/H-3156-2013; De Bundel, Dimitri/AAG-9453-2020; Parker, Michael W/F-9069-2013; De Bundel, Dimitri/C-5701-2015; Morton, Craig/GON-8638-2022	Ye, Siying/0000-0002-0882-1642; Parker, Michael W/0000-0002-3101-1138; Morton, Craig/0000-0001-5452-5193; De Bundel, Dimitri/0000-0002-6234-9908; Yeatman, Holly/0000-0002-3963-4540; Ascher, David/0000-0003-2948-2413; Chai, Siew Yeen/0000-0001-7209-4112	National Health and Medical Research Council of Australia (NHMRC) [454714, 520695]; Neurosciences Victoria; Alzheimer's Drug DiscoveryFoundation/ Institute for the Study of Aging, USA; Research Foundation, Flanders, Belgium; Australian Postgraduate Award; Colin North and Major Engineering; Australian Research Council Federation	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Neurosciences Victoria; Alzheimer's Drug DiscoveryFoundation/ Institute for the Study of Aging, USA; Research Foundation, Flanders, Belgium(FWO); Australian Postgraduate Award(Australian Government); Colin North and Major Engineering; Australian Research Council Federation(Australian Research Council)	This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC development grants 454714 and 520695), Neurosciences Victoria, and Alzheimer's Drug Discovery Foundation/ Institute for the Study of Aging, USA. D.D.B. is a Scientific Research Fellow of the Research Foundation, Flanders, Belgium. D.B.A is an Australian Postgraduate Award Scholar and a recipient of a St. Vincent's Institute Foundation Scholarship sponsored by Colin North and Major Engineering. M.W.P. is an Australian Research Council Federation Fellow and an NHMRC Honorary Fellow. S.Y.C. is an NHMRC Senior Research Fellow. The authors acknowledge the contribution of Dr. Keith Watson in the design of the analogues of HFI-142, Prof. William Charman for the solubility and blood brain barrier permeability studies, and Mr. Tom Vale for assistance with the animal surgery.	Al-Mousawi SM, 1999, ORG PREP PROCED INT, V31, P305, DOI 10.1080/00304949909458324; Albiston AL, 2004, BEHAV BRAIN RES, V154, P239, DOI 10.1016/j.bbr.2004.02.012; Albiston AL, 2003, TRENDS ENDOCRIN MET, V14, P72, DOI 10.1016/S1043-2760(02)00037-1; Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200; Albiston AL, 2007, PHARMACOL THERAPEUT, V116, P417, DOI 10.1016/j.pharmthera.2007.07.006; Axen A, 2006, J PEPT SCI, V12, P705, DOI 10.1002/psc.782; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; BRASZKO JJ, 1988, NEUROSCIENCE, V27, P777, DOI 10.1016/0306-4522(88)90182-0; Chai SY, 2004, CELL MOL LIFE SCI, V61, P2728, DOI 10.1007/s00018-004-4246-1; Chai SY, 2000, J CHEM NEUROANAT, V20, P339, DOI 10.1016/S0891-0618(00)00112-5; Dash PK, 2006, J NEUROSCI, V26, P8048, DOI 10.1523/JNEUROSCI.0671-06.2006; Demaegdt H, 2006, EUR J PHARMACOL, V546, P19, DOI 10.1016/j.ejphar.2006.07.005; Diano S, 2006, NAT NEUROSCI, V9, P381, DOI 10.1038/nn1656; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Fernando RN, 2005, J COMP NEUROL, V487, P372, DOI 10.1002/cne.20585; Fernando RN, 2008, EUR J NEUROSCI, V28, P588, DOI 10.1111/j.1460-9568.2008.06347.x; Funahashi S, 2006, NEUROSCIENCE, V139, P251, DOI 10.1016/j.neuroscience.2005.07.003; Furey ML, 2000, SCIENCE, V290, P2315, DOI 10.1126/science.290.5500.2315; Garreau I, 1998, PEPTIDES, V19, P1339, DOI 10.1016/S0196-9781(98)00075-8; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; Hillisch A, 2004, DRUG DISCOV TODAY, V9, P659, DOI 10.1016/S1359-6446(04)03196-4; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kesner RP, 2001, LEARN MEMORY, V8, P87, DOI 10.1101/lm.29401; Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549; KOBORI T, 2000, Patent No. 6066672; Korol DL, 1998, AM J CLIN NUTR, V67, p764S, DOI 10.1093/ajcn/67.4.764S; Kramar EA, 2001, BRAIN RES, V897, P114, DOI 10.1016/S0006-8993(01)02100-X; Lee J, 2004, NEUROSCIENCE, V124, P341, DOI 10.1016/j.neuroscience.2003.12.006; Lee J, 2001, NEUROPHARMACOLOGY, V40, P618, DOI 10.1016/S0028-3908(00)00188-X; LEE MK, 1988, BEHAV NEUROSCI, V102, P591, DOI 10.1037/0735-7044.102.4.591; Lew RA, 2003, J NEUROCHEM, V86, P344, DOI 10.1046/j.1471-4159.2003.01852.x; Loging W, 2007, NAT REV DRUG DISCOV, V6, P220, DOI 10.1038/nrd2265; MANNING CA, 1993, NEUROBIOL AGING, V14, P523, DOI 10.1016/0197-4580(93)90034-9; McNay EC, 2000, P NATL ACAD SCI USA, V97, P2881, DOI 10.1073/pnas.050583697; Moeller I, 1996, BRAIN RES, V712, P307, DOI 10.1016/0006-8993(95)01482-9; Nyberg G, 1996, J CHROMATOGR A, V723, P43, DOI 10.1016/0021-9673(95)00811-X; Olson ML, 2004, PEPTIDES, V25, P233, DOI 10.1016/j.peptides.2003.12.005; Parent MB, 1997, NEUROBIOL LEARN MEM, V68, P75, DOI 10.1006/nlme.1997.3769; Parkes M, 2000, BEHAV NEUROSCI, V114, P307, DOI 10.1037/0735-7044.114.2.307; Pederson ES, 2001, REGUL PEPTIDES, V102, P147, DOI 10.1016/S0167-0115(01)00312-3; Pederson ES, 1998, REGUL PEPTIDES, V74, P97, DOI 10.1016/S0167-0115(98)00028-7; Ragozzino ME, 1998, J NEUROSCI, V18, P1595; Rogi T, 1996, J BIOL CHEM, V271, P56, DOI 10.1074/jbc.271.1.56; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Wayner MJ, 2001, PEPTIDES, V22, P1403, DOI 10.1016/S0196-9781(01)00475-2; Wisniewski Konstanty, 1993, Polish Journal of Pharmacology, V45, P23; Wright JW, 2008, PROG NEUROBIOL, V84, P157, DOI 10.1016/j.pneurobio.2007.10.009; WRIGHT JW, 1993, BRAIN RES BULL, V32, P497, DOI 10.1016/0361-9230(93)90297-O; Wright JW, 1999, J NEUROSCI, V19, P3952; Wright JW, 1996, PEPTIDES, V17, P1365, DOI 10.1016/S0196-9781(96)00226-4; Wright JW, 1996, BRAIN RES, V717, P1, DOI 10.1016/0006-8993(95)01454-3	53	83	84	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4209	4217		10.1096/fj.08-112227	http://dx.doi.org/10.1096/fj.08-112227			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18716029				2022-12-28	WOS:000261254800020
J	Keserue, B; Barbosa-Sicard, E; Popp, R; Fisslthaler, B; Dietrich, A; Gudermann, T; Hammock, BD; Falck, JR; Weissmann, N; Busse, R; Fleming, I				Keserue, Benjamin; Barbosa-Sicard, Eduardo; Popp, Ruediger; Fisslthaler, Beate; Dietrich, Alexander; Gudermann, Thomas; Hammock, Bruce D.; Falck, John R.; Weissmann, Norbert; Busse, Rudi; Fleming, Ingrid			Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response	FASEB JOURNAL			English	Article						cytochrome P-450; Rho kinase; TRP channels; caveolae	20-HYDROXYEICOSATETRAENOIC ACID; CYTOCHROME-P450 EPOXYGENASES; CORONARY-ARTERIES; P-450 METABOLITES; RHO-KINASE; HYPERTENSION; LUNG; ENDOTHELIUM; CHANNELS; RABBIT	Recent findings have indicated a role for cytochrome P-450 (CYP) epoxygenase-derived epoxyeicosatrienoic acids (EETs) in acute hypoxic pulmonary vasoconstriction (HPV). Given that the intracellular concentration of EETs is determined by the soluble epoxide hydrolase (sEH), we assessed the influence of the sEH and 11,12-EET on pulmonary artery pressure and HPV in the isolated mouse lung. In lungs from wild-type mice, HPV was significantly increased by sEH inhibition, an effect abolished by pretreatment with CYP epoxygenase inhibitors and the EET antagonist 14,15-EEZE. HPV and EET production were greater in lungs from sEH(-/-) mice than from wild-type mice and sEH inhibition had no further effect on HPV, while MSPPOH and 14,15-EEZE decreased the response. 11,12-EET increased pulmonary artery pressure in a concentration-dependent manner and enhanced HPV via a Rho-dependent mechanism. Both 11,12-EET and hypoxia elicited the membrane translocation of a transient receptor potential (TRP) C6-V5 fusion protein, the latter effect was sensitive to 14,15-EEZE. Moreover, while acute hypoxia and 11,12-EET increased pulmonary pressure in lungs from TRPC6(+/-) mice, lungs from TRPC6(-/-) mice did not respond to either stimuli. These data demonstrate that CYP-derived EETs are involved in HPV and that EET-induced pulmonary contraction under normoxic and hypoxic conditions involves a TRPC6-dependent pathway.-Keseru, B., Barbosa-Sicard, E., Popp, R., Fisslthaler, B., Dietrich, A., Gudermann, T., Hammock, B. D., Falck, J. R., Weissmann, N., Busse, R., Fleming, I. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J. 22, 4306-4315 (2008)	[Keserue, Benjamin; Barbosa-Sicard, Eduardo; Popp, Ruediger; Fisslthaler, Beate; Busse, Rudi; Fleming, Ingrid] Goethe Univ, Inst Kardiovaskulare Physiol, Vasc Signalling Grp, D-60590 Frankfurt, Germany; [Dietrich, Alexander; Gudermann, Thomas] Univ Marburg, Inst Pharmakol & Toxikol, D-3550 Marburg, Germany; [Weissmann, Norbert] Univ Giessen, Univ Giessen Lung Ctr, Dept Internal Med 2 5, Giessen, Germany; [Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	Goethe University Frankfurt; Philipps University Marburg; Justus Liebig University Giessen; University of California System; University of California Davis; University of Texas System; University of Texas Southwestern Medical Center Dallas	Fleming, I (corresponding author), Goethe Univ, Inst Kardiovaskulare Physiol, Vasc Signalling Grp, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	fleming@em.uni-frankfurt.de	Fleming, Ingrid/L-1225-2014; Fleming, Ingrid/AAB-6123-2022; Dietrich, Alexander/G-8619-2013; Falck, John R/B-3030-2011	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Dietrich, Alexander/0000-0002-1168-8707; Falck, John R/0000-0002-9219-7845; Weissmann, Norbert/0000-0003-2675-3871	Deutsche Forschungsgemeinschaft [FI 830/2-3, GRK 757]; National Institute of Environmental Health Sciences [R37 ES02710, P42 ES004699]; U.S. Public Health Service; National Institutes of Health [GM-31278, HL-85727]; Robert A. Welch Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, R37ES002710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors are indebted to Isabel Winter and Ewa Bieniek for expert technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (FI 830/2-3, GRK 757, and Exzellenzcluster 147 "Cardio-Pulmonary Systems"). Partial support was provided by National Institute of Environmental Health Sciences R37 ES02710 and P42 ES004699, as well as by the U.S. Public Health Service, National Institutes of Health (GM-31278 and HL-85727), and the Robert A. Welch Foundation.	Alvarez DF, 2004, AM J PHYSIOL-LUNG C, V286, pL445, DOI 10.1152/ajplung.00150.2003; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Basora N, 2003, J BIOL CHEM, V278, P31709, DOI 10.1074/jbc.M304437200; Birks EK, 1997, AM J PHYSIOL-LUNG C, V272, pL823, DOI 10.1152/ajplung.1997.272.5.L823; Chiamvimonvat N, 2007, J CARDIOVASC PHARM, V50, P225, DOI 10.1097/FJC.0b013e3181506445; Corenblum MJ, 2008, HYPERTENSION, V51, P567, DOI 10.1161/HYPERTENSIONAHA.107.102160; Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005; Dorrance AM, 2005, J CARDIOVASC PHARM, V46, P842, DOI 10.1097/01.fjc.0000189600.74157.6d; Earley S, 2003, AM J PHYSIOL-HEART C, V285, pH127, DOI 10.1152/ajpheart.01052.2002; ESCALANTE B, 1993, EUR J PHARMACOL, V235, P1, DOI 10.1016/0014-2999(93)90812-V; Fagan KA, 2004, AM J PHYSIOL-LUNG C, V287, pL656, DOI 10.1152/ajplung.00090.2003; Fleming I, 2007, ARTERIOSCL THROM VAS, V27, P2612, DOI 10.1161/ATVBAHA.107.152074; Fleming I, 2007, TRENDS PHARMACOL SCI, V28, P448, DOI 10.1016/j.tips.2007.08.002; Gauthier KM, 2002, CIRC RES, V90, P1028, DOI 10.1161/01.RES.0000018162.87285.F8; Gschwendtner A, 2008, STROKE, V39, P1593, DOI 10.1161/STROKEAHA.107.502179; Hutchens MP, 2008, RESUSCITATION, V76, P89, DOI 10.1016/j.resuscitation.2007.06.031; Ichinose F, 2002, J CLIN INVEST, V109, P1493, DOI 10.1172/JCI200214294; Jung O, 2005, HYPERTENSION, V45, P759, DOI 10.1161/01.HYP.0000153792.29478.1d; Kiss L, 2008, ANAL BIOANAL CHEM, V390, P697, DOI 10.1007/s00216-007-1718-9; Lin MJ, 2004, CIRC RES, V95, P496, DOI 10.1161/01.RES.0000138952.16382.ad; Luria A, 2007, J BIOL CHEM, V282, P2891, DOI 10.1074/jbc.M608057200; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; Michaelis UR, 2006, PHARMACOL THERAPEUT, V111, P584, DOI 10.1016/j.pharmthera.2005.11.003; Michaelis UR, 2005, J CELL SCI, V118, P5489, DOI 10.1242/jcs.02674; Morisseau C, 2002, BIOCHEM PHARMACOL, V63, P1599, DOI 10.1016/S0006-2952(02)00952-8; Moudgil R, 2005, J APPL PHYSIOL, V98, P390, DOI 10.1152/japplphysiol.00733.2004; Moudgil R, 2006, MICROCIRCULATION, V13, P615, DOI 10.1080/10739680600930222; Muller DN, 2007, BIOCHEM J, V403, P109, DOI 10.1042/BJ20061328; Pokreisz P, 2006, HYPERTENSION, V47, P762, DOI 10.1161/01.HYP.0000208299.62535.58; Randriamboavonjy V, 2003, HYPERTENSION, V41, P801, DOI 10.1161/01.HYP.0000047240.33861.6B; Robertson TP, 2000, BRIT J PHARMACOL, V131, P5, DOI 10.1038/sj.bjp.0703537; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Singh I, 2007, J BIOL CHEM, V282, P7833, DOI 10.1074/jbc.M608288200; Spector AA, 2007, AM J PHYSIOL-CELL PH, V292, pC996, DOI 10.1152/ajpcell.00402.2006; Stephenson AH, 2003, AM J PHYSIOL-HEART C, V284, pH2153, DOI 10.1152/ajpheart.00844.2002; Tan JZ, 1997, ADV EXP MED BIOL, V407, P561; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vriens J, 2005, CIRC RES, V97, P908, DOI 10.1161/01.RES.0000187474.47805.30; Weir EK, 2006, CARDIOVASC RES, V71, P630, DOI 10.1016/j.cardiores.2006.04.014; Weissmann N, 2004, RESP PHYSIOL NEUROBI, V139, P191, DOI 10.1016/j.resp.2003.10.003; Weissmann N, 2006, P NATL ACAD SCI USA, V103, P19093, DOI 10.1073/pnas.0606728103; Yu ZG, 2000, CIRC RES, V87, P992, DOI 10.1161/01.RES.87.11.992; Zhu DL, 2000, AM J PHYSIOL-LUNG C, V278, pL335, DOI 10.1152/ajplung.2000.278.2.L335; Zhu DL, 2000, AM J PHYSIOL-HEART C, V279, pH1526, DOI 10.1152/ajpheart.2000.279.4.H1526	45	93	95	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4306	4315		10.1096/fj.08-112821	http://dx.doi.org/10.1096/fj.08-112821			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18725458	Green Published			2022-12-28	WOS:000261254800029
J	Alvarez, AR; Klein, A; Castro, J; Cancino, GI; Amigo, J; Mosqueira, M; Vargas, LM; Yevenes, LF; Bronfman, FC; Zanlungo, S				Alvarez, Alejandra R.; Klein, Andres; Castro, Juan; Cancino, Gonzalo I.; Amigo, Julio; Mosqueira, Matias; Vargas, Lina M.; Yevenes, L. Fernanda; Bronfman, Francisca C.; Zanlungo, Silvana			Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease	FASEB JOURNAL			English	Article						neurodegeneration; c-Abl/p73; cholesterol	ABL TYROSINE KINASE; AMYOTROPHIC-LATERAL-SCLEROSIS; UNFOLDED PROTEIN RESPONSE; CELL-DEATH; NEURONAL DEATH; ENDOPLASMIC-RETICULUM; CEREBROSPINAL-FLUID; ANTICANCER DRUG; P73; MICE	Niemann-Pick type C (NPC) disease is a fatal autosomal recessive disorder characterized by the accumulation of free cholesterol and glycosphingo-lipids in the endosomal-lysosomal system. Patients with NPC disease have markedly progressive neuronal loss, mainly of cerebellar Purkinje neurons. There is strong evidence indicating that cholesterol accumulation and trafficking defects activate apoptosis in NPC brains. The purpose of this study was to analyze the relevance of apoptosis and particularly the proapoptotic c-Abl/p73 system in cerebellar neuron degeneration in NPC disease. We used the NPC1 mouse model to evaluate c-Abl/p73 expression and activation in the cerebellum and the effect of therapy with the c-Abl-specific inhibitor imatinib. The proapoptotic c-Abl/p73 system and the p73 target genes are expressed in the cerebellums of NPC mice. Furthermore, inhibition of c-Abl with imatinib preserved Purkinje neurons and reduced general cell apoptosis in the cerebellum, improved neurological symptoms, and increased the survival of NPC mice. Moreover, this prosurvival effect correlated with reduced mRNA levels of p73 proapoptotic target genes. Our results suggest that the c-Abl/p73 pathway is involved in NPC neurodegeneration and show that treatment with c-Abl inhibitors is useful in delaying progressive neurodegeneration, supporting the use of imatinib for clinical treatment of patients with NPC disease.	[Alvarez, Alejandra R.; Cancino, Gonzalo I.; Amigo, Julio; Vargas, Lina M.; Yevenes, L. Fernanda] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Santiago, Chile; [Klein, Andres; Castro, Juan; Mosqueira, Matias; Zanlungo, Silvana] Pontificia Univ Catolica Chile, Fac Med, Dept Gastroenterol, Santiago, Chile; [Bronfman, Francisca C.] Pontificia Univ Catolica Chile, Joaquin V Luco CRCP, Dept Ciencias Fisiol, Fac Ciencias Biol, Santiago, Chile	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile	Alvarez, AR (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Alameda 340,Casilla 114-D, Santiago, Chile.	aalvarez@bio.puc.cl; silvana@med.puc.cl	Mosqueira, Matias/C-5899-2019; Cancino, Gonzalo/ABF-6049-2021	Mosqueira, Matias/0000-0001-7744-9138; Cancino, Gonzalo/0000-0001-8697-7282; amigo, julio/0000-0002-6481-8034; Zanlungo, Silvana/0000-0001-8383-9829; KLEIN, ANDRES/0000-0002-9951-2174; Alvarez Rojas, Alejandra/0000-0002-8129-9280	Ara Parseghian Medical Research Foundation; Fondo Nacional de Desarrollo Cientifico y Tecnologico [1040782, 1080221, 1030415, 1070622]	Ara Parseghian Medical Research Foundation; Fondo Nacional de Desarrollo Cientifico y Tecnologico(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT)	This work was supported by grants from the Ara Parseghian Medical Research Foundation and by Fondo Nacional de Desarrollo Cientifico y Tecnologico (grants 1040782 and 1080221 to A.R.A. and 1030415 and 1070622 to S.Z.). The authors thank the Ara Parseghian Medical Research Foundation for their continued support.	Alvarez AR, 2004, NEUROBIOL DIS, V17, P326, DOI 10.1016/j.nbd.2004.06.007; Amigo L, 2002, HEPATOLOGY, V36, P819, DOI 10.1053/jhep.2002.35617; Bascunan-Castillo Eric C., 2004, Journal of Applied Genetics, V45, P461; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brady RO, 2006, REJUV RES, V9, P237, DOI 10.1089/rej.2006.9.237; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Bu BT, 2002, J NEUROSCI, V22, P6515; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Cabrera-Socorro A, 2006, EUR J NEUROSCI, V23, P2109, DOI 10.1111/j.1460-9568.2006.04750.x; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Erickson RP, 2002, J NEUROSCI RES, V68, P738, DOI 10.1002/jnr.10257; Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; Garver WS, 2007, AM J MED GENET A, V143A, P1204, DOI 10.1002/ajmg.a.31735; Garver WS, 2007, J CELL BIOCHEM, V101, P498, DOI 10.1002/jcb.21200; Gong JG, 1999, NATURE, V399, P806; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hoshino M, 2006, J CELL BIOL, V172, P589, DOI 10.1083/jcb.200509132; Huang JQ, 1997, HUM MOL GENET, V6, P1879, DOI 10.1093/hmg/6.11.1879; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Jacobs WB, 2004, NEUROSCIENTIST, V10, P443, DOI 10.1177/1073858404263456; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Ko DC, 2005, PLOS GENET, V1, P81, DOI 10.1371/journal.pgen.0010007; Koh CHV, 2006, CELL SIGNAL, V18, P1572, DOI 10.1016/j.cellsig.2005.12.006; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li H, 2005, J NEUROPATH EXP NEUR, V64, P323, DOI 10.1093/jnen/64.4.323; Liao GH, 2007, AM J PATHOL, V171, P962, DOI 10.2353/ajpath.2007.070052; Liscum L, 2004, BBA-MOL CELL BIOL L, V1685, P22, DOI 10.1016/j.bbalip.2004.08.008; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Martin LJ, 2007, J COMP NEUROL, V500, P20, DOI 10.1002/cne.21160; Oyama K, 2006, TOHOKU J EXP MED, V209, P263, DOI 10.1620/tjem.209.263; Pacheco CD, 2007, HUM MOL GENET, V16, P1495, DOI 10.1093/hmg/ddm100; Patterson MC, 2007, LANCET NEUROL, V6, P765, DOI 10.1016/S1474-4422(07)70194-1; Patterson MC, 2003, NEUROLOGIST, V9, P301, DOI 10.1097/01.nrl.0000094627.78754.5b; Pentchev P., 1995, METABOLIC MOL BASES, P2625; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pozniak CD, 2002, J NEUROSCI, V22, P9800; Reddy JV, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000019; Simakajornboon N, 2001, BRAIN RES, V895, P111, DOI 10.1016/S0006-8993(01)02054-6; Sullivan D, 2005, AM J PSYCHIAT, V162, P1021, DOI 10.1176/appi.ajp.162.5.1021-a; TANAKA J, 1988, J NEUROPATH EXP NEUR, V47, P291, DOI 10.1097/00005072-198805000-00008; Terrinoni A, 2004, ONCOGENE, V23, P3721, DOI 10.1038/sj.onc.1207342; Tessitore A, 2004, MOL CELL, V15, P753, DOI 10.1016/j.molcel.2004.08.029; Tsai KKC, 2003, CANCER RES, V63, P3418; Vanier MT, 2003, CLIN GENET, V64, P269, DOI 10.1034/j.1399-0004.2003.00147.x; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Voikar V, 2002, BEHAV BRAIN RES, V132, P1, DOI 10.1016/S0166-4328(01)00380-1; Walkley SU, 2004, BBA-MOL CELL BIOL L, V1685, P48, DOI 10.1016/j.bbalip.2004.08.011; Walterfang M, 2006, J NEUROPSYCH CLIN N, V18, P158, DOI 10.1176/appi.neuropsych.18.2.158; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wilson C, 2004, NEUROPATH APPL NEURO, V30, P19, DOI 10.1046/j.0305-1846.2003.00496.x; Wolff NC, 2003, BLOOD, V101, P5010, DOI 10.1182/blood-2002-10-3059; Wu YP, 2005, MOL GENET METAB, V84, P9, DOI 10.1016/j.ymgme.2004.08.017; Yu WX, 2005, J BIOL CHEM, V280, P11731, DOI 10.1074/jbc.M412898200; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	62	75	83	5	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3617	3627		10.1096/fj.07-102715	http://dx.doi.org/10.1096/fj.07-102715			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18591368				2022-12-28	WOS:000259642600023
J	Dobrosi, N; Toth, BI; Nagy, G; Dozsa, A; Geczy, T; Nagy, L; Zouboulis, CC; Paus, R; Kovacs, L; Biro, T				Dobrosi, Nora; Toth, Balazs I.; Nagy, Georgina; Dozsa, Aniko; Geczy, Tamas; Nagy, Laszlo; Zouboulis, Christos C.; Paus, Ralf; Kovacs, Laszlo; Biro, Tamas			Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling	FASEB JOURNAL			English	Article						cannabinoid receptor subtypes; human sebaceous gland-derived SZ95 sebocytes; acne vulgaris; signal transduction; peroxisome proliferator-activated receptor; gene expression	PROLIFERATOR-ACTIVATED RECEPTOR; PROTEIN-KINASE-C; SEBACEOUS GLAND; PPAR-GAMMA; ENDOGENOUS CANNABINOIDS; PROSTAGLANDIN E-2; SYSTEM; CB2; ANANDAMIDE; DIFFERENTIATION	We had previously shown that both locally produced endocannabinoids and exocannabinoids, via cannabinoid receptor-1 (CBI), are powerful inhibitors of human hair growth. To further investigate the role of the cannabinoid system in pilosebaceous unit biology, we have explored in the current study whether and how endocannabinoids have an impact on human sebaceous gland biology, using human SZ95 sebocytes as cell culture model. Here, we provide the first evidence that SZ95 sebocytes express CB2 but not CBI. Also, prototypic endocannabinoids (arachidonoyl ethanolamide/anandamide, 2-arachidonoyl glycerol) are present in SZ95 sebocytes and dose-dependently induce lipid production and (chiefly apoptosis-driven) cell death. Endocannabinoids also up-regulate the expression of key genes involved in lipid synthesis (e.g., PPAR transcription factors and some of their target genes). These actions are selectively mediated by CB2-coupled signaling involving the MAPK pathway, as revealed by specific agonists/antagonists and by RNA interference. Because cells with "silenced" CB2 exhibited significantly suppressed basal lipid production, our results collectively suggest that human sebocytes utilize a paracrine-autocrine, endogenously active, CB2-mediated endocannabinoid signaling system for positively regulating lipid production and cell death. CB2 antagonists or agonists therefore deserve to be explored in the management of skin disorders characterized by sebaceous gland dysfunctions (e.g., acne vulgaris, seborrhea, dry skin).	[Dobrosi, Nora; Toth, Balazs I.; Geczy, Tamas; Kovacs, Laszlo; Biro, Tamas] Univ Debrecen, Dept Physiol, Med & Hlth Sci Ctr, Res Ctr Mol Med, H-4032 Debrecen, Hungary; [Nagy, Georgina] Univ Debrecen, Dept Dermatol, Med & Hlth Sci Ctr, Res Ctr Mol Med, H-4032 Debrecen, Hungary; [Dozsa, Aniko; Nagy, Laszlo] Univ Debrecen, Dept Biochem & Mol Biol, Med & Hlth Sci Ctr, Res Ctr Mol Med, H-4032 Debrecen, Hungary; [Zouboulis, Christos C.] Dessau Med Ctr, Dept Dermatol, Dessau, Germany; [Zouboulis, Christos C.] Dessau Med Ctr, Dept Venereol, Dessau, Germany; [Zouboulis, Christos C.] Dessau Med Ctr, Dept Allergol, Dessau, Germany; [Zouboulis, Christos C.] Dessau Med Ctr, Dept Immunol, Dessau, Germany; [Zouboulis, Christos C.] Univ Med Berlin, Inst Clin Pharmacol & Toxicol, Charite, Lab Biogerontol Dermatopharmacol & Dermatoendocri, Berlin, Germany; [Paus, Ralf] Med Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany; [Paus, Ralf] Univ Manchester, Sch Translat Med, Manchester M13 9PL, Lancs, England	University of Debrecen; University of Debrecen; University of Debrecen; Dessau Medical Center; Dessau Medical Center; Dessau Medical Center; Dessau Medical Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; University of Manchester	Biro, T (corresponding author), Univ Debrecen, Dept Physiol, Med & Hlth Sci Ctr, Res Ctr Mol Med, Nagyerdei Krt 98,POB 22, H-4032 Debrecen, Hungary.	biro@phys.dote.hu	Tóth, Balázs István/K-1214-2013; Nagy, Laszlo/A-3814-2008; Zouboulis, Christos C./I-4493-2013; Paus, Ralf/F-6243-2011	Tóth, Balázs István/0000-0002-4103-4333; Nagy, Laszlo/0000-0001-6653-2155; Zouboulis, Christos C./0000-0003-1646-2608; Geczy, Tamas/0000-0002-8199-8831	Hungarian research [OTKA T049231, OTKA K063153, ETT 480/2006, ETT 482/2006, RET 06/2004]; DFG [Pa 345/11-2]; European Academy of Dermatology, and Venereology (EADV) European Dermatology Research Award; Janos Bolyai scholarship of the Hungarian Academy of Sciences	Hungarian research(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); DFG(German Research Foundation (DFG)); European Academy of Dermatology, and Venereology (EADV) European Dermatology Research Award; Janos Bolyai scholarship of the Hungarian Academy of Sciences(Hungarian Academy of Sciences)	This work was supported in part, by Hungarian research grants (OTKA T049231, OTKA K063153, ETT 480/2006, ETT 482/2006, RET 06/2004) to T.B., by a DFG grant (Pa 345/11-2) to R.P., and by the European Academy of Dermatology, and Venereology (EADV) European Dermatology Research Award to C.C.Z. The authors declare no competing financial interests. T.B. is a recipient of the Janos Bolyai scholarship of the Hungarian Academy of Sciences.	Alestas T, 2006, J MOL MED, V84, P75, DOI 10.1007/s00109-005-0715-8; Batkai S, 2007, FASEB J, V21, P1788, DOI 10.1096/fj.06-7451com; Biro T, 1998, BLOOD, V91, P1332, DOI 10.1182/blood.V91.4.1332; Blazquez C, 2006, FASEB J, V20, P2633, DOI 10.1096/fj.06-6638fje; Bodo E, 2004, J INVEST DERMATOL, V123, P410, DOI 10.1111/j.0022-202X.2004.23209.x; Bodo E, 2005, AM J PATHOL, V166, P985, DOI 10.1016/S0002-9440(10)62320-6; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen WC, 2003, J INVEST DERMATOL, V121, P441, DOI 10.1046/j.1523-1747.2003.12411.x; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Ganceviciene R, 2007, EXP DERMATOL, V16, P547, DOI 10.1111/j.1600-0625.2007.00565.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griger Z, 2007, J MOL MED-JMM, V85, P1031, DOI 10.1007/s00109-007-0209-y; Huffman JW, 2000, CURR PHARM DESIGN, V6, P1323, DOI 10.2174/1381612003399347; Ibrahim MM, 2005, P NATL ACAD SCI USA, V102, P3093, DOI 10.1073/pnas.0409888102; Karsak M, 2007, SCIENCE, V316, P1494, DOI 10.1126/science.1142265; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Lenman A, 2007, BRIT J PHARMACOL, V151, P1343, DOI 10.1038/sj.bjp.0707352; Lo Celso C, 2008, STEM CELLS, V26, P1241, DOI 10.1634/stemcells.2007-0651; Maccarrone M, 2000, FEBS LETT, V468, P176, DOI 10.1016/S0014-5793(00)01223-0; Maccarrone M, 2003, J BIOL CHEM, V278, P33896, DOI 10.1074/jbc.M303994200; Maccarrone M, 2003, CELL DEATH DIFFER, V10, P946, DOI 10.1038/sj.cdd.4401284; Maldonado R, 2006, TRENDS NEUROSCI, V29, P225, DOI 10.1016/j.tins.2006.01.008; Maldonado R, 2002, J NEUROSCI, V22, P3326; Matias I, 2008, NEUROPHARMACOLOGY, V54, P206, DOI 10.1016/j.neuropharm.2007.06.011; Nong L, 2001, ADV EXP MED BIOL, V493, P229; O'Sullivan SE, 2007, BRIT J PHARMACOL, V152, P576, DOI 10.1038/sj.bjp.0707423; Ozaita A, 2007, J NEUROCHEM, V102, P1105, DOI 10.1111/j.1471-4159.2007.04642.x; Pacher P, 2005, HANDB EXP PHARMACOL, V168, P599; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Papp H, 2004, CELL MOL LIFE SCI, V61, P1095, DOI 10.1007/s00018-004-4014-2; Paradisi A, 2008, J BIOL CHEM, V283, P6005, DOI 10.1074/jbc.M707964200; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Piomelli Daniele, 2005, Curr Opin Investig Drugs, V6, P672; Rajesh M, 2008, BRIT J PHARMACOL, V153, P347, DOI 10.1038/sj.bjp.0707569; Shappell SB, 2001, CANCER RES, V61, P497; Sharkey KA, 2007, EUR J NEUROSCI, V25, P2773, DOI 10.1111/j.1460-9568.2007.05521.x; Stander S, 2005, J DERMATOL SCI, V38, P177, DOI 10.1016/j.jdermsci.2005.01.007; Storr MA, 2007, CURR OPIN PHARMACOL, V7, P575, DOI 10.1016/j.coph.2007.08.008; Szatmari I, 2007, BLOOD, V110, P3271, DOI 10.1182/blood-2007-06-096222; Telek A, 2007, FASEB J, V21, P3534, DOI 10.1096/fj.06-7689com; Toth BI, 2005, J INVEST DERMATOL, V124, pA68; Toyoda Masahiko, 2001, Medical Electron Microscopy, V34, P29, DOI 10.1007/s007950100002; Trivedi NR, 2006, J INVEST DERMATOL, V126, P2002, DOI 10.1038/sj.jid.5700336; Vellani V, 2008, NEUROPHARMACOLOGY, V55, P1274, DOI 10.1016/j.neuropharm.2008.01.010; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Wagner JA, 2005, J CARDIOVASC PHARM, V46, P348, DOI 10.1097/01.fjc.0000175437.87283.f2; Wahl P, 2001, MOL PHARMACOL, V59, P9, DOI 10.1124/mol.59.1.9; Wright KL, 2008, BRIT J PHARMACOL, V153, P263, DOI 10.1038/sj.bjp.0707486; Wrobel A, 2003, J INVEST DERMATOL, V120, P175, DOI 10.1046/j.1523-1747.2003.12029.x; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Zhang QW, 2006, J INVEST DERMATOL, V126, P42, DOI 10.1038/sj.jid.5700028; Zouboulis CC, 2005, EXP DERMATOL, V14, P144, DOI 10.1111/j.0906-6705.2005.0285c.x; Zouboulis CC, 2004, EXP DERMATOL, V13, P31, DOI 10.1111/j.1600-0625.2004.00254.x; Zouboulis CC, 2003, J INVEST DERMATOL, V120, pXIV, DOI 10.1046/j.1523-1747.2003.12263.x; Zouboulis CC, 2002, P NATL ACAD SCI USA, V99, P7148, DOI 10.1073/pnas.102180999; Zouboulis CC, 1998, DERMATOLOGY, V196, P21, DOI 10.1159/000017861; Zouboulis CC, 1999, J INVEST DERMATOL, V113, P1011, DOI 10.1046/j.1523-1747.1999.00771.x	63	100	103	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3685	3695		10.1096/fj.07-104877	http://dx.doi.org/10.1096/fj.07-104877			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18596221				2022-12-28	WOS:000259642600029
J	Fan, XJ; Krieg, S; Kuo, CJ; Wiegand, SJ; Rabinovitch, M; Druzin, ML; Brenner, RM; Giudice, LC; Nayak, NR				Fan, Xiujun; Krieg, Sacha; Kuo, Calvin J.; Wiegand, Stanley J.; Rabinovitch, Marlene; Druzin, Maurice L.; Brenner, Robert M.; Giudice, Linda C.; Nayak, Nihar R.			VEGF blockade inhibits angiogenesis and reepithelialization of endometrium	FASEB JOURNAL			English	Article						VEGF Trap; luminal epithelium; rhesus macaque; mouse; hypoxia	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTORS; FACTOR EXPRESSION; STROMAL CELLS; MOUSE UTERUS; NEUROPILIN-1; PROLIFERATION; LOCALIZATION; RECEPTORS; ACID	Despite extensive literature on vascular endothelial growth factor (VEGF) expression and regulation by steroid hormones, the lack of clear understanding of the mechanisms of angiogenesis in the endometrium is a major limitation for use of antiangiogenic therapy targeting endometrial vessels. In the current work, we used the rhesus macaque as a primate model and the decidualized mouse uterus as a murine model to examine angiogenesis during endometrial breakdown and regeneration. We found that blockade of VEGF action with VEGF Trap, a potent VEGF blocker, completely inhibited neovascularization during endometrial regeneration in both models but had no marked effect on preexisting or newly formed vessels, suggesting that VEGF is essential for neoangiogenesis but not survival of mature vessels in this vascular bed. Blockade of VEGF also blocked reepithelialization in both the postmenstrual endometrium and the mouse uterus after decidual breakdown, evidence that VEGF has pleiotropic effects in the endometrium. In vitro studies with a scratch wound assay showed that the migration of luminal epithelial cells during repair involved signaling through VEGF receptor 2-neuropilin 1 (VEGFR2-NP1) receptors on endometrial stromal cells. The leading front of tissue growth during endometrial repair was strongly hypoxic, and this hypoxia was the local stimulus for VEGF expression and angiogenesis in this tissue. In summary, we provide novel experimental data indicating that VEGF is essential for endometrial neoangiogenesis during postmenstrual/postpartum repair.	[Fan, Xiujun; Krieg, Sacha; Druzin, Maurice L.; Nayak, Nihar R.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA; [Kuo, Calvin J.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Rabinovitch, Marlene] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Wiegand, Stanley J.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; [Brenner, Robert M.] Oregon Natl Primate Res Ctr, Beaverton, OR USA; [Giudice, Linda C.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA	Stanford University; Stanford University; Stanford University; Regeneron; Oregon Health & Science University; Oregon National Primate Research Center; University of California System; University of California San Francisco	Nayak, NR (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, 300 Pasteur Dr,HH-333, Stanford, CA 94305 USA.	nayakn@stanford.edu		Druzin, Maurice/0000-0001-7185-6664; Kuo, Calvin/0000-0002-7427-5985	Andrew Mellon Foundation; U.S. National Institutes of Health (NIH); NIH [1U54HD055769]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD055764] Funding Source: NIH RePORTER	Andrew Mellon Foundation; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by grants from the Andrew Mellon Foundation, the U.S. National Institutes of Health (NIH) Building Interdisciplinary Research Careers in Women's Health, the Children Health Initiative at Stanford to N.R.N., and NIH Specialized Cooperative Centers Program in Reproduction (SCCPR) 1U54HD055769. We thank Sabita Dhal (Stanford University, Stanford, CA, USA), Kunie Mall (Oregon National Primate Research Center, Beaverton, OR, USA), and Kim Chi Vo (University of California, San Francisco, CA, USA) for technical assistance. S.J.W. is an employee of Regeneron Pharmaceuticals, holds an equity position in the company, anti is an inventor on several patents related to the VEGF Trap.	Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHARNOCKJONES DS, 1993, BIOL REPROD, V48, P1120, DOI 10.1095/biolreprod48.5.1120; Cooke PS, 1997, P NATL ACAD SCI USA, V94, P6535, DOI 10.1073/pnas.94.12.6535; Critchley HOD, 2006, ENDOCRINOLOGY, V147, P744, DOI 10.1210/en.2005-1153; Daikoku T, 2003, J BIOL CHEM, V278, P7683, DOI 10.1074/jbc.M211390200; Dvorak HF, 2005, J THROMB HAEMOST, V3, P1835, DOI 10.1111/j.1538-7836.2005.01361.x; FERENCZY A, 1979, AM J OBSTET GYNECOL, V133, P859, DOI 10.1016/0002-9378(79)90302-8; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Franck-Lissbrant I, 1998, ENDOCRINOLOGY, V139, P451, DOI 10.1210/en.139.2.451; Germeyer A, 2005, J CLIN ENDOCR METAB, V90, P1783, DOI 10.1210/jc.2004-1769; Girling Jane E., 2005, Angiogenesis, V8, P89, DOI 10.1007/s10456-005-9006-9; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Halder JB, 2000, GENESIS, V26, P213, DOI 10.1002/(SICI)1526-968X(200003)26:3<213::AID-GENE7>3.0.CO;2-M; Hastings JM, 2003, ENDOCRINOLOGY, V144, P326, DOI 10.1210/en.2002-220641; Heryanto B, 2003, REPRODUCTION, V125, P337, DOI 10.1530/reprod/125.3.337; HESS AP, 2005, KNOBIL NEILLS PHYSL, V1, P337; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Jabbour HN, 2006, ENDOCR REV, V27, P17, DOI 10.1210/er.2004-0021; Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005; Lathi RB, 2005, J CLIN ENDOCR METAB, V90, P1599, DOI 10.1210/jc.2004-1676; LUDWIG H, 1991, ANN NY ACAD SCI, V622, P28, DOI 10.1111/j.1749-6632.1991.tb37848.x; Nayak NR, 2005, MOL HUM REPROD, V11, P791, DOI 10.1093/molehr/gah237; Nayak NR, 2002, J CLIN ENDOCR METAB, V87, P1845, DOI 10.1210/jc.87.4.1845; Popovici RM, 1999, J CLIN ENDOCR METAB, V84, P2245, DOI 10.1210/jc.84.6.2245; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; Raleigh JA, 1998, CANCER RES, V58, P3765; Semenza GL, 2000, CANCER METAST REV, V19, P59, DOI 10.1023/A:1026544214667; Sharkey AM, 2000, J CLIN ENDOCR METAB, V85, P402, DOI 10.1210/jc.85.1.402; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Smith SK, 2001, TRENDS ENDOCRIN MET, V12, P147, DOI 10.1016/S1043-2760(01)00379-4; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; Zhang J, 2002, HUM REPROD, V17, P265, DOI 10.1093/humrep/17.2.265	35	144	151	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3571	3580		10.1096/fj.08-111401	http://dx.doi.org/10.1096/fj.08-111401			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18606863	Green Published			2022-12-28	WOS:000259642600019
J	Venkatesan, B; Ghosh-Choudhury, N; Das, F; Mahimainathan, L; Kamat, A; Kasinath, BS; Abboud, HE; Choudhury, GG				Venkatesan, Balachandar; Ghosh-Choudhury, Nandini; Das, Falguni; Mahimainathan, Lenin; Kamat, Amrita; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh			Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B	FASEB JOURNAL			English	Article						SIRT1; Akt kinase; CDK2	INDUCED DNA-SYNTHESIS; PROTEIN-TYROSINE PHOSPHATASES; GROWTH-FACTOR; INSULIN SENSITIVITY; C-FOS; CALORIC RESTRICTION; AKT KINASE; YEAST SIR2; CYCLIN D1; IN-VIVO	Mesangioproliferative glomerulonephritis is associated with overactive PDGF receptor signal transduction. We show that the phytoalexin resveratrol dose dependently inhibits PDGF-induced DNA synthesis in mesangial cells with an IC50 of 10 mu M without inducing apoptosis. Remarkably, the increased SIRT1 deacetylase activity induced by resveratrol was not necessary for this inhibitory effect. Resveratrol significantly blocked PDGF-stimulated c-Src and Akt kinase activation, resulting in reduced cyclin D1 expression and attenuated pRb phosphorylation and cyclin-dependent kinase-2 (CDK2) activity. Furthermore, resveratrol inhibited PDGFR phosphorylation at the PI 3 kinase and Grb-2 binding sites tyrosine-751 and tyrosine-716, respectively. This deficiency in PDGFR phosphorylation resulted in significant inhibition of PI 3 kinase and Erk1/2 MAPK activity. Interestingly, resveratrol increased the activity of protein tyrosine phosphatase PTP1B, which dephosphorylates PDGF-stimulated phosphorylation at tyrosine-751 and tyrosine-716 on PDGFR with concomitant reduction in Akt and Erk1/2 kinase activity. PTP1B significantly inhibited PDGF-induced DNA synthesis without inducing apoptosis. These results for the first time provide evidence that the stilbene resveratrol targets PTP1B to inhibit PDGFR mitogenic signaling.	[Venkatesan, Balachandar; Das, Falguni; Mahimainathan, Lenin; Kamat, Amrita; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, OBrien Kidney Res Ctr, Dept Med, San Antonio, TX 78229 USA; [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, OBrien Kidney Res Ctr, Dept Pathol, San Antonio, TX 78229 USA; [Kamat, Amrita; Choudhury, Goutam Ghosh] Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA; [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Choudhury, GG (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, OBrien Kidney Res Ctr, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	choudhuryg@uthscsa.edu		/0000-0001-5077-3552	National Institutes of Health (NIH) [RO1 DK 50190]; Juvenile Diabetes Research Foundation; NIH [RO1 AR52425, RO1 DK 33665]; VA Merit Review and Morrison Trust; VA VISN; American Diabetes Association [077295]; VA Research Service Merit; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033665, R01DK077295, R01DK050190] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit Review and Morrison Trust(US Department of Veterans Affairs); VA VISN; American Diabetes Association(American Diabetes Association); VA Research Service Merit(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr. Brent Wagner for critically reading the manuscript. This work was supported by National Institutes of Health (NIH) grant RO1 DK 50190, the Juvenile Diabetes Research Foundation, and a VA Merit Review grant to G.G.C., who is a research career scientist in the Department of Veterans Affairs. N.G.C. is supported by NIH RO1 AR52425 and VA Merit Review and Morrison Trust grants. A.K. is a recipient of a VA VISN grant. B.S.K. is supported by grants from the NIH O'Brien Kidney Center, NIH RO1 DK 077295, the American Diabetes Association, and a VA Research Service Merit. Review grant. H.E.A. is supported by NIH RO1 DK 33665 and VA Merit Review grants.	ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; Ahmad KA, 2007, MOL CANCER THER, V6, P1006, DOI 10.1158/1535-7163.MCT-06-0491; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Alkhalaf M, 2007, PHARMACOLOGY, V80, P134, DOI 10.1159/000103253; Alkhalaf M, 2006, FREE RADICAL BIO MED, V41, P318, DOI 10.1016/j.freeradbiomed.2006.04.019; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Aziz MH, 2006, MOL CANCER THER, V5, P1335, DOI 10.1158/1535-7163.MCT-05-0526; Banerjee S, 2002, CANCER RES, V62, P4945; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Bourdeau A, 2005, CURR OPIN CELL BIOL, V17, P203, DOI 10.1016/j.ceb.2005.02.001; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chang YZ, 2006, ARTERIOSCL THROM VAS, V26, P501, DOI 10.1161/01.ATV.0000201070.71787.b8; Chiara F, 2004, J BIOL CHEM, V279, P19732, DOI 10.1074/jbc.M314070200; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; CHOUDHURY GG, 1994, KIDNEY INT, V46, P37, DOI 10.1038/ki.1994.242; Choudhury GG, 2003, CELL SIGNAL, V15, P161, DOI 10.1016/S0898-6568(02)00057-8; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; Choudhury GG, 2000, KIDNEY INT, V57, P908, DOI 10.1046/j.1523-1755.2000.00907.x; Choudhury GG, 2006, CELL SIGNAL, V18, P1854, DOI 10.1016/j.cellsig.2006.02.003; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Das F, 2007, FEBS LETT, V581, P5259, DOI 10.1016/j.febslet.2007.10.014; Das F, 2008, CELL SIGNAL, V20, P409, DOI 10.1016/j.cellsig.2007.10.027; de Boer VCJ, 2006, MECH AGEING DEV, V127, P618, DOI 10.1016/j.mad.2006.02.007; de la Lastra CA, 2005, MOL NUTR FOOD RES, V49, P405; Dorrie J, 2001, CANCER RES, V61, P4731; Dube N, 2005, BBA-PROTEINS PROTEOM, V1754, P108, DOI 10.1016/j.bbapap.2005.07.030; Egawa K, 2001, J BIOL CHEM, V276, P10207, DOI 10.1074/jbc.M009489200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7; FLOEGE J, 1993, J CLIN INVEST, V92, P2952, DOI 10.1172/JCI116918; Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007; Frojdo S, 2007, BIOCHEM J, V406, P511, DOI 10.1042/BJ20070236; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Fulda S, 2006, CANCER DETECT PREV, V30, P217, DOI 10.1016/j.cdp.2006.03.007; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gilbert RE, 2001, KIDNEY INT, V59, P1324, DOI 10.1046/j.1523-1755.2001.0590041324.x; Godichaud S, 2006, INT J BIOCHEM CELL B, V38, P629, DOI 10.1016/j.biocel.2005.11.001; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Heldin CH, 2002, ARCH BIOCHEM BIOPHYS, V398, P284, DOI 10.1006/abbi.2001.2707; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jefferson JA, 1999, J NEPHROL, V12, P297; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; Kaeberlein M, 2007, AGING CELL, V6, P415, DOI 10.1111/j.1474-9726.2007.00314.x; Kaeberlein M, 2006, NATURE, V444, P280, DOI 10.1038/nature05308; Kim AL, 2006, EXP DERMATOL, V15, P538, DOI 10.1111/j.1600-0625.2006.00445.x; KIYOMOTO H, 1994, FEBS LETT, V353, P217, DOI 10.1016/0014-5793(94)01039-0; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kuwajerwala N, 2002, CANCER RES, V62, P2488; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Leibiger IB, 2006, NAT MED, V12, P34, DOI 10.1038/nm0106-34; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Liu YL, 2004, BIOCHEM PHARMACOL, V67, P777, DOI 10.1016/j.bcp.2003.09.025; Mahimainathan L, 2005, AM J PHYSIOL-RENAL, V289, pF72, DOI 10.1152/ajprenal.00277.2004; Mgbonyebi OP, 1998, INT J ONCOL, V12, P865; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakamura H, 2001, KIDNEY INT, V59, P2134, DOI 10.1046/j.1523-1755.2001.0590062134.x; Olson ER, 2005, AM J PHYSIOL-HEART C, V288, pH1131, DOI 10.1152/ajpheart.00763.2004; Paternot S, 2006, CELL CYCLE, V5, P61, DOI 10.4161/cc.5.1.2265; Pozo-Guisado E, 2004, INT J CANCER, V109, P167, DOI 10.1002/ijc.11720; Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu S, 2002, ENDOCRINOLOGY, V143, P4563, DOI 10.1210/en.2002-220517; SHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674, DOI 10.1152/ajprenal.1988.255.4.F674; SILVER BJ, 1989, P NATL ACAD SCI USA, V86, P1056, DOI 10.1073/pnas.86.3.1056; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014; Tallquist M, 2004, CYTOKINE GROWTH F R, V15, P205, DOI 10.1016/j.cytogfr.2004.03.003; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Venkatesan BA, 2006, CELL SIGNAL, V18, P508, DOI 10.1016/j.cellsig.2005.05.022; Venkatesan B, 2007, J CELL PHYSIOL, V211, P457, DOI 10.1002/jcp.20953; WENZEL UO, 1995, J CLIN INVEST, V95, P1244, DOI 10.1172/JCI117774; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zabolotny JM, 2007, CELL METAB, V6, P247, DOI 10.1016/j.cmet.2007.09.004; Zang MW, 2006, DIABETES, V55, P2180, DOI 10.2337/db05-1188; Zhang W, 2007, J NEURO-ONCOL, V81, P231, DOI 10.1007/s11060-006-9226-x	94	33	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3469	3482		10.1096/fj.08-109488	http://dx.doi.org/10.1096/fj.08-109488			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18567737	Green Published			2022-12-28	WOS:000259642600009
J	Abtin, A; Eckhart, L; Mildner, M; Gruber, F; Schroder, JM; Tschachler, E				Abtin, Arby; Eckhart, Leopold; Mildner, Michael; Gruber, Florian; Schroeder, Jens-Michael; Tschachler, Erwin			Flagellin is the principal inducer of the antimicrobial peptide S100A7c (psoriasin) in human epidermal keratinocytes exposed to Escherichia coli	FASEB JOURNAL			English	Article						innate immunity; Toll-like receptor; TLR; pathogen-associated molecular pattern; PAMP; antimicrobial defense	TOLL-LIKE-RECEPTORS; INVASIVE BACTERIAL-INFECTION; INNATE IMMUNE-RESPONSE; EPITHELIAL-CELLS; MOLECULAR-CLONING; TLR EXPRESSION; BETA-DEFENSINS; HUMAN SKIN; KAPPA-B; DIFFERENTIATION	Epidermal keratinocytes (KCs) express antimicrobial peptides as a part of the innate immune response. It has recently been shown that the culture supernatant of Escherichia coli induces the expression of S100A7c (psoriasin) in KCs and that S100A7c efficiently kills E. coli. Here we have investigated which of the microbial components triggers the up-regulation of S100A7c expression. Exposure of human primary KCs to ligands of the human Toll-like receptors (TLRs) revealed that only the TLR5 ligand flagellin strongly induced the expression of S100A7c mRNA and protein, whereas all other TLR ligands had no significant effect. In contrast to the supernatant from flagellated wild-type (WT) E. coli, the supernatant of a flagellin-deficient E. coli strain (Delta FliC) did not induce S100A7c expression. Small interfering RNA-mediated knockdown of TLR5 expression suppressed the ability of KCs to up-regulate S100A7c expression in response to both flagellin and WT E. coli supernatant. Taken together, our data demonstrate that bacterial flagellin is essential and sufficient for the induction of S100A7c expression in KCs by E. coli.	[Abtin, Arby; Eckhart, Leopold; Mildner, Michael; Gruber, Florian; Tschachler, Erwin] Med Univ Vienna, Dept Dermatol, A-1090 Vienna, Austria; [Schroeder, Jens-Michael] Univ Kiel, Dept Dermatol, Univ Hosp Schleswig Holstein, D-2300 Kiel, Germany; [Tschachler, Erwin] Ctr Rech & Invest Epiderm & Sensorielles, Neuilly Sur Seine, France	Medical University of Vienna; University of Kiel; Schleswig Holstein University Hospital	Tschachler, E (corresponding author), Med Univ Vienna, Dept Dermatol, Waehringer Guertal 18-20, A-1090 Vienna, Austria.	erwin.tschachler@meduniwien.ac.at	Schroeder, Jens M/B-3994-2009	Gruber, Florian/0000-0003-1094-5641; Eckhart, Leopold/0000-0002-5645-2036; Mildner, Michael/0000-0002-6892-925X; Tschachler, Erwin/0000-0002-0248-1798				Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Baker BS, 2003, BRIT J DERMATOL, V148, P670, DOI 10.1046/j.1365-2133.2003.05287.x; Bates D, 2005, MOL MICROBIOL, V57, P380, DOI 10.1111/j.1365-2958.2005.04693.x; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bojar RA, 2002, WORLD J MICROB BIOT, V18, P889, DOI 10.1023/A:1021271028979; Boni R, 1997, BRIT J DERMATOL, V137, P39, DOI 10.1046/j.1365-2133.1997.17651853.x; Boniface K, 2007, J IMMUNOL, V178, P4615, DOI 10.4049/jimmunol.178.7.4615; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; Buechau AS, 2007, J INVEST DERMATOL, V127, P2596, DOI 10.1038/sj.jid.5700946; Chiller K, 2001, J INVEST DERM SYMP P, V6, P170, DOI 10.1046/j.0022-202x.2001.00043.x; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; Cole AM, 2001, FEBS LETT, V504, P5, DOI 10.1016/S0014-5793(01)02731-4; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; Hahn Y, 2007, MOL BIOL EVOL, V24, P2203, DOI 10.1093/molbev/msm146; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; Huang YC, 2007, J BIOL CHEM, V282, P4626, DOI 10.1074/jbc.M607321200; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kawai K, 2003, J INVEST DERMATOL, V121, P217, DOI 10.1046/j.1523-1747.2003.12305.x; Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x; Kulski JK, 2003, J MOL EVOL, V56, P397, DOI 10.1007/s00239-002-2410-5; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Lee RT, 1997, J IMMUNOL, V159, P5084; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; Martinsson H, 2005, EXP DERMATOL, V14, P161, DOI 10.1111/j.0906-6705.2005.00239.x; Mempel M, 2003, J INVEST DERMATOL, V121, P1389, DOI 10.1111/j.1523-1747.2003.12630.x; Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344; Mildner M, 2006, BIOCHEM BIOPH RES CO, V348, P76, DOI 10.1016/j.bbrc.2006.07.035; Miller LS, 2007, SEMIN IMMUNOPATHOL, V29, P15, DOI 10.1007/s00281-007-0061-8; Miller LS, 2005, J IMMUNOL, V174, P6137, DOI 10.4049/jimmunol.174.10.6137; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; MURTHY ARK, 1993, J IMMUNOL, V151, P6291; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Sahl HG, 2005, J LEUKOCYTE BIOL, V77, P466, DOI 10.1189/jlb.0804452; Schaefer TM, 2005, J IMMUNOL, V174, P992, DOI 10.4049/jimmunol.174.2.992; Schroder JM, 2006, CELL MOL LIFE SCI, V63, P469, DOI 10.1007/s00018-005-5364-0; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Vora P, 2004, J IMMUNOL, V173, P5398, DOI 10.4049/jimmunol.173.9.5398; Voss E, 2006, J BIOL CHEM, V281, P2005, DOI 10.1074/jbc.M511044200; Wildman KAH, 2003, BIOCHEMISTRY-US, V42, P6545, DOI 10.1021/bi0273563; Wolf R, 2003, FASEB J, V17, P1969, DOI 10.1096/fj.03-0148fje; Wolf R, 2006, J INVEST DERMATOL, V126, P1600, DOI 10.1038/sj.jid.5700210; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	55	63	66	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2168	2176		10.1096/fj.07-104117	http://dx.doi.org/10.1096/fj.07-104117			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263703				2022-12-28	WOS:000257292500009
J	Akhmetshina, A; Dees, C; Pileckyte, M; Maurer, B; Axmann, R; Jungel, A; Zwerina, J; Gay, S; Schett, G; Distler, O; Distler, JHW				Akhmetshina, Alfiya; Dees, Clara; Pileckyte, Margarita; Maurer, Britta; Axmann, Roland; Juengel, Astrid; Zwerina, Jochen; Gay, Steffen; Schett, Georg; Distler, Oliver; Distler, Joerg H. W.			Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis	FASEB JOURNAL			English	Article						systemic sclerosis; scleroderma; fibroblasts; TGF beta; translational	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW FIBROSIS; SYSTEMIC-SCLEROSIS; TYROSINE KINASE; TGF-BETA; BCR-ABL; IMATINIB; SRC; PHARMACOKINETICS	Abelson kinase (c-abl) and platelet-derived growth factor (PDGF) are key players in the pathogenesis of systemic sclerosis (SSc). The aim of the present study was to evaluate the antifibrotic potential of dasatinib and nilotinib, 2 novel inhibitors of c-abl and PDGF, which are well tolerated and have recently been approved. Dasatinib and nilotinib dose-dependently reduced the mRNA and protein levels of extracellular matrix proteins in human stimulated dermal fibroblasts from SSc patients (IC50 of 0.5-2.0 nM for dasatinib and 0.8-2.5 nM for nilotinib). In a mouse model of bleomycin-induced dermal fibrosis, dasatinib and nilotinib potently reduced the dermal thickness, the number of myofibroblasts, and the collagen content of the skin in a dose-dependent manner at well-tolerated doses. These data indicate that dasatinib and nilotinib potently inhibit the synthesis of extracellular matrix in vitro and in vivo at biologically relevant concentrations. Thus, we provide the first evidence that dasatinib and nilotinib might be promising drugs for the treatment of patients with SSc.	[Akhmetshina, Alfiya; Dees, Clara; Axmann, Roland; Zwerina, Jochen; Schett, Georg; Distler, Joerg H. W.] Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany; [Akhmetshina, Alfiya; Dees, Clara; Axmann, Roland; Zwerina, Jochen; Schett, Georg; Distler, Joerg H. W.] Univ Erlangen Nurnberg, Inst Clin Immunol, D-91054 Erlangen, Germany; [Pileckyte, Margarita] Kaunas Med Univ Hosp, Dept Rheumatol, Kaunas, Lithuania; [Maurer, Britta; Juengel, Astrid; Gay, Steffen; Distler, Oliver] Univ Zurich Hosp, Ctr Expt Rheumatol, CH-8091 Zurich, Switzerland; [Maurer, Britta; Juengel, Astrid; Gay, Steffen; Distler, Oliver] Univ Zurich Hosp, Zurich Ctr Integrat Human Physiol, CH-8091 Zurich, Switzerland	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Hospital of Lithuanian University of Health Sciences Kauno Klinikos; Lithuanian University of Health Sciences; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Zurich Center Integrative Human Physiology (ZIHP)	Distler, JHW (corresponding author), Univ Erlangen Nurnberg, Dept Internal Med 3, Univ Str 29, D-91054 Erlangen, Germany.	joerg.distler@uk-erlangen.de	Distler, Oliver/AAE-6225-2019	Distler, Oliver/0000-0002-0546-8310				Abdollahi A, 2005, J EXP MED, V201, P925, DOI 10.1084/jem.20041393; Atallah E, 2007, CLIN LYMPHOMA MYELOM, V7, pS105, DOI 10.3816/CLM.2007.s.010; Beham-Schmid C, 2002, BLOOD, V99, P381, DOI 10.1182/blood.V99.1.381; Bueso-Ramos CE, 2004, CANCER-AM CANCER SOC, V101, P332, DOI 10.1002/cncr.20380; Czochra P, 2006, J HEPATOL, V45, P419, DOI 10.1016/j.jhep.2006.04.010; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Distler JHW, 2005, P NATL ACAD SCI USA, V102, P2892, DOI 10.1073/pnas.0409781102; Distler JHW, 2006, ARTHRITIS RHEUM-US, V54, P214, DOI 10.1002/art.21497; Distler JHW, 2007, ARTHRITIS RHEUM-US, V56, P311, DOI 10.1002/art.22314; Dorey K, 2001, ONCOGENE, V20, P8075, DOI 10.1038/sj.onc.1205017; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Hesselstrand R, 1998, ANN RHEUM DIS, V57, P682, DOI 10.1136/ard.57.11.682; Kamath AV, 2008, CANCER CHEMOTH PHARM, V61, P365, DOI 10.1007/s00280-007-0478-8; Kantarjian H, 2006, NAT REV DRUG DISCOV, V5, P717, DOI 10.1038/nrd2135; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kaur P, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-67; LEROY EC, 1988, J RHEUMATOL, V15, P202; Luo FR, 2006, CLIN CANCER RES, V12, P7180, DOI 10.1158/1078-0432.CCR-06-1112; O'Hare T, 2005, CLIN CANCER RES, V11, P6987, DOI 10.1158/1078-0432.CCR-05-0622; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Santiago B, 2005, J INVEST DERMATOL, V125, P450, DOI 10.1111/j.0022-202X.2005.23859.x; SCHEJA A, 1993, BRIT J RHEUMATOL, V32, P59; SKHIRTLADZE C, 2008, ARTHRITIS R IN PRESS; Sonnylal S, 2007, ARTHRITIS RHEUM-US, V56, P334, DOI 10.1002/art.22328; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Varga J, 2007, J CLIN INVEST, V117, P557, DOI 10.1172/JCI31139; Wang SN, 2005, FASEB J, V19, P1, DOI 10.1096/fj.04-2370com; Yoshiji H, 2005, AM J PHYSIOL-GASTR L, V288, pG907, DOI 10.1152/ajpgi.00420.2004	29	157	161	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2214	2222		10.1096/fj.07-105627	http://dx.doi.org/10.1096/fj.07-105627			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18326784				2022-12-28	WOS:000257292500014
J	Fligny, C; Fromes, Y; Bonnin, P; Darmon, M; Bayard, E; Launay, JM; Cote, F; Mallet, J; Vodjdani, G				Fligny, Cecile; Fromes, Yves; Bonnin, Philippe; Darmon, Michele; Bayard, Elisa; Launay, Jean-Marie; Cote, Francine; Mallet, Jacques; Vodjdani, Guilan			Maternal serotonin influences cardiac function in adult offspring	FASEB JOURNAL			English	Article						maternal effect; tryptophan hydroxylase 1-invalidated mouse; heart failure animal model; dilated cardiomyopathy	PRIMARY PULMONARY-HYPERTENSION; PLASMA SEROTONIN; 5-HT2B RECEPTOR; HEART-FAILURE; 2B RECEPTOR; 5-HYDROXYTRYPTAMINE; TRANSPORTER; CATECHOLAMINES; HYPERTROPHY; DISEASES	Using the Tph1-invalidated mouse line, in which blood is depleted in serotonin (5-hydroxytryptamine, 5-HT), we have demonstrated previously that maternal 5-HT is required for normal embryonic development. Here, we address the issue of the influence of the maternal 5-HT concentration on the cardiac function of the offspring as adults. We investigated the cardiac phenotype of Tph1-invalidated mice born to Tph1 heterozygous and null mothers. Functionally, all mutants display a significant decrease of cardiac contractility, indicative of impaired left ventricular function. They exhibit progressive dilated cardiomyopathy and are unable to adapt appropriately to a pharmacological stress. Moreover, we show that the cardiopathy is more severe in adult Tph1(-/-) mice born to homozygous mothers than to heterozygous mothers. Importantly, the severity of the cardiac phenotype is inversely correlated with the plasma 5-HT concentration but not the whole-blood 5-HT concentration. Thus, plasma 5-HT concentration may be a useful index of heart failure. These findings show that cardiac function, through the plasma 5-HT concentration, is influenced by the maternal serotonergic status.	[Fligny, Cecile; Bayard, Elisa; Cote, Francine; Mallet, Jacques; Vodjdani, Guilan] Univ Paris 06, Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmission & Proc Neurodegen, CNRS,UMR 7091, F-75013 Paris, France; [Fromes, Yves] Univ Paris 06, INSERM, Inst Myol, U852, F-75013 Paris, France; [Darmon, Michele] Univ Paris 06, INSERM, UMR 677, F-75013 Paris, France; [Bonnin, Philippe] Univ Paris 07, INSERM, Ctr Rech Cardiovasc Physiol Explorat Fonctionnnel, U689, Paris, France; [Launay, Jean-Marie] Hop Lariboisiere, AP HP, Serv Biochim, F-75475 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Launay, JM (corresponding author), Univ Paris 06, Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmission & Proc Neurodegen, CNRS,UMR 7091, Batiment CERVI,83 Blvd Hop, F-75013 Paris, France.	mallet@chups.jussieu.fr; vodjdani@chups.jussieu.fr	VODJDANI, Guilan/GSN-1174-2022; Darmon, Michele/F-8708-2011; Fromes, Yves/J-9602-2013; FROMES, Yves/AAB-9267-2020; Bonnin, Philippe/Y-5872-2019	Darmon, Michele/0000-0001-9730-6273; Fromes, Yves/0000-0002-6792-9549; Bonnin, Philippe/0000-0003-3184-3740				Anderson GM, 2007, PEDIATR NEUROL, V36, P138, DOI 10.1016/j.pediatrneurol.2006.11.007; Bonnin P, 2007, ULTRASOUND MED BIOL, V33, P561, DOI 10.1016/j.ultrasmedbio.2006.09.010; Brattelid T, 2004, N-S ARCH PHARMACOL, V370, P157, DOI 10.1007/s00210-004-0963-0; Brenner B, 2007, J NEUROCHEM, V102, P206, DOI 10.1111/j.1471-4159.2007.04542.x; Brouri F, 2002, EUR J PHARMACOL, V456, P69, DOI 10.1016/S0014-2999(02)02643-2; Callebert J, 2006, J PHARMACOL EXP THER, V317, P724, DOI 10.1124/jpet.105.098269; Chakraborti S, 2000, CELL SIGNAL, V12, P499, DOI 10.1016/S0898-6568(00)00087-5; Chang AS, 1996, MOL BRAIN RES, V43, P185, DOI 10.1016/S0169-328X(96)00172-6; Choi DS, 1997, DEVELOPMENT, V124, P1745; Connors SL, 2006, PEDIATR NEUROL, V35, P182, DOI 10.1016/j.pediatrneurol.2006.02.010; Cote F, 2004, TRENDS MOL MED, V10, P232, DOI 10.1016/j.molmed.2004.03.007; Cote F, 2003, P NATL ACAD SCI USA, V100, P13525, DOI 10.1073/pnas.2233056100; Cote F, 2007, P NATL ACAD SCI USA, V104, P329, DOI 10.1073/pnas.0606722104; DAPRADA M, 1979, BRIT J PHARMACOL, V65, P653; GERSHON MD, 1965, SCIENCE, V149, P197, DOI 10.1126/science.149.3680.197; Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002; Guilluy C, 2007, J BIOL CHEM, V282, P2918, DOI 10.1074/jbc.M604195200; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; HOYER D, 1994, PHARMACOL REV, V46, P157; Jaffre F, 2004, CIRCULATION, V110, P969, DOI 10.1161/01.CIR.0000139856.20505.57; Kaumann AJ, 2006, PHARMACOL THERAPEUT, V111, P674, DOI 10.1016/j.pharmthera.2005.12.004; Kereveur A, 2000, ARTERIOSCL THROM VAS, V20, P2233, DOI 10.1161/01.ATV.20.10.2233; Launay JM, 2002, NAT MED, V8, P1129, DOI 10.1038/nm764; LECHIN F, 1994, J MED, V25, P181; Lechin F, 1996, ANN ALLERG ASTHMA IM, V77, P245, DOI 10.1016/S1081-1206(10)63263-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maurer-Spurej E, 2005, CELL MOL LIFE SCI, V62, P159, DOI 10.1007/s00018-004-4262-1; Mongue-Din H, 2007, PFLUG ARCH EUR J PHY, V454, P165, DOI 10.1007/s00424-006-0197-8; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2003, CIRCULATION, V107, P3223, DOI 10.1161/01.CIR.0000074224.57016.01; Nebigil CG, 2001, CIRCULATION, V103, P2973, DOI 10.1161/01.CIR.103.24.2973; Qvigstad E, 2005, CIRC RES, V97, P268, DOI 10.1161/01.RES.0000176970.22603.8d; Qvigstad E, 2005, CARDIOVASC RES, V65, P869, DOI 10.1016/j.cardiores.2004.11.017; RAPPORT MM, 1948, J BIOL CHEM, V174, P735; RAPPORT MM, 1949, J BIOL CHEM, V180, P961; Sari Y, 2003, INT J DEV NEUROSCI, V21, P417, DOI 10.1016/j.ijdevneu.2003.10.002; Tevaearai HT, 2004, TRENDS CARDIOVAS MED, V14, P252, DOI 10.1016/j.tcm.2004.07.002; TWAROG BM, 1953, AM J PHYSIOL, V175, P157, DOI 10.1152/ajplegacy.1953.175.1.157; ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W; Vialou V, 2007, NEUROSCIENCE, V144, P616, DOI 10.1016/j.neuroscience.2006.09.058; Villalon CM, 2007, N-S ARCH PHARMACOL, V376, P45, DOI 10.1007/s00210-007-0179-1; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Watts SW, 2005, CLIN SCI, V108, P399, DOI 10.1042/CS20040364; Zolkowska D, 2006, J PHARMACOL EXP THER, V318, P604, DOI 10.1124/jpet.106.101618	45	26	27	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2340	2349		10.1096/fj.07-100743	http://dx.doi.org/10.1096/fj.07-100743			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18267982				2022-12-28	WOS:000257292500026
J	Jiang, HM; Rhee, SM; Ho, CH; Grinnell, F				Jiang, Hongmei; Rhee, Sangmyung; Ho, Chin-Han; Grinnell, Frederick			Distinguishing fibroblast promigratory and procontractile growth factor environments in 3-D collagen matrices	FASEB JOURNAL			English	Article						cell migration; cell contraction; platelet-derived growth factor; lysophosphatidic acid; sphingosine-1-phosphate; wound repair	PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; SPHINGOSINE 1-PHOSPHATE; GEL CONTRACTION; BINDING PROTEIN; ENDOTHELIAL-CELLS; WOUND CONTRACTION; TISSUE-REPAIR; I COLLAGEN; MIGRATION	Understanding growth factor function during wound repair is necessary for the development of therapeutic interventions to improve healing outcomes. In the current study, we compare the effects of serum and purified growth factors on human fibroblast function in three different collagen matrix models: cell migration in nested matrices, floating matrix contraction, and stressed-released matrix contraction. The results of these studies indicate that platelet-derived growth factor (PDGF) is unique in its capacity to promote cell migration. Serum, lysophosphatidic acid, sphingosine-1-phophate (S1P), and endothelin-1 promote stressed-released matrix contraction but not cell migration. In addition, we found that S1P inhibits fibroblast migration and treatment of serum to remove lipid growth factors or treatment of cells to interfere with S1P(2) receptor function increases serum promigratory activity. Our findings suggest that different sets of growth factors generate promigratory and procontractile tissue environments for fibroblasts and that the balance between PDGF and S1P is a key determinant of fibroblast promigratory activity.	[Jiang, Hongmei; Rhee, Sangmyung; Ho, Chin-Han; Grinnell, Frederick] Univ Texas SW Med Sch, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas SW Med Sch, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	frederick.grinnell@utsouthwestern.edu			NIGMS NIH HHS [GM-31321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031321, R37GM031321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe M, 2003, J BIOL CHEM, V278, P47707, DOI 10.1074/jbc.M306228200; ABE M, 2007, J CELL BIOCH; Abraham David J, 2007, Curr Rheumatol Rep, V9, P136, DOI 10.1007/s11926-007-0008-z; Ahlfors JEW, 2007, BIOMATERIALS, V28, P2183, DOI 10.1016/j.biomaterials.2006.12.030; Aiba-Kojima E, 2007, WOUND REPAIR REGEN, V15, P511, DOI 10.1111/j.1524-475X.2007.00259.x; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Arikawa K, 2003, J BIOL CHEM, V278, P32841, DOI 10.1074/jbc.M305024200; BAROCAS VH, 1995, J BIOMECH ENG-T ASME, V117, P161, DOI 10.1115/1.2795998; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; BELL E, 1983, J INVEST DERMATOL, V81, pS2, DOI 10.1111/1523-1747.ep12539993; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Chen WYJ, 2007, WOUND REPAIR REGEN, V15, P434, DOI 10.1111/j.1524-475X.2007.00250.x; Clark RAF, 2007, J INVEST DERMATOL, V127, P1018, DOI 10.1038/sj.jid.5700715; Comoglio PM, 2005, NAT MED, V11, P1156, DOI 10.1038/nm1105-1156; Cooke ME, 2000, J CELL SCI, V113, P2375; Cross KJ, 2003, SURG CLIN N AM, V83, P531, DOI 10.1016/S0039-6109(02)00202-5; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Darby IA, 2007, INT REV CYTOL, V257, P143, DOI 10.1016/S0074-7696(07)57004-X; Davidson Jeffrey M, 2007, Int J Low Extrem Wounds, V6, P8, DOI 10.1177/1534734607299180; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; Diegelmann RF, 2004, FRONT BIOSCI-LANDMRK, V9, P283, DOI 10.2741/1184; EHRLICH HP, 1990, TISSUE CELL, V22, P407, DOI 10.1016/0040-8166(90)90070-P; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fu XB, 2005, WOUND REPAIR REGEN, V13, P122, DOI 10.1111/j.1067-1927.2005.130202.x; Gao ZY, 2005, J BIOL CHEM, V280, P9375, DOI 10.1074/jbc.M413081200; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goparaju SK, 2005, MOL CELL BIOL, V25, P4237, DOI 10.1128/MCB.25.10.4237-4249.2005; Grinnell F, 2006, EXP CELL RES, V312, P86, DOI 10.1016/j.yexcr.2005.010.001; Grinnell F, 2003, TRENDS CELL BIOL, V13, P264, DOI 10.1016/S0962-8924(03)00057-6; Grinnell F, 2003, MOL BIOL CELL, V14, P384, DOI 10.1091/mbc.E02-08-0493; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; Grinnell F, 1996, J INVEST DERMATOL, V106, P335, DOI 10.1111/1523-1747.ep12342990; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GUIDRY C, 1991, J CELL BIOL, V115, P873, DOI 10.1083/jcb.115.3.873; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; JOHNSON TM, 1993, J DERMATOL SURG ONC, V19, P1074, DOI 10.1111/j.1524-4725.1993.tb01002.x; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Li J, 2007, CLIN DERMATOL, V25, P9, DOI 10.1016/j.clindermatol.2006.09.007; Li W, 2004, MOL BIOL CELL, V15, P294, DOI 10.1091/mbc.e03-05-0352; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Menke NB, 2007, CLIN DERMATOL, V25, P19, DOI 10.1016/j.clindermatol.2006.12.005; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Olutoye OO, 1996, J PEDIATR SURG, V31, P91, DOI 10.1016/S0022-3468(96)90326-7; Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2; Parizi M, 2000, EXP CELL RES, V254, P210, DOI 10.1006/excr.1999.4754; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Peters SLM, 2007, CURR OPIN PHARMACOL, V7, P186, DOI 10.1016/j.coph.2006.09.008; Rhee S, 2006, J CELL BIOL, V172, P423, DOI 10.1083/jcb.200505175; Rhee S, 2007, P NATL ACAD SCI USA, V104, P5425, DOI 10.1073/pnas.0608030104; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roeder BA, 2002, J BIOMECH ENG-T ASME, V124, P214, DOI 10.1115/1.1449904; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; Silver F.H., 2002, SKIN RES TECHNOL, V8, P1; Skuta G, 1999, J BIOL CHEM, V274, P30163, DOI 10.1074/jbc.274.42.30163; Smith KD, 2006, EXP CELL RES, V312, P1970, DOI 10.1016/j.yexcr.2006.02.022; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; TINGSTROM A, 1992, J CELL SCI, V102, P315; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Wakatsuki T, 2000, BIOPHYS J, V79, P2353, DOI 10.1016/S0006-3495(00)76481-2; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Watterson KR, 2007, WOUND REPAIR REGEN, V15, P607, DOI 10.1111/j.1524-475X.2007.00292.x; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wilhelmi BJ, 1998, ANN PLAS SURG, V41, P215, DOI 10.1097/00000637-199808000-00019; WYSOCKI AB, 1993, J INVEST DERMATOL, V101, P64, DOI 10.1111/1523-1747.ep12359590; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yanase M, 2000, BIOCHEM BIOPH RES CO, V277, P72, DOI 10.1006/bbrc.2000.3634; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yee HF, 2001, BIOCHEM BIOPH RES CO, V280, P1340, DOI 10.1006/bbrc.2001.4291	73	47	47	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2151	2160		10.1096/fj.07-097014	http://dx.doi.org/10.1096/fj.07-097014			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18272655				2022-12-28	WOS:000257292500007
J	Liu, YY; Yu, JY; Yin, DM; Patwardhan, GA; Gupta, V; Hirabayashi, Y; Holleran, WM; Giuliano, AE; Jazwinski, SM; Gouaze-Andersson, V; Consoli, DP; Cabot, MC				Liu, Yong-Yu; Yu, Jing Yuan; Yin, Dongmei; Patwardhan, Gauri Anand; Gupta, Vineet; Hirabayashi, Yoshio; Holleran, Walter M.; Giuliano, Armando E.; Jazwinski, S. Michal; Gouaze-Andersson, Valerie; Consoli, David P.; Cabot, Myles C.			A role for ceramide in driving cancer cell resistance to doxorubicin	FASEB JOURNAL			English	Article						glucosylceramide synthase; Sp1; transcription; gene regulation	GLUCOSYLCERAMIDE SYNTHASE EXPRESSION; MULTIDRUG-RESISTANCE; BREAST-CANCER; P-GLYCOPROTEIN; UP-REGULATION; ADRIAMYCIN RESISTANCE; ANTICANCER AGENTS; INDUCED APOPTOSIS; PROMOTER ACTIVITY; DRUG-RESISTANCE	Advanced cancers acquire resistance to chemotherapy, and this results in treatment failure. The cellular mechanisms of chemotherapy resistance are not well understood. Here, for the first time, we show that ceramide contributes to cellular resistance to doxorubicin through up-regulating the gene expression of glucosylceramide synthase (GCS). Ceramide, a cellular lipid messenger, modulates doxorubicin-induced cell death. GCS catalyzes ceramide glycosylation, converting ceramide to glucosylceramide; this process hastens ceramide clearance and limits ceramide-induced apoptosis. In the present study, we evaluated the role of the GCS gene in doxorubicin resistance using several paired wild-type and drug-resistant (doxorubicin-selected) cancer cell lines, including breast, ovary, cervical, and colon. GCS was overexpressed in all drug-resistant counterparts, and suppressing GCS overexpression using antisense oligonucleotide restored doxorubicin sensitivity. Characterizing the effect mechanism showed that doxorubicin exposure increased ceramide levels, enhanced GCS expression, and imparted cellular resistance. Exogenous C6-ceramide and sphingomyelinase treatments mimicked the influence of doxorubicin on GCS, activating the GCS promoter and upregulating GCS gene expression. Fumonisin B-1, an inhibitor of ceramide synthesis, significantly suppressed doxorubicin-up-regulated GCS expression. Promoter truncation, point mutation, gel-shift, and protein-DNA ELISA analysis showed that transcription factor Sp1 was essential for ceramide-induced GCS up-regulation. These data indicate that ceramide-governed GCS gene expression drives cellular resistance to doxorubicin.	[Liu, Yong-Yu; Yin, Dongmei; Patwardhan, Gauri Anand; Gupta, Vineet] Univ Louisiana Monroe, Dept Basic Pharmaceut Sci, Monroe, LA 71209 USA; [Yu, Jing Yuan; Giuliano, Armando E.; Gouaze-Andersson, Valerie; Consoli, David P.; Cabot, Myles C.] John Wayne Canc Inst, St Johns Hlth Ctr, Dept Expt Therapeut, Santa Monica, CA USA; [Hirabayashi, Yoshio] RIKEN Brain Sci Inst, Neuronal Circuit Mech Res Grp, Saitama, Japan; [Holleran, Walter M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Holleran, Walter M.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; [Jazwinski, S. Michal] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA	University of Louisiana System; University of Louisiana Monroe; John Wayne Cancer Institute; RIKEN; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tulane University	Liu, YY (corresponding author), Univ Louisiana Monroe, Dept Basic Pharmaceut Sci, 700 Univ Ave, Monroe, LA 71209 USA.	yliu@ulm.edu	Liu, Yong-Yu/H-8593-2014; Gouaze-Andersson, Valerie/O-9180-2014	Gouaze-Andersson, Valerie/0000-0002-1797-515X; Hirabayashi, Yoshio/0000-0002-5774-7354; Liu, Yong-Yu/0000-0002-7968-0162	NCRR NIH HHS [P20 RR16456, P20 RR016456] Funding Source: Medline; NIGMS NIH HHS [GM77391] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077391] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe A, 1996, BBA-LIPID LIPID MET, V1299, P333, DOI 10.1016/0005-2760(95)00217-0; Adam D, 2002, TRENDS IMMUNOL, V23, P1, DOI 10.1016/S1471-4906(01)02091-9; AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358; Bektas M, 2003, GLYCOCONJUGATE J, V20, P39, DOI 10.1023/B:GLYC.0000016741.88476.8b; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; Buzas B, 2002, NEUROREPORT, V13, P1707, DOI 10.1097/00001756-200210070-00003; Chen CC, 2001, MOL PHARMACOL, V59, P493, DOI 10.1124/mol.59.3.493; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gouaze V, 2005, CANCER RES, V65, P3861, DOI 10.1158/0008-5472.CAN-04-2329; Gouaze V, 2004, MOL CANCER THER, V3, P633; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, J BIOL CHEM, V264, P9960; Ichikawa S, 1998, BIOCHEM BIOPH RES CO, V253, P707, DOI 10.1006/bbrc.1998.9855; Itoh M, 2003, CLIN CANCER RES, V9, P415; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kawase M, 2002, BBA-MOL CELL BIOL L, V1584, P104, DOI 10.1016/S1388-1981(02)00301-3; Kim WH, 2000, BIOCHEM CELL BIOL, V78, P127, DOI 10.1139/bcb-78-2-127; Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Komori H, 2000, FEBS LETT, V475, P247, DOI 10.1016/S0014-5793(00)01696-3; Kourousis C, 1998, AM J CLIN ONCOL-CANC, V21, P226, DOI 10.1097/00000421-199806000-00003; Kudoh K, 2000, CANCER RES, V60, P4161; LAI GM, 1991, INT J CANCER, V49, P696, DOI 10.1002/ijc.2910490512; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Liang Y, 2001, EUR J CANCER, V37, P1041, DOI 10.1016/S0959-8049(01)00086-7; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Liu YY, 2004, J LIPID RES, V45, P933, DOI 10.1194/jlr.M300486-JLR200; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; Lucci A, 1999, CANCER-AM CANCER SOC, V86, P300, DOI 10.1002/(SICI)1097-0142(19990715)86:2<300::AID-CNCR14>3.0.CO;2-H; Lucci A, 1998, ANTICANCER RES, V18, P475; Maestre N, 2001, CANCER RES, V61, P2558; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Murate T, 2002, J BIOL CHEM, V277, P9936, DOI 10.1074/jbc.M111594200; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Park IN, 2004, MOL PHARMACOL, V65, P1475, DOI 10.1124/mol.65.6.1475; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Reynolds CP, 2004, CANCER LETT, V206, P169, DOI 10.1016/j.canlet.2003.08.034; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Scholl SM, 1995, EUR J CANCER, V31A, P1969, DOI 10.1016/0959-8049(95)00454-8; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Shabbits J A, 2001, Expert Rev Anticancer Ther, V1, P585, DOI 10.1586/14737140.1.4.585; SHEN DW, 1986, J BIOL CHEM, V261, P7762; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Sun YL, 2006, NEOPLASMA, V53, P1; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; Uchida Y, 2004, CANCER RES, V64, P6271, DOI 10.1158/0008-5472.CAN-03-1476; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Watts GS, 2001, J PHARMACOL EXP THER, V299, P434; Wooten LG, 2005, J BIOL CHEM, V280, P28867, DOI 10.1074/jbc.M413444200; Wu DY, 2003, J BIOL CHEM, V278, P10983, DOI 10.1074/jbc.M207470200	64	116	119	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2541	2551		10.1096/fj.07-092981	http://dx.doi.org/10.1096/fj.07-092981			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18245173				2022-12-28	WOS:000257292500045
J	Lofgren, K; Wahlstrom, A; Lundberg, P; Langel, U; Graslund, A				Lofgren, Kajsa; Wahlstrom, Anna; Lundberg, Pontus; Langel, Ulo; Graslund, Astrid			Antiprion properties of prion protein-derived cell-penetrating peptides	FASEB JOURNAL			English	Article						scrapie; prion conversion; N terminus; therapy; signal peptide	HEPARAN-SULFATE; CULTURED-CELLS; IN-VITRO; PRPC; TRANSLOCATION; RECEPTOR; BINDING; PART; PH	In prion diseases, the cellular prion protein (PrPC) becomes misfolded into the pathogenic scrapie isoform (PrPSc) responsible for prion infectivity. We show here that peptides derived from the prion protein N terminus have potent antiprion effects. These peptides are composed of a hydrophobic sequence followed by a basic segment. They are known to have cell-penetrating ability like regular cell-penetrating peptides (CPPs), short peptides that can penetrate cellular membranes. Healthy (GT1-1) and scrapie-infected (ScGT1-1) mouse neuronal hypothalamic cells were treated with various CPPs, including the prion protein-derived CPPs. Lysates were analyzed for altered protein levels of PrPC or PrPSc. Treatment with the prion protein-derived CPPs mouse mPrP(1-28) or bovine bPrP(1-30) significantly reduced PrPSc levels in prion-infected cells but had no effect on PrPC levels in noninfected cells. Further, presence of prion protein-derived CPPs significantly prolonged the time before infection was manifested when infecting GT1-1 cells with scrapie. Treatment with other CPPs (penetratin, transportan-10, or poly-L-arginine) or prion protein-derived peptides lacking CPP function (mPr(23-28), mPrP(19-30), or mPrP(23-50)) had no effect on PrPSc levels. The results suggest a mechanism by which the signal sequence guides the prion protein-derived CPP into a cellular compartment, where the basic segment binds specifically to PrPSc and disables formation of prions.	[Lofgren, Kajsa; Wahlstrom, Anna; Langel, Ulo; Graslund, Astrid] Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs, SE-10691 Stockholm, Sweden; [Lundberg, Pontus; Langel, Ulo] Stockholm Univ, Dept Neurochem & Neurotoxicol, SE-10691 Stockholm, Sweden	Stockholm University; Stockholm University	Graslund, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs, SE-10691 Stockholm, Sweden.	astrid@dbb.su.se		Langel, Ulo/0000-0001-6107-0844				Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Gilch S, 2007, J MOL BIOL, V371, P362, DOI 10.1016/j.jmb.2007.05.052; Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i; Gu YP, 2003, NEUROBIOL DIS, V12, P133, DOI 10.1016/S0969-9961(02)00014-1; Gyllberg H, 2006, FEBS LETT, V580, P2603, DOI 10.1016/j.febslet.2006.03.092; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Horonchik L, 2005, J BIOL CHEM, V280, P17062, DOI 10.1074/jbc.M500122200; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; Lasmezas CI, 2003, BRIT MED BULL, V66, P61, DOI 10.1093/bmb/66.1.61; Lau AL, 2007, P NATL ACAD SCI USA, V104, P11551, DOI 10.1073/pnas.0704260104; Letoha T, 2005, J PEPT SCI, V11, P805, DOI 10.1002/psc.678; Lindegren H, 2003, J NEUROSCI RES, V71, P291, DOI 10.1002/jnr.10473; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Lundberg P, 2002, BIOCHEM BIOPH RES CO, V299, P85, DOI 10.1016/S0006-291X(02)02595-0; Magzoub M, 2004, Q REV BIOPHYS, V37, P147, DOI 10.1017/S0033583505004014; Magzoub M, 2005, BIOCHEMISTRY-US, V44, P14890, DOI 10.1021/bi051356w; Magzoub M, 2005, BBA-BIOMEMBRANES, V1716, P126, DOI 10.1016/j.bbamem.2005.09.009; Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065; Oglecka K, 2008, BBA-BIOMEMBRANES, V1778, P206, DOI 10.1016/j.bbamem.2007.09.034; Ostlund P, 2001, J BIOL CHEM, V276, P36110, DOI 10.1074/jbc.M105710200; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Schatzl HM, 1997, J VIROL, V71, P8821; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; Supattapone S, 2004, J MOL MED, V82, P348, DOI 10.1007/s00109-004-0534-3; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Taylor DR, 2006, MOL MEMBR BIOL, V23, P89, DOI 10.1080/09687860500449994; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604; Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010	32	27	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2177	2184		10.1096/fj.07-099549	http://dx.doi.org/10.1096/fj.07-099549			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18296502				2022-12-28	WOS:000257292500010
J	Visanji, NP; Orsi, A; Johnston, TH; Howson, PA; Dixon, K; Callizot, N; Brotchie, JM; Rees, DD				Visanji, Naomi P.; Orsi, Antonia; Johnston, Tom H.; Howson, Patrick A.; Dixon, Kimberly; Callizot, Noelle; Brotchie, Jonathan M.; Rees, Daryl D.			PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease	FASEB JOURNAL			English	Article						BDNF; GDNF; neurorestorative; striatum; Cogane	NIGRAL DOPAMINE NEURONS; SUBSTANTIA-NIGRA; FUNCTIONAL RECOVERY; PRIMATE MODELS; RAT MODEL; CELL-CULTURES; GENE-TRANSFER; IN-VIVO; 2 PARTS; GDNF	Many experimental data support the enhancement of neurotrophic factors as a means to modify neurodegeneration in Parkinson's disease. However, the translation of this to the clinic has proven problematic. This is likely due to the complex nature of the surgical gene delivery and cell-based approaches adopted to deliver proteinaceous neurotrophic factors to targets within the central nervous system. We investigated the ability of a novel, orally active, nonpeptide neurotrophic factor inducer, PYM50028 (Cogane), to restore dopaminergic function after 1-methyl-4-phenylpyridinium (MPP+) -induced damage to mesencephalic neurons in vitro and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -lesioned mice. In rat mesencephalic neurons, administration of PYM50028, either before or after MPP+, significantly prevented and reversed both MPP+ -induced neuronal atrophy and cell loss. These effects were potent and of a magnitude equivalent to those achieved by a combination of brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF). Oral administration of PYM50028 (10 mg/kg/day for 60 days) to MPTP-lesioned mice, commencing after a striatal impairment was evident, resulted in a significant elevation of striatal GDNF (297%) and BDNF (511%), and attenuated the loss of striatal dopaminergic transporter levels and dopaminergic neurons in the substantia nigra. PYM50028 did not inhibit monoamine oxidase B in vitro, nor did it alter brain levels of MPP+ in vivo. PYM50028 has neuroprotective and neurorestorative potential and is in clinical development for the treatment of neurodegenerative disorders, including Parkinson's disease.	[Visanji, Naomi P.; Johnston, Tom H.; Dixon, Kimberly; Brotchie, Jonathan M.] Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; [Orsi, Antonia; Howson, Patrick A.; Callizot, Noelle; Rees, Daryl D.] Phytopharm Plc, Godmanchester, Cambs, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Brotchie, JM (corresponding author), Toronto Western Res Inst, MCL 11-419, Toronto, ON M5T 2S8, Canada.	brotchie@uhnres.utoronto.ca	Visanji, Naomi P/AAW-4618-2021; Johnston, Tom H/D-2531-2018	Johnston, Tom H/0000-0002-1537-8175; Brotchie, Jonathan/0000-0003-2337-0816; Visanji, Naomi/0000-0001-5968-7845				ALTAR CA, 1994, J NEUROCHEM, V63, P1021; Bjorklund A, 2003, LANCET NEUROL, V2, P437, DOI 10.1016/S1474-4422(03)00442-3; Chauhan NB, 2001, J CHEM NEUROANAT, V21, P277, DOI 10.1016/S0891-0618(01)00115-6; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Dawson TM, 2002, NAT NEUROSCI, V5, P1058, DOI 10.1038/nn941; Ericson C, 2005, EUR J NEUROSCI, V22, P2755, DOI 10.1111/j.1460-9568.2005.04503.x; Eslamboli A, 2005, REV NEUROSCIENCE, V16, P303; Fabbrini G, 2007, MOVEMENT DISORD, V22, P1379, DOI 10.1002/mds.21475; FADDA E, 1993, NEUROSCI LETT, V159, P147, DOI 10.1016/0304-3940(93)90820-B; Feng LY, 1999, MOL BRAIN RES, V66, P62, DOI 10.1016/S0169-328X(99)00015-7; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Gerhardt GA, 1999, BRAIN RES, V817, P163, DOI 10.1016/S0006-8993(98)01244-X; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Grandoso L, 2007, INT J PHARMACEUT, V343, P69, DOI 10.1016/j.ijpharm.2007.05.027; Grondin R, 2002, BRAIN, V125, P2191, DOI 10.1093/brain/awf234; Hung H C, 1996, Brain Res Mol Brain Res, V41, P14; Jackson-Lewis V, 2007, NAT PROTOC, V2, P141, DOI 10.1038/nprot.2006.342; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; Klein RL, 1999, BRAIN RES, V847, P314, DOI 10.1016/S0006-8993(99)02116-2; Kobori N, 2006, BRAIN RES, V1086, P142, DOI 10.1016/j.brainres.2006.02.111; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Levivier M, 1995, J NEUROSCI, V15, P7810, DOI 10.1523/jneurosci.15-12-07810.1995; Lotharius J, 1999, J NEUROSCI, V19, P1284; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; McBride JL, 2006, P NATL ACAD SCI USA, V103, P9345, DOI 10.1073/pnas.0508875103; Nishio T, 1998, NEUROREPORT, V9, P2847, DOI 10.1097/00001756-199808240-00030; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; Oiwa Y, 2006, NEUROL MED-CHIR, V46, P267, DOI 10.2176/nmc.46.267; Ostergaard K, 1996, EXP NEUROL, V142, P340, DOI 10.1006/exnr.1996.0203; Palfi S, 2002, J NEUROSCI, V22, P4942, DOI 10.1523/JNEUROSCI.22-12-04942.2002; Rosenblad C, 2000, EXP NEUROL, V161, P503, DOI 10.1006/exnr.1999.7296; Saavedra A, 2005, FREE RADICAL BIO MED, V39, P1611, DOI 10.1016/j.freeradbiomed.2005.08.005; SCHINELLI S, 1988, J NEUROCHEM, V50, P1900, DOI 10.1111/j.1471-4159.1988.tb02495.x; Sherer TB, 2006, MOVEMENT DISORD, V21, P136, DOI 10.1002/mds.20861; Singh Shalini, 2006, Indian Journal of Experimental Biology, V44, P699; Slevin JT, 2007, J NEUROSURG, V106, P614, DOI 10.3171/jns.2007.106.4.614; Son JH, 1999, J NEUROSCI, V19, P10, DOI 10.1523/JNEUROSCI.19-01-00010.1999; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0	41	64	72	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2488	2497		10.1096/fj.07-095398	http://dx.doi.org/10.1096/fj.07-095398			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18364399				2022-12-28	WOS:000257292500040
J	Yang, KP; Guan, HY; Arany, E; Hill, DJ; Cao, XA				Yang, Kaiping; Guan, Haiyan; Arany, Edith; Hill, David J.; Cao, Xiang			Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor	FASEB JOURNAL			English	Article						obesity; Zucker rat; adipogenesis; 3T3-L1 cells	11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; LOW-PROTEIN-DIET; MESSENGER-RNA; METABOLIC SYNDROME; GENE-EXPRESSION; MOLECULAR PATHWAYS; KINASE ACTIVATION; OBESE-PATIENTS; ADULT DISEASE; BODY-WEIGHT	Neuropeptide Y (NPY) is synthesized in neural tissue of the central and peripheral nervous systems and has a number of important functions besides regulating appetite and energy homeostasis. Here we identify a novel site of NPY biosynthesis and a role for NPY in promoting proliferation of adipocyte precursor cells. We show that NPY mRNA is not only expressed in visceral adipose tissue (VAT) but that its levels are up-regulated 6-fold in our early-life programmed rat model of increased visceral adiposity. This is accompanied by a parallel rise in NPY protein, demonstrating that VAT is a novel peripheral site of NPY biosynthesis. Furthermore, NPY mRNA expression is also elevated > 2-fold in VAT of obese Zucker rats. Importantly, NPY stimulates proliferation of primary rat preadipocytes as well as 3T3-L1 preadipocytes in vitro. This mitogenic effect appears to be mediated by the Y1 receptor and involves the activation of extracellular related kinase 1/2. In addition, insulin and glucocorticoid up-regulate VAT NPY expression in lean but not obese Zucker rats. Taken together, these results suggest that an enhanced local expression of NPY within VAT may be a common feature of and contribute to the molecular mechanisms underlying increased visceral adiposity.	[Yang, Kaiping; Guan, Haiyan; Cao, Xiang] Victoria Res Labs, Childrens Hlth Res Inst, London, ON N6A 4G5, Canada; [Yang, Kaiping; Guan, Haiyan; Cao, Xiang] Univ Western Ontario, Dept Obstet & Gynecol, London, ON, Canada; [Yang, Kaiping; Guan, Haiyan; Arany, Edith; Hill, David J.; Cao, Xiang] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Arany, Edith; Hill, David J.] Univ Western Ontario, Lawson Hlth Res Inst, Dept Med, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Yang, KP (corresponding author), Victoria Res Labs, Childrens Hlth Res Inst, Rm A5-132,Westminster Campus,800 Commissioners R, London, ON N6A 4G5, Canada.	kyang@uwo.ca	Arany, Edith/AAK-2159-2020; Arany, Edith/C-3464-2013; Hill, David J/G-3302-2011	Arany, Edith/0000-0001-9994-8958; Hill, David J/0000-0002-2490-5678				Bartness TJ, 1998, AM J PHYSIOL-REG I, V275, pR1399, DOI 10.1152/ajpregu.1998.275.5.R1399; BESTETTI GE, 1990, ENDOCRINOLOGY, V126, P1880, DOI 10.1210/endo-126-4-1880; Bowers RR, 2004, AM J PHYSIOL-REG I, V286, pR1167, DOI 10.1152/ajpregu.00558.2003; Bradley RL, 2005, OBES RES, V13, P653, DOI 10.1038/oby.2005.73; Burns SP, 1997, J CLIN INVEST, V100, P1768, DOI 10.1172/JCI119703; Byrne CD, 2000, J CLIN PATHOL, V53, P822, DOI 10.1136/jcp.53.11.822; Cho YR, 2004, BIOCHEM BIOPH RES CO, V314, P773, DOI 10.1016/j.bbrc.2003.12.170; Chronwall BA, 2004, PEPTIDES, V25, P359, DOI 10.1016/j.peptides.2004.02.013; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; Desbriere R, 2006, OBESITY, V14, P794, DOI 10.1038/oby.2006.92; ERICSSON A, 1991, EXP CELL RES, V192, P604, DOI 10.1016/0014-4827(91)90082-6; Fliers E, 2003, J NEUROENDOCRINOL, V15, P1005, DOI 10.1046/j.1365-2826.2003.01096.x; Foster MT, 2006, AM J PHYSIOL-REG I, V291, pR1630, DOI 10.1152/ajpregu.00197.2006; Froguel P, 2001, EXP BIOL MED, V226, P991, DOI 10.1177/153537020122601105; FROST SC, 1985, J BIOL CHEM, V260, P2646; Gomez-Sanchez EP, 2005, AM J PHYSIOL-ENDOC M, V288, pE342, DOI 10.1152/ajpendo.00355.2004; Guan HY, 2005, AM J PHYSIOL-ENDOC M, V288, pE663, DOI 10.1152/ajpendo.00461.2004; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Hansel DE, 2001, NATURE, V410, P940, DOI 10.1038/35073601; Heise T, 2007, DIABETES OBES METAB, V9, P648, DOI 10.1111/j.1463-1326.2007.00756.x; HIGUCHI H, 1988, J BIOL CHEM, V263, P6288; Hofbauer K, 2002, INT J OBESITY, V26, pS18, DOI 10.1038/sj.ijo.0802124; Holness MJ, 2000, BIOCHEM J, V349, P657, DOI 10.1042/bj3490657; Joanette EA, 2004, ENDOCRINOLOGY, V145, P3004, DOI 10.1210/en.2003-0796; Julan L, 2005, ENDOCRINOLOGY, V146, P1482, DOI 10.1210/en.2004-1357; KALINYAK JE, 1989, J CLIN INVEST, V84, P1843, DOI 10.1172/JCI114370; Kalra SP, 2004, NEUROPEPTIDES, V38, P201, DOI 10.1016/j.npep.2004.06.003; Keffel S, 1999, J PHARMACOL EXP THER, V291, P1172; Kos K, 2007, AM J PHYSIOL-ENDOC M, V293, pE1335, DOI 10.1152/ajpendo.00333.2007; Kraiczi H, 1997, PEPTIDES, V18, P1597, DOI 10.1016/S0196-9781(97)00248-9; Krysiak R, 2001, J PEPT SCI, V7, P571, DOI 10.1002/psc.354; Kuo LE, 2007, NAT MED, V13, P803, DOI 10.1038/nm1611; Lindsay RS, 2003, J CLIN ENDOCR METAB, V88, P2738, DOI 10.1210/jc.2002-030017; Liu RH, 2002, INT J OBESITY, V26, P318, DOI 10.1038/sj.ijo.0801924; LUNDBERG JM, 1985, BIOCHEM BIOPH RES CO, V133, P30, DOI 10.1016/0006-291X(85)91837-6; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Montagne CT, 2000, DIABETES, V49, P883, DOI 10.2337/diabetes.49.6.883; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Osmond C, 2000, ENVIRON HEALTH PERSP, V108, P545, DOI 10.1289/ehp.00108s3545; Ozanne SE, 2004, CLIN SCI, V106, P141, DOI 10.1042/CS20030278; Ozanne SE, 1996, AM J PHYSIOL-ENDOC M, V271, pE1128, DOI 10.1152/ajpendo.1996.271.6.E1128; Ozanne SE, 2001, BRIT MED BULL, V60, P143, DOI 10.1093/bmb/60.1.143; Ozanne SE, 1996, AM J PHYSIOL-ENDOC M, V270, pE559, DOI 10.1152/ajpendo.1996.270.4.E559; Paulmyer-Lacroix O, 2002, J CLIN ENDOCR METAB, V87, P2701, DOI 10.1210/jc.87.6.2701; Pedrazzini T, 2003, CELL MOL LIFE SCI, V60, P350, DOI 10.1007/s000180300029; Pellieux C, 2000, P NATL ACAD SCI USA, V97, P1595, DOI 10.1073/pnas.030533197; Petrik J, 1999, ENDOCRINOLOGY, V140, P4861, DOI 10.1210/en.140.10.4861; Petry CJ, 2001, MOL CELL ENDOCRINOL, V185, P81, DOI 10.1016/S0303-7207(01)00627-X; Petry CJ, 1997, CLIN SCI, V93, P147, DOI 10.1042/cs0930147; Pons J, 2003, CAN J PHYSIOL PHARM, V81, P177, DOI 10.1139/Y02-166; Purdy LP, 1996, DIABETOLOGIA, V39, P1126; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ruscica M, 2006, ENDOCRINOLOGY, V147, P1466, DOI 10.1210/en.2005-0925; Serradeil-Le Gal C, 2000, FEBS LETT, V475, P150, DOI 10.1016/S0014-5793(00)01649-5; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003-0031; Tomlinson JW, 2002, J CLIN ENDOCR METAB, V87, P5630, DOI 10.1210/jc.2002-020687; Turtzo LC, 2001, P NATL ACAD SCI USA, V98, P12385, DOI 10.1073/pnas.231478898; VALET P, 1990, J CLIN INVEST, V85, P291, DOI 10.1172/JCI114425; Wake DJ, 2003, J CLIN ENDOCR METAB, V88, P3983, DOI 10.1210/jc.2003-030286; Youngstrom TG, 1998, AM J PHYSIOL-REG I, V275, pR1488, DOI 10.1152/ajpregu.1998.275.5.R1488; Zhang T, 2007, J CELL BIOCHEM, V101, P381, DOI 10.1002/jcb.21176; Zukowska-Grojec Z, 1998, REGUL PEPTIDES, V75-6, P231, DOI 10.1016/S0167-0115(98)00073-1	65	123	131	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2452	2464		10.1096/fj.07-100735	http://dx.doi.org/10.1096/fj.07-100735			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18323405				2022-12-28	WOS:000257292500037
J	Chen, GL; Zhou, XY; Nicolaou, P; Rodriguez, P; Song, GJ; Mitton, B; Pathak, A; Zachariah, A; Fan, GC; Dorn, GW; Kranias, EG				Chen, Guoli; Zhou, Xiaoyang; Nicolaou, Persoulla; Rodriguez, Patricia; Song, Guojie; Mitton, Bryan; Pathak, Anand; Zachariah, Amit; Fan, Guo-Chang; Dorn, Gerald W., II; Kranias, Evangelia G.			A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation	FASEB JOURNAL			English	Article						cardiac function; phospholamban; heart failure	PROTEIN PHOSPHATASE INHIBITOR-1; HEART-FAILURE; TROPONIN-I; SIGNAL-TRANSDUCTION; HORMONAL-REGULATION; CARDIAC MYOCYTES; BINDING PROTEIN; RABBIT HEART; PHOSPHORYLATION; RECEPTORS	Aberrant beta-adrenergic signaling and depressed calcium homeostasis, associated with an imbalance of protein kinase A and phosphatase-1 activities, are hallmarks of heart failure. Phosphatase-1 is restrained by its endogenous inhibitor, protein phosphatase inhibitor-1 (PPI-1). We assessed 352 normal subjects, along with 959 patients with heart failure and identified a polymorphism in PPI-1 (G147D) exclusively in black subjects. To determine whether the G147D variant could affect cardiac function, we infected adult cardiomyocytes with adenoviruses expressing D147 or wild-type (G147) PPI-1. Under basal conditions, there were no significant differences in fractional shortening or contraction or relaxation rates. However, the enhancement of contractile parameters after isoproterenol stimulation was significantly blunted in D147 compared with G147 and control myocytes. Similar findings were observed in calcium kinetics. The attenuated beta-agonist response was associated with decreased (50%) phosphorylation of phospholamban (PLN) at serine 16, whereas phosphorylation of troponin I and ryanodine receptor was unaltered. These findings suggest that the human G147D PPI-1 can attenuate responses of cardiomyocytes to beta-adrenergic agonists by decreasing PLN phosphorylation and therefore may contribute to deteriorated function in heart failure.	[Chen, Guoli; Zhou, Xiaoyang; Nicolaou, Persoulla; Rodriguez, Patricia; Song, Guojie; Mitton, Bryan; Pathak, Anand; Zachariah, Amit; Fan, Guo-Chang; Kranias, Evangelia G.] Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; [Dorn, Gerald W., II] Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; [Song, Guojie] Jiaxing Univ Coll Med, Jiaxing, Peoples R China; [Kranias, Evangelia G.] Acad Athens, Fdn Biomed Res, Ctr Basic Res, Div Mol Biol, Athens, Greece	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Jiaxing University; Academy of Athens	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	litsa.kranias@uc.edu	Fan, Guo-Chang/E-1153-2012	Fan, Guo-Chang/0000-0002-0439-8277	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087861, P50HL077101, R01HL064018] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26507, P50 HL077101, R01 HL064018, HL-77101, HL-64018, R01 HL087861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD Z, 1989, J BIOL CHEM, V264, P3859; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Chu GX, 2000, J BIOL CHEM, V275, P38938, DOI 10.1074/jbc.M004079200; DEPAOLIROACH AA, 2003, HDB CELL SIGNALING, P613; El-Armouche A, 2004, CARDIOVASC RES, V61, P87, DOI 10.1016/j.cardiores.2003.11.005; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Fan GC, 2004, AM J PHYSIOL-HEART C, V287, pH1705, DOI 10.1152/ajpheart.01211.2003; Fan GC, 2004, CIRC RES, V94, P1474, DOI 10.1161/01.RES.0000129179.66631.00; Feldman DS, 2005, NAT CLIN PRACT CARD, V2, P475, DOI 10.1038/ncpcardio0309; GAUTEL M, 1995, EMBO J, V14, P1952, DOI 10.1002/j.1460-2075.1995.tb07187.x; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; Gupta RC, 2003, AM J PHYSIOL-HEART C, V285, pH2373, DOI 10.1152/ajpheart.00442.2003; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HOFMANN PA, 1994, CIRC RES, V74, P718, DOI 10.1161/01.RES.74.4.718; KRANIAS EG, 1982, NATURE, V298, P182, DOI 10.1038/298182a0; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; Marian AJ, 2006, J MOL CELL CARDIOL, V41, P11, DOI 10.1016/j.yjmcc.2006.04.001; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Pathak A, 2005, CIRC RES, V96, P756, DOI 10.1161/01.RES.0000161256.85833.fa; Rodriguez P, 2007, AM J PHYSIOL-HEART C, V293, pH762, DOI 10.1152/ajpheart.00104.2007; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Weiser DC, 2004, J BIOL CHEM, V279, P48904, DOI 10.1074/jbc.M404416200	25	14	14	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1790	1796		10.1096/fj.07-097428	http://dx.doi.org/10.1096/fj.07-097428			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18192322	Green Accepted			2022-12-28	WOS:000256352700019
J	Grumolato, L; Ghzili, H; Montero-Hadjadje, M; Gasman, S; Lesage, J; Tanguy, Y; Galas, L; Ait-Ali, D; Leprince, J; Guerineau, NC; Elkahloun, AG; Fournier, A; Vieau, D; Vaudry, H; Anouar, Y				Grumolato, Luca; Ghzili, Hafida; Montero-Hadjadje, Maite; Gasman, Stephane; Lesage, Jean; Tanguy, Yannick; Galas, Ludovic; Ait-Ali, Djida; Leprince, Jerome; Guerineau, Nathalie C.; Elkahloun, Abdel G.; Fournier, Alain; Vieau, Didier; Vaudry, Hubert; Anouar, Youssef			Selenoprotein T is a PACAP-regulated gene involved in intracellular Ca2+ mobilization and neuroendocrine secretion	FASEB JOURNAL			English	Article						cell differentiation; pituitary adenylate cyclase-activating polypeptide; cAMP; PC12 cells	CYCLASE-ACTIVATING POLYPEPTIDE; PHEOCHROMOCYTOMA CELLS; ENDOPLASMIC-RETICULUM; MUSCULAR-DYSTROPHY; SIGNALING PATHWAYS; NEUROPEPTIDE-Y; NEURAL CREST; PC12 CELLS; CYCLIC-AMP; G-PROTEIN	Selenoproteins contain the essential trace element selenium, the deficiency of which is associated with cancer or accelerated aging. Although selenoproteins are thought to be instrumental for the effects of selenium, the biological function of many of these proteins remains unknown. Here, we studied the role of selenoprotein T (SelT), a selenocysteine (Sec)-containing protein with no known function, which we have identified as a novel target gene of the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) during PC12 cell differentiation. SelT was found to be ubiquitously expressed throughout embryonic development and in adulthood in rat. Immunocytochemical analysis revealed that SelT is mainly localized to the endoplasmic reticulum through a hydrophobic domain. PACAP and cAMP induced a rapid and long-lasting increase in SelT gene expression in PC12 cells, in a Ca2+-dependent manner. These results suggested a possible role of SelT in PACAP signaling during PC12 cell differentiation. Indeed, overexpression of SelT in PC12 cells provoked an increase in the concentration of intracellular Ca2+ ([Ca2+](i)) that was dependent on the Sec residue. Conversely, SelT gene knockdown inhibited the PACAP-induced increase in [Ca2+] i and reduced hormone secretion. These findings demonstrate the implication of a selenoprotein in the regulation of Ca2+ homeostasis and neuroendocrine secretion in response to a cAMP-stimulating trophic factor.	[Grumolato, Luca; Ghzili, Hafida; Montero-Hadjadje, Maite; Tanguy, Yannick; Galas, Ludovic; Ait-Ali, Djida; Leprince, Jerome; Vaudry, Hubert; Anouar, Youssef] Univ Rouen, INSERM, Lab Cellular & Mol Neuroendocrinol, CNRS,European Inst Peptide Res,IFRMP 23,UA,U413, F-76821 Mont St Aignan, France; [Gasman, Stephane] Univ Strasbourg, CNRS, Inst Neurosci Cellulaires & Integrat,LC2, Dept Neurotransmiss & Neuroendocrine Secret,UMR 7, Strasbourg, France; [Lesage, Jean] Univ Lille 1, Perinatal Stress Unit, Dept Adaptat Neurosci & Physiol, F-59655 Villeneuve Dascq, France; [Guerineau, Nathalie C.] Univ Montpellier I, CNRS, INSERM, Funct Genom Inst,Dept Endocrinol,UMR5203,U661, Montpellier, France; [Guerineau, Nathalie C.] Univ Montpellier 2, Montpellier, France; [Elkahloun, Abdel G.] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; [Fournier, Alain] Univ Quebec, Inst Natl Rech Sci, Inst Armand Frappier, Montreal, PQ H3C 3P8, Canada	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Quebec; Institut national de la recherche scientifique (INRS); University of Quebec Montreal	Anouar, Y (corresponding author), Univ Rouen, INSERM, Lab Cellular & Mol Neuroendocrinol, CNRS,European Inst Peptide Res,IFRMP 23,UA,U413, F-76821 Mont St Aignan, France.	youssef.anouar@univ-rouen.fr	lesage, jean/R-5019-2018; stéphane, gasman/Q-1145-2019; Grumolato, Luca/A-1697-2015; Leprince, Jerome/N-9083-2017; Montero-Hadjadje, Maite/AAC-5692-2019; Anouar, Youssef/F-9683-2017; Gasman, Stephane/D-5113-2017; galas, ludovic/A-2500-2014	lesage, jean/0000-0002-6329-1613; stéphane, gasman/0000-0001-8415-1276; Grumolato, Luca/0000-0001-8231-3032; Montero-Hadjadje, Maite/0000-0001-8859-893X; Gasman, Stephane/0000-0001-8415-1276; vieau, didier/0000-0002-3254-3662; Leprince, Jerome/0000-0002-7814-9927; Guerineau, Nathalie/0000-0003-2517-4210	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZICHG200346, Z01HG200346] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Baqui MMA, 2000, ENDOCRINOLOGY, V141, P4309, DOI 10.1210/en.141.11.4309; Bilodeau ML, 2000, MOL CELL BIOL, V20, P3004, DOI 10.1128/MCB.20.9.3004-3014.2000; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DiCicco-Bloom E, 2000, DEV BIOL, V219, P197, DOI 10.1006/dbio.2000.9604; Diwadkar-Navsariwala V, 2006, P NATL ACAD SCI USA, V103, P8179, DOI 10.1073/pnas.0508218103; Ferguson AD, 2006, J BIOL CHEM, V281, P3536, DOI 10.1074/jbc.M511386200; Ferreiro A, 2002, AM J HUM GENET, V71, P739, DOI 10.1086/342719; Galas L, 2002, ENDOCRINOLOGY, V143, P1686, DOI 10.1210/en.143.5.1686; Gasman S, 2004, MOL BIOL CELL, V15, P520, DOI 10.1091/mbc.E03-06-0402; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grumolato L, 2003, ENDOCRINOLOGY, V144, P2368, DOI 10.1210/en.2002-0106; Grumolato L, 2003, EUR J NEUROSCI, V17, P71, DOI 10.1046/j.1460-9568.2003.02426.x; Guirland C, 2003, J NEUROSCI, V23, P2274; Hamelink C, 2002, J NEUROSCI, V22, P5310; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Higo T, 2005, CELL, V120, P85, DOI 10.1016/j.cell.2004.11.048; Hu YJ, 2003, CANCER RES, V63, P3347; Hu YJ, 2001, CANCER RES, V61, P2307; Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2003, MOL CELL BIOL, V23, P1477, DOI 10.1128/MCB.23.5.1477-1488.2003; Lamouche S, 1999, AM J PHYSIOL-REG I, V276, pR162, DOI 10.1152/ajpregu.1999.276.1.R162; Lazarovici P, 1998, MOL PHARMACOL, V54, P547, DOI 10.1124/mol.54.3.547; Lesage J, 2001, ENDOCRINOLOGY, V142, P1692, DOI 10.1210/en.142.5.1692; Li Y, 2004, J CELL BIOL, V164, P35, DOI 10.1083/jcb.200307010; Mabuchi T, 2004, J NEUROSCI, V24, P7283, DOI 10.1523/JNEUROSCI.0983-04.2004; MAY V, 1995, J NEUROCHEM, V65, P978; Moghadaszadeh B, 2001, NAT GENET, V29, P17, DOI 10.1038/ng713; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Osipenko ON, 2000, J BIOL CHEM, V275, P16626, DOI 10.1074/jbc.M909636199; Petit N, 2003, HUM MOL GENET, V12, P1045, DOI 10.1093/hmg/ddg115; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Sakai Y, 2002, REGUL PEPTIDES, V109, P149, DOI 10.1016/S0167-0115(02)00198-2; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; Tanaka K, 1996, ENDOCRINOLOGY, V137, P956, DOI 10.1210/en.137.3.956; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Taupenot L, 1999, HYPERTENSION, V34, P1152, DOI 10.1161/01.HYP.34.5.1152; Thisse C, 2003, GENE EXPR PATTERNS, V3, P525, DOI 10.1016/S1567-133X(03)00054-1; Turquier V, 2001, MOL PHARMACOL, V60, P42, DOI 10.1124/mol.60.1.42; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2002, J NEUROCHEM, V83, P1272, DOI 10.1046/j.1471-4159.2002.01242.x; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; Zheng Y, 2005, J CELL PHYSIOL, V205, P97, DOI 10.1002/jcp.20378	50	110	121	3	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1756	1768		10.1096/fj.06-075820	http://dx.doi.org/10.1096/fj.06-075820			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198219				2022-12-28	WOS:000256352700016
J	Khan, AA; Mao, XO; Banwait, S; DerMardirossian, CM; Bokoch, GM; Jin, KL; Greenberg, DA				Khan, Adil A.; Mao, Xiao Ou; Banwait, Surita; DerMardirossian, Celine M.; Bokoch, Gary M.; Jin, Kunlin; Greenberg, David A.			Regulation of hypoxic neuronal death signaling by neuroglobin	FASEB JOURNAL			English	Article						soma; polarity; DISC; death-inducing signaling complex	CELL-DEATH; APOPTOSIS; RECEPTOR; RAFTS; ACTIVATION; MEDIATION; CHANNELS	The signal transduction pathways involved in neuronal death are not well understood. Neuroglobin (Ngb), a recently discovered vertebrate globin expressed predominantly in the brain, shows increased expression in neurons in response to oxygen deprivation and protects neurons from ischemic and hypoxic death. The mechanism of this neuroprotection is unclear. We examined the surface distribution of raft membrane microdomains in cortical neuron cultures during hypoxia using the raft marker cholera toxin B (CTx-B) subunit. Mechanistically, we demonstrate that hypoxia induces rapid polarization of somal membranes and aggregation of microdomains with the subjacent mitochondrial network. This signaling complex is formed well before neurons commit to die, consistent with an early role in death signal transduction. Neurons from Ngb-overexpressing transgenic (Ngb-Tg) mice do not undergo microdomain polarization or mitochondrial aggregation in response to, and are resistant to death from hypoxia. We link the protective actions of Ngb to inhibition of Pak1 kinase activity and Rac1-GDP-dissociation inhibitor disassociation, and inhibition of actin assembly and death-signaling module polarization.	[Khan, Adil A.; Mao, Xiao Ou; Banwait, Surita; Jin, Kunlin; Greenberg, David A.] Buck Inst Age Res, Novato, CA 94945 USA; [DerMardirossian, Celine M.; Bokoch, Gary M.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA USA	Buck Institute for Research on Aging; Scripps Research Institute	Khan, AA (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	akhan@buckinstitute.org	DerMardirossian, Celine/P-1020-2015		NINDS NIH HHS [P01 NS035965-080002, NS35965, P01 NS035965] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035965] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Conforti L, 2000, J PHYSIOL-LONDON, V524, P783, DOI 10.1111/j.1469-7793.2000.00783.x; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Friedman JE, 1998, NEUROSCIENCE, V82, P421; Furne C, 2006, P NATL ACAD SCI USA, V103, P4128, DOI 10.1073/pnas.0507864103; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haga N, 2003, ONCOGENE, V22, P5579, DOI 10.1038/sj.onc.1206576; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Khan AA, 2007, P NATL ACAD SCI USA, V104, P19114, DOI 10.1073/pnas.0706167104; Khan AA, 2006, P NATL ACAD SCI USA, V103, P17944, DOI 10.1073/pnas.0607497103; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Namura S, 1998, J NEUROSCI, V18, P3659; Pal S, 2003, J NEUROSCI, V23, P4798; Raman N, 1999, AM J PHYSIOL-CELL PH, V276, pC1312, DOI 10.1152/ajpcell.1999.276.6.C1312; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Vallone B, 2004, P NATL ACAD SCI USA, V101, P17351, DOI 10.1073/pnas.0407633101; VAN AL, 1997, GENE DEV, V11, P2295; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Zhu LP, 2000, CELL CALCIUM, V28, P107, DOI 10.1054/ceca.2000.0138	35	73	80	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1737	1747		10.1096/fj.07-100784	http://dx.doi.org/10.1096/fj.07-100784			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198211	Green Accepted			2022-12-28	WOS:000256352700014
J	Bard, JD; Gelebart, P; Amin, HM; Young, LC; Ma, Y; Lai, R				Bard, J. Dien; Gelebart, P.; Amin, H. M.; Young, L. C.; Ma, Y.; Lai, R.			Signal transducer and activator of transcription 3 is a transcriptional factor regulating the gene expression of SALL4	FASEB JOURNAL			English	Article						cell signaling; luciferase assay; chromatin immunoprecipitation	EMBRYONIC STEM-CELLS; LEUKEMIA INHIBITORY FACTOR; BREAST-CANCER; SELF-RENEWAL; FACTOR-RECEPTOR; MOUSE EMBRYOS; ONCOSTATIN M; DNA-BINDING; IN-VITRO; ES CELLS	Both signal transducer and activator of transcription 3 (STAT3) and SALL4 are important in maintaining the pluripotent and self-renewal state of embryonic stem cells. We hypothesized that STAT3, a latent transcriptional factor, may regulate the gene expression of SALL4. In support of this hypothesis, DNA sequence analysis of the SALL4 gene promoter revealed four putative STAT3-binding sites. Using a SALL4-luciferase reporter gene assay, we found that modulation of the STAT3 activity significantly up-regulated the luciferase activity. By chromatin immunoprecipitation, the segment of the SALL4 promoter showing the highest affinity to STAT3 was localized to -366 to -163, in which there was only one putative STAT3 binding site starting at -199. Site-directed mutagenesis of all four putative STAT3-binding sites in the SALL4 promoter significantly reduced its responsiveness to STAT3, although the most dramatic effect was seen at the binding site starting at -199. We further tested the functional relationship between STAT3 and SALL4 using MDA-MB-231, a breast cell line carrying constitutive SALL4 expression and STAT3 activity. Down-regulation of the STAT3 activity using a dominant-negative construct resulted in a significant decrease in the expression of SALL4. To conclude, our data suggest that STAT3 and SALL4 probably cooperate in both physiological and pathological states.-Dien Bard, J., Gelebart, P., Amin, H. M., Young, L. C., Ma, Y., Lai, R. Signal transducer and activator of transcription 3 is a transcriptional factor regulating the gene expression of SALL4. FASEB J. 23, 1405-1414 (2009)	[Bard, J. Dien; Gelebart, P.; Young, L. C.; Lai, R.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 1Z2, Canada; [Amin, H. M.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Ma, Y.] Nevada Canc Ctr, Dept Hematopathol, Las Vegas, NV USA	University of Alberta; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego	Lai, R (corresponding author), Univ Alberta, Dept Lab Med & Pathol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	raymondl@cancerboard.ab.ca	Young, Leah/AAN-3579-2020; Young, Leah C/B-9051-2012; Gelebart, Pascal/AAI-1439-2020	Young, Leah C/0000-0001-7156-1006; Gelebart, Pascal/0000-0003-2434-8987	Canadian Institute of Health Research; Canadian Cancer Society; Lymphoma Research Foundation of Canada Fellowship Award	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Lymphoma Research Foundation of Canada Fellowship Award	We thank Dr. Hanan Armanious for her technical assistance. This study was supported by research grants from the Canadian Institute of Health Research and the Canadian Cancer Society awarded to R.L. P.G. is a recipient of a Lymphoma Research Foundation of Canada Fellowship Award.	Al-Baradie R, 2002, AM J HUM GENET, V71, P1195, DOI 10.1086/343821; Amin HM, 2003, ARCH PATHOL LAB MED, V127, P424; Amin HM, 2004, ONCOGENE, V23, P5426, DOI 10.1038/sj.onc.1207703; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bohm J, 2006, BIOCHEM BIOPH RES CO, V348, P898, DOI 10.1016/j.bbrc.2006.07.124; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Chambers I, 2004, CLONING STEM CELLS, V6, P386, DOI 10.1089/clo.2004.6.386; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Cui W, 2006, MODERN PATHOL, V19, P1585, DOI 10.1038/modpathol.3800694; Dien J, 2006, AM J PATHOL, V169, P633, DOI 10.2353/ajpath.2006.051109; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Guo Y, 2008, STEM CELLS, V26, P30, DOI 10.1634/stemcells.2007-0401; Kohlhase J, 1996, GENOMICS, V38, P291, DOI 10.1006/geno.1996.0631; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; Qian L, 2006, BIOCHEM BIOPH RES CO, V345, P660, DOI 10.1016/j.bbrc.2006.04.153; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Scholz A, 2003, GASTROENTEROLOGY, V125, P891, DOI 10.1016/S0016-5085(03)01064-3; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Skinnider BF, 1999, HEMATOL ONCOL, V17, P137, DOI 10.1002/(SICI)1099-1069(199912)17:4<137::AID-HON642>3.3.CO;2-M; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481	44	43	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1405	1414		10.1096/fj.08-117721	http://dx.doi.org/10.1096/fj.08-117721			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19151334				2022-12-28	WOS:000266651700017
J	Wu, D; Li, Y; Song, GJ; Zhang, D; Shaw, N; Liu, ZJ				Wu, Dong; Li, Yang; Song, Gaojie; Zhang, David; Shaw, Neil; Liu, Zhi-Jie			Crystal structure of human esterase D: a potential genetic marker of retinoblastoma	FASEB JOURNAL			English	Article						Wilson disease; X-ray; endogenous uveitis; hydrolase fold; carcinoma	S-FORMYLGLUTATHIONE HYDROLASE; LINKAGE; CLONING; MODEL; CHROMOSOME-13; ASSIGNMENT; IDENTITY	Retinoblastoma (RB), a carcinoma of the retina, is caused by mutations in the long arm of chromosome 13, band 13q14. The esterase D (ESD) gene maps at a similar location as the RB gene locus and therefore serves as a potential marker for the prognosis of retinoblastoma. Because very little is known about the structure and function of ESD, we determined the 3-dimensional structure of the enzyme at 1.5 angstrom resolution using X-ray crystallography. ESD shows a single domain with an alpha/beta-hydrolase fold. A number of insertions are observed in the canonical alpha/beta-hydrolase fold. The active site is located in a positively charged, shallow cleft on the surface lined by a number of aromatic residues. Superimposition studies helped identify the typical catalytic triad residues-Ser-153, His264, and Asp230-involved in catalysis. Mutagenesis of any of the catalytic triad residues to alanine abolished the enzyme activity. Backbone amides of Leu54 and Met150 are involved in the formation of the oxyanion hole. Interestingly, a M150A mutation increased the enzyme activity by 62%. The structure of human ESD determined in this study will aid the elucidation of the physiological role of the enzyme in the human body and will assist in the early diagnosis of retinoblastoma. Wu, D., Li, Y., Song, G., Zhang, D., Shaw, N., Liu, Z. J. Crystal structure of human esterase D: a potential genetic marker of retinoblastoma. FASEB J. 23, 1441-1446 (2009)	[Wu, Dong; Li, Yang; Song, Gaojie; Zhang, David; Shaw, Neil; Liu, Zhi-Jie] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Shaw, N (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Lu, Beijing 100101, Peoples R China.	neilshaw@moon.ibp.ac.cn; zjliu@ibp.ac.cn	Liu, Zhi-Jie/A-3946-2012; Li, Yang/G-3685-2011; Li, Yang/M-1246-2013	Liu, Zhi-Jie/0000-0001-7279-2893; Shaw, Neil/0000-0003-2722-9967	National Natural Science Foundation of China [20572063, 30670427, 30721003]; Ministry of Science and Technology of China [2006AA02A316, 2006CB910901]; Ministry of Health of China [2008ZX10404]; China Postdoctoral Science Foundation [20070420533]; Chinese Academy of Sciences research [07CF09]; Office of Basic Energy Sciences; U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [W-31-109-Eng-38]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Ministry of Health of China; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Chinese Academy of Sciences research(Chinese Academy of Sciences); Office of Basic Energy Sciences(United States Department of Energy (DOE)); U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE))	This work was funded by the National Natural Science Foundation of China (grants 20572063, 30670427, and 30721003), the Ministry of Science and Technology of China (grants 2006AA02A316 and 2006CB910901), the Ministry of Health of China (grant 2008ZX10404), the China Postdoctoral Science Foundation (20070420533), and a Chinese Academy of Sciences research grant (07CF09). Crystallographic data were collected at SER-CAT 22-ID beamline at the Advanced Photon Source (Argonne National Laboratory, Lemont, IL, USA). The use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract W-31-109-Eng-38. Atomic coordinates and structure factors of human esterase D have been deposited in the Protein Data Bank under accession code 3FCX.	BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; COWELL JK, 1987, ARCH DIS CHILD, V62, P8, DOI 10.1136/adc.62.1.8; EIBERG H, 1986, HUM GENET, V74, P174, DOI 10.1007/BF00282085; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FRYDMAN M, 1985, P NATL ACAD SCI USA, V82, P1819, DOI 10.1073/pnas.82.6.1819; Harms N, 1996, J BACTERIOL, V178, P6296, DOI 10.1128/jb.178.21.6296-6299.1996; Kim MH, 2008, PROTEINS, V70, P578, DOI 10.1002/prot.21680; Larsen NA, 2006, BIOCHEMISTRY-US, V45, P10184, DOI 10.1021/bi060950i; Lebedev AA, 2008, ACTA CRYSTALLOGR D, V64, P33, DOI 10.1107/S0907444907049839; LEE EYHP, 1986, P NATL ACAD SCI USA, V83, P6337, DOI 10.1073/pnas.83.17.6337; LEE WH, 1986, P NATL ACAD SCI USA, V83, P6790, DOI 10.1073/pnas.83.18.6790; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Legler PM, 2008, BIOCHEMISTRY-US, V47, P9592, DOI 10.1021/bi8010016; LOUGHNA S, 1993, AM J HUM GENET, V53, P810; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Okunuki Y, 2008, MOL VIS, V14, P1094; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ronning DR, 2000, NAT STRUCT BIOL, V7, P141; Schefler AC, 2008, CURR OPIN OPHTHALMOL, V19, P526, DOI 10.1097/ICU.0b013e328312975b; Shields CL, 2006, J PEDIAT OPHTH STRAB, V43, P313, DOI 10.3928/01913913-20060901-08; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SPARKES RS, 1980, SCIENCE, V208, P1042, DOI 10.1126/science.7375916; SQUIRE J, 1986, P NATL ACAD SCI USA, V83, P6573, DOI 10.1073/pnas.83.17.6573; Stols L, 2002, PROTEIN EXPRES PURIF, V25, P8, DOI 10.1006/prep.2001.1603; VARKI A, 1986, P NATL ACAD SCI USA, V83, P882, DOI 10.1073/pnas.83.4.882; YOUNG LJS, 1988, HUM GENET, V79, P137, DOI 10.1007/BF00280552; YUZBASIYANGURKAN V, 1993, GENOMICS, V15, P86, DOI 10.1006/geno.1993.1013	28	27	32	2	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1441	1446		10.1096/fj.08-125286	http://dx.doi.org/10.1096/fj.08-125286			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19126594				2022-12-28	WOS:000266651700020
J	French, CJ; Spees, JL; Zaman, AKMT; Taatjes, DJ; Sobel, BE				French, Christopher J.; Spees, Jeffrey L.; Zaman, A. K. M. Tarikuz; Taatjes, Douglas J.; Sobel, Burton E.			The magnitude and temporal dependence of apoptosis early after myocardial ischemia with or without reperfusion	FASEB JOURNAL			English	Article						multiple assays; infarction; TUNEL; caspase 3; ssDNA	INTERNUCLEOSOMAL DNA CLEAVAGE; DEXAMETHASONE-TREATED RATS; CELL-DEATH; HEART-FAILURE; CARDIOMYOCYTE APOPTOSIS; INFARCT SIZE; TUNEL; END; MYOCYTES; DISEASE	In view of the conventional wisdom in the cardiology literature that apoptosis is extensive early after myocardial ischemia, predicated largely from results with the TUNEL assay known to be nonspecific, this study was performed to delineate its extent with multiple assays and at multiple intervals. Coronary occlusion with and without subsequent revascularization was induced in 10-wk-old C57BL6 mice subjected to 1 or 4 h of transient ligation followed by 24 h of reperfusion, or 24 h persistent ligation. Apoptosis was quantified throughout the left ventricle immunohistochemically by assay of TUNEL, single-stranded DNA (ssDNA), and cleaved caspase 3; electron microscopy (EM); and activity assays of caspase 3 and 8. TUNEL staining was marked, but ssDNA and cleaved caspase 3 staining were significantly less (P<0.001 compared with TUNEL), and apoptosis defined by EM was virtually absent in all groups. Caspase 3 and caspase 8 activities per milligram protein were not significantly different from those in normal hearts. Only rare, potentially apoptotic cells were seen by EM in hearts from any group. Thus, the results with TUNEL were not specific, and the extent of apoptosis was markedly less than that predicated on the results with the TUNEL procedure. Apoptosis is de minimus early after transitory or persistent ischemia, though it is overestimated by TUNEL assays. Thus, antiapoptotic interventions per se are not likely to preserve substantial amounts of myocardium early after ischemic insults.-French, C. J., Spees, J. L., Tarikuz Zaman, A. K. M., Taatjes, D. J., Sobel, B. E. The magnitude and temporal dependence of apoptosis early after myocardial ischemia with or without reperfusion. FASEB J. 23, 1177-1185 (2009)	[Sobel, Burton E.] Univ Vermont, Cardiovasc Res Inst, Colchester Res Facil, Dept Med, Colchester, VT 05446 USA; [Taatjes, Douglas J.] Univ Vermont, Cardiovasc Res Inst, Dept Pathol, Colchester, VT 05446 USA	University of Vermont; University of Vermont	Sobel, BE (corresponding author), Univ Vermont, Cardiovasc Res Inst, Colchester Res Facil, Dept Med, 208 S Pk Dr, Colchester, VT 05446 USA.	burton.sobel@uvm.edu			U.S. National Institutes of Health [RO1 HL085210]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085210] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported in part by U.S. National Institutes of Health grant NIH RO1 HL085210 (J. L. S.). We appreciate the expert technical assistance of Ms. Patricia Baumann, Ms. Keara McElroy-Yaggy, Ms. Dagnija Neimane, and Ms. Marilyn Wadsworth and preparation of the manuscript by Ms. Lori Dales. We appreciate also helpful discussions during the course of our study with Drs. Ralph Budd and David Schneider.	Abbate A, 2007, INT J CARDIOL, V114, P118, DOI 10.1016/j.ijcard.2005.11.025; Abbate A, 2007, INT J CARDIOL, V121, P109, DOI 10.1016/j.ijcard.2006.08.077; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT RE, 1958, CIRC RES, V6, P699, DOI 10.1161/01.RES.6.6.699; Buja LM, 1998, CIRCULATION, V98, P1355, DOI 10.1161/01.CIR.98.14.1355; CAULFIELD J, 1959, AM J PATHOL, V35, P489; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; COLLINS RJ, 1992, INT J RADIAT BIOL, V61, P451, DOI 10.1080/09553009214551201; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Dong Z, 1997, AM J PATHOL, V151, P1205; Doukas J, 2006, P NATL ACAD SCI USA, V103, P19866, DOI 10.1073/pnas.0606956103; Frankfurt OS, 1996, EXP CELL RES, V226, P387, DOI 10.1006/excr.1996.0240; Freude B, 2000, J MOL CELL CARDIOL, V32, P197, DOI 10.1006/jmcc.1999.1066; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Hayakawa K, 2002, CIRCULATION, V105, P3039, DOI 10.1161/01.CIR.0000018651.89208.69; Hikoso S, 2007, J AM COLL CARDIOL, V50, P453, DOI 10.1016/j.jacc.2007.03.053; Ito Y, 2006, J HISTOCHEM CYTOCHEM, V54, P683, DOI 10.1369/jhc.5A6799.2006; Kajstura J, 1996, LAB INVEST, V74, P86; Kang PM, 2000, J CARD FAIL, V6, P43, DOI 10.1016/S1071-9164(00)80005-6; Kanoh M, 1999, CIRCULATION, V99, P2757, DOI 10.1161/01.CIR.99.21.2757; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Kockx MM, 1996, AM J PATHOL, V148, P1771; Kockx MM, 1998, AM J PATHOL, V152, P885; Kumar D, 2003, J LAB CLIN MED, V142, P288, DOI 10.1016/S0022-2143(03)00148-3; Lipsic E, 2006, CARDIOVASC DRUG THER, V20, P135, DOI 10.1007/s10557-006-7680-5; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Ohno M, 1998, CIRCULATION, V98, P1422, DOI 10.1161/01.CIR.98.14.1422; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Rao KNS, 2008, FUTUR CARDIOL, V4, P57, DOI 10.2217/14796678.4.1.57; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Saraste A, 1997, CIRCULATION, V95, P320; Sloop GD, 1999, ARCH PATHOL LAB MED, V123, P529; Sobel BE, 2005, PHARMACOINVASIVE THE, P3; Sobel BE, 2006, BIOCHEM BIOPH RES CO, V346, P102, DOI 10.1016/j.bbrc.2006.05.078; SUN XM, 1992, BIOCHEM PHARMACOL, V44, P2131; Taatjes DJ, 2008, HISTOCHEM CELL BIOL, V129, P33, DOI 10.1007/s00418-007-0356-9; Taatjes DJ, 2007, HISTOCHEM CELL BIOL, V128, P275, DOI 10.1007/s00418-007-0323-5; Takernura G, 2006, J CELL MOL MED, V10, P56, DOI 10.1111/j.1582-4934.2006.tb00291.x; Veinot JP, 1997, HUM PATHOL, V28, P485, DOI 10.1016/S0046-8177(97)90039-3; Walker JA, 2001, J PATHOL, V195, P275; Watanabe M, 2002, MICROSC MICROANAL, V8, P375, DOI 10.1017/S1431927602010346; Xiang GS, 2005, J AM COLL CARDIOL, V46, P536, DOI 10.1016/j.jacc.2005.04.047; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667; Zaman AKMT, 2007, HISTOCHEM CELL BIOL, V128, P135, DOI 10.1007/s00418-007-0300-z; Zavitsanou K, 2007, J MOL HISTOL, V38, P313, DOI 10.1007/s10735-007-9104-7; Zhao ZQ, 2000, CARDIOVASC RES, V45, P651, DOI 10.1016/S0008-6363(99)00354-5; Zhao ZQ, 2000, J SURG RES, V94, P133, DOI 10.1006/jsre.2000.6029	48	16	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1177	1185		10.1096/fj.08-116509	http://dx.doi.org/10.1096/fj.08-116509			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19095733	Green Published			2022-12-28	WOS:000266651600022
J	Mayers, JR; Iliff, BW; Swoap, SJ				Mayers, Jared R.; Iliff, Benjamin W.; Swoap, Steven J.			Resveratrol treatment in mice does not elicit the bradycardia and hypothermia associated with calorie restriction	FASEB JOURNAL			English	Article						obesity; dieting; body temperature; heart rate	SMALL-MOLECULE ACTIVATORS; CEREVISIAE LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; HEART-RATE; DIETARY RESTRICTION; BODY-TEMPERATURE; SIRT1; DISEASE; LEPTIN; EXPRESSION	Dietary supplementation with resveratrol may produce calorie restriction-like effects on metabolic and longevity endpoints in mice. In this study, we sought to determine whether resveratrol treatment elicited other hallmark changes associated with calorie restriction, namely bradycardia and decreased body temperature. We found that during short-term treatment, wild-type mice on a calorie-restricted diet experienced significant decreases in both heart rate and body temperature after only 1 day whereas those receiving resveratrol exhibited no such change after 1 wk. We also used ob/ob mice to study the effects of long-term treatment because previous studies had indicated the therapeutic value of resveratrol against the linked morbidities of obesity and diabetes. After 12 wk, resveratrol treatment had produced no changes in either heart rate or body temperature. Strikingly, and in contrast to previous findings, we found that resveratrol-treated mice had significantly reduced endurance in a treadmill test. Quantitative reverse transcriptase-polymerase chain reaction suggested that a proposed target of resveratrol, Sirt1, was activated in resveratrol-treated ob/ob mice. Thus, we conclude that the bradycardia and hypothermia associated with calorie restriction occur through mechanisms unaffected by the actions of resveratrol and that further studies are needed to examine the differential effects of resveratrol in a leptin-deficient background.-Mayers, J. R., Iliff, B. W., Swoap, S. J. Resveratrol treatment in mice does not elicit the bradycardia and hypothermia associated with calorie restriction. FASEB J. 23, 1032-1040 (2009)	[Mayers, Jared R.; Iliff, Benjamin W.; Swoap, Steven J.] Williams Coll, Dept Biol, Williamstown, MA 01267 USA	Williams College	Swoap, SJ (corresponding author), Williams Coll, Dept Biol, Williamstown, MA 01267 USA.	sswoap@williams.edu		Mayers, Jared/0000-0002-8607-1787	U.S. National Institutes of Health [R15 HL081101-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL081101] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health grant R15 HL081101-01 to S.J.S.	Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Bass TM, 2007, MECH AGEING DEV, V128, P546, DOI 10.1016/j.mad.2007.07.007; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357; Chen D, 2007, TRENDS MOL MED, V13, P64, DOI 10.1016/j.molmed.2006.12.004; Chen WP, 2007, EUR J PHARMACOL, V568, P269, DOI 10.1016/j.ejphar.2007.04.062; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kaeberlein M, 2006, NATURE, V444, P280, DOI 10.1038/nature05308; Kakuma T, 2000, ENDOCRINOLOGY, V141, P4576, DOI 10.1210/en.141.12.4576; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lane MA, 1999, TOXICOL SCI, V52, P41, DOI 10.1093/toxsci/52.suppl_1.41; Lane MA, 1996, P NATL ACAD SCI USA, V93, P4159, DOI 10.1073/pnas.93.9.4159; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Mager DE, 2006, FASEB J, V20, P631, DOI 10.1096/fj.05-5263com; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ogden CL, 2008, JAMA-J AM MED ASSOC, V299, P2401, DOI 10.1001/jama.299.20.2401; Overton JM, 2004, PHYSIOL BEHAV, V81, P749, DOI 10.1016/j.physbeh.2004.04.025; Pagano C, 2008, NUTR METAB CARDIOVAS, V18, P189, DOI 10.1016/j.numecd.2006.05.009; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rikke BA, 2003, MECH AGEING DEV, V124, P663, DOI 10.1016/S0047-6374(03)00003-4; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sowden GL, 2007, AM J PHYSIOL-REG I, V292, pR962, DOI 10.1152/ajpregu.00405.2006; Stanley S, 2005, PHYSIOL REV, V85, P1131, DOI 10.1152/physrev.00015.2004; Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014; Swoap SJ, 2008, AM J PHYSIOL-HEART C, V294, pH1581, DOI 10.1152/ajpheart.01000.2007; Swoap SJ, 2004, AM J PHYSIOL-REG I, V286, pR108, DOI 10.1152/ajpregu.00405.2003; Varady KA, 2007, AM J CLIN NUTR, V86, P7, DOI 10.1093/ajcn/86.1.7; Viswanathan M, 2005, DEV CELL, V9, P605, DOI 10.1016/j.devcel.2005.09.017; Wolf G, 2006, NUTR REV, V64, P89, DOI [10.1111/j.1753-4887.2006.tb00192.x, 10.1301/nr.2006.feb.89-92]; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	53	31	33	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1032	1040		10.1096/fj.08-115923	http://dx.doi.org/10.1096/fj.08-115923			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19056839	Green Published			2022-12-28	WOS:000266651600007
J	Fiume, R; Ramazzotti, G; Teti, G; Chiarini, F; Faenza, I; Mazzotti, G; Billi, AM; Cocco, L				Fiume, Roberta; Ramazzotti, Giulia; Teti, Gabriella; Chiarini, Francesca; Faenza, Irene; Mazzotti, Giovanni; Billi, Anna Maria; Cocco, Lucio			Involvement of nuclear PLC beta 1 in lamin B1 phosphorylation and G(2)/M cell cycle progression	FASEB JOURNAL			English	Article						JNK; PKC alpha; nucleus; inositide signaling	PROTEIN-KINASE-C; GROWTH-FACTOR-I; PHOSPHOLIPASE-C; ERYTHROLEUKEMIA-CELLS; SWISS 3T3-CELLS; HL-60 CELLS; ACTIVATION; IDENTIFICATION; TRANSCRIPTION; ORGANIZATION	Inositide-specific phospholipase C beta 1 (PLC beta 1) signaling in cell proliferation has been investigated thoroughly in the G(1) cell cycle phase. However, little is known about its involvement in G(2)/M progression. We used murine erythroleukemia cells to investigate the role of PLC beta 1 in G(2)/M cell cycle progression and screened a number of candidate intermediate players, particularly mitogen-activated protein kinase (MAPK) and protein kinase C (PKC), which can, potentially, transduce serum mitogenic stimulus and induce lamin B1 phosphorylation, leading to G(2)/M progression. We report that PLC beta 1 colocalizes and physically interacts with lamin B1. Studies of the effects of inhibitors and selective si-RNA mediated silencing showed a role of JNK, PKC alpha, PKC beta I, and the beta 1 isoform of PI-PLC in cell accumulation in G(2)/M [as observed by fluorescence-activated cell sorter (FACS)]. To shed light on the mechanism, we considered that the final signaling target was lamin B1 phosphorylation. When JNK, PKC alpha, or PLC beta 1 were silenced, lamin B1 exhibited a lower extent of phosphorylation, as compared to control. The salient features to emerge from these studies are a common pathway in which JNK is likely to represent a link between mitogenic stimulus and activation of PLC beta 1, and, foremost, the finding that the PLC beta 1-mediated pathway represents a functional nuclear inositide signaling in the G(2)/M transition.-Fiume, R., Ramazzotti, G., Teti, G., Chiarini, F., Faenza, I., Mazzotti, G., Billi, A. M., Cocco, L., Involvement of nuclear PLC beta 1 in lamin B1 phosphorylation and G(2)/M cell cycle progression. FASEB J. 23, 957-966 (2009)	[Fiume, Roberta; Ramazzotti, Giulia; Teti, Gabriella; Chiarini, Francesca; Faenza, Irene; Mazzotti, Giovanni; Billi, Anna Maria; Cocco, Lucio] Univ Bologna, Cellular Signaling Lab, Dept Human Anat Sci, I-40126 Bologna, Italy	University of Bologna	Cocco, L (corresponding author), Univ Bologna, Cellular Signaling Lab, Dept Human Anat Sci, Via Irnerio 48, I-40126 Bologna, Italy.	lucio.cocco@unibo.it	Ramazzotti, Giulia/AAC-4597-2022; Faenza, Irene/AAC-4606-2022; RAMAZZOTTI, GIULIA/AGZ-9499-2022; Cocco, Lucio/AAI-2206-2020	Faenza, Irene/0000-0002-5227-3567; RAMAZZOTTI, GIULIA/0000-0001-9684-714X; Cocco, Lucio/0000-0002-9206-8277; teti, gabriella/0000-0001-9817-8437; FIUME, ROBERTA/0000-0001-7757-4000	Italian MIUR-FIRB (Human Proteome Net); MIUR-COFIN; Carisbo Foundation	Italian MIUR-FIRB (Human Proteome Net)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); MIUR-COFIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Carisbo Foundation(Fondazione Carisbo)	This work was supported by Italian MIUR-FIRB (Human Proteome Net), MIUR-COFIN, and the Carisbo Foundation.	Avazeri N, 2000, MOL BIOL CELL, V11, P4369, DOI 10.1091/mbc.11.12.4369; Bavelloni A, 2006, PROTEOMICS, V6, P5725, DOI 10.1002/pmic.200600318; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Cocco L, 1996, ADV ENZYME REGUL, V36, P101, DOI 10.1016/0065-2571(95)00007-0; Cocco L, 2001, BBA-MOL CELL BIOL L, V1530, P1, DOI 10.1016/S1388-1981(00)00169-4; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Fukuda T, 2005, GENES CELLS, V10, P655, DOI 10.1111/j.1365-2443.2005.00866.x; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; Horne MM, 2003, J CELL BIOL, V161, P1021, DOI 10.1083/jcb.200304144; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lukinovic-Skudar V, 2005, BBA-MOL CELL BIOL L, V1733, P148, DOI 10.1016/j.bbalip.2004.12.009; Lukinovic-Skudar V, 2007, BBA-MOL CELL BIOL L, V1771, P514, DOI 10.1016/j.bbalip.2007.02.002; Manzoli L, 2005, PROG LIPID RES, V44, P185, DOI 10.1016/j.plipres.2005.04.003; MARTELLI AM, 1994, CANCER RES, V54, P2536; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Neri LM, 1999, J CELL BIOCHEM, V75, P36, DOI 10.1002/(SICI)1097-4644(19991001)75:1<36::AID-JCB4>3.0.CO;2-R; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Spann TP, 2002, J CELL BIOL, V156, P603, DOI 10.1083/jcb.200112047; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Tabellini G, 2002, CELL SIGNAL, V14, P819, DOI 10.1016/S0898-6568(02)00021-9; Tang CW, 2008, J CELL SCI, V121, P1014, DOI 10.1242/jcs.020982; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; Xu AM, 2001, J BIOL CHEM, V276, P14980, DOI 10.1074/jbc.M009144200	28	45	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2009	23	3					957	966		10.1096/fj.08-121244	http://dx.doi.org/10.1096/fj.08-121244			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19028838				2022-12-28	WOS:000265506300031
J	Martin, J; Duncan, FJ; Keiser, T; Shin, S; Kusewitt, DF; Oberyszyn, T; Satoskar, AR; VanBuskirk, AM				Martin, Jason; Duncan, F. Jason; Keiser, Tracy; Shin, Samuel; Kusewitt, Donna F.; Oberyszyn, Tatiana; Satoskar, Abhay R.; VanBuskirk, Anne M.			Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB) -induced nonmelanoma skin cancer (NMSC)	FASEB JOURNAL			English	Article						angiogenesis; tumorigenesis; edema	HUMAN BREAST-CANCER; REGULATORY ROLE; UNITED-STATES; EXPRESSION; CELLS; P53; INFLAMMATION; HYPOXIA; DAMAGE; PHOTOCARCINOGENESIS	Mounting evidence suggests that macrophage migration inhibitory factor (MIF) may serve as an important link between chronic inflammation and cancer development. The proinflammatory and proangiogenic activities of MIF position it as a potentially important player in the development and progression of nonmelanoma skin cancer (NMSC). To assess the role of MIF in the development and progression of NMSC, we exposed MIF-/- BALB/c mice to acute and chronic ultraviolet B (UVB) irradiation. Our studies demonstrate that MIF-/- BALB/c mice have a significantly diminished acute inflammatory response to UVB exposure compared to wild-type mice, as measured by myeloperoxidase activity, dermal neutrophil infiltration, and edematous response. Relative to wild-type mice, MIF-/- mice also show significantly lower vascular endothelial growth factor (VEGF) concentrations in whole skin and significantly lower 8-oxo-dG adduct concentrations in epidermal DNA following UVB exposure. Furthermore, MIF-/- mice showed significant increases in p53 activity, epidermal thickness, and epidermal cell proliferation following acute UVB insult. In response to chronic UVB exposure, MIF-/- mice showed a 45% reduction in tumor incidence, significantly less angiogenesis, and delayed tumor progression when compared to their wild-type counterparts. These data indicate that MIF plays an important role in UVB-induced NMSC development and progression.-Martin, J., Duncan, F. J., Keiser, T., Shin, S., Kusewitt, D. F., Oberyszyn, T., Satoskar, A. R., VanBuskirk, A. M. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB) -induced nonmelanoma skin cancer (NMSC). FASEB J. 23, 720-730 (2009)	[Keiser, Tracy; Satoskar, Abhay R.] Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; [Martin, Jason; Duncan, F. Jason; Shin, Samuel; VanBuskirk, Anne M.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA; [Kusewitt, Donna F.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Oberyszyn, Tatiana; VanBuskirk, Anne M.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [VanBuskirk, Anne M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Satoskar, AR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.	satoskar.2@osu.edu	Oberyszyn, Tatiana/E-3774-2011; Kusewitt, Donna F/E-8107-2011; Satoskar, Abhay/AAB-7748-2019	Oberyszyn, Tatiana/0000-0002-5308-0855				Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bando H, 2003, BIOMED PHARMACOTHER, V57, P333, DOI 10.1016/S0753-3322(03)00098-2; Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; Baugh JA, 2002, GENES IMMUN, V3, P170, DOI 10.1038/sj.gene.6363867; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; Berton TR, 2005, ONCOGENE, V24, P2449, DOI 10.1038/sj.onc.1208462; Besaratinia A, 2005, P NATL ACAD SCI USA, V102, P10058, DOI 10.1073/pnas.0502311102; Bolontrade MF, 1998, CARCINOGENESIS, V19, P2107, DOI 10.1093/carcin/19.12.2107; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Bucala R, 2007, IMMUNITY, V26, P281, DOI 10.1016/j.immuni.2007.03.005; Budiyanto A, 2002, PHOTOCHEM PHOTOBIOL, V76, P397, DOI 10.1562/0031-8655(2002)076<0397:FOCPDA>2.0.CO;2; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chen JG, 2001, DERMATOL SURG, V27, P1035, DOI 10.1046/j.1524-4725.2001.01004.x; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Chuang TY, 1999, J EUR ACAD DERMATOL, V12, P126, DOI 10.1016/S0926-9959(98)00147-0; Cooke MS, 2000, FREE RADICAL RES, V33, P369, DOI 10.1080/10715760000300911; Dahle Jostein, 2005, J Carcinog, V4, P11, DOI 10.1186/1477-3163-4-11; Daun JM, 2000, AM J PHYSIOL-REG I, V279, pR1043, DOI 10.1152/ajpregu.2000.279.3.R1043; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; de Gruijl FR, 2002, EXP DERMATOL, V11, P37, DOI 10.1034/j.1600-0625.11.s.1.9.x; De Haes P, 2005, J PHOTOCH PHOTOBIO B, V78, P141, DOI 10.1016/j.jphotobiol.2004.09.010; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; Donn RP, 2001, ARTHRITIS RHEUM-US, V44, P1782, DOI 10.1002/1529-0131(200108)44:8<1782::AID-ART314>3.0.CO;2-#; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Ehrhart JC, 2003, PHOTOCH PHOTOBIO SCI, V2, P825, DOI 10.1039/b302281a; Ferrara N, 2001, Am J Physiol Cell Physiol, V280, pC1358; Gerber B, 2002, PHOTOCHEM PHOTOBIOL, V76, P664, DOI 10.1562/0031-8655(2002)076<0664:UESOS>2.0.CO;2; Halliday GA, 2005, MUTAT RES-FUND MOL M, V571, P107, DOI 10.1016/j.mrfmmm.2004.09.013; Hatton JL, 2007, J INVEST DERMATOL, V127, P1507, DOI 10.1038/sj.jid.5700746; HAWK JLM, 1988, BRIT J DERMATOL, V118, P27, DOI 10.1111/j.1365-2133.1988.tb01746.x; Hoi AY, 2006, J IMMUNOL, V177, P5687, DOI 10.4049/jimmunol.177.8.5687; Housman TS, 2003, J AM ACAD DERMATOL, V48, P425, DOI 10.1067/mjd.2003.186; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Javeed A, 2008, INFLAMM RES, V57, P45, DOI 10.1007/s00011-007-7110-6; Jung HY, 2008, J BIOL CHEM, V283, P20383, DOI 10.1074/jbc.M800050200; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kobayashi S, 1999, HEPATOLOGY, V29, P1752, DOI 10.1002/hep.510290610; Koong AC, 2000, CANCER RES, V60, P883; Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455; LUNDBERG C, 1983, INFLAMMATION, V7, P247, DOI 10.1007/BF00917262; Marks Robin, 1995, Journal of Dermatology (Tokyo), V22, P853, DOI 10.1111/j.1346-8138.1995.tb03935.x; Meyer-Siegler K, 1998, DIAGN MOL PATHOL, V7, P44, DOI 10.1097/00019606-199802000-00008; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102; Morand EF, 2005, FRONT BIOSCI-LANDMRK, V10, P12, DOI 10.2741/1501; OSTERLIND A, 1991, Current Opinion in Oncology, V3, P355; Piskin G, 2005, ARCH DERMATOL RES, V296, P339, DOI 10.1007/s00403-004-0522-z; Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287; Roger T, 2005, EUR J IMMUNOL, V35, P3405, DOI 10.1002/eji.200535413; Sams RL, 2002, TOXICOL APPL PHARM, V184, P136, DOI 10.1006/taap.2002.9498; Sasaki S, 2004, KIDNEY INT, V65, P469, DOI 10.1111/j.1523-1755.2004.00394.x; SAVAGE JE, 1993, J INVEST DERMATOL, V101, P532, DOI 10.1111/1523-1747.ep12365905; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Strom SS, 1997, CLIN PLAST SURG, V24, P627; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; Thomas-Ahner JM, 2007, CANCER RES, V67, P3468, DOI 10.1158/0008-5472.CAN-06-3798; van der Kemp PA, 2002, PHOTOCHEM PHOTOBIOL, V76, P640, DOI 10.1562/0031-8655(2002)076<0640:UBIIOH>2.0.CO;2; White ES, 2001, J IMMUNOL, V166, P7549, DOI 10.4049/jimmunol.166.12.7549; Wilgus TA, 2000, PROSTAG OTH LIPID M, V62, P367, DOI 10.1016/S0090-6980(00)00089-7; Wilgus TA, 2003, MOL CARCINOGEN, V38, P49, DOI 10.1002/mc.10141; Winner M, 2007, CANCER RES, V67, P186, DOI 10.1158/0008-5472.CAN-06-3292; Wulff BC, 2008, PHOTOCHEM PHOTOBIOL, V84, P317, DOI 10.1111/j.1751-1097.2007.00257.x; Zhang Wei, 2002, Hepatobiliary Pancreat Dis Int, V1, P577	68	35	38	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					720	730		10.1096/fj.08-119628	http://dx.doi.org/10.1096/fj.08-119628			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18952710				2022-12-28	WOS:000265506300008
J	Luo, S; Levine, RL				Luo, Shen; Levine, Rodney L.			Methionine in proteins defends against oxidative stress	FASEB JOURNAL			English	Article						norleucine; elongation factor Tu; hypochlorous acid	SULFOXIDE-REDUCTASE-A; PERFORMANCE LIQUID-CHROMATOGRAPHY; WERNER SYNDROME PROTEIN; ESCHERICHIA-COLI-CELLS; SACCHAROMYCES-CEREVISIAE; GLUTAMINE-SYNTHETASE; ANTIOXIDANT DEFENSE; CELLULAR-REGULATION; OXIDIZED PROTEINS; CRYSTAL-STRUCTURE	A variety of reactive oxygen species react readily with methionine residues in proteins to form methionine sulfoxide, thus scavenging the reactive species. Most cells contain methionine sulfoxide reductases, which catalyze a thioredoxin-dependent reduction of methionine sulfoxide back to methionine. Thus, methionine residues may act as catalytic antioxidants, protecting both the protein where they are located and other macromolecules. To test this hypothesis directly, we replaced 40% of the methionine residues in Escherichia coli with norleucine, the carbon-containing analog, in which the sulfur of methionine is substituted by a methylene group (-CH2-). The intracellular free methionine and S-adenosylmethionine pools were not altered, nor was the specific activity of the key enzyme, glutamine synthetase. When unstressed, both control and norleucine-substituted cells survived equally well at stationary phase for at least 32 h. However, oxidative stress was more damaging to the norleucine-substituted cells. They died more rapidly than control cells when challenged by hypochlorite, hydrogen peroxide, or ionizing radiation. One of the most abundant proteins in the cell, elongation factor Tu, was found to be more oxidatively modified in norleucine-substituted cells, consistent with loss of the antioxidant defense provided by methionine residues. The results of these studies support the hypothesis that methionine in protein acts as an endogenous antioxidant in cells. - Luo, S., Levine, R. L. Methionine in proteins defends against oxidative stress. FASEB J. 23, 464-472 (2009)	[Luo, Shen; Levine, Rodney L.] NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, RL (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 50,Rm 2351, Bethesda, MD 20892 USA.	rlevine@nih.gov	Levine, Rodney L/D-9885-2011	Luo, Shen/0000-0002-1912-6741	Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000225, ZIAHL000225] Funding Source: NIH RePORTER	Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors thank Elena K. Gaidamakova and Alexander Vasilenko for performing the irradiation of the E. coli. This research was supported by the Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health.	ANFINSEN CB, 1969, J BIOL CHEM, V244, P5149; BARKER DG, 1979, J MOL BIOL, V133, P217, DOI 10.1016/0022-2836(79)90531-X; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Cabreiro F, 2007, BIOCHIMIE, V89, P1388, DOI 10.1016/j.biochi.2007.05.005; Cabreiro F, 2008, J BIOL CHEM, V283, P16673, DOI 10.1074/jbc.M708580200; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; COWIE DB, 1959, BIOCHIM BIOPHYS ACTA, V34, P39, DOI 10.1016/0006-3002(59)90230-6; Daly MJ, 2007, PLOS BIOL, V5, P769, DOI 10.1371/journal.pbio.0050092; Douglas T, 2004, J BACTERIOL, V186, P3590, DOI 10.1128/JB.186.11.3590-3598.2004; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; FARBER JM, 1986, J BIOL CHEM, V261, P4574; GILLES AM, 1988, J BIOL CHEM, V263, P8204; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; IIDA H, 1988, MOL CELL BIOL, V8, P5555, DOI 10.1128/MCB.8.12.5555; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KITZLER JW, 1990, J BACTERIOL, V172, P686, DOI 10.1128/jb.172.2.686-690.1990; Kohen R, 1985, Free Radic Res Commun, V1, P79, DOI 10.3109/10715768509056540; KOPOLDOVA J, 1967, RADIAT RES, V30, P261, DOI 10.2307/3572051; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7; Levine RL, 2000, METH MOL B, V99, P15; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; Liu X, 2006, P NATL ACAD SCI USA, V103, P13694, DOI 10.1073/pnas.0606321103; Luo S, 2006, ANAL BIOCHEM, V350, P233, DOI 10.1016/j.ab.2005.10.048; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; Marchetti MA, 2006, EXP EYE RES, V83, P1281, DOI 10.1016/j.exer.2006.07.005; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MINAKAMI H, 1990, FREE RADICAL BIO MED, V8, P387, DOI 10.1016/0891-5849(90)90105-R; Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; NAIDER F, 1972, BIOCHEMISTRY-US, V11, P3202, DOI 10.1021/bi00767a010; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nystrom Thomas, 2006, Methods Biochem Anal, V49, P89; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; RANDHAWA ZI, 1994, BIOCHEMISTRY-US, V33, P4352, DOI 10.1021/bi00180a032; REDDY VY, 1994, J BIOL CHEM, V269, P4683; REDDY VY, 1989, J BIOL CHEM, V264, P13801; Reverter-Branchat G, 2004, J BIOL CHEM, V279, P31983, DOI 10.1074/jbc.M404849200; Romero HM, 2004, PLANT PHYSIOL, V136, P3784, DOI 10.1104/pp.104.046656; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Schoneich C, 2005, BBA-PROTEINS PROTEOM, V1703, P111, DOI 10.1016/j.bbapap.2004.09.009; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Song HW, 1999, J MOL BIOL, V285, P1245, DOI 10.1006/jmbi.1998.2387; St John G, 2001, P NATL ACAD SCI USA, V98, P9901; Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; Stadtman ER, 2002, MOL CELL BIOCHEM, V234, P3, DOI 10.1023/A:1015916831583; Taggart C, 2000, J BIOL CHEM, V275, P27258; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; Wang Y, 2001, FREE RADICAL BIO MED, V31, P1448, DOI 10.1016/S0891-5849(01)00728-6; Weissbach H, 2005, BBA-PROTEINS PROTEOM, V1703, P203, DOI 10.1016/j.bbapap.2004.10.004; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P1159, DOI 10.1073/pnas.0308215100; Zhang Z, 2004, P NATL ACAD SCI USA, V101, P9491, DOI 10.1073/pnas.0402961101	61	307	314	1	45	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					464	472		10.1096/fj.08-118414	http://dx.doi.org/10.1096/fj.08-118414			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18845767	Green Published			2022-12-28	WOS:000262892900018
J	Brunk, I; Blex, C; Sanchis-Segura, C; Sternberg, J; Perreau-Lenz, S; Bilbao, A; Hortnagl, H; Baron, J; Juranek, J; Laube, G; Birnbaumer, L; Spanagel, R; Ahnert-Hilger, G				Brunk, Irene; Blex, Christian; Sanchis-Segura, Carles; Sternberg, Jan; Perreau-Lenz, Stephanie; Bilbao, Ainhoa; Hoertnagl, Heide; Baron, Jens; Juranek, Judyta; Laube, Gregor; Birnbaumer, Lutz; Spanagel, Rainer; Ahnert-Hilger, Gudrun			Deletion of Go2 alpha abolishes cocaine-induced behavioral sensitization by disturbing the striatal dopamine system	FASEB JOURNAL			English	Article						vesicular regulation; VMAT2; locomotor activity; psychostimulants	VESICULAR MONOAMINE; PROTEIN; REWARD; VMAT2; MICE; TRANSPORTERS; EXPRESSION; LOCOMOTION; RESPONSES; KNOCKOUT	The alpha-subunits of the trimeric Go class of GTPases, comprising the splice variants Go1 alpha and Go2 alpha, are abundantly expressed in brain and reside on both plasma membrane and synaptic vesicles. Go2 alpha is involved in the vesicular storage of monoamines but its physiological relevance is still obscure. We now show that genetic depletion of Go2 alpha reduces motor activity induced by dopamine-enhancing drugs like cocaine, as repeated injections of cocaine fail to provoke behavioral sensitization in Go2 alpha(-/-) mice. In Go2 alpha(-/-) mice, D1 receptor signaling in the striatum is attenuated due to a reduced expression of Golf alpha and Gs alpha. Following cocaine treatment, Go2 alpha(-/-) mice have lower D1 and higher D2 receptor amounts compared to wild-type mice. The lack of behavioral sensitization correlates with reduced dopamine levels in the striatum and decreased expression of tyrosine hydroxylase. One reason for the neurochemical changes may be a reduced uptake of monoamines by synaptic vesicles from Go2 alpha(-/-) mice as a consequence of a lowered set point for filling. We conclude that Go2 alpha optimizes vesicular filling which is instrumental for normal dopamine functioning and for the development of drug-induced behavioral sensitization.	[Sanchis-Segura, Carles; Perreau-Lenz, Stephanie; Bilbao, Ainhoa; Spanagel, Rainer] Cent Inst Mental Hlth, Dept Psychopharmacol, D-68159 Mannheim, Germany; [Brunk, Irene; Blex, Christian; Sternberg, Jan; Baron, Jens; Juranek, Judyta; Laube, Gregor; Ahnert-Hilger, Gudrun] Charite, Ctr Anat, Inst Integrat Neuroanat, Berlin, Germany; [Sanchis-Segura, Carles; Perreau-Lenz, Stephanie; Bilbao, Ainhoa; Spanagel, Rainer] Charite, Inst Pharmacol, Berlin, Germany; [Birnbaumer, Lutz] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA	Central Institute of Mental Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Spanagel, R (corresponding author), Cent Inst Mental Hlth, Dept Psychopharmacol, J5, D-68159 Mannheim, Germany.	gudrun.ahnert@charite.de; rainer.spanagel@zi-mannheim.de	s, c/Y-9655-2019; Perreau-Lenz, Stephanie/D-2309-2014; Juranek, Judyta/AAH-6473-2020; Juranek, Judyta K/I-1120-2013; Baron, Jens M/N-2934-2016; Sanchis-Segura, Carla/C-5222-2012; Bilbao, Ainhoa/AAW-6230-2020	s, c/0000-0002-6951-5972; Perreau-Lenz, Stephanie/0000-0001-9529-6403; Juranek, Judyta/0000-0001-8665-6606; Baron, Jens M/0000-0002-1174-6946; Sanchis-Segura, Carla/0000-0002-6951-5972; Brunk, Irene/0000-0002-2668-7002; Blex, Christian/0000-0002-8493-3523	Deutsche Forshungsgemeinschaft [AH 67/3-3]; Forschungsforderung der Charite; German Federal Ministry of Education and Research (BMBF; Nationales Genomforschungsnetz); Intramural Research Program of the National Institutes of Health [Z01ES01643]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101643, ZIGES101643] Funding Source: NIH RePORTER	Deutsche Forshungsgemeinschaft(German Research Foundation (DFG)); Forschungsforderung der Charite; German Federal Ministry of Education and Research (BMBF; Nationales Genomforschungsnetz)(Federal Ministry of Education & Research (BMBF)); Intramural Research Program of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the Deutsche Forshungsgemeinschaft (AH 67/3-3), the Forschungsforderung der Charite to G.A.H., by the German Federal Ministry of Education and Research (BMBF; Nationales Genomforschungsnetz) to R.S., and by the Intramural Research Program of the National Institutes of Health to L.B. (Z01ES01643). Technical assistance of Marion Mobes and Birgit Metze (both Charite) is gratefully acknowledged.	Abarca C, 2002, P NATL ACAD SCI USA, V99, P9026, DOI 10.1073/pnas.142039099; Ahnert-Hilger G, 2004, REV PHYSIOL BIOCH P, V150, P140, DOI 10.1007/s10254-003-0020-2; BARDO MT, 1995, NEUROSCI BIOBEHAV R, V19, P39, DOI 10.1016/0149-7634(94)00021-R; Becher A, 1999, J NEUROSCI, V19, P1922; Brunk I, 2006, HANDB EXP PHARM, V175, P305; Brunk I, 2006, J BIOL CHEM, V281, P33373, DOI 10.1074/jbc.M603204200; Corvol JC, 2007, NEUROPSYCHOPHARMACOL, V32, P1109, DOI 10.1038/sj.npp.1301230; Dhingra A, 2002, J NEUROSCI, V22, P4878, DOI 10.1523/JNEUROSCI.22-12-04878.2002; Dhingra A, 2000, J NEUROSCI, V20, P9053; Edwards RH, 2007, NEURON, V55, P835, DOI 10.1016/j.neuron.2007.09.001; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; Frank ST, 2008, SYNAPSE, V62, P243, DOI 10.1002/syn.20489; Gainetdinov RR, 2002, TRENDS PHARMACOL SCI, V23, P367, DOI 10.1016/S0165-6147(02)02044-8; GERMAN DC, 1981, BRAIN RES BULL, V6, P131, DOI 10.1016/S0361-9230(81)80037-8; Holtje M, 2000, J NEUROSCI, V20, P2131; HORTNAGL H, 1993, J NEUROSCI, V13, P2939; Hummel M, 2002, J CELL PHYSIOL, V191, P17, DOI 10.1002/jcp.10078; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3269, DOI 10.1073/pnas.95.6.3269; Jiang MS, 2001, P NATL ACAD SCI USA, V98, P3577, DOI 10.1073/pnas.051632598; LEOPOLDT D, 1997, N-S ARCH PHARMACOL, V356, P116; Liu XY, 2006, NEURON, V52, P897, DOI 10.1016/j.neuron.2006.10.011; Pahner I, 2003, MOL CELL NEUROSCI, V23, P398, DOI 10.1016/S1044-7431(03)00059-9; Pothos EN, 2000, J NEUROSCI, V20, P7297; Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x; Sora I, 2001, P NATL ACAD SCI USA, V98, P5300, DOI 10.1073/pnas.091039298; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030; Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x; Uhl GR, 2000, FASEB J, V14, P2459, DOI 10.1096/fj.00-0205rev; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x; Winter S, 2005, J NEUROSCI, V25, P4672, DOI 10.1523/JNEUROSCI.0549-05.2005; Zhuang XX, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-16-j0001.2000	35	14	14	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3736	3746		10.1096/fj.08-111245	http://dx.doi.org/10.1096/fj.08-111245			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18606864	Green Published			2022-12-28	WOS:000259642600034
J	Chen, JQ; Hui, ST; Couto, FM; Mungrue, IN; Davis, DB; Attie, AD; Lusis, AJ; Davis, RA; Shalev, A				Chen, Junqin; Hui, Simon T.; Couto, Francesca M.; Mungrue, Imran N.; Davis, Dawn B.; Attie, Alan D.; Lusis, Aldons J.; Davis, Roger A.; Shalev, Anath			Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes	FASEB JOURNAL			English	Article						apoptosis; islets; obesity; insulin sensitivity; bTKO; TXNIP	UP-REGULATED PROTEIN-1; INSULIN-RESISTANCE; GLUCOSE; MICE; STREPTOZOTOCIN; APOPTOSIS; EXPRESSION; TXNIP; SUSCEPTIBILITY; AUTOIMMUNE	Pancreatic beta-cell loss through apoptosis represents a key factor in the pathogenesis of diabetes; however, no effective approaches to block this process and preserve endogenous beta-cell mass are currently available. To study the role of thioredoxin-interacting protein (TXNIP), a proapoptotic beta-cell factor we recently identified, we used HcB-19 (TXNIP nonsense mutation) and beta-cell-specific TXNIP knockout (bTKO) mice. Interestingly, HcB-19 mice demonstrate increased adiposity, but have lower blood glucose levels and increased pancreatic beta-cell mass (as assessed by morphometry). Moreover, HcB-19 mice are resistant to streptozotocin-induced diabetes. When intercrossed with obese, insulin-resistant, and diabetic mice, double-mutant BTBRlep(ob/ob) txnip(hcb/hcb) are even more obese, but are protected against diabetes and beta-cell apoptosis, resulting in a 3-fold increase in beta-cell mass. Beta-cell-specific TXNIP deletion also enhanced beta-cell mass (P < 0.005) and protected against diabetes, and terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) revealed a similar to 50-fold reduction in beta-cell apoptosis in streptozotocin-treated bTKO mice. We further discovered that TXNIP deficiency induces Akt/Bcl-xL signaling and inhibits mitochondrial beta-cell death, suggesting that these mechanisms may mediate the beta-cell protective effects of TXNIP deficiency. These results suggest that lowering beta-cell TXNIP expression could serve as a novel strategy for the treatment of type 1 and type 2 diabetes by promoting endogenous beta-cell survival.	[Chen, Junqin; Couto, Francesca M.; Davis, Dawn B.; Shalev, Anath] Univ Wisconsin, Dept Med, Madison, WI 53792 USA; [Davis, Dawn B.; Attie, Alan D.] Univ Wisconsin, Dept Biochem, Madison, WI 53792 USA; [Hui, Simon T.; Davis, Roger A.] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; [Mungrue, Imran N.; Lusis, Aldons J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; California State University System; San Diego State University; University of California System; University of California Los Angeles	Shalev, A (corresponding author), Univ Wisconsin, Endocrine Sect, Clin Sci Ctr H4 526, 600 Highland Ave, Madison, WI 53792 USA.	as7@medicine.wisc.edu	Davis, Dawn/B-1624-2013	Davis, Dawn/0000-0002-0239-4715; Mungrue, Imran/0000-0002-0870-7161	American Diabetes Association [ADA; 7-07-CD-22]; Juvenile Diabetes Research Foundation [1-2007-790]; National Institutes of Health [NIH; R01DK-078752]; ADA [1-05-IN-06]; NIH [R01HL-51648]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078752] Funding Source: NIH RePORTER	American Diabetes Association(American Diabetes Association); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ADA(American Diabetes Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Geetu Saxena, Hyunjoo Cha-Molstad, and Mary Rabaglia for their excellent technical assistance. This work was Supported by grants from the American Diabetes Association (ADA; 7-07-CD-22), Juvenile Diabetes Research Foundation (1-2007-790) and National Institutes of Health (NIH; R01DK-078752) to A.S. and from ADA (1-05-IN-06) and NIH (R01HL-51648) to R.D.	Babaya N, 2005, BIOCHEM BIOPH RES CO, V328, P158, DOI 10.1016/j.bbrc.2004.12.149; Bock T, 2003, DIABETES, V52, P1716, DOI 10.2337/diabetes.52.7.1716; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; BONNERWEIR S, 1994, RECENT PROG HORM RES, V49, P91; Cardinal JW, 2001, MOL CELL BIOL, V21, P5605, DOI 10.1128/MCB.21.16.5605-5613.2001; Chen J, 2008, DIABETES, V57, P938, DOI 10.2337/db07-0715; Chutkow WA, 2008, J BIOL CHEM, V283, P2397, DOI 10.1074/jbc.M708169200; Clee Susanne M, 2005, Am J Ther, V12, P491, DOI 10.1097/01.mjt.0000178781.89789.25; Diabet Control Complications Trial Res Grp, 1998, ANN INTERN MED, V128, P517, DOI 10.7326/0003-4819-128-7-199804010-00001; Dickson LM, 2004, AM J PHYSIOL-ENDOC M, V287, pE192, DOI 10.1152/ajpendo.00031.2004; Fatrai S, 2006, DIABETES, V55, P318, DOI 10.2337/diabetes.55.02.06.db05-0757; Herold KC, 1996, J IMMUNOL, V156, P3521; Hotta M, 1998, J EXP MED, V188, P1445, DOI 10.1084/jem.188.8.1445; Hui STY, 2008, P NATL ACAD SCI USA, V105, P3921, DOI 10.1073/pnas.0800293105; Hui TY, 2004, J BIOL CHEM, V279, P24387, DOI 10.1074/jbc.M401280200; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Kwan EP, 2006, DIABETES, V55, P1421, DOI 10.2337/db05-1263; Lan H, 2003, DIABETES, V52, P688, DOI 10.2337/diabetes.52.3.688; Lee JY, 2006, J BIOL CHEM, V281, P2649, DOI 10.1074/jbc.M512373200; Mandrup-Poulsen T, 2003, BIOCHEM PHARMACOL, V66, P1433, DOI 10.1016/S0006-2952(03)00494-5; Mandrup-Poulsen T, 2001, DIABETES, V50, pS58, DOI 10.2337/diabetes.50.2007.S58; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Minn AH, 2005, ENDOCRINOLOGY, V146, P2397, DOI 10.1210/en.2004-1378; Minn AH, 2005, BIOCHEM BIOPH RES CO, V336, P770, DOI 10.1016/j.bbrc.2005.08.161; Minn AH, 2005, MOL ENDOCRINOL, V19, P794, DOI 10.1210/me.2004-0119; Muller A, 2002, IMMUNOBIOLOGY, V205, P35, DOI 10.1078/0171-2985-00109; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Nishiyama A, 2001, IUBMB LIFE, V52, P29, DOI 10.1080/15216540252774739; Parikh H, 2007, PLOS MED, V4, P868, DOI 10.1371/journal.pmed.0040158; Patwari P, 2006, J BIOL CHEM, V281, P21884, DOI 10.1074/jbc.M600427200; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Shalev A, 2002, ENDOCRINOLOGY, V143, P3695, DOI 10.1210/en.2002-220564; Sheth SS, 2005, J LIPID RES, V46, P123, DOI 10.1194/jlr.M400341-JLR200; STOCHR JP, 2000, DIABETES, V49, P1946; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Yamanaka H, 2000, BIOCHEM BIOPH RES CO, V271, P796, DOI 10.1006/bbrc.2000.2699	39	159	164	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3581	3594		10.1096/fj.08-111690	http://dx.doi.org/10.1096/fj.08-111690			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18552236	Green Published			2022-12-28	WOS:000259642600020
J	Nechama, M; Ben-Dov, IZ; Briata, P; Gherzi, R; Naveh-Many, T				Nechama, Morris; Ben-Dov, Iddo Z.; Briata, Paola; Gherzi, Roberto; Naveh-Many, Tally			The mRNA decay promoting factor K-homology splicing regulator protein post-transcriptionally determines parathyroid hormone mRNA levels	FASEB JOURNAL			English	Article						AUF1; Unr; ARE; calcium; phosphorus; chronic kidney disease	AU-RICH ELEMENT; GENE-EXPRESSION; 3'-UNTRANSLATED REGION; BINDING PROTEIN; KSRP; CALCIUM; IDENTIFICATION; DEGRADATION; STABILITY; EXOSOME	Serum calcium and phosphate concentrations and experimental chronic kidney failure control parathyroid hormone (PTH) gene expression post-transcriptionally through regulated binding of the transacting proteins AUF1 and upstream of N-ras (Unr) to an AU-rich element (ARE) in PTH mRNA 3'-untranslated region (3'UTR). We show that the mRNA decay promoting K-homology splicing regulator protein (KSRP) binds to PTH mRNA in intact parathyroid glands and in transfected cells. This binding is decreased in glands from calcium-depleted or experimental chronic kidney failure rats in which PTH mRNA is more stable compared to parathyroid glands from control and phosphorus-depleted rats in which PTH mRNA is less stable. PTH mRNA decay depends on the KSRP-recruited exosome in parathyroid extracts. In transfected cells, KSRP overexpression and knockdown experiments show that KSRP decreases PTH mRNA stability and steady-state levels through the PTH mRNA ARE. Overexpression of isoform p45 of the PTH mRNA stabilizing protein AUF1 blocks KSRP-PTH mRNA binding and partially prevents the KSRP mediated decrease in PTH mRNA levels. Therefore, calcium or phosphorus depletion, as well as chronic kidney failure, regulate the interaction of KSRP and AUF1 with PTH mRNA and its half-life. Our data indicate a novel role for KSRP in PTH gene expression.	[Nechama, Morris; Ben-Dov, Iddo Z.; Naveh-Many, Tally] Hadassah Hebrew Univ, Minerva Ctr Calcium & Bone Metab, Med Ctr, Serv Nephrol, IL-91120 Jerusalem, Israel; [Briata, Paola; Gherzi, Roberto] Ist Nazl Ric Canc, I-16132 Genoa, Italy	Hebrew University of Jerusalem; Hadassah University Medical Center; University of Genoa; IRCCS AOU San Martino IST	Naveh-Many, T (corresponding author), Hadassah Hebrew Univ, Minerva Ctr Calcium & Bone Metab, Med Ctr, Serv Nephrol, POB 12000, IL-91120 Jerusalem, Israel.	tally@cc.huji.ac.il	Ben-Dov, Iddo/F-3282-2010; Briata, Paola/AAC-6039-2020; Gherzi, Roberto/AAA-7256-2020	Ben-Dov, Iddo/0000-0002-9180-3604; Briata, Paola/0000-0003-3470-0454; Gherzi, Roberto/0000-0001-8654-0611	Italian Istituto Superiore di Sanita [526D/39]; Associazione Italiana Ricerca sul Cancro; German Federal Ministry of Education and Research (BMBF)	Italian Istituto Superiore di Sanita; Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	Calcium and Bone Metabolism (T.N.M.), by a grant from the Italian Istituto Superiore di Sanita (526D/39), an American-Italian Senior Scholar Consultancy 2006/2007 (P.B), and by a grant from the Associazione Italiana Ricerca sul Cancro (R.G.). Minerva is funded through the German Federal Ministry of Education and Research (BMBF).	Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Bell O, 2005, MOL ENDOCRINOL, V19, P516, DOI 10.1210/me.2004-0108; Ben-Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chou CF, 2006, MOL CELL BIOL, V26, P3695, DOI 10.1128/MCB.26.10.3695-3706.2006; Dinur M, 2006, MOL ENDOCRINOL, V20, P1652, DOI 10.1210/me.2005-0333; Epstein E, 2000, J CLIN INVEST, V105, P505, DOI 10.1172/JCI8557; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Gherzi R, 2007, PLOS BIOL, V5, P82, DOI 10.1371/journal.pbio.0050005; Kilav R, 2004, J BIOL CHEM, V279, P2109, DOI 10.1074/jbc.M305302200; KILAV R, 1995, J CLIN INVEST, V96, P327, DOI 10.1172/JCI118038; Kilav R, 2001, J BIOL CHEM, V276, P8727, DOI 10.1074/jbc.M005471200; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Levi R, 2006, J AM SOC NEPHROL, V17, P107, DOI 10.1681/ASN.2005070679; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Naveh-Many T, 2007, CURR OPIN NEPHROL HY, V16, P305, DOI 10.1097/MNH.0b013e3281c55ede; Pullmann R, 2007, MOL CELL BIOL, V27, P6265, DOI 10.1128/MCB.00500-07; Ruggiero T, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-28; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; SILVER J, 2002, PRINCIPLES BONE BIOL, P407; Snee M, 2002, J CELL SCI, V115, P4661, DOI 10.1242/jcs.00137; TADESSE H, 2007, HUM MOL GENET, P506; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001	30	47	49	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3458	3468		10.1096/fj.08-107250	http://dx.doi.org/10.1096/fj.08-107250			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18583400				2022-12-28	WOS:000259642600008
J	Okada, S; Misaka, T; Tanaka, Y; Matsumoto, I; Ishibashi, K; Sasaki, S; Abe, K				Okada, Shinji; Misaka, Takumi; Tanaka, Yasuko; Matsumoto, Ichiro; Ishibashi, Kenichi; Sasaki, Sei; Abe, Keiko			Aquaporin-11 knockout mice and polycystic kidney disease animals share a common mechanism of cyst formation	FASEB JOURNAL			English	Article						subcellular aquaporin; DNA microarray; histochemical analysis; ER stress	ENDOPLASMIC-RETICULUM STRESS; EPIDERMAL GROWTH-FACTOR; RENAL EPITHELIAL-CELLS; PRIMARY CILIA; AUTOSOMAL-DOMINANT; DOMAIN PROTEIN; SUBCELLULAR-LOCALIZATION; RETINAL DEGENERATION; EXTRACELLULAR-MATRIX; MESSENGER-RNA	Aquaporin-11 (AQP11), a new member of the aquaporin family, is localized in the endoplasmic reticulum (ER). Aqp11(-/-) mice neonatally suffer from polycystic kidneys derived from the proximal tubule. Its onset is proceeded by the vacuolization of ER. However, the mechanism for the formation of vacuoles and cysts remains to be clarified. Here, we show that Aqp11(-/-) mice and polycystic kidney disease (PKD) animals share a common pathogenic mechanism of cyst formation. We performed microarray analyses and histochemical staining to characterize the effects of the disruption of Aqp11 on kidneys of 1-wk-old mice. Microarray analyses revealed that the significantly changed functional categories in Aqp11(-/-) mice were similar to those in PKD animals. Histochemical studies showed expression changes of 3 genes, Myc, Egfr, Egf, which are assumed to be involved in the proliferation of cystic cells in PKD. We actually confirmed the activation of cell proliferation in the proximal tubule cells with vacuolized ER. Furthermore, three genes associated with the remodeling of the extracellular matrix, Mmp12, Timp1, Tgfb1, were up-regulated in the fibroblasts. We also demonstrated the activation of apoptosis via the ER-stress pathway in the proximal tubule cells with vacuolized ER. These results provide new insights into the physiological roles of AQP11.	[Okada, Shinji; Misaka, Takumi; Matsumoto, Ichiro; Abe, Keiko] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; [Tanaka, Yasuko; Ishibashi, Kenichi] Meiji Pharmaceut Univ, Dept Med Physiol, Tokyo, Japan; [Sasaki, Sei] Tokyo Med & Dent Univ, Dept Nephrol, Tokyo, Japan	University of Tokyo; Meiji Pharmaceutical University; Tokyo Medical & Dental University (TMDU)	Abe, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	aka7308@mail.ecc.u-tokyo.ac.jp	OKADA, Shinji/AFS-7710-2022	OKADA, Shinji/0000-0002-4465-9961; Misaka, Takumi/0000-0002-9547-5767	Ministry of, Education, Culture. Sports, Science and Technology [161080044, 17780099]; Salt Science Research Foundation [0745]	Ministry of, Education, Culture. Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Salt Science Research Foundation	The work was partly supported by grants-in-aid 161080044 (to K.A.) and 17780099 (to S.O.) from the Ministry of, Education, Culture. Sports, Science and Technology, and 0745 (to S.O.) from the Salt Science Research Foundation.	Agre Peter, 2006, Proc Am Thorac Soc, V3, P5, DOI 10.1513/pats.200510-109JH; Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bisceglia M, 2006, ADV ANAT PATHOL, V13, P26, DOI 10.1097/01.pap.0000201831.77472.d3; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; Chang B, 2006, HUM MOL GENET, V15, P1847, DOI 10.1093/hmg/ddl107; Cowley BD, 1995, J AM SOC NEPHROL, V6, P1679; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Drenth JPH, 2005, TRENDS MOL MED, V11, P37, DOI 10.1016/j.molmed.2004.11.004; Ferrier DEK, 2001, EVOL DEV, V3, P263, DOI 10.1046/j.1525-142x.2001.003004263.x; Gattone VH, 2002, KIDNEY INT, V62, P1560, DOI 10.1046/j.1523-1755.2002.00632.x; Gorelick Daniel A., 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-14; Hayashi T, 1997, GENOMICS, V44, P131, DOI 10.1006/geno.1997.4851; Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ishibashi K, 2006, CELL MOL BIOL, V52, P20, DOI 10.1170/T745; Ishibashi K, 2006, BBA-BIOMEMBRANES, V1758, P989, DOI 10.1016/j.bbamem.2006.02.024; Itoh T, 2005, BIOCHEM BIOPH RES CO, V330, P832, DOI 10.1016/j.bbrc.2005.03.046; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; Lee JE, 2004, J BIOCHEM MOL BIOL, V37, P612; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Liu YH, 2006, KIDNEY INT, V69, P213, DOI 10.1038/sj.ki.5000054; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Mollet G, 2005, HUM MOL GENET, V14, P645, DOI 10.1093/hmg/ddi061; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Morishita Y, 2005, MOL CELL BIOL, V25, P7770, DOI 10.1128/MCB.25.17.7770-7779.2005; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Obermuller N, 2001, AM J PHYSIOL-RENAL, V280, pF540, DOI 10.1152/ajprenal.2001.280.3.F540; Oike H, 2007, J NEUROSCI, V27, P5584, DOI 10.1523/JNEUROSCI.0651-07.2007; Olbrich H, 2003, NAT GENET, V34, P455, DOI 10.1038/ng1216; Onuchic LF, 2002, AM J HUM GENET, V70, P1305, DOI 10.1086/340448; Otto E, 2002, AM J HUM GENET, V71, P1161, DOI 10.1086/344395; Otto EA, 2005, NAT GENET, V37, P282, DOI 10.1038/ng1520; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Parker E, 2007, KIDNEY INT, V72, P157, DOI 10.1038/sj.ki.5002229; Ramasubbu K, 1998, J AM SOC NEPHROL, V9, P937; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Sayer JA, 2006, NAT GENET, V38, P674, DOI 10.1038/ng1786; Schieren G, 2006, NEPHROL DIAL TRANSPL, V21, P1816, DOI 10.1093/ndt/gfl071; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Sugiyama N, 2006, GENES CELLS, V11, P1213, DOI 10.1111/j.1365-2443.2006.01011.x; Torres VE, 2006, NAT CLIN PRACT NEPHR, V2, P40, DOI 10.1038/ncpneph0070; Verrecchia F, 2007, WORLD J GASTROENTERO, V13, P3056, DOI 10.3748/wjg.v13.i22.3056; Ward CJ, 2003, HUM MOL GENET, V12, P2703, DOI 10.1093/hmg/ddg274; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; WU Z, 2004, DEPARTMENT BIOSTATIS; Xiong HQ, 2002, GENOMICS, V80, P96, DOI 10.1006/geno.2002.6802; Yakata K, 2007, BBA-BIOMEMBRANES, V1768, P688, DOI 10.1016/j.bbamem.2006.11.005; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Zhang MZ, 2004, P NATL ACAD SCI USA, V101, P2311, DOI 10.1073/pnas.0400073101; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	53	42	43	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3672	3684		10.1096/fj.08-111872	http://dx.doi.org/10.1096/fj.08-111872			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18606867				2022-12-28	WOS:000259642600028
J	Zavan, B; Vindigni, V; Lepidi, S; Iacopetti, I; Avruscio, G; Abatangelo, G; Cortivo, R				Zavan, Barbara; Vindigni, Vincenzo; Lepidi, Sandro; Iacopetti, Ilaria; Avruscio, Giampiero; Abatangelo, Giovanni; Cortivo, Roberta			Neoarteries grown in vivo using a tissue-engineered hyaluronan-based scaffold	FASEB JOURNAL			English	Article						elastin; vascular prosthesis; remodeling; surgery	BLOOD-VESSEL; VASCULAR AUTOGRAFTS; ELASTIN; CELLS	Vascular tissue engineering has emerged as a promising technology for the design of an ideal, responsive, living conduit with properties similar to that of native tissue. The missing link in tissue-engineered blood vessels is elastin biosynthesis. Several biomaterials are currently used but few support elastin biosynthesis in a 3-D array. In previous studies, we demonstrated that a hyaluronan-based scaffold (HYAFF-11 (TM)) grafted in the infrarenal rat aorta successfully guided the complete regeneration of a well-functioning small-diameter (2 mm) neoartery. The aim of the present study was to test the ability of HYAFF-11 biodegradable grafts to develop into neovessels of larger size (4 mm) in a porcine model, focusing on extracellular matrix (ECM) remodeling and elastin biosynthesis. HYAFF-11 tubes (diameter 4 mm, length 5 cm) were implanted in an end-to-end fashion in the common carotid artery. Grafts were analyzed for patency with a Duplex scan every 15 days. ECM components were evaluated by histological and molecular biological methods. All the animals survived the observation period without complications. Intimal hyperplasia (initiating at the anastomotic site) and graft thrombosis led to 3 cases of partial or complete occlusion, as demonstrated by histological examination. There were no signs of stenoses or aneurysms in the remaining grafts. After 5 months, the biomaterial was almost completely degraded and replaced by a neoartery segment composed of mature smooth muscle cells, collagen, and elastin fibers organized in layers and was completely covered on the luminal surface by endothelial cells (vWF(+)). Whereas in previous small animal studies, patency rates were not optimal, those obtained in the present study using hyaluronan-based grafts of larger size confirmed the ability of these constructs to guide the development of a well-functioning neoartery, with the remarkable additional attribute of facilitating the formation of organized layers of elastin fibers.	[Vindigni, Vincenzo] Univ Padua, Clin Plast Surg, I-35100 Padua, Italy; [Zavan, Barbara; Abatangelo, Giovanni; Cortivo, Roberta] Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35100 Padua, Italy; [Lepidi, Sandro] Univ Padua, Clin Vasc Surg, I-35100 Padua, Italy; [Avruscio, Giampiero] Univ Padua, Unit Angiol, I-35100 Padua, Italy; [Iacopetti, Ilaria] Univ Padua, Dept Vet Sci, I-35100 Padua, Italy	University of Padua; University of Padua; University of Padua; University of Padua; University of Padua	Vindigni, V (corresponding author), Univ Padua, Clin Plast Surg, Via Giustiniani 2, I-35100 Padua, Italy.	vincenzo.vindigni@unipd.it	Vindigni, Vincenzo/K-5059-2016	Vindigni, Vincenzo/0000-0001-6638-9010; Lepidi, Sandro/0000-0003-2201-6081				Alsberg E, 2002, P NATL ACAD SCI USA, V99, P12025, DOI 10.1073/pnas.192291499; Joddar B, 2007, BIOMATERIALS, V28, P3918, DOI 10.1016/j.biomaterials.2007.05.019; Joddar B, 2006, BIOMATERIALS, V27, P5698, DOI 10.1016/j.biomaterials.2006.07.020; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Kerdjoudj H, 2007, CLIN HEMORHEOL MICRO, V37, P89; Kielty CM, 2002, J CELL SCI, V115, P2817; L'Heureux N, 2006, NAT MED, V12, P361, DOI 10.1038/nm1364; L'Heureux N, 2007, NEW ENGL J MED, V357, P1451, DOI 10.1056/NEJMc071536; L'Heureux N, 2007, NAT CLIN PRACT CARD, V4, P389, DOI 10.1038/ncpcardio0930; Lepidi S, 2005, FASEB J, V19, P103, DOI 10.1096/fj.05-4802fje; Lepidi S, 2006, EUR J VASC ENDOVASC, V32, P411, DOI 10.1016/j.ejvs.2006.02.012; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Long JL, 2003, MATRIX BIOL, V22, P339, DOI 10.1016/S0945-053X(03)00052-0; Mann BK, 2001, ANAT RECORD, V263, P367, DOI 10.1002/ar.1116; Matsumura G, 2003, BIOMATERIALS, V24, P2303, DOI 10.1016/S0142-9612(03)00043-7; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Patel A, 2006, CARDIOVASC RES, V71, P40, DOI 10.1016/j.cardiores.2006.02.021; Ratcliffe A, 2000, MATRIX BIOL, V19, P353, DOI 10.1016/S0945-053X(00)00080-9; Remuzzi A, 2004, TISSUE ENG, V10, P699, DOI 10.1089/1076327041348347; Ross JJ, 2003, MATRIX BIOL, V22, P477, DOI 10.1016/S0945-053X(03)00078-7; Shin'oka T, 2005, J THORAC CARDIOV SUR, V129, P1330, DOI 10.1016/j.jtcvs.2004.12.047; Tonello C, 2003, BIOMATERIALS, V24, P1205, DOI 10.1016/S0142-9612(02)00450-7; Turner NJ, 2004, BIOMATERIALS, V25, P5955, DOI 10.1016/j.biomaterials.2004.02.002; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; Ye Q, 2000, EUR J CARDIO-THORAC, V17, P449, DOI 10.1016/S1010-7940(00)00371-7; Zhang WJ, 2007, J CELL MOL MED, V11, P945, DOI 10.1111/j.1582-4934.2007.00099.x; [No title captured]	28	57	58	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2853	2861		10.1096/fj.08-107284	http://dx.doi.org/10.1096/fj.08-107284			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18385214				2022-12-28	WOS:000258089300025
J	Logrip, ML; Janak, PH; Ron, D				Logrip, Marian L.; Janak, Patricia H.; Ron, Dorit			Dynorphin is a downstream effector of striatal BDNF regulation of ethanol intake	FASEB JOURNAL			English	Article						MAP kinase; alcohol; addiction; TrkB; ERK	MESSENGER-RNA EXPRESSION; NEUROTROPHIC FACTOR EXPRESSION; PRODYNORPHIN SYSTEM ACTIVITY; KAPPA-OPIOID RECEPTORS; NUCLEUS-ACCUMBENS; HOMEOSTATIC PATHWAY; NOR-BINALTORPHIMINE; ALCOHOL-CONSUMPTION; DISCRETE REGIONS; DOPAMINE RELEASE	We recently identified brain-derived neurotrophic factor (BDNF) in the dorsal striatum to be a major component of a homeostatic pathway controlling ethanol consumption (1, 2). We hypothesized that ethanol-mediated activation of the BDNF signaling cascade is required for the ethanol-related function of the neurotrophic factor. Here, we demonstrate that exposure of striatal neurons to ethanol results in the activation of the BDNF receptor TrkB, leading to the activation of the mitogen-activated protein kinase (MAP kinase) signaling pathway and the subsequent increase in the expression of preprodynorphin (Pdyn) via BDNF. Finally, we show that activation of the dynorphin receptor, the kappa opioid receptor (KOR), is required for the BDNF-mediated decrease in ethanol intake, illustrating a function of dynorphin in BDNF's homeostatic control of ethanol consumption. Taken together, these results demonstrate that BDNF regulates ethanol intake by initiation of MAP kinase signaling and the ensuing production of downstream gene products, including Pdyn.	[Logrip, Marian L.; Janak, Patricia H.; Ron, Dorit] Univ Calif San Francisco, Ernest Gallo Res Ctr, Emeryville, CA 94608 USA; [Logrip, Marian L.; Janak, Patricia H.; Ron, Dorit] Univ Calif San Francisco, Neurosci Grad Program, Emeryville, CA 94608 USA; [Janak, Patricia H.; Ron, Dorit] Univ Calif San Francisco, Dept Neurol, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ron, D (corresponding author), Univ Calif San Francisco, Ernest Gallo Res Ctr, 5858 Horton St,Ste 200, Emeryville, CA 94608 USA.	dorit.ron@ucsf.edu		Janak, Patricia/0000-0002-3333-9049; Logrip, Marian L/0000-0001-6602-1283	NIAAA NIH HHS [F31 AA015462] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F31AA015462] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; Barnea A, 2001, BRAIN RES, V919, P57, DOI 10.1016/S0006-8993(01)02999-7; Beadles-Bohling AS, 2000, NEUROCHEM INT, V37, P463, DOI 10.1016/S0197-0186(00)00056-5; BERHOW MT, 1995, NEUROSCIENCE, V68, P969, DOI 10.1016/0306-4522(95)00207-Y; Blednov YA, 2006, ALCOHOL, V40, P73, DOI 10.1016/j.alcohol.2006.12.002; Bolanos CA, 2004, NEUROMOL MED, V5, P69, DOI 10.1385/NMM:5:1:069; BROADBEAR JH, 1994, PSYCHOPHARMACOLOGY, V115, P311, DOI 10.1007/BF02245071; Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; Chefer VI, 2006, EUR J NEUROSCI, V23, P229, DOI 10.1111/j.1460-9568.2005.04525.x; Cowen MS, 2001, ALCOHOL CLIN EXP RES, V25, P1126, DOI 10.1111/j.1530-0277.2001.tb02326.x; CROLL SD, 1994, EUR J NEUROSCI, V6, P1343, DOI 10.1111/j.1460-9568.1994.tb00325.x; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DICHIARA G, 1985, EUR J PHARMACOL, V115, P131, DOI 10.1016/0014-2999(85)90598-9; DOLE VP, 1985, P NATL ACAD SCI USA, V82, P3469, DOI 10.1073/pnas.82.10.3469; Doyon WM, 2006, NEUROPHARMACOLOGY, V51, P487, DOI 10.1016/j.neuropharm.2006.04.005; Eckardt MJ, 1998, ALCOHOL CLIN EXP RES, V22, P998, DOI 10.1111/j.1530-0277.1998.tb03695.x; ENDOH T, 1992, ARCH INT PHARMACOD T, V316, P30; Fagergren P, 2003, EUR J NEUROSCI, V17, P2212, DOI 10.1046/j.1460-9568.2003.02636.x; Falk T, 2006, J COMP NEUROL, V494, P275, DOI 10.1002/cne.20819; Gerdeman GL, 2003, TRENDS NEUROSCI, V26, P184, DOI 10.1016/S0166-2236(03)00065-1; GERFEN CR, 1988, BRAIN RES, V460, P161, DOI 10.1016/0006-8993(88)91217-6; Graham DL, 2007, NAT NEUROSCI, V10, P1029, DOI 10.1038/nn1929; Grant BF, 2004, DRUG ALCOHOL DEPEN, V74, P223, DOI 10.1016/j.drugalcdep.2004.02.004; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Grimm JW, 2003, J NEUROSCI, V23, P742; GULYA K, 1993, MOL BRAIN RES, V20, P1, DOI 10.1016/0169-328X(93)90105-X; He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272; Hensler JG, 2003, J NEUROCHEM, V85, P1139, DOI 10.1046/j.1471-4159.2003.01748.x; Holter SM, 2000, PSYCHOPHARMACOLOGY, V153, P93, DOI 10.1007/s002130000601; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; HUNT WA, 1979, ALCOHOL CLIN EXP RES, V3, P359, DOI 10.1111/j.1530-0277.1979.tb05336.x; Jamensky NT, 1997, ALCOHOL CLIN EXP RES, V21, P1455; Jeanblanc J, 2006, J NEUROSCI, V26, P1457, DOI 10.1523/JNEUROSCI.3786-05.2006; Kovacs KM, 2005, ALCOHOL CLIN EXP RES, V29, P730, DOI 10.1097/01.ALC.0000164361.62346.D6; Le Foll B, 2005, NEUROREPORT, V16, P175, DOI 10.1097/00001756-200502080-00022; Lindholm S, 2001, BEHAV BRAIN RES, V120, P137, DOI 10.1016/S0166-4328(00)00368-5; Lindholm S, 2000, ALCOHOL, V22, P165, DOI 10.1016/S0741-8329(00)00118-X; Liu QR, 2006, BRAIN RES, V1067, P1, DOI 10.1016/j.brainres.2005.10.004; Lu L, 2005, NAT NEUROSCI, V8, P212, DOI 10.1038/nn1383; Marinelli PW, 2006, ALCOHOL CLIN EXP RES, V30, P982, DOI 10.1111/j.1530-0277.2006.00112.x; MARSH HN, 1993, J NEUROSCI, V13, P4281; Mathieu-Kia AM, 1998, MOL BRAIN RES, V54, P141, DOI 10.1016/S0169-328X(97)00338-0; Matsushita S, 2004, ALCOHOL CLIN EXP RES, V28, P1609, DOI 10.1097/01.ALC.0000145697.81741.D2; McGough NNH, 2004, J NEUROSCI, V24, P10542, DOI 10.1523/JNEUROSCI.3714-04.2004; Meredith GE, 2002, BRAIN RES, V949, P218, DOI 10.1016/S0006-8993(02)03160-8; Mitchell JM, 2005, PSYCHOPHARMACOLOGY, V182, P384, DOI 10.1007/s00213-005-0067-7; NAWA H, 1995, EUR J NEUROSCI, V7, P1527, DOI 10.1111/j.1460-9568.1995.tb01148.x; Pandey SC, 2004, J NEUROSCI, V24, P5022, DOI 10.1523/JNEUROSCI.5557-03.2004; Pandey SC, 2006, J NEUROSCI, V26, P8320, DOI 10.1523/JNEUROSCI.4988-05.2006; PANULA P, 1981, BRAIN RES, V219, P202, DOI 10.1016/0006-8993(81)90283-3; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Pierce RC, 2001, REV NEUROSCIENCE, V12, P95; Ploj K, 2000, BRAIN RES BULL, V53, P219, DOI 10.1016/S0361-9230(00)00328-2; POLL G, 1939, ANN SURVEYS TAKEN 19; Przewlocka B, 1997, NEUROSCI LETT, V238, P13, DOI 10.1016/S0304-3940(97)00829-X; Ron D, 2000, FASEB J, V14, P2303, DOI 10.1096/fj.00-0143com; Sato M, 2001, J NEUROSCI, V21, P3797, DOI 10.1523/JNEUROSCI.21-11-03797.2001; Saylor AJ, 2006, EXP NEUROL, V199, P362, DOI 10.1016/j.expneurol.2006.01.004; Schlussman SD, 2005, BRAIN RES BULL, V67, P169, DOI 10.1016/j.brainresbull.2005.04.018; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Segal M, 2003, EUR J NEUROSCI, V17, P2573, DOI 10.1046/j.1460-9568.2003.02696.x; SEIZINGER BR, 1983, PHARMACOL BIOCHEM BE, V18, P361, DOI 10.1016/0091-3057(83)90200-9; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; Shi X, 2006, NEUROSCIENCE, V138, P1289, DOI 10.1016/j.neuroscience.2005.12.024; SIGNS SA, 1987, NEUROPHARMACOLOGY, V26, P1653, DOI 10.1016/0028-3908(87)90016-5; SMITH AJW, 1994, MOL BRAIN RES, V21, P359, DOI 10.1016/0169-328X(94)90268-2; SPANAGEL R, 1990, J NEUROCHEM, V55, P1734, DOI 10.1111/j.1471-4159.1990.tb04963.x; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Spanagel R, 1996, PHARMACOL BIOCHEM BE, V54, P645, DOI 10.1016/0091-3057(95)02288-0; SPANGLER R, 1993, MOL BRAIN RES, V19, P323, DOI 10.1016/0169-328X(93)90133-A; Tapia-Arancibia L, 2001, J NEUROSCI RES, V63, P200, DOI 10.1002/1097-4547(20010115)63:2<200::AID-JNR1012>3.0.CO;2-Q; Thompson AC, 2000, J NEUROSCI, V20, P9333; Turchan J, 1998, NEUROSCIENCE, V85, P1051, DOI 10.1016/S0306-4522(97)00639-8; Uhl GR, 2001, AM J HUM GENET, V69, P1290, DOI 10.1086/324467; Valjent E, 2004, EUR J NEUROSCI, V19, P1826, DOI 10.1111/j.1460-9568.2004.03278.x; Walker BM, 2008, NEUROPSYCHOPHARMACOL, V33, P643, DOI 10.1038/sj.npp.1301438; WANG JQ, 1995, NEUROSCIENCE, V68, P83, DOI 10.1016/0306-4522(95)00100-W; Williams KL, 1998, ALCOHOL CLIN EXP RES, V22, P1634, DOI 10.1111/j.1530-0277.1998.tb03960.x; Xuei X, 2006, MOL PSYCHIATR, V11, P1016, DOI 10.1038/sj.mp.4001882; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yin HH, 2006, NAT REV NEUROSCI, V7, P464, DOI 10.1038/nrn1919; You ZB, 1999, J PHARMACOL EXP THER, V290, P1307; Zapata A, 2006, ALCOHOL CLIN EXP RES, V30, P592, DOI 10.1111/j.1530-0277.2006.00069.x; Zapata A, 2006, NEUROPSYCHOPHARMACOL, V31, P396, DOI 10.1038/sj.npp.1300833; Zhang DS, 2002, J NEUROCHEM, V82, P1453, DOI 10.1046/j.1471-4159.2002.01089.x; Zhang Y, 2004, PSYCHOPHARMACOLOGY, V172, P422, DOI 10.1007/s00213-003-1688-3	90	74	76	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2393	2404		10.1096/fj.07-099135	http://dx.doi.org/10.1096/fj.07-099135			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18310464				2022-12-28	WOS:000257292500031
J	Wakao, H; Wakao, R; Sakata, S; Iwabuchi, K; Oda, A; Fujita, H				Wakao, Hiroshi; Wakao, Rika; Sakata, Sakura; Iwabuchi, Kazuya; Oda, Atsushi; Fujita, Hiroyoshi			In vitro induction of natural killer T cells from embryonic stem cells prepared using somatic cell nuclear transfer	FASEB JOURNAL			English	Article						adjuvant effect; in vitro differentiation; transplantable lymphocytes; tumor rejection	NKT CELLS; DENDRITIC CELLS; TUMOR-IMMUNITY; IMMUNOREGULATORY AXIS; MICE; LINEAGE; THYMUS; GENERATION; THYMOCYTES; SELECTION	The ectopic expression of the Notch receptor ligand delta-like 1 on stromal cells allows the induction of T cells from embryonic stem cells (ESCs). However, these in vitro-generated T cells are not transplantable because they are too immature to mount an immune response in an immunocompromised animal. We efficiently generated a subset of T cells called invariant natural killer T (iNKT) cells from ESCs derived from peripheral iNKT cells using somatic cell nuclear transfer (ntESCs). These iNKT cells matured autonomously in vivo and exhibited an adjuvant effect accompanying the production of interferon-gamma in an antigen-specific manner. This adjuvant effect culminated in the inhibition of inoculated tumor cell growth. Our results indicate that ntESC-derived iNKT cells are transplantable lymphocytes that will be beneficial for the induction of immune tolerance and the treatment of autoimmune diseases, tumors, and infections.	[Wakao, Hiroshi; Oda, Atsushi; Fujita, Hiroyoshi] Hokkaido Univ, Sch Med, Dept Environm Biol, Sapporo, Hokkaido 0608638, Japan; [Iwabuchi, Kazuya] Hokkaido Univ, Div Immunobiol, Inst Med Genet, Sapporo, Hokkaido 0608638, Japan; [Wakao, Rika] Rikagaku Kenkyusho RIKEN, Res Ctr Allergy & Immunol, Dev Genet Grp, Yokohama, Japan; [Sakata, Sakura] Rikagaku Kenkyusho RIKEN, Res Ctr Allergy & Immunol, Immune Regulat Grp, Yokohama, Japan	Hokkaido University; Hokkaido University; RIKEN; RIKEN	Wakao, H (corresponding author), Hokkaido Univ, Sch Med, Dept Environm Biol, N15W7, Sapporo, Hokkaido 0608638, Japan.	hwakao@med.hokudai.ac.jp	WAKAO, Hiroshi/A-4242-2012					Ambrosino E, 2007, J IMMUNOL, V179, P5126, DOI 10.4049/jimmunol.179.8.5126; Baldwin TA, 2004, J IMMUNOL, V173, P6515, DOI 10.4049/jimmunol.173.11.6515; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; Benlagha K, 2005, J EXP MED, V202, P485, DOI 10.1084/jem.20050456; Benlagha K, 2002, SCIENCE, V296, P553, DOI 10.1126/science.1069017; BRADBURY A, 1990, EUR J IMMUNOL, V20, P1831, DOI 10.1002/eji.1830200830; Cho SK, 1999, P NATL ACAD SCI USA, V96, P9797, DOI 10.1073/pnas.96.17.9797; Coles MC, 2000, J IMMUNOL, V164, P2412, DOI 10.4049/jimmunol.164.5.2412; Crowe NY, 2002, J EXP MED, V196, P119, DOI 10.1084/jem.20020092; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Egawa T, 2005, IMMUNITY, V22, P705, DOI 10.1016/j.immuni.2005.03.011; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Gapin L, 2001, NAT IMMUNOL, V2, P971, DOI 10.1038/ni710; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594; Gonzalez-Aseguinolaza G, 2002, J EXP MED, V195, P617, DOI 10.1084/jem.20011889; Inoue K, 2005, CURR BIOL, V15, P1114, DOI 10.1016/j.cub.2005.05.021; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Kronenberg M, 2005, NATURE, V435, P598, DOI 10.1038/nature03725; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nakano T, 1995, Semin Immunol, V7, P197, DOI 10.1016/1044-5323(95)90047-0; Parekh VV, 2005, J CLIN INVEST, V115, P2572, DOI 10.1172/JCI24762; Rothenberg EV, 2002, IMMUNOL REV, V187, P96, DOI 10.1034/j.1600-065X.2002.18709.x; Schmitt TM, 2004, NAT IMMUNOL, V5, P410, DOI 10.1038/ni1055; Shimizu K, 2007, J EXP MED, V204, P2641, DOI 10.1084/jem.20070458; Shimizu K, 2007, J IMMUNOL, V178, P2853, DOI 10.4049/jimmunol.178.5.2853; Smyth MJ, 2002, CURR OPIN IMMUNOL, V14, P165, DOI 10.1016/S0952-7915(02)00316-3; Stewart TJ, 2003, CANCER RES, V63, P3058; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Terabe M, 2007, TRENDS IMMUNOL, V28, P491, DOI 10.1016/j.it.2007.05.008; Wakao H, 2007, J IMMUNOL, V179, P3888, DOI 10.4049/jimmunol.179.6.3888	36	7	10	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2223	2231		10.1096/fj.07-104687	http://dx.doi.org/10.1096/fj.07-104687			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18323403				2022-12-28	WOS:000257292500015
J	Tokunou, T; Miller, R; Patwari, P; Davis, ME; Segers, VFM; Grodzinsky, AJ; Lee, RT				Tokunou, Tomotake; Miller, Rachel; Patwari, Parth; Davis, Michael E.; Segers, Vincent F. M.; Grodzinsky, Alan J.; Lee, Richard T.			Engineering insulin-like growth factor-1 for local delivery	FASEB JOURNAL			English	Article						heparin binding domain; tissue repair; biosynthesis	HEPARIN-BINDING EGF; EMBRYONIC STEM-CELLS; ARTICULAR-CARTILAGE; SKELETAL-MUSCLE; RECEPTOR; IGF-1; HORMONE; REGENERATION; ACTIVATION; EXPRESSION	Insulin-like growth factor-1 (IGF-1) is a small protein that promotes cell survival and growth, often acting over long distances. Although for decades IGF-1 has been considered to have therapeutic potential, systemic side effects of IGF-1 are significant, and local delivery of IGF-1 for tissue repair has been a long-standing challenge. In this study, we designed and purified a novel protein, heparin-binding IGF-1 (XpHB-IGF-1), which is a fusion protein of native IGF-1 with the heparin-binding domain of heparin-binding epidermal growth factor-like growth factor. Xp-HB-IGF1 bound selectively to heparin as well as the cell surfaces of 3T3 fibroblasts, neonatal cardiac myocytes and differentiating ES cells. Xp-HB-IGF-1 activated the IGF-1 receptor and Akt with identical kinetics and dose response, indicating no compromise of biological activity due to the heparin-binding domain. Because cartilage is a proteoglycan-rich environment and IGF-1 is a known stimulus for chondrocyte biosynthesis, we then studied the effectiveness of Xp-HB-IGF-1 in cartilage. Xp-HB-IGF-1 was selectively retained by cartilage explants and led to sustained chondrocyte proteoglycan biosynthesis compared to IGF-1. These data show that the strategy of engineering a "long- distance" growth factor like IGF-1 for local delivery may be useful for tissue repair and minimizing systemic effects.	[Tokunou, Tomotake; Patwari, Parth; Davis, Michael E.; Segers, Vincent F. M.; Lee, Richard T.] Harvard Univ, Sch Med, Div Cardiovasc, Brigham & Womens Hosp,Dept Med, Boston, MA USA; [Miller, Rachel; Grodzinsky, Alan J.; Lee, Richard T.] MIT, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Lee, RT (corresponding author), Partners Res Facil, 65 Landsdowne St, Cambridge, MA 02139 USA.	rlee@partners.org	Tokunou, Tomotake/AAG-3403-2019; Segers, Vincent F/J-1191-2019	Segers, Vincent F/0000-0001-7796-2222; Miller, Rachel/0000-0002-4486-5757; Lee, Richard/0000-0003-4687-1381	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL073574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB003805] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL073574, F32 HL073574-03] Funding Source: Medline; NIBIB NIH HHS [R01 EB003805, EB003805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; Bhakta NR, 2000, J BIOL CHEM, V275, P5860, DOI 10.1074/jbc.275.8.5860; Bonassar LJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P57, DOI 10.1006/abbi.2000.1820; Capito RM, 2007, GENE THER, V14, P721, DOI 10.1038/sj.gt.3302918; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Coffer PJ, 1998, BIOCHEM J, V335, P1; Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09; Denley A, 2005, CYTOKINE GROWTH F R, V16, P421, DOI 10.1016/j.cytogfr.2005.04.004; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Fraidenraich D, 2004, SCIENCE, V306, P247, DOI 10.1126/science.1102612; Frystyk J, 2004, GROWTH HORM IGF RES, V14, P337, DOI 10.1016/j.ghir.2004.06.001; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; Hameed M, 2003, J PHYSIOL-LONDON, V547, P247, DOI 10.1113/jphysiol.2002.032136; Harmer NJ, 2003, BIOPHYS CHEM, V100, P545, DOI 10.1016/S0301-4622(02)00305-8; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; JABRI N, 1994, DIABETES, V43, P369, DOI 10.2337/diabetes.43.3.369; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MILNER SJ, 1995, BIOCHEM J, V308, P865, DOI 10.1042/bj3080865; Milner SJ, 1999, BIOTECHNOL BIOENG, V62, P693; Mourkioti F, 2005, TRENDS IMMUNOL, V26, P535, DOI 10.1016/j.it.2005.08.002; Musaro A, 2007, EXP GERONTOL, V42, P76, DOI 10.1016/j.exger.2006.05.004; Nixon AJ, 2000, CLIN ORTHOP RELAT R, pS201, DOI 10.1097/00003086-200010001-00026; Ozdinler PH, 2006, NAT NEUROSCI, V9, P1371, DOI 10.1038/nn1789; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; Robinson CJ, 2006, J BIOL CHEM, V281, P1731, DOI 10.1074/jbc.M510760200; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; Schmidt MB, 2006, OSTEOARTHR CARTILAGE, V14, P403, DOI 10.1016/j.joca.2005.10.011; Shavlakadze T, 2005, GROWTH HORM IGF RES, V15, P4, DOI 10.1016/j.ghir.2004.11.001; Takahashi T, 2003, CIRCULATION, V107, P1912, DOI 10.1161/01.CIR.0000064899.53876.A3; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Topalli I, 2004, BRAIN RES, V1030, P116, DOI 10.1016/j.brainres.2004.09.057; Vincent TL, 2007, OSTEOARTHR CARTILAGE, V15, P752, DOI 10.1016/j.joca.2007.01.021; Wilkinson-Berka JL, 2006, CURR MED CHEM, V13, P3307, DOI 10.2174/092986706778773086; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshioka J, 2005, P NATL ACAD SCI USA, V102, P10622, DOI 10.1073/pnas.0501198102	38	32	45	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1886	1893		10.1096/fj.07-100925	http://dx.doi.org/10.1096/fj.07-100925			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18285400	Green Accepted			2022-12-28	WOS:000256352700028
J	Jakubowski, H; Perla-Kajan, J; Finnell, RH; Cabrera, RM; Wang, H; Gupta, S; Kruger, WD; Kraus, JP; Shih, DM				Jakubowski, Hieronim; Perla-Kajan, Joanna; Finnell, Richard H.; Cabrera, Robert M.; Wang, Hong; Gupta, Sapna; Kruger, Warren D.; Kraus, Jan P.; Shih, Diana M.			Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice	FASEB JOURNAL			English	Article						methionine; thiolactone; liver damage; atherothrombosis	CYSTATHIONINE-BETA-SYNTHASE; METHYLENETETRAHYDROFOLATE REDUCTASE; PATHOLOGICAL CONSEQUENCES; POSSIBLE MECHANISM; MOLECULAR-BASIS; THIOLACTONE; HYPERHOMOCYSTEINEMIA; HUMANS; PLASMA; DEFICIENT	Genetic disorders of homocysteine (Hcy) or folate metabolism or high-methionine diets elevate plasma Hcy and its atherogenic metabolite Hcy- thiolactone. In humans, severe hyperhomocysteinemia due to genetic alterations in cystathionine beta-synthase (Cbs) or methylenetetrahydrofolate reductase (Mthfr) results in neurological abnormalities and premature death from vascular complications. In mouse models, dietary or genetic hyperhomocysteinemia results in liver or brain pathological changes and accelerates atherosclerosis. Hcy- thiolactone has the ability to form isopeptide bonds with protein lysine residues, which generates modified proteins (N-Hcy-protein) with autoimmunogenic and prothrombotic properties. Our aim was to determine how N-Hcy-protein levels are affected by genetic or nutritional disorders in Hcy or folate metabolism in mice. We found that plasma N-Hcy-protein was elevated 10-fold in mice fed a high-methionine diet compared with the animals fed a normal commercial diet. We also found that inactivation of Cbs, Mthfr, or the proton-coupled folate transporter (Pcft) gene resulted in a 10- to 30-fold increase in plasma or serum N- Hcy- protein levels. Liver N- Hcy- protein was elevated 3.4-fold in severely and 11-fold in extremely hyperhomocysteinemic Cbs-deficient mice, 3.6-fold in severely hyperhomocysteinemic Pcft mice, but was not elevated in mildly hyperhomocysteinemic Mthfr-deficient animals, suggesting that mice have a capacity to prevent accumulation of N-Hcy-protein in their organs. These findings provide evidence that N- Hcy- protein is an important metabolite associated with Hcy pathophysiology in the mouse.-Jakubowski, H., Perla-Kajan, J., Finnell, R. H., Cabrera, R. M., Wang, H., Gupta, S., Kruger, W. D., Kraus, J. P., and Shih, D. M. Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. FASEB J. 23, 1721-1727 (2009)	[Jakubowski, Hieronim; Perla-Kajan, Joanna] Univ Med & Dent New Jersey, New Jersey Med Sch, Int Ctr Publ Hlth, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA; [Jakubowski, Hieronim; Perla-Kajan, Joanna] Univ Life Sci, Dept Biochem & Biotechnol, Poznan, Poland; [Finnell, Richard H.; Cabrera, Robert M.] Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Texas Inst Genom Med, Houston, TX USA; [Wang, Hong] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19122 USA; [Gupta, Sapna; Kruger, Warren D.] Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA; [Kraus, Jan P.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Shih, Diana M.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Poznan University of Life Sciences; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Fox Chase Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Int Ctr Publ Hlth, Dept Microbiol & Mol Genet, 225 Warren St, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017; kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018; Perla-Kajan, Joanna/F-2965-2010; Finnell, Richard/D-8174-2018	Jakubowski, Hieronim/0000-0001-5845-4409; kruger, warren/0000-0002-4990-3695; Perla-Kajan, Joanna/0000-0002-0791-5057; Finnell, Richard/0000-0002-5962-8754	American Heart Association; Ministry of Science and Higher Education, Poland; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077288, R01HL117654, R01HL067033, R01HL082774] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); Ministry of Science and Higher Education, Poland(Ministry of Science and Higher Education, Poland); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported in part by grants from the American Heart Association and the Ministry of Science and Higher Education, Poland. We thank Rima Rozen (McGill University, Montreal, QC, Canada) for providing plasma and tissue samples from Mthfr-deficient mice. We also thank anonymous reviewers for their helpful comments.	Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Chwatko G, 2005, CLIN CHEM, V51, P408, DOI 10.1373/clinchem.2004.042531; Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035; Chwatko G, 2007, FASEB J, V21, P1707, DOI 10.1096/fj.06-7435com; Ferretti G, 2004, J CELL BIOCHEM, V92, P351, DOI 10.1002/jcb.20069; Gu WJ, 2008, ADV THER, V25, P914, DOI 10.1007/s12325-008-0097-8; Gupta S, 2008, HUM MUTAT, V29, P1048, DOI 10.1002/humu.20773; Gupta S, 2009, FASEB J, V23, P883, DOI 10.1096/fj.08-120584; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2005, CLIN CHEM LAB MED, V43, P1011, DOI 10.1515/CCLM.2005.177; Jakubowski H, 2004, CELL MOL LIFE SCI, V61, P470, DOI 10.1007/s00018-003-3204-7; Jakubowski H, 2002, J BIOL CHEM, V277, P30425, DOI 10.1074/jbc.C200267200; Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5; Jakubowski H, 2001, J NUTR, V131, p2983S, DOI 10.1093/jn/131.11.2983S; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; Jakubowski H, 2008, ANAL BIOCHEM, V380, P257, DOI 10.1016/j.ab.2008.05.049; Jakubowski H, 2007, CLIN CHEM LAB MED, V45, P1704, DOI 10.1515/CCLM.2007.338; Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S; Jakubowski H, 2008, FASEB J, V22, P4071, DOI 10.1096/fj.08-112086; Jakubowsky H., 2005, AMINOACYL TRNA SYNTH, P384; Lentz SR, 2005, J THROMB HAEMOST, V3, P1646, DOI 10.1111/j.1538-7836.2005.01364.x; Maron BA, 2009, ANNU REV MED, V60, P39, DOI 10.1146/annurev.med.60.041807.123308; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 2001, METABOLIC MOL BASES, V2, P2007; Perla-Kajan J, 2008, BIOMED PHARMACOTHER, V62, P473, DOI 10.1016/j.biopha.2008.04.001; Perna AF, 2006, KIDNEY INT, V69, P869, DOI 10.1038/sj.ki.5000070; Qiu A, 2007, AM J PHYSIOL-CELL PH, V293, pC1669, DOI 10.1152/ajpcell.00202.2007; Robert K, 2005, GASTROENTEROLOGY, V128, P1405, DOI 10.1053/j.gastro.2005.02.034; Rosenblatt D. S., 2001, METABOLIC MOL BASES, V8th, P3897; Strauss KA, 2007, MOL GENET METAB, V91, P165, DOI 10.1016/j.ymgme.2007.02.012; Uji Y, 2002, CLIN CHEM, V48, P941; Undas A, 2005, THROMB HAEMOSTASIS, V93, P346, DOI 10.1160/TH04-08-0493; Undas A, 2004, STROKE, V35, P1299, DOI 10.1161/01.STR.0000128412.59768.6e; Undas A, 2006, THROMB HAEMOSTASIS, V96, P342, DOI 10.1160/TH06-04-0228; Wang GP, 2002, ARTERIOSCL THROM VAS, V22, P1777, DOI 10.1161/01.ATV.0000035404.18281.37; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Yang X, 2006, CLIN CHIM ACTA, V364, P230, DOI 10.1016/j.cccn.2005.07.007; Yap S, 2001, ARTERIOSCL THROM VAS, V21, P2080, DOI 10.1161/hq1201.100225; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97	43	87	88	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1721	1727		10.1096/fj.08-127548	http://dx.doi.org/10.1096/fj.08-127548			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19204075	Green Published			2022-12-28	WOS:000266652400012
J	Mikelis, C; Sfaelou, E; Koutsioumpa, M; Kieffer, N; Papadimitriou, E				Mikelis, Constantinos; Sfaelou, Evanthia; Koutsioumpa, Marina; Kieffer, Nelly; Papadimitriou, Evangelia			Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta	FASEB JOURNAL			English	Article						heparin affin regulatory peptide; heparin-binding growth associated molecule; angiogenesis; tumor growth; glioma	GROWTH-FACTOR PLEIOTROPHIN; PROSTATE-CANCER CELLS; C6 GLIOMA-CELLS; BETA(3) INTEGRIN; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; UP-REGULATION; IN-VITRO; ANGIOGENESIS; ACTIVATION	We have previously shown that the angiogenic growth factor pleiotrophin (PTN) induces migration of endothelial cells through binding to its receptor protein tyrosine phosphatase beta/zeta (RPTP beta/zeta). In this study, we show that a monoclonal antibody against alpha(v)beta(3) but not alpha(5)beta(1) integrin abolished PTN-induced human endothelial cell migration in a concentration-dependent manner. Integrin alpha(v)beta(3) was found to directly interact with PTN in an RGD-independent manner, whereas a synthetic peptide corresponding to the specificity loop of the beta(3) integrin extracellular domain ((CYD)-C-177-MKTTC184) inhibited PTN-alpha(v)beta(3) interaction and totally abolished PTN-induced endothelial cell migration. Interestingly, alpha(v)beta(3) was also found to directly interact with RPTP beta/zeta, and PTN-induced Y773 phosphorylation of beta(3) integrin was dependent on both RPTP beta/zeta and the downstream c-src kinase activation. Midkine was found to interact with RPTP beta/zeta, but not with alpha(v)beta(3), and caused a small but statistically significant decrease in cell migration. In the same line, PTN decreased migration of different glioma cell lines that express RPTP beta/zeta but do not express alpha(v)beta(3), while it stimulated migration of U87MG cells that express alpha(v)beta(3) on their cell membrane. Overexpression or down-regulation of beta 3 stimulated or abolished, respectively, the effect of PTN on cell migration. Collectively, these data suggest that alpha(v)beta(3) is a key molecule that determines the stimulatory or inhibitory effect of PTN on cell migration.-Mikelis, C., Sfaelou, E., Koutsioumpa, M., Kieffer, N., Papadimitriou, E. Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. FASEB J. 23, 1459-1469 (2009)	[Mikelis, Constantinos; Sfaelou, Evanthia; Koutsioumpa, Marina; Papadimitriou, Evangelia] Univ Patras, Dept Pharm, Mol Pharmacol Lab, GR-26504 Patras, Greece; [Kieffer, Nelly] Jiao Tong Univ, Sch Med, Rui Jin Hosp, Sino French Res Ctr Life Sci & Genom,CNRS,LIA124, Shanghai 200030, Peoples R China	University of Patras; Shanghai Jiao Tong University	Papadimitriou, E (corresponding author), Univ Patras, Dept Pharm, Mol Pharmacol Lab, GR-26504 Patras, Greece.	epapad@upatras.gr	Papadimitriou, Evangelia/F-3396-2010; Mikelis, Constantinos/AGF-9423-2022; Papadimitriou, Evangelia/ABG-1356-2020; KOUTSIOUMPA, MARINA/CAI-1960-2022	Papadimitriou, Evangelia/0000-0001-6429-4325; KOUTSIOUMPA, MARINA/0000-0002-6359-573X	E.U.; Greek Ministry of Development-GSRT [PENED 036Delta560]	E.U.(European Commission); Greek Ministry of Development-GSRT(Greek Ministry of Development-GSRT)	This research project is cofinanced by the E.U.-European Social Fund (75%) and the Greek Ministry of Development-GSRT (25%) (PENED 036 Delta 560). We are grateful to Drs. Vasilis Roukos, Zoi Lygerou, Yannis Misirlis, and Mr. Stergios Dermenoudis for their kind hospitality and help with confocal microscopy.	Arias-Salgado EG, 2005, J CELL BIOL, V170, P837, DOI 10.1083/jcb.200503125; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Chen HM, 2007, BLOOD, V110, P287, DOI 10.1182/blood-2006-08-042374; Chen YQ, 1997, INT J CANCER, V72, P642, DOI 10.1002/(SICI)1097-0215(19970807)72:4<642::AID-IJC16>3.0.CO;2-D; Chow JPH, 2008, J BIOL CHEM, V283, P30879, DOI 10.1074/jbc.M802976200; Ezquerra L, 2008, GROWTH FACTORS, V26, P44, DOI 10.1080/08977190801987711; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Fukazawa N, 2008, MOL CELL BIOL, V28, P4494, DOI 10.1128/MCB.00074-08; Garwood J, 2003, J BIOL CHEM, V278, P24164, DOI 10.1074/jbc.M211721200; Harroch S, 2002, NAT GENET, V32, P411, DOI 10.1038/ng1004; Hatziapostolou M, 2006, J BIOL CHEM, V281, P32217, DOI 10.1074/jbc.M607104200; Heroult M, 2004, ONCOGENE, V23, P1745, DOI 10.1038/sj.onc.1206879; Hodivala-Dilke KM, 2003, CELL TISSUE RES, V314, P131, DOI 10.1007/s00441-003-0774-5; Huang Y, 2006, BLOOD, V107, P3564, DOI 10.1182/blood-2005-07-2961; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Koutsioumpa M, 2009, EUR J PHARMACOL, V602, P245, DOI 10.1016/j.ejphar.2008.11.046; Li G, 2006, J BIOL CHEM, V281, P10663, DOI 10.1074/jbc.M512509200; Lorente G, 2005, NEURO-ONCOLOGY, V7, P154, DOI 10.1215/S1152851704000547; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; Mahabeleshwar GH, 2008, CELL CYCLE, V7, P335, DOI 10.4161/cc.7.3.5234; Mahabeleshwar GH, 2007, CIRC RES, V101, P570, DOI 10.1161/CIRCRESAHA.107.155655; Maile LA, 2006, MOL ENDOCRINOL, V20, P405, DOI 10.1210/me.2005-0241; Mikelis C, 2008, CONNECT TISSUE RES, V49, P149, DOI 10.1080/03008200802148652; Mikelis C, 2007, RECENT PAT ANTI-CANC, V2, P175, DOI 10.2174/157489207780832405; Muramatsu H, 2004, J CELL SCI, V117, P5405, DOI 10.1242/jcs.01423; Parthymou A, 2004, INT J CANCER, V110, P807, DOI 10.1002/ijc.20188; Parthymou A, 2008, EUR J CELL BIOL, V87, P17, DOI 10.1016/j.ejcb.2007.07.007; Patsenker E, 2007, J HEPATOL, V46, P878, DOI 10.1016/j.jhep.2006.11.011; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; Polykratis A, 2005, J BIOL CHEM, V280, P22454, DOI 10.1074/jbc.M414407200; Polytarchou C, 2005, J BIOL CHEM, V280, P40428, DOI 10.1074/jbc.M505120200; Polytarchou C, 2009, INT J CANCER, V124, P1785, DOI 10.1002/ijc.24084; Reardon DA, 2006, J CLIN ONCOL, V24, P1253, DOI 10.1200/JCO.2005.04.5302; Ren J, 2007, J MOL CELL CARDIOL, V42, P367, DOI 10.1016/j.yjmcc.2006.11.002; Sato Y, 2002, J BIOCHEM, V131, P877, DOI 10.1093/oxfordjournals.jbchem.a003178; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Schmitz M, 2007, INT J CANCER, V120, P1284, DOI 10.1002/ijc.22359; Schneider GB, 1999, BONE, V24, P321, DOI 10.1016/S8756-3282(99)00007-1; Schnell O, 2008, BRAIN PATHOL, V18, P378, DOI 10.1111/j.1750-3639.2008.00137.x; Shattil SJ, 2005, TRENDS CELL BIOL, V15, P399, DOI 10.1016/j.tcb.2005.06.005; Stupack DG, 2004, CURR TOP DEV BIOL, V64, P207, DOI 10.1016/S0070-2153(04)64009-9; Switala-Jelen K, 2004, FOLIA BIOL-PRAGUE, V50, P143; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Vulin AI, 2005, ENDOCRINOLOGY, V146, P3535, DOI 10.1210/en.2004-1386; Wang DJ, 2003, HYPERTENSION, V42, P88, DOI 10.1161/01.HYP.0000074905.22908.A6; Yuki T, 2006, AM J PHYSIOL-GASTR L, V291, pG735, DOI 10.1152/ajpgi.00388.2005	50	65	66	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1459	1469		10.1096/fj.08-117564	http://dx.doi.org/10.1096/fj.08-117564			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19141530				2022-12-28	WOS:000266651700022
J	Yasuda, D; Okuno, T; Yokomizo, T; Hori, T; Hirota, N; Hashidate, T; Miyano, M; Shimizu, T; Nakamura, M				Yasuda, Daisuke; Okuno, Toshiaki; Yokomizo, Takehiko; Hori, Tetsuya; Hirota, Nobuaki; Hashidate, Tomomi; Miyano, Masashi; Shimizu, Takao; Nakamura, Motonao			Helix 8 of leukotriene B-4 type-2 receptor is required for the folding to pass the quality control in the endoplasmic reticulum	FASEB JOURNAL			English	Article						G protein-coupled receptor; trafficking; pharmacological chaperone; ERAD; 12-HHT	PROTEIN-COUPLED RECEPTOR; VASOPRESSIN V1B/V3 RECEPTOR; CELL-SURFACE EXPRESSION; CRYSTAL-STRUCTURE; PHARMACOLOGICAL CHAPERONES; MELANOCORTIN-4 RECEPTOR; SIGNAL-TRANSDUCTION; THERAPEUTIC TARGET; IN-VIVO; TRANSPORT	Many G protein-coupled receptors (GPCRs) possess a putative cytoplasmic helical domain, termed helix 8 (H8), at the proximal region of the C-terminal tail. However, the significance of this domain is not fully understood. Here, we demonstrate the requirement of H8 for the proper folding of GPCRs for passage through the quality control in the endoplasmic reticulum (ER). In the human leukotriene B-4 type-2 receptor (hBLT2), lack of H8 led to an accumulation of the receptor (hBLT2/Delta H8) in the ER. Similar results were obtained in two representative human GPCRs, dopamine type-1 and lysophosphatidic acid type-2 receptors, which were engineered to lack H8. Treatment with the several ligands, which act as pharmacological chaperones, facilitated the surface expression of hBLT2/Delta H8. The surface-trafficked hBLT2/Delta H8 exhibited an agonist-evoked increase in Ca2+, demonstrating that H8 is not critical for ligand binding and activation of coupled G proteins. Thus, these results suggest that the H8 region of hBLT2 plays an important role in transport-competent receptor folding.-Yasuda, D., Okuno, T., Yokomizo, T., Hori, T., Hirota, N., Hashidate, T., Miyano, M., Shimizu, T., Nakamura, M. Helix 8 of leukotriene B4 type-2 receptor is required for the folding to pass the quality control in the endoplasmic reticulum. FASEB J. 23, 1470-1481 (2009)	[Nakamura, Motonao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; [Okuno, Toshiaki; Yokomizo, Takehiko] Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Fukuoka 812, Japan; [Hori, Tetsuya; Miyano, Masashi] Spring 8, Harima Inst, RIKEN, Struct Biophys Lab, Kobe, Hyogo, Japan	University of Tokyo; Kyushu University; Japan Synchrotron Radiation Research Institute; RIKEN	Nakamura, M (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	moto-nakamura@umin.net	Yokomizo, Takehiko/P-5673-2016; Miyano, Masashi/R-2785-2016; Shimizu, Takao/AAV-7052-2021	Yokomizo, Takehiko/0000-0002-5219-1553; Miyano, Masashi/0000-0003-2253-6175; Yasuda, Daisuke/0000-0001-5513-0695	Ministry of Education, Culture, Sports, Science, and Technology of Japan; Japan Society for the Promotion of Science; Center for NanoBio Integration at the University of Tokyo	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Center for NanoBio Integration at the University of Tokyo	We are grateful to Drs. S. Ishii, Y. Kita, and H. Shindou, and to N. Murakami (the University of Tokyo) and to all members of our laboratory for technical advice and useful discussions. This work was supported in part by a grant-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to T. S.) and grants from the Japan Society for the Promotion of Science (Global COE program) and the Center for NanoBio Integration at the University of Tokyo.	Anavi-Goffer S, 2007, J BIOL CHEM, V282, P25100, DOI 10.1074/jbc.M703388200; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Conn PM, 2007, PHARMACOL REV, V59, P225, DOI 10.1124/pr.59.3.2; Delos Santos NM, 2006, J BIOL CHEM, V281, P12896, DOI 10.1074/jbc.M508500200; Duvernay MT, 2004, J BIOL CHEM, V279, P30741, DOI 10.1074/jbc.M313881200; Fan J, 2005, MOL ENDOCRINOL, V19, P2579, DOI 10.1210/me.2004-0301; Fitzsimmons TJ, 2003, J BIOL CHEM, V278, P14313, DOI 10.1074/jbc.M211946200; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Ghosh M, 2006, J BIOL CHEM, V281, P16615, DOI 10.1074/jbc.M601770200; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iizuka Y, 2005, J BIOL CHEM, V280, P24816, DOI 10.1074/jbc.M413257200; Ishii S, 2005, J BIOL CHEM, V280, P9083, DOI 10.1074/jbc.M407832200; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; Janovick JA, 2002, J CLIN ENDOCR METAB, V87, P3255, DOI 10.1210/jc.87.7.3255; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang DS, 2002, MOL PHARMACOL, V62, P281, DOI 10.1124/mol.62.2.281; Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Murakami M, 2008, NATURE, V453, P363, DOI 10.1038/nature06925; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Okuno T, 2008, J EXP MED, V205, P759, DOI 10.1084/jem.20072329; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Robert J, 2005, J BIOL CHEM, V280, P42198, DOI 10.1074/jbc.M510180200; Robert J, 2005, J BIOL CHEM, V280, P2300, DOI 10.1074/jbc.M410655200; Rutz C, 2006, J BIOL CHEM, V281, P24910, DOI 10.1074/jbc.M601554200; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Simonin F, 2004, J NEUROCHEM, V89, P766, DOI 10.1111/j.1471-4159.2004.02411.x; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tan CM, 2003, J BIOL CHEM, V278, P35678, DOI 10.1074/jbc.M301888200; Udawela M, 2004, SEMIN CELL DEV BIOL, V15, P299, DOI 10.1016/j.semcdb.2003.12.019; VanLeeuwen D, 2003, J BIOL CHEM, V278, P15935, DOI 10.1074/jbc.M211546200; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Zhong M, 2004, BIOCHEMISTRY-US, V43, P3490, DOI 10.1021/bi035899m	52	23	23	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1470	1481		10.1096/fj.08-125385	http://dx.doi.org/10.1096/fj.08-125385			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19126593				2022-12-28	WOS:000266651700023
J	Zhang, YM; Herbert, BS; Rajashekhar, G; Ingram, DA; Yoder, MC; Clauss, M; Rehman, J				Zhang, Yanmin; Herbert, Brittney-Shea; Rajashekhar, Gangaraju; Ingram, David A.; Yoder, Mervin C.; Clauss, Matthias; Rehman, Jalees			Premature senescence of highly proliferative endothelial progenitor cells is induced by tumor necrosis factor-alpha via the p38 mitogen-activated protein kinase pathway	FASEB JOURNAL			English	Article						cytokines; aging; inflammation; vascular cells	P16(INK4A); TELOMERASE; BLOOD; EXPRESSION; HIERARCHY	Senescence of endothelial cells increases with systemic aging and is thought to contribute to the development of atherosclerosis. Cell therapy with highly proliferative endothelial progenitor cells (EPCs) is an emerging therapeutic option to promote endothelial regeneration, but little is known about their senescence and their vulnerability to inflammatory stressors. We therefore studied the senescence of proliferative human EPCs and investigated the effects of the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) on their senescence. Human EPCs had a significantly lower rate of senescence at baseline, compared with that of mature endothelial cells. However, EPCs up-regulated the expression of the senescence-associated cell cycle arrest protein p16(INK4a) and markedly increased measured senescence levels when exposed to chronic TNF-alpha treatment. Analysis of telomere length showed that the increases in senescence were not related to changes in telomere length. Inhibition of the p38 mitogen-activated protein kinase pathway blocked the induction of p16(INK4a) and cellular senescence. In conclusion, highly proliferative EPCs have a low rate of intrinsic senescence but are vulnerable to premature senescence induction by chronic proinflammatory stimulation. These findings will lead to a better understanding of physiological endothelial regeneration as well as to targeted therapies with the aim of promoting endothelial regeneration through endothelial progenitor cells.-Zhang, Y., Herbert, B.-S., Rajashekhar, G., Ingram, D. A., Yoder, M. C., Clauss, M., Rehman. J. Premature senescence of highly proliferative endothelial progenitor cells is induced by tumor necrosis factor-alpha via the p38 mitogen-activated protein kinase pathway. FASEB J. 23, 1358-1365 (2009)	[Zhang, Yanmin; Rehman, Jalees] Univ Chicago, Pritzker Sch Med, Cardiol Sect, Chicago, IL 60637 USA; [Zhang, Yanmin; Rehman, Jalees] Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; [Herbert, Brittney-Shea] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Rajashekhar, Gangaraju; Clauss, Matthias] Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA; [Ingram, David A.; Yoder, Mervin C.] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Rajashekhar, Gangaraju; Clauss, Matthias] Indiana Ctr Vasc Biol & Med, Indianapolis, IN USA	University of Chicago; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Rehman, J (corresponding author), Univ Chicago, Pritzker Sch Med, Cardiol Sect, 5841 S Maryland Ave,Mail Code 6080, Chicago, IL 60637 USA.	jrehman@medicine.bsd.uchicago.edu	Rehman, Jalees/GVU-1981-2022; Gangaraju, Rajashekhar/I-7852-2019; Gangaraju, Rajashekhar/I-6620-2013; Rehman, Jalees/J-8258-2012; Rehman, Jalees/B-8064-2009	Rehman, Jalees/0000-0002-2787-9292; Gangaraju, Rajashekhar/0000-0002-6664-8286; Gangaraju, Rajashekhar/0000-0003-3337-1329; Rehman, Jalees/0000-0002-2787-9292; Yoder, Mervin/0000-0003-4354-7631; Clauss, Matthias/0000-0001-5180-3899	U.S. National Institutes of Health [K08-HL080082]; Indiana Genomics Initiative (INGEN) of Indiana University; Lilly Endowment; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL080082] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Indiana Genomics Initiative (INGEN) of Indiana University; Lilly Endowment; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Erin Gentry for her technical assistance. This work was supported in part by U.S. National Institutes of Health grant K08-HL080082 (principal investigator J.R.). B.-S.H. acknowledges support from the Indiana Genomics Initiative (INGEN) of Indiana University, supported in part by the Lilly Endowment. D.A.I. and M.C.Y own stock in EndGenitor Technologies, Inc. (Indianapolis, IN, USA). They have also acted as consultants to and served as officers or members of the board of EndGenitor Technologies, Inc., within the past 2 years.	Abdel-Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989; Assmus B, 2003, CIRC RES, V92, P1049, DOI 10.1161/01.RES.0000070067.64040.7C; Chen J, 2006, AM J PHYSIOL-HEART C, V290, pH1575, DOI 10.1152/ajpheart.00364.2005; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gulati R, 2003, CIRC RES, V93, P1023, DOI 10.1161/01.RES.0000105569.77539.21; Gutierrez J, 2006, CIRC RES, V99, P924, DOI 10.1161/01.RES.0000248212.86638.e9; Ha JM, 2007, FEBS LETT, V581, P2663, DOI 10.1016/j.febslet.2007.05.010; Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842; Herbert B-S, 2003, ANAL TELOMERES TELOM; Herbert BS, 2006, NAT PROTOC, V1, P1583, DOI 10.1038/nprot.2006.239; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood-2004-08-3057; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Kupatt C, 2005, FASEB J, V19, P1576, DOI 10.1096/fj.04-3282fje; Minamino T, 2007, CIRC RES, V100, P15, DOI 10.1161/01.RES.0000256837.40544.4a; Murasawa S, 2002, CIRCULATION, V106, P1133, DOI 10.1161/01.CIR.0000027584.85865.B4; Opitz CA, 2007, FEBS LETT, V581, P4927, DOI 10.1016/j.febslet.2007.09.032; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Rajashekhar G, 2007, PHYSIOL GENOMICS, V31, P104, DOI 10.1152/physiolgenomics.00157.2006; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Rehman J, 2008, CIRC RES, V102, P1146, DOI 10.1161/CIRCRESAHA.108.177311; Seeger FH, 2005, CIRCULATION, V111, P1184, DOI 10.1161/01.CIR.0000157156.85397.A1; Yan GJ, 2008, CIRC RES, V103, P591, DOI 10.1161/CIRCRESAHA.108.173963; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Yoon CH, 2005, CIRCULATION, V112, P1618, DOI 10.1161/CIRCULATIONAHA.104.503433; Zhou Z, 2008, AM J PHYSIOL-RENAL, V295, pF932, DOI 10.1152/ajprenal.00066.2008	30	96	99	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1358	1365		10.1096/fj.08-110296	http://dx.doi.org/10.1096/fj.08-110296			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19124561	Green Published			2022-12-28	WOS:000266651700012
J	Huggins, A; Paschalidis, N; Flower, RJ; Perretti, M; D'Acquisto, F				Huggins, Anthony; Paschalidis, Nikolaos; Flower, Roderick J.; Perretti, Mauro; D'Acquisto, Fulvio			Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation	FASEB JOURNAL			English	Article						inflammation; antigen presenting cells; formyl peptide receptor ligand	NF-KAPPA-B; FORMYL PEPTIDE RECEPTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; LIPOXIN A(4) RECEPTOR; TOLL-LIKE RECEPTORS; CD4(+) T-CELLS; IN-VIVO; TRANSLATING INNATE; ADAPTIVE IMMUNITY; SIGNALING MODULE	Dendritic cells play a key role in the adaptive immune system by influencing T-cell differentiation. Annexin-1 (Anx-A1) has recently been shown to modulate the adaptive immune response by regulating T-cell activation and differentiation. Here we investigated the role of endogenous Anx-A1 in dendritic cells as major cellular counterpart of T-cell-driven immune response. We found that Anx-A1(-/-) bone marrow-derived dendritic cells show an increased number of CD11c(+) cells expressing high levels of some maturation markers, such as CD40, CD54, and CD80, coupled to a decreased capacity to take up antigen compared to control Anx-A1(+/+) cells. However, analysis of LPS-treated dendritic cells from Anx-A1(-/-) mice demonstrated a diminished up-regulation of maturation markers, a decreased migratory activity in vivo, and an attenuated production of the inflammatory cytokines interleukin (IL)-1 beta, tumor necrosis factor (TNF)-alpha, and IL-12. This defect was also accompanied by impaired nuclear factor (NF)-kappa B/DNA-binding activity and lack of Anx-A1 signaling, as demonstrated by the reduced activation of extracellular-signal regulated kinase (ERK)1/2 and Akt compared to cells from control littermates. As a consequence of this phenotype, Anx-A1(-/-) dendritic cells showed an impaired capacity to stimulate T-cell proliferation and differentiation in mixed leukocyte reaction. Together, these findings suggest that inhibition of Anx-A1 expression or function in dendritic cells might represent a useful way to modulate the adaptive immune response and pathogen-induced T-cell-driven immune diseases.-Huggins, A., Paschalidis, N., Flower, R. J., Perretti, M., D'Acquisto, F. Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation. FASEB J. 23, 985-996 (2009)	[Huggins, Anthony; Paschalidis, Nikolaos; Flower, Roderick J.; Perretti, Mauro; D'Acquisto, Fulvio] Barts & London Med Sch, William Harvey Res Inst, London EC1M 6BQ, England	University of London; Queen Mary University London	D'Acquisto, F (corresponding author), Barts & London Med Sch, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	f.dacquisto@qmul.ac.uk	D'Acquisto, Fulvio/E-7204-2018	D'Acquisto, Fulvio/0000-0002-4513-1608; Paschalidis, Nikolaos/0000-0001-6278-4144	St. Bartholomew's and The Royal London Charitable foundation [RAB05/PJ/10]; Arthritis Research Campaign studentship [16125]; Medical Research Council UK; Medical Research Council [G0400327] Funding Source: researchfish; MRC [G0400327] Funding Source: UKRI	St. Bartholomew's and The Royal London Charitable foundation; Arthritis Research Campaign studentship(Versus Arthritis); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dr. Magali Perederzoli- Ribeil and Dr. Andre Sampaio for their scientific support. F. D. is supported by a New Investigator Award fellowship of the Medical Research Council UK. A. H. is supported by a studentship of the St. Bartholomew's and The Royal London Charitable foundation (RAB05/PJ/10). N. P. is supported by an Arthritis Research Campaign studentship (16125). Experimental work was supported by the St. Bartholomew's and The Royal London Charitable foundation (RAB05/PJ/10).	Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bouma G, 2007, BLOOD, V110, P4278, DOI 10.1182/blood-2007-06-096875; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chatterjee BE, 2005, J LEUKOCYTE BIOL, V78, P639, DOI 10.1189/jlb.0405206; Clark GJ, 2000, MICROBES INFECT, V2, P257, DOI 10.1016/S1286-4579(00)00302-6; D'Acquisto F, 2008, RHEUMATOLOGY, V47, P636, DOI 10.1093/rheumatology/ken062; D'Acquisto F, 2007, EUR J IMMUNOL, V37, P3131, DOI 10.1002/eji.200636792; D'Acquisto F, 2007, BLOOD, V109, P1095, DOI 10.1182/blood-2006-05-022798; Damazo AS, 2005, AM J PATHOL, V166, P1607, DOI 10.1016/S0002-9440(10)62471-6; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Gavins FNE, 2005, PROSTAG LEUKOTR ESS, V73, P211, DOI 10.1016/j.plefa.2005.05.008; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gripentrog JM, 2005, CELL SIGNAL, V17, P1300, DOI 10.1016/j.cellsig.2005.01.006; Gutcher I, 2007, J CLIN INVEST, V117, P1119, DOI 10.1172/JCI31720; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; Jorritsma PJ, 2003, J IMMUNOL, V170, P2427, DOI 10.4049/jimmunol.170.5.2427; Kassiotis G, 2003, J EXP MED, V197, P1007, DOI 10.1084/jem.20021812; Lammermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887; Lammermann T, 2008, IMMUNOL REV, V221, P26, DOI 10.1111/j.1600-065X.2008.00592.x; Langenkamp A, 2002, EUR J IMMUNOL, V32, P2046, DOI 10.1002/1521-4141(200207)32:7<2046::AID-IMMU2046>3.0.CO;2-M; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Le YY, 2002, INT IMMUNOPHARMACOL, V2, P1, DOI 10.1016/S1567-5769(01)00150-3; Lindner I, 2007, ADV EXP MED BIOL, V590, P1; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008; Perretti M, 2003, TRENDS PHARMACOL SCI, V24, P574, DOI 10.1016/j.tips.2003.09.010; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rescher U, 2006, BBA-MOL CELL RES, V1763, P1320, DOI 10.1016/j.bbamcr.2006.08.041; Sanchez-Sanchez N, 2006, J IMMUNOL, V176, P5153, DOI 10.4049/jimmunol.176.9.5153; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; Sousa CRE, 2004, CURR OPIN IMMUNOL, V16, P21, DOI 10.1016/j.coi.2003.11.007; Sousa CRE, 2001, IMMUNITY, V14, P495; Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; van Duivenvoorde LM, 2006, IMMUNOBIOLOGY, V211, P627, DOI 10.1016/j.imbio.2006.05.014; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Wang ZG, 2002, GENE, V299, P57, DOI 10.1016/S0378-1119(02)01012-0; Yang D, 2002, J LEUKOCYTE BIOL, V72, P598; Yoshimura S, 2001, INT IMMUNOL, V13, P675, DOI 10.1093/intimm/13.5.675; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837	52	36	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2009	23	4					985	996		10.1096/fj.08-119040	http://dx.doi.org/10.1096/fj.08-119040			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19029200				2022-12-28	WOS:000266651600003
J	Magalhaes, ES; Paiva, CN; Souza, HSP; Pyrrho, AS; Mourao-Sa, D; Figueiredo, RT; Vieira-De-Abreu, A; Dutra, HS; Silveira, MS; Gaspar-Elsas, MIC; Xavier-Elsas, P; Bozza, PT; Bozza, MT				Magalhaes, Elizabeth S.; Paiva, Claudia N.; Souza, Heitor S. P.; Pyrrho, Alexandre S.; Mourao-Sa, Diego; Figueiredo, Rodrigo T.; Vieira-de-Abreu, Adriana; Dutra, Helio S.; Silveira, Mariana S.; Gaspar-Elsas, Maria Ignez C.; Xavier-Elsas, Pedro; Bozza, Patricia T.; Bozza, Marcelo T.			Macrophage migration inhibitory factor is critical to interleukin-5-driven eosinophilopoiesis and tissue eosinophilia triggered by Schistosoma mansoni infection	FASEB JOURNAL			English	Article						Th2 response; apoptosis; inflammation; granuloma; MIF	FACTOR MIF; GRANULOMA-FORMATION; REGULATORY ROLE; ASTHMA; MICE; APOPTOSIS; SURVIVAL; INFLAMMATION; RECRUITMENT; ACTIVATION	Macrophage migration inhibitory factor (MIF) participates in the pathogenesis of inflammatory diseases, including asthma, in which it enhances airway hypersensitivity and tissue eosinophilia. Herein, we investigated the role of MIF in eosinophilopoiesis and tissue eosinophilia using Schistosoma mansoni infection. MIF-deficient (Mif(-/-)) mice had similar numbers of adult worms, eggs, and granulomas compared to wildtype mice, but the size of granulomas was strikingly reduced due to smaller numbers of eosinophils. MIF did not affect the acquired response to infection, as Mif(-/-) mice produced normal amounts of Th2 cytokines and IgE. Nevertheless, recombinant MIF (rMIF) behaved as a chemoattractant for eosinophils, what could partially explain the reduced eosinophilia in infected Mif(-/-) mice. Moreover, the percentage of eosinophils was reduced in bone marrows of Mif(-/-) mice chronically infected with S. mansoni compared to wild type. Mif(-/-) had impaired eosinophilopoiesis in response to interleukin (IL)-5 and addition of rMIF to bone marrow cultures from IL-5 transgenic mice enhanced the generation of eosinophils. In the absence of MIF, eosinophil precursors were unable to survive the IL-5-supplemented cell culture, and were ingested by macrophages. Treatment with pancaspase inhibitor z-VAD or rMIF promoted the survival of eosinophil progenitors. Together, these results indicate that MIF participates in IL-5-driven maturation of eosinophils and in tissue eosinophilia associated with S. mansoni infection.-Magalhaes, E. S., Paiva, C. N., Souza, H. S. P., Pyrrho, A. S., Mourao-Sa, D., Figueiredo, R. T., Vieira-de-Abreu, A., Dutra, H. S., Silveira, M. S., Gaspar-Elsas, M. I. C., Xavier-Elsas, P., Bozza, P. T., Bozza, M. T. Macrophage migration inhibitory factor is critical to IL-5-driven eosinophilopoiesis and tissue eosinophilia triggered by Schistosoma mansoni infection. FASEB J. 23, 1262-1271 (2009)	[Magalhaes, Elizabeth S.; Paiva, Claudia N.; Mourao-Sa, Diego; Figueiredo, Rodrigo T.; Xavier-Elsas, Pedro; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Immunol, Inst Microbiol, BR-21941902 Rio De Janeiro, Brazil; [Souza, Heitor S. P.] Univ Fed Rio de Janeiro, Dept Clin Med, Fac Med, BR-21941902 Rio De Janeiro, Brazil; [Pyrrho, Alexandre S.] Univ Fed Rio de Janeiro, Dept Farm, Inst Biol, BR-21941902 Rio De Janeiro, Brazil; [Dutra, Helio S.] Univ Fed Rio de Janeiro, Dept Histol & Embriol, Inst Ciencias Biomed, BR-21941902 Rio De Janeiro, Brazil; [Silveira, Mariana S.] Univ Fed Rio de Janeiro, Lab Neurogenese, Inst Biofisca, BR-21941902 Rio De Janeiro, Brazil; [Vieira-de-Abreu, Adriana] Inst Oswaldo Cruz, Lab Imunofarmacol, BR-20001 Rio De Janeiro, Brazil; [Gaspar-Elsas, Maria Ignez C.] Fiocruz MS, Dept Pediat, Inst Fernandes Figueira, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz	Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Dept Immunol, Inst Microbiol, CCS Bloco 1,UFRJ Ave Carlos Chagas Filho,373 Cida, BR-21941902 Rio De Janeiro, Brazil.	mbozza@micro.ufrj.br	Xavier-Elsas, Pedro/Q-9070-2019; Mourao-Sa, Diego/C-5977-2009; Bozza, Patricia T./AAM-4537-2021; de Souza, Heitor Siffert Pereira/G-3297-2012; Silveira, Mariana/M-4865-2013; Bozza, Patricia T./AAE-2933-2021; Figueiredo, Rodrigo/F-5176-2016	Xavier-Elsas, Pedro/0000-0003-3057-6062; Bozza, Patricia T./0000-0001-8349-9529; de Souza, Heitor Siffert Pereira/0000-0002-3647-7324; Silveira, Mariana/0000-0002-0496-1517; Figueiredo, Rodrigo/0000-0002-7551-8782; Mourao, Diego/0000-0001-6618-6969; Bozza, Marcelo/0000-0003-3683-7550	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Amano T, 2007, INFLAMM RES, V56, P24, DOI 10.1007/s00011-007-5184-9; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Borchers MT, 2002, J LEUKOCYTE BIOL, V71, P1033; Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; DAVID JR, 1980, AM J TROP MED HYG, V29, P842, DOI 10.4269/ajtmh.1980.29.842; Davies SJ, 2005, INT J PARASITOL, V35, P851, DOI 10.1016/j.ijpara.2005.02.017; Davies SJ, 2004, INT J PARASITOL, V34, P27, DOI 10.1016/j.ijpara.2003.10.010; Denkinger CM, 2004, ARCH IMMUNOL THER EX, V52, P389; DOLBER PC, 1993, J HISTOCHEM CYTOCHEM, V41, P465, DOI 10.1177/41.3.7679127; Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404, DOI 10.1165/ajrcmb.17.4.2691; Falcone FH, 2001, J IMMUNOL, V167, P5348, DOI 10.4049/jimmunol.167.9.5348; Fallon PG, 2000, J IMMUNOL, V164, P2585, DOI 10.4049/jimmunol.164.5.2585; Farahi N, 2007, J IMMUNOL, V179, P1264, DOI 10.4049/jimmunol.179.2.1264; Flaster H, 2007, MOL ENDOCRINOL, V21, P1267, DOI 10.1210/me.2007-0065; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; Hoontrakoon R, 2002, AM J RESP CELL MOL, V26, P404, DOI 10.1165/ajrcmb.26.4.4517; Hu JS, 2006, AM J PATHOL, V169, P424, DOI 10.2353/ajpath.2006.051234; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; KARIYAWASAM HH, 2007, CURR OPIN IMMUNOL; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Leeto M, 2006, AM J PATHOL, V169, P1701, DOI 10.2353/ajpath.2006.060346; LENZI H L, 1987, Memorias do Instituto Oswaldo Cruz, V82, P67, DOI 10.1590/S0074-02761987000800011; Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X; Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102; Nagase H, 2001, INT ARCH ALLERGY IMM, V125, P29, DOI 10.1159/000053849; Nakamaru Y, 2005, CYTOKINE, V31, P103, DOI 10.1016/j.cyto.2005.04.002; Ohnmacht C, 2007, J IMMUNOL, V179, P4766, DOI 10.4049/jimmunol.179.7.4766; Padigel UM, 2006, INFECT IMMUN, V74, P3232, DOI 10.1128/IAI.02067-05; Petering H, 1999, BLOOD, V93, P694, DOI 10.1182/blood.V93.2.694.402k31_694_702; Powell ND, 2005, J IMMUNOL, V175, P5611, DOI 10.4049/jimmunol.175.9.5611; Reiman RM, 2006, INFECT IMMUN, V74, P1471, DOI 10.1128/IAI.74.3.1471-1479.2006; Rodriguez-Sosa M, 2003, INFECT IMMUN, V71, P1247, DOI 10.1128/IAI.71.3.1247-1254.2003; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Sabroe I, 2000, CLIN EXP ALLERGY, V30, P1194; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; SHER A, 1990, P NATL ACAD SCI USA, V87, P61, DOI 10.1073/pnas.87.1.61; Stavitsky AB, 2003, PARASITE IMMUNOL, V25, P369, DOI 10.1046/j.1365-3024.2003.00641.x; Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933; Vermeire JJ, 2008, TRENDS PARASITOL, V24, P355, DOI 10.1016/j.pt.2008.04.007; Wang FZ, 2005, MED HYPOTHESES, V65, P1082, DOI 10.1016/j.mehy.2005.05.047; Wilson MS, 2007, IMMUNOL CELL BIOL, V85, P148, DOI 10.1038/sj.icb.7100014; Yamaguchi E, 2000, CLIN EXP ALLERGY, V30, P1244; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; Yousefi S, 1997, INT ARCH ALLERGY IMM, V112, P9, DOI 10.1159/000237424	53	35	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1262	1271		10.1096/fj.08-124248	http://dx.doi.org/10.1096/fj.08-124248			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19088181				2022-12-28	WOS:000266651600030
J	Van Gammeren, D; Damrauer, JS; Jackman, RW; Kandarian, SC				Van Gammeren, Darin; Damrauer, Jeffrey S.; Jackman, Robert W.; Kandarian, Susan C.			The I kappa B kinases IKK alpha and IKK beta are necessary and sufficient for skeletal muscle atrophy	FASEB JOURNAL			English	Article						muscle wasting; inhibitor of kappa B kinase; IKK complex; NF-kappa B signaling	GENE-TRANSFER; ACTIVATION; PATHWAYS; PHOSPHORYLATION; ELECTROPORATION; TRANSCRIPTION; DEREPRESSION; EXPRESSION	Nuclear factor-kappa B (NF-kappa B) signaling is necessary for many types of muscle atrophy, yet only some of the required components have been identified. Gene transfer of a dominant negative (d.n.) IKK beta into rat soleus muscles showed complete inhibition of 7-day disuse-induced activation of a kappa B reporter gene, while overexpression of wild-type (w.t.) IKK beta did not. Overexpression of a d.n. IKK beta-EGFP fusion protein showed that atrophy was inhibited by 50%, indicating that IKK beta is required for the atrophy process. Overexpression of constitutively active (c.a.) IKK beta-EGFP showed a marked increase in NF-kappa B activity and a decrease in fiber size of weight-bearing soleus muscles, while muscles overexpressing w.t. IKK beta-HA had no effect. The same results were found for IKK alpha; overexpression of a d.n. form of the protein decreased unloading-induced NF-kappa B activation and inhibited atrophy by 50%, while overexpression of the w.t. protein had no effect. Overexpression of a c. a. IKK alpha-EGFP fusion protein showed that IKK alpha was sufficient to activate NF-kappa B activity and induce fiber atrophy in muscle. Overexpression of d.n. IKK beta plus d.n. IKK alpha showed an additive effect on the inhibition of disuse atrophy (70%), suggesting that both kinases of the IKK complex are required for muscle atrophy. These data show that both IKK alpha and IKK beta are necessary and sufficient for physiological muscle atrophy. - Van Gammeren, D., Damrauer, J.S., Jackman, R. W., Kandarian, S. C. The I kappa B kinases IKK alpha and IKK beta are necessary and sufficient for skeletal muscle atrophy. FASEB J. 23, 362-370 (2009)	[Kandarian, Susan C.] Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA	Boston University	Kandarian, SC (corresponding author), Boston Univ, Dept Hlth Sci, 635 Commonwealth Ave,Rm 443, Boston, MA 02215 USA.	skandar@bu.edu	Damrauer, Jeffrey/AAW-3845-2020	Damrauer, Jeffrey/0000-0001-8148-0285	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [F32 AR054265, AR41705]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR054265, R01AR041705] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by a Ruth L. Kirschstein National Research Service Award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to D. V. G. (F32 AR054265) and an R01 award from NIAMS to S. K. (AR41705). We thank Mary Rhoads and Angie Cornwell for technical assistance.	Acharyya S, 2005, CANCER CELL, V8, P421, DOI 10.1016/j.ccr.2005.10.004; Alzghoul MB, 2004, FASEB J, V18, P221, DOI 10.1096/fj.03-0293fje; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bakkar N, 2008, J CELL BIOL, V180, P787, DOI 10.1083/jcb.200707179; Bar-Shai M, 2008, FREE RADICAL BIO MED, V44, P202, DOI 10.1016/j.freeradbiomed.2007.03.019; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Dona M, 2003, BIOCHEM BIOPH RES CO, V312, P1132, DOI 10.1016/j.bbrc.2003.11.032; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1081, DOI 10.1016/j.bcp.2006.06.017; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hasselgren PO, 2005, INT J BIOCHEM CELL B, V37, P2156, DOI 10.1016/j.biocel.2005.01.017; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hunter RB, 2004, J CLIN INVEST, V114, P1504, DOI 10.1172/JCI200421696; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; Judge AR, 2007, AM J PHYSIOL-CELL PH, V292, pC372, DOI 10.1152/ajpcell.00293.2006; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Koncarevic A, 2007, FASEB J, V21, P427, DOI 10.1096/fj.06-6665com; Mitchell-Felton H, 1999, AM J PHYSIOL-CELL PH, V277, pC1269, DOI 10.1152/ajpcell.1999.277.6.C1269; Mourkioti F, 2006, J CLIN INVEST, V116, P2945, DOI 10.1172/JCI28721; Park GY, 2006, J BIOL CHEM, V281, P18684, DOI 10.1074/jbc.M600733200; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Peter I, 1999, Twin Res, V2, P1, DOI 10.1375/twin.2.1.1; Polkinghorne E, 2008, AM J PHYSIOL-ENDOC M, V294, pE316, DOI 10.1152/ajpendo.00537.2007; Rana ZA, 2004, ACTA PHYSIOL SCAND, V181, P233, DOI 10.1111/j.1365-201X.2004.01282.x; Rossini K, 2002, BASIC APPL MYOL, V12, P97; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schertzer JD, 2006, MOL THER, V13, P795, DOI 10.1016/j.ymthe.2005.09.019; Taylor J, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-11; VANGAMMEREN D, 2006, FRONTIERS MYOGENESIS, P28; Xiao GT, 2006, CYTOKINE GROWTH F R, V17, P281, DOI 10.1016/j.cytogfr.2006.04.005; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	40	79	80	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					362	370		10.1096/fj.08-114249	http://dx.doi.org/10.1096/fj.08-114249			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18827022	Green Published			2022-12-28	WOS:000262892900008
J	Grinnell, F				Grinnell, Frederick			Discovery in the lab: Plato's paradox and Delbruck's principle of limited sloppiness	FASEB JOURNAL			English	Article									Univ Texas SW Med Sch, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas SW Med Sch, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	frederick.grinnell@utsouthwestern.edu						[Anonymous], 1989, OXFORD ENGLISH DICT; Aristotle, POSTERIOR ANAL; Bernard C., 1957, INTRO LIT CORRES TON; DULBECCO R, 1999, COMMUNICATION   0114; Grinnell F., 2009, EVERYDAY PRACTICE SC; Hayes W, 1982, BIOGRAPHICAL MEMOIRS, V28, P58; Jowett B., MENO; Peirce Charles Sanders, 1931, COLLECTED PAPERS CS, V5, P188; Polanyi M., 1983, TACIT DIMENSION; Popper K., 1959, LOGIC SCI DISCOVERY; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; WILSON AT, 1955, J AM CHEM SOC, V77, P5948, DOI 10.1021/ja01627a050	12	2	3	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2009	23	1					7	9		10.1096/fj.09-0102ufm	http://dx.doi.org/10.1096/fj.09-0102ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	19118078				2022-12-28	WOS:000262095500002
J	Nakanishi, M; Kurisaki, A; Hayashi, Y; Warashina, M; Ishiura, S; Kusuda-Furue, M; Asashima, M				Nakanishi, Mio; Kurisaki, Akira; Hayashi, Yohei; Warashina, Masaki; Ishiura, Shoichi; Kusuda-Furue, Miho; Asashima, Makoto			Directed induction of anterior and posterior primitive streak by Wnt from embryonic stem cells cultured in a chemically defined serum-free medium	FASEB JOURNAL			English	Article						mesendoderm; endoderm; regenerative medicine; brachyury; sox17	MOUSE EMBRYO; DEFINITIVE ENDODERM; MESODERM FORMATION; GENE; DIFFERENTIATION; GASTRULATION; EXPRESSION; BODIES; MICE; REQUIREMENT	Formation of the primitive streak (PS) is the initial specification step that generates all the mesodermal and endodermal tissue lineages during early differentiation. Thus, a therapeutically compatible and efficient method for differentiation of the PS is crucial for regenerative medicine. In this study, we developed chemically defined serum-free culture conditions for the differentiation of embryonic stem (ES) cells into the PS-like cells. Cultures supplemented with Wnt showed induction of expression of a PS marker, the brachyury gene, followed by induction of the anterior PS markers goosecoid and foxa2, a posterior PS marker, evx1, and the endoderm marker sox17. Similar differentiation of PS by Wnt was also observed in human ES cells. Moreover, we revealed that the activation of the Wnt canonical pathway is essential for PS differentiation in mouse ES cells. These results demonstrated that Wnt is an essential and sufficient factor for the induction of the PS-like cells in vitro. These conditions of induction could constitute the initial step in generating therapeutically useful cells of the definitive endoderm lineage, such as hepatocytes and pancreatic endocrine cells, under chemically defined conditions. Nakanishi, M., Kurisaki, A., Hayashi, Y., Warashina, M., Ishiura, S., Kusuda-Furue, M., Asashima, M. Directed induction of anterior and posterior primitive streak by Wnt from embryonic stem cells cultured in a chemically defined serum-free medium. FASEB J. 23, 114-122 (2009)	[Nakanishi, Mio; Hayashi, Yohei; Ishiura, Shoichi; Asashima, Makoto] Univ Tokyo, Dept Life Sci Biol, Grad Sch Arts & Sci, Meguro Ku, Tokyo 1538902, Japan; [Kurisaki, Akira; Asashima, Makoto] Natl Inst Adv Ind Sci & Technol, Organ Dev Res Lab, Tsukuba, Japan; [Warashina, Masaki] Wako Pure Chem Ind Ltd, Genome Res Labs, Kobe, Hyogo, Japan; [Kusuda-Furue, Miho] Natl Inst Biomed Innovat, Div Bioresources, Osaka, Japan; [Kusuda-Furue, Miho; Asashima, Makoto] Japan Sci & Technol Agcy, Int Cooperat Res Project ICORP, Tokyo, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Health Sciences - Japan; Japan Science & Technology Agency (JST)	Asashima, M (corresponding author), Univ Tokyo, Dept Life Sci Biol, Grad Sch Arts & Sci, Meguro Ku, 3-8-1 Komaba, Tokyo 1538902, Japan.	asashi@bio.c.u-tokyo.ac.jp	Hayashi, Yohei/AAF-6059-2020; Asashima, Makoto/O-8389-2018; Hayashi, Yohei/L-8190-2019	Hayashi, Yohei/0000-0001-5490-7052; Asashima, Makoto/0000-0002-0012-026X; Furue, Miho/0000-0001-5032-9953	Takeda Pharmaceuticals Company, Inc; Ministry of Health, Labor and Welfare of Japan; Naito Foundation,; Wako Pure Chemical Industries, Ltd	Takeda Pharmaceuticals Company, Inc(Takeda Pharmaceutical Company Ltd); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Naito Foundation,; Wako Pure Chemical Industries, Ltd	We thank Drs. N. Nakatsuji and H. Suemori (Kyoto University, Kyoto, Japan) for providing human KhES-1 cell line. We thank Drs. T. Michiue and H. Danno for discussion. We also gratefully acknowledge Takeda Pharmaceuticals Company, Inc. for its generous support of this study. This work was supported in part by a grant-in-aid for scientific research from the Ministry of Health, Labor and Welfare of Japan, by a grant from the Naito Foundation, and by Wako Pure Chemical Industries, Ltd.	Aumailley M, 2000, J CELL SCI, V113, P259; Bader A, 2001, DIFFERENTIATION, V68, P31, DOI 10.1046/j.1432-0436.2001.068001031.x; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Brennan J, 2001, NATURE, V411, P965, DOI 10.1038/35082103; CONLON FL, 1994, DEVELOPMENT, V120, P1919; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001; Dunn NR, 2004, DEVELOPMENT, V131, P1717, DOI 10.1242/dev.01072; DUSH MK, 1992, DEV BIOL, V151, P273, DOI 10.1016/0012-1606(92)90232-6; Furue M, 2005, IN VITRO CELL DEV-AN, V41, P19; Gadue P, 2006, P NATL ACAD SCI USA, V103, P16806, DOI 10.1073/pnas.0603916103; Hayashi Y, 2007, STEM CELLS, V25, P3005, DOI 10.1634/stemcells.2007-0103; Inman KE, 2006, GENE EXPR PATTERNS, V6, P783, DOI 10.1016/j.modgep.2006.01.010; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; Kelly OG, 2004, DEVELOPMENT, V131, P2803, DOI 10.1242/dev.01137; Kinder SJ, 2001, DEVELOPMENT, V128, P3623; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Lickert H, 2002, DEV CELL, V3, P171, DOI 10.1016/S1534-5807(02)00206-X; Lindsley RC, 2006, DEVELOPMENT, V133, P3787, DOI 10.1242/dev.02551; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Liu Y, 2004, DEV BIOL, V270, P411, DOI 10.1016/j.ydbio.2004.03.017; Liu Y, 2007, P NATL ACAD SCI USA, V104, P3859, DOI 10.1073/pnas.0609100104; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Stemmler MP, 2003, DEV DYNAM, V227, P238, DOI 10.1002/dvdy.10301; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yasunaga M, 2005, NAT BIOTECHNOL, V23, P1542, DOI 10.1038/nbt1167; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502	36	67	70	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					114	122		10.1096/fj.08-111203	http://dx.doi.org/10.1096/fj.08-111203			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18809738				2022-12-28	WOS:000262095500014
J	Zhu, PX; Hata, RJ; Cao, F; Gu, F; Hanakawa, Y; Hashimoto, K; Sakanaka, M				Zhu, Pengxiang; Hata, Ryuji; Cao, Fang; Gu, Feng; Hanakawa, Yasushi; Hashimoto, Koji; Sakanaka, Masahiro			Ramified microglial cells promote astrogliogenesis and maintenance of neural stem cells through activation of Stat3 function	FASEB JOURNAL			English	Article						neurogenesis; NSC; SOCS3; AG490; notch	FIBROBLAST-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; ASTROCYTIC DIFFERENTIATION; STEM/PROGENITOR CELLS; PRECURSOR CELLS; ADULT BRAIN; NEUROGENESIS; EXPRESSION; NOTCH; SOX9	The differentiation and proliferation of neural stem cells (NSCs) are regulated by a combination of their intrinsic properties (e.g., transcription factors, epigenetic factors, and microRNA regulation) and cell-extrinsic properties from the microenvironment around NSC (e.g., cytokines, growth factors, and cell-cell contact). Recently, there has been a great interest in clarifying the mechanism of the influence of the microenvironment on NSCs, especially cell-cell contact between NSCs and other types of cells nearby. In this study, we investigated whether microglial (Mi) cells influence the fate of NSCs. Coculture study showed that ramified Mi cells promoted astrogliogenesis and maintenance of NSCs through their paracrine effects. This microglia-induced astrogliogenesis was inhibited by AG490 and by overexpression of the dominant-negative form of Stat3 and SOCS3. Promoter assay revealed transactivation of Stat3 function in NSCs by Mi cells. Gene expression study revealed that mRNA of Notch family members (notch1-3) and sox9 in NSCs was significantly upregulated by Mi cells, and this up-regulation was inhibited by AG490. These results demonstrated that ramified Mi cells promoted astrogliogenesis and maintenance of NSCs by activating Stat3 function and via notch and sox9 signaling pathways. -Zhu, P., Hata, R., Cao, F., Gu, F., Hanakawa, Y., Hashimoto, K., Sakanaka, M. Ramified microglial cells promote astrogliogenesis and maintenance of neural stem cells through activation of Stat3 function. FASEB J. 22, 3866-3877 (2008)	[Zhu, Pengxiang; Hata, Ryuji; Cao, Fang; Gu, Feng; Sakanaka, Masahiro] Ehime Univ, Grad Sch Med, Dept Funct Histol, Toon, Ehime 7910295, Japan; [Hanakawa, Yasushi; Hashimoto, Koji] Ehime Univ, Grad Sch Med, Dept Dermatol, Toon, Ehime 7910295, Japan	Ehime University; Ehime University	Hata, RJ (corresponding author), Ehime Univ, Grad Sch Med, Dept Funct Histol, Toon, Ehime 7910295, Japan.	hata@m.ehime-u.ac.jp		Zhu, Pengxiang/0000-0002-7770-5178				Aarum J, 2003, P NATL ACAD SCI USA, V100, P15983, DOI 10.1073/pnas.2237050100; ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Battista D, 2006, EUR J NEUROSCI, V23, P83, DOI 10.1111/j.1460-9568.2005.04539.x; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Cao F, 2006, J NEUROCHEM, V98, P459, DOI 10.1111/j.1471-4159.2006.03890.x; Chojnacki A, 2003, J NEUROSCI, V23, P1730; Dono R, 2003, AM J PHYSIOL-REG I, V284, pR867, DOI 10.1152/ajpregu.00533.2002; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gu F, 2005, J NEUROSCI RES, V81, P163, DOI 10.1002/jnr.20561; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasky JL, 2005, PEDIATR RES, V57, p104R, DOI 10.1203/01.PDR.0000159632.70510.3D; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nakanishi M, 2007, EUR J NEUROSCI, V25, P649, DOI 10.1111/j.1460-9568.2007.05309.x; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Rajan P, 1998, J NEUROSCI, V18, P3620; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Seymour PA, 2007, P NATL ACAD SCI USA, V104, P1865, DOI 10.1073/pnas.0609217104; Shimazaki T, 2001, J NEUROSCI, V21, P7642, DOI 10.1523/JNEUROSCI.21-19-07642.2001; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; SUZUMURA A, 1987, J NEUROIMMUNOL, V15, P263, DOI 10.1016/0165-5728(87)90121-4; Taga T, 2005, CLIN REV ALLERG IMMU, V28, P249, DOI 10.1385/CRIAI:28:3:249; Taylor MK, 2007, DEVELOPMENT, V134, P2435, DOI 10.1242/dev.005520; Walton NM, 2006, GLIA, V54, P815, DOI 10.1002/glia.20419; Yoshimatsu T, 2006, DEVELOPMENT, V133, P2553, DOI 10.1242/dev.02419; Yu PJ, 2007, J CELL BIOCHEM, V100, P1100, DOI 10.1002/jcb.21116; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	38	37	39	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3866	3877		10.1096/fj.08-105908	http://dx.doi.org/10.1096/fj.08-105908			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18685078				2022-12-28	WOS:000260503000015
J	Kreth, S; Ledderose, C; Kaufmann, I; Groeger, G; Thiel, M				Kreth, Simone; Ledderose, Carola; Kaufmann, Ines; Groeger, Gabriele; Thiel, Manfred			Differential expression of 5 '-UTR splice variants of the adenosine A(2A) receptor gene in human granulocytes: identification, characterization, and functional impact on activation	FASEB JOURNAL			English	Article						sepsis; 5 '-untranslated region; alternative transcripts	5' UNTRANSLATED REGION; OPEN READING FRAMES; NF-KAPPA-B; HUMAN NEUTROPHILS; MESSENGER-RNA; ALTERNATIVE PROMOTERS; ENDOTHELIAL-CELLS; IMMUNE-RESPONSE; PLASMA-MEMBRANE; TH1 CYTOKINES	A key step in the pathogenesis of sepsis is the excessive and uncontrolled activation of polymorphonuclear neutrophils (PMNs). An inflammation-controlling function of adenosine receptors has been presumed; however, their role in PMN of sepsis patients is poorly defined. We investigated the expression of adenosine receptors in resting and lipopolysaccharide (LPS)-activated human PMNs, and in PMNs of sepsis patients. Our studies revealed that native human PMNs express almost equal distributions of all four adenosine receptor subtype transcripts, whereas exclusively the A(2A) receptor (A(2A)R) was up-regulated in LPS-stimulated PMNs and PMNs of sepsis patients. As a possible mechanism, we identified and fully characterized eight 5'-untranslated region (UTR) splice variants of the A(2A)R gene resulting from alternative transcription and/or splicing of five noncoding exons. We report a differential, activation state-specific expression of 5'-UTR variants within the same cell type, indicating a new mechanism to modulate gene expression: In resting human PMNs, mainly A(2A)R transcripts with long 5'-UTRs are expressed, whereas in stimulated PMNs and PMNs of septic patients, short 5'-UTRs predominate. Transcripts with short 5'-UTRs are more efficiently translated into protein. The correlation between changes of transcript patterns and A(2A)R up-regulation offers interesting clues regarding the course of sepsis.	[Kreth, Simone; Ledderose, Carola; Kaufmann, Ines; Groeger, Gabriele; Thiel, Manfred] Univ Munich, Dept Anaesthesiol, Munich, Germany	University of Munich	Thiel, M (corresponding author), Klinikum Grosshadern, Clin Anaesthesiol, Marchioninistr 15, D-81375 Munich, Germany.	mthiel@med.uni-muenchen.de		Kreth, Simone/0000-0002-0073-2098				Anney RJ, 2002, MOL PSYCHIATR, V7, P493, DOI 10.1038/sj.mp.4001003; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bouma MG, 1997, J IMMUNOL, V158, P5400; CRONSTEIN BN, 1986, J CLIN INVEST, V78, P760, DOI 10.1172/JCI112638; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; Engemaier E, 2006, GENOMICS, V87, P254, DOI 10.1016/j.ygeno.2005.10.001; Falleni A, 1999, J CELL BIOCHEM, V75, P235, DOI 10.1002/(SICI)1097-4644(19991101)75:2<235::AID-JCB6>3.0.CO;2-K; Fortin A, 2006, J LEUKOCYTE BIOL, V79, P574, DOI 10.1189/jlb.0505249; Fredholm BB, 1996, N-S ARCH PHARMACOL, V354, P262, DOI 10.1007/BF00171056; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gessi S, 2002, MOL PHARMACOL, V61, P415, DOI 10.1124/mol.61.2.415; Gomez G, 2003, BLOOD, V102, P4472, DOI 10.1182/blood-2002-11-3624; Haschemi A, 2007, J IMMUNOL, V178, P5921, DOI 10.4049/jimmunol.178.9.5921; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hoesel LM, 2005, SHOCK, V24, P40, DOI 10.1097/01.shk.0000170353.80318.d5; Johnson JL, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-28; Khoa ND, 2006, MOL PHARMACOL, V69, P1311, DOI 10.1124/mol.105.016857; Khoa ND, 2003, J IMMUNOL, V171, P3991, DOI 10.4049/jimmunol.171.8.3991; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Kirkpatrick P, 2002, NAT REV DRUG DISCOV, V1, P99, DOI 10.1038/nrd738; Kos M, 2002, J BIOL CHEM, V277, P37131, DOI 10.1074/jbc.M206325200; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Linden J, 2006, J CLIN INVEST, V116, P1835, DOI 10.1172/JCI29125; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Morello S, 2006, J IMMUNOL, V177, P7173, DOI 10.4049/jimmunol.177.10.7173; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Murphree LJ, 2005, BIOCHEM J, V391, P575, DOI 10.1042/BJ20050888; Nakanishi T, 2006, CANCER RES, V66, P5007, DOI 10.1158/0008-5472.CAN-05-4572; Noon LA, 2006, J MOL ENDOCRINOL, V37, P415, DOI 10.1677/jme.1.02023; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Payton SG, 2007, BBA-GENE STRUCT EXPR, V1769, P131, DOI 10.1016/j.bbaexp.2006.12.006; Peters K, 2003, CARDIOVASC RES, V60, P49, DOI 10.1016/S0008-6363(03)00397-3; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; Sauter KS, 2007, VET IMMUNOL IMMUNOP, V118, P92, DOI 10.1016/j.vetimm.2007.04.017; Sitkovsky MV, 2005, TRENDS IMMUNOL, V26, P299, DOI 10.1016/j.it.2005.04.004; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Tamassia N, 2007, J IMMUNOL, V178, P7344, DOI 10.4049/jimmunol.178.11.7344; Thiel M, 1998, HEPATOLOGY, V28, P1538, DOI 10.1002/hep.510280614; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Van Der Zee J, 2002, INT J HYPERTHER, V18, P1; Varani K, 2006, AM J RESP CRIT CARE, V173, P398, DOI 10.1164/rccm.200506-869OC; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Walsh NC, 2003, GENE, V307, P111, DOI 10.1016/S0378-1119(03)00449-9; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933; Yu LQ, 2004, BRAIN RES, V1000, P156, DOI 10.1016/j.brainres.2003.11.072; Zhang N, 2006, BLOOD, V108, P38, DOI 10.1182/blood-2005-06-2599; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	50	22	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3276	3286		10.1096/fj.07-101097	http://dx.doi.org/10.1096/fj.07-101097			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18541693				2022-12-28	WOS:000258761300020
J	Jay, SM; Shepherd, BR; Bertram, JP; Pober, JS; Saltzman, WM				Jay, Steven M.; Shepherd, Benjamin R.; Bertram, James P.; Pober, Jordan S.; Saltzman, W. Mark			Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation	FASEB JOURNAL			English	Article						tissue engineering; VEGF; therapeutic revascularization	ISCHEMIC SKELETAL-MUSCLE; IN-VIVO; BIOLOGICAL-ACTIVITY; SUSTAINED DELIVERY; CONTROLLED-RELEASE; PROTEIN DELIVERY; ANGIOGENESIS; TISSUE; MICROSPHERES; REGENERATION	Transplantation of Bcl-2-transduced human umbilical vein endothelial cells (ECs) in protein gels into the gastrocnemius muscle improves local reperfusion in immunodeficient mouse hosts with induced hind limb ischemia. We tested the hypothesis that incorporation of local, sustained growth factor delivery could enhance and accelerate this effect. Tissue engineering scaffolds often use synthetic polymers to enable controlled release of proteins, but most synthetic delivery systems have major limitations, most notably hydrophobicity and inefficient protein loading. Here, we report the development of a novel alginate-based delivery system for vascular endothelial growth factor-A(165) (VEGF) that exhibits superior loading efficiency and physical properties to previous systems in vitro. In vivo, VEGF released from alginate microparticles within protein gels was biologically active and, when combined with EC transplantation, led to increased survival of transplanted cells at 28 days. The composite graft described also improved early (14 days) tissue perfusion and late (28 days) muscle myoglobin expression, a sign of recovery from ischemia, compared with EC transplantation and VEGF delivery separately. We conclude that our improved approach to sustained VEGF delivery in tissue engineering is useful in vivo and that the integration of high efficiency protein delivery enhances the therapeutic effect of protein gel-based EC transplantation.	[Jay, Steven M.; Shepherd, Benjamin R.; Bertram, James P.; Pober, Jordan S.; Saltzman, W. Mark] Yale Univ, Dept Biomed Engn, New Haven, CT 06511 USA; [Jay, Steven M.; Shepherd, Benjamin R.; Pober, Jordan S.; Saltzman, W. Mark] Yale Univ, Dept Immunobiol, New Haven, CT 06511 USA; [Jay, Steven M.; Shepherd, Benjamin R.; Pober, Jordan S.; Saltzman, W. Mark] Yale Univ, Interdepartmental Program Vasc Biol & Therapeut, New Haven, CT 06511 USA	Yale University; Yale University; Yale University	Saltzman, WM (corresponding author), Yale Univ, Dept Biomed Engn, 55 Prospect St,MEC 415, New Haven, CT 06511 USA.	mark.saltzman@yale.edu	Jay, Steven/ABD-4344-2021	Jay, Steven/0000-0002-3827-5988	NHLBI NIH HHS [R01 HL085416, R01-HL-085416-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085416] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007; Choi SH, 2006, INT J PHARMACEUT, V311, P223, DOI 10.1016/j.ijpharm.2005.12.023; Cleland JL, 2001, J CONTROL RELEASE, V72, P13, DOI 10.1016/S0168-3659(01)00258-9; Elcin YM, 2001, ARTIF ORGANS, V25, P558, DOI 10.1046/j.1525-1594.2001.025007558.x; Enis DR, 2005, P NATL ACAD SCI USA, V102, P425, DOI 10.1073/pnas.0408357102; Faranesh AZ, 2004, MAGN RESON MED, V51, P1265, DOI 10.1002/mrm.20092; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fleming AB, 2001, J CONTROL RELEASE, V70, P29, DOI 10.1016/S0168-3659(00)00318-7; Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2; Gu F, 2004, J CONTROL RELEASE, V96, P463, DOI 10.1016/j.jconrel.2004.02.021; Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A; Hill E, 2006, P NATL ACAD SCI USA, V103, P2494, DOI 10.1073/pnas.0506004103; Huang M, 2007, BIOMACROMOLECULES, V8, P1607, DOI 10.1021/bm061211k; Jain RK, 2005, NAT BIOTECHNOL, V23, P821, DOI 10.1038/nbt0705-821; Kim TK, 2002, J PHARM PHARMACOL, V54, P897, DOI 10.1211/002235702760089009; King TW, 2000, J BIOMED MATER RES, V51, P383, DOI 10.1002/1097-4636(20000905)51:3<383::AID-JBM12>3.0.CO;2-D; KLOCK G, 1994, APPL MICROBIOL BIOT, V40, P638; Lee CH, 2001, INT J PHARMACEUT, V221, P1, DOI 10.1016/S0378-5173(01)00691-3; Lee H, 2002, TRANSPLANTATION, V73, P1589, DOI 10.1097/00007890-200205270-00011; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Mahoney MJ, 2006, TISSUE ENG, V12, P1915, DOI 10.1089/ten.2006.12.1915; Mahoney MJ, 2001, NAT BIOTECHNOL, V19, P934, DOI 10.1038/nbt1001-934; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420; Peters MC, 2002, J BIOMED MATER RES, V60, P668, DOI 10.1002/jbm.10134; Peters MC, 1998, J BIOMAT SCI-POLYM E, V9, P1267, DOI 10.1163/156856298X00389; Pieper JS, 2002, J BIOMED MATER RES, V62, P185, DOI 10.1002/jbm.10267; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rajagopalan S, 2003, CIRCULATION, V108, P1933, DOI 10.1161/01.CIR.0000093398.16124.29; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; Saltzman WM, 1999, PHARMACEUT RES, V16, P232, DOI 10.1023/A:1018824324275; Saltzman WM, 2002, NAT REV DRUG DISCOV, V1, P177, DOI 10.1038/nrd744; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Silva EA, 2007, J THROMB HAEMOST, V5, P590, DOI 10.1111/j.1538-7836.2007.02386.x; Smith MK, 2006, TISSUE ENG, V12, P235, DOI 10.1089/ten.2006.12.235; Smith MK, 2004, TISSUE ENG, V10, P63, DOI 10.1089/107632704322791709; van Weel V, 2004, CIRC RES, V95, P58, DOI 10.1161/01.RES.0000133247.69803.c3; Wallace DG, 2003, ADV DRUG DELIVER REV, V55, P1631, DOI 10.1016/j.addr.2003.08.004; Wang X, 2007, BIOMATERIALS, V28, P4161, DOI 10.1016/j.biomaterials.2007.05.036; Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102; Zheng CH, 2004, BIOCHEM BIOPH RES CO, V323, P1321, DOI 10.1016/j.bbrc.2004.09.007	43	50	52	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2949	2956		10.1096/fj.08-108803	http://dx.doi.org/10.1096/fj.08-108803			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18450813	Green Published			2022-12-28	WOS:000258089300035
J	MacLean, HE; Chiu, WSM; Notini, AJ; Axell, AM; Davey, RA; McManus, JF; Ma, C; Plant, DR; Lynch, GS; Zajac, JD				MacLean, Helen E.; Chiu, W. S. Maria; Notini, Amanda J.; Axell, Anna-Maree; Davey, Rachel A.; McManus, Julie F.; Ma, Cathy; Plant, David R.; Lynch, Gordon S.; Zajac, Jeffrey D.			Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice	FASEB JOURNAL			English	Article						hypertrophy anabolic; knockout; strength; polyamine	LEVATOR ANI MUSCLE; MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; YOUNG MEN; TESTOSTERONE; GROWTH; CELLS; HYPERTROPHY; STRENGTH; INSULIN	To identify mechanisms of anabolic androgen action in muscle, we generated male and female genomic androgen receptor (AR) knockout (ARKO) mice, and characterized muscle mass, contractile function, and gene expression. Muscle mass is decreased in ARKO males, but normal in ARKO females. The levator ani muscle, which fails to develop in normal females, is also absent in ARKO males. Force production is decreased from fast-twitch ARKO male muscle, and slow-twitch muscle has increased fatigue resistance. Microarray analysis shows up-regulation of genes encoding slow-twitch muscle contractile proteins. Real-time PCR confirms that expression of genes encoding polyamine biosynthetic enzymes, ornithine decarboxylase (Odc1), and S-adenosylmethionine decarboxylase (Amd1), is reduced in ARKO muscle, suggesting androgens act through regulation of polyamine biosynthesis. Altered expression of regulators of myoblast progression from proliferation to terminal differentiation suggests androgens also promote muscle growth by maintaining myoblasts in the proliferate state and delaying differentiation (increased Cdkn1c and Igf2, decreased Itg1bp3). A similar pattern of gene expression is observed in orchidectomized male mice, during androgen withdrawal-dependent muscle atrophy. In conclusion, androgens are not required for peak muscle mass in females. In males, androgens act through the AR to regulate multiple gene pathways that control muscle mass, strength, and fatigue resistance.	[MacLean, Helen E.; Chiu, W. S. Maria; Notini, Amanda J.; Axell, Anna-Maree; Davey, Rachel A.; McManus, Julie F.; Ma, Cathy; Zajac, Jeffrey D.] Univ Melbourne, Dept Med, Heidelberg, Vic, Australia; [Plant, David R.; Lynch, Gordon S.] Univ Melbourne, Dept Physiol, Melbourne, Vic, Australia	University of Melbourne; University of Melbourne	MacLean, HE (corresponding author), Austin Hosp, Melbourne, Vic 3084, Australia.	hmaclean@unimelb.edu.au	Zajac, Jeffrey/ABC-3767-2021; Lynch, Gordon/G-9553-2015	Zajac, Jeffrey/0000-0003-3933-5708; Lynch, Gordon/0000-0001-9220-9810; DAVEY, RACHEL A/0000-0001-5121-0209				Abukhalaf IK, 2002, PHARMACOLOGY, V65, P145, DOI 10.1159/000058041; Altuwaijri S, 2004, ENDOCRINE, V25, P27, DOI 10.1385/ENDO:25:1:27; Armstrong DD, 2005, AM J PHYSIOL-CELL PH, V289, pC853, DOI 10.1152/ajpcell.00093.2005; Axell AM, 2006, AM J PHYSIOL-ENDOC M, V291, pE506, DOI 10.1152/ajpendo.00058.2006; Bhasin S, 2005, J CLIN ENDOCR METAB, V90, P678, DOI 10.1210/jc.2004-1184; Bhasin S, 2001, AM J PHYSIOL-ENDOC M, V281, pE1172, DOI 10.1152/ajpendo.2001.281.6.E1172; Chen Y, 2005, J ENDOCRINOL, V186, P21, DOI 10.1677/joe.1.05976; Childs AC, 2003, CELL MOL LIFE SCI, V60, P1394, DOI 10.1007/s00018-003-2332-4; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; Davey RA, 2006, AM J PHYSIOL-ENDOC M, V291, pE429, DOI 10.1152/ajpendo.00124.2006; Doumit ME, 1996, ENDOCRINOLOGY, V137, P1385, DOI 10.1210/en.137.4.1385; FORGER NG, 1992, J NEUROBIOL, V23, P1192, DOI 10.1002/neu.480230910; Franke WW, 1997, CLIN CHEM, V43, P1262; Fulco CS, 1999, ACTA PHYSIOL SCAND, V167, P233; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Glenmark B, 2004, AM J PHYSIOL-ENDOC M, V287, pE1125, DOI 10.1152/ajpendo.00098.2004; HOBBS CJ, 1993, J CLIN ENDOCR METAB, V77, P776, DOI 10.1210/jc.77.3.776; Jones MEE, 2006, TRENDS ENDOCRIN MET, V17, P53, DOI 10.1016/j.tem.2006.01.004; JOUBERT Y, 1994, DEV BIOL, V162, P104, DOI 10.1006/dbio.1994.1070; Li J, 1999, J CELL BIOL, V147, P1391, DOI 10.1083/jcb.147.7.1391; Lin HY, 2005, DIABETES, V54, P1717, DOI 10.2337/diabetes.54.6.1717; MacLean HE, 1997, J STEROID BIOCHEM, V62, P233, DOI 10.1016/S0960-0760(97)00049-6; MacLean HE, 2008, PHYSIOL GENOMICS, V33, P133, DOI 10.1152/physiolgenomics.00260.2007; MATSUMINE H, 1986, J CLIN ENDOCR METAB, V63, P717, DOI 10.1210/jcem-63-3-717; Matsumoto T, 2005, J BIOCHEM, V138, P105, DOI 10.1093/jb/mvi118; Mauras N, 1998, J CLIN ENDOCR METAB, V83, P1886, DOI 10.1210/jc.83.6.1886; Notini AJ, 2005, J MOL ENDOCRINOL, V35, P547, DOI 10.1677/jme.1.01884; Poortmans A, 1998, ANAT REC, V251, P20, DOI 10.1002/(SICI)1097-0185(199805)251:1<20::AID-AR5>3.0.CO;2-I; POWERS ML, 1975, ENDOCRINOLOGY, V97, P1043; SCHMID C, 1983, FEBS LETT, V161, P117, DOI 10.1016/0014-5793(83)80742-X; Schroeder ET, 2003, AM J PHYSIOL-ENDOC M, V285, pE16, DOI 10.1152/ajpendo.00032.2003; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; Sheffield-Moore M, 2000, ANN MED, V32, P181, DOI 10.3109/07853890008998825; Singh R, 2003, ENDOCRINOLOGY, V144, P5081, DOI 10.1210/en.2003-0741; Steelman CA, 2006, FASEB J, V20, P580, DOI 10.1096/fj.05-5125fje; Tomczak KK, 2003, FASEB J, V17, P403, DOI 10.1096/f.03-0568fje; VENABLE JH, 1966, AM J ANAT, V119, P271, DOI 10.1002/aja.1001190206; Xu TS, 2004, J STEROID BIOCHEM, V92, P447, DOI 10.1016/j.jsbmb.2004.07.008; Yang LY, 2000, J NEUROBIOL, V44, P308, DOI 10.1002/1097-4695(20000905)44:3<308::AID-NEU2>3.0.CO;2-M; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	42	140	143	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2676	2689		10.1096/fj.08-105726	http://dx.doi.org/10.1096/fj.08-105726			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18390925				2022-12-28	WOS:000258089300008
J	Oyesanya, RA; Lee, ZP; Wu, JH; Chen, J; Song, YD; Mukherjee, A; Dent, P; Kordula, T; Zhou, HP; Fang, XJ				Oyesanya, Regina A.; Lee, Zendra P.; Wu, Jinhua; Chen, Jing; Song, Yuanda; Mukherjee, Abir; Dent, Paul; Kordula, Tomasz; Zhou, Huiping; Fang, Xianjun			Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells	FASEB JOURNAL			English	Article						C/EBP; GPCR; HuR; receptor tyrosine kinase	PROTEIN-COUPLED RECEPTOR; GROWTH-FACTOR RECEPTOR; MESSENGER-RNA; C/EBP-BETA; BINDING PROTEINS; OVER-EXPRESSION; GENE-EXPRESSION; IN-VIVO; C-JUN; HUR	Emerging evidence suggests that lysophosphatidic acid (LPA) is a physiological regulator of cyclooxygenase-2 (Cox-2) expression. Herein we used ovarian cancer cells as a model to investigate the molecular mechanisms that link the LPA G protein-coupled receptors (GPCRs) to Cox-2 expression. LPA stimulated Cox-2 expression and release of prostaglandins though the LPA(1), LPA(2), and LPA(5) receptors. The effect of LPA involves both transcriptional activation and post-transcriptional enhancement of Cox-2 mRNA stability. The consensus sites for C/EBP in the Cox-2 promoter were essential for transcriptional activation of Cox-2 by LPA. The NF-kappa B and AP-1 transcription factors commonly involved in inducible Cox-2 expression were dispensable. Dominant-negative C/EPB beta inhibited LPA activation of the Cox-2 promoter and expression. Furthermore, LPA stimulated C/EBP beta phosphorylation and activity through a novel mechanism integrating GPCR signals and a permissive activity from a receptor tyrosine kinase (RTK). This role of RTK was not consistent with LPA activation of C/EBP through transactivation of RTK, as full activation of RTKs with their own agonists only weakly stimulated C/EBP. In addition to the transcriptional activation, the RNA stabilization protein HuR bound to and protected Cox-2 mRNA in LPA-stimulated cells, indicating an active role for HuR in sustaining Cox-2 induction during physiological responses.	[Oyesanya, Regina A.; Lee, Zendra P.; Wu, Jinhua; Chen, Jing; Song, Yuanda; Mukherjee, Abir; Dent, Paul; Kordula, Tomasz; Fang, Xianjun] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, Richmond, VA 23298 USA; [Zhou, Huiping] Virginia Commonwealth Univ, Sch Med, Dept Microbiol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Fang, XJ (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, Box 980614,1101 E Marshall St, Richmond, VA 23298 USA.	xfang@vcu.edu	Zhou, Huiping/H-6875-2019; Zhou, Huiping/J-3639-2015	Zhou, Huiping/0000-0002-0050-372X; 	NCI NIH HHS [P30 CA016059, P30 CA16059, CA102196, R01 CA102196] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102196, P30CA016059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BROWN PH, 1993, ONCOGENE, V8, P877; Cesena TI, 2007, J BIOL CHEM, V282, P956, DOI 10.1074/jbc.M511451200; Chen LC, 2004, BBA-MOL CELL BIOL L, V1683, P38, DOI 10.1016/j.bbalip.2004.04.003; Cok SJ, 2003, J BIOL CHEM, V278, P36157, DOI 10.1074/jbc.M302547200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Denkert C, 2004, CANCER RES, V64, P189, DOI 10.1158/0008-5472.CAN-03-1987; Denkert C, 2006, MODERN PATHOL, V19, P1261, DOI 10.1038/modpathol.3800645; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Hahn A, 2002, BIOCHEM J, V362, P33, DOI 10.1042/0264-6021:3620033; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HOWE LR, 1993, J BIOL CHEM, V268, P20717; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Huang MC, 2004, ONCOGENE, V23, P122, DOI 10.1038/sj.onc.1206986; Ki SH, 2007, J BIOL CHEM, V282, P1938, DOI 10.1074/jbc.M606080200; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Lee HK, 2006, NUCLEIC ACIDS RES, V34, P5705, DOI 10.1093/nar/gkl698; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Liao ZX, 2007, DRUGS, V67, P821, DOI 10.2165/00003495-200767060-00001; McAllister-Lucas LM, 2007, P NATL ACAD SCI USA, V104, P139, DOI 10.1073/pnas.0601947103; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Muehlich S, 2004, ATHEROSCLEROSIS, V175, P261, DOI 10.1016/j.atherosclerosis.2004.04.011; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nie M, 2003, MOL CELL BIOL, V23, P9233, DOI 10.1128/MCB.23.24.9233-9244.2003; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Park SY, 2006, CELL SIGNAL, V18, P1063, DOI 10.1016/j.cellsig.2005.08.018; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rubio I, 2003, BIOCHEM J, V376, P571, DOI 10.1042/BJ20031410; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Shida D, 2005, WORLD J GASTROENTERO, V11, P5638, DOI 10.3748/wjg.v11.i36.5638; Sivashanmugam P, 2004, J BIOL CHEM, V279, P21154, DOI 10.1074/jbc.M313776200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Symowicz J, 2005, CANCER RES, V65, P2234, DOI 10.1158/0008.5472.CAN-04-2781; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; Wang DH, 2007, P NATL ACAD SCI USA, V104, P145, DOI 10.1073/pnas.0601894104; Wu J, 2002, BBA-MOL CELL BIOL L, V1582, P100, DOI 10.1016/S1388-1981(02)00143-9; Wu KK, 2005, ARTERIOSCL THROM VAS, V25, P679, DOI 10.1161/01.ATV.0000157899.35660.61; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Zaslavsky A, 2006, BBA-MOL CELL BIOL L, V1761, P1200, DOI 10.1016/j.bbalip.2006.08.011	62	38	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2639	2651		10.1096/fj.07-101428	http://dx.doi.org/10.1096/fj.07-101428			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18362203	Green Published			2022-12-28	WOS:000258089300005
J	Xie, B; Shen, JK; Dong, A; Swaim, M; Hackett, SF; Wyder, L; Worpenberg, S; Barbieri, S; Campochiaro, PA				Xie, Bing; Shen, Jikui; Dong, Aling; Swaim, Mara; Hackett, Sean F.; Wyder, Lorenza; Worpenberg, Susanne; Barbieri, Samuel; Campochiaro, Peter A.			An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization	FASEB JOURNAL			English	Article						age-related macular degeneration; angiogenesis; chemokines; diabetic retinopathy; inflammation; stromalderived factor-1; vascular endothelial growth factor	CHOROIDAL NEOVASCULARIZATION; UP-REGULATION; EXPRESSION; METARGIDIN; PROTEIN; DOMAIN; CELLS; MICE; ALPHA(V)BETA(3); RETINOPATHY	Proteins with a disintegrin and a metalloproteinase domain (ADAMs) are a family of membrane-bound proteinases that bind integrins through their disintegrin domain. In this study, we have found modest expression of ADAM15 in pericytes in normal retina and strong up-regulation of ADAM15 in retinal vascular endothelial cells in ischemic retina. Increased expression of vascular endothelial growth factor (VEGF) in the retina in the absence of ischemia also increased ADAM15 levels, and knockdown of Vegf mRNA in ischemic retina reduced Adam15 mRNA. Mice deficient in ADAM15 showed a significant reduction in ischemia-induced retinal neovascularization, choroidal neovascularization at rupture sites in Bruch's membrane, and VEGF-induced subretinal neovascularization. ADAM15-deficient mice also showed reduced levels of VEGF(164), VEGF receptor 1, and VEGF receptor 2 in ischemic retina. These data suggest that ADAM15 and VEGF participate in an amplification loop; VEGF increases expression of ADAM15, which in turn increases expression of VEGF and its receptors. Perturbation of the loop by elimination of ADAM15 suppresses ocular neovascularization in 3 different model systems, and thus ADAM15 provides a new therapeutic target for diseases complicated by neovascularization.	[Xie, Bing; Shen, Jikui; Dong, Aling; Swaim, Mara; Hackett, Sean F.; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; [Xie, Bing; Shen, Jikui; Dong, Aling; Swaim, Mara; Hackett, Sean F.; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; [Wyder, Lorenza; Worpenberg, Susanne; Barbieri, Samuel] Expertise Platform Proteases, Novartis Inst Biomed Res, Basel, Switzerland; [Xie, Bing] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China	Johns Hopkins University; Johns Hopkins University; Novartis; Shanghai Jiao Tong University	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@jhmi.edu		Xie, Bing/0000-0003-2335-5966	NEI NIH HHS [R01 EY012609, P30 EY001765, P30EY1765] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Horiuchi K, 2003, MOL CELL BIOL, V23, P5614, DOI 10.1128/MCB.23.16.5614-5624.2003; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Komiya K, 2005, ARTHRITIS RES THER, V7, pR1158, DOI 10.1186/ar1796; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Luna J, 1996, LAB INVEST, V75, P563; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; Nath D, 1999, J CELL SCI, V112, P579; Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431; Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Saunders WB, 2006, J CELL BIOL, V175, P179, DOI 10.1083/jcb.200603176; Sennino B, 2007, CANCER RES, V67, P7358, DOI 10.1158/0008-5472.CAN-07-0293; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shen JK, 2007, INVEST OPHTH VIS SCI, V48, P4335, DOI 10.1167/iovs.07-0113; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Sounni NE, 2004, J BIOL CHEM, V279, P13564, DOI 10.1074/jbc.M307688200; SUNDBERG C, 1993, AM J PATHOL, V143, P1377; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; Trochon V, 1998, Angiogenesis, V2, P277, DOI 10.1023/A:1009206817829; Trochon-Joseph V, 2004, CANCER RES, V64, P2062, DOI 10.1158/0008-5472.CAN-03-3272; Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941; Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	35	27	29	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2775	2783		10.1096/fj.07-099283	http://dx.doi.org/10.1096/fj.07-099283			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18381816	Green Published			2022-12-28	WOS:000258089300018
J	Bhavsar, PK; Sukkar, MB; Khorasani, N; Lee, KY; Chung, KF				Bhavsar, Pankaj K.; Sukkar, Maria B.; Khorasani, Nadia; Lee, Kang-Yun; Chung, Kian Fan			Glucocorticoid suppression of CX(3)CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappa B	FASEB JOURNAL			English	Article						epithelial cells; transcription factor; displacement; chromatin	TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE-CELLS; INTERFERON-GAMMA; TNF-ALPHA; EPITHELIAL-CELLS; IFN-GAMMA; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; RESPONSE ELEMENT; IMMUNE-SYSTEM	Glucocorticoids are an important anti-inflammatory treatment of many inflammatory diseases including asthma. However, the mechanisms by which they mediate their suppressive effects are not fully understood. Respiratory epithelial cells are a source of CX(3)CL1 (fractalkine), which mediates cell adhesion and acts as a chemoattractant for monocytes, T cells, and mast cells. We show, in lung A549 epithelial cells, that the tumor necrosis factor-alpha (TNF-alpha) and IFN gamma synergistically induced protein release and mRNA expression of CX(3)CL1 is inhibited by dexamethasone, without interfering with cytokine-induced nuclear translocation of NF-kappa B, and by an inhibitor of I kappa B kinase 2, AS602868. DNA binding assays confirmed the ability of NF-kappa B to bind to the proximal CX(3)CL1 promoter. Chromatin immunoprecipitation assays showed a 5-fold increase in the recruitment of NF-kappa B to the CX(3)CL1 gene promoter in response to IFN gamma/TNF-alpha; this too was reversed by dexamethasone. In contrast, dexamethasone did not displace NF-kappa B from the granulocytemacrophage colony-stimulating factor gene promoter. We conclude that CX(3)CL1 expression is regulated through the NF-kappa B pathway and that dexamethasone inhibits CX(3)CL1 expression through a glucocorticoid receptor-dependent (RU486 sensitive) mechanism. This study also provides support for the action of glucocorticoids mediating their suppressive effects on expression by interfering with the binding of transcriptional activators at native gene promoters.	[Bhavsar, Pankaj K.; Sukkar, Maria B.; Khorasani, Nadia; Lee, Kang-Yun; Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London SW3 6LY, England	Imperial College London	Bhavsar, PK (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, Guy Scadding Bldg,Dovehouse St, London SW3 6LY, England.	p.bhavsar@imperial.ac.uk	Chung, Kian Fan/B-1872-2012; Sukkar, Maria B/L-6917-2013; Chung, Kian Fan/I-8456-2019	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Sukkar, Maria/0000-0003-4591-2399	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		ABBINANTENISSEN JM, 1995, AM J PHYSIOL-LUNG C, V268, pL601, DOI 10.1152/ajplung.1995.268.4.L601; Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARKER JNWN, 1990, J CLIN INVEST, V85, P605, DOI 10.1172/JCI114481; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Catley MC, 2005, BRIT J PHARMACOL, V145, P114, DOI 10.1038/sj.bjp.0706170; Chen YM, 2003, BRIT J PHARMACOL, V138, P950, DOI 10.1038/sj.bjp.0705088; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; El-Shazly A, 2006, J IMMUNOL, V176, P1860, DOI 10.4049/jimmunol.176.3.1860; Fahy OL, 2003, LAB INVEST, V83, P721, DOI 10.1097/01.LAB.0000069518.49544.B8; Frelin C, 2003, ONCOGENE, V22, P8187, DOI 10.1038/sj.onc.1206963; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Imaizumi T, 2000, TOHOKU J EXP MED, V192, P127, DOI 10.1620/tjem.192.127; Imanishi D, 2000, J IMMUNOL, V165, P3907, DOI 10.4049/jimmunol.165.7.3907; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; Kochetkova M, 1996, J BIOL CHEM, V271, P14438, DOI 10.1074/jbc.271.24.14438; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lee AH, 2000, BIOCHEM J, V350, P131, DOI 10.1042/0264-6021:3500131; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Menetski JP, 2000, J BIOL CHEM, V275, P7619, DOI 10.1074/jbc.275.11.7619; Murphy PM, 2000, PHARMACOL REV, V52, P145; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Ning W, 2004, P NATL ACAD SCI USA, V101, P14895, DOI 10.1073/pnas.0401168101; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Novac N, 2006, FASEB J, V20, P1074, DOI 10.1096/fj.05-5457com; OHMORI Y, 1995, J IMMUNOL, V154, P5235; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rimaniol AC, 2003, J ALLERGY CLIN IMMUN, V112, P1139, DOI 10.1016/j.jaci.2003.09.041; SCHEINMAN RI, 1995, SCIENCE, V270, P286; Sukkar MB, 2004, AM J PHYSIOL-LUNG C, V287, pL1230, DOI 10.1152/ajplung.00014.2004; Yoshida H, 2001, NEUROSCI LETT, V303, P132, DOI 10.1016/S0304-3940(01)01699-8	39	42	45	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1807	1816		10.1096/fj.07-094235	http://dx.doi.org/10.1096/fj.07-094235			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230685				2022-12-28	WOS:000256352700021
J	Clark, PA; Moioli, EK; Sumner, DR; Mao, JJ				Clark, Paul A.; Moioli, Eduardo K.; Sumner, D. Rick; Mao, Jeremy J.			Porous implants as drug delivery vehicles to augment host tissue integration	FASEB JOURNAL			English	Article						stem cells; transforming growth factor-beta; bone morphogenetic proteins; osteoblasts; wound healing; controlled release	MESENCHYMAL STEM-CELLS; GROWTH-FACTOR BETA-1; TITANIUM IMPLANTS; OSTEOGENIC DIFFERENTIATION; BONE REGENERATION; RHTGF-BETA-2; SCAFFOLDS; SURFACES; INGROWTH; RELEASE	The common premise of synthetic implants in the restoration of diseased tissues and organs is to use inert and solid materials. Here, a porous titanium implant was fabricated for the delivery of microencapsulated bioactive cues. Control- released transforming growth factor-beta 1 (TGF-beta 1) promoted the proliferation and migration of human mesenchymal stem cells into porous implants in vitro. At 4 wk of implantation in the rabbit humerus, control- released TGF-beta 1 from porous implants significantly increased bone- to- implant contact (BIC) by 96% and bone ingrowth by 50% over placebos. Control- released 100 ng TGF-beta 1 induced equivalent BIC and bone ingrowth to adsorbed 1 mu g TGF-beta 1, suggesting that controlled release is effective at 10- fold less drug dose than adsorption. Histomorphometry, scanning electron microscopy, and microcomputed tomography showed that control- released TGF-beta 1 enhanced bone ingrowth in the implant's pores and surface. These findings suggest that solid prostheses can be transformed into porous implants to serve as drug delivery carriers, from which control- released bioactive cues augment host tissue integration.	[Moioli, Eduardo K.; Mao, Jeremy J.] Columbia Univ, Med Ctr, Coll Dent Med, Fu Fdn Sch Engn & Appl Sci,Dept Biomed Engn, New York, NY 10032 USA; [Clark, Paul A.] Univ Wisconsin, Dept Neurol Surg, Madison, WI USA; [Sumner, D. Rick] Rush Univ, Dept Anat & Cell Biol, Chicago, IL 60612 USA	Columbia University; University of Wisconsin System; University of Wisconsin Madison; Rush University	Mao, JJ (corresponding author), Columbia Univ, Med Ctr, Coll Dent Med, Fu Fdn Sch Engn & Appl Sci,Dept Biomed Engn, 630 W 168 St,PH7E-CDM, New York, NY 10032 USA.	jmao@columbia.edu		Sumner, Dale/0000-0001-9575-3862	NIBIB NIH HHS [EB02332] Funding Source: Medline; NIDCR NIH HHS [RC2 DE020767, DE015391] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [RC2DE020767, R01DE015391] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776; Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/1547328041797552; Alhadlaq A, 2004, ANN BIOMED ENG, V32, P911, DOI 10.1023/B:ABME.0000032454.53116.ee; Alliston Tamara N., 2000, P233; An Y. H., 2000, MECH TESTING BONE BO, P41; Clark PA, 2005, J APPL PHYSIOL, V98, P1922, DOI 10.1152/japplphysiol.01080.2004; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; De Ranieri A, 2005, BONE, V37, P55, DOI 10.1016/j.bone.2005.03.011; Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019; Doll B, 2001, CRIT REV EUKAR GENE, V11, P173; Holland TA, 2007, OSTEOARTHR CARTILAGE, V15, P187, DOI 10.1016/j.joca.2006.07.006; Hong L, 2005, ANN BIOMED ENG, V33, P511, DOI 10.1007/s10439-005-2510-7; Hunziker EB, 1996, J BONE JOINT SURG AM, V78A, P721, DOI 10.2106/00004623-199605000-00012; Ingham E, 2000, P I MECH ENG H, V214, P21, DOI 10.1243/0954411001535219; Leach JK, 2004, EXPERT OPIN BIOL TH, V4, P1015, DOI 10.1517/14712598.4.7.1015; Lind M, 1998, ACTA ORTHOP SCAND, V69, P2; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; Liu Y, 2007, BIOMATERIALS, V28, P2677, DOI 10.1016/j.biomaterials.2007.02.003; Lossdorfer S, 2004, J BIOMED MATER RES A, V70A, P361, DOI 10.1002/jbm.a.30025; Lu L, 2000, J BIOMED MATER RES, V50, P440, DOI 10.1002/(SICI)1097-4636(20000605)50:3<440::AID-JBM19>3.0.CO;2-G; Marion NW, 2006, METHOD ENZYMOL, V420, P339, DOI 10.1016/S0079-6879(06)20016-8; MCKOY BE, 2000, MECH TESTING BONE BO, P439; Meredith DO, 2007, J MATER SCI-MATER M, V18, P405, DOI 10.1007/s10856-006-0706-5; Misch CE., 1993, CONT IMPLANT DENT, V1st; Moioli EK, 2007, ADV DRUG DELIVER REV, V59, P308, DOI 10.1016/j.addr.2007.03.019; Moioli EK, 2007, WOUND REPAIR REGEN, V15, P413, DOI 10.1111/j.1524-475X.2007.00244.x; Moioli EK, 2006, TISSUE ENG, V12, P537, DOI 10.1089/ten.2006.12.537; Nebe JGB, 2007, MACROMOL BIOSCI, V7, P567, DOI 10.1002/mabi.200600293; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; ROBERTS AB, 2000, SKELETAL GROWTH FACT, P233; Schliephake H, 2005, J BIOMED MATER RES B, V73B, P88, DOI 10.1002/jbm.b.30183; Sumner D. R., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P333; Sumner DR, 2006, J BONE JOINT SURG AM, V88A, P806, DOI 10.2106/JBJS.E.00846; Sumner DR, 2001, J ORTHOP RES, V19, P85; Yamamoto M, 2000, J CONTROL RELEASE, V64, P133, DOI 10.1016/S0168-3659(99)00129-7; Zhang H, 2005, J BIOMED MATER RES A, V75A, P98, DOI 10.1002/jbm.a.30400; Zhang R, 2004, J BIOMED MATER RES B, V71B, P408, DOI 10.1002/jbm.b.30110; [No title captured]	40	22	25	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1684	1693		10.1096/fj.07-094789	http://dx.doi.org/10.1096/fj.07-094789			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198217				2022-12-28	WOS:000256352700009
J	Stromberg, PE; Woolsey, CA; Clark, AT; Clark, JA; Turnbull, IR; McConnell, KW; Chang, KC; Chung, CS; Ayala, A; Buchman, TG; Hotchkiss, RS; Coopersmith, CM				Stromberg, Paul E.; Woolsey, Cheryl A.; Clark, Andrew T.; Clark, Jessica A.; Turnbull, Isaiah R.; McConnell, Kevin W.; Chang, Katherine C.; Chung, Chun-Shiang; Ayala, Alfred; Buchman, Timothy G.; Hotchkiss, Richard S.; Coopersmith, Craig M.			CD4+ lymphocytes control gut epithelial apoptosis and mediate survival in sepsis	FASEB JOURNAL			English	Article						crosstalk; intestine; Bcl-2; cell death; cecal ligation and puncture	HUMAN LEUKEMIA-CELLS; IMPROVES SURVIVAL; T-CELLS; INTESTINAL EPITHELIUM; CECAL LIGATION; BCL-2; EXPRESSION; MOLECULES; INJURY; OVEREXPRESSION	Lymphocytes help determine whether gut epithelial cells proliferate or differentiate but are not known to affect whether they live or die. Here, we report that lymphocytes play a controlling role in mediating gut epithelial apoptosis in sepsis but not under basal conditions. Gut epithelial apoptosis is similar in unmanipulated Rag-1(-/-) and wild-type (WT) mice. However, Rag-1(-/-) animals have a 5-fold augmentation in gut epithelial apoptosis following cecal ligation and puncture (CLP) compared to septic WT mice. Reconstitution of lymphocytes in Rag-1(-/-) mice via adoptive transfer decreases intestinal apoptosis to levels seen in WT animals. Subset analysis indicates that CD4(+) but not CD8(+), gamma delta, or B cells are responsible for the antiapoptotic effect of lymphocytes on the gut epithelium. Gut-specific overexpression of Bcl-2 in transgenic mice decreases mortality following CLP. This survival benefit is lymphocyte dependent since gut-specific overexpression of Bcl-2 fails to alter survival when the transgene is overexpressed in Rag-1(-/-) mice. Further, adoptively transferring lymphocytes to Rag-1(-/-) mice that simultaneously overexpress gut-specific Bcl-2 results in improved mortality following sepsis. Thus, sepsis unmasks CD4(+) lymphocyte control of gut apoptosis that is not present under homeostatic conditions, which acts as a key determinant of both cellular survival and host mortality.-Stromberg, P. E., Woolsey, C. A., Clark, A. T., Clark, J. A., Turnbull, I. R., McConnell, K. W., Chang, K. C., Chung, C.-S., Ayala, A., Buchman, T. G., Hotchkiss, R. S., Coopersmith, C. M. CD4(+) lymphocytes control gut epithelial apoptosis and mediate survival in sepsis. FASEB J. 23, 1817-1825 (2009)	[Stromberg, Paul E.; Woolsey, Cheryl A.; Clark, Andrew T.; Clark, Jessica A.; Turnbull, Isaiah R.; McConnell, Kevin W.; Buchman, Timothy G.; Coopersmith, Craig M.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; [Chang, Katherine C.; Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Chung, Chun-Shiang; Ayala, Alfred] Brown Univ, Sch Med, Providence, RI 02912 USA; [Chung, Chun-Shiang; Ayala, Alfred] Rhode Isl Hosp, Dept Surg, Providence, RI USA	Washington University (WUSTL); Washington University (WUSTL); Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Coopersmith, CM (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	coopersmithc@wustl.edu		Buchman, Timothy/0000-0001-7350-5921; Ayala, Alfred/0000-0002-5034-2995; Dominguez Rieg, Jessica/0000-0001-6190-7464	National Institutes of Health [GM072808, GM66202, GM008795, GM055194, GM044118, DK052574]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066202, R01GM044118, T32GM008795, R01GM055194, R01GM072808, R37GM044118] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Washington University Digestive Diseases Research Morphology Core. This study was supported by funding from the National Institutes of Health (GM072808, GM66202, GM008795, GM055194, GM044118, DK052574).	Alverdy JC, 2003, CRIT CARE MED, V31, P598, DOI 10.1097/01.CCM.0000045576.55937.67; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; BAKER CC, 1983, SURGERY, V94, P331; Bilbault P, 2007, CRIT CARE MED, V35, P69, DOI 10.1097/01.CCM.0000251133.26979.F4; Caruso R, 2007, GASTROENTEROLOGY, V132, P166, DOI 10.1053/j.gastro.2006.09.053; Chen Jun, 2002, Mol Cancer Ther, V1, P961; Chen WJ, 2001, IMMUNITY, V14, P715, DOI 10.1016/S1074-7613(01)00147-9; Chen YP, 2002, P NATL ACAD SCI USA, V99, P14338, DOI 10.1073/pnas.212290499; Clark JA, 2007, SHOCK, V28, P384, DOI 10.1097/shk.0b013e31805569df; Coopersmith CM, 2003, CRIT CARE MED, V31, P1630, DOI 10.1097/01.CCM.0000055385.29232.11; Coopersmith CM, 2002, CRIT CARE MED, V30, P195, DOI 10.1097/00003246-200201000-00028; Coopersmith CM, 2002, JAMA-J AM MED ASSOC, V287, P1716, DOI 10.1001/jama.287.13.1716; Coopersmith CM, 1999, AM J PHYSIOL-GASTR L, V276, pG677, DOI 10.1152/ajpgi.1999.276.3.G677; Crimi E, 2006, FREE RADICAL RES, V40, P665, DOI 10.1080/10715760600669612; Dahan S, 2007, IMMUNOL REV, V215, P243, DOI 10.1111/j.1600-065X.2006.00484.x; Dasmahapatra G, 2006, MOL PHARMACOL, V69, P288, DOI 10.1124/mol.105.016154; De Freitas I, 2004, CHEST, V125, P2238, DOI 10.1378/chest.125.6.2238; De Maio A, 2005, SHOCK, V23, P11, DOI 10.1097/01.shk.0000144134.03598.c5; Enoh VT, 2008, SHOCK, V29, P56, DOI 10.1097/shk.0b013e318070c8b9; George NM, 2007, GENE DEV, V21, P1937, DOI 10.1101/gad.1553607; Halpern MD, 2006, BIOL NEONATE, V89, P227, DOI 10.1159/000090015; Hassoun HT, 2001, SHOCK, V15, P1, DOI 10.1097/00024382-200115010-00001; Hershberg RM, 2000, IMMUNOL TODAY, V21, P123, DOI 10.1016/S0167-5699(99)01575-3; Hershberg RM, 1998, J CLIN INVEST, V102, P792, DOI 10.1172/JCI3201; Hershberg RM, 1997, J CLIN INVEST, V100, P204, DOI 10.1172/JCI119514; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; Hotchkiss RS, 2003, P NATL ACAD SCI USA, V100, P6724, DOI 10.1073/pnas.1031788100; Iwata A, 2003, J IMMUNOL, V171, P3136, DOI 10.4049/jimmunol.171.6.3136; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; Kim JM, 1998, J CLIN INVEST, V102, P1815, DOI 10.1172/JCI2466; Martignoni A, 2008, SHOCK, V29, P591, DOI 10.1097/SHK.0b013e318157f427; MAYER L, 1991, GASTROENTEROLOGY, V100, P3, DOI 10.1016/0016-5085(91)90575-6; Nakazawa A, 2004, GASTROENTEROLOGY, V126, P1347, DOI 10.1053/j.gastro.2004.02.004; POWRIE F, 1995, IMMUNITY, V3, P171, DOI 10.1016/1074-7613(95)90086-1; Scumpia PO, 2006, J IMMUNOL, V177, P7943, DOI 10.4049/jimmunol.177.11.7943; Tang L, 2000, BIOCHEM PHARMACOL, V60, P1445, DOI 10.1016/S0006-2952(00)00463-9; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Vyas D, 2007, HISTOL HISTOPATHOL, V22, P623, DOI 10.14670/HH-22.623; Wisnoski N, 2007, SHOCK, V27, P251, DOI 10.1097/01.shk.0000239780.33398.e4; Zaborina O, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030035	42	33	35	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1817	1825		10.1096/fj.08-119024	http://dx.doi.org/10.1096/fj.08-119024			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19158156	Green Published			2022-12-28	WOS:000266652400022
J	Tippmann, F; Hundt, J; Schneider, A; Endres, K; Fahrenholz, F				Tippmann, Frank; Hundt, Jana; Schneider, Anja; Endres, Kristina; Fahrenholz, Falk			Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin	FASEB JOURNAL			English	Article						Alzheimer's disease; amyloid precursor protein; shedding; nuclear receptors; vitamin A	AMYLOID-PRECURSOR-PROTEIN; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; NEUROBLASTOMA-CELLS; VITAMIN-A; X-RECEPTOR; HIPPOCAMPAL-NEURONS; RESPONSE ELEMENT; BETA-PEPTIDE; EXPRESSION	Late-onset Alzheimer's disease is often connected with nutritional misbalance, such as enhanced cholesterol intake, deficiency in polyunsaturated fatty acids, or hypovitaminosis. The alpha-secretase ADAM10 has been found to be regulated by retinoic acid, the bioreactive metabolite of vitamin A. Here we show that retinoids induce gene expression of ADAM10 and alpha-secretase activity by nonpermissive retinoid acid receptor/retinoid X receptor (RAR/RXR) heterodimers, whereby alpha- and beta-isotypes of RAR play a major role. However, ligands of other RXR binding partners, such as the vitamin D receptor, do not stimulate alpha-secretase activity. On the basis of these findings, we examined the effect of synthetic retinoids and found a strong enhancement of nonamyloidogenic processing of the amyloid precursor protein by the vitamin A analog acitretin: it stimulated ADAM10 promoter activity with an EC50 of 1.5 mu M and led to an increase of mature ADAM10 protein that resulted in a two- to three-fold increase of the ratio between alpha- and beta-secretase activity in neuroblastoma cells. The alpha-secretase stimulation by acitretin was completely inhibited by the ADAM10-specific inhibitor GI254023X. Intracerebral injection of acitretin in APP/PS1-21 transgenic mice led to a reduction of A beta(40) and A beta(42). The results of this study may have clinical relevance because acitretin has been approved for the treatment of psoriasis since 1997 and found generally safe for long-term use in humans.-Tippmann, F., Hundt, J., Schneider, A., Endres, K., Fahrenholz, F. Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 23, 1643-1654 (2009)	[Tippmann, Frank; Hundt, Jana; Endres, Kristina; Fahrenholz, Falk] Johannes Gutenberg Univ Mainz, Inst Biochem, D-55099 Mainz, Germany; [Schneider, Anja] Univ Med, Dept Psychiat & Psychotherapy, Gottingen, Germany; [Schneider, Anja] Max Planck Inst Expt Med, D-37075 Gottingen, Germany	Johannes Gutenberg University of Mainz; Max Planck Society	Fahrenholz, F (corresponding author), Johannes Gutenberg Univ Mainz, Inst Biochem, Becherweg 30, D-55099 Mainz, Germany.	fahrenho@uni-mainz.de	Schneider, Anja/F-5293-2010; Endres, Kristina/K-4960-2015	Schneider, Anja/0000-0001-9540-8700	Forschungsfond of the Johannes Gutenberg-University, Mainz; Deutsche Forschungsgemeinschaft	Forschungsfond of the Johannes Gutenberg-University, Mainz; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Dr. Claudia Prinzen (Johannes Gutenberg- University, Mainz)for cloning of the human ADAM10 promoter luciferase construct and of RARE luciferase vector and Daniela Kaleve (Johannes Gutenberg-University, Mainz) for studies with overexpressed RARs. This work was supported by grants from the Forschungsfond of the Johannes Gutenberg-University, Mainz (to K.E.), and of the Deutsche Forschungsgemeinschaft (to F.F.).	ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Armstrong JL, 2005, BRIT J CANCER, V92, P696, DOI 10.1038/sj.bjc.6602398; ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; Belandia B, 1998, J BIOL CHEM, V273, P30366, DOI 10.1074/jbc.273.46.30366; Bell KFS, 2008, NEUROBIOL AGING, V29, P554, DOI 10.1016/j.neurobiolaging.2006.11.004; BORNEMANN LD, 1988, BIOPHARM DRUG DISPOS, V9, P119, DOI 10.1002/bod.2510090112; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cappai R, 2008, NEUROCHEM RES, V33, P526, DOI 10.1007/s11064-007-9469-8; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Cedazo-Minguez A, 2001, NEUROSCIENCE, V105, P651, DOI 10.1016/S0306-4522(01)00224-X; Chen N, 2008, FASEB J, V22, P236, DOI 10.1096/fj.07-8739com; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; Cocco S, 2002, NEUROSCIENCE, V115, P475, DOI 10.1016/S0306-4522(02)00423-2; Colciaghi F, 2002, MOL MED, V8, P67, DOI 10.1007/BF03402076; Connor MJ, 1997, MOL CHEM NEUROPATHOL, V30, P239, DOI 10.1007/BF02815101; Endres K, 2005, FEBS J, V272, P5808, DOI 10.1111/j.1742-4658.2005.04976.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Gezen-Ak D, 2007, TOHOKU J EXP MED, V212, P275, DOI 10.1620/tjem.212.275; Goodman AB, 2003, P NATL ACAD SCI USA, V100, P2901, DOI 10.1073/pnas.0437937100; Goodman AB, 2006, J CELL PHYSIOL, V209, P598, DOI 10.1002/jcp.20784; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Holback S, 2005, J NEUROCHEM, V95, P1059, DOI 10.1111/j.1471-4159.2005.03440.x; Holback S, 2008, BIOCHEM BIOPH RES CO, V365, P298, DOI 10.1016/j.bbrc.2007.10.167; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; Jimenez-Jimenez FJ, 1999, EUR J NEUROL, V6, P495, DOI 10.1046/j.1468-1331.1999.640495.x; KOBAYASHI M, 1994, FEBS LETT, V337, P259, DOI 10.1016/0014-5793(94)80204-1; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; Krezel W, 1999, NEUROSCIENCE, V89, P1291, DOI 10.1016/S0306-4522(98)00342-X; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LANNFELT L, 1995, NAT MED, V1, P829, DOI 10.1038/nm0895-829; LARSEN FG, 1992, CLIN PHARMACOKINET, V23, P42, DOI 10.2165/00003088-199223010-00004; Latasa MJ, 1998, ENDOCRINOLOGY, V139, P2692, DOI 10.1210/en.139.6.2692; Lee CS, 2005, EXPERT OPIN PHARMACO, V6, P1725, DOI 10.1517/14656566.6.10.1725; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; Melino G, 1996, CELL GROWTH DIFFER, V7, P787; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mingaud F, 2008, J NEUROSCI, V28, P279, DOI 10.1523/JNEUROSCI.4065-07.2008; Misner DL, 2001, P NATL ACAD SCI USA, V98, P11714, DOI 10.1073/pnas.191369798; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P194, DOI 10.1001/archneur.60.2.194; Post A, 2006, BIOL PSYCHIAT, V59, P858, DOI 10.1016/j.biopsych.2005.09.007; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Prinzen C, 2005, FASEB J, V19, P1522, DOI 10.1096/fj.04-3619fje; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; Rizzo Giovanni, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P289, DOI 10.2174/1568008054863781; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; Saurat JH, 1999, J AM ACAD DERMATOL, V41, pS2, DOI 10.1016/S0190-9622(99)70358-0; Sennvik K, 2000, NEUROSCI LETT, V278, P169, DOI 10.1016/S0304-3940(99)00929-5; SHALITA AR, 1992, J AM ACAD DERMATOL, V27, pS1, DOI 10.1016/S0190-9622(08)80251-4; TALLMAN MS, 1992, J CLIN PHARMACOL, V32, P868, DOI 10.1002/j.1552-4604.1992.tb04633.x; Taylor CJ, 2008, NEUROBIOL DIS, V31, P250, DOI 10.1016/j.nbd.2008.04.011; Tian KR, 1997, BIOCHEMISTRY-US, V36, P5669, DOI 10.1021/bi9627020; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; ZAMAN Z, 1992, AGE AGEING, V21, P91, DOI 10.1093/ageing/21.2.91	64	167	168	2	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1643	1654		10.1096/fj.08-121392	http://dx.doi.org/10.1096/fj.08-121392			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19144697				2022-12-28	WOS:000266652400004
J	Harja, E; Chang, JS; Lu, Y; Leitges, M; Zou, YS; Schmidt, AM; Yan, SF				Harja, Evis; Chang, Jong Sun; Lu, Yan; Leitges, Michael; Zou, Yu Shan; Schmidt, Ann Marie; Yan, Shi-Fang			Mice deficient in PKC beta and apolipoprotein E display decreased atherosclerosis	FASEB JOURNAL			English	Article						signal transduction; MMP-2; JNK; Egr-1	KINASE-C-BETA; LOW-DENSITY-LIPOPROTEIN; NH2-TERMINAL PROTEIN-KINASES; EARLY GROWTH RESPONSE-1; SMOOTH-MUSCLE-CELLS; GLUCOSE-TRANSPORT; RETINAL HEMODYNAMICS; INCREASED EXPRESSION; MESANGIAL CELLS; DIABETIC-RATS	Endothelial activation is a central initiating event in atheroma formation. Evidence from our laboratory and others has demonstrated links between activation of early growth response-1 (Egr-1) and atherosclerosis and also has demonstrated that activated protein kinase C (PKC) beta II is a critical upstream regulator of Egr-1 in response to vascular stress. We tested the role of PKC beta in regulating key events linked to atherosclerosis and show that the aortas of apoE(-/-) mice display an age-dependent increase in PKC beta II antigen in membranous fractions vs. C57BL/6 animals with a similar to 2-fold increase at age 6 wk and a similar to 4.5-fold increase at age 24 wk. Consistent with important roles for PKC beta in atherosclerosis, a significant decrease in atherosclerotic lesion area was evident in PKC beta(-/-)/apoE(-/-) vs. apoE(-/-) mice by similar to 5-fold, in parallel with significantly reduced vascular transcripts for Egr-1 and matrix metalloproteinase (MMP)-2 antigen and activity vs. apoE(-/-) mice. Significant reduction in atherosclerosis of similar to 2-fold was observed in apoE(-/-) mice fed ruboxistaurin chow (PKC beta inhibitor) vs. vehicle. In primary murine and human aortic endothelial cells, the PKC beta-JNK mitogen-activated protein kinase pathway importantly contributes to oxLDL-mediated induction of MMP2 expression. Blockade of PKC beta may be beneficial in mitigating endothelial perturbation and atherosclerosis.-Harja, E., Chang, J. S., Lu, Y., Leitges, M., Zou, Y. S., Schmidt, A. M., Yan, S.-F. Mice deficient in PKC beta and apolipoprotein E display decreased atherosclerosis. FASEB J. 23, 1081-1091 (2009)	[Yan, Shi-Fang] Columbia Univ, Dept Surg, Coll Phys & Surg, Div Surg Sci, New York, NY 10032 USA; [Leitges, Michael] Univ Oslo, Biotechnol Ctr Oslo, Oslo, Norway	Columbia University; University of Oslo	Yan, SF (corresponding author), Columbia Univ, Dept Surg, Coll Phys & Surg, Div Surg Sci, 630 W 168th St,BB1705, New York, NY 10032 USA.	sy18@columbia.edu	Leitges, Michael/AAN-1953-2021	Leitges, Michael/0000-0003-4203-6995	LeDucq Foundation; Surgical Research Fund of Columbia University; National Heart, Lung, and Blood Institute [RO1 HL073325, HL60901]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060901, R01HL073325] Funding Source: NIH RePORTER	LeDucq Foundation(Leducq Foundation); Surgical Research Fund of Columbia University; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We gratefully acknowledge grant support provided by the LeDucq Foundation, the Surgical Research Fund of Columbia University, and National Heart, Lung, and Blood Institute grants (RO1 HL073325) and (HL60901). We are grateful to L. Woods for her expert assistance in preparation of the manuscript.	ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Beckman JA, 2002, CIRC RES, V90, P107, DOI 10.1161/hh0102.102359; Braiman L, 1999, DIABETES, V48, P1922, DOI 10.2337/diabetes.48.10.1922; Bursell SE, 1997, INVEST OPHTH VIS SCI, V38, P2711; Chait A, 1992, CURR OPIN LIPIDOL, V3, P389; Danis RP, 1998, INVEST OPHTH VIS SCI, V39, P171; Erl W, 1998, ATHEROSCLEROSIS, V136, P297, DOI 10.1016/S0021-9150(97)00223-2; Fischer B, 2002, J IMMUNOL, V168, P2828, DOI 10.4049/jimmunol.168.6.2828; Fujita T, 2004, J CLIN INVEST, V113, P1615, DOI 10.1172/JCI200419225; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Griendling KK, 1997, CIRCULATION, V96, P3264; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; Harja E, 2004, CIRC RES, V94, P333, DOI 10.1161/01.RES.0000112405.61577.95; Hein TW, 2000, AM J PHYSIOL-HEART C, V278, pH175, DOI 10.1152/ajpheart.2000.278.1.H175; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Hu YH, 1997, J BIOL CHEM, V272, P9113; Idris I, 2001, DIABETOLOGIA, V44, P659, DOI 10.1007/s001250051675; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Kalra VK, 1996, AM J PHYSIOL-HEART C, V271, pH2025, DOI 10.1152/ajpheart.1996.271.5.H2025; Kobayashi M, 2005, J ATHEROSCLER THROMB, V12, P138, DOI 10.5551/jat.12.138; Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439; Kreuzer J, 1996, J MOL MED-JMM, V74, P161; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; MOREL DW, 1983, J LIPID RES, V24, P1070; Nakamura J, 1999, DIABETES, V48, P2090, DOI 10.2337/diabetes.48.10.2090; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; Nechushtan H, 2000, BLOOD, V95, P1752, DOI 10.1182/blood.V95.5.1752.005k18_1752_1757; Nishio H, 2001, HISTOCHEM J, V33, P167, DOI 10.1023/A:1017952310800; Park CW, 2000, DIABETOLOGIA, V43, P1544, DOI 10.1007/s001250051567; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Reusch HP, 1997, BIOCHEM BIOPH RES CO, V237, P239, DOI 10.1006/bbrc.1997.7121; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Seguin CA, 2008, SPINE, V33, P356, DOI 10.1097/BRS.0b013e3181642a5e; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; Standaert ML, 1999, ENDOCRINOLOGY, V140, P4470, DOI 10.1210/en.140.10.4470; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Takagi C, 1996, INVEST OPHTH VIS SCI, V37, P2504; Yan SF, 2000, J BIOL CHEM, V275, P11921, DOI 10.1074/jbc.275.16.11921; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YUE TL, 1980, EUR J PHARMACOL, V345, P61	49	64	65	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1081	1091		10.1096/fj.08-120345	http://dx.doi.org/10.1096/fj.08-120345			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19036858	Green Published			2022-12-28	WOS:000266651600012
J	Noble, W; Garwood, C; Stephenson, J; Kinsey, AM; Hanger, DP; Anderton, BH				Noble, Wendy; Garwood, Claire; Stephenson, John; Kinsey, Anna M.; Hanger, Diane P.; Anderton, Brian H.			Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease	FASEB JOURNAL			English	Article						caspase-3; therapeutic; neurodegeneration; tauopathy; beta-amyloid	AMYOTROPHIC-LATERAL-SCLEROSIS; PAIRED HELICAL FILAMENTS; CEREBELLAR GRANULE NEURONS; MOUSE MODEL; MICROGLIAL ACTIVATION; HUNTINGTONS-DISEASE; CASPASE-CLEAVAGE; CELL-DEATH; NEUROFIBRILLARY TANGLES; IN-VIVO	Alzheimer's disease (AD) is characterized by the presence of neurofibrillary tangles of hyperphosphorylated, aggregated tau protein and extracellular deposits of beta-amyloid peptide. Increased beta-amyloid levels are thought to precede tangle formation, but tau pathology is more closely related to neuronal death. Minocycline, a tetracycline derivative, has potent antiinflammatory, antiapoptotic, and neuroprotective effects in several models of neurodegenerative disease, including models of AD with amyloid pathology. We have used both in vitro and in vivo models of AD to determine whether minocycline may have therapeutic efficacy against tau pathology. In primary cortical neurons, minocycline prevents beta-amyloid-induced neuronal death, reduces caspase-3 activation, and lowers generation of caspase-3-cleaved tau fragments. Treatment of tangle-forming transgenic mice (htau line) with minocycline results in reduced levels of tau phosphorylation and insoluble tau aggregates. The in vivo effects of minocycline are also associated with reduced caspase-3 activation and lowered tau cleavage by caspase-3. In tau mice, we find that conformational changes in tau are susceptible to minocycline treatment, but are not directly associated with the amount of tau fragments produced, highlighting a dissociation between the development of these pathological tau species. These results suggest a possible novel therapeutic role for minocycline in the treatment of AD and related tauopathies.-Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D. P., Anderton, B. H. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 23, 739-750 (2009)	[Noble, Wendy; Garwood, Claire; Stephenson, John; Hanger, Diane P.; Anderton, Brian H.] Kings Coll London, Inst Psychiat, Dept Neurosci, MRC Ctr Neurodegenerat Res, London SE5 8AF, England; [Kinsey, Anna M.] Kings Coll London, Inst Psychiat, Div Old Age Psychiat, MRC Ctr Neurodegenerat Res, London SE5 8AF, England	University of London; King's College London; University of London; King's College London	Noble, W (corresponding author), Kings Coll London, Inst Psychiat, Dept Neurosci, MRC Ctr Neurodegenerat Res, PO37,Crespigny Pk, London SE5 8AF, England.	wendy.noble@iop.kcl.ac.uk	Hanger, Diane/C-5697-2009; Noble, Wendy/C-3756-2009	Hanger, Diane/0000-0002-3044-9816; Noble, Wendy/0000-0002-7898-4295; Garwood, Claire/0000-0001-8611-177X; Kinsey, Anna/0000-0001-8987-5353	Medical Research Council; Alzheimer's Society UK; Alzheimer's Research Trust; MRC [G0700355] Funding Source: UKRI; Alzheimers Research UK [ART-EG2004A-1] Funding Source: researchfish; Medical Research Council [G0700355] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimer's Society UK; Alzheimer's Research Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank Professor Peter Davies (Albert Einstein College of Medicine, Bronx, NY, USA) for his generous gift of tau antibodies. This work was supported by the Medical Research Council, the Alzheimer's Society UK, and the Alzheimer's Research Trust.	Ackerley S, 2000, J CELL BIOL, V150, P165, DOI 10.1083/jcb.150.1.165; Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Andorfer C, 2005, J NEUROSCI, V25, P5446, DOI 10.1523/JNEUROSCI.4637-04.2005; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Bellucci A, 2004, AM J PATHOL, V165, P1643, DOI 10.1016/S0002-9440(10)63421-9; Benatar M, 2007, NEUROBIOL DIS, V26, P1, DOI 10.1016/j.nbd.2006.12.015; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Brecht S, 2001, MOL BRAIN RES, V94, P25, DOI 10.1016/S0006-8993(01)02767-6; Castanares M, 2005, BIOCHEM BIOPH RES CO, V337, P663, DOI 10.1016/j.bbrc.2005.09.101; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cho JH, 2004, J BIOL CHEM, V279, P54716, DOI 10.1074/jbc.M403364200; Choi Y, 2007, NEUROPSYCHOPHARMACOL, V32, P2393, DOI 10.1038/sj.npp.1301377; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Cotman CW, 2005, J NEUROPATH EXP NEUR, V64, P104, DOI 10.1093/jnen/64.2.104; Cribbs DH, 2004, AM J PATHOL, V165, P353, DOI 10.1016/S0002-9440(10)63302-0; Dickson DW, 2004, J CLIN INVEST, V114, P23, DOI 10.1172/JC1200422317; Diguet E, 2003, ANN NEUROL, V54, P841, DOI 10.1002/ana.10818; Duyckaerts C, 1997, NEUROBIOL AGING, V18, P267, DOI 10.1016/S0197-4580(97)80306-5; Familian A, 2006, GLIA, V53, P233, DOI 10.1002/glia.20268; Fan LW, 2006, EUR J NEUROSCI, V24, P341, DOI 10.1111/j.1460-9568.2006.04918.x; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Guillozet-Bongaarts AL, 2005, NEUROBIOL AGING, V26, P1015, DOI 10.1016/j.neurobiolaging.2004.09.019; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hersch S, 2003, ANN NEUROL, V54, P841, DOI 10.1002/ana.21891; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Ishizawa T, 2003, J NEUROPATH EXP NEUR, V62, P389, DOI 10.1093/jnen/62.4.389; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kelleher I, 2007, J NEUROCHEM, V103, P2256, DOI 10.1111/j.1471-4159.2007.04930.x; Leigh PN, 2008, LANCET NEUROL, V7, P119, DOI 10.1016/S1474-4422(08)70006-1; Lin SZ, 2003, LIFE SCI, V72, P1635, DOI 10.1016/S0024-3205(02)02442-6; Marks N, 1999, NEUROCHEM INT, V35, P195, DOI 10.1016/S0197-0186(99)00061-3; NAGY Z, 1995, DEMENTIA, V6, P21, DOI 10.1159/000106918; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Pi RB, 2004, J NEUROCHEM, V91, P1219, DOI 10.1111/j.1471-4159.2004.02796.x; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Ryu JK, 2004, GLIA, V48, P85, DOI 10.1002/glia.20051; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Seabrook TJ, 2006, GLIA, V53, P776, DOI 10.1002/glia.20338; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Town T, 2002, J NEUROSCI RES, V69, P362, DOI 10.1002/jnr.10299; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhang WH, 2003, ANN NEUROL, V53, P267, DOI 10.1002/ana.10476; Zhang XD, 2004, MOL CANCER THER, V3, P187; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	54	94	95	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2009	23	3					739	750		10.1096/fj.08-113795	http://dx.doi.org/10.1096/fj.08-113795			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19001528				2022-12-28	WOS:000265506300010
J	Jin, Y; Kim, HP; Cao, JF; Zhang, M; Ifedigbo, E; Choi, AMK				Jin, Yang; Kim, Hong Pyo; Cao, Jiaofei; Zhang, Meng; Ifedigbo, Emeka; Choi, Augustine M. K.			Caveolin-1 regulates the secretion and cytoprotection of Cyr61 in hyperoxic cell death	FASEB JOURNAL			English	Article						CNN; exocytosis; signaling	VEIN ENDOTHELIAL-CELLS; IMMEDIATE-EARLY GENE; CCN FAMILY; BREAST-CANCER; AKT PATHWAY; ACTIVATION; EXPRESSION; INTEGRINS; MEMBRANE; RECEPTOR	Cysteine-rich 61 (Cyr61) belongs to the CCN family and mediates cell proliferation, survival, and apoptosis. Our previous studies showed that Cyr61 protected against hyperoxia-induced lung cell death via Akt phosphorylation. Caveolin-1 (cav-1), a 22-kDa trans-membrane scaffolding protein, is the principal structural component of caveolae. Emerging data show that cav-1 regulates signal transduction-associated proteins that reside in the caveolae. Numerous integrin-related pathways, including PI3K/Akt-induced cell survival are controlled by cav-1-mediated signaling. Our data showed that recombinant Cyr61 promoted cell proliferation and resistance to hyperoxia-induced cell death in vitro. Neutralizing antibodies reversed the above effects, indicating functional role of secreted Cyr61 in response to hyperoxic stress. While deletion of cav-1 protected cells from hyperoxia-induced cell death, Cyr61-neutralizing antibodies abolished this protective effect. Furthermore, Cyr61 and cav-1 colocalized and physically interacted via integrins in bronchial epithelial cells. Deletion of cav-1 increased extracellular and decreased cytosolic Cyr61, both in vitro and in vivo. Pretreatment with Brefeldin A increased intracellular Cyr61 in cav-1(-/-) cells, while decreasing extracellular Cyr61. Taken together, Cav-1/Cyr61 interaction via integrins represents a novel pathway of Cyr61 signaling involving cav-1-dependent processes, which play a critical role in regulating hyperoxia-induced cell death. - Jin, Y., Kim, H. P., Cao, J., Zhang, M., Ifedigbo, E., Choi, A. M. K. Caveolin-1 regulates the secretion and cytoprotection of Cyr61 in hyperoxic cell death. FASEB J. 23, 341-350 (2009)	[Kim, Hong Pyo; Cao, Jiaofei; Ifedigbo, Emeka; Choi, Augustine M. K.] Harvard Univ, Sch Med, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Boston, MA 02115 USA; [Jin, Yang; Zhang, Meng] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Choi, AMK (corresponding author), Harvard Univ, Sch Med, Div Pulm & Crit Care Med, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	amchoi@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL085601] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL085601] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Del Pozo MA, 2007, TRENDS CELL BIOL, V17, P246, DOI 10.1016/j.tcb.2007.03.001; Desnoyers L, 2004, CURR PHARM DESIGN, V10, P3913, DOI 10.2174/1381612043382567; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Echarri A, 2006, CELL CYCLE, V5, P2179, DOI 10.4161/cc.5.19.3264; Head BP, 2008, FASEB J, V22, P828, DOI 10.1096/fj.07-9299com; Jin Y, 2005, AM J RESP CELL MOL, V33, P297, DOI 10.1165/rcmb.2005-0144OC; Kim SM, 2004, J VIROL, V78, P13479, DOI 10.1128/JVI.78.24.13479-13488.2004; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Lechner A, 2000, BONE, V27, P53, DOI 10.1016/S8756-3282(00)00294-5; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin BR, 2007, MOL CANCER RES, V5, P1111, DOI 10.1158/1541-7786.MCR-06-0289; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Ning W, 2004, P NATL ACAD SCI USA, V101, P14895, DOI 10.1073/pnas.0401168101; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Salanueva IJ, 2007, J CELL MOL MED, V11, P969, DOI 10.1111/j.1582-4934.2007.00109.x; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Schutze N, 2005, PROTEIN EXPRES PURIF, V42, P219, DOI 10.1016/j.pep.2005.03.031; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Spisni E, 2005, BIOCHEM BIOPH RES CO, V338, P1383, DOI 10.1016/j.bbrc.2005.10.099; Wang XM, 2006, J EXP MED, V203, P2895, DOI 10.1084/jem.20061536; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yoshida Y, 2007, BIOCHEM BIOPH RES CO, V355, P611, DOI 10.1016/j.bbrc.2007.01.195	36	29	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					341	350		10.1096/fj.08-108423	http://dx.doi.org/10.1096/fj.08-108423			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18801924	Green Published			2022-12-28	WOS:000262892900006
J	Herrlich, A; Klinman, E; Fu, J; Sadegh, C; Lodish, H				Herrlich, Andreas; Klinman, Eva; Fu, Jonathan; Sadegh, Cameron; Lodish, Harvey			Ectodomain cleavage of the EGF ligands HB-EGF, neuregulin1-beta, and TGF-alpha is specifically triggered by different stimuli and involves different PKC isoenzymes	FASEB JOURNAL			English	Article						osmotic stress; G-protein; EGF receptor	EPIDERMAL-GROWTH-FACTOR; AMYLOID PRECURSOR PROTEIN; MATRIX METALLOPROTEINASES; CONVERTING-ENZYME; LYSOPHOSPHATIDIC ACID; RECEPTOR ACTIVATION; SECRETASE CLEAVAGE; COUPLED RECEPTORS; CANCER-CELLS; MEMBRANE	Metalloproteinase cleavage of transmembrane proteins (ectodomain cleavage), including the epidermal growth factor (EGF) ligands heparin-binding EGF-like growth factor (HB-EGF), neuregulin (NRG), and transforming growth factor-alpha (TGF-alpha), is important in many cellular signaling pathways and is disregulated in many diseases. It is largely unknown how physiological stimuli of ectodomain cleavage hypertonic stress, phorbol ester, or activation of G-protein-coupled receptors [e.g., by lysophosphatidic acid (LPA)]-are molecularly connected to metalloproteinase activation. To study this question, we developed a fluorescence-activated cell sorting (FACS) -based assay that measures cleavage of EGF ligands in single living cells. EGF ligands expressed in mouse lung epithelial cells are differentially and specifically cleaved depending on the stimulus. Inhibition of protein kinase C (PKC) isoenzymes or metalloproteinase inhibition by batimastat (BB94) showed that different regulatory signals are used by different stimuli and EGF substrates, suggesting differential effects that act on the substrate, the metalloproteinase, or both. For example, hypertonic stress led to strong cleavage of HB-EGF and NRG but only moderate cleavage of TGF-alpha. HB-EGF, NRG, and TGF-alpha cleavage was not dependent on PKC, and only HB-EGF and NRG cleavage were inhibited by BB94. In contrast, phorbol 12-myristate-13-acetate (TPA) -induced cleavage of HB-EGF, NRG, and TGF-alpha was dependent on PKC and sensitive to BB94 inhibition. LPA led to significant cleavage of only NRG and TGF-alpha and was inhibited by BB94; only LPA-induced NRG cleavage required PKC. Surprisingly, specific inhibition of atypical PKCs zeta and iota [not activated by diacylglycerol (DAG) and calcium] significantly enhanced TPA-induced NRG cleavage. Employed in a high-throughput cloning strategy, our cleavage assay should allow the identification of candidate proteins involved in signal transduction of different extracellular stimuli into ectodomain cleavage.- Herrlich, A., Klinman, E., Fu, J., Sadegh, C., Lodish, H. Ectodomain cleavage of the EGF ligands HB-EGF, neuregulin1-beta, and TGF-alpha is specifically triggered by different stimuli and involves different PKC isoenzymes. FASEB J. 22, 4281-4295 (2008)	[Herrlich, Andreas; Klinman, Eva; Fu, Jonathan; Sadegh, Cameron; Lodish, Harvey] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Herrlich, Andreas] Brigham & Womens Hosp, Renal Unit, Boston, MA 02115 USA; [Klinman, Eva; Lodish, Harvey] MIT, Dept Bioengn, Cambridge, MA 02139 USA; [Fu, Jonathan; Sadegh, Cameron; Lodish, Harvey] MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Lodish, H (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu		Klinman, Eva/0000-0003-1427-0194; SADEGH, CAMERON/0000-0003-2231-9015	Fidelity Research Foundation; K99 National Institutes of Health	Fidelity Research Foundation; K99 National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Cary Lai (The Scripps Research Institute, La Jolla, CA, USA), Dr. Michael Klagsbrun (Children's Hospital, Boston, MA, USA), and Dr. Joaquin Arribas (Valle D'Hebron University, Spain) for the provision of cDNA constructs. We thank Klaus Maskos (Max Plank Institute for Biochemistry, Martinsried, Germany) for provision of BB94. A. H.'s research was supported by funds from the Fidelity Research Foundation and a K99 National Institutes of Health grant.	Arribas J, 2006, CANCER METAST REV, V25, P57, DOI 10.1007/s10555-006-7889-6; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bogan JS, 2003, NATURE, V425, P727, DOI 10.1038/nature01989; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Citron M, 2004, TRENDS PHARMACOL SCI, V25, P92, DOI 10.1016/j.tips.2003.12.004; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Herrlich A, 2004, P NATL ACAD SCI USA, V101, P15799, DOI 10.1073/pnas.0406853101; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Hiraoka Y, 2007, J NEUROCHEM, V102, P1595, DOI 10.1111/j.1471-4159.2007.04685.x; Horiuchi K, 2007, MOL BIOL CELL, V18, P176, DOI 10.1091/mbc.E06-01-0014; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kadota N, 2000, J BIOCHEM-TOKYO, V128, P941, DOI 10.1093/oxfordjournals.jbchem.a022845; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lin JQ, 2001, J BIOL CHEM, V276, P30127, DOI 10.1074/jbc.M010237200; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Mifune M, 2005, J BIOL CHEM, V280, P26592, DOI 10.1074/jbc.M502906200; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Mori S, 2003, J BIOL CHEM, V278, P46029, DOI 10.1074/jbc.M306393200; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Nishi E, 2006, J BIOL CHEM, V281, P31164, DOI 10.1074/jbc.M601316200; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Peterson JT, 2004, HEART FAIL REV, V9, P63, DOI 10.1023/B:HREV.0000011395.11179.af; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shah BH, 2004, J BIOL CHEM, V279, P414, DOI 10.1074/jbc.M309083200; Shah BH, 2005, MOL ENDOCRINOL, V19, P2535, DOI 10.1210/me.2005-0082; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Takenobu H, 2003, J BIOL CHEM, V278, P17255, DOI 10.1074/jbc.M211835200; Tanaka M, 2004, J BIOL CHEM, V279, P41950, DOI 10.1074/jbc.M400086200; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang X, 2006, CELL STRUCT FUNCT, V31, P15, DOI 10.1247/csf.31.15; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103	47	27	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4281	4295		10.1096/fj.08-113852	http://dx.doi.org/10.1096/fj.08-113852			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18757500	Green Published			2022-12-28	WOS:000261254800027
J	Weinlander, K; Naschberger, E; Lehmann, MH; Tripal, P; Paster, W; Stockinger, H; Hohenadl, C; Sturzl, M				Weinlaender, Kristina; Naschberger, Elisabeth; Lehmann, Michael H.; Tripal, Philipp; Paster, Wolfgang; Stockinger, Hannes; Hohenadl, Christine; Stuerzl, Michael			Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin alpha(4) expression	FASEB JOURNAL			English	Article						angiogenesis; inflammation; integrins; large GTPase	MAMMARY EPITHELIAL-CELLS; TUMOR ANGIOGENESIS; GROWTH-FACTOR; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; INFLAMMATORY CYTOKINES; NUCLEOTIDE-BINDING; GENE PROMOTER; FIBRONECTIN; INTERFERON	Human guanylate binding protein-1 (GBP-1) is a large GTPase that is induced by inflammatory cytokines and acts antiangiogenically through the inhibition of endothelial cell proliferation and migration. In this study, we detected that GBP-1-expressing cells show a significantly reduced spreading and migration on fibronectin matrices. Investigating possible mechanisms of these effects, we found that integrin alpha(4) (ITGA4) was consistently up-regulated at both the RNA and protein level in GBP-1-expressing cell cultures. Inhibition of cell spreading and migration by GBP-1 was dependent on the binding of ITGA4 to fibronectin. The inflammatory cytokines IL-1 beta and TNF-alpha induced ITGA4 expression in HUVECs and inhibited spreading and migration. Knockdown of GBP-1 by shRNA abrogated inflammatory cytokine induced ITGA4 expression and restored spreading and migration capabilities of the cells. These results show that inhibition of endothelial cell spreading and migration by inflammatory cytokines is mediated by GBP-1 through induction of ITGA4 expression. Endothelial cell migration is a key process during angiogenesis. Therefore, ITGA4 may be a novel molecular target to modulate angiogenesis in human disease.	[Weinlaender, Kristina; Naschberger, Elisabeth; Lehmann, Michael H.; Tripal, Philipp; Stuerzl, Michael] Univ Erlangen Nurnberg, Div Mol & Expt Surg, Dept Surg, D-91054 Erlangen, Germany; [Paster, Wolfgang; Stockinger, Hannes] Med Univ Vienna, Dept Mol Immunol, Ctr Physiol Pathophysiol & Immunol, Vienna, Austria; [Hohenadl, Christine] Univ Vet Med, Dept Pathobiol, Inst Virol, Vienna, Austria	University of Erlangen Nuremberg; Medical University of Vienna; University of Veterinary Medicine Vienna	Sturzl, M (corresponding author), Univ Erlangen Nurnberg, Div Mol & Expt Surg, Dept Surg, Schwabachanlage 10, D-91054 Erlangen, Germany.	michael.stuerzl@uk-erlangen.de	Stockinger, Hannes/E-5173-2011; Lehmann, Michael H./A-1983-2013; Naschberger, Elisabeth/AAV-5289-2021; Stürzl, Michael/B-3019-2015	Stockinger, Hannes/0000-0001-6404-4430; Lehmann, Michael H./0000-0002-1037-8600; Naschberger, Elisabeth/0000-0003-1291-622X; Stürzl, Michael/0000-0002-9276-2824; Paster, Wolfgang/0000-0002-5537-2886; Tripal, Philipp/0000-0003-0568-1725	University of Erlangen-Nuremberg; Deutsche Forschungsgemeinschaft [STU 317/2-1, DFG-GK 1071, DFG SPP 1130]	University of Erlangen-Nuremberg; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Melanie Nurtsch, Gertrud Hoffmann, and Mahimaidos Manoharan for excellent technical assistance, Susanne Reed and Matthew Miller for reading the manuscript (Division of Molecular and Experimental Surgery, University of Erlangen), and Ludger Klein-Hitpass (Institute for Cell Biology, University of Essen) for Affymetrix GeneChip hybridization and partial analysis. We also thank Dr. Christoph Garlichs (Department of Medicine II, Cardiology and Angiology, University of Erlangen) for kindly providing the FACSCalibur. We are very grateful to Werner Hohenberger (Director of the Department of Surgery, University of Erlangen) for his generous support. This work was supported by grants from the Interdisciplinary Center for Clinical Research (IZKF) of the University of Erlangen-Nuremberg and the Deutsche Forschungsgemeinschaft (STU 317/2-1, DFG-GK 1071, DFG SPP 1130) to M.S. The authors have no conflicting financial interests.	AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; Anderson SL, 1999, VIROLOGY, V256, P8, DOI 10.1006/viro.1999.9614; Boyer L, 2004, MOL BIOL CELL, V15, P1124, DOI 10.1091/mbc.E03-05-0301; Brakebusch C, 2005, CANCER METAST REV, V24, P403, DOI 10.1007/s10555-005-5132-5; Brezinschek RI, 1996, AM J PATHOL, V149, P1651; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carter CC, 2005, ARCH VIROL, V150, P1213, DOI 10.1007/s00705-004-0489-2; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Degrandi D, 2007, J IMMUNOL, V179, P7729, DOI 10.4049/jimmunol.179.11.7729; DIATLOFFZITO C, 1995, GENE, V163, P301, DOI 10.1016/0378-1119(95)00275-B; Dow JK, 2000, UROLOGY, V55, P800, DOI 10.1016/S0090-4295(00)00457-X; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; FRIESEL R, 1987, J CELL BIOL, V104, P689, DOI 10.1083/jcb.104.3.689; Goldfinger LE, 2003, J CELL BIOL, V162, P731, DOI 10.1083/jcb.200304031; Guenzi E, 2003, EMBO J, V22, P3772, DOI 10.1093/emboj/cdg382; Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Jia YF, 2004, CANCER RES, V64, P8674, DOI 10.1158/0008-5472.CAN-04-0069; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kirschner KM, 2006, J BIOL CHEM, V281, P31930, DOI 10.1074/jbc.M602668200; Kraynack NC, 2002, AM J PHYSIOL-LUNG C, V283, pL604, DOI 10.1152/ajplung.00459.2001; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lehmann MH, 2002, BIOTECHNIQUES, V33, P766, DOI 10.2144/02334bm10; Lehmann MH, 2001, IMMUNOL LETT, V76, P111, DOI 10.1016/S0165-2478(01)00178-X; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Livant DL, 2000, J CLIN INVEST, V105, P1537, DOI 10.1172/JCI8527; Lubeseder-Martellato C, 2002, AM J PATHOL, V161, P1749, DOI 10.1016/S0002-9440(10)64452-5; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Mantovani A, 1998, TRANSPLANT P, V30, P4239, DOI 10.1016/S0041-1345(98)01402-X; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOULD AP, 1991, J BIOL CHEM, V266, P3579; Naschberger E, 2004, BIOCHEM J, V379, P409, DOI 10.1042/BJ20031873; Naschberger E, 2006, AM J PATHOL, V169, P1088, DOI 10.2353/ajpath.2006.060244; NICOSIA RF, 1993, J CELL PHYSIOL, V154, P654, DOI 10.1002/jcp.1041540325; Olszewski MA, 2006, J INTERF CYTOK RES, V26, P328, DOI 10.1089/jir.2006.26.328; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Praefcke GJK, 2004, J MOL BIOL, V344, P257, DOI 10.1016/j.jmb.2004.09.026; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Schellerer VS, 2007, LAB INVEST, V87, P1159, DOI 10.1038/labinvest.3700671; Schubert SW, 2008, J BIOL CHEM, V283, P5460, DOI 10.1074/jbc.M710110200; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P997, DOI 10.1016/0006-291X(87)90350-0; Tripal P, 2007, J INTERF CYTOK RES, V27, P44, DOI 10.1089/jir.2007.0086; Veikkola T, 2000, CANCER RES, V60, P203; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; White ES, 2003, AM J RESP CRIT CARE, V168, P436, DOI 10.1164/rccm.200301-041OC; White ES, 2001, J IMMUNOL, V167, P5362, DOI 10.4049/jimmunol.167.9.5362; Wiesner S, 2005, CELL MOL LIFE SCI, V62, P1081, DOI 10.1007/s00018-005-4522-8; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zaniolo K, 2004, INVEST OPHTH VIS SCI, V45, P1692, DOI 10.1167/iovs.03-0908; Zhang Y, 2004, EXP CELL RES, V295, P48, DOI 10.1016/j.yexcr.2003.12.011; Zhu PP, 2003, J BIOL CHEM, V278, P49063, DOI 10.1074/jbc.M306702200	75	54	55	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4168	4178		10.1096/fj.08-107524	http://dx.doi.org/10.1096/fj.08-107524			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18697840				2022-12-28	WOS:000261254800016
J	Mariotti, S; Sargentini, V; Marcantonio, C; Todero, E; Teloni, R; Gagliardi, MC; Ciccaglione, AR; Nisini, R				Mariotti, Sabrina; Sargentini, Valeria; Marcantonio, Cinzia; Todero, Emiliano; Teloni, Raffaela; Gagliardi, Maria Cristina; Ciccaglione, Anna Rita; Nisini, Roberto			T-cell-mediated and antigen-dependent differentiation of human monocyte into different dendritic cell subsets: a feedback control of Th1/Th2 responses	FASEB JOURNAL			English	Article						antigen presentation/processing; cytokines; cell differentiation; chronic inflammation; T-cell clones	COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; IN-VIVO; LANGERHANS CELLS; ANTITUMOR IMMUNITY; BLOOD MONOCYTES; SOLUBLE-ANTIGEN; STEADY-STATE; LYMPH-NODES; IFN-GAMMA	It is well established that human monocytes differentiate into dendritic cells (DCs) when cultured with certain cytokine cocktails, such as granulocyte-macrophage colony-stimulating factor and interleukin-4. Conversely, it is not completely established which cell population synthesizes the cytokines required for monocyte differentiation and how their secretion is regulated. We show that on specific activation T cells induce the differentiation into DCs of antigen-presenting and bystander monocytes. Monocytes exposed to cytokines released by Th1 and Th0 lymphocytes differentiate into DCs with a reduced antigen uptake and antigen presentation capacity. Moreover, these DCs show a limited capacity to induce Th1 polarization of naive T cells but are capable of priming interleukin-10-secreting T cells. Conversely, DCs derived from monocytes sensing cytokines released by Th2 lymphocytes are antigen-presenting-cell (APC) endowed with a marked Th1 polarization capacity. Monocytes are corecruited with lymphocytes in chronic inflammation sites; thus our results suggest that functionally different DCs can be generated in environments characterized by the prevalent release of Th1-, Th0-, or Th2-associated cytokines. Because the APC capacities of these DCs have opposite functional consequences, a contribution in the regulation of the ongoing immune response by monocyte-derived inflammatory DCs is envisaged.	[Mariotti, Sabrina; Sargentini, Valeria; Marcantonio, Cinzia; Todero, Emiliano; Teloni, Raffaela; Gagliardi, Maria Cristina; Ciccaglione, Anna Rita; Nisini, Roberto] Ist Super Sanita, Dipartimento Malattie Infett Parassitarie & Immun, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Nisini, R (corresponding author), Ist Super Sanita, Dipartimento Malattie Infett Parassitarie & Immun, Viale Regina Elena 299, I-00161 Rome, Italy.	roberto.nisini@iss.it	Nisini, Roberto/M-4363-2015; MARCANTONIO, CINZIA/M-2963-2015; Gagliardi, Maria Cristina/AAA-9273-2019; CICCAGLIONE, ANNA RITA/M-2956-2015; MARIOTTI, SABRINA/M-4361-2015	Nisini, Roberto/0000-0003-1077-423X; MARCANTONIO, CINZIA/0000-0002-7392-9780; CICCAGLIONE, ANNA RITA/0000-0002-3791-3781; MARIOTTI, SABRINA/0000-0002-7009-7616; gagliardi, maria cristina/0000-0003-3176-5439	EC project MILD-TB [037326]	EC project MILD-TB	We thank Prof. Antonio Cassone and Prof. Vincenzo Barnaba for suggestions and critical reading of the manuscript. This paper was partially supported by the EC project MILD-TB, contract no. 037326. The authors declare no financial conflict of interest.	Accapezzato D, 2005, J EXP MED, V202, P817, DOI 10.1084/jem.20051106; Agrawal A, 2003, NATURE, V424, P329, DOI 10.1038/nature01794; Brossart P, 1998, BLOOD, V92, P4238, DOI 10.1182/blood.V92.11.4238.423k16_4238_4247; Chang CCJ, 2000, J IMMUNOL, V165, P3584, DOI 10.4049/jimmunol.165.7.3584; Comes A, 2002, EUR J IMMUNOL, V32, P1914, DOI 10.1002/1521-4141(200207)32:7<1914::AID-IMMU1914>3.0.CO;2-P; Dannull J, 2005, BLOOD, V105, P3206, DOI 10.1182/blood-2004-10-3944; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; de la Salle H, 2005, SCIENCE, V310, P1321, DOI 10.1126/science.1115301; De Libero G, 2006, FEBS LETT, V580, P5580, DOI 10.1016/j.febslet.2006.08.029; Ebner S, 2002, J IMMUNOL, V168, P6199, DOI 10.4049/jimmunol.168.12.6199; Fogg DK, 2006, SCIENCE, V311, P83, DOI 10.1126/science.1117729; Gangenahalli GU, 2005, STEM CELLS DEV, V14, P140, DOI 10.1089/scd.2005.14.140; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Gogolak P, 2007, BLOOD, V109, P643, DOI 10.1182/blood-2006-04-016840; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hegde S, 2007, J LEUKOCYTE BIOL, V81, P1224, DOI 10.1189/jlb.1206718; Iwamoto S, 2007, J IMMUNOL, V179, P1449, DOI 10.4049/jimmunol.179.3.1449; Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Levings MK, 2002, INT ARCH ALLERGY IMM, V129, P263, DOI 10.1159/000067596; Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889; Liu GT, 2004, EUR J IMMUNOL, V34, P1680, DOI 10.1002/eji.200425081; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MAGGI E, 1992, J IMMUNOL, V148, P2142; Menges M, 2002, J EXP MED, V195, P15, DOI 10.1084/jem.20011341; Mohamadzadeh M, 2001, J EXP MED, V194, P1013, DOI 10.1084/jem.194.7.1013; Naik SH, 2006, NAT IMMUNOL, V7, P663, DOI 10.1038/ni1340; Nisini R, 1997, J VIROL, V71, P2241, DOI 10.1128/JVI.71.3.2241-2251.1997; Okano F, 2005, J IMMUNOL, V174, P2645, DOI 10.4049/jimmunol.174.5.2645; Pape KA, 2007, IMMUNITY, V26, P491, DOI 10.1016/j.immuni.2007.02.011; Prete SP, 2007, INT IMMUNOPHARMACOL, V7, P321, DOI 10.1016/j.intimp.2006.11.003; Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019; Qu CF, 2004, J EXP MED, V200, P1231, DOI 10.1084/jem.20032152; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Tan TT, 2007, CURR OPIN IMMUNOL, V19, P209, DOI 10.1016/j.coi.2007.01.001; Ullrich E, 2007, CANCER RES, V67, P851, DOI 10.1158/0008-5472.CAN-06-3766; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011; Villadangos JA, 2005, SEMIN IMMUNOL, V17, P262, DOI 10.1016/j.smim.2005.05.015; Villadangos JA, 2007, IMMUNITY, V26, P390, DOI 10.1016/j.immuni.2007.04.006; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wirths S, 2002, CANCER RES, V62, P5065; Woerly G, 1999, J EXP MED, V190, P487, DOI 10.1084/jem.190.4.487; Yi HF, 2007, CYTOKINE, V37, P35, DOI 10.1016/j.cyto.2007.02.012; Zhang AL, 2007, BLOOD, V110, P2484, DOI 10.1182/blood-2007-02-076364; Zou GM, 2002, EUR CYTOKINE NETW, V13, P186	55	11	12	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3370	3379		10.1096/fj.08-108209	http://dx.doi.org/10.1096/fj.08-108209			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18556459				2022-12-28	WOS:000258761300029
J	Ndengele, MM; Cuzzocrea, S; Esposito, E; Mazzon, E; Di Paola, R; Matuschak, GM; Salvemini, D				Ndengele, Michael M.; Cuzzocrea, Salvatore; Esposito, Emanuela; Mazzon, Emanuela; Di Paola, Rosanna; Matuschak, George M.; Salvemini, Daniela			Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity	FASEB JOURNAL			English	Article						superoxide; nitric oxide; PGE2; COX-1; COX-2; hyperalgesia	ASPIRIN-LIKE DRUGS; INDUCED PAW EDEMA; NF-KAPPA-B; NITRIC-OXIDE; PROSTAGLANDIN BIOSYNTHESIS; SUPEROXIDE-DISMUTASE; INDUCED HYPERALGESIA; PROTEIN-KINASE; HAIRY SKIN; RAT	Peroxynitrite (ONOO-), the reaction product of the interaction between superoxide (O2(center dot-)) and nitric oxide (center dot NO), is a potent proinflammatory and cytotoxic nitrooxidative species. Its role as a mediator of hyperalgesia (clinically defined as an augmented sensitivity to painful stimuli) is not known. In light of the known proinflammatory properties of ONOO-, our study addressed its potential involvement in the development of hyperalgesia associated with tissue damage and inflammation. Intraplantar injection in rats of the ONOO- precursor O2(center dot-) (1 mu M) led to the development of thermal hyperalgesia associated with a profound localized inflammatory response. Both events were blocked by L-NAME (N-G-nitro-L-arginine methyl ester, 3-30 mg/kg), a nitric oxide synthase inhibitor, or by FeTM-4-PyP5+ [Fe(III) 5,10,15,20-tetrakis(N-methylpyridinium-4-yl) porphyrin, 3-30 mg/kg], an ONOO- decomposition catalyst. These results suggested that locally synthesized ONOO- produced in situ by O-2(center dot-) and center dot NO is key in the development of inflammatory hyperalgesia. The direct link between ONOO- and hyperalgesia was further supported by demonstrating that intraplantar injection of soluble ONOO- itself ( 1 mu M) similarly led to inflammatory hyperalgesia. ONOO- generated by the interaction between exogenous administration of O2(center dot-) and endogenous center dot NO, or provided by direct injection of ONOO-, activated the transcription factor NF-kappa B in paw tissues, enhancing expression of the inducible but not the constitutive cyclooxygenase enzyme (COX-2 and COX-1, respectively). ONOO--mediated hyperalgesia was blocked in a dose-dependent manner by intraperitoneal injections of indomethacin (10 mg/kg), a nonselective COX-1/COX-2 inhibitor, or NS398 [N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide; 10 mg/kg] a selective COX-2 inhibitor, as well as by an anti-prostaglandin (PG) E-2 antibody (200 mu g). In another established model of inflammation-related hyperalgesia by intraplantar injection of carrageenan in rats, inhibition of ONOO- with FeTM-4-PyP5+ (3-30 mg/kg) inhibited the development of hyperalgesia and the release of PGE(2) in paw tissue exudates. Furthermore, FeTM-4-PyP5+ synergized with indomethacin and NS397 (1-10 together, these data show for the first time that ONOO- is a potent mediator of inflammation-derived hyperalgesia operating via the COX-to-PGE(2) pathway. These results provide a pharmacological rationale for the development of inhibitors of peroxynitrite biosynthesis as novel nonnarcotic analgesics. The broad implications of our study are that dual inhibition of both ONOO- formation and COX activity may provide an alternative therapeutic approach to the management of pain: effective analgesia with reduced side-effects typically associated with the use of COX inhibitors.	[Ndengele, Michael M.; Matuschak, George M.; Salvemini, Daniela] St Louis Univ, Sch Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, St Louis, MO 63104 USA; [Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy; [Cuzzocrea, Salvatore; Esposito, Emanuela; Mazzon, Emanuela; Di Paola, Rosanna] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy	Saint Louis University; University of Messina; IRCCS Bonino Pulejo	Salvemini, D (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, Div Pulm Crit Care & Sleep Med, 1402 S Grand Blvd,Deslodge Towers,7th Floor, St Louis, MO 63104 USA.	salvemd@slu.edu	Mazzon, Emanuela/AAL-4334-2020; di paola, rosanna/U-4356-2019	di paola, rosanna/0000-0001-6725-8581; mazzon, emanuela/0000-0002-5073-717X; Esposito, Emanuela/0000-0002-2663-6387				Aley KO, 1998, J NEUROSCI, V18, P7008; Andrew D, 1999, J NEUROPHYSIOL, V82, P2649, DOI 10.1152/jn.1999.82.5.2649; BATINICHABERLE I, 2007, 5 INT C PER REACT NI; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bezerra MM, 2007, N-S ARCH PHARMACOL, V374, P265, DOI 10.1007/s00210-006-0123-9; Brune K, 1994, Drugs, V47 Suppl 5, P21, DOI 10.2165/00003495-199400475-00005; Buritova J, 1996, BRAIN RES, V715, P217, DOI 10.1016/0006-8993(95)01574-4; Cheng HF, 2006, AM J PHYSIOL-RENAL, V290, pF1391, DOI 10.1152/ajprenal.00315.2005; COLLIER HOJ, 1972, NATURE-NEW BIOL, V236, P141, DOI 10.1038/newbio236141a0; Cuzzocrea S, 2007, KIDNEY INT, V71, P290, DOI 10.1038/sj.ki.5002058; D'Acquisto F, 2000, GENE THER, V7, P1731, DOI 10.1038/sj.gt.3301295; DAVIS KD, 1993, J NEUROPHYSIOL, V69, P1071, DOI 10.1152/jn.1993.69.4.1071; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; Eligini S, 2001, BRIT J PHARMACOL, V133, P1163, DOI 10.1038/sj.bjp.0704163; Esposito E, 2005, ENDOCRINOLOGY, V146, P3301, DOI 10.1210/en.2005-0375; FERREIRA SH, 1978, PROSTAGLANDINS, V16, P31, DOI 10.1016/0090-6980(78)90199-5; FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Guay J, 2004, J BIOL CHEM, V279, P24866, DOI 10.1074/jbc.M403106200; Guhring H, 2000, J NEUROSCI, V20, P6714, DOI 10.1523/JNEUROSCI.20-17-06714.2000; Habib A, 1997, J IMMUNOL, V158, P3845; Haddad JJ, 2002, BRIT J PHARMACOL, V135, P520, DOI 10.1038/sj.bjp.0704467; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hirata T, 1997, BRIT J PHARMACOL, V122, P447, DOI 10.1038/sj.bjp.0701399; Ibuki T, 1997, PAIN, V70, P125, DOI 10.1016/S0304-3959(96)03283-6; KHASAR SG, 1995, NEUROSCIENCE, V67, P189, DOI 10.1016/0306-4522(94)00632-F; Khattab MM, 2006, EUR J PHARMACOL, V548, P167, DOI 10.1016/j.ejphar.2006.08.007; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARTIN HA, 1987, NEUROSCIENCE, V22, P651, DOI 10.1016/0306-4522(87)90360-5; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Matata BM, 2002, J BIOL CHEM, V277, P2330, DOI 10.1074/jbc.M106393200; McInnis J, 2002, J PHARMACOL EXP THER, V301, P478, DOI 10.1124/jpet.301.2.478; Milne B, 2001, ANESTH ANALG, V93, P728, DOI 10.1097/00000539-200109000-00037; Mitchell JA, 2006, NAT REV DRUG DISCOV, V5, P75, DOI 10.1038/nrd1929; MNICH SJ, 1995, J IMMUNOL, V155, P4437; Mollace V, 2005, PHARMACOL REV, V57, P217, DOI 10.1124/pr.57.2.1; MONCADA S, 1975, EUR J PHARMACOL, V31, P250, DOI 10.1016/0014-2999(75)90047-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1973, NATURE, V246, P217, DOI 10.1038/246217a0; Morioka N, 2002, NEUROPHARMACOLOGY, V43, P868, DOI 10.1016/S0028-3908(02)00143-0; Muscoli C, 2004, PAIN, V111, P96, DOI 10.1016/j.pain.2004.06.004; Muscoli C, 2007, J CLIN INVEST, V117, P3530, DOI 10.1172/JCI32420; Ndengele MM, 2005, SHOCK, V23, P186, DOI 10.1097/01.shk.0000144130.36771.d6; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Perkins DJ, 1999, J LEUKOCYTE BIOL, V65, P792, DOI 10.1002/jlb.65.6.792; Ridger VC, 1997, BRIT J PHARMACOL, V122, P1083, DOI 10.1038/sj.bjp.0701498; RUEFF A, 1993, NEUROSCIENCE, V54, P527, DOI 10.1016/0306-4522(93)90272-H; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; Salvemini D, 1998, DRUG NEWS PERSPECT, V11, P204; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Salvemini D, 1996, EUR J PHARMACOL, V303, P217, DOI 10.1016/0014-2999(96)00140-9; Salvemini D, 2001, BRIT J PHARMACOL, V132, P815, DOI 10.1038/sj.bjp.0703841; Sandrini G, 2002, NEUROSCI LETT, V317, P135, DOI 10.1016/S0304-3940(01)02447-8; SCHAIBLE HG, 1988, J PHYSIOL-LONDON, V403, P91, DOI 10.1113/jphysiol.1988.sp017240; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; TAIWO YO, 1991, NEUROSCIENCE, V44, P131, DOI 10.1016/0306-4522(91)90255-M; TAIWO YO, 1990, NEUROSCIENCE, V38, P757, DOI 10.1016/0306-4522(90)90068-F; Tassorelli C, 2006, EUR J PHARMACOL, V534, P103, DOI 10.1016/j.ejphar.2006.01.023; Trostchansky A, 2007, FREE RADICAL BIO MED, V42, P1029, DOI 10.1016/j.freeradbiomed.2007.01.009; Tsatsanis C, 2006, INT J BIOCHEM CELL B, V38, P1654, DOI 10.1016/j.biocel.2006.03.021; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; VonKnethen A, 1997, FASEB J, V11, P887; Wang ZQ, 2004, J PHARMACOL EXP THER, V309, P869, DOI 10.1124/jpet.103.064154; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; WILLIS AL, 1973, PROSTAG OTH LIPID M, V3, P353, DOI 10.1016/0090-6980(73)90073-7; YAKSH TL, 1993, AGENT ACTION SUPPL, V41, P89; Yang TX, 2006, AM J PHYSIOL-RENAL, V291, pF891, DOI 10.1152/ajprenal.00512.2005; Zhang Y, 1997, J PHARMACOL EXP THER, V283, P1069	77	71	74	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3154	3164		10.1096/fj.08-108159	http://dx.doi.org/10.1096/fj.08-108159			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18497304				2022-12-28	WOS:000258761300008
J	Wright, GL; Maroulakou, IG; Eldridge, J; Liby, TL; Sridharan, V; Tsichlis, PN; Muise-Helmericks, RC				Wright, Gary L.; Maroulakou, Ioanna G.; Eldridge, Juanita; Liby, Tiera L.; Sridharan, Vijayalakshmi; Tsichlis, Philip N.; Muise-Helmericks, Robin C.			VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase	FASEB JOURNAL			English	Article						angiogenesis; VEGF signal transduction; Akt kinase; PGC-1 alpha; mitochondrial protein import	NF-KAPPA-B; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; GAMMA COACTIVATOR-1; GLUCOSE-HOMEOSTASIS; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; PROTEIN IMPORT; GROWTH-FACTORS; RECEPTOR	The growth factor, vascular endothelial growth factor (VEGF), induces angiogenesis and promotes endothelial cell (EC) proliferation. Affymetrix gene array analyses show that VEGF stimulates the expression of a cluster of nuclear-encoded mitochondrial genes, suggesting a role for VEGF in the regulation of mitochondrial biogenesis. We show that the serine threonine kinase Akt3 specifically links VEGF to mitochondrial biogenesis. A direct comparison of Akt1 vs. Akt3 gene silencing was performed in ECs and has uncovered a discrete role for Akt3 in the control of mitochondrial biogenesis. Silencing of Akt3, but not Akt1, results in a decrease in mitochondrial gene expression and mtDNA content. Nuclear-encoded mitochondrial gene transcripts are also found to decrease when Akt3 expression is silenced. Concurrent with these changes in mitochondrial gene expression, lower O-2 consumption was observed. VEGF stimulation of the major mitochondrial import protein TOM70 is also blocked by Akt3 inhibition. In support of a role for Akt3 in the regulation of mitochondrial biogenesis, Akt3 silencing results in the cytoplasmic accumulation of the master regulator of mitochondrial biogenesis, PGC-1 alpha, and a reduction in known PGC-1 alpha target genes. Finally, a subtle but significant, abnormal mitochondrial phenotype is observed in the brain tissue of AKT3 knockout mice. These results suggest that Akt3 is important in coordinating mitochondrial biogenesis with growth factor-induced increases in cellular energy demands.	[Eldridge, Juanita; Liby, Tiera L.; Muise-Helmericks, Robin C.] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; [Wright, Gary L.; Sridharan, Vijayalakshmi] Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA; [Maroulakou, Ioanna G.; Tsichlis, Philip N.] Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA USA	Medical University of South Carolina; Medical University of South Carolina; Tufts Medical Center	Muise-Helmericks, RC (corresponding author), Med Univ S Carolina, Dept Cell Biol & Anat, Hollings Canc Ctr Rm 320,86 Jonathan Lucas St, Charleston, SC 29425 USA.	musehelm@musc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016434] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084565, R01HL084302] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR16434, P20 RR016434] Funding Source: Medline; NHLBI NIH HHS [R01 HL084565, HL084565, R01 HL084302] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asin-Cayuela J, 2007, TRENDS BIOCHEM SCI, V32, P111, DOI 10.1016/j.tibs.2007.01.003; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; Bouzakri K, 2006, DIABETES, V55, P785, DOI 10.2337/diabetes.55.03.06.db05-0796; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; COFFA S, 1998, MAT SCI SEMICON PROC, V1, P1; Cristiano BE, 2006, CANCER RES, V66, P11718, DOI 10.1158/0008-5472.CAN-06-1968; de Gannes FMP, 2000, NEUROCHEM INT, V36, P233; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fieber CB, 2006, EXP CELL RES, V312, P1164, DOI 10.1016/j.yexcr.2006.01.022; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Goffart S, 2004, CARDIOVASC RES, V64, P198, DOI 10.1016/j.cardiores.2004.06.030; GRIMES GW, 1974, J CELL BIOL, V61, P565, DOI 10.1083/jcb.61.3.565; GWOSDOW G, 1976, RES COMMUN CHEM PATH, V14, P763; Hallmann Anna, 2004, Folia Morphol (Warsz), V63, P407; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Hood DA, 2006, J EXP BIOL, V209, P2265, DOI 10.1242/jeb.02182; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Kurukulasuriya R, 2003, CURR MED CHEM, V10, P123, DOI 10.2174/0929867033368556; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; MacKenzie JA, 2007, BBA-MOL BASIS DIS, V1772, P509, DOI 10.1016/j.bbadis.2006.12.002; Mambo E, 2005, INT J CANCER, V116, P920, DOI 10.1002/ijc.21110; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Mende I, 2001, ONCOGENE, V20, P4419, DOI 10.1038/sj.onc.1204486; Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; OLDENDORF WH, 1977, ANN NEUROL, V1, P409, DOI 10.1002/ana.410010502; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pletjushkina OY, 2006, BBA-BIOENERGETICS, V1757, P518, DOI 10.1016/j.bbabio.2006.03.018; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rantanen A, 2000, Hum Reprod, V15 Suppl 2, P86; Rasbach KA, 2007, J BIOL CHEM, V282, P2355, DOI 10.1074/jbc.M608009200; Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB; Ryan MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI 10.1146/annurev.biochem.76.052305.091720; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; SCHNELLMANN RG, 1989, TOXICOL APPL PHARM, V99, P19, DOI 10.1016/0041-008X(89)90107-5; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Singh KK, 2004, ANN NY ACAD SCI, V1019, P260, DOI 10.1196/annals.1297.043; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Tokunaga E, 2006, INT J CANCER, V118, P284, DOI 10.1002/ijc.21358; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Tu BP, 2005, SCIENCE, V310, P1152, DOI 10.1126/science.1120499; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	67	84	88	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3264	3275		10.1096/fj.08-106468	http://dx.doi.org/10.1096/fj.08-106468			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18524868	Green Published			2022-12-28	WOS:000258761300019
J	Dallabrida, SM; Ismail, NS; Pravda, EA; Parodi, EM; Dickie, R; Durand, EM; Lai, J; Cassiola, F; Rogers, RA; Rupnick, MA				Dallabrida, Susan M.; Ismail, Nesreen S.; Pravda, Elke A.; Parodi, Emily M.; Dickie, Renee; Durand, Ellen M.; Lai, Jean; Cassiola, Flavia; Rogers, Rick A.; Rupnick, Maria A.			Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy	FASEB JOURNAL			English	Article						cardiac myocytes; endothelial cells; integrinlinked kinase; AMP-activated protein kinase; Tie2	ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; ENDOTHELIAL-CELLS; RECEPTOR-BINDING; TIE2 RECEPTOR; GENE-TRANSFER; EXPRESSION; LIGAND; GROWTH; HEART	Angiopoietins were thought to be endothelial cell-specific via the tie2 receptor. We showed that angiopoietin-1 (ang1) also interacts with integrins on cardiac myocytes (CMs) to increase survival. Because ang1 monomers bind and activate integrins (not tie2), we determined their function in vivo. We examined monomer and multimer expressions during physiological and pathological cardiac remodeling and overexpressed ang1 monomers in phenylephrine-induced cardiac hypertrophy. Cardiac ang1 levels (mRNA, protein) increased during postnatal development and decreased with phenylephrine-induced cardiac hypertrophy, whereas tie2 phosphorylations were unchanged. We found that most or all of the changes during cardiac remodeling were in monomers, offering an explanation for unchanged tie2 activity. Heart tissue contains abundant ang1 monomers and few multimers (Western blotting). We generated plasmids that produce ang1 monomers (ang1-256), injected them into mice, and confirmed cardiac expression (immunohistochemistry, RT-PCR). Ang1 monomers localize to CMs, smooth muscle cells, and endothelial cells. In phenylephrine-induced cardiac hypertrophy, ang1-256 reduced left ventricle (LV)/tibia ratios, fetal gene expressions (atrial and brain natriuretic peptides, skeletal actin, beta-myosin heavy chain), and fibrosis (collagen III), and increased LV prosurvival signaling (akt, MAPK(p42/44)), and AMPK(T172). However, tie2 phosphorylations were unchanged. Ang1-256 increased integrin-linked kinase, a key regulator of integrin signaling and cardiac health. Collectively, these results.	[Dallabrida, Susan M.; Ismail, Nesreen S.; Pravda, Elke A.; Parodi, Emily M.; Durand, Ellen M.; Cassiola, Flavia; Rogers, Rick A.; Rupnick, Maria A.] Childrens Hosp, Vasc Biol Div, Boston, MA 02115 USA; [Dallabrida, Susan M.; Rupnick, Maria A.] Harvard Univ, Med Sch Affiliates, Boston, MA 02115 USA; [Dickie, Renee; Lai, Jean; Rogers, Rick A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Dallabrida, Susan M.; Ismail, Nesreen S.; Pravda, Elke A.; Parodi, Emily M.; Durand, Ellen M.; Cassiola, Flavia; Rogers, Rick A.; Rupnick, Maria A.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Dallabrida, Susan M.; Ismail, Nesreen S.; Pravda, Elke A.; Parodi, Emily M.; Durand, Ellen M.; Cassiola, Flavia; Rogers, Rick A.; Rupnick, Maria A.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital	Rupnick, MA (corresponding author), Childrens Hosp, Vasc Biol Div, 1 Blackfan Cir,Karp Bldg RB 11-211, Boston, MA 02115 USA.	maria.rupnick@childrens.harvard.edu			NATIONAL CANCER INSTITUTE [R21CA107976, P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL071840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK063970] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA107976-02, P01 CA045548-20, R21 CA107976-01, R21-CA107976-01, P01-CA45548, R21 CA107976, P01 CA045548] Funding Source: Medline; NHLBI NIH HHS [K02 HL071840, K02 HL071840-04, K02-HL071840-01, K02 HL071840-05] Funding Source: Medline; NIDDK NIH HHS [K01 DK063970-02, K01-DK063970-01, K01 DK063970-03, K01 DK063970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baba HA, 2003, CARDIOVASC RES, V59, P390, DOI 10.1016/S0008-6363(03)00393-6; Bragonzi A, 1999, GENE THER, V6, P1995, DOI 10.1038/sj.gt.3301039; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082; Chemin I, 1998, J VIRAL HEPATITIS, V5, P369, DOI 10.1046/j.1365-2893.1998.00126.x; Chen Shi-lin, 2003, Zhonghua Yi Xue Za Zhi, V83, P637; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5553, DOI 10.1073/pnas.0307575101; Dallabrida SM, 2005, CIRC RES, V96, DOI 10.1161/01.RES.0000158285.57191.60; Dallabrida SM, 2003, BIOCHEM BIOPH RES CO, V311, P563, DOI 10.1016/j.bbrc.2003.10.007; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Davis S, 2003, NAT STRUCT BIOL, V10, P38, DOI 10.1038/nsb880; DUMONT DJ, 1992, ONCOGENE, V7, P1471; Fedak PWM, 2005, CARDIOVASC PATHOL, V14, P49, DOI 10.1016/j.carpath.2005.01.005; Ferrari S, 1999, BBA-GENE STRUCT EXPR, V1447, P219, DOI 10.1016/S0167-4781(99)00153-0; Goede V, 1998, LAB INVEST, V78, P1385; Hannigan GE, 2007, CIRC RES, V100, P1408, DOI 10.1161/01.RES.0000265233.40455.62; Hardie DG, 2004, J CLIN INVEST, V114, P465, DOI 10.1172/JCI200422683; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115; Kim KT, 2005, J BIOL CHEM, V280, P20126, DOI 10.1074/jbc.M500292200; KIM NN, 1995, AM J PHYSIOL-ENDOC M, V269, pE426, DOI 10.1152/ajpendo.1995.269.3.E426; KORHONEN J, 1992, BLOOD, V80, P2548; Latronico MVG, 2004, ANN NY ACAD SCI, V1015, P250, DOI 10.1196/annals.1302.021; MCMAHON DK, 1994, AM J PHYSIOL, V266, pC1795, DOI 10.1152/ajpcell.1994.266.6.C1795; Mitcheson JS, 1998, CARDIOVASC RES, V39, P280, DOI 10.1016/S0008-6363(98)00128-X; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Ravingerova T, 2003, MOL CELL BIOCHEM, V247, P127, DOI 10.1023/A:1024119224033; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Sandhu R, 2004, CARDIOVASC RES, V64, P115, DOI 10.1016/j.cardiores.2004.05.013; Schoenfeld JR, 1998, J MOL CELL CARDIOL, V30, P2269, DOI 10.1006/jmcc.1998.0787; Siddiqui AJ, 2003, BIOCHEM BIOPH RES CO, V310, P1002, DOI 10.1016/j.bbrc.2003.09.111; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takahashi K, 2003, MOL THER, V8, P584, DOI 10.1016/S1525-0016(03)00230-2; Weber CC, 2005, J BIOL CHEM, V280, P22445, DOI 10.1074/jbc.M410367200; White DE, 2006, GENE DEV, V20, P2355, DOI 10.1101/gad.1458906; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200	38	36	37	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					3010	3023		10.1096/fj.07-100966	http://dx.doi.org/10.1096/fj.07-100966			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18502941	Green Accepted, Green Published			2022-12-28	WOS:000258089300041
J	Klinge, CM; Wickramasinghe, NS; Ivanova, MM; Dougherty, SM				Klinge, Carolyn M.; Wickramasinghe, Nalinie S.; Ivanova, Margarita M.; Dougherty, Susan M.			Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells	FASEB JOURNAL			English	Article						nongenomic estrogen action; membrane-associated estrogen receptor; red wine polyphenols	ESTROGEN-RECEPTOR-BETA; INITIATED SIGNALING PATHWAYS; MODERATE WINE CONSUMPTION; PLASMA-MEMBRANE; RED WINE; TYROSINE PHOSPHORYLATION; NO SYNTHASE; GENE-EXPRESSION; PROTEIN-KINASE; CANCER CELLS	Epidemiological studies correlate moderate red wine consumption to reduced incidence of cardiovascular disease. Resveratrol is a polyphenolic compound in red wine that has cardioprotective effects in rodents. Although endothelial cell (EC) studies indicate that micromolar resveratrol has diverse biological activities, these concentrations are not physiologically relevant because human oral ingestion provides only brief exposure to nanomolar plasma levels. Previously, we reported that nanomolar resveratrol activated ERK1/2 signaling in bovine aortic ECs (BAECs). The goal of this study was to determine the mechanisms by which nanomolar resveratrol rapidly activates endothelial nitric oxide synthase (eNOS) in human umbilical vein ECs (HUVECs). We report for the first time that resveratrol increased interaction between estrogen receptor alpha (ER alpha), caveolin-1 (Cav-1) and c-Src, and increased phosphorylation of Cav-1, c-Src, and eNOS. Pretreatment with the lipid raft disruptor beta-methyl cyclodextrin or G alpha inhibitor pertussis toxin blocked resveratrol- and E-2-induced eNOS activation and NO production. Depletion of endogenous ER alpha, not ER beta, by siRNA attenuated resveratrol- and E2-induced ERK1/2, Src, and eNOS phosphorylation. Our data demonstrate that nanomolar resveratrol induces ER alpha-Cav-1-c-SRC interaction, resulting in NO production through a G alpha-protein-coupled mechanism. This study provides important new insights into mechanisms for the beneficial effects of resveratrol in ECs.	Univ Louisville, Dept Biochem & Mol Biol, Sch Med, Louisville, KY 40292 USA; Univ Louisville, Ctr Genet & Mol Med, Sch Med, Louisville, KY 40292 USA	University of Louisville; University of Louisville	Klinge, CM (corresponding author), Univ Louisville, Dept Biochem & Mol Biol, Sch Med, Louisville, KY 40292 USA.	carolyn.klinge@louisville.edu	Ivanova, Margarita/AAM-4510-2021	Klinge, Carolyn/0000-0002-3358-4378; Ivanova, Margarita/0000-0002-6197-8606				Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; Ashby J, 1999, J APPL TOXICOL, V19, P39, DOI 10.1002/(SICI)1099-1263(199901/02)19:1&lt;39::AID-JAT534&gt;3.0.CO;2-M; Baron-Menguy C, 2007, FASEB J, V21, P3511, DOI 10.1096/fj.06-7782com; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; Bradamante S, 2003, EUR J PHARMACOL, V465, P115, DOI 10.1016/S0014-2999(03)01441-9; Bulayeva NN, 2005, AM J PHYSIOL-ENDOC M, V288, pE388, DOI 10.1152/ajpendo.00349.2004; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Chambliss KL, 2005, MOL ENDOCRINOL, V19, P277, DOI 10.1210/me.2004-0008; Chambliss KL, 2002, STEROIDS, V67, P413, DOI 10.1016/S0039-128X(01)00177-5; Chen WP, 2007, EUR J PHARMACOL, V554, P196, DOI 10.1016/j.ejphar.2006.10.016; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Cordova AC, 2005, J AM COLL SURGEONS, V200, P428, DOI 10.1016/j.jamcollsurg.2004.10.030; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Filardo E, 2007, ENDOCRINOLOGY, V148, P3236, DOI 10.1210/en.2006-1605; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Foley EF, 2000, CANCER RES, V60, P245; Fournier B, 2001, J BIOL CHEM, V276, P35444, DOI 10.1074/jbc.M105418200; Frasor J, 2003, ENDOCRINOLOGY, V144, P3159, DOI 10.1210/en.2002-0143; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gilad LA, 2007, J MOL ENDOCRINOL, V38, P603, DOI 10.1677/JME-06-0040; Gingerich S, 2005, ENDOCRINOLOGY, V146, P2933, DOI 10.1210/en.2004-1375; Gingerich S, 2006, HYPERTENSION, V48, P1130, DOI 10.1161/01.HYP.0000248754.67128.ff; Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009-9120(02)00397-1; Greger JG, 2007, MOL CELL BIOL, V27, P1904, DOI 10.1128/MCB.01732-06; Greger JG, 2006, STEROIDS, V71, P317, DOI 10.1016/j.steroids.2005.09.016; Guo XM, 2005, J BIOL CHEM, V280, P19704, DOI 10.1074/jbc.M501244200; Hartman J, 2006, CANCER RES, V66, P11207, DOI 10.1158/0008-5472.CAN-06-0017; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Ihionkhan CE, 2002, CIRC RES, V91, P814, DOI 10.1161/01.RES.0000038304.62046.4C; Joy S, 2006, J BIOL CHEM, V281, P27335, DOI 10.1074/jbc.M602803200; Kim Jin Kyung, 2006, Nucl Recept Signal, V4, pe013; Kim Kyung Hee, 2005, Sci STKE, V2005, ppe28; Kiss AL, 2005, MOL CELL ENDOCRINOL, V245, P128, DOI 10.1016/j.mce.2005.11.005; Klinge CM, 2005, J BIOL CHEM, V280, P7460, DOI 10.1074/jbc.M411565200; Klinge CM, 2003, J AGR FOOD CHEM, V51, P1850, DOI 10.1021/jf0259821; Klinge CM, 2001, ARCH BIOCHEM BIOPHYS, V390, P64, DOI 10.1006/abbi.2001.2366; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Levenson AS, 2002, CANCER RES, V62, P4419; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Li L, 2007, P NATL ACAD SCI USA, V104, P16468, DOI 10.1073/pnas.0704315104; Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029; Marier JF, 2002, J PHARMACOL EXP THER, V302, P369, DOI 10.1124/jpet.102.033340; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; Mineo C, 2006, CARDIOVASC RES, V70, P31, DOI 10.1016/j.cardiores.2006.01.025; Morani A, 2006, P NATL ACAD SCI USA, V103, P7165, DOI 10.1073/pnas.0602194103; Moriarty K, 2006, ENDOCRINOLOGY, V147, P5557, DOI 10.1210/en.2006-0729; Niles RM, 2006, J NUTR, V136, P2542, DOI 10.1093/jn/136.10.2542; O'Lone R, 2007, MOL ENDOCRINOL, V21, P1281, DOI 10.1210/me.2006-0497; Orallo F, 2002, MOL PHARMACOL, V61, P294, DOI 10.1124/mol.61.2.294; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200; Pedram A, 2006, MOL ENDOCRINOL, V20, P1996, DOI 10.1210/me.2005-0525; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Podar K, 2004, CANCER RES, V64, P7500, DOI 10.1158/0008-5472.CAN-04-0124; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004-0115; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Reineri S, 2007, BBA-MOL CELL RES, V1773, P273, DOI 10.1016/j.bbamcr.2006.12.001; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Sacanella E, 2007, AM J CLIN NUTR, V86, P1463, DOI 10.1093/ajcn/86.5.1463; Sato M, 2002, ANN NY ACAD SCI, V957, P122, DOI 10.1111/j.1749-6632.2002.tb02911.x; Scobie GA, 2002, STEROIDS, V67, P985, DOI 10.1016/S0039-128X(02)00047-8; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Sladek CD, 2008, FRONT NEUROENDOCRIN, V29, P114, DOI 10.1016/j.yfrne.2007.08.005; Stoclet JC, 2004, EUR J PHARMACOL, V500, P299, DOI 10.1016/j.ejphar.2004.07.034; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011; Watson Cheryl S, 2005, EMBO Rep, V6, P116; Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Yu CW, 2002, PHARM RES-DORDR, V19, P1907, DOI 10.1023/A:1021414129280; Zhang WH, 2003, FEBS LETT, V546, P17, DOI 10.1016/S0014-5793(03)00436-8; Zhang WH, 2000, P NATL ACAD SCI USA, V97, P5936, DOI 10.1073/pnas.97.11.5936; Zhuang LY, 2002, CANCER RES, V62, P2227	85	132	136	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2185	2197		10.1096/fj.07-103366	http://dx.doi.org/10.1096/fj.07-103366			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18296501				2022-12-28	WOS:000257292500011
J	Sekkali, B; Tran, HT; Crabbe, E; De Beule, C; Van Roy, F; Vleminckx, K				Sekkali, Belaid; Tran, Hong Thi; Crabbe, Ellen; De Beule, Christophe; Van Roy, Frans; Vleminckx, Kris			Chicken beta-globin insulator overcomes variegation of transgenes in Xenopus embryos	FASEB JOURNAL			English	Article						transcriptional silencing; heterochromatin; position effect variegation	ENHANCER-BLOCKING ACTIVITY; LOCUS-CONTROL REGIONS; GENE-EXPRESSION; CHROMATIN INSULATOR; LAEVIS EMBRYOS; HETEROCHROMATIN; DROSOPHILA; CELLS; VECTORS; DISEASE	Chromatin structure and gene transcription regulation are intimately linked, and mosaic expression of randomly integrated transgenes into the genome is frequently observed. This variegation of transgene expression is likely due to the genomic integration site, which can affect the behavior of the integrated DNA sequence in a positive or a negative way. Insulators are a class of DNA elements that can protect genes from inappropriate signals emanating from their environment by acting as boundaries that prevent the spreading of nearby condensed chromatin that may otherwise silence expression. Here we show that transgenes escape this silencing in Xenopus laevis and Xenopus tropicalis embryos and that a stable, uniform, and heritable expression pattern is obtained when transgenes are flanked with tandem copies of the chicken beta-globin 5'HS4 insulator. Our data also indicate that the insulator confers copy-number-dependent transgene expression and can increase transgene expression from weak regulatory elements. Hence, it will be an invaluable tool for generating stable lines expressing different levels of a particular coding sequence.	[Sekkali, Belaid; Tran, Hong Thi; Crabbe, Ellen; De Beule, Christophe; Van Roy, Frans; Vleminckx, Kris] Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; [Sekkali, Belaid; Tran, Hong Thi; Crabbe, Ellen; De Beule, Christophe; Van Roy, Frans; Vleminckx, Kris] Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Vleminckx, K (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Technol Pk 927, B-9052 Ghent, Belgium.	kris.vleminckx@dmbr.ugent.be	Vleminckx, Kris/J-5699-2013; van Roy, Frans M/C-6123-2009; Tran, Hong/C-6831-2015	van Roy, Frans M/0000-0003-4358-1039; 				Allen BG, 2005, NAT METHODS, V2, P975, DOI 10.1038/NMETH814; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; BROWN AL, 1986, J BIOL CHEM, V261, P3144; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Dobie K, 1997, TRENDS GENET, V13, P127, DOI 10.1016/S0168-9525(97)01097-4; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; Gdula DA, 1996, P NATL ACAD SCI USA, V93, P9378, DOI 10.1073/pnas.93.18.9378; Grosveld F, 1998, ANN NY ACAD SCI, V850, P18, DOI 10.1111/j.1749-6632.1998.tb10458.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hirsch N, 2002, DEV DYNAM, V225, P522, DOI 10.1002/dvdy.10188; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; Kleinjan DJ, 1998, HUM MOL GENET, V7, P1611, DOI 10.1093/hmg/7.10.1611; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Li QL, 2002, BLOOD, V100, P3077, DOI 10.1182/blood-2002-04-1104; Milot E, 1996, TRENDS GENET, V12, P123, DOI 10.1016/0168-9525(96)30019-X; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; Recillas-Targa F, 2002, P NATL ACAD SCI USA, V99, P6883, DOI 10.1073/pnas.102179399; Recillas-Targa F, 1999, P NATL ACAD SCI USA, V96, P14354, DOI 10.1073/pnas.96.25.14354; Truffinet W, 2005, IMMUNOL LETT, V96, P303, DOI 10.1016/j.imlet.2004.09.002; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Yannaki E, 2002, MOL THER, V5, P589, DOI 10.1006/mthe.2002.0582	25	17	18	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2534	2540		10.1096/fj.07-098111	http://dx.doi.org/10.1096/fj.07-098111			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18359926				2022-12-28	WOS:000257292500044
J	Urushitani, M; Abou Ezzi, S; Matsuo, A; Tooyama, I; Julien, JP				Urushitani, Makoto; Abou Ezzi, Samer; Matsuo, Akinori; Tooyama, Ikuo; Julien, Jean-Pierre			The endoplasmic reticulum-Golgi pathway is a target for translocation and aggregation of mutant superoxide dismutase linked to ALS	FASEB JOURNAL			English	Article						digitonin; microsome; live imaging; green fluorescent protein; electron immunomicroscopy	AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEATH; CU,ZN-SUPEROXIDE DISMUTASE; RAT-LIVER; SOD1; PROTEINS; MUTATIONS; SECRETION; TOXICITY; DEGENERATION	Mutations in superoxide dismutase 1 (SOD1) are responsible for 20% cases of familial amyotrophic lateral sclerosis (ALS). However, the mechanism of motor neuron degeneration caused by ALS-linked SOD1 mutants is not fully understood. Here, we used novel live cell imaging techniques to demonstrate the subcellular localization of EGFP-fused SOD1 of both wild-type (WT) and ALS-linked mutant forms in the endoplasmic reticulum (ER) and Golgi. The presence of WT and mutant SOD1 species in luminal structures was further confirmed by immunoblotting analysis of microsomal fractions from spinal cord lysates of SOD1 transgenic mice prepared by sucrose density-gradient ultracentrifugation. Chemical cross-linking studies also revealed an age-dependent aggregation of mutant SOD1, but not of WT SOD1, prominently in the microsomal fraction. Cell-free translocation assays provided evidence that monomeric SOD1 is a molecular form that can be translocated into luminal structures in the presence of ATP. Our finding that the ER-Golgi pathway is a predominant cellular site of aggregation of mutant SOD1 suggests that secretion could play a key role in pathogenesis, which is in line with the view that the disease is non-cell autonomous.	[Urushitani, Makoto; Abou Ezzi, Samer; Julien, Jean-Pierre] Univ Laval, Res Ctr CHUQ, Dept Anat & Physiol, Quebec City, PQ G1V 4G2, Canada; [Urushitani, Makoto; Matsuo, Akinori; Tooyama, Ikuo] Shiga Univ Med Sci, Mol Neurosci Res Ctr, Shiga, Japan	Laval University; Shiga University of Medical Science	Julien, JP (corresponding author), Univ Laval, Res Ctr CHUQ, Dept Anat & Physiol, 2705 Boul Laurier, Quebec City, PQ G1V 4G2, Canada.	jean-pierre.julien@crchul.ulaval.ca		Urushitani, Makoto/0000-0003-2773-9836; Tooyama, Ikuo/0000-0001-8054-9666				Bergemalm D, 2006, J NEUROSCI, V26, P4147, DOI 10.1523/JNEUROSCI.5461-05.2006; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FURUKAWA Y, 2004, J BIOL CHEM, V279, P17266; Furukawa Y., 2005, P NATL ACAD SCI USA, V280, P7148; GELLER BL, 1982, J BIOL CHEM, V257, P8945; Gomes C, 2007, NEUROSCI LETT, V428, P43, DOI 10.1016/j.neulet.2007.09.024; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Jaarsma D, 2000, NEUROBIOL DIS, V7, P623, DOI 10.1006/nbdi.2000.0299; JADOT M, 1985, BIOCHEM J, V225, P645, DOI 10.1042/bj2250645; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Jonsson PA, 2006, BRAIN, V129, P451, DOI 10.1093/brain/awh704; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kato S, 2000, AMYOTROPH LATERAL SC, V1, P163, DOI 10.1080/14660820050515160; Kikuchi H, 2006, P NATL ACAD SCI USA, V103, P6025, DOI 10.1073/pnas.0509227103; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; LIOU W, 1993, FREE RADICAL BIO MED, V14, P201, DOI 10.1016/0891-5849(93)90011-I; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; Martin ME, 2000, J BIOL CHEM, V275, P19050, DOI 10.1074/jbc.275.25.19050; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; Miyakawa K, 2003, J BIOL CHEM, V278, P35718, DOI 10.1074/jbc.M300690200; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; RABOUILLE C, 1993, J CELL BIOL, V120, P897, DOI 10.1083/jcb.120.4.897; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Rakhit R, 2007, NAT MED, V13, P754, DOI 10.1038/nm1559; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Santillo M, 2007, J NEUROCHEM, V102, P679, DOI 10.1111/j.1471-4159.2007.04538.x; Sattler T, 2000, J CELL BIOL, V151, P529, DOI 10.1083/jcb.151.3.529; Shaw BF, 2007, TRENDS BIOCHEM SCI, V32, P78, DOI 10.1016/j.tibs.2006.12.005; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Turner BJ, 2005, J NEUROSCI, V25, P108, DOI 10.1523/JNEUROSCI.4253-04.2005; Urushitani M, 2006, NAT NEUROSCI, V9, P108, DOI 10.1038/nn1603; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Urushitani M, 2007, P NATL ACAD SCI USA, V104, P2495, DOI 10.1073/pnas.0606201104; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Zhang FJ, 2006, BBA-GEN SUBJECTS, V1760, P404, DOI 10.1016/j.bbagen.2005.11.024	46	68	72	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2476	2487		10.1096/fj.07-092783	http://dx.doi.org/10.1096/fj.07-092783			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18337461				2022-12-28	WOS:000257292500039
J	Fablet, M; Lerat, E; Rebollo, R; Horard, B; Burlet, N; Martinez, S; Brasset, E; Gilson, E; Vaury, C; Vieira, C				Fablet, Marie; Lerat, Emmanuelle; Rebollo, Rita; Horard, Beatrice; Burlet, Nelly; Martinez, Sonia; Brasset, Emilie; Gilson, Eric; Vaury, Chantal; Vieira, Cristina			Genomic environment influences the dynamics of the tirant LTR retrotransposon in Drosophila	FASEB JOURNAL			English	Article						chromatin; endogenous retrovirus; natural populations	ELEMENT COPY NUMBER; TRANSPOSABLE ELEMENTS; MELANOGASTER GENOME; NATURAL-POPULATIONS; SIMULANS; HETEROCHROMATIN; SEQUENCES; RETROVIRUSES; EXPRESSION; EVOLUTION	Combining genome sequence analysis and functional analysis, we show that some full-length copies of tirant are present in heterochromatic regions in Drosophila simulans and that when tested in vitro, these copies have a functional promoter. However, when inserted in heterochromatic regions, tirant copies are inactive in vivo, and only transcription of euchromatic copies can be detected. Thus, our data indicate that the localization of the element is a hallmark of its activity in vivo and raise the question of genomic invasions by transposable elements and the importance of their genomic integration sites.-Fablet, M., Lerat, E., Rebollo, R., Horard, B., Burlet, N., Martinez, S., Brasset, E., Gilson, E., Vaury, C., Vieira, C. Genomic environment influences the dynamics of the tirant LTR retrotransposon in Drosophila. FASEB J. 23, 1482-1489 (2009)	[Fablet, Marie; Lerat, Emmanuelle; Rebollo, Rita; Burlet, Nelly; Martinez, Sonia; Vieira, Cristina] Univ Lyon 1, CNRS, UMR5558, Lab Biometrie & Biol Evolut, F-69622 Villeurbanne, France; [Horard, Beatrice; Gilson, Eric] Univ Lyon 1, Fac Med Lyon Sud, CNRS, ENS Lyon,Lab Biol Mol Cellule,HCL,UMR 5161, Pierre Benite, France; [Brasset, Emilie; Vaury, Chantal] Clermont Univ, CNRS, UMR 6247, Fac Med,INSERM,U931, Clermont Ferrand, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; Centre National de la Recherche Scientifique (CNRS); CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA)	Vieira, C (corresponding author), Univ Lyon 1, CNRS, UMR5558, Lab Biometrie & Biol Evolut, F-69622 Villeurbanne, France.	vieira@biomserv.univ-lyon1.fr	Vaury, Chantal/I-4658-2015; Vieira, Cristina/Q-3137-2017; Brasset, Emilie/J-6684-2015	Vaury, Chantal/0000-0002-7725-5760; Vieira, Cristina/0000-0003-3414-3993; LERAT, Emmanuelle/0000-0001-6757-8796; Brasset, Emilie/0000-0003-2479-7969; BURLET, Nelly/0000-0003-3231-4154; Rebollo, Rita/0000-0002-8138-5082	Centre National de la Recherche Scientifique [UMR 5558, GDR 2157]; ARC (ARECA program on epigenetic profiling)	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); ARC (ARECA program on epigenetic profiling)	We thank Christian Biemont for useful comments, and Monika Ghosh for reviewing the English text. The work in C. Vieira's laboratory was funded by the Centre National de la Recherche Scientifique (UMR 5558 and GDR 2157 on TEs). The work in E.G.'s laboratory was funded by ARC (ARECA program on epigenetic profiling).	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barolo S, 2000, BIOTECHNIQUES, V29, P726, DOI 10.2144/00294bm10; Bergman CM, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-11-r112; Biemont C, 2005, CYTOGENET GENOME RES, V110, P25, DOI 10.1159/000084935; Biemont C, 2003, EVOLUTION, V57, P159, DOI 10.1111/j.0014-3820.2003.tb00225.x; Biemont C, 1997, GENETICA, V100, P161, DOI 10.1023/A:1018329528314; Biemont C, 2006, NATURE, V443, P521, DOI 10.1038/443521a; Bonnivard E, 1997, GENET RES, V69, P197, DOI 10.1017/S0016672397002826; Busseau I, 2001, MOL BIOL EVOL, V18, P196, DOI 10.1093/oxfordjournals.molbev.a003793; CHARLESWORTH B, 1994, GENET RES, V64, P183, DOI 10.1017/S0016672300032845; CHARLESWORTH B, 1989, ANNU REV GENET, V23, P251, DOI 10.1146/annurev.ge.23.120189.001343; Costas J, 2001, J MOL EVOL, V52, P342, DOI 10.1007/s002390010164; DANIELS SB, 1986, J MOL EVOL, V23, P138, DOI 10.1007/BF02099908; Desset S, 1999, MOL BIOL EVOL, V16, P54, DOI 10.1093/oxfordjournals.molbev.a026038; Desset S, 2003, GENETICS, V164, P501; Ebert A, 2006, CHROMOSOME RES, V14, P377, DOI 10.1007/s10577-006-1066-1; EICKBUSH DG, 1995, GENETICS, V139, P671; Fablet M, 2006, GENE, V375, P54, DOI 10.1016/j.gene.2006.02.008; Felsenstein J, 1989, CLADISTICS, V5, P3; Hoskins RA, 2007, SCIENCE, V316, P1625, DOI 10.1126/science.1139816; Junakovic N, 1998, J MOL EVOL, V46, P661, DOI 10.1007/PL00006346; KAMINKER JS, 2002, GENOME BIOL, V0003; Kapitonov VV, 2003, P NATL ACAD SCI USA, V100, P6569, DOI 10.1073/pnas.0732024100; KIM A, 1994, P NATL ACAD SCI USA, V91, P1285, DOI 10.1073/pnas.91.4.1285; Kogan GL, 2003, MOL GENET GENOMICS, V269, P234, DOI 10.1007/s00438-003-0827-1; Lerat E, 2003, GENOME RES, V13, P1889, DOI 10.1101/gr.827603; Matyunina LV, 1996, P NATL ACAD SCI USA, V93, P7097, DOI 10.1073/pnas.93.14.7097; Mugnier N, 2005, MOL BIOL EVOL, V22, P747, DOI 10.1093/molbev/msi060; Mugnier N, 2008, GENE, V411, P87, DOI 10.1016/j.gene.2008.01.010; Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004; PRUDHOMME N, 1995, GENETICS, V139, P697; Sandmann T, 2006, NAT PROTOC, V1, P2839, DOI 10.1038/nprot.2006.383; Strohner R, 2004, MOL CELL BIOL, V24, P1791, DOI 10.1128/MCB.24.4.1791-1798.2004; Sun XP, 2003, GENOME RES, V13, P182, DOI 10.1101/gr.681703; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; VAURY C, 1989, CHROMOSOMA, V98, P215, DOI 10.1007/BF00329686; Vernhettes S, 1998, MOL BIOL EVOL, V15, P827, DOI 10.1093/oxfordjournals.molbev.a025988; Vieira C, 1999, MOL BIOL EVOL, V16, P1251, DOI 10.1093/oxfordjournals.molbev.a026215; Vieira C, 2004, GENETICA, V120, P115, DOI 10.1023/B:GENE.0000017635.34955.b5	39	10	10	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1482	1489		10.1096/fj.08-123513	http://dx.doi.org/10.1096/fj.08-123513			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19141532				2022-12-28	WOS:000266651700024
J	Nader, N; Chrousos, GP; Kino, T				Nader, Nancy; Chrousos, George P.; Kino, Tomoshige			Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications	FASEB JOURNAL			English	Article						brain-muscle-arnt-like protein 1; hypothalamic-pituitary-adrenal axis; GREs; GILZ; G6Pase; histone acetyltransferase	PITUITARY-ADRENAL AXIS; CLINICAL-IMPLICATIONS; NERVOUS-SYSTEM; GENE-EXPRESSION; DNA-BINDING; KAPPA-B; STRESS; INTERACTS; PROMOTER; DISEASES	Glucocorticoids, end products of the hypothalamic-pituitary-adrenal axis, influence functions of virtually all organs and tissues through the glucocorticoid receptor (GR). Circulating levels of glucocorticoids fluctuate naturally in a circadian fashion and regulate the transcriptional activity of GR in target tissues. The basic helix-loop-helix protein CLOCK, a histone acetyltransferase (HAT), and its heterodimer partner BMAL1 are self-oscillating transcription factors that generate circadian rhythms in both the central nervous system and periphery. We found that CLOCK/BMAL1 repressed GR-induced transcriptional activity in a HAT-activity-dependent fashion. In serum-shock-synchronized cells, transactivational activity of GR, accessed by mRNA expression of an endogenous-responsive gene, fluctuated spontaneously in a circadian fashion in reverse phase with CLOCK/BMAL1 mRNA expression. CLOCK and GR interacted with each other physically, and CLOCK suppressed binding of GR to its DNA recognition sequences by acetylating multiple lysine residues located in its hinge region. These findings indicate that CLOCK/BMAL1 functions as a reverse-phase negative regulator of glucocorticoid action in target tissues, possibly by antagonizing biological actions of diurnally fluctuating circulating glucocorticoids. Further, these results suggest that a peripheral target tissue circadian rhythm indirectly influences the functions of every organ and tissue inside the body through modulation of the ubiquitous and diverse actions of glucocorticoids.-Nader, N., Chrousos, G. P., Kino, T. Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications. FASEB J. 23, 1572-1583 (2009)	[Nader, Nancy; Chrousos, George P.; Kino, Tomoshige] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Pediat Endocrinol, Program Reprod & Adult Endocrinol, NIH,Clin Res Ctr, Bethesda, MD 20892 USA; [Chrousos, George P.] Univ Athens, Sch Med, Dept Pediat 1, GR-11527 Athens, Greece	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Athens Medical School; National & Kapodistrian University of Athens	Kino, T (corresponding author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Pediat Endocrinol, Program Reprod & Adult Endocrinol, NIH,Clin Res Ctr, Bldg 10,Rm 1-3140,10 Ctr Dr MSC 1109, Bethesda, MD 20892 USA.	kinot@mail.nih.gov	Nader, Nader/E-6358-2014	Nader, Nader/0000-0002-5744-7319	Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000618, ZIAHD000615, ZIAHD008732] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008732, Z01HD000615, Z01HD000618] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This study was funded by the Intramural Research Program of Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH. We thank Drs. R. M. Evans (Salk Institute, La Jolla, CA, USA), G. L. Hager (National Cancer Institute, Bethesda, MD, USA), G. A. FitzGerald (University of Pennsylvania, Philadelphia, PA, USA), P. Sassone-Corsi (University of California, Irvine, CA, USA), and J. H. Segars (NIH, Bethesda, MD, USA) for providing plasmids and K. Zachman and Dr. T. Shibata for superb technical assistance.	Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Blind RD, 2008, J STEROID BIOCHEM, V109, P150, DOI 10.1016/j.jsbmb.2008.01.002; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Buijs RM, 2003, J ENDOCRINOL, V177, P17, DOI 10.1677/joe.0.1770017; Cardone L, 2005, SCIENCE, V309, P1390, DOI 10.1126/science.1110689; Cermakian N, 2000, NAT REV MOL CELL BIO, V1, P59, DOI 10.1038/35036078; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chrousos G.P., 2001, ENDOCRINOLOGY METABO, V4th ed., P609; Chrousos GP, 2007, STRESS, V10, P213, DOI 10.1080/10253890701292119; Chrousos George P, 2005, Sci STKE, V2005, ppe48, DOI 10.1126/stke.3042005pe48; Chrousos GP, 2000, INT J OBESITY, V24, pS50, DOI 10.1038/sj.ijo.0801278; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Chrousos GP, 2000, ANN NY ACAD SCI, V917, P38, DOI 10.1111/j.1749-6632.2000.tb05371.x; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; Crofford LJ, 1997, J CLIN ENDOCR METAB, V82, P1279, DOI 10.1210/jc.82.4.1279; De Martino MU, 2004, MOL ENDOCRINOL, V18, P820, DOI 10.1210/me.2003-0341; Dickmeis T, 2007, PLOS BIOL, V5, P854, DOI 10.1371/journal.pbio.0050078; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Green CB, 2003, SCIENCE, V301, P319, DOI 10.1126/science.1087824; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirayama J, 2007, NATURE, V450, P1086, DOI 10.1038/nature06394; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Ichijo T, 2005, J BIOL CHEM, V280, P42067, DOI 10.1074/jbc.M509338200; Ichijo T, 2008, MOL CELL ENDOCRINOL, V283, P19, DOI 10.1016/j.mce.2007.10.014; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Kino T, 2005, J CELL BIOL, V169, P885, DOI 10.1083/jcb.200409150; Kino T, 2004, ESSAYS BIOCHEM, V40, P137, DOI 10.1042/bse0400137; Kino T, 2003, J STEROID BIOCHEM, V85, P457, DOI 10.1016/S0960-0760(03)00218-8; Kino T, 2002, J VIROL, V76, P9724, DOI 10.1128/JVI.76.19.9724-9734.2002; KINO T, 2004, HDB STRESS BRAIN 1, P295; Kino T, 2007, MOL ENDOCRINOL, V21, P1552, DOI 10.1210/me.2006-0345; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; Lonard DM, 2007, ENDOCR REV, V28, P575, DOI 10.1210/er.2007-0012; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Mirani M, 2002, J IMMUNOL, V169, P6361, DOI 10.4049/jimmunol.169.11.6361; Nascimento AS, 2006, J MOL BIOL, V360, P586, DOI 10.1016/j.jmb.2006.05.008; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Rosen J, 2005, ENDOCR REV, V26, P452, DOI 10.1210/er.2005-0002; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Schibler U, 2005, CELL METAB, V2, P278, DOI 10.1016/j.cmet.2005.10.001; Smit P, 2005, J CLIN ENDOCR METAB, V90, P2994, DOI 10.1210/jc.2004-2298; van Rossum EFC, 2005, TRENDS ENDOCRIN MET, V16, P445, DOI 10.1016/j.tem.2005.10.009; Vander Kooi BT, 2005, MOL ENDOCRINOL, V19, P3001, DOI 10.1210/me.2004-0497; Vgontzas AN, 1999, J CLIN ENDOCR METAB, V84, P2603, DOI 10.1210/jc.84.8.2603; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	56	231	236	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1572	1583		10.1096/fj.08-117697	http://dx.doi.org/10.1096/fj.08-117697			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19141540	Green Published			2022-12-28	WOS:000266651700032
J	Argellati, F; Domenicotti, C; Passalacqua, M; Janda, E; Melloni, E; Marinari, UM; Pronzato, MA; Ricciarelli, R				Argellati, Francesca; Domenicotti, Cinzia; Passalacqua, Mario; Janda, Elzbieta; Melloni, Edon; Marinari, Umberto M.; Pronzato, Maria A.; Ricciarelli, Roberta			Protein kinase C-dependent alpha-secretory processing of the amyloid precursor protein is mediated by phosphorylation of myosin II-B	FASEB JOURNAL			English	Article						Alzheimer's disease; neurodegeneration; signaling	HEAVY-CHAIN ISOFORMS; LOCALIZATION; IDENTIFICATION; VESICLES; CLEAVAGE; PEPTIDE; BINDING; MICE	A substantial body of evidence indicates that protein kinase C (PKC) is involved in the alpha-secretory processing of the amyloid precursor protein (APP), an event that reduces the formation of the pathogenic amyloid-beta peptide. Recently, we have shown that trafficking and processing of APP are both impaired by knockdown of myosin II-B, one of the major neuronal motor proteins. Here, we provide evidence that the alpha-secretory processing of APP is mediated by PKC-dependent phosphorylation of myosin II-B. This signaling pathway provides an important link between APP and the neuronal cytoskeleton and might be crucial for the understanding of the biological and pathological roles of APP.-Argellati, F., Domenicotti, C., Passalacqua, M., Janda, E., Melloni, E., Marinari, U. M., Pronzato, M. A., Ricciarelli, R. Protein kinase C-dependent alpha-secretory processing of the amyloid precursor protein is mediated by phosphorylation of myosin II-B. FASEB J. 23, 1246-1251 (2009)	[Argellati, Francesca; Domenicotti, Cinzia; Passalacqua, Mario; Melloni, Edon; Marinari, Umberto M.; Pronzato, Maria A.; Ricciarelli, Roberta] Univ Genoa, Dept Expt Med, Genoa, Italy; [Janda, Elzbieta] Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy	University of Genoa; Magna Graecia University of Catanzaro	Ricciarelli, R (corresponding author), Via LB Alberti 2, I-16132 Genoa, Italy.	ricciarelli@medicina.unige.it	Janda, Elzbieta/AAD-5126-2022; Ricciarelli, Roberta/AAE-8063-2019; Domenicotti, Cinzia/C-7786-2011; Janda, Elzbieta/AFQ-7061-2022; Passalacqua, Mario/W-1973-2019	Janda, Elzbieta/0000-0002-6787-7291; Janda, Elzbieta/0000-0002-6787-7291; Passalacqua, Mario/0000-0003-2779-6259; Ricciarelli, Roberta/0000-0002-2053-2501	Fondazione CARIGE; Genoa University [2006065711_002]	Fondazione CARIGE(Fondazione Carige); Genoa University	We thank Prof. S. Ravid and Drs. S. Massone and L. Vattuone for their productive suggestions. This work was supported by grants from Fondazione CARIGE, Genoa University, PRIN (2006065711_002).	Ben-Ya'acov A, 2003, J BIOL CHEM, V278, P40032, DOI 10.1074/jbc.M306948200; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CONTI MA, 1991, BIOCHEMISTRY-US, V30, P966, DOI 10.1021/bi00218a012; Conti MA, 2008, J CELL SCI, V121, P11, DOI 10.1242/jcs.007112; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Even-Faitelson L, 2006, MOL BIOL CELL, V17, P2869, DOI 10.1091/mbc.e05-11-1001; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Ma XF, 2007, MOL BIOL CELL, V18, P2305, DOI 10.1091/mbc.E07-01-0073; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Massone S, 2007, BIOCHEM BIOPH RES CO, V362, P633, DOI 10.1016/j.bbrc.2007.08.061; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; MURAKAMI N, 1994, J BIOL CHEM, V269, P16082; Neco P, 2008, J BIOL CHEM, V283, P10949, DOI 10.1074/jbc.M709058200; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Rosenberg M, 2006, MOL BIOL CELL, V17, P1364, DOI 10.1091/mbc.e05-07-0597; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Straussman R, 2001, J CELL SCI, V114, P3047; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243	31	6	7	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1246	1251		10.1096/fj.08-119263	http://dx.doi.org/10.1096/fj.08-119263			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19103644				2022-12-28	WOS:000266651600028
J	Bessac, BF; Sivula, M; von Hehn, CA; Caceres, AI; Escalera, J; Jordt, SE				Bessac, Bret F.; Sivula, Michael; von Hehn, Christian A.; Caceres, Ana I.; Escalera, Jasmine; Jordt, Sven-Eric			Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases	FASEB JOURNAL			English	Article						sensory neurons; pain; nociception; analgesia; TRP channels	ION-CHANNEL TRPA1; DYSFUNCTION SYNDROME RADS; RIOT CONTROL AGENTS; TOLUENE DIISOCYANATE; SENSORY IRRITATION; METHYL ISOCYANATE; CIGARETTE-SMOKE; ACTIVATION; RESPONSES; PAIN	The release of methyl isocyanate in Bhopal, India, caused the worst industrial accident in history. Exposures to industrial isocyanates induce lacrimation, pain, airway irritation, and edema. Similar responses are elicited by chemicals used as tear gases. Despite frequent exposures, the biological targets of isocyanates and tear gases in vivo have not been identified, precluding the development of effective countermeasures. We use Ca2+ imaging and electrophysiology to show that the noxious effects of isocyanates and those of all major tear gas agents are caused by activation of Ca2+ influx and membrane currents in mustard oil-sensitive sensory neurons. These responses are mediated by transient receptor potential ankyrin 1 (TRPA1), an ion channel serving as a detector for reactive chemicals. In mice, genetic ablation or pharmacological inhibition of TRPA1 dramatically reduces isocyanate-and tear gas-induced nocifensive behavior after both ocular and cutaneous exposures. We conclude that isocyanates and tear gas agents target the same neuronal receptor, TRPA1. Treatment with TRPA1 antagonists may prevent and alleviate chemical irritation of the eyes, skin, and airways and reduce the adverse health effects of exposures to a wide range of toxic noxious chemicals.-Bessac, B. F., Sivula, M., von Hehn, C. A., Caceres, A. I., Escalera, J., Jordt, S.-E. Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 23, 1102-1114 (2009)	[Bessac, Bret F.; Sivula, Michael; von Hehn, Christian A.; Caceres, Ana I.; Escalera, Jasmine; Jordt, Sven-Eric] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Jordt, SE (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,POB 208066, New Haven, CT 06520 USA.	sven.jordt@yale.edu	Caceres, Ana I/E-5542-2012; Jordt, Sven-Eric/ABE-6517-2020; Bessac, Bret/AAZ-1550-2020	Caceres, Ana I/0000-0001-7219-8851; Jordt, Sven-Eric/0000-0001-6171-5622; Bessac, Brett/0000-0002-0522-4455	National Institutes of Health Counter-ACT (Countermeasures Against Chemical Threats); National Institute of Environmental Health Sciences (NIEHS) [F31ES015932]; ONES (Outstanding New Environmental Scientists) [U01 ES015674, R01 ES015056]; Spanish Foundation for Science and Technology [2007-0480]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES017218, R01ES015056, U01ES015674, F31ES015932] Funding Source: NIH RePORTER	National Institutes of Health Counter-ACT (Countermeasures Against Chemical Threats)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); ONES (Outstanding New Environmental Scientists); Spanish Foundation for Science and Technology; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Carrie Redlich for scientific advice. This work was funded by the National Institutes of Health Counter-ACT (Countermeasures Against Chemical Threats) and National Institute of Environmental Health Sciences (NIEHS) ONES (Outstanding New Environmental Scientists) programs (awards U01 ES015674 and R01 ES015056 to S.-E. J. from NIEHS), a NIEHS predoctoral fellowship to J.E. (F31ES015932), and a Ministry of Education and Science/Fulbright fellowship from the Spanish Foundation for Science and Technology to A. C. (2007-0480). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the federal government. S.J. serves on the Scientific Advisory Board of Hydra Biosciences, a biotech startup company in Cambridge, MA, USA. Hydra Biosciences provided the TRPA1 antagonist HC-030031 used in this study. We are grateful to Aiwei Sui and Marian Brackmann for technical support.	ALARIE Y, 1973, TOXICOL APPL PHARM, V24, P279, DOI 10.1016/0041-008X(73)90148-8; ALARIE Y, 1987, ENVIRON HEALTH PERSP, V72, P159, DOI 10.2307/3430291; Andersson DA, 2008, J NEUROSCI, V28, P2485, DOI 10.1523/JNEUROSCI.5369-07.2008; Andre E, 2008, J CLIN INVEST, V118, P2574, DOI 10.1172/JCI34886; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bautista DM, 2005, P NATL ACAD SCI USA, V102, P12248, DOI 10.1073/pnas.0505356102; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Bessac BF, 2008, J CLIN INVEST, V118, P1899, DOI 10.1172/JCI34192; Bessac BF, 2007, J PHYSIOL-LONDON, V582, P1073, DOI 10.1113/jphysiol.2007.130534; Blain Peter G., 2003, Toxicological Reviews, V22, P103, DOI 10.2165/00139709-200322020-00005; Brone B, 2008, TOXICOL APPL PHARM, V231, P150, DOI 10.1016/j.taap.2008.04.005; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CONE JE, 1994, CHEST, V106, P500, DOI 10.1378/chest.106.2.500; CULLEN MR, 1987, OCCUP MED, V2, P655; Dai Y, 2007, J CLIN INVEST, V117, P1979, DOI 10.1172/JCI30951; DETORRES JP, 2006, RESP MED EXTRA, V2, P13; Dhara VR, 2002, ARCH ENVIRON HEALTH, V57, P391, DOI 10.1080/00039890209601427; Doerner JF, 2007, J BIOL CHEM, V282, P13180, DOI 10.1074/jbc.M607849200; Escalera J, 2008, J BIOL CHEM, V283, P24136, DOI 10.1074/jbc.M710280200; FERGUSON JS, 1991, TOXICOL APPL PHARM, V107, P253, DOI 10.1016/0041-008X(91)90207-U; Gerhold KA, 2008, J PHYSIOL-LONDON, V586, P3303, DOI 10.1113/jphysiol.2008.158030; GOLDMAN LR, 1987, WESTERN J MED, V147, P95; GORDON T, 1985, AM REV RESPIR DIS, V132, P1106; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA BN, 1987, ENVIRON HEALTH PERSP, V72, P105, DOI 10.2307/3430282; Herrick CA, 2002, J ALLERGY CLIN IMMUN, V109, P873, DOI 10.1067/mai.2002.123533; Hill AR, 2000, MEDICINE, V79, P234, DOI 10.1097/00005792-200007000-00004; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; HU H, 1989, JAMA-J AM MED ASSOC, V262, P660; Jordt S. E., 2007, V45, P253; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Karagama YG, 2003, J ROY SOC MED, V96, P172, DOI 10.1258/jrsm.96.4.172; Kim D, 2007, J NEUROSCI, V27, P6500, DOI 10.1523/JNEUROSCI.0623-07.2007; Koehler G A, 1993, Prehosp Disaster Med, V8, P359; Lee SP, 2008, BRIT J PHARMACOL, V153, P1739, DOI 10.1038/bjp.2008.85; Lu SG, 2006, J PHYSIOL-LONDON, V577, P169, DOI 10.1113/jphysiol.2006.116418; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; Macpherson LJ, 2005, CURR BIOL, V15, P929, DOI 10.1016/j.cub.2005.04.018; MAPP CE, 1991, EUR J PHARMACOL, V200, P73, DOI 10.1016/0014-2999(91)90667-F; McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104; Millqvist E, 1998, ALLERGY, V53, P1208, DOI 10.1111/j.1398-9995.1998.tb03843.x; Morris JB, 2005, TOXICOL SCI, V83, P380, DOI 10.1093/toxsci/kfi038; Morris JB, 1999, J APPL PHYSIOL, V87, P1877, DOI 10.1152/jappl.1999.87.5.1877; Mutch J R, 1944, Br J Ophthalmol, V28, P317, DOI 10.1136/bjo.28.7.317; Nagata K, 2005, J NEUROSCI, V25, P4052, DOI 10.1523/JNEUROSCI.0013-05.2005; Nassenstein C, 2008, J PHYSIOL-LONDON, V586, P1595, DOI 10.1113/jphysiol.2007.148379; Olajos EJ, 2001, J APPL TOXICOL, V21, P355, DOI 10.1002/jat.767; Petrus M, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-40; Prezant DJ, 2008, MT SINAI J MED, V75, P89, DOI 10.1002/msj.20028; Pruett SB, 2001, J TOXICOL ENV HEAL B, V4, P207, DOI 10.1080/109374001300339818; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; SANGHA GK, 1979, TOXICOL APPL PHARM, V50, P533, DOI 10.1016/0041-008X(79)90408-3; Sartori M., 1939, WAR GASES CHEM ANAL, V118, pe19; Shakeri MS, 2008, OCCUP MED-OXFORD, V58, P205, DOI 10.1093/occmed/kqn013; Simon SA, 2008, J CLIN INVEST, V118, P2383, DOI 10.1172/JCI36111; Taylor-Clark TE, 2008, J PHYSIOL-LONDON, V586, P3447, DOI 10.1113/jphysiol.2008.153585; Thomas RJ, 2002, MIL MED, V167, P136, DOI 10.1093/milmed/167.2.136; THOMPSON JE, 1987, AM REV RESPIR DIS, V136, P43, DOI 10.1164/ajrccm/136.1.43; Treudler R, 1999, BRIT J DERMATOL, V140, P531; Vaca FE, 1996, AM J EMERG MED, V14, P402, DOI 10.1016/S0735-6757(96)90060-1; VARMA DR, 1993, J TOXICOL ENV HEALTH, V40, P513, DOI 10.1080/15287399309531816; Varma S, 2001, CLIN EXP DERMATOL, V26, P248, DOI 10.1046/j.1365-2230.2001.00806.x; Vaughan RP, 2006, TOXICOL SCI, V93, P411, DOI 10.1093/toxsci/kfl061; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Wang HB, 2005, NEURON, V46, P9, DOI 10.1016/j.neuron.2005.03.011; Warden CR, 2005, CRIT CARE CLIN, V21, P719, DOI 10.1016/j.ccc.2005.05.008; Wisnewski AV, 2008, CLIN EXP ALLERGY, V38, P957, DOI 10.1111/j.1365-2222.2008.02982.x; Wisnewski AV, 2001, CURR OPIN ALLERGY CL, V1, P169, DOI 10.1097/00130832-200104000-00009; WOOLRICH PF, 1982, AM IND HYG ASSOC J, V43, P89, DOI 10.1080/15298668291409415; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813; Zurborg S, 2007, NAT NEUROSCI, V10, P277, DOI 10.1038/nn1843; 1991, MMWR MORB MORTAL WKL, V40, P825; 1991, MMWR MORB MORTAL WKL, V40, P833; 2004, MMWR MORB MORTAL WKL, V53, P740	78	116	119	2	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1102	1114		10.1096/fj.08-117812	http://dx.doi.org/10.1096/fj.08-117812			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19036859	Green Published			2022-12-28	WOS:000266651600014
J	Hudes, ML; McCann, JC; Ames, BN				Hudes, Mark L.; McCann, Joyce C.; Ames, Bruce N.			Unusual clustering of coefficients of variation in published articles from a medical biochemistry department in India	FASEB JOURNAL			English	Review						lipoic acid; oxidative stress; antioxidants; aging; data variability; data manipulation	ALPHA-LIPOIC-ACID; INDUCED OXIDATIVE STRESS; ADJUVANT-INDUCED ARTHRITIS; GLYCOLATE TREATED RATS; URINARY RISK-FACTORS; SWISS ALBINO MICE; PERCHLOROETHYLENE-INDUCED ALTERATIONS; NITROSODIETHYLAMINE-INDUCED HEPATOMA; CISPLATIN-INDUCED NEPHROTOXICITY; CADMIUM-INDUCED HEPATOTOXICITY	A simple statistical method is described to test whether data are consistent with minimum statistical variability expected in a biological experiment. The method is applied to data presented in data tables in a subset of 84 articles among more than 200 published by 3 investigators in a small medical biochemistry department at a major university in India and to 29 "control" articles selected by key word PubMed searches. Major conclusions include: 1) unusual clustering of coefficients of variation (CVs) was observed for data from the majority of articles analyzed that were published by the 3 investigators from 2000-2007; unusual clustering was not observed for data from any of their articles examined that were published between 1992 and 1999; and 2) among a group of 29 control articles retrieved by PubMed key word, title, or title/abstract searches, unusually clustered CVs were observed in 3 articles. Two of these articles were coauthored by 1 of the 3 investigators, and 1 was from the same university but a different department. We are unable to offer a statistical or biological explanation for the unusual clustering observed.-Hudes, M. L., McCann, J. C., Ames, B. N. Unusual clustering of coefficients of variation in published articles from a medical biochemistry department in India. FASEB J. 23, 689-703 (2009)	[Hudes, Mark L.; McCann, Joyce C.; Ames, Bruce N.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	McCann, JC (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	jmccann@chori.org; bames@chori.org						Albano CB, 2002, NEUROCHEM RES, V27, P359, DOI 10.1023/A:1015591628503; Amudha G, 2007, INT IMMUNOPHARMACOL, V7, P1442, DOI 10.1016/j.intimp.2007.06.010; Amudha G, 2007, EUR J PHARMACOL, V571, P209, DOI 10.1016/j.ejphar.2007.05.047; Amudha G, 2007, MOL CELL BIOCHEM, V301, P165, DOI 10.1007/s11010-006-9408-z; Anuradha B, 1999, J APPL TOXICOL, V19, P405, DOI 10.1002/(SICI)1099-1263(199911/12)19:6<405::AID-JAT598>3.0.CO;2-O; Arivazhagan P, 2004, ANN NY ACAD SCI, V1019, P350, DOI 10.1196/annals.1297.060; Arivazhagan P, 2003, J GERONTOL A-BIOL, V58, P788, DOI 10.1093/gerona/58.9.B788; Arivazhagan P, 2002, EXP GERONTOL, V37, P1489, DOI 10.1016/S0531-5565(02)00122-5; Arivazhagan P, 2001, EXP GERONTOL, V37, P81, DOI 10.1016/S0531-5565(01)00147-4; Arivazhagan P, 2000, PHARMACOL RES, V42, P223, DOI 10.1006/phrs.2000.0680; Arivazhagan P, 2000, PHARMACOL RES, V42, P219, DOI 10.1006/phrs.2000.0679; Augustyniak A, 2005, NUTRITION, V21, P925, DOI 10.1016/j.nut.2005.01.006; BABU E, 1995, MOL CELL BIOCHEM, V144, P7, DOI 10.1007/BF00926734; Babu E, 1999, RENAL FAILURE, V21, P209, DOI 10.3109/08860229909066985; Balu M, 2006, BRAIN RES BULL, V68, P469, DOI 10.1016/j.brainresbull.2005.10.007; Balu M, 2005, NEUROSCI LETT, V383, P295, DOI 10.1016/j.neulet.2005.04.042; Banu SM, 2004, HUM EXP TOXICOL, V23, P527, DOI 10.1191/0960327104ht484oa; Chen Q, 2006, J PHARMACOL EXP THER, V319, P1405, DOI 10.1124/jpet.106.110262; Chodon D, 2007, TOXICOL IN VITRO, V21, P887, DOI 10.1016/j.tiv.2007.01.023; Chodon D, 2007, MOL CELL BIOCHEM, V297, P73, DOI 10.1007/s11010-006-9324-2; Coskun S, 2005, MOL CELL BIOCHEM, V280, P135, DOI 10.1007/s11010-005-8421-y; Deepa PR, 2006, INT J CARDIOL, V106, P338, DOI 10.1016/j.ijcard.2005.02.012; Deepa PR, 2003, MOL CELL BIOCHEM, V254, P111, DOI 10.1023/A:1027324318973; EBRAHIM AS, 1995, MOL CELL BIOCHEM, V144, P13, DOI 10.1007/BF00926735; Ebrahim AS, 2001, DRUG CHEM TOXICOL, V24, P429, DOI 10.1081/DCT-100106267; Ebrahim AS, 1996, J APPL TOXICOL, V16, P339, DOI 10.1002/(SICI)1099-1263(199607)16:4<339::AID-JAT352>3.0.CO;2-3; Faine LA, 2006, EXP TOXICOL PATHOL, V57, P221, DOI 10.1016/j.etp.2005.10.001; Geetha T, 1999, MOL CELL BIOCHEM, V201, P83, DOI 10.1023/A:1007056300503; Geetha T, 1998, PHARMACOL RES, V37, P191, DOI 10.1006/phrs.1997.0278; Gupta R, 2006, J APPL TOXICOL, V26, P213, DOI 10.1002/jat.1131; Haripriya D, 2004, BIOGERONTOLOGY, V5, P355, DOI 10.1007/s10522-004-2575-y; Hung CR, 2005, WORLD J GASTROENTERO, V11, P5853, DOI 10.3748/wjg.v11.i37.5853; Jagadeeswaran R, 2000, FITOTERAPIA, V71, P395, DOI 10.1016/S0367-326X(00)00138-6; JAYANTHI S, 1994, PHARMACOL RES, V30, P281, DOI 10.1016/1043-6618(94)80110-X; Josephine A, 2007, MOL NUTR FOOD RES, V51, P1413, DOI 10.1002/mnfr.200700127; Josephine A, 2007, BASIC CLIN PHARMACOL, V101, P9, DOI 10.1111/j.1742-7843.2007.00081.x; Josephine A, 2007, BIOL PHARM BULL, V30, P1254, DOI 10.1248/bpb.30.1254; Josephine A, 2007, ARCH TOXICOL, V81, P371, DOI 10.1007/s00204-006-0151-8; Juliet PAR, 2003, J GERONTOL A-BIOL, V58, P970; Kadirvel R, 2007, HUM EXP TOXICOL, V26, P939, DOI 10.1177/0960327107087909; Kanter M, 2005, BIOL TRACE ELEM RES, V107, P277, DOI 10.1385/BTER:107:3:277; Kerner J, 2001, AM J PHYSIOL-ENDOC M, V281, pE1054; Klepac N, 2006, BIOMED PHARMACOTHER, V60, P32, DOI 10.1016/j.biopha.2005.08.005; Kumaran S, 2005, MOL CELL BIOCHEM, V280, P83, DOI 10.1007/s11010-005-8234-z; Latha RM, 1998, GEN PHARMACOL-VASC S, V31, P601, DOI 10.1016/S0306-3623(98)00049-4; LEHMANN E. L., 2005, TESTING STAT HYPOTHE; Lei YC, 2005, ENVIRON RES, V99, P335, DOI 10.1016/j.envres.2005.03.011; Leichtweis SB, 1996, ACTA PHYSIOL SCAND, V156, P51, DOI 10.1046/j.1365-201X.1996.427148000.x; Lenin M, 2001, PROSTAG LEUKOTR ESS, V65, P265, DOI 10.1054/plef.2001.0324; Liu CZ, 2006, NEUROSCI LETT, V393, P45, DOI 10.1016/j.neulet.2005.09.049; Luczaj W, 2004, J TOXICOL ENV HEAL A, V67, P595, DOI 10.1080/15287390490425579; Malini MM, 1995, JPN J MED SCI BIOL, V48, P211, DOI 10.7883/yoken1952.48.211; Mastrocola R, 2005, J ENDOCRINOL, V187, P37, DOI 10.1677/joe.1.06269; Montilla P, 2006, CLIN NUTR, V25, P146, DOI 10.1016/j.clnu.2005.10.004; Montilla P, 2005, J BIOCHEM MOL BIOL, V38, P539, DOI 10.5483/BMBRep.2005.38.5.539; Mosoni L, 2004, EXP GERONTOL, V39, P203, DOI 10.1016/j.exger.2003.10.014; Murah G, 2007, J GERONTOL A-BIOL, V62, P824, DOI 10.1093/gerona/62.8.824; Murali G, 2008, INT J DEV NEUROSCI, V26, P211, DOI 10.1016/j.ijdevneu.2007.12.004; Muthuswamy AD, 2006, CLIN CHIM ACTA, V368, P84, DOI 10.1016/j.cca.2005.12.010; Muthuvel R, 2006, CLIN CHIM ACTA, V365, P297, DOI 10.1016/j.cca.2005.09.006; Mythili Y, 2007, LIFE SCI, V80, P1993, DOI 10.1016/j.lfs.2007.02.040; Mythili Y, 2004, CHEM-BIOL INTERACT, V151, P13, DOI 10.1016/j.cbi.2004.10.004; Nagaraj M, 2000, J APPL TOXICOL, V20, P413, DOI 10.1002/1099-1263(200009/10)20:5<413::AID-JAT706>3.0.CO;2-Y; NAIK AK, 2005, EUR J PAIN, V10, P573; Ozturk H, 2006, PEDIATR SURG INT, V22, P191, DOI 10.1007/s00383-005-1621-4; Padmavathi R, 2006, COMP BIOCHEM PHYS C, V143, P349, DOI 10.1016/j.cbpc.2006.03.009; Palanivel R, 2002, ANN NY ACAD SCI, V958, P382; Patel MA, 2007, CLIN BIOCHEM, V40, P57, DOI 10.1016/j.clinbiochem.2006.08.014; Payne JA, 2003, AM J PHYSIOL-REG I, V285, pR542, DOI 10.1152/ajpregu.00056.2003; Prahalathan C, 2004, MOL CELL BIOCHEM, V267, P209, DOI 10.1023/B:MCBI.0000049385.13773.23; Pustovrh MC, 2005, FREE RADICAL RES, V39, P1285, DOI 10.1080/10715760500188796; Rajkapoor B, 2006, J ETHNOPHARMACOL, V104, P407, DOI 10.1016/j.jep.2005.08.074; Ramanathan K, 2002, HUM EXP TOXICOL, V21, P675, DOI 10.1191/0960327102ht307oa; Rani PJA, 2001, EXP GERONTOL, V36, P1713, DOI 10.1016/S0531-5565(01)00116-4; Rasool M, 2007, FUND CLIN PHARMACOL, V21, P157, DOI 10.1111/j.1472-8206.2006.00461.x; Sakthivel R, 2007, CLIN CHIM ACTA, V382, P1, DOI 10.1016/j.cca.2007.02.044; Sandhya P, 1997, J APPL TOXICOL, V17, P405; Sangeetha P, 2005, EXP GERONTOL, V40, P820, DOI 10.1016/j.exger.2005.07.008; Saravanan N, 1996, BRIT J UROL, V78, P22, DOI 10.1046/j.1464-410X.1996.00394.x; Saravanan N, 1995, PHARMACOL RES, V32, P165, DOI 10.1016/S1043-6618(05)80010-6; Savitha S, 2007, MECH AGEING DEV, V128, P206, DOI 10.1016/j.mad.2006.11.029; Savitha S, 2005, CLIN CHIM ACTA, V355, P173, DOI 10.1016/j.cccn.2004.12.005; Savitha S, 2007, EUR J PHARMACOL, V574, P61, DOI 10.1016/j.ejphar.2007.07.016; SELVAM GS, 1992, PHARMACOL RES, V26, P385, DOI 10.1016/1043-6618(92)90237-6; Selvendiran K, 2004, CLIN CHIM ACTA, V350, P73, DOI 10.1016/j.cccn.2004.07.004; Selvendiran K, 2003, FITOTERAPIA, V74, P109, DOI 10.1016/S0367-326X(02)00304-0; Senthilnathan P, 2006, CANCER SCI, V97, P658, DOI 10.1111/j.1349-7006.2006.00224.x; Sethumadhavan S, 2006, J GERONTOL A-BIOL, V61, P650, DOI 10.1093/gerona/61.7.650; Sethumadhavan S, 2006, BIOGERONTOLOGY, V7, P101, DOI 10.1007/s10522-006-6497-8; Shimizu MHM, 2004, EXP GERONTOL, V39, P825, DOI 10.1016/j.exger.2004.02.009; Sivaprasad R, 2002, ARCH TOXICOL, V76, P437, DOI 10.1007/s00204-002-0350-x; Striegel-Moore RH, 2006, PREV MED, V42, P223, DOI 10.1016/j.ypmed.2005.11.018; SUBHA K, 1993, PHARMACOL RES, V27, P289, DOI 10.1006/phrs.1993.1029; SUBHA K, 1992, BIOCHEM INT, V27, P1011; Sudhahar V, 2007, MOL CELL BIOCHEM, V295, P189, DOI 10.1007/s11010-006-9288-2; Sudhahar V, 2006, LIFE SCI, V78, P1329, DOI 10.1016/j.lfs.2005.07.011; Sudhahar V, 2007, VASC PHARMACOL, V46, P412, DOI 10.1016/j.vph.2006.12.005; Sudharsan PT, 2006, MOL CELL BIOCHEM, V282, P23, DOI 10.1007/s11010-006-1169-1; Sudharsan PT, 2005, J PHARM PHARMACOL, V57, P1437, DOI 10.1211/jpp.57.11.0009; Suh JH, 2005, REDOX REP, V10, P52, DOI 10.1179/135100005X21624; SUMATHI R, 1993, PHARMACOL RES, V27, P309, DOI 10.1006/phrs.1993.1031; Sumathi R, 1996, JPN J MED SCI BIOL, V49, P39, DOI 10.7883/yoken1952.49.39; Sunitha S, 2001, FITOTERAPIA, V72, P516, DOI 10.1016/S0367-326X(01)00259-3; Tamilselvan J, 2007, FREE RADICAL BIO MED, V43, P1656, DOI 10.1016/j.freeradbiomed.2007.08.028; Tamilselvan J, 2007, REJUV RES, V10, P311, DOI 10.1089/rej.2007.0541; Thangasamy T, 2008, CLIN CHIM ACTA, V389, P19, DOI 10.1016/j.cca.2007.11.013; Thirunavukkarasu C, 2008, MOL CELL BIOCHEM, V310, P129, DOI 10.1007/s11010-007-9673-5; Thirunavukkarasu C, 2005, MOL CELL BIOCHEM, V280, P165, DOI 10.1007/s11010-005-8907-7; Thirunavukkarasu C, 2003, BIOMED PHARMACOTHER, V57, P416, DOI 10.1016/j.biopha.2003.08.023; Thirunavukkarasu C, 2002, CELL BIOCHEM FUNCT, V20, P347, DOI 10.1002/cbf.979; Thirunavukkarasu C, 2001, CELL BIOCHEM FUNCT, V19, P265, DOI 10.1002/cbf.924; Thompson DR, 2007, J PEDIATR-US, V150, P18, DOI 10.1016/j.jpeds.2006.09.039; Varalakshmi P, 2003, MOL CELL BIOCHEM, V248, P35, DOI 10.1023/A:1024141128546; Veena CK, 2007, HUM EXP TOXICOL, V26, P923, DOI 10.1177/0960327107087792; VEENA CK, 2007, CLIN EXP NEPHROL, V11, P196; Veena CK, 2008, EUR J PHARMACOL, V579, P330, DOI 10.1016/j.ejphar.2007.09.044; Veena CK, 2007, J PHARM PHARMACOL, V59, P419, DOI 10.1211/jpp.59.3.0012; Vidya L, 2000, FITOTERAPIA, V71, P535, DOI 10.1016/S0367-326X(00)00192-1; Vidya L, 2002, PHYTOTHER RES, V16, P514, DOI 10.1002/ptr.940	119	9	9	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					689	703		10.1096/fj.08-108910	http://dx.doi.org/10.1096/fj.08-108910			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18940892				2022-12-28	WOS:000265506300004
J	Nakatani, T; Sarraj, B; Ohnishi, M; Densmore, MJ; Taguchi, T; Goetz, R; Mohammadi, M; Lanske, B; Razzaque, MS				Nakatani, Teruyo; Sarraj, Bara; Ohnishi, Mutsuko; Densmore, Michael J.; Taguchi, Takashi; Goetz, Regina; Mohammadi, Moosa; Lanske, Beate; Razzaque, M. Shawkat			In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis	FASEB JOURNAL			English	Article						kidney; vitamin D; PTH; NaPi2a; calcification; survival	MINERAL ION METABOLISM; PARATHYROID-HORMONE; TUMORAL CALCINOSIS; PHYSIOLOGICAL-ROLE; MISSENSE MUTATION; RENAL DAMAGE; MUTANT MICE; COLLAGEN; PROTEIN; COTRANSPORTER	A major breakthrough in systemic phosphate homeostasis regulation was achieved by the demonstration of strikingly similar physical, morphological, and biochemical phenotypes of fibroblast growth factor 23 (Fgf23) and klotho ablated mice, which led to identification of klotho as an Fgf23 signaling cofactor. Here, we generated Fgf23 and klotho double-knockout (Fgf23(-/-)/klotho(-/-)) mice to test the hypothesis whether Fgf23 has a klotho-independent function. Fgf23(-/-)/klotho(-/-) mice are viable and have high serum phosphate levels, similar to Fgf23(-/-) and klotho(-/-) single-knockout mice. In addition, the Fgf23(-/-)/klotho(-/-) mice have increased renal expression of the sodium/phosphate cotransporter NaP(i)2a and of 1-alpha-hydroxylase concomitant with increased serum levels of 1,25-dihydroxyvitamin-D, as also observed in the Fgf23(-/-) and klotho(-/-) mice. Moreover, Fgf23(-/-)/klotho(-/-) mice show soft tissue and vascular calcification, severe muscle wasting, hypogonadism, pulmonary emphysema, distention of intestinal wall, and skin atrophy, all of which are also seen in Fgf23(-/-) and klotho(-/-) mice. Notably, injection of bioactive FGF23 protein into Fgf23(-/-)/klotho(-/-) and klotho(-/-) mice does not lower serum phosphate, whereas in wild-type and Fgf23(-/-) mice, it reduces serum phosphate. Together, these results provide compelling evidence that Fgf23 does not have a klotho-independent role in the regulation of systemic phosphate and vitamin D homeostasis. - Nakatani, T., Sarraj, B., Ohnishi, M., Densmore, M. J., Taguchi, T., Goetz, R., Mohammadi, M., Lanske, B., Razzaque, M. S. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J. 23, 433-441 (2009)	[Nakatani, Teruyo; Ohnishi, Mutsuko; Densmore, Michael J.; Lanske, Beate; Razzaque, M. Shawkat] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; [Sarraj, Bara] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Taguchi, Takashi; Razzaque, M. Shawkat] Nagasaki Univ, Dept Pathol, Sch Biomed Sci, Nagasaki 852, Japan; [Goetz, Regina; Mohammadi, Moosa] NYU, Sch Med, Dept Pharmacol, New York, NY USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; Nagasaki University; New York University	Razzaque, MS (corresponding author), Harvard Univ, Sch Dent Med, Dept Dev Biol, Rm 304,188 Longwood Ave, Boston, MA 02115 USA.	mrazzaque@hms.harvard.edu	Mohammadi, Moosa/ABA-6745-2020; Goetz, Regina/M-2411-2019; kasaei, fahime/T-7197-2018; Razzaque, Mohammed S./K-4282-2019	Mohammadi, Moosa/0000-0003-2434-9437; Goetz, Regina/0000-0003-3681-4703; Lanske, Beate/0000-0003-4638-804X	U.S. National Institutes of Health [R01-DE13686, R01-DK073944, R01-DK077276]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077276, R01DK073944] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Ms. K. Egashira (Department of Pathology, Nagasaki University School of Biomedical Sciences, Japan) for preparing the histology sections. The research work was supported in part by U.S. National Institutes of Health grants R01-DE13686 (to M.M.), R01-DK073944 (to B.L.), and R01-DK077276 (to M.S.R.).	Bai XY, 2004, ENDOCRINOLOGY, V145, P5269, DOI 10.1210/en.2004-0233; Benet-Pages A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034; Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249-06; Ichikawa S, 2007, J CLIN INVEST, V117, P2684, DOI 10.1172/JCI31330; Keusch I, 1998, KIDNEY INT, V54, P1224, DOI 10.1046/j.1523-1755.1998.00115.x; Kirkeby S, 2005, J IMMUNOL METHODS, V301, P102, DOI 10.1016/j.jim.2005.04.006; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Lanske B, 2007, CURR OPIN NEPHROL HY, V16, P311, DOI 10.1097/MNH.0b013e3281c55eca; Lanske B, 2007, AGEING RES REV, V6, P73, DOI 10.1016/j.arr.2007.02.002; Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91; Liu D, 2008, AM J NEPHROL, V28, P555, DOI 10.1159/000115290; Liu X, 2006, DRUG METAB REV, V38, P49; Memon F, 2008, KIDNEY INT, V74, P566, DOI 10.1038/ki.2008.218; Miyamoto KI, 2007, AM J NEPHROL, V27, P503, DOI 10.1159/000107069; Nabeshima Y, 2008, AM J NEPHROL, V28, P455, DOI 10.1159/000112824; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; Razzaque MS, 2008, NEPHROL DIAL TRANSPL, V23, P459, DOI 10.1093/ndt/gfm702; Razzaque MS, 2007, NAT CLIN PRACT ENDOC, V3, P788, DOI 10.1038/ncpendmet0667; Razzaque MS, 2007, AGEING RES REV, V6, P211, DOI 10.1016/j.arr.2007.06.001; Razzaque MS, 2007, J ENDOCRINOL, V194, P1, DOI 10.1677/JOE-07-0095; Razzaque MS, 2006, TRENDS MOL MED, V12, P298, DOI 10.1016/j.molmed.2006.05.002; Razzaque Mohammed S., 2002, Medical Electron Microscopy, V35, P68, DOI 10.1007/s007950200009; Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05-5432fje; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; Razzaque MS, 1997, J PATHOL, V183, P24; Razzaque MS, 1998, MODERN PATHOL, V11, P1183; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Sitara D, 2006, AM J PATHOL, V169, P2161, DOI 10.2353/ajpath.2006.060329; Taguchi T, 2007, TRENDS MOL MED, V13, P45, DOI 10.1016/j.molmed.2006.12.001; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Wang H, 2008, J BONE MINER RES, V23, P939, DOI 10.1359/JBMR.080220; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yamazaki Y, 2008, J BONE MINER RES, V23, P1509, DOI 10.1359/JBMR.080417; Yu XJ, 2005, ENDOCRINOLOGY, V146, P4647, DOI 10.1210/en.2005-0670; Yu XJ, 2005, CYTOKINE GROWTH F R, V16, P221, DOI 10.1016/j.cytogfr.2005.01.002; Zha Y, 2008, AM J NEPHROL, V28, P755, DOI 10.1159/000128607; Zha Y, 2006, ENDOCRINOLOGY, V147, P5690, DOI 10.1210/en.2006-0302	38	186	209	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					433	441		10.1096/fj.08-114397	http://dx.doi.org/10.1096/fj.08-114397			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18835926	Green Published			2022-12-28	WOS:000262892900015
J	Reutershan, J; Vollmer, I; Stark, S; Wagner, R; Ngamsri, KC; Eltzschig, HK				Reutershan, Joerg; Vollmer, Irene; Stark, Stefanie; Wagner, Rosalyn; Ngamsri, Kristian-Christos; Eltzschig, Holger K.			Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs	FASEB JOURNAL			English	Article						acute lung injury; ARDS; neutrophil; PMN; migration; chemotaxis	BRONCHOALVEOLAR LAVAGE FLUID; ISCHEMIA-REPERFUSION INJURY; DEAMINASE-DEFICIENT MICE; INDUCIBLE FACTOR-I; ECTO-5'-NUCLEOTIDASE CD73; TISSUE-DAMAGE; NUCLEOTIDE PHOSPHOHYDROLYSIS; PULMONARY INFLAMMATION; RECEPTOR PROTECTS; HYPOXIA	Extracellular adenosine has been implicated as anti-inflammatory signaling molecule during acute lung injury (ALI). The main source of extracellular adenosine stems from a coordinated two-step enzymatic conversion of precursor nucleotides via the ectoapyrase (CD39) and the ecto-5'-nucleotidase (CD73). In the present study, we hypothesized a critical role of CD39 and CD73 in mediating pulmonary neutrophil (PMN) transmigration during lipopolysaccharide (LPS)-induced lung injury. Initial studies revealed that pulmonary CD39 and CD73 transcript levels were elevated following LPS exposure in vivo. Moreover, LPS-induced accumulation of PMN into the lungs was enhanced in cd39(-/-) or cd73(-/-) mice, particularly into the interstitial and intra-alveolar compartment. Such increases in PMN trafficking were accompanied by corresponding changes in alveolar-capillary leakage. Similarly, inhibition of extracellular nucleotide phosphohydrolysis with the nonspecific ecto-nucleoside-triphosphate-diphosphohydrolases inhibitor POM-1 confirmed increased pulmonary PMN accumulation in wild-type, but not in gene-targeted mice for cd39 or cd73. Finally, treatment with apyrase or nucleotidase was associated with attenuated pulmonary neutrophil accumulation and pulmonary edema during LPS-induced lung injury. Taken together, these data reveal a previously unrecognized role for CD39 and CD73 in attenuating PMN trafficking into the lungs during LPS-induced lung injury and suggest treatment with their soluble compounds as a therapeutic strategy. - Reutershan, J., Vollmer, I., Stark, S., Wagner, R., Ngamsri, K.-C., Eltzschig, H. K. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 23, 473-482 (2009)	[Reutershan, Joerg; Vollmer, Irene; Stark, Stefanie; Wagner, Rosalyn; Ngamsri, Kristian-Christos; Eltzschig, Holger K.] Univ Tubingen, Dept Anesthesiol & Intens Care Med, Tubingen, Germany; [Eltzschig, Holger K.] Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Dept Anesthesiol & Perioperat Med, Denver, CO USA	Eberhard Karls University of Tubingen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Eltzschig, HK (corresponding author), Univ Colorado Denver, Mucosal Inflammat Program, Dept Anesthesiol & Perioperat Med, 12700 E 19th Ave,Mailstop B112,Res Complex 2,Room, Aurora, CO 80045 USA.	holger.eltzschig@ucdenver.edu			German Research Foundation [RE 1683/3-1]; Foundation for Anesthesia Education and Research	German Research Foundation(German Research Foundation (DFG)); Foundation for Anesthesia Education and Research	We thank Linda F. Thompson and Simon C. Robson for kindly providing us with gene-targeted mice, and Christa E. Mueller for pharmacological compounds. This study was supported by a German Research Foundation grant (RE 1683/3-1 to J.R.) and a Foundation for Anesthesia Education and Research grant to H.K.E.	Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 2003, TRENDS PHARMACOL SCI, V24, P66, DOI 10.1016/S0165-6147(02)00045-7; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; Day YJ, 2004, AM J PHYSIOL-GASTR L, V286, pG285, DOI 10.1152/ajpgi.00348.2003; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; Eckle T, 2008, AM J PHYSIOL-LUNG C, V295, pL718, DOI 10.1152/ajplung.90298.2008; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Eckle T, 2008, CIRCULATION, V118, P166, DOI 10.1161/CIRCULATIONAHA.107.758516; Eckle T, 2008, BLOOD, V111, P2024, DOI 10.1182/blood-2007-10-117044; Eckle T, 2007, J IMMUNOL, V178, P8127, DOI 10.4049/jimmunol.178.12.8127; Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697; Eltzschig HK, 2004, BLOOD, V104, P3986, DOI 10.1182/blood-2004-06-2066; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Eltzschig HK, 2008, TRENDS CARDIOVAS MED, V18, P103, DOI 10.1016/j.tcm.2008.01.006; Eltzschig HK, 2006, CIRC RES, V99, P1100, DOI 10.1161/01.RES.0000250174.31269.70; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009; Fozard JR, 1999, PULM PHARMACOL THER, V12, P111, DOI 10.1006/pupt.1999.0191; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; GREEN TP, 1988, J LAB CLIN MED, V111, P173; Grenz A, 2008, PLOS MED, V5, P968, DOI 10.1371/journal.pmed.0050137; Grenz A, 2007, J AM SOC NEPHROL, V18, P833, DOI 10.1681/ASN.2006101141; Grenz A, 2007, FASEB J, V21, P2863, DOI 10.1096/fj.06-7947com; Hart ML, 2008, FASEB J, V22, P2784, DOI 10.1096/fj.07-103911; Hart ML, 2008, ARTERIOSCL THROM VAS, V28, P1477, DOI 10.1161/ATVBAHA.108.169219; Huszar E, 2002, EUR RESPIR J, V20, P1393, DOI 10.1183/09031936.02.00005002; Kohler D, 2007, CIRCULATION, V116, P1784, DOI 10.1161/CIRCULATIONAHA.107.690180; Linden J, 2005, MOL PHARMACOL, V67, P1385, DOI 10.1124/mol.105.011783; Martin TR, 2002, J CLIN INVEST, V110, P1603, DOI 10.1172/JCI200217302; Mills JH, 2008, P NATL ACAD SCI USA, V105, P9325, DOI 10.1073/pnas.0711175105; Muller CE, 2006, BIOORG MED CHEM LETT, V16, P5943, DOI 10.1016/j.bmcl.2006.09.003; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Olson TS, 2002, AM J PHYSIOL-REG I, V282, pR1245, DOI 10.1152/ajpregu.00540.2001; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reutershan J, 2005, AM J PHYSIOL-LUNG C, V289, pL807, DOI 10.1152/ajplung.00477.2004; Reutershan J, 2006, J CLIN INVEST, V116, P695, DOI 10.1172/JCI27009; Reutershan J, 2006, ANESTHESIOLOGY, V104, P511, DOI 10.1097/00000542-200603000-00019; Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254; Reutershan J, 2007, AM J RESP CRIT CARE, V175, P1027, DOI 10.1164/rccm.200612-1822OC; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Sun CX, 2005, J CLIN INVEST, V115, P35, DOI 10.1172/JCI200522656; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Van Linden A, 2007, EXPERT OPIN BIOL TH, V7, P1437, DOI 10.1517/14712598.7.9.1437; Volmer JB, 2006, J IMMUNOL, V176, P4449, DOI 10.4049/jimmunol.176.7.4449; Wang LF, 2002, AM J RESP CRIT CARE, V165, P1634, DOI 10.1164/rccm.2110017; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Yang D, 2008, P NATL ACAD SCI USA, V105, P792, DOI 10.1073/pnas.0705563105; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933; Yang ZQ, 2005, CIRCULATION, V111, P2190, DOI 10.1161/01.CIR.0000163586.62253.A5	59	160	170	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					473	482		10.1096/fj.08-119701	http://dx.doi.org/10.1096/fj.08-119701			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18838482				2022-12-28	WOS:000262892900019
J	Cai, ZP; Shen, ZY; Van Kaer, L; Becker, LC				Cai, Zheqing P.; Shen, Zhenyun; Van Kaer, Luc; Becker, Lewis C.			Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency	FASEB JOURNAL			English	Article						ubiquitin-proteasome system; reperfusion injury; ubiquitin; phosphatase and tensin homologue deleted on chromosome 10 PTEN; Akt	TUMOR-SUPPRESSOR PTEN; PROTEIN-DEGRADATION; PROTEASOME SYSTEM; 26S PROTEASOME; UP-REGULATION; KINASE; LMP2; PHYSIOLOGY; INHIBITION; INTERFERON	The ubiquitin-proteasome system plays an important role in many cellular processes through degradation of specific proteins. Low molecular mass polypeptide 2 (LMP-2 or beta(1i)) is one important subunit of the immunoproteasome. Ischemic preconditioning (IPC) activates cell signaling pathways and generates cardioprotection but has not been linked to LMP-2 function previously. LMP-2 knockout mice (C57BL6 background) and wild-type C57BL6 mice were subjected to 30 min of ischemia (I-30) and 120 min of reperfusion (R-120) with or without preceding IPC (10 min of infusion and 5 min of reperfusion). IPC significantly increased left ventricular developed pressure and decreased infarct size in wild-type mice, but this protective effect of IPC was lost in LMP-2 knockout mice. IPC-mediated degradation of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and activation of the downstream protein kinase Akt were impaired in LMP-2 knockout hearts. The impairment of PTEN degradation was associated with defective immunoproteasomes and decreased proteolytic activities. When LMP-2 knockout mice were pretreated with the PTEN inhibitor bpV(HOpic), cardiac function was significantly improved, and myocardial infarct size was significantly reduced after I-30/R-120. In conclusion, LMP-2 is required for normal proteasomal function and IPC induction in the heart. Its action may be related to PTEN protein degradation.	[Cai, Zheqing P.; Becker, Lewis C.] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; [Shen, Zhenyun] Peking Univ, Hosp 3, Dept Thorac Surg, Beijing 100871, Peoples R China; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37212 USA	Johns Hopkins University; Peking University; Vanderbilt University	Cai, ZP (corresponding author), 720 Rutland Ave,Ross 333, Baltimore, MD 21205 USA.	czheqin1@jhmi.edu	Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309	National Heart, Lung, and Blood Institute, National Institutes of Health [P01-HL65608]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. Public Health Service grant P01-HL65608 from the National Heart, Lung, and Blood Institute, National Institutes of Health.	Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Barton LF, 2002, J IMMUNOL, V169, P3046, DOI 10.4049/jimmunol.169.6.3046; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Cai ZQ, 2005, CIRC RES, V97, P1351, DOI 10.1161/01.RES.0000195656.52760.30; Callahan MK, 2006, J IMMUNOL, V177, P8393, DOI 10.4049/jimmunol.177.12.8393; Depre C, 2006, CIRCULATION, V114, P1821, DOI 10.1161/CIRCULATIONAHA.106.637827; Ding QX, 2006, ANTIOXID REDOX SIGN, V8, P130, DOI 10.1089/ars.2006.8.130; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; FRENTZEL S, 1993, EUR J BIOCHEM, V216, P119, DOI 10.1111/j.1432-1033.1993.tb18123.x; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Gomes AV, 2006, ANTIOXID REDOX SIGN, V8, P1677, DOI 10.1089/ars.2006.8.1677; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Huang SJ, 2008, AM J PHYSIOL-HEART C, V294, pH1298, DOI 10.1152/ajpheart.00765.2007; Kotamraju S, 2006, FREE RADICAL BIO MED, V40, P1034, DOI 10.1016/j.freeradbiomed.2005.10.052; Liu C, 2005, NEUROSCIENCE, V134, P69, DOI 10.1016/j.neuroscience.2005.03.036; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Martin S, 2004, NEUROSCI LETT, V357, P76, DOI 10.1016/j.neulet.2003.10.085; Meller R, 2006, J BIOL CHEM, V281, P7429, DOI 10.1074/jbc.M512138200; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Mocanu MM, 2007, BRIT J PHARMACOL, V150, P833, DOI 10.1038/sj.bjp.0707155; Murphy E, 2004, CIRC RES, V94, P7, DOI 10.1161/01.RES.0000108082.76667.F4; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Powell SR, 2006, AM J PHYSIOL-HEART C, V291, pH1, DOI 10.1152/ajpheart.00062.2006; Powell SR, 2005, ANTIOXID REDOX SIGN, V7, P538, DOI 10.1089/ars.2005.7.538; Pradillo JM, 2005, J CEREBR BLOOD F MET, V25, P193, DOI 10.1038/sj.jcbfm.9600019; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Schmidt M, 1997, MOL BIOL REP, V24, P103, DOI 10.1023/A:1006826725056; Schmidt M, 1999, J MOL BIOL, V288, P117, DOI 10.1006/jmbi.1999.2660; Schwartzbauer G, 2001, J BIOL CHEM, V276, P35786, DOI 10.1074/jbc.M102479200; Stansfield WE, 2008, AM J PHYSIOL-HEART C, V294, pH645, DOI 10.1152/ajpheart.00196.2007; Strohm C, 2000, J CARDIOVASC PHARM, V36, P218, DOI 10.1097/00005344-200008000-00012; Tong HY, 2000, CIRC RES, V87, P309, DOI 10.1161/01.RES.87.4.309; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; Wang HX, 2006, J CELL PHYSIOL, V206, P616, DOI 10.1002/jcp.20508; Willis MS, 2006, J MOL CELL CARDIOL, V41, P567, DOI 10.1016/j.yjmcc.2006.07.015; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306; Zong C, 2006, CIRC RES, V99, P372, DOI 10.1161/01.RES.0000237389.40000.02	44	47	53	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4248	4257		10.1096/fj.08-105940	http://dx.doi.org/10.1096/fj.08-105940			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18728217	Green Published			2022-12-28	WOS:000261254800024
J	Senf, SM; Dodd, SL; McClung, JM; Judge, AR				Senf, Sarah M.; Dodd, Stephen L.; McClung, Joseph M.; Judge, Andrew R.			Hsp70 overexpression inhibits NF-kappa B and Foxo3a transcriptional activities and prevents skeletal muscle atrophy	FASEB JOURNAL			English	Article						atrogin-1/MAFbx; MuRF1; immobilization	UBIQUITIN LIGASES; OXIDATIVE STRESS; PROTEIN; EXPRESSION; ACTIVATION; MASS; DEGRADATION; ATROGIN-1; PATHWAY; ALPHA	Heat shock protein 70 (Hsp70) is a highly conserved and ubiquitous protein that is reported to provide cytoprotection in various cell types and tissues. However, the importance of Hsp70 expression during skeletal muscle atrophy, when Hsp70 levels are significantly decreased, is not known. The current study aimed to determine whether plasmid-mediated overexpression of Hsp70, in the soleus muscle of rats, was sufficient to regulate specific atrophy signaling pathways and attenuate skeletal muscle disuse atrophy. We found that Hsp70 overexpression prevented disuse muscle fiber atrophy and inhibited the increased promoter activities of atrogin-1 and MuRF1. Importantly, the transcriptional activities of Foxo3a and NF-kappa B, which are implicated in the regulation of atrogin-1 and MuRF1, were abolished by Hsp70. These data suggest that Hsp70 may regulate key atrophy genes through inhibiting Foxo3a and NF-kappa B activities during disuse. Indeed, we show that specific inhibition of Foxo3a prevented the increases in both atrogin-1 and MuRF1 promoter activities during disuse. However, inhibition of NF-kappa B did not affect the activation of either promoter, suggesting its requirement for disuse atrophy is through its regulation of other atrophy genes. We conclude that overexpression of Hsp70 is sufficient to inhibit key atrophy signaling pathways and prevent skeletal muscle atrophy.-Senf, S. M., Dodd, S. L., McClung, J. M., Judge, A. R. Hsp70 overexpression inhibits NF-kappa B and Foxo3a transcriptional activities and prevents skeletal muscle atrophy. FASEB J. 22, 3836-3845 (2008)	[Senf, Sarah M.; Dodd, Stephen L.; McClung, Joseph M.; Judge, Andrew R.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Judge, AR (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, 25 Stadium Rd, Gainesville, FL 32611 USA.	ajudge@hhp.ufl.edu		Judge, Sarah/0000-0002-3974-0247	NIAMS NIH HHS [R03 AR056418] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR056418] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahtikoski AM, 2003, ACTA PHYSIOL SCAND, V177, P473, DOI 10.1046/j.1365-201X.2003.01061.x; Alzghoul MB, 2004, FASEB J, V18, P221, DOI 10.1096/fj.03-0293fje; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BOOTH FW, 1973, J APPL PHYSIOL, V34, P404, DOI 10.1152/jappl.1973.34.3.404; Broome CS, 2006, FASEB J, V20, P1549, DOI 10.1096/fj.05-4935fje; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cao PR, 2005, INT J BIOCHEM CELL B, V37, P2088, DOI 10.1016/j.biocel.2004.11.010; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Costelli P, 2003, CURR OPIN CLIN NUTR, V6, P407, DOI 10.1097/01.mco.0000078984.18774.02; Dehoux M, 2007, AM J PHYSIOL-ENDOC M, V292, pE145, DOI 10.1152/ajpendo.00085.2006; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Giresi PG, 2005, PHYSIOL GENOMICS, V21, P253, DOI 10.1152/physiolgenomics.00249.2004; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guzhova IV, 1997, CELL STRESS CHAPERON, V2, P132, DOI 10.1379/1466-1268(1997)002<0132:MSPHIW>2.3.CO;2; Hunter RB, 2004, J CLIN INVEST, V114, P1504, DOI 10.1172/JCI200421696; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Judge AR, 2007, AM J PHYSIOL-CELL PH, V292, pC372, DOI 10.1152/ajpcell.00293.2006; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kawamura I, 1999, GENE THER, V6, P91, DOI 10.1038/sj.gt.3300819; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Koncarevic A, 2007, FASEB J, V21, P427, DOI 10.1096/fj.06-6665com; Krawiec BJ, 2005, AM J PHYSIOL-ENDOC M, V289, pE969, DOI 10.1152/ajpendo.00126.2005; KU Z, 1995, AM J PHYSIOL-CELL PH, V268, pC1369, DOI 10.1152/ajpcell.1995.268.6.C1369; Lawler JM, 2006, MUSCLE NERVE, V33, P200, DOI 10.1002/mus.20454; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; Liu YF, 2006, FRONT BIOSCI-LANDMRK, V11, P2802, DOI 10.2741/2011; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Milne KJ, 2002, J APPL PHYSIOL, V93, P561, DOI 10.1152/japplphysiol.00528.2001; Mitchell-Felton H, 1999, AM J PHYSIOL-CELL PH, V277, pC1269, DOI 10.1152/ajpcell.1999.277.6.C1269; Mourkioti F, 2006, J CLIN INVEST, V116, P2945, DOI 10.1172/JCI28721; Naito H, 2000, J APPL PHYSIOL, V88, P359, DOI 10.1152/jappl.2000.88.1.359; Oishi Y, 2003, JPN J PHYSIOL, V53, P281, DOI 10.2170/jjphysiol.53.281; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Rana ZA, 2004, ACTA PHYSIOL SCAND, V181, P233, DOI 10.1111/j.1365-201X.2004.01282.x; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Selsby JT, 2007, J APPL PHYSIOL, V102, P1702, DOI 10.1152/japplphysiol.00722.2006; Selsby JT, 2005, AM J PHYSIOL-REG I, V289, pR134, DOI 10.1152/ajpregu.00497.2004; Stevenson EJ, 2003, J PHYSIOL-LONDON, V551, P33, DOI 10.1113/jphysiol.2003.044701; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; THOMASON DB, 1989, AM J PHYSIOL, V257, pR300, DOI 10.1152/ajpregu.1989.257.2.R300; Thompson HS, 2001, ACTA PHYSIOL SCAND, V171, P187, DOI 10.1046/j.1365-201x.2001.00795.x; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; ZHENG Z, 2007, J CEREB BLOOD FLOW M	54	218	227	3	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3836	3845		10.1096/fj.08-110163	http://dx.doi.org/10.1096/fj.08-110163			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18644837	Green Published			2022-12-28	WOS:000260503000012
J	Roepke, TK; Kontogeorgis, A; Ovanez, C; Xu, XH; Young, JB; Purtell, K; Goldstein, PA; Christini, DJ; Peters, NS; Akar, FG; Gutstein, DE; Lerner, DJ; Abbott, GW				Roepke, Torsten K.; Kontogeorgis, Andrianos; Ovanez, Christopher; Xu, Xianghua; Young, Jeffrey B.; Purtell, Kerry; Goldstein, Peter A.; Christini, David J.; Peters, Nicholas S.; Akar, Fadi G.; Gutstein, David E.; Lerner, Daniel J.; Abbott, Geoffrey W.			Targeted deletion of kcne2 impairs ventricular repolarization via disruption of I-K,I-slow1 and I-to,I-f	FASEB JOURNAL			English	Article						cardiac arrhythmia; Kv1.5; Kv4.2; long QT syndrome; MiRP1; potassium channel	LONG-QT SYNDROME; TRANSIENT OUTWARD CURRENT; KV4 ALPHA-SUBUNIT; INDUCED CARDIAC-ARRHYTHMIA; GATED POTASSIUM CHANNEL; MINK-RELATED PEPTIDE-1; RECTIFIER K+ CURRENT; MOLECULAR-BASIS; CAENORHABDITIS-ELEGANS; HEART DEVELOPMENT	Mutations in human KCNE2, which encodes the MiRP1 potassium channel ancillary subunit, associate with long QT syndrome (LQTS), a defect in ventricular repolarization. The precise cardiac role of MiRP1 remains controversial, in part, because it has marked functional promiscuity in vitro. Here, we disrupted the murine kcne2 gene to define the role of MiRP1 in murine ventricles. kcne2 disruption prolonged ventricular action potential duration (APD), suggestive of reduced repolarization capacity. Accordingly, kcne2 (-/-) ventricles exhibited a 50% reduction in I-K,I-slow1, generated by Kv1.5-a previously unknown partner for MiRP1. I-to,I-f, generated by Kv4 alpha subunits, was also diminished, by similar to 25%. Ventricular MiRP1 protein coimmunoprecipitated with native Kv1.5 and Kv4.2 but not Kv1.4 or Kv4.3. Unexpectedly, kcne2 (-/-) ventricular membrane fractions exhibited 50% less mature Kv1.5 protein than wild type, and disruption of Kv1.5 trafficking to the intercalated discs. Consistent with the reduction in ventricular K+ currents and prolonged ventricular APD, kcne2 deletion lengthened the QT(c) under sevoflurane anesthesia. Thus, targeted disruption of kcne2 has revealed a novel cardiac partner for MiRP1, a novel role for MiRPs in alpha subunit targeting in vivo, and a role for MiRP1 in murine ventricular repolarization with parallels to that proposed for the human heart.	[Roepke, Torsten K.; Xu, Xianghua; Young, Jeffrey B.; Purtell, Kerry; Christini, David J.; Abbott, Geoffrey W.] Cornell Univ, Weill Med Coll, Greenberg Div Cardiol, New York, NY 10065 USA; [Roepke, Torsten K.; Xu, Xianghua; Young, Jeffrey B.; Purtell, Kerry; Abbott, Geoffrey W.] Cornell Univ, Dept Pharmacol, New York, NY 10065 USA; [Goldstein, Peter A.] Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10065 USA; [Kontogeorgis, Andrianos; Peters, Nicholas S.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Cardiol, London, England; [Kontogeorgis, Andrianos; Gutstein, David E.] NYU, Sch Med, Dept Med, Div Cardiol, New York, NY USA; [Gutstein, David E.] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; [Ovanez, Christopher; Akar, Fadi G.] Mt Sinai Sch Med, Cardiovasc Res Ctr, New York, NY USA; [Lerner, Daniel J.] FoxHollow Technol, Redwood City, CA USA	Cornell University; Cornell University; Cornell University; Imperial College London; New York University; New York University; Icahn School of Medicine at Mount Sinai	Abbott, GW (corresponding author), Cornell Univ, Weill Med Coll, Greenberg Div Cardiol, Starr 463,1300 York Ave, New York, NY 10065 USA.	gwa200@med.cornell.edu		Ovanez, Christopher/0000-0001-9175-1966; Christini, David/0000-0003-0852-2922; Abbott, Geoffrey/0000-0003-4552-496X	National Institutes of Health [R01 HL079275]; LAVA [HL081336]; American Heart Association [0830126N]; British Heart Foundation [RG/05/009]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081336, R01HL079275] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); LAVA; American Heart Association(American Heart Association); British Heart Foundation(British Heart Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Financial support was provided by the National Institutes of Health (R01 HL079275, LAVA; HL081336. D.E.G.), the American Heart Association (grant-in-aid, G.W.A., D.E.G.; 0830126N, F.G.A), and the British Heart Foundation (RG/05/009, N.S.P.). We are grateful for advice and technical assistance from Dr. Krista La Perle, Director of the Genetically Engineered Mouse Phenotyping Service Facility at Sloan-Kettering Institute; Leona Cohen-Gould. Director of the Electron Microscopy and Histology Core Facility at Weill Cornell Medical College; the Molecular Cytology Core Facility of of Memorial Sloan Kettering Cancer Center; and Dr. David Wilkes.	Abbott GW, 2007, J ELECTROCARDIOL, V40, pS42, DOI 10.1016/j.jelectrocard.2007.05.021; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Anantharam A, 2003, J PHARMACOL EXP THER, V307, P831, DOI 10.1124/jpet.103.054569; Anantharam A, 2003, J BIOL CHEM, V278, P11739, DOI 10.1074/jbc.M212751200; Appleton GO, 2004, J INTERV CARD ELECTR, V11, P5, DOI 10.1023/B:JICE.0000035922.14870.56; Babij P, 1998, CIRC RES, V83, P668, DOI 10.1161/01.RES.83.6.668; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Brunner M, 2001, AM J PHYSIOL-HEART C, V281, pH1201, DOI 10.1152/ajpheart.2001.281.3.H1201; Chun KRJ, 2004, EXP MOL MED, V36, P367, DOI 10.1038/emm.2004.48; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Deschenes I, 2002, FEBS LETT, V528, P183, DOI 10.1016/S0014-5793(02)03296-9; Folco EJ, 2004, AM J PHYSIOL-HEART C, V287, pH681, DOI 10.1152/ajpheart.00152.2004; Franco D, 2001, CARDIOVASC RES, V52, P65, DOI 10.1016/S0008-6363(01)00349-2; Guo WN, 2005, CIRC RES, V97, P1342, DOI 10.1161/01.RES.0000196559.63223.aa; Guo WN, 1999, J PHYSIOL-LONDON, V521, P587, DOI 10.1111/j.1469-7793.1999.00587.x; Guo WN, 2000, CIRC RES, V87, P73, DOI 10.1161/01.RES.87.1.73; Gutstein DE, 2005, AM J PHYSIOL-HEART C, V289, pH1091, DOI 10.1152/ajpheart.00095.2005; Gutstein DE, 2003, AM J PHYSIOL-HEART C, V285, pH1091, DOI 10.1152/ajpheart.00100.2003; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; Jiang M, 2004, CIRCULATION, V109, P1783, DOI 10.1161/01.CIR.0000124225.43852.50; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; Kang JS, 2006, ANESTHESIOLOGY, V104, P1015, DOI 10.1097/00000542-200605000-00018; Kobayashi S, 2001, EUR J PHARMACOL, V430, P149, DOI 10.1016/S0014-2999(01)01381-4; Kodirov SA, 2004, AM J PHYSIOL-HEART C, V286, pH368, DOI 10.1152/ajpheart.00303.2003; Kuenszberg E, 2000, EUR J ANAESTH, V17, P662, DOI 10.1046/j.1365-2346.2000.00739.x; Kuryshev YA, 2001, AM J PHYSIOL-CELL PH, V281, pC290, DOI 10.1152/ajpcell.2001.281.1.C290; Lewis A, 2004, J BIOL CHEM, V279, P7884, DOI 10.1074/jbc.M310501200; Li HL, 2004, AM J PHYSIOL-HEART C, V286, pH319, DOI 10.1152/ajpheart.00665.2003; Liu Jie, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P1754; London B, 2001, CIRC RES, V88, P940, DOI 10.1161/hh0901.090929; London B, 1998, P NATL ACAD SCI USA, V95, P2926, DOI 10.1073/pnas.95.6.2926; Lundquist Andrew L, 2005, J Mol Cell Cardiol, V38, P277, DOI 10.1016/j.yjmcc.2004.11.012; Matsuda T, 2001, LIFE SCI, V68, P2017, DOI 10.1016/S0024-3205(01)01003-7; MAYS DJ, 1995, J CLIN INVEST, V96, P282, DOI 10.1172/JCI118032; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Mitchell GF, 1998, AM J PHYSIOL-HEART C, V274, pH747, DOI 10.1152/ajpheart.1998.274.3.H747; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Murata M, 2001, AM J PHYSIOL-HEART C, V281, pH2575, DOI 10.1152/ajpheart.2001.281.6.H2575; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Park KH, 2003, FASEB J, V17, DOI 10.1096/fj.03-0577fje; Park KH, 2007, J BIOL CHEM, V282, P19799, DOI 10.1074/jbc.M701625200; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; Pourrier M, 2003, CIRC RES, V93, P189, DOI 10.1161/01.RES.0000084851.60947.B5; Qu JH, 2004, J BIOL CHEM, V279, P43497, DOI 10.1074/jbc.M405018200; Radicke S, 2006, CARDIOVASC RES, V71, P695, DOI 10.1016/j.cardiores.2006.06.017; Reymond A, 2002, NATURE, V420, P582, DOI 10.1038/nature01178; Roepke TK, 2006, J BIOL CHEM, V281, P23740, DOI 10.1074/jbc.M604155200; Salama G, 2007, J PHYSIOL-LONDON, V578, P43, DOI 10.1113/jphysiol.2006.118745; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Veugelers M, 2004, P NATL ACAD SCI USA, V101, P14222, DOI 10.1073/pnas.0405535101; WANG ZG, 1993, CIRC RES, V73, P1061, DOI 10.1161/01.RES.73.6.1061; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Wickenden AD, 1999, CIRC RES, V85, P1067; Wickenden AD, 1999, AM J PHYSIOL-HEART C, V276, pH1599, DOI 10.1152/ajpheart.1999.276.5.H1599; Wu DM, 2006, HEART RHYTHM, V3, P1469, DOI 10.1016/j.hrthm.2006.08.019; Xu HD, 1999, J GEN PHYSIOL, V113, P661, DOI 10.1085/jgp.113.5.661; Xu HD, 1999, J PHYSIOL-LONDON, V519, P11, DOI 10.1111/j.1469-7793.1999.0011o.x; Yang YQ, 2004, AM J HUM GENET, V75, P899, DOI 10.1086/425342; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zaritsky JJ, 2001, J PHYSIOL-LONDON, V533, P697, DOI 10.1111/j.1469-7793.2001.t01-1-00697.x; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839; Zhu XR, 1999, RECEPTOR CHANNEL, V6, P387	69	83	85	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3648	3660		10.1096/fj.08-110171	http://dx.doi.org/10.1096/fj.08-110171			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18603586	Green Published			2022-12-28	WOS:000259642600026
J	Smith, EL; Schuchman, EH				Smith, Eric L.; Schuchman, Edward H.			The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases	FASEB JOURNAL			English	Review						ceramide; human pathology; lysosomal enzyme	NIEMANN-PICK-DISEASE; RADIATION-INDUCED APOPTOSIS; HUMAN GLIOMA-CELLS; HUMAN COLON-CANCER; DELTA-MEDIATED PHOSPHORYLATION; CENTRAL-NERVOUS-SYSTEM; DEFICIENT MOUSE MODEL; RICH MEMBRANE RAFTS; SECRETORY SPHINGOMYELINASE; ENDOTHELIAL APOPTOSIS	Acid sphingomyelinase (ASM; E.C. 3.1.4.12) is best known for its involvement in the lysosomal storage disorder Niemann-Pick disease (NPD). Through studies that began by investigating this rare disease, recent findings have uncovered the important role of this enzyme in the initiation of ceramide-mediated signal transduction. This unique function involves translocation of the enzyme from intracellular compartments to the outer leaflet of the cell membrane, where hydrolysis of sphingomyelin into ceramide initiates membrane reorganization and facilitates the formation and coalescence of lipid microdomains. These microdomains are sites of protein-protein interactions that lead to downstream signaling, and perturbation of microdomain formation influences the pathophysiology of many common diseases. The initial observations implicating ASM in this process have come from studies using cells from patients with NPD or from ASM knockout (ASMKO) mice, where the genetic deficiency of this enzymatic activity has been shown to protect these cells and animals from stress-induced and developmental apoptosis. This review will discuss the complex biology of this enzyme in the context of these new findings and its recently reported importance in common human diseases, including cancer, sepsis, cardiovascular, pulmonary, liver, and neurological diseases as well as the potential for using ASM (or ASM inhibitors) as therapeutic agents.	[Smith, Eric L.; Schuchman, Edward H.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Genet & Genom Sci, 1425 Madison Ave,Rm 14-20A, New York, NY 10029 USA.	edward.schuchman@mssm.edu			National Institutes of Health [5 T32 GM007280]; March of Dunes Birth Defects Foundation; Genzyme Corporation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dunes Birth Defects Foundation; Genzyme Corporation(Sanofi-AventisGenzyme Corporation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	E.H.S. acknowledges the many students, fellows, and technicians who have worked in his laboratory over the past 20 years on ASM. He also thanks the many collaborators who have assisted in these studies, and especially the NPD families who have contributed invaluable research materials. Support for ASM research in his laboratory has been front the National Institutes of Health, March of Dunes Birth Defects Foundation, and Genzyme Corporation. E.L.S. is supported by a MSTP grant (5 T32 GM007280) from the National Institutes of Health.	Argaud L, 2004, AM J PHYSIOL-HEART C, V286, pH246, DOI 10.1152/ajpheart.00638.2003; Bezombes C, 2001, FASEB J, V15, P297; Bionda C, 2007, FREE RADICAL BIO MED, V43, P681, DOI 10.1016/j.freeradbiomed.2007.04.031; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; Brown M, 2003, SCIENCE, V302; Buccoliero R, 2004, J INHERIT METAB DIS, V27, P641, DOI 10.1023/B:BOLI.0000042958.22066.6c; CHAO R, 1992, J BIOL CHEM, V267, P23459; Chiantia S, 2007, LANGMUIR, V23, P7659, DOI 10.1021/la7010919; Cordis GA, 1998, J PHARMACEUT BIOMED, V16, P1189, DOI 10.1016/S0731-7085(97)00260-4; Cui JH, 2004, J AM COLL SURGEONS, V198, P770, DOI 10.1016/j.jamcollsurg.2003.12.016; Cuschieri Joseph, 2007, Surg Infect (Larchmt), V8, P91, DOI 10.1089/sur.2006.050; Der P, 2006, J MOL CELL CARDIOL, V40, P313, DOI 10.1016/j.yjmcc.2005.10.005; Dhami R, 2001, LAB INVEST, V81, P987, DOI 10.1038/labinvest.3780311; Dimanche-Boitrel MT, 2005, DRUG RESIST UPDATE, V8, P5, DOI 10.1016/j.drup.2005.02.003; Doehner W, 2007, EUR HEART J, V28, P821, DOI 10.1093/eurheartj/ehl541; Duan RD, 1996, DIGEST DIS SCI, V41, P1801, DOI 10.1007/BF02088748; Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568; Elojeimy S, 2007, MOL THER, V15, P1259, DOI 10.1038/sj.mt.6300167; FERLINZ K, 1994, BIOCHEM J, V301, P855, DOI 10.1042/bj3010855; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; Finnegan CM, 2007, J VIROL, V81, P5294, DOI 10.1128/JVI.02553-06; Finnegan CM, 2004, P NATL ACAD SCI USA, V101, P15452, DOI 10.1073/pnas.0402874101; FOWLER S, 1969, BIOCHIM BIOPHYS ACTA, V191, P481, DOI 10.1016/0005-2744(69)90271-X; Galvan C, 2008, MOL BIOL CELL, V19, P509, DOI 10.1091/mbc.E07-05-0439; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garnacho C, 2008, J PHARMACOL EXP THER, V325, P400, DOI 10.1124/jpet.107.133298; GATT S, 1976, BIOCHEM BIOPH RES CO, V68, P235, DOI 10.1016/0006-291X(76)90034-6; GATT S, 1963, J BIOL CHEM, V238, P3131; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Gorski Andrzej, 2003, Med Immunol, V2, P2, DOI 10.1186/1476-9433-2-2; Grammatikos G, 2007, ANTIOXID REDOX SIGN, V9, P1449, DOI 10.1089/ars.2007.1673; Grassme H, 2005, J BIOL CHEM, V280, P26256, DOI 10.1074/jbc.M500835200; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grassme H, 2007, PROG LIPID RES, V46, P161, DOI 10.1016/j.plipres.2007.03.002; Guilbault C, 2008, AM J RESP CELL MOL, V38, P47, DOI 10.1165/rcmb.2007-0036OC; Gulbins E, 2004, J MOL MED, V82, P357, DOI 10.1007/s00109-004-0539-y; Gulbins E, 2003, PHARMACOL RES, V47, P393, DOI 10.1016/S1043-6618(03)00052-5; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Han Xianlin, 2005, Current Alzheimer Research, V2, P65, DOI 10.2174/1567205052772786; Hara S, 2004, ONCOL REP, V12, P119; Hara S, 2004, CELL DEATH DIFFER, V11, P853, DOI 10.1038/sj.cdd.4401428; Hauck CR, 2000, FEBS LETT, V478, P260, DOI 10.1016/S0014-5793(00)01851-2; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; Herschkovitz A, 2007, J BIOL CHEM, V282, P18018, DOI 10.1074/jbc.M610949200; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Ikegami M, 2003, AM J PHYSIOL-LUNG C, V284, pL518, DOI 10.1152/ajplung.00258.2002; Kim SS, 2002, ONCOGENE, V21, P2020, DOI 10.1038/sj.onc.1205037; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Kornhuber J, 2005, J NEURAL TRANSM, V112, P1583, DOI 10.1007/s00702-005-0374-5; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Lang PA, 2007, NAT MED, V13, P164, DOI 10.1038/nm1539; Lansmann S, 1996, FEBS LETT, V399, P227, DOI 10.1016/S0014-5793(96)01331-2; Li YQ, 2003, CANCER RES, V63, P5950; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Marathe S, 1999, ARTERIOSCL THROM VAS, V19, P2648, DOI 10.1161/01.ATV.19.11.2648; McCollister BD, 2007, INFECT IMMUN, V75, P5346, DOI 10.1128/IAI.00689-07; McGovern MM, 2004, J PEDIATR-US, V145, P77, DOI 10.1016/j.jpeds.2004.02.048; Mendelson DS, 2006, RADIOLOGY, V238, P339, DOI 10.1148/radiol.2381041696; Mikami T, 2002, J NEUROL SCI, V199, P39, DOI 10.1016/S0022-510X(02)00106-5; Morales A, 2007, ONCOGENE, V26, P905, DOI 10.1038/sj.onc.1209834; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Ng CG, 2006, J VIROL, V80, P10989, DOI 10.1128/JVI.01154-06; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Pena LA, 2000, CANCER RES, V60, P321; Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238; Pittis M G, 2004, Hum Mutat, V24, P186, DOI 10.1002/humu.9263; Prinetti A, 2006, BIOCHEM J, V395, P311, DOI 10.1042/BJ20051184; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; RAUVALA H, 1984, J LIPID RES, V25, P1257; Rebillard A, 2007, CANCER RES, V67, P7865, DOI 10.1158/0008-5472.CAN-07-0353; Riboni L, 2002, GLIA, V39, P105, DOI 10.1002/glia.10087; Ro HA, 2004, J BIOL CHEM, V279, P37115, DOI 10.1074/jbc.M403099200; Rylova SN, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1057; SAKURAGAWA N, 1982, J BIOCHEM, V92, P637, DOI 10.1093/oxfordjournals.jbchem.a133974; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sawada M, 2002, EXP CELL RES, V273, P157, DOI 10.1006/excr.2001.5437; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Schuchman EH, 2007, J INHERIT METAB DIS, V30, P654, DOI 10.1007/s10545-007-0632-9; SCHUCHMAN EH, 1992, GENOMICS, V12, P197, DOI 10.1016/0888-7543(92)90366-Z; Selzner M, 2001, CANCER RES, V61, P1233; Simonaro CM, 2006, AM J HUM GENET, V78, P865, DOI 10.1086/503750; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; STEINHART WL, 1984, INTERVIROLOGY, V21, P70, DOI 10.1159/000149504; Straczkowski M, 2007, DIABETOLOGIA, V50, P2366, DOI 10.1007/s00125-007-0781-2; Suit HD, 2003, SCIENCE, V302; Summers SA, 2006, PROG LIPID RES, V45, P42, DOI 10.1016/j.plipres.2005.11.002; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890; Tani M, 2007, CELL SIGNAL, V19, P229, DOI 10.1016/j.cellsig.2006.07.001; Teichgraber V, 2008, NAT MED, V14, P382, DOI 10.1038/nm1748; THANNHAUSER S. J., 1940, JOUR BIOL CHEM, V135, P1; Thon L, 2005, FASEB J, V19, P1945, DOI 10.1096/fj.05-3726com; Tuder RM, 2003, AM J RESP CELL MOL, V28, P551, DOI 10.1165/rcmb.F269; Utermohlen O, 2003, J IMMUNOL, V170, P2621, DOI 10.4049/jimmunol.170.5.2621; von Bismarck P, 2008, AM J RESP CRIT CARE, V177, P1233, DOI 10.1164/rccm.200705-752OC; Wong ML, 2000, P NATL ACAD SCI USA, V97, P8681, DOI 10.1073/pnas.150098097; YAMAGUCHI S, 1978, J BIOL CHEM, V253, P4090; Yu ZF, 2000, J MOL NEUROSCI, V15, P85, DOI 10.1385/JMN:15:2:85; Zeidan YH, 2008, FASEB J, V22, P183, DOI 10.1096/fj.07-8967com; Zeidan YH, 2007, J BIOL CHEM, V282, P11549, DOI 10.1074/jbc.M609424200	109	165	175	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3419	3431		10.1096/fj.08-108043	http://dx.doi.org/10.1096/fj.08-108043			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18567738	Green Published			2022-12-28	WOS:000259642600004
J	Lu, DC; Zhang, H; Zador, Z; Verkman, AS				Lu, Daniel C.; Zhang, Hua; Zador, Zsolt; Verkman, A. S.			Impaired olfaction in mice lacking aquaporin-4 water channels	FASEB JOURNAL			English	Article						smell; water permeability; olfactogram	MULTIPLE-SCLEROSIS; ORTHOGONAL ARRAYS; RETINAL FUNCTION; KNOCKOUT MICE; BRAIN; CELLS; K+; EPITHELIUM; MUCOSA; KIR4.1	Aquaporin-4 (AQP4) is a water-selective transport protein expressed in glial cells throughout the central nervous system. AQP4 deletion in mice produces alterations in several neuroexcitation phenomena, including hearing, vision, epilepsy, and cortical spreading depression. Here, we report defective olfaction and electroolfactogram responses in AQP4-null mice. Immunofluorescence indicated strong AQP4 expression in supportive cells of the nasal olfactory epithelium. The olfactory epithelium in AQP4-null mice had identical appearance, but did not express AQP4, and had similar to 12-fold reduced osmotic water permeability. Behavioral analysis showed greatly impaired olfaction in AQP4-null mice, with latency times of 17 +/- 0.7 vs. 55 +/- 5 s in wild-type vs. AQP4-null mice in a buried food pellet test, which was confirmed using an olfactory maze test. Electroolfactogram voltage responses to multiple odorants were reduced in AQP4-null mice, with maximal responses to triethylamine of 0.80 +/- 0.07 vs. 0.28 +/- 0.03 mV. Similar olfaction and electroolfactogram defects were found in outbred (CD1) and inbred (C57/b16) mouse genetic backgrounds. Our results establish AQP4 as a novel determinant of olfaction, the deficiency of which probably impairs extracellular space K+ buffering in the olfactory epithelium.	[Lu, Daniel C.; Zhang, Hua; Zador, Zsolt; Verkman, A. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Lu, Daniel C.; Zhang, Hua; Zador, Zsolt; Verkman, A. S.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Lu, Daniel C.; Zador, Zsolt] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	alan.verkman@ucsf.edu		zador, zsolt/0000-0003-4297-616X; Zador, Zsolt/0000-0001-9767-3372	U. S. National Institutes of Health [DK35124, EY13574, EB00415, HL59198, DK72517, HL73856]; Research Development Program; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R01DK035124, R37DK035124] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Development Program; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank L. Qian for mouse breeding and genotype analysis. This work was supported by grants from the U. S. National Institutes of Health (DK35124, EY13574, EB00415, HL59198, DK72517, and HL73856) and Research Development Program and Drug Discovery grants from the Cystic Fibrosis Foundation.	Ablimit A, 2006, ARCH HISTOL CYTOL, V69, P1, DOI 10.1679/aohc.69.1; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Auguste KI, 2007, FASEB J, V21, P108, DOI 10.1096/fj.06-6848com; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; Da T, 2004, INVEST OPHTH VIS SCI, V45, P4477, DOI 10.1167/iovs.04-0940; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Doty RL, 1997, NEW ENGL J MED, V336, P1918, DOI 10.1056/NEJM199706263362617; EDWARDS DA, 1972, BEHAV BIOL, V7, P823, DOI 10.1016/S0091-6773(72)80174-3; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; ESPOSITO G, 2007, HUM MOL GENET; GETCHELL ML, 1984, ANAT REC, V208, P553, DOI 10.1002/ar.1092080411; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; HEMDAL P, 1993, NEUROPSYCHOLOGIA, V31, P977, DOI 10.1016/0028-3932(93)90152-P; HENKIN R. I., 1966, LIFE SCI, V5, P331, DOI 10.1016/0024-3205(66)90018-X; HOFFER A, 1962, AM J PSYCHIAT, V119, P72; KHAYARI A, 1991, BRAIN RES, V539, P1, DOI 10.1016/0006-8993(91)90679-P; LANCET D, 1993, P NATL ACAD SCI USA, V90, P3715, DOI 10.1073/pnas.90.8.3715; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Li J, 2002, INVEST OPHTH VIS SCI, V43, P573; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; Lien CW, 1999, BIOSCI BIOTECH BIOCH, V63, P1553, DOI 10.1271/bbb.63.1553; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Magzoub M, 2006, J PHYS CHEM B, V110, P21216, DOI 10.1021/jp0633392; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053; Nathan BP, 2004, BEHAV BRAIN RES, V150, P1, DOI 10.1016/S0166-4328(03)00219-5; Nomura T, 2004, ARCH HISTOL CYTOL, V67, P159, DOI 10.1679/aohc.67.159; OTTOSON D, 1956, ACTA PHYSL SCAND S, V35, P122; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Paunio T, 2001, HUM MOL GENET, V10, P3037, DOI 10.1093/hmg/10.26.3037; Rash JE, 2005, J NEUROCYTOL, V34, P307, DOI 10.1007/s11068-005-8360-2; Roemer SF, 2007, BRAIN, V130, P1194, DOI 10.1093/brain/awl371; Ruiz-Ederra J, 2007, J BIOL CHEM, V282, P21866, DOI 10.1074/jbc.M703236200; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Schaefer ML, 2000, J NEUROSCI, V20, P4809; Scott JW, 1996, J NEUROPHYSIOL, V75, P2036, DOI 10.1152/jn.1996.75.5.2036; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Sorbo JG, 2007, FEBS LETT, V581, P4884, DOI 10.1016/j.febslet.2007.09.018; TEICHER MH, 1977, SCIENCE, V198, P635, DOI 10.1126/science.918660; TROTIER D, 1986, BRAIN RES, V374, P205, DOI 10.1016/0006-8993(86)90413-0; TUCKER D, 1965, COLD SPRING HARB SYM, V30, P207, DOI 10.1101/SQB.1965.030.01.023; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Weiler E, 2005, J NEUROCYTOL, V34, P217, DOI 10.1007/s11068-005-8355-z; Yang BX, 1996, J BIOL CHEM, V271, P4577; ZADOR Z, 2007, FASEB J, V22, P326; Zhang H, 2008, MOL CELL NEUROSCI, V37, P1, DOI 10.1016/j.mcn.2007.08.007; Zhang RR, 2008, SMART STRUCT SYST, V4, P1	51	69	81	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3216	3223		10.1096/fj.07-104836	http://dx.doi.org/10.1096/fj.07-104836			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18511552	Green Published			2022-12-28	WOS:000258761300014
J	Andreeva, AV; Kutuzov, MA; Voyno-Yasenetskaya, TA				Andreeva, Alexandra V.; Kutuzov, Mikhail A.; Voyno-Yasenetskaya, Tatyana A.			G alpha 12 is targeted to the mitochondria and affects mitochondrial morphology and motility	FASEB JOURNAL			English	Article						heterotrimeric G proteins; Bcl-2; Hsp90; mitochondrial fission; organelle motility	PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; OUTER-MEMBRANE; ANTIAPOPTOTIC FUNCTION; ACTIN-FILAMENTS; BCL-2; FUSION; HSP90; STIMULATION; ACTIVATION	G alpha 12 constitutes, along with G alpha 13, one of the four families of alpha subunits of heterotrimeric G proteins. We found that the N terminus of G alpha 12, but not those of other G alpha subunits, contains a predicted mitochondrial targeting sequence. Using confocal microscopy and cell fractionation, we demonstrated that up to 40% of endogenous G alpha 12 in human umbilical vein endothelial cells colocalize with mitochondrial markers. N-terminal sequence of G alpha 12 fused to GFP efficiently targeted the fusion protein to mitochondria. G alpha 12 with mutated mitochondrial targeting sequence was still located in mitochondria, suggesting the existence of additional mechanisms for mitochondrial localization. Lysophosphatidic acid, one of the known stimuli transduced by G alpha 12/13, inhibited mitochondrial motility, while depletion of endogenous G alpha 12 increased mitochondrial motility. G alpha 12Q229L variants uncoupled from RhoGEFs (but not fully functional activated G alpha 12Q229L) induced transformation of the mitochondrial network into punctate mitochondria and resulted in a loss of mitochondrial membrane potential. All examined G alpha 12Q229L variants reduced phosphorylation of Bcl-2 at Ser-70, while only mutants unable to bind RhoGEFs also decreased cellular levels of Bcl-2. These G alpha 12 mutants were also more efficient Hsp90 interactors. These findings are the first demonstration of a heterotrimeric G protein alpha subunit specifically targeted to mitochondria and involved in the control of mitochondrial morphology and dynamics.	[Andreeva, Alexandra V.; Kutuzov, Mikhail A.; Voyno-Yasenetskaya, Tatyana A.] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Dept Pharmacol, MC 868,909 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu		Kutuzov, Mikhail/0000-0003-3386-4350	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065160, R55GM056159, R01GM056159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06078] Funding Source: Medline; NIGMS NIH HHS [R55 GM056159, R01 GM065160, R01 GM056159, GM56159, GM65160] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreeva AV, 2006, MOL PHARMACOL, V69, P975, DOI 10.1124/mol.105.018846; Andreeva AV, 2005, J BIOL CHEM, V280, P30376, DOI 10.1074/jbc.M502844200; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Bockaert J, 2002, INT REV CYTOL, V212, P63; Brichese L, 2004, CELL CYCLE, V3, P1312, DOI 10.4161/cc.3.10.1166; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270; Chisari M, 2007, J BIOL CHEM, V282, P24092, DOI 10.1074/jbc.M704246200; Cismowski MJ, 2006, SEMIN CELL DEV BIOL, V17, P334, DOI 10.1016/j.semcdb.2006.03.003; Cohen-Saidon C, 2006, BLOOD, V107, P1413, DOI 10.1182/blood-2005-07-2648; Collins TJ, 2003, J EXP BIOL, V206, P1993, DOI 10.1242/jeb.00244; Cortese JD, 1998, EXP CELL RES, V240, P122, DOI 10.1006/excr.1998.4004; Davidson SM, 2007, CIRC RES, V100, P1128, DOI 10.1161/01.RES.0000261970.18328.1d; Delivani P, 2006, MOL CELL, V21, P761, DOI 10.1016/j.molcel.2006.01.034; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Fan ACY, 2006, J BIOL CHEM, V281, P33313, DOI 10.1074/jbc.M605250200; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; Hampoelz B, 2004, CELL, V119, P453, DOI 10.1016/j.cell.2004.10.025; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.053850; Krendel M, 1998, CELL MOTIL CYTOSKEL, V40, P368, DOI 10.1002/(SICI)1097-0169(1998)40:4<368::AID-CM5>3.3.CO;2-R; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Kutuzov MA, 2005, J BIOL CHEM, V280, P25388, DOI 10.1074/jbc.M413202200; Kuyznierewicz I, 2002, CELL BIOL INT, V26, P99, DOI 10.1006/cbir.2001.0823; Landry Y, 2006, CURR MED CHEM, V13, P51, DOI 10.2174/092986706775197953; Ligon LA, 2000, J COMP NEUROL, V427, P351, DOI 10.1002/1096-9861(20001120)427:3<351::AID-CNE3>3.0.CO;2-R; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Minin AA, 2006, J CELL SCI, V119, P659, DOI 10.1242/jcs.02762; Morfini G, 2006, NAT NEUROSCI, V9, P907, DOI 10.1038/nn1717; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122; Patel TB, 2004, PHARMACOL REV, V56, P371, DOI 10.1124/pr.56.3.4; Ponimaskin E, 1998, FEBS LETT, V429, P370, DOI 10.1016/S0014-5793(98)00638-3; Quintero M, 2006, P NATL ACAD SCI USA, V103, P5379, DOI 10.1073/pnas.0601026103; Ramamurthy S, 2006, J NEUROSCI RES, V84, P1402, DOI 10.1002/jnr.21061; Rezaul K, 2005, MOL CELL PROTEOMICS, V4, P169, DOI 10.1074/mcp.M400115-MCP200; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Sabath E, 2008, J CELL SCI, V121, P814, DOI 10.1242/jcs.014878; Sage D, 2005, IEEE T IMAGE PROCESS, V14, P1372, DOI 10.1109/TIP.2005.852787; Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Yaffe MP, 1999, NAT CELL BIOL, V1, pE149, DOI 10.1038/14101; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yanamadala V, 2007, J BIOL CHEM, V282, P24352, DOI 10.1074/jbc.M702804200; Yi MQ, 2004, J CELL BIOL, V167, P661, DOI 10.1083/jcb.200406038; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zhu DG, 2007, MOL PHARMACOL, V71, P1268, DOI 10.1124/mol.106.033555; Zhu DG, 2004, J BIOL CHEM, V279, P54983, DOI 10.1074/jbc.C400508200	60	30	30	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2821	2831		10.1096/fj.07-104224	http://dx.doi.org/10.1096/fj.07-104224			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18367648	Green Published			2022-12-28	WOS:000258089300022
J	Coric, T; Passamaneck, YJ; Zhang, P; Di Gregorio, A; Canessa, CM				Coric, Tatjana; Passamaneck, Yale J.; Zhang, Ping; Di Gregorio, Anna; Canessa, Cecilia M.			Simple chordates exhibit a proton-independent function of acid-sensing ion channels	FASEB JOURNAL			English	Article						ascidian; degenerin/epithelial sodium channel (ENaC) family; proton gating; Ciona; knockdown expression	CENTRAL-NERVOUS-SYSTEM; CIONA-INTESTINALIS; CONTRIBUTES; EXPRESSION; GENOME; LOCOMOTION; INSIGHTS; NEURONS; TOUCH; GENE	Acid-sensing ion channels (ASICs) constitute a family of neuron-specific voltage-insensitive sodium channels gated by extracellular protons. Functions of ASICs in mammals include nociception, mechano-sensation, and modulation of synaptic transmission. However, the role protons play in mediating the effects of ASICs remains elusive. We have examined ASICs from the ascidian Ciona intestinalis, a simple chordate organism whose nervous system in the larval stage exhibits high similarity to that of higher vertebrates. We found that the ascidian genome contains a single ASIC gene that gives rise to two splice forms analogous to the mammalian ASIC1 and ASIC2. CiASIC is expressed in most neurons of the larva but is absent in the adult. Despite high sequence similarity with mammalian counterparts, CiASIC is proton-insensitive when examined in heterologous systems or in larval neurons; the latter rules out the possibility that proton sensitivity is conferred by accessory proteins or particular factors present only in Ciona neurons. Down-regulation of the CiASIC transcript by double-stranded RNA disrupted the regular pattern of larval swimming, implying that proton-independent mechanisms mediate the effects of ASIC in vivo. Together the data identify ASIC as a highly conserved channel distinctive of chordate nervous systems and show that protons are not essential for ASIC function.	[Coric, Tatjana; Zhang, Ping; Canessa, Cecilia M.] Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; [Passamaneck, Yale J.; Di Gregorio, Anna] Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA	Yale University; Cornell University	Canessa, CM (corresponding author), Yale Univ, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	cecilia.canessa@yale.edu	Di Gregorio, Anna/C-4766-2008		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD050704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054062] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainsley JA, 2003, CURR BIOL, V13, P1557, DOI 10.1016/S0960-9822(03)00596-7; BONE Q, 1992, J MAR BIOL ASSOC UK, V72, P161, DOI 10.1017/S0025315400048864; Brown ER, 2005, EUR J NEUROSCI, V22, P2541, DOI 10.1111/j.1460-9568.2005.04420.x; CLONEY RA, 1982, AM ZOOL, V22, P817; Corbo JC, 1997, DEVELOPMENT, V124, P589; Coric T, 2005, J PHYSIOL-LONDON, V568, P725, DOI 10.1113/jphysiol.2005.087734; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; Dehal P, 2005, PLOS BIOL, V3, P1700, DOI 10.1371/journal.pbio.0030314; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; Imai JH, 2007, J COMP NEUROL, V501, P316, DOI 10.1002/cne.21246; Imai JH, 2007, J COMP NEUROL, V501, P335, DOI 10.1002/cne.21247; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; NICOL D, 1991, J COMP NEUROL, V309, P415, DOI 10.1002/cne.903090402; Oda-Ishii I, 2007, DEV DYNAM, V236, P1806, DOI 10.1002/dvdy.21213; Ohno S., 1970, P1; OKAMURA Y, 1994, NEURON, V13, P937, DOI 10.1016/0896-6273(94)90259-3; Okamura Y, 2005, PHYSIOL GENOMICS, V22, P269, DOI 10.1152/physiolgenomics.00229.2004; Passamaneck YJ, 2005, DEV DYNAM, V233, P1, DOI 10.1002/dvdy.20300; Paukert M, 2004, J BIOL CHEM, V279, P18783, DOI 10.1074/jbc.M401477200; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Roza C, 2004, J PHYSIOL-LONDON, V558, P659, DOI 10.1113/jphysiol.2004.066001; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Zega G, 2006, J EXP BIOL, V209, P3405, DOI 10.1242/jeb.02421	29	19	19	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1914	1923		10.1096/fj.07-100313	http://dx.doi.org/10.1096/fj.07-100313			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18211956				2022-12-28	WOS:000256352700031
J	de Melo-Martin, I; Intemann, K				de Melo-Martin, Inmaculada; Intemann, Kristen			How do disclosure policies fail? Let us count the ways	FASEB JOURNAL			English	Article						financial conflicts; conflict of interest; prevention of bias	CONFLICT-OF-INTEREST; CLINICAL-TRIAL; RULES; ETHICS	The disclosure policies of scientific journals now require that investigators provide information about financial interests relevant to their research. The main goals of these policies are to prevent bias from occurring, to help identify bias when it occurs, and to avoid the appearance of bias. We argue here that such policies do little to help achieve these goals, and we suggest more effective alternatives.-De Melo-Martin, I., Intemann, K. How do disclosure policies fail? Let us count the ways. FASEB J. 23, 1638-1642 (2009)	[de Melo-Martin, Inmaculada] Weill Cornell Med Coll, Dept Publ Hlth, Div Med Eth, New York, NY 10021 USA; [Intemann, Kristen] Montana State Univ, Dept Hist & Philosophy, Bozeman, MT 59717 USA	Cornell University; Montana State University System; Montana State University Bozeman	de Melo-Martin, I (corresponding author), Weill Cornell Med Coll, Dept Publ Hlth, Div Med Eth, 411 E 69th St, New York, NY 10021 USA.	imd2001@med.cornell.edu	de Melo-Martin, Inmaculada/AEE-1312-2022	de Melo-Martin, Inmaculada/0000-0001-8656-8497				Abaid LN, 2007, OBSTET GYNECOL, V109, P1434, DOI 10.1097/01.AOG.0000266557.11064.2a; American Society of Clinical Oncology, 2006, J Clin Oncol, V24, P519; Boyd EA, 2003, ACAD MED, V78, P769, DOI 10.1097/00001888-200308000-00002; Cain DM, 2008, JAMA-J AM MED ASSOC, V299, P2893, DOI 10.1001/jama.299.24.2893; Campbell P, 2001, NATURE, V412, P751, DOI 10.1038/35090688; Dalton R, 2005, NATURE, V434, P687, DOI 10.1038/434687b; DeAngelis CD, 2001, JAMA-J AM MED ASSOC, V286, P89, DOI 10.1001/jama.286.1.89; Dinan Michaela A, 2006, Account Res, V13, P325, DOI 10.1080/08989620601003414; Douglas H., 2007, VALUE FREE SCI IDEAL, P120, DOI DOI 10.1093/ACPROF:OSO/9780195308969.003.0009; Drazen JM, 2002, NEW ENGL J MED, V346, P1901, DOI 10.1056/NEJMe020074; Ehringhaus SH, 2008, JAMA-J AM MED ASSOC, V299, P665, DOI 10.1001/jama.299.6.665; Elliott KC, 2008, ACCOUNT RES, V15, P1, DOI 10.1080/08989620701783725; Horton R, 1997, LANCET, V349, P1112, DOI 10.1016/S0140-6736(97)22016-7; *INT COMM MED J ED, 2007, BIOMEDICAL J UNPUB; James A, 2003, LANCET, V361, P8, DOI 10.1016/S0140-6736(03)12184-8; Kaiser J, 2006, SCIENCE, V314, P740; KASSIRER JP, 1993, NEW ENGL J MED, V329, P570, DOI 10.1056/NEJM199308193290810; Laine C, 2007, JAMA-J AM MED ASSOC, V298, P93, DOI 10.1001/jama.298.1.jed70037; Lievre M, 2001, BRIT MED J, V322, P603, DOI 10.1136/bmj.322.7286.603; Lipton Shira, 2004, Account Res, V11, P83, DOI 10.1080/03050620490512241; McCrary SV, 2000, NEW ENGL J MED, V343, P1621, DOI 10.1056/NEJM200011303432207; Mello MM, 2005, NEW ENGL J MED, V352, P2202, DOI 10.1056/NEJMsa044115; MELLO MM, 2005, ACCOUNT RES, V12, P63; Psaty BM, 2003, JAMA-J AM MED ASSOC, V289, P2128, DOI 10.1001/jama.289.16.2128; ROTHMAN KJ, 1993, JAMA-J AM MED ASSOC, V269, P2782, DOI 10.1001/jama.269.21.2782; ROTHMAN KJ, 1991, J CLIN EPIDEMIOL, V44, pS25; Safer DJ, 2002, J NERV MENT DIS, V190, P583, DOI 10.1097/00005053-200209000-00002; Schroter S, 2004, BRIT MED J, V328, P742, DOI 10.1136/bmj.38035.705185.F6; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; Twombly R, 2007, J NATL CANCER I, V99, P6, DOI 10.1093/jnci/djk037; vom Saal FS, 2005, ENVIRON HEALTH PERSP, V113, P926, DOI 10.1289/ehp.7713; Wadman M, 2005, NATURE, V434, P3, DOI 10.1038/434003a; 2006, NAT MED, V12, P979	33	25	26	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1638	1642		10.1096/fj.08-125963	http://dx.doi.org/10.1096/fj.08-125963			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19176877				2022-12-28	WOS:000266652400003
J	Zarubica, A; Plazzo, AP; Stockl, M; Trombik, T; Hamon, Y; Muller, P; Pomorski, T; Herrmann, A; Chimini, G				Zarubica, Ana; Plazzo, Anna Pia; Stoeckl, Martin; Trombik, Tomasz; Hamon, Yannick; Mueller, Peter; Pomorski, Thomas; Herrmann, Andreas; Chimini, Giovanna			Functional implications of the influence of ABCA1 on lipid microenvironment at the plasma membrane: a biophysical study	FASEB JOURNAL			English	Article						FLIM; TfR; cholesterol; phosphatidylserine; FRAP	FLUORESCENCE LIFETIME; CHOLESTEROL EFFLUX; CELL-MEMBRANES; SURFACE; RAFTS; PHOSPHATIDYLSERINE; PHOSPHOLIPIDS; TRANSPORTER; VESICLES; ACTIVATION	The ABCA1 transporter orchestrates cellular lipid homeostasis by promoting the release of cholesterol to plasmatic acceptors. The molecular mechanism is, however, unknown. We report here on the biophysical analysis in living HeLa cells of the ABCA1 lipid microenvironment at the plasma membrane. The modifications of membrane attributes induced by ABCA1 were assessed at both the outer and inner leaflet by monitoring either the lifetime of membrane inserted fluorescent lipid analogues by fluorescence lifetime imaging microscopy (FLIM) or, respectively, the membrane translocation of cationic sensors. Analysis of the partitioning of dedicated probes in plasma membrane blebs vesiculated from these cells allowed visualization of ABCA1 partitioning into the liquid disordered-like phase and corroborated the idea that ABCA1 destabilizes the lipid arrangement at the membrane. Specificity was demonstrated by comparison with cells expressing an inactive transporter. The physiological relevance of these modifications was finally demonstrated by the reduced membrane mobility and function of transferrin receptors under the influence of an active ABCA1. Collectively, these data assess that the control of both transversal and lateral lipid distribution at the membrane is the primary function of ABCA1 and positions the effluxes of cholesterol from cell membranes downstream to the redistribution of the sterol into readily extractable membrane pools.-Zarubica, A., Plazzo, A. P., Stockl, M., Trombik, T., Hamon, Y., Muller, P., Pomorski, T., Herrmann, A., Chimini, G. Functional implications of the influence of ABCA1 on lipid microenvironment at the plasma membrane: a biophysical study. FASEB J. 23, 1775-1785 (2009)	[Zarubica, Ana; Trombik, Tomasz; Hamon, Yannick; Chimini, Giovanna] Univ Aix Marseille 2, Ctr Natl Rech Sci, Inst Natl Sante & Rech Med, Ctr Immunol Marseille Luminy, F-13288 Marseille 09, France; [Plazzo, Anna Pia; Stoeckl, Martin; Mueller, Peter; Pomorski, Thomas; Herrmann, Andreas] Humboldt Univ, Inst Biol Biophys, Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Humboldt University of Berlin	Chimini, G (corresponding author), Univ Aix Marseille 2, Ctr Natl Rech Sci, Inst Natl Sante & Rech Med, Ctr Immunol Marseille Luminy, Parc Sci Luminy Case 906, F-13288 Marseille 09, France.	chimini@ciml.univ-mrs.fr	Trombik, Tomasz/X-6504-2019; Stöckl, Martin/AAM-6743-2020; Trombik, Tomasz/AAP-2750-2021; HAMON, Yannick YH/N-5372-2016; Pomorski, Thomas Günther/G-4804-2014; HAMON, Yannick/S-3118-2019; Stöckl, Martin T/I-6554-2016	Stöckl, Martin/0000-0001-7986-9291; Trombik, Tomasz/0000-0003-3643-8381; HAMON, Yannick YH/0000-0002-7636-2310; Pomorski, Thomas Günther/0000-0002-4889-0829; HAMON, Yannick/0000-0002-7636-2310; Stöckl, Martin T/0000-0001-7986-9291				Alder-Baerens N, 2005, J BIOL CHEM, V280, P26321, DOI 10.1074/jbc.M413993200; Attie AD, 2007, TRENDS BIOCHEM SCI, V32, P172, DOI 10.1016/j.tibs.2007.02.001; Baumgart T, 2007, BBA-BIOMEMBRANES, V1768, P2182, DOI 10.1016/j.bbamem.2007.05.012; Baumgart T, 2007, P NATL ACAD SCI USA, V104, P3165, DOI 10.1073/pnas.0611357104; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chattopadhyay A, 2002, J PHYS CHEM B, V106, P13002, DOI 10.1021/jp021801m; CHATTOPADHYAY A, 1993, BIOCHEMISTRY-US, V32, P3804, DOI 10.1021/bi00065a037; Combes V, 2005, AM J PATHOL, V166, P295, DOI 10.1016/S0002-9440(10)62253-5; de Almeida RFM, 2007, BIOPHYS J, V93, P539, DOI 10.1529/biophysj.106.098822; De Gassart A, 2008, P NATL ACAD SCI USA, V105, P3491, DOI 10.1073/pnas.0708874105; Dufort L., 2007, HIGH DENSITY LIPOPRO, P113; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Gaus K, 2005, J CELL BIOL, V171, P121, DOI 10.1083/jcb.200505047; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Goodwin JS, 2005, BIOPHYS J, V89, P1398, DOI 10.1529/biophysj.104.055640; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HO C, 1992, BIOCHIM BIOPHYS ACTA, V1104, P273, DOI 10.1016/0005-2736(92)90041-J; HO CJ, 1994, BBA-BIOMEMBRANES, V1193, P307, DOI 10.1016/0005-2736(94)90167-8; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; Koseki M, 2007, J LIPID RES, V48, P299, DOI 10.1194/jlr.M600428-JLR200; Landry YD, 2006, J BIOL CHEM, V281, P36091, DOI 10.1074/jbc.M602247200; Lange Y, 2005, J BIOL CHEM, V280, P36126, DOI 10.1074/jbc.M507149200; Lange Y, 2007, BIOCHEMISTRY-US, V46, P2233, DOI 10.1021/bi6023397; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Maldonado RA, 2004, NATURE, V431, P527, DOI 10.1038/nature02916; Marchetti M, 2006, MOL BIOL CELL, V17, P2896, DOI 10.1091/mbc.E06-01-0076; Margineanu A, 2007, BIOPHYS J, V93, P2877, DOI 10.1529/biophysj.106.100743; McMullen TPW, 2000, BIOPHYS J, V79, P2056, DOI 10.1016/S0006-3495(00)76453-8; Meder D, 2006, P NATL ACAD SCI USA, V103, P329, DOI 10.1073/pnas.0509885103; Ohvo-Rekila H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163-7827(01)00020-0; Radhakrishnan A, 2000, BIOCHEMISTRY-US, V39, P8119, DOI 10.1021/bi0005097; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Rigot W, 2002, J LIPID RES, V43, P2077, DOI 10.1194/jlr.M200279-JLR200; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Sengupta P, 2008, BBA-BIOMEMBRANES, V1778, P20, DOI 10.1016/j.bbamem.2007.08.028; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Stockl M, 2008, J BIOL CHEM, V283, P30828, DOI 10.1074/jbc.M801418200; Tam SP, 2006, AM J PHYSIOL-CELL PH, V291, pC490, DOI 10.1152/ajpcell.00055.2006; Thymiakou E, 2007, BIOCHEMISTRY-US, V46, P11473, DOI 10.1021/bi700994m; Trompier D, 2006, J BIOL CHEM, V281, P20283, DOI 10.1074/jbc.M601072200; van Meer G, 2006, FEBS LETT, V580, P1171, DOI 10.1016/j.febslet.2005.12.019; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Williamson P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000729; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; YGUERABIDE J, 1982, BIOPHYS J, V40, P69, DOI 10.1016/S0006-3495(82)84459-7; Young SG, 1999, NAT GENET, V22, P316, DOI 10.1038/11878; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200; Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamem.2007.03.026	53	36	37	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1775	1785		10.1096/fj.08-122192	http://dx.doi.org/10.1096/fj.08-122192			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19151332				2022-12-28	WOS:000266652400018
J	Kimberley, FC; van Bostelen, L; Cameron, K; Hardenberg, G; Marquart, JA; Hahne, M; Medema, JP				Kimberley, Fiona C.; van Bostelen, Liesbeth; Cameron, Katherine; Hardenberg, Gijs; Marquart, J. Arnoud; Hahne, Michael; Medema, Jan Paul			The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking	FASEB JOURNAL			English	Article						proliferation; B cells; signaling; tumors; immunoglobulins	TUMOR-NECROSIS-FACTOR; B-CELL MATURATION; PROLIFERATION-INDUCING LIGAND; HIGH-AFFINITY RECEPTOR; TNF FAMILY; ACTIVATING FACTOR; CUTTING EDGE; T-CELL; IGA PRODUCTION; MYELOMA CELLS	A proliferation-inducing ligand (APRIL) (also known as TALL-2 and TRDL-1) is a member of the tumor necrosis factor (TNF) superfamily that has tumorigenic properties but is also important for the induction of humoral immune responses. APRIL binds two TNF receptors: transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B-cell maturation antigen (BCMA) as well as heparan sulfate proteoglycans (HSPGs). The aim of this study was to clarify the role of the HSPG interaction in canonical APRIL signaling, because it has been proposed to act as a docking site and also to play a role in direct signaling. In this study, we generated point mutants of soluble APRIL that lack either the capacity to bind HSPGs or TACI and BCMA and then tested the function of these mutants in mouse B-cell assays. In contrast to previous reports, we found that APRIL alone is sufficient to costimulate B-cell proliferation and drive IgA production and does not require artificial antibody cross-linking. We found no evidence that APRIL requires signaling through HSPGs but, notably, were able to show that binding of APRIL to HSPGs is crucial for mediating natural APRIL cross-linking to allow for optimal activation of murine B cells.-Kimberley, F. C., van Bostelen, L., Cameron, K., Hardenberg, G., Marquart, J. A., Hahne, M., Medema, J. P. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. FASEB J. 23, 1584-1595 (2009)	[Kimberley, Fiona C.; van Bostelen, Liesbeth; Cameron, Katherine; Hardenberg, Gijs; Medema, Jan Paul] Univ Amsterdam, LEXOR, Ctr Expt Mol Med, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Marquart, J. Arnoud] Univ Amsterdam, Dept Expt Vasc Med, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Hahne, Michael] CNRS, Inst Genet Mol Montpellier, UMR5535, Montpellier, France	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Medema, JP (corresponding author), Univ Amsterdam, LEXOR, Ctr Expt Mol Med, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.p.medema@amc.uva.nl		Medema, Jan Paul/0000-0003-3045-2924	TI-Pharma; Dutch Cancer Society [20032812, 2007-3750]; Stichting Vanderes; Fondation de France and Association pour la Recherche sur le Cancer	TI-Pharma; Dutch Cancer Society(KWF Kankerbestrijding); Stichting Vanderes; Fondation de France and Association pour la Recherche sur le Cancer	We thank the animal caretakers at the Academic Medical Center, University of Amsterdam. The work in this study was supported by TI-Pharma, Dutch Cancer Society grants 20032812 and 2007-3750, and Stichting Vanderes. M. H. is supported by the Fondation de France and Association pour la Recherche sur le Cancer. The authors declare no competing financial interests.	Baeg GH, 2004, DEV BIOL, V276, P89, DOI 10.1016/j.ydbio.2004.08.023; Belnoue E, 2008, BLOOD, V111, P2755, DOI 10.1182/blood-2007-09-110858; Benson MJ, 2008, J IMMUNOL, V180, P3655, DOI 10.4049/jimmunol.180.6.3655; Bischof D, 2006, BLOOD, V107, P3235, DOI 10.1182/blood-2005-01-0256; Bossen C, 2008, BLOOD, V111, P1004, DOI 10.1182/blood-2007-09-110874; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; Chiu A, 2007, BLOOD, V109, P729, DOI 10.1182/blood-2006-04-015958; Day ES, 2005, BIOCHEMISTRY-US, V44, P1919, DOI 10.1021/bi048227k; Deshayes F, 2004, ONCOGENE, V23, P3005, DOI 10.1038/sj.onc.1207350; Garner OB, 2008, IMMUNOLOGY, V125, P420, DOI 10.1111/j.1365-2567.2008.02856.x; Gorelik L, 2004, J IMMUNOL, V172, P762, DOI 10.4049/jimmunol.172.2.762; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Gross JA, 2001, IMMUNITY, V15, P289, DOI 10.1016/S1074-7613(01)00183-2; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Hardenberg G, 2008, IMMUNOL CELL BIOL, V86, P530, DOI 10.1038/icb.2008.17; Hardenberg G, 2007, EUR J IMMUNOL, V37, P2900, DOI 10.1002/eji.200737210; He B, 2004, J IMMUNOL, V172, P3268, DOI 10.4049/jimmunol.172.5.3268; He B, 2003, J IMMUNOL, V171, P5215, DOI 10.4049/jimmunol.171.10.5215; Hendriks J, 2005, CELL DEATH DIFFER, V12, P637, DOI 10.1038/sj.cdd.4401647; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Hsu BL, 2002, J IMMUNOL, V168, P5993, DOI 10.4049/jimmunol.168.12.5993; Huard B, 2008, J CLIN INVEST, V118, P2887, DOI 10.1172/JCI33760; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Kanswal S, 2008, J IMMUNOL, V181, P976, DOI 10.4049/jimmunol.181.2.976; Kern C, 2004, BLOOD, V103, P679, DOI 10.1182/blood-2003-02-0540; Kolfschoten GA, 2003, BIOCHEM PHARMACOL, V66, P1427, DOI 10.1016/S0006-2952(03)00493-3; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Ng LG, 2004, J IMMUNOL, V173, P807, DOI 10.4049/jimmunol.173.2.807; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Patel DR, 2004, J BIOL CHEM, V279, P16727, DOI 10.1074/jbc.M312316200; Pelekanou V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-76; Planelles L, 2007, HAEMATOLOGICA, V92, P1284, DOI 10.3324/haematol.10317; Planelles Lourdes, 2008, Curr Mol Med, V8, P829, DOI 10.2174/156652408786733711; Pradet-Balade B, 2002, EMBO J, V21, P5711, DOI 10.1093/emboj/cdf565; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Sakurai D, 2007, BLOOD, V109, P2961, DOI 10.1182/blood-2006-08-041772; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shulga-Morskaya S, 2004, J IMMUNOL, V173, P2331, DOI 10.4049/jimmunol.173.4.2331; Tezuka H, 2007, NATURE, V448, P929, DOI 10.1038/nature06033; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Varfolomeev E, 2004, MOL CELL BIOL, V24, P997, DOI 10.1128/MCB.24.3.997-1006.2004; Wallweber HJA, 2004, J MOL BIOL, V343, P283, DOI 10.1016/j.jmb.2004.08.040; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Yaccoby S, 2008, LEUKEMIA, V22, P406, DOI 10.1038/sj.leu.2405048; Yang M, 2005, J IMMUNOL, V175, P2814, DOI 10.4049/jimmunol.175.5.2814; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802	55	69	73	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1584	1595		10.1096/fj.08-124669	http://dx.doi.org/10.1096/fj.08-124669			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19141538				2022-12-28	WOS:000266651700033
J	Chiu, HJ; Fischman, DA; Hammerling, U				Chiu, Haw-Jyh; Fischman, Donald A.; Hammerling, Ulrich			Vitamin A depletion causes oxidative stress, mitochondrial dysfunction, and PARP-1-dependent energy deprivation	FASEB JOURNAL			English	Article						lymphocytes; mitochondrion; reactive oxygen species; bioenergetics	PROTEIN-KINASE-C; APOPTOSIS INDUCING FACTOR; POLY(ADP-RIBOSE) POLYMERASE; CELL-DEATH; RETRO-RETINOIDS; COMPLEX-III; DNA-REPAIR; ANHYDRORETINOL; GROWTH; PARP	A significant unresolved question is how vitamin A deprivation causes, and why retinoic acid fails to reverse, immunodeficiency. When depleted of vitamin A, T cells undergo programmed cell death (PCD), which is enhanced by the natural competitor of retinol, anhydroretinol. PCD does not happen by apoptosis, despite the occurrence of shared early events, including mitochondrial membrane depolarization, permeability transition pore opening, and cytochrome c release. It also lacks caspase-3 activation, chromatin condensation, and endonuclease-mediated DNA degradation, hallmarks of apoptosis. PCD following vitamin A deprivation exhibits increased production of reactive oxygen species (ROS), drastic reductions in ATP and NAD(+) levels, and activation of poly-(ADP-ribose) polymerase (PARP) -1. These latter steps are causative because neutralizing ROS, imposing hypoxic conditions, or inhibiting PARP-1 by genetic or pharmacologic approaches prevents energy depletion and PCD. The data highlight a novel regulatory role of vitamin A in mitochondrial energy homeostasis. -Chiu, H.-J., Fischman, D. A., Hammerling, U. Vitamin A depletion causes oxidative stress, mitochondrial dysfunction, and PARP1-dependent energy deprivation. FASEB J. 22, 3878-3887 (2008)	[Chiu, Haw-Jyh; Hammerling, Ulrich] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10065 USA; [Fischman, Donald A.] Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Hammerling, U (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave, New York, NY 10065 USA.	u-hammerling@ski.mskcc.org			National Institutes of Health [CA 089362, DK 069348]; NATIONAL CANCER INSTITUTE [R01CA089362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069348] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors are indebted to Dr. Valina Dawson (Johns Hopkins University School of Medicine, Baltimore, MD, USA) for sharing PARP-1<SUP>-/-</SUP> MEFs. This work was supported by grants from the National Institutes of Health, CA 089362 and DK 069348.	ARNOLD F, 1987, BRIT J EXP PATHOL, V68, P569; Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen YQ, 1999, CANCER RES, V59, P3985; Cipriani G, 2005, J BIOL CHEM, V280, P17227, DOI 10.1074/jbc.M414526200; DE LUCA LM, 1991, FASEB J, V5, P2924; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; DERGUINI F, 1995, J BIOL CHEM, V270, P18875, DOI 10.1074/jbc.270.32.18875; DERGUINI F, 1994, BIOCHEMISTRY-US, V33, P623, DOI 10.1021/bi00169a001; Dmitrovsky E, 2004, J NATL CANCER I, V96, P1264, DOI 10.1093/jnci/djh268; Eguchi Y, 1997, CANCER RES, V57, P1835; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; Faderl S, 2003, LEUKEMIA RES, V27, P259, DOI 10.1016/S0145-2126(02)00162-5; Farivar AS, 2005, ANN THORAC SURG, V80, P950, DOI 10.1016/j.athoracsur.2005.02.035; Fossati S, 2007, NEUROCHEM INT, V50, P203, DOI 10.1016/j.neuint.2006.08.009; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; Guzy RD, 2006, EXP PHYSIOL, V91, P807, DOI 10.1113/expphysiol.2006.033506; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hail N, 2006, APOPTOSIS, V11, P1677, DOI 10.1007/s10495-006-9289-3; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Hoyos B, 2005, J BIOL CHEM, V280, P6872, DOI 10.1074/jbc.M412695200; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; Imam A, 2001, FASEB J, V15, P28; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Korichneva I, 2003, J PHARMACOL EXP THER, V305, P426, DOI 10.1124/jpet.103.048900; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; Korichneva I, 1999, J CELL SCI, V112, P2521; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Miwa M, 2007, CANCER SCI, V98, P1528, DOI 10.1111/j.1349-7006.2007.00567.x; Morales MC, 2005, ANTICANCER RES, V25, P1945; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OConnell MJ, 1996, J EXP MED, V184, P549, DOI 10.1084/jem.184.2.549; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pieper AA, 2000, MOL MED, V6, P271, DOI 10.1007/BF03401936; Quijano C, 2007, AM J PHYSIOL-HEART C, V293, pH3404, DOI 10.1152/ajpheart.00761.2007; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Shah GM, 1996, BBA-MOL CELL RES, V1312, P1, DOI 10.1016/0167-4889(96)00004-3; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SIMMEN HP, 1994, INFECTION, V22, P386, DOI 10.1007/BF01715494; Simon MC, 2006, ADV EXP MED BIOL, V588, P165; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Wang HM, 2003, ANN NY ACAD SCI, V991, P132; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008	62	50	53	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3878	3887		10.1096/fj.08-112375	http://dx.doi.org/10.1096/fj.08-112375			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18676402	Green Published			2022-12-28	WOS:000260503000016
J	Baron, R; Nemirovsky, A; Harpaz, I; Cohen, H; Owens, T; Monsonego, A				Baron, Rona; Nemirovsky, Anna; Harpaz, Idan; Cohen, Hagit; Owens, Trevor; Monsonego, Alon			IFN-gamma enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						cytokine; immunity; aging; neurodegenerative disease; neuronal repair	CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; AMYLOID BETA-PEPTIDE; INTERFERON-GAMMA; HIPPOCAMPAL NEUROGENESIS; TRANSGENIC MICE; NEURONAL DIFFERENTIATION; ADULT NEUROGENESIS; NEURITE OUTGROWTH; NITRIC-OXIDE	The generation of new neurons and glia from a precursor stem cell appears to take place in the adult brain. However, new neurons generated in the dentate gyrus decline sharply with age and to an even greater extent in neurodegenerative diseases. Here we raise the question whether peripheral immune mechanisms can generate immunity to such deficits in neuronal repair. We demonstrate that in contrast to primarily innate immunity cytokines, such as interleukin-6 and tumor necrosis factor-alpha, the adaptive immunity cytokine IFN-gamma enhances neurogenesis in the dentate gyrus of adult mice and improves the spatial learning and memory performance of the animals. In older mice, the effect of IFN-gamma is more pronounced in both wild-type mice and mice with Alzheimer's-like disease and is associated with neuroprotection. In addition, IFN-gamma reverses the increase in oligodendrogenesis observed in a mouse model of Alzheimer's disease. We demonstrate that limited amounts of IFN-gamma in the brain shape the neuropoietic milieu to enhance neurogenesis, possibly representing the normal function of the immune system in controlling brain inflammation and repair.	[Baron, Rona; Nemirovsky, Anna; Harpaz, Idan; Monsonego, Alon] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; [Harpaz, Idan; Cohen, Hagit] Ben Gurion Univ Negev, Fac Hlth Sci, Anxiety & Stress Res Unit, Minist Hlth,Mental Hlth Ctr, IL-84105 Beer Sheva, Israel; [Nemirovsky, Anna; Harpaz, Idan; Monsonego, Alon] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, IL-84105 Beer Sheva, Israel; [Owens, Trevor] Univ So Denmark, Ctr Med Biotechnol, Odense, Denmark	Ben Gurion University; Ben Gurion University; Ben Gurion University; University of Southern Denmark	Monsonego, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.	alonmon@bgu.ac.il		Owens, Trevor/0000-0001-9315-6036				Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Aharoni R, 2005, J NEUROSCI, V25, P8217, DOI 10.1523/JNEUROSCI.1859-05.2005; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Balabanov R, 2007, J NEUROSCI, V27, P2013, DOI 10.1523/JNEUROSCI.4689-06.2007; Blasko I, 2001, J NEUROIMMUNOL, V116, P1, DOI 10.1016/S0165-5728(01)00279-X; Blasko I, 2000, NEUROBIOL DIS, V7, P682, DOI 10.1006/nbdi.2000.0321; Buckwalter MS, 2006, J NEUROSCI, V26, P11437, DOI 10.1523/JNEUROSCI.2436-06.2006; Buckwalter MS, 2006, AM J PATHOL, V169, P154, DOI 10.2353/ajpath.2006.051272; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103; Corbin JG, 1996, MOL CELL NEUROSCI, V7, P354, DOI 10.1006/mcne.1996.0026; Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje; Franklin K, 2007, MOUSE BRAIN STEROTAX; Gao X, 2000, MOL CELL NEUROSCI, V16, P338, DOI 10.1006/mcne.2000.0883; Golde S, 2002, J NEUROCHEM, V82, P269, DOI 10.1046/j.1471-4159.2002.00973.x; Hallam DM, 2000, J NEUROIMMUNOL, V110, P66, DOI 10.1016/S0165-5728(00)00289-7; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Hohlfeld R, 2006, NEUROL SCI, V27, pS1, DOI 10.1007/s10072-006-0537-7; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Kaneko N, 2006, NEUROPSYCHOPHARMACOL, V31, P2619, DOI 10.1038/sj.npp.1301137; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kim SJ, 2007, NEUROCHEM RES, V32, P1399, DOI 10.1007/s11064-007-9323-z; Kleinschek MA, 2007, J EXP MED, V204, P161, DOI 10.1084/jem.20061738; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kwidzinski E, 2005, FASEB J, V19, P1347, DOI 10.1096/fj.04-3228fje; Lee J, 2006, J NEUROSCI RES, V83, P1552, DOI 10.1002/jnr.20831; McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monsonego A, 2006, P NATL ACAD SCI USA, V103, P5048, DOI 10.1073/pnas.0506209103; Monsonego A, 2003, J IMMUNOL, V171, P2216, DOI 10.4049/jimmunol.171.5.2216; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Phillips LM, 1999, J NEUROIMMUNOL, V96, P218, DOI 10.1016/S0165-5728(99)00034-X; Renno T, 1998, MOL CELL NEUROSCI, V12, P376, DOI 10.1006/mcne.1998.0725; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; Song JH, 2005, J BIOL CHEM, V280, P12896, DOI 10.1074/jbc.M412139200; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Tran EH, 2000, J IMMUNOL, V164, P2759, DOI 10.4049/jimmunol.164.5.2759; Turnley AM, 2002, NAT NEUROSCI, V5, P1155, DOI 10.1038/nn954; Turnley AM, 2001, NEUROREPORT, V12, P3443, DOI 10.1097/00001756-200111160-00013; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wheeler RD, 2006, IMMUNOLOGY, V118, P527, DOI 10.1111/j.1365-2567.2006.02395.x; WINNER B, 2007, NEUROBIOL A IN PRESS; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; Xie Z, 2002, J NEUROSCI, V22, P3484; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562; Zhang PL, 2006, MOL CELL NEUROSCI, V31, P387, DOI 10.1016/j.mcn.2005.10.014; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	54	119	123	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2843	2852		10.1096/fj.08-105866	http://dx.doi.org/10.1096/fj.08-105866			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18390924				2022-12-28	WOS:000258089300024
J	Shin, SS; Kim, TM; Kim, SY; Kim, TW; Seo, HW; Lee, SK; Kwon, SC; Lee, GS; Kim, H; Lim, JM; Han, JY				Shin, Sang Su; Kim, Tae Min; Kim, Sun Young; Kim, Tae Wan; Seo, Hee Won; Lee, Seul Ki; Kwon, Se Chang; Lee, Gwan Sun; Kim, Heebal; Lim, Jeong Mook; Han, Jae Yong			Generation of transgenic quail through germ cell-mediated germline transmission	FASEB JOURNAL			English	Article						primordial germ cells; lentiviral vector; avian transgenesis	LENTIVIRAL VECTORS; RECIPIENT EMBRYOS; GENE-TRANSFER; CHICK-EMBRYO; STEM-CELLS; IN-VITRO; EXPRESSION; CHIMERAS; GENOME; VIRUS	Here, we describe the production of transgenic quail via a germline transmission system using postmigratory gonadal primordial germ cells (gPGCs). gPGCs retrieved from the embryonic gonads of 5-day-old birds were transduced with a lentiviral vector and subsequently transferred into recipient embryos. Testcross and genetic analyses revealed that among three germline chimeric G0 quail, one male produced transgenic offspring; of 310 hatchlings from the transgenic germline chimera, 24 were identified as donor-derived offspring, and 6 were transgenic (6/310, 1.9%). Conventional transgenesis using stage X blastodermal embryos was also conducted, but the efficiency of transgenesis was similar between the two systems (< 1.6 vs. 1.9% for the conventional and gPGC-mediated systems, respectively). However, substantial advantages can be gained from gPGC-mediated method in that it enables an induced germline modification, whereas direct retroviral transfer to stage X embryos causes mosaic integration. The use of gonadal PGCs for transgenesis may lead to the production of bioreactors.	[Shin, Sang Su; Kim, Tae Min; Kim, Sun Young; Kim, Tae Wan; Seo, Hee Won; Kim, Heebal; Lim, Jeong Mook; Han, Jae Yong] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea; [Lee, Seul Ki] Avicore Biotechnol Inst Incorp, Gyeonggi Do, South Korea; [Kwon, Se Chang; Lee, Gwan Sun] Hanmi Pharm Co Ltd, Hanmi Res Ctr, Gyeonggi Do, South Korea	Seoul National University (SNU); Hanmi Pharmaceutical	Han, JY (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea.	jaehan@snu.ac.kr	Kim, Heebal/A-8889-2016; Kim, Tae Wan/GRK-0135-2022	Kim, Heebal/0000-0003-3064-1303; Kim, Tae Wan/0000-0002-0831-6881				Barr SD, 2005, J VIROL, V79, P12035, DOI 10.1128/JVI.79.18.12035-12044.2005; Chapman SC, 2005, DEVELOPMENT, V132, P935, DOI 10.1242/dev.01652; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; Han JY, 2002, THERIOGENOLOGY, V58, P1531, DOI 10.1016/S0093-691X(02)01061-0; Hofmann A, 2003, EMBO REP, V4, P1054, DOI 10.1038/sj.embor.7400007; Ivarie R, 2003, TRENDS BIOTECHNOL, V21, P14, DOI 10.1016/S0167-7799(02)00009-4; Karagenc L, 1996, DEV GENET, V19, P290, DOI 10.1002/(SICI)1520-6408(1996)19:4<290::AID-DVG2>3.3.CO;2-S; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Kim MA, 2005, THERIOGENOLOGY, V63, P774, DOI 10.1016/j.theriogenology.2004.04.014; Koo BC, 2006, FASEB J, V20, P2251, DOI 10.1096/fj.06-5866com; LeDouarin NM, 1997, INT REV CYTOL, V175, P241, DOI 10.1016/S0074-7696(08)62128-2; Lillico SG, 2007, P NATL ACAD SCI USA, V104, P1771, DOI 10.1073/pnas.0610401104; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; McGrew MJ, 2004, EMBO REP, V5, P728, DOI 10.1038/sj.embor.7400171; MEYER DB, 1964, DEV BIOL, V10, P154, DOI 10.1016/0012-1606(64)90009-0; Mizuarai S, 2001, BIOCHEM BIOPH RES CO, V286, P456, DOI 10.1006/bbrc.2001.5422; Mozdziak PE, 2003, DEV DYNAM, V226, P439, DOI 10.1002/dvdy.10234; Opsahl ML, 2002, GENETICS, V160, P1107; Park TS, 2003, BIOL REPROD, V68, P1657, DOI 10.1095/biolreprod.102.006825; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; SALTER DW, 1987, VIROLOGY, V157, P236, DOI 10.1016/0042-6822(87)90334-5; Sang H, 2006, NAT BIOTECHNOL, V24, P955, DOI 10.1038/nbt0806-955; Scott BB, 2005, P NATL ACAD SCI USA, V102, P16443, DOI 10.1073/pnas.0508437102; SELLECK MAJ, 1996, METHODS CELL BIOL, V51; Smith J, 2000, ANIM GENET, V31, P96, DOI 10.1046/j.1365-2052.2000.00565.x; Sugiyama O, 2005, MOL THER, V11, P390, DOI 10.1016/j.ymthe.2004.10.019; Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939; van de Lavoir MC, 2006, NATURE, V441, P766, DOI 10.1038/nature04831	29	55	58	4	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2435	2444		10.1096/fj.07-101485	http://dx.doi.org/10.1096/fj.07-101485			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263695				2022-12-28	WOS:000257292500035
J	Maisey, HC; Quach, D; Hensler, ME; Liu, GY; Gallo, RL; Nizet, V; Doran, KS				Maisey, Heather C.; Quach, Darin; Hensler, Mary E.; Liu, George Y.; Gallo, Richard L.; Nizet, Victor; Doran, Kelly S.			A group B streptococcal pilus protein promotes phagocyte resistance and systemic virulence	FASEB JOURNAL			English	Article						Streptococcus agalactiae; pili; GBS; macrophage; neutrophil; antimicrobial peptides	ESCHERICHIA-COLI STRAINS; LACTOCOCCUS-LACTIS; ANTIMICROBIAL PEPTIDES; TYPE-1 FIMBRIAE; MECHANISMS; EXPRESSION; ANTIGENS; BACTERIA; ADHESION; MUTANTS	Group B Streptococcus (GBS) is a major cause of invasive bacterial infections in newborns and certain adult populations. Surface filamentous appendages known as pili have been recently identified in GBS. However, little is known about the role of these structures in disease pathogenesis. In this study we sought to probe potential functional role(s) of PilB, the major GBS pilus protein subunit, by coupling analysis of an isogenic GBS pilB knockout strain with heterologous expression of the pilB gene in the nonpathogenic bacterium Lactococcus lactis. We found the knockout GBS strain that lacked PilB was more susceptible than wild-type (WT) GBS to killing by isolated macrophages and neutrophils. Survival was linked to the ability of PilB to mediate GBS resistance to cathelicidin antimicrobial peptides. Furthermore, the PilB-deficient GBS mutant was more readily cleared from the mouse bloodstream and less-virulent in vivo compared to the WT parent strain. Strikingly, overexpression of the pilB gene alone in L. lactis enhanced resistance to phagocyte killing, increased bloodstream survival, and conferred virulence in a mouse challenge model. Together these data demonstrate that the pilus backbone subunit, PilB, plays an integral role in GBS virulence and suggests a novel role for gram-positive pili in thwarting the innate defenses of phagocyte killing.	[Quach, Darin; Doran, Kelly S.] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; [Quach, Darin; Doran, Kelly S.] San Diego State Univ, Ctr Microbial Sci, San Diego, CA 92182 USA; [Maisey, Heather C.; Hensler, Mary E.; Nizet, Victor; Doran, Kelly S.] Univ Calif San Diego, Sch Med, Dept Pediat, Div Pharmacol & Drug Discovery, La Jolla, CA 92093 USA; [Gallo, Richard L.] Univ Calif San Diego, Sch Med, Dept Med, Div Dermatol, La Jolla, CA 92093 USA; [Nizet, Victor] Univ Calif San Diego, Sch Med, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Liu, George Y.] Cedars Sinai Med Ctr, Div Pediat Infect Dis, Los Angeles, CA 90048 USA; [Liu, George Y.] Cedars Sinai Med Ctr, Immunobiol Res Inst, Los Angeles, CA 90048 USA	California State University System; San Diego State University; California State University System; San Diego State University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Doran, KS (corresponding author), San Diego State Univ, Dept Biol, Rm 317,5500 Campanile Dr, San Diego, CA 92182 USA.	kdoran@sciences.sdsu.edu	Nizet, Victor/AAF-3190-2019; Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Nizet, Victor/0000-0003-3847-0422; Quach, Darin/0000-0002-3244-5376	NIAID NIH HHS [R01 AI052453-07, R01 AI052453, R37 AI052453] Funding Source: Medline; NIAMS NIH HHS [R01 AR052728, R01 AR052728-04] Funding Source: Medline; NINDS NIH HHS [R01 NS051247, R01NS051247] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052453, R37AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051247] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Althouse C, 2003, INFECT IMMUN, V71, P6446, DOI 10.1128/IAI.71.11.6446-6452.2003; Andres E, 2004, J INTERN MED, V255, P519, DOI 10.1046/j.1365-2796.2003.01278.x; Barocchi MA, 2006, P NATL ACAD SCI USA, V103, P2857, DOI 10.1073/pnas.0511017103; BLUMENSTOCK E, 1982, INFECT IMMUN, V35, P264, DOI 10.1128/IAI.35.1.264-269.1982; Braff MH, 2007, J INFECT DIS, V195, P1365, DOI 10.1086/513277; Buccato S, 2006, J INFECT DIS, V194, P331, DOI 10.1086/505433; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; CISAR JO, 1988, INFECT IMMUN, V56, P2984, DOI 10.1128/IAI.56.11.2984-2989.1988; Doran KS, 2004, MOL MICROBIOL, V54, P23, DOI 10.1111/j.1365-2958.2004.04266.x; Dramsi S, 2006, MOL MICROBIOL, V60, P1401, DOI 10.1111/j.1365-2958.2006.05190.x; DUGUID JP, 1969, J MED MICROBIOL, V2, P535, DOI 10.1099/00222615-2-4-535; FIVESTAYLOR PM, 1985, INFECT IMMUN, V47, P752, DOI 10.1128/IAI.47.3.752-759.1985; Framson PE, 1997, APPL ENVIRON MICROB, V63, P3539, DOI 10.1128/AEM.63.9.3539-3547.1997; FREITAG NE, 1995, MOL MICROBIOL, V16, P575, DOI 10.1111/j.1365-2958.1995.tb02420.x; Frick IM, 2003, J BIOL CHEM, V278, P16561, DOI 10.1074/jbc.M301995200; GBARAH A, 1993, INFECT IMMUN, V61, P1687, DOI 10.1128/IAI.61.5.1687-1693.1993; GIBBONS RJ, 1988, INFECT IMMUN, V56, P439, DOI 10.1128/IAI.56.2.439-445.1988; GOETZ MB, 1987, J INFECT DIS, V156, P229, DOI 10.1093/infdis/156.1.229; Gutekunst H, 2003, INFECT IMMUN, V71, P5056, DOI 10.1128/IAI.71.9.5056-5064.2003; Hamilton A, 2006, INFECT IMMUN, V74, P6179, DOI 10.1128/IAI.00895-06; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; Jin T, 2004, J IMMUNOL, V172, P1169, DOI 10.4049/jimmunol.172.2.1169; KEITH BR, 1990, INFECT IMMUN, V58, P3448, DOI 10.1128/IAI.58.10.3448-3454.1990; KOGA T, 1993, INFECT IMMUN, V61, P1371, DOI 10.1128/IAI.61.4.1371-1377.1993; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Lauer P, 2005, SCIENCE, V309, P105, DOI 10.1126/science.1111563; Liu GY, 2004, P NATL ACAD SCI USA, V101, P14491, DOI 10.1073/pnas.0406143101; LOCK R, 1990, INFECT IMMUN, V58, P37, DOI 10.1128/IAI.58.1.37-42.1990; Maione D, 2005, SCIENCE, V309, P148, DOI 10.1126/science.1109869; Maisey HC, 2007, J BACTERIOL, V189, P1464, DOI 10.1128/JB.01153-06; Mellata M, 2003, INFECT IMMUN, V71, P494, DOI 10.1128/IAI.71.1.494-503.2003; Mora M, 2005, P NATL ACAD SCI USA, V102, P15641, DOI 10.1073/pnas.0507808102; Mygind PH, 2005, NATURE, V437, P975, DOI 10.1038/nature04051; Nizet V, 2006, CURR ISSUES MOL BIOL, V8, P11; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; Poyart C, 2003, MOL MICROBIOL, V49, P1615, DOI 10.1046/j.1365-2958.2003.03655.x; Pritzlaff CA, 2001, MOL MICROBIOL, V39, P236, DOI 10.1046/j.1365-2958.2001.02211.x; Rosini R, 2006, MOL MICROBIOL, V61, P126, DOI 10.1111/j.1365-2958.2006.05225.x; Saito T, 1997, ARCH ORAL BIOL, V42, P539, DOI 10.1016/S0003-9969(97)00054-X; Sauer FG, 2000, CURR OPIN MICROBIOL, V3, P65, DOI 10.1016/S1369-5274(99)00053-3; Scott JR, 2006, MOL MICROBIOL, V62, P320, DOI 10.1111/j.1365-2958.2006.05279.x; Telford JL, 2006, NAT REV MICROBIOL, V4, P509, DOI 10.1038/nrmicro1443; Timmer AM, 2006, MOL MICROBIOL, V62, P15, DOI 10.1111/j.1365-2958.2006.05337.x; Ton-That H, 2004, TRENDS MICROBIOL, V12, P228, DOI 10.1016/j.tim.2004.03.004; WEERKAMP AH, 1986, J BACTERIOL, V165, P746, DOI 10.1128/jb.165.3.746-755.1986; Whittaker CJ, 1996, ANNU REV MICROBIOL, V50, P513, DOI 10.1146/annurev.micro.50.1.513; WILKINSON HW, 1977, J CLIN MICROBIOL, V6, P183; Wilson WW, 2001, J MICROBIOL METH, V43, P153, DOI 10.1016/S0167-7012(00)00224-4; YANAGAWA R, 1968, JPN J VET RES, V16, P31	51	85	93	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1715	1724		10.1096/fj.07-093963	http://dx.doi.org/10.1096/fj.07-093963			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198218	Green Accepted			2022-12-28	WOS:000256352700012
J	Haas, F				Haas, Francois			German science and black racism - roots of the Nazi Holocaust	FASEB JOURNAL			English	Article						eugenics; racial hygiene; Nazi medicine; Social Darwinism; Herero	RACE	The Nazi's cornerstone precept of "racial hygiene" gave birth to their policy of "racial cleansing" that led to the murders of millions. It was developed by German physicians and scientists in the late 19th century and is rooted in the period's Social Darwinism that placed blacks at the bottom of the racial ladder. This program was first manifested in the near-extermination of the African Herero people during the German colonial period. After WWI, the fear among the German populace that occupying African troops and their Afro-German children would lead to "bastardization" of the German people formed a unifying racial principle that the Nazis exploited. They extended this mind-set to a variety of "unworthy" groups, leading to the physician-administered racial Nuremberg laws, the Sterilization laws, the secret sterilization of Afro-Germans, and the German euthanasia program. This culminated in the extermination camps.	[Haas, Francois] NYU, Sch Med, New York Univ Inst Community Hlth & Res, New York, NY USA	New York University	Haas, F (corresponding author), 400 E 34th St,RR114, New York, NY 10016 USA.	francois.haas@med.nyu.edu		Haas, Francois/0000-0003-2298-1383				ABEL W, 1934, BASTARD RHEIN, V2, P4; ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; [Anonymous], 1921, NY TIMES, P1; [Anonymous], 1993, HIST PUBLIC HLTH; [Anonymous], 1934, NY TIMES; CAMPT T, 2005, OTHER GERMANS BLACKS; Campt TM, 2003, CALLALOO, V26, P322, DOI 10.1353/cal.2003.0036; CHARATAN F, 2004, BRIT MED J, V329, P899; Fetzer C, 1913, Z MORPHOL ANTHROPOL, V16, P95; Fleck Ludwik, 1979, GENESIS DEV SCI FACT; Galton Francis, 1907, INQUIRIES HUMAN FACU; Gewald Jan-Bart, 1999, HERERO HEROES; GRAY A, 1919, J COMP LEGIS INTERNA, V1, P25; Hecht JM, 2000, J HIST IDEAS, V61, P285, DOI 10.1353/jhi.2000.0018; Hitler Adolf, 1943, MEIN KAMPF; KATER MH, 1989, AM HIST REV, V94, P11, DOI 10.2307/1862076; Kestling Robert W., 1998, J NEGRO HIST, V83, P84, DOI [10.2307/2668561, DOI 10.2307/2668561]; LIFTON RJ, 1986, NAZI DOCTORS; Madley B, 2005, EUR HIST Q, V35, P429, DOI 10.1177/0265691405054218; MOREL ED, 1920, NATION          0327, P893; NELSON KL, 1970, J MOD HIST, V42, P606, DOI 10.1086/244041; *OFF STRAT SERV, 1982, WANN PROT 1944 REP A, V11; POMMERIN R, 1982, GER STUD REV, V5, P315, DOI 10.2307/1428948; Proctor Robert N., 1988, RACIAL HYGIENE MED N; Scheck R, 2005, J MOD HIST, V77, P325, DOI 10.1086/431817; SILVESTER J, 2003, WORDS CANNOT BE FOUN, V11; STONE D, 2001, PATTERNS PREJUDICE, V35, P34; Swan Jon, 1991, MHQ Q J MILITARY HIS, V3, P36; Weikart R, 2003, GER STUD REV, V26, P273, DOI 10.2307/1433326; WEILKART R, 1993, J HIST IDEAS, V54, P469; Weiss S.F., 1990, WELLBORNE SCI EUGENI, P8	31	14	15	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2008	22	2					332	337		10.1096/fj.08-0202ufm	http://dx.doi.org/10.1096/fj.08-0202ufm			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	257TY	18239065				2022-12-28	WOS:000252822600002
J	Abdul-Hafez, A; Shu, RJ; Uhal, BD				Abdul-Hafez, Amal; Shu, Ruijie; Uhal, Bruce D.			JunD and HIF-1 alpha mediate transcriptional activation of angiotensinogen by TGF-beta 1 in human lung fibroblasts	FASEB JOURNAL			English	Article						idiopathic pulmonary fibrosis; local angiotensin system; angiotensinogen promoter; activation protein-1	IDIOPATHIC PULMONARY-FIBROSIS; ALVEOLAR EPITHELIAL-CELLS; TRANSFORMING GROWTH FACTOR-BETA(1); BLEOMYCIN-INDUCED APOPTOSIS; DISEASE PROGRESSION; MESANGIAL CELLS; LIVER FIBROSIS; STELLATE CELLS; IN-VITRO; EXPRESSION	Earlier work showed that TGF-beta 1 potently increases angiotensinogen (AGT) gene mRNA in primary human lung fibroblasts. Here the mechanism of TGF-beta 1-induced AGT expression was studied in the IMR90 human lung fibroblast cell line. The increase in AGT mRNA induced by TGF-beta 1 was completely blocked by actinomycin-D. TGF-beta 1 increased the activity of a full-length human AGT promoter-luciferase reporter (AGT-LUC) but did not alter AGT mRNA half-life. Serial deletion analyses revealed that 67% of TGF-beta-inducible AGT-LUC activity resides in a small domain of the AGT core promoter; this domain contains binding sites for hypoxia-inducible factor (HIF)-1 and activation protein-1 (AP-1) transcription factors. TGF-beta 1 increased HIF-1 alpha protein abundance and the activity of a hypoxia-responsive element reporter; overexpression of HIF-1 increased basal AGT-LUC activity. Both oligonucleotide pulldown and chromatin immunoprecipitation assays revealed increased binding of JunD and HIF-1 alpha to the AGT core promoter in response to TGF-beta 1. TGF-beta 1-inducible AGT-LUC was reduced by an AP-1 dominant negative or by mutation of the AP-1 site. Knockdown of either JunD or HIF-1 alpha individually by siRNA partially reduced AGT-LUC. In contrast, simultaneous knockdown of both JunD and HIF-1 alpha completely eliminated TGF-beta 1-inducible AGT-LUC activity. These data suggest that TGF-beta 1 up-regulates AGT transcription in human lung fibroblasts through a mechanism that requires both JunD and HIF-1 alpha binding to the AGT core promoter. They also suggest a molecular mechanism linking hypoxia signaling and fibrogenic stimuli in the lungs.-Abdul-Hafez, A., Shu, R., Uhal, B. D. JunD and HIF-1 alpha mediate transcriptional activation of angiotensinogen by TGF-beta 1 in human lung fibroblasts. FASEB J. 23, 1655-1662 (2009)	[Abdul-Hafez, Amal; Shu, Ruijie; Uhal, Bruce D.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Michigan State University	Uhal, BD (corresponding author), Michigan State Univ, Dept Physiol, 3197 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	uhal@msu.edu	Abdul-Hafez, Amal/HCH-3743-2022	Abdul-Hafez, Amal/0000-0002-2895-7862	Public Health Service [HL-45136]; American Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045136, R29HL045136] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by Public Health Service grant HL-45136 to B.D.U. and by an American Heart Association predoctoral fellowship to A.A.-H.	Campbell SE, 1997, J MOL CELL CARDIOL, V29, P1947, DOI 10.1006/jmcc.1997.0435; Dixon JB, 2003, J HEPATOL, V39, P967, DOI 10.1016/S0168-8278(03)00459-8; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; Jeunemaitre X, 2004, HANDB EXP PHARM, V163/1, P173; Jiang YL, 2007, ACTA BIOCH BIOPH SIN, V39, P73, DOI 10.1111/j.1745-7270.2007.00249.x; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; Ko SH, 2006, J CELL BIOCHEM, V98, P343, DOI 10.1002/jcb.20797; Krick S, 2005, AM J RESP CELL MOL, V32, P395, DOI 10.1165/rcmb.2004-0314OC; Li XP, 2006, AM J PHYSIOL-LUNG C, V291, pL887, DOI 10.1152/ajplung.00432.2005; Li XP, 2004, AM J PHYSIOL-LUNG C, V287, pL46, DOI 10.1152/ajplung.00442.2003; Li XP, 2003, AM J PHYSIOL-LUNG C, V284, pL501, DOI 10.1152/ajplung.00273.2002; Marshall RP, 2004, AM J PHYSIOL-LUNG C, V286, pL156, DOI 10.1152/ajplung.00313.2002; Marshall RP, 2000, AM J RESP CRIT CARE, V161, P1999, DOI 10.1164/ajrccm.161.6.9907004; McMahon S, 2006, J BIOL CHEM, V281, P24171, DOI 10.1074/jbc.M604507200; Molina-Molina M, 2008, EUR RESPIR J, V32, P1004, DOI 10.1183/09031936.00015808; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Pfafflin A, 2006, CELL PHYSIOL BIOCHEM, V18, P199, DOI 10.1159/000097667; Powell EE, 2000, HEPATOLOGY, V31, P828, DOI 10.1053/he.2000.6253; Ray S, 2005, GASTROENTEROLOGY, V129, P1616, DOI 10.1053/j.gastro.2005.07.055; Shah R, 2006, HUM GENET, V120, P461, DOI 10.1007/s00439-006-0194-1; Sherman CT, 2001, MOL ENDOCRINOL, V15, P441, DOI 10.1210/me.15.3.441; Shi YF, 2007, FEBS LETT, V581, P203, DOI 10.1016/j.febslet.2006.12.010; Tzouvelekis A, 2007, AM J RESP CRIT CARE, V176, P1108, DOI 10.1164/rccm.200705-683OC; Uhal BD, 1998, AM J PHYSIOL-LUNG C, V275, pL1192, DOI 10.1152/ajplung.1998.275.6.L1192; Uhal BD, 1995, AM J PHYSIOL-LUNG C, V269, pL819, DOI 10.1152/ajplung.1995.269.6.L819; Uhal BD, 2007, CURR PHARM DESIGN, V13, P1247, DOI 10.2174/138161207780618885; Wang RG, 1999, AM J PHYSIOL-LUNG C, V277, pL1158, DOI 10.1152/ajplung.1999.277.6.L1158; Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143, DOI 10.1152/ajplung.2000.279.1.L143; Weber K T, 2000, J Renin Angiotensin Aldosterone Syst, V1, P295, DOI 10.3317/jraas.2000.058; Xaubet A, 2003, AM J RESP CRIT CARE, V168, P431, DOI 10.1164/rccm.200210-1165OC; Xiao F, 2006, J GASTROEN HEPATOL, V21, P1488, DOI 10.1111/j.1440-1746.2006.04527.x; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200; Yoshiji H, 2001, HEPATOLOGY, V34, P745, DOI 10.1053/jhep.2001.28231; [No title captured]	36	33	34	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1655	1662		10.1096/fj.08-114611	http://dx.doi.org/10.1096/fj.08-114611			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19211927	Green Published			2022-12-28	WOS:000266652400005
J	Liberman, AC; Druker, J; Refojo, D; Holsboer, F; Arzt, E				Liberman, Ana C.; Druker, Jimena; Refojo, Damian; Holsboer, Florian; Arzt, Eduardo			Glucocorticoids inhibit GATA-3 phosphorylation and activity in T cells	FASEB JOURNAL			English	Article						GCs; T helper 2; p38 mitogen-activated protein kinase; interleukin 5	TRANSCRIPTION FACTOR GATA-3; NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; CYTOKINE GENE-EXPRESSION; DEVELOPING TH1 CELLS; C-JUN; INTERLEUKIN-5 GENE; IFN-GAMMA; ANTIINFLAMMATORY ACTION; MAPK PHOSPHATASE-1	Glucocorticoid (GC) immunosuppression and anti-inflammatory action involve the regulation of several transcription factors (TFs). GCs inhibit the acute production of T-helper (Th) 1 and Th2 cytokines but ultimately favor a shift toward Th2 phenotype. GCs inhibit the transcriptional activity of T-bet Th1 TF by a transrepression mechanism. Here we analyze GC regulation of GATA-3, the master driver of Th2 differentiation. We found that GCs inhibit GATA-3 transcriptional activity. We demonstrate that this mechanism does not involve physical interaction between the glucocorticoid receptor (GR) and GATA-3 or reduction of GATA-3 binding to DNA, as described previously for T-bet. Instead, GCs inhibit GATA-3 activity by inhibition of p38 mitogen-activated protein kinase induced GATA-3 phosphorylation. GCs also inhibit GATA-3 mRNA and protein expression. Finally, GATA-3 inhibition affects the interleukin-5 gene, a central Th2 cytokine. The IC50 of dexamethasone is 10 nM with a maximum effect at 100 nM. All inhibitory actions were blocked by the GR antagonist RU38486 (1 uM), proving the specificity of GR action. In view of the crucial role of GATA-3 in T-cell differentiation and inflammation, we propose that the mechanism of GATA-3 inhibition compared with that in T-bet may have relevant implications in understanding and modulating the anti-inflammatory and Th-regulatory properties of GCs. Liberman, A. C., Druker, J., Refojo, D., Holsboer, F., Arzt, E. Glucocorticoids inhibit GATA-3 phosphorylation and activity in T cells. FASEB J. 23, 1558-1571 (2009)	[Liberman, Ana C.; Druker, Jimena; Refojo, Damian; Arzt, Eduardo] Univ Buenos Aires, Lab Fisiol & Biol Mol, FCEN, Dept Fisiol & Biol Mol & Celular, RA-1428 Buenos Aires, DF, Argentina; [Liberman, Ana C.; Druker, Jimena; Refojo, Damian; Arzt, Eduardo] Consejo Nacl Invest Cient & Tecn, Inst Fisiol & Biol Mol & Neurosci, IFIBYNE, RA-1033 Buenos Aires, DF, Argentina; [Refojo, Damian; Holsboer, Florian] Max Planck Inst Psychiat, D-80804 Munich, Germany	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Max Planck Society	Arzt, E (corresponding author), Univ Buenos Aires, Lab Fisiol & Biol Mol, FCEN, Dept Fisiol & Biol Mol & Celular, Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.	earzt@fbmc.fcen.uba.ar		Refojo, Damian/0000-0002-9798-6413	Max Planck Society, Germany; University of Buenos Aires (UBA); CONICET; Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina	Max Planck Society, Germany(Max Planck Society); University of Buenos Aires (UBA)(University of Buenos Aires); CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina(ANPCyT)	We thank Drs. Dietmar Spengler (Max Planck Institute of Psychiatry, Munich, Germany), Anuradha Ray (University of Pittsburgh School of Medicine, Pittsburgh, PA, USA), Jeffrey Leiden (Harvard Medical School and Center for Prevention of Cardiovascular Disease, Harvard School of Public Health, Boston, MA, USA), Takashi Yokota (Institute of Medical Science, University of Tokyo, Tokyo, Japan), and Tamara Tanos and Omar Cosso (Universidad de Buenos Aires and IFIBYNE-CONICET, Buenos Aires, Argentina) for providing the plasmids used in this work. This work was supported by grants from the Max Planck Society, Germany; and the University of Buenos Aires (UBA), the CONICET, and the Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina.	Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Beck IM, 2008, EMBO J, V27, P1682, DOI 10.1038/emboj.2008.95; BETZ M, 1991, J IMMUNOL, V146, P108; Biola A, 2000, FEBS LETT, V487, P229, DOI 10.1016/S0014-5793(00)02297-3; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Cho JY, 2003, INT IMMUNOL, V15, P1149, DOI 10.1093/intimm/dxg113; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; Costas M, 1996, J CLIN INVEST, V98, P1409, DOI 10.1172/JCI118928; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; DAYNES RA, 1989, EUR J IMMUNOL, V19, P2319, DOI 10.1002/eji.1830191221; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; Furst R, 2007, FASEB J, V21, P74, DOI 10.1096/fj.06-6752com; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.3.CO;2-4; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Hwang ES, 2002, J IMMUNOL, V169, P248, DOI 10.4049/jimmunol.169.1.248; Hwang ES, 2005, J EXP MED, V202, P1289, DOI 10.1084/jem.20051044; Jee YK, 2005, J BIOL CHEM, V280, P23243, DOI 10.1074/jbc.M503659200; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Klein-Hessling S, 2003, J IMMUNOL, V170, P2956, DOI 10.4049/jimmunol.170.6.2956; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; Kovalovsky D, 1998, EUR J IMMUNOL, V28, P2075; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; LAUE L, 1988, J STEROID BIOCHEM, V29, P591, DOI 10.1016/0022-4731(88)90156-2; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; LEE HJ, 1993, J IMMUNOL, V151, P6135; Liberman AC, 2007, FASEB J, V21, P1177, DOI 10.1096/fj.06-7452com; Maneechotesuwan K, 2007, J IMMUNOL, V178, P2491, DOI 10.4049/jimmunol.178.4.2491; Miyaura H, 2002, J IMMUNOL, V168, P1087, DOI 10.4049/jimmunol.168.3.1087; Mori A, 1997, BLOOD, V89, P2891, DOI 10.1182/blood.V89.8.2891; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Novac N, 2006, FASEB J, V20, P1074, DOI 10.1096/fj.05-5457com; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Paez-Pereda M, 2003, P NATL ACAD SCI USA, V100, P1034, DOI 10.1073/pnas.0237312100; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pelaia G, 2001, BIOCHEM PHARMACOL, V62, P1719, DOI 10.1016/S0006-2952(01)00791-2; Quan A, 2001, J ALLERGY CLIN IMMUN, V108, P340; RAIDEN S, 1995, J CLIN IMMUNOL, V15, P242, DOI 10.1007/BF01540881; Ramirez F, 1998, Dev Immunol, V6, P233, DOI 10.1155/1998/73401; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; Stranick KS, 1997, J BIOL CHEM, V272, P16453, DOI 10.1074/jbc.272.26.16453; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	68	58	60	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2009	23	5					1558	1571		10.1096/fj.08-121236	http://dx.doi.org/10.1096/fj.08-121236			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19124555				2022-12-28	WOS:000266651700031
J	Valdez, DJ; Nieto, PS; Garbarino-Pico, E; Avalle, LB; Diaz-Fajreldines, H; Schurrer, C; Cheng, KM; Guido, ME				Valdez, Diego J.; Nieto, Paula S.; Garbarino-Pico, Eduardo; Avalle, Lucia B.; Diaz-Fajreldines, Hugo; Schurrer, Clemar; Cheng, Kimberly M.; Guido, Mario E.			A nonmammalian vertebrate model of blindness reveals functional photoreceptors in the inner retina	FASEB JOURNAL			English	Article						phototransduction; feeding activity rhythms; pupillary responses; extraretinal photoreceptors; vitamin A-based photopigment	EXTRARETINAL LIGHT PERCEPTION; GANGLION-CELLS; NON-CONE; NON-ROD; MOLECULAR-CLONING; VISUAL PIGMENTS; CIRCADIAN CLOCK; CHICKEN; MELANOPSIN; PINEAL	In mammals, photoreceptors located in the inner retina convey photic information to the brain, regulating diverse non-image-forming tasks such as pupillary light reflexes and photic synchronization (entrainment) of daily activity rhythms. In nonmammalian vertebrates, the retina, deep brain photoreceptors, and pineal organ may be photoreceptive. Here we investigated light perception in the absence of functional cone and rod photoreceptors using GUCY1* chickens, birds carrying a null mutation that causes blindness at hatch. They showed light responses in both the pupillary light reflex and the entrainment of feeding rhythms to a 12:12 h light-dark cycle. Light responses persisted even when the extraretinal photoperception was abolished, but they were lost after enucleation; this strongly indicates the essential role played by the inner retina. A sensitivity spectrum study for the pupillary reflex that combined pupil responses to different monochromatic lights of various intensities demonstrated that a single opsin/vitamin A-based photopigment peaking at 484 nm drives photic responses; the best fit (lowest sum of squares, R-2 = 0.9622) was attained with an opsin: vitamin A2 template. The results are the first characterization of functional inner retinal photoreceptors participating in the regulation of non-image-forming activities in nonmammalian vertebrates.-Valdez, D. J., Nieto, P. S., Garbarino-Pico, E., Avalle, L. B., Diaz-Fajreldines, H., Schurrer, C., Cheng, K. M., Guido, M. E. A nonmammalian vertebrate model of blindness reveals functional photoreceptors in the inner retina. FASEB J. 23, 1186-1195 (2009)	[Valdez, Diego J.; Nieto, Paula S.; Garbarino-Pico, Eduardo; Guido, Mario E.] Univ Nacl Cordoba, CIQUIBIC, Dept Quim Biol, Fac Ciencias Quim, RA-5000 Cordoba, Argentina; [Avalle, Lucia B.; Schurrer, Clemar] Univ Nacl Cordoba, Fac Matemat Astron & Fis, RA-5000 Cordoba, Argentina; [Diaz-Fajreldines, Hugo] Inst Neurociencias Cordoba, Cordoba, Argentina; [Cheng, Kimberly M.] Univ British Columbia, Fac Land & Food Syst, Avian Res Ctr, Vancouver, BC V5Z 1M9, Canada	National University of Cordoba; National University of Cordoba; University of British Columbia	Guido, ME (corresponding author), Univ Nacl Cordoba, CIQUIBIC, Dept Quim Biol, Fac Ciencias Quim, RA-5000 Cordoba, Argentina.	mguido@fcq.unc.edu.ar		Garbarino Pico, Eduardo/0000-0002-2931-2038; Valdez, Diego Javier/0000-0002-4467-6761	Fundacion Antorchas, Fundacion Florencio Fiorini; Agencia Nacional de Promocion Cientifica y Tecnica (FONCyT); CAEN-International Society for Neurochemistry; Consejo Nacional de Investigaciones Cientificas y Tecnicas de la Republica Argentina (CONICET); Secretar a de Ciencia y Tecnica-Universidad Nacional de Cordoba (SeCyT-UNC)	Fundacion Antorchas, Fundacion Florencio Fiorini; Agencia Nacional de Promocion Cientifica y Tecnica (FONCyT)(ANPCyTFONCyT); CAEN-International Society for Neurochemistry; Consejo Nacional de Investigaciones Cientificas y Tecnicas de la Republica Argentina (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Secretar a de Ciencia y Tecnica-Universidad Nacional de Cordoba (SeCyT-UNC)(Secretaria de Ciencia y Tecnologia (SECYT))	We thank Dr. Carlos Mas, Dr. Agata Carpentieri, and Dr. Pablo Rodriguez for assistance. We are grateful to Dr. Michael Menaker for his comments on the results, to Dr. Russell Van Gelder and Dr. Dan Tu for advice on the iris preparation, to Dr. Silvina Perez for suggestions about sensitivity spectrum analysis, and to Dr. Ignacio Provencio (University of Virginia, Charlottesville, VA, USA) for the gift of the fitting templates. This work has been supported by the Fundacion Antorchas, Fundacion Florencio Fiorini, Agencia Nacional de Promocion Cientifica y Tecnica (FONCyT), CAEN-International Society for Neurochemistry, Consejo Nacional de Investigaciones Cientificas y Tecnicas de la Republica Argentina (CONICET), and Secretar a de Ciencia y Tecnica-Universidad Nacional de Cordoba (SeCyT-UNC).	Arendt D, 2003, INT J DEV BIOL, V47, P563; Babity J M, 1997, Methods Mol Biol, V85, P285; Bailey MJ, 2004, INVEST OPHTH VIS SCI, V45, P769, DOI 10.1167/iovs.03-1125; BARRETT RK, 1991, BRAIN RES, V563, P87, DOI 10.1016/0006-8993(91)91518-6; Bellingham J, 2006, PLOS BIOL, V4, P1334, DOI 10.1371/journal.pbio.0040254; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Bowmaker JK, 1997, VISION RES, V37, P2183, DOI 10.1016/S0042-6989(97)00026-6; Brandstatter R, 2003, J NEUROENDOCRINOL, V15, P398, DOI 10.1046/j.1365-2826.2003.01003.x; CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; CASSONE VM, 1984, J EXP ZOOL, V232, P539, DOI 10.1002/jez.1402320321; Chaurasia SS, 2005, J NEUROCHEM, V92, P158, DOI 10.1111/j.1471-4159.2004.02874.x; CHENG KM, 1980, POULTRY SCI, V59, P2179, DOI 10.3382/ps.0592179; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIN JP, 1981, PINEAL GLAND, V1, P27; Contin MA, 2006, FASEB J, V20, P2648, DOI 10.1096/fj.06-6133fje; David-Gray ZK, 1998, NAT NEUROSCI, V1, P655, DOI 10.1038/3656; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Farber DB, 1997, CURR OPIN NEUROBIOL, V7, P666, DOI 10.1016/S0959-4388(97)80087-6; Foster RG, 2002, PROG RETIN EYE RES, V21, P507, DOI 10.1016/S1350-9462(02)00036-8; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; GAMLIN PDR, 1984, J COMP NEUROL, V226, P523, DOI 10.1002/cne.902260407; Garbarino-Pico E, 2004, J BIOL CHEM, V279, P51172, DOI 10.1074/jbc.M309248200; Garbarino-Pico E, 2004, J NEUROSCI RES, V76, P642, DOI 10.1002/jnr.20126; Guido ME, 2002, NEUROCHEM RES, V27, P1473, DOI 10.1023/A:1021696321391; Gwinner E, 2001, PHILOS T R SOC B, V356, P1801, DOI 10.1098/rstb.2001.0959; Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; Heidel J, 1999, J AUST MATH SOC B, V41, P83, DOI 10.1017/S0334270000011048; Kubo Y, 2006, J NEUROCHEM, V97, P1155, DOI 10.1111/j.1471-4159.2006.03826.x; Kumbalasiri T, 2005, EXP EYE RES, V81, P368, DOI 10.1016/j.exer.2005.05.004; Lima LHRG, 2006, BIOL RHYTHM RES, V37, P393, DOI 10.1080/09291010600870230; LUCAS R, 2003, NAT NEUROSCI, V4, P621; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Lythgoe J.N., 1979, ECOLOGY VISION; McGoogan JM, 1999, AM J PHYSIOL-REG I, V277, pR1418, DOI 10.1152/ajpregu.1999.277.5.R1418; MCMILLAN F, 1975, ARCH OPHTHALMOL-CHIC, V93, P420; MENAKER M, 1968, P NATL ACAD SCI USA, V60, P146, DOI 10.1073/pnas.60.1.146; MENAKER M, 1968, P NATL ACAD SCI USA, V59, P414, DOI 10.1073/pnas.59.2.414; MENAKER M, 1976, PHOTOCHEM PHOTOBIOL, V23, P299, DOI 10.1111/j.1751-1097.1976.tb07251.x; MENAKER M, 1971, BIOL REPROD, V4, P295, DOI 10.1093/biolreprod/4.3.295; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; PARTRIDGE JC, 1991, VISION RES, V31, P619, DOI 10.1016/0042-6989(91)90002-M; Peirson S, 2006, NEURON, V49, P331, DOI 10.1016/j.neuron.2006.01.006; Peirson SN, 2005, METHOD ENZYMOL, V393, P697, DOI 10.1016/S0076-6879(05)93037-1; PILAR G, 1987, J NEUROSCI, V7, P3813, DOI 10.1523/jneurosci.07-12-03813.1987; PROVENCIO I, 1992, VISION RES, V32, P2201, DOI 10.1016/0042-6989(92)90084-V; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Semple-Rowland SL, 1998, P NATL ACAD SCI USA, V95, P1271, DOI 10.1073/pnas.95.3.1271; Semple-Rowland SL, 1999, EXP EYE RES, V69, P579, DOI 10.1006/exer.1999.0743; SKARF B, 1999, NEUROOPHTHALMOLOGY, P7; TABATA M, 1992, NATO ADV SCI INST SE, V236, P223; Tomonari S, 2005, DEV DYNAM, V234, P783, DOI 10.1002/dvdy.20600; Tomonari S, 2007, GENE EXPR PATTERNS, V7, P746, DOI 10.1016/j.modgep.2007.06.001; Tosini G, 2000, CHRONOBIOL INT, V17, P599, DOI 10.1081/CBI-100101067; Tu DC, 2004, SCIENCE, V306, P129, DOI 10.1126/science.1101484; ULSHAFER RJ, 1984, EXP EYE RES, V39, P125, DOI 10.1016/0014-4835(84)90003-4; UNDERWOOD H, 1982, EXPERIENTIA, V38, P1013, DOI 10.1007/BF01955345; Underwood Herbert, 2001, Handbook of Behavioral Neurobiology, V12, P111; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481	59	22	24	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1186	1195		10.1096/fj.08-117085	http://dx.doi.org/10.1096/fj.08-117085			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19074512				2022-12-28	WOS:000266651600023
J	Haskell-Luevano, C; Schaub, JW; Andreasen, A; Haskell, KR; Moore, MC; Koerper, LM; Rouzaud, F; Baker, HV; Millard, WJ; Walter, G; Litherland, SA; Xiang, ZM				Haskell-Luevano, Carrie; Schaub, Jay W.; Andreasen, Amy; Haskell, Kim R.; Moore, Marcus C.; Koerper, Lorraine M.; Rouzaud, Francois; Baker, Henry V.; Millard, William J.; Walter, Glenn; Litherland, S. A.; Xiang, Zhimin			Voluntary exercise prevents the obese and diabetic metabolic syndrome of the melanocortin-4 receptor knockout mouse	FASEB JOURNAL			English	Article						energy homeostasis; leptin; insulin; alpha-melanocyte stimulating hormone	AGOUTI-RELATED PROTEIN; BODY-COMPOSITION ANALYSIS; FRAMESHIFT MUTATION; ARCUATE NUCLEUS; MORBID-OBESITY; FOOD-INTAKE; IN-VIVO; PROOPIOMELANOCORTIN NEURONS; MOLECULAR-CLONING; RAT HYPOTHALAMUS	Exercise is a mechanism for maintenance of body weight in humans. Morbidly obese human patients have been shown to possess single nucleotide polymorphisms in the melanocortin-4 receptor (MC4R). MC4R knockout mice have been well characterized as a genetic model that possesses phenotypic metabolic disorders, including obesity, hyperphagia, hyperinsulinemia, and hyperleptinemia, similar to those observed in humans possessing dysfunctional hMC4Rs. Using this model, we examined the effect of voluntary exercise of MC4R knockout mice that were allowed access to a running wheel for a duration of 8 wk. Physiological parameters that were measured included body weight, body composition of fat and lean mass, food consumption, body length, and blood levels of cholesterol and nonfasted glucose, insulin, and leptin. At the termination of the experiment, hypothalamic mRNA expression levels of neuropeptide Y (NPY), agouti-related protein (AGRP), proopiomelanocortin (POMC), cocaine-and amphetamine-regulated transcript (CART), orexin, brain-derived neurotropic factor (BDNF), phosphatase with tensin homology (Pten), melanocortin-3 receptor (MC3R), and NPY-Y1R were determined. In addition, islet cell distribution and function in the pancreas were examined. In the exercising MC4R knockout mice, the pancreatic islet cell morphology and other physiological parameters resembled those observed in the wild-type littermate controls. Gene expression profiles identified exercise as having a significant effect on hypothalamic POMC, orexin, and MC3R levels. Genotype had a significant effect on AGRP, POMC, CART, and NPY-Y1R, with an exercise and genotype interaction effect on NPY gene expression. These data support the hypothesis that voluntary exercise can prevent the genetic predisposition of melanocortin-4 receptor-associated obesity and diabetes.-Haskell-Luevano, C., Schaub, J. W., Andreasen, A., Haskell, K. R., Moore, M. C., Koerper, L. M., Rouzaud, F., Baker, H. V., Millard, W. J., Walter, G., Litherland, S. A., Xiang, Z. Voluntary exercise prevents the obese and diabetic metabolic syndrome of the melanocortin-4 receptor knockout mouse. FASEB J. 23, 642-655 (2009)	[Haskell-Luevano, Carrie; Schaub, Jay W.; Andreasen, Amy; Haskell, Kim R.; Moore, Marcus C.; Koerper, Lorraine M.; Rouzaud, Francois; Millard, William J.; Xiang, Zhimin] Univ Florida, Dept Pharmacodynam, Coll Pharm, Gainesville, FL 32610 USA; [Baker, Henry V.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; [Walter, Glenn] Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA; [Litherland, S. A.] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Haskell-Luevano, C (corresponding author), Univ Florida, Dept Pharmacodynam, Coll Pharm, POB 100487, Gainesville, FL 32610 USA.	carrie@cop.ufl.edu		Baker, Henry/0000-0002-8273-5320	American Diabetes Association Research Award; National Institutes of Health [RO1DK057080]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057080] Funding Source: NIH RePORTER	American Diabetes Association Research Award(American Diabetes Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by an American Diabetes Association Research Award and National Institutes of Health grant RO1DK057080 (C. H. L.). We thank Dr. Dennis Huszar and Millennium Pharmaceuticals (Cambridge, MA, USA) for providing the MC4RKO mice. We thank Dr. Maureen Keller-Wood, Dr. Charles Wood, and Dr. Hendrik Luesch for the expert technical assistance and discussions regarding the RT-PCR experiments, Dr. Maureen Keller-Wood for assistance with the statistical analysis, and Dr. Martha Campbell-Thompson and the Pathology Molecular Core for help with pancreatic islet cell staining and quantitation.	BAETENS D, 1978, DIABETES, V27, P1, DOI 10.2337/diabetes.27.1.1; Bagnol D, 1999, J NEUROSCI, V19; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Baskin DG, 1999, DIABETES, V48, P828, DOI 10.2337/diabetes.48.4.828; Bi S, 2005, ENDOCRINOLOGY, V146, P1676, DOI 10.1210/en.2004-1441; Broberger C, 1997, NEUROENDOCRINOLOGY, V66, P393, DOI 10.1159/000127265; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Butler AA, 2001, NAT NEUROSCI, V4, P605, DOI 10.1038/88423; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; CARPENTER KJ, 1958, AM J PHYSIOL, V193, P499, DOI 10.1152/ajplegacy.1958.193.3.499; Che FY, 2005, J BIOL CHEM, V280, P4451, DOI 10.1074/jbc.M411178200; Chen AS, 2000, TRANSGENIC RES, V9, P145, DOI 10.1023/A:1008983615045; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Chiu S, 2004, OBES RES, V12, P1243, DOI 10.1038/oby.2004.158; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; Coutinho AE, 2006, PHYSIOL BEHAV, V87, P360, DOI 10.1016/j.physbeh.2005.10.006; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Daniels D, 2003, BRAIN RES, V986, P1, DOI 10.1016/S0006-8993(03)03162-7; De Souza J, 2000, NEUROENDOCRINOLOGY, V72, P126, DOI 10.1159/000054579; Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46; Droste SK, 2003, ENDOCRINOLOGY, V144, P3012, DOI 10.1210/en.2003-0097; Dubern B, 2001, J PEDIATR-US, V139, P204, DOI 10.1067/mpd.2001.116284; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Garris DR, 2004, PATHOBIOLOGY, V71, P231, DOI 10.1159/000080056; GOODRICK CL, 1978, PHYSIOL BEHAV, V21, P345, DOI 10.1016/0031-9384(78)90093-8; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Grill HJ, 1998, J NEUROSCI, V18, P10128; Gu W, 1999, DIABETES, V48, P635, DOI 10.2337/diabetes.48.3.635; HAGAN MM, 2000, AM J PHYSIOL-REG I, V52, P83; Hager J, 1998, NAT GENET, V20, P304, DOI 10.1038/3123; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; Haskell-Luevano C, 2001, REGUL PEPTIDES, V99, P1, DOI 10.1016/S0167-0115(01)00234-8; Hinney A, 2000, EUR J PHARMACOL, V410, P147, DOI 10.1016/S0014-2999(00)00812-8; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Irani BG, 2005, BIOCHEM BIOPH RES CO, V326, P638, DOI 10.1016/j.bbrc.2004.11.084; Jegou S, 2000, J NEUROENDOCRINOL, V12, P501, DOI 10.1046/j.1365-2826.2000.00477.x; Kawaguchi M, 2005, AM J PHYSIOL-REG I, V288, pR1800, DOI 10.1152/ajpregu.00805.2004; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; Kirk R.E., 1968, EXPT DESIGN PROCEDUR; Kiwaki K, 2004, AM J PHYSIOL-ENDOC M, V286, pE551, DOI 10.1152/ajpendo.00126.2003; Koehl M, 2008, FASEB J, V22, P2253, DOI 10.1096/fj.07-099101; KONDA Y, 1994, J BIOL CHEM, V269, P13162; Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Krude H, 2000, TRENDS ENDOCRIN MET, V11, P15, DOI 10.1016/S1043-2760(99)00213-1; Levin BE, 2006, INT J OBESITY, V30, P722, DOI 10.1038/sj.ijo.0803192; Li JY, 2002, J BIOL CHEM, V277, P9069, DOI 10.1074/jbc.M110467200; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Lubrano-Berthelier C, 2003, HUM MOL GENET, V12, P145, DOI 10.1093/hmg/ddg016; Marsh DJ, 1999, BRAIN RES, V848, P66, DOI 10.1016/S0006-8993(99)01962-9; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; McNulty JC, 2005, J MOL BIOL, V346, P1059, DOI 10.1016/j.jmb.2004.12.030; Mergen M, 2001, J CLIN ENDOCR METAB, V86, P3448, DOI 10.1210/jc.86.7.3448; Moran TH, 2006, PHILOS T R SOC B, V361, P1211, DOI 10.1098/rstb.2006.1857; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Narath E, 2001, EXP GERONTOL, V36, P1699, DOI 10.1016/S0531-5565(01)00145-0; Nguyen KTT, 2006, MOL CELL BIOL, V26, P4511, DOI 10.1128/MCB.00238-06; Ning K, 2006, EMBO J, V25, P2377, DOI 10.1038/sj.emboj.7601118; Oliff HS, 1998, MOL BRAIN RES, V61, P147, DOI 10.1016/S0169-328X(98)00222-8; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Patterson CM, 2008, AM J PHYSIOL-REG I, V294, pR290, DOI 10.1152/ajpregu.00661.2007; Proneth B, 2006, CHEM BIOL DRUG DES, V67, P215, DOI 10.1111/j.1747-0285.2006.00362.x; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428; Sina M, 1999, AM J HUM GENET, V65, P1501, DOI 10.1086/302660; Sutton GM, 2006, ENDOCRINOLOGY, V147, P2183, DOI 10.1210/en.2005-1209; Taicher GZ, 2003, ANAL BIOANAL CHEM, V377, P990, DOI 10.1007/s00216-003-2224-3; Tinsley FC, 2004, OBES RES, V12, P150, DOI 10.1038/oby.2004.20; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Vink T, 2001, MOL PSYCHIATR, V6, P325, DOI 10.1038/sj.mp.4000854; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Xu BJ, 2003, NAT NEUROSCI, V6, P736, DOI 10.1038/nn1073; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; Yeo GSH, 2003, HUM MOL GENET, V12, P561, DOI 10.1093/hmg/ddg057; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; Yuan Q, 2004, OBES RES, V12, P1179, DOI 10.1038/oby.2004.147	85	48	55	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					642	655		10.1096/fj.08-109686	http://dx.doi.org/10.1096/fj.08-109686			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18971258	Green Published			2022-12-28	WOS:000262892900035
J	Bussolati, B; Bruno, S; Grange, C; Ferrando, U; Camussi, G				Bussolati, Benedetta; Bruno, Stefania; Grange, Cristina; Ferrando, Ugo; Camussi, Giovanni			Identification of a tumor-initiating stem cell population in human renal carcinomas	FASEB JOURNAL			English	Article						angiogenesis; CD105; tumorigenesis; kidney tumor; progenitors; mesenchymal stem cells	IN-VITRO PROPAGATION; BREAST-CANCER CELLS; PROGENITOR CELLS; STROMAL CELLS; HUMAN KIDNEY; ANGIOGENESIS; CONTRIBUTE; MUTATIONS; MARROW; MICE	The purpose of the present study was to search for the presence of a tumor-initiating stem cell population in renal carcinomas. Based on the recent identification of mesenchymal stem cells in normal kidneys, we sorted cells expressing the mesenchymal stem cell marker CD105 from 5 human renal carcinomas. Because the CD105(+) but not the CD105(-) population showed enhanced tumorigenicity when injected in severely compromised immunodeficient (SCID) mice, we cloned and characterized CD105(+) cells and evaluated their stemness, differentiative ability, and serial tumor generation. Characterization of the phenotype of CD105(+) clones revealed several stem cell properties: 1) clonogenic ability, 2) expression of nestin, Nanog, Oct4 stem cell markers, and lack of differentiative epithelial markers, 3) ability to grow in non-adhesive spheroids, 4) an vitro differentiation into epithelial and endothelial cell types, and 5) generation in vivo of serially transplantable carcinomas containing an undifferentiated CD105(+) tumorigenic and a differentiated CD105(-) nontumorigenic population. In addition, some vessels present in carcinomas generated from CD105(+) clones were of human origin, suggesting the capability of tumor-initiating stem cells to in vivo differentiate also in endothelial cells. In conclusion, we demonstrate that CD105(+) cells and clones derived from renal carcinomas were enriched in tumor-initiating cells with stem characteristics.	Ctr Mol Biotechnol, Dept Internal Med, Turin, Italy; Ctr Res Expt Med, Turin, Italy		Camussi, G (corresponding author), Osped Maggiore G Giovanni Battista, Cattedra Nefrol, Dipartimento Med Interna, Corso Dogliotti 14, I-10126 Turin, Italy.	giovanni.camussi@unito.it	Bussolati, Benedetta/AAA-9058-2022; Camussi, Giovanni/J-7624-2016	Bussolati, Benedetta/0000-0002-3663-5134; Camussi, Giovanni/0000-0003-2795-232X; BRUNO, Stefania/0000-0002-8879-9536; GRANGE, CRISTINA/0000-0002-6960-5476	Associazione Italian, per la Ricerca sin Cancro (AIRC); Italian Ministry of University and Research (MIUR) COFIN; MIUR; Italian Ministry of Health (Ricerca Finalizzata 02; Progetto S. Paolo Oncologia; Progetti Finalizzati Regione Piemonte, Oncoprot	Associazione Italian, per la Ricerca sin Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR) COFIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); MIUR(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Health (Ricerca Finalizzata 02(Ministry of Health, Italy); Progetto S. Paolo Oncologia; Progetti Finalizzati Regione Piemonte, Oncoprot	This work was supported by the Associazione Italian, per la Ricerca sin Cancro (AIRC), Italian Ministry of University and Research (MIUR) COFIN and MIUR ex60% grants, the Italian Ministry of Health (Ricerca Finalizzata 02), the Progetto S. Paolo Oncologia, and the Progetti Finalizzati Regione Piemonte, Oncoprot.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aractingi S, 2005, CANCER RES, V65, P1755, DOI 10.1158/0008-5472.CAN-04-2783; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Barozzi P, 2003, NAT MED, V9, P554, DOI 10.1038/nm862; Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498; Bussolati B, 2005, AM J PATHOL, V166, P545, DOI 10.1016/S0002-9440(10)62276-6; BUSSOLATI B, 2008, J CELL MOL MED  0409; Cantley LG, 2005, NAT CLIN PRACT NEPHR, V1, P22, DOI 10.1038/ncpneph0021; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932; Dekel B, 2006, CANCER RES, V66, P6040, DOI 10.1158/0008-5472.CAN-05-4528; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508; Galie M, 2008, ONCOGENE, V27, P2542, DOI 10.1038/sj.onc.1210920; Gupta S, 2006, J AM SOC NEPHROL, V17, P3028, DOI 10.1681/ASN.2006030275; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Humphreys BD, 2008, ANNU REV MED, V59, P311, DOI 10.1146/annurev.med.59.061506.154239; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Khoury Joseph D, 2002, Ann Diagn Pathol, V6, P154, DOI 10.1053/adpa.2002.33901; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Lane BR, 2005, CURR OPIN UROL, V15, P289, DOI 10.1097/01.mou.0000178336.94991.17; Larkin JMG, 2007, NAT CLIN PRACT ONCOL, V4, P470, DOI 10.1038/ncponc0901; Lazzeri E, 2007, J AM SOC NEPHROL, V18, P3128, DOI 10.1681/ASN.2007020210; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li H, 2007, CANCER RES, V67, P10889, DOI 10.1158/0008-5472.CAN-07-2665; Liu BB, 2005, J CANCER RES CLIN, V131, P631, DOI 10.1007/s00432-005-0007-2; Liu L, 2007, ARCH PATHOL LAB MED, V131, P1290; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pelham RJ, 2006, P NATL ACAD SCI USA, V103, P19848, DOI 10.1073/pnas.0609635104; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Plotkin MD, 2006, AM J PHYSIOL-RENAL, V291, pF902, DOI 10.1152/ajprenal.00396.2005; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128	41	247	263	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2008	22	10					3696	3705		10.1096/fj.08-102590	http://dx.doi.org/10.1096/fj.08-102590			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18614581				2022-12-28	WOS:000259642600030
J	Marin, I; van Egmond, WN; van Haastert, PJM				Marin, Ignacio; van Egmond, Wouter N.; van Haastert, Peter J. M.			The Roco protein family: a functional perspective	FASEB JOURNAL			English	Review						LRRK2; GbpC; GTPase; kinase; signaling; Parkinson disease	PARKINSONS-DISEASE; KINASE-ACTIVITY; SIGNALING PATHWAY; LRRK2 GENE; IDENTIFICATION; DICTYOSTELIUM; MUTATIONS; CHEMOTAXIS; LOCALIZATION; TRANSDUCTION	In this review, we discuss the evolutionary, biochemical, and functional data available for members of the Roco protein family. They are characterized by having a conserved supradomain that contains a Ras-like GTPase domain, called Roc, and a characteristic COR (C-terminal of Roc) domain. A kinase domain and diverse regulatory and protein protein interaction domains are also often found in Roco proteins. First detected in the slime mold Dictyostelium discoideum, they have a broad phylogenetic range, being present in both prokaryotes and eukaryotes. The functions of these proteins are diverse. The best understood are Dictyostelium Rocos, which are involved in cell division, chemotaxis, and development. However, this family has received extensive attention because mutations in one of the human Roco genes (LRRK2) cause familial Parkinson disease. Other human Rocos are involved in epilepsy and cancer. Biochemical data suggest that Roc domains are capable of activating kinase domains intramolecularly. Interestingly, some of the dominant, disease-causing mutations in both the GTPase and kinase domains of LRRK2 increase kinase activity. Thus, Roco proteins may act as stand-alone transduction units, performing roles that were thought so far to require multiple proteins, as occur in the Ras transduction pathway.	[Marin, Ignacio] Consejo Super Invest Cient IBV CSIC, Inst Biomed Valencia, Valencia, Spain; [van Egmond, Wouter N.; van Haastert, Peter J. M.] Univ Groningen, Dept Mol Cell Biol, Groningen, Netherlands	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); University of Groningen	Marin, I (corresponding author), Consejo Super Invest Cient IBV CSIC, Inst Biomed Valencia, Valencia, Spain.	imarin@ibv.csic.es	Marin, Ignacio/A-9524-2009	Marin, Ignacio/0000-0002-1315-8961				Abe T, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng095; Abysalh JC, 2003, MOL BIOL CELL, V14, P14, DOI 10.1091/mbc.E02-06-0335; Araki T, 2003, J CELL SCI, V116, P2907, DOI 10.1242/jcs.00501; Berg D, 2005, BRAIN, V128, P3000, DOI 10.1093/brain/awh666; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Biskup S, 2006, ANN NEUROL, V60, P557, DOI 10.1002/ana.21019; Bosgraaf L, 2005, J CELL SCI, V118, P1899, DOI 10.1242/jcs.02317; Bosgraaf L, 2003, BBA-MOL CELL RES, V1643, P5, DOI 10.1016/j.bbamcr.2003.08.008; Bosgraaf L, 2002, J MUSCLE RES CELL M, V23, P781, DOI 10.1023/A:1024431813040; Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; Carland FM, 1996, DEVELOPMENT, V122, P1811; Chen-Plotkin AS, 2008, NEUROLOGY, V70, P521, DOI 10.1212/01.WNL.0000280574.17166.26; Cnops G, 2006, PLANT CELL, V18, P852, DOI 10.1105/tpc.105.040568; Cnops G, 1996, MOL GEN GENET, V253, P32, DOI 10.1007/s004380050293; Cnops G, 2000, DEVELOPMENT, V127, P3385; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Dachsel JC, 2007, PARKINSONISM RELAT D, V13, P382, DOI 10.1016/j.parkreldis.2007.01.008; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Deng JP, 2008, P NATL ACAD SCI USA, V105, P1499, DOI 10.1073/pnas.0709098105; Gloeckner CJ, 2006, HUM MOL GENET, V15, P223, DOI 10.1093/hmg/ddi439; Goldberg JM, 2006, FEBS LETT, V580, P2059, DOI 10.1016/j.febslet.2006.03.008; Goldberg JM, 2002, P NATL ACAD SCI USA, V99, P6749, DOI 10.1073/pnas.102167299; Goldberg JM, 2006, PLOS GENET, V2, P291, DOI 10.1371/journal.pgen.0020038; Greggio E, 2007, J NEUROCHEM, V102, P93, DOI 10.1111/j.1471-4159.2007.04523.x; Guo LX, 2007, EXP CELL RES, V313, P3658, DOI 10.1016/j.yexcr.2007.07.007; Hatano T, 2007, HUM MOL GENET, V16, P678, DOI 10.1093/hmg/ddm013; Haugarvoll K, 2007, NEUROSCI LETT, V416, P299, DOI 10.1016/j.neulet.2007.02.020; Henshall DC, 2004, ANN NEUROL, V55, P485, DOI 10.1002/ana.20001; Higashi S, 2007, BRAIN RES, V1155, P208, DOI 10.1016/j.brainres.2007.04.034; Iaccarino C, 2007, HUM MOL GENET, V16, P1319, DOI 10.1093/hmg/ddm080; Ito G, 2007, BIOCHEMISTRY-US, V46, P1380, DOI 10.1021/bi061960m; Jaleel M, 2007, BIOCHEM J, V405, P307, DOI 10.1042/BJ20070209; Korr D, 2006, CELL SIGNAL, V18, P910, DOI 10.1016/j.cellsig.2005.08.015; Kuwayama H, 1998, FEBS LETT, V424, P248, DOI 10.1016/S0014-5793(98)00183-5; Lee SB, 2007, BIOCHEM BIOPH RES CO, V358, P534, DOI 10.1016/j.bbrc.2007.04.156; Lewis PA, 2007, BIOCHEM BIOPH RES CO, V357, P668, DOI 10.1016/j.bbrc.2007.04.006; Li XT, 2007, J NEUROCHEM, V103, P238, DOI 10.1111/j.1471-4159.2007.04743.x; Li YH, 2006, HUM MOL GENET, V15, P2560, DOI 10.1093/hmg/ddl178; MacLeod D, 2006, NEURON, V52, P587, DOI 10.1016/j.neuron.2006.10.008; Marin I, 2008, J MOL EVOL, V67, P41, DOI 10.1007/s00239-008-9122-4; Marin I, 2006, MOL BIOL EVOL, V23, P2423, DOI 10.1093/molbev/msl114; Mata IF, 2006, TRENDS NEUROSCI, V29, P286, DOI 10.1016/j.tins.2006.03.006; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Paisan-Ruiz C, 2008, HUM MUTAT, V29, P485, DOI 10.1002/humu.20668; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Sakabe T, 1999, CANCER RES, V59, P511; Sakaguchi-Nakashima A, 2007, CURR BIOL, V17, P592, DOI 10.1016/j.cub.2007.01.074; Sawai S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r144; Smith WLW, 2006, NAT NEUROSCI, V9, P1231, DOI 10.1038/nn1776; Smith WW, 2005, P NATL ACAD SCI USA, V102, P18676, DOI 10.1073/pnas.0508052102; Sun BG, 2003, MOL BIOL CELL, V14, P4526, DOI 10.1091/mbc.e03-01-0039; Tagawa H, 2004, ONCOGENE, V23, P2576, DOI 10.1038/sj.onc.1207352; Taylor JP, 2006, TRENDS MOL MED, V12, P76, DOI 10.1016/j.molmed.2005.12.004; Taylor JP, 2007, NEUROGENETICS, V8, P95, DOI 10.1007/s10048-006-0075-8; Thomas B, 2007, HUM MOL GENET, V16, pR183, DOI 10.1093/hmg/ddm159; Veltman DM, 2008, J CELL BIOL, V180, P747, DOI 10.1083/jcb.200709180; Vogel C, 2004, J MOL BIOL, V336, P809, DOI 10.1016/j.jmb.2003.12.026; West AB, 2005, P NATL ACAD SCI USA, V102, P16842, DOI 10.1073/pnas.0507360102; Yang S, 2007, GENOMICS, V89, P451, DOI 10.1016/j.ygeno.2006.12.001; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	60	93	97	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3103	3110		10.1096/fj.08-111310	http://dx.doi.org/10.1096/fj.08-111310			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18523161	Green Submitted			2022-12-28	WOS:000258761300002
J	Sun, F; Mi, ZB; Condliffe, SB; Bertrand, CA; Gong, XY; Lu, XL; Zhang, RL; Latoche, JD; Pilewski, JM; Robbins, PD; Frizzell, RA				Sun, Fei; Mi, Zhibao; Condliffe, Steven B.; Bertrand, Carol A.; Gong, Xiaoyan; Lu, Xiaoli; Zhang, Ruilin; Latoche, Joseph D.; Pilewski, Joseph M.; Robbins, Paul D.; Frizzell, Raymond A.			Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia	FASEB JOURNAL			English	Article						CFTR; Aha1; rescue; PTD	PROTEIN-KINASE-A; DELTA-F508 CFTR; IN-VIVO; MULTIDOMAIN PROTEIN; MOLECULAR-BASIS; WILD-TYPE; DEGRADATION; DOMAIN; TRANSDUCTION; MATURATION	Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF). The most common mutation, Delta F508, omits the phenylalanine residue at position 508 in the first nucleotide binding domain (NBD1) of CFTR. The mutant protein is retained in the endoplasmic reticulum and degraded by the ubiquitin-proteasome system. We demonstrate that expression of NBD1 plus the regulatory domain (RD) of Delta F508 CFTR (Delta FRD) restores the biogenesis of mature Delta F508 CFTR protein. In addition, Delta FRD elicited a cAMP-stimulated anion conductance response in primary human bronchial epithelial (HBE) cells isolated from homozygous Delta F508 CF patients. A protein transduction domain (PTD) could efficiently transduce (similar to 90%) airway epithelial cells. When fused to a PTD, direct addition of the Delta FRD peptide conferred a dose-dependent, cAMP-stimulated anion efflux to Delta F508 HBE cells. Hsp70 and Hsp90 associated equally with WT and Delta F508 CFTR, whereas nearly twice as much of the Hsp90 cochaperone, Aha1, associated with Delta F508 CFTR. Expression of Delta FRD produced a dose-dependent removal of Aha1 from Delta F508 CFTR that correlated with its functional rescue. These findings indicate that disruption of the excessive association of the cochaperone, Aha1, with Delta F508 CFTR is associated with the correction of its maturation, trafficking and regulated anion channel activity in human airway epithelial cells. Thus, PTD-mediated Delta FRD fragment delivery may provide a therapy for CF.	[Sun, Fei; Condliffe, Steven B.; Bertrand, Carol A.; Gong, Xiaoyan; Zhang, Ruilin; Pilewski, Joseph M.; Frizzell, Raymond A.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; [Mi, Zhibao; Lu, Xiaoli; Robbins, Paul D.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15261 USA; [Latoche, Joseph D.; Pilewski, Joseph M.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA.	frizzell@pitt.edu	Pilewski, Joseph/AAF-5149-2021; lu, xl/HDO-8340-2022	Latoche, Joseph/0000-0002-4800-5623	U. S. National Institutes of Health [DK68196, DK72506, DK725076]; Cystic Fibrosis Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068196, P30DK072506] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Yuee Wang for technical assistance, Dr. John R. Riordan (University of North Carolina, Chapel Hill, NC, USA) for M3A7 antibody, and Dr. William E. Balch (Scripps Research Institute, La Jolla, CA, USA) for polyclonal Aha1 antibody. Funding was provided by the U. S. National Institutes of Health (DK68196, DK72506, and DK725076) and the Cystic Fibrosis Foundation.	Agashe VR, 2004, CELL, V117, P199, DOI 10.1016/S0092-8674(04)00299-5; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Brodsky JL, 2001, AM J PHYSIOL-LUNG C, V281, pL39, DOI 10.1152/ajplung.2001.281.1.L39; Cao GD, 2002, J NEUROSCI, V22, P5423; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clarke LL, 2004, AM J PHYSIOL-CELL PH, V287, pC192, DOI 10.1152/ajpcell.00337.2003; Cormet-Boyaka E, 2004, P NATL ACAD SCI USA, V101, P8221, DOI 10.1073/pnas.0400459101; Cui LY, 2007, J MOL BIOL, V365, P981, DOI 10.1016/j.jmb.2006.10.086; Davis P B, 2001, Pediatr Rev, V22, P257, DOI 10.1542/pir.22-8-257; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Devor DC, 2000, AM J PHYSIOL-CELL PH, V279, pC461, DOI 10.1152/ajpcell.2000.279.2.C461; Du K, 2005, NAT STRUCT MOL BIOL, V12, P17, DOI 10.1038/nsmb882; Gius DR, 1999, CANCER RES, V59, P2577; HAMILTON RL, 1991, J LIPID RES, V32, P529; Jansens A, 2002, SCIENCE, V298, P2401, DOI 10.1126/science.1078376; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnson LG, 1996, HUM GENE THER, V7, P51, DOI 10.1089/hum.1996.7.1-51; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kleizen B, 2005, MOL CELL, V20, P277, DOI 10.1016/j.molcel.2005.09.007; Lewis HA, 2005, J BIOL CHEM, V280, P1346, DOI 10.1074/jbc.M410968200; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Mendoza JL, 2007, J BIOENERG BIOMEMBR, V39, P499, DOI 10.1007/s10863-007-9117-7; Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137; Owsianik G, 2003, FEBS LETT, V554, P173, DOI 10.1016/S0014-5793(03)01162-1; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Rapp UK, 2003, TRENDS MICROBIOL, V11, P519, DOI 10.1016/j.tim.2003.09.001; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Schultz BD, 1999, J MEMBRANE BIOL, V170, P51, DOI 10.1007/s002329900537; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Sun F, 2006, J BIOL CHEM, V281, P36856, DOI 10.1074/jbc.M607085200; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; VANGINKEL FW, 1995, HUM GENE THER, V6, P895, DOI 10.1089/hum.1995.6.7-895; Varga K, 2004, J BIOL CHEM, V279, P22578, DOI 10.1074/jbc.M401522200; Wang W, 2004, TRENDS BIOTECHNOL, V22, P431, DOI 10.1016/j.tibtech.2004.07.002; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; Wang Y, 2007, J BIOL CHEM, V282, P33247, DOI 10.1074/jbc.C700175200; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	48	48	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3255	3263		10.1096/fj.07-105338	http://dx.doi.org/10.1096/fj.07-105338			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18556464	Green Published			2022-12-28	WOS:000258761300018
J	Shorter, K; Farjo, NP; Picksley, SM; Randall, VA				Shorter, Katie; Farjo, Nilofer P.; Picksley, Steven M.; Randall, Valerie A.			Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil	FASEB JOURNAL			English	Article						alopecia; hirsutism; tolbutamide; sulfonylurea receptors SUR1 and SUR2B	DERMAL PAPILLA CELLS; 2-PERCENT TOPICAL MINOXIDIL; ANDROGENETIC ALOPECIA; ORGAN-CULTURE; GROWTH-FACTOR; FOLLOW-UP; IN-VITRO; SULFONYLUREA; EXPRESSION; OPENERS	Hair disorders cause psychological distress but are generally poorly controlled; more effective treatments are required. Despite the long-standing use of minoxidil for balding, its mechanism is unclear; suggestions include action on vasculature or follicle cells. Similar drugs also stimulate hair, implicating ATP-sensitive potassium (KATP) channels. To investigate whether KATP channels are present in human follicles, we used organ culture, molecular biological, and immunohistological approaches. Minoxidil and tolbutamide, a KATP channel blocker, opposed each other's effects on the growing phase (anagen) of scalp follicles cultured in media with and without insulin. Reverse transcriptase-polymerase chain reaction identified KATP channel component gene expression including regulatory sulfonylurea receptors (SUR) SUR1 and SUR2B but not SUR2A and pore-forming subunits (Kir) Kir6.1 and Kir6.2. When hair bulb tissues were examined separately, epithelial matrix expressed SUR1 and Kir6.2, whereas both dermal papilla and sheath exhibited SUR2B and Kir6.1. Immunohistochemistry demonstrated similar protein distributions. Thus, human follicles respond biologically to KATP channel regulators in culture and express genes and proteins for two KATP channels, Kir6.2/SUR1 and Kir6.1/ SUR2B; minoxidil only stimulates SUR2 channels. These findings indicate that human follicular dermal papillae contain KATP channels that can respond to minoxidil and that tolbutamide may suppress hair growth clinically; novel drugs designed specifically for these channels could treat hair disorders.	[Shorter, Katie; Picksley, Steven M.; Randall, Valerie A.] Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; [Farjo, Nilofer P.] Farjo Med Ctr, Manchester, Lancs, England	University of Bradford	Randall, VA (corresponding author), Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England.	v.a.randall@bradford.ac.uk						Ashcroft FM, 2000, TRENDS PHARMACOL SCI, V21, P439; Ashcroft FM, 2006, NATURE, V440, P440, DOI 10.1038/nature04707; Boyera N, 1997, SKIN PHARMACOL, V10, P206, DOI 10.1159/000211506; BUHL AE, 1993, J INVEST DERMATOL, V101, pS148, DOI 10.1111/1523-1747.ep12363290; BUHL AE, 1989, J INVEST DERMATOL, V92, P315, DOI 10.1111/1523-1747.ep12277095; BUNKER CB, 1987, BRIT J DERMATOL, V140, P294; BURTON JL, 1979, BRIT J DERMATOL, V101, P593, DOI 10.1111/j.1365-2133.1979.tb15106.x; CHADHURY S, 2001, J PROJ PSYCHOL MENT, V8, P143; CROFT NJ, 2003, HAIR SCI TECHNOLOGY, P69; Curley M, 2002, MOL HUM REPROD, V8, P941, DOI 10.1093/molehr/8.10.941; Dabrowski M, 2003, DIABETOLOGIA, V46, P1375, DOI 10.1007/s00125-003-1198-1; Davies GC, 2005, J INVEST DERMATOL, V124, P686, DOI 10.1111/j.0022-202X.2005.23643.x; Davis-Taber R, 2000, GENE, V256, P261, DOI 10.1016/S0378-1119(00)00338-3; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; EDWARDS G, 1990, PHARMACOL THERAPEUT, V48, P237, DOI 10.1016/0163-7258(90)90082-D; Girman CJ, 1998, DERMATOLOGY, V197, P223, DOI 10.1159/000018001; GOLDBERG MR, 1988, J CARDIOVASC PHARM, V12, pS41, DOI 10.1097/00005344-198812002-00008; Han JH, 2004, J DERMATOL SCI, V34, P91, DOI 10.1016/j.jdermsci.2004.01.002; Hansen JB, 2006, CURR MED CHEM, V13, P361, DOI 10.2174/092986706775527947; IMAI R, 1993, ARCH DERMATOL RES, V284, P466, DOI 10.1007/BF00373358; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Jahangir A, 2005, J MOL CELL CARDIOL, V39, P99, DOI 10.1016/j.yjmcc.2005.04.006; KLIGMAN AM, 1959, J INVEST DERMATOL, V33, P307, DOI 10.1038/jid.1959.156; KOBLENZER PJ, 1968, ANN NY ACAD SCI, V150, P373, DOI 10.1111/j.1749-6632.1968.tb19062.x; Kwon OS, 2006, ARCH DERMATOL RES, V297, P367, DOI 10.1007/s00403-005-0619-z; Kym PR, 1996, J MED CHEM, V39, P4897, DOI 10.1021/jm960300k; Lachgar S, 1998, BRIT J DERMATOL, V138, P407; Li M, 2001, J INVEST DERMATOL, V117, P1594, DOI 10.1046/j.0022-202x.2001.01570.x; LITT JZ, 2007, LITTS DRUG ERUPTION; Magerl M, 2004, EXP DERMATOL, V13, P635, DOI 10.1111/j.0906-6705.2004.00207.x; Malester B, 2007, FASEB J, V21, P2162, DOI 10.1096/fj.06-7821com; MEISHERI KD, 1993, BIOCHEM PHARMACOL, V45, P271, DOI 10.1016/0006-2952(93)90061-Z; Messenger AG, 2004, BRIT J DERMATOL, V150, P186, DOI 10.1111/j.1365-2133.2004.05785.x; Nagashima K, 2004, DIABETES RES CLIN PR, V66, pS75, DOI 10.1016/j.diabres.2003.12.011; Nakaya Y, 1994, J Dermatol Sci, V7 Suppl, pS104, DOI 10.1016/0923-1811(94)90041-8; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; OLSEN EA, 1990, J AM ACAD DERMATOL, V22, P643, DOI 10.1016/0190-9622(90)70089-Z; Olsen EA, 2002, J AM ACAD DERMATOL, V47, P377, DOI 10.1067/mjd.2002.124088; OLSEN EA, 1987, J AM ACAD DERMATOL, V16, P688, DOI 10.1016/S0190-9622(87)70089-9; Philpott MP, 1996, DERMATOL CLIN, V14, P595, DOI 10.1016/S0733-8635(05)70387-9; PHILPOTT MP, 1991, ANN NY ACAD SCI, V642, P148; PHILPOTT MP, 1994, J INVEST DERMATOL, V102, P857, DOI 10.1111/1523-1747.ep12382494; PHILPOTT MP, 1990, J CELL SCI, V97, P463; Price VH, 1999, J AM ACAD DERMATOL, V41, P717, DOI 10.1016/S0190-9622(99)70006-X; Randall VA, 2003, J INVEST DERM SYMP P, V8, P39, DOI 10.1046/j.1523-1747.2003.12170.x; Randall VA, 2001, LANCET, V358, P1922, DOI 10.1016/S0140-6736(01)06943-4; Randall VA, 2005, ENDOCRINOLOGY, P3295; Randall VA, 2007, SEMIN CELL DEV BIOL, V18, P274, DOI 10.1016/j.semcdb.2007.02.004; Reynolds AJ, 2004, DIFFERENTIATION, V72, P566, DOI 10.1111/j.1432-0436.2004.07209010.x; Reynolds AJ, 1999, NATURE, V402, P33, DOI 10.1038/46938; Ross EK, 2005, DERMATOL CLIN, V23, P227, DOI 10.1016/j.det.2004.09.008; SAITOH M, 1970, J INVEST DERMATOL, V54, P65, DOI 10.1111/1523-1747.ep12551679; Sakita S, 1999, BRIT J DERMATOL, V140, P294; Sanders DA, 1996, J INVEST DERMATOL, V107, P229, DOI 10.1111/1523-1747.ep12329697; Sato T, 1999, J DERMATOL SCI, V19, P123, DOI 10.1016/S0923-1811(98)00048-6; WESTER RC, 1984, J INVEST DERMATOL, V82, P515, DOI 10.1111/1523-1747.ep12261084; Yoshida H, 2004, J MOL CELL CARDIOL, V37, P857, DOI 10.1016/j.yjmcc.2004.05.022; Yunoki T, 2003, BRIT J PHARMACOL, V139, P652, DOI 10.1038/sj.bjp.0705268; ZINS GR, 1988, CLIN DERMATOL, V6, P132, DOI 10.1016/0738-081X(88)90078-8	61	80	85	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1725	1736		10.1096/fj.07-099424	http://dx.doi.org/10.1096/fj.07-099424			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18258787				2022-12-28	WOS:000256352700013
J	Kesimer, M; Scull, M; Brighton, B; DeMaria, G; Burns, K; O'Neal, W; Pickles, RJ; Sheehan, JK				Kesimer, Mehmet; Scull, Margaret; Brighton, Brian; DeMaria, Genevieve; Burns, Kimberlie; O'Neal, Wanda; Pickles, Raymond J.; Sheehan, John K.			Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense	FASEB JOURNAL			English	Article						mucins; influenza virus; mucus; glycocalyx; sialic acid	TUMOR-DERIVED EXOSOMES; PROTEOMIC ANALYSIS; CELL EXOSOMES; SIALIC-ACID; MUC1 MUCIN; IN-VITRO; CANCER; MICROVESICLES; EXPRESSION; BIOGENESIS	Airway mucus forms the structural basis of the local innate immune defense mechanism. It is an integrated, active, viscoelastic gel matrix evolved to protect the exposed lung from physical, chemical, and pathological erosion. Exosomes are biologically active vesicles secreted by different cell types including epithelial, hematopoietic, and some tumor cells. They are also present in some biological fluids such as serum, urine, breast milk, and bronchoalveolar lavage fluid. In this study, we demonstrate for the first time that exosome-like vesicles with antiviral properties are present in human tracheobronchial epithelial (HTBE) cell culture secretions. These vesicles have been isolated by differential centrifugation and are characterized further by mass spectrometry, flow cytometry, immunoblotting, electron microscopy, and light-scattering methods. HTBE vesicles exhibited characteristic exosomal size (30-100 nm) and morphology (cup-shaped) with a buoyant density in sucrose of 1.12-1.18 g/ml. Biochemical characterization further revealed typical surface, cytoskeletal, and cytoplasmic proteins characteristic of exosomes, including the multivesicular and late endosomal membrane markers Tsg101 and CD63. The presence of RNA was also observed. The epithelial mucins MUC1, MUC4, and MUC16 also contributed to the vesicles' structure. Notably, alpha-2,6-linked sialic acid was associated with these mucin molecules and subsequent functional analysis showed that these vesicles have a neutralizing effect on human influenza virus, which is known to bind sialic acid. Taken together, these findings suggest that airway epithelial cells release exosome-like vesicles and that these structures may be involved in diverse physiological processes in airway biology, including innate mucosal defense.-Kesimer, M., Scull, M., Brighton, B., DeMaria, G., Burns, K., O'Neal, W., Pickles, R. J., Sheehan, J. K. Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J. 23, 1858-1868 (2009)	[Kesimer, Mehmet; DeMaria, Genevieve; Sheehan, John K.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC USA; [Scull, Margaret; Pickles, Raymond J.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; [Brighton, Brian; Burns, Kimberlie; O'Neal, Wanda] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Sheehan, JK (corresponding author), 4021 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	kesimer@med.unc.edu	Scull, Margaret/K-9963-2019; , Mehmet Kesimer/AHB-9223-2022	Scull, Margaret/0000-0002-6860-2468	National Heart, Lung, and Blood Institute/National Institutes of Health (NHLBI/NIH) [HL084934, HL HL77844-1]; NIH Molecular Biology of Viral Diseases [5-T32-AI007419]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL084934, R01HL077844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007419] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute/National Institutes of Health (NHLBI/NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH Molecular Biology of Viral Diseases; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank the UNC Cystic Fibrosis Center Tissue Procurement and Culture Core. This work was supported by a gift from an anonymous donor for research targeted to proteomics of cystic fibrosis lung disease (J.K.S.) and National Heart, Lung, and Blood Institute/National Institutes of Health (NHLBI/NIH) grants HL084934 and HL HL77844-1. M. S. is a recipient of the George H. Hitchings Fund for Health Research and Science Education of the Triangle Community Foundation. This work was also supported by NIH Molecular Biology of Viral Diseases training grant 5-T32-AI007419.	Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703; Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969; Agrawal B, 2005, INT IMMUNOL, V17, P391, DOI 10.1093/intimm/dxh219; Aupeix K, 1997, J CLIN INVEST, V99, P1546, DOI 10.1172/JCI119317; Bard MP, 2004, AM J RESP CELL MOL, V31, P114, DOI 10.1165/rcmb.2003-0238OC; Belisle JA, 2007, IMMUNOLOGY, V122, P418, DOI 10.1111/j.1365-2567.2007.02660.x; Bhatnagar S, 2007, BLOOD, V110, P3234, DOI 10.1182/blood-2007-03-079152; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; BRAGA VMM, 1992, DEVELOPMENT, V115, P427; Buschow SI, 2005, BLOOD CELL MOL DIS, V35, P398, DOI 10.1016/j.bcmd.2005.08.005; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Cho JA, 2005, INT J CANCER, V114, P613, DOI 10.1002/ijc.20757; Clayton A, 2003, EUR J IMMUNOL, V33, P522, DOI 10.1002/immu.200310028; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Fulcher M Leslie, 2005, Methods Mol Med, V107, P183; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; HEARN PR, 1981, J CELL SCI, V47, P227; Hegmans JPJJ, 2004, AM J PATHOL, V164, P1807, DOI 10.1016/S0002-9440(10)63739-X; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Kapsogeorgou EK, 2005, ARTHRITIS RHEUM-US, V52, P1517, DOI 10.1002/art.21005; Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005; Kesimer M, 2009, AM J PHYSIOL-LUNG C, V296, pL92, DOI 10.1152/ajplung.90388.2008; Kreda SM, 2005, MOL BIOL CELL, V16, P2154, DOI 10.1091/mbc.E04-11-1010; Li XB, 2006, J CELL MOL MED, V10, P364, DOI 10.1111/j.1582-4934.2006.tb00405.x; Ogawa Y, 2008, BIOL PHARM BULL, V31, P1059, DOI 10.1248/bpb.31.1059; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Potolicchio A, 2005, J IMMUNOL, V175, P2237, DOI 10.4049/jimmunol.175.4.2237; RAMPHAL R, 1983, INFECT IMMUN, V41, P339, DOI 10.1128/IAI.41.1.339-344.1983; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Reid CJ, 1997, AM J RESP CELL MOL, V17, P592, DOI 10.1165/ajrcmb.17.5.2798; Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x; Rump A, 2004, J BIOL CHEM, V279, P9190, DOI 10.1074/jbc.M312372200; Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x; Sheehan John K, 2006, Novartis Found Symp, V279, P155; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Skokos D, 2001, J IMMUNOL, V166, P868, DOI 10.4049/jimmunol.166.2.868; Takahashi Y, 2004, INFECT IMMUN, V72, P3876, DOI 10.1128/IAI.72.7.3876-3882.2004; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; THORNTON DJ, 1995, ANAL BIOCHEM, V227, P162, DOI 10.1006/abio.1995.1266; Ueno K, 2008, AM J RESP CELL MOL, V38, P263, DOI 10.1165/rcmb.2007-0336RC; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Van Niel G, 2003, GUT, V52, P1690, DOI 10.1136/gut.52.12.1690; van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128; Whiteside TL, 2005, BRIT J CANCER, V92, P209, DOI 10.1038/sj.bjc.6602360; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	55	253	264	1	68	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1858	1868		10.1096/fj.08-119131	http://dx.doi.org/10.1096/fj.08-119131			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19190083	Green Published			2022-12-28	WOS:000266652400026
J	Penaloza, C; Estevez, B; Orlanski, S; Sikorska, M; Walker, R; Smith, C; Smith, B; Lockshin, RA; Zakeri, Z				Penaloza, Carlos; Estevez, Brian; Orlanski, Shari; Sikorska, Marianna; Walker, Roy; Smith, Catherine; Smith, Brandon; Lockshin, Richard A.; Zakeri, Zahra			Sex of the cell dictates its response: differential gene expression and sensitivity to cell death inducing stress in male and female cells	FASEB JOURNAL			English	Article						apoptosis; estrogen; ethanol; gender; testosterone	GENDER-DIFFERENCES; AUTOIMMUNE-DISEASES; MOUSE-BRAIN; ESTROGENS; MICE; DIMORPHISM; CYP7B; MEN	Sexual dimorphisms are typically attributed to the hormonal differences arising once sex differentiation has occurred. However, in some sexually dimorphic diseases that differ in frequency but not severity, the differences cannot be logically connected to the sex hormones. Therefore, we asked whether any aspect of sexual dimorphism could be attributed to chromosomal rather than hormonal differences. Cells taken from mice at d 10.5 postconception ( PC) before sexual differentiation, at d 17.5 PC after the first embryonic assertion of sexual hormones, and at postnatal day 17 ( puberty) were cultured and exposed to 400 mu M ethanol or 20 mu M camptothecin or to infection with influenza A virus ( multiplicity of infection of 5). The results showed that untreated male and female cells of the same age grew at similar rates and manifested similar morphology. However, they responded differently to the applied stressors, even before the production of fetal sex hormones. Furthermore, microarray and qPCR analyses of the whole 10.5 PC embryos also revealed differences in gene expression between male and female tissues. Likewise, the exposure of cells isolated from fetuses and adolescent mice to the stressors and/or sex hormones yielded expression patterns that reflected chromosomal sex, with ethanol feminizing male cells and masculinizing female cells. We conclude that cells differ innately according to sex irrespective of their history of exposure to sex hormones. These differences may have consequences in the course of sexually dimorphic diseases and their therapy.-Penaloza, C., Estevez, B., Orlanski, S., Sikorska, M., Walker, R., Smith, C., Smith, B., Lockshin R. A., Zakeri, Z. Sex of the cell dictates its response: differential gene expression and sensitivity to cell death inducing stress in male and female cells. FASEB J. 23, 1869-1879 (2009)	[Penaloza, Carlos; Estevez, Brian; Orlanski, Shari; Zakeri, Zahra] CUNY Queens Coll, Flushing, NY 11367 USA; [Penaloza, Carlos; Estevez, Brian; Orlanski, Shari; Zakeri, Zahra] CUNY, Grad Ctr, Flushing, NY 11367 USA; [Sikorska, Marianna; Walker, Roy; Smith, Catherine; Smith, Brandon] CNR, Inst Biol Sci, Ottawa, ON, Canada; [Lockshin, Richard A.] St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA	City University of New York (CUNY) System; Queens College NY (CUNY); City University of New York (CUNY) System; National Research Council Canada; Saint John's University	Zakeri, Z (corresponding author), CUNY Queens Coll, 65-30 Kissena Blvd, Flushing, NY 11367 USA.	zahra_zakeri@hotmail.com		Estevez, Brian/0000-0002-1863-7224	National Institutes of Health [RO3]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by funding from National Institutes of Health Grant RO3 to Z. Z.; Minority Access to Research Careers Undergraduate Student Training for Academic Research (MARC U-STAR) to Z. Z.; and the National Science Foundation New York City Louis Stokes Alliance for Minority Participation (LSAMP) and the City University of New York Alliance for Graduate Education and the Professoriate (CUNY AGEP). We thank Ms. Nikezic-Ardolic for technical impact on the original idea and methodologies for this manuscript. We also thank Dr. Tahereh Entezari- Zaher, Dr. Mohammad Javdan, and Tamjeed Sikder for technical and intellectual assistance.	Ahuja HS, 1997, DEV DYNAM, V208, P466; Amador-Noguez D, 2005, BIOCHEM BIOPH RES CO, V332, P1086, DOI 10.1016/j.bbrc.2005.05.063; Angele MK, 2003, AM J PHYSIOL-ENDOC M, V285, pE189, DOI 10.1152/ajpendo.00035.2003; Bain C, 2004, JNCI-J NATL CANCER I, V96, P826, DOI 10.1093/jnci/djh143; BEESON PB, 1994, AM J MED, V96, P457, DOI 10.1016/0002-9343(94)90173-2; Ceribelli A, 2007, J THORAC ONCOL, V2, pS15, DOI 10.1097/01.JTO.0000268635.25579.7e; Colantuoni C, 2002, BIOINFORMATICS, V18, P1540, DOI 10.1093/bioinformatics/18.11.1540; Cutolo M, 2006, ANN NY ACAD SCI, V1089, P538, DOI 10.1196/annals.1386.043; Dewing P, 2003, MOL BRAIN RES, V118, P82, DOI 10.1016/S0169-328X(03)00339-5; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Dulos J, 2005, ARTHRITIS RHEUM-US, V52, P770, DOI 10.1002/art.20950; Gompel A, 2007, Menopause Int, V13, P65, DOI 10.1258/175404507780796433; Heyer A, 2005, J CEREBR BLOOD F MET, V25, P427, DOI 10.1038/sj.jcbfm.9600056; Higashi E, 2007, DRUG METAB DISPOS, V35, P1935, DOI 10.1124/dmd.107.016568; Isensee J, 2008, J MOL MED, V86, P61, DOI 10.1007/s00109-007-0240-z; Karafolas N., 1996, Optical Fiber Technology: Materials, Devices and Systems, V2, P149, DOI 10.1006/ofte.1996.0017; Lockshin MD, 2001, J APPL PHYSIOL, V91, P2366, DOI 10.1152/jappl.2001.91.5.2366; Lockshin MD, 2007, ARTHRITIS RHEUM, V56, P1048, DOI 10.1002/art.22631; Lockshin MD, 2006, ORTHOP CLIN N AM, V37, P629, DOI 10.1016/j.ocl.2006.08.002; Mollerup S, 1999, CANCER RES, V59, P3317; Nickerson M, 2006, J APPL PHYSIOL, V101, P566, DOI 10.1152/japplphysiol.00259.2006; Nikezic-Ardolic M, 1999, LUPUS, V8, P375, DOI 10.1177/096120339900800509; Peippo JP, 2002, MOL HUM REPROD, V8, P923, DOI 10.1093/molehr/8.10.923; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; Shulman Lisa M, 2006, Expert Rev Neurother, V6, P407; Tang WJ, 2006, BIOCHEM BIOPH RES CO, V344, P540, DOI 10.1016/j.bbrc.2006.03.175; Vaccarino V, 1999, NEW ENGL J MED, V341, P217, DOI 10.1056/NEJM199907223410401; Walker PR, 2004, ARTIF INTELL MED, V31, P137, DOI 10.1016/j.artmed.2004.01.008; WORKMAN C, 2002, GENOME BIOL, V0003; Xu J, 2002, HUM MOL GENET, V11, P1409, DOI 10.1093/hmg/11.12.1409; Zorgdrager A, 2002, EUR NEUROL, V48, P204, DOI 10.1159/000066166	32	81	85	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1869	1879		10.1096/fj.08-119388	http://dx.doi.org/10.1096/fj.08-119388			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19190082	Green Published			2022-12-28	WOS:000266652400027
J	Yip, L; Woehrle, T; Corriden, R; Hirsh, M; Chen, Y; Inoue, Y; Ferrari, V; Insel, PA; Junger, WG				Yip, Linda; Woehrle, Tobias; Corriden, Ross; Hirsh, Mark; Chen, Yu; Inoue, Yoshiaki; Ferrari, Vhe; Insel, Paul A.; Junger, Wolfgang G.			Autocrine regulation of T-cell activation by ATP release and P2X(7) receptors	FASEB JOURNAL			English	Article						interleukin-2; NFAT; calcium signaling; real-time PCR; siRNA silencing	EXTRACELLULAR ADENOSINE-TRIPHOSPHATE; OF-FUNCTION; L-SELECTIN; CALCIUM; POLYMORPHISM; EXPRESSION; KINASE; LYMPHOCYTES; CHANNEL; IMPAIRS	T-cell activation requires the influx of extracellular calcium, although mechanistic details regarding such activation are not fully defined. Here, we show that P2X(7) receptors play a key role in calcium influx and downstream signaling events associated with the activation of T cells. By real-time PCR and immunohistochemistry, we find that Jurkat T cells and human CD4(+) T cells express abundant P2X(7) receptors. We show, using a novel fluorescent microscopy technique, that T-cell receptor (TCR) stimulation triggers the rapid release of ATP (<100 mu M). This release of ATP is required for TCR- mediated calcium influx, NFAT activation, and interleukin-2 (IL-2) production. TCR activation up-regulates P2X(7) receptor gene expression. Removal of extracellular ATP by apyrase or alkaline phosphatase treatment, inhibition of ATP release with the maxi-anion channel blocker gadolinium chloride, or siRNA silencing of P2X(7) receptors blocks calcium entry and inhibits T-cell activation. Moreover, lymphocyte activation is impaired in C57BL/6 mice that express poorly functional P2X(7) receptors, compared to control BALB/c mice, which express fully functional P2X(7) receptors. We conclude that ATP release and autocrine, positive feedback through P2X(7) receptors is required for the effective activation of T cells.-Yip, L., Woehrle, T., Corriden, R., Hirsh, M., Chen, Y., Inoue, Y., Ferrari, V., Insel, P. A., Junger, W. G. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 23, 1685-1693 (2009)	[Junger, Wolfgang G.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; [Yip, Linda; Corriden, Ross; Hirsh, Mark; Chen, Yu; Inoue, Yoshiaki; Ferrari, Vhe; Junger, Wolfgang G.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Corriden, Ross; Insel, Paul A.] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA; [Insel, Paul A.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Yip, Linda] Stanford Univ, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University	Junger, WG (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave,E-ST-8M10C, Boston, MA 02215 USA.	wjunger@bidmc.harvard.edu	Junger, Wolfgang G/I-1932-2013	Junger, Wolfgang G/0000-0003-3350-8452	National Institute of General Medical Sciences [R01 GM-51477, GM-60475, GM-66232]; Lymphoma and Leukemia Society; DOD/CDMRP [PR043034]; NIH GCRC [5MO1-RR-00827-25]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066232, T32GM007752, R01GM051477, R01GM060475] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Lymphoma and Leukemia Society(Leukemia and Lymphoma Society); DOD/CDMRP(United States Department of Defense); NIH GCRC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. Amnon Altman for his advice and Dr. Marion Schneider for the helpful discussions of our results. This study was supported in part by National Institute of General Medical Sciences grants R01 GM-51477, GM-60475 (W.G.J.), and GM-66232; a grant from the Lymphoma and Leukemia Society (P.A.I.); DOD/CDMRP grant PR043034 (W.G.J.); and NIH GCRC grant 5MO1-RR-00827-25.	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Aswad F, 2006, CELL IMMUNOL, V243, P58, DOI 10.1016/j.cellimm.2006.12.003; BALASUBRAMANYAM M, 1995, CELL CALCIUM, V18, P526, DOI 10.1016/0143-4160(95)90015-2; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; BLANCHARD DK, 1995, BLOOD, V85, P3173, DOI 10.1182/blood.V85.11.3173.bloodjournal85113173; Boudreault F, 2002, AM J PHYSIOL-CELL PH, V282, pC219, DOI 10.1152/ajpcell.00317.2001; Budagian V, 2003, J BIOL CHEM, V278, P1549, DOI 10.1074/jbc.M206383200; Cabrini G, 2005, J IMMUNOL, V175, P82, DOI 10.4049/jimmunol.175.1.82; Cahalan MD, 2007, CELL CALCIUM, V42, P133, DOI 10.1016/j.ceca.2007.03.002; Charvet C, 2005, J BIOL CHEM, V280, P15289, DOI 10.1074/jbc.M500275200; Chen LF, 2006, CRIT REV IMMUNOL, V26, P499, DOI 10.1615/CritRevImmunol.v26.i6.30; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Corriden R, 2007, AM J PHYSIOL-CELL PH, V293, pC1420, DOI 10.1152/ajpcell.00271.2007; Costello PS, 2002, NAT IMMUNOL, V3, P1082, DOI 10.1038/ni848; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Dubyak GR, 2000, J AUTONOM NERV SYST, V81, P64, DOI 10.1016/S0165-1838(00)00155-7; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/pnas.87.21.8267; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; Gever JR, 2006, PFLUG ARCH EUR J PHY, V452, P513, DOI 10.1007/s00424-006-0070-9; Glass R, 2000, CELL TISSUE RES, V300, P295, DOI 10.1007/s004410000206; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2006, BLOOD, V107, P4946, DOI 10.1182/blood-2005-07-2994; Hirsh MI, 2008, CRIT CARE MED, V36, P3220, DOI 10.1097/CCM.0b013e31818f238e; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Jamieson GP, 1996, J CELL PHYSIOL, V166, P637, DOI 10.1002/(SICI)1097-4652(199603)166:3<637::AID-JCP19>3.0.CO;2-3; Klapperstuck M, 2001, J PHYSIOL-LONDON, V534, P25, DOI 10.1111/j.1469-7793.2001.00025.x; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Leybaert L, 2003, CELL COMMUN ADHES, V10, P251, DOI 10.1080/15419060390262985; Liu HT, 2008, CELL RES, V18, P558, DOI 10.1038/cr.2008.49; Loomis WH, 2003, J BIOL CHEM, V278, P4590, DOI 10.1074/jbc.M207868200; Mehta VB, 2001, J BIOL CHEM, V276, P3820, DOI 10.1074/jbc.M006814200; MURGIA M, 1993, J BIOL CHEM, V268, P8199; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Pangrsic T, 2007, J BIOL CHEM, V282, P28749, DOI 10.1074/jbc.M700290200; Ralevic V, 1998, PHARMACOL REV, V50, P413; REDEGELD F, 1991, J IMMUNOL, V147, P3638; Rothermel Annette L., 2004, BMC Immunology, V5, P1; Saunders BM, 2003, J IMMUNOL, V171, P5442, DOI 10.4049/jimmunol.171.10.5442; Schenk U, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1160583; SHIVNAN E, 1995, J IMMUNOL, V154, P1146; Sluyter R, 2004, J IMMUNOL, V172, P3399, DOI 10.4049/jimmunol.172.6.3399; Soto F, 1999, NEUROPHARMACOLOGY, V38, P141, DOI 10.1016/S0028-3908(98)00158-0; Surprenant A, 2009, ANNU REV PHYSIOL, V71, P333, DOI 10.1146/annurev.physiol.70.113006.100630; Tsukimoto M, 2006, J IMMUNOL, V177, P2842, DOI 10.4049/jimmunol.177.5.2842; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200; Yegutkin GG, 2008, BBA-MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024; Yegutkin GG, 2006, MOL BIOL CELL, V17, P3378, DOI 10.1091/mbc.E05-10-0993; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Yip L, 2007, SHOCK, V27, P242, DOI 10.1097/01.shk.0000245014.96419.3a; Yoon MJ, 2007, BIOL PHARM BULL, V30, P671, DOI 10.1248/bpb.30.671; Zeyda M, 2006, PROG LIPID RES, V45, P187, DOI 10.1016/j.plipres.2006.01.002	55	214	221	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1685	1693		10.1096/fj.08-126458	http://dx.doi.org/10.1096/fj.08-126458			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19211924	Green Published			2022-12-28	WOS:000266652400008
J	Graner, MW; Alzate, O; Dechkovskaia, AM; Keene, JD; Sampson, JH; Mitchell, DA; Bigner, DD				Graner, Michael W.; Alzate, Oscar; Dechkovskaia, Angelika M.; Keene, Jack D.; Sampson, John H.; Mitchell, Duane A.; Bigner, Darell D.			Proteomic and immunologic analyses of brain tumor exosomes	FASEB JOURNAL			English	Article						microvesicles; heat shock proteins; antibody; T cells; EGFRvIII; patient sera	CELL-DERIVED-EXOSOMES; GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; BIOLOGICAL SIGNIFICANCE; RELEASED MICROVESICLES; MULTIVESICULAR BODY; MURINE ASTROCYTOMA; SURFACE EXPRESSION; SHOCK PROTEINS; MECHANISMS	Brain tumors are horrific diseases with almost universally fatal outcomes; new therapeutics are desperately needed and will come from improved understandings of glioma biology. Exosomes are endosomally derived 30-100 nm membranous vesicles released from many cell types into the extracellular milieu; surprisingly, exosomes are virtually unstudied in neuro-oncology. These microvesicles were used as vaccines in other tumor settings, but their immunological significance is unevaluated in brain tumors. Our purpose here is to report the initial biochemical, proteomic, and immunological studies on murine brain tumor exosomes, following known procedures to isolate exosomes. Our findings show that these vesicles have biophysical characteristics and proteomic profiles similar to exosomes from other cell types but that brain tumor exosomes have unique features (e. g., very basic isoelectric points, expressing the mutated tumor antigen EGFRvIII and the putatively immunosuppressive cytokine TGF-beta). Administration of such exosomes into syngeneic animals produced both humoral and cellular immune responses in immunized hosts capable of rejecting subsequent tumor challenges but failed to prolong survival in established orthotopic models. Control animals received saline or cell lysate vaccines and showed no antitumor responses. Exosomes and microvesicles isolated from sera of patients with brain tumors also possess EGFR, EGFRvIII, and TGF-beta. We conclude that exosomes released from brain tumor cells are biochemically/biophysically like other exosomes and have immune-modulating properties. They can escape the blood-brain barrier, with potential systemic and distal signaling and immune consequences.-Graner, M. W., Alzate, O., Dechkovskaia, A. M., Keene, J. D., Sampson, J. H., Mitchell, D. A., Bigner, D. D. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 23, 1541-1557 (2009)	[Graner, Michael W.; Sampson, John H.; Bigner, Darell D.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Alzate, Oscar] Duke Univ, Med Ctr, Dept Neurosci Neuroprote, Durham, NC 27710 USA; [Dechkovskaia, Angelika M.; Sampson, John H.; Mitchell, Duane A.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Keene, Jack D.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; [Graner, Michael W.; Alzate, Oscar; Dechkovskaia, Angelika M.; Keene, Jack D.; Sampson, John H.; Mitchell, Duane A.; Bigner, Darell D.] Duke Univ, Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University	Graner, MW (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3050,210 Sands Bldg, Durham, NC 27710 USA.	granermichael@yahoo.com	, Proteomics Core UNC/AFQ-7201-2022; Alzate, Oscar/A-2533-2008	Sampson, John/0000-0002-0104-7658; Alzate, Oscar/0000-0002-1083-2551	Duke University Brain Cancer Specialized Programs of Research Excellence [5 P50 CA108786-02]; SPORE Career Development Award; National Institute of Neurological Disorders and Stroke SRC [5 P50 20023-21]; Pediatric Brain Tumor Foundation; Brian Cless Research Foundation; Southeast Brain Tumor Foundation; NATIONAL CANCER INSTITUTE [P50CA108786] Funding Source: NIH RePORTER	Duke University Brain Cancer Specialized Programs of Research Excellence; SPORE Career Development Award; National Institute of Neurological Disorders and Stroke SRC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Pediatric Brain Tumor Foundation; Brian Cless Research Foundation; Southeast Brain Tumor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Sara Miller of the Duke University Cancer Center electron microscopy facility for performing the electron microscopy; R. Ian Cumming, Shelley Davis, and Nichole Satterwhite for superb technical support; and Dr. Steve Griffiths (Atlantic Cancer Research Institute, Moncton, NB, Canada) for ideas and sharing unpublished observations. This work was supported by the Duke University Brain Cancer Specialized Programs of Research Excellence 5 P50 CA108786-02; SPORE Career Development Award (to M. W. G.); National Institute of Neurological Disorders and Stroke SRC 5 P50 20023-21; the Pediatric Brain Tumor Foundation; the Brian Cless Research Foundation; and the Southeast Brain Tumor Foundation (to M. W. G.).	Abusamra AJ, 2005, BLOOD CELL MOL DIS, V35, P169, DOI 10.1016/j.bcmd.2005.07.001; Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Altieri SL, 2004, J IMMUNOTHER, V27, P282, DOI 10.1097/00002371-200407000-00004; Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bard MP, 2004, AM J RESP CELL MOL, V31, P114, DOI 10.1165/rcmb.2003-0238OC; Bausero MA, 2004, TUMOR BIOL, V25, P243, DOI 10.1159/000081387; Bu N, 2006, LEUKEMIA LYMPHOMA, V47, P913, DOI 10.1080/10428190500376191; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Calzolari A, 2006, J CELL SCI, V119, P4486, DOI 10.1242/jcs.03228; Chaput N, 2006, J LEUKOCYTE BIOL, V80, P471, DOI 10.1189/jlb.0206094; Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; Clayton A, 2005, BLOOD CELL MOL DIS, V34, P206, DOI 10.1016/j.bcmd.2005.03.003; Clayton A, 2007, CANCER RES, V67, P7458, DOI 10.1158/0008-5472.CAN-06-3456; DAUM G, 1988, BIOCHIM BIOPHYS ACTA, V939, P277, DOI 10.1016/0005-2736(88)90071-5; de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871; Delcayre A, 2006, CURR OPIN MOL THER, V8, P31; Denzer K, 2000, J CELL SCI, V113, P3365; Dudani AK, 2005, BIOCHEM CELL BIOL, V83, P28, DOI 10.1139/O04-109; Elsner L, 2007, J IMMUNOL, V179, P5523, DOI 10.4049/jimmunol.179.8.5523; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Escudier B, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-10; Fecci PE, 2006, CANCER RES, V66, P3294, DOI 10.1158/0008-5472.CAN-05-3773; Feng HP, 2001, BLOOD, V97, P3505, DOI 10.1182/blood.V97.11.3505; FRIEDMAN HS, 1985, J NEUROPATH EXP NEUR, V44, P592, DOI 10.1097/00005072-198511000-00005; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; GARG PK, 1995, NUCL MED BIOL, V22, P467, DOI 10.1016/0969-8051(94)00134-6; Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804; Gerbod-Giannone MC, 2006, P NATL ACAD SCI USA, V103, P3112, DOI 10.1073/pnas.0510345103; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Gomez GG, 2006, GENE THER MOL BIOL, V10A, P133; Graner MW, 2007, J NEUROSCI, V27, P11214, DOI 10.1523/JNEUROSCI.3588-07.2007; Graner MW, 2005, NEURO-ONCOLOGY, V7, P260, DOI 10.1215/S1152851704001188; Hegmans JPJJ, 2004, AM J PATHOL, V164, P1807, DOI 10.1016/S0002-9440(10)63739-X; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; Jin M, 2005, PROTEOMICS, V5, P1940, DOI 10.1002/pmic.200401057; Johnstone RM, 2006, BLOOD CELL MOL DIS, V36, P315, DOI 10.1016/j.bcmd.2005.12.001; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Keller S, 2007, KIDNEY INT, V72, P1095, DOI 10.1038/sj.ki.5002486; Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005; Khan WA, 2000, TOXICOL SCI, V57, P112, DOI 10.1093/toxsci/57.1.112; Kim JW, 2005, CLIN CANCER RES, V11, P1010; Kim SH, 2006, MOL THER, V13, P289, DOI 10.1016/j.ymthe.2005.09.015; Kuan C T, 2000, Brain Tumor Pathol, V17, P71, DOI 10.1007/BF02482738; Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078-0432.CCR-05-2797; Kuate S, 2007, VIROLOGY, V362, P26, DOI 10.1016/j.virol.2006.12.011; Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375; Mangeney M, 2005, CANCER RES, V65, P2588, DOI 10.1158/0008-5472.CAN-04-4231; Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876; Mignot G, 2006, J CELL MOL MED, V10, P376, DOI 10.1111/j.1582-4934.2006.tb00406.x; Mitchell DA, 2008, NEURO-ONCOLOGY, V10, P10, DOI 10.1215/15228517-2007-035; Morishima A, 2003, J BIOL CHEM, V278, P38188, DOI 10.1074/jbc.M306336200; Morse MA, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-9; Moscatello DK, 1997, CANCER RES, V57, P1419; Mourad PD, 2005, SURG NEUROL, V63, P511, DOI 10.1016/j.surneu.2004.08.062; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Olofsson S, 2005, ANN MED, V37, P154, DOI 10.1080/07853890510007340; Osorio C, 2007, NEUROBIOL AGING, V28, P1853, DOI 10.1016/j.neurobiolaging.2006.08.011; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; Parker Carol E., 2005, V301, P117; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Pelchen-Matthews A, 2004, TRENDS MICROBIOL, V12, P310, DOI 10.1016/j.tim.2004.05.004; Pinaud R, 2008, EUR J NEUROSCI, V27, P1409, DOI 10.1111/j.1460-9568.2008.06102.x; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Potolicchio A, 2005, J IMMUNOL, V175, P2237, DOI 10.4049/jimmunol.175.4.2237; RUBARTELLI A, 1993, CYTOKINE, V5, P117, DOI 10.1016/1043-4666(93)90050-F; Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102; Sampson JH, 2000, P NATL ACAD SCI USA, V97, P7503, DOI 10.1073/pnas.130166597; Sampson JH, 1997, NEUROSURGERY, V41, P1365, DOI 10.1097/00006123-199712000-00024; Savina A, 2002, J CELL SCI, V115, P2505; Segura E, 2005, BLOOD, V106, P216, DOI 10.1182/blood-2005-01-0220; SERANO RD, 1980, ACTA NEUROPATHOL, V51, P53, DOI 10.1007/BF00688850; Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Taieb J, 2005, CRIT REV IMMUNOL, V25, P215, DOI 10.1615/CritRevImmunol.v25.i3.30; Taylor DD, 2003, CLIN CANCER RES, V9, P5113; Taylor DD, 2005, BRIT J CANCER, V92, P305, DOI 10.1038/sj.bjc.6602316; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Valenti R, 2007, CANCER RES, V67, P2912, DOI 10.1158/0008-5472.CAN-07-0520; Valenti R, 2006, CANCER RES, V66, P9290, DOI 10.1158/0008-5472.CAN-06-1819; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Wieckowski E, 2006, IMMUNOL RES, V36, P247, DOI 10.1385/IR:36:1:247; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wikstrand CJ, 1997, CANCER RES, V57, P4130; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Yang G, 1997, PROSTATE, V33, P151, DOI 10.1002/(SICI)1097-0045(19971101)33:3<151::AID-PROS1>3.0.CO;2-M; Yu SH, 2007, J IMMUNOL, V178, P6867, DOI 10.4049/jimmunol.178.11.6867; Zhou H, 2006, KIDNEY INT, V69, P1471, DOI 10.1038/sj.ki.5000273; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	95	290	311	1	34	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1541	1557		10.1096/fj.08-122184	http://dx.doi.org/10.1096/fj.08-122184			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19109410	Green Published			2022-12-28	WOS:000266651700030
J	Houard, X; Ollivier, V; Louedec, L; Michel, JB; Back, M				Houard, Xavier; Ollivier, Veronique; Louedec, Liliane; Michel, Jean-Baptiste; Back, Magnus			Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B-4 as a major chemotactic factor released from the intraluminal thrombus	FASEB JOURNAL			English	Article						lipoxygenase; granulocyte; eicosanoids; leukotriene receptors	MURAL THROMBUS; 5-LIPOXYGENASE PATHWAY; POLYMORPHONUCLEAR LEUKOCYTES; ARTERIAL-WALL; ATHEROSCLEROSIS; RECEPTORS; RECRUITMENT; INVOLVEMENT; EXPRESSION; EVOLUTION	Development and progression of acquired abdominal aortic aneurysms (AAAs) have been associated with different inflammatory mediators. The aim of the present study was to elucidate the topology and the potential mechanisms linking the leukotriene pathway to human AAAs. Human aneurysmal lesions were obtained from 24 patients undergoing surgery, and the intraluminal thrombus was separated from the vascular wall. Histological examination revealed major expression of the leukotriene-producing enzymes 5-lipoxygenase and LTA(4) hydrolase, as well as the two receptors for leukotriene B-4 (BLT1R and BLT2R), corresponding to neutrophils in the luminal part of the thrombus. In contrast, in the vascular wall, the leukotriene pathway mainly localized in macrophage-rich adventitial areas. Furthermore, conditioned media of the intraluminal thrombus contained significantly higher concentrations of leukotriene B-4 than that derived from the vascular wall, which were significantly correlated to other neutrophil-derived mediators, such as elastase/alpha(1)-antitrypsin complexes, myeloperoxidase, and MMP9/NGAL complexes. Finally, the neutrophil-chemotactic activity of the conditioned media from the intraluminal thrombus exhibited major inhibition by antagonists of the leukotriene B-4 receptors. Taken together, these results indicate neutrophil-derived leukotriene B-4 as a major neutrophil chemotactic factor released from the intraluminal thrombus of human AAAs and suggest that targeting BLT receptors may represent a potential medical therapeutic strategy in the prevention of AAA progression in humans.-Houard, X., Ollivier, V., Louedec, L., Michel, J.-B., Back, M. Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B-4 as a major chemotactic factor released from the intraluminal thrombus. FASEB J. 23, 1376-1383 (2009)	[Houard, Xavier; Ollivier, Veronique; Louedec, Liliane; Michel, Jean-Baptiste; Back, Magnus] Univ Paris 07, Bichat Claude Bernard Hosp, INSERM, Cardiovasc Hematol Bioengn & Remodeling U698, Paris, France; [Back, Magnus] Karolinska Univ Hosp, Dept Cardiol, Stockholm, Sweden; [Back, Magnus] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Michel, JB (corresponding author), Hop X Bichat, INSERM, Cardiovasc Hematol Bioengn & Remodeling U698, 46 Rue Henri Huchard, F-75877 Paris 18, France.	jean-baptiste.michel@inserm.fr	Michel, Jean-Baptiste/AAH-9336-2020; Ollivier, Véronique/AAA-2241-2022; Back, Magnus/E-4879-2011	Back, Magnus/0000-0003-0853-5141; Ollivier, Veronique/0000-0003-1318-1712	Fondation Lefoulon-Delalande; French National Academy of Medicine; French-Swedish Foundation; Leducq Foundation; Fondation pour la Recherche Medicale; European Union	Fondation Lefoulon-Delalande; French National Academy of Medicine; French-Swedish Foundation; Leducq Foundation(Leducq Foundation); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); European Union(European Commission)	X.H. was supported by the Fondation Lefoulon-Delalande, and M. B. was supported by the French National Academy of Medicine and the French-Swedish Foundation. This study was supported by grants from the Leducq Foundation, the Fondation pour la Recherche Medicale, and the European Union "Fighting Aneurysmal Disease." We thank Dr. Uriel Sebbag and Dr. Tonino Palombi (Centre Cardiologique du Nord, St. Denis, France) for providing us with aneurysmal samples.	Adolph R, 1997, J VASC SURG, V25, P916, DOI 10.1016/S0741-5214(97)70223-4; Ahluwalia N, 2007, J IMMUNOL, V179, P691, DOI 10.4049/jimmunol.179.1.691; Alexander JJ, 2004, J SURG RES, V117, P163, DOI 10.1016/j.jss.2003.11.011; Back M, 2005, P NATL ACAD SCI USA, V102, P17501, DOI 10.1073/pnas.0505845102; Back M, 2007, CIRC RES, V100, P946, DOI 10.1161/01.RES.0000264498.60702.0d; Back M, 2008, CURR ATHEROSCLER REP, V10, P244, DOI 10.1007/s11883-008-0038-7; Back M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001351; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Cao RY, 2007, PROSTAG OTH LIPID M, V84, P34, DOI 10.1016/j.prostaglandins.2007.03.005; Carrell TWG, 2006, VASCULAR, V14, P9, DOI 10.2310/6670.2006.00008; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1665, DOI 10.1161/01.ATV.0000172632.96987.2d; de Gaetano G, 1999, HAEMOSTASIS, V29, P41; Eliason JL, 2005, CIRCULATION, V112, P232, DOI 10.1161/CIRCULATIONAHA.104.517391; Folkesson M, 2007, THROMB HAEMOSTASIS, V98, P427, DOI 10.1160/TH06-11-0638; Fontaine V, 2004, AM J PATHOL, V164, P2077, DOI 10.1016/S0002-9440(10)63766-2; Fontaine V, 2002, AM J PATHOL, V161, P1701, DOI 10.1016/S0002-9440(10)64447-1; Gacko M, 1998, CLIN CHIM ACTA, V271, P171, DOI 10.1016/S0009-8981(97)00246-5; GADALETA D, 1994, SURGERY, V116, P847; Hannawa KK, 2005, CIRCULATION, V112, P241, DOI 10.1161/CIRCULATIONAHA.105.535625; Hayashi S, 2000, CIRCULATION, V102, P1710, DOI 10.1161/01.CIR.102.14.1710; Hobeika MJ, 2007, J VASC SURG, V45, P849, DOI 10.1016/j.jvs.2006.09.066; Houard X, 2007, J PATHOL, V212, P20, DOI 10.1002/path.2148; Kazi M, 2003, J VASC SURG, V38, P1283, DOI 10.1016/S0741-5214(03)00791-2; Leclercq A, 2007, J LEUKOCYTE BIOL, V82, P1420, DOI 10.1189/jlb.1106671; Lindholt JS, 2008, VASC ENDOVASC SURG, V42, P329, DOI 10.1177/1538574408315205; Michel JB, 2007, ARTERIOSCL THROM VAS, V27, P1259, DOI 10.1161/ATVBAHA.106.137851; Mtairag EM, 2002, ARTERIOSCL THROM VAS, V22, P1824, DOI 10.1161/01.ATV.0000037102.31086.F4; Pagano MB, 2007, P NATL ACAD SCI USA, V104, P2855, DOI 10.1073/pnas.0606091104; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Sakalihasan N, 1996, J VASC SURG, V24, P127, DOI 10.1016/S0741-5214(96)70153-2; Sakata K, 2004, BRIT J PHARMACOL, V141, P449, DOI 10.1038/sj.bjp.0705641; Sarda-Mantel L, 2006, ARTERIOSCL THROM VAS, V26, P2153, DOI 10.1161/01.ATV.0000237605.25666.13; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Touat Z, 2006, AM J PATHOL, V168, P1022, DOI 10.2353/ajpath.2006.050868; Trottier MD, 2008, P NATL ACAD SCI USA, V105, P2028, DOI 10.1073/pnas.0712003105; Vicioso MA, 1998, EUR CYTOKINE NETW, V9, P247; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhao L, 2004, NAT MED, V10, P966, DOI 10.1038/nm1099	42	89	92	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2009	23	5					1376	1383		10.1096/fj.08-116202	http://dx.doi.org/10.1096/fj.08-116202			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19136615				2022-12-28	WOS:000266651700014
J	Chabwine, JN; Talavera, K; Verbert, L; Eggermont, J; Vanderwinden, JM; De Smedt, H; Van Den Bosch, L; Robberecht, W; Callewaert, G				Chabwine, J. N.; Talavera, K.; Verbert, L.; Eggermont, J.; Vanderwinden, J. -M.; De Smedt, H.; Van Den Bosch, L.; Robberecht, W.; Callewaert, G.			Differential contribution of the Na+-K+-2Cl(-) cotransporter NKCC1 to chloride handling in rat embryonic dorsal root ganglion neurons and motor neurons	FASEB JOURNAL			English	Article						GABA receptor; bumetanide; primary afferent depolarization; kinetic model	NA-K-CL; PRESYNAPTIC INHIBITION; MEDIATED INHIBITION; EXCITATORY ACTIONS; CHICK-EMBRYO; GABA; CELLS; MOTONEURON; CURRENTS; BRAIN	Plasma membrane chloride (Cl-) pathways play an important role in neuronal physiology. Here, we investigated the role of NKCC1 cotransporters (a secondary active Cl- uptake mechanism) in Cl- handling in cultured rat dorsal root ganglion neurons (DRGNs) and motor neurons (MNs) derived from fetal stage embryonic day 14. Gramicidin-perforated patch-clamp recordings revealed that DRGNs accumulate intracellular Cl- through a bumetanide- and Na+-sensitive mechanism, indicative of the functional expression of NKCC1. Western blotting confirmed the expression of NKCC1 in both DRGNs and MNs, but immunocytochemistry experiments showed a restricted expression in dendrites of MNs, which contrasts with a homogeneous expression in DRGNs. Both MNs and DRGNs could be readily loaded with or depleted of Cl- during GABA(A) receptor activation at depolarizing or hyperpolarizing membrane potentials. After loading, the rate of recovery to the resting Cl- concentration (i.e., [Cl-](i) decrease) was similar in both cell types and was unaffected by lowering the extracellular Na+ concentration. In contrast, the recovery on depletion (i. e., [Cl-](i) increase) was significantly faster in DRGNs in control conditions but not in low extracellular Na+. The experimental observations could be reproduced by a mathematical model for intracellular Cl- kinetics, in which DRGNs show higher NKCC1 activity and smaller Cl--handling volume than MNs. On the basis of these results, we conclude that embryonic DRGNs show a higher somatic functional expression of NKCC1 than embryonic MNs. The high NKCC1 activity in DRGNs is important for maintaining high [Cl-](i), whereas lower NKCC1 activity in MNs allows large [Cl-](i) variations during neuronal activity.-Chabwine, J. N., Talavera, K., Verbert, L., Eggermont, J., Vanderwinden, J.-M., De Smedt, H., Van Den Bosch, L., Robberecht, W., Callewaert, G. Differential contribution of the Na+-K+-2Cl(-) cotransporter NKCC1 to chloride handling in rat embryonic dorsal root ganglion neurons and motor neurons. FASEB J. 23, 1168-1176 (2009)	[Chabwine, J. N.; Talavera, K.; Verbert, L.; Eggermont, J.; De Smedt, H.; Callewaert, G.] Katholieke Univ Leuven VIB, Dept Mol & Cell Biol, Vesalius Res Ctr, B-3000 Louvain, Belgium; [Van Den Bosch, L.; Robberecht, W.] Katholieke Univ Leuven VIB, Neurobiol Lab, Vesalius Res Ctr, B-3000 Louvain, Belgium; [Vanderwinden, J. -M.] Univ Libre Bruxelles, Neurophysiol Lab, Brussels, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; Universite Libre de Bruxelles	Chabwine, JN (corresponding author), Katholieke Univ Leuven VIB, Dept Mol & Cell Biol, Vesalius Res Ctr, Campus Gasthuisberg O&N1,Herestr 49-802, B-3000 Louvain, Belgium.	jo.nsimy@gmail.com	Van Den Bosch, Ludo/B-7258-2012; Talavera, Karel/K-7990-2014	Talavera, Karel/0000-0002-3124-138X; Van Den Bosch, Ludo/0000-0003-0104-4067; Eggermont, Jan/0000-0002-8497-1159				Achilles K, 2007, J NEUROSCI, V27, P8616, DOI 10.1523/JNEUROSCI.5041-06.2007; ALVAREZLEEFMANS FJ, 1988, J PHYSIOL-LONDON, V406, P225, DOI 10.1113/jphysiol.1988.sp017378; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Ben-Ari Y, 2007, PHYSIOL REV, V87, P1215, DOI 10.1152/physrev.00017.2006; Ben-Ari Y, 2006, EPILEPTIC DISORD, V8, P91; Capo-Aponte JE, 2007, EXP EYE RES, V84, P361, DOI 10.1016/j.exer.2006.10.011; Chabwine JN, 2004, NEUROSCI LETT, V365, P69, DOI 10.1016/j.neulet.2004.04.049; Chub N, 2006, J NEUROPHYSIOL, V95, P323, DOI 10.1152/jn.00162.2005; Chub N, 2001, J NEUROPHYSIOL, V85, P2166, DOI 10.1152/jn.2001.85.5.2166; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; Delpire E, 2000, NEWS PHYSIOL SCI, V15, P309, DOI 10.1152/physiologyonline.2000.15.6.309; Delpy A, 2008, J PHYSIOL-LONDON, V586, P1059, DOI 10.1113/jphysiol.2007.146993; Devor M, 1999, PAIN, pS27, DOI 10.1016/S0304-3959(99)00135-9; Di Ciano-Oliveira C, 2005, AM J PHYSIOL-CELL PH, V289, pC68, DOI 10.1152/ajpcell.00631.2004; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; Genzen JR, 2001, J NEUROPHYSIOL, V86, P1773, DOI 10.1152/jn.2001.86.4.1773; Gillen CM, 1999, AM J PHYSIOL-CELL PH, V276, pC328, DOI 10.1152/ajpcell.1999.276.2.C328; Gold MS, 2004, J NEUROPHYSIOL, V91, P2524, DOI 10.1152/jn.00866.2003; Gulledge AT, 2003, NEURON, V37, P299, DOI 10.1016/S0896-6273(02)01146-7; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC441, DOI 10.1152/ajpcell.1999.277.3.C441; Hoffmann EK, 2007, COMP BIOCHEM PHYS A, V148, P29, DOI 10.1016/j.cbpa.2006.11.023; Hoffmann EK, 2007, AM J PHYSIOL-CELL PH, V292, pC1854, DOI 10.1152/ajpcell.00474.2006; Holohean AM, 1996, BRAIN RES, V711, P138, DOI 10.1016/0006-8993(95)01414-4; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Valencia-de Ita S, 2006, J NEUROPHYSIOL, V95, P3553, DOI 10.1152/jn.01091.2005; Kahle KT, 2006, PHYSIOLOGY, V21, P326, DOI 10.1152/physiol.00015.2006; Kahle KT, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/9/E22; Laird JMA, 2004, NEUROSCI LETT, V361, P200, DOI 10.1016/j.neulet.2003.12.015; Lytle C, 2002, AM J PHYSIOL-CELL PH, V283, pC1422, DOI 10.1152/ajpcell.00130.2002; MAA E, 2007, EPILEPSIA, V48, pS6; Martin DJ, 2002, NEUROPHARMACOLOGY, V42, P353, DOI 10.1016/S0028-3908(01)00181-2; Mercado A, 2004, NEUROCHEM RES, V29, P17, DOI 10.1023/B:NERE.0000010432.44566.21; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Rivera C, 2005, J PHYSIOL-LONDON, V562, P27, DOI 10.1113/jphysiol.2004.077495; Rocha-Gonzalez HI, 2008, J NEUROPHYSIOL, V100, P169, DOI 10.1152/jn.01007.2007; Rudomin P, 1999, EXP BRAIN RES, V129, P1, DOI 10.1007/s002210050933; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; SCHLATTER E, 1983, PFLUG ARCH EUR J PHY, V396, P210, DOI 10.1007/BF00587857; Stein V, 2003, NEURON, V37, P375, DOI 10.1016/S0896-6273(03)00056-4; Sun DD, 1999, J NEUROPHYSIOL, V81, P1939, DOI 10.1152/jn.1999.81.4.1939; Sung KW, 2000, J NEUROSCI, V20, P7531; Tyzio R, 2006, SCIENCE, V314, P1788, DOI 10.1126/science.1133212; Van Damme P, 2003, J NEUROSCI, V23, P4942; Van Den Bosch L, 2000, J NEUROL SCI, V180, P29, DOI 10.1016/S0022-510X(00)00414-7; Vandenberghe W, 1998, BRAIN RES, V807, P1, DOI 10.1016/S0006-8993(98)00569-1; Willis WD, 1999, EXP BRAIN RES, V124, P395, DOI 10.1007/s002210050637; Yan YP, 2003, BRAIN RES, V961, P22, DOI 10.1016/S0006-8993(02)03832-5	51	13	13	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1168	1176		10.1096/fj.08-116012	http://dx.doi.org/10.1096/fj.08-116012			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19103648	Green Accepted			2022-12-28	WOS:000266651600021
J	Leung, WC; Hessel, S; Meplan, C; Flint, J; Oberhauser, V; Tourniaire, F; Hesketh, JE; von Lintig, J; Lietz, G				Leung, W. C.; Hessel, S.; Meplan, C.; Flint, J.; Oberhauser, V.; Tourniaire, F.; Hesketh, J. E.; von Lintig, J.; Lietz, G.			Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15,15 '-monoxygenase alter beta-carotene metabolism in female volunteers	FASEB JOURNAL			English	Article						vitamin A; SNP; triglyceride-rich lipoprotein; supplementation; nutrient-gene interaction	VITAMIN-A INTAKE; BETA,BETA-CAROTENE 15,15'-MONOOXYGENASE; DOUBLE-TRACER; EXPRESSION; CONVERSION; RETINOL; WOMEN; 15,15-MONOOXYGENASE; EQUIVALENCE; VARIABILITY	The key enzyme responsible for beta-carotene conversion into retinal is beta-carotene 15,15'-monoxygenase (BCMO1). Since it has been reported that the conversion of beta-carotene into vitamin A is highly variable in up to 45% of healthy individuals, we hypothesized that genetic polymorphisms in the BCMO1 gene could contribute to the occurrence of the poor converter phenotype. Here we describe the screening of the total open reading frame of the BCMO1 coding region that led to the identification of two common nonsynonymous single nucleotide polymorphisms (R267S: rs12934922; A379V: rs7501331) with variant allele frequencies of 42 and 24%, respectively. In vitro biochemical characterization of the recombinant 267S + 379V double mutant revealed a reduced catalytic activity of BCMO1 by 57% (P<0.001). Assessment of the responsiveness to a pharmacological dose of beta-carotene in female volunteers confirmed that carriers of both the 379V and 267S + 379V variant alleles had a reduced ability to convert beta-carotene, as indicated through reduced retinyl palmitate: beta-carotene ratios in the triglyceride-rich lipoprotein fraction [-32% (P=0.005) and -69% (P=0.001), respectively] and increased fasting beta-carotene concentrations [+160% (P=0.025) and +240% (P=0.041), respectively]. Our data show that there is genetic variability in beta-carotene metabolism and may provide an explanation for the molecular basis of the poor converter phenotype within the population.-Leung, W. C., Hessel, S., Meplan, C., Flint, J., Oberhauser, V., Tourniaire, F., Hesketh, J. E., von Lintig, J., Lietz, G. Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15,15'-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J. 23, 1041-1053 (2009)	[Tourniaire, F.; Lietz, G.] Univ Newcastle, Sch Agr Food & Rural Dev, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Leung, W. C.; Hessel, S.; Meplan, C.; Tourniaire, F.; Hesketh, J. E.; Lietz, G.] Univ Newcastle, Human Nutr Res Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Meplan, C.; Flint, J.; Hesketh, J. E.] Univ Newcastle, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Hessel, S.; Oberhauser, V.; von Lintig, J.] Inst Biol Anim Physiol & Neurobiol 1, Freiburg, Germany; [von Lintig, J.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Case Western Reserve University	Lietz, G (corresponding author), Univ Newcastle, Sch Agr Food & Rural Dev, Agr Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	georg.lietz@ncl.ac.uk	Lietz, Georg/A-4084-2012; Tourniaire, Franck/K-9131-2017	Tourniaire, Franck/0000-0002-6394-7045; Flint, James/0000-0003-2923-7813; von Lintig, Johannes/0000-0002-2079-2143	Biotechnology and Biological Sciences Research Council; European Nutrigenomics Organisation NuGO	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Nutrigenomics Organisation NuGO	This work was supported by a Biotechnology and Biological Sciences Research Council studentship to W. C. L. and a research grant from the European Nutrigenomics Organisation NuGO. We thank Andrew Dodd and David Lamb for help in the analysis of the BCMO1 promoter. We also thank Simon Kometa for help with the statistical analysis, Tevfik Dorak for help with Haploview, and Muriel Caslake and Dermot Neely for help and advice in the TRL separation. We acknowledge the help of Sophie Whelan during the intervention study. In addition, we thank DSM (Heerlen, Basel, Switzerland) for kindly supplying us with the beta-carotene supplement.	Bachmann H, 2002, J NUTR, V132, P3616, DOI 10.1093/jn/132.12.3616; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Barua AB, 2000, J NUTR, V130, P1996, DOI 10.1093/jn/130.8.1996; Borel P, 1998, J LIPID RES, V39, P2250; Borel P, 2009, BRIT J NUTR, V101, P680, DOI 10.1017/S0007114508030754; Cornish-Bowden A, 2012, FUNDAMENTALS ENZYME, V4th; de Pee S, 2007, INT J VITAM NUTR RES, V77, P182, DOI 10.1024/0300-9831.77.3.182; *DEP HLTH, 2003, AD AG 19 64 YEARS VI, V3; *DEP HLTH, 2003, AD AG 19 64 YEARS EN, V2; During A, 1996, ANAL BIOCHEM, V241, P199, DOI 10.1006/abio.1996.0400; During A, 1998, J NUTR, V128, P1614, DOI 10.1093/jn/128.10.1614; Edwards AJ, 2001, AM J CLIN NUTR, V74, P348; Feskanich D, 2002, JAMA-J AM MED ASSOC, V287, P47, DOI 10.1001/jama.287.1.47; Gong XM, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-7; Herbeth B, 2007, J AM COLL NUTR, V26, P655, DOI 10.1080/07315724.2007.10719644; Hessel S, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706763200; Hickenbottom SJ, 2002, AM J CLIN NUTR, V75, P900, DOI 10.1093/ajcn/75.5.900; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Lemke SL, 2003, J LIPID RES, V44, P1591, DOI 10.1194/jlr.M300116-JLR200; Lin YM, 2000, AM J CLIN NUTR, V71, P1545; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; Lindqvist A, 2004, J HISTOCHEM CYTOCHEM, V52, P491, DOI 10.1177/002215540405200407; Lindqvist A, 2007, J NUTR, V137, P2346, DOI 10.1093/jn/137.11.2346; Meplan C, 2007, FASEB J, V21, P3063, DOI 10.1096/fj.07-8166com; Miller M, 2002, J NUTR, V132, p2867S, DOI 10.1093/jn/132.9.2867S; OLSON JA, 1994, J NUTR, V124, pS1461, DOI 10.1093/jn/124.suppl_8.1461S; Park CS, 2008, BIOTECHNOL LETT, V30, P735, DOI 10.1007/s10529-007-9598-9; Poliakov E, 2005, J BIOL CHEM, V280, P29217, DOI 10.1074/jbc.M500409200; Seino Y, 2008, J BIOL CHEM, V283, P4905, DOI 10.1074/jbc.M707928200; Strobel M, 2007, EUR J NUTR, V46, P1, DOI 10.1007/s00394-007-1001-z; Tang GW, 2003, AM J CLIN NUTR, V78, P259, DOI 10.1093/ajcn/78.2.259; Underwood BA, 2004, J NUTR, V134, p231S, DOI 10.1093/jn/134.1.231S; VANVLIET T, 1995, AM J CLIN NUTR, V62, P110, DOI 10.1093/ajcn/62.1.110; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wang ZX, 2004, BRIT J NUTR, V91, P121, DOI 10.1079/BJN20031030; West KP, 2002, J NUTR, V132, p2857S, DOI 10.1093/jn/132.9.2857S; Wyss A, 2004, J NUTR, V134, p246S, DOI 10.1093/jn/134.1.246S	37	147	152	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1041	1053		10.1096/fj.08-121962	http://dx.doi.org/10.1096/fj.08-121962			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19103647				2022-12-28	WOS:000266651600008
J	Sheng, JZ; Ella, S; Davis, MJ; Hill, MA; Braun, AP				Sheng, Jian-zhong; Ella, Srikanth; Davis, Michael J.; Hill, Michael A.; Braun, Andrew P.			Openers of SKCa and IKCa channels enhance agonist-evoked endothelial nitric oxide synthesis and arteriolar vasodilation	FASEB JOURNAL			English	Article						hyperpolarization; calcium; resistance artery; myogenic tone; Ca2+-activated; relaxation	ACTIVATED POTASSIUM CHANNELS; CA2+-ACTIVATED K+ CHANNELS; MIDDLE CEREBRAL-ARTERY; RAT MESENTERIC-ARTERY; HAMSTER FEED ARTERIES; SMALL-CONDUCTANCE; HYPERPOLARIZING FACTOR; MEDIATED DILATIONS; BLOOD-PRESSURE; CALCIUM	Recent data have led us to hypothesize that selective activation of endothelial small- and/or intermediate-conductance, calcium-activated potassium channels (SKCa and IKCa channels, respectively) by the opener compounds NS309 and DCEBIO would augment stimulated nitric oxide (NO) synthesis and vasodilation in resistance arteries. Experimentally, ATP-evoked changes in membrane potential, cytosolic Ca2+, and NO synthesis were recorded by patch clamp and microfluorimetry in single human endothelial cells. Agonist-evoked inhibition of myogenic tone in isolated, pressurized arterioles from rat cremaster skeletal muscle was analyzed by video microscopy. NS309 and DCEBIO enhanced ATP-evoked membrane hyperpolarization and cytosolic Ca2+ transients, along with acute NO synthesis in isolated endothelial cells. The acetylcholine-mediated inhibition of myogenic tone (IC50 = 237 nM) was left-shifted in the presence of NS309 and DCEBIO (10, 100, and 1000 nM) to IC50 values of 101, 78, and 43 nM; endothelial denudation inhibited this drug effect. L-NAME attenuated the acetylcholine-induced inhibition of myogenic tone but did not interfere with NS309 and DCEBIO-evoked vasodilation. Collectively, our data demonstrate that drug-induced enhancement of endothelial SKCa and IKCa channel activities represents a novel cellular mechanism to increase vasodilation of small-resistance arterioles, thereby highlighting these channels as potential therapeutic targets in cardiovascular disease states associated with compromised NO signaling.-Sheng, J.S., Ella, S., Davis, M. J., Hill, M. A., Braun, A. P. Openers of SKCa and IKCa channels enhance agonist-evoked endothelial nitric oxide synthesis and arteriolar vasodilation. FASEB J. 23, 1138-1145 (2009)	[Braun, Andrew P.] Univ Calgary, Dept Pharmacol & Therapeut, Fac Med, Libin Cardiovasc Inst,Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; [Ella, Srikanth; Davis, Michael J.; Hill, Michael A.] Univ Missouri, Dept Med Pharmacol & Physiol, Dalton Cardiovasc Res Ctr, Columbia, MO USA	Libin Cardiovascular Institute Of Alberta; University of Calgary; University of Missouri System; University of Missouri Columbia	Braun, AP (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, Fac Med, Libin Cardiovasc Inst,Smooth Muscle Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	abraun@ucalgary.ca	Hill, Michael/AAV-5350-2020	Hill, Michael/0000-0002-4455-2072	Canadian Institutes of Health Research; U.S. National Institutes of Health [NHLBI-71796]; Alberta Heritage Foundation for Medical Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric)	This work was supported by operating grants from the Canadian Institutes of Health Research ( A. P. B.) and the U.S. National Institutes of Health (M.J.D., NHLBI-71796). A senior research scholarship to A. P. B. from the Alberta Heritage Foundation for Medical Research during the initial stages of this work is gratefully acknowledged.	Absi M, 2007, BRIT J PHARMACOL, V151, P332, DOI 10.1038/sj.bjp.0707222; Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Burnham MP, 2002, BRIT J PHARMACOL, V135, P1133, DOI 10.1038/sj.bjp.0704551; Busse R, 2002, TRENDS PHARMACOL SCI, V23, P374, DOI 10.1016/S0165-6147(02)02050-3; Crane GJ, 2003, J PHYSIOL-LONDON, V553, P183, DOI 10.1113/jphysiol.2003.051896; Davis MJ, 2005, MICROCIRCULATION, V12, P361, DOI 10.1080/10739680590934772; Domeier TL, 2007, J PHYSIOL-LONDON, V579, P175, DOI 10.1113/jphysiol.2006.124529; Doughty JM, 1999, AM J PHYSIOL-HEART C, V276, pH1107, DOI 10.1152/ajpheart.1999.276.3.H1107; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Feelisch M, 1998, N-S ARCH PHARMACOL, V358, P113, DOI 10.1007/PL00005231; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; Kamouchi M, 1999, GEN PHYSIOL BIOPHYS, V18, P199; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kohler R, 2007, KIDNEY INT, V72, P145, DOI 10.1038/sj.ki.5002303; Kohler R, 2000, CIRC RES, V87, P496; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; Ledoux J, 2008, P NATL ACAD SCI USA, V105, P9627, DOI 10.1073/pnas.0801963105; Ledoux J, 2008, J GEN PHYSIOL, V131, P125, DOI 10.1085/jgp.200709875; Leuranguer V, 2008, N-S ARCH PHARMACOL, V377, P101, DOI 10.1007/s00210-008-0267-x; Marchenko SM, 1996, J PHYSIOL-LONDON, V492, P53, DOI 10.1113/jphysiol.1996.sp021288; MCININGER GA, 1991, AM J PHYSIOL-HEART C, V261, pH950; McNeish AJ, 2006, STROKE, V37, P1277, DOI 10.1161/01.STR.0000217307.71231.43; RUSKO J, 1992, J PHYSIOL-LONDON, V455, P601, DOI 10.1113/jphysiol.1992.sp019318; Sheng JZ, 2007, AM J PHYSIOL-CELL PH, V293, pC458, DOI 10.1152/ajpcell.00036.2007; Sheng JZ, 2005, J PHARMACOL EXP THER, V315, P931, DOI 10.1124/jpet.105.087932; Si H, 2006, CIRC RES, V99, P537, DOI 10.1161/01.RES.0000238377.08219.0c; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Sokoya EM, 2007, J VASC RES, V44, P169, DOI 10.1159/000099630; Stankevicius E, 2006, BRIT J PHARMACOL, V149, P560, DOI 10.1038/sj.bjp.0706886; Strobaek D, 2004, BBA-BIOMEMBRANES, V1665, P1, DOI 10.1016/j.bbamem.2004.07.006; Taylor MS, 2003, CIRC RES, V93, P124, DOI 10.1161/01.RES.0000081980.63146.69; Uhrenholt TR, 2007, AM J PHYSIOL-HEART C, V292, pH1634, DOI 10.1152/ajpheart.00605.2006; Wulff H, 2007, CURR MED CHEM, V14, P1437, DOI 10.2174/092986707780831186	33	70	73	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2009	23	4					1138	1145		10.1096/fj.08-120451	http://dx.doi.org/10.1096/fj.08-120451			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19074509	Green Published			2022-12-28	WOS:000266651600017
J	Izzotti, A; Calin, GA; Arrigo, P; Steele, VE; Croce, CM; De Flora, S				Izzotti, Alberto; Calin, George A.; Arrigo, Patrizio; Steele, Vernon E.; Croce, Carlo M.; De Flora, Silvio			Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke	FASEB JOURNAL			English	Article						mirnome; transcriptome; proteome; microarrays	GENE-EXPRESSION; CANCER; CHEMOPREVENTION; POLYMORPHISM; CARCINOGENS; INHIBITION; MODULATION; APOPTOSIS; PROFILES; GENOME	Although microRNAs have been investigated extensively in cancer research, little is known regarding their response to noxious agents in apparently healthy tissues. We analyzed the expression of 484 miRNAs in the lungs of rats exposed to environmental cigarette smoke (ECS) for 28 days. ECS down-regulated 126 miRNAs (26.0%) at least 2-fold and 24 miRNAs more than 3-fold. We previously demonstrated that 107 of 4858 genes (2.9%) and 50 of 518 proteins (9.7%) were up-regulated by ECS in the same tissue, which is consistent with the role of microRNAs as negative regulators of gene expression. The most remarkably down-regulated microRNAs belonged to the families of let-7, miR-10, miR-26, miR-30, miR-34, miR-99, miR-122, miR-123, miR-124, miR-125, miR-140, miR-145, miR-146, miR-191, miR-192, miR-219, miR-222, and miR-223, which regulate stress response, apoptosis, proliferation, angiogenesis, and expression of genes. In contrast, miR-294, an inhibitor of transcriptional repressor genes, was up-regulated by ECS. There was a strong parallelism in dysregulation of rodent microRNAs and their human homologues, which are often transcribed from genes localized in fragile sites deleted in lung cancer. Five ECS-down-regulated microRNAs are known to be affected by single nucleotide polymorphisms. Thus, changes in microRNA expression are an early event following exposure to cigarette smoke.-Izzotti, A., Calin, G. A., Arrigo, P., Steele, V. E., Croce, C. M., De Flora, S. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J. 23, 806-812 (2009)	[Izzotti, Alberto; De Flora, Silvio] Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Arrigo, Patrizio] CNR, Inst Study Macromol, Genoa, Italy; [Steele, Vernon E.] NCI, Rockville, MD USA; [Croce, Carlo M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Genoa; University of Texas System; UTMD Anderson Cancer Center; Consiglio Nazionale delle Ricerche (CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it	Young, Richard A/F-6495-2012; Calin, George/E-9390-2011	Young, Richard A/0000-0001-8855-8647; izzotti, alberto/0000-0002-8588-0347; Calin, George/0000-0001-6704-5615; arrigo, patrizio/0000-0002-6735-0211	U.S. National Cancer Institute [N01-CN 53301]	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the U.S. National Cancer Institute (contract N01-CN 53301).	Balansky R, 1996, CANCER RES, V56, P1642; Balansky R, 2007, CARCINOGENESIS, V28, P2236, DOI 10.1093/carcin/bgm122; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; De Flora S, 2003, CANCER RES, V63, P793; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Duan RH, 2007, HUM MOL GENET, V16, P1124, DOI 10.1093/hmg/ddm062; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; International Agency for Research on Cancer, 2004, IARC MON EV CARC RIS, V83; Izzotti A, 2005, MUTAT RES-FUND MOL M, V591, P212, DOI 10.1016/j.mrfmmm.2005.03.032; Izzotti A, 2005, EUR J CANCER, V41, P1864, DOI 10.1016/j.ejca.2005.04.011; Izzotti A, 2004, CANCER RES, V64, P8566, DOI 10.1158/0008-5472.CAN-04-1420; Izzotti A, 2004, FASEB J, V18, P1559, DOI 10.1096/fj.04-1877fje; Izzotti A, 2003, FASEB J, V17, P1127, DOI 10.1096/fj.02-0967fje; Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499; Izzotti A, 2007, CARCINOGENESIS, V28, P892, DOI 10.1093/carcin/bgl208; Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Karp X, 2005, SCIENCE, V310, P1288, DOI 10.1126/science.1121566; Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Marsit CJ, 2006, CANCER RES, V66, P10843, DOI 10.1158/0008-5472.CAN-06-1894; Pedersen IM, 2007, NATURE, V449, P919, DOI 10.1038/nature06205; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Sagar J, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-9; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Shan Y, 2007, GASTROENTEROLOGY, V133, P1166, DOI 10.1053/j.gastro.2007.08.002; *US DEP HHS, 1989, DHHS PUBL, P43; Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	43	349	367	1	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					806	812		10.1096/fj.08-121384	http://dx.doi.org/10.1096/fj.08-121384			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18952709	Green Published			2022-12-28	WOS:000265506300016
J	Bonetto, S; Spadola, L; Buchanan, AG; Jermutus, L; Lund, J				Bonetto, Stephane; Spadola, Loredana; Buchanan, Andrew G.; Jermutus, Lutz; Lund, John			Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human Fc gamma RI	FASEB JOURNAL			English	Article						effector functions; phage display; single-chain homodimer; molecular modeling; discontinuous interface; consensus sequence	AFFINITY IGE RECEPTOR; CRYSTAL-STRUCTURE; BINDING PEPTIDE; PHAGE DISPLAY; INTERACTION SITES; MOLECULAR-BASIS; COMPLEX; RECOGNITION; FRAGMENT; DOMAIN	Identification of short, structured peptides able to mimic potently protein-protein interfaces remains a challenge in drug discovery. We report here the use of a naive cyclic peptide phage display library to identify peptide ligands able to recognize and mimic IgG1-Fc functions with Fc gamma RI. Selection by competing off binders to Fc gamma RI with IgG1 allowed the isolation of a family of peptides sharing the common consensus sequence TX2CXX theta PXLLGC Phi XE (theta represents a hydrophobic residue, Phi is usually an acidic residue, and X is any residue) and able to inhibit IgG1 binding to Fc gamma RI. In soluble form, these peptides antagonize superoxide generation mediated by IgG1. In complexed form, they trigger phagocytosis and a superoxide burst. Unlike IgG, these peptides are strictly Fc gamma RI-specific among the Fc gamma Rs. Molecular modeling studies suggest that these peptides can adopt 2 distinct and complementary conformers, each able to mimic the discontinuous interface contacts constituted by the C gamma 2-A and -B chains of Fc for Fc gamma RI. In addition, by covalent homodimerization, we engineered a synthetic bivalent 37-mer peptide that retains the ability to trigger effector functions. We demonstrate here that it is feasible to maintain IgG-Fc function within a small structured peptide. These peptides represent a new format for modulation of effector functions. Bonetto, S., Spadola, L., Buchanan, A. G., Jermutus, L. Lund, J. Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human Fc gamma RI. FASEB J. 23, 575-585 (2009)	[Bonetto, Stephane; Buchanan, Andrew G.; Jermutus, Lutz; Lund, John] MedImmune, Res, Cambridge CB21 6GH, England; [Spadola, Loredana] AstraZeneca R&D, DECS Global Cpds Sci, Molndal, Sweden	AstraZeneca; Medimmune; AstraZeneca	Jermutus, L (corresponding author), MedImmune, Res, Granta Pk,Milstein Bldg, Cambridge CB21 6GH, England.	jermutusl@medimmune.com; lundj@medimmune.com	Jermutus, Lutz/AAU-2047-2020	Buchanan, Andrew/0000-0002-5191-7682				Berntzen G, 2006, PROTEIN ENG DES SEL, V19, P121, DOI 10.1093/protein/gzj011; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; Cendron AC, 2008, MOL IMMUNOL, V45, P307, DOI 10.1016/j.molimm.2007.06.152; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; England BP, 2000, P NATL ACAD SCI USA, V97, P6862, DOI 10.1073/pnas.110053997; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; Jefferis R, 2002, IMMUNOL LETT, V82, P57, DOI 10.1016/S0165-2478(02)00019-6; Kato K, 2000, J MOL BIOL, V295, P213, DOI 10.1006/jmbi.1999.3351; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lauth X, 2005, J BIOL CHEM, V280, P9272, DOI 10.1074/jbc.M411154200; Lazar GA, 2006, P NATL ACAD SCI USA, V103, P4005, DOI 10.1073/pnas.0508123103; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LU ZY, 1992, EUR J IMMUNOL, V22, P2819, DOI 10.1002/eji.1830221110; LUND J, 1992, MOL IMMUNOL, V29, P53, DOI 10.1016/0161-5890(92)90156-R; LUND J, 1991, J IMMUNOL, V147, P2657; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Marino M, 2000, NAT BIOTECHNOL, V18, P735, DOI 10.1038/77296; MORGAN A, 1995, IMMUNOLOGY, V86, P319; Mori T, 2004, CURR PHARM DESIGN, V10, P2335, DOI 10.2174/1381612043383944; Nakamura GR, 2002, P NATL ACAD SCI USA, V99, P1303, DOI 10.1073/pnas.022635599; Nakamura GR, 2001, BIOCHEMISTRY-US, V40, P9828, DOI 10.1021/bi0109360; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; POUND JD, 1993, MOL IMMUNOL, V30, P233, DOI 10.1016/0161-5890(93)90052-D; Qiu XQ, 2007, NAT BIOTECHNOL, V25, P921, DOI 10.1038/nbt1320; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Radaev S, 2002, MOL IMMUNOL, V38, P1073, DOI 10.1016/S0161-5890(02)00036-6; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Schweitzer-Stenner R, 2005, J IMMUNOL, V174, P4461, DOI 10.4049/jimmunol.174.8.4461; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Sheridan JA, 1999, J PEPT SCI, V5, P555, DOI 10.1002/(SICI)1099-1387(199912)5:12<555::AID-PSC220>3.0.CO;2-G; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 2001, J MOL BIOL, V309, P737, DOI 10.1006/jmbi.2001.4670; Stamos J, 2004, STRUCTURE, V12, P1289, DOI 10.1016/j.str.2004.04.015; Tamm A, 1997, Int Rev Immunol, V16, P57, DOI 10.3109/08830189709045703; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Wong C, 2001, CANCER IMMUNOL IMMUN, V50, P93, DOI 10.1007/s002620100174	49	10	13	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					575	585		10.1096/fj.08-117069	http://dx.doi.org/10.1096/fj.08-117069			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18957574	Green Published, hybrid			2022-12-28	WOS:000262892900029
J	Zheng, W; Kuhlicke, J; Jaeckel, K; Eltzschig, HK; Singh, A; Sjoeblom, M; Riederer, B; Weinhold, C; Seidler, U; Colgan, SP; Karhausen, J				Zheng, Wen; Kuhlicke, Johannes; Jaeckel, Kristian; Eltzschig, Holger K.; Singh, Anurag; Sjoeblom, Markus; Riederer, Brigitte; Weinhold, Cornelia; Seidler, Ursula; Colgan, Sean P.; Karhausen, Joern			Hypoxia inducible factor-1 (HIF-1)-mediated repression of cystic fibrosis transmembrane conductance regulator (CFTR) in the intestinal epithelium	FASEB JOURNAL			English	Article						anion transporter; ion movement; fluid secretion; mucosa	CAMP RESPONSE ELEMENT; DUODENAL BICARBONATE SECRETION; ACTIVATED PROTEIN-KINASE; ION-TRANSPORT; NA-K-2CL COTRANSPORTER; EXPERIMENTAL COLITIS; CHLORIDE SECRETION; BINDING PROTEIN; CHOLERA-TOXIN; CL-SECRETION	Diarrhea is widespread in intestinal diseases involving ischemia and/or hypoxia. Since hypoxia alters stimulated Cl- and water flux, we investigated the influence of such a physiologically and pathophysiologically important signal on expression of the cystic fibrosis transmembrane conductance regulator (CFTR). Located on the apical membrane, this cAMP-activated Cl- channel determines salt and fluid transport across mucosal surfaces. Our studies revealed depression of CFTR mRNA, protein, and function in hypoxic epithelia. Chromatin immunoprecipitation identified a previously unappreciated binding site for the hypoxia inducible factor-1 (HIF-1), and promoter studies established its relevance by loss of repression following point mutation. Consequently, HIF-1 overexpressing cells exhibited significantly reduced transport capacity in colorimetric Cl- efflux studies, altered short circuit measurements, and changes in transepithelial fluid movement. Whole-body hypoxia in wild-type mice resulted in significantly reduced small intestinal fluid and HCO3- secretory responses to forskolin. Experiments performed in Cftr(-/-) and Nkcc1(-/-) mice underlined the role of altered CFTR expression for these functional changes, and work in conditional Hif1a mutant mice verified HIF-1-dependent CFTR regulation in vivo. In summary, our study clarifies CFTR regulation and introduces the concept of a HIF-1-orchestrated response designed to regulate ion and fluid movement across hypoxic intestinal epithelia.-Zheng, W., Kuhlicke, J., Jackel, K., Eltzschig, H. K., Singh, A., Sjoblom, M., Riederer, B., Weinhold, C., Seidler, U., Colgan, S. P., Karhausen, J. Hypoxia inducible factor-1 (HIF-1) -mediated repression of cystic fibrosis transmembrane conductance regulator (CFTR) in the intestinal epithelium. FASEB J. 23, 204-213 (2009)	[Kuhlicke, Johannes; Jaeckel, Kristian; Eltzschig, Holger K.; Karhausen, Joern] Univ Tubingen, Univ Klin Anasthesiol & Intensivmed, D-72076 Tubingen, Germany; [Zheng, Wen; Singh, Anurag; Sjoeblom, Markus; Riederer, Brigitte; Weinhold, Cornelia; Seidler, Ursula] Hannover Med Sch, Abt Gastroenterol Hepatol & Endokirnol, D-30623 Hannover, Germany; [Eltzschig, Holger K.; Colgan, Sean P.] Univ Colorado, Hlth Sci Ctr, Div Gastroenterol, Mucosal Inflammat Program, Denver, CO USA	Eberhard Karls University of Tubingen; Hannover Medical School; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Karhausen, J (corresponding author), Univ Tubingen, Univ Klin Anasthesiol & Intensivmed, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	joern.karhausen@medizin.uni-tuebingen.de	Seidler, Ursula/HII-8049-2022; karhausen, jorn/X-8813-2019; Colgan, Sean P./B-4573-2009	Seidler, Ursula/0000-0002-9600-2769; karhausen, jorn/0000-0002-4240-229X; Singh, Anurag Kumar/0000-0003-0818-0993	Deutsche Forschungsgemeinschaft [KA2330/ 1-2, Se460/13-4]; SFB621 [C9]; European Community [LSHM-CT-2005-018932]; U.S. National Institutes of Health [HL60569, DK50189]; Interdisziplinares Zentrum fur Klinische Forschung, University of Tubingen; Lower Saxony Ministry of Science; Hannover Biomedical Research School	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); SFB621(German Research Foundation (DFG)); European Community(European Commission); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Interdisziplinares Zentrum fur Klinische Forschung, University of Tubingen; Lower Saxony Ministry of Science; Hannover Biomedical Research School	Support came from grants KA2330/ 1-2 (J. Karhausen) and Se460/13-4 (U.S.) of the Deutsche Forschungsgemeinschaft, SFB621 grant C9 (U.S.), a training grant of EuroCareCF (to J. Karhausen; EuroCareCF is supported by the European Community's Sixth Framework Programme for Research, contract LSHM-CT-2005-018932), and U.S. National Institutes of Health grants HL60569 and DK50189 (S.P.C.). The Interdisziplinares Zentrum fur Klinische Forschung, University of Tubingen, gave support through a Verbundprojekt (J. Karhausen and H.K.E.) and within the Promotionskolleg (K.J.). M. S. was supported by an exchange scientists grant from the Lower Saxony Ministry of Science, and A.S. by a Ph.D. grant from the Hannover Biomedical Research School. The authors thank Dr. B. Scholte and Prof. K. Unertl for exceedingly helpful discussions and support and Michaela Hoch-Gutbrot and Irene Vollmer for technical assistance.	BEBOCK Z, 1999, AM J PHYSIOL-CELL PH, V280, pC135; Broere N, 2007, J BIOL CHEM, V282, P37575, DOI 10.1074/jbc.M704878200; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; Chappe V, 2005, EMBO J, V24, P2730, DOI 10.1038/sj.emboj.7600747; Clayburgh DR, 2005, J CLIN INVEST, V115, P2702, DOI 10.1172/JCI24970; Comerford KM, 2002, CANCER RES, V62, P3387; Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012; Cummins EP, 2005, PFLUG ARCH EUR J PHY, V450, P363, DOI 10.1007/s00424-005-1413-7; CUTHBERT AW, 1995, J PHYSIOL-LONDON, V482, P449, DOI 10.1113/jphysiol.1995.sp020531; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; DEJONGE HR, 2006, PED PULMONOL S, V29, P148; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Field M, 2003, J CLIN INVEST, V111, P931, DOI 10.1172/JCI200318326; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Fouassier L, 2007, AM J PHYSIOL-GASTR L, V293, pG25, DOI 10.1152/ajpgi.00175.2006; Frede S, 2007, METHOD ENZYMOL, V435, P405, DOI 10.1016/S0076-6879(07)35021-0; Furuta GT, 2000, J LEUKOCYTE BIOL, V68, P251; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004; Hallows KR, 2003, AM J PHYSIOL-CELL PH, V284, pC1297, DOI 10.1152/ajpcell.00227.2002; Hartmann H, 2008, GASTROENTEROLOGY, V134, P756, DOI 10.1053/j.gastro.2007.12.008; HAUSER CJ, 1988, J LAB CLIN MED, V112, P68; Hogan DL, 1997, GASTROENTEROLOGY, V113, P533, DOI 10.1053/gast.1997.v113.pm9247473; Ibla JC, 2006, AM J PHYSIOL-CELL PH, V291, pC282, DOI 10.1152/ajpcell.00564.2005; Karhausen J, 2005, J CELL BIOCHEM, V95, P1264, DOI 10.1002/jcb.20489; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; Kles KA, 2002, AM J PHYSIOL-GASTR L, V283, pG1336, DOI 10.1152/ajpgi.00055.2002; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; Li J, 2008, EXP EYE RES, V86, P684, DOI 10.1016/j.exer.2008.01.017; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; MacVinish LJ, 2007, BRIT J PHARMACOL, V150, P1055, DOI 10.1038/sj.bjp.0707175; Maduke M, 2000, ANNU REV BIOPH BIOM, V29, P411, DOI 10.1146/annurev.biophys.29.1.411; Mairbaurl H, 1997, AM J PHYSIOL-LUNG C, V273, pL797, DOI 10.1152/ajplung.1997.273.4.L797; MATTHEWS JB, 1995, J CLIN INVEST, V96, P117, DOI 10.1172/JCI118010; Matthews RP, 1996, J BIOL CHEM, V271, P31869, DOI 10.1074/jbc.271.50.31869; Papen M, 2001, CELL PHYSIOL BIOCHEM, V11, P187, DOI 10.1159/000047805; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; ROBINSON JWL, 1981, GUT, V22, P512, DOI 10.1136/gut.22.6.512; Rosenberger P, 2007, FASEB J, V21, P2613, DOI 10.1096/fj.06-8004com; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SEIDLER U, 2007, EUR J PHYSL, V455, P757; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Sjoblom M, 2007, AM J PHYSIOL-GASTR L, V292, pG899, DOI 10.1152/ajpgi.00398.2006; Sreenarasimhaiah Jayaprakash, 2005, Curr Gastroenterol Rep, V7, P421, DOI 10.1007/s11894-005-0013-1; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Tang WM, 2004, J BIOMOL SCREEN, V9, P607, DOI 10.1177/1087057104266740; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Taylor CT, 1999, J BIOL CHEM, V274, P19447, DOI 10.1074/jbc.274.27.19447; Taylor CT, 1998, J PHARMACOL EXP THER, V284, P568; Uramoto H, 2003, JPN J PHYSIOL, V53, P357, DOI 10.2170/jjphysiol.53.357; Walker J, 2003, AM J PHYSIOL-GASTR L, V285, pG850, DOI 10.1152/ajpgi.00077.2003; Walker NM, 2002, GASTROENTEROLOGY, V123, P531, DOI 10.1053/gast.2002.34757; White NL, 1998, HUM MOL GENET, V7, P363, DOI 10.1093/hmg/7.3.363; Wodopia R, 2000, AM J PHYSIOL-LUNG C, V279, pL1110, DOI 10.1152/ajplung.2000.279.6.L1110; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; Zaidi T, 2004, INVEST OPHTH VIS SCI, V45, P4066, DOI 10.1167/iovs.04-0627; Zhou BY, 2007, AM J PHYSIOL-CELL PH, V292, pC1280, DOI 10.1152/ajpcell.00070.2006	62	68	68	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					204	213		10.1096/fj.08-110221	http://dx.doi.org/10.1096/fj.08-110221			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18779379	Green Published			2022-12-28	WOS:000262095500023
J	Baetz, A; Koelsche, C; Strebovsky, J; Heeg, K; Dalpke, AH				Baetz, Andrea; Koelsche, Christian; Strebovsky, Julia; Heeg, Klaus; Dalpke, Alexander H.			Identification of a nuclear localization signal in suppressor of cytokine signaling 1	FASEB JOURNAL			English	Article						cell activation; cytokine receptors; inflammation; signal transduction	NF-KAPPA-B; SOCS-BOX MOTIF; NEGATIVE REGULATION; UBIQUITIN LIGASE; IFN-GAMMA; IN-VIVO; DEGRADATION; PROTEINS; RECEPTOR; SUBUNIT	Suppressor of cytokine signaling (SOCS) proteins are inducible feedback inhibitors of janus kinase and signal transducer and activators of transcription signaling pathways. In addition, SOCS1 has been identified to regulate stability of nuclear NF-kappa B subunits. However, details about the regulation of the nuclear pool of SOCS1 are unknown. Using different experimental approaches, we observed that SOCS1 but no further SOCS family members localized to the nucleus when expressed in various cell lines. Nuclear transport was confirmed for endogenous SOCS1 in macrophages stimulated with IFN-gamma. Sequence analysis revealed a bipartite nuclear localization signal (NLS) located between the src-homology 2 (SH2) domain and the SOCS box of SOCS1. Deletion of this region, introduction of a series of R/A point mutations, or substitution of this sequence with the respective region of SOCS3 resulted in loss of nuclear localization. Fusion of the SOCS1-NLS to cytokine-inducible SH2 region containing protein (CIS) resulted in nuclear localization of this otherwise cytoplasmic protein. SOCS1 mutants with loss of nuclear localization were still effective in suppressing IFN-alpha-mediated STAT1 tyrosine phosphorylation. However, they showed decreased inhibition of IFN-alpha-mediated induction of CD54. The results identify a hitherto unknown transport of SOCS1 into the nucleus which extends the spectrum of SOCS1 inhibitory activity.-Baetz, A., Koelsche, C., Strebovsky, J., Heeg, K., Dalpke, A. H. Identification of a nuclear localization signal in suppressor of cytokine signaling 1. FASEB J. 22, 4296-4305 (2008)	[Baetz, Andrea; Koelsche, Christian; Strebovsky, Julia; Heeg, Klaus; Dalpke, Alexander H.] Univ Heidelberg, Inst Hyg, Dept Hyg & Med Microbiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Dalpke, AH (corresponding author), Univ Heidelberg, Inst Hyg, Dept Hyg & Med Microbiol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	alexander.dalpke@med.uni-heidelberg.de	Kölsche, Christian/Q-8854-2019	Koelsche, Christian/0000-0001-8763-8864	German Research Foundation [Da592/2,-3]	German Research Foundation(German Research Foundation (DFG))	This work was supported by grants of the German Research Foundation to A. D. (Da592/2, -3).	Ahmed CMI, 2006, J IMMUNOL, V177, P315, DOI 10.4049/jimmunol.177.1.315; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Ben-Yair L, 2002, PROTEIN EXPRES PURIF, V25, P456, DOI 10.1016/S1046-5928(02)00044-X; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Bullock AN, 2007, STRUCTURE, V15, P1493, DOI 10.1016/j.str.2007.09.016; Bullock AN, 2006, P NATL ACAD SCI USA, V103, P7637, DOI 10.1073/pnas.0601638103; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Eyles JL, 2002, J BIOL CHEM, V277, P43735, DOI 10.1074/jbc.M208586200; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kamio M, 2004, ONCOGENE, V23, P3107, DOI 10.1038/sj.onc.1207453; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Ketteler R, 2003, J BIOL CHEM, V278, P2654, DOI 10.1074/jbc.M211236200; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Lee KH, 2008, FEBS LETT, V582, P2319, DOI 10.1016/j.febslet.2008.05.039; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Metcalf D, 2002, P NATL ACAD SCI USA, V99, P943, DOI 10.1073/pnas.022628499; Naka T, 2005, ADV IMMUNOL, V87, P61, DOI 10.1016/S0065-2776(05)87003-8; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Saleh AZM, 2004, ONCOGENE, V23, P7076, DOI 10.1038/sj.onc.1207955; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; Subramaniam PS, 2004, FEBS LETT, V578, P207, DOI 10.1016/j.febslet.2004.10.085; Vuong BQ, 2004, MOL CELL BIOL, V24, P9092, DOI 10.1128/MCB.24.20.9092-9101.2004; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498	39	33	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4296	4305		10.1096/fj.08-116079	http://dx.doi.org/10.1096/fj.08-116079			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18725457				2022-12-28	WOS:000261254800028
J	Zhao, JM; Wen, YJ; Li, Q; Wang, YS; Wu, HB; Xu, JR; Chen, XC; Wu, Y; Fan, LY; Yang, HS; Liu, T; Ding, ZY; Du, XB; Diao, P; Li, J; Wu, HB; Kan, B; Lei, S; Deng, HX; Mao, YQ; Zhao, X; Wei, YQ				Zhao, Ju-mei; Wen, Yan-jun; Li, Qiu; Wang, Yong-sheng; Wu, Hong-bo; Xu, Jian-rong; Chen, Xian-cheng; Wu, Yang; Fan, Ling-yu; Yang, Han-shuo; Liu, Tao; Ding, Zhen-yu; Du, Xiao-bo; Diao, Peng; Li, Jiong; Wu, Hong-bing; Kan, Bing; Lei, Song; Deng, Hong-xin; Mao, Yong-qiu; Zhao, Xia; Wei, Yu-quan			A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus	FASEB JOURNAL			English	Article						apoptosis; cellular immune response; plasmid DNA; cationic liposome; cytotoxic T lymphocytes; CTLs	T-CELLS; IN-VIVO; DENDRITIC CELLS; TUMOR-CELLS; APOPTOSIS; INDUCTION; IMMUNOTHERAPY; INVOLVEMENT; GROWTH; DNA	The matrix (M) protein of vesicular stomatitis virus (VSV) plays a key role in inducing cell apoptosis during infection. To investigate whether M protein-mediated apoptosis could be used in cancer therapy, its cDNA was amplified and cloned into eukaryotic expression vector pcDNA3.1(+). The recombinant plasmid or the control empty plasmid pcDNA3.1(+) was mixed with cationic liposome and introduced into various tumor cell lines in vitro, including lung cancer cell LLC, A549, colon cancer cell CT26 and fibrosarcoma cell MethA. Our data showed that the M protein induced remarkable apoptosis of cancer cells in vitro compared with controls. Fifty micrograms of plasmid in a complex with 250 mu g cationic liposome was injected intratumorally into mice bearing LLC or MethA tumor model every 3 days for 6 times. It was found that the tumors treated with M protein plasmid grew much more slowly, and the survival of the mice was significantly prolonged compared with the mice treated with the control plasmid. In MethA fibrosarcoma, the tumors treated with M protein plasmid were even completely regressed, and the mice acquired longtime protection against the same tumor cell in rechallenge experiments. Both apoptotic cells and CD8(+) T cells were widely distributed in M protein plasmid-treated tumor tissue. Activated cytotoxic T lymphocytes (CTLs) were further detected by means of 51Cr release assay in the spleen of the treated mice. These results showed that M protein of VSV can act as both apoptosis inducer and immune response initiator, which may account for its extraordinary antitumor effect and warrant its further development in cancer gene therapy.-Zhao, J., Wen, Y., Li, Q., Wang, Y., Wu, H., Xu, J., Chen, X., Wu, Y., Fan, L., Yang, H., Liu, T., Ding, Z., Du, X., Diao, P., Li, J., Wu, H., Kan, B., Lei, S., Deng, H., Mao, Y., Zhao, X., Wei, Y. A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J. 22, 4272-4280 (2008)	[Zhao, Ju-mei; Wen, Yan-jun; Li, Qiu; Wang, Yong-sheng; Wu, Hong-bo; Chen, Xian-cheng; Wu, Yang; Fan, Ling-yu; Yang, Han-shuo; Liu, Tao; Ding, Zhen-yu; Du, Xiao-bo; Diao, Peng; Li, Jiong; Wu, Hong-bing; Kan, Bing; Lei, Song; Deng, Hong-xin; Mao, Yong-qiu; Zhao, Xia; Wei, Yu-quan] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Xu, Jian-rong] Sichuan Univ, Coll Life Sci, Chengdu 610041, Sichuan, Peoples R China; [Zhao, Ju-mei] Yanan Univ, Coll Med, Dept Pharmacol, Yanan, Shanxi, Peoples R China	Sichuan University; Sichuan University; Yanan University	Wen, YJ (corresponding author), Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.	julio_wy@sohu.com		Wei, Yu-quan/0000-0002-6211-3217	The National Key Basic Research Program (973 Program) of China [2004CB518800, 2004CB518706]; Hi-tech Research and Development Program ( 863 Program) of China [2007AA021106, 2006AA02Z488]	The National Key Basic Research Program (973 Program) of China(National Basic Research Program of China); Hi-tech Research and Development Program ( 863 Program) of China(National High Technology Research and Development Program of China)	This work is supported by The National Key Basic Research Program (973 Program) of China (2004CB518800 and 2004CB518706), Hi-tech Research and Development Program ( 863 Program) of China (2007AA021106, 2006AA02Z488).	BARRY MA, 1993, CANCER RES, V53, P2349; Ben-Efraim S, 2000, BIOMED PHARMACOTHER, V54, P268, DOI 10.1016/S0753-3322(00)80070-0; Ding HF, 2002, ANN MED, V34, P451, DOI 10.1080/078538902321012405; Fields RC, 1998, P NATL ACAD SCI USA, V95, P9482, DOI 10.1073/pnas.95.16.9482; GORCZYCA W, 1993, CANCER RES, V53, P3186; Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; Preynat-Seauve O, 2006, J IMMUNOL, V176, P61, DOI 10.4049/jimmunol.176.1.61; PUDDINGTON L, 1986, J VIROL, V60, P708, DOI 10.1128/JVI.60.2.708-717.1986; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Schirrmacher V, 1999, GENE THER, V6, P63, DOI 10.1038/sj.gt.3300787; Tousignant JD, 2000, HUM GENE THER, V11, P2493, DOI 10.1089/10430340050207984; WEI YQ, 1994, CANCER RES, V54, P4952; Wei YQ, 1996, CANCER RES, V56, P1104; WEI YQ, 1992, HUM PATHOL, V23, P421, DOI 10.1016/0046-8177(92)90090-P; Yew NS, 2005, ADV GENET, V53, P189, DOI 10.1016/S0065-2660(05)53007-4; YEWDELL JW, 1986, J EXP MED, V163, P1529, DOI 10.1084/jem.163.6.1529; Zhang H., 2007, Experimental Oncology, V29, P85	20	24	24	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4272	4280		10.1096/fj.08-110049	http://dx.doi.org/10.1096/fj.08-110049			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18716030				2022-12-28	WOS:000261254800026
J	Donnelly, S; Stack, CM; O'Neill, SM; Sayed, AA; Williams, DL; Dalton, JP				Donnelly, Sheila; Stack, Colin M.; O'Neill, Sandra M.; Sayed, Ahmed A.; Williams, David L.; Dalton, John P.			Helminth 2-Cys peroxiredoxin drives Th2 responses through a mechanism involving alternatively activated macrophages	FASEB JOURNAL			English	Article						antioxidant; immune modulation; innate immunity	FASCIOLA-HEPATICA; LIVER FLUKE; BIOCHEMICAL-CHARACTERIZATION; SCHISTOSOMA-JAPONICUM; PARASITIC HELMINTH; CATHEPSIN L1; CELLS; YM1; DIFFERENTIATION; EXPRESSION	During helminth infections, alternatively activated macrophages (AAMacs) are key to promoting Th2 responses and suppressing Th1-driven inflammatory pathology. Th2 cytokines IL-4 and/or IL-13 are believed to be important in the induction and activation of AAMacs. Using murine models for the helminth infections caused by Fasciola hepatica (Fh) and Schistosoma mansoni (Sm), we show that a secreted antioxidant, peroxiredoxin (Prx), induces alternative activation of macrophages. These activated, Ym1-expressing macrophages enhanced the secretion of IL-4, IL-5, and IL-13 from naive CD4(+) T cells. Administration of recombinant FhPrx and SmPrx to wild-type and IL-4(-/-) and IL-13(-/-) mice induced the production of AAMacs. In addition, Prx stimulated the expression of markers of AAMacs (particularly, Ym1) in vitro, and therefore can act independently of IL-4/IL-13 signaling. The immunomodulatory property of Prx is not due to its antioxidant activity, as an inactive recombinant variant with active site Cys residues replaced by Gly could also induce AAMacs and Th2 responses. Immunization of mice with recombinant Prx or passive transfer of anti-Prx antibodies prior to infection with Fh not only blocked the induction of AAMacs but also the development of parasite-specific Th2 responses. We propose that Prx activates macrophages as an initial step in the induction of Th2 responses by helminth parasites and is thereby a novel pathogen-associated molecular pattern.-Donnelly, S., Stack, C. M., O'Neill, S. M., Sayed, A. A., Williams, D. L., Dalton, J. P. Helminth 2-Cys peroxiredoxin drives Th2 responses through a mechanism involving alternatively activated macrophages. FASEB J. 22, 4022-4032 (2008)	[Donnelly, Sheila; Stack, Colin M.; Dalton, John P.] Univ Technol Sydney, Inst Biotechnol Infect Dis, Sydney, NSW 2007, Australia; [O'Neill, Sandra M.] Dublin City Univ, Sch Nursing, Dublin 9, Ireland; [Sayed, Ahmed A.; Williams, David L.] Illinois State Univ, Dept Biol Sci, Normal, IL 61761 USA	University of Technology Sydney; Dublin City University; Illinois State University	Dalton, JP (corresponding author), Univ Technol Sydney, Inst Biotechnol Infect Dis, Level 6,Bldg 4,Cnr Thomas & Harris St, Sydney, NSW 2007, Australia.	john.dalton@uts.edu.au	Donnelly, Sheila/H-7733-2014; Dalton, John/K-4457-2014; Stack, Colin M/D-4601-2009	Stack, Colin/0000-0002-7539-7677; Donnelly, Sheila/0000-0003-2005-3698	National Health and Medical Research Council of Australia [352912]; New South Wales Government; Australian Research Council (ARC) [DP0557819]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065622] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); New South Wales Government; Australian Research Council (ARC)(Australian Research Council); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S.D. and J.P.D. were supported by the National Health and Medical Research Council of Australia Project, grant 352912. J.P.D. is a recipient of a New South Wales Government 2003 BioFirst Award 2004. C. M. S. was funded by the Australian Research Council (ARC), DP0557819. We thank Weibo Xu for excellent technical assistance.	AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Anthony RM, 2006, NAT MED, V12, P955, DOI 10.1038/nm1451; Arora M, 2006, P NATL ACAD SCI USA, V103, P7777, DOI 10.1073/pnas.0508492103; Atochina O, 2001, J IMMUNOL, V167, P4293, DOI 10.4049/jimmunol.167.8.4293; Atochina O, 2008, IMMUNOLOGY, V125, P111, DOI 10.1111/j.1365-2567.2008.02826.x; Brys L, 2005, J IMMUNOL, V174, P6095, DOI 10.4049/jimmunol.174.10.6095; CALLAHAN HL, 1988, PARASITOL TODAY, V4, P218, DOI 10.1016/0169-4758(88)90162-7; Cass CL, 2007, MOL BIOCHEM PARASIT, V155, P84, DOI 10.1016/j.molbiopara.2007.06.002; Chang JW, 2005, FEBS LETT, V579, P2873, DOI 10.1016/j.febslet.2005.04.028; Collins PR, 2004, J BIOL CHEM, V279, P17038, DOI 10.1074/jbc.M308831200; CRABTREE JE, 1986, PARASITE IMMUNOL, V8, P265, DOI 10.1111/j.1365-3024.1986.tb01038.x; Donnelly S, 2005, INFECT IMMUN, V73, P166, DOI 10.1128/IAI.73.1.166-173.2005; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Falcone FH, 2001, J IMMUNOL, V167, P5348, DOI 10.4049/jimmunol.167.9.5348; Giguere P, 2007, FEBS LETT, V581, P3863, DOI 10.1016/j.febslet.2007.07.011; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; GRZYCH JM, 1991, J IMMUNOL, V146, P1322; Hayashi N, 1999, J IMMUNOL, V163, P6702; Henkle-Duhrsen K, 2001, MOL BIOCHEM PARASIT, V114, P129, DOI 10.1016/S0166-6851(01)00252-3; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hung SL, 2002, J LEUKOCYTE BIOL, V72, P72; Jin HM, 1998, GENOMICS, V54, P316, DOI 10.1006/geno.1998.5593; Kang SW, 2005, TRENDS MOL MED, V11, P571, DOI 10.1016/j.molmed.2005.10.006; Kreider T, 2007, CURR OPIN IMMUNOL, V19, P448, DOI 10.1016/j.coi.2007.07.002; Kumagai T, 2006, MOL BIOCHEM PARASIT, V149, P135, DOI 10.1016/j.molbiopara.2006.05.004; Loke P, 2000, EUR J IMMUNOL, V30, P1127, DOI 10.1002/(SICI)1521-4141(200004)30:4&lt;1127::AID-IMMU1127&gt;3.0.CO;2-#; Loke P'ng, 2002, BMC Immunol, V3, P7, DOI 10.1186/1471-2172-3-7; MacDonald AS, 2002, INFECT IMMUN, V70, P427, DOI 10.1128/IAI.70.2.427-433.2002; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; McGonigle S, 1998, PARASITOL TODAY, V14, P139, DOI 10.1016/S0169-4758(97)01211-8; McManus DP, 2006, PARASITOLOGY, V133, pS43, DOI 10.1017/S0031182006001806; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Mulcahy G, 2004, ADV DRUG DELIVER REV, V56, P853, DOI 10.1016/j.addr.2003.10.033; Noel W, 2004, TRENDS PARASITOL, V20, P126, DOI 10.1016/j.pt.2004.01.004; O'Neill SM, 2000, PARASITE IMMUNOL, V22, P147, DOI 10.1046/j.1365-3024.2000.00290.x; Park SY, 2007, CANCER RES, V67, P9294, DOI 10.1158/0008-5472.CAN-07-0651; Pearce EJ, 2004, IMMUNOL REV, V201, P117, DOI 10.1111/j.0105-2896.2004.00187.x; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; Raes G, 2002, J LEUKOCYTE BIOL, V71, P597; Sayed AA, 2004, J BIOL CHEM, V279, P26159, DOI 10.1074/jbc.M401748200; Sekiya M, 2006, FEBS LETT, V580, P5016, DOI 10.1016/j.febslet.2006.08.019; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sinha P, 2005, CANCER RES, V65, P11743, DOI 10.1158/0008-5472.CAN-05-0045; Stack CM, 2007, J BIOL CHEM, V282, P16532, DOI 10.1074/jbc.M611501200; Street M, 1999, J IMMUNOL, V163, P4489; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Williams DL, 2001, INFECT IMMUN, V69, P1134, DOI 10.1128/IAI.69.2.1134-1141.2001; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336; 97925196	52	172	182	4	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					4022	4032		10.1096/fj.08-106278	http://dx.doi.org/10.1096/fj.08-106278			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18708590	Green Published			2022-12-28	WOS:000260503000030
J	Niederberger, E; Geisslinger, G				Niederberger, Ellen; Geisslinger, Gerd			The IKK-NF-kappa B pathway: a source for novel molecular drug targets in pain therapy?	FASEB JOURNAL			English	Review						inflammation; nervous system; neuropathy	NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR DECOY; FIBROBLAST-LIKE SYNOVIOCYTES; COLLAGEN-INDUCED ARTHRITIS; PERIPHERAL-NERVE INJURY; GLYCATION END-PRODUCTS; DORSAL-ROOT GANGLIA; SPINAL-CORD-INJURY; NEUROPATHIC PAIN; TNF-ALPHA	Several studies indicate that the nuclear factor-kappa B (NF-kappa B) -activation cascade plays a crucial role not only in immune responses, inflammation, and apoptosis but also in the development and processing of pathological pain. Accordingly, a pharmacological intervention into this pathway may have antinociceptive effects and could provide novel treatment strategies for pain and inflammation. In this review we summarize the role of NF-kappa B in the nervous system, its impact on nociception, and several approaches that investigated the effects of various modulators of the classical I-kappa B-kinase-NF-kappa B signal transduction pathway in inflammatory nociception and neuropathic pain. The results indicate that NF-kappa B has an impact on nociceptive transmission and processing and that a number of substances that inhibit the NF-kappa B-activating cascade are capable of reducing the nociceptive response in different animal models. Therefore, a modulation of specific participants in the NF-kappa B signal transduction might exert a useful approach for the development of new painkillers.	[Niederberger, Ellen; Geisslinger, Gerd] Univ Frankfurt Klinikum, Pharmazentrum Frankfurt ZAFES, Inst Klin Pharmakol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Niederberger, E (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum Frankfurt ZAFES, Inst Klin Pharmakol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	e.niederberger@em.uni-frankfurt.de			Deutsche Forschungsgemeinschaft (DFG) [N1 705/2-1]; Ministry of Science and Technology [01EM0511]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	Supported by the Deutsche Forschungsgemeinschaft (DFG, project N1 705/2-1), the DFG graduate Study program GK1172 "Biologicals," and the Ministry of Science and Technology (Bundesministerium fur Bildung and Forschung 01EM0511).	Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Aupperle KR, 2001, CELL IMMUNOL, V214, P54, DOI 10.1006/cimm.2002.1885; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bierhaus A, 2004, J CLIN INVEST, V114, P1741, DOI 10.1172/JCI200418058; Blackwell NM, 2004, ARTHRITIS RHEUM-US, V50, P2675, DOI 10.1002/art.20467; Braddock M, 2004, NAT REV DRUG DISCOV, V3, P1, DOI 10.1038/nrd1342; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Cavaletti G, 2007, HAEMATOLOGICA, V92, P1308, DOI 10.3324/haematol.11752; D'Acquisto F, 2000, GENE THER, V7, P1731, DOI 10.1038/sj.gt.3301295; D'Acquisto F, 2006, CURR OPIN PHARMACOL, V6, P387, DOI 10.1016/j.coph.2006.02.009; Davis AJ, 1996, BRIT J PHARMACOL, V118, P2206, DOI 10.1111/j.1476-5381.1996.tb15664.x; di Meglio P, 2005, ARTHRITIS RHEUM-US, V52, P951, DOI 10.1002/art.20960; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Ebersberger A, 2006, NEUROREPORT, V17, P1615, DOI 10.1097/01.wnr.0000236867.76347.60; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Fernyhough P, 2005, J NEUROSCI, V25, P1682, DOI 10.1523/JNEUROSCI.3127-04.2005; Frelin C, 2005, BLOOD, V105, P804, DOI 10.1182/blood-2004-04-1463; Fu ES, 2007, NEUROREPORT, V18, P713, DOI 10.1097/WNR.0b013e3280d9e869; GEISSLINGER G, 1994, LIFE SCI, V54, pPL173, DOI 10.1016/0024-3205(94)00555-9; George A, 2000, PAIN, V88, P267, DOI 10.1016/S0304-3959(00)00333-X; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; HACKER H, 2006, SCI STKE, V357, pRE13, DOI DOI 10.1126/STKE.3572006RE13; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Haslbeck KM, 2007, NEUROL RES, V29, P103, DOI 10.1179/174313206X152564; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hofmann MA, 2002, GENES IMMUN, V3, P123, DOI 10.1038/sj.gene.6363861; Igwe OJ, 2005, NEUROSCI LETT, V381, P114, DOI 10.1016/j.neulet.2005.02.020; Inoue G, 2006, SPINE, V31, P2904, DOI 10.1097/01.brs.0000248424.46652.67; Iseki A, 2000, BIOCHEM BIOPH RES CO, V276, P88, DOI 10.1006/bbrc.2000.3452; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Jin SH, 2002, ANN NY ACAD SCI, V973, P414, DOI 10.1111/j.1749-6632.2002.tb04674.x; Kaltschmidt B, 2006, MOL CELL BIOL, V26, P2936, DOI 10.1128/MCB.26.8.2936-2946.2006; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kassed CA, 2002, EXP NEUROL, V176, P277, DOI 10.1006/exnr.2002.7967; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; Kim JM, 2005, CLIN EXP IMMUNOL, V140, P450, DOI 10.1111/j.1365-2249.2005.02804.x; Laughlin TM, 2000, PAIN, V84, P159, DOI 10.1016/S0304-3959(99)00195-5; Lawrance IC, 2003, GASTROENTEROLOGY, V125, P1750, DOI 10.1053/j.gastro.2003.08.027; Ledeboer A, 2005, EUR J NEUROSCI, V22, P1977, DOI 10.1111/j.1460-9568.2005.04379.x; Lee KM, 2004, EUR J NEUROSCI, V19, P3375, DOI 10.1111/j.0953-816X.2004.03441.x; Li HQ, 2007, ANESTHESIOLOGY, V107, P469, DOI 10.1097/01.anes.0000278907.37774.8d; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lianxu C, 2006, OSTEOARTHR CARTILAGE, V14, P367, DOI 10.1016/j.joca.2005.10.009; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; Liu YL, 2007, NEUROPHARMACOLOGY, V52, P708, DOI 10.1016/j.neuropharm.2006.09.011; Lv P, 2007, ARCH MED RES, V38, P15, DOI 10.1016/j.arcmed.2006.09.006; Ma VY, 1998, BRAIN RES, V797, P243, DOI 10.1016/S0006-8993(98)00380-1; Ma ZL, 2007, ANN CLIN LAB SCI, V37, P349; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; MALMBERG AB, 1994, EUR J PHARMACOL, V256, P205, DOI 10.1016/0014-2999(94)90247-X; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; McIntyre KW, 2003, ARTHRITIS RHEUM-US, V48, P2652, DOI 10.1002/art.11131; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Meunier A, 2007, MOL THER, V15, P687, DOI 10.1038/sj.mt.6300107; Morishita R, 2004, CURR OPIN PHARMACOL, V4, P139, DOI 10.1016/j.coph.2003.10.008; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; Niederberger E, 2006, BIOCHEM BIOPH RES CO, V342, P940, DOI 10.1016/j.bbrc.2006.02.040; Niederberger E, 2003, J PHARMACOL EXP THER, V304, P1153, DOI 10.1124/jpet.102.044016; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; Niederberger E, 2007, EUR J PHARMACOL, V559, P55, DOI 10.1016/j.ejphar.2006.11.074; O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070; Ohtori S, 2004, SPINE, V29, P1082, DOI 10.1097/00007632-200405150-00006; OKA T, 1993, BRAIN RES, V624, P61, DOI 10.1016/0006-8993(93)90060-Z; Palladino MA, 2003, NAT REV DRUG DISCOV, V2, P736, DOI 10.1038/nrd1175; Paris D, 2007, NEUROSCI LETT, V415, P11, DOI 10.1016/j.neulet.2006.12.029; Park HJ, 2002, NEUROSCI LETT, V319, P141, DOI 10.1016/S0304-3940(01)02582-4; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Petersen Steffen B., 2001, Journal of Biomedicine and Biotechnology, V1, P62, DOI 10.1155/S1110724301000249; Podolin PL, 2005, J PHARMACOL EXP THER, V312, P373, DOI 10.1124/jpet.104.074484; Pollock G, 2005, EXP BRAIN RES, V165, P470, DOI 10.1007/s00221-005-2318-6; Reuter U, 2002, ANN NEUROL, V51, P507, DOI 10.1002/ana.10159; Ribeiro RA, 2000, EUR J PHARMACOL, V391, P97, DOI 10.1016/S0014-2999(99)00918-8; Rudolph D, 2000, GENE DEV, V14, P854; Sakaue G, 2001, NEUROREPORT, V12, P2079, DOI 10.1097/00001756-200107200-00008; Sarchielli P, 2006, CEPHALALGIA, V26, P1071, DOI 10.1111/j.1468-2982.2006.01164.x; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Scholzke MN, 2003, EUR J NEUROSCI, V18, P3305, DOI 10.1111/j.1460-9568.2003.03079.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Singh Amanpreet, 2003, Inflammopharmacology, V11, P249, DOI 10.1163/156856003322315596; Sommer C, 1998, PAIN, V74, P83, DOI 10.1016/S0304-3959(97)00154-1; Sommer C, 2001, J PERIPHER NERV SYST, V6, P67, DOI 10.1046/j.1529-8027.2001.01010.x; Steenvoorden MMC, 2006, ARTHRITIS RHEUM-US, V54, P253, DOI 10.1002/art.21523; Strickland I, 2006, ANN RHEUM DIS, V65, P75, DOI 10.1136/ard.2006.058438; Sun T, 2006, BRIT J ANAESTH, V97, P553, DOI 10.1093/bja/ael209; Sunahori K, 2006, ARTHRITIS RHEUM-US, V54, P97, DOI 10.1002/art.21524; Sweeney SE, 2005, J IMMUNOL, V174, P6424, DOI 10.4049/jimmunol.174.10.6424; Takasaki I, 2005, EUR J PHARMACOL, V524, P80, DOI 10.1016/j.ejphar.2005.09.045; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tegeder I, 2004, J NEUROSCI, V24, P1637, DOI 10.1523/JNEUROSCI.3118-03.2004; Tegeder I, 2001, FASEB J, V15, P2, DOI 10.1096/fasebj.15.1.2; Tomita T, 2000, RHEUMATOLOGY, V39, P749, DOI 10.1093/rheumatology/39.7.749; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Wang SX, 2004, J NEUROSCI, V24, P8595, DOI 10.1523/JNEUROSCI.3058-04.2004; Watkins LR, 1997, PAIN, V71, P225, DOI 10.1016/S0304-3959(97)03369-1; Wei XH, 2007, EXP NEUROL, V205, P471, DOI 10.1016/j.expneurol.2007.03.012; Wu F, 2007, J IMMUNOL, V179, P6988, DOI 10.4049/jimmunol.179.10.6988; Xie WY, 2006, NEUROSCI LETT, V393, P255, DOI 10.1016/j.neulet.2005.09.077; Xu JT, 2006, PAIN, V123, P306, DOI 10.1016/j.pain.2006.03.011; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhang RX, 2004, NEUROSCI LETT, V359, P85, DOI 10.1016/j.neulet.2004.02.014	120	157	172	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3432	3442		10.1096/fj.08-109355	http://dx.doi.org/10.1096/fj.08-109355			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18559989				2022-12-28	WOS:000259642600005
J	Falagas, ME; Kouranos, VD; Arencibia-Jorge, R; Karageorgopoulos, DE				Falagas, Matthew E.; Kouranos, Vasilios D.; Arencibia-Jorge, Ricardo; Karageorgopoulos, Drosos E.			Comparison of SCImago journal rank indicator with journal impact factor	FASEB JOURNAL			English	Article						bibliometric analysis; quality of publications; bibliographic databases; mathematical computing; scientometrics	SCIENTIFIC JOURNALS; SELF-CITATION; LANGUAGE; SCIENCE; EDITORS; TRENDS; PUBLICATION; ENGLISH; SCOPUS; BIAS	The application of currently available sophisticated algorithms of citation analysis allows for the incorporation of the "quality" of citations in the evaluation of scientific journals. We sought to compare the newly introduced SCImago journal rank (SJR) indicator with the journal impact factor ( IF). We retrieved relevant information from the official Web sites hosting the above indices and their source databases. The SJR indicator is an open-access resource, while the journal IF requires paid subscription. The SJR indicator ( based on Scopus data) lists considerably more journal titles published in a wider variety of countries and languages, than the journal IF ( based on Web of Science data). Both indices divide citations to a journal by articles of the journal, during a specific time period. However, contrary to the journal IF, the SJR indicator attributes different weight to citations depending on the "prestige" of the citing journal without the influence of journal self-citations; prestige is estimated with the application of the PageRank algorithm in the network of journals. In addition, the SJR indicator includes the total number of documents of a journal in the denominator of the relevant calculation, whereas the journal IF includes only "citable" articles ( mainly original articles and reviews). A 3-yr period is analyzed in both indices but with the use of different approaches. Regarding the top 100 journals in the 2006 journal IF ranking order, the median absolute change in their ranking position with the use of the SJR indicator is 32 (1st quartile: 12; 3rd quartile: 75). Although further validation is warranted, the novel SJR indicator poses as a serious alternative to the well-established journal IF, mainly due to its openaccess nature, larger source database, and assessment of the quality of citations.	[Falagas, Matthew E.; Kouranos, Vasilios D.; Karageorgopoulos, Drosos E.] Alfa Inst Biomed Sci, Athens, Greece; [Falagas, Matthew E.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; [Falagas, Matthew E.] Henry Dunant Hosp, Dept Med, Athens, Greece; [Arencibia-Jorge, Ricardo] Natl Ctr Sci Res, Network Scientometr Studies Higher Educ, Havana 6880, Cuba	Alfa Institute Of Biomedical Sciences; Tufts University; Henry Dunant Hospital	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, 9 Neapoleos St, Maroussi 15123, Greece.	m.falagas@aibs.gr	Arencibia-Jorge, Ricardo/B-1330-2016; Karageorgopoulos, Drosos/K-9241-2018; Arencibia-Jorge, Ricardo/AAK-3567-2020	Arencibia-Jorge, Ricardo/0000-0001-8907-2454; Karageorgopoulos, Drosos/0000-0002-9959-9978; Arencibia-Jorge, Ricardo/0000-0001-8907-2454; Kouranos, Vasileios/0000-0002-2723-0928				Aleixandre-Benavent R, 2007, NEUROLOGIA, V22, P19; Andersen Julia, 2006, Journal of Microbiology Immunology and Infection, V39, P436; [Anonymous], 2005, NATURE, V435, P1003, DOI 10.1038/4351003a; [Anonymous], 2006, PLOS MED, V3, P707, DOI 10.1371/journal.pmed.0030291; Bakkalbasi Nisa, 2006, Biomed Digit Libr, V3, P7, DOI 10.1186/1742-5581-3-7; Bergstrom C., 2007, COLL RES LIB NEWS, V68, P314, DOI [10.5860/crln.68.5.7804, DOI 10.5860/CRLN.68.5.7804]; Bollen J, 2006, SCIENTOMETRICS, V69, P669, DOI 10.1007/s11192-006-0176-z; Cameron BD, 2005, PORTAL-LIBR ACAD, V5, P105, DOI 10.1353/pla.2005.0003; Chew M, 2007, J ROY SOC MED, V100, P142, DOI 10.1258/jrsm.100.3.142; De Moya-Anegon F, 2007, SCIENTOMETRICS, V73, P53, DOI 10.1007/s11192-007-1681-4; Dellavalle RP, 2007, J AM ACAD DERMATOL, V57, P116, DOI 10.1016/j.jaad.2007.03.005; Falagas ME, 2007, INT J IMPOT RES, V19, P443, DOI 10.1038/sj.ijir.3901583; Falagas ME, 2008, FASEB J, V22, P338, DOI 10.1096/fj.07-9492LSF; Falagas ME, 2006, MAYO CLIN PROC, V81, P1401, DOI 10.4065/81.10.1401; Falagas ME, 2006, FASEB J, V20, P1039, DOI 10.1096/fj.06-0603ufm; Fassoulaki A, 2002, ACTA ANAESTH SCAND, V46, P902, DOI 10.1034/j.1399-6576.2002.460723.x; Gallagher EJ, 1998, ANN EMERG MED, V31, P83, DOI 10.1016/S0196-0644(98)70286-0; Garfield E, 2006, JAMA-J AM MED ASSOC, V295, P90, DOI 10.1001/jama.295.1.90; Garfield E, 1996, BRIT MED J, V313, P411, DOI 10.1136/bmj.313.7054.411; GARFIELD E, 1972, SCIENCE, V178, P471, DOI 10.1126/science.178.4060.471; Gross P L, 1927, Science, V66, P385, DOI 10.1126/science.66.1713.385; Hemmingsson A, 2002, AM J ROENTGENOL, V178, P767, DOI 10.2214/ajr.178.3.1780767; Hoeffel C, 1998, ALLERGY, V53, P1225, DOI 10.1111/j.1398-9995.1998.tb03848.x; Joseph KS, 1999, CAN MED ASSOC J, V161, P977; KODRZYCKI YK, 2005, NEW APPROACHES RANKI, P5; LIEBOWITZ SJ, 1984, J ECON LIT, V22, P77; Miguel A, 2002, EUR RADIOL, V12, P248, DOI 10.1007/s003300100894; Mueller PS, 2006, SWISS MED WKLY, V136, P441; PAGE L., 1998, 199966 STANF INFOLAB, P161; Palacios-Huerta I, 2004, ECONOMETRICA, V72, P963, DOI 10.1111/j.1468-0262.2004.00519.x; PINSKI G, 1976, INFORM PROCESS MANAG, V12, P297, DOI 10.1016/0306-4573(76)90048-0; Postma E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000999; PRICE DJD, 1965, SCIENCE, V149, P510; Rossner M, 2007, J CELL BIOL, V179, P1091, DOI 10.1083/jcb.200711140; Saha S, 2003, J MED LIBR ASSOC, V91, P42; SCImago, 2021, SJR SCIMAGO J COUNTR; *SCIMAGO RES GROUP, DESCR SCIMAGO J RANK; Smith R, 2006, INT J EPIDEMIOL, V35, P1129, DOI 10.1093/ije/dyl191; Weale Andy R, 2004, BMC Med Res Methodol, V4, P14, DOI 10.1186/1471-2288-4-14; Winkmann G, 2002, KLIN MONATSBL AUGENH, V219, P72, DOI 10.1055/s-2002-23505; Yu G, 2005, SCIENTOMETRICS, V64, P235, DOI 10.1007/s11192-005-0249-4	41	303	323	5	163	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2623	2628		10.1096/fj.08-107938	http://dx.doi.org/10.1096/fj.08-107938			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18408168				2022-12-28	WOS:000258089300003
J	Spadaro, M; Caorsi, C; Ceruti, P; Varadhachary, A; Forni, G; Pericle, F; Giovarelli, M				Spadaro, Michela; Caorsi, Cristiana; Ceruti, Patrizia; Varadhachary, Atul; Forni, Guido; Pericle, Federica; Giovarelli, Mirella			Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells	FASEB JOURNAL			English	Article						adaptive immunity; antigen presentation; T-cell activation	RECEPTOR-RELATED PROTEIN; BOVINE LACTOFERRIN; T-LYMPHOCYTES; IN-VIVO; BINDING; LIPOPOLYSACCHARIDE; ACTIVATION; CYTOKINES; RESPONSES; SURVIVAL	Lactoferrin (LF) is an important protein component of the innate immune system that is broadly distributed within the body fluids. LF is endowed with multiple biological activities. Talactoferrin (TLF), a recombinant human LF, is in clinical development as an anticancer agent and is entering Phase III clinical trials. Here, we show that TLF induces the maturation of human dendritic cells (DCs) derived from monocytes. TLF, at physiologically relevant concentrations ( 100 mu g/ml) up-regulates the expression of human leukocyte antigen (HLA) class II, CD83, CD80, and CD86 costimulatory molecule and CXCR4 and CCR7 chemokine receptors, acting primarily through the p38 MAPK signaling pathway. DCs matured by TLF displayed an enhanced release of IL-8 and CXCL10, as well as a significantly reduced production of IL-6, IL-10, and CCL20. They also display a reduced ability to take up antigen and increased capacity to trigger proliferation and release IFN-gamma in the presence of allogeneic human T cells. TLF-matured DCs are able to prime naive T cells to respond to KLH antigen and display a significantly increased capacity to present Flu-MA(58-66) peptide to HLA-A2-matched T cells. These data suggest that a key immunomodulatory function that may be mediated by TLF is to link the innate with adaptive immunity through DC maturation.	[Caorsi, Cristiana; Ceruti, Patrizia; Giovarelli, Mirella] Univ Turin, Dept Med & Expt Oncol, Ctr Expt Res & Med Studies, I-10126 Turin, Italy; [Spadaro, Michela; Forni, Guido] Univ Turin, Dept Clin & Biol Sci, Ctr Mol Biotechnol, I-10126 Turin, Italy; [Varadhachary, Atul; Pericle, Federica] Agennix Inc, Houston, TX USA	University of Turin; University of Turin	Giovarelli, M (corresponding author), Univ Turin, Dept Med & Expt Oncol, Ctr Expt Res & Med Studies, Corso Raffaello 30, I-10126 Turin, Italy.	mirella.giovarelli@unito.it	Spadaro, Michela/F-1399-2016	Giovarelli, Mirella/0000-0002-7397-3466; Spadaro, Michela/0000-0001-7544-8879				Aerts-Toegaert C, 2007, EUR J IMMUNOL, V37, P686, DOI 10.1002/eji.200636535; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Baker EN, 2005, CELL MOL LIFE SCI, V62, P2531, DOI 10.1007/s00018-005-5368-9; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; BIRGENS HS, 1994, ADV EXP MED BIOL, V357, P99; CHIAPPA M, 2007, J EXP MED, V203, P2847; Chorny A, 2006, ANN NY ACAD SCI, V1088, P187, DOI 10.1196/annals.1366.004; COLOMBO MP, 1992, CANCER RES, V52, P4853; Curran CS, 2006, CELL IMMUNOL, V242, P23, DOI 10.1016/j.cellimm.2006.08.006; Edde L, 2001, AM J PHYSIOL-GASTR L, V281, pG1140, DOI 10.1152/ajpgi.2001.281.5.G1140; FABER JM, 1997, J LEUKOCYTE BIOL, V61, P246; Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011; Fischer R, 2006, BIOCHEM CELL BIOL, V84, P303, DOI 10.1139/O06-058; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; GAHR M, 1991, J LEUKOCYTE BIOL, V49, P427, DOI 10.1002/jlb.49.5.427; Gliemann J, 1998, BIOL CHEM, V379, P951; Grey A, 2004, MOL ENDOCRINOL, V18, P2268, DOI 10.1210/me.2003-0456; Groot F, 2005, J VIROL, V79, P3009, DOI 10.1128/JVI.79.5.3009-3015.2005; Guillen C, 2002, J IMMUNOL, V168, P3950, DOI 10.4049/jimmunol.168.8.3950; Hanson L A, 1995, Pediatr Allergy Immunol, V6 Suppl 8, P7; Hayes TG, 2006, INVEST NEW DRUG, V24, P233, DOI 10.1007/s10637-005-3690-6; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hirano N, 2006, BLOOD, V107, P1528, DOI 10.1182/blood-2005-05-2073; Huang RQ, 2007, J BIOMED SCI, V14, P121, DOI 10.1007/s11373-006-9121-7; Humrich JY, 2006, IMMUNOLOGY, V117, P238, DOI 10.1111/j.1365-2567.2005.02292.x; Kane SV, 2003, AM J GASTROENTEROL, V98, P1309, DOI 10.1016/S0002-9270(03)00232-6; Kanyshkova TG, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1, DOI 10.1023/A:1002817226110; Kim KD, 2006, EXP MOL MED, V38, P72, DOI 10.1038/emm.2006.9; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Legrand D, 2005, CELL MOL LIFE SCI, V62, P2549, DOI 10.1007/s00018-005-5370-2; LEVAY PF, 1995, HAEMATOLOGICA, V80, P252; MAZURIER J, 1994, ADV EXP MED BIOL, V357, P111; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; Mincheva-Nilsson L, 1997, SCAND J IMMUNOL, V46, P609, DOI 10.1046/j.1365-3083.1997.d01-165.x; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; Paesano R, 2006, BIOCHEM CELL BIOL, V84, P377, DOI 10.1139/O06-040; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; Sorg RV, 2003, J IMMUNOTHER, V26, P374, DOI 10.1097/00002371-200307000-00010; Sozzani S, 1998, J IMMUNOL, V161, P1083; Spadaro M, 2007, CANCER RES, V67, P6425, DOI 10.1158/0008-5472.CAN-06-4080; SRINIVAS S, 2006, ASCO ANNU MEET P I, V24, P4600; Suzuki YA, 2005, CELL MOL LIFE SCI, V62, P2560, DOI 10.1007/s00018-005-5371-1; Suzuki YA, 2001, BIOCHEMISTRY-US, V40, P15771, DOI 10.1021/bi0155899; Takayama Y, 2003, J BIOL CHEM, V278, P22112, DOI 10.1074/jbc.M300894200; Thomas LL, 2002, J IMMUNOL, V169, P993, DOI 10.4049/jimmunol.169.2.993; Troost FJ, 2002, J NUTR, V132, P2597, DOI 10.1093/jn/132.9.2597; Tsuda H, 2002, BIOCHEM CELL BIOL, V80, P131, DOI 10.1139/o01-239; Ueno H, 2006, CANCER SCI, V97, P1105, DOI 10.1111/j.1349-7006.2006.00274.x; Varadhachary A, 2004, INT J CANCER, V111, P398, DOI 10.1002/ijc.20271; WANG Y, 2006, ASCO ANN M P, V24, P7095; Ward PP, 2005, CELL MOL LIFE SCI, V62, P2540, DOI 10.1007/s00018-005-5369-8; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WRIGHT DG, 1979, J IMMUNOL, V123, P285; Yoneyama H, 2002, J EXP MED, V195, P1257, DOI 10.1084/jem.20011983; Zhu KJ, 2000, CHINESE MED J-PEKING, V113, P1124; Zimecki M, 2002, IMMUNOBIOLOGY, V205, P120, DOI 10.1078/0171-2985-00115	60	101	108	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2747	2757		10.1096/fj.07-098038	http://dx.doi.org/10.1096/fj.07-098038			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18364398				2022-12-28	WOS:000258089300015
J	Vincent, A; Ducourouble, MP; Van Seuningen, I				Vincent, Audrey; Ducourouble, Marie-Paule; Van Seuningen, Isabelle			Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases	FASEB JOURNAL			English	Article						acetylation; chromatin; Sp1; pancreas; carcinogenesis; 5'-UTR	PANCREATIC-CANCER; TRANSCRIPTIONAL REPRESSION; ABERRANT EXPRESSION; TGF-BETA; PROMOTER; BINDING; INHIBITION; CARCINOMA; GROWTH; PROGRESSION	The human gene MUC4 encodes a transmembrane mucin, ligand of ErbB2, that is associated with pancreatic tumor progression. In the normal pancreas, MUC4 is not expressed, whereas activation of its expression is observed in the early steps of pancreatic carcinogenesis. The molecular mechanisms responsible for MUC4 gene activation are however still unknown. The MUC4 5'-flanking region being GC-rich and including two CpG islands, we hypothesized that epigenetic regulation may be involved and undertook to decipher the molecular phenomenons implied. By treating cancer cell lines with 5-aza-2'-deoxycytidine (5-aza) and trichostatin A (TSA), we were able to restore MUC4 expression in a cell-specific manner. We showed by bisulfite-treated genomic DNA sequencing and chromatin immunoprecipitation that methylation of five CpG sites and establishment of a repressive histone code at the 5'-untranslated region were associated with MUC4 silencing and impaired its activation by Sp1. Direct involvement of DNMT3A, DNMT3B, HDAC1, and HDAC3 was demonstrated by RNA interference and chromatin immunoprecipitation. Moreover, inhibition of histone deacetylation by TSA was associated with strong MUC4 repression in high-expressing cells. In conclusion, this work shows for the first time the importance of epigenetics in regulating MUC4 expression and may represent a new strategy to inhibit its expression in epithelial tumors.	[Vincent, Audrey; Ducourouble, Marie-Paule; Van Seuningen, Isabelle] INSERM, U837, Jean Pierre Aubert Res Ctr, F-59045 Lille, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Van Seuningen, I (corresponding author), INSERM, U837, Jean Pierre Aubert Res Ctr, Pl Verdun, F-59045 Lille, France.	isabelle.vanseuningen@inserm.fr	Vincent, Audrey/I-2934-2016; VAN SEUNINGEN, Isabelle/N-6176-2016	Vincent, Audrey/0000-0003-0058-2058; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694				Augenlicht L, 2003, ONCOGENE, V22, P4983, DOI 10.1038/sj.onc.1206521; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CARRAWAY CA, 2007, SCI STKE, V381, pRE3; Carraway KL, 2007, CURR TOP DEV BIOL, V78, P1, DOI 10.1016/S0070-2153(06)78001-2; Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Donadelli M, 2007, BBA-MOL CELL RES, V1773, P1095, DOI 10.1016/j.bbamcr.2007.05.002; ESTELLER M, 2005, ANN REV PHARM TOXICO, V45, P9; Fauquette V, 2005, BIOCHEM J, V386, P35, DOI 10.1042/BJ20040706; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; GASTON K, 1995, GENE, V157, P257, DOI 10.1016/0378-1119(95)00120-U; Gaudier E, 2004, AM J PHYSIOL-GASTR L, V287, pG1168, DOI 10.1152/ajpgi.00219.2004; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; Grady WM, 2001, CANCER RES, V61, P900; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Jhala N, 2006, AM J CLIN PATHOL, V126, P572, DOI 10.1309/CEV30BE088CBDQD9; Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karagianni P, 2007, ONCOGENE, V26, P5439, DOI 10.1038/sj.onc.1210612; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; Matsubayashi H, 2006, CANCER RES, V66, P1208, DOI 10.1158/0008-5472.CAN-05-2664; Moniaux N, 2004, J HISTOCHEM CYTOCHEM, V52, P253, DOI 10.1177/002215540405200213; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Saitou M, 2005, J CLIN PATHOL, V58, P845, DOI 10.1136/jcp.2004.023572; Sansom OJ, 2007, NAT CLIN PRACT ONCOL, V4, P305, DOI 10.1038/ncponc0812; Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010; Scott GK, 2002, MOL CANCER THER, V1, P385; Shames DS, 2007, CANCER LETT, V251, P187, DOI 10.1016/j.canlet.2006.10.014; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Singh AP, 2006, PROSTATE, V66, P421, DOI 10.1002/pros.20372; Singh M, 2007, PANCREATOLOGY, V7, P9, DOI 10.1159/000101873; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Van Seuningen I, 2000, BIOCHEM J, V348, P675; Vincent A, 2007, ONCOGENE, V26, P6566, DOI 10.1038/sj.onc.1210479; Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007; Yamane K, 2005, J CELL PHYSIOL, V202, P822, DOI 10.1002/jcp.20205; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	47	56	56	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					3035	3045		10.1096/fj.07-103390	http://dx.doi.org/10.1096/fj.07-103390			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18492726	Green Submitted			2022-12-28	WOS:000258089300043
J	Renko, K; Hofmann, PJ; Stoedter, M; Hollenbach, B; Behrends, T; Kohrle, J; Schweizer, U; Schomburg, L				Renko, Kostja; Hofmann, Peter J.; Stoedter, Mette; Hollenbach, Birgit; Behrends, Thomas; Koehrle, Josef; Schweizer, Ulrich; Schomburg, Lutz			Down-regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in mice	FASEB JOURNAL			English	Article						trace element; LPS; translation; transport; critical illness	REAL-TIME PCR; EXPRESSION; LIVER; SELENOCYSTEINE; SEPSIS; PLASMA; GENE; SUPPLEMENTATION; CYTOKINES; KIDNEY	The acute-phase response (APR) is characterized by an impaired metabolism of the essential trace element selenium (Se). Moreover, low-Se concentrations correlate to mortality risk in sepsis. Therefore, we analyzed the expression of the central Se transport and storage protein selenoprotein P (Sepp1) during an APR in mice. Serum Se and Sepp1 concentrations declined in parallel after injection of lipopolysaccharide to 50 and 39% of control-injected littermates, respectively. This negative APR proceeded largely independent from hepatic Sepp1 transcript concentrations. Instead, we identified a set of hepatic transcripts involved in Se metabolism, which declined coordinately during the APR, including the selenocysteine-specific elongation factor (EFsec), selenophosphate-synthetase 2 (Sephs2), selenocysteine-tRNA[Ser]Sec synthase (SecS), and phosphoseryl-tRNA[Ser]Sec kinase (Pstk). Pstk reacted most strongly and qualified as a new limiting factor for Sepp1 biosynthesis in siRNA-mediated knockdown experiments in hepatocytes in culture. Analogous experiments were performed with mice transgenic for hepatocyte-specific human Sepp1 cDNA to verify this hypothesis. Similar kinetics and effect sizes of Sepp1 expression were observed as before in wild-type mice. We conclude that hepatic translation of Sepp1 mRNA is specifically impaired during the APR. This deficit disrupts regular Se metabolism, transport, and supply to peripheral tissues and likely aggravates the pathological status.-Renko, K., Hofmann, P. J., Stoedter, M., Hollenbach, B., Behrends, T., Kohrle, J., Schweizer, U., Schomburg, L. Down-regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in mice. FASEB J. 23, 1758-1765 (2009)	[Renko, Kostja; Hofmann, Peter J.; Stoedter, Mette; Hollenbach, Birgit; Behrends, Thomas; Koehrle, Josef; Schweizer, Ulrich; Schomburg, Lutz] Charite, Inst Expt Endocrinol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schomburg, L (corresponding author), Charite, Inst Expt Endocrinol, Augustenburger Pl 1, D-13353 Berlin, Germany.	lutz.schomburg@charite.de	Schomburg, Lutz/D-8096-2013; Köhrle, Josef/AAH-6438-2020; Schweizer, Ulrich/E-8105-2013	Schomburg, Lutz/0000-0001-9445-1555; Köhrle, Josef/0000-0002-9187-9078; Schweizer, Ulrich/0000-0003-1380-4780	Deutsche Forschungsgemeinschaft DFG [Scho849/2-2, GraKo1208]; Charite Berlin; Deutsche Krebshilfe [10-1792SchoII]	Deutsche Forschungsgemeinschaft DFG(German Research Foundation (DFG)); Charite Berlin; Deutsche Krebshilfe(Deutsche Krebshilfe)	Financial support was provided by the Deutsche Forschungsgemeinschaft DFG (Scho849/2-2, GraKo1208), Charite Berlin (personal grant to L.S.), and Deutsche Krebshilfe (10-1792SchoII). The excellent technical assistance of Silke Kappler, Katja Schreiber, and Vartiter Seher is gratefully acknowledged.	Agay D, 2005, BURNS, V31, P366, DOI 10.1016/j.burns.2004.11.010; Angstwurm MWA, 2007, CRIT CARE MED, V35, P118, DOI 10.1097/01.CCM.0000251124.83436.0E; Angstwurm MWA, 1999, CRIT CARE MED, V27, P1807, DOI 10.1097/00003246-199909000-00017; Arthur JR, 2003, J NUTR, V133, p1457S, DOI 10.1093/jn/133.5.1457S; Becker S, 2006, BIOCHEM BIOPH RES CO, V339, P833, DOI 10.1016/j.bbrc.2005.11.105; BERGER MM, 1992, CLIN NUTR, V11, P75, DOI 10.1016/0261-5614(92)90014-H; Berry MJ, 2001, BIOFACTORS, V14, P17, DOI 10.1002/biof.5520140104; Broome CS, 2004, AM J CLIN NUTR, V80, P154; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; Carlson BA, 2004, P NATL ACAD SCI USA, V101, P12848, DOI 10.1073/pnas.0402636101; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Deicher R, 2006, EUR J CLIN INVEST, V36, P301, DOI 10.1111/j.1365-2362.2006.01633.x; Dreher I, 1997, J BIOL CHEM, V272, P29364, DOI 10.1074/jbc.272.46.29364; Dumitrescu AM, 2005, NAT GENET, V37, P1247, DOI 10.1038/ng1654; Forceville X, 1998, CRIT CARE MED, V26, P1536, DOI 10.1097/00003246-199809000-00021; Gao Y, 2006, CYTOKINE, V33, P246, DOI 10.1016/j.cyto.2006.02.005; Gromer S, 2005, CELL MOL LIFE SCI, V62, P2414, DOI 10.1007/s00018-005-5143-y; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; HAWKER FH, 1990, CRIT CARE MED, V18, P442, DOI 10.1097/00003246-199004000-00020; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hollenbach B, 2008, J TRACE ELEM MED BIO, V22, P24, DOI 10.1016/j.jtemb.2007.11.003; Hurwitz BE, 2007, ARCH INTERN MED, V167, P148, DOI 10.1001/archinte.167.2.148; Maehira F, 2002, CLIN CHIM ACTA, V316, P137, DOI 10.1016/S0009-8981(01)00744-6; Mishra V, 2007, CLIN NUTR, V26, P41, DOI 10.1016/j.clnu.2006.10.003; Nichol C, 1998, CLIN CHEM, V44, P1764; Olson GE, 2008, J BIOL CHEM, V283, P6854, DOI 10.1074/jbc.M709945200; Olson GE, 2007, J BIOL CHEM, V282, P12290, DOI 10.1074/jbc.M611403200; Papp LV, 2006, MOL CELL BIOL, V26, P4895, DOI 10.1128/MCB.02284-05; Pattyn F, 2006, NUCLEIC ACIDS RES, V34, pD684, DOI 10.1093/nar/gkj155; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Powell-Tuck J, 2007, P NUTR SOC, V66, P16, DOI 10.1017/S0029665107005253; Rayman MP, 2002, P NUTR SOC, V61, P203, DOI 10.1079/PNS2002153; Reddi AS, 2001, KIDNEY INT, V59, P1342, DOI 10.1046/j.1523-1755.2001.0590041342.x; Renko K, 2008, BIOCHEM J, V409, P741, DOI 10.1042/BJ20071172; Riese C, 2006, ENDOCRINOLOGY, V147, P5883, DOI 10.1210/en.2006-0689; Sattar N, 1997, ANN CLIN BIOCHEM, V34, P437, DOI 10.1177/000456329703400419; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; Schomburg L, 2007, CRIT CARE MED, V35, P995, DOI 10.1097/01.CCM.0000257479.88792.A5; Schweizer U, 2005, BIOCHEM J, V386, P221, DOI 10.1042/BJ20041973; Squires JE, 2007, MOL CELL BIOL, V27, P7848, DOI 10.1128/MCB.00793-07; Stamoulis I, 2007, DIGEST DIS SCI, V52, P1595, DOI 10.1007/s10620-006-9462-0; Xu XM, 2005, J BIOL CHEM, V280, P41568, DOI 10.1074/jbc.M506696200; Xu XM, 2007, BIOCHEM J, V404, P115, DOI 10.1042/BJ20070165	43	113	118	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1758	1765		10.1096/fj.08-119370	http://dx.doi.org/10.1096/fj.08-119370			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19136613				2022-12-28	WOS:000266652400016
J	De Miranda, J; Yaddanapudi, K; Hornig, M; Lipkin, WI				De Miranda, Joari; Yaddanapudi, Kavitha; Hornig, Mady; Lipkin, W. Ian			Astrocytes recognize intracellular polyinosinic-polycytidylic acid via MDA-5	FASEB JOURNAL			English	Article						ds-RNA; TLR-3; RIG-I; CNS; innate immunity	DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTOR-3; NF-KAPPA-B; RIG-I; CUTTING EDGE; ADAPTER; ROLES; ACTIVATION; MICROGLIA; RESPONSES	RNA virus replication results in expression of double-stranded RNA (ds-RNA) molecules that trigger innate immune responses through interactions with both intracellular and extracellular receptors. We investigated the contributions of the extracellular and intracellular pathways to innate immunity in murine astrocyte primary cultures using polyinosinic-polycytidylic acid (poly I:C), a synthetic ds-RNA molecule designed to mimic RNA virus infection. Whereas extracellular poly I:C (naked poly I:C) mainly induced the expression of regulated on activation normal T-cell expressed and secreted (RANTES), interleukin-8 (IL-8), and tumor necrosis factor alpha (TNF-alpha), intracellular delivery of poly I:C (complexed poly I:C) chiefly induced expression of IFN-beta and IL-6. Experiments with astrocytes from Toll-like receptor 3 (TLR-3) knockout mice indicated that naked poly I:C signals via a TLR-3-dependent NF-kappa B pathway. Complexed poly I:C induced the expression of the intracellular ds-RNA sensor proteins, retinoic acid inducible gene I (RIG-I), and melanoma differentiation-associated gene 5 (MDA-5). However, transfection of astrocytes with dominant negative forms of the helicases implicated MDA-5, but not RIG-I, as the intracellular sensor of poly I:C. Complexed poly I:C-mediated MDA-5 stimulation transmitted "downstream" signals, resulting in activation of the transcription factors NF-kappa B and IRF-3. Our results illustrate the intricacy of extracellular and intracellular ds-RNA recognition in viral infections of the central nervous system and indicate the importance of MDA-5 helicase as an intracellular ds-RNA sensor in astrocytes. De Miranda, J., Yaddanapudi, K., Hornig, M., Lipkin, W. I. Astrocytes recognize intracellular polyinosinic-polycytidylic acid via MDA-5. FASEB J. 23, 1064-1071 (2009)	[De Miranda, Joari; Yaddanapudi, Kavitha; Hornig, Mady; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA	Columbia University	Lipkin, WI (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, 722 W 168th St,Rm 1801, New York, NY 10032 USA.	wil2001@columbia.edu	Hornig, Mady/AAE-8431-2020; Lipkin, W. Ian/ABE-6216-2020	Hornig, Mady/0000-0001-7572-3092; Lipkin, W. Ian/0000-0002-8768-9386	U.S. National Institutes of Health [U54-AI057158-Lipkin]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057158] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank Vishal Kapoor for technical assistance and Robert Serge for help with statistical analysis. This work was supported by a grant from the U.S. National Institutes of Health (Northeast Biodefense Center U54-AI057158-Lipkin).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Carpentier PA, 2007, GLIA, V55, P239, DOI 10.1002/glia.20450; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; GIULIAN D, 1995, J NEUROSCI, V15, P7712; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2008, J EXP MED, V205, P1601, DOI 10.1084/jem.20080091; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Niederberger E, 2008, FASEB J, V22, P3432, DOI 10.1096/fj.08-109355; Park C, 2006, GLIA, V53, P248, DOI 10.1002/glia.20278; Scumpia PO, 2005, GLIA, V52, P153, DOI 10.1002/glia.20234; Takahashi K, 2006, J IMMUNOL, V176, P4520, DOI 10.4049/jimmunol.176.8.4520; Takeuchi O, 2008, CURR OPIN IMMUNOL, V20, P17, DOI 10.1016/j.coi.2008.01.002; Town T, 2006, J IMMUNOL, V176, P3804, DOI 10.4049/jimmunol.176.6.3804; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	20	43	43	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1064	1071		10.1096/fj.08-121434	http://dx.doi.org/10.1096/fj.08-121434			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19036857	Green Published			2022-12-28	WOS:000266651600010
J	Holtje, M; Djalali, S; Hofmann, F; Munster-Wandowski, A; Hendrix, S; Boato, F; Dreger, SC; Grosse, G; Henneberger, C; Grantyn, R; Just, I; Ahnert-Hilger, G				Hoeltje, Markus; Djalali, Susann; Hofmann, Fred; Muenster-Wandowski, Agnieszka; Hendrix, Sven; Boato, Francesco; Dreger, Stefanie C.; Grosse, Gisela; Henneberger, Christian; Grantyn, Rosemarie; Just, Ingo; Ahnert-Hilger, Gudrun			A 29-amino acid fragment of Clostridium botulinum C3 protein enhances neuronal outgrowth, connectivity, and reinnervation	FASEB JOURNAL			English	Article						regeneration; hippocampus; axon	RHO-GTPASES; NEUROTROPHIC FACTOR; SYNAPTOTAGMIN-I; NEURITE GROWTH; REGENERATION; INHIBITION; ASTROCYTES; EXPRESSION; RELEASE; NERVE	Small GTPases of the Rho family play versatile roles in the formation and development of axons and dendrites, effects often studied by the Rho-inactivating C3 transferase (C3bot) from Clostridium botulinum. Recently, we reported that transferase-deficient C3bot also exerted axonotrophic activity. Using overlapping peptides from the C3bot sequence, we identified a small peptide of 29 amino acids (covering residues 154-182) from the C-terminal region of C3bot that promotes both axonal and dendritic growth, as well as branching of hippocampal neurons, at sub-micromolar concentrations. Several C3bot constructs, including the short peptide, enhanced the number of axonal segments from mid-to higher-order segments. C3bot(154-182) also increased the number of synaptophysin-expressing terminals, up-regulated various synaptic proteins, and functionally increased the glutamate uptake. Staining against the vesicular glutamate and GABA transporters further revealed that the effect was attributable to a higher number of glutamatergic and GABAergic inputs on proximal dendrites of enhanced green fluorescent protein (EGFP)-transfected neurons. Using organotypical slice cultures, we also detected trophic effects of C3bot(154-182) on length and density of outgrowing fibers from the entorhinal cortex that were comparable to the effects elicited by full-length C3bot. In addition, an enhanced reinnervation was observed in a hippocampal-entorhinal lesion model. In summary, the neurotrophic effect of C3bot is executed by a C-terminal peptide fragment covering aa 154-182 of C3; it triggers dendritic and axonal growth and branching as well as increased synaptic connectivity. In contrast to full-length C3, this C3 peptide selectively acts on neurons but not on glial cells. Holtje, M., Djalali, S., Hofmann, F., Munster-Wandowski, A., Hendrix, S., Boato, F., Dreger, S. C., Grosse, G., Henneberger, C., Grantyn, R., Just, I., Ahnert-Hilger, G. A 29-amino acid fragment of Clostridium botulinum C3 protein enhances neuronal outgrowth, connectivity, and reinnervation. FASEB J. 23, 1115-1126 (2009)	[Hoeltje, Markus] Charite, Inst Integrat Neuroanat, Ctr Anat, AG Funkt Zellbiol, D-10115 Berlin, Germany; [Hendrix, Sven; Boato, Francesco] Charite, Ctr Anat, Inst Zell & Neurobiol, D-10115 Berlin, Germany; [Henneberger, Christian; Grantyn, Rosemarie] Charite, Johannes Muller Inst Neurophysiol, AG Entwicklungsphysiol, D-10115 Berlin, Germany; [Hofmann, Fred; Dreger, Stefanie C.; Just, Ingo] Hannover Med Sch, Inst Toxikol, D-30623 Hannover, Germany; [Hendrix, Sven] Hasselt Univ, Dept Morphol, Hasselt, Belgium; [Hendrix, Sven] Hasselt Univ, Biomed Res Inst, Hasselt, Belgium	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School; Hasselt University; Hasselt University	Holtje, M (corresponding author), Charite, Inst Integrat Neuroanat, Ctr Anat, AG Funkt Zellbiol, Philippstr 12, D-10115 Berlin, Germany.	markus.hoeltje@charite.de	Henneberger, Christian/C-1557-2008; Hendrix, Sven/F-4059-2010; Münster-Wandowski, Agnieszka/Q-5690-2016	Henneberger, Christian/0000-0002-5391-7387; Hendrix, Sven/0000-0003-2344-7369; Münster-Wandowski, Agnieszka/0000-0002-5401-0218; Holtje, Markus/0000-0003-3193-4140; Boato, Francesco/0000-0001-9741-8021	Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors are indebted to Ursel Tofote, Birgit Metze, and Sandra Hagemann for their engaged and skillfull technical assistance. Work was supported by a grant from the Deutsche Forschungsgemeinschaft to G. A. H. and I.J. F.B. is a member of the CORTEX network [Marie Curie Early Stage Training (EST) Programme].	Ahnert-Hilger G, 2004, J NEUROCHEM, V90, P9, DOI 10.1111/j.1471-4159.2004.02475.x; Arakawa Y, 2003, J CELL BIOL, V161, P381, DOI 10.1083/jcb.200210149; Barth H, 1999, J BIOL CHEM, V274, P27407, DOI 10.1074/jbc.274.39.27407; Bertrand J, 2007, NEUROBIOL DIS, V25, P65, DOI 10.1016/j.nbd.2006.08.008; Bertrand J, 2005, J NEUROSCI, V25, P1113, DOI 10.1523/JNEUROSCI.3931-04.2005; Brunig I, 2001, EUR J NEUROSCI, V13, P1320, DOI 10.1046/j.0953-816x.2001.01506.x; Chan CCM, 2007, GLIA, V55, P369, DOI 10.1002/glia.20466; Dong M, 2006, SCIENCE, V312, P592, DOI 10.1126/science.1123654; Dong M, 2003, J CELL BIOL, V162, P1293, DOI 10.1083/jcb.200305098; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Freund P, 2006, NAT MED, V12, P790, DOI 10.1038/nm1436; FROTSCHER M, 1993, P NATL ACAD SCI USA, V90, P10400, DOI 10.1073/pnas.90.21.10400; Gallo G, 2006, J CELL SCI, V119, P3413, DOI 10.1242/jcs.03084; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; Hechler D, 2006, BRAIN RES REV, V52, P160, DOI 10.1016/j.brainresrev.2006.01.005; Henneberger C, 2005, NEUROSCIENCE, V135, P749, DOI 10.1016/j.neuroscience.2005.06.044; Holtje M, 2008, J BIOL CHEM, V283, P9289, DOI 10.1074/jbc.M706499200; Hoffmann A, 2008, GLIA, V56, P1162, DOI 10.1002/glia.20687; Holtje M, 2005, J NEUROCHEM, V95, P1237, DOI 10.1111/j.1471-4159.2005.03443.x; Hu Y, 2007, MOL CELL NEUROSCI, V34, P88, DOI 10.1016/j.mcn.2006.10.005; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; Jokic N, 2006, EMBO REP, V7, P1162, DOI 10.1038/sj.embor.7400826; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Neiiendam JL, 2004, J NEUROCHEM, V91, P920, DOI 10.1111/j.1471-4159.2004.02779.x; Prang P, 2001, EXP NEUROL, V169, P135, DOI 10.1006/exnr.2001.7648; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rind HB, 2005, J NEUROSCI, V25, P539, DOI 10.1523/JNEUROSCI.4322-04.2005; Rummel A, 2004, J BIOL CHEM, V279, P30865, DOI 10.1074/jbc.M403945200; Schmitt KRL, 2007, NEUROSCI RES, V59, P68, DOI 10.1016/j.neures.2007.05.011; Singh B, 2006, J NEUROSCI, V26, P7189, DOI 10.1523/JNEUROSCI.5474-05.2006; Steup A, 2000, MOL CELL NEUROSCI, V15, P141, DOI 10.1006/mcne.1999.0818; Sun JJ, 2004, NAT STRUCT MOL BIOL, V11, P868, DOI 10.1038/nsmb818; Vogelsgesang M, 2007, N-S ARCH PHARMACOL, V374, P347, DOI 10.1007/s00210-006-0113-y; Watabe-Uchida M, 2006, J NEUROSCI, V26, P10633, DOI 10.1523/JNEUROSCI.4084-06.2006; Woo S, 2006, J NEUROSCI, V26, P1418, DOI 10.1523/JNEUROSCI.4209-05.2006	36	43	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1115	1126		10.1096/fj.08-116855	http://dx.doi.org/10.1096/fj.08-116855			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19047066				2022-12-28	WOS:000266651600015
J	Di Capite, J; Shirley, A; Nelson, C; Bates, G; Parekh, AB				Di Capite, Joseph; Shirley, Anna; Nelson, Charmaine; Bates, Grant; Parekh, Anant B.			Intercellular Ca2+ wave propagation involving positive feedback between CRAC channels and cysteinyl leukotrienes	FASEB JOURNAL			English	Article						paracrine signal; mast cells	SEASONAL ALLERGIC RHINITIS; HUMAN MAST-CELLS; CURRENT I-CRAC; PLASMA-MEMBRANE; CYSLT(1) RECEPTOR; CALCIUM-CHANNELS; STORE DEPLETION; C-4 SECRETION; PORE SUBUNIT; RELEASE	Mast cells are key components of the immune system, where they help orchestrate the inflammatory response. Aberrant mast cell activation is linked to a variety of allergic diseases, including asthma, eczema, rhinitis, and nasal polyposis, which in combination affect up to 20% of the population in industrialized countries. On activation, mast cells release a variety of signals that target the bronchi and vasculature and recruit other immune cells to the inflammatory site. Prominent among such signals are the cysteinyl leukotrienes, a family of potent proinflammatory lipid mediators comprising leukotriene C-4 (LTC4), LTD4, and LTE4. LTC4, the parent compound, is secreted from mast cells following Ca2+ influx through store-operated calcium release-activated calcium ( CRAC) channels. Here, we show that activated mast cells release a paracrine signal that evokes Ca2+ signals in spatially separate resting mast cells. The paracrine signal was identified as a cysteinyl leukotriene because 1) RNAi knockdown or pharmacological block of the 5-lipoxygenase enzyme prevented activated mast cells from stimulating resting cells. 2) Block of cysteinyl leukotriene type I receptors on resting mast cells with the clinically prescribed receptor antagonist montelukast prevented their activation by active mast cells. 3) RNAi knockdown of cysteinyl leukotriene type I receptors on resting cells prevented them from responding to the paracrine signal derived from activated mast cells. 4) Purified LTC4 evoked Ca2+ signals in mast cells that were identical to those triggered by the paracrine signal. Low levels of stimulus intensity released sufficient levels of leukotriene to activate resting cells. Leukotriene secretion still occurred tens of minutes after stimulation, suggesting a role as a long-lasting trigger in mast cell activation. Stimulation of the cysteinyl leukotriene receptor activated CRAC channels and evoked prominent store-operated Ca2+ entry. This resulted in further cysteinyl leukotriene production, triggering a positive feedback cascade. Acutely isolated mast cells from patients with allergic rhinitis exhibited store-operated Ca2+ influx through CRAC channels and responded to cysteinyl leukotrienes. Histological analysis of samples taken from patients revealed clustering of mast cells, often located within 20 mu m of each other, a distance sufficient for paracrine signaling by leukotrienes to operate effectively. We conclude that a positive-feedback cascade involving CRAC channels and cysteinyl leukotrienes constitute a novel mechanism for sustaining mast cell activation.-Di Capite, J., Shirley, A., Nelson, C., Bates, G., Parekh, A. B. Intercellular Ca2+ wave propagation involving positive feedback between CRAC channels and cysteinyl leukotrienes. FASEB J. 23, 894-905 (2009)	[Di Capite, Joseph; Shirley, Anna; Nelson, Charmaine; Parekh, Anant B.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Bates, Grant] John Radcliffe Hosp, Dept Ear Nose & Throat Surg, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Parekh, AB (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Parks Rd, Oxford OX1 3PT, England.	anant.parekh@dpag.ox.ac.uk			Medical Research Council; Medical Research Council [G0601485] Funding Source: researchfish; MRC [G0601485] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a Medical Research Council Programme Grant to A. B. P. J.D.C. holds a Christopher Welch Scholarship.	Baba Y, 2008, NAT IMMUNOL, V9, P81, DOI 10.1038/ni1546; Bakowski D, 2002, CELL CALCIUM, V32, P379, DOI 10.1016/S0143416002001914; Bakowski D, 2002, PFLUG ARCH EUR J PHY, V443, P892, DOI 10.1007/s00424-001-0775-8; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; Bakowski D, 2007, CELL CALCIUM, V42, P333, DOI 10.1016/j.ceca.2007.01.005; Beindl W, 1996, MOL PHARMACOL, V50, P415; Borish L, 2003, J ALLERGY CLIN IMMUN, V112, P1021, DOI 10.1016/j.jaci.2003.09.015; Boyce JA, 2007, IMMUNOL REV, V217, P168, DOI 10.1111/j.1600-065X.2007.00512.x; Chang WC, 2004, J BIOL CHEM, V279, P29994, DOI 10.1074/jbc.M403969200; Chang WC, 2008, J BIOL CHEM, V283, P4622, DOI 10.1074/jbc.M705002200; Chang WC, 2007, J IMMUNOL, V179, P5255, DOI 10.4049/jimmunol.179.8.5255; Chang WC, 2006, FASEB J, V20, P2381, DOI 10.1096/fj.06-6016fje; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hsieh Jie-Cheng, 2004, Pediatric Asthma Allergy & Immunology, V17, P59, DOI 10.1089/088318704322994958; Kawano T, 2003, J ALLERGY CLIN IMMUN, V112, P369, DOI 10.1067/mai.2003.1636; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Lynch KR, 1999, NATURE, V399, P789; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; Moreau B, 2005, J BIOL CHEM, V280, P8776, DOI 10.1074/jbc.M409619200; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peters-Golden M, 2006, CLIN EXP ALLERGY, V36, P689, DOI 10.1111/j.1365-2222.2006.02498.x; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Putney J W Jr, 2001, Mol Interv, V1, P84; Rius M, 2008, J PHARMACOL EXP THER, V324, P86, DOI 10.1124/jpet.107.131342; Robbie-Ryan M, 2002, CURR OPIN IMMUNOL, V14, P728, DOI 10.1016/S0952-7915(02)00394-1; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Sjostrom M, 2002, BBA-MOL CELL BIOL L, V1583, P53, DOI 10.1016/S1388-1981(02)00160-9; Steinke JW, 2004, CURR ALLERGY ASTHM R, V4, P217, DOI 10.1007/s11882-004-0029-x; TAKASAKA T, 1986, ACTA OTO-LARYNGOL, P39; Thompson C, 2006, AM J RESP CELL MOL, V35, P697, DOI 10.1165/rcmb.2005-0407OC; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Volovitz B, 1999, J ALLERGY CLIN IMMUN, V104, P1162, DOI 10.1016/S0091-6749(99)70008-4; VOOGD TE, 1993, PHARMACOL REV, V45, P177; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	48	33	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2009	23	3					894	905		10.1096/fj.08-118935	http://dx.doi.org/10.1096/fj.08-118935			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18978154				2022-12-28	WOS:000265506300025
J	Zou, HF; Thomas, SM; Yan, ZW; Grandis, JR; Vogt, A; Li, LY				Zou, Huafei; Thomas, Sufi M.; Yan, Zhen-Wen; Grandis, Jennifer R.; Vogt, Andreas; Li, Lu-Yuan			Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells	FASEB JOURNAL			English	Article						siRNA; mitogenesis; oncogenesis; secretion; therapeutic	GASTRIN-RELEASING-PEPTIDE; PROTEIN-COUPLED RECEPTORS; TGF-ALPHA; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; TUMOR-GROWTH; NUDE-MICE; ACTIVATION; DROSOPHILA; EXPRESSION	Epidermal growth factor receptor (EGFR) is an activated oncogene in many cancers. It can be transactivated by ligands of G protein-coupled receptors (GPCRs). We show here that a novel gene, human rhomboid family-1 (RHBDF1), which was recently reported to have a pivotal role in epithelial cancer cell growth in culture and in xenograft tumors, participates in the modulation of GPCR-mediated EGFR transactivation. The RHBDF1 protein localizes mainly in the endoplasmic reticulum. Silencing the RHBDF1 gene in head and neck squamous cancer cell line 1483 cells with siRNA causes an inhibition of gastrin-releasing peptide (GRP) -induced phosphorylation of EGFR and EGFR-dependent signaling proteins p44/42 MAPK and AKT, accompanied by an inhibition of GRP-induced survival, proliferation, and invasion of the cells. The EGFR signaling pathway itself remains intact, however, as the cells remain responsive to exogenous EGF. In addition, RHBDF1 gene silencing disrupts GRP-stimulated secretion of EGFR ligand TGF-alpha, but not the production of latent TGF-alpha, whereas engineered overexpression of RHBDF1 markedly accelerates the secretion of TGF-alpha. These findings are consistent with the view that RHBDF1 is critically involved in a GPCR ligand-stimulated process leading to the activation of latent EGFR ligands. - Zou, H., Thomas, S. M., Yan, Z.-W., Grandis, J. R., Vogt, A., Li, L.-Y. Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J. 23, 425-432 (2009)	[Zou, Huafei; Thomas, Sufi M.; Yan, Zhen-Wen; Grandis, Jennifer R.; Vogt, Andreas; Li, Lu-Yuan] Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA; [Zou, Huafei; Yan, Zhen-Wen; Li, Lu-Yuan] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Thomas, Sufi M.; Grandis, Jennifer R.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; [Vogt, Andreas] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Li, LY (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, 5117 Ctr Ave,G12C, Pittsburgh, PA 15213 USA.	lil@upmc.edu	Thomas, Sufi Mary/AFR-1642-2022; Li, Luyuan/E-8951-2012; Thomas, Sufi/O-1487-2018	Thomas, Sufi Mary/0000-0001-5370-0842; Thomas, Sufi/0000-0001-5370-0842	Flight Attendant Medical Research Institute; Henry L. Hillman Foundation; Pennsylvania Department of Health;  [DOD BC073645];  [P01CA78039];  [P50CA097190];  [R01CA098372]; NATIONAL CANCER INSTITUTE [R01CA098372, P01CA078039, P50CA097190] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute; Henry L. Hillman Foundation; Pennsylvania Department of Health; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The study has been supported in part by grants from Flight Attendant Medical Research Institute (L.Y.L.), the Henry L. Hillman Foundation (L.Y.L.), Pennsylvania Department of Health (L.Y.L.), DOD BC073645 (L.Y.L.), P01CA78039 (A.V.), P50CA097190 (J.R.G.) and R01CA098372 (J.R.G.).	AKIYAMA T, 1985, BIOCHEM BIOPH RES CO, V131, P442, DOI 10.1016/0006-291X(85)91822-4; BERGER MS, 1987, BRIT J CANCER, V56, P533, DOI 10.1038/bjc.1987.238; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Bhola NE, 2008, FRONT BIOSCI-LANDMRK, V13, P1857, DOI 10.2741/2805; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; Brodsky JL, 2007, BIOCHEM J, V404, P353, DOI 10.1042/BJ20061890; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chatzistamou I, 2001, CANCER LETT, V171, P37, DOI 10.1016/S0304-3835(01)00543-2; Culi J, 2004, EMBO J, V23, P1372, DOI 10.1038/sj.emboj.7600132; DEMICHELE MAA, 1994, AM J RESP CELL MOL, V11, P66, DOI 10.1165/ajrcmb.11.1.8018339; Emens Leisha A, 2005, Am J Ther, V12, P243; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; Gallio M, 2002, P NATL ACAD SCI USA, V99, P12208, DOI 10.1073/pnas.192138799; Golembo M, 1996, DEVELOPMENT, V122, P3363; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Harris A L, 1992, J Natl Cancer Inst Monogr, P181; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOLODKIN AL, 1994, DEVELOPMENT, V120, P1731; Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008-5472.CAN-05-0216; Lango MN, 2002, J NATL CANCER I, V94, P375; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lui VWY, 2003, ONCOGENE, V22, P6183, DOI 10.1038/sj.onc.1206720; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Miyazaki M, 1998, EUR J CANCER, V34, P710, DOI 10.1016/S0959-8049(97)10123-X; Nakagawa T, 2005, DEV DYNAM, V233, P1315, DOI 10.1002/dvdy.20450; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; Piiper A, 2003, J BIOL CHEM, V278, P7065, DOI 10.1074/jbc.M211234200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RADULOVIC S, 1994, ACTA ONCOL, V33, P693, DOI 10.3109/02841869409121784; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SACKS PG, 1988, CANCER RES, V48, P2858; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Terashi H, 1998, J DERMATOL SCI, V17, P93, DOI 10.1016/S0923-1811(97)00079-0; Thomas SM, 2005, NEOPLASIA, V7, P426, DOI 10.1593/neo.04454; TODD R, 1989, CARCINOGENESIS, V10, P1553, DOI 10.1093/carcin/10.8.1553; Tsruya R, 2002, GENE DEV, V16, P222, DOI 10.1101/gad.214202; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; Urban S, 2006, GENE DEV, V20, P3054, DOI 10.1101/gad.1488606; Vogt A, 2004, ONCOL RES, V14, P305; Xiao DM, 2002, REGUL PEPTIDES, V109, P141, DOI 10.1016/S0167-0115(02)00197-0; Yan ZW, 2008, MOL CANCER THER, V7, P1355, DOI 10.1158/1535-7163.MCT-08-0104; Zhang Q, 2004, CANCER RES, V64, P6166, DOI 10.1158/0008-5472.CAN-04-0504; Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103	49	61	64	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					425	432		10.1096/fj.08-112771	http://dx.doi.org/10.1096/fj.08-112771			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18832597	Green Published			2022-12-28	WOS:000262892900014
J	Wong, GW; Krawczyk, SA; Kitidis-Mitrokostas, C; Ge, GT; Spooner, E; Hug, C; Gimeno, R; Lodish, HF				Wong, G. William; Krawczyk, Sarah A.; Kitidis-Mitrokostas, Claire; Ge, Guangtao; Spooner, Eric; Hug, Christopher; Gimeno, Ruth; Lodish, Harvey F.			Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin	FASEB JOURNAL			English	Article						C1q/TNF family; adipokine; diabetes; obesity	COMPLEMENT-RELATED PROTEIN; CONSERVED LYSINE RESIDUES; TYPE-2 DIABETIC-PATIENTS; FATTY-ACID OXIDATION; INSULIN-RESISTANCE; COLLAGENOUS DOMAIN; HORMONE ADIPONECTIN; POSTTRANSLATIONAL MODIFICATIONS; PLASMA-CONCENTRATIONS; LIPID-METABOLISM	Adiponectin is a major insulin-sensitizing, multimeric hormone derived from adipose tissue that acts on muscle and liver to regulate whole-body glucose and lipid metabolism. Here, we describe a novel and highly conserved paralog of adiponectin designated as C1q/TNF-related protein (CTRP) 9. Of all the CTRP paralogs, CTRP9 shows the highest degree of amino acid identity to adiponectin in its globular C1q domain. CTRP9 is expressed predominantly in adipose tissue and females expresses higher levels of the transcript than males. Moreover, its expression levels in ob/ob mice changed in an age-dependent manner, with significant up-regulation in younger mice. CTRP9 is a secreted glycoprotein with multiple post-translational modifications in its collagen domain that include hydroxylated prolines and hydroxylated and glycosylated lysines. It is secreted as multimers (predominantly trimers) from transfected cells and circulates in the mouse serum with levels varying according to sex and metabolic state of mice. Furthermore, CTRP9 and adiponectin can be secreted as heterooligomers when cotransfected into mammalian cells, and in vivo, adiponectin/CTRP9 complexes can be reciprocally coimmunoprecipitated from the serum of adiponectin and CTRP9 transgenic mice. Biochemical analysis demonstrates that adiponectin and CTRP9 associate via their globular C1q domain, and this interaction does not require their conserved N-terminal cysteines or their collagen domains. Furthermore, we show that adiponectin and CTRP9 form heterotrimers. In cultured myotubes, CTRP9 specifically activates AMPK, Akt, and p44/42 MAPK signaling pathways. Adenovirus-mediated overexpression of CTRP9 in obese (ob/ob) mice significantly lowered serum glucose levels. Collectively, these results suggest that CTRP9 is a novel adipokine, and further study of CTRP9 will yield novel mechanistic insights into its physiological and metabolic function. Wong, G. W., Krawczyk, S. A., Kitidis-Mitrokostas, C., Ge, G., Spooner, E., Hug, C., Gimeno, R., Lodish, H. F. Identification and characterization of CTRP9, a novel secreted glycoprotein from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J. 23, 241-258 (2009)	[Wong, G. William; Krawczyk, Sarah A.; Kitidis-Mitrokostas, Claire; Ge, Guangtao; Spooner, Eric; Hug, Christopher; Lodish, Harvey F.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Gimeno, Ruth] Wyeth Res, Cardiovasc & Metab Dis, Cambridge, MA USA; [Hug, Christopher] Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA; [Hug, Christopher] Harvard Univ, Sch Med, Boston, MA USA; [Lodish, Harvey F.] MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Pfizer; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	gwwong@jhmi.edu; gwwong@jhmi.edu		Wong, G. William/0000-0002-5286-6506	U. S. National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R37 DK47618 - 19]; NIH [HL077499 - 01, F32DK067835]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL077499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK067835, R37DK047618] Funding Source: NIH RePORTER	U. S. National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs. Prakash Rao, Joseph Marszalek, Alec Cheng Cheng Zhang, and Kelly Wong for helpful comments during the course of this work. This work was supported in part by U. S. National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant R37 DK47618 - 19 (to H. F. L.), NIH KO8 grant HL077499 - 01 (to C. H.), and NIH National Research Service Award postdoctoral fellowship F32DK067835 (to G. W. W.)	Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Aso Y, 2006, DIABETES, V55, P1954, DOI 10.2337/db05-1525; Bao DS, 2006, MOL CELL BIOL, V26, P9327, DOI 10.1128/MCB.01161-06; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bobbert T, 2005, DIABETES, V54, P2712, DOI 10.2337/diabetes.54.9.2712; Cai GW, 2004, DIABETES, V53, P1369, DOI 10.2337/diabetes.53.5.1369; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2004, ENDOCRINOLOGY, V145, P367, DOI 10.1210/en.2003-1068; Combs TP, 2003, DIABETES, V52, P268, DOI 10.2337/diabetes.52.2.268; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Fisher FM, 2005, DIABETOLOGIA, V48, P1084, DOI 10.1007/s00125-005-1758-7; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536; Hirai H, 2005, NAT NEUROSCI, V8, P1534, DOI 10.1038/nn1576; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Khoshnoodi J, 2006, J BIOL CHEM, V281, P38117, DOI 10.1074/jbc.R600025200; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kondo H, 2002, DIABETES, V51, P2325, DOI 10.2337/diabetes.51.7.2325; KONDO N, 1992, J BIOL CHEM, V267, P473; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Ma K, 2002, J BIOL CHEM, V277, P34658, DOI 10.1074/jbc.C200362200; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Pang Z, 2000, J NEUROSCI, V20, P6333, DOI 10.1523/JNEUROSCI.20-17-06333.2000; Richards AA, 2006, MOL ENDOCRINOL, V20, P1673, DOI 10.1210/me.2005-0390; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Satoh H, 2005, DIABETES, V54, P1304, DOI 10.2337/diabetes.54.5.1304; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Shibata R, 2005, NAT MED, V11, P1096, DOI 10.1038/nm1295; STOKES DG, 1991, J BIOL CHEM, V266, P8626; Suzuki S, 2007, FEBS LETT, V581, P809, DOI 10.1016/j.febslet.2007.01.046; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tonelli J, 2004, DIABETES, V53, P1621, DOI 10.2337/diabetes.53.6.1621; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Tsao TS, 2003, J BIOL CHEM, V278, P50810, DOI 10.1074/jbc.M309469200; Vasseur F, 2002, HUM MOL GENET, V11, P2607, DOI 10.1093/hmg/11.21.2607; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V; Waki H, 2005, ENDOCRINOLOGY, V146, P790, DOI 10.1210/en.2004-1096; Waki H, 2003, J BIOL CHEM, V278, P40352, DOI 10.1074/jbc.M300365200; Wang Y, 2002, J BIOL CHEM, V277, P19521, DOI 10.1074/jbc.M200601200; Wang Y, 2006, PROTEOMICS, V6, P3862, DOI 10.1002/pmic.200500840; Wang Y, 2006, J BIOL CHEM, V281, P16391, DOI 10.1074/jbc.M513907200; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Wong GW, 2004, P NATL ACAD SCI USA, V101, P10302, DOI 10.1073/pnas.0403760101; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Xu AM, 2005, J BIOL CHEM, V280, P18073, DOI 10.1074/jbc.M414231200; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yamauchi Toshimasa, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P243, DOI 10.2174/1568008033340090; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	66	215	231	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					241	258		10.1096/fj.08-114991	http://dx.doi.org/10.1096/fj.08-114991			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18787108	Green Published			2022-12-28	WOS:000262095500027
J	Noh, YW; Lim, YT; Chung, BH				Noh, Young-Woock; Lim, Yong Taik; Chung, Bong Hyun			Noninvasive imaging of dendritic cell migration into lymph nodes using near-infrared fluorescent semiconductor nanocrystals	FASEB JOURNAL			English	Article						immunotherapeutic cells; quantum dots; in vivo imaging; fluorescent probes	MESENCHYMAL STEM-CELLS; MOUSE BONE-MARROW; CDTE QUANTUM DOTS; IN-VIVO; CANCER-IMMUNOTHERAPY; MELANOMA PATIENTS; LIVE CELLS; TRACKING; VACCINES; DIAGNOSTICS	Effective tracking of immunotherapeutic cells is essential for monitoring the migration of injected cells to the target tissue. Here we report the use of near-infrared (NIR) -emitting fluorescent semiconductor nanocrystals, called quantum dots (QDs), for noninvasive in vivo tracking of dendritic cell ( DC) migration into lymph nodes. The effect of QDs on DC viability and maturation was systematically investigated using MTT assays and FACS analysis. We found that the labeling of DCs with QDs had no effect on DC phenotype or maturation potential. Cytokine and migration assays revealed that there were no significant changes in either cytokine production or chemokine-dependent migration of QD-labeled DCs relative to unlabeled cells; in both labeled and unlabeled cells, cytokine production and migratory capacity was increased by stimulation with lipopolysaccharide. Furthermore, QDs did not influence allogenic naive T cell activation or uptake of exogenous antigens. Notably, we also demonstrated that it was possible to track QD-labeled DCs injected into the footpad into popliteal and inguinal lymph nodes using NIR fluorescence. Taken together, our protocols establish the potential of noninvasive in vivo imaging of NIR-emitting QDs for tracking immunotherapeutic cells. -Noh, Y.- W., Lim, Y. T., Chung, B. H. Noninvasive imaging of dendritic cell migration into lymph nodes using near-infrared fluorescent semiconductor nanocrystals. FASEB J. 22, 3908-3918 (2008)	[Noh, Young-Woock; Lim, Yong Taik; Chung, Bong Hyun] Korea Res Inst Biosci & Biotechnol, BioNanotechnol Res Ctr, Taejon 305333, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Lim, YT (corresponding author), Korea Res Inst Biosci & Biotechnol, BioNanotechnol Res Ctr, POB 115, Taejon 305333, South Korea.	yongtaik@kribb.re.kr; chungbh@kribb.re.kr			Korea government (MEST); KRIBB Research Initiative Program	Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); KRIBB Research Initiative Program	This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST) and KRIBB Research Initiative Program. We thank Dr. Chong Kil Lee (Chungbuk National University, Cheongju, South Korea) for providing cell lines.	Ahrens ET, 2005, NAT BIOTECHNOL, V23, P983, DOI 10.1038/nbt1121; Azzazy HME, 2007, CLIN BIOCHEM, V40, P917, DOI 10.1016/j.clinbiochem.2007.05.018; Ballou B, 2007, BIOCONJUGATE CHEM, V18, P389, DOI 10.1021/bc060261j; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Baumjohann D, 2006, IMMUNOBIOLOGY, V211, P587, DOI 10.1016/j.imbio.2006.05.011; Baumjohann D, 2006, EUR J IMMUNOL, V36, P2544, DOI 10.1002/eji.200535742; Byrne SJ, 2006, J MATER CHEM, V16, P2896, DOI 10.1039/b605333e; Cai WB, 2006, NANO LETT, V6, P669, DOI 10.1021/nl052405t; Cambi A, 2007, NANO LETT, V7, P970, DOI 10.1021/nl0700503; Cho SJ, 2007, LANGMUIR, V23, P1974, DOI 10.1021/la060093j; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; de Vries IJM, 2005, NAT BIOTECHNOL, V23, P1407, DOI 10.1038/nbt1154; de Vries IJM, 2003, CANCER RES, V63, P12; Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111; Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194; Eggert AAO, 2003, IMMUNOL LETT, V89, P17, DOI 10.1016/S0165-2478(03)00105-6; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Gaponik N, 2003, NANO LETT, V3, P369, DOI 10.1021/nl0259333; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hardman R, 2006, ENVIRON HEALTH PERSP, V114, P165, DOI 10.1289/ehp.8284; Hoshino A, 2004, BIOCHEM BIOPH RES CO, V314, P46, DOI 10.1016/j.bbrc.2003.11.185; Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920; Kim SW, 2005, J AM CHEM SOC, V127, P10526, DOI 10.1021/ja0434331; KUPIECWEGLINSKI JW, 1988, J EXP MED, V167, P632, DOI 10.1084/jem.167.2.632; Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780; Lesterhuis WJ, 2004, ANN ONCOL, V15, P145, DOI 10.1093/annonc/mdh919; Lim Yong Taik, 2003, Mol Imaging, V2, P50, DOI 10.1162/153535003765276282; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Olasz EB, 2002, J IMMUNOL METHODS, V260, P137, DOI 10.1016/S0022-1759(01)00528-2; Parungo CP, 2005, CHEST, V127, P1799, DOI 10.1378/chest.127.5.1799; Pozzolini M, 2003, ANAL BIOCHEM, V313, P338, DOI 10.1016/S0003-2697(02)00631-0; Rosen AB, 2007, STEM CELLS, V25, P2128, DOI 10.1634/stemcells.2006-0722; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; Schimmelpfennig CH, 2005, AM J PATHOL, V167, P1321, DOI 10.1016/S0002-9440(10)61219-9; Schuler G, 2003, CURR OPIN IMMUNOL, V15, P138, DOI 10.1016/S0952-7915(03)00015-3; Shah LS, 2007, NANO LETT, V7, P3071, DOI 10.1021/nl071547f; Shen ZH, 1997, J IMMUNOL, V158, P2723; Soltesz EG, 2005, ANN THORAC SURG, V79, P269, DOI 10.1016/j.athoracsur.2004.06.055; Verdijk P, 2007, INT J CANCER, V120, P978, DOI 10.1002/ijc.22385; Weissleder R, 2001, NAT BIOTECHNOL, V19, P316, DOI 10.1038/86684	45	62	62	4	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2008	22	11					3908	3918		10.1096/fj.08-112896	http://dx.doi.org/10.1096/fj.08-112896			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18682573				2022-12-28	WOS:000260503000019
J	Lee, SJ; Chan, TH; Chen, TC; Liao, BK; Hwang, PP; Lee, H				Lee, Shyh-Jye; Chan, Tun-Hao; Chen, Tzu-Cheng; Liao, Bo-Kai; Hwang, Pung-Pung; Lee, Hsinyu			LPA(1) is essential for lymphatic vessel development in zebrafish	FASEB JOURNAL			English	Article						lysophosphatidic acid; G protein-coupled receptor; endothelial cell; thoracic duct; morpholino	LYSOPHOSPHATIDIC ACID RECEPTOR; PROTEIN-COUPLED RECEPTOR; SMOOTH-MUSCLE-CELLS; SPHINGOSINE 1-PHOSPHATE; VASCULAR DEVELOPMENT; SIGNALING DEFICITS; ENDOTHELIAL-CELLS; DORSAL AORTA; EXPRESSION; LYSOPHOSPHOLIPIDS	Lysophosphatidic acid (LPA) has long been implicated in regulating vascular development via endothelial cell-expressed G protein-coupled receptors. However, because of a lack of notable vascular defects reported in LPA receptor knockout mouse studies, the regulation of vasculature by LPA receptors in vivo is still uncertain. Using zebrafish as a model, we studied the gene expression patterns and functions of an LPA receptor, LPA(1), during embryonic development, in particular, vascular formation. Whole-mount in situ hybridization experiments revealed that zebrafish lpa(1) (zlpa(1)) was ubiquitously expressed early in development, and its expression domains were later localized to the head region and the vicinity of the dorsal aorta. The expression of zlpa(1) surrounding the dorsal aorta suggests its role in vasculature development. Knocking down of zLPA(1) by injecting morpholino (MO) oligonucleotides at 0.625-1.25 ng per embryo resulted in the absence of thoracic duct and edema in pericardial sac and trunk in a dose-dependent manner. These zlpa(1)-MO-resulted defects could be specifically rescued by ectopic expression of zlpa(1). In addition, overexpression of vegf-c, a well-known lymphangiogenic factor, also partially ameliorated the inhibition of thoracic duct development. Taken together, these results demonstrate that LPA, is necessary for lymphatic vessel formation during embryonic development in zebrafish.	[Lee, Shyh-Jye; Chan, Tun-Hao; Chen, Tzu-Cheng; Lee, Hsinyu] Natl Taiwan Univ, Inst Zool, Taipei 106, Taiwan; [Lee, Shyh-Jye; Lee, Hsinyu] Natl Taiwan Univ, Dept Life Sci, Taipei 106, Taiwan; [Liao, Bo-Kai; Hwang, Pung-Pung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University; Academia Sinica - Taiwan	Lee, SJ (corresponding author), Natl Taiwan Univ, Inst Zool, 1 Roosevelt Rd,Sect 4, Taipei 106, Taiwan.	jefflee@ntu.edu.tw; hsinyulee@ntu.edu.tw	Liao, Bo-Kai/ABD-5143-2020; hwang, pp/A-3641-2011; Hwang, Pung-Pung/AAH-1538-2022; Hwang, Pung-Pung/AEQ-4633-2022; Lee, Shyh-Jye/C-6092-2008	Liao, Bo-Kai/0000-0003-4742-4487; Lee, Shyh-Jye/0000-0001-8452-9152; Lee, Hsinyu/0000-0002-1477-0183	National Science Council of Taiwan [NSC95-2311-B-002-015-MY3]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by a grant (NSC95-2311-B-002-015-MY3) to S.J.L. from the National Science Council of Taiwan.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005; Birgbauer E, 2006, CELL MOL LIFE SCI, V63, P2695, DOI 10.1007/s00018-006-6155-y; Cerutis DR, 1997, AM J PHYSIOL-LUNG C, V273, pL10, DOI 10.1152/ajplung.1997.273.1.L10; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Cleaver O, 1998, DEVELOPMENT, V125, P3905; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Covassin LD, 2006, P NATL ACAD SCI USA, V103, P6554, DOI 10.1073/pnas.0506886103; Devoto SH, 1996, DEVELOPMENT, V122, P3371; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; Eriksson J, 2000, J MORPHOL, V244, P167, DOI 10.1002/(SICI)1097-4687(200006)244:3<167::AID-JMOR2>3.0.CO;2-J; Estivill-Torrus G, 2008, CEREB CORTEX, V18, P938, DOI 10.1093/cercor/bhm132; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayashi K, 2001, CIRC RES, V89, P251, DOI 10.1161/hh1501.094265; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kuchler AM, 2006, CURR BIOL, V16, P1244, DOI 10.1016/j.cub.2006.05.026; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lai SL, 2005, MOL REPROD DEV, V71, P186, DOI 10.1002/mrd.20290; Langlois S, 2004, BLOOD, V103, P3020, DOI 10.1182/blood-2003-08-2968; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lin CI, 2006, J CELL BIOCHEM, V99, P1216, DOI 10.1002/jcb.20963; Lin CL, 2007, BIOCHEM BIOPH RES CO, V363, P1001, DOI 10.1016/j.bbrc.2007.09.081; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Niki T, 2000, CLIN CANCER RES, V6, P2431; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Ny A, 2006, EXP CELL RES, V312, P684, DOI 10.1016/j.yexcr.2005.10.018; Ober EA, 2004, EMBO REP, V5, P78, DOI 10.1038/sj.embor.7400047; Oliver G, 2004, NAT REV IMMUNOL, V4, P35, DOI 10.1038/nri1258; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84; Schulze C, 1997, J NEUROCHEM, V68, P991; Spohr TCDSE, 2008, J BIOL CHEM, V283, P7470, DOI 10.1074/jbc.M707758200; Stickney HL, 2000, DEV DYNAM, V219, P287; Su JL, 2007, BRIT J CANCER, V96, P541, DOI 10.1038/sj.bjc.6603487; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; Thisse B, 2005, HIGH THROUGHPUT EXPR; Thisse B, 2004, ZFIN DIRECT DATA SUB; THISSE C, 1993, DEVELOPMENT, V119, P1203; Toews ML, 1997, J APPL PHYSIOL, V83, P1216, DOI 10.1152/jappl.1997.83.4.1216; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; TOKUMURA A, 1995, RES COMMUN MOL PATH, V90, P96; Valentine WJ, 2008, J BIOL CHEM, V283, P12175, DOI 10.1074/jbc.M708847200; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; Weinstein BM, 2002, SEMIN CELL DEV BIOL, V13, P515, DOI 10.1016/S1084952102001052; Wu WT, 2005, ENDOCRINOLOGY, V146, P3387, DOI 10.1210/en.2004-1654; Yaniv K, 2006, NAT MED, V12, P711, DOI 10.1038/nm1427; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Yoshida K, 2003, CIRCULATION, V108, P1746, DOI 10.1161/01.CIR.0000089374.35455.F3; zu Heringdorf DM, 2007, BBA-BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026	60	31	33	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3706	3715		10.1096/fj.08-106088	http://dx.doi.org/10.1096/fj.08-106088			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18606866	Green Submitted			2022-12-28	WOS:000259642600031
J	Vukojevic, V; Ming, Y; D'Addario, C; Hansen, M; Langel, U; Schulz, R; Johansson, B; Rigler, R; Terenius, L				Vukojevic, Vladana; Ming, Yu; D'Addario, Claudio; Hansen, Mats; Langel, Ulo; Schulz, Ruediger; Johansson, Bjoern; Rigler, Rudolf; Terenius, Lars			mu-opioid receptor activation in live cells	FASEB JOURNAL			English	Article						G protein-coupled receptor; GPCR; protein/lipid microdomains; fluorescence correlation spectroscopy; FCS	FLUORESCENCE CORRELATION SPECTROSCOPY; LIPID-PROTEIN INTERACTIONS; SINGLE DNA-MOLECULES; NERVE GROWTH-FACTOR; PC12 CELLS; CROSS-CORRELATION; CONFORMATIONAL TRANSITIONS; TRANSMEMBRANE RECEPTORS; LATERAL DIFFUSION; PLASMA-MEMBRANE	Interaction of the mu-opioid receptor (MOP) with selected ligands was investigated in live cells using advanced imaging by confocal laser scanning microscopy integrated with fluorescence correlation spectroscopy and fluorescence cross-correlation spectroscopy. In PC12 cells stably transformed to express the fluorescently labeled MOP-enhanced green fluorescent protein construct, two pools of MOP were identified that could be discriminated by differences in their lateral mobility in the cell membrane. The majority of MOP receptors (80 +/- 10%) were characterized by a diffusion coefficient D-MOP,D-1 = (4 +/- 2) X 10(-11) m(2) s(-1), compared with the slowly moving fraction, D-MOP,D- 2 = (4 +/- 2) x 10(-12) m(2) s(-1). On stimulation with selected agonists ([D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin, enkephalin-heptapeptide Tyr-Gly-Gly-Phe-Met-Arg-Phe, morphine, and methadone), surface density of the MOP decreased, whereas the lateral mobility increased. In contrast, antagonists (naloxone and naltrexone) "froze" the receptor in the membrane, i.e., increased MOP surface density and decreased lateral mobility. Agonist activation was also accompanied by pronounced changes in the dynamics of plasma membrane lipids, as revealed by the general lipid marker 1,1'-dioctadecyl-3,3,3',3'-tetramethylindo-carbocyanine perchlorate dye. The results provide new information about MOP activation in live cells at the molecular level, with a special focus on the dynamics of the intricate interplay between this receptor and the surrounding lipids.	[Vukojevic, Vladana] Karolinska Inst, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Rigler, Rudolf] Karolinska Inst, Dept Med Biochem & Biophys, S-17176 Stockholm, Sweden; [Hansen, Mats; Langel, Ulo] Stockholm Univ, Dept Neurochem, Arrhenius Labs Nat Sci, S-10691 Stockholm, Sweden; [Schulz, Ruediger] Univ Munich, Inst Pharmacol Toxicol & Pharm, Munich, Germany	Karolinska Institutet; Karolinska Institutet; Stockholm University; University of Munich	Vukojevic, V (corresponding author), Karolinska Inst, Dept Clin Neurosci, CMM L8 01, S-17176 Stockholm, Sweden.	vladana.vnkojevic@ki.se	DAddario, Claudio/A-5970-2010; Vukojevic, Vladana B/AAY-3144-2021	d'addario, claudio/0000-0002-1275-098X; Langel, Ulo/0000-0001-6107-0844; Vukojevic, Vladana/0000-0003-0873-5653	Swedish Research Council; Cancerdegradome; The AFA Insurance	Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancerdegradome; The AFA Insurance	We thank Dr. Marcus Heidkamp (C. Zeiss) for excellent support and the Knut and Alice Wallenberg Foundation for funding (L.T., R.R.). Financial support from the Swedish Research Council, Cancerdegradome, and The AFA Insurance is gratefully acknowledged. We thank Agneta Gunnar for technical assistance.	Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Arispe N, 2002, FASEB J, V16, P1526, DOI 10.1096/fj.02-0829com; Bacia K, 2004, BIOPHYS J, V87, P1034, DOI 10.1529/biophysj.104.040519; Bacia K, 2002, BIOPHYS J, V83, P1184, DOI 10.1016/S0006-3495(02)75242-9; Barnett-Norris J, 2005, LIFE SCI, V77, P1625, DOI 10.1016/j.lfs.2005.05.040; Bates IR, 2006, BIOCHEM CELL BIOL, V84, P825, DOI 10.1139/O06-189; Briddon SJ, 2007, TRENDS PHARMACOL SCI, V28, P637, DOI 10.1016/j.tips.2007.09.008; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen Y, 2006, METHODS, V39, P147, DOI 10.1016/j.ymeth.2006.05.008; CHIPKIN RE, 1984, LIFE SCI, V34, P1809, DOI 10.1016/0024-3205(84)90673-8; Edman L, 1996, P NATL ACAD SCI USA, V93, P6710, DOI 10.1073/pnas.93.13.6710; Edman L, 2000, P NATL ACAD SCI USA, V97, P8266, DOI 10.1073/pnas.130589397; EHRENBER.M, 1974, CHEM PHYS, V4, P390, DOI 10.1016/0301-0104(74)85005-6; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102; GREENBERG ML, 1993, J MEMBRANE BIOL, V131, P115, DOI 10.1007/BF02791320; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Haupts U, 1998, P NATL ACAD SCI USA, V95, P13573, DOI 10.1073/pnas.95.23.13573; Haustein E, 2007, ANNU REV BIOPH BIOM, V36, P151, DOI 10.1146/annurev.biophys.36.040306.132612; Hebert TE, 2006, CELL BIOCHEM BIOPHYS, V45, P85, DOI 10.1385/CBB:45:1:85; Heinze KG, 2004, BIOPHYS J, V86, P506, DOI 10.1016/S0006-3495(04)74129-6; Horner KA, 2004, BRAIN RES, V1028, P121, DOI 10.1016/j.brainres.2004.07.055; Jacoby E, 2006, CHEMMEDCHEM, V1, P760, DOI 10.1002/cmdc.200600134; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; KOLB VM, 1983, LIFE SCI, V33, P423, DOI 10.1016/0024-3205(83)90532-5; KOPPEL DE, 1976, BIOPHYS J, V16, P1315, DOI 10.1016/S0006-3495(76)85776-1; KOPPEL DE, 1974, PHYS REV A, V10, P1938, DOI 10.1103/PhysRevA.10.1938; KRUMINS SA, 1987, NEUROCHEM RES, V12, P231, DOI 10.1007/BF00972131; Lefkowitz RJ, 2007, ACTA PHYSIOL, V190, P9, DOI 10.1111/j.1365-201X.2007.01693.x; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Leitenberger SM, 2008, LANGMUIR, V24, P1254, DOI 10.1021/la702319q; Levin MK, 2004, DIFFERENTIATION, V72, P1, DOI 10.1111/j.1432-0436.2004.07201002.x; Li J, 2001, MOL PHARMACOL, V60, P1064, DOI 10.1124/mol.60.5.1064; Licht SS, 2003, BIOCHEMISTRY-US, V42, P2916, DOI 10.1021/bi026059v; Loura LMS, 2000, BBA-BIOMEMBRANES, V1467, P101, DOI 10.1016/S0005-2736(00)00211-X; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Maudsley S, 2005, J PHARMACOL EXP THER, V314, P485, DOI 10.1124/jpet.105.083121; Naji A, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2739526; Peiro S, 2000, J BIOL CHEM, V275, P37846, DOI 10.1074/jbc.M000487200; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pineyro G, 2007, CELL SIGNAL, V19, P8, DOI 10.1016/j.cellsig.2006.05.026; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; Rigler R, 1998, J BIOTECHNOL, V63, P97, DOI 10.1016/S0168-1656(98)00079-0; RIGLER R, 1973, Q REV BIOPHYS, V6, P139, DOI 10.1017/S003358350000113X; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Sanchez SA, 2005, ACCOUNTS CHEM RES, V38, P469, DOI 10.1021/ar040026l; Schulz R, 2002, J PHARMACOL EXP THER, V300, P376, DOI 10.1124/jpet.300.2.376; Schwille P, 1997, BIOPHYS J, V72, P1878, DOI 10.1016/S0006-3495(97)78833-7; Schwille P, 1999, CYTOMETRY, V36, P176, DOI 10.1002/(SICI)1097-0320(19990701)36:3<176::AID-CYTO5>3.0.CO;2-F; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Sun ZX, 2005, NEUROSCI LETT, V391, P71, DOI 10.1016/j.neulet.2005.08.034; Swinton DJ, 2000, ANAL CHEM, V72, P3725, DOI 10.1021/ac0000933; Tang N, 2007, EXP BRAIN RES, V183, P241, DOI 10.1007/s00221-007-1036-7; Thompson N. L., 1991, TOPICS FLUORESCENCE, V1, P337; Thompson NL, 2002, CURR OPIN STRUC BIOL, V12, P634, DOI 10.1016/S0959-440X(02)00368-8; TOCANNE JF, 1994, CHEM PHYS LIPIDS, V73, P139, DOI 10.1016/0009-3084(94)90179-1; Vukojevic V, 2005, CELL MOL LIFE SCI, V62, P535, DOI 10.1007/s00018-004-4305-7; Wachsmuth M, 2000, J MOL BIOL, V298, P677, DOI 10.1006/jmbi.2000.3692; Wang DX, 2007, J PHARMACOL EXP THER, V321, P544, DOI 10.1124/jpet.106.118810; Wennmalm S, 1999, CHEM PHYS, V247, P61, DOI 10.1016/S0301-0104(99)00125-1; Wennmalm S, 1997, P NATL ACAD SCI USA, V94, P10641, DOI 10.1073/pnas.94.20.10641; Widengren J, 1998, CELL MOL BIOL, V44, P857; Widengren J, 1999, CHEM PHYS, V250, P171, DOI 10.1016/S0301-0104(99)00255-4; WIDENGREN J, 1995, J PHYS CHEM-US, V99, P13368, DOI 10.1021/j100036a009; Widengren J., 1997, J FLUORESCENCE, V7, p211S; Xu W, 2006, J PHARMACOL EXP THER, V317, P1295, DOI 10.1124/jpet.105.099507; Xu ZQD, 2007, ACTA PHYSIOL, V190, P39, DOI 10.1111/j.1365-201X.2007.01695.x; Zarnegar P, 2006, NEUROSCI LETT, V396, P197, DOI 10.1016/j.neulet.2005.11.040; Zhao H, 2006, MOL PHARMACOL, V69, P1421, DOI 10.1124/mol.105.020024; Zollner C, 2007, Handb Exp Pharmacol, P31	72	27	27	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3537	3548		10.1096/fj.08-108894	http://dx.doi.org/10.1096/fj.08-108894			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18587007				2022-12-28	WOS:000259642600016
J	Shi, H; Scheffler, JM; Pleitner, JM; Zeng, C; Park, S; Hannon, KM; Grant, AL; Gerrard, DE				Shi, Hao; Scheffler, Jason M.; Pleitner, Jonathan M.; Zeng, Caiyun; Park, Sungkwon; Hannon, Kevin M.; Grant, Alan L.; Gerrard, David E.			Modulation of skeletal muscle fiber type by mitogen-activated protein kinase signaling	FASEB JOURNAL			English	Article						ERK1/2; MKP-1; plasticity; signal transduction	MYOSIN HEAVY-CHAIN; HEAVY-CHAIN-2 GENE-EXPRESSION; MAP KINASE; GROWTH-FACTOR; SLOW; CALCINEURIN; PATHWAY; DIFFERENTIATION; ISOFORM; PHOSPHORYLATION	Skeletal muscle is composed of diverse fiber types, yet the underlying molecular mechanisms responsible for this diversification remain unclear. Herein, we report that the extracellular signal-regulated kinase (ERK) 1/2 pathway, but not p38 or c-Jun NH2-terminal kinase (JNK), is preferentially activated in fast-twitch muscles. Pharmacological blocking of ERK1/2 pathway increased slow-twitch fiber type-specific reporter activity and repressed those associated with the fast-twitch fiber phenotype in vitro. Overexpression of a constitutively active ERK2 had an opposite effect. Inhibition of ERK signaling in cultured myotubes increased slow-twitch fiber-specific protein accumulation while repressing those characteristic of fast-twitch fibers. Overexpression of MAP kinase phosphatase-1 (MKP1) in mouse and rat muscle fibers containing almost exclusively type IIb or IIx fast myosin heavy chain (MyHC) isoforms induced de novo synthesis of the slower, more oxidative type IIa and I MyHCs in a time-dependent manner. Conversion to the slower phenotype was confirmed by up-regulation of slow reporter gene activity and down-regulation of fast reporter activities in response to forced MKP1 expression in vivo. In addition, activation of ERK2 signaling induced up-regulation of fast-twitch fiber program in soleus. These data suggest that the MAPK signaling, most likely the ERK1/2 pathway, is necessary to preserve the fast-twitch fiber phenotype with a concomitant repression of slow- twitch fiber program.	[Shi, Hao; Scheffler, Jason M.; Pleitner, Jonathan M.; Zeng, Caiyun; Park, Sungkwon; Grant, Alan L.; Gerrard, David E.] Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA; [Hannon, Kevin M.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Gerrard, DE (corresponding author), Purdue Univ, Dept Anim Sci, 915 W State St, W Lafayette, IN 47907 USA.	dgerrard@purdue.edu	gerrard, david/AAG-7507-2019	Scheffler, Jason/0000-0001-6360-8820; gerrard, david/0000-0002-3482-1400				Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Depreux FFS, 2000, MEAT SCI, V56, P261, DOI 10.1016/S0309-1740(00)00051-6; DiMario JX, 2001, EXP CELL RES, V263, P23, DOI 10.1006/excr.2000.5094; Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo-reports/kve177; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; Grifone R, 2004, MOL CELL BIOL, V24, P6253, DOI 10.1128/MCB.24.14.6253-6267.2004; Hagiwara N, 2005, DEV DYNAM, V234, P301, DOI 10.1002/dvdy.20535; Hagiwara N, 2007, DEV DYNAM, V236, P2062, DOI 10.1002/dvdy.21223; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Higginson J, 2002, PFLUG ARCH EUR J PHY, V445, P437, DOI 10.1007/s00424-002-0939-1; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Jordan T, 2005, J CELL SCI, V118, P2295, DOI 10.1242/jcs.02341; Jordan T, 2004, J CELL SCI, V117, P6175, DOI 10.1242/jcs.01543; Jordan T, 2003, J CELL BIOL, V162, P843, DOI 10.1083/jcb.200303164; Keren A, 2006, MOL CELL ENDOCRINOL, V252, P224, DOI 10.1016/j.mce.2006.03.017; Kramer HF, 2007, J APPL PHYSIOL, V103, P388, DOI 10.1152/japplphysiol.00085.2007; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Long YC, 2004, P NUTR SOC, V63, P227, DOI 10.1079/PNS2004346; Maggs AM, 2000, J MUSCLE RES CELL M, V21, P101, DOI 10.1023/A:1005639229497; Meissner JD, 2007, J BIOL CHEM, V282, P7265, DOI 10.1074/jbc.M609076200; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Pette D, 2001, HISTOCHEM CELL BIOL, V115, P359, DOI 10.1007/s004180100268; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Shi H, 2007, AM J PHYSIOL-CELL PH, V292, pC1681, DOI 10.1152/ajpcell.00466.2006; Stefanovsky V, 2006, MOL CELL, V21, P629, DOI 10.1016/j.molcel.2006.01.023; Strle K, 2006, ENDOCRINOLOGY, V147, P4363, DOI 10.1210/en.2005-1541; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; Swoap SJ, 1998, AM J PHYSIOL-CELL PH, V274, pC681, DOI 10.1152/ajpcell.1998.274.3.C681; Treinies I, 1999, MOL CELL BIOL, V19, P321; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu JJ, 2006, CELL METAB, V4, P61, DOI 10.1016/j.cmet.2006.05.010; Wu JJ, 2005, MOL CELL BIOL, V25, P4792, DOI 10.1128/MCB.25.11.4792-4803.2005; Yeow K, 2002, BIOCHEM BIOPH RES CO, V293, P112, DOI 10.1016/S0006-291X(02)00190-0	52	61	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2990	3000		10.1096/fj.07-097600	http://dx.doi.org/10.1096/fj.07-097600			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18417546				2022-12-28	WOS:000258089300039
J	Chen, SY; Pan, CJ; Nandigama, K; Mansfield, BC; Ambudkar, SV; Chou, JY				Chen, Shih-Yin; Pan, Chi-Jiunn; Nandigama, Krishnamachary; Mansfield, Brian C.; Ambudkar, Suresh V.; Chou, Janice Y.			The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic	FASEB JOURNAL			English	Article						proteoliposomes; glucose-6-phosphatase-alpha; endoplasmic reticulum; chorogenic acid; vanadate	ESCHERICHIA-COLI; MICROSOMAL GLUCOSE-6-PHOSPHATASE; GLUCOSE 6-PHOSPHATASE; TRANSMEMBRANE TOPOLOGY; ENZYME-DEFICIENT; CHROMOSOME 11Q23; ANION-EXCHANGE; NON-A; GENE; MUTATIONS	Glycogen storage disease type Ib (GSD-Ib) is caused by deficiencies in the glucose-6-phosphate (G6P) transporter (G6PT) that have been well characterized. Interestingly, deleterious mutations in the G6PT gene were identified in clinical cases of GSD type Ic (GSD-Ic) proposed to be deficient in an inorganic phosphate (P-i) transporter. We hypothesized that G6PT is both the G6P and Pi transporter. Using reconstituted proteoliposomes we show that both G6P and P-i are efficiently taken up into P-i-loaded G6PT-proteoliposomes. The G6P uptake activity decreases as the internal: external P-i ratio decreases and the P-i uptake activity decreases in the presence of external G6P. Moreover, G6P or P-i uptake activity is not detectable in P-i-loaded proteoliposomes containing the p.R28H G6PT null mutant. The G6PT-proteoliposome-mediated G6P or P-i uptake is inhibited by cholorgenic acid and vanadate, both specific G6PT inhibitors. Glucose-6-phosphatase-alpha (G6Pase-alpha), which facilitates microsomal G6P uptake by G6PT, fails to stimulate G6P uptake in P-i-loaded G6PT-proteoliposomes, suggesting that the G6Pase-alpha-mediated stimulation is caused by decreasing G6P and increasing P-i concentrations in microsomes. Taken together, our results suggest that G6PT has a dual role as a G6P and a P-i transporter and that GSD-Ib and GSD-Ic are deficient in the same G6PT gene.	[Chen, Shih-Yin; Pan, Chi-Jiunn; Mansfield, Brian C.; Chou, Janice Y.] NICHHD, Sect Cellular Differentiat, Heritable Disorders Branch, Natl Inst Hlth, Bethesda, MD 20892 USA; [Nandigama, Krishnamachary; Ambudkar, Suresh V.] Natl Canc Inst, Cell Biol Lab, Ctr Canc Res, Natl Inst Hlth, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chou, JY (corresponding author), NICHHD, Sect Cellular Differentiat, Heritable Disorders Branch, Natl Inst Hlth, Bldg 10,Rm 9D42,10 Ctr Dr, Bethesda, MD 20892 USA.	chouja@mail.nih.gov	Ambudkar, Suresh V/L-1317-2016	Mansfield, Brian/0000-0002-8533-2789	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC010030, Z01BC010030] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AMBUDKAR SV, 1986, J BIOL CHEM, V261, P9083; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; ARION WJ, 1980, J BIOL CHEM, V255, P396; ARION WJ, 1972, J BIOL CHEM, V247, P2558; ARION WJ, 1976, J BIOL CHEM, V251, P4901; Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; Chen LY, 2000, J BIOL CHEM, V275, P34280, DOI 10.1074/jbc.M006439200; Chen LY, 2002, HUM MOL GENET, V11, P3199, DOI 10.1093/hmg/11.25.3199; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; CHOU JY, 2003, MEMBRANE TRANSPORTER, P191; Davies DR, 2004, FEBS LETT, V577, P315, DOI 10.1016/j.febslet.2004.10.022; Galli L, 1999, FEBS LETT, V459, P255, DOI 10.1016/S0014-5793(99)01248-X; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; Ghosh A, 2002, J BIOL CHEM, V277, P32837, DOI 10.1074/jbc.M201853200; GITZELMANN R, 1993, EUR J PEDIATR, V152, pS33; GOLDRICK D, 1988, J BACTERIOL, V179, P3421; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; Janecke AR, 2000, HUM GENET, V107, P285, DOI 10.1007/s004390000371; LEI KJ, 1994, J CLIN INVEST, V93, P1994, DOI 10.1172/JCI117192; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1995, AM J HUM GENET, V57, P766; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1999, HUM GENET, V105, P515, DOI 10.1007/s004390051140; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; MALONEY PC, 1990, MICROBIOL REV, V54, P1; NARISAWA K, 1978, BIOCHEM BIOPH RES CO, V83, P1360, DOI 10.1016/0006-291X(78)91371-2; NILSSON OS, 1978, EUR J BIOCHEM, V82, P627, DOI 10.1111/j.1432-1033.1978.tb12059.x; NORDLIE RC, 1983, J BIOL CHEM, V258, P9739; Pan CJ, 1999, J BIOL CHEM, V274, P13865, DOI 10.1074/jbc.274.20.13865; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENIOR B, 1968, NEW ENGL J MED, V279, P958, DOI 10.1056/NEJM196810312791802; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SINGH J, 1981, BIOCHIM BIOPHYS ACTA, V678, P477, DOI 10.1016/0304-4165(81)90129-X; SONNA LA, 1988, J BIOL CHEM, V263, P6625; Veiga-Da-Cunha M, 1999, EUR J HUM GENET, V7, P717, DOI 10.1038/sj.ejhg.5200366; Veiga-da-Cunha M, 1998, AM J HUM GENET, V63, P976, DOI 10.1086/302068; VIANNA AL, 1969, J BIOL CHEM, V244, P4027; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WESTON LA, 1987, J BACTERIOL, V169, P3546, DOI 10.1128/jb.169.8.3546-3555.1987	46	39	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2206	2213		10.1096/fj.07-104851	http://dx.doi.org/10.1096/fj.07-104851			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18337460				2022-12-28	WOS:000257292500013
J	Menendez, A; Calarese, DA; Stanfield, RL; Chow, KC; Scanlan, CN; Kunert, R; Katinger, H; Burton, DR; Wilson, IA; Scott, JK				Menendez, Alfredo; Calarese, Daniel A.; Stanfield, Robyn L.; Chow, Keith C.; Scanlan, Chris N.; Kunert, Renate; Katinger, Herman; Burton, Dennis R.; Wilson, Ian A.; Scott, Jamie K.			A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120	FASEB JOURNAL			English	Article						peptide mimics; HIV-1 envelope proteins; crystal structure; phage-displayed peptide libraries	IMMUNODEFICIENCY-VIRUS TYPE-1; CROSS-CLADE NEUTRALIZATION; HIGH-AFFINITY MIMOTOPE; CAPSULAR POLYSACCHARIDE; CRYPTOCOCCUS-NEOFORMANS; FILAMENTOUS PHAGE; MONOCLONAL-ANTIBODIES; ANTICARBOHYDRATE ANTIBODIES; ANTI-HIV-1 ANTIBODY; SEROGROUP-C	MAb 2G12 neutralizes HIV-1 by binding with high affinity to a cluster of high-mannose oligosaccharides on the envelope glycoprotein, gp120. Screening of phage-displayed peptide libraries with 2G12 identified peptides that bind specifically, with Kds ranging from 0.4 to 200 mu M. The crystal structure of a 21-mer peptide ligand in complex with 2G12 Fab was determined at 2.8 angstrom resolution. Comparison of this structure with previous structures of 2G12-carbohydrate complexes revealed striking differences in the mechanism of 2G12 binding to peptide vs. carbohydrate. The peptide occupies a site different from, but adjacent to, the primary carbohydrate-binding site on 2G12, and makes only slightly fewer contacts to the Fab than Man(9)GlcNAC(2) (51 vs. 56, respectively). However, only two antibody contacts with the peptide are hydrogen bonds in contrast to six with Man(9)GlcNAC(2), and only three of the antibody residues that interact with Man(9)GlcNAC(2) also contact the peptide. Thus, this mechanism of peptide binding to 2G12 does not support structural mimicry of the native carbohydrate epitope on gp120, since it neither replicates the oligosaccharide footprint on the antibody nor most of the contact residues. Moreover, 2G12.1 peptide is not an immunogenic mimic of the 2G12 epitope, since antisera produced against it did not bind gp120.	[Menendez, Alfredo; Chow, Keith C.; Scott, Jamie K.] Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Scott, Jamie K.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada; [Calarese, Daniel A.; Stanfield, Robyn L.; Burton, Dennis R.; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA USA; [Scanlan, Chris N.; Burton, Dennis R.] Scripps Res Inst, Dept Immunol, La Jolla, CA USA; [Kunert, Renate; Katinger, Herman] Univ Nat Resources & Appl Life Sci, Inst Appl Microbiol, Vienna, Austria	Simon Fraser University; Scripps Research Institute; Simon Fraser University; Scripps Research Institute; Scripps Research Institute; University of Natural Resources & Life Sciences, Vienna	Wilson, IA (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	wilson@scripps.edu; jkscott@sfu.ca	Stanfield, Robyn/AAH-3190-2019; Kunert, Renate E/B-9185-2018	Kunert, Renate E/0000-0002-3397-3621	NIAID NIH HHS [R21 AI049808-01, AI33292, R01 AI049111-03, R01 AI049111, AI49808, R01 AI049111-01A1, R01 AI049111-02, R37 AI033292, AI49111, R01 AI033292, R21 AI049808-02] Funding Source: Medline; NIGMS NIH HHS [GM46192, R01 GM046192] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033292, R37AI033292, R21AI049808, R01AI049111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046192] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams EW, 2004, CHEM BIOL, V11, P875, DOI 10.1016/j.chembiol.2004.04.010; Barbas C.F., 2001, PHAGE DISPLAY LAB MA; Beenhouwer DO, 2002, J IMMUNOL, V169, P6992, DOI 10.4049/jimmunol.169.12.6992; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; Brett PJ, 2002, J BIOL CHEM, V277, P20468, DOI 10.1074/jbc.M200387200; Buchwald UK, 2005, INFECT IMMUN, V73, P325, DOI 10.1128/IAI.73.1.325-333.2005; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102; Clement MJ, 2003, J BIOL CHEM, V278, P47928, DOI 10.1074/jbc.M308259200; Craig L, 1998, J MOL BIOL, V281, P183, DOI 10.1006/jmbi.1998.1907; DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443; Dudkin VY, 2004, J AM CHEM SOC, V126, P9560, DOI 10.1021/ja047720g; Geng XD, 2004, ANGEW CHEM INT EDIT, V43, P2562, DOI 10.1002/anie.200353626; Haaparanta T, 1995, MOL DIVERS, V1, P39, DOI 10.1007/BF01715808; Johnson MA, 2003, J BIOL CHEM, V278, P24740, DOI 10.1074/jbc.M301846200; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; Krauss IJ, 2007, J AM CHEM SOC, V129, P11042, DOI 10.1021/ja074804r; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Lee HK, 2004, ANGEW CHEM INT EDIT, V43, P1000, DOI 10.1002/anie.200353105; Lesinski GB, 2001, VACCINE, V19, P1717, DOI 10.1016/S0264-410X(00)00397-2; Li HG, 2004, ORG BIOMOL CHEM, V2, P483, DOI 10.1039/b314565d; Lou Q, 1999, J PEPT RES, V53, P252, DOI 10.1034/j.1399-3011.1999.00025.x; Luo P, 2000, J BIOL CHEM, V275, P16146, DOI 10.1074/jbc.M909121199; Maitta RW, 2004, INFECT IMMUN, V72, P196, DOI 10.1128/IAI.72.1.196-208.2004; Mandal M, 2004, ANGEW CHEM INT EDIT, V43, P2557, DOI 10.1002/anie.200353625; Manoutcharian K, 1999, CLIN IMMUNOL, V91, P117, DOI 10.1006/clim.1998.4669; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Menendez A, 2005, ANAL BIOCHEM, V336, P145, DOI 10.1016/j.ab.2004.09.048; Menendez A, 2004, J MOL BIOL, V338, P311, DOI 10.1016/j.jmb.2004.02.051; Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; Pincus S H, 2001, Int Rev Immunol, V20, P221, DOI 10.3109/08830180109043035; Pincus SH, 1998, J IMMUNOL, V160, P293; Prinz DM, 2004, J IMMUNOL METHODS, V285, P1, DOI 10.1016/j.jim.2003.08.005; Prinz DM, 2003, IMMUNOLOGY, V110, P242, DOI 10.1046/j.1365-2567.2003.01732.x; Roux KH, 2004, MOL IMMUNOL, V41, P1001, DOI 10.1016/j.molimm.2004.05.008; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Saphire EO, 2007, J MOL BIOL, V369, P696, DOI 10.1016/j.jmb.2007.01.060; Scanlan CN, 2003, ADV EXP MED BIOL, V535, P205; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Tumanova O. Yu., 2002, Molekulyarnaya Biologiya (Moscow), V36, P657; Valadon P, 1998, J IMMUNOL, V161, P1829; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; van Houten NE, 2006, VACCINE, V24, P4188, DOI 10.1016/j.vaccine.2006.01.001; Vyas NK, 2003, P NATL ACAD SCI USA, V100, P15023, DOI 10.1073/pnas.2431286100; Wang JS, 2007, ORG BIOMOL CHEM, V5, P1529, DOI 10.1039/b702961f; Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020; Young ACM, 1997, J MOL BIOL, V274, P622, DOI 10.1006/jmbi.1997.1407; ZHONG GM, 1994, J BIOL CHEM, V269, P24183; Zwick MB, 1998, ANAL BIOCHEM, V264, P87, DOI 10.1006/abio.1998.2793; Zwick MB, 2001, J VIROL, V75, P6692, DOI 10.1128/JVI.75.14.6692-6699.2001	59	25	31	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2008	22	5					1380	1392		10.1096/fj.07-8983com	http://dx.doi.org/10.1096/fj.07-8983com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18198210	Green Accepted			2022-12-28	WOS:000255898700011
J	Singh, G; Popli, S; Hari, Y; Malhotra, P; Mukherjee, S; Bhatnagar, RK				Singh, Gatikrushna; Popli, Sonam; Hari, Yukti; Malhotra, Pawan; Mukherjee, Sunil; Bhatnagar, Raj K.			Suppression of RNA silencing by Flock house virus B2 protein is mediated through its interaction with the PAZ domain of Dicer	FASEB JOURNAL			English	Article						viral suppressors; RNAi sensor line	DOUBLE-STRANDED-RNA; SMALL INTERFERING RNA; STRUCTURAL BASIS; ANIMAL VIRUS; RECOGNITION; BINDING; CELLS; PLANT; BETANODAVIRUS; INDUCTION	RNA silencing is a conserved pathway that functions as an antiviral mechanism. The majority of viruses encode silencing suppressors that interfere with siRNA- and miRNA-guided silencing pathways. The insect flock house virus B2 protein (FHVB2) functions as an RNAi silencing suppressor that inhibits siRNA biogenesis. Here, we describe the generation of a GFP silent sensor line (Sf21) and a GFP sensor line expressing FHVB2 to study RNAi suppression mechanisms. Overexpression of FHVB2 resulted in suppression of GFP-RNAi and resumption of GFP expression. Protein fractionation studies with FHVB2-transfected cells showed that FHVB2 associates with a high-molecular-weight complex of Dicer and dsRNA/siRNAs. Yeast two-hybrid and pulldown assays revealed an interaction between FHVB2 and Drosophila Dicer proteins that appeared to involve PAZ domains. To map the FHVB2 domains interacting with Dicer, we used a 17-residue C-terminal deletion mutant. RNAi suppression was reversed in cells transfected with the FHVB2 mutant as revealed by loss of GFP. Additional yeast two-hybrid and in vitro pulldown assays confirmed that the C-terminal region of FHVB2 was involved in the interaction with the PAZ domains of Dicers. These results thus reveal a novel interaction between FHVB2 and Dicer that leads to suppression of siRNA biogenesis.-Singh, G., Popli, S., Hari, Y., Malhotra, P., Mukherjee, S., Bhatnagar, R. K. Suppression of RNA silencing by Flock house virus B2 protein is mediated through its interaction with the PAZ domain of Dicer. FASEB J. 23, 1845-1857 (2009)	[Singh, Gatikrushna; Popli, Sonam; Hari, Yukti; Malhotra, Pawan; Mukherjee, Sunil; Bhatnagar, Raj K.] Int Ctr Genet Engn & Biotechnol, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Malhotra, P (corresponding author), Int Ctr Genet Engn & Biotechnol, Aruna Asaf Ali Marg, New Delhi 110067, India.	pawanm@icgeb.res.in; sunilm@icgeb.res.in; raj@icgeb.res.in	Popli, Sonam/AAR-1900-2021; Singh, Gatikrushna/H-9639-2017	Popli, Sonam/0000-0001-7450-6862; 				Agrawal N, 2004, BIOCHEM BIOPH RES CO, V320, P428, DOI 10.1016/j.bbrc.2004.05.184; Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003; Baulcombe D, 2002, CURR BIOL, V12, pR82, DOI 10.1016/S0960-9822(02)00665-6; Baumberger N, 2007, CURR BIOL, V17, P1609, DOI 10.1016/j.cub.2007.08.039; Bennasser Y, 2005, IMMUNITY, V22, P607, DOI 10.1016/j.immuni.2005.03.010; Chao JA, 2005, NAT STRUCT MOL BIOL, V12, P952, DOI 10.1038/nsmb1005; Chen HY, 2008, EMBO REP, V9, P754, DOI 10.1038/embor.2008.118; Ding SW, 2007, CELL, V130, P413, DOI 10.1016/j.cell.2007.07.039; Dorner S, 2006, P NATL ACAD SCI USA, V103, P11880, DOI 10.1073/pnas.0605210103; Fenner BJ, 2007, J VIROL, V81, P5449, DOI 10.1128/JVI.00009-07; Fenner BJ, 2006, J VIROL, V80, P6822, DOI 10.1128/JVI.00079-06; Haasnoot J, 2007, PLOS PATHOG, V3, P794, DOI 10.1371/journal.ppat.0030086; Hemmes H, 2007, RNA, V13, P1079, DOI 10.1261/rna.444007; Karjee Sumona, 2008, V442, P187, DOI 10.1007/978-1-59745-191-8_14; Kim JK, 2005, SCIENCE, V308, P1164, DOI 10.1126/science.1109267; Lakatos L, 2004, EMBO J, V23, P876, DOI 10.1038/sj.emboj.7600096; Lakatos L, 2006, EMBO J, V25, P2768, DOI 10.1038/sj.emboj.7601164; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Li HW, 2005, FEBS LETT, V579, P5965, DOI 10.1016/j.febslet.2005.08.034; Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948; Li WX, 2004, P NATL ACAD SCI USA, V101, P1350, DOI 10.1073/pnas.0308308100; Lingel A, 2005, EMBO REP, V6, P1149, DOI 10.1038/sj.embor.7400583; Lingel A, 2004, NAT STRUCT MOL BIOL, V11, P576, DOI 10.1038/nsmb777; Lu R, 2005, NATURE, V436, P1040, DOI 10.1038/nature03870; Lu SH, 2004, J VIROL, V78, P12868, DOI 10.1128/JVI.78.23.12868-12876.2004; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; MacRae IJ, 2007, NAT STRUCT MOL BIOL, V14, P934, DOI 10.1038/nsmb1293; MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638; Martin-Hernandez AM, 2008, J VIROL, V82, P4064, DOI 10.1128/JVI.02438-07; Matzke MA, 2004, PLOS BIOL, V2, P582, DOI 10.1371/journal.pbio.0020133; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Molnar A, 2005, J VIROL, V79, P7812, DOI 10.1128/JVI.79.12.7812-7818.2005; Obbard DJ, 2006, CURR BIOL, V16, P580, DOI 10.1016/j.cub.2006.01.065; Silhavy D, 2004, TRENDS PLANT SCI, V9, P76, DOI 10.1016/j.tplants.2003.12.010; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Sullivan CS, 2005, J VIROL, V79, P7371, DOI 10.1128/JVI.79.12.7371-7379.2005; Tomoyasu Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r10; Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147; Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555; Zhang XR, 2006, GENE DEV, V20, P3255, DOI 10.1101/gad.1495506	40	60	61	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1845	1857		10.1096/fj.08-125120	http://dx.doi.org/10.1096/fj.08-125120			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19193719				2022-12-28	WOS:000266652400025
J	Huang, W; Eum, SY; Andras, IE; Hennig, B; Toborek, M				Huang, Wen; Eum, Sung Yong; Andras, Ibolya E.; Hennig, Bernhard; Toborek, Michal			PPAR alpha and PPAR gamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities	FASEB JOURNAL			English	Article						peroxisome proliferator-activated receptor; human immunodeficiency virus-1; brain endothelial cells; blood-brain barrier	BLOOD-BRAIN-BARRIER; PROLIFERATOR-ACTIVATED-RECEPTOR; TAT-INDUCED ALTERATIONS; CEREBROSPINAL-FLUID; MONOCYTE MIGRATION; ADHESION MOLECULE; ENDOTHELIAL-CELLS; ZONULA OCCLUDENS; DISRUPTION; EXPRESSION	The blood-brain barrier (BBB) plays an important role in HIV trafficking into the brain and the development of the central nervous system complications in HIV infection. Tight junctions are the main structural and functional elements that regulate the BBB integrity. Exposure of human brain microvascular endothelial cells (hCMEC/D3 cell line) to HIV-infected monocytes resulted in decreased expression of tight junction proteins, such as junctional adhesion molecule-A (JAM)-A, occludin, and zonula occludens (ZO)-1. Control experiments involved exposure to uninfected monocytes. Alterations of tight junction protein expression were associated with increased endothelial permeability and elevated transendothelial migration of HIV-infected monocytes across an in vitro model of the BBB. Notably, overexpression of the peroxisome proliferator-activated receptor (PPAR)alpha or PPAR gamma attenuated HIV-mediated dysregulation of tight junction proteins. With the use of exogenous PPAR gamma agonists and silencing of PPAR alpha or PPAR gamma, these protective effects were connected to down-regulation of matrix metalloproteinase (MMP) and proteasome activities. Indeed, the HIV-induced decrease in the expression of JAM-A and occludin was restored by inhibition of MMP activity. Moreover, both MMP and proteasome inhibitors attenuated HIV-mediated altered expression of ZO-1. The present data indicate that down-regulation of MMP and proteasome activities constitutes a novel mechanism of PPAR-induced protections against HIV-induced disruption of brain endothelial cells.-Huang, W., Eum, S. Y., Andras, I. E., Hennig, B., Toborek, M. PPAR alpha and PPAR gamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J. 23, 1596-1606 (2009)	[Toborek, Michal] Univ Kentucky, Med Ctr, Mol Neurosci & Vasc Biol Lab, Dept Neurosurg, Lexington, KY 40536 USA; [Hennig, Bernhard] Univ Kentucky, Coll Agr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Toborek, M (corresponding author), Univ Kentucky, Med Ctr, Mol Neurosci & Vasc Biol Lab, Dept Neurosurg, 593 Wethington Bldg,900 S Limestone, Lexington, KY 40536 USA.	michal.toborek@uky.edu			 [MH-63022];  [MH-072567];  [NS-39254]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063022, R01MH072567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039254] Funding Source: NIH RePORTER	; ; ; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants MH-63022, MH-072567, and NS-39254. PYK-JRCSF was obtained through the AIDS Research and Reference Reagent Program, National Institute on Aging, National Institutes of Health.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Andras IE, 2008, MOL PHARMACOL, V73, P1424, DOI 10.1124/mol.107.042028; Andras IE, 2005, J CEREBR BLOOD F MET, V25, P1159, DOI 10.1038/sj.jcbfm.9600115; Avison MJ, 2002, TRENDS NEUROSCI, V25, P468, DOI 10.1016/S0166-2236(02)02234-8; Banks WA, 2006, CURR HIV RES, V4, P259, DOI 10.2174/157016206777709447; Boven LA, 2000, NEUROPATH APPL NEURO, V26, P356, DOI 10.1046/j.1365-2990.2000.00255.x; Cabrero A., 2002, Current Drug Targets - Inflammation and Allergy, V1, P243, DOI 10.2174/1568010023344616; CANN AJ, 1990, J VIROL, V64, P4735, DOI 10.1128/JVI.64.10.4735-4742.1990; Chiba H, 2008, BBA-BIOMEMBRANES, V1778, P588, DOI 10.1016/j.bbamem.2007.08.017; Conant K, 1999, ANN NEUROL, V46, P391, DOI 10.1002/1531-8249(199909)46:3<391::AID-ANA15>3.0.CO;2-0; D Kanmogne G, 2007, J CEREBR BLOOD F MET, V27, P123, DOI 10.1038/sj.jcbfm.9600330; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; Dueck M, 2007, VIROLOGY, V361, P1, DOI 10.1016/j.virol.2007.01.018; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Garcia-Bueno B, 2005, BIOL PSYCHIAT, V57, P885, DOI 10.1016/j.biopsych.2005.01.007; Girao H, 2007, J CELL BIOCHEM, V102, P719, DOI 10.1002/jcb.21351; Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hayes MM, 2002, J BIOL CHEM, V277, P16913, DOI 10.1074/jbc.M200875200; Huang W, 2008, J NEUROCHEM, V107, P497, DOI 10.1111/j.1471-4159.2008.05626.x; Israelian-Konaraki Zarmen, 2005, Cardiol Rev, V13, P240, DOI 10.1097/01.crd.0000137255.54390.12; Kamin D, 2005, J CLIN ENDOCR METAB, V90, P3423, DOI 10.1210/jc.2005-0287; Kintscher U, 2000, EUR J PHARMACOL, V401, P259, DOI 10.1016/S0014-2999(00)00461-1; Krebs F C, 2000, Adv Pharmacol, V49, P315; Lemoine M, 2006, AIDS, V20, P387, DOI 10.1097/01.aids.0000206503.01536.11; Li AC, 2006, ANNU REV PHARMACOL, V46, P1, DOI 10.1146/annurev.pharmtox.46.120604.141247; Liuzzi GM, 2000, J NEUROVIROL, V6, P156, DOI 10.3109/13550280009013159; Lopez-Herrera A, 2005, BBA-MOL BASIS DIS, V1741, P55, DOI 10.1016/j.bbadis.2004.12.001; Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022; Lui WY, 2005, J CELL PHYSIOL, V203, P564, DOI 10.1002/jcp.20254; Lytle C, 2005, INFLAMM BOWEL DIS, V11, P231, DOI 10.1097/01.MIB.0000160805.46235.eb; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; McCoig C, 2004, PEDIATR INFECT DIS J, V23, P114, DOI 10.1097/01.inf.0000109247.67480.7a; Muranaka K, 2006, INVEST OPHTH VIS SCI, V47, P4547, DOI 10.1167/iovs.05-1432; Nagasawa M, 2007, BIOCHEM PHARMACOL, V74, P1738, DOI 10.1016/j.bcp.2007.08.020; Nakamuta S, 2008, J NEUROVIROL, V14, P186, DOI 10.1080/13550280801993630; Pascale JM, 1997, CLIN DIAGN LAB IMMUN, V4, P474, DOI 10.1128/CDLI.4.4.474-477.1997; Pereira AMM, 2005, CLIN EXP METASTAS, V22, P285, DOI 10.1007/s10585-005-8672-8; Persidsky Y, 1997, J IMMUNOL, V158, P3499; Persidsky Y, 2001, J NEUROIMMUNOL, V114, P57, DOI 10.1016/S0165-5728(00)00454-9; Persidsky Y, 2006, IMMUNOL REV, V213, P180, DOI 10.1111/j.1600-065X.2006.00440.x; Persidsky Y, 2006, BLOOD, V107, P4770, DOI 10.1182/blood-2005-11-4721; Piccinini M, 2003, CURR DRUG TARGETS, V4, P657; Ramirez SH, 2008, J IMMUNOL, V180, P1854, DOI 10.4049/jimmunol.180.3.1854; REDDY MM, 1989, J CLIN LAB ANAL, V3, P199, DOI 10.1002/jcla.1860030402; Reijerkerk A, 2006, FASEB J, V20, P2550, DOI 10.1096/fj.06-6099fje; Rhodes R H, 1991, Pathol Annu, V26 Pt 2, P247; Rizzo G, 2006, CURR OPIN PHARMACOL, V6, P421, DOI 10.1016/j.coph.2006.03.012; Rumbaugh J, 2006, FASEB J, V20, P1736, DOI 10.1096/fj.05-5619fje; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; SINGER EJ, 1994, J ACQ IMMUN DEF SYND, V7, P265; Sixt SU, 2007, AM J PHYSIOL-LUNG C, V292, pL1280, DOI 10.1152/ajplung.00140.2006; Sporer B, 1998, J INFECT DIS, V178, P854, DOI 10.1086/515342; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Takaki K, 2006, INFLAMM RES, V55, P10, DOI 10.1007/s00011-005-0002-8; Toborek M, 2005, CELL MOL NEUROBIOL, V25, P181, DOI 10.1007/s10571-004-1383-x; van Wijk JPH, 2005, ANN INTERN MED, V143, P337, DOI 10.7326/0003-4819-143-5-200509060-00009; Varley CL, 2006, J CELL PHYSIOL, V208, P407, DOI 10.1002/jcp.20676; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Wu DT, 2000, J NEUROVIROL, V6, pS82; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zhong Y, 2008, J NEUROSCI, V28, P7788, DOI 10.1523/JNEUROSCI.0061-08.2008; Zozulya AL, 2007, J IMMUNOL, V178, P520, DOI 10.4049/jimmunol.178.1.520	69	90	94	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1596	1606		10.1096/fj.08-121624	http://dx.doi.org/10.1096/fj.08-121624			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19141539	Green Published			2022-12-28	WOS:000266651700034
J	Amniai, L; Barbier, P; Sillen, A; Wieruszeski, JM; Peyrot, V; Lippens, G; Landrieu, I				Amniai, Laziza; Barbier, Pascale; Sillen, Alain; Wieruszeski, Jean-Michel; Peyrot, Vincent; Lippens, Guy; Landrieu, Isabelle			Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules	FASEB JOURNAL			English	Article						post-translational modifications; nuclear magnetic resonance spectroscopy; kinase; phosphorylation; diagnostic antibodies; unfolded protein	GLYCOGEN-SYNTHASE KINASE-3-BETA; PAIRED HELICAL FILAMENTS; MONOCLONAL-ANTIBODIES; STRUCTURAL BASIS; NMR ASSIGNMENT; PROLINE-RICH; PROTEIN-TAU; PHOSPHORYLATION; HYPERPHOSPHORYLATION; ABILITY	In Alzheimer disease (AD)-affected neurons, the Tau protein is found in an aggregated and hyperphosphorylated state. A common hypothesis is that Tau hyperphosphorylation causes its dissociation from the microtubular surface, with consequently a breakdown of the microtubules (MTs) and aggregation of the unbound Tau. We evaluated the effect of Tau phosphorylation on both tubulin assembly and MT binding. We show that the cyclin-dependent kinase 2/cyclin A3 kinase complex can generate the AT8 and AT180 AD-specific phospho-epitopes and use NMR spectroscopy to validate qualitatively and quantitatively the phospho content of our samples. The simultaneous presence of both epitopes disables the tubulin assembly capacity of Tau in conditions whereby Tau is the driving force for the assembly process but does not, however, inhibit MT assembly when the latter is driven by an increased tubulin concentration. When compared to the isolated MT binding repeats (K-d = 0.3 mu M), the phospho-Tau retains a substantial affinity for preformed MTs (K-d = 11 nM), suggesting that the phosphorylated proline-rich region still participates in the binding event. Our results hence indicate that the sole phosphorylation at the AT8/AT180 epitopes, although leading to a functional defect for Tau, is not sufficient for its dissociation from the MT surface and subsequent aggregation as observed in AD.-Amniai, L., Barbier, P., Sillen, A., Wieruszeski, J.-M., Peyrot, V., Lippens, G., Landrieu, I. Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. FASEB J. 23, 1146-1152 (2009)	[Landrieu, Isabelle] Univ Sci & Technol Lille 1, CNRS, UMR 8576, UGSF IFR 147, F-59655 Villeneuve Dascq, France; [Barbier, Pascale; Peyrot, Vincent] Univ Aix Marseille, INSERM, UMR 911, Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Landrieu, I (corresponding author), Univ Sci & Technol Lille 1, CNRS, UMR 8576, UGSF IFR 147, F-59655 Villeneuve Dascq, France.	isabelle.landrieu@univ-lille1.fr	peyrot, vincent/B-6365-2015; Barbier, Pascale/AAE-1781-2019; Landrieu, Isabelle/AAF-8495-2019	Landrieu, Isabelle/0000-0002-4883-2637; Lippens, Guy/0000-0002-8236-0901	CNRS/Region Nord-Pas de Calais (France); Region Nord; CNRS; Pasteur Institute of Lille; European Community (FEDER),; French Research Ministry; University of Sciences and Technologies of Lille I;  [ANR-05-blanc-6320-01]	CNRS/Region Nord-Pas de Calais (France)(Centre National de la Recherche Scientifique (CNRS)Region Hauts-de-France); Region Nord(Region Hauts-de-France); CNRS(Centre National de la Recherche Scientifique (CNRS)); Pasteur Institute of Lille; European Community (FEDER),(European Commission); French Research Ministry(Ministry of Research, France); University of Sciences and Technologies of Lille I; 	We thank Soazic Douillard and Diane Allegro for technical assistance; Jane Endicott and Martin Noble (University of Oxford, Oxford, UK) for providing the clones, protocols, and advice necessary to prepare the CDK2/CycA3 kinase; David Eliezer (Cornell University, Ithaca, NY, USA) for sending the K18 expression plasmid; Andre Van de Voorde for help with the AT8 and AT180 monoclonal antibodies; and Beno t Gigant and Marcel Knossow for insightful discussion on the Tau/tubulin interaction. L. A. was supported by a predoctoral fellowship of the CNRS/Region Nord-Pas de Calais (France). This work was supported by an ANR-05-blanc-6320-01 grant. The NMR facilities were funded by the Region Nord, CNRS, Pasteur Institute of Lille, European Community (FEDER), French Research Ministry, and the University of Sciences and Technologies of Lille I.	Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Ball LJ, 2005, ANGEW CHEM INT EDIT, V44, P2852, DOI 10.1002/anie.200400618; Barbier P, 1998, BIOCHEMISTRY-US, V37, P758, DOI 10.1021/bi970568t; Bienkiewicz EA, 1999, J BIOMOL NMR, V15, P203, DOI 10.1023/A:1008375029746; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Chohan MO, 2006, FEBS LETT, V580, P3973, DOI 10.1016/j.febslet.2006.06.021; Devred F, 2004, BIOCHEMISTRY-US, V43, P10520, DOI 10.1021/bi0493160; Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Landrieu I, 2006, J AM CHEM SOC, V128, P3575, DOI 10.1021/ja054656+; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Lippens G, 2004, CHEMBIOCHEM, V5, P73, DOI 10.1002/cbic.200300763; Lippens G, 2007, PRION, V1, P21, DOI 10.4161/pri.1.1.4055; Makrides V, 2004, P NATL ACAD SCI USA, V101, P6746, DOI 10.1073/pnas.0400992101; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; Preuss U, 1997, J CELL SCI, V110, P789; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; Selenko P, 2008, NAT STRUCT MOL BIOL, V15, P321, DOI 10.1038/nsmb.1395; Sengupta A, 1997, MOL CELL BIOCHEM, V167, P99, DOI 10.1023/A:1006883924775; Sillen A, 2007, BIOCHEMISTRY-US, V46, P3055, DOI 10.1021/bi061920i; Smet C, 2004, CHEMBIOCHEM, V5, P1639, DOI 10.1002/cbic.200400145; Wang YY, 2007, CHINESE J CHEM, V25, P68, DOI 10.1002/cjoc.200790019; Welburn Julie, 2004, V296, P219; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	46	68	71	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1146	1152		10.1096/fj.08-121590	http://dx.doi.org/10.1096/fj.08-121590			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19074508				2022-12-28	WOS:000266651600018
J	Edelstein, C; Philips, B; Pfaffinger, D; Scanu, AM				Edelstein, Celina; Philips, Binu; Pfaffinger, Ditta; Scanu, Angelo M.			The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin	FASEB JOURNAL			English	Article						human embryonic kidney cells; HEK 293; kringle V; monoclonal antibody T15		Lipoprotein (a) [Lp(a)], a cardiovascular risk factor, is a low-density lipoprotein (LDL) variant shown to bind to oxidized phospholipids (oxPLs); however, its binding mode and origin have not been clearly established. We isolated both LDL and Lp(a) from the plasma of a population of high-Lp(a) subjects and in each Lp(a) particle separated apolipoprotein(a) [apo(a)], from the LDL component, Lp(a(-)). These products were assayed by an ELISA using monoclonal antibody T15 with a known specificity for oxPLs. In each subject, the T15 reactivity was confined to apo(a). Moreover, the amount of oxPL bound to apo(a) was unaffected by plasma Lp(a) levels and apo(a) size polymorphism. We have previously shown that kringle V (KV) is the site of oxPL linkage in human apo(a). In this work, we expressed in human embryonic kidney cells a KV-containing recombinant that, when purified from the medium, contained oxPLs. In summary, in human plasma Lp(a), the oxPLs are located in apo(a) and not in the circulating LDLs, suggesting a cellular origin. This latter concept is supported by the studies in which an expressed KV-containing apo(a) microdomain exhibited oxPL reactivity. Thus, apo(a) can undergo potentially pathogenic posttranslational modifications in a cellular environment able to generate oxPL.-Edelstein, C., Philips, B., Pfaffinger, D., Scanu, A. M. The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin. FASEB J. 23, 950-956 (2009)	[Edelstein, Celina; Philips, Binu; Pfaffinger, Ditta; Scanu, Angelo M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Scanu, Angelo M.] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Scanu, AM (corresponding author), Univ Chicago, Dept Med, MC5041,5841 S Maryland Ave, Chicago, IL 60637 USA.	ascanu@medicine.bsd.uchicago.edu			U. S. National Institutes of Health, National Heart, Lung and Blood Institute (NIH-NLBI) [HL63200]; NIH-NHLBI Cardiovascular Pathophysiology and Biochemistry [T31 HL07237]	U. S. National Institutes of Health, National Heart, Lung and Blood Institute (NIH-NLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH-NHLBI Cardiovascular Pathophysiology and Biochemistry(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by U. S. National Institutes of Health, National Heart, Lung and Blood Institute (NIH-NLBI) grant HL63200. B. P. was supported by NIH-NHLBI Cardiovascular Pathophysiology and Biochemistry training grant T31 HL07237.	Bergmark C, 2008, J LIPID RES, V49, P2230, DOI 10.1194/jlr.M800174-JLR200; Berliner JA, 2005, NEW ENGL J MED, V353, P9, DOI 10.1056/NEJMp058118; Edelstein C, 1996, J LIPID RES, V37, P1786; Edelstein C, 2003, J BIOL CHEM, V278, P52841, DOI 10.1074/jbc.M310425200; Edelstein C, 1995, BIOCHEMISTRY-US, V34, P16483, DOI 10.1021/bi00050a032; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200; JOY ST, 2008, VASC DIS PREV, V5, P1; Klezovitch O, 2001, J BIOL CHEM, V276, P46864, DOI 10.1074/jbc.M107943200; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; PHILIPS B, 2008, VASC DIS PREV, V5, P150; PHILIPS B, 2008, ANN C ART THROMB VAS, V161, P37; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; Scanu AM, 1999, TRENDS CARDIOVAS MED, V9, P196, DOI 10.1016/S1050-1738(00)00020-7; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; Scanu AM, 2008, AM J CARDIOL, V101, p44B, DOI 10.1016/j.amjcard.2008.02.031; Scanu Angelo M, 2003, Curr Atheroscler Rep, V5, P106, DOI 10.1007/s11883-003-0081-3; Schneider M, 2005, J LIPID RES, V46, P769, DOI 10.1194/jlr.M400467-JLR200; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472; Tsimikas S, 2003, J AM COLL CARDIOL, V41, P360, DOI 10.1016/S0735-1097(02)02769-9; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	23	10	11	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					950	956		10.1096/fj.08-122002	http://dx.doi.org/10.1096/fj.08-122002			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19001055	Green Published			2022-12-28	WOS:000265506300030
J	Wu, F; Gehring, H				Wu, Fang; Gehring, Heinz			Structural requirements for novel coenzyme-substrate derivatives to inhibit intracellular ornithine decarboxylase and cell proliferation	FASEB JOURNAL			English	Article						transition-state mimics; DFMO; polyamine metabolism; pyridoxyl-amino acid analogs; drug design; anti-cancer compounds	POLYAMINE METABOLISM; ENZYME-INHIBITORS; CRYSTAL-STRUCTURE; CANCER; GROWTH; DIFLUOROMETHYLORNITHINE; ANTIBODIES; DISCOVERY; APOPTOSIS; ANALOGS	Creating transition-state mimics has proven to be a powerful strategy in developing inhibitors to treat malignant diseases in several cases. In the present study, structurally diverse coenzyme-substrate derivatives mimicking this type for pyridoxal 5'-phosphate-dependent human ornithine decarboxylase (hODC), a potential anticancer target, were designed, synthesized, and tested to elucidate the structural requirements for optimal inhibition of intracellular ODC as well as of tumor cell proliferation. Of 23 conjugates, phosphopyridoxyl- and pyridoxyl-L-tryptophan methyl ester (pPTME, PTME) proved significantly more potent in suppression proliferation (IC50 up to 25 mu M) of glioma cells (LN229) than alpha-DL-difluoromethylornithine (DFMO), a medically used irreversible inhibitor of ODC. In agreement with molecular modeling predictions, the inhibitory action of pPTME and PTME toward intracellular ODC of LN229 cells exceeded that of the previous designed lead compound POB. The inhibitory active compounds feature hydrophobic side chain fragments and a kind of polyamine motif (-NH-(CHX)(4)-NH-). In addition, they induce, as polyamine analogs often do, the activity of the polyamine catabolic enzymes polyamine oxidase and spermine/spermidine N-1-acetyltransferase up to 250 and 780%, respectively. The dual-action mode of these compounds in LN229 cells affects the intracellular polyamine metabolism and might underlie the more favorable cell proliferation inhibition in comparison with DFMO.-Wu, F., Gehring, H. Structural requirements for novel coenzyme-substrate derivatives to inhibit intracellular ornithine decarboxylase and cell proliferation. FASEB J.23, 565-574 (2009)	[Wu, Fang; Gehring, Heinz] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Gehring, H (corresponding author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	gehring@bioc.uzh.ch	Wu, Fang/B-1945-2008	Wu, Fang/0000-0002-4194-2243				Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; Amadasi A, 2007, CURR MED CHEM, V14, P1291, DOI 10.2174/092986707780597899; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Basu I, 2007, J BIOL CHEM, V282, P21477, DOI 10.1074/jbc.M702287200; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Christen P, 2001, CHEM REC, V1, P436, DOI 10.1002/tcr.10005; Dai HQ, 1999, CANCER RES, V59, P4944; Dufe VT, 2007, BIOCHEM J, V405, P261, DOI 10.1042/BJ20070188; Duranton B, 2002, CELL BIOL TOXICOL, V18, P381, DOI 10.1023/A:1020863506170; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; EWING TJA, 1998, DOCK 4 0 USER MANUAL; FLAMIGNI F, 1984, BIOCHIM BIOPHYS ACTA, V802, P245, DOI 10.1016/0304-4165(84)90168-5; GEISTLICH A, 1993, EXP CELL RES, V204, P329, DOI 10.1006/excr.1993.1040; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GLIKMAN P, 1989, CANCER RES, V49, P1371; Gramatikova S, 2002, J IMMUNOL METHODS, V269, P99, DOI 10.1016/S0022-1759(02)00227-2; Gramatikova SI, 1996, J BIOL CHEM, V271, P30583, DOI 10.1074/jbc.271.48.30583; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; HELLER JS, 1975, BIOCHIM BIOPHYS ACTA, V403, P197, DOI 10.1016/0005-2744(75)90022-4; IKAWA M, 1967, ARCH BIOCHEM BIOPHYS, V118, P497, DOI 10.1016/0003-9861(67)90378-5; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Jackson LK, 2003, BIOCHEMISTRY-US, V42, P2933, DOI 10.1021/bi026795z; KAMETANI T, 1972, J MED CHEM, V15, P203, DOI 10.1021/jm00272a021; Khomutov AR, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1159, DOI 10.1023/A:1020919525067; KHOMUTOV RM, 1971, BIOCHEM J, V124, P99, DOI 10.1042/bj1240099; KUMAGAI H, 1969, AGR BIOL CHEM TOKYO, V33, P1210, DOI 10.1080/00021369.1969.10859449; Levin VA, 2003, CLIN CANCER RES, V9, P981; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Messing E, 2006, J UROLOGY, V176, P500, DOI 10.1016/j.juro.2006.03.061; Nickel KP, 1999, CANCER LETT, V140, P105, DOI 10.1016/S0304-3835(99)00063-4; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; RASO V, 1975, BIOCHEMISTRY-US, V14, P591, DOI 10.1021/bi00674a020; Robertson JG, 2005, BIOCHEMISTRY-US, V44, P5561, DOI 10.1021/bi050247e; ROBSON LC, 1980, VITAMIN B6 METABOLIS, P205; Seiler N, 2003, CURR DRUG TARGETS, V4, P537, DOI 10.2174/1389450033490885; Silverman RB, 2008, ANGEW CHEM INT EDIT, V47, P3500, DOI 10.1002/anie.200704280; Tang L, 2005, J BIOL CHEM, V280, P31220, DOI 10.1074/jbc.M500805200; Ulrich S, 2006, CANCER RES, V66, P7348, DOI 10.1158/0008-5472.CAN-05-2777; Vlastos AT, 2005, CLIN CANCER RES, V11, P390; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wallick CJ, 2005, ONCOGENE, V24, P5606, DOI 10.1038/sj.onc.1208808; Wu F, 2008, FASEB J, V22, P890, DOI 10.1096/fj.07-9566com; Wu F, 2007, MOL CANCER THER, V6, P1831, DOI 10.1158/1535-7163.MCT-07-0045; ZHANG Z, 1991, P NATL ACAD SCI USA, V88, P10407, DOI 10.1073/pnas.88.23.10407	48	8	8	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					565	574		10.1096/fj.08-115121	http://dx.doi.org/10.1096/fj.08-115121			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18922879				2022-12-28	WOS:000262892900028
J	Bunbury, A; Potolicchio, I; Maitra, R; Santambrogio, L				Bunbury, Allyson; Potolicchio, Ilaria; Maitra, Radhashree; Santambrogio, Laura			Functional analysis of monocyte MHC class II compartments	FASEB JOURNAL			English	Article						MHCII trafficking; calcium flux; MIIC; lysosomes; cathepsins	DENDRITIC CELLS; SECRETORY LYSOSOMES; MULTIVESICULAR BODIES; ANTIGEN PRESENTATION; PLASMA-MEMBRANE; MOLECULES; COMPLEX; GRANULES; NEUTROPHILS; INVOLVEMENT	Circulating monocytes, as dendritic cell and macrophage precursors, exhibit several functions usually associated with antigen-presenting cells, such as phagocytosis and presence of endosomal/lysosomal degradative compartments particularly enriched in Lamp-1, MHC class II molecules, and other proteins related to antigen processing and MHC class II loading [MHC class II compartments (MIICs)]. Ultrastructural analysis of these organelles indicates that, differently from the multivesicular bodies present in dendritic cells, in monocytes the MIICs are characterized by a single perimetral membrane surrounding an electron-dense core. Analysis of their content reveals enrichment in myeloperoxidase, an enzyme classically associated with azurophilic granules in granulocytes and mast cell secretory lysosomes. Elevation in intracellular free calcium levels in monocytes induced secretion of beta-hexosaminidase, cathepsins, and myeloperoxidase in the extracellular milieu; surface up-regulation of MHC class II molecules; and appearance of lysosomal resident proteins. The Ca2+-regulated surface transport mechanism of MHC class II molecules observed in monocytes is different from the tubulovesicular organization of the multivesicular bodies previously reported in dendritic cells and macrophages. Hence, in monocytes, MHC class II-enriched organelles combine degradative functions typical of lysosomes and regulated secretion typical of secretory lysosomes. More important, Ca2+-mediated up-regulation of surface MHC class II molecules is accompanied by extracellular release of lysosomal resident enzymes. Bunbury, A., Potolicchio, I., Maitra, R., Santambrogio, L. Functional analysis of monocyte MHC class II compartments. FASEB J. 23, 164-171 (2009)	[Bunbury, Allyson; Potolicchio, Ilaria; Maitra, Radhashree; Santambrogio, Laura] Albert Einstein Coll Med, Dept Pathol, New York, NY USA	Yeshiva University	Santambrogio, L (corresponding author), Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lsantamb@aecom.yu.edu			U.S. National Institutes of Health; Irene Diamond Professorships in Immunology	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Irene Diamond Professorships in Immunology	This work was supported by the U.S. National Institutes of Health (L.S.) and Irene Diamond Professorships in Immunology (L.S.). The authors declare no conflicts of interest.	Barois N, 2002, TRAFFIC, V3, P894, DOI 10.1034/j.1600-0854.2002.31205.x; Calafat J, 1997, BLOOD, V90, P1255, DOI 10.1182/blood.V90.3.1255.1255_1255_1266; CALAFAT J, 1994, J CELL BIOL, V126, P967, DOI 10.1083/jcb.126.4.967; Carven GJ, 2004, J BIOL CHEM, V279, P16561, DOI 10.1074/jbc.M314315200; Dugast M, 2005, J BIOL CHEM, V280, P19656, DOI 10.1074/jbc.M501357200; FITTSCHEN C, 1994, J CLIN INVEST, V93, P247, DOI 10.1172/JCI116952; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Griffiths G, 2002, SEMIN CELL DEV BIOL, V13, P279, DOI 10.1016/S1084-9521(02)00057-5; Holt OJ, 2006, J BIOCHEM, V140, P7, DOI 10.1093/jb/mvj126; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; Kleijmeer Monique J., 1996, Methods (Orlando), V10, P191, DOI 10.1006/meth.1996.0095; McCormick PJ, 2005, P NATL ACAD SCI USA, V102, P7910, DOI 10.1073/pnas.0502206102; Murk JL, 2002, SEMIN CELL DEV BIOL, V13, P303, DOI 10.1016/S1084952102000605; Murk JLAN, 2004, TRAFFIC, V5, P936, DOI 10.1111/j.1600-0854.2004.00235.x; Murk JLAN, 2003, P NATL ACAD SCI USA, V100, P13332, DOI 10.1073/pnas.2232379100; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; Ohmura-Hoshino M, 2006, J IMMUNOL, V177, P341, DOI 10.4049/jimmunol.177.1.341; PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Polasek J, 2005, PLATELETS, V16, P500, DOI 10.1080/09537100500169926; Potolicchio H, 2005, J IMMUNOL, V175, P4935, DOI 10.4049/jimmunol.175.8.4935; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Raptis SZ, 2005, IMMUNITY, V22, P679, DOI 10.1016/j.immuni.2005.03.015; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Santambrogio L, 2005, NAT IMMUNOL, V6, P1020, DOI 10.1038/ni1250; Santambrogio L, 2006, IMMUNITY, V25, P857, DOI 10.1016/j.immuni.2006.11.007; Stern LJ, 2006, CURR OPIN IMMUNOL, V18, P64, DOI 10.1016/j.coi.2005.11.005; Stinchcombe JC, 2003, SEMIN IMMUNOL, V15, P301, DOI 10.1016/j.smim.2003.09.003; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Tapper H, 1996, J LEUKOCYTE BIOL, V59, P613, DOI 10.1002/jlb.59.5.613; Vaaraniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603; van Niel G, 2006, IMMUNITY, V25, P885, DOI 10.1016/j.immuni.2006.11.001; van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128; Vincent-Schneider H, 2001, J CELL SCI, V114, P323	36	14	15	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					164	171		10.1096/fj.08-109439	http://dx.doi.org/10.1096/fj.08-109439			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18815360	Green Published			2022-12-28	WOS:000262095500019
J	Fortin, CF; Ear, T; McDonald, PP				Fortin, Carl F.; Ear, Thornin; McDonald, Patrick P.			Autocrine role of endogenous interleukin-18 on inflammatory cytokine generation by human neutrophils	FASEB JOURNAL			English	Article						signaling pathways; granulocytes	NF-KAPPA-B; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; ANTIMICROBIAL HOST RESPONSE; MESSENGER-RNA EXPRESSION; IL-18 BINDING-PROTEIN; TUMOR-NECROSIS-FACTOR; INTERFERON-GAMMA; IFN-GAMMA; STIMULATED NEUTROPHILS; GENE-EXPRESSION	Neutrophils are key players of innate immunity and influence inflammatory and immune reactions through the production of numerous cytokines. Interleukin-18 (IL-18) is known to stimulate several neutrophil responses, and recent evidence suggests that neutrophils might represent a source of IL-18. Here, we show that neutrophils constitutively produce both IL-18 and its antagonist, IL-18BP. Cell activation does not affect IL-18BP release but leads to an increased gene expression and secretion of IL-18, a process that depends on NF-kappa B activation. Moreover, endogenous IL-18 feeds back on the neutrophils to augment cytokine generation in lipopolysaccharide-treated cells. Accordingly, exogenous IL-18 can induce the gene expression and release of several inflammatory cytokines in neutrophils, including its own expression. We finally report that IL-18 activates the p38 MAPK, MEK/ERK, and PI3K/Akt pathways in neutrophils. The IKK cascade is also activated by IL-18, resulting in I kappa B-alpha degradation, NF-kappa B activation, and RelA phosphorylation. Accordingly, these pathways contribute to the generation of inflammatory cytokines in IL-18-stimulated neutrophils. By contrast, the phosphorylation and DNA-binding activity of various STAT proteins were not induced by IL-18. Collectively, our results unveil new interactions between IL-18 and neutrophils and further support a role for these cells in influencing both innate and adaptive immunity.-Fortin, C. F., Ear, T., McDonald, P. P. Autocrine role of endogenous interleukin-18 on inflammatory cytokine generation by human neutrophils. FASEB J. 23, 194-203 (2009)	[McDonald, Patrick P.] Univ Sherbrooke, Fac Med, Div Pulm, Sherbrooke, PQ J1H 5N4, Canada; CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	McDonald, PP (corresponding author), Univ Sherbrooke, Fac Med, Div Pulm, 3001 12E Ave Nord,Piece 4849, Sherbrooke, PQ J1H 5N4, Canada.	patrick.mcdonald@usherbrooke.ca		Fortin, Carl/0000-0002-4495-7408	Canadian Arthritis Society; Canadian Foundation for Innovation; Canadian Institutes of Health Research	Canadian Arthritis Society; Canadian Foundation for Innovation(Canada Foundation for Innovation); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	C.F.F. performed the experiments, analyzed the results, drew the figures, and wrote the first draft of the article. T. E. performed the experiments; P.P.M. designed the research and wrote the final version of the article. This work was supported by grants to P.P.M. from the Canadian Arthritis Society, and from the Canadian Foundation for Innovation. C.F.F. is the recipient of a studentship from the Canadian Institutes of Health Research.	BAZZONI F, 1991, J LEUKOCYTE BIOL, V50, P223, DOI 10.1002/jlb.50.3.223; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; Cannetti CA, 2003, J IMMUNOL, V171, P1009, DOI 10.4049/jimmunol.171.2.1009; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; Cassatella MA, 1997, EUR J IMMUNOL, V27, P111, DOI 10.1002/eji.1830270117; CASSATELLA MA, 1995, EUR J IMMUNOL, V25, P1, DOI 10.1002/eji.1830250102; Cassatella MA, 1999, ADV IMMUNOL, V73, P369, DOI 10.1016/S0065-2776(08)60791-9; Chandrasekar B, 2004, BIOCHEM BIOPH RES CO, V319, P304, DOI 10.1016/j.bbrc.2004.04.185; Chandrasekar B, 2003, BIOCHEM BIOPH RES CO, V303, P1152, DOI 10.1016/S0006-291X(03)00496-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cloutier A, 2007, J LEUKOCYTE BIOL, V81, P567, DOI 10.1189/jlb.0806536; Conti B, 1999, MOL BRAIN RES, V67, P46, DOI 10.1016/S0169-328X(99)00034-0; Dai SM, 2007, ANN RHEUM DIS, V66, P1411, DOI 10.1136/ard.2006.067793; Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114; Ear T, 2005, J IMMUNOL, V175, P1834, DOI 10.4049/jimmunol.175.3.1834; Elbim C, 2005, CLIN DIAGN LAB IMMUN, V12, P436, DOI 10.1128/CDLI.12.3.436-446.2005; Ethuin F, 2004, LAB INVEST, V84, P1363, DOI 10.1038/labinvest.3700148; GASPERINI S, 1995, J INFLAMM, V45, P143; Grandjean-Laquerriere A, 2007, CYTOKINE, V37, P76, DOI 10.1016/j.cyto.2007.02.020; Hayashi N, 2007, P NATL ACAD SCI USA, V104, P14765, DOI 10.1073/pnas.0706378104; Hong TP, 2000, EUR CYTOKINE NETW, V11, P193; Hoshino T, 2007, AM J RESP CRIT CARE, V176, P49, DOI 10.1164/rccm.200603-316OC; Jablonska E, 2005, CYTOKINE, V30, P93, DOI 10.1016/j.cyto.2004.12.004; Jablonska E, 2002, IMMUNOL INVEST, V31, P159, DOI 10.1081/IMM-120016237; Jablonska E, 2001, IMMUNOL INVEST, V30, P221, DOI 10.1081/IMM-100105066; Kampfer H, 2000, EUR CYTOKINE NETW, V11, P626; KASAMA T, 1994, J IMMUNOL, V152, P3559; Kim SH, 2000, P NATL ACAD SCI USA, V97, P1190, DOI 10.1073/pnas.97.3.1190; Klein SA, 1999, CYTOKINE, V11, P451, DOI 10.1006/cyto.1998.0424; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauw FN, 2002, J IMMUNOL, V168, P372, DOI 10.4049/jimmunol.168.1.372; Lee KS, 2006, MOL PHARMACOL, V70, P1184, DOI 10.1124/mol.106.024737; Leung BP, 2001, J IMMUNOL, V167, P2879, DOI 10.4049/jimmunol.167.5.2879; Li XL, 2007, AM J PHYSIOL-LUNG C, V292, pL1193, DOI 10.1152/ajplung.00408.2006; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; Marshall JD, 1999, CLIN IMMUNOL, V90, P15, DOI 10.1006/clim.1998.4633; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; McDonald PP, 1998, BIOCHEMISTRY-US, V37, P13165, DOI 10.1021/bi972539o; McDonald PP, 1998, CELL IMMUNOL, V184, P45, DOI 10.1006/cimm.1998.1255; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; MEDA L, 1994, CELL IMMUNOL, V157, P448, DOI 10.1006/cimm.1994.1241; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Paulukat J, 2001, J IMMUNOL, V167, P7038, DOI 10.4049/jimmunol.167.12.7038; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Robertson SE, 2006, EUR J IMMUNOL, V36, P722, DOI 10.1002/eji.200535402; Scapini P, 2003, J EXP MED, V197, P297, DOI 10.1084/jem.20021343; Scapini P, 2001, EUR J IMMUNOL, V31, P1981, DOI 10.1002/1521-4141(200107)31:7<1981::AID-IMMU1981>3.0.CO;2-X; Stoll S, 1998, EUR J IMMUNOL, V28, P3231, DOI 10.1002/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-Q; Tecchio C, 2004, BLOOD, V103, P3837, DOI 10.1182/blood-2003-08-2806; TIKU K, 1986, J IMMUNOL, V136, P3677; Veenstra KG, 2002, J IMMUNOL, V168, P2282, DOI 10.4049/jimmunol.168.5.2282; Wang JM, 2007, J IMMUNOL, V178, P6777, DOI 10.4049/jimmunol.178.11.6777; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; Weijer S, 2003, INFECT IMMUN, V71, P5488, DOI 10.1128/IAI.71.10.5488-5497.2003; Wyman TH, 2002, J LEUKOCYTE BIOL, V72, P401	60	52	54	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					194	203		10.1096/fj.08-110213	http://dx.doi.org/10.1096/fj.08-110213			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18780764				2022-12-28	WOS:000262095500022
J	Hamidouche, Z; Hay, E; Vaudin, P; Charbord, P; Schule, R; Marie, PJ; Fromigue, O				Hamidouche, Zahia; Haye, Eric; Vaudin, Pascal; Charbord, Pierre; Schuele, Roland; Marie, Pierre J.; Fromigue, Olivia			FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression	FASEB JOURNAL			English	Article						osteogenesis; signaling; cell therapy	LIM-ONLY PROTEIN; OSTEOGENIC DIFFERENTIATION; STEM-CELLS; GLUCOCORTICOIDS INHIBIT; STROMAL CELLS; BONE MASS; MARROW; COACTIVATOR; DISRUPTION; INTERACTS	The differentiation of bone marrow mesenchymal stem cells (MSCs) into osteoblasts is a crucial step in bone formation. However, the mechanisms involved in the early stages of osteogenic differentiation are not well understood. In this study, we identified FHL2, a member of the LIM-only subclass of the LIM protein superfamily, that is up-regulated during early osteoblast differentiation induced by dexamethasone in murine and human MSCs. Gain-of-function studies showed that FHL2 promotes the expression of the osteoblast transcription factor Runx2, alkaline phosphatase, type I collagen, as well as in vitro extracellular matrix mineralization in murine and human mesenchymal cells. Knocking down FHL2 using sh-RNA reduces basal and dexamethasone-induced osteoblast marker gene expression in MSCs. We demonstrate that FHL2 interacts with beta-catenin, a key player involved in bone formation induced by Wnt signaling. FHL2-beta-catenin interaction potentiates beta-catenin nuclear translocation and TCF/LEF transcription, resulting in increased Runx2 and alkaline phosphatase expression, which was inhibited by the Wnt inhibitor DKK1. Reduction of Runx2 transcriptional activity using a mutant Runx2 results in inhibition of FHL2-induced alkaline phosphatase expression in MSCs. These findings reveal that FHL2 acts as an endogenous activator of mesenchymal cell differentiation into osteoblasts and mediates osteogenic differentiation induced by dexamethasone in MSCs through activation of Wnt/beta-catenin signaling-dependent Runx2 expression.-Hamidouche, Z., Hay, E., Vaudin, P., Charbord, P., Schule, R., Marie, P. J., and Fromigue, O. FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression. FASEB J. 22, 3813-3822 (2008)	[Marie, Pierre J.] Hop Lariboisiere, INSERM, U606, F-75475 Paris 10, France; [Hamidouche, Zahia; Haye, Eric; Marie, Pierre J.; Fromigue, Olivia] Univ Paris 07, Paris, France; [Vaudin, Pascal] Univ Tours, Tours, France; [Charbord, Pierre] INSERM ESPRI, Tours, France; [Schuele, Roland] Univ Frauenklin, Freiburg, Germany; [Schuele, Roland] Zentrum Klin Forsch, Freiburg, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Freiburg	Marie, PJ (corresponding author), Hop Lariboisiere, INSERM, U606, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	pierre.marie@inserm.fr	Vaudin, Pascal/J-1870-2014; Fromigue, Olivia/B-8225-2013	Fromigue, Olivia/0000-0002-3050-6155; charbord, pierre/0000-0002-2254-3300; Hay, Eric/0000-0002-0131-9983	INSERM; Etablissement Francais du Sang, France [2004-08, 2005.11]; Integrated Project of the European Commission FP6 [LSHB-CT-2003-503161]; Association Rhumatisme et Travail, Hopital Lariboisiere, Paris, France	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Etablissement Francais du Sang, France; Integrated Project of the European Commission FP6(European Commission); Association Rhumatisme et Travail, Hopital Lariboisiere, Paris, France	The authors thank Dr. J. Dennis (Case Western Reserve University, Cleveland, OH, USA) for providing the BMC10 cell line, Biopredic (Rennes, France) for the hMSCs, and Dr. G. Karsenty (Department of Genetics and Development, Columbia University, New York, NY, USA) for the gift of mutant Runx2 cDNA. This work was funded in part by INSERM, the Etablissement Francais du Sang (EFS, Scientific Council No. 2004-08 and 2005.11, France), the Integrated Project of the European Commission FP6 research funding program (contract LSHB-CT-2003-503161 GENOSTEM) and Association Rhumatisme et Travail, Hopital Lariboisiere, Paris, France.	Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080; Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070-2153(06)76004-5; BELLOWS CG, 1987, ENDOCRINOLOGY, V121, P1985, DOI 10.1210/endo-121-6-1985; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413; Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154-006-9002-4; Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284; Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016; Delorme Bruno, 2007, V140, P67; Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700; Eijken M, 2008, J CELL BIOCHEM, V104, P568, DOI 10.1002/jcb.21651; Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22-5-849; Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211; Fromigue O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873; Fromigue O, 1997, CYTOKINE, V9, P613, DOI 10.1006/cyto.1997.0209; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006-1372; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Govoni KE, 2006, CALCIFIED TISSUE INT, V79, P112, DOI 10.1007/s00223-006-0074-7; Gunther T, 2005, EMBO J, V24, P3049, DOI 10.1038/sj.emboj.7600773; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kassem M, 2008, CELL TISSUE RES, V331, P157, DOI 10.1007/s00441-007-0509-0; Kimelman N, 2006, REGEN MED, V1, P549, DOI 10.2217/17460751.1.4.549; Komori T, 2008, FRONT BIOSCI-LANDMRK, V13, P898, DOI 10.2741/2730; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Lai CF, 2006, J BONE MINER RES, V21, P17, DOI 10.1359/JBMR.050915; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Lian JB, 2003, CALCIFIED TISSUE INT, V72, P631, DOI 10.1007/s00223-002-1058-x; Lian JB, 1998, BIOCHEM SOC T, V26, P14, DOI 10.1042/bst0260014; Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186; Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025; OWEN M, 1988, J CELL SCI, P63; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Sher LB, 2006, CALCIFIED TISSUE INT, V79, P118, DOI 10.1007/s00223-005-0297-z; Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003-0655; Shibamoto S, 1998, GENES CELLS, V3, P659; Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955-2964.2006; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200; Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105-2896.2005.00332.x; Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004-1050; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200	56	127	131	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3813	3822		10.1096/fj.08-106302	http://dx.doi.org/10.1096/fj.08-106302			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18653765				2022-12-28	WOS:000260503000010
J	Wang, HW; Liu, PY; Oyama, N; Rikitake, Y; Kitamoto, S; Gitlin, J; Liao, JK; Boisvert, WA				Wang, Hong-Wei; Liu, Ping-Yen; Oyama, Naotsugu; Rikitake, Yoshiyuki; Kitamoto, Shiro; Gitlin, Jonathan; Liao, James K.; Boisvert, William A.			Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice	FASEB JOURNAL			English	Article						Rho kinase; vascular; foam cell; cell migration	LOW-DENSITY-LIPOPROTEIN; RHO-KINASE INHIBITOR; TRANSENDOTHELIAL MIGRATION; SCAVENGER RECEPTORS; ENDOTHELIAL-CELLS; IN-VIVO; MACROPHAGES; HYPERTROPHY; ACTIVATION; MECHANISM	Rho kinases (ROCKS) are serine-threonine protein kinases that regulate the actin cytoskeleton. Recent studies suggest that ROCKs also play an important role in cardiovascular disease. However, the isoform- and tissue-specific role of ROCKS in mediating this process is unknown. Using homologous recombination, we generated mutant mice harboring alleles with homozygous deletion of ROCK1 (ROCK1(-/-)). Most ROCK1(-/-) mice die perinatally. However, a few ROCK1(-/-) mice survive to adulthood, are phenotypically normal, and have no apparent compensatory changes in ROCK2. Using these ROCK1(-/-) mice, we show that ROCK1 in bone marrow-derived macrophages is critical to the development of atherosclerosis, in part, by mediating foam cell formation and macrophage chemotaxis. Lipid accumulation and atherosclerotic lesions were reduced in atherosclerosis-prone LDLR-/- mice, whose bone marrows have been replaced with bone marrows derived from ROCK1(-/-) mice. Bone marrow-derived ROCK1-deficient macrophages exhibited impaired chemotaxis to monocyte chemotactic protein-1 and showed reduced ability to take up lipids and to develop into foam cells when exposed to modified low-density lipoprotein. These findings indicate that ROCK1 in bone marrow-derived cells is a critical mediator of atherogenesis and suggest that macrophage ROCK1 may be an important therapeutic target for vascular inflammation and atherosclerosis.	Brigham & Womens Hosp, Vasc Med Res Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liao, JK (corresponding author), Brigham & Womens Hosp, 65 Landsdowne St,Rm 275, Cambridge, MA 02139 USA.	jliao@rics.bwh.harvard.edu			National Institutes of Health [HL-052233, HL-069474]; Asahi-Kasei Pharmaceuticals, Inc; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069474, R01HL052233, R01HL080187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062729] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asahi-Kasei Pharmaceuticals, Inc; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr. Daniela Ahl for help with bone marrow transplantation experiments. This study is supported by grants from the National Institutes of Health (HL-052233 to J.K.L. and HL-069474 to WAB.). J.K.L. is it consultant for Asahi-Kasei Pharmaceuticals, Inc.	Abe K, 2004, CIRC RES, V94, P385, DOI 10.1161/01.RES.0000111804.34509.94; Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Bolz SS, 2000, CIRCULATION, V102, P2402, DOI 10.1161/01.CIR.102.19.2402; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Essler M, 1999, J BIOL CHEM, V274, P30361, DOI 10.1074/jbc.274.43.30361; Fox R, 2007, EMBO J, V26, P505, DOI 10.1038/sj.emboj.7601522; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; Galbraith CG, 2007, SCIENCE, V315, P992, DOI 10.1126/science.1137904; Hagerty L, 2007, J BIOL CHEM, V282, P4884, DOI 10.1074/jbc.M609990200; Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28; Honing H, 2004, J LEUKOCYTE BIOL, V75, P523, DOI 10.1189/jlb.0203054; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Katsumata N, 1997, CIRCULATION, V96, P4357; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kruth HS, 2005, J BIOL CHEM, V280, P2352, DOI 10.1074/jbc.M407167200; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Liu PY, 2007, J AM COLL CARDIOL, V49, P1619, DOI 10.1016/j.jacc.2006.12.043; Mallat Z, 2003, CIRC RES, V93, P884, DOI 10.1161/01.RES.0000099062.55042.9A; Miyata K, 2000, ARTERIOSCL THROM VAS, V20, P2351, DOI 10.1161/01.ATV.20.11.2351; Mukai Yasushi, 2001, FASEB Journal, V15, P1062; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Noma K, 2006, AM J PHYSIOL-CELL PH, V290, pC661, DOI 10.1152/ajpcell.00459.2005; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rikitake Y, 2005, CIRCULATION, V112, P2959, DOI 10.1161/CIRCULATIONAHA.105.584623; Rikitake Y, 2005, STROKE, V36, P2251, DOI 10.1161/01.STR.0000181077.84981.11; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sandquist JC, 2006, J BIOL CHEM, V281, P35873, DOI 10.1074/jbc.M605343200; Sasaki Y, 2002, PHARMACOL THERAPEUT, V93, P225, DOI 10.1016/S0163-7258(02)00191-2; Sawada N, 2000, CIRCULATION, V101, P2030, DOI 10.1161/01.CIR.101.17.2030; Seibold S, 2004, J AM SOC NEPHROL, V15, P3026, DOI 10.1097/01.ASN.0000146425.58046.6A; Shimizu Y, 2005, J CELL BIOL, V168, P941, DOI 10.1083/jcb.200411179; Simoes RL, 2005, J IMMUNOL, V175, P1843, DOI 10.4049/jimmunol.175.3.1843; Smith A, 2003, J CELL SCI, V116, P3123, DOI 10.1242/jcs.00606; Stroeken PJM, 2006, J CELL PHYSIOL, V208, P620, DOI 10.1002/jcp.20699; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Thumkeo D, 2003, MOL CELL BIOL, V23, P5043, DOI 10.1128/MCB.23.14.5043-5055.2003; Toshima Y, 2000, STROKE, V31, P2245, DOI 10.1161/01.STR.31.9.2245; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wang YX, 2005, CIRCULATION, V111, P2219, DOI 10.1161/01.CIR.0000163544.17221.BE; Watanabe T, 2005, HYPERTENSION, V46, P738, DOI 10.1161/01.HYP.0000184226.99196.b5; White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Wustner D, 2005, TRAFFIC, V6, P396, DOI 10.1111/j.1600-0854.2005.00285.x; Yoneda A, 2005, J CELL BIOL, V170, P443, DOI 10.1083/jcb.200412043; Yoneda A, 2007, MOL BIOL CELL, V18, P66, DOI 10.1091/mbc.E06-08-0684	52	57	67	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2008	22	10					3561	3570		10.1096/fj.08-108829	http://dx.doi.org/10.1096/fj.08-108829			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18556458	Green Published			2022-12-28	WOS:000259642600018
J	Fauquier, L; Duboe, C; Jore, C; Trouche, D; Vandel, L				Fauquier, Lucas; Duboe, Carine; Jore, Cecile; Trouche, Didier; Vandel, Laurence			Dual role of the arginine methyltransferase CARM1 in the regulation of c-Fos target genes	FASEB JOURNAL			English	Article						p160 proteins; MMPs; AP-1; transcription; mRNA stability; post-transcriptional regulation	AU-RICH ELEMENTS; TRANSCRIPTIONAL COACTIVATOR; MATRIX METALLOPROTEINASES; HISTONE H3; PROTEIN; METHYLATION; ACTIVATION; SRC-1; EXPRESSION; STABILITY	Fos proteins, the prototypic members of basic region-leucine zipper ( bZIP) transcription factors, bind to other bZIP proteins to form the activator protein-1 (AP-1) complex, which regulates the expression of a plethora of target genes. Notably, c-Fos target genes include members of the matrix metalloproteinase (MMP) gene family and c-fos is overexpressed in a number of metastatic cancers, suggesting its direct involvement in this process. Here, we reveal that c-Fos-mediated transcriptional activation is regulated by the protein arginine methyltransferase CARM1 and by all three members of the p160 protein family of coactivators. Carm1-deficient cells showed a dramatic reduction in the expression level of c-Fos target genes MMP-1b, -3, and -13, indicating a major role for CARM1 in regulating the expression of these genes. RNA interference combined with quantitative polymerase chain reaction demonstrated that CARM1 and p160 proteins synergize to activate expression of MMP-1b, -3, and -13 in vivo. Furthermore, we show that CARM1 also regulates MMP expression at the post-transcriptional level, either positively or negatively. Our data indicate that CARM1 can play a dual role in the expression of AP-1 target genes involved in cancer or other diseases by acting at the transcriptional as well as at the post-transcriptional levels.	[Fauquier, Lucas; Duboe, Carine; Jore, Cecile; Vandel, Laurence] Univ Toulouse 3, CNRS, Ctr Dev Biol, UMR 5547, F-31062 Toulouse, France; [Trouche, Didier] Lab Biol Cellulaire & Mol Controle Proliferat, UMR 5088, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Vandel, L (corresponding author), Univ Toulouse 3, CNRS, Ctr Dev Biol, UMR 5547, 118 Route Narbonne, F-31062 Toulouse, France.	vandel@cict.fr		Vandel, Laurence/0000-0002-3692-2942; Trouche, Didier/0000-0003-1398-6481	Centre National de la Recherche Scientifique; Fondation pour la Recherche Medicale; Universite Paul Sabatier Toulouse; Ministere de l'Education Nationale et de la Recherche; Association pour la Recherche contre le Cancer	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Universite Paul Sabatier Toulouse; Ministere de l'Education Nationale et de la Recherche; Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer)	We are grateful to Drs. Lucas Waltzer and Julie Batut for critical reading of the manuscript and to Dr. Sandra Wenk for helpful discussions. We thank Dr. Mark Bedford (University of Texas, Smithville, TX, USA), Drs. Hinrich Gronemeyer and Claudine Gaudon (Institut de Genetique et de Biologie Moleculaire et Cellulaire, Illkirch, France), Dr. Marc Piechaczyk (Institut de Genetique Moleculaire, Montpellier, France), Dr. Michael Stallcup (University of Southern California, Los Angeles, CA, USA), Dr. Tony Kouzarides (University of Cambridge, Cambridge, UK), Dr. Rene Bernards ( The Netherlands Cancer Institute, Amsterdam, The Netherlands), and Jean-Marie Garnier and Cathie Erb (Institut de Genetique et de Biologie Moleculaire et Cellulaire, Illkirch, France) for reagents. This work was supported by an Action Thematique et Incitative sur Programme grant from the Centre National de la Recherche Scientifique and grants from the Fondation pour la Recherche Medicale and the Association pour la Recherche contre le Cancer and from Universite Paul Sabatier Toulouse to L. V. L. F. received a studentship from the Ministere de l'Education Nationale et de la Recherche and from the Association pour la Recherche contre le Cancer.	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Brook M, 2006, MOL CELL BIOL, V26, P2408, DOI 10.1128/MCB.26.6.2408-2418.2006; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Eberhardt W, 2007, PHARMACOL THERAPEUT, V114, P56, DOI 10.1016/j.pharmthera.2007.01.002; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103; Feng Q, 2006, MOL CELL BIOL, V26, P7846, DOI 10.1128/MCB.00568-06; Fujiwara T, 2006, MOL CELL BIOL, V26, P2273, DOI 10.1128/MCB.26.6.2273-2285.2006; Gebhardt C, 2005, AM J PATHOL, V167, P243, DOI 10.1016/S0002-9440(10)62969-0; Gehin M, 2002, MOL CELL BIOL, V22, P5923, DOI 10.1128/MCB.22.16.5923-5937.2002; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lee YH, 2005, P NATL ACAD SCI USA, V102, P3611, DOI 10.1073/pnas.0407159102; Lemaitre Vincent, 2006, Birth Defects Research, V78, P1, DOI 10.1002/bdrc.20065; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Levy N, 2008, MOL ENDOCRINOL, V22, P287, DOI 10.1210/me.2007-0340; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Naeem H, 2007, MOL CELL BIOL, V27, P120, DOI 10.1128/MCB.00815-06; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Nishihara E, 2003, J NEUROSCI, V23, P213; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Pullmann R, 2005, J BIOL CHEM, V280, P22819, DOI 10.1074/jbc.M501106200; Rydziel S, 2004, J BIOL CHEM, V279, P5397, DOI 10.1074/jbc.M311984200; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105-2896.2005.00332.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948; Zika E, 2005, P NATL ACAD SCI USA, V102, P16321, DOI 10.1073/pnas.0505045102	52	19	19	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3337	3347		10.1096/fj.07-104604	http://dx.doi.org/10.1096/fj.07-104604			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18511550				2022-12-28	WOS:000258761300026
J	Liu, F; Liang, ZH; Wegiel, J; Hwang, YW; Iqbal, K; Grundke-Iqbal, I; Ramakrishna, N; Gong, CX				Liu, Fei; Liang, Zhihou; Wegiel, Jerzy; Hwang, Yu-Wen; Iqbal, Khalid; Grundke-Iqbal, Inge; Ramakrishna, Narayan; Gong, Cheng-Xin			Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome	FASEB JOURNAL			English	Article						tau; hyperphosphorylation; GSK-3 beta; trisomy 21	PAIRED HELICAL FILAMENTS; SYNDROME CRITICAL REGION; ALZHEIMERS-DISEASE; PROTEIN-TAU; SUBCELLULAR-LOCALIZATION; PHOSPHORYLATES TAU; REGULATED KINASE; FUNCTIONAL-LINK; HUMAN HOMOLOG; BRAIN	Adults with Down syndrome (DS) develop Alzheimer neurofibrillary degeneration in the brain, but the underlying molecular mechanism is unknown. Here, we report that the presence of an extra copy of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A (Dyrk1A) gene due to trisomy 21 resulted in overexpression of Dyrk1A and elevated kinase activity in DS brain. Dyrk1A phosphorylated tau at several sites, and these sites were hyperphosphorylated in adult DS brains. Phosphorylation of tau by Dyrk1A primed its further phosphorylation by glycogen synthase kinase-3 beta (GSK-3 beta). Dyrk1A-induced tau phosphorylation inhibited tau's biological activity and promoted its self-aggregation. In Ts65Dn mouse brain, an extra copy of the Dyrk1A gene caused increased expression and activity of Dyrk1A and resulted in increased tau phosphorylation. These findings strongly suggest a novel mechanism by which the overexpression of Dyrk1A in DS brain causes neurofibrillary degeneration via hyperphosphorylating tau.	[Liu, Fei; Liang, Zhihou; Iqbal, Khalid; Grundke-Iqbal, Inge; Gong, Cheng-Xin] New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA; [Wegiel, Jerzy] New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA; [Hwang, Yu-Wen; Ramakrishna, Narayan] New York State Inst Basic Res Dev Disabil, Dept Mol Biol, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities; Institute for Basic Research in Developmental Disabilities; Institute for Basic Research in Developmental Disabilities	Gong, CX (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	cxgong@mail.csi.cuny.edu			New York State Office of Mental Retardation and Developmental Disabilities; U. S. National Institutes of Health [AG027429, HD043960, HD038295, AG019158]; U. S. Alzheimer's Association [IIRG-05-13095]; Li Foundation, Inc.; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038295, R01HD043960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027429, R01AG019158] Funding Source: NIH RePORTER	New York State Office of Mental Retardation and Developmental Disabilities; U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U. S. Alzheimer's Association(Alzheimer's Association); Li Foundation, Inc.; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in part, by the New York State Office of Mental Retardation and Developmental Disabilities and by grants from the U. S. National Institutes of Health (AG027429 to C.-X. G., HD043960 to J.W., HD038295 to Y.-W. H., AG019158 to K. I.), the U. S. Alzheimer's Association (IIRG-05-13095 to C.-X. G.) and the Li Foundation, Inc. ( to C.-X. G.). We thank Dr. A. del C. Alonso for help with electron microscopy, Dr. D. Miller for support and advice, Dr. E. El-Akkad for preparation of recombinant tau<INF>441</INF>, Dr. J. Currie for critical reading of the manuscript and suggestions, Ms. M. Marlow for editorial suggestions, and Ms. J. Murphy for secretarial assistance.	Ahn KJ, 2006, NEUROBIOL DIS, V22, P463, DOI 10.1016/j.nbd.2005.12.006; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678; Avila Jesus, 2007, Expert Rev Neurother, V7, P1527, DOI 10.1586/14737175.7.11.1527; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Chen-Hwang MC, 2002, J BIOL CHEM, V277, P17597, DOI 10.1074/jbc.M111101200; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Davisson M T, 1993, Prog Clin Biol Res, V384, P117; de Graaf Katrin, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-7; Dowjat WK, 2007, NEUROSCI LETT, V413, P77, DOI 10.1016/j.neulet.2006.11.026; Ermak G, 2006, FEBS J, V273, P2100, DOI 10.1111/j.1742-4658.2006.05217.x; Ferrer I, 2005, NEUROBIOL DIS, V20, P392, DOI 10.1016/j.nbd.2005.03.020; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; Gong CX, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/31825; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GONG CX, 1994, J NEUROCHEM, V62, P803; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; Guimera J, 1996, HUM MOL GENET, V5, P1305, DOI 10.1093/hmg/5.9.1305; Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631; Hammerle B, 2003, EUR J NEUROSCI, V17, P2277, DOI 10.1046/j.1460-9568.2003.02665.x; Hanger DP, 2007, J BIOL CHEM, V282, P23645, DOI 10.1074/jbc.M703269200; Harris CD, 2005, CELL MOL LIFE SCI, V62, P2477, DOI 10.1007/s00018-005-5085-4; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Holland AJ, 1998, BRIT J PSYCHIAT, V172, P493, DOI 10.1192/bjp.172.6.493; Huang Y, 2004, BIOCHEMISTRY-US, V43, P10173, DOI 10.1021/bi036060+; Kannanayakal TJ, 2008, NEUROSCI LETT, V431, P141, DOI 10.1016/j.neulet.2007.11.066; Kannanayakal TJ, 2006, ACTA NEUROPATHOL, V111, P413, DOI 10.1007/s00401-006-0049-9; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; Kim EJ, 2006, J BIOL CHEM, V281, P33250, DOI 10.1074/jbc.M606147200; Kimura R, 2007, HUM MOL GENET, V16, P15, DOI 10.1093/hmg/ddl437; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Liu F, 2002, NEUROSCIENCE, V115, P829, DOI 10.1016/S0306-4522(02)00510-9; Liu F, 2007, EUR J NEUROSCI, V26, P3429, DOI 10.1111/j.1460-9568.2007.05955.x; Liu SJ, 2004, J BIOL CHEM, V279, P50078, DOI 10.1074/jbc.M406109200; Marti E, 2003, BRAIN RES, V964, P250, DOI 10.1016/S0006-8993(02)04069-6; Murakami N, 2006, J BIOL CHEM, V281, P23712, DOI 10.1074/jbc.M513497200; Olson LE, 2004, SCIENCE, V306, P687, DOI 10.1126/science.1098992; Park J, 2007, MOL CELL NEUROSCI, V36, P270, DOI 10.1016/j.mcn.2007.07.007; Perez M, 2002, EUR J BIOCHEM, V269, P1484, DOI 10.1046/j.1432-1033.2002.02794.x; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Riley KP, 2002, ANN NEUROL, V51, P567, DOI 10.1002/ana.10161; Ryoo SR, 2008, J NEUROCHEM, V104, P1333, DOI 10.1111/j.1471-4159.2007.05075.x; Ryoo SR, 2007, J BIOL CHEM, V282, P34850, DOI 10.1074/jbc.M707358200; Shukkur EA, 2006, HUM MOL GENET, V15, P2752, DOI 10.1093/hmg/ddl211; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; Takashima A, 2006, J ALZHEIMERS DIS, V9, P309; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tatebayashi Y, 1999, J NEUROSCI, V19, P5245; Wegiel J, 2004, BRAIN RES, V1010, P69, DOI 10.1016/j.brainres.2004.03.008; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	60	165	171	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3224	3233		10.1096/fj.07-104539	http://dx.doi.org/10.1096/fj.07-104539			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18509201	Green Published			2022-12-28	WOS:000258761300015
J	Bjork, K; Rimondini, R; Hansson, AC; Terasmaa, A; Hyytia, P; Heilig, M; Sommer, WH				Bjork, K.; Rimondini, R.; Hansson, A. C.; Terasmaa, A.; Hyytia, P.; Heilig, M.; Sommer, W. H.			Modulation of voluntary ethanol consumption by beta-arrestin 2	FASEB JOURNAL			English	Article						alcoholism; animal model; brain; gene expression; ethanol preference	C-FOS EXPRESSION; NUCLEUS-ACCUMBENS; ANTISENSE OLIGONUCLEOTIDE; MORPHINE ANALGESIA; ALCOHOL-DRINKING; ANIMAL-MODELS; DOPAMINE; GENES; TRANSMISSION; GENETICS	Beta-arrestin 2 is a multifunctional key component of the G protein-coupled receptor complex and is involved in mu-opiate and dopamine D2 receptor signaling, both of which are thought to mediate the rewarding effects of ethanol consumption. We identified elevated expression of the beta-arrestin 2 gene (Arrb2) in the striatum and the hippocampus of ethanol-preferring AA rats compared to their nonpreferring counterpart ANA line. Differential mRNA expression was accompanied by different levels of Arrb2 protein. The elevated expression was associated with a 7-marker haplotype in complete linkage disequilibrium, which segregated fully between the lines, and was unique to the preferring line. Furthermore, a single, distinct, and highly significant quantitative trait locus for Arrb2 expression in hippocampus and striatum was identified at the locus of this gene, providing evidence that genetic variation may affect a cis-regulatory mechanism for expression and regional control of Arrb2. These findings were functionally validated using mice lacking Arrb2, which displayed both reduced voluntary ethanol consumption and ethanol-induced psychomotor stimulation. Our results demonstrate that beta-arrestin 2 modulates acute responses to ethanol and is an important mediator of ethanol reward.	[Bjork, K.; Hansson, A. C.; Terasmaa, A.; Heilig, M.; Sommer, W. H.] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA; [Bjork, K.; Rimondini, R.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Hyytia, P.] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Karolinska Institutet; Finland National Institute for Health & Welfare	Sommer, WH (corresponding author), NIAAA, Lab Clin & Translat Studies, NIH, 10 Ctr Dr,B 10,R 15330, Bethesda, MD 20892 USA.	wolfgang.sommer@mail.nih.gov	Terasmaa, Anton/I-3312-2015; Tanda, Gianluigi/Q-4976-2019; Rimondini, Roberto/B-2500-2010; Sommer, Wolfgang H./I-4809-2019; Hansson, Anita C/K-8146-2013; Tanda, Gianluigi/B-3318-2009; roberto, rimondini/AAC-3525-2019	Terasmaa, Anton/0000-0002-5139-1764; Tanda, Gianluigi/0000-0001-9526-9878; Rimondini, Roberto/0000-0003-4099-513X; Sommer, Wolfgang H./0000-0002-5903-6521; Tanda, Gianluigi/0000-0001-9526-9878; roberto, rimondini/0000-0003-4099-513X; Hyytia, Petri/0000-0002-0284-1298	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arlinde C, 2004, PHARMACOGENOMICS J, V4, P208, DOI 10.1038/sj.tpj.6500243; Beaulieu JM, 2007, TRENDS PHARMACOL SCI, V28, P166, DOI 10.1016/j.tips.2007.02.006; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Bjork K, 2006, FASEB J, V20, P1826, DOI 10.1096/fj.06-5896com; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2003, J NEUROSCI, V23, P10265; Bontempi B, 1997, J NEUROSCI, V17, P8596; Chesler EJ, 2004, NAT NEUROSCI, V7, P485, DOI 10.1038/nn0504-485; Crabbe JC, 2006, ADDICT BIOL, V11, P195, DOI 10.1111/j.1369-1600.2006.00038.x; Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032; Edenberg HJ, 2006, ADDICT BIOL, V11, P386, DOI 10.1111/j.1369-1600.2006.00035.x; Egli M, 2005, ADDICT BIOL, V10, P309, DOI 10.1080/13556210500314550; Enoch Mary-Anne, 2003, Am J Pharmacogenomics, V3, P217, DOI 10.2165/00129785-200303040-00001; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Garcia MM, 2003, NEUROSCIENCE, V119, P787, DOI 10.1016/S0306-4522(02)00975-2; Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635; Gurevich EV, 2002, NEUROSCIENCE, V109, P421, DOI 10.1016/S0306-4522(01)00511-5; Hall FS, 2001, PSYCHOPHARMACOLOGY, V154, P43, DOI 10.1007/s002130000622; Hansson AC, 2003, J NEUROSCI, V23, P6013, DOI 10.1523/JNEUROSCI.23-14-06013.2003; HANSSON AC, 2008, J EUR NEUROSCI, DOI DOI 10.1111/J1460-9568.2008.06159.X; Hansson AC, 2007, NEUROPSYCHOPHARMACOL, V32, P117, DOI 10.1038/sj.npp.1301034; HEILIG M, 1993, EUR J PHARMACOL, V236, P339, DOI 10.1016/0014-2999(93)90610-T; HUGHES P, 1995, PHARMACOL REV, V47, P133; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Jiang BH, 2006, NEUROSCI LETT, V400, P150, DOI 10.1016/j.neulet.2006.02.071; JOHNSON SW, 1992, J NEUROSCI, V12, P483; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KIIANMAA K, 1979, PHARMACOL BIOCHEM BE, V10, P603, DOI 10.1016/0091-3057(79)90240-5; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; Moller C, 1997, ALCOHOL CLIN EXP RES, V21, P656, DOI 10.1111/j.1530-0277.1997.tb03818.x; Muller MM, 2006, P NATL ACAD SCI USA, V103, P14250, DOI 10.1073/pnas.0606668103; Okvist A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000930; Oswald LM, 2004, PHYSIOL BEHAV, V81, P339, DOI 10.1016/j.physbeh.2004.02.008; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Peirce JL, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-7; Peoples RW, 1996, ANNU REV PHARMACOL, V36, P185, DOI 10.1146/annurev.pa.36.040196.001153; RASSNICK S, 1993, BRAIN RES, V623, P16, DOI 10.1016/0006-8993(93)90004-7; Roberts AJ, 2000, J PHARMACOL EXP THER, V293, P1002; Saba L, 2006, MAMM GENOME, V17, P669, DOI 10.1007/s00335-005-0190-0; SOMMER W, 1993, NEUROREPORT, V5, P277, DOI 10.1097/00001756-199312000-00024; Sommer W, 1996, P NATL ACAD SCI USA, V93, P14134, DOI 10.1073/pnas.93.24.14134; Sommer W, 2006, ADDICT BIOL, V11, P289, DOI 10.1111/j.1369-1600.2006.00037.x; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Sumner BEH, 2004, PSYCHOPHARMACOLOGY, V171, P306, DOI 10.1007/s00213-003-1579-7; Tanda GL, 1998, EUR J NEUROSCI, V10, P1179, DOI 10.1046/j.1460-9568.1998.00135.x; ULM RR, 1995, J CLIN PSYCHIAT, V56, P5; Wang JT, 2003, NEUROINFORMATICS, V1, P299, DOI 10.1385/NI:1:4:299; WEISS F, 1993, J PHARMACOL EXP THER, V267, P250	54	30	30	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2552	2560		10.1096/fj.07-102442	http://dx.doi.org/10.1096/fj.07-102442			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18367649				2022-12-28	WOS:000257292500046
J	Maedler, K; Schulthess, FT; Bielman, C; Berney, T; Bonny, C; Prentki, M; Donath, MY; Roduit, R				Maedler, Kathrin; Schulthess, Fabienne T.; Bielman, Christelle; Berney, Thierry; Bonny, Christophe; Prentki, Marc; Donath, Marc Y.; Roduit, Raphael			Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases	FASEB JOURNAL			English	Article						diabetes; islets; capase 1	HUMAN PANCREATIC-ISLETS; MESSENGER-RNA LEVELS; CHRONIC HYPERGLYCEMIA; CHRONIC EXPOSURE; PROLONGED EXPOSURE; OXIDATIVE STRESS; GENE-EXPRESSION; NORMAL RATS; JNK; TOXICITY	c-Jun N-terminal kinases (SAPK/JNKs) are activated by inflammatory cytokines, and JNK signaling is involved in insulin resistance and beta-cell secretory function and survival. Chronic high glucose concentrations and leptin induce interleukin-1 beta (IL-1 beta) secretion from pancreatic islets, an event that is possibly causal in promoting beta-cell dysfunction and death. The present study provides evidence that chronically elevated concentrations of leptin and glucose induce beta-cell apoptosis through activation of the JNK pathway in human islets and in insulinoma (INS 832/13) cells. JNK inhibition by the dominant inhibitor JNK-binding domain of IB1/JIP-1 (JNKi) reduced JNK activity and apoptosis induced by leptin and glucose. Exposure of human islets to leptin and high glucose concentrations leads to a decrease of glucose-induced insulin secretion, which was partly restored by JNKi. We detected an interplay between the JNK cascade and the caspase 1/IL-1 beta-converting enzyme in human islets. The caspase 1 gene, which contains a potential activating protein-1 binding site, was up-regulated in pancreatic sections and in isolated islets from type 2 diabetic patients. Similarly, cultured human islets exposed to high glucose- and leptin-induced caspase 1 and JNK inhibition prevented this up-regulation. Therefore, JNK inhibition may protect beta-cells from the deleterious effects of high glucose and leptin in diabetes.	[Maedler, Kathrin; Schulthess, Fabienne T.] Univ Calif Los Angeles, Larry L Hillblom Islet Res Ctr, Los Angeles, CA USA; [Bielman, Christelle; Bonny, Christophe] Ctr Hosp Univ Vaudois Lausanne, Med Genet Serv, Lausanne, France; [Bonny, Christophe] Ctr Med Univ Geneva, Dept Surg, Geneva, Switzerland; [Prentki, Marc] Univ Montreal, Mol Nutr Unit, Montreal, PQ, Canada; [Prentki, Marc] Univ Montreal, Montreal Diabet Res Ctr, Montreal, PQ, Canada; [Prentki, Marc] Univ Montreal, Ctr Rech CHUM, Montreal, PQ, Canada; [Prentki, Marc] Univ Montreal, Dept Biochem & Nutr, Montreal, PQ, Canada; [Donath, Marc Y.] Univ Zurich, Univ Zurich Hosp, Div Endocrinol & Diabet, CH-8006 Zurich, Switzerland; [Roduit, Raphael] Inst Rech Ophtalmol, Sion, Switzerland	University of California System; University of California Los Angeles; University of Geneva; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Zurich; University Zurich Hospital	Maedler, K (corresponding author), Univ Bremen, Ctr Biomol Interactions Bremen, NW2,Box 33 04 40, D-28334 Bremen, Germany.	kmaedler@uni-bremen.de	Maedler, Kathrin/ABE-3022-2021; Bonny, Christophe/AAV-7214-2021; Berney, Thierry/ABE-9450-2021; Roduit, Raphael/AAC-3890-2021	Maedler, Kathrin/0000-0002-7436-1197; Berney, Thierry/0000-0002-4230-9378; Roduit, Raphael/0000-0001-7440-2799				Abdelli S, 2004, DIABETES, V53, P2815, DOI 10.2337/diabetes.53.11.2815; Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; Beltowski J, 2006, ATHEROSCLEROSIS, V189, P47, DOI 10.1016/j.atherosclerosis.2006.03.003; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Butler AE, 2004, DIABETES, V53, P1509, DOI 10.2337/diabetes.53.6.1509; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; De Marinis L, 2004, J CLIN ENDOCR METAB, V89, P174, DOI 10.1210/jc.2002-021308; Donath MY, 1999, DIABETES, V48, P738, DOI 10.2337/diabetes.48.4.738; Donath MY, 2005, DIABETES, V54, pS108, DOI 10.2337/diabetes.54.suppl_2.S108; Donath MY, 2004, DIABETOLOGIA, V47, P581, DOI 10.1007/s00125-004-1336-4; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; Eldor R, 2006, DIABETES RES CLIN PR, V74, pS3, DOI 10.1016/j.diabres.2006.06.004; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Haefliger JA, 2003, J CELL SCI, V116, P1463, DOI 10.1242/jcs.00356; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hotamisligil GS, 2005, DIABETES, V54, pS73, DOI 10.2337/diabetes.54.suppl_2.S73; Ingelsson E, 1998, IMMUNOL LETT, V63, P125, DOI 10.1016/S0165-2478(98)00062-5; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KAISER N, 1991, ENDOCRINOLOGY, V129, P2067, DOI 10.1210/endo-129-4-2067; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Koyama K, 1997, DIABETES, V46, P1276, DOI 10.2337/diabetes.46.8.1276; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; LEAHY JL, 1988, DIABETES, V37, P217, DOI 10.2337/diabetes.37.2.217; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Linetsky E, 1997, DIABETES, V46, P1120, DOI 10.2337/diabetes.46.7.1120; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; Lupi R, 1999, BIOCHEM BIOPH RES CO, V256, P637, DOI 10.1006/bbrc.1999.0384; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Maedler K, 2004, P NATL ACAD SCI USA, V101, P8138, DOI 10.1073/pnas.0305683101; Maedler K, 2001, DIABETES, V50, P69, DOI 10.2337/diabetes.50.1.69; Maedler K, 2001, DIABETES, V50, P1683, DOI 10.2337/diabetes.50.8.1683; Major CD, 2001, DIABETES, V50, P2721, DOI 10.2337/diabetes.50.12.2721; Marshak S, 1999, DIABETES, V48, P1230, DOI 10.2337/diabetes.48.6.1230; Matarese G., 2002, Current Drug Targets - Inflammation and Allergy, V1, P13, DOI 10.2174/1568010023344931; MINE T, 2004, DIABETES S2, V53, P2475; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Nikulina MA, 2003, CYTOKINE, V24, P13, DOI 10.1016/S1043-4666(03)00242-4; Oberholzer J, 2000, TRANSPLANTATION, V69, P1115, DOI 10.1097/00007890-200003270-00016; Otero M, 2005, FEBS LETT, V579, P295, DOI 10.1016/j.febslet.2004.11.024; Pallett AL, 1997, BIOCHEM BIOPH RES CO, V238, P267, DOI 10.1006/bbrc.1997.7274; Papaccio G, 2005, J CELL PHYSIOL, V203, P94, DOI 10.1002/jcp.20198; Pickup JC, 2000, CLIN ENDOCRINOL, V52, P107, DOI 10.1046/j.1365-2265.2000.00921.x; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; ROBERTSON RP, 1992, J CLIN INVEST, V90, P320, DOI 10.1172/JCI115865; ROBERTSON RP, 1989, DIABETES, V38, P1501, DOI 10.2337/diabetes.38.12.1501; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; Roduit R, 1997, FEBS LETT, V415, P179, DOI 10.1016/S0014-5793(97)01115-0; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Seufert J, 2004, DIABETES, V53, pS152, DOI 10.2337/diabetes.53.2007.S152; Seufert J, 1999, J CLIN ENDOCR METAB, V84, P670, DOI 10.1210/jc.84.2.670; Seufert J, 1999, P NATL ACAD SCI USA, V96, P674, DOI 10.1073/pnas.96.2.674; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P9558, DOI 10.1073/pnas.95.16.9558; Storling J, 2005, ENDOCRINOLOGY, V146, P3026, DOI 10.1210/en.2005-0036; Tajiri Y, 1997, ENDOCRINOLOGY, V138, P273, DOI 10.1210/en.138.1.273; UNGER RH, 1985, DIABETOLOGIA, V28, P119; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513	68	84	92	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1905	1913		10.1096/fj.07-101824	http://dx.doi.org/10.1096/fj.07-101824			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18263705	Green Accepted			2022-12-28	WOS:000256352700030
J	Luque-Ortega, JR; van't Hof, W; Veerman, ECI; Saugar, JM; Rivas, L				Roman Luque-Ortega, Juan; van't Hof, Wim; Veerman, Enno C. I.; Saugar, Jose M.; Rivas, Luis			Human antimicrobial peptide histatin 5 is a cell-penetrating peptide targeting mitochondrial ATP synthesis in Leishmania	FASEB JOURNAL			English	Article						bioenergetics; ATP synthase; Trypanosomatidae; histidine-rich peptide	CANDIDA-ALBICANS; DONOVANI PROMASTIGOTES; INTRACELLULAR DELIVERY; CONTAINING MOUTHRINSE; MICROBIAL EVALUATION; ANTIFUNGAL ACTIVITY; MEMBRANE; MELITTIN; PROTEINS; MECHANISM	Histatin 5 (Hst5) is a human salivary antimicrobial peptide that targets fungal mitochondria. In the human parasitic protozoa Leishmania, the mitochondrial ATP production is essential, as it lacks the bioenergetic switch between glycolysis and oxidative phosphorylation described in some yeasts. On these premises, Hst5 activity was assayed on both stages of its life cycle, promastigotes and amastigotes (LC50 = 7.3 and 14.4 mu M, respectively). In a further step, its lethal mechanism was studied. The main conclusions drawn were as follows: 1) Hst5 causes limited and temporary damage to the plasma membrane of the parasites, as assessed by electron microscopy, depolarization, and entrance of the vital dye SYTOX Green; 2) Hst5 translocates into the cytoplasm of Leishmania in an achiral receptor-independent manner with accumulation into the mitochondrion, as shown by confocal microscopy; and 3) Hst5 produces a bioenergetic collapse of the parasite, caused essentially by the decrease of mitochondrial ATP synthesis through inhibition of F1F0-ATPase, with subsequent fast ATP exhaustion. By using the Hst5 enantiomer, it was found that the key steps of its lethal mechanism involved no chiral recognition. Hst5 thus constitutes the first leishmanicidal peptide with a defined nonstereospecific intracellular target. The prospects of its development, by its own or as a carrier molecule for other leishmanicidal molecules, into a novel anti-Leishmania drug with a preferential subcellular accumulation are discussed.	[van't Hof, Wim; Veerman, Enno C. I.] Acad Ctr Dent Amsterdam, Dept Oral Biochem, NL-1066 EA Amsterdam, Netherlands; [Roman Luque-Ortega, Juan; Saugar, Jose M.; Rivas, Luis] CSIC, Ctr Invest Biol, Madrid 28040, Spain	Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Rivas, L (corresponding author), CSIC, Ctr Invest Biol, Ramiro Maeztu 9, Madrid 28040, Spain.	luis.rivas@cib.csic.es	Rivas, Luis/O-8657-2017; Saugar, Jose M./C-7047-2008; Ortega, Juan Roman Luque/M-7583-2019	Rivas, Luis/0000-0002-2958-3233; Saugar, Jose M./0000-0001-8950-5766; 				Alberio SO, 2004, PARASITOL RES, V92, P246, DOI 10.1007/s00436-003-1027-y; Alvar J, 2006, TRENDS PARASITOL, V22, P552, DOI 10.1016/j.pt.2006.09.004; Alvarez-Fortes E, 1998, MOL BIOCHEM PARASIT, V93, P191, DOI 10.1016/S0166-6851(98)00029-2; Baev D, 2004, J BIOL CHEM, V279, P55060, DOI 10.1074/jbc.M411031200; Baev D, 2002, INFECT IMMUN, V70, P4777, DOI 10.1128/IAI.70.9.4777-4784.2002; Basu MK, 2004, CURR MOL MED, V4, P681, DOI 10.2174/1566524043360186; Bera A, 2003, MOL BIOCHEM PARASIT, V127, P23, DOI 10.1016/S0166-6851(02)00300-6; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; Chicharro C, 2001, ANTIMICROB AGENTS CH, V45, P2441, DOI 10.1128/AAC.45.9.2441-2449.2001; Corradin S, 2002, BIOCHEM J, V367, P761, DOI 10.1042/BJ20020386; DAS A, 1993, MOL BIOCHEM PARASIT, V60, P293, DOI 10.1016/0166-6851(93)90140-S; den Hertog AL, 2004, BIOCHEM J, V379, P665, DOI 10.1042/BJ20031785; Diaz-Achirica P, 1998, BIOCHEM J, V330, P453, DOI 10.1042/bj3300453; DIAZACHIRICA P, 1994, EUR J BIOCHEM, V224, P257, DOI 10.1111/j.1432-1033.1994.tb20019.x; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; Fitzgerald-Hughes DH, 2007, ANTIMICROB AGENTS CH, V51, P2793, DOI 10.1128/AAC.00094-07; Ghosh S, 2003, BIOCHEM J, V369, P447, DOI 10.1042/BJ20021684; Gledhill JR, 2005, BIOCHEM J, V386, P591, DOI 10.1042/BJ20041513; Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007; Gyurko C, 2000, ANTIMICROB AGENTS CH, V44, P348, DOI 10.1128/AAC.44.2.348-354.2000; Handman E, 2000, ADV PARASIT, V44, P1; Hannaert Veronique, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated; Haukland HH, 2001, FEBS LETT, V508, P389, DOI 10.1016/S0014-5793(01)03100-3; Helmerhorst EJ, 1999, J BIOL CHEM, V274, P7286, DOI 10.1074/jbc.274.11.7286; Helmerhorst EJ, 2001, J BIOL CHEM, V276, P5643, DOI 10.1074/jbc.M008229200; Helmerhorst EJ, 2001, P NATL ACAD SCI USA, V98, P14637, DOI 10.1073/pnas.141366998; Huang HW, 2006, BBA-BIOMEMBRANES, V1758, P1292, DOI 10.1016/j.bbamem.2006.02.001; Kavanagh K, 2004, J PHARM PHARMACOL, V56, P285, DOI 10.1211/0022357022971; Koczan G, 2002, BIOCONJUGATE CHEM, V13, P518, DOI 10.1021/bc015530e; Koshlukova SE, 1999, J BIOL CHEM, V274, P18872, DOI 10.1074/jbc.274.27.18872; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Li XWS, 2006, J BIOL CHEM, V281, P22453, DOI 10.1074/jbc.M604064200; Li XWS, 2003, J BIOL CHEM, V278, P28553, DOI 10.1074/jbc.M300680200; Luque-Ortega JR, 2004, ANTIMICROB AGENTS CH, V48, P1534, DOI 10.1128/AAC.48.5.1534-1540.2004; Luque-Ortega JR, 2003, BIOCHEM J, V375, P221, DOI 10.1042/BJ20030544; Luque-Ortega JR, 2001, ANTIMICROB AGENTS CH, V45, P1121, DOI 10.1128/AAC.45.4.1121-1125.2001; Mangoni ML, 2005, J BIOL CHEM, V280, P984, DOI 10.1074/jbc.M410795200; Mickels N, 2001, J CLIN PERIODONTOL, V28, P404, DOI 10.1034/j.1600-051x.2001.028005404.x; MUKKADA AJ, 1985, SCIENCE, V229, P1099, DOI 10.1126/science.4035350; Opperdoes FR, 2007, TRENDS PARASITOL, V23, P149, DOI 10.1016/j.pt.2007.02.004; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Otvos L, 2005, J PEPT SCI, V11, P697, DOI 10.1002/psc.698; Paris C, 2004, ANTIMICROB AGENTS CH, V48, P852, DOI 10.1128/AAC.48.3.852-859.2004; Podda E, 2006, BBA-GEN SUBJECTS, V1760, P1732, DOI 10.1016/j.bbagen.2006.09.006; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; Thevissen K, 2005, PEPTIDES, V26, P1113, DOI 10.1016/j.peptides.2005.01.008; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735; Van Dyke T, 2002, J CLIN PERIODONTOL, V29, P168, DOI 10.1034/j.1600-051x.2002.290212.x; van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521; VanHellemond JJ, 1997, MOL BIOCHEM PARASIT, V85, P135, DOI 10.1016/S0166-6851(97)02828-4; Veerman ECI, 2007, J BIOL CHEM, V282, P18831, DOI 10.1074/jbc.M610555200; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; Vylkova S, 2006, ANTIMICROB AGENTS CH, V50, P324, DOI 10.1128/AAC.50.1.324-331.2006; Vylkova S, 2007, EUKARYOT CELL, V6, P1876, DOI 10.1128/EC.00039-07; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; ZILBERSTEIN D, 1985, P NATL ACAD SCI USA, V82, P1716, DOI 10.1073/pnas.82.6.1716	61	90	95	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1817	1828		10.1096/fj.07-096081	http://dx.doi.org/10.1096/fj.07-096081			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230684	Green Submitted			2022-12-28	WOS:000256352700022
J	Pederson, T				Pederson, Thoru			Turning a PAGE: the overnight sensation of SDS-polycrylamide gel electrophoresis	FASEB JOURNAL			English	Article							PROTEINS; CHAINS	The zonal separation of proteins on the basis of net charge was initially conducted on paper, then in columns of sucrose and later in gels of starch and polyacrylamide, with appropriate electric fields. Then, in 1964, a graduate student at MIT discovered the power of sodium dodecyl sulfate (SDS) to dissociate the envelope proteins of Escherichia coli and to dramatically enhance their electrophoretic resolution when the detergent was included in the gel. While this Ph.D. thesis work continued, a group at the Albert Einstein College of Medicine published in 1965 the use of SDS to disrupt poliovirus particles and to resolve the proteins in gels containing SDS. This group soon followed with a publication (1966) on the application of this new method to the study of immunoglobulin heavy and light chain synthesis. Because of concurrent advances in gel filtration and other methods of protein separation, SDS gel electrophoresis had its greatest impact not in biochemistry but in cell biology and virology. Ingenious devices were soon introduced that facilitated the application of this method to radioactive protein mixtures, followed by the introduction of slab gels for the simultaneous resolution of multiple samples in parallel lanes in a single run. As we today routinely perform "SDS PAGE" (as the method become known, to the great irritation of journal copyeditors and nomenclature committees at the time), it is fitting to pause-four decades later, and remember the pioneers who made SDS gel electrophoresis a reality, a true milestone that caught on almost overnight.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Program Cell Dynam, 377 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu						DOBZHANSKY T, 1951, GENETICS ORIGIN SPEC, P12; DUBOS R, 1976, L PASTEUR FREE LANCE, P94; FAIRBANK.G, 1965, BIOCHEM BIOPH RES CO, V20, P393, DOI 10.1016/0006-291X(65)90589-9; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FAIRBANKS G, 1988, RED CELL MEMBRANES, P17; FAIRBANKS G, 1970, THESIS MIT; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER WG, 1964, J MOL BIOL, V9, P109, DOI 10.1016/S0022-2836(64)80094-2; Maizel JV, 2000, TRENDS BIOCHEM SCI, V25, P590, DOI 10.1016/S0968-0004(00)01693-5; Michaux C, 2008, J MOL BIOL, V375, P1477, DOI 10.1016/j.jmb.2007.11.026; REID MS, 1968, ANAL BIOCHEM, V22, P374, DOI 10.1016/0003-2697(68)90278-9; SHAPIRO AL, 1966, NATURE, V211, P243, DOI 10.1038/211243a0; SHAPIRO AL, 1967, BIOCHEM BIOPH RES CO, V28, P815, DOI 10.1016/0006-291X(67)90391-9; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; SUMMERS DF, 1965, P NATL ACAD SCI USA, V154, P505; 1970, NATURE, V228, P415	16	16	16	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2008	22	4					949	953		10.1096/fj.08-0402ufm	http://dx.doi.org/10.1096/fj.08-0402ufm			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	282PZ	18378803				2022-12-28	WOS:000254581000002
J	Berrocal, M; Marcos, D; Sepulveda, MR; Perez, M; Avila, J; Mata, AM				Berrocal, Maria; Marcos, Daniel; Rosario Sepulveda, M.; Perez, Mar; Avila, Jesus; Mata, Ana M.			Altered Ca2+ dependence of synaptosomal plasma membrane Ca2+-ATPase in human brain affected by Alzheimer's disease	FASEB JOURNAL			English	Article						neurodegeneration; amyloid; beta-peptide; postmortem; activity	BETA-PROTEIN; LIPID RAFTS; HIPPOCAMPAL-NEURONS; ATPASE ACTIVITY; CALCIUM PUMPS; NA+/K+-ATPASE; PIG BRAIN; CHOLESTEROL; CEREBELLUM; HOMEOSTASIS	High-affinity Ca2+ transport ATPases play a crucial role in controlling cytosolic Ca2+. The amyloid beta-peptide (A beta) is a neurotoxic agent found in affected neurons in Alzheimer's disease (AD) that has been implicated in dysregulation of Ca2+ homeostasis. Using kinetic assays, we have shown that the Ca2+ dependencies of intracellular Ca2+-ATPase (SERCA and SPCA) activity are the same in human AD and normal brain but that of plasma membrane Ca2+-ATPase (PMCA) is different. The addition of A beta to normal brain decreases the PMCA activity measured at pCa 5.5, resulting in the same Ca2+ dependency as that seen in AD brain, whereas the addition of A beta to AD brain has no effect on PMCA activity. A beta also decreases the activity of PMCA purified from pig cerebrum, the effect being isoform specific. The level of inhibition of purified PMCA caused by A beta is reduced by cholesterol, and the level of inhibition of PMCA activity by A beta in the raft fraction of pig synaptosomal membranes is lower than for the nonraft fraction. We conclude that the effect of A beta on PMCA activity could be important in amyloid toxicity, resulting in cytoplasmic Ca2+ dysregulation and could explain the different Ca2+ dependencies of PMCA activity observed in normal and AD brain.-Berrocal, M., Marcos, D., Sepulveda, M. R., Perez, M., A Avila, J., Mata, A. M. Altered Ca2+ dependence of synaptosomal plasma membrane Ca2+-ATPase in human brain affected by Alzheimer's disease. FASEB J. 23, 1826-1834 (2009)	[Berrocal, Maria; Marcos, Daniel; Rosario Sepulveda, M.; Mata, Ana M.] Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol & Genet, E-06071 Badajoz, Spain; [Perez, Mar; Avila, Jesus] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid, Spain	Universidad de Extremadura; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Mata, AM (corresponding author), Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol & Genet, Avda Elvas S-N, E-06071 Badajoz, Spain.	anam@unex.es	Sepulveda, M. Rosario/L-4907-2014; Avila, Jesus/I-2610-2015; Berrocal Carrillo, María/H-1527-2018; Mata, Ana M./J-8460-2014; Marcos, Daniel/J-9730-2014; Mar, Perez/Y-2055-2019	Sepulveda, M. Rosario/0000-0002-2375-5866; Avila, Jesus/0000-0002-6288-0571; Berrocal Carrillo, María/0000-0003-0684-3853; Mata, Ana M./0000-0002-2887-7854; Marcos, Daniel/0000-0002-1007-1780; Mar, Perez/0000-0002-8477-9554				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Arispe N, 2002, FASEB J, V16, P1526, DOI 10.1096/fj.02-0829com; Arispe N, 2007, BBA-BIOMEMBRANES, V1768, P1952, DOI 10.1016/j.bbamem.2007.03.014; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Bezprozvanny I, 2008, TRENDS NEUROSCI, V31, P454, DOI 10.1016/j.tins.2008.06.005; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Dante S, 2006, EUR BIOPHYS J BIOPHY, V35, P523, DOI 10.1007/s00249-006-0062-x; Dickey CA, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-7; Esposito C, 2006, J PEPT SCI, V12, P766, DOI 10.1002/psc.811; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; HUGHES G, 1994, BIOCHEMISTRY-US, V33, P4745, DOI 10.1021/bi00182a001; Ji SR, 2002, J BIOL CHEM, V277, P6273, DOI 10.1074/jbc.M104146200; Kakio A, 2001, J BIOL CHEM, V276, P24985, DOI 10.1074/jbc.M100252200; Mall S, 2006, J BIOL CHEM, V281, P36597, DOI 10.1074/jbc.M606869200; MARK RJ, 1995, J NEUROSCI, V15, P6239; Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0; Mattson MP, 2007, AGING CELL, V6, P337, DOI 10.1111/j.1474-9726.2007.00275.x; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; MCWHIRTER JM, 1987, BIOCHEM J, V245, P713, DOI 10.1042/bj2450713; Palacios J, 2003, BBA-BIOMEMBRANES, V1611, P197, DOI 10.1016/S0005-2736(03)00057-9; Parkin ET, 1999, J NEUROCHEM, V72, P1534, DOI 10.1046/j.1471-4159.1999.721534.x; Salvador JM, 2001, J BIOCHEM-TOKYO, V129, P621, DOI 10.1093/oxfordjournals.jbchem.a002899; Salvador JM, 1998, ARCH BIOCHEM BIOPHYS, V351, P272, DOI 10.1006/abbi.1997.0562; Salvador JM, 1996, BIOCHEM J, V315, P183, DOI 10.1042/bj3150183; Sepulveda MR, 2007, J NEUROCHEM, V103, P1009, DOI 10.1111/j.1471-4159.2007.04794.x; Sepulveda MR, 2006, J BIOL CHEM, V281, P447, DOI 10.1074/jbc.M506950200; Sepulveda MR, 2005, J NEUROCHEM, V95, P673, DOI 10.1111/j.1471-4159.2005.03401.x; Sepulveda MR, 2004, BBA-BIOMEMBRANES, V1665, P75, DOI 10.1016/j.bbamem.2004.06.016; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Strehler EE, 2007, ANN NY ACAD SCI, V1099, P226, DOI 10.1196/annals.1387.023; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; Waschuk SA, 2001, J BIOL CHEM, V276, P33561, DOI 10.1074/jbc.M103598200; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847; Yagyu K, 2001, J NEUROCHEM, V78, P569, DOI 10.1046/j.1471-4159.2001.00446.x; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yip CM, 2001, J MOL BIOL, V311, P723, DOI 10.1006/jmbi.2001.4881	38	48	49	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2009	23	6					1826	1834		10.1096/fj.08-121459	http://dx.doi.org/10.1096/fj.08-121459			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19144698	Green Submitted			2022-12-28	WOS:000266652400023
J	Corbetta, S; Gualdoni, S; Ciceri, G; Monari, M; Zuccaro, E; Tybulewicz, VLJ; de Curtis, I				Corbetta, Sara; Gualdoni, Sara; Ciceri, Gabriele; Monari, Marta; Zuccaro, Emanuela; Tybulewicz, Victor L. J.; de Curtis, Ivan			Essential role of Rac1 and Rac3 GTPases in neuronal development	FASEB JOURNAL			English	Article						hippocampus; hilar mossy cells; dendritic spines; axons	MOUSE DENTATE GYRUS; MOSSY CELLS; RHO FAMILY; SYNAPTIC CONNECTIONS; HIPPOCAMPAL-NEURONS; RHESUS-MONKEY; MIGRATION; PROTEINS; MICE; IDENTIFICATION	Rac GTPases are members of the Rho family regulating the actin cytoskeleton and implicated in neuronal development. Ubiquitous Rac1 and neuron-specific Rac3 GTPases are coexpressed in the developing mammalian brain. We used Cre-mediated conditional deletion of Rac1 in neurons combined with knockout of neuron-specific Rac3 to study the role of these GTPases in neural development. We found that lack of both genes causes motor behavioral defects, epilepsy, and premature death of mice. Deletion of either GTPase does not produce evident phenotypes. Double-knockout mice show specific defects in the development of the hippocampus. Selective impairment of the dorsal hilus of double-knockout animals is associated with alteration in the formation of the hippocampal circuitry. Axonal pathways to and from the dorsal hilus are affected because of the deficit of hilar mossy cells. Moreover, analysis of Rac function in hippocampal cultures shows that spine formation is strongly hampered only in neurons lacking both Rac proteins. These findings show for the first time that both Rac1 and Rac3 are important for the development of the nervous system, wherein they play complementary roles during late stages of neuronal and brain development.-Corbetta, S., Gualdoni, S., Ciceri, G., Monari, M., Zuccaro, E., Tybulewicz, V. L. J., de Curtis, I. Essential role of Rac1 and Rac3 GTPases in neuronal development. FASEB J. 23, 1347-1357 (2009)	[Corbetta, Sara; Gualdoni, Sara; Ciceri, Gabriele; Monari, Marta; Zuccaro, Emanuela; de Curtis, Ivan] Ist Sci San Raffaele, Cell Adhes Unit, I-20132 Milan, Italy; [Corbetta, Sara; Gualdoni, Sara; Ciceri, Gabriele; Monari, Marta; Zuccaro, Emanuela; de Curtis, Ivan] San Raffaele Univ, Milan, Italy; [Tybulewicz, Victor L. J.] Natl Inst Med Res, Ridgeway, Div Immune Cell Biol, London NW7 1AA, England	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; MRC National Institute for Medical Research	de Curtis, I (corresponding author), Ist Sci San Raffaele, Cell Adhes Unit, Via Olgettina 58, I-20132 Milan, Italy.	decurtis.ivan@hsr.it		Tybulewicz, Victor/0000-0003-2439-0798; monari, marta/0000-0003-4071-270X; Ciceri, Gabriele/0000-0002-8481-9771; DE CURTIS, Ivanmatteo/0000-0002-7651-1515	Telethon-Italy [GGP05051]; Fondazione Cariplo; Medical Research Council [MC_U117527252] Funding Source: researchfish; MRC [MC_U117527252] Funding Source: UKRI	Telethon-Italy(Fondazione Telethon); Fondazione Cariplo(Fondazione Cariplo); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Laura Croci, the personnel of the Alembic facility, Claudia Asperti, and Fabio Monzani for technical help. This work was supported by Telethon-Italy (Grant GGP05051) and by Fondazione Cariplo. We thank Jamey Marth (University of California, San Diego, CA, USA) for SynI-Cre mice; Louis Reichardt (University of California, San Francisco, CA, USA) for the pEGFP-Cre plasmid; and Virginia Lee (University of Pennsylvania School of Medicine, Philadelphia, PA, USA), Richard Palmiter (University of Washington School of Medicine, Seattle, WA, USA), and Flavia Valtorta (University Vita-Salute San Raffaele, Milan, Italy) for antibodies. We also thank Marco de Curtis, Jacopo Meldolesi, Anna Mondino, Flavia Valtorta, and Larry Wrabetz for helpful discussions.	Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Bolis A, 2003, EUR J NEUROSCI, V18, P2417, DOI 10.1046/j.1460-9568.2003.02938.x; Chen L, 2007, J NEUROSCI, V27, P3884, DOI 10.1523/JNEUROSCI.3509-06.2007; Cho YJ, 2005, MOL CELL BIOL, V25, P5777, DOI 10.1128/MCB.25.13.5777-5785.2005; Corbetta S, 2005, MOL CELL BIOL, V25, P5763, DOI 10.1128/MCB.25.13.5763-5776.2005; Corbetta S, 2008, BEHAV BRAIN RES, V186, P246, DOI 10.1016/j.bbr.2007.08.019; De Curtis I, 2008, DEV NEUROSCI-BASEL, V30, P47, DOI 10.1159/000109851; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FROTSCHER M, 1991, J COMP NEUROL, V312, P145, DOI 10.1002/cne.903120111; Fujise N, 1999, BRAIN RES, V816, P500, DOI 10.1016/S0006-8993(98)01202-5; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Gualdoni S, 2007, BIOL CELL, V99, P455, DOI 10.1042/BC20060119; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Li G, 2008, DEV NEUROSCI-BASEL, V30, P255, DOI 10.1159/000110347; Liu Y, 1996, EXP BRAIN RES, V108, P389; Lundquist EA, 2001, DEVELOPMENT, V128, P4475; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Malosio ML, 1997, J NEUROSCI, V17, P6717; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; NOWAKOWSKI RS, 1981, J COMP NEUROL, V196, P129, DOI 10.1002/cne.901960110; NOWAKOWSKI RS, 1979, J NEUROCYTOL, V8, P697, DOI 10.1007/BF01206671; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Philips A, 2003, BIOL CELL, V95, P295, DOI 10.1016/S0248-4900(03)00052-2; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; RIBAK CE, 1985, J NEUROCYTOL, V14, P835, DOI 10.1007/BF01170832; Rico B, 2004, NAT NEUROSCI, V7, P1059, DOI 10.1038/nn1317; SCHLESSINGER AR, 1975, J COMP NEUROL, V159, P149, DOI 10.1002/cne.901590202; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Tada T, 2006, CURR OPIN NEUROBIOL, V16, P95, DOI 10.1016/j.conb.2005.12.001; VALTORTA F, 1988, NEUROSCIENCE, V24, P593, DOI 10.1016/0306-4522(88)90353-3; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	40	65	65	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2009	23	5					1347	1357		10.1096/fj.08-121574	http://dx.doi.org/10.1096/fj.08-121574			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19126596				2022-12-28	WOS:000266651700011
J	Procko, E; O'Mara, ML; Bennett, WFD; Tieleman, DP; Gaudet, R				Procko, Erik; O'Mara, Megan L.; Bennett, W. F. Drew; Tieleman, D. Peter; Gaudet, Rachelle			The mechanism of ABC transporters: general lessons from structural and functional studies of an antigenic peptide transporter	FASEB JOURNAL			English	Review						ATP hydrolysis; membrane protein structure; homology model; ATPase; accessory domains; asymmetry	MHC CLASS-I; NUCLEOTIDE-BINDING DOMAINS; MAJOR HISTOCOMPATIBILITY COMPLEX; TERMINAL TRANSMEMBRANE DOMAIN; RESISTANCE PROTEIN MRP1; SENSITIVE K+ CHANNELS; ATP-BINDING; ESCHERICHIA-COLI; MULTIDRUG TRANSPORTER; CRYSTAL-STRUCTURE	The shuttling of substrates across a cellular membrane frequently requires a specialized ATP-binding cassette (ABC) transporter, which couples the energy of ATP binding and hydrolysis to substrate transport. Due to its importance in immunity, the ABC transporter associated with antigen processing (TAP) has been studied extensively and is an excellent model for other ABC transporters. The TAP protein pumps cytosolic peptides into the endoplasmic reticulum for loading onto class I major histocompatibility complex (MHC) for subsequent immune surveillance. Here, we outline a potential mechanism for the TAP protein with supporting evidence from bacterial transporter structures. The similarities and differences between TAP and other transporters support the notion that ABC transporters in general have adapted around a universal transport mechanism.-Procko, E., O'Mara, M. L., Bennett, W. F. D., Tieleman, D. P., Gaudet, R. The mechanism of ABC transporters: general lessons from structural and functional studies of an antigenic peptide transporter. FASEB J. 23, 1287-1302 (2009)	[Procko, Erik; Gaudet, Rachelle] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [O'Mara, Megan L.; Bennett, W. F. Drew; Tieleman, D. Peter] Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	Harvard University; University of Calgary	Gaudet, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	gaudet@mcb.harvard.edu	Tieleman, D. Peter/A-4790-2011; O'Mara, Megan L/A-4962-2011; O'Mara, Megan/ABF-8913-2020; Gaudet, Rachelle/I-4133-2014; Gaudet, Rachelle/Y-3985-2019; O'Mara, Megan/AAY-5934-2021	Tieleman, D. Peter/0000-0001-5507-0688; O'Mara, Megan L/0000-0002-8764-1585; Gaudet, Rachelle/0000-0002-9177-054X; Gaudet, Rachelle/0000-0002-9177-054X; O'Mara, Megan/0000-0002-8764-1585; Bennett, Drew/0000-0003-3993-9077; Procko, Erik/0000-0002-0028-490X	American Cancer Society [RSG GMC-111847]; Merck-Wiley Fellowship; Canadian Institutes of Health Research (CIHR); Alberta Heritage Foundation for Medical Research Council; AHFMR Senior Scholar	American Cancer Society(American Cancer Society); Merck-Wiley Fellowship; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation for Medical Research Council; AHFMR Senior Scholar	The authors thank lab members for discussions and advice. Work in R.G.'s group is partly funded by the American Cancer Society (grant RSG GMC-111847 to R. G.), and E. P. is supported by a Merck-Wiley Fellowship. Work in D.P.T.'s group is supported by the Canadian Institutes of Health Research (CIHR). M.L.O. is a CIHR postdoctoral fellow. W. F. D. B. is supported by studentships from the Alberta Heritage Foundation for Medical Research Council. D.P.T. is a CIHR New Investigator and AHFMR Senior Scholar.	Ahn JH, 2003, J BIOL CHEM, V278, P39600, DOI 10.1074/jbc.M304236200; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Al-Shawi MK, 2005, J BIOENERG BIOMEMBR, V37, P489, DOI 10.1007/s10863-005-9497-5; Alberts P, 2001, CURR BIOL, V11, P242, DOI 10.1016/S0960-9822(01)00073-2; Babenko AP, 2003, J BIOL CHEM, V278, P41577, DOI 10.1074/jbc.C300363200; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Basso C, 2003, J GEN PHYSIOL, V122, P333, DOI 10.1085/jgp.200308798; Benabdelhak H, 2005, BIOCHEM J, V386, P489, DOI 10.1042/BJ20041282; Bhatia A, 2005, BIOCHEMISTRY-US, V44, P10893, DOI 10.1021/bi0503807; Biemans-Oldehinkel E, 2006, FEBS LETT, V580, P1023, DOI 10.1016/j.febslet.2005.11.079; Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Bouabe H, 2003, EUR J BIOCHEM, V270, P4531, DOI 10.1046/j.1432-1033.2003.03848.x; Bryan J, 2004, DIABETES, V53, pS104, DOI 10.2337/diabetes.53.suppl_3.S104; Campbell JD, 2005, FEBS LETT, V579, P4193, DOI 10.1016/j.febslet.2005.06.027; Chan KW, 2003, EMBO J, V22, P3833, DOI 10.1093/emboj/cdg376; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Davidson AL, 1996, J BIOL CHEM, V271, P4858; Davidson AL, 2007, TRENDS MICROBIOL, V15, P448, DOI 10.1016/j.tim.2007.09.005; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DeLano W.L, PYMOL MOL GRAPHICS S; Deverson EV, 1998, J IMMUNOL, V160, P2767; Dietrich D, 2009, MOL BIOL CELL, V20, P530, DOI 10.1091/mbc.E08-07-0745; Ernst R, 2008, P NATL ACAD SCI USA, V105, P5069, DOI 10.1073/pnas.0800191105; Gadsby DC, 2006, NATURE, V440, P477, DOI 10.1038/nature04712; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gerber S, 2008, SCIENCE, V321, P246, DOI 10.1126/science.1156213; Grote M, 2008, BIOPHYS J, V95, P2924, DOI 10.1529/biophysj.108.132456; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herget M, 2007, J BIOL CHEM, V282, P3871, DOI 10.1074/jbc.M608480200; Hewitt EW, 2001, EMBO J, V20, P387, DOI 10.1093/emboj/20.3.387; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Hollenstein K, 2007, CURR OPIN STRUC BIOL, V17, P412, DOI 10.1016/j.sbi.2007.07.003; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2003, J BIOL CHEM, V278, P3599, DOI 10.1074/jbc.M210480200; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hvorup RN, 2007, SCIENCE, V317, P1387, DOI 10.1126/science.1145950; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jha S, 2004, FEMS YEAST RES, V5, P63, DOI 10.1016/j.femsyr.2004.07.002; Jones PM, 2009, PROTEINS, V75, P387, DOI 10.1002/prot.22250; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Kadaba NS, 2008, SCIENCE, V321, P250, DOI 10.1126/science.1157987; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Karcher A, 2005, STRUCTURE, V13, P649, DOI 10.1016/j.str.2005.02.008; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Kreimer DI, 2000, BIOCHEMISTRY-US, V39, P14183, DOI 10.1021/bi001066+; Kyritsis C, 2001, J BIOL CHEM, V276, P48031, DOI 10.1074/jbc.M108528200; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Lapinski PE, 2003, J BIOL CHEM, V278, P8229, DOI 10.1074/jbc.M208930200; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Linder JU, 2006, CELL MOL LIFE SCI, V63, P1736, DOI 10.1007/s00018-006-6072-0; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lubelski J, 2006, BIOCHEMISTRY-US, V45, P648, DOI 10.1021/bi051276s; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuoka T, 2000, CIRC RES, V87, P873, DOI 10.1161/01.RES.87.10.873; Momburg F, 1996, J IMMUNOL, V156, P1756; Moody JE, 2005, J BIOENERG BIOMEMBR, V37, P475, DOI 10.1007/s10863-005-9494-8; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Oldham ML, 2007, NATURE, V450, P515, DOI 10.1038/nature06264; Oloo EO, 2006, J BIOL CHEM, V281, P28397, DOI 10.1074/jbc.M513614200; Oloo EO, 2004, J BIOL CHEM, V279, P45013, DOI 10.1074/jbc.M405084200; Orelle C, 2008, P NATL ACAD SCI USA, V105, P12837, DOI 10.1073/pnas.0803799105; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Oswald C, 2006, N-S ARCH PHARMACOL, V372, P385, DOI 10.1007/s00210-005-0031-4; Pakotiprapha D, 2008, MOL CELL, V29, P122, DOI 10.1016/j.molcel.2007.10.026; Park S, 2008, J PROTEOME RES, V7, P1721, DOI 10.1021/pr7007847; Peelman F, 2003, J MOL BIOL, V325, P259, DOI 10.1016/S0022-2836(02)01105-1; Perria CL, 2006, J BIOL CHEM, V281, P39839, DOI 10.1074/jbc.M605492200; Pinkett HW, 2007, SCIENCE, V315, P373, DOI 10.1126/science.1133488; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; Procko E, 2005, IMMUNOL CELL BIOL, V83, P475, DOI 10.1111/j.1440-1711.2005.01354.x; Procko E, 2008, BIOCHEMISTRY-US, V47, P5699, DOI 10.1021/bi7024854; Procko E, 2006, MOL CELL, V24, P51, DOI 10.1016/j.molcel.2006.07.034; Rufer E, 2007, J IMMUNOL, V179, P5717, DOI 10.4049/jimmunol.179.9.5717; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schrodt S, 2006, J BIOL CHEM, V281, P6455, DOI 10.1074/jbc.M509784200; Seliger B, 2001, CANCER RES, V61, P8647; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Sinha SC, 2007, REV PHYSIOL BIOCH P, V157, P105, DOI 10.1007/112_0603; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sonne J, 2007, BIOPHYS J, V92, P2727, DOI 10.1529/biophysj.106.097972; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; Tan P, 2002, J IMMUNOL, V168, P1950, DOI 10.4049/jimmunol.168.4.1950; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; Vergani P, 2003, J GEN PHYSIOL, V121, P17, DOI 10.1085/jgp.20028673; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Ward A, 2007, P NATL ACAD SCI USA, V104, P19005, DOI 10.1073/pnas.0709388104; Weng JW, 2008, BIOPHYS J, V94, P612, DOI 10.1529/biophysj.107.110734; Yang TY, 2005, CLIN CANCER RES, V11, P3614, DOI 10.1158/1078-0432.CCR-04-1804; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003; Zaitseva J, 2006, EMBO J, V25, P3432, DOI 10.1038/sj.emboj.7601208; Zhang DW, 2006, J BIOL CHEM, V281, P4507, DOI 10.1074/jbc.M512277200	108	110	114	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1287	1302		10.1096/fj.08-121855	http://dx.doi.org/10.1096/fj.08-121855			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19174475				2022-12-28	WOS:000266651700006
J	Antony, J; Kellershohn, K; Mohr-Andra, M; Kebig, A; Prilla, S; Muth, M; Heller, E; Disingrini, T; Dallanoce, C; Bertoni, S; Schrobang, J; Trankle, C; Kostenis, E; Christopoulos, A; Holtje, HD; Barocelli, E; De Amici, M; Holzgrabe, U; Mohr, K				Antony, Johannes; Kellershohn, Kerstin; Mohr-Andrae, Marion; Kebig, Anna; Prilla, Stefanie; Muth, Mathias; Heller, Eberhard; Disingrini, Teresa; Dallanoce, Clelia; Bertoni, Simona; Schrobang, Jasmin; Traenkle, Christian; Kostenis, Evi; Christopoulos, Arthur; Hoeltje, Hans-Dieter; Barocelli, Elisabetta; De Amici, Marco; Holzgrabe, Ulrike; Mohr, Klaus			Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity	FASEB JOURNAL			English	Article						agonism; allosterism; muscarinic acetylcholine receptor; signal trafficking; subtype selectivity; dynamic mass redistribution	MUSCARINIC ACETYLCHOLINE-RECEPTORS; PROTEIN-COUPLED RECEPTORS; COMMON ALLOSTERIC SITE; 7-TRANSMEMBRANE RECEPTORS; MOLECULAR-MECHANISMS; LIGAND-BINDING; OXOTREMORINE-M; M-2 RECEPTOR; AMINO-ACIDS; MODULATORS	Selective modulation of cell function by G protein-coupled receptor (GPCR) activation is highly desirable for basic research and therapy but difficult to achieve. We present a novel strategy toward this goal using muscarinic acetylcholine receptors as a model. The five subtypes bind their physiological transmitter in the highly conserved orthosteric site within the transmembrane domains of the receptors. Orthosteric muscarinic activators have no binding selectivity and poor signaling specificity. There is a less well conserved allosteric site at the extracellular entrance of the binding pocket. To gain subtype-selective receptor activation, we synthesized two hybrids fusing a highly potent oxotremorine-like orthosteric activator with M-2-selective bis(ammonio)alkane-type allosteric fragments. Radioligand binding in wild-type and mutant receptors supplemented by receptor docking simulations proved M-2 selective and true allosteric/orthosteric binding. G protein activation measurements using orthosteric and allosteric blockers identified the orthosteric part of the hybrid to engender receptor activation. Hybrid-induced dynamic mass redistribution in CHO-hM(2) cells disclosed pathway-specific signaling. Selective receptor activation (M-2>M-1>M-3) was verified in living tissue preparations. As allosteric sites are increasingly recognized on GPCRs, the dualsteric concept of GPCR targeting represents a new avenue toward potent agonists for selective receptor and signaling pathway activation. - Antony, J., Kellershohn, K., Mohr-Andra, M., Kebig, A., Prilla, S., Muth, M., Heller, E., Disingrini, T., Dallanoce, C., Bertoni, S., Schrobang, J., Trankle, C., Kostenis, E., Christopoulos, A., Holtje, H.-D., Barocelli, E., De Amici, M., Holzgrabe, U., Mohr, K. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J. 23, 442-450 (2009)	[Antony, Johannes; Kellershohn, Kerstin; Mohr-Andrae, Marion; Kebig, Anna; Prilla, Stefanie; Traenkle, Christian; Mohr, Klaus] Univ Bonn, Pharmacol & Toxicol Sect, Inst Pharm, D-53121 Bonn, Germany; [Kostenis, Evi] Univ Bonn, Inst Pharmaceut Biol, D-53121 Bonn, Germany; [Muth, Mathias; Heller, Eberhard; Holzgrabe, Ulrike] Univ Wurzburg, Dept Pharmaceut Chem, Inst Pharm, Wurzburg, Germany; [Disingrini, Teresa; Dallanoce, Clelia; De Amici, Marco] Univ Milan, Inst Med & Toxicol Chem Pietro Pratesi, Milan, Italy; [Bertoni, Simona; Barocelli, Elisabetta] Univ Parma, Dept Pharmacol Biol & Appl Chem Sci, I-43100 Parma, Italy; [Schrobang, Jasmin; Hoeltje, Hans-Dieter] Univ Dusseldorf, Inst Pharmaceut & Med Chem, Dusseldorf, Germany; [Christopoulos, Arthur] Monash Univ, Drug Discovery Biol Lab, Dept Pharmacol, Clayton, Vic 3800, Australia	University of Bonn; University of Bonn; University of Wurzburg; University of Milan; University of Parma; Heinrich Heine University Dusseldorf; Monash University	Mohr, K (corresponding author), Univ Bonn, Pharmacol & Toxicol Sect, Inst Pharm, Gerhard Domagk Str 3, D-53121 Bonn, Germany.	k.mohr@uni-bonn.de	Christopoulos, Arthur/B-6207-2013; Bertoni, Simona/AAJ-8961-2020; Barocelli, Elisabetta/C-4509-2013; De Amici, Marco/F-9684-2015	Christopoulos, Arthur/0000-0003-4442-3294; De Amici, Marco/0000-0002-0236-0662; Dallanoce, Clelia/0000-0002-7383-1484; Holzgrabe, Ulrike/0000-0002-0364-7278	Deutsche Forschungsgemeinschaft (DFG); University of Milan [MO821/1-4, HO1368/7-4]; DFG-funded research training group [GRK677]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); University of Milan; DFG-funded research training group(German Research Foundation (DFG))	The work was supported by grants of the Deutsche Forschungsgemeinschaft (DFG) to K.M. and U.H. (MO821/1-4, HO1368/7-4) and a grant from the University of Milan to M.D.A. (FIRST 2006). J.A. received a scholarship of the DFG-funded research training group GRK677. E.K. and K. M. are members of Bonn University Center for Innovative Drugs and Therapies. The skillful laboratory work of S. Jepards (GRK677-funded undergraduate research student) is acknowledged. A.C. is a Senior Research Fellow of the National Health and Medical Research Council of Australia. We thank Corning Life Sciences for making the Epic system available to us.	Barocelli E, 2000, LIFE SCI, V67, P717, DOI 10.1016/S0024-3205(00)00661-5; Birdsall NJM, 2005, MINI-REV MED CHEM, V5, P523, DOI 10.2174/1389557054023251; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Dallanoce C, 1999, BIOORGAN MED CHEM, V7, P1539, DOI 10.1016/S0968-0896(99)00107-8; Disingrini T, 2006, J MED CHEM, V49, P366, DOI 10.1021/jm050769s; EHLERT FJ, 1988, MOL PHARMACOL, V33, P187; Fang Ye, 2007, Journal of Pharmacological and Toxicological Methods, V55, P314, DOI 10.1016/j.vascn.2006.11.001; Fang Y, 2006, BIOPHYS J, V91, P1925, DOI [10.1529/biophysj.105.077818, 10.1529/biophysj.105.007818]; FURCHGOTT RF, 1967, ANN NY ACAD SCI, V144, P882, DOI 10.1111/j.1749-6632.1967.tb53817.x; Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/j.tips.2007.06.005; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; HILF G, 1989, EUR J BIOCHEM, V186, P725, DOI 10.1111/j.1432-1033.1989.tb15266.x; Jager D, 2007, J BIOL CHEM, V282, P34968, DOI 10.1074/jbc.M705563200; Kholodenko BN, 2006, NAT REV MOL CELL BIO, V7, P165, DOI 10.1038/nrm1838; Kostenis E, 1996, TRENDS PHARMACOL SCI, V17, P280, DOI 10.1016/0165-6147(96)10034-1; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; Langmead CJ, 2006, TRENDS PHARMACOL SCI, V27, P475, DOI 10.1016/j.tips.2006.07.009; Lanzafame A, 1996, EUR J PHARMACOL, V316, P27, DOI 10.1016/S0014-2999(96)00639-5; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; May LT, 2007, ANNU REV PHARMACOL, V47, P1, DOI 10.1146/annurev.pharmtox.47.120505.105159; Mistry R, 2005, BRIT J PHARMACOL, V144, P566, DOI 10.1038/sj.bjp.0706090; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Prilla S, 2006, MOL PHARMACOL, V70, P181, DOI 10.1124/mol.106.023481; Raasch A, 2002, J MED CHEM, V45, P3809, DOI 10.1021/jm020871e; Shirey JK, 2008, NAT CHEM BIOL, V4, P42, DOI 10.1038/nchembio.2007.55; STOCKTON JM, 1983, MOL PHARMACOL, V23, P551; Sur C, 2003, P NATL ACAD SCI USA, V100, P13674, DOI 10.1073/pnas.1835612100; Trankle C, 2005, MOL PHARMACOL, V68, P1597, DOI 10.1124/mol.105.017707; Trankle C, 2003, MOL PHARMACOL, V64, P180, DOI 10.1124/mol.64.1.180; Trankle C, 1998, MOL PHARMACOL, V53, P304, DOI 10.1124/mol.53.2.304; Valant C, 2008, J BIOL CHEM, V283, P29312, DOI 10.1074/jbc.M803801200; Voigtlander U, 2003, MOL PHARMACOL, V64, P21, DOI 10.1124/mol.64.1.21; Wess J, 2005, MOL PHARMACOL, V68, P1506, DOI 10.1124/mol.105.019141; Wess J, 2007, NAT REV DRUG DISCOV, V6, P721, DOI 10.1038/nrd2379	35	112	114	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					442	450		10.1096/fj.08-114751	http://dx.doi.org/10.1096/fj.08-114751			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18842964				2022-12-28	WOS:000262892900016
J	Graham, JD; Hanson, AR; Croft, AJ; Fox, AH; Clarke, CL				Graham, J. Dinny; Hanson, Adrienne R.; Croft, Amanda J.; Fox, Archa H.; Clarke, Christine L.			Nuclear matrix binding is critical for progesterone receptor movement into nuclear foci	FASEB JOURNAL			English	Article						intranuclear trafficking; breast cancer	GLUCOCORTICOID-RECEPTOR; ESTROGEN-RECEPTOR; LIVING CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; SUBNUCLEAR DISTRIBUTION; BIOLOGICAL-CONTROL; ANDROGEN RECEPTOR; LIGAND; LOCALIZATION	The ovarian hormone progesterone is essential for normal breast development, and progesterone analogues are implicated in increasing breast cancer risk. The progesterone receptor (PR) is a transcription factor that, when ligand activated, moves rapidly into nuclear foci associated with transcriptional activity. However, the role of intranuclear trafficking signals in the focal location of PR is unknown. We have identified a mutation in PR that ablates its binding to the nuclear matrix and prevents PR movement into nuclear foci. Nuclear matrix binding mutants lack transcriptional activity and inhibit dimerization, demonstrating the critical role of matrix binding for PR dynamics and activity. DNA binding of PR is required for fidelity of location in foci, as DNA binding domain (DBD) mutants form aberrant foci with reduced mobility and altered tethering to the nucleus. Mutations in either the nuclear matrix targeting sequence or DBD domains were dominant in preventing wild-type receptor from moving to appropriate nuclear locations, demonstrating that both partner proteins in a PR dimer must have intact intranuclear trafficking signals for correct receptor positioning within the nucleus. This study has demonstrated that positioning of PR in foci within the nucleus is critically regulated by intranuclear trafficking signals, which play a key role in transcriptional activity and are relevant to its action in normal and malignant breast cells.-Graham, J. D., Hanson, A. R., Croft, A. C., Fox, A. H., Clarke, C. L. Nuclear matrix binding is critical for progesterone receptor movement into nuclear foci. FASEB J. 23, 546-556 (2009)	[Graham, J. Dinny; Croft, Amanda J.; Clarke, Christine L.] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia; [Hanson, Adrienne R.; Fox, Archa H.] Univ Western Australia, Med Res Ctr, Western Australian Inst Med Res, Perth, WA 6009, Australia	University of Sydney; Westmead Institute for Medical Research; University of Western Australia	Clarke, CL (corresponding author), Westmead Millennium Inst, Westmead Inst Canc Res, Darcy Rd, Westmead, NSW 2145, Australia.	christine_clarke@wmi.usyd.edu.au	Fox, Archa H/H-9219-2014; Clarke, Christine/B-7127-2009	Fox, Archa H/0000-0003-1962-270X; Clarke, Christine/0000-0001-7568-111X	National Health and Medical Research Council of Australia; National Breast Cancer Foundation	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation	These studies were supported by grants from the National Health and Medical Research Council of Australia and the National Breast Cancer Foundation.	Arnett-Mansfield RL, 2007, MOL ENDOCRINOL, V21, P14, DOI 10.1210/me.2006-0041; Arnett-Mansfield RL, 2004, J CLIN ENDOCR METAB, V89, P1429, DOI 10.1210/jc.2003-031111; BARRACK ER, 1983, ENDOCRINOLOGY, V113, P430, DOI 10.1210/endo-113-1-430; Conneely OM, 2003, STEROIDS, V68, P771, DOI 10.1016/S0039-128X(03)00126-0; Cook PR, 2002, NAT GENET, V32, P347, DOI 10.1038/ng1102-347; DeFranco DB, 2000, CRIT REV EUKAR GENE, V10, P39; DeFranco DB, 2002, MOL ENDOCRINOL, V16, P1449, DOI 10.1210/me.16.7.1449; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Fraser P, 2007, NATURE, V447, P413, DOI 10.1038/nature05916; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hager GL, 2002, CURR OPIN GENET DEV, V12, P137, DOI 10.1016/S0959-437X(02)00278-2; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Li XT, 2004, MECH AGEING DEV, V125, P669, DOI 10.1016/j.mad.2004.04.007; Marcelli M, 2006, J CELL BIOCHEM, V98, P770, DOI 10.1002/jcb.20593; Martin S, 2003, CHROMOSOME RES, V11, P461, DOI 10.1023/A:1024926710797; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; METZGER DA, 1990, ENDOCRINOLOGY, V126, P2190, DOI 10.1210/endo-126-4-2190; Milhon J, 1997, MOL ENDOCRINOL, V11, P1795, DOI 10.1210/me.11.12.1795; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Mote PA, 1999, J CLIN ENDOCR METAB, V84, P2963, DOI 10.1210/jc.84.8.2963; Nagaich AK, 2004, MOL CELL, V14, P163, DOI 10.1016/S1097-2765(04)00178-9; Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Santen RJ, 2003, STEROIDS, V68, P953, DOI 10.1016/S0039-128X(03)00138-7; SCHUCHARD M, 1991, BIOCHEMISTRY-US, V30, P9516, DOI 10.1021/bi00103a019; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; VANSTEENSEL B, 1995, J CELL SCI, V108, P3003; Vicent GP, 2004, MOL CELL, V16, P439, DOI 10.1016/j.molcel.2004.10.025; Zaidi SK, 2007, NAT REV CANCER, V7, P454, DOI 10.1038/nrc2149; Zaidi SK, 2004, J BIOL CHEM, V279, P43363, DOI 10.1074/jbc.R400020200; Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430	47	8	10	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					546	556		10.1096/fj.08-113639	http://dx.doi.org/10.1096/fj.08-113639			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18931262				2022-12-28	WOS:000262892900026
J	Gunning, AP; Bongaerts, RJM; Morris, VJ				Gunning, A. Patrick; Bongaerts, Roy J. M.; Morris, Victor J.			Recognition of galactan components of pectin by galectin-3	FASEB JOURNAL			English	Article						flow cytometry; AFM; antimetastasis activity; polygalacturonic acid; RGI	ATOMIC-FORCE MICROSCOPY; HUMAN BREAST-CARCINOMA; RHAMNOGALACTURONAN-I; CITRUS PECTIN; CELL-ADHESION; APOPTOSIS; ARABINOGALACTAN; INHIBITORS; CANCER; POLYSACCHARIDES	It has been reported that modified forms of pectin possess anticancer activity. To account for this bioactivity, it has been proposed that fragments of pectin molecules can act by binding to and inhibiting the various roles of the mammalian protein galectin 3 (Gal3) in cancer progression and metastasis. Despite this clear molecular hypothesis and evidence for the bioactivity of modified pectin, the structural origins of the "bioactive fragments" of pectin molecules are currently ill defined. By using a combination of fluorescence microscopy, flow cytometry, and force spectroscopy, it has been possible to demonstrate, for the first time, specific binding of a pectin galactan to the recombinant form of human Gal3. Present studies suggest that bioactivity resides in the neutral sugar side chains of pectin polysaccharides and that these components could be isolated and modified to optimize bioactivity. - Gunning, A. P., Bongaerts, R. J. M., Morris, V. J. Recognition of galactan components of pectin by galectin-3. FASEB J. 23, 415-424 (2009)	[Gunning, A. Patrick; Bongaerts, Roy J. M.; Morris, Victor J.] Inst Food Res, Norwich NR4 7UA, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Gunning, AP (corresponding author), Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	patrick.gunning@bbsrc.ac.uk			Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000; BEUTH J, 1988, CLIN EXP METASTAS, V6, P115, DOI 10.1007/BF01784842; BHATIA SK, 1989, ANAL BIOCHEM, V178, P408, DOI 10.1016/0003-2697(89)90662-3; Birdsall B, 2001, BIOCHEMISTRY-US, V40, P4859, DOI 10.1021/bi002907f; Collins PM, 2007, ACTA CRYSTALLOGR D, V63, P415, DOI 10.1107/S090744490605270X; COLQUHOUN IJ, 1990, CARBOHYD RES, V206, P131, DOI 10.1016/0008-6215(90)84012-J; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Gunning AP, 2008, FASEB J, V22, P2331, DOI 10.1096/fj.07-100578; INOHARA H, 1995, CANCER RES, V55, P3267; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LEROUGE P, 1993, CARBOHYD RES, V243, P359, DOI 10.1016/0008-6215(93)87039-U; Mazurek N, 2007, J BIOL CHEM, V282, P21337, DOI 10.1074/jbc.M608810200; MEYER G, 1988, APPL PHYS LETT, V53, P1045, DOI 10.1063/1.100061; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Nangia-Makker P, 2002, TRENDS MOL MED, V8, P187, DOI 10.1016/S1471-4914(02)02295-5; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; Obro J, 2004, PHYTOCHEMISTRY, V65, P1429, DOI 10.1016/j.phytochem.2004.05.002; Olano-Martin E, 2003, ANTICANCER RES, V23, P341; Parris M. Kidd, 1996, ALTERN MED REV, V1, P4; PIENTA KJ, 1995, J NATL CANCER I, V87, P348, DOI 10.1093/jnci/87.5.348; PLATT D, 1992, J NATL CANCER I, V84, P438, DOI 10.1093/jnci/84.6.438; Renard CMGC, 1996, CARBOHYD RES, V286, P139, DOI 10.1016/0008-6215(96)00056-0; Ridley BL, 2001, PHYTOCHEMISTRY, V57, P929, DOI 10.1016/S0031-9422(01)00113-3; Sathisha UV, 2007, GLYCOCONJUGATE J, V24, P497, DOI 10.1007/s10719-007-9042-3; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Sorme P, 2005, J AM CHEM SOC, V127, P1737, DOI 10.1021/ja043475p; Sorme P, 2003, METHOD ENZYMOL, V363, P157; Sorme PA, 2003, FASEB J, V17, pA162; Takenaka Y, 2002, GLYCOCONJUGATE J, V19, P543, DOI 10.1023/B:GLYC.0000014084.01324.15; THIBAULT JF, 1993, CARBOHYD RES, V238, P271, DOI 10.1016/0008-6215(93)87019-O; Touhami A, 2003, MICROBIOL-SGM, V149, P2873, DOI 10.1099/mic.0.26431-0; Touhami A, 2003, LANGMUIR, V19, P1745, DOI 10.1021/la026145w; UHLENBRUCK G, 1986, NATURWISSENSCHAFTEN, V73, P626, DOI 10.1007/BF00368781; Warfield PR, 1997, INVAS METAST, V17, P101; WONG CK, 1994, J INT MED RES, V22, P299, DOI 10.1177/030006059402200601; Yapo BM, 2007, CARBOHYD POLYM, V69, P426, DOI 10.1016/j.carbpol.2006.12.024; Zubieta MR, 2006, AM J PATHOL, V168, P1666, DOI 10.2353/ajpath.2006.050971	40	121	128	1	42	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					415	424		10.1096/fj.08-106617	http://dx.doi.org/10.1096/fj.08-106617			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18832596				2022-12-28	WOS:000262892900013
J	Kasperczyk, H; Baumann, B; Debatin, KM; Fulda, S				Kasperczyk, Hubert; Baumann, Bernd; Debatin, Klaus-Michael; Fulda, Simone			Characterization of sonic hedgehog as a novel NF-kappa B target gene that promotes NF-kappa B-mediated apoptosis resistance and tumor growth in vivo	FASEB JOURNAL			English	Article						cancer; cell death	PANCREATIC-CARCINOMA CELLS; HUMAN PROSTATE-CANCER; INHIBITION; ACTIVATION; EXPRESSION; PATHWAY; SUFFICIENT; NEOPLASIA; XIAP	To explore mechanisms controlling sonic hedgehog (Shh) expression in human cancers, we investigated regulation of Shh by the transcription factor NF-kappa B. We identify putative NF-kappa B binding sites in the human Shh promoter region that specifically bind NF-kappa B complexes. Further, NF-kappa B activation by tumor necrosis factor alpha (TNF-alpha) or p65 overexpression stimulates Shh promoter activity and p65 binds to Shh promoter in vivo. NF-kappa B-mediated transcriptional activation of Shh is mapped to a minimal NF-kappa B consensus site at position + 139 of Shh promoter. NF-kappa B activation results in increased Shh mRNA and protein expression in vitro and, notably, also in vivo in a genetic mouse model of inducible NF-kappa B activity. Specific NF-kappa B inhibition by inhibitory NF-kappa B alpha (I kappa-B alpha) superrepressor or p65 knockdown inhibits NF-kappa B-induced Shh promoter activation and Shh expression. NF-kappa B-mediated Shh expression promotes proliferation and confers resistance to TRAIL-induced apoptosis. Silencing of Shh prevents NF-kappa B-stimulated proliferation, while the addition of Shh rescues the proliferation defect imposed by NF-kappa B inhibition. Notably, NF-kappa B-stimulated tumor growth is significantly impaired by Shh knockdown in an in vivo model of pancreatic cancer. By demonstrating that NF-kappa B regulates Shh expression, which contributes to NF-kappa B-mediated proliferation and apoptosis resistance in vitro and in vivo, our findings have important implications to target aberrant Shh expression in human cancers.-Kasperczyk, H., Baumann, B., Debatin, K.-M., Fulda, S. Characterization of sonic hedgehog as a novel NF-kappa B target gene that promotes NF-kappa B-mediated apoptosis resistance and tumor growth in vivo. FASEB J. 23, 21-33 (2009)	[Kasperczyk, Hubert; Debatin, Klaus-Michael; Fulda, Simone] Univ Childrens Hosp, D-89075 Ulm, Germany; [Baumann, Bernd] Univ Ulm, Inst Physiol Chem, Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft;  [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); 	We thank R. Toftgard (Karolinska Institute, Sweden) for providing the vector encoding the N-terminal fragment of human Shh (PShhHN1-CMV5), M. Jovanovic and A. Dittrich for expert technical assistance, and H. Hahn (University of Goettingen, Germany) for helpful discussions and critical reading of the manuscript. This work has been partially supported by a grant from the Deutsche Forschungsgemeinschaft and by IAP6/18 (to S.F.).	Algul H, 2002, J GASTROINTEST CANC, V31, P71, DOI 10.1385/IJGC:31:1-3:71; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Baumann B, 2007, J CLIN INVEST, V117, P1502, DOI 10.1172/JCI30876; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Giagkousiklidis S, 2007, ONCOGENE, V26, P7006, DOI 10.1038/sj.onc.1210502; Guy RK, 2000, P NATL ACAD SCI USA, V97, P7307, DOI 10.1073/pnas.97.13.7307; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Ingham PW, 2006, NAT REV GENET, V7, P841, DOI 10.1038/nrg1969; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kasperczyk H, 2005, ONCOGENE, V24, P6945, DOI 10.1038/sj.onc.1208842; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kitazawa S, 1998, BBA-GENE STRUCT EXPR, V1443, P358, DOI 10.1016/S0167-4781(98)00243-7; Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510; Kunzi-Rapp K, 2001, J UROLOGY, V166, P1502, DOI 10.1016/S0022-5347(05)65820-X; Nakashima H, 2006, CANCER RES, V66, P7041, DOI 10.1158/0008-5472.CAN-05-4588; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Schmidt-Ullrich R, 2006, DEVELOPMENT, V133, P1045, DOI 10.1242/dev.02278; Suhasini M, 1999, ONCOGENE, V18, P7360, DOI 10.1038/sj.onc.1203158; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Vogler M, 2007, ONCOGENE, V26, P248, DOI 10.1038/sj.onc.1209776; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493	30	110	115	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					21	33		10.1096/fj.08-111096	http://dx.doi.org/10.1096/fj.08-111096			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18772349				2022-12-28	WOS:000262095500005
J	Kunduzova, O; Alet, N; Delesque-Touchard, N; Millet, L; Castan-Laurell, I; Muller, C; Dray, C; Schaeffer, P; Herault, JP; Savi, P; Bono, F; Valet, P				Kunduzova, O.; Alet, N.; Delesque-Touchard, N.; Millet, L.; Castan-Laurell, I.; Muller, C.; Dray, C.; Schaeffer, P.; Herault, J. P.; Savi, P.; Bono, F.; Valet, P.			Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes	FASEB JOURNAL			English	Article						apelinergic system; adipocyte; neovascularization; hypoxia; fat grafting; angiogenesis	ENDOGENOUS PEPTIDE LIGAND; HUMAN APJ RECEPTOR; GROWTH-FACTORS; MESSENGER-RNA; HYPOXIA; CELLS; ADIPOCYTES; EXPRESSION; BLOOD; DIFFERENTIATION	Adipose tissue is an active endocrine organ that produces a variety of secretory factors involved in the initiation of angiogenic processes. The bioactive peptide apelin is the endogenous ligand of the G protein-coupled receptor, APJ. Here we investigated the potential role of apelin and its receptor, APJ, in the angiogenic responses of human endothelial cells and the development of a functional vascular network in a model of adipose tissue development in mice. Treatment of human umbilical vein endothelial cells with apelin dose-dependently increased angiogenic responses, including endothelial cell migration, proliferation, and Matrigel (R) capillary tubelike structure formation. These endothelial effects of apelin were due to activation of APJ, because siRNA directed against APJ, which led to long-lasting down-regulation of APJ mRNA, abolished cell migration induced by apelin in contrast to control nonsilencing siRNA. Hypoxia up-regulated the expression of apelin in 3T3F442A adipocytes, and we therefore determined whether apelin could play a role in adipose tissue angiogenesis in vivo. Epididymal white adipose tissue (EWAT) transplantation was performed as a model of adipose tissue angiogenesis. Transplantation led to increased apelin mRNA levels 2 and 5 days after transplantation associated with tissue hypoxia, as evidenced by hydroxyprobe staining on tissue sections. Graft revascularization evolved in parallel, as the first functional vessels in EWAT grafts were observed 2 days after transplantation and a strong angiogenic response was apparent on day 14. This was confirmed by determination of graft hemoglobin levels, which are indicative of functional vascularization and were strongly increased 5 and 14 days after transplantation. The role of apelin in the graft neovascularization was then assessed by local delivery of stable complex apelin-targeting siRNA leading to dramatically reduced apelin mRNA levels and vascularization (quantified by hemogloblin content) in grafted EWAT on day 5 when compared with control siRNA. Taken together, our data provide the first evidence that apelin/APJ signaling pathways play a critical role in the development of the functional vascular network in adipose tissue. In addition, we have shown that adipocyte-derived apelin can be up-regulated by hypoxia. These findings provide novel insights into the complex relationship between adipose tissue and endothelial vascular function and may lead to new therapeutic strategies to modulate angiogenesis.	[Kunduzova, O.] Fac Med Toulouse, INSERM, U858, Toulouse 4, France; [Kunduzova, O.; Castan-Laurell, I.; Muller, C.; Dray, C.; Valet, P.] Univ Toulouse, Inst Med Mol Rangueil, IFR31, Toulouse, France; Sanofi Aventis Res, Angiogenesis & Thrombosis Dept, Toulouse, France; [Muller, C.] CNRS, Inst Pharmacol & Biol Struct, UMR 5089, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Universite de Toulouse; Sanofi-Aventis; Sanofi France; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Kunduzova, O (corresponding author), Fac Med Toulouse, INSERM, U858, Toulouse 4, France.	oxana.koundouzova@toulouse.inserm.fr	dray, cedric/N-7440-2017; Schaeffer, Paul/D-7069-2014; Valet, Philippe/N-7472-2017; MULLER, Catherine/M-2185-2018; Schaeffer, Paul/AAZ-9961-2020; MULLER, Catherine/E-2060-2011	Schaeffer, Paul/0000-0002-2835-1801; Valet, Philippe/0000-0001-6520-7393; Schaeffer, Paul/0000-0002-2835-1801; Kunduzova, Oksana/0000-0003-2503-6555; DRAY, Cedric/0000-0002-4712-791X; Castan-Laurell, Isabelle/0000-0002-0488-9789				Ahima RS, 2006, OBESITY, V14, P242, DOI 10.1038/oby.2006.317; Boucher J, 2005, ENDOCRINOLOGY, V146, P1764, DOI 10.1210/en.2004-1427; Cheng X, 2003, EUR J PHARMACOL, V470, P171, DOI 10.1016/S0014-2999(03)01821-1; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; Daviaud D, 2006, FASEB J, V20, P1528, DOI 10.1096/fj.05-5243fje; Drabkin DL, 1932, J BIOL CHEM, V98, P719; Farkasfalvi K, 2007, BIOCHEM BIOPH RES CO, V357, P889, DOI 10.1016/j.bbrc.2007.04.017; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; Fons P, 2004, J CELL PHYSIOL, V200, P351, DOI 10.1002/jcp.20076; Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA; Glassford AJ, 2007, AM J PHYSIOL-ENDOC M, V293, pE1590, DOI 10.1152/ajpendo.00490.2007; Hausman GJ, 2004, J ANIM SCI, V82, P925; Hickey MM, 2006, CURR TOP DEV BIOL, V76, P217, DOI 10.1016/S0070-2153(06)76007-0; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Hosoya M, 2000, J BIOL CHEM, V275, P21061, DOI 10.1074/jbc.M908417199; Kalin RE, 2007, DEV BIOL, V305, P599, DOI 10.1016/j.ydbio.2007.03.004; Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042; Lolmede K, 2003, INT J OBESITY, V27, P1187, DOI 10.1038/sj.ijo.0802407; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; Ruggeri B, 2003, CANCER RES, V63, P5978; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Suhardja A, 2003, MICROSC RES TECHNIQ, V60, P70, DOI 10.1002/jemt.10245; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Xie H, 2007, APOPTOSIS, V12, P247, DOI 10.1007/s10495-006-0489-7; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	34	83	87	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4146	4153		10.1096/fj.07-104018	http://dx.doi.org/10.1096/fj.07-104018			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18708591				2022-12-28	WOS:000261254800014
J	Klootwijk, RD; Savelkoul, PJM; Ciccone, C; Manoli, I; Caplen, NJ; Krasnewich, DM; Gahl, WA; Huizing, M				Klootwijk, Riko D.; Savelkoul, Paul J. M.; Ciccone, Carla; Manoli, Irini; Caplen, Natasha J.; Krasnewich, Donna M.; Gahl, William A.; Huizing, Marjan			Allele-specific silencing of the dominant disease allele in sialuria by RNA interference	FASEB JOURNAL			English	Article						real-time PCR; feedback inhibition; sialic acid; UDP-GlcNAc 2-epimerase/ManNAc kinase; siRNA; allosteric site	N-ACETYLGLUCOSAMINE 2-EPIMERASE; AMYOTROPHIC-LATERAL-SCLEROSIS; IN-VIVO; PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE; REGULATORY MUTATIONS; MOUSE MODEL; GENE; DELIVERY; SUPERACTIVITY; PURIFICATION	Dominant disease alleles are attractive therapeutic targets for allele-specific gene silencing by small interfering RNA ( siRNA). Sialuria is a dominant disorder caused by missense mutations in the allosteric site of GNE, coding for the rate-limiting enzyme of sialic acid biosynthesis, UDP-GlcNAc 2-epimerase/ManNAc kinase. The resultant loss of feedback inhibition of GNE-epimerase activity by CMP-sialic acid causes excessive production of free sialic acid. For this study we employed synthetic siRNAs specifically targeting the dominant GNE mutation c. 797G > A (p.R266Q) in sialuria fibroblasts. We demonstrated successful siRNA-mediated down-regulation of the mutant allele by allele-specific real-time PCR. Importantly, mutant allele-specific silencing resulted in a significant decrease of free sialic acid, to within the normal range. Feedback inhibition of GNE-epimerase activity by CMP-sialic acid recovered after silencing demonstrating specificity of this effect. These findings indicate that allele-specific silencing of a mutated allele is a viable therapeutic strategy for autosomal dominant diseases, including sialuria.-Klootwijk, R. D., Savelkoul, P. J. M., Ciccone, C., Manoli, I., Caplen, N. J., Krasnewich, D. M., Gahl, W. A., Huizing, M. Allele-specific silencing of the dominant disease allele in sialuria by RNA interference. FASEB J. 22, 3846-3852 (2008)	[Klootwijk, Riko D.; Savelkoul, Paul J. M.; Ciccone, Carla; Manoli, Irini; Krasnewich, Donna M.; Gahl, William A.; Huizing, Marjan] NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA; [Caplen, Natasha J.] NCI, Gene Silencing Sect, Genet Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Gahl, William A.] NIH, Off Rare Dis, Intramural Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Huizing, M (corresponding author), NHGRI, Med Genet Branch, NIH, 10 Ctr Dr,MSC 1851, Bethesda, MD 20892 USA.	mhuizing@mail.nih.gov	Huizing, Marjan/AAR-8860-2020; Caplen, Natasha J/H-2768-2016	Caplen, Natasha J/0000-0002-0001-9460; Manoli, Irini/0000-0003-1543-2941	National Human Genome Research Institute; National Cancer Institute; National Institutes of Health, Bethesda, MD, USA; NATIONAL CANCER INSTITUTE [ZIABC010613, Z01BC010613] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000215, ZIAHG200322, Z01HG200322] Funding Source: NIH RePORTER	National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health, Bethesda, MD, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by the Intramural Research programs of the National Human Genome Research Institute and the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.	Aartsma-Rus A, 2007, RNA, V13, P1609, DOI 10.1261/rna.653607; Abdelgany A, 2003, HUM MOL GENET, V12, P2637, DOI 10.1093/hmg/ddg280; BECKER MA, 1995, J CLIN INVEST, V96, P2133, DOI 10.1172/JCI118267; Becker MA, 1996, J BIOL CHEM, V271, P19894, DOI 10.1074/jbc.271.33.19894; Birchall J, 2007, EXPERT OPIN DRUG DEL, V4, P575, DOI 10.1517/17425247.4.6.575; Cashman SM, 2005, GENE THER, V12, P1223, DOI 10.1038/sj.gt.3302512; Ding HL, 2003, AGING CELL, V2, P209, DOI 10.1046/j.1474-9728.2003.00054.x; Enns GM, 2001, J INHERIT METAB DIS, V24, P328, DOI 10.1023/A:1010588115479; Fang J, 2002, BIOCHEM J, V363, P81, DOI 10.1042/0264-6021:3630081; Ferreira H, 1999, MOL GENET METAB, V67, P131, DOI 10.1006/mgme.1999.2852; Gaither LA, 2007, EXPERT REV PROTEOMIC, V4, P411, DOI 10.1586/14789450.4.3.411; Gonzalez-Alegre P, 2005, J NEUROSCI, V25, P10502, DOI 10.1523/JNEUROSCI.3016-05.2005; Grimm D, 2007, J CLIN INVEST, V117, P3633, DOI 10.1172/JCI34129; Helip-Wooley Amanda, 2007, P499, DOI 10.1007/978-0-387-70909-3_31; Hickerson RP, 2008, J INVEST DERMATOL, V128, P594, DOI 10.1038/sj.jid.5701060; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Huizing M., 2005, DRUG DISCOV TODAY DI, V2, P519, DOI [10.1016/j.ddmec.2005.11.003, DOI 10.1016/J.DDMEC.2005.11.003]; Kawasumi M, 2007, J INVEST DERMATOL, V127, P1577, DOI 10.1038/sj.jid.5700853; KRASNEWICH DM, 1993, BIOCHEM MED METAB B, V49, P90, DOI 10.1006/bmmb.1993.1010; Lemyre E, 1999, AM J MED GENET, V82, P385, DOI 10.1002/(SICI)1096-8628(19990219)82:5<385::AID-AJMG6>3.3.CO;2-V; Leroy JG, 2001, AM J HUM GENET, V68, P1419, DOI 10.1086/320598; Livak K. J., 1997, ABI PRISM 7700 SEQUE, V2; Massaro D, 2004, AM J PHYSIOL-LUNG C, V287, pL1066, DOI 10.1152/ajplung.00067.2004; Maxwell MM, 2004, P NATL ACAD SCI USA, V101, P3178, DOI 10.1073/pnas.0308726100; Miller VM, 2003, P NATL ACAD SCI USA, V100, P7195, DOI 10.1073/pnas.1231012100; MONTREUIL J, 1967, CR ACAD SCI D NAT, V265, P97; Nakai N, 2007, GENE THER, V14, P357, DOI 10.1038/sj.gt.3302868; O'Reilly M, 2007, AM J HUM GENET, V81, P127, DOI 10.1086/519025; Rodriguez-Lebron E, 2006, GENE THER, V13, P576, DOI 10.1038/sj.gt.3302702; Rodriguez-Lebron E, 2005, MOL THER, V12, P618, DOI 10.1016/j.ymthe.2005.05.006; Saito Y, 2005, J BIOL CHEM, V280, P42826, DOI 10.1074/jbc.M507685200; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; SEPPALA R, 1991, J BIOL CHEM, V266, P7456; Shukla V, 2007, NAT GENET, V39, P1145, DOI 10.1038/ng2096; Sparks SE, 2005, GLYCOBIOLOGY, V15, P1102, DOI 10.1093/glycob/cwi100; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Suda T, 2003, INT J MOL MED, V12, P243; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki A, 2007, NATURE, V446, P1023, DOI 10.1038/nature05816; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585; WEISS P, 1989, J BIOL CHEM, V264, P17635; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Xia XG, 2006, NEUROBIOL DIS, V23, P578, DOI 10.1016/j.nbd.2006.04.019	43	13	13	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2008	22	11					3846	3852		10.1096/fj.08-110890	http://dx.doi.org/10.1096/fj.08-110890			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18653764	Green Published			2022-12-28	WOS:000260503000013
J	Oudhoff, MJ; Bolscher, JGM; Nazmi, K; Kalay, H; van't Hof, W; Amerongen, AVN; Veerman, ECI				Oudhoff, Menno J.; Bolscher, Jan G. M.; Nazmi, Kamran; Kalay, Hakan; van't Hof, Wim; Amerongen, Arie V. Nieuw; Veerman, Enno C. I.			Histatins are the major wound-closure stimulating factors in human saliva as identified in a cell culture assay	FASEB JOURNAL			English	Article						cell migration; ERK1/2; antimicrobial peptides; epithelial cells; Candida albicans	EPIDERMAL-GROWTH-FACTOR; ANTIMICROBIAL PEPTIDES; FACTOR RECEPTOR; ORAL KERATINOCYTES; SUBMAXILLARY GLAND; MIGRATION; MOUSE; LL-37; PROLIFERATION; ACTIVATION	Wounds in the oral cavity heal much faster than skin lesions. Among other factors, saliva is generally assumed to be of relevance to this feature. Rodent saliva contains large amounts of growth factors such as epidermal growth factor (EGF) and nerve growth factor (NGF). In humans, however, the identity of the involved compounds has remained elusive, especially since EGF and NGF concentrations are similar to 100,000 times lower than those in rodent saliva. Using an in vitro model for wound closure, we examined the properties of human saliva and the fractions that were obtained from saliva by high-performance liquid chromotography (HPLC) separation. We identified histatin 1 (Hst1) and histatin 2 (Hst2) as major wound-closing factors in human saliva. In contrast, the D-enantiomer of Hst2 did not induce wound closure, indicating stereospecific activation. Furthermore, histatins were actively internalized by epithelial cells and specifically used the extracellular signal-regulated kinases 1/2 (ERK1/2) pathway, thereby enhancing epithelial migration. This study demonstrates that members of the histatin family, which up to now were implicated in the antifungal weaponry of saliva, exert a novel function that likely is relevant for oral wound healing.-Oudhoff, M. J., Bolscher, J. G. M., Nazmi, K., Kalay, H., van 't Hof, W., Nieuw Amerongen, A. V., Veerman, E. C. I. Histatins are the major wound-closure stimulating factors in human saliva as identified in a cell culture assay. FASEB J. 22, 3805-3812 (2008)	[Oudhoff, Menno J.; Bolscher, Jan G. M.; Nazmi, Kamran; van't Hof, Wim; Amerongen, Arie V. Nieuw; Veerman, Enno C. I.] Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Oral Biochem, NL-1081 BT Amsterdam, Netherlands; [Oudhoff, Menno J.; Bolscher, Jan G. M.; Nazmi, Kamran; van't Hof, Wim; Amerongen, Arie V. Nieuw; Veerman, Enno C. I.] Vrije Univ Amsterdam, Dept Oral Biochem, NL-1081 BT Amsterdam, Netherlands; [Kalay, Hakan] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands	Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Oudhoff, MJ (corresponding author), Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Oral Biochem, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	mj.oudhoff@vumc.nl	Bolscher, Jan/ABF-6102-2021	Bolscher, Jan/0000-0001-5669-6164; Oudhoff, Menno/0000-0002-1180-8975	VU Medical Center, Amsterdam, The Netherlands [U0126, SB203580]; Netherlands Institute for Dental Sciences (IOT)	VU Medical Center, Amsterdam, The Netherlands(Netherlands Government); Netherlands Institute for Dental Sciences (IOT)	We thank F. Faulhaber, T. Duin, and D. M. Pegtel for excellent technical assistance. We also thank S. I. Gringhuis (VU Medical Center, Amsterdam, The Netherlands) for the kind gift of the inhibitors U0126 and SB203580. This work was supported by the Netherlands Institute for Dental Sciences (IOT).	Aarbiou J, 2006, INFLAMM RES, V55, P119, DOI 10.1007/s00011-005-0062-9; Amerongen AVN, 2002, ORAL DIS, V8, P12, DOI 10.1034/j.1601-0825.2002.1o816.x; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; Bercier JG, 1999, J ORAL PATHOL MED, V28, P26, DOI 10.1111/j.1600-0714.1999.tb01990.x; BODNER L, 1993, ARCH ORAL BIOL, V38, P17, DOI 10.1016/0003-9969(93)90149-G; Bolscher JGM, 2006, PEPTIDES, V27, P1, DOI 10.1016/j.peptides.2005.06.012; COHEN S, 1963, J INVEST DERMATOL, V40, P1; COHEN S, 1962, J BIOL CHEM, V237, P1555; den Hertog AL, 2005, BIOCHEM J, V388, P689, DOI 10.1042/BJ20042099; Engeland CG, 2006, ARCH SURG-CHICAGO, V141, P1193, DOI 10.1001/archsurg.141.12.1193; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; Frey MR, 2004, J BIOL CHEM, V279, P44513, DOI 10.1074/jbc.M406253200; Groschl M, 2005, J MOL ENDOCRINOL, V34, P353, DOI 10.1677/jme.1.01658; Gusman H, 2004, ARCH ORAL BIOL, V49, P11, DOI 10.1016/S0003-9969(03)00182-1; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; HUTSON JM, 1979, NATURE, V279, P793, DOI 10.1038/279793a0; Jagla W, 1999, CELL TISSUE RES, V298, P161, DOI 10.1007/s004419900087; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KONTUREK SJ, 1988, GASTROENTEROLOGY, V94, P1300, DOI 10.1016/0016-5085(88)90667-1; MATTHAY MA, 1993, J CELL SCI, V106, P869; MURPHY RA, 1980, J HISTOCHEM CYTOCHEM, V28, P890, DOI 10.1177/28.8.6969274; Nam JW, 2007, ORAL DIS, V13, P187, DOI 10.1111/j.1601-0825.2006.01265.x; Niyonsaba F, 2007, J INVEST DERMATOL, V127, P594, DOI 10.1038/sj.jid.5700599; Ohshima M, 2002, EUR J ORAL SCI, V110, P130, DOI 10.1034/j.1600-0722.2002.11179.x; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Storesund T, 2008, EUR J ORAL SCI, V116, P135, DOI 10.1111/j.1600-0722.2007.00516.x; THESLEFF I, 1988, LIFE SCI, V43, P13, DOI 10.1016/0024-3205(88)90231-7; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; van 't Hof W, 2001, BIOL CHEM, V382, P597, DOI 10.1515/BC.2001.072; VANSETTEN GB, 1995, LARYNGOSCOPE, V105, P610, DOI 10.1288/00005537-199506000-00009; Veerman ECI, 1996, EUR J ORAL SCI, V104, P346, DOI 10.1111/j.1600-0722.1996.tb00090.x; Veerman ECI, 2007, J BIOL CHEM, V282, P18831, DOI 10.1074/jbc.M610555200; von Haussen J, 2008, LUNG CANCER, V59, P12, DOI 10.1016/j.lungcan.2007.07.014; Wang Q, 2005, EMBO REP, V6, P942, DOI 10.1038/sj.embor.7400491; XU T, 1990, J DENT RES, V69, P1717, DOI 10.1177/00220345900690110301	36	154	159	2	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2008	22	11					3805	3812		10.1096/fj.08-112003	http://dx.doi.org/10.1096/fj.08-112003			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18650243				2022-12-28	WOS:000260503000009
J	Rabaneda, LG; Carrasco, M; Lopez-Toledano, MA; Murillo-Carretero, M; Ruiz, FA; Estrada, C; Castro, C				Rabaneda, Luis G.; Carrasco, Manuel; Lopez-Toledano, Miguel A.; Murillo-Carretero, Maribel; Ruiz, Felix A.; Estrada, Carmen; Castro, Carmen			Homocysteine inhibits proliferation of neuronal precursors in the mouse adult brain by impairing the basic fibroblast growth factor signaling cascade and reducing extracellular regulated kinase 1/2-dependent cyclin E expression	FASEB JOURNAL			English	Article						hyperhomocysteinemia; neurogenesis; subventricular zone; dentate gyrus; dementia	NEURAL STEM-CELLS; MILD COGNITIVE IMPAIRMENT; LONG-TERM POTENTIATION; DENTATE GYRUS; SUBVENTRICULAR ZONE; NITRIC-OXIDE; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; MAMMALIAN BRAIN; OLFACTORY-BULB	Hyperhomocysteinemia (HHcy)-abnormally elevated plasma levels of homocysteine (Hcy)-has been associated with the development of neurodegenerative dementia and mild cognitive impairment. This association suggests that HHcy might facilitate memory loss in the elderly. As memory loss can occur through a deteriorated neurogenic capacity, we have studied the effects of Hcy on neural progenitor cells (NPCs) both in vitro and in vivo. We show that Hcy exerts an antiproliferative effect on basic fibroblast growth factor (bFGF) -stimulated NPCs isolated from the postnatal subventricular zone (SVZ), accompanied by inactivation of the extracellular signal-regulated kinase (Erk1/2) and inhibition of Erk1/2-dependent expression of cyclin E. Using a mice model we show that, under normal folate conditions, HHcy exerts an inhibitory effect on adult brain neurogenesis. This inhibition occurs in the caudal areas of the dentate gyrus (DG) of the hippocampus, a neurogenic area mainly involved in learning and memory performance, and in the SVZ, recently implicated in olfactory learning performance. In both areas reduced number of proliferative neuroblasts were found. Since neuroblasts are primarily bFGF-responsive progenitors already committed to a neuronal phenotype, our results strongly suggest that excess Hcy inhibits neurogenesis in the DG and SVZ by inhibiting the bFGF-dependent activation of Erk1/2 in these cells.-Rabaneda, L. G., Carrasco, M., Lo pez-Toledano, M. A., Murillo-Carretero, M., Ruiz, F. A., Estrada, C., Castro, C. Homocysteine inhibits proliferation of neuronal precursors in the mouse adult brain by impairing the bFGF signaling cascade and reducing Erk1/2-dependent cyclin E expression. FASEB J. 22, 3823-3835 (2008)	[Rabaneda, Luis G.; Carrasco, Manuel; Lopez-Toledano, Miguel A.; Murillo-Carretero, Maribel; Ruiz, Felix A.; Estrada, Carmen; Castro, Carmen] Univ Cadiz, Area Fisiol, Fac Med, Cadiz, Spain; [Ruiz, Felix A.] Hosp Univ Puerta Mar, Cadiz, Spain	Universidad de Cadiz; Universidad de Cadiz; Hospital Universitario Puerta del Mar	Castro, C (corresponding author), Plaza Falla 9, Cadiz 11003, Spain.	carmen.castro@uca.es	Lopez-Toledano, Miguel A./C-3471-2008; Carmen, Castro/C-7813-2009; Ruiz, Felix A./B-1032-2008; Carrasco, Manuel/L-8997-2014	Lopez-Toledano, Miguel A./0000-0002-5743-3750; Carmen, Castro/0000-0002-6802-0572; Ruiz, Felix A./0000-0003-0748-5015; Carrasco, Manuel/0000-0001-6666-676X; Murillo-Carretero, Maria Isabel/0000-0003-4782-937X	Spanish Ministerio de Educacion y Ciencia [SAF2005-05834, AP 2006-3924]	Spanish Ministerio de Educacion y Ciencia(Spanish Government)	We thank Antonio Torres and Jose M. Martinez for technical assistance. This work was supported by grants from the Spanish Ministerio de Educacion y Ciencia (SAF2005-05834). C. C. and F. R. are researchers in the Ramon y Cajal Program of the Spanish Ministerio de Educacion y Ciencia. L. G. R. is the recipient of a fellowship from the Spanish Ministerio de Educacion y Ciencia (AP 2006-3924).	Aimone JB, 2006, NAT NEUROSCI, V9, P723, DOI 10.1038/nn1707; Algaidi SA, 2006, EXP NEUROL, V197, P8, DOI 10.1016/j.expneurol.2005.07.003; Alvarez-Maqueda M, 2004, ATHEROSCLEROSIS, V172, P229, DOI 10.1016/j.atherosclerosis.2003.11.005; Brown JC, 1998, BIOCHEM BIOPH RES CO, V251, P669, DOI 10.1006/bbrc.1998.9535; Bull ND, 2005, J NEUROSCI, V25, P10815, DOI 10.1523/JNEUROSCI.3249-05.2005; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chen ZT, 2005, INT J DEV NEUROSCI, V23, P465, DOI 10.1016/j.ijdevneu.2005.05.007; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Courtemanche C, 2004, J IMMUNOL, V173, P3186, DOI 10.4049/jimmunol.173.5.3186; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 1997, J NEUROSCI, V17, P5046; Durga J, 2007, LANCET, V369, P208, DOI 10.1016/S0140-6736(07)60109-3; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; Gould E, 1997, J NEUROSCI, V17, P2492; Greicius MD, 2003, HIPPOCAMPUS, V13, P164, DOI 10.1002/hipo.10064; Haan MN, 2007, AM J CLIN NUTR, V85, P511, DOI 10.1093/ajcn/85.2.511; Heo JS, 2006, AM J PHYSIOL-CELL PH, V290, pC123, DOI 10.1152/ajpcell.00142.2005; Huang RFS, 1999, J NUTR, V129, P25, DOI 10.1093/jn/129.1.25; Jessberger S, 2003, EUR J NEUROSCI, V18, P2707, DOI 10.1111/j.1460-9568.2003.02986.x; Keilhoff Gerburg, 2006, Neuropsychopharmacology, V31, P1165; Kempermann G, 2000, Prog Brain Res, V127, P35; KOURY MJ, 1994, P NATL ACAD SCI USA, V91, P4067, DOI 10.1073/pnas.91.9.4067; Kruman II, 2005, NEUROREPORT, V16, P1055, DOI 10.1097/00001756-200507130-00005; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Maguire EA, 1997, J NEUROSCI, V17, P7103; Matarredona ER, 2004, BRAIN RES, V995, P274, DOI 10.1016/j.brainres.2003.10.010; Moreno-Lopez B, 2004, J NEUROSCI, V24, P85, DOI 10.1523/JNEUROSCI.1574-03.2004; Moser MB, 1998, J NEUROSCI, V18, P7535; Quadri P, 2004, AM J CLIN NUTR, V80, P114; Ravaglia G, 2006, DEMENT GERIATR COGN, V21, P51, DOI 10.1159/000089515; Ravaglia G, 2007, NEUROBIOL AGING, V28, P1810, DOI 10.1016/j.neurobiolaging.2006.08.012; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; Robert K, 2005, NEUROSCIENCE, V133, P925, DOI 10.1016/j.neuroscience.2005.03.034; Rochefort C, 2002, J NEUROSCI, V22, P2679, DOI 10.1523/JNEUROSCI.22-07-02679.2002; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schwahn BC, 2003, FASEB J, V17, P512, DOI 10.1096/fj.02-0456fje; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Shi SS, 1999, ANTIOXID REDOX SIGN, V1, P123, DOI 10.1089/ars.1999.1.1-123; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007; Tashiro A, 2007, J NEUROSCI, V27, P3252, DOI 10.1523/JNEUROSCI.4941-06.2007; Torroglosa A, 2007, STEM CELLS, V25, P88, DOI 10.1634/stemcells.2006-0131; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163; Zhao MR, 2007, BIOL PSYCHIAT, V62, P381, DOI 10.1016/j.biopsych.2006.10.019	57	49	51	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2008	22	11					3823	3835		10.1096/fj.08-109306	http://dx.doi.org/10.1096/fj.08-109306			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18703672				2022-12-28	WOS:000260503000011
J	Arbab, AS; Janic, B; Knight, RA; Anderson, SA; Pawelczyk, E; Rad, AM; Read, EJ; Pandit, SD; Frank, JA				Arbab, Ali S.; Janic, Branislava; Knight, Robert A.; Anderson, Stasia A.; Pawelczyk, Edyta; Rad, Ali M.; Read, Elizabeth J.; Pandit, Sunil D.; Frank, Joseph A.			Detection of migration of locally implanted AC133(+) stem cells by cellular magnetic resonance imaging with histological findings	FASEB JOURNAL			English	Article						MRI; magnetically labeled AC133(+) cells; tumors; angiogenesis	ENDOTHELIAL PROGENITOR CELLS; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GROWTH-FACTOR; TUMOR ANGIOGENESIS; BLOOD; DIFFERENTIATION; TRAFFICKING; NEOVASCULARIZATION; MOBILIZATION; FERUMOXIDES	This study investigated the factors responsible for migration and homing of magnetically labeled AC133(+) cells at the sites of active angiogenesis in tumor. AC133(+) cells labeled with ferumoxide-protamine sulfate were mixed with either rat glioma or human melanoma cells and implanted in flank of nude mice. An MRI of the tumors including surrounding tissues was performed. Tumor sections were stained for Prussian blue (PB), platelet-derived growth factor (PDGF), hypoxia-inducible factor-1 alpha (HIF-1 alpha), stromal cell derived factor-1 (SDF-1), matrix metalloproteinase-2 (MMP-2), vascular endothelial growth factor (VEGF), and endothelial markers. Fresh snap-frozen strips from the central and peripheral parts of the tumor were collected for Western blotting. MRIs demonstrated hypointense regions at the periphery of the tumors where the PB+/AC133(+) cells were positive for endothelial cells markers. At the sites of PB+/AC133(+) cells, both HIF-1 alpha and SDF-1 were strongly positive and PDGF and MMP-2 showed generalized expression in the tumor and surrounding tissues. There was no significant association of PB+/AC133(+) cell localization and VEGF expression in tumor cells. Western blot demonstrated strong expression of the SDF-1, MMP-2, and PDGF at the peripheral parts of the tumors. HIF-1 alpha was expressed at both the periphery and central parts of the tumor. This work demonstrates that magnetically labeled cells can be used as probes for MRI and histological identification of administered cells.	[Arbab, Ali S.; Janic, Branislava; Knight, Robert A.; Rad, Ali M.] Henry Ford Hosp, Dept Radiol, Mol & Cellular Imaging Lab, Detroit, MI 48202 USA; [Anderson, Stasia A.] NHLBI, Mouse Core Imaging Facil, Bethesda, MD 20892 USA; [Pawelczyk, Edyta; Frank, Joseph A.] NIH, Expt Neuroimaging Sect, Lab Diagnost Radiol Res, Bethesda, MD 20892 USA; [Read, Elizabeth J.] NIH, Cell Proc Sect, Dept Transfus Med, Bethesda, MD 20892 USA; [Pandit, Sunil D.] NIH, Mol Imaging Lab, Ctr Clin, Bethesda, MD 20892 USA	Henry Ford Health System; Henry Ford Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Arbab, AS (corresponding author), Henry Ford Hlth Syst, Dept Radiol, 1 Ford Pl,2F,Box 82, Detroit, MI 48202 USA.	saali@rad.hfh.edu	Arbab, Ali/AAS-1933-2020; Frank, Joseph/W-2021-2019	Anderson, Stasia/0000-0002-2566-6947	Intramural Research Program; National Institutes of Health [5R01CA122031]; NATIONAL CANCER INSTITUTE [R01CA122031] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZICHL005909] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL090007] Funding Source: NIH RePORTER	Intramural Research Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CLINICAL CENTER	We thank Gene T. Yocum for help during the labeling of AC133<SUP>+</SUP> cells at the National Institutes of Health. We thank Dr. A. S. M. Iskander for help in sectioning of collected tumor samples and collection of AC133<SUP>+</SUP> cells from cord blood, and Dr. Hanh M. Khuu for supervision during collection of AC133<SUP>+</SUP> from volunteers. This work was supported in part by the Intramural Research Program of the Clinical Center at the National Institutes of Health and an extramural funding grant (5R01CA122031).	Agbulut O, 2004, J AM COLL CARDIOL, V44, P458, DOI 10.1016/j.jacc.2004.03.083; Allanore Y, 2007, CLIN EXP RHEUMATOL, V25, P60; Anderson SA, 2005, BLOOD, V105, P420, DOI 10.1182/blood-2004-06-2222; Anderson SA, 2004, ANN NEUROL, V55, P654, DOI 10.1002/ana.20066; Arbab AS, 2006, STEM CELLS, V24, P671, DOI 10.1634/stemcells.2005-0017; Arbab AS, 2005, NMR BIOMED, V18, P553, DOI 10.1002/nbm.991; Arbab AS, 2004, BLOOD, V104, P1217, DOI 10.1182/blood-2004-02-0655; Arbab AS, 2004, HUM GENE THER, V15, P351, DOI 10.1089/104303404322959506; ARBAB AS, 2006, MOL IMAGING, V5, P233; Asahara T, 2004, AM J PHYSIOL-CELL PH, V287, pC572, DOI 10.1152/ajpcell.00330.2003; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Detwiller KY, 2005, CANCER RES, V65, P5881, DOI 10.1158/0008-5472.CAN-04-4078; Ellis LM, 2001, SEMIN ONCOL, V28, P94, DOI 10.1053/sonc.2001.28560; Fan CL, 2003, ACTA PHARMACOL SIN, V24, P212; Ferrari N, 2003, GENE THER, V10, P647, DOI 10.1038/sj.gt.3301883; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Fomchenko EI, 2007, NEUROSURG CLIN N AM, V18, P39, DOI 10.1016/j.nec.2006.10.006; Gehling UM, 2000, BLOOD, V95, P3106; Gill M, 2001, CIRC RES, V88, P167; Hilbe W, 2004, J CLIN PATHOL, V57, P965, DOI 10.1136/jcp.2004.016444; Hotfilder M, 1997, KLIN PADIATR, V209, P265, DOI 10.1055/s-2008-1043960; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Moore XL, 2004, GENE THER, V11, P811, DOI 10.1038/sj.gt.3302151; Murohara T, 2001, TRENDS CARDIOVAS MED, V11, P303, DOI 10.1016/S1050-1738(01)00128-1; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Pawelczyk E, 2008, STEM CELLS, V26, P1366, DOI 10.1634/stemcells.2007-0707; Peterson DA, 2004, J CLIN INVEST, V114, P312, DOI 10.1172/jc1200422540; Pomyje J, 2003, EUR J HAEMATOL, V70, P143, DOI 10.1034/j.1600-0609.2003.00040.x; Rad AM, 2007, J MAGN RESON IMAGING, V26, P366, DOI 10.1002/jmri.20978; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Rigolin GM, 2007, EUR J HAEMATOL, V78, P365, DOI 10.1111/j.1600-0609.2007.00839.x; Rustemeyer P, 2007, J IMMUNOASS IMMUNOCH, V28, P13, DOI 10.1080/15321810601025549; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; SAMEJIMA N, 1988, JPN J SURG, V18, P235, DOI 10.1007/BF02471439; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; Yoshida D, 2006, J NEURO-ONCOL, V76, P13, DOI 10.1007/s11060-005-3279-0; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	54	50	53	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3234	3246		10.1096/fj.07-105676	http://dx.doi.org/10.1096/fj.07-105676			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18556461	Green Published			2022-12-28	WOS:000258761300016
J	Filiano, AJ; Bailey, CDC; Tucholski, J; Gundemir, S; Johnson, GVW				Filiano, Anthony J.; Bailey, Craig D. C.; Tucholski, Janusz; Gundemir, Soner; Johnson, Gail V. W.			Transglutaminase 2 protects against ischemic insult, interacts with HIF1 beta, and attenuates HIF1 signaling	FASEB JOURNAL			English	Article						oxygen and glucose deprivation; hypoxia; neuron	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FACTOR-I HIF-1; TISSUE-TYPE TRANSGLUTAMINASE; NEUROBLASTOMA SH-SY5Y CELLS; PIG LIVER TRANSGLUTAMINASE; CEREBRAL-ARTERY OCCLUSION; HUNTINGTONS-DISEASE BRAIN; DELAYED NEURONAL DEATH; CREB-BINDING PROTEIN; CROSS-LINKING	Transglutaminase 2 (TG2) is a multifunctional enzyme that has been implicated in the pathogenesis of neurodegenerative diseases, ischemia, and stroke. The mechanism by which TG2 modulates disease progression have not been elucidated. In this study we investigate the role of TG2 in the cellular response to ischemia and hypoxia. TG2 is up-regulated in neurons exposed to oxygen and glucose deprivation (OGD), and increased TG2 expression protects neurons against OGD-induced cell death independent of its transamidating activity. We identified hypoxia inducible factor 1 beta (HIF1 beta) as a TG2 binding partner. HIF1 beta and HIF1 alpha together form the heterodimeric transcription factor hypoxia inducible factor 1(HIF1). TG2 and the transaminase-inactive mutant C277S-TG2 inhibited a HIF-dependent transcription reporter assay under hypoxic conditions without affecting nuclear protein levels for HIF1 alpha or HIF1 beta, their ability to form the HIF1 heterodimeric transcription factor, or HIF1 binding to its DNA response element. Interestingly, TG2 attenuates the up-regulation of the HIF-dependent proapoptotic gene Bnip3 in response to OGD but had no effect on the expression of VEGF, which has been linked to prosurvival processes. This study demonstrates for the first time that TG2 protects against OGD, interacts with HIF1 beta, and attenuates the HIF1 hypoxic response pathway. These results indicate that TG2 may play an important role in protecting against the delayed neuronal cell death in ischemia and stroke.	[Filiano, Anthony J.; Gundemir, Soner; Johnson, Gail V. W.] Univ Rochester, Dept Anesthesiol, Rochester, NY 14642 USA; [Filiano, Anthony J.; Gundemir, Soner; Johnson, Gail V. W.] Univ Rochester, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; [Filiano, Anthony J.; Johnson, Gail V. W.] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; [Bailey, Craig D. C.; Tucholski, Janusz] Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA	University of Rochester; University of Rochester; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Rochester, Dept Anesthesiol, 601 Elmwood Ave,Box 604, Rochester, NY 14642 USA.	gail_johnsonvoll@urmc.rochester.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404; Bailey, Craig/0000-0002-4320-6872; Gundemir, Soner/0000-0002-9997-3552	NATIONAL INSTITUTE ON AGING [R01AG012396] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG012396, AG012396] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Akimov SS, 2001, J CELL SCI, V114, P2989; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bailey CDC, 2005, J NEUROCHEM, V92, P83, DOI 10.1111/j.1471-4159.2004.02839.x; Bailey CDC, 2004, MOL CELL NEUROSCI, V25, P493, DOI 10.1016/j.mcn.2003.11.016; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; BIRCKBICHLER PJ, 1981, P NATL ACAD SCI-BIOL, V78, P5005, DOI 10.1073/pnas.78.8.5005; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen CH, 2007, J NEUROCHEM, V102, P1831, DOI 10.1111/j.1471-4159.2007.04652.x; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FACCHIANO F, 1993, J BIOL CHEM, V268, P4588; Fath DM, 2006, J BIOL CHEM, V281, P13612, DOI 10.1074/jbc.M600456200; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Halterman MW, 1999, EXP NEUROL, V159, P65, DOI 10.1006/exnr.1999.7160; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Ientile R, 2004, NEUROSCI LETT, V363, P173, DOI 10.1016/j.neulet.2004.04.003; Ientile R, 2002, NEUROSCIENCE, V115, P723, DOI 10.1016/S0306-4522(02)00482-7; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; Joshi S, 2006, ONCOGENE, V25, P240, DOI 10.1038/sj.onc.1209027; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kasper LH, 2006, CELL CYCLE, V5, P142, DOI 10.4161/cc.5.2.2353; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Katoh S, 1996, EXP CELL RES, V222, P255, DOI 10.1006/excr.1996.0032; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kress GJ, 2002, J NEUROSCI, V22, P5848; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Lee MJ, 2004, MOL CELL BIOL, V24, P3918, DOI 10.1128/MCB.24.9.3918-3927.2004; Lesort M, 1999, J NEUROCHEM, V73, P2018; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MACCIONI RB, 1986, MOL CELL BIOCHEM, V69, P161; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Mastroberardino P, 2002, CELL DEATH DIFFER, V9, P873, DOI 10.1038/sj.cdd.4401093; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; Murthy SNP, 2002, P NATL ACAD SCI USA, V99, P2738, DOI 10.1073/pnas.052715799; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; PASTUSZKO A, 1986, J NEUROCHEM, V46, P499, DOI 10.1111/j.1471-4159.1986.tb12996.x; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PERRY MJM, 1993, INT J DEV NEUROSCI, V11, P325, DOI 10.1016/0736-5748(93)90004-W; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Pilpel Y, 2006, J NEUROCHEM, V97, P1379, DOI 10.1111/j.1471-4159.2006.03825.x; Rameau GA, 2000, NEUROPHARMACOLOGY, V39, P2255, DOI 10.1016/S0028-3908(00)00066-6; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Szondy Z, 2006, CELL DEATH DIFFER, V13, P1827, DOI 10.1038/sj.cdd.4401889; Tolentino PJ, 2004, J NEUROCHEM, V89, P1301, DOI 10.1111/j.1471-4159.2004.02436.x; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Tucholski J, 2003, J BIOL CHEM, V278, P26838, DOI 10.1074/jbc.M303683200; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Van Hoecke M, 2007, MOL CELL NEUROSCI, V34, P40, DOI 10.1016/j.mcn.2006.09.009; Verma A, 2006, CANCER RES, V66, P10525, DOI 10.1158/0008-5472.CAN-06-2387; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Zemaitaitis MO, 2003, J NEUROPATH EXP NEUR, V62, P173, DOI 10.1093/jnen/62.2.173	84	60	60	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2662	2675		10.1096/fj.07-097709	http://dx.doi.org/10.1096/fj.07-097709			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18375543	Green Published			2022-12-28	WOS:000258089300007
J	Gembardt, F; Heringer-Walther, S; van Esch, JHM; Sterner-Kock, A; van Veghel, R; Le, TH; Garrelds, IM; Coffman, TM; Danser, AHJ; Schultheiss, HP; Walther, T				Gembardt, Florian; Heringer-Walther, Silvia; van Esch, Joep H. M.; Sterner-Kock, Anja; van Veghel, Richard; Le, Thu H.; Garrelds, Ingrid M.; Coffman, Thomas M.; Danser, A. H. Jan; Schultheiss, Heinz-Peter; Walther, Thomas			Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors	FASEB JOURNAL			English	Article						hemodynamics; receptor genes; transgenic mice; transmembrane-spanning receptors	BLOOD-PRESSURE; AT(2) RECEPTOR; MESSENGER-RNA; AT(1) RECEPTORS; TYPE-2 RECEPTOR; DEFICIENT MICE; URINARY-TRACT; AT2 RECEPTOR; KIDNEY; EXPRESSION	Angiotensin II activates two distinct receptors, the angiotensin II receptors type 1 (AT1) and type 2 (AT2). In rodents, two AT1 subtypes were identified (AT1a and AT1b). To determine receptor-specific functions and possible angiotensin II effects independent of its three known receptors we generated mice deficient in either one of the angiotensin II receptors, in two, or in all three (triple knockouts). Triple knockouts were vital and fertile, but survival was impaired. Hypotension and renal histological abnormalities in triple knockouts were comparable to those in mice lacking both AT1 subtypes. All combinations lacking AT1a were distinguished by reduced heart rate. AT1a deletion impaired the in vivo pressor response to angiotensin II bolus injection, whereas deficiency for AT1b and/or AT2 had no effect. However, the additional lack of AT1b in AT1a-deficient mice further impaired the vasoconstrictive capacity of angiotensin II. Although general vasoconstrictor properties were not changed, angiotensin II failed to alter blood pressure in triple knockouts, indicating that there are no other receptors involved in direct angiotensin II pressor effects. Our data identify mice deficient in all three angiotensin II receptors as an ideal tool to better understand the structure and function of the renin-angiotensin system and to search for angiotensin II effects independent of AT1 and AT2.	[Gembardt, Florian; Heringer-Walther, Silvia; van Esch, Joep H. M.; van Veghel, Richard; Garrelds, Ingrid M.; Danser, A. H. Jan; Schultheiss, Heinz-Peter; Walther, Thomas] Charite, Dept Cardiol, Berlin, Germany; [Gembardt, Florian; Heringer-Walther, Silvia; van Esch, Joep H. M.; van Veghel, Richard; Garrelds, Ingrid M.; Danser, A. H. Jan; Schultheiss, Heinz-Peter; Walther, Thomas] Erasmus MC, Dept Pharmacol, Rotterdam, Netherlands; [Sterner-Kock, Anja] Free Univ Berlin, Inst Vet Pathol, D-1000 Berlin, Germany; [Le, Thu H.; Coffman, Thomas M.] Durham VA Med Ctr, Durham, NC USA; [Le, Thu H.; Coffman, Thomas M.] Duke Univ, Dept Med, Durham, NC USA; [Gembardt, Florian; Heringer-Walther, Silvia; Schultheiss, Heinz-Peter; Walther, Thomas] Univ Hull, Hull York Med Sch, Dept Biomed Sci, Kingston Upon Hull HU6 7RX, N Humberside, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Erasmus University Rotterdam; Erasmus MC; Free University of Berlin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; University of Hull; University of York - UK	Walther, T (corresponding author), Univ Hull, Hull York Med Sch, Dept Biomed Sci, Wolfson Bldg,Cottingham Rd, Kingston Upon Hull HU6 7RX, N Humberside, England.	thomas.walther@hyms.ac.uk	Danser, Jan/GLR-1479-2022; Gembardt, Florian/H-2360-2011	Gembardt, Florian/0000-0003-2739-345X				AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; Alexiou T, 2005, J HYPERTENS, V23, P945, DOI 10.1097/01.hjh.0000166834.32817.41; Andresen BT, 2005, AM J PHYSIOL-RENAL, V288, pF763, DOI 10.1152/ajprenal.00323.2004; Batenburg WW, 2006, J HYPERTENS, V24, P1355, DOI 10.1097/01.hjh.0000234116.17778.63; BURSON JM, 1994, AM J PHYSIOL, V267, pE260, DOI 10.1152/ajpendo.1994.267.2.E260; Crowley SD, 2007, TRENDS CARDIOVAS MED, V17, P30, DOI 10.1016/j.tcm.2006.11.002; DANSER AHJ, 1994, HYPERTENSION, V24, P37, DOI 10.1161/01.HYP.24.1.37; Dendorfer A, 2005, HANDB EXP PHARM, V170, P407; Dendorfer A, 1998, BASIC RES CARDIOL, V93, P24; GASC JM, 1994, HYPERTENSION, V24, P531, DOI 10.1161/01.HYP.24.5.531; Gembardt F, 2005, PEPTIDES, V26, P1270, DOI 10.1016/j.peptides.2005.01.009; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; Gross V, 2000, KIDNEY INT, V57, P191, DOI 10.1046/j.1523-1755.2000.00820.x; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; IWAI N, 1992, BIOCHEM BIOPH RES CO, V188, P298, DOI 10.1016/0006-291X(92)92384-A; Kihara M, 1998, KIDNEY INT, V53, P548, DOI 10.1046/j.1523-1755.1998.00801.x; Konstam MA, 2005, AM HEART J, V150, P123, DOI 10.1016/j.ahj.2004.10.035; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Li Q, 1996, BRIT J PHARMACOL, V118, P1653, DOI 10.1111/j.1476-5381.1996.tb15588.x; McEwan PE, 2000, J CARDIOVASC PHARM, V36, pS144, DOI 10.1097/00005344-200036051-00045; Miyazaki Y, 2001, COMP BIOCHEM PHYS A, V128, P89, DOI 10.1016/S1095-6433(00)00299-3; Niimura F, 1995, J CLIN INVEST, V96, P2947, DOI 10.1172/JCI118366; Nishimura H, 1999, MOL CELL, V3, P1, DOI 10.1016/S1097-2765(00)80169-0; Oliverio MI, 1998, P NATL ACAD SCI USA, V95, P15496, DOI 10.1073/pnas.95.26.15496; Ouyang X, 2005, AM J PHYSIOL-RENAL, V289, pF902, DOI 10.1152/ajprenal.00141.2005; Reid JL, 2005, J RENIN-ANGIO-ALDO S, V6, P15, DOI 10.3317/jraas.2005.002; Schmieder RE, 2007, LANCET, V369, P1208, DOI 10.1016/S0140-6736(07)60242-6; SHANMUGAM S, 1995, KIDNEY INT, V47, P1095, DOI 10.1038/ki.1995.156; Siragy HM, 1999, P NATL ACAD SCI USA, V96, P6506, DOI 10.1073/pnas.96.11.6506; Steckelings UM, 2005, PEPTIDES, V26, P1401, DOI 10.1016/j.peptides.2005.03.010; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Tokuyama H, 2007, NEPHRON PHYSIOL, V106, P54, DOI 10.1159/000103910; van Esch JHM, 2006, BRIT J PHARMACOL, V148, P452, DOI 10.1038/sj.bjp.0706762; von Bohlen und Halbach O, 2001, REGUL PEPTIDES, V99, P209, DOI 10.1016/S0167-0115(01)00258-0; Walther T, 2004, EUR J PHARMACOL, V493, P161, DOI 10.1016/j.ejphar.2004.04.032; Walther T, 2007, CIRCULATION, V115, P333, DOI 10.1161/CIRCULATIONAHA.106.643296; Zhai PY, 2005, J CLIN INVEST, V115, P3045, DOI 10.1172/JCI25330	39	37	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					3068	3077		10.1096/fj.08-108316	http://dx.doi.org/10.1096/fj.08-108316			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18497303				2022-12-28	WOS:000258089300046
J	Guinez, C; Mir, AM; Dehennaut, V; Cacan, R; Harduin-Lepers, A; Michalski, JC; Lefebvre, T				Guinez, Celine; Mir, Anne-Marie; Dehennaut, Vanessa; Cacan, Rene; Harduin-Lepers, Anne; Michalski, Jean-Claude; Lefebvre, Tony			Protein ubiquitination is modulated by O-GlcNAc glycosylation	FASEB JOURNAL			English	Article						OGT RNA interference; heat shock; proteasomal degradation	NUCLEOCYTOPLASMIC PROTEINS; PHOSPHORYLATION; DEGRADATION; TURNOVER; NUCLEAR; GLUCOSE; STRESS; SENSOR	During the past two decades, O-GlcNAc modification of cytosolic and nuclear proteins has been intensively studied. Nevertheless, the function of this post-translational modification remains unclear. It has been recently speculated that O-GlcNAc could act as a protective signal against proteasomal degradation, both by modifying target substrates and/or by inhibiting the proteasome itself. In this work, we have investigated the putative relation between O-GlcNAc and the ubiquitin pathway. First, we showed that the level of both modifications increased rapidly after thermal stress but, unlike ubiquitinated proteins, O-GlcNAc-modified proteins failed to be stabilized by inhibiting proteasome function. Increasing O-GlcNAc levels, using glucosamine or PUGNAc, enhanced ubiquitination. Inversely, when O-GlcNAc levels were reduced, using forskolin or glucose deprivation, ubiquitination decreased. Targeted-RNA interference of O-GlcNAc transferase also reduced ubiquitination and moreover halved cell thermotolerance. Finally, we demonstrated that the ubiquitin-activating enzyme E1 was O-GlcNAc modified and that its glycosylation and its interaction with Hsp70 varied according to the conditions of cell culture. Altogether, these results show that O-GlcNAc and ubiquitin are not strictly antagonistic post-translational modifications, but rather that the former might regulate the latter, and also suggest that E1 could be one of the common links between the two pathways.	[Guinez, Celine; Mir, Anne-Marie; Dehennaut, Vanessa; Cacan, Rene; Harduin-Lepers, Anne; Michalski, Jean-Claude; Lefebvre, Tony] USTL, Lab Glycobiol Struct & Fonctionnelle, CNRS, UMR 8576,IFR 147, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Lefebvre, T (corresponding author), USTL, Lab Glycobiol Struct & Fonctionnelle, CNRS, UMR 8576,IFR 147, F-59655 Villeneuve Dascq, France.	tony.lefebvre@univ-lille1.fr	dehennaut, vanessa/I-7435-2018; Anne, Harduin-Lepers/O-7503-2017; Lefebvre, Tony/AAZ-1724-2021; Lefebvre, Tony/AAW-9169-2021	dehennaut, vanessa/0000-0001-6421-0793; Anne, Harduin-Lepers/0000-0002-1233-3799; Lefebvre, Tony/0000-0001-9883-2240; 				Cacan R, 1998, BIOCHIMIE, V80, P59, DOI 10.1016/S0300-9084(98)80057-6; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; Cole RN, 2001, J NEUROCHEM, V79, P1080, DOI 10.1046/j.1471-4159.2001.00655.x; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Guinez C, 2006, GLYCOBIOLOGY, V16, P22, DOI 10.1093/glycob/cwj041; Guinez C, 2004, BIOCHEM BIOPH RES CO, V319, P21, DOI 10.1016/j.bbrc.2004.04.144; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Lefebvre T, 2001, BIOCHEM J, V360, P179, DOI 10.1042/0264-6021:3600179; Love, 2005, SCI STKE, V2005, DOI DOI 10.1126/STKE.3122005RE13; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; MAYER J, 2005, ESSAYS BIOCH UBIQUIT; Minegishi N, 2005, GENES CELLS, V10, P693, DOI 10.1111/j.1365-2443.2005.00864.x; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Pines J, 2005, NAT CELL BIOL, V7, P731, DOI 10.1038/ncb0805-731; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Sohn KC, 2004, BIOCHEM BIOPH RES CO, V322, P1045, DOI 10.1016/j.bbrc.2004.08.023; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; Walgren JLE, 2003, AM J PHYSIOL-ENDOC M, V284, pE424, DOI 10.1152/ajpendo.00382.2002; Windheim M, 2008, BIOCHEM J, V409, P723, DOI 10.1042/BJ20071338; Yang WH, 2006, NAT CELL BIOL, V8, P1074, DOI 10.1038/ncb1470; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zachara NE, 2004, TRENDS CELL BIOL, V14, P218, DOI 10.1016/j.tcb.2004.03.005; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	27	82	85	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2901	2911		10.1096/fj.07-102509	http://dx.doi.org/10.1096/fj.07-102509			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18434435				2022-12-28	WOS:000258089300030
J	Rotem, S; Radzishevsky, IS; Bourdetsky, D; Navon-Venezia, S; Carmeli, Y; Mor, A				Rotem, Shahar; Radzishevsky, Inna S.; Bourdetsky, Dmitry; Navon-Venezia, Shiri; Carmeli, Yehuda; Mor, Amram			Analogous oligo-acyl-lysines with distinct antibacterial mechanisms	FASEB JOURNAL			English	Article						host defense peptides; peptidomimetics; mechanism of action; intracellular targets	CATIONIC ANTIMICROBIAL PEPTIDES; MEMBRANE-BINDING PROPERTIES; DERMASEPTIN S4 DERIVATIVES; DE-NOVO DESIGN; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; CYTOPLASMIC MEMBRANE; NEUTROPHIL DEFENSIN; ANTIBIOTIC-ACTIVITY	Bactericidal properties were recently shown to emerge from hydrophobicity and charge buildup in oligo-acyl-lysine (OAK) peptide mimetics. Toward understanding the attributes that govern the activity of this novel antimicrobial system, we compared the functional and mechanistic properties of a known octamer and a newly generated hexamer analog. The data provide strong evidence for multiple similarities that included high tissue stability, low hemolysis, large-spectrum antibacterial activity in vitro, and the ability to prevent Escherichia coli-induced mortality in vivo. Despite these similarities, however, the octamer mode of action involved membrane disruption, unlike the hexamer, which acted predominantly through inhibition of DNA functions with characteristically slower bactericidal kinetics. Collectively, the data support the view that the analogous OAKs induced bacterial death by distinct mechanisms and further suggest that relatively minor differences in the sequence of host defense peptides are responsible for selecting one mechanism over another, possibly in conjunction with differential binding affinities to the external and/or cytoplasmic membrane.	[Mor, Amram] Technion Israel Inst Technol, Dept Biotechnol & Food Engn, LAPI, Haifa, Israel; [Navon-Venezia, Shiri; Carmeli, Yehuda] Tel Aviv Sourasky Med Ctr, Dept Epidemiol, Tel Aviv, Israel	Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Mor, A (corresponding author), Technion Israel Inst Technol, Dept Biotechnol & Food Engn, LAPI, Haifa, Israel.	amor@tx.technion.ac.il		Radzishevsky, Inna/0000-0001-7748-7599; Navon-Venezia, Shiri/0000-0002-4916-110X				Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; Bradshaw JP, 2003, BIODRUGS, V17, P233, DOI 10.2165/00063030-200317040-00002; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Frimodt-Moller N., 1999, HDB ANIMAL MODELS IN, P127, DOI [10.1016/B978-012775390-4/50153-6, DOI 10.1016/B978-012775390-4/50153-6]; Gaidukov L, 2003, BIOCHEMISTRY-US, V42, P12866, DOI 10.1021/bi034514x; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Gordon YJ, 2005, CURR EYE RES, V30, P505, DOI 10.1080/02713680590968637; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; HOBEN HJ, 1982, APPL ENVIRON MICROB, V44, P1246, DOI 10.1128/AEM.44.5.1246-1247.1982; Iverson BL, 1997, NATURE, V385, P113, DOI 10.1038/385113a0; Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05; Kirshenbaum K, 1998, P NATL ACAD SCI USA, V95, P4303, DOI 10.1073/pnas.95.8.4303; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Lee IH, 1997, INFECT IMMUN, V65, P2898, DOI 10.1128/IAI.65.7.2898-2903.1997; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Liu DH, 2001, J AM CHEM SOC, V123, P7553, DOI 10.1021/ja0107475; Lockwood NA, 2004, BIOCHEM J, V378, P93, DOI 10.1042/BJ20031393; Majerle A, 2003, J ANTIMICROB CHEMOTH, V51, P1159, DOI 10.1093/jac/dkg219; Marynka K, 2007, CHEM BIOL, V14, P75, DOI 10.1016/j.chembiol.2006.11.009; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P15144, DOI 10.1021/bi9811617; Minahk CJ, 2003, LETT APPL MICROBIOL, V37, P374, DOI 10.1046/j.1472-765X.2003.01411.x; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; MOR A, 1994, J BIOL CHEM, V269, P31635; Morton CO, 2007, MOL MICROBIOL, V65, P494, DOI 10.1111/j.1365-2958.2007.05801.x; Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002; Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097; Patch JA, 2003, J AM CHEM SOC, V125, P12092, DOI 10.1021/ja037320d; Patrzykat A, 2002, ANTIMICROB AGENTS CH, V46, P605, DOI 10.1128/AAC.46.3.605-614.2002; Radzishevsky I, 2007, ANTIMICROB AGENTS CH, V51, P1753, DOI 10.1128/AAC.01288-06; Radzishevsky IS, 2007, NAT BIOTECHNOL, V25, P657, DOI 10.1038/nbt1309; Radzishevsky IS, 2005, ANTIMICROB AGENTS CH, V49, P2412, DOI 10.1128/AAC.49.6.2412-2420.2005; Rotem S, 2006, ANTIMICROB AGENTS CH, V50, P2666, DOI 10.1128/AAC.00030-06; Rozek A, 2003, BIOCHEMISTRY-US, V42, P14130, DOI 10.1021/bi035643g; Rydlo T, 2006, ANTIMICROB AGENTS CH, V50, P490, DOI 10.1128/AAC.50.2.490-497.2006; Sahl HG, 2005, J LEUKOCYTE BIOL, V77, P466, DOI 10.1189/jlb.0804452; Schwetz BA, 2001, JAMA-J AM MED ASSOC, V285, P724, DOI 10.1001/jama.285.6.724-a; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Shalev DE, 2006, J BIOL CHEM, V281, P9432, DOI 10.1074/jbc.M513051200; Tew GN, 2002, P NATL ACAD SCI USA, V99, P5110, DOI 10.1073/pnas.082046199; Tossi A, 1997, Methods Mol Biol, V78, P133; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; Xiong YQ, 1999, ANTIMICROB AGENTS CH, V43, P1111, DOI 10.1128/AAC.43.5.1111; Yang D, 2004, ANNU REV IMMUNOL, V22, P181, DOI 10.1146/annurev.immunol.22.012703.104603; Yeaman MR, 1998, J CLIN INVEST, V101, P178, DOI 10.1172/JCI562; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang LJ, 2000, ANTIMICROB AGENTS CH, V44, P3317, DOI 10.1128/AAC.44.12.3317-3321.2000	50	59	59	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2652	2661		10.1096/fj.07-105015	http://dx.doi.org/10.1096/fj.07-105015			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18385215				2022-12-28	WOS:000258089300006
J	Beamer, CA; Holian, A				Beamer, Celine A.; Holian, Andrij			Silica suppresses Toll-like receptor ligand-induced dendritic cell activation	FASEB JOURNAL			English	Article						pattern recognition receptor; costimulatory molecule; TLR4; MARCO	SCAVENGER RECEPTOR; CRYSTALLINE SILICA; T-CELL; PULMONARY CLEARANCE; TH2 RESPONSES; UNITED-STATES; NITRIC-OXIDE; MACROPHAGES; EXPOSURE; ANTIGEN	Inhalation of silica, without evidence of silicosis, is believed to predispose individuals to bacterial infections and impair respiratory immune functions. Silica may alter the sensitivity of antigen-presenting cells (APCs), such as macrophages and dendritic cells (DCs), to other types of infection; however, the exact nature of these exchanges remains uncertain. The purpose of the present study is to characterize the effect of silica exposure on innate pulmonary defense mechanisms following Toll-like receptor (TLR) ligand-induced activation using DCs as a model APC and determine whether these signals act in synergy or opposition to one another. Using C57B1/6 mice, pattern recognition receptor expression on DCs was examined in vitro and in vivo using flow cytometry, and the activation state of pulmonary and granulocyte-macrophage colony-stimulating factor-derived DCs was assessed in response to silica in combination with TLR ligands (lipopolysaccharide, cytosine-phosphate-guanine, or polyinosinic: polycytidylic acid) using flow cytometry and measurement of cytokine production. In this study, silica attenuated TLR ligand-dependent DC activation with regards to accessory molecule expression as well as nitric oxide and inflammatory cytokine production. Furthermore, silica's ability to modulate TLR ligand-dependent DC activation did not appear to be dependent on the class A scavenger receptors. Taken together, silica's ability to alter susceptibility to infection may be due to impaired inflammatory responses and reduced antibacterial activity.	[Beamer, Celine A.; Holian, Andrij] Univ Montana, Ctr Environm Hlth Sci, Sch Pharm & Allied Hlth Sci, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA	University of Montana System; University of Montana	Beamer, CA (corresponding author), Univ Montana, Ctr Environm Hlth Sci, Sch Pharm & Allied Hlth Sci, Dept Biomed & Pharmaceut Sci, 32 Campus Dr,Skaggs Bldg,Rm 285A, Missoula, MT 59812 USA.	celine.beamer@umontana.edu		Holian, Andrij/0000-0003-0072-4538; Beamer, Celine/0000-0003-4995-6145	NCRR NIH HHS [P20 RR17670, P20 RR017670] Funding Source: Medline; NIEHS NIH HHS [ES-015294, ES-013044, F32 ES013044, R01 ES015294] Funding Source: Medline; NIGMS NIH HHS [P30 GM103338] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015294, F32ES013044] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonini JM, 2000, INHAL TOXICOL, V12, P1017; Antonini JM, 2000, LUNG, V178, P341, DOI 10.1007/s004080000038; Bang KM, 2005, INT J TUBERC LUNG D, V9, P437; Beamer CA, 2005, AM J PHYSIOL-LUNG C, V289, pL186, DOI 10.1152/ajplung.00474.2004; Beamer CA, 2007, AM J RESP CELL MOL, V37, P729, DOI 10.1165/rcmb.2007-0099OC; Becker M, 2006, EUR J IMMUNOL, V36, P950, DOI 10.1002/eji.200535660; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552; Choi JK, 2005, J ENVIRON PATHOL TOX, V24, P163, DOI 10.1615/JEnvPathToxOncol.v24.i3.30; Coleman JW, 2002, CLIN EXP IMMUNOL, V129, P4, DOI 10.1046/j.1365-2249.2002.01918.x; COWIE RL, 1994, AM J RESP CRIT CARE, V150, P1460, DOI 10.1164/ajrccm.150.5.7952577; Dahl M, 2007, J CLIN INVEST, V117, P757, DOI 10.1172/JCI29968; del Hoyo GM, 2002, BLOOD, V99, P999, DOI 10.1182/blood.V99.3.999; Delclaux C, 2003, EUR RESPIR J, V22, p10S, DOI 10.1183/09031936.03.00420203; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Ding M, 2006, AM J PHYSIOL-LUNG C, V290, pL291, DOI 10.1152/ajplung.00053.2005; Ding M, 2002, INT IMMUNOPHARMACOL, V2, P173, DOI 10.1016/S1567-5769(01)00170-9; Granucci F, 2003, BLOOD, V102, P2940, DOI 10.1182/blood-2002-12-3651; Hamilton RF, 2006, J BIOL CHEM, V281, P34218, DOI 10.1074/jbc.M605229200; HANNA PC, 1993, P NATL ACAD SCI USA, V90, P10198, DOI 10.1073/pnas.90.21.10198; Hwang M, 2007, J BIOMED MATER RES A, V80A, P513, DOI 10.1002/jbm.a.31106; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kaisho T, 2004, MICROBES INFECT, V6, P1388, DOI 10.1016/j.micinf.2004.08.019; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2001, EUR RESPIR J, V18, P692; Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Migliaccio CT, 2005, TOXICOL APPL PHARM, V205, P168, DOI 10.1016/j.taap.2004.11.005; Ovrevik J, 2004, TOXICOL SCI, V81, P480, DOI 10.1093/toxsci/kfh214; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Parks CG, 2002, ARTHRITIS RHEUM-US, V46, P1840, DOI 10.1002/art.10368; Piercy J, 2006, IMMUNOLOGY, V118, P250, DOI 10.1111/j.1365-2567.2006.02363.x; Rao TD, 1998, IMMUNOL INVEST, V27, P181, DOI 10.3109/08820139809089455; Rees D, 2007, INT J TUBERC LUNG D, V11, P474; Robbins CS, 2004, AM J RESP CELL MOL, V30, P202, DOI 10.1165/rcmb.2003-0259OC; Saalmuller A, 2006, VET MICROBIOL, V117, P32, DOI 10.1016/j.vetmic.2006.04.007; Saeki H, 1996, VET PARASITOL, V61, P201, DOI 10.1016/0304-4017(95)00823-3; Samarasinghe R, 2006, J INTERF CYTOK RES, V26, P893, DOI 10.1089/jir.2006.26.893; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Stumbles PA, 1999, IMMUNOL CELL BIOL, V77, P428, DOI 10.1046/j.1440-1711.1999.00850.x; Swanson KA, 2004, J IMMUNOL, V173, P4875, DOI 10.4049/jimmunol.173.8.4875; Swanson KA, 2004, AM J RESP CELL MOL, V30, P311, DOI 10.1165/rcmb.2003-0268OC; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Tsoumakidou M, 2006, IMMUNOL CELL BIOL, V84, P267, DOI 10.1111/j.1440-1711.2006.01428.x; VOGEL SN, 1982, INFECT IMMUN, V38, P681, DOI 10.1128/IAI.38.2.681-685.1982; Wan H, 2005, CELL MOL IMMUNOL, V2, P28; Wang SD, 2004, MICROBES INFECT, V6, P759, DOI 10.1016/j.micinf.2004.03.007; ZIMMERMAN BT, 1986, IMMUNOLOGY, V59, P521	55	21	21	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2053	2063		10.1096/fj.07-095299	http://dx.doi.org/10.1096/fj.07-095299			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18180331				2022-12-28	WOS:000256352700044
J	Voisin, T; El Firar, A; Rouyer-Fessard, C; Gratio, V; Laburthe, M				Voisin, Thierry; El Firar, Aadil; Rouyer-Fessard, Christiane; Gratio, Valerie; Laburthe, Marc			A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism	FASEB JOURNAL			English	Article						hypocretin; cancer cell death; colon cancer; tyrosine phosphatase; SHP-2	CANCER CELL-PROLIFERATION; COLON-CANCER; NEUROBLASTOMA-CELLS; EPIDERMAL-GROWTH; TYPE-2 RECEPTOR; LEUKEMIA-CELLS; CA2+ ENTRY; T-CELLS; ACTIVATION; PHOSPHATASE	Orexins acting at the G protein-coupled receptor (GPCR) OX1R have recently been shown to promote dramatic apoptosis in cancer cells. We report here that orexin-induced apoptosis is driven by an immunoreceptor tyrosine-based inhibitory motif (ITIM) ((IIYNFL)-N-358) present in the OX1R. This effect is mediated by SHP-2 phosphatase recruitment via a mechanism that requires Gq protein but is independent of phospholipase C activation. This is based on the following observations: 1) mutation of Y-358 into F abolished orexin-induced tyrosine phosphorylation in ITIM, orexin-induced apoptosis, and uncoupled OX1R from Gq protein in transfected Chinese hamster ovary (CHO) cells; 2) orexin-induced apoptosis in CHO cells expressing recombinant OX1R and in colon cancer cells expressing the native receptor was abolished by treatment with the tyrosine phosphatase inhibitor PAO and by transfection with a dominant-negative mutant of SHP-2; 3) orexins were unable to promote apoptosis in fibroblast cells invalidated for the G alpha q subunit and transfected with OX1R cDNA, whereas they promoted apoptosis in cells equipped with G alpha q and OX1R; and 4) the phospholipase C inhibitor U-73122 blocked orexin-stimulated inositol phosphate formation, whereas it had no effect on orexin-induced apoptosis in CHO cells expressing OX1R. These data unravel a novel mechanism, whereby ITIM-expressing GPCRs may trigger apoptosis.	INSERM, U773, Ctr Rech Biomed Bichat Beaujon CRB3, F-75018 Paris, France; Univ Paris Diderot, UMR 773, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Voisin, T (corresponding author), INSERM, U773, Ctr Rech Biomed Bichat Beaujon CRB3, F-75018 Paris, France.	tvoisin@bichat.inserm.fr	voisin, thierry/R-1241-2017; LABURTHE, Marc/C-1875-2012	voisin, thierry/0000-0002-4320-5183; 				Akl H, 2007, LEUKEMIA, V21, P788, DOI 10.1038/sj.leu.2404585; Barrow AD, 2006, EUR J IMMUNOL, V36, P1646, DOI 10.1002/eji.200636195; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Caravatta L, 2008, J CELL PHYSIOL, V214, P192, DOI 10.1002/jcp.21186; Cetin S, 2007, AM J PHYSIOL-GASTR L, V292, pG1347, DOI 10.1152/ajpgi.00375.2006; Chen J, 2004, ONCOGENE, V23, P3659, DOI 10.1038/sj.onc.1207471; Darmoul D, 2004, MOL CANCER RES, V2, P514; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Duchesne C, 2003, J BIOL CHEM, V278, P14274, DOI 10.1074/jbc.M300425200; Edmunds C, 1999, EUR J IMMUNOL, V29, P3507, DOI 10.1002/(SICI)1521-4141(199911)29:11<3507::AID-IMMU3507>3.0.CO;2-9; Ferjoux G, 2003, MOL BIOL CELL, V14, P3911, DOI 10.1091/mbc.E03-02-0069; Ferrand A, 2005, J BIOL CHEM, V280, P10710, DOI 10.1074/jbc.M413309200; Frucht H, 1999, CLIN CANCER RES, V5, P2532; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; Gentili C, 2006, J ENDOCRINOL, V188, P69, DOI 10.1677/joe.1.06397; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hoff H, 2007, EUR J IMMUNOL, V37, P1072, DOI 10.1002/eji.200636240; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Johansson L, 2007, BRIT J PHARMACOL, V150, P97, DOI 10.1038/sj.bjp.0706959; Larsson KP, 2005, J BIOL CHEM, V280, P1771, DOI 10.1074/jbc.M406073200; Lawson AE, 2000, BLOOD, V96, P2084, DOI 10.1182/blood.V96.6.2084.h8002084_2084_2092; Magga J, 2006, BIOCHEM PHARMACOL, V71, P827, DOI 10.1016/j.bcp.2005.12.021; MAORET JJ, 1994, BIOCHEM BIOPH RES CO, V203, P465, DOI 10.1006/bbrc.1994.2205; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; Nakamura K, 2000, J IMMUNOL, V164, P631, DOI 10.4049/jimmunol.164.2.631; Nasman J, 2006, J NEUROSCI, V26, P10658, DOI 10.1523/JNEUROSCI.2609-06.2006; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rouet-Benzineb P, 2004, J BIOL CHEM, V279, P45875, DOI 10.1074/jbc.M404136200; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sakurai T, 2007, NAT REV NEUROSCI, V8, P171, DOI 10.1038/nrn2092; Sly LM, 2003, EXP HEMATOL, V31, P1170, DOI 10.1016/j.exphem.2003.09.011; Smart D, 2000, BRIT J PHARMACOL, V129, P1289, DOI 10.1038/sj.bjp.0703257; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Teijeiro R, 2002, CELL PHYSIOL BIOCHEM, V12, P31, DOI 10.1159/000047824; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Voisin T, 2003, CELL MOL LIFE SCI, V60, P72, DOI 10.1007/s000180300005; Voisin T, 2006, ENDOCRINOLOGY, V147, P4977, DOI 10.1210/en.2006-0201; Wang N, 2006, J BIOL CHEM, V281, P21878, DOI 10.1074/jbc.M605018200; Wojciechowski W, 2005, J IMMUNOL, V174, P7859, DOI 10.4049/jimmunol.174.12.7859; Yuan LP, 2005, J BIOL CHEM, V280, P42701, DOI 10.1074/jbc.M506768200; Zocchi MR, 2001, EUR J IMMUNOL, V31, P3667, DOI 10.1002/1521-4141(200112)31:12<3667::AID-IMMU3667>3.0.CO;2-G	48	41	50	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1993	2002		10.1096/fj.07-098723	http://dx.doi.org/10.1096/fj.07-098723			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198212				2022-12-28	WOS:000256352700038
J	Syriani, E; Gomez-Cabrero, A; Bosch, M; Moya, A; Abad, E; Gual, A; Gasull, X; Morales, M				Syriani, Enrique; Gomez-Cabrero, Azucena; Bosch, Marta; Moya, Alicia; Abad, Elena; Gual, Arcadi; Gasull, Xavier; Morales, Miguel			Profilin induces lamellipodia by growth factor-independent mechanism	FASEB JOURNAL			English	Article						actin cytoskeleton; cell spreading; lamella; protein transduction	TRABECULAR MESHWORK CELLS; IN-VIVO; INTRAOCULAR-PRESSURE; PROTEIN TRANSDUCTION; FUSION PROTEINS; CULTURED-CELLS; STRESS FIBERS; ACTIN; RAC; MOTILITY	Profilin has been implicated in cell motility and in a variety of cellular processes, such as membrane extension, endocytosis, and formation of focal complexes. In vivo, profilin replenish the pool of ATP-actin monomers by increasing the rate of nucleotide exchange of ADP-actin for ATP-actin, promoting the incorporation of new actin monomers at the barbed end of actin filaments. For this report, we generated a membrane-permeable version of profilin I (PTD4-PfnI) for the alteration of intracellular profilin levels taking advantage of the protein transduction technique. We show that profilin I induces lamellipodia formation independently of growth factor presence in primary bovine trabecular meshwork (BTM) cells. The effects are time- and concentration-dependent and specific to the profilin I isoform. Profilin II, the neuronal isoform, failed to extend lamellipodia in the same degree as profilin I. H133S, a mutation in the polyproline binding domain, showed a reduced ability to induce lamellipodia. H199E, mutation in the actin binding domain failed to induce membrane spreading and inhibit fetal bovine serum (FBS)-induced lamellipodia extension. Incubation with a synthetic polyproline domain peptide (GP5)3, fused to a transduction domain, abolished lamellipodia. induction by profilin or FBS. Time-lapse microscopy confirmed the effects of profilin on lamellipodia extension with a higher spreading velocity than FBS. PTD4-Pfn I was found in the inner lamellipodia domain, at the membrane leading edge where it colocalizes with endogenous profilin. While FBS-induced lamellipodia formation activates Rac1, PTD4-Pfn I stimulation did not induce Rac1 activation. We propose a role of profilin I favoring lamellipodia. formation by a mechanism downstream of growth factor.	[Syriani, Enrique; Gomez-Cabrero, Azucena; Moya, Alicia; Abad, Elena; Gual, Arcadi; Gasull, Xavier; Morales, Miguel] Univ Barcelona, Fac Med, Dept Physiol Sci 1, IDIBAPS, Barcelona 7, Spain; [Bosch, Marta] Univ Barcelona, Fac Med, Dept Cellular Biol, Barcelona 7, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona	Morales, M (corresponding author), Univ Barcelona, Fac Med, Dept Physiol Sci 1, IDIBAPS, Barcelona 7, Spain.	miguelmorales@ub.cdu	Gual, Arcadi/U-8272-2017; Morales, Miguel/G-8995-2014; Gasull, Xavier/T-9630-2017; Bosch, Marta/AAU-9099-2020	Gual, Arcadi/0000-0002-8604-3903; Morales, Miguel/0000-0002-8885-2333; Gasull, Xavier/0000-0002-6154-8323; Bosch, Marta/0000-0003-3934-6781				Ackermann M, 2003, NAT NEUROSCI, V6, P1194, DOI 10.1038/nn1135; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; BjorkegrenSjogren C, 1997, FEBS LETT, V418, P258, DOI 10.1016/S0014-5793(97)01376-8; Bompard G, 2004, J CELL BIOL, V166, P957, DOI 10.1083/jcb.200403127; Braun A, 2002, GENE, V283, P219, DOI 10.1016/S0378-1119(01)00855-1; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; Cramer LP, 1999, CURR BIOL, V9, P1095, DOI 10.1016/S0960-9822(99)80478-3; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Devineni N, 1999, BRAIN RES, V823, P129, DOI 10.1016/S0006-8993(99)01147-6; Dong JX, 2000, BBA-MOL CELL RES, V1497, P253, DOI 10.1016/S0167-4889(00)00056-2; Dubin-Thaler BJ, 2004, BIOPHYS J, V86, P1794, DOI 10.1016/S0006-3495(04)74246-0; Evans NJ, 2006, EXP BIOL MED, V231, P882; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; Gomez-Cabrero A, 2005, MOL VIS, V11, P1071; Grenklo S, 2004, EUR J CELL BIOL, V83, P413, DOI 10.1078/0171-9335-00400; Hinz B, 1999, EXP CELL RES, V251, P234, DOI 10.1006/excr.1999.4541; Ho A, 2001, CANCER RES, V61, P474; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kovacs M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Lambrechts A, 2006, J CELL SCI, V119, P1570, DOI 10.1242/jcs.02884; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Llobet A, 2003, NEWS PHYSIOL SCI, V18, P205, DOI 10.1152/nips.01443.2003; Llobet A, 1999, INVEST OPHTH VIS SCI, V40, P113; Mayboroda O, 1997, CELL MOTIL CYTOSKEL, V37, P166, DOI 10.1002/(SICI)1097-0169(1997)37:2<166::AID-CM9>3.0.CO;2-6; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Mimuro H, 2000, J BIOL CHEM, V275, P28893, DOI 10.1074/jbc.M003882200; Moens PDJ, 2007, BBA-BIOMEMBRANES, V1768, P439, DOI 10.1016/j.bbamem.2006.12.012; Moissoglu K, 2006, MOL BIOL CELL, V17, P2770, DOI 10.1091/mbc.E06-01-0005; Moldovan NI, 1997, CURR BIOL, V7, P24, DOI 10.1016/S0960-9822(06)00024-8; Morales M, 2007, EUR J PHARMACOL, V567, P145, DOI 10.1016/j.ejphar.2007.04.020; Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824; Obermann H, 2005, MOL HUM REPROD, V11, P53, DOI 10.1093/molehr/gah132; Posern G, 2000, J CELL PHYSIOL, V183, P416, DOI 10.1002/(SICI)1097-4652(200006)183:3<416::AID-JCP15>3.0.CO;2-R; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rothkegel M, 1996, J CELL SCI, V109, P83; Sathish K, 2004, CELL SIGNAL, V16, P589, DOI 10.1016/j.cellsig.2003.10.001; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Singh SS, 1996, BIOCHEMISTRY-US, V35, P16544, DOI 10.1021/bi9609634; STAMER WD, 1995, CURR EYE RES, V14, P611, DOI 10.3109/02713689508998409; Stradal TEB, 2004, TRENDS CELL BIOL, V14, P303, DOI 10.1016/j.tcb.2004.04.007; Stuven T, 2003, EMBO J, V22, P5928, DOI 10.1093/emboj/cdg565; Suetsugu S, 1999, FEBS LETT, V457, P470, DOI 10.1016/S0014-5793(99)01086-8; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Witke W, 2001, P NATL ACAD SCI USA, V98, P3832, DOI 10.1073/pnas.051515498; Wittenmayer N, 2000, EUR J BIOCHEM, V267, P5247, DOI 10.1046/j.1432-1327.2000.01600.x; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yamazaki D, 2005, GENES CELLS, V10, P381, DOI 10.1111/j.1365-2443.2005.00845.x	64	13	13	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1581	1596		10.1096/fj.06-7654com	http://dx.doi.org/10.1096/fj.06-7654com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18184720				2022-12-28	WOS:000255898700030
J	Zeng, FH; Xu, J; Harris, RC				Zeng, Fenghua; Xu, Jie; Harris, Raymond C.			Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells	FASEB JOURNAL			English	Article						E3 ubiquitin ligase; PY motif mutation; PI3 kinase; nuclear translocation	ENDOCYTIC DOWN-REGULATION; GROWTH-FACTOR RECEPTOR; WW DOMAIN; TRANSCRIPTIONAL COACTIVATOR; NUCLEAR-LOCALIZATION; CONTAINING PROTEINS; LIDDLES-SYNDROME; LIGAND; CANCER; YAP	ErbB4, a type I transmembrane receptor tyrosine kinase, is a member of the epidermal growth factor receptor family. Its cleavage releases an intracellular C-terminal domain (ICD), which can be either degraded following ubiqitination or translocated to the nucleus and regulate gene expression. There are 2 ErbB4 ICD isoforms: CYT-1 and CYT-2. We and others have previously reported that following cleavage, CYT-2 selectively translocates to the nucleus. In the current study we found that following cleavage, the intracellular levels of CYT-1 ICD decreased rapidly, while levels of CYT-2 ICD remained relatively stable. CYT-1 ICD degradation could be prevented by administration of either the proteasome inhibitor lactacystin or the lysosome inhibitor chloroquine, indicating both proteasomal and lysosomal degradation. Further studies implicated Nedd4, an E3 ubiquitin ligase, as a mediator of CYT-1 ubiquitination and degradation. The interaction of Nedd4 with CYT-1 was shown by coimmnunoprecipitation, an in vitro direct binding assay, and an in vitro ubiquitination assay. Three PPxY or PY motifs present in the CYT-1 C terminus are necessary for binding by Nedd4 WW domains, because impaired interactions are seen in mutation of any of the PY motifs. Nedd4-CYT-1 binding was associated with increased CYT-1 ubiquitination following proteasome inhibitor treatment. Impaired Nedd4 binding to CYT-1 by PY motif mutations led to increased CYT-1 ICD stability, whereas only one of the PY motif mutations (Y1056A), which disrupts the binding sites for both a WW domain and an SH2 domain of PI3 kinase, demonstrated enhanced nuclear translocation following HB-EGF treatment. These studies indicate that Nedd4 mediates ErbB4 CYT-1 ICD ubiquitination and degradation, and the prevention of both WW binding and PI3 kinase activity are required for ErbB4 nuclear translocation.-Zeng, F., Xu, J., Harris, R. C. Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells. FASEB J. 23, 1935-1945 (2009)	[Harris, Raymond C.] Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol & Hypertens, Nashville, TN 37232 USA; [Harris, Raymond C.] Nashville Vet Affairs Hosp, Nashville, TN USA	Vanderbilt University	Harris, RC (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol & Hypertens, C-3121 Med Ctr N, Nashville, TN 37232 USA.	ray.harris@vanderbilt.edu			Department of Veterans Affairs (R.H.); National Institutes of Health [DK51265]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051265] Funding Source: NIH RePORTER	Department of Veterans Affairs (R.H.)(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by funds from the Department of Veterans Affairs (R.H.) and National Institutes of Health grant DK51265 (R.H.).	Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Baulida J, 1996, J BIOL CHEM, V271, P5251; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Furuhashi M, 2005, J CLIN ENDOCR METAB, V90, P340, DOI 10.1210/jc.2004-1027; Gallo RM, 2006, BIOCHEM BIOPH RES CO, V349, P372, DOI 10.1016/j.bbrc.2006.08.055; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Hamburger AW, 1997, ANTICANCER RES, V17, P2197; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jones FE, 2008, J MAMMARY GLAND BIOL, V13, P247, DOI 10.1007/s10911-008-9076-6; Kaiser P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-233; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Levy F, 2005, MOL BIOL CELL, V16, P1777, DOI 10.1091/mbc.E04-09-0803; Longva KE, 2005, INT J CANCER, V116, P359, DOI 10.1002/ijc.21015; Luo J, 2005, P NATL ACAD SCI USA, V102, P10238, DOI 10.1073/pnas.0504378102; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Omerovic J, 2007, FASEB J, V21, P2849, DOI 10.1096/fj.06-7925com; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Sundvall M, 2007, ONCOGENE, V26, P6905, DOI 10.1038/sj.onc.1210501; Sundvall M, 2008, P NATL ACAD SCI USA, V105, P4162, DOI 10.1073/pnas.0708333105; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Zeng F, 2007, MOL BIOL CELL, V18, P4446, DOI 10.1091/mbc.E07-03-0223	33	37	39	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1935	1945		10.1096/fj.08-121947	http://dx.doi.org/10.1096/fj.08-121947			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19193720	Green Published			2022-12-28	WOS:000266652400032
J	Bartling, B; Desole, M; Rohrbach, S; Silber, RE; Simm, A				Bartling, Babett; Desole, Maximilian; Rohrbach, Susanne; Silber, Rolf-Edgar; Simm, Andreas			Age-associated changes of extracellular matrix collagen impair lung cancer cell migration	FASEB JOURNAL			English	Article						advanced glycation end products; tumor stroma; invasiveness; adhesion; proliferation; matrix metalloproteinase	ADVANCED GLYCATION ENDPRODUCTS; MAILLARD REACTION; CROSS-LINKING; EPITHELIAL-CELLS; TUMOR-CELLS; METHYLGLYOXAL; FIBROBLASTS; PROTEINS; ADHESION; GROWTH	Although advanced age is linked with an increased incidence of lung carcinomas, elderly patients develop fewer metastatic tumors than their younger counterparts. Since extracellular matrix controls carcinogenesis, we studied the effect of aged fibrillar collagen (rat tail) on the invasiveness of lung carcinoma cells (H322, H358). Two- and three-dimensional invasion assays revealed a reduced migration of lung cancer cells through a matrix of collagen from old (24 mo) compared with young (2 mo) or adult (12 mo) rats. This was most strongly observed for H322 cells, which had a better migration behavior than H358 cells. Since old collagen was increasingly modified by advanced glycation end products (AGEs; fluorescing AGEs, nonfluorescing carboxymethyllysine), we generated different AGE-collagens by treating collagen with ribose or alpha-dicarbonyls. Similarly to old collagen, AGE-collagen reduced the invasive migration of H322 cells. Subsequent analyses demonstrated that old and AGE-collagens impair distinct mechanisms contributing to cell migration, i.e., efficient cell adhesion and proteolytic degradation of collagen by membrane-type matrix metalloproteinase (MT-MMP; MT-MMP3 in H322 cells). Our data indicate that age-related alterations of the extracellular matrix contribute to a less invasive behavior of lung carcinoma cells, in which AGE modifications of aged collagen seem to play an important role. Bartling, B., Desole, M., Rohrbach, S., Silber, R.-E., Simm, A. Age-associated changes of extracellular matrix collagen impair lung cancer cell migration. FASEB J. 23, 1510-1520 (2009)	[Bartling, Babett; Desole, Maximilian; Silber, Rolf-Edgar; Simm, Andreas] Univ Hosp Halle Saale, Dept Cardiothorac Surg, D-06120 Halle, Saale, Germany; [Rohrbach, Susanne] Univ Halle Wittenberg, Inst Pathophysiol, Halle, Saale, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Bartling, B (corresponding author), Univ Hosp Halle Saale, Dept Cardiothorac Surg, Ernst Grube Str 40, D-06120 Halle, Saale, Germany.	babett.bartling@medizin.uni-halle.de			Deutsche Krebshilfe [107078]; Bundesministerium fur Bildung und Forschung (BMBF) [FKZ SI/07, FKZ3/30]; Deutsche Forschungsgemeinschaft (DFG) [Si-1317/1-1]	Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This study was supported by Deutsche Krebshilfe (107078), Wilhelm Roux grants of the Bundesministerium fur Bildung und Forschung (BMBF; FKZ SI/07, FKZ3/30), and Deutsche Forschungsgemeinschaft (DFG; Si-1317/1-1).	Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; ALBINI A, 1987, CANCER RES, V47, P3239; Avery NC, 2006, PATHOL BIOL, V54, P387, DOI 10.1016/j.patbio.2006.07.005; Bartling B, 2006, EXP GERONTOL, V41, P532, DOI 10.1016/j.exger.2006.02.006; Bartling B, 2007, EUR J CANCER, V43, P1935, DOI 10.1016/j.ejca.2007.06.010; Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3; BELLMUNT MJ, 1995, BBA-MOL BASIS DIS, V1272, P53, DOI 10.1016/0925-4439(95)00069-G; BELLMUNT MJ, 1995, LUNG, V173, P177; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Bobbink IWG, 1997, DIABETES, V46, P87, DOI 10.2337/diabetes.46.1.87; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Davenport EA, 1996, EXP CELL RES, V223, P155, DOI 10.1006/excr.1996.0069; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; DEYL Z, 1971, EXP GERONTOL, V6, P227, DOI 10.1016/0531-5565(71)90035-0; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; DYER DG, 1991, Z ERNAHRUNGSWISS, V30, P29, DOI 10.1007/BF01910730; EBBESEN P, 1984, MECH AGEING DEV, V25, P269, DOI 10.1016/0047-6374(84)90001-0; EGYUD LG, 1968, SCIENCE, V160, P1140, DOI 10.1126/science.160.3832.1140; ERSHLER WB, 1983, J AM GERIATR SOC, V31, P673, DOI 10.1111/j.1532-5415.1983.tb04153.x; ERSHLER WB, 1984, JNCI-J NATL CANCER I, V72, P161, DOI 10.1093/jnci/72.1.161; Ghosh M, 2006, TOXICOL APPL PHARM, V212, P45, DOI 10.1016/j.taap.2005.07.003; Ishikawa S, 2004, CLIN CANCER RES, V10, P6579, DOI 10.1158/1078-0432.CCR-04-0272; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kim SH, 2007, J SURG ONCOL, V95, P337, DOI 10.1002/jso.20643; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Krtolica A, 2002, INT J BIOCHEM CELL B, V34, P1401, DOI 10.1016/S1357-2725(02)00053-5; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lederer MO, 1999, BIOORGAN MED CHEM, V7, P2499, DOI 10.1016/S0968-0896(99)00212-6; Lingelbach LB, 2000, J NUTR, V130, P1247, DOI 10.1093/jn/130.5.1247; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; McCarthy AD, 2004, INT J BIOCHEM CELL B, V36, P840, DOI 10.1016/j.biocel.2003.09.006; MIKSIK I, 1991, J GERONTOL, V46, pB111, DOI 10.1093/geronj/46.3.B111; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; Morita K, 2005, WOUND REPAIR REGEN, V13, P93, DOI 10.1111/j.1067-1927.2005.130112.x; Munch G, 1999, NAT BIOTECHNOL, V17, P1006, DOI 10.1038/13704; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; PIANTANELLI L, 1988, ANN NY ACAD SCI, V521, P99, DOI 10.1111/j.1749-6632.1988.tb35268.x; Ray M, 1997, MOL CELL BIOCHEM, V177, P21, DOI 10.1023/A:1006831511527; RAY S, 1994, BIOCHEM J, V303, P69, DOI 10.1042/bj3030069; Reigle KL, 2008, J CELL BIOCHEM, V104, P1684, DOI 10.1002/jcb.21735; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sakata N, 2000, CONNECT TISSUE RES, V41, P213, DOI 10.3109/03008200009005291; Sell DR, 2001, J GERONTOL A-BIOL, V56, pB405, DOI 10.1093/gerona/56.9.B405; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Simm A, 1997, FEBS LETT, V410, P481, DOI 10.1016/S0014-5793(97)00644-3; STREULI CH, 1990, J CELL BIOL, V110, P1405; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; Weisberg E, 1997, CRIT REV ONCOGENESIS, V8, P343, DOI 10.1615/CritRevOncog.v8.i4.40; Zamir E, 2001, J CELL SCI, V114, P3583; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200	57	39	39	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1510	1520		10.1096/fj.08-122648	http://dx.doi.org/10.1096/fj.08-122648			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19109409				2022-12-28	WOS:000266651700027
J	Gao, B; Sherman, P; Luo, L; Bowie, J; Zhu, SY				Gao, Bin; Sherman, Patrick; Luo, Lan; Bowie, John; Zhu, Shunyi			Structural and functional characterization of two genetically related meucin peptides highlights evolutionary divergence and convergence in antimicrobial peptides	FASEB JOURNAL			English	Article						innate immunity; NMR structure; venomous arthropod; gene cloning; virus fusion domain	PROTEIN SECONDARY STRUCTURE; CODON-SUBSTITUTION MODELS; SCORPION-VENOM; ANTIBACTERIAL PEPTIDES; CYTOLYTIC PEPTIDES; AMPHIBIAN SKIN; DEFENSINS; SELECTION; TOXINS; DOMAIN	Both vertebrates and invertebrates employ alpha-helical antimicrobial peptides (AMPs) as an essential component of their innate immune system. However, evolutionary relation of these immune molecules remains unresolved. Venoms, as key weapons of venomous arthropods for prey and defense, receive increasing recognition as an emerging source of such peptides. From a cDNA library prepared from the venom gland of the scorpion Mesobuthus eupeus, clones encoding precursors of two new AMPs, named meucin-13 (IFGAIAGLLKNIF-NH2) and meucin-18 (FFGHLFKLATKIIPSLFQ), have been isolated. The precursor of meucins consists of a signal peptide, a mature peptide, and an acidic propeptide, in which dibasic residues as the typical processing signal are located between the mature and propeptide. Meucin-13 is an ortholog of several previously described AMPs from scorpion venom and has also detectable sequence similarity to temporins, a large family of AMPs from frog skin, whereas meucin-18 displays some similarity to AMPs from diverse origin including arthropod venoms, fish mast cells, and frog skins. These two meucin peptides form alpha-helical structure in the presence of 50% trifluoroethanol (TFE), a membrane-mimicking environment, as identified by circular dichroism (CD) spectroscopy. This finding is further verified by their NMR structures that show a typical alpha-helical amphipathic design, a structural prerequisite for cytolytic activity. Meucins exhibit extensive cytolytic effects on both prokaryotic and eukaryotic cells (gram(+) and gram(-) bacteria, fungi, yeasts, rabbit erythrocytes, and rat dorsal root ganglion cells) at micromolar concentrations. It is remarkable that muecin-18 was 2- to > 14-fold more potent than meucin-13 against nearly all the cells tested. Structural differences in hydrophilic/hydrophobic balance and cationic amino acid location between two meucins could account for their differential potency. Despite these differences, commonalities at precursor organization, three-dimensional structure, and biological function suggests that meucins are two evolutionarily related AMPs and likely originated from a common ancestor by gene duplication. Our work presented here also provides new insights into an evolutionary link among AMPs from invertebrates and vertebrates and clues for evolutionary convergence between AMPs and virus fusion domains.-Gao, B., Sherman, P., Luo, L., Bowie, J., Zhu, S. Structural and functional characterization of two genetically related meucin peptides highlights evolutionary divergence and convergence in antimicrobial peptides. FASEB J. 23, 1230-1245 (2009)	[Gao, Bin; Luo, Lan; Zhu, Shunyi] Chinese Acad Sci, Inst Zool, Grp Anim Innate Immun, State Key Lab Integrated Management Pest Insects, Beijing 100101, Peoples R China; [Sherman, Patrick; Bowie, John] Univ Adelaide, Dept Chem, Adelaide, SA, Australia	Chinese Academy of Sciences; Institute of Zoology, CAS; University of Adelaide	Zhu, SY (corresponding author), Chinese Acad Sci, Inst Zool, Grp Anim Innate Immun, State Key Lab Integrated Management Pest Insects, Datun Rd, Beijing 100101, Peoples R China.	zhusy@ioz.ac.cn			National Natural Science Foundation of China [90608009, 30621003, 30570381]; Chinese Academy of Sciences	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by grants from the National Natural Science Foundation of China ( 90608009, 30621003, and 30570381) and the Bairen Plan from the Chinese Academy of Sciences.	Amino R, 2002, J BIOL CHEM, V277, P6207, DOI 10.1074/jbc.M109874200; Andersson M, 2003, CELL MOL LIFE SCI, V60, P599, DOI 10.1007/s000180300051; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Bowdish DME, 2006, CURR TOP MICROBIOL, V306, P27; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Brown KL, 2006, CURR OPIN IMMUNOL, V18, P24, DOI 10.1016/j.coi.2005.11.004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulet P, 2004, IMMUNOL REV, V198, P169, DOI 10.1111/j.0105-2896.2004.0124.x; Comeron JM, 1995, J MOL EVOL, V41, P1152, DOI 10.1007/BF00173196; Conde R, 2000, FEBS LETT, V471, P165, DOI 10.1016/S0014-5793(00)01384-3; Conlon JM, 2004, BBA-PROTEINS PROTEOM, V1696, P1, DOI 10.1016/j.bbapap.2003.09.004; Corzo G, 2001, BIOCHEM J, V359, P35, DOI 10.1042/0264-6021:3590035; Dai L, 2001, BIOCHEM BIOPH RES CO, V286, P820, DOI 10.1006/bbrc.2001.5472; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; Duda TF, 1999, P NATL ACAD SCI USA, V96, P6820, DOI 10.1073/pnas.96.12.6820; Elgar D, 2006, AFR J BIOTECHNOL, V5, P2495; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; Ferrandon D, 1998, EMBO J, V17, P1217, DOI 10.1093/emboj/17.5.1217; Fjell CD, 2007, BIOINFORMATICS, V23, P1148, DOI 10.1093/bioinformatics/btm068; GAETA BA, 1998, DATABASE SEARCHING U; Gao B, 2008, INSECT MOL BIOL, V17, P405, DOI 10.1111/j.1365-2583.2008.00810.x; Gao B, 2007, PEPTIDES, V28, P2299, DOI 10.1016/j.peptides.2007.10.004; Han X, 2004, BIOINFORMATICS, V20, P970, DOI 10.1093/bioinformatics/bth027; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HANZAWA H, 1990, FEBS LETT, V269, P413, DOI 10.1016/0014-5793(90)81206-4; Hultmark D., 1998, TECHNIQUES INSECT IM, P103; Klaudiny J, 2005, INSECT BIOCHEM MOLEC, V35, P11, DOI 10.1016/j.ibmb.2004.09.007; Kozlov SA, 2006, J BIOL CHEM, V281, P20983, DOI 10.1074/jbc.M602168200; Kuhn-Nentwig L, 2003, CELL MOL LIFE SCI, V60, P2651, DOI 10.1007/s00018-003-3106-8; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; Lee K, 2004, BIOCHEM BIOPH RES CO, V323, P712, DOI 10.1016/j.bbrc.2004.08.144; Li JX, 2007, MOL CELL PROTEOMICS, V6, P882, DOI 10.1074/mcp.M600334-MCP200; Lorenzini DM, 2003, DEV COMP IMMUNOL, V27, P781, DOI 10.1016/S0145-305X(03)00058-2; Mader JS, 2006, EXPERT OPIN INV DRUG, V15, P933, DOI 10.1517/13543784.15.8.933; Mangoni ML, 2006, CELL MOL LIFE SCI, V63, P1060, DOI 10.1007/s00018-005-5536-y; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Mygind PH, 2005, NATURE, V437, P975, DOI 10.1038/nature04051; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Pukala TL, 2007, FEBS J, V274, P1778, DOI 10.1111/j.1742-4658.2007.05726.x; Rinaldi AC, 2002, CURR OPIN CHEM BIOL, V6, P799, DOI 10.1016/S1367-5931(02)00401-5; Silphaduang U, 2001, NATURE, V414, P268, DOI 10.1038/35104690; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Suzuki H, 2007, PEPTIDES, V28, P2061, DOI 10.1016/j.peptides.2007.07.028; Tennessen JA, 2005, J EVOLUTION BIOL, V18, P1387, DOI 10.1111/j.1420-9101.2005.00925.x; Tennessen JA, 2007, J MOL EVOL, V65, P605, DOI 10.1007/s00239-007-9045-5; Tian CH, 2008, TOXICON, V51, P555, DOI 10.1016/j.toxicon.2007.11.010; TOSSI A, 1997, ANTIBACTERIAL PEPTID, P133; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wong H, 1997, EUR J BIOCHEM, V247, P545, DOI 10.1111/j.1432-1033.1997.00545.x; WUTHRUCH K, 1986, NMR PROTEINS NUCL AC; Yang ZH, 2002, MOL BIOL EVOL, V19, P908, DOI 10.1093/oxfordjournals.molbev.a004148; Yang ZH, 2000, GENETICS, V155, P431; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Yount NY, 2004, P NATL ACAD SCI USA, V101, P7363, DOI 10.1073/pnas.0401567101; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zelezetsky I, 2005, PEPTIDES, V26, P2368, DOI 10.1016/j.peptides.2005.05.002; Zhao CQ, 2001, INFECT IMMUN, V69, P2684, DOI 10.1128/IAI.69.4.2684-2691.2001; Zhu S, 2006, FEBS LETT, V580, P6825, DOI 10.1016/j.febslet.2006.11.040; Zhu S, 2005, CELL MOL LIFE SCI, V62, P2257, DOI 10.1007/s00018-005-5200-6; Zhu S, 2004, CELL MOL LIFE SCI, V61, P1751, DOI 10.1007/s00018-004-4149-1; Zhu SY, 2008, TRENDS MICROBIOL, V16, P353, DOI 10.1016/j.tim.2008.05.007; Zhu SY, 2008, MOL IMMUNOL, V45, P2531, DOI 10.1016/j.molimm.2008.01.007; Zhu SY, 2008, MOL IMMUNOL, V45, P828, DOI 10.1016/j.molimm.2007.06.354; Zhu SY, 2009, FASEB J, V23, P13, DOI 10.1096/fj.08-114579; Zhu SY, 2004, J MOL EVOL, V58, P145, DOI 10.1007/s00239-003-2534-2; Zhu SY, 2003, FASEB J, V17, P1765, DOI 10.1096/fj.02-1044fje	71	61	66	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1230	1245		10.1096/fj.08-122317	http://dx.doi.org/10.1096/fj.08-122317			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19088182				2022-12-28	WOS:000266651600027
J	Raad, H; Paclet, MH; Boussetta, T; Kroviarski, Y; Morel, F; Quinn, MT; Gougerot-Pocidalo, MA; Dang, PMC; El-Benna, J				Raad, Houssam; Paclet, Marie-Helene; Boussetta, Tarek; Kroviarski, Yolande; Morel, Francoise; Quinn, Mark T.; Gougerot-Pocidalo, Marie-Anne; Dang, Pham My-Chan; El-Benna, Jamel			Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91(phox)/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67(phox), and p47(phox)	FASEB JOURNAL			English	Article						neutrophils; PMN; cytochrome b558; inflammation; innate immunity	RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; SITE-DIRECTED MUTAGENESIS; COLONY-STIMULATING FACTOR; CYTOCHROME B(558); HUMAN-NEUTROPHILS; FLAVOCYTOCHROME B(558); COMPONENT P47(PHOX); FLAVOPROTEIN DOMAIN; ACTIVATION	Neutrophils generate microbicidal oxidants through activation of a multicomponent enzyme called NADPH oxidase. During activation, the cytosolic NADPH oxidase components (p47(phox), p67(phox), p40(phox), and Rac2) translocate to the membranes, where they associate with flavocytochrome b(558), which is composed of gp91(phox)/NOX2 and p22(phox), to form the active system. During neutrophil stimulation, p47(phox), p67(phox), p40(phox), and p22(phox) are phosphorylated; however, the phosphorylation of gp91(phox)/NOX2 and its potential role have not been defined. In this study, we show that gp91(phox) is phosphorylated in stimulated neutrophils. The gp91(phox) phosphoprotein is absent in neutrophils from chronic granulomatous disease patients deficient in gp91(phox), which confirms that this phosphoprotein is gp91(phox). The protein kinase C inhibitor GF109203X inhibited phorbol 12-myristate 13-acetate-induced phosphorylation of gp91(phox), and protein kinase C (PKC) phosphorylated the recombinant gp91(phox)-cytosolic carboxy-terminal flavoprotein domain. Two-dimensional tryptic peptide mapping analysis showed that PKC phosphorylated the gp91(phox)-cytosolic tail on the same peptides that were phosphorylated on gp91(phox) in intact cells. In addition, PKC phosphorylation increased diaphorase activity of the gp91(phox) flavoprotein cytosolic domain and its binding to Rac2, p67(phox), and p47(phox). These results demonstrate that gp91(phox) is phosphorylated in human neutrophils by PKC to enhance its catalytic activity and assembly of the complex. Phosphorylation of gp91(phox)/NOX2 is a novel mechanism of NADPH oxidase regulation.-Raad, H., Paclet, M.-H., Boussetta, T., Kroviarski, Y., Morel, F., Quinn, M. T., Gougerot-Pocidalo, M.-A., Dang, P. M.-C., El-Benna, J. Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91(phox)/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67(phox), and p47(phox). FASEB J. 23, 1011-1022 (2009)	[El-Benna, Jamel] Univ Paris 07, INSERM, Fac Med Xavier Bichat, U773,CRB3,UMRS 773, F-75018 Paris, France; [Paclet, Marie-Helene; Morel, Francoise] CHU Grenoble, UMR CNRS 5525, GREPI, TIMC IMAG, F-38043 Grenoble, France; [Kroviarski, Yolande; Gougerot-Pocidalo, Marie-Anne] CHU Xavier Bichat, AP HP, CIB Phenogen, Paris, France; [Quinn, Mark T.] Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Grenoble Alpes; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Montana State University System; Montana State University Bozeman	El-Benna, J (corresponding author), Univ Paris 07, INSERM, Fac Med Xavier Bichat, U773,CRB3,UMRS 773, 16 Rue Henri Huchard, F-75018 Paris, France.	jamel.elbenna@inserm.fr	Paclet, Marie-Hélène/AAS-5029-2020	Quinn, Mark/0000-0001-8114-5073	FRM (Fondation pour la Recherche Medicale); ARC (Association pour la Recherche sur le Cancer); Region Rhone-Alpes; CGD Research Trust 2006, UK; "Delegation Regionale de la Recherche Clinique," CHU Grenoble, France; U.S. National Institutes of Health [AR42426, RR020185]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM110732] Funding Source: NIH RePORTER	FRM (Fondation pour la Recherche Medicale)(Fondation pour la Recherche Medicale); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer); Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); CGD Research Trust 2006, UK; "Delegation Regionale de la Recherche Clinique," CHU Grenoble, France; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We dedicate this work to the memory of Bernard M. Babior, who is no longer among us. We thank Mary Dinauer (Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Bloomington, IN, USA) and Ulla Knaus (Scripps Research Institute, La Jolla, CA, USA) for the generous gift of NOX2 cDNA and pGex-Rac2 plasmid. H. R. is a recipient of the FRM (Fondation pour la Recherche Medicale) fellowship. This work was supported by ARC (Association pour la Recherche sur le Cancer); the "Region Rhone-Alpes, program Emergence 2003," France; the CGD Research Trust 2006, UK; the "Delegation Regionale de la Recherche Clinique," CHU Grenoble, France; and U.S. National Institutes of Health grants AR42426 and RR020185.	Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BABIOR BM, 1984, BLOOD, V64, P959; Batot G, 1998, BBA-MOL BASIS DIS, V1406, P188, DOI 10.1016/S0925-4439(98)00004-0; BATOT G, 1995, EUR J BIOCHEM, V234, P208, DOI 10.1111/j.1432-1033.1995.208_c.x; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bouin AP, 1998, J BIOL CHEM, V273, P30097, DOI 10.1074/jbc.273.46.30097; Burritt JB, 2003, J IMMUNOL, V170, P6082, DOI 10.4049/jimmunol.170.12.6082; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CROSS AR, 1994, J BIOL CHEM, V269, P21448; Dang PMC, 2006, J CLIN INVEST, V116, P2033, DOI 10.1172/JCI27544; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; El-Benna J, 2005, ARCH IMMUNOL THER EX, V53, P199; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; GARCIA RC, 1988, BIOCHEM J, V252, P901, DOI 10.1042/bj2520901; Gerard B, 2001, Hum Mutat, V18, P163, DOI 10.1002/humu.1166; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Han CH, 2001, J BIOCHEM-TOKYO, V129, P513, DOI 10.1093/oxfordjournals.jbchem.a002885; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Jagnandan D, 2007, J BIOL CHEM, V282, P6494, DOI 10.1074/jbc.M608966200; Kao YY, 2008, J BIOL CHEM, V283, P12736, DOI 10.1074/jbc.M801010200; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Li JR, 1997, BIOCHEMISTRY-US, V36, P5529, DOI 10.1021/bi963013r; Nisimoto Y, 2004, BIOCHEMISTRY-US, V43, P9567, DOI 10.1021/bi0400249; Ogasawara Y, 2008, J BIOL CHEM, V283, P8885, DOI 10.1074/jbc.M708106200; Paclet MH, 2004, BIOCHEM J, V382, P981, DOI 10.1042/BJ20040954; Paclet MH, 2001, EUR J BIOCHEM, V268, P5197, DOI 10.1046/j.0014-2956.2001.02455.x; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Regier DS, 2000, J BIOL CHEM, V275, P28406, DOI 10.1074/jbc.M004703200; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; Taylor RM, 2003, BBA-BIOMEMBRANES, V1612, P65, DOI 10.1016/S0005-2736(03)00086-5; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	53	136	141	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1011	1022		10.1096/fj.08-114553	http://dx.doi.org/10.1096/fj.08-114553			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19028840	Green Published			2022-12-28	WOS:000266651600005
J	Athirakul, K; Bradbury, JA; Graves, JP; DeGraff, LM; Ma, JX; Zhao, Y; Couse, JF; Quigley, R; Harder, DR; Zhao, XY; Imig, JD; Pedersen, TL; Newman, JW; Hammock, BD; Conley, AJ; Korach, KS; Coffman, TM; Zeldin, DC				Athirakul, Krairerk; Bradbury, J. Alyce; Graves, Joan P.; DeGraff, Laura M.; Ma, Jixiang; Zhao, Yun; Couse, John F.; Quigley, Raymond; Harder, David R.; Zhao, Xueying; Imig, John D.; Pedersen, Theresa L.; Newman, John W.; Hammock, Bruce D.; Conley, Alan J.; Korach, Kenneth S.; Coffman, Thomas M.; Zeldin, Darryl C.			Increased blood pressure in mice lacking cytochrome P450 2J5	FASEB JOURNAL			English	Article						hypertension; estrogen; proximal tubule; vascular responsiveness; eicosanoid	SPONTANEOUSLY HYPERTENSIVE-RATS; ESTROGEN-RECEPTOR-BETA; ARACHIDONIC-ACID; 20-HYDROXYEICOSATETRAENOIC ACID; NITRIC-OXIDE; POSTMENOPAUSAL WOMEN; LUTEINIZING-HORMONE; ANGIOTENSIN-II; EPOXYEICOSATRIENOIC ACIDS; CARDIOVASCULAR FUNCTION	The cytochrome P450 (CYP) enzymes participate in a wide range of biochemical functions, including metabolism of arachidonic acid and steroid hormones. Mouse CYP2J5 is abundant in the kidney where its products, the cis-epoxyeicosatrienoic acids (EETs), modulate sodium transport and vascular tone. To define the physiological role of CYP2J5 in the kidney, knockout mice were generated using a conventional gene targeting approach. Cyp2j5 (-/-) mice develop normally and exhibit no overt renal pathology. While renal EET biosynthesis was apparently unaffected by the absence of CYP2J5, deficiency of this CYP in female mice was associated with increased blood pressure, enhanced proximal tubular transport rates, and exaggerated afferent arteriolar responses to angiotensin II and endothelin I. Interestingly, plasma 17 beta-estradiol levels were reduced in female Cyp2j5 (-/-) mice and estrogen replacement restored blood pressure and vascular responsiveness to normal levels. There was no evidence of enhanced estrogen metabolism, or altered expression or activities of steroidogenic enzymes in female Cyp2j5 (-/-) mice, but their plasma levels of luteinizing hormone and follicle stimulating hormone were inappropriately low. Together, our findings illustrate a sex-specific role for CYP2J5 in regulation of blood pressure, proximal tubular transport, and afferent arteriolar responsiveness via an estrogen-dependent mechanism.	[Bradbury, J. Alyce; Graves, Joan P.; DeGraff, Laura M.; Ma, Jixiang; Zhao, Yun; Couse, John F.; Korach, Kenneth S.; Zeldin, Darryl C.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA; [Athirakul, Krairerk; Coffman, Thomas M.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Quigley, Raymond] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Harder, David R.] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; [Zhao, Xueying; Imig, John D.] Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA; [Pedersen, Theresa L.; Newman, John W.; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Pedersen, Theresa L.; Newman, John W.; Hammock, Bruce D.] Univ Calif Davis, Canc Res Ctr, Davis, CA 95616 USA; [Conley, Alan J.] Univ Calif Davis, Dept Populat Hlth & Reprod, Davis, CA 95616 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Medical College of Wisconsin; University System of Georgia; Augusta University; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Zeldin, DC (corresponding author), NIEHS, NIH, 111 T W Alexander Dr,Bldg 101,Rm D236, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Imig, John/0000-0002-9668-2899; Newman, John/0000-0001-9632-6571; Korach, Kenneth/0000-0002-7765-418X; Quigley, Raymond/0000-0003-4186-7527	NIH [HL6876, DK38226, ES004699, ES02710, MH39917, DK069896]; National Institute of Environmental Health Sciences [Z01 ES025034]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025034, ZIAES070065] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Drs. Michael Fessler and Robert Langenbach for helpful comments during the preparation of this manuscript, Dr. Howard Rockman for assistance with echocardiography, and Dr. Beverly Koller for assistance with generation of the Cyp2j5 (-/-) mice. This research was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences Z01 ES025034 (K.S.K., D.C.Z.), and NIH grants HL6876 (D.R.H.), DK38226 (J.D.I.), ES004699 (B.D.H.), ES02710 (B.D.H.), MH39917 (A.J.C.) and DK069896 (T.M.C.).	August P, 1999, J CLIN ENDOCR METAB, V84, P1862, DOI 10.1210/jc.84.6.1862; Bayorh MA, 2001, CLIN EXP HYPERTENS, V23, P241, DOI 10.1081/CEH-100102663; Capdevila JH, 2000, J LIPID RES, V41, P163; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CHAKRAVARTI S, 1976, BRIT MED J, V2, P784, DOI 10.1136/bmj.2.6039.784; Christin-Maitre S, 2003, J CLIN ENDOCR METAB, V88, P5405, DOI 10.1210/jc.2003-030094; Conley AJ, 1997, BIOL REPROD, V56, P789, DOI 10.1095/biolreprod56.4.789; Corbin CJ, 2001, MOL CELL ENDOCRINOL, V172, P115, DOI 10.1016/S0303-7207(00)00373-7; Couse JF, 2003, MOL ENDOCRINOL, V17, P1039, DOI 10.1210/me.2002-0398; Couse JF, 2004, ENDOCRINOLOGY, V145, P4693, DOI 10.1210/en.2004-0548; Darblade B, 2002, CIRC RES, V90, P413, DOI 10.1161/hh0402.105096; Dubey RK, 2001, HYPERTENSION, V37, P640, DOI 10.1161/01.HYP.37.2.640; ESCALANTE B, 1993, EUR J PHARMACOL, V235, P1, DOI 10.1016/0014-2999(93)90812-V; Esposito G, 2002, CIRCULATION, V105, P85, DOI 10.1161/hc0102.101365; Gainer JV, 2005, CIRCULATION, V111, P63, DOI 10.1161/01.CIR.0000151309.82473.59; GEE DM, 1983, BIOL REPROD, V28, P598, DOI 10.1095/biolreprod28.3.598; Gurley SB, 2006, AM J PHYSIOL-RENAL, V290, pF214, DOI 10.1152/ajprenal.00204.2005; Hinojosa-Laborde C, 2004, HYPERTENSION, V44, P405, DOI 10.1161/01.HYP.0000142893.08655.96; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; HOEG JM, 1977, AM J PHYSIOL, V233, pH369, DOI 10.1152/ajpheart.1977.233.3.H369; Holla VR, 2001, P NATL ACAD SCI USA, V98, P5211, DOI 10.1073/pnas.081627898; Huang A, 2004, MICROCIRCULATION, V11, P9, DOI 10.1080/10739680490266162; Imig JD, 2000, AM J HYPERTENS, V13, P810, DOI 10.1016/S0895-7061(00)00264-8; Imig JD, 1996, AM J PHYSIOL-REG I, V270, pR217, DOI 10.1152/ajpregu.1996.270.1.R217; Imig JD, 2001, J VASC RES, V38, P247, DOI 10.1159/000051053; Ishizuka Tsuneo, 2004, Nihon Jinzo Gakkai Shi, V46, P685; Jespersen C M, 1983, J Hypertens, V1, P361, DOI 10.1097/00004872-198312000-00007; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; King Lorraine M, 2005, Pharmacogenet Genomics, V15, P7, DOI 10.1097/01213011-200501000-00002; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Lee AJ, 2003, ENDOCRINOLOGY, V144, P3382, DOI 10.1210/en.2003-0192; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma J, 2004, MOL PHARMACOL, V65, P730, DOI 10.1124/mol.65.3.730; Ma JX, 1999, J BIOL CHEM, V274, P17777, DOI 10.1074/jbc.274.25.17777; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; Maier KG, 2001, CURR OPIN NEPHROL HY, V10, P81, DOI 10.1097/00041552-200101000-00013; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; Manhem K, 1998, J HUM HYPERTENS, V12, P323, DOI 10.1038/sj.jhh.1000563; Martins D, 2001, J Gend Specif Med, V4, P10; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; McGiff JC, 2001, CURR OPIN NEPHROL HY, V10, P231, DOI 10.1097/00041552-200103000-00012; Mercuro G, 1997, AM J CARDIOL, V80, P652, DOI 10.1016/S0002-9149(97)00444-X; Muller-Delp JM, 2003, AM J PHYSIOL-HEART C, V285, pH2150, DOI 10.1152/ajpheart.00966.2002; Nakagawa K, 2006, J CLIN INVEST, V116, P1696, DOI 10.1172/JCI27546; NEGROVILAR A, 1985, ENDOCRINOLOGY, V116, P2663, DOI 10.1210/endo-116-6-2663; Newman JW, 2002, J LIPID RES, V43, P1563, DOI 10.1194/jlr.D200018-JLR200; Nickenig G, 1998, CIRCULATION, V97, P2197, DOI 10.1161/01.CIR.97.22.2197; Oltman CL, 1998, CIRC RES, V83, P932; Oyekan AO, 1999, J CLIN INVEST, V104, P1131, DOI 10.1172/JCI6786; Peng N, 2003, HYPERTENSION, V41, P1164, DOI 10.1161/01.HYP.0000065387.09043.2E; Qu W, 2001, J BIOL CHEM, V276, P25467, DOI 10.1074/jbc.M100545200; Quigley R, 2000, AM J PHYSIOL-RENAL, V278, pF949, DOI 10.1152/ajprenal.2000.278.6.F949; Reckelhoff JF, 1999, HYPERTENSION, V34, P920, DOI 10.1161/01.HYP.34.4.920; Reckelhoff JF, 2000, HYPERTENSION, V35, P480, DOI 10.1161/01.HYP.35.1.480; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Sambrook J., 1989, MOL CLONING, V1; SCHALCH DS, 1968, J CLIN INVEST, V47, P665, DOI 10.1172/JCI105762; Schwartzman ML, 1996, NEPHRON, V73, P652; Seely EW, 1999, HYPERTENSION, V33, P1190, DOI 10.1161/01.HYP.33.5.1190; SIMON G, 1995, AM J HYPERTENS, V8, P645, DOI 10.1016/0895-7061(95)00047-S; SNYDER G, 1986, BIOCHEM BIOPH RES CO, V139, P1188, DOI 10.1016/S0006-291X(86)80303-5; Tang AC, 2005, HORM BEHAV, V47, P350, DOI 10.1016/j.yhbeh.2004.10.010; Tsuchiya Y, 2005, CANCER LETT, V227, P115, DOI 10.1016/j.canlet.2004.10.007; Wei Y, 2004, J GEN PHYSIOL, V124, P719, DOI 10.1085/jgp.200409140; Widder J, 2003, HYPERTENSION, V42, P991, DOI 10.1161/01.HYP.0000098661.37637.89; WIINBERG N, 1995, AM J HYPERTENS, V8, P978, DOI 10.1016/0895-7061(95)00216-2; Yu ZG, 2000, MOL PHARMACOL, V57, P1011; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	70	45	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4096	4108		10.1096/fj.08-114413	http://dx.doi.org/10.1096/fj.08-114413			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18716027	Green Published			2022-12-28	WOS:000261254800009
J	Briguet, A; Erb, M; Courdier-Fruh, I; Barzaghi, P; Santos, G; Herzner, H; Lescop, C; Siendt, H; Henneboehle, M; Weyermann, P; Magyar, JP; Dubach-Powell, J; Metz, G; Meier, T				Briguet, Alexandre; Erb, Michael; Courdier-Fruh, Isabelle; Barzaghi, Patrizia; Santos, Gesa; Herzner, Holger; Lescop, Cyrille; Siendt, Herve; Henneboehle, Marco; Weyermann, Philipp; Magyar, Josef P.; Dubach-Powell, Judith; Metz, Guenther; Meier, Thomas			Effect of calpain and proteasome inhibition on Ca2+-dependent proteolysis and muscle histopathology in the mdx mouse	FASEB JOURNAL			English	Article						Duchenne muscular dystrophy; dystrophin deficiency; small-molecule inhibitors; calpastatin; in vivo efficacy	DYSTROPHIN-GLYCOPROTEIN COMPLEX; DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; MICE; EXPRESSION; PROTEINS; FIBERS; MYOTUBES; CHANNELS; RESCUES	Dystrophin deficiency is the underlying molecular cause of progressive muscle weakness observed in Duchenne muscular dystrophy (DMD). Loss of functional dystrophin leads to elevated levels of intracellular Ca2+, a key step in the cellular pathology of DMD. The cysteine protease calpain is activated in dystrophin-deficient muscle, and its inhibition is regarded as a potential therapeutic approach. In addition, previous work has shown that the ubiquitin-proteasome system also contributes to muscle protein breakdown in dystrophic muscle and, therefore, also qualifies as a potential target for therapeutic intervention in DMD. The relative contribution of calpain- and proteasome-mediated proteolysis induced by increased Ca2+ levels was characterized in cultured muscle cells and revealed initial Ca2+ influx-dependent calpain activity and subsequent Ca2+-independent activity of the ubiquitin-proteasome system. We then set out to optimize novel small-molecule inhibitors that inhibit both calpain as well as the 20S proteasome in a cellular system with impaired Ca2+ homeostasis. On administration of such inhibitors to mdx mice, quantitative histological parameters improved significantly, in particular with compounds strongly inhibiting the 20S proteasome. To investigate the role of calpain inhibition without interfering with the ubiquitin-proteasome system, we crossed mdx mice with transgenic mice, overexpressing the endogenous calpain inhibitor calpastatin. Although our data show that proteolysis by calpain is strongly inhibited in the transgenic mdx mouse, this calpain inhibition did not ameliorate muscle histology. Our results indicate that inhibition of the proteasome rather than calpain is required for histological improvement of dystrophin-deficient muscle. In conclusion, we have identified novel proteasome inhibitors that qualify as potential candidates for pharmacological intervention in muscular dystrophy.	[Briguet, Alexandre; Erb, Michael; Courdier-Fruh, Isabelle; Barzaghi, Patrizia; Santos, Gesa; Herzner, Holger; Lescop, Cyrille; Siendt, Herve; Henneboehle, Marco; Weyermann, Philipp; Magyar, Josef P.; Dubach-Powell, Judith; Metz, Guenther; Meier, Thomas] Santhera Pharmaceut Switzerland Ltd, CH-4410 Liestal, Switzerland		Metz, G (corresponding author), Santhera Pharmaceut Switzerland Ltd, Hammerstr 47, CH-4410 Liestal, Switzerland.	guenther.metz@santhera.com						Adams J, 1999, CANCER RES, V59, P2615; Alderton JM, 2000, J BIOL CHEM, V275, P9452, DOI 10.1074/jbc.275.13.9452; AOYAGI T, 1969, J ANTIBIOT, V22, P558, DOI 10.7164/antibiotics.22.558; ARRIBAS J, 1993, J BIOL CHEM, V268, P21165; Assereto S, 2006, AM J PHYSIOL-CELL PH, V290, pC577, DOI 10.1152/ajpcell.00434.2005; Badalamente MA, 2000, MUSCLE NERVE, V23, P106, DOI 10.1002/(SICI)1097-4598(200001)23:1<106::AID-MUS14>3.0.CO;2-D; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Bonuccelli G, 2003, AM J PATHOL, V163, P1663, DOI 10.1016/S0002-9440(10)63523-7; Bonuccelli G, 2007, CELL CYCLE, V6, P1242, DOI 10.4161/cc.6.10.4182; Briguet A, 2004, NEUROMUSCULAR DISORD, V14, P675, DOI 10.1016/j.nmd.2004.06.008; Burdi R, 2006, NEUROMUSCULAR DISORD, V16, P237, DOI 10.1016/j.nmd.2006.01.013; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Courdier-Fruh I, 2002, NEUROMUSCULAR DISORD, V12, pS95, DOI 10.1016/S0960-8966(02)00089-5; Donkor IO, 2000, CURR MED CHEM, V7, P1171, DOI 10.2174/0929867003374129; Dunant P, 2003, MOL THER, V8, P80, DOI 10.1016/S1525-0016(03)00129-1; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; HARRIS AS, 1988, J NEUROSCI, V8, P2640; Kisselev AF, 2006, J BIOL CHEM, V281, P8582, DOI 10.1074/jbc.M509043200; Lescop C, 2005, BIOORG MED CHEM LETT, V15, P5176, DOI 10.1016/j.bmcl.2005.08.064; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; Menconi MJ, 2004, SURGERY, V136, P135, DOI 10.1016/j.surg.2004.03.014; Moll J, 2001, NATURE, V413, P302, DOI 10.1038/35095054; Neuhof C, 2004, BIOL CHEM, V385, P1077, DOI 10.1515/BC.2004.139; Nowak KJ, 2004, EMBO REP, V5, P872, DOI 10.1038/sj.embor.7400221; Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u; Petrof BJ, 1998, MOL CELL BIOCHEM, V179, P111, DOI 10.1023/A:1006812004945; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Spencer MJ, 2002, HUM MOL GENET, V11, P2645, DOI 10.1093/hmg/11.21.2645; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; Tanahashi-Hori T, 2003, J BIOL CHEM, V278, P16237, DOI 10.1074/jbc.M301331200; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3	35	42	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4190	4200		10.1096/fj.07-099036	http://dx.doi.org/10.1096/fj.07-099036			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18728218				2022-12-28	WOS:000261254800018
J	Coutant, J; Yu, HF; Clement, MJ; Alfsen, A; Toma, F; Curmi, PA; Bomsel, M				Coutant, Jerome; Yu, Huifeng; Clement, Marie-Jeanne; Alfsen, Annette; Toma, Flavio; Curmi, Patrick A.; Bomsel, Morgane			Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1	FASEB JOURNAL			English	Article						2F5 IgG; 4E10 IgG; glycosphingolipid; mucosa; HIV envelope glycoprotein; NMR	NEUTRALIZING ANTI-GP41 2F5; PROXIMAL EXTERNAL REGION; MONOCLONAL-ANTIBODIES; DENDRITIC CELLS; MEMBRANE-FUSION; GP41 ECTODOMAIN; VIRUS; PROTEIN; GLYCOPROTEIN; TRANSCYTOSIS	In terms of background, the solution structure of monomeric peptide P1 (residues 649-683), located in the conserved membrane proximal region (MPER) of HIV-1 envelope glycoprotein gp41, is first reported here in dodecylphosphocholine (DPC) micelles. P1 is the minimal MPER region that permits interaction with the mucosal galactosyl ceramide HIV-receptor; it also contains epitopes recognized by major gp41-specific, broadly neutralizing immunoglobulin Gs (IgGs), 2F5 and 4E10, determinant in HIV fusion/infection. Our principal findings were as follows: the structural stability of P1 is pH dependent, as the alpha-helix comprising Q653 I682, present at pH 3.3, is destabilized at higher pH values. At pH 6, the E-rich N-terminal half of P1 (residues 650 666), partially overlapping the 2F5-specific epitope, becomes fully disordered, while the W-rich C-terminal half conserves two shorter helices (W666-W670 and W672 W680), separated by a well-defined bend overlapped by the 4E10-specific epitope. The two IgGs bind to P1 on DPC micelles with binding parameters (K-d) in the nanomolar range. Next, P1 was derivatized with phosphatidylethanolamine at its C terminal and inserted into liposomes of varied lipid composition, thereby enabling P1 to move laterally. Alternatively, an infectious virus-binding assay was established. The Kd of both 2F5 and 4E10 IgGs measured on viral liposome and virus are similar and much lower than for the binding of the free peptide. In conclusion, P1, in a lipid environment, is an optimized MPER-derived peptide suitable for designing an immunogen inducing broadly neutralizing antibodies to HIV. Coutant, J., Yu, H., Clement, M.- J., Alfsen, A., Toma, F., Curmi, P. A., Bomsel, M. Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J. 22, 4338-4351 (2008)	[Yu, Huifeng; Alfsen, Annette; Bomsel, Morgane] Univ Paris 05, CNRS,UMR 8104, Dept Biol Cellulaire,Inst Cochin, Entre Muqueuse VIH & Immun Muqueuse, F-75014 Paris, France; [Coutant, Jerome; Clement, Marie-Jeanne; Toma, Flavio; Curmi, Patrick A.] Univ Evry, INSERM, U829, UEVE, Evry, France; [Yu, Huifeng; Alfsen, Annette; Bomsel, Morgane] INSERM, U567, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bomsel, M (corresponding author), Univ Paris 05, CNRS,UMR 8104, Dept Biol Cellulaire,Inst Cochin, Entre Muqueuse VIH & Immun Muqueuse, 22 Rue Mechain, F-75014 Paris, France.	flavio.toma@univ-evry.fr; pcurmi@univ-evry.fr; morgane.bomsel@inserm.fr	CURMI, Patrick/G-4036-2013; Bomsel, Morgane/GSN-1948-2022	CURMI, Patrick A./0000-0001-5045-8501; Bomsel, Morgane/0000-0002-9577-7474	ANRS; Sidaction-Ensemble contre le SIDA	ANRS(ANRSFrench National Research Agency (ANR)); Sidaction-Ensemble contre le SIDA	We thank B. Weksler for English editing. H.Y. benefited from financial support by Sidaction and Agence Nationale de Recherche sur le SIDA (ANRS), M. B. and P. C. were supported by grants from ANRS, and M. B. was supported by a grant from Sidaction-Ensemble contre le SIDA. We are grateful to S. Fleury (Mymetics, Nyon, Switzerland) for providing P1-PE. We gratefully thank the Conseil Regional d'Ile de France, the Conseil General de l'Essonne, the Genopole, the Commissariat a l'Ennergie Atomique, and the Association Francaise contre les Myopathies for the NMR equipment of INSERM/UEVE U829.	Alam SM, 2008, J VIROL, V82, P115, DOI 10.1128/JVI.00927-07; Alam SM, 2007, J IMMUNOL, V178, P4424, DOI 10.4049/jimmunol.178.7.4424; Alfsen A, 2002, J BIOL CHEM, V277, P25649, DOI 10.1074/jbc.M200554200; Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barbato G, 2003, J MOL BIOL, V330, P1101, DOI 10.1016/S0022-2836(03)00611-9; Berjanskii MV, 2006, NUCLEIC ACIDS RES, V34, pW63, DOI 10.1093/nar/gkl341; Beswick V, 1996, BIOCHEMISTRY-US, V35, P14717, DOI 10.1021/bi961710d; Biron Z, 2005, BIOCHEMISTRY-US, V44, P13602, DOI 10.1021/bi0509245; Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y; Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X; BOMSEL M, 2006, PCT IB 2006 000466 I; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011; Cardoso RMF, 2007, J MOL BIOL, V365, P1533, DOI 10.1016/j.jmb.2006.10.088; Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Fantini J, 2000, GLYCOCONJUGATE J, V17, P173, DOI 10.1023/A:1026580905156; GODDARD TD, 1982, SPARKY 3; Killian JA, 2006, CURR OPIN STRUC BIOL, V16, P473, DOI 10.1016/j.sbi.2006.06.007; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V96, P1156, DOI 10.1016/0006-291X(80)90073-X; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Le Lan C, 2006, FEBS LETT, V580, P5301, DOI 10.1016/j.febslet.2006.08.075; Lenz O, 2005, J BIOL CHEM, V280, P4095, DOI 10.1074/jbc.M411088200; Magerus-Chatinet A, 2007, VIROLOGY, V362, P67, DOI 10.1016/j.virol.2006.11.035; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Matoba N, 2004, P NATL ACAD SCI USA, V101, P13584, DOI 10.1073/pnas.0405297101; Matoba N, 2006, VACCINE, V24, P5047, DOI 10.1016/j.vaccine.2006.03.045; Maurin T, 2007, J MOL BIOL, V367, P702, DOI 10.1016/j.jmb.2007.01.031; McLaughlin S, 2005, J GEN PHYSIOL, V126, P41, DOI 10.1085/jgp.200509274; Munoz-Barroso I, 1999, J VIROL, V73, P6089; Nyholm TKM, 2007, BIOCHEMISTRY-US, V46, P1457, DOI 10.1021/bi061941c; Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Sabado RL, 2007, EUR J IMMUNOL, V37, P1752, DOI 10.1002/eji.200636981; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; Sanchez-Martinez S, 2006, FEBS LETT, V580, P2395, DOI 10.1016/j.febslet.2006.03.067; Sanchez-Martinez S, 2006, AIDS RES HUM RETROV, V22, P998, DOI 10.1089/aid.2006.22.998; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450; Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018; Tamm LK, 2003, CURR OPIN STRUC BIOL, V13, P453, DOI 10.1016/S0959-440X(03)00107-6; TAMM LK, 2007, BIOCHIM BIOPHYS ACTA, V12, P3052; Vidricaire G, 2007, J MOL BIOL, V368, P1267, DOI 10.1016/j.jmb.2007.03.003; Wang JH, 2007, J VIROL, V81, P8933, DOI 10.1128/JVI.00878-07; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yu HF, 2008, CELL CALCIUM, V43, P73, DOI 10.1016/j.ceca.2007.04.011; Zanetti G, 2006, PLOS PATHOG, V2, DOI 10.1371/journal.ppat.0020083; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817; Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	63	27	29	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4338	4351		10.1096/fj.08-113142	http://dx.doi.org/10.1096/fj.08-113142			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18776068				2022-12-28	WOS:000261254800032
J	Tohyama, D; Yamaguchi, A; Yamashita, T				Tohyama, Daisuke; Yamaguchi, Atsushi; Yamashita, Toshihide			Inhibition of a eukaryotic initiation factor (eIF2B delta/F11A3.2) during adulthood extends lifespan in Caenorhabditis elegans	FASEB JOURNAL			English	Article						aging; daf-16	SYSTEMATIC RNAI SCREEN; HEAT-SHOCK-FACTOR; TRANSLATION INITIATION; DEVELOPMENTAL ARREST; LONGEVITY; DAF-16; GENES; GENETICS; STRESS; REPRODUCTION	The critical role of protein synthesis in regulating lifespan has been evidenced. This study shows that adult-onset RNAi inactivation of eukaryotic initiation factor 2B delta (eIF2B delta/F11A3.2), a subunit of eIF2B, extends the mean lifespan of Caenorhabditis elegans. eIF2B is a GDP-GTP exchange factor for eIF2-a rate-limiting factor for protein synthesis initiation. S-35-methionine incorporation assay showed that global protein synthesis is reduced by eIF2B delta/F11A3.2 RNAi. Inhibition of eIF2B delta/F11A3.2 during adulthood conferred thermal and oxidative stress resistance and reduced the fecundity and fat storage, suggesting the possible trade-offs of resources between reproduction and somatic maintenance. Lifespan extension by adult-onset eIF2B delta/F11A3.2 RNAi is suppressed in FOXO transcription factor daf-16 deletion mutants. Adult-onset eIF2B delta/F11A3.2 RNAi increases the expression of stress-resistant genes, including hsp-16.2, hsp-70, hsp90, and sod-3, some of which are reported to be targets of DAF-16. Adult-onset eIF2B delta/F11A3.2 RNAi in daf-16 mutants reduced fecundity, but did not extend lifespan. Furthermore, adult-onset eIF2B delta/F11A3.2 RNAi did not extend the lifespan of germline-defective glp-4 organisms. Thus, it is possible that eIF2B delta/F11A3.2 RNAi during adulthood prolongs lifespan via daf-16, which induces stress resistance in organisms. This might be the mechanism, at least in part, for trade-offs of resources between reproduction and somatic maintenance.-Tohyama, D., Yamaguchi, A., Yamashita, T. Inhibition of a eukaryotic initiation factor (eIF2B delta/F11A3.2) during adulthood extends lifespan in Caenorhabditis elegans. FASEB J. 22, 4327-4337 ( 2008)	[Tohyama, Daisuke; Yamaguchi, Atsushi; Yamashita, Toshihide] Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, Chiba 2608670, Japan; [Yamashita, Toshihide] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Osaka, Japan	Chiba University; Osaka University	Yamaguchi, A (corresponding author), Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	atsyama@restaff.chiba-u.jp		Yamashita, Toshihide/0000-0003-4559-7018				Alcedo J, 2004, NEURON, V41, P45, DOI 10.1016/S0896-6273(03)00816-X; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Barnes AI, 2006, P ROY SOC B-BIOL SCI, V273, P939, DOI 10.1098/rspb.2005.3388; Berman JR, 2006, CELL, V124, P1055, DOI 10.1016/j.cell.2006.01.039; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188; Braeckman BP, 2007, EXP GERONTOL, V42, P90, DOI 10.1016/j.exger.2006.04.010; BRENNER S, 1974, GENETICS, V77, P71; Chen D, 2007, AGING CELL, V6, P525, DOI 10.1111/j.1474-9726.2007.00305.x; Cui YX, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r122; Curran SP, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030056; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; FRIEDMAN DB, 1988, GENETICS, V118, P75; Gems D, 1998, GENETICS, V150, P129; Gerisch B, 2001, DEV CELL, V1, P841, DOI 10.1016/S1534-5807(01)00085-5; Grune T, 2005, FREE RADICAL BIO MED, V39, P1208, DOI 10.1016/j.freeradbiomed.2005.06.009; Hajdu-Cronin YM, 2004, GENETICS, V168, P1937, DOI 10.1534/genetics.104.028423; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Hansen M, 2007, AGING CELL, V6, P95, DOI 10.1111/j.1474-9726.2006.00267.x; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Henderson ST, 2006, J GERONTOL A-BIOL, V61, P444, DOI 10.1093/gerona/61.5.444; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Hoogewijs D, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-9; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; LARSEN PL, 1995, GENETICS, V139, P1567; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Li WS, 2007, DEV CELL, V12, P235, DOI 10.1016/j.devcel.2006.12.002; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Medwar P. B., 1952, UNSOLVED PROBLEM BIO; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Mukhopadhyay A, 2005, CELL METAB, V2, P35, DOI 10.1016/j.cmet.2005.06.004; Mukhopadhyay A, 2007, TRENDS CELL BIOL, V17, P65, DOI 10.1016/j.tcb.2006.12.004; Mukhopadhyay A, 2006, EXP GERONTOL, V41, P928, DOI 10.1016/j.exger.2006.05.020; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Pan KZ, 2007, AGING CELL, V6, P111, DOI 10.1111/j.1474-9726.2006.00266.x; Partridge L, 2005, CELL, V120, P461, DOI 10.1016/j.cell.2005.01.026; Pavitt GD, 2005, BIOCHEM SOC T, V33, P1487, DOI 10.1042/BST0331487; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Proud CG, 2006, BIOCHEM SOC T, V34, P213, DOI 10.1042/BST0340213; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Singh V, 2006, P NATL ACAD SCI USA, V103, P13092, DOI 10.1073/pnas.0604050103; Syntichaki P, 2007, NATURE, V445, P922, DOI 10.1038/nature05603; Terman A, 2007, J PATHOL, V211, P134, DOI 10.1002/path.2094; Tissenbaum HA, 1998, GENETICS, V148, P703; Van Voorhies WA, 1999, P NATL ACAD SCI USA, V96, P11399, DOI 10.1073/pnas.96.20.11399; Vernace VA, 2007, AGING CELL, V6, P599, DOI 10.1111/j.1474-9726.2007.00329.x; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042	69	23	34	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4327	4337		10.1096/fj.08-112953	http://dx.doi.org/10.1096/fj.08-112953			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18728216				2022-12-28	WOS:000261254800031
J	Holguin, S; Martinez, J; Chow, C; Wurtman, R				Holguin, Sarah; Martinez, Joseph; Chow, Camille; Wurtman, Richard			Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils	FASEB JOURNAL			English	Article						choline; omega-3 fatty acids; pyrimidines; behavior	POLYUNSATURATED FATTY-ACIDS; SPATIAL TASK-PERFORMANCE; ALPHA-LINOLENIC ACID; DOCOSAHEXAENOIC ACID; RANDOMIZED-TRIAL; IMPOVERISHED RATS; VISUAL-ATTENTION; CYTIDINE KINASE; BRAIN-FUNCTION; BREAST-MILK	This study examined the effects on cognitive behaviors of giving normal adult gerbils three compounds, normally in the circulation, which interact to increase brain phosphatides, synaptic proteins, dendritic spines, and neurotransmitter release. Animals received supplemental uridine (as its monophosphate, UMP; 0.5%) and choline (0.1%) via the diet, and docosahexaenoic acid (DHA; 300 mg/kg/day) by gavage, for 4 wk, and then throughout the subsequent period of behavioral training and testing. As shown previously, giving all three compounds caused highly significant (P < 0.001) increases in total brain phospholipids and in each major phosphatide; giving DHA or UMP ( plus choline) produced smaller increases in some of the phosphatides. DHA plus choline improved performance on the four-arm radial maze, T-maze, and Y-maze tests; coadministering UMP further enhanced these increases. ( Uridine probably acts by generating both CTP, which can be limiting in phosphatide synthesis, and UTP, which activates P2Y receptors coupled to neurite outgrowth and protein synthesis. All three compounds also act by enhancing the substrate-saturation of phosphatide-synthesizing enzymes.) These findings demonstrate that a treatment that increases synaptic membrane content can enhance cognitive functions in normal animals. -Holguin, S., Martinez, J., Chow, C., Wurtman, R. Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J. 22, 3938-3946 (2008)	[Holguin, Sarah; Martinez, Joseph; Chow, Camille; Wurtman, Richard] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Wurtman, R (corresponding author), MIT, Dept Brain & Cognit Sci, 43 Vassar St,46-5023, Cambridge, MA 02139 USA.	dick@mit.edu		Chow, Camille/0000-0002-4859-0957	National Institutes of Health [MH-28283]; Center for Brain Sciences; Metabolism Charitable Trust	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Brain Sciences; Metabolism Charitable Trust	We thank Lisa Teather for advice and assistance in preparing this paper, and Tim Maher for providing the rotarod testing apparatus. We also thank Rona Stephanopoulos and Paul Jaffe for their assistance with behavior and biochemistry assays. This study was supported by National Institutes of Health grant MH-28283 and the Center for Brain Sciences and Metabolism Charitable Trust.	Anderson EP, 1973, ENZYMES, P49; Auestad N, 2003, PEDIATRICS, V112, pE177, DOI 10.1542/peds.112.3.e177; BELL MV, 1989, BIOCHEM J, V264, P909, DOI 10.1042/bj2640909; Birch EE, 2007, EARLY HUM DEV, V83, P279, DOI 10.1016/j.earlhumdev.2006.11.003; Bofill-Cardona E, 2000, MOL PHARMACOL, V57, P1165; Brenna JT, 2002, CURR OPIN CLIN NUTR, V5, P127, DOI 10.1097/00075197-200203000-00002; Cansev M, 2007, NEUROSCIENCE, V148, P421, DOI 10.1016/j.neuroscience.2007.06.016; Cansev M, 2005, BRAIN RES, V1058, P101, DOI 10.1016/j.brainres.2005.07.054; Carlson SE, 1996, LIPIDS, V31, P85, DOI 10.1007/BF02522416; COHEN BM, 1995, JAMA-J AM MED ASSOC, V274, P902, DOI 10.1001/jama.274.11.902; Eilander A, 2007, PROSTAG LEUKOTR ESS, V76, P189, DOI 10.1016/j.plefa.2007.01.003; Farooqui AA, 2007, J NEUROCHEM, V101, P577, DOI 10.1111/j.1471-4159.2006.04371.x; Fedorova I, 2007, PROSTAG LEUKOTR ESS, V77, P269, DOI 10.1016/j.plefa.2007.10.013; FOLCH J, 1957, J BIOL CHEM, V226, P497; GALLI C, 1993, PROSTAG LEUKOTR ESS, V48, P51, DOI 10.1016/0952-3278(93)90009-L; Gamoh S, 1999, NEUROSCIENCE, V93, P237, DOI 10.1016/S0306-4522(99)00107-4; Gamoh S, 2001, CLIN EXP PHARMACOL P, V28, P266, DOI 10.1046/j.1440-1681.2001.03437.x; Gilani GS, 2007, J AOAC INT, V90, P1440; Green KN, 2007, J NEUROSCI, V27, P4385, DOI 10.1523/JNEUROSCI.0055-07.2007; Green P, 2001, BBA-MOL CELL BIOL L, V1532, P203, DOI 10.1016/S1388-1981(01)00132-9; GREENBERG N, 1977, BIOCHEM J, V164, P379, DOI 10.1042/bj1640379; Hart SL, 2006, J PEDIATR PSYCHOL, V31, P221, DOI 10.1093/jpepsy/jsj069; Holguin S, 2008, BEHAV BRAIN RES, V191, P11, DOI 10.1016/j.bbr.2008.02.042; Ikemoto A, 2001, J LIPID RES, V42, P1655; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; LABARCA C, 1980, ANAL BIOCHEM, V102, P4; Levant B, 2004, BEHAV BRAIN RES, V152, P49, DOI 10.1016/j.bbr.2003.09.029; Li JY, 2001, J CEREBR BLOOD F MET, V21, P929, DOI 10.1097/00004647-200108000-00005; Lim SY, 2005, J NEUROCHEM, V95, P848, DOI 10.1111/j.1471-4159.2005.03427.x; Lopez-Garcia E, 2004, J NUTR, V134, P1806, DOI 10.1093/jn/134.7.1806; Marszalek JR, 2005, ANNU REV CELL DEV BI, V21, P633, DOI 10.1146/annurev.cellbio.21.122303.120624; Marszalek JR, 2005, J BIOL CHEM, V280, P10817, DOI 10.1074/jbc.M411750200; MILLINGTON WR, 1982, J NEUROCHEM, V38, P1748, DOI 10.1111/j.1471-4159.1982.tb06658.x; Moriguchi T, 2003, J NEUROCHEM, V87, P297, DOI 10.1046/j.1471-4159.2003.01966.x; Nolan MF, 2003, CELL, V115, P551, DOI 10.1016/S0092-8674(03)00884-5; ORENGO A, 1969, J BIOL CHEM, V244, P2204; OTT T, 1978, MED BIOL, V56, P133; Pooler AM, 2005, NEUROSCIENCE, V134, P207, DOI 10.1016/j.neuroscience.2005.03.050; Ropp PA, 1998, ARCH BIOCHEM BIOPHYS, V359, P63, DOI 10.1006/abbi.1998.0890; Ropp PA, 1996, ARCH BIOCHEM BIOPHYS, V336, P105, DOI 10.1006/abbi.1996.0537; Ross BM, 1997, LIPIDS, V32, P351, DOI 10.1007/s11745-997-0044-x; Sakamoto T, 2007, BRAIN RES, V1182, P50, DOI 10.1016/j.brainres.2007.08.089; Sinclair AJ, 2002, LIPIDS, V37, P1113, DOI 10.1007/s11745-002-1008-x; SKOLD O, 1960, J BIOL CHEM, V274, P902; SPANNER S, 1979, BIOCHEM J, V178, P753, DOI 10.1042/bj1780753; Suzuki NN, 2004, STRUCTURE, V12, P751, DOI 10.1016/j.str.2004.02.038; SVANBORG A, 1961, ACTA MED SCAND, V169, P43; Teather LA, 2006, J NUTR, V136, P2834, DOI 10.1093/jn/136.11.2834; ULUS IH, 1989, BRAIN RES, V484, P217, DOI 10.1016/0006-8993(89)90364-8; Wainwright P E, 1998, Nutr Neurosci, V1, P281, DOI 10.1080/1028415X.1998.11747238; Wainwright PE, 2002, P NUTR SOC, V61, P61, DOI 10.1079/PNS2001130; Werkman SH, 1996, LIPIDS, V31, P91, DOI 10.1007/BF02522417; Willatts P, 1998, LIPIDS, V33, P973, DOI 10.1007/s11745-998-0294-7; Wurtman RJ, 2006, BRAIN RES, V1088, P83, DOI 10.1016/j.brainres.2006.03.019; Xia HJ, 2005, CELL RES, V15, P83, DOI 10.1038/sj.cr.7290270; Xiao Y, 2006, BIOMED ENVIRON SCI, V19, P474	56	76	80	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3938	3946		10.1096/fj.08-112425	http://dx.doi.org/10.1096/fj.08-112425			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18606862	Green Published			2022-12-28	WOS:000260503000022
J	Kim, MJ; Chia, IV; Costantini, F				Kim, Min Jung; Chia, Ian V.; Costantini, Frank			SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability	FASEB JOURNAL			English	Article						Wnt signaling; disheveled; beta-catenin	RECEPTOR-RELATED PROTEIN-5; WNT SIGNALING PATHWAY; BETA-CATENIN; SUMO-1 MODIFICATION; DOMAINS; ARKADIA; PHOSPHORYLATION; DEGRADATION; ACTIVATION; MODIFIER-1	Axin is a scaffold protein for the beta-catenin destruction complex, and a negative regulator of canonical Wnt signaling. Previous studies implicated the six C-terminal amino acids (C6 motif) in the ability of Axin to activate c-Jun N-terminal kinase, and identified them as a SUMOylation target. Deletion of the C6 motif of mouse Axin in vivo reduced the steady-state protein level, which caused embryonic lethality. Here, we report that this deletion (Axin-Delta C6) causes a reduced half-life in mouse embryonic fibroblasts and an increased susceptibility to ubiquitination in HEK 293T cells. We confirmed the C6 motif as a SUMOylation target in vitro, and found that mutating the C-terminal SUMOylation target residues increased the susceptibility of Axin to polyubiquitination and reduced its steady-state level. Heterologous SUMOylation target sites could replace C6 in providing this protective effect. These findings suggest that SUMOylation of the C6 motif may prevent polyubiquitination, thus increasing the stability of Axin. Although C6 deletion also caused increased association of Axin with Dvl-1, this interaction was not altered by mutating the lysine residues in C6, nor could heterologous SUMOylation motifs replace the C6 motif in this assay. Therefore, some other specific property of the C6 motif seems to reduce the interaction of Axin with Dvl-1.-Kim, M. J., Chia, I. V., Costantini, F. SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability. FASEB J. 22, 3785-3794 (2008)	[Kim, Min Jung; Chia, Ian V.; Costantini, Frank] Columbia Univ, Dept Genet & Dev, Med Ctr, New York, NY 10032 USA	Columbia University	Costantini, F (corresponding author), Columbia Univ, Dept Genet & Dev, Med Ctr, 701 W 168th St, New York, NY 10032 USA.	fdc3@columbia.edu			National Institute of Child Health and Human Development [HD44265]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044265] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by grant HD44265 to F. C. from the National Institute of Child Health and Human Development. We thank Zaiqi Wu for excellent technical assistance, David Virshup (Huntsman Cancer Institute, Salt Lake City, UT, USA) for the anti-Axin antiserum, and Eek-hoon Jho (University of Seoul, Seoul, South Korea) and Wei Hsu (University of Rochester, Rochester, NY, USA) for comments on the manuscript.	Boutell C, 2003, J VIROL, V77, P8686, DOI 10.1128/JVI.77.16.8686-8694.2003; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Chia IV, 2005, MOL CELL BIOL, V25, P4371, DOI 10.1128/MCB.25.11.4371-4376.2005; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Episkopou V, 2001, NATURE, V410, P825, DOI 10.1038/35071095; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Julius MA, 2000, BIOCHEM BIOPH RES CO, V276, P1162, DOI 10.1006/bbrc.2000.3607; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu W, 2006, EMBO J, V25, P1646, DOI 10.1038/sj.emboj.7601057; Luo W, 2004, NEUROSIGNALS, V13, P99, DOI 10.1159/000076563; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Niederlander C, 2001, NATURE, V410, P830, DOI 10.1038/35071103; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247	35	37	39	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3785	3794		10.1096/fj.08-113910	http://dx.doi.org/10.1096/fj.08-113910			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18632848	Green Published			2022-12-28	WOS:000260503000007
J	Quenet, D; Gasser, V; Fouillen, L; Cammas, F; Sanglier-Cianferani, S; Losson, R; Dantzer, F				Quenet, Delphine; Gasser, Veronique; Fouillen, Laetitia; Cammas, Florence; Sanglier-Cianferani, Sarah; Losson, Regine; Dantzer, Francoise			The histone subcode: poly(ADP-ribose) polymerase-1 (Parp-1) and Parp-2 control cell differentiation by regulating the transcriptional intermediary factor TIF1 beta and the heterochromatin protein HP1 alpha	FASEB JOURNAL			English	Article						epigenetics; pericentric heterochromatin; post-translational modification; protein interactions	ZINC FINGER PROTEINS; FUNCTIONAL INTERACTION; DNA-REPAIR; HP1; EXPRESSION; INTERACTS; CHROMATIN; FAMILY; CONTRIBUTES; MAINTENANCE	Recent advances reveal emerging unique functions of poly(ADP-ribose) polymerase-1 (Parp-1) and Parp-2 in heterochromatin integrity and cell differentiation. However, the chromatin-mediated molecular and cellular events involved remain elusive. Here we describe specific physical and functional interactions of Parp-1 and Parp-2 with the transcriptional intermediary factor (TIF1 beta) and the heterochromatin proteins (HP1) that affect endodermal differentiation. We show that Parp-2 binds to TIF1 beta with high affinity both directly and through HP1 alpha. Both partners colocalize at pericentric heterochromatin in primitive endoderm-like cells. Parp-2 also binds to HP1 beta but not to HP1 gamma. In contrast Parp-1 binds weakly to TIF1 beta and HP1 beta only. Both Parps selectively poly(ADP-ribosyl) ate HP1 alpha. Using shRNA approaches, we provide evidence for distinct participation of both Parps in endodermal differentiation. Whereas Parp-2 and its activity are required for the relocation of TIF1 beta to heterochromatic foci during primitive endodermal differentiation, Parp-1 and its activity modulate TIF1 beta-HP1 alpha association with consequences on parietal endodermal differentiation. Both Parps control TIF1 beta transcriptional activity. In addition, this work identifies both Parps as new modulators of the HP1-mediated subcode histone. -Quenet, D., Gasser, V., Fouillen, L., Cammas, F., Sanglier-Cianferani, S., Losson, R., Dantzer, F. The histone subcode: poly(ADP-ribose) polymerase-1 (Parp-1) and Parp-2 control cell differentiation by regulating the transcriptional intermediary factor TIF1 beta and the heterochromatin protein HP1 alpha. FASEB J. 22, 3853-3865 (2008)	[Quenet, Delphine; Gasser, Veronique; Dantzer, Francoise] ESBS, Dept IDG, UMR7175, F-67412 Illkirch Graffenstaden, France; [Cammas, Florence; Losson, Regine] Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; [Fouillen, Laetitia; Sanglier-Cianferani, Sarah] Ecole Chim Polymeres & Mat, Lab Spectrometrie Masse Bioorgan, UMR7178, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3)	Dantzer, F (corresponding author), ESBS, Dept IDG, UMR7175, Bld S Brant, F-67412 Illkirch Graffenstaden, France.	fdantzer@esbs.u-strasbg.fr	Dantzer, Françoise/O-2126-2016; Cammas, florence m/D-1823-2017; FOUILLEN, Laetitia/AAV-9710-2020	Cammas, florence m/0000-0003-4117-8182; FOUILLEN, Laetitia/0000-0002-1204-9296; Dantzer, Francoise/0000-0003-0945-8483; Cianferani, Sarah/0000-0003-4013-4129	Association pour la Recherche Contre le Cancer; Ligue Nationale Contre le Cancer et Comite Regional; Centre National de la Recherche Scientifique; Agence Nationale de la Recherche	Association pour la Recherche Contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale Contre le Cancer et Comite Regional(Ligue nationale contre le cancer); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de la Recherche(French National Research Agency (ANR))	We thank V. Schreiber for critical reading of the manuscript and A. van Dorsselear for access to the proteomic platform. This work was supported by Association pour la Recherche Contre le Cancer, Ligue Nationale Contre le Cancer et Comite Regional, Centre National de la Recherche Scientifique, and Agence Nationale de la Recherche.	Aldinucci A, 2007, J IMMUNOL, V179, P305, DOI 10.4049/jimmunol.179.1.305; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bai P, 2007, J BIOL CHEM, V282, P37738, DOI 10.1074/jbc.M701021200; Cammas F, 2000, DEVELOPMENT, V127, P2955; Cammas F, 2004, GENE DEV, V18, P2147, DOI 10.1101/gad.302904; Cammas F, 2002, J CELL SCI, V115, P3439; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; Dantzer F, 2006, P NATL ACAD SCI USA, V103, P14854, DOI 10.1073/pnas.0604252103; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Eskeland R, 2007, MOL CELL BIOL, V27, P453, DOI 10.1128/MCB.01576-06; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; LE DB, 1996, EMBO J, V15, P6701; Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383; Lomberk G, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-228; Maeda Y, 2006, J BIOL CHEM, V281, P9600, DOI 10.1074/jbc.M510435200; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Meder VS, 2005, J CELL SCI, V118, P211, DOI 10.1242/jcs.01606; Miguet L, 2006, PROTEOMICS, V6, P153, DOI 10.1002/pmic.200500133; Muchardt C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nusinow DA, 2007, J BIOL CHEM, V282, P12851, DOI 10.1074/jbc.M610502200; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Saxena A, 2002, J BIOL CHEM, V277, P26921, DOI 10.1074/jbc.M200620200; Saxena A, 2002, HUM MOL GENET, V11, P2319, DOI 10.1093/hmg/11.19.2319; Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; SCHULTZ MJ, 2001, RRD IMMUNOL 1, V3, P1; Singh PB, 2002, J STRUCT BIOL, V140, P10, DOI 10.1016/S1047-8477(02)00536-1; Sripathy SP, 2006, MOL CELL BIOL, V26, P8623, DOI 10.1128/MCB.00487-06; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Weber P, 2002, DEVELOPMENT, V129, P2329; Yelamos J, 2006, EMBO J, V25, P4350, DOI 10.1038/sj.emboj.7601301	43	50	50	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2008	22	11					3853	3865		10.1096/fj.08-113464	http://dx.doi.org/10.1096/fj.08-113464			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18676401	Green Submitted			2022-12-28	WOS:000260503000014
J	Whitney, NP; Peng, H; Erdmann, NB; Tian, C; Monaghan, DT; Zheng, JC				Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Monaghan, Daniel T.; Zheng, Jialin C.			Calcium-permeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons	FASEB JOURNAL			English	Article						glutamate; Q/R editing; neurogenesis; dendritic arborization; ADAR2	CENTRAL-NERVOUS-SYSTEM; ADULT-RAT HIPPOCAMPUS; STEM-CELLS; GLUTAMATE RECEPTORS; ACID RECEPTORS; MESSENGER-RNA; SUBUNIT COMPOSITION; RELATIVE ABUNDANCE; CA2+ PERMEABILITY; SPIDER TOXIN	We identify calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on human neural progenitor cells (NPCs) and present a physiological role in neurogenesis. RNA editing of the GluR2 subunit at the Q/R site is responsible for making most AMPA receptors impermeable to calcium. Because a single-point mutation could eliminate the need for editing at the Q/R site and Q/R-unedited GluR2 exists during embryogenesis, the Q/R-unedited GluR2 subunit presumably has some important actions early in development. Using calcium imaging, we found that NPCs contain calcium-permeable AMPA receptors, whereas NPCs differentiated to neurons and astrocytes express calcium-impermeable AMPA receptors. We utilized reverse-transcription polymerase chain reaction and BbvI digestion to demonstrate that NPCs contain Q/R-unedited GluR2, and differentiated cells contain Q/R-edited GluR2 subunits. This is consistent with the observation that the nuclear enzyme responsible for Q/R-editing, adenosine deaminase (ADAR2), is increased during differentiation. Activation of calcium-permeable AMPA receptors induces NPCs to differentiate to the neuronal lineage and increases dendritic arbor formation in NPCs differentiated to neurons. AMPA-induced differentiation of NPCs to neurons is abrogated by overexpression of ADAR2 in NPCs. This elucidates the role of AMPA receptors as inductors of neurogenesis and provides a possible explanation for why the Q/R editing process exists.	[Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Monaghan, Daniel T.; Zheng, Jialin C.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Monaghan, Daniel T.; Zheng, Jialin C.] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Zheng, Jialin C.] Univ Nebraska, Med Ctr, Lab Neurotoxicol, Omaha, NE 68198 USA; [Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Zheng, Jialin C.] Univ Nebraska, Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Whitney, NP (corresponding author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr, Omaha, NE 68198 USA.	jzheng@unmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS043985, R01NS041858] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015635, P20 RR15635] Funding Source: Medline; NINDS NIH HHS [R01 NS041858, R01 NS 41858, P01 NS043985] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai F, 2003, NEUROPHARMACOLOGY, V44, P1013, DOI 10.1016/S0028-3908(03)00104-7; Barbon A, 2003, MOL BRAIN RES, V117, P168, DOI 10.1016/S0169-328X(03)00317-6; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548; BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528; Brorson JR, 1999, J NEUROSCI, V19, P9149; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; Chappell AS, 2007, NEUROLOGY, V68, P1008, DOI 10.1212/01.wnl.0000260240.46070.7c; Dingledine R, 1999, PHARMACOL REV, V51, P7; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Iino M, 1996, J PHYSIOL-LONDON, V496, P431, DOI 10.1113/jphysiol.1996.sp021696; Ingvar M, 1997, EXP NEUROL, V146, P553, DOI 10.1006/exnr.1997.6581; Jia YS, 2002, J PHYSIOL-LONDON, V543, P35, DOI 10.1113/jphysiol.2002.020172; Kask K, 1998, P NATL ACAD SCI USA, V95, P13777, DOI 10.1073/pnas.95.23.13777; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Kawahara Y, 2003, EUR J NEUROSCI, V18, P23, DOI 10.1046/j.1460-9568.2003.02718.x; Kohr G, 1998, NEUROPHARMACOLOGY, V37, P1411, DOI 10.1016/S0028-3908(98)00149-X; Konig N, 2001, JPN J PHARMACOL, V86, P1, DOI 10.1254/jjp.86.1; Kung SS, 2001, FEBS LETT, V509, P277, DOI 10.1016/S0014-5793(01)03183-0; Kwak S, 2005, J MOL MED, V83, P110, DOI 10.1007/s00109-004-0599-z; Lee JC, 1998, BRAIN RES PROTOC, V3, P142, DOI 10.1016/S1385-299X(98)00035-X; Luk KC, 2003, J NEUROSCI, V23, P2239; Lynch G, 1997, EXP NEUROL, V145, P89, DOI 10.1006/exnr.1997.6447; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Mackowiak M, 2002, NEUROPHARMACOLOGY, V43, P1, DOI 10.1016/S0028-3908(02)00066-7; Mansour M, 2001, NEURON, V32, P841, DOI 10.1016/S0896-6273(01)00520-7; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; Miller FD, 2003, CURR OPIN NEUROBIOL, V13, P391, DOI 10.1016/s0959-4388(03)00072-2; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Murray TK, 2003, J PHARMACOL EXP THER, V306, P752, DOI 10.1124/jpet.103.049445; Nacher J, 2006, HIPPOCAMPUS, V16, P267, DOI 10.1002/hipo.20160; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; O'Neill MJ, 2004, CNS NEUROL DISORD-DR, V3, P181, DOI 10.2174/1568007043337508; Palmer CL, 2005, PHARMACOL REV, V57, P253, DOI 10.1124/pr.57.2.7; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Paupard MC, 2000, NEUROSCIENCE, V95, P869; PellegriniGiampietro DE, 1997, TRENDS NEUROSCI, V20, P464, DOI 10.1016/S0166-2236(97)01100-4; PENDE M, 1994, P NATL ACAD SCI USA, V91, P3215, DOI 10.1073/pnas.91.8.3215; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Peng PL, 2006, NEURON, V49, P719, DOI 10.1016/j.neuron.2006.01.025; Quirk JC, 2002, CNS DRUG REV, V8, P255; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Sans N, 2003, J NEUROSCI, V23, P9367; Slavov D, 2002, GENE, V299, P83, DOI 10.1016/S0378-1119(02)01016-8; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Suzuki M, 2006, EUR J NEUROSCI, V24, P645, DOI 10.1111/j.1460-9568.2006.04957.x; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Voss OP, 2007, NEUROPHARMACOLOGY, V52, P590, DOI 10.1016/j.neuropharm.2006.09.001; Washburn MS, 1996, J PHARMACOL EXP THER, V278, P669; Webb SE, 2005, CELL CALCIUM, V37, P375, DOI 10.1016/j.ceca.2005.01.005; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Zheng JL, 2004, NEUROINFORMATICS, V2, P303, DOI 10.1385/NI:2:3:303; Zheng JL, 1999, J NEUROIMMUNOL, V98, P185, DOI 10.1016/S0165-5728(99)00049-1	60	71	76	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2888	2900		10.1096/fj.07-104661	http://dx.doi.org/10.1096/fj.07-104661			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18403631	Green Published			2022-12-28	WOS:000258089300029
J	Nakajima, KI; Morita, Y; Koizumi, A; Asakura, T; Terada, T; Ito, K; Shimizu-Ibuka, A; Maruyama, JI; Kitamoto, K; Misaka, T; Abe, K				Nakajima, Ken-ichiro; Morita, Yuji; Koizumi, Ayako; Asakura, Tomiko; Terada, Tohru; Ito, Keisuke; Shimizu-Ibuka, Akiko; Maruyama, Jun-ichi; Kitamoto, Katsuhiko; Misaka, Takumi; Abe, Keiko			Acid-induced sweetness of neoculin is ascribed to its pH-dependent agonistic-antagonistic interaction with human sweet taste receptor	FASEB JOURNAL			English	Article						G protein-coupled receptors; histidine; sweet protein	MODIFYING ACTIVITY; ASPERGILLUS-ORYZAE; PROTEIN; T1R3; PURIFICATION; SUBUNITS; DOMAIN; MODEL; SITE	Neoculin (NCL) is a sweet protein that also has taste-modifying activity to convert sourness to sweetness. However, it has been unclear how NCL induces this unique sensation. Here we quantitatively evaluated the pH-dependent acid-induced sweetness of NCL using a cell-based assay system. The human sweet taste receptor, hT1R2-hT1R3, was functionally expressed in HEK293T cells together with G alpha protein. When NCL was applied to the cells under different pH conditions, it activated hT1R2-hT1R3 in a pH-dependent manner as the condition changed from pH 8 to 5. The pH-response sigmoidal curve resembled the imidazole titration curve, suggesting that His residues were involved in the taste-modifying activity. We then constructed an NCL variant in which all His residues were replaced with Ala and found that the variant elicited strong sweetness at neutral pH as well as at acidic pH. Since NCL and the variant elicited weak and strong sweetness at the same neutral pH, respectively, we applied different proportions of NCL-variant mixtures to the cells at this pH. As a result, NCL competitively inhibits the variant-induced receptor activation. All these data suggest that NCL acts as an hT1R2-hT1R3 agonist at acidic pH but functionally changes into its antagonist at neutral pH.	[Nakajima, Ken-ichiro; Morita, Yuji; Koizumi, Ayako; Asakura, Tomiko; Terada, Tohru; Ito, Keisuke; Misaka, Takumi; Abe, Keiko] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; [Terada, Tohru; Abe, Keiko] Univ Tokyo, Grad Sch Agr & Life Sci, Agr Bioinformat Res Unit, Tokyo 1138657, Japan; [Maruyama, Jun-ichi; Kitamoto, Katsuhiko] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biotechnol, Tokyo 1138657, Japan; [Shimizu-Ibuka, Akiko] Tokyo Univ Agr, Dept Nutr Sci, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo University of Agriculture	Abe, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	aka7308@mail.ecc.u-tokyo.ac.jp	Terada, Tohru/W-2956-2019; Ito, Keisuke/J-5926-2013	Terada, Tohru/0000-0002-7091-0646; Nakajima, Ken-ichiro/0000-0003-1932-418X; SHIMIZU-IBUKA, Akiko/0000-0002-5310-9216; Ito, Keisuke/0000-0002-8719-9635; Misaka, Takumi/0000-0002-9547-5767				Albert Steven M, 2002, Curr Psychiatry Rep, V4, P64, DOI 10.1007/s11920-002-0015-8; CASE DA, 2004, AMBER 8; Chandrashekar J, 2006, NATURE, V444, P288, DOI 10.1038/nature05401; Cui M, 2006, CURR PHARM DESIGN, V12, P4591, DOI 10.2174/138161206779010350; Galindo-Cuspinera V, 2006, NATURE, V441, P354, DOI 10.1038/nature04765; Ito K, 2007, BIOCHEM BIOPH RES CO, V360, P407, DOI 10.1016/j.bbrc.2007.06.064; Jang HJ, 2007, P NATL ACAD SCI USA, V104, P15069, DOI 10.1073/pnas.0706890104; Jiang PH, 2005, J BIOL CHEM, V280, P34296, DOI 10.1074/jbc.M505255200; Jiang PH, 2004, J BIOL CHEM, V279, P45068, DOI 10.1074/jbc.M406779200; Jin FJ, 2007, APPL MICROBIOL BIOT, V76, P1059, DOI 10.1007/s00253-007-1088-4; Koizumi A, 2007, BIOCHEM BIOPH RES CO, V358, P585, DOI 10.1016/j.bbrc.2007.04.171; KURIHARA Y, 1992, CRIT REV FOOD SCI, V32, P231, DOI 10.1080/10408399209527598; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Nakajima K, 2006, NEUROREPORT, V17, P1241, DOI 10.1097/01.wnr.0000230513.01339.3b; Nakajima K, 2006, APPL ENVIRON MICROB, V72, P3716, DOI 10.1128/AEM.72.5.3716-3723.2006; Nie Y, 2005, CURR BIOL, V15, P1948, DOI 10.1016/j.cub.2005.09.037; Nie YL, 2006, CHEM SENSES, V31, P505, DOI 10.1093/chemse/bjj053; Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033; Schiffman SS, 2000, PHYSIOL BEHAV, V68, P469, DOI 10.1016/S0031-9384(99)00205-X; Shimizu-Ibuka A, 2006, J MOL BIOL, V359, P148, DOI 10.1016/j.jmb.2006.03.030; Shirasuka Y, 2004, BIOSCI BIOTECH BIOCH, V68, P1403, DOI 10.1271/bbb.68.1403; Simmerling C, 2002, J AM CHEM SOC, V124, P11258, DOI 10.1021/ja0273851; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Winnig M, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-66; Xu H, 2004, P NATL ACAD SCI USA, V101, P14258, DOI 10.1073/pnas.0404384101; YAMASHITA H, 1990, J BIOL CHEM, V265, P15770	27	24	25	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2323	2330		10.1096/fj.07-100289	http://dx.doi.org/10.1096/fj.07-100289			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263698				2022-12-28	WOS:000257292500024
J	Rozenfeld, R; Devi, LA				Rozenfeld, Raphael; Devi, Lakshmi A.			Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3	FASEB JOURNAL			English	Article						endocannabinoid; G-protein-coupled receptors; intracellular signaling; lysosomal sorting; addiction; drug of abuse; THC	LYSOSOMAL MEMBRANE-GLYCOPROTEINS; DELTA-OPIOID RECEPTORS; COUPLED RECEPTORS; INTRACELLULAR-TRANSPORT; SIGNAL-TRANSDUCTION; SURFACE EXPRESSION; SYNAPTIC VESICLES; LIPID MEDIATORS; COMPLEX; CELLS	Cannabinoid receptor 1 (CB1) is an abundant G protein-coupled receptor, involved in a number of physiological processes. This receptor is localized at the plasma membrane, as well as in intracellular vesicles. The trafficking events leading to this intracellular localization remain controversial. In this study, we examine the differential trafficking of CB1 receptors and its implication on signaling. We find that the transfected tagged receptors are predominantly at the plasma membrane, whereas endogenous receptors exhibit an intracellular localization. We also find that intracellular endogenous CB1 receptors do not have an endocytic origin. Instead, these receptors associate with the adaptor protein AP-3 and traffic to the lysosomes. siRNA-mediated AP-3 delta knockdown leads to enhanced cell surface localization of CB1 receptors. Finally, we show that CB1 receptors in the late endosomal/lysosomal compartment are associated with heterotrimeric G proteins and mediate signal transduction. These results suggest that intracellular CB1 receptors are functional and that their spatial segregation is likely to significantly affect receptor function.	[Rozenfeld, Raphael; Devi, Lakshmi A.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Devi, LA (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, 19-84 Annenberg Bldg,1 Gustave L Levy Pl, New York, NY 10029 USA.	lakshmi.devi@mssm.edu	Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NCI NIH HHS [R24 CA095823] Funding Source: Medline; NIDA NIH HHS [R01 DA011322, DA11322, R01 DA008863, DA08863, R37 DA008863, K05 DA019521-08, R01 DA008863-17, DA19521, K05 DA019521, R01 DA011322-12, R56 DA008863] Funding Source: Medline; NINDS NIH HHS [NS053751, R03 NS053751-01S1, R03 NS053751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA095823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS053751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA019521, R01DA011322, R01DA008863, R56DA008863, R37DA008863] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ARONIN N, 1992, J NEUROSCI, V12, P3435; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Cahill CM, 2007, TRENDS PHARMACOL SCI, V28, P23, DOI 10.1016/j.tips.2006.11.003; Danglot L, 2007, BIOL CELL, V99, P349, DOI 10.1042/BC20070029; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Gobeil F, 2006, CAN J PHYSIOL PHARM, V84, P287, DOI 10.1139/Y05-127; Guan JS, 2005, CELL, V122, P619, DOI 10.1016/j.cell.2005.06.010; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Heimann AS, 2007, P NATL ACAD SCI USA, V104, P20588, DOI 10.1073/pnas.0706980105; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Kreitzer AC, 2002, CURR OPIN NEUROBIOL, V12, P324, DOI 10.1016/S0959-4388(02)00328-8; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Leterrier C, 2006, J NEUROSCI, V26, P3141, DOI 10.1523/JNEUROSCI.5437-05.2006; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Lloyd VK, 1999, GENOME, V42, P1183, DOI 10.1139/gen-42-6-1183; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Marrache AM, 2005, ENDOTHELIUM-J ENDOTH, V12, P63, DOI 10.1080/10623320590933815; McDonald NA, 2007, MOL PHARMACOL, V71, P976, DOI 10.1124/mol.106.029348; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Newell-Litwa K, 2007, J CELL SCI, V120, P531, DOI 10.1242/jcs.03365; Nyiri G, 2005, NEUROSCIENCE, V136, P811, DOI 10.1016/j.neuroscience.2005.01.026; O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Peden AA, 2002, J CELL BIOL, V156, P327, DOI 10.1083/jcb.200107140; Revankar CM, 2007, ACS CHEM BIOL, V2, P536, DOI 10.1021/cb700072n; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rios C, 2006, BRIT J PHARMACOL, V148, P387, DOI 10.1038/sj.bjp.0706757; Rozenfeld R, 2007, FASEB J, V21, P2455, DOI 10.1096/fj.06-7793com; Scales SJ, 2000, INT REV CYTOL, V195, P67; Seong E, 2005, MOL BIOL CELL, V16, P128, DOI 10.1091/mbc.E04-10-0892; Spritz RA, 1999, TRENDS GENET, V15, P337, DOI 10.1016/S0168-9525(99)01785-0; Stasyk T, 2007, MOL CELL PROTEOMICS, V6, P908, DOI 10.1074/mcp.M600463-MCP200; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; THOMAS BF, 1990, J PHARMACOL EXP THER, V255, P624; TSUKAGUCHI H, 1995, J CLIN INVEST, V96, P2043, DOI 10.1172/JCI118252; Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541; Uthayakumar S, 1995, CELL MOL BIOL RES, V41, P405; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yang W, 2000, J CELL SCI, V113, P4077; Zhu T, 2006, CAN J PHYSIOL PHARM, V84, P377, DOI 10.1139/Y05-147	52	117	117	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2311	2322		10.1096/fj.07-102731	http://dx.doi.org/10.1096/fj.07-102731			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18267983	Green Accepted			2022-12-28	WOS:000257292500023
J	Gupta, S; Kuhnisch, J; Mustafa, A; Lhotak, S; Schlachterman, A; Slifker, MJ; Klein-Szanto, A; High, KA; Austin, RC; Kruger, WD				Gupta, Sapna; Kuehnisch, Jirko; Mustafa, Aladdin; Lhotak, Sarka; Schlachterman, Alexander; Slifker, Michael J.; Klein-Szanto, Andres; High, Katherine A.; Austin, Richard C.; Kruger, Warren D.			Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia	FASEB JOURNAL			English	Article						osteoporosis; ER stress; inborn error of metabolism; sulfur metabolism	ENDOPLASMIC-RETICULUM STRESS; CARDIOVASCULAR-DISEASE; VASCULAR-DISEASE; HOMOCYSTEINE METABOLISM; GENE-EXPRESSION; NATURAL-HISTORY; RISK-FACTOR; B-VITAMINS; FOLIC-ACID; HOMOCYSTINURIA	Untreated cystathionine beta-synthase (CBS) deficiency in humans is characterized by extremely elevated plasma total homocysteine (tHcy>200 mu M), with thrombosis as the major cause of morbidity. Treatment with vitamins and diet leads to a dramatic reduction in thrombotic events, even though patients often still have severe elevations in tHcy (>80 mu M). To understand the difference between extreme and severe hyperhomocysteinemia, we have examined two mouse models of CBS deficiency: Tg-hCBS Cbs(-/-) mice, with a mean serum tHcy of 169 mu M, and Tg-I278T Cbs(-/-) mice, with a mean tHcy of 296 mu M. Only Tg-I278T Cbs(-/-) animals exhibited strong biological phenotypes, including facial alopecia, osteoporosis, endoplasmic reticulum (ER) stress in the liver and kidney, and a 20% reduction in mean survival time. Metabolic profiling of serum and liver reveals that Tg-I278T Cbs(-/-) mice have significantly elevated levels of free oxidized homocysteine but not protein-bound homocysteine in serum and elevation of all forms of homocysteine and S-adenosylhomocysteine in the liver compared to Tg- hCBS Cbs(-/-) mice. RNA profiling of livers indicate that Tg-I278T Cbs(-/-) and Tg- hCBS Cbs(-/-) mice have unique gene signatures, with minimal overlap. Our results indicate that there is a clear pathogenic threshold effect for tHcy and bring into question the idea that mild elevations in tHcy are directly pathogenic. Gupta, S., Kuhnisch, J., Mustafa, A., Lhotak, S., Schlachterman, A., Slifker, M. J., Klein-Szanto, A., High, K. A., Austin, R. C., Kruger, W. D. Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia. FASEB J. 23, 883-893 (2009)	[Slifker, Michael J.; Kruger, Warren D.] Fox Chase Canc Ctr, Div Populat Sci, Biostat Facil, Philadelphia, PA 19111 USA; [Kuehnisch, Jirko] Charite, Inst Med Genet, Berlin, Germany; [Lhotak, Sarka; Austin, Richard C.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Schlachterman, Alexander; High, Katherine A.] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA	Fox Chase Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; McMaster University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Kruger, WD (corresponding author), Fox Chase Canc Ctr, Div Populat Sci, Biostat Facil, 333 Cottman Ave, Philadelphia, PA 19111 USA.	warren.kruger@fccc.edu	High, Katherine A./AAB-9322-2020; Kühnisch, Jirko/M-3744-2019; Kruger, Warren/Y-2541-2018; Kühnisch, Jirko/L-7761-2013; kruger, warren/A-6407-2008; Klein-Szanto, A./E-6218-2010	Kühnisch, Jirko/0000-0003-4744-5421; kruger, warren/0000-0002-4990-3695; 	National Institutes of Health [HL16237, CA06927]; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Sequencing, DNA Microarray, Biostatistics and Bioinformatics, Transgenic Mouse, and Laboratory Animal facilities of Fox Chase Cancer Center for their assistance. This work was supported by grants HL16237 and CA06927 from the National Institutes of Health and an appropriation from the Commonwealth of Pennsylvania to the Fox Chase Cancer Center.	Aijarnali MN, 2008, J CLIN INVEST, V118, P1825, DOI 10.1172/JCI32878; Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227; Colgan SM, 2007, INT J BIOCHEM CELL B, V39, P1843, DOI 10.1016/j.biocel.2007.05.002; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Glushchenko AV, 2007, ANTIOXID REDOX SIGN, V9, P1883, DOI 10.1089/ars.2007.1809; Gupta S, 2008, HUM MUTAT, V29, P1048, DOI 10.1002/humu.20773; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hossain GS, 2003, J BIOL CHEM, V278, P30317, DOI 10.1074/jbc.M212897200; Jacobsen DW, 1998, CLIN CHEM, V44, P1833; Jhee KH, 2005, ANTIOXID REDOX SIGN, V7, P813, DOI 10.1089/ars.2005.7.813; Ji C, 2003, GASTROENTEROLOGY, V124, P1488, DOI 10.1016/S0016-5085(03)00276-2; Kraus JP, 1999, HUM MUTAT, V13, P362; Kruger WD, 2003, HUM MUTAT, V22, P434, DOI 10.1002/humu.10290; Leclerc D, 2008, J BIOL CHEM, V283, P3151, DOI 10.1074/jbc.M708598200; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; MALLOY MH, 1981, AM J CLIN NUTR, V34, P2619, DOI 10.1093/ajcn/34.12.2619; Mengesdorf T, 2002, P NATL ACAD SCI USA, V99, P15042, DOI 10.1073/pnas.232588799; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Mudd S., 2001, METABOLIC MOL BASES, P2007; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Robert K, 2005, ANAT REC PART A, V282A, P1, DOI 10.1002/ar.a.20145; Robert K, 2004, ANAT REC PART A, V280A, P1072, DOI 10.1002/ar.a.20082; Rumfelt LL, 2006, J EXP MED, V203, P675, DOI 10.1084/jem.20052444; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; STEEGERSTHEUNISSEN RPM, 1994, METABOLISM, V43, P1475, DOI 10.1016/0026-0495(94)90004-3; UELAND PM, 1982, PHARMACOL REV, V34, P223; van Meurs JBJ, 2004, NEW ENGL J MED, V350, P2033, DOI 10.1056/NEJMoa032546; Wang LQ, 2005, HUM MOL GENET, V14, P2201, DOI 10.1093/hmg/ddi224; Wang LQ, 2004, CIRC RES, V94, P1318, DOI 10.1161/01.RES.0000129182.46440.4a; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; Yap S, 2000, SEMIN THROMB HEMOST, V26, P335, DOI 10.1055/s-2000-8100; Yap S, 2001, ARTERIOSCL THROM VAS, V21, P2080, DOI 10.1161/hq1201.100225; Zhang YL, 2006, J CHEM ENG JPN, V39, P587, DOI 10.1252/jcej.39.587	42	85	94	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					883	893		10.1096/fj.08-120584	http://dx.doi.org/10.1096/fj.08-120584			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18987302	Green Published			2022-12-28	WOS:000265506300024
J	Gualandris, A; Noghero, A; Geuna, M; Arese, M; Valdembri, D; Serini, G; Bussolino, F				Gualandris, Anna; Noghero, Alessio; Geuna, Massimo; Arese, Marco; Valdembri, Donatella; Serini, Guido; Bussolino, Federico			Microenvironment drives the endothelial or neural fate of differentiating embryonic stem cells coexpressing neuropilin-1 and Flk-1	FASEB JOURNAL			English	Article						cell commitment; endothelial differentiation; embryoid bodies	PROGENITOR CELLS; NERVOUS-SYSTEM; MOUSE EMBRYO; BONE-MARROW; IN-VITRO; ARTERIAL DIFFERENTIATION; VASCULAR MORPHOGENESIS; MEMBRANE-PROTEIN; VESSEL FORMATION; GROWTH-FACTOR	The observation that the architecture of the cardiovascular and nervous systems is drawn by common guidance cues and the closeness between neural progenitors and endothelial cells in the vascular niche strongly suggests the existence of links between endothelial and neural cell fates. We identified an embryonic stem cell-derived discrete, nonclonal cell population expressing the two vascular endothelial growth factor receptors neuropilin-1 (Nrp1) and Flk1 that differentiates in vitro toward endothelial or neural phenotypes depending on microenvironmental cues. When microinjected in the chick embryo, Nrp1(+) cells integrate within the host, developing vessels and brain, and acquire endothelial and neural markers, respectively. These results show that precursors of endothelial cells and precursors of neural cells arise from the same pool of differentiating embryonic stem cells and share the expression of Nrp1 and Flk1. These data reinforce the parallelism between vascular and nervous system at the level of cell fate and commitment and open new perspective in regenerative medicine of neurovascular diseases.-Gualandris, A., Noghero, A., Geuna, M., Arese, M., Valdembri, D., Serini, G., Bussolino, F. Microenvironment drives the endothelial or neural fate of differentiating embryonic stem cells coexpressing neuropilin-1 and Flk-1. FASEB J. 23, 68-78 (2009)	[Gualandris, Anna; Noghero, Alessio; Geuna, Massimo; Arese, Marco; Valdembri, Donatella; Serini, Guido; Bussolino, Federico] Univ Turin, Dept Oncol Sci, Inst Canc Res & Treatment, IRCC,Sch Med, I-10060 Candiolo, TO, Italy; [Gualandris, Anna; Noghero, Alessio; Arese, Marco; Valdembri, Donatella; Serini, Guido; Bussolino, Federico] Univ Turin, Div Mol Angiogenesis, I-10060 Candiolo, TO, Italy; [Geuna, Massimo] Univ Turin, Div Clin & Expt Cytometry, I-10060 Candiolo, TO, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Turin	Gualandris, A (corresponding author), Univ Turin, Dept Oncol Sci, Inst Canc Res & Treatment, IRCC,Sch Med, Str Prov 142,Km 3 95, I-10060 Candiolo, TO, Italy.	anna.gualandris@ircc.it	NOGHERO, Alessio/AAL-1573-2020; Serini, Guido/AAF-2873-2021; Bussolino, Federico/AES-3951-2022; arese, marco/J-6119-2013; Geuna, Massimo/AAY-1441-2021; Bussolino, Federico/K-2500-2016	NOGHERO, Alessio/0000-0002-8266-9247; Serini, Guido/0000-0002-3502-8367; arese, marco/0000-0002-7384-9406; Geuna, Massimo/0000-0002-6475-5547; Gualandris, anna/0000-0002-2889-4080; Valdembri, Donatella/0000-0003-4590-417X; Bussolino, Federico/0000-0002-5348-1341	Istituto Superiore di Sanita'; Associazione Italiana per la Ricerca sul Cancro, Regione Piemonte; 6FP European Community [LSHM-CT-2003-503254]; Fondazione Cassa di Risparmio di Torino and Ministero della Salute; Ministero dell'Universita' (PRIN2007); Telethon, Italy [GGP04127]	Istituto Superiore di Sanita'; Associazione Italiana per la Ricerca sul Cancro, Regione Piemonte(Fondazione AIRC per la ricerca sul cancroRegione Piemonte); 6FP European Community(European Commission); Fondazione Cassa di Risparmio di Torino and Ministero della Salute; Ministero dell'Universita' (PRIN2007)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Telethon, Italy(Fondazione Telethon)	This work was supported by Istituto Superiore di Sanita' (Programma Nazionale sulle Cellule Staminali, VI Programma nazionale AIDS), Associazione Italiana per la Ricerca sul Cancro, Regione Piemonte (Progetto di Ricerca sanitaria Finalizzata 2006, Ricerca Scientifica 2004, grants A150 and D10), 6FP European Community (LSHM-CT-2003-503254), Fondazione Cassa di Risparmio di Torino and Ministero della Salute (Programma di Ricerca Finalizzata 2006 and Programma Straordinario di Ricerca Oncologica 2006), Ministero dell'Universita' (PRIN2007), and Telethon, Italy GGP04127. We thank Dr. Alexandra L. Joyner (Developmental Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA) for the gift of W4 129SvEv ES cells, Dr. Andras Nagy (Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada) and Anna-Katerina Hadjantonakis (Developmental Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA) for R1 EYFP-expressing ES cells, Dr. Timm Schroeder (Institute of Cell Research, Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Neuherberg, Germany) for OP9 and PA6 cells and helpful suggestions, L. Primo for suggestions and comments, and Dr. S. Geuna for assistance with confocal microscopy. We thank Famarco and Susatrasporti S.p.A. for white Leghorn chicken eggs, and the Developmental Studies Hybridoma Bank of the University of Iowa for antibodies.	Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Auerbach W, 2000, BIOTECHNIQUES, V29, P1024, DOI 10.2144/00295st04; Betsholtz C, 2005, EXP SUPPL, V94, P115; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Bussolino F, 2006, ENDOTHELIUM-J ENDOTH, V13, P81, DOI 10.1080/10623320600698003; Buzanska L, 2002, J CELL SCI, V115, P2131; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; Choi K, 1998, DEVELOPMENT, V125, P725; Ema M, 2003, TRENDS CARDIOVAS MED, V13, P254, DOI 10.1016/S1050-1738(03)00105-1; Fons P, 2004, J CELL PHYSIOL, V200, P351, DOI 10.1002/jcp.20076; Fujisawa H, 1995, DEV NEUROSCI-BASEL, V17, P343, DOI 10.1159/000111304; Gago N, 2003, MOL CELL NEUROSCI, V22, P162, DOI 10.1016/S1044-7431(02)00030-1; Goolsby J, 2003, P NATL ACAD SCI USA, V100, P14926, DOI 10.1073/pnas.2434383100; Gualandris A, 2000, MOL BIOL CELL, V11, P4295, DOI 10.1091/mbc.11.12.4295; Hadjantonakis Anna-Katerina, 2002, BMC Biotechnol, V2, P11, DOI 10.1186/1472-6750-2-11; Hirashima M, 1999, BLOOD, V93, P1253, DOI 10.1182/blood.V93.4.1253.404k31_1253_1263; Huber TL, 2004, NATURE, V432, P625, DOI 10.1038/nature03122; Kattman SJ, 2006, DEV CELL, V11, P723, DOI 10.1016/j.devcel.2006.10.002; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; Kiefer JC, 2007, DEV DYNAM, V236, P2356, DOI 10.1002/dvdy.21218; Kinder SJ, 2001, TRENDS CARDIOVAS MED, V11, P177, DOI 10.1016/S1050-1738(01)00091-3; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Korn J, 2002, J COMP NEUROL, V442, P78, DOI 10.1002/cne.1423; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Li ZJ, 2005, J CELL BIOCHEM, V95, P559, DOI 10.1002/jcb.20436; Maurer MH, 2003, NEUROSCI LETT, V344, P165, DOI 10.1016/S0304-3940(03)00407-5; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Motoike T, 2003, GENESIS, V35, P153, DOI 10.1002/gene.10175; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Mukouyama YS, 2005, DEVELOPMENT, V132, P941, DOI 10.1242/dev.01675; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Nanka O, 2001, ANAT EMBRYOL, V204, P407, DOI 10.1007/s004290100212; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Sarnat HB, 1998, BRAIN DEV-JPN, V20, P88, DOI 10.1016/S0387-7604(97)00111-3; Schroeder T, 2006, MECH DEVELOP, V123, P570, DOI 10.1016/j.mod.2006.05.002; Shraga-Heled N, 2007, FASEB J, V21, P915, DOI 10.1096/fj.06-6277com; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Ueno H, 2006, DEV CELL, V11, P519, DOI 10.1016/j.devcel.2006.08.001; Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018-004-4144-6; Wu SM, 2006, CELL, V127, P1137, DOI 10.1016/j.cell.2006.10.028; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yasunaga M, 2005, NAT BIOTECHNOL, V23, P1542, DOI 10.1038/nbt1167; Ying QL, 2003, METHOD ENZYMOL, V365, P327; Zappone MV, 2000, DEVELOPMENT, V127, P2367	48	13	14	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2009	23	1					68	78		10.1096/fj.08-112847	http://dx.doi.org/10.1096/fj.08-112847			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18757501				2022-12-28	WOS:000262095500009
J	Flockhart, RJ; Diffey, BL; Farr, PM; Lloyd, J; Reynolds, NJ				Flockhart, R. J.; Diffey, B. L.; Farr, P. M.; Lloyd, J.; Reynolds, N. J.			NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure	FASEB JOURNAL			English	Article						UVB; action spectrum; skin equivalents; cyclosporin A	ACTIVATED T-CELLS; NUCLEAR FACTOR; TRANSCRIPTION FACTORS; ACTION SPECTRUM; CYCLOOXYGENASE-2 TRANSCRIPTION; SKIN-CANCER; EXPRESSION; CALCINEURIN; FAMILY; LOCALIZATION	The nuclear factor of activated T cells (NFAT) transcription factors are regulated by calcium/calcineurin signals and play important roles in T cells, muscle, bone, and neural tissue. NFAT is expressed in the epidermis, and although recent data suggest that NFAT is involved in the skin's responses to ultraviolet radiation (UVR), the wavelengths of radiation that activate NFAT and the biological function of UV-activated NFAT remain undefined. We demonstrate that NFAT transcriptional activity is preferentially induced by UVB wavelengths in keratinocytes. The derived action spectrum for NFAT activation indicates that NFAT transcriptional activity is inversely associated with wavelength. UVR also evoked NFAT2 nuclear translocation in a parallel wavelength-dependent fashion and both transcriptional activation and nuclear translocation were inhibited by the calcineurin inhibitor cyclosporin A. UVR also evoked NFAT2 nuclear translocation in three-dimensional skin equivalents. Evidence suggests that COX-2 contributes to UV-induced carcinogenesis. Inhibiting UV-induced NFAT activation in keratinocytes, reduced COX-2 protein induction, and increased UV-induced apoptosis. COX-2 luciferase reporters lacking functional NFAT binding sites were less responsive to UVR, highlighting that NFAT is required for UV-induced COX-2 induction. Taken together, these data suggest that the proinflammatory, antiapoptotic, and procarcinogenic functions of UV-activated COX-2 may be mediated, in part, by upstream NFAT signaling.	[Flockhart, R. J.; Diffey, B. L.; Reynolds, N. J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Lloyd, J.] Royal Victoria Infirm, Dept Med Phys, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Reynolds, NJ (corresponding author), Newcastle Univ, Inst Cellular Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.reynolds@ncl.ac.uk		Reynolds, Nick/0000-0002-6484-825X	The British Skin Foundation; Wellcome Trust	The British Skin Foundation; Wellcome Trust(Wellcome Trust)	This work was funded by The British Skin Foundation (R.J.F.) and Wellcome Trust Research Leave Fellowship (N.J.R.). The authors thank D. Cantrell (ICRF, London, UK) for NFAT2 cDNA, D. J. McKean (Mayo Foundation, Rochester, MN, USA) for the NFAT luciferase reporter vector, and M. A. Iniguez (Centro de Biologia Molecular, Madrid, Spain) for COX-2 luciferase reporter vectors.	Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Akunda JK, 2007, MOL CARCINOGEN, V46, P354, DOI 10.1002/mc.20290; Al-Daraji WI, 2002, J INVEST DERMATOL, V118, P779, DOI 10.1046/j.1523-1747.2002.01709.x; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Benedito AB, 2005, J BIOL CHEM, V280, P2818, DOI 10.1074/jbc.M408741200; Blanke C, 2004, CANCER INVEST, V22, P271, DOI 10.1081/CNV-120030216; Botti C, 1998, INT J BIOL MARKER, V13, P51; Buchholz M, 2007, CELL CYCLE, V6, P16, DOI 10.4161/cc.6.1.3650; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Corral RS, 2007, ONCOGENE, V26, P958, DOI 10.1038/sj.onc.1209856; DEGRUIJL FR, 1993, CANCER RES, V53, P53; Diffey BL, 2002, METHODS, V28, P4, DOI 10.1016/S1046-2023(02)00204-9; Ding J, 2006, J BIOL CHEM, V281, P24405, DOI 10.1074/jbc.M600751200; FARR PM, 1991, BRIT J DERMATOL, V124, P443, DOI 10.1111/j.1365-2133.1991.tb00623.x; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; FISCHER T, 1984, INT J DERMATOL, V23, P633, DOI 10.1111/j.1365-4362.1984.tb01220.x; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028; Hedin KE, 1997, J IMMUNOL, V159, P5431; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horio T, 1998, CLIN DERMATOL, V16, P59, DOI 10.1016/S0738-081X(97)00170-3; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Huang CS, 2000, J BIOL CHEM, V275, P9143, DOI 10.1074/jbc.275.13.9143; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jayanthi S, 2005, P NATL ACAD SCI USA, V102, P868, DOI 10.1073/pnas.0404990102; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Loh C, 1996, MOL CELL BIOL, V16, P3945; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Mahns A, 2004, PHOTOCH PHOTOBIO SCI, V3, P257, DOI 10.1039/b309067a; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; Maziere C, 2005, FREE RADICAL BIO MED, V39, P1629, DOI 10.1016/j.freeradbiomed.2005.08.003; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; McKinlay AF., 1987, CIE J, P83; Meric JB, 2006, CRIT REV ONCOL HEMAT, V59, P51, DOI 10.1016/j.critrevonc.2006.01.003; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Onguru O, 2005, ENDOCR PATHOL, V16, P253, DOI 10.1385/EP:16:4:253; PARRISH JA, 1981, J INVEST DERMATOL, V76, P359, DOI 10.1111/1523-1747.ep12520022; Patel RN, 1999, J IMMUNOL, V163, P3459; Penn I, 1998, Clin Transpl, P147; Pu WT, 2003, CIRC RES, V92, P725, DOI 10.1161/01.RES.0000069211.82346.46; Santini MP, 2001, P NATL ACAD SCI USA, V98, P9575, DOI 10.1073/pnas.161299698; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Sevigny MB, 2006, FEBS LETT, V580, P6533, DOI 10.1016/j.febslet.2006.10.073; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Sheil AGR, 1998, TRANSPLANT P, V30, P2055, DOI 10.1016/S0041-1345(98)00539-9; Sinicrope FA, 2004, CANCER METAST REV, V23, P63, DOI 10.1023/A:1025863029529; Tang QB, 2001, CANCER RES, V61, P4329; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; Turner H, 1998, J EXP MED, V188, P527, DOI 10.1084/jem.188.3.527; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002; Yarosh DB, 2005, J INVEST DERMATOL, V125, P1020, DOI 10.1111/j.0022-202X.2005.23858.x; Yiu GK, 2006, J BIOL CHEM, V281, P12210, DOI 10.1074/jbc.M600184200; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	64	48	48	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4218	4227		10.1096/fj.08-113076	http://dx.doi.org/10.1096/fj.08-113076			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18708588	hybrid, Green Published			2022-12-28	WOS:000261254800021
J	Nelson, GN; Roh, JD; Mirensky, TL; Wang, Y; Yi, T; Tellides, G; Pober, JS; Shkarin, P; Shapiro, EM; Saltzman, WM; Papademetris, X; Fahmy, TM; Breuer, CK				Nelson, G. N.; Roh, J. D.; Mirensky, T. L.; Wang, Y.; Yi, T.; Tellides, G.; Pober, J. S.; Shkarin, P.; Shapiro, E. M.; Saltzman, W. M.; Papademetris, X.; Fahmy, T. M.; Breuer, C. K.			Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo	FASEB JOURNAL			English	Article						SCID/bg; animal model; arterial grafts; MRI	MESENCHYMAL STEM-CELLS; SINGLE MAMMALIAN-CELLS; IRON-OXIDE PARTICLES; BONE-MARROW-CELLS; PROGENITOR CELLS; MOUSE MODEL; NANOPARTICLES; AUTOGRAFTS; RAT; DIFFERENTIATION	This pilot study examines noninvasive MR monitoring of tissue-engineered vascular grafts (TEVGs) in vivo using cells labeled with iron oxide nanoparticles. Human aortic smooth muscle cells (hASMCs) were labeled with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles. The labeled hASMCs, along with human aortic endothelial cells, were incorporated into eight TEVGs and were then surgically implanted as aortic interposition grafts in a C. B-17 SCID/bg mouse host. USPIO-labeled hASMCs persisted in the grafts throughout a 3 wk observation period and allowed noninvasive MR imaging of the human TEVGs for real-time, serial monitoring of hASMC retention. This study demonstrates the feasibility of applying noninvasive imaging techniques for evaluation of in vivo TEVG performance. -Nelson, G. N., Roh, J. D., Mirensky, T. L., Wang, Y., Yi, T., Tellides, G., Pober, J. S., Shkarin, P., Shapiro, E. M., Saltzman, W. M., Papademetris, X., Fahmy, T. M., Breuer, C. K.. Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo. FASEB J. 22, 3888-3895 (2008)	[Nelson, G. N.; Roh, J. D.; Mirensky, T. L.; Wang, Y.; Yi, T.; Tellides, G.; Pober, J. S.; Saltzman, W. M.; Fahmy, T. M.; Breuer, C. K.] Yale Univ, Sch Med, Interdept Program Vasc Biol & Therapeut, New Haven, CT 06520 USA; [Shkarin, P.; Shapiro, E. M.; Papademetris, X.] Yale Univ, Dept Radiol, Sch Med, New Haven, CT 06520 USA; [Saltzman, W. M.; Papademetris, X.; Fahmy, T. M.] Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Breuer, CK (corresponding author), Yale Univ, Sch Med, Interdept Program Vasc Biol & Therapeut, Amistad Res Bldg,10 Amistad St,Rm 301B,POB 208089, New Haven, CT 06520 USA.	christopher.breuer@yale.edu		Breuer, Christopher/0000-0003-0987-3898	U. S. National Institutes of Health [K08HL83980-2, R01 EB006494-01, P01-HL070295]; American Surgical Association; Yale University Office of Student Research; Yale University Department of Surgery Ohse; Howard Hughes Medical Institute Medical Research Training Fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295, K08HL083980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB006494] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Surgical Association; Yale University Office of Student Research; Yale University Department of Surgery Ohse; Howard Hughes Medical Institute Medical Research Training Fellowship(Howard Hughes Medical Institute); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank Nancy Troiano and Chris Coady for their help in GMA and paraffin embedding. This work was supported by grants from the U. S. National Institutes of Health (NIH; K08HL83980-2, R01 EB006494-01 P01-HL070295), the American Surgical Association, the Yale University Office of Student Research, and the Yale University Department of Surgery Ohse Grant Program. In addition, this work was performed as part of an NIH-sponsored Howard Hughes Medical Institute Medical Research Training Fellowship. The authors declare they have no competing financial interests.	Anderson SA, 2005, BLOOD, V105, P420, DOI 10.1182/blood-2004-06-2222; Anderson SA, 2004, ANN NEUROL, V55, P654, DOI 10.1002/ana.20066; Arbab AS, 2003, RADIOLOGY, V229, P838, DOI 10.1148/radiol.2293021215; Arbab AS, 2005, NMR BIOMED, V18, P383, DOI 10.1002/nbm.970; Blake P, 2003, J NEURO-OPHTHALMOL, V23, P34, DOI 10.1097/00041327-200303000-00009; Breslau J, 1999, AM J NEURORADIOL, V20, P670; Briley-Saebo KC, 2006, INVEST RADIOL, V41, P560, DOI 10.1097/01.rli.0000221321.90261.09; Bulte JWM, 2004, BLOOD, V104, P3410, DOI 10.1182/blood-2004-06-2117; Bulte JWM, 2002, J CEREBR BLOOD F MET, V22, P899, DOI 10.1097/00004647-200208000-00001; Cao F, 2007, J TISSUE ENG REGEN M, V1, P465, DOI 10.1002/term.55; Dodd SJ, 1999, BIOPHYS J, V76, P103, DOI 10.1016/S0006-3495(99)77182-1; Foster-Gareau P, 2003, MAGN RESON MED, V49, P968, DOI 10.1002/mrm.10417; Hilderbrand SA, 2005, BIOCONJUGATE CHEM, V16, P1275, DOI 10.1021/bc0501799; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; Ko IK, 2007, ANN BIOMED ENG, V35, P101, DOI 10.1007/s10439-006-9204-7; Kostura L, 2004, NMR BIOMED, V17, P513, DOI 10.1002/nbm.925; Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Luker GD, 2008, J NUCL MED, V49, P1, DOI 10.2967/jnumed.107.045799; Matsumura G, 2003, CIRCULATION, V108, P1729, DOI 10.1161/01.CIR.0000092165.32213.61; Matsumura G, 2003, BIOMATERIALS, V24, P2303, DOI 10.1016/S0142-9612(03)00043-7; Modo M, 2005, MOL IMAGING, V4, P143; Roh JD, 2008, BIOMATERIALS, V29, P1454, DOI 10.1016/j.biomaterials.2007.11.041; Runge V M, 2000, J Magn Reson Imaging, V12, P205, DOI 10.1002/1522-2586(200008)12:2<205::AID-JMRI1>3.0.CO;2-P; Shapiro EM, 2005, MAGNET RESON MED, V53, P329, DOI 10.1002/mrm.20342; Shin'oka T, 2005, J THORAC CARDIOV SUR, V129, P1330, DOI 10.1016/j.jtcvs.2004.12.047; Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717; Terrovitis JV, 2006, TISSUE ENG, V12, P2765, DOI 10.1089/ten.2006.12.2765; Zhang Q, 2003, DEFENCE SCI J, V53, P259, DOI 10.14429/dsj.53.2274; Zhang RL, 2003, NEUROSCIENCE, V116, P373, DOI 10.1016/S0306-4522(02)00696-6	30	34	37	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2008	22	11					3888	3895		10.1096/fj.08-107367	http://dx.doi.org/10.1096/fj.08-107367			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18711027	Green Published			2022-12-28	WOS:000260503000017
J	Cavet, ME; Pang, JJ; Yin, GY; Berk, BC				Cavet, Megan E.; Pang, Jinjiang; Yin, Guoyong; Berk, Bradford C.			An epidermal growth factor (EGF)-dependent interaction between GIT1 and sorting nexin 6 promotes degradation of the EGF receptor	FASEB JOURNAL			English	Article						G-protein coupled receptor; tyrosine kinase; signal transduction; endosome; receptor trafficking	GTPASE-ACTIVATING PROTEINS; ANGIOTENSIN-II; CELL-SURFACE; FAMILY; TRAFFICKING; COMPLEX; PIX; PATHWAYS; LOCALIZATION; ENDOCYTOSIS	G-protein coupled receptor (GPCR) kinase-2 interacting protein 1 (GIT1) is a multifunctional scaffolding protein that regulates epidermal growth factor receptor (EGFR) signaling pathways. We demonstrate that GIT1 interacts with sorting nexin 6 (SNX6), a member of the SNX family that increases EGFR trafficking between endosomes and lysosomes, thereby enhancing EGFR degradation. The GIT1-SNX6 interaction is increased 3-fold after treatment with EGF for 60 min. The second coiled-coil domain (CC2; as 424-474) of GIT1 mediates binding to SNX6. Subcellular fractionation and confocal microscopy data indicate that GIT1 and SNX6 interact in endosomes. Knockdown of GIT1 expression by small interfering RNA decreased the rate of EGF-induced EGFR degradation. Expression of exogenous GIT1 or SNX6 alone did not alter EGFR degradation; however, coexpression of GIT1 and SNX6 decreased EGFR levels both basally and in response to EGF. In contrast, expression of GIT1(CC2 deleted) and SNX6 did not reduce EGFR levels, demonstrating that the interaction between GIT1 and SNX6 was required to regulate EGFR trafficking. Phosphorylation of the EGFR substrate phospholipase C-gamma was decreased by coexpression of GIT1 and SNX6. These data demonstrate an endosomal, EGF-regulated interaction between SNX6 and GIT1 that enhances degradation of the EGFR, and thereby alters EGFR signaling. Our findings suggest a new role for GIT1 in tyrosine kinase receptor trafficking.	Univ Rochester, Cardiovasc Res Inst, Sch Med, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Aab Cardiovasc Res Inst, Sch Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Inst, Sch Med, Dept Med, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115	U.S. National Institutes of Health [HL63462]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063462] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health grant HL63462 to B.C.B.	Amerongen GPV, 2004, CIRC RES, V94, P1041, DOI 10.1161/01.RES.0000125627.77235.0C; Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Feng QY, 2006, NAT CELL BIOL, V8, P945, DOI 10.1038/ncb1453; Goehler H, 2004, MOL CELL, V15, P853, DOI 10.1016/j.molcel.2004.09.016; Gullapalli A, 2004, MOL BIOL CELL, V15, P2143, DOI 10.1091/mbc.E03-09-0711; Haendeler J, 2003, J BIOL CHEM, V278, P49936, DOI 10.1074/jbc.M307317200; Haendeler J, 2000, CIRC RES, V86, P729, DOI 10.1161/01.RES.86.7.729; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hanson BJ, 2003, J BIOL CHEM, V278, P34617, DOI 10.1074/jbc.M300143200; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kurten RC, 2001, J CELL SCI, V114, P1743; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; Manabe R, 2002, J CELL SCI, V115, P1497; Matafora V, 2001, J CELL SCI, V114, P4509; Paris S, 2003, BIOCHEM J, V372, P391, DOI 10.1042/BJ20030047; Paris S, 2002, INT J BIOCHEM CELL B, V34, P826, DOI 10.1016/S1357-2725(02)00008-0; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Pons V, 2003, J BIOL CHEM, V278, P21155, DOI 10.1074/jbc.M211008200; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 2004, CELL SIGNAL, V16, P1001, DOI 10.1016/j.cellsig.2004.02.002; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Yin GY, 2004, MOL CELL BIOL, V24, P875, DOI 10.1128/MCB.24.2.875-885.2004; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	39	25	27	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2008	22	10					3607	3616		10.1096/fj.07-094086	http://dx.doi.org/10.1096/fj.07-094086			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18523162	Green Published			2022-12-28	WOS:000259642600022
J	Fainaru, O; Adini, I; Benny, O; Bazinet, L; Pravda, E; D'Amato, R; Folkman, J				Fainaru, Ofer; Adini, Irit; Benny, Ofra; Bazinet, Lauren; Pravda, Elke; D'Amato, Robert; Folkman, Judah			Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability	FASEB JOURNAL			English	Article						pulmonary edema; angiogenesis; delayed-type hypersensitivity	GROWTH-FACTOR; INTERENDOTHELIAL JUNCTIONS; PERMEABILITY FACTOR; MOLECULAR-BASIS; ANGIOGENESIS; MICE; INTERLEUKIN-2; IMMUNOTHERAPY; SENSITIZATION; MECHANISM	The endothelium lining blood vessels serves as a barrier against vascular hyperpermeability, and its maintenance is critical to organ health. Inflammatory mediators evoke tissue edema by disrupting the expression of membrane junctional proteins, which mediate binding between endothelial cell membranes. Endothelial cell-cell junctions form a diffusion barrier between the intravascular and interstitial space. To prevent the morbidity and mortality caused by exaggerated vascular permeability associated with pathological states (e.g., inflammatory and hypersensitivity disorders, pulmonary edema, traumatic lung injury, cerebral edema resulting from stroke, and others), it is important to develop therapeutic approaches to stabilize these interendothelial junctions. Vascular endothelial growth factor (VEGF), a potent proangiogenic cytokine, was first described as vascular permeability factor (VPF). Doxycycline, a tetracycline derivative, has been shown to inhibit angiogenesis in both humans and animal models. We now report that oral doxycycline prevents VPF/VEGF-induced vascular permeability, interleukin-2-induced pulmonary edema, and delayed-type hypersensitivity (DTH) in mice. Remarkably, doxycycline also inhibits tumor growth and tumor-associated vascular hyperpermeability. Finally, we show that doxycycline targets the adherens junction in vascular endothelial cells by inducing the total amount of VE-cadherin expression while decreasing the degree of its phosphorylation. The potential of doxycyline as a therapeutic inhibitor of vascular hyperpermeability in human clinical conditions is promising and warrants further studies.	[Fainaru, Ofer; Benny, Ofra; Bazinet, Lauren; Pravda, Elke; D'Amato, Robert; Folkman, Judah] Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program,Dept Surg, Boston, MA 02115 USA; [Adini, Irit; D'Amato, Robert] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Fainaru, O (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program,Dept Surg, 300 Longnwood Ave, Boston, MA 02115 USA.	ofer.fainaru@childrens.harvard.edu	Benny, Ofra/AAB-3294-2021		Fulbright and Rothschild Foundations; European Molecular Biology Organization (EMBO) Fellowship; Department of Defense award [W81XWH-05-1-0115]	Fulbright and Rothschild Foundations; European Molecular Biology Organization (EMBO) Fellowship(European Molecular Biology Organization (EMBO)); Department of Defense award(United States Department of Defense)	This research was supported by the Fulbright and Rothschild Foundations and the European Molecular Biology Organization (EMBO) Fellowship (O.F.), and Department of Defense award W81XWH-05-1-0115) (to J.F). We thank Dr. Harold Dvorak for helpful discussions and pathological slide analysis. Dr. Donald Ingber for critically reviewing the manuscript, Kristin Johnson for photography and graphic art, and Steven A. Rosenberg for the generous gift of IL-2.	ASHERSON GL, 1968, IMMUNOLOGY, V15, P405; BERTHIAUME Y, 1995, AM J RESP CRIT CARE, V152, P329, DOI 10.1164/ajrccm.152.1.7599842; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Carmeliet P., 2000, ANN NY ACAD SCI, V902, P62; Chen B, 2006, CLIN CANCER RES, V12, P917, DOI 10.1158/1078-0432.CCR-05-1673; Claffey KP, 1996, CANCER RES, V56, P172; DVORAK AM, 1984, CLIN IMMUNOL IMMUNOP, V32, P142, DOI 10.1016/0090-1229(84)90116-8; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Esser S, 1998, J CELL SCI, V111, P1853; Feng D, 2000, MICROVASC RES, V59, P24, DOI 10.1006/mvre.1999.2207; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; GAD SC, 1986, TOXICOL APPL PHARM, V84, P93, DOI 10.1016/0041-008X(86)90419-9; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; GILBERTSONBEADLING S, 1995, CANCER CHEMOTH PHARM, V36, P418, DOI 10.1007/BF00686191; Golub L M, 1998, Adv Dent Res, V12, P12; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Han XN, 2004, AM J PHYSIOL-LUNG C, V286, pL259, DOI 10.1152/ajplung.00187.2003; Hoyt JC, 2006, J IMMUNOL, V176, P567, DOI 10.4049/jimmunol.176.1.567; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; Leach L, 2005, ADV MOL CEL, V35, P251, DOI 10.1016/S1569-2558(05)35009-0; Lim MJ, 2001, MICROVASC RES, V62, P366, DOI 10.1006/mvre.2001.2355; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; MIER JW, 1988, PATHOL IMMUNOPATH R, V7, P459, DOI 10.1159/000157075; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; Moses MA, 2006, NEW ENGL J MED, V354, P2621, DOI 10.1056/NEJMc053410; Prall AK, 2002, J VASC SURG, V35, P923, DOI 10.1067/mva.2002.123757; RAMIREZ MM, 1995, MICROVASC RES, V50, P223, DOI 10.1006/mvre.1995.1055; ROSENBERG SA, 1986, ANNU REV IMMUNOL, V4, P681, DOI 10.1146/annurev.immunol.4.1.681; Satchi-Fainaro R, 2005, CANCER CELL, V7, P251, DOI 10.1016/j.ccr.2005.02.007; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272; SUOMALAINEN K, 1992, ANTIMICROB AGENTS CH, V36, P227, DOI 10.1128/AAC.36.1.227; Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014; Wedam SB, 2006, J CLIN ONCOL, V24, P769, DOI 10.1200/JCO.2005.03.4645; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Zhao XY, 2001, AM J PHYSIOL-LUNG C, V281, pL879, DOI 10.1152/ajplung.2001.281.4.L879	37	55	59	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2008	22	10					3728	3735		10.1096/fj.08-110494	http://dx.doi.org/10.1096/fj.08-110494			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18606869				2022-12-28	WOS:000259642600033
J	McArthur, JD; McKay, FC; Ramachandran, V; Shyam, P; Cork, AJ; Sanderson-Smith, ML; Cole, JN; Ringdahl, U; Sjobring, U; Ranson, M; Walker, MJ				McArthur, Jason D.; McKay, Fiona C.; Ramachandran, Vidiya; Shyam, Priya; Cork, Amanda J.; Sanderson-Smith, Martina L.; Cole, Jason N.; Ringdahl, Ulrika; Sjobring, Ulf; Ranson, Marie; Walker, Mark J.			Allelic variants of streptokinase from Streptococcus pyogenes display functional differences in plasminogen activation	FASEB JOURNAL			English	Article						bacterial pathogenesis; virulence; invasive disease	GROUP-A STREPTOCOCCI; M-PROTEIN; POSTSTREPTOCOCCAL GLOMERULONEPHRITIS; HISTIDINE-RESIDUES; VIRULENCE FACTORS; INVASIVE DISEASE; BINDING-PROTEIN; SURFACE PROTEIN; TISSUE TROPISM; FIBRINOGEN	A common mammalian defense mechanism employed to prevent systemic dissemination of invasive bacteria involves occlusion of local microvasculature and encapsulation of bacteria within fibrin networks. Acquisition of plasmin activity at the bacterial cell surface circumvents this defense mechanism, allowing invasive disease initiation. To facilitate this process, S. pyogenes secretes streptokinase, a plasminogen-activating protein. Streptokinase polymorphism exhibited by S. pyogenes isolates is well characterized. However, the functional differences displayed by these variants and the biological significance of this variation has not been elucidated. Phylogenetic analysis of ska sequences from 28 S. pyogenes isolates revealed 2 main sequence clusters (clusters 1 and 2). All strains secreted streptokinase, as determined by Western blotting, and were capable of acquiring cell surface plasmin activity after incubation in human plasma. Whereas culture supernatants from strains containing cluster 1 ska alleles also displayed soluble plasminogen activation activity, supernatants from strains containing cluster 2 ska alleles did not. Furthermore, plasminogen activation activity in culture supernatants from strains containing cluster 2 ska alleles could only be detected when plasminogen was prebound with fibrinogen. This study indicates that variant streptokinase proteins secreted by S. pyogenes isolates display differing plasminogen activation characteristics and may therefore play distinct roles in disease pathogenesis.	[McArthur, Jason D.; McKay, Fiona C.; Ramachandran, Vidiya; Shyam, Priya; Cork, Amanda J.; Sanderson-Smith, Martina L.; Cole, Jason N.; Ranson, Marie; Walker, Mark J.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; [Ringdahl, Ulrika; Sjobring, Ulf] Lund Univ, Sect Microbiol Immunol & Glycobiol, Dept Lab Med, Lund, Sweden	University of Wollongong; Lund University	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Ranson, Marie/GRO-5792-2022; Cork, Amanda/C-3830-2012; Sanderson-Smith, Martina/O-9387-2019; Walker, Mark J./F-6940-2011; Ranson, Marie/A-6324-2008; Sanderson-Smith, Martina L/H-9614-2013; Ranson, Marie/AAC-4468-2019	Ranson, Marie/0000-0002-5570-9645; Cork, Amanda/0000-0003-2207-6877; Ranson, Marie/0000-0002-5570-9645; Sanderson-Smith, Martina L/0000-0002-6366-4993; Ranson, Marie/0000-0002-5570-9645; Walker, Mark/0000-0001-7423-2769; McKay, Fiona Catherine/0000-0002-9610-0668	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by grants from the National Health and Medical Research Council of Australia and from the University Research Committee at the University of Wollongong. A. C. and M. S-S. were recipients of Australian postgraduate awards. F. C. M. was the recipient of a National Health and Medical Research Council biomedical postgraduate scholarship.	Aziz RK, 2004, MOL MICROBIOL, V51, P123, DOI 10.1046/j.1365-2958.2003.03797.x; BERGE A, 1993, J BIOL CHEM, V268, P25417; Bessen DE, 1999, J INFECT DIS, V179, P627, DOI 10.1086/314631; CHIBBER BAK, 1985, BIOCHEMISTRY-US, V24, P3429, DOI 10.1021/bi00335a006; Cole JN, 2006, FASEB J, V20, P1745, DOI 10.1096/fj.06-5804fje; Coleman JL, 1999, J LAB CLIN MED, V134, P567, DOI 10.1016/S0022-2143(99)90095-1; D'Costa SS, 1998, MICROB PATHOGENESIS, V24, P341, DOI 10.1006/mpat.1998.0207; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Derbise A, 2004, INFECT IMMUN, V72, P94, DOI 10.1128/IAI.72.1.94-105.2004; Kalia A, 2004, J BACTERIOL, V186, P110, DOI 10.1128/JB.186.1.110-121.2004; KAPUR V, 1995, MOL MICROBIOL, V16, P509, DOI 10.1111/j.1365-2958.1995.tb02415.x; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Kunamneni A, 2007, J THROMB THROMBOLYS, V23, P9, DOI 10.1007/s11239-006-9011-x; KUUSELA P, 1992, INFECT IMMUN, V60, P196, DOI 10.1128/IAI.60.1.196-201.1992; Levi M, 2004, CIRCULATION, V109, P2698, DOI 10.1161/01.CIR.0000131660.51520.9A; Lizano S, 2005, INFECT IMMUN, V73, P4451, DOI 10.1128/IAI.73.7.4451-4453.2005; Lottenberg Richard, 1994, Trends in Microbiology, V2, P20, DOI 10.1016/0966-842X(94)90340-9; MALKE H, 1993, ZBL BAKT-INT J MED M, V278, P246; McArthur JD, 2006, MOL MICROBIOL, V59, P1, DOI 10.1111/j.1365-2958.2005.04967.x; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; MUSSER JM, 1994, ARCH PATHOL LAB MED, V118, P128; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; Pancholi V, 2003, INT J MED MICROBIOL, V293, P391, DOI 10.1078/1438-4221-00283; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; PEAKE PW, 1991, APMIS, V99, P460, DOI 10.1111/j.1699-0463.1991.tb05176.x; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Ranson M, 2003, FRONT BIOSCI, V8, pS294, DOI 10.2741/1044; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; Rezcallah MS, 2004, MICROBIOL-SGM, V150, P365, DOI 10.1099/mic.0.26826-0; Ringdahl U, 2000, MOL MICROBIOL, V37, P1318, DOI 10.1046/j.1365-2958.2000.02062.x; Sanderson-Smith M, 2006, J BIOL CHEM, V281, P3217, DOI 10.1074/jbc.M508758200; Sanderson-Smith ML, 2007, J BACTERIOL, V189, P1435, DOI 10.1128/JB.01218-06; Sanderson-Smith ML, 2006, J BIOL CHEM, V281, P25965, DOI 10.1074/jbc.M603846200; Svensson MD, 2000, MOL MICROBIOL, V38, P242, DOI 10.1046/j.1365-2958.2000.02144.x; Svensson MD, 2002, MICROBIOL-SGM, V148, P3933, DOI 10.1099/00221287-148-12-3933; TEWODROS W, 1995, MICROB PATHOGENESIS, V18, P53; Walker MJ, 2007, NAT MED, V13, P981, DOI 10.1038/nm1612; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WANG H, 1995, J INFECT DIS, V171, P85, DOI 10.1093/infdis/171.1.85; WHITNACK E, 1982, J CLIN INVEST, V69, P1042, DOI 10.1172/JCI110508; Winram SB, 1998, MICROBIOL-SGM, V144, P2025, DOI 10.1099/00221287-144-8-2025; Wistedt AC, 1998, J BIOL CHEM, V273, P24420, DOI 10.1074/jbc.273.38.24420	43	47	49	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3146	3153		10.1096/fj.08-109348	http://dx.doi.org/10.1096/fj.08-109348			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18511548				2022-12-28	WOS:000258761300007
J	Ristorcelli, E; Beraud, E; Verrando, P; Villard, C; Lafitte, D; Sbarra, V; Lombardo, D; Verine, A				Ristorcelli, Elodie; Beraud, Evelyne; Verrando, Patrick; Villard, Claude; Lafitte, Daniel; Sbarra, Veronique; Lombardo, Dominique; Verine, Alain			Human tumor nanoparticles induce apoptosis of pancreatic cancer cells	FASEB JOURNAL			English	Article						exosomes; cell death; proliferation	LIPID RAFTS; BIOLOGICAL SIGNIFICANCE; LYMPHOCYTE-RESPONSES; EXOSOMES; PTEN; KINASE; PATHWAY; PHOSPHATASE; VESICLES; CERAMIDE	Exosomes are vesicles secreted by most hematopoietic cells on fusion of multivesicular endosomes with the plasma membrane. Many studies have reported that exosomes may also be released by tumor cells. Exosomes are believed to play an antitumor role through immune cells. We asked whether tumor exosomes have biological activities on tumor cells. We report that human pancreatic tumor nanoparticles, exosome-like as characterized by proteomic analyses and rich in lipid rafts, decreased tumor cell proliferation. Nanoparticles increased Bax and decreased Bcl-2 expressions. Caspase-3 and -9 but not caspase-8 inhibitors impaired apoptosis, which implicates the mitochondria apoptotic pathway. The ceramide-sphingomyelin apoptotic pathway was inoperative. Moreover, nanoparticles induced phosphatase and tensin homolog ( PTEN) and glycogen synthase kinase (GSK)-3 beta activation and decreased pyruvate dehydrogenase activity. In nanoparticle-treated cells, PTEN formed complexes with actin, beta-catenin, and GSK-3 beta. Thus, beta-catenin may no longer be available to activate the survival pathway. Nanoparticles triggered the down-regulation of cyclin D1 and poly(ADP-ribose) polymerase. Hence, nanoparticles counteracted the constitutively activated phosphatidylinositol 3-kinase/Akt survival pathway to drive tumor cells toward apoptosis. Our study provides the first evidence of an apoptotic function of tumor-derived nanoparticles on tumor cells. We propose a new role for nanoparticles, i.e., as signal carriers for interaction between cells, which may have implications in physiopathological situations.	[Ristorcelli, Elodie; Beraud, Evelyne; Verrando, Patrick; Villard, Claude; Lafitte, Daniel; Sbarra, Veronique; Lombardo, Dominique; Verine, Alain] Aix Marseille Univ, Fac Med, INSERM, UMR 911, F-13385 Marseille 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Lombardo, D (corresponding author), Aix Marseille Univ, Fac Med, INSERM, UMR 911, 27 Bld Jean Moulin, F-13385 Marseille 05, France.	dominique.lombardo@medecine.univ-mrs.fr	Verrando, Patrick/M-4163-2018	lafitte, daniel/0000-0001-9921-7522; Villard, claude/0000-0002-6600-0762	INSERM (Paris, France); Universite de la Mediterranee (Marseille, France)	INSERM (Paris, France)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite de la Mediterranee (Marseille, France)	The authors are grateful to J. Courageot (electron microscopy core facility, School of Medicine, Marseille, France) and C. Franceschi [INSERM Unite Mixte de Recherche (UMR) 911] for microscopy experiments. J. Bertrand-Michel (INSERM UMR563, Toulouse, France) is gratefully acknowledged for lipid analyses. This work was supported by institutional funding from INSERM (Paris, France) and from Universite de la Mediterranee (Marseille, France).	Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Andre F, 2004, J IMMUNOL, V172, P2126, DOI 10.4049/jimmunol.172.4.2126; Aubert-Jousset E, 2004, STRUCTURE, V12, P1437, DOI 10.1016/j.str.2004.05.016; Byrne RD, 2007, CELL SIGNAL, V19, P321, DOI 10.1016/j.cellsig.2006.07.004; Clayton A, 2007, CANCER RES, V67, P7458, DOI 10.1158/0008-5472.CAN-06-3456; de Gassart A, 2004, TRAFFIC, V5, P896, DOI 10.1111/j.1600-0854.2004.00223.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Domingos PM, 2007, CURR OPIN GENET DEV, V17, P294, DOI 10.1016/j.gde.2007.05.009; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Fasano C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000612; Faure J, 2006, MOL CELL NEUROSCI, V31, P642, DOI 10.1016/j.mcn.2005.12.003; Fevrier B, 2004, CURR OPIN CELL BIOL, V16, P415, DOI 10.1016/j.ceb.2004.06.003; Friess H, 1998, GUT, V43, P414, DOI 10.1136/gut.43.3.414; Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804; Geminard C, 2001, J BIOL CHEM, V276, P9910, DOI 10.1074/jbc.M009641200; Gericke A, 2006, GENE, V374, P1, DOI 10.1016/j.gene.2006.02.024; Hao SG, 2007, IMMUNOLOGY, V120, P90, DOI 10.1111/j.1365-2567.2006.02483.x; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; Janowska-Wieczorek A, 2005, INT J CANCER, V113, P752, DOI 10.1002/ijc.20657; Johnstone RM, 2006, BLOOD CELL MOL DIS, V36, P315, DOI 10.1016/j.bcmd.2005.12.001; Koga K, 2005, ANTICANCER RES, V25, P3703; Lafitte D, 2002, CLIN BIOCHEM, V35, P581, DOI 10.1016/S0009-9120(02)00362-4; Lai JP, 2007, BRIT J PHARMACOL, V152, P1172, DOI 10.1038/sj.bjp.0707501; Laulagnier K, 2005, BLOOD CELL MOL DIS, V35, P116, DOI 10.1016/j.bcmd.2005.05.010; Laulagnier K, 2004, BIOCHEM J, V380, P161, DOI 10.1042/BJ20031594; Levade T, 2002, NEUROCHEM RES, V27, P601, DOI 10.1023/A:1020215815013; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Maffucci T, 2005, CANCER RES, V65, P8339, DOI 10.1158/0008-5472.CAN-05-0121; Michel V, 2007, BIOL CELL, V99, P129, DOI 10.1042/BC20060051; Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Pilzer D, 2005, SPRINGER SEMIN IMMUN, V27, P375, DOI 10.1007/s00281-005-0004-1; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rebai O, 2005, ARTERIOSCL THROM VAS, V25, P359, DOI 10.1161/01.ATV.0000151618.49109.bd; Salama-Cohen P, 2005, MOL BIOL CELL, V16, P339, DOI 10.1091/mbc.e04-05-0438; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Soo PC, 2007, J BACTERIOL, V189, P109, DOI 10.1128/JB.00710-06; Subra C, 2007, BIOCHIMIE, V89, P205, DOI 10.1016/j.biochi.2006.10.014; Taieb J, 2005, CRIT REV IMMUNOL, V25, P215, DOI 10.1615/CritRevImmunol.v25.i3.30; Tan J, 2005, CANCER RES, V65, P9012, DOI 10.1158/0008-5472.CAN-05-1226; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Villa I, 2001, IMMUNOLOGY, V102, P165, DOI 10.1046/j.1365-2567.2001.01178.x; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Zhu Y, 2006, APOPTOSIS, V11, P197, DOI 10.1007/s10495-006-3714-5; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	53	110	118	0	34	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3358	3369		10.1096/fj.07-102855	http://dx.doi.org/10.1096/fj.07-102855			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18511551				2022-12-28	WOS:000258761300028
J	Watson, CS; Jeng, YJ; Kochukov, MY				Watson, Cheryl S.; Jeng, Yow-Jiun; Kochukov, Mikhail Y.			Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation	FASEB JOURNAL			English	Article						calcium; ERK activation; prolactin release; nonmonotonic dose responses; membrane estrogen receptors	RECEPTOR-ALPHA LEVELS; BREAST-CANCER-CELLS; PROLACTIN-RELEASE; PLASMA-MEMBRANE; STEROID ACTIONS; DOWNS-SYNDROME; GROWTH-FACTOR; MCF-7 CELLS; BISPHENOL-A; ACTIVATION	Physiological estrogens, including estrone (E(1)), estradiol (E(2)), and estriol (E(3)), fluctuate with life stage, suggesting specific roles for them in biological and disease processes. We compared their non-genomic signaling and functional actions in GH3/B6/F10 rat pituitary tumor cells. All hormones caused prolactin release at 1 min; the lowest effective concentrations were 10(-11) M E(2), 10(-10) M E(1), and 10(-7) M E(3). All estrogens increased the oscillation frequency of calcium (Ca) spikes, with the same time delay (similar to 200 s) at all levels (10(-15) to 10(-9) M). At some concentrations, E(1) and E(3) provoked more Ca-responding cells than E(2). The amplitude and volume of Ca peaks were elevated by all hormones at >= 10(-15) M. All hormones caused cell proliferation, with the lowest effective concentrations of E(2) (10(-15) M) > E(1) (10(-12) M) > E(3) (10(-10) M); E(2) caused higher maximal cell numbers at most concentrations. All estrogens caused oscillating extracellular-regulated kinase (ERK) activations, with relative potencies of E(1) and E(2) > E(3). All estrogens were ineffective in activation of ERKs or causing proliferation in a subline expressing low levels of membrane estrogen receptor-alpha. Dose-response patterns were frequently non-monotonic. Therefore, the hormones E(1) and E(3), which have been designated "weak" estrogens in genomic actions, are strong estrogens in the nongenomic signaling pathways and functional responses in the pituitary.	[Watson, Cheryl S.; Jeng, Yow-Jiun; Kochukov, Mikhail Y.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Watson, CS (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.		Kochukov, Mikhail/P-5656-2018	Kochukov, Mikhail/0000-0002-8723-6360	National Institutes of Environmental Health Sciences; American Institute for Cancer Research	National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Institute for Cancer Research	We gratefully acknowledge funding from the National Institutes of Environmental Health Sciences and the American Institute for Cancer Research that supported these studies. We also thank Dr. David Konkel for expert editing of our article.	ADAMS JB, 1992, INT J CANCER, V50, P854, DOI 10.1002/ijc.2910500603; Ahamed S, 2001, MOL CARCINOGEN, V30, P88, DOI 10.1002/1098-2744(200102)30:2&lt;88::AID-MC1017&gt;3.0.CO;2-E; Alonso-Magdalena P, 2005, ENVIRON HEALTH PERSP, V113, P969, DOI 10.1289/ehp.8002; ANDERSON JN, 1975, ENDOCRINOLOGY, V96, P160, DOI 10.1210/endo-96-1-160; Bulayeva NN, 2005, AM J PHYSIOL-ENDOC M, V288, pE388, DOI 10.1152/ajpendo.00349.2004; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003; Campbell CH, 2001, STEROIDS, V66, P727, DOI 10.1016/S0039-128X(01)00106-4; CAMPBELL CH, 1997, CELL CYCLE REGULATIO; Chard T, 1995, J PERINAT MED, V23, P421; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; DANIELPOUR D, 1984, ENDOCRINOLOGY, V115, P1221, DOI 10.1210/endo-115-3-1221; DANNIES PS, 1985, BIOCHEM ACTION HORM, P289; DESLYPERE JP, 1985, J CLIN ENDOCR METAB, V61, P564, DOI 10.1210/jcem-61-3-564; DUFY B, 1979, SCIENCE, V204, P509, DOI 10.1126/science.107590; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Gorski J, 1997, PROG CLIN BIOL RES, V396, P233; Greenlee H, 2007, BREAST CANCER RES TR, V102, P111, DOI 10.1007/s10549-006-9308-7; Greenspan F. S., 2004, BASIC CLIN ENDOCRINO, P925; Jansson L, 2001, ARTHRITIS RHEUM, V44, P2168, DOI 10.1002/1529-0131(200109)44:9<2168::AID-ART370>3.0.CO;2-2; Meinhardt U, 2002, SEMIN REPROD MED, V20, P277, DOI 10.1055/s-2002-35374; Nevalainen MT, 1997, J CLIN INVEST, V99, P618, DOI 10.1172/JCI119204; Newby D, 2000, PLACENTA, V21, P263, DOI 10.1053/plac.1999.0469; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; Norfleet AM, 2000, FASEB J, V14, P157, DOI 10.1096/fasebj.14.1.157; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OGASAWARA M, 1988, IN VITRO CELL DEV B, V24, P911; PAPPAS TC, 1994, ENDOCRINE, V2, P813; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PIETRAS RJ, 1975, NATURE, V253, P357, DOI 10.1038/253357a0; Prior JC, 2005, ENDOCRINE, V26, P297, DOI 10.1385/ENDO:26:3:297; Richardson, 2000, Prim Care Update Ob Gyns, V7, P215, DOI 10.1016/S1068-607X(00)00049-4; RUCCI N, BONE, V34, P697; Shenhav S, 2003, ACTA OBSTET GYN SCAN, V82, P912, DOI 10.1034/j.1600-0412.2003.00250.x; Steiner M, 2003, J AFFECT DISORDERS, V74, P67, DOI 10.1016/S0165-0327(02)00432-9; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Vanson A, 1996, GEN COMP ENDOCR, V102, P342, DOI 10.1006/gcen.1996.0077; Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Watson CS, 2002, STEROIDS, V67, P429, DOI 10.1016/S0039-128X(01)00172-6; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Watson CS, 2003, EXP BIOL MED, V228, P1272, DOI 10.1177/153537020322801106; WATSON CS, 1999, STKE, pPE1; Williams CL, 1998, HORM BEHAV, V34, P80, DOI 10.1006/hbeh.1998.1480; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR130, DOI 10.1186/bcr959; Zivadinovic D, 2005, BREAST CANCER RES, V7, pR101, DOI 10.1186/bcr958; Zsarnovszky A, 2005, ENDOCRINOLOGY, V146, P5388, DOI 10.1210/en.2005-0565	49	63	69	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3328	3336		10.1096/fj.08-107672	http://dx.doi.org/10.1096/fj.08-107672			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18541692	Green Published			2022-12-28	WOS:000258761300025
J	Calvo, AC; Pey, AL; Ying, M; Loer, CM; Martinez, A				Calvo, Ana C.; Pey, Angel L.; Ying, Ming; Loer, Curtis M.; Martinez, Aurora			Anabolic function of phenylalanine hydroxylase in Caenorhabditis elegans	FASEB JOURNAL			English	Article						phenylketonuria; melanin; cuticle; oxygen radical scavenging; tetrahydrobiopterin	OXIDATIVE STRESS; ESCHERICHIA-COLI; C-ELEGANS; LIFE-SPAN; SYSTEM; FLUORESCENCE; TYROSINE; PROTEIN; FAMILY; GENE	In humans, liver phenylalanine hydroxylase (PAH) has an established catabolic function, and mutations in PAH cause phenylketonuria, a genetic disease characterized by neurological damage, if not treated. To obtain novel evolutionary insights and information on molecular mechanisms operating in phenylketonuria, we investigated PAH in the nematode Caenorhabditis elegans (cePAH), where the enzyme is coded by the pah-1 gene, expressed in the hypodermis. CePAH presents similar molecular and kinetic properties to human PAH [S-0.5(L-Phe) similar to 150 mu M; K-m for tetrahydrobiopterin (BH4) similar to 35 mu M and comparable V-max], but cePAH is devoid of positive cooperativity for L-Phe, an important regulatory mechanism of mammalian PAH that protects the nervous system from excess L-Phe. Pah-1 knockout worms show no obvious neurological defects, but in combination with a second cuticle synthesis mutation, they display serious cuticle abnormalities. We found that pah-1 knockouts lack a yellow-orange pigment in the cuticle, identified as melanin by spectroscopic techniques, and which is detected in C. elegans for the first time. Pah-1 mutants show stimulation of superoxide dismutase activity, suggesting that cuticle melanin functions as oxygen radical scavenger. Our results uncover both an important anabolic function of PAH and the change in regulation of the enzyme along evolution.	[Calvo, Ana C.; Pey, Angel L.; Ying, Ming; Martinez, Aurora] Univ Bergen, Dept Biomed, N-5009 Bergen, Norway; [Loer, Curtis M.] Univ San Diego, Dept Biol, San Diego, CA 92110 USA	University of Bergen; University of San Diego	Martinez, A (corresponding author), Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.	aurora.martinez@biomed.uib.no	Martinez, Aurora/M-3088-2019	Martinez, Aurora/0000-0003-1643-6506; Pey, Angel Luis/0000-0001-7706-3243				ABITA JP, 1984, J BIOL CHEM, V259, P4560; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Alper S, 2007, MOL CELL BIOL, V27, P5544, DOI 10.1128/MCB.02070-06; BEL Y, 1992, INSECT BIOCHEM MOLEC, V22, P633, DOI 10.1016/0965-1748(92)90041-C; Bilinska B, 2001, SPECTROCHIM ACTA A, V57, P2525, DOI 10.1016/S1386-1425(01)00519-4; BLAXTER M, 1999, C ELEGANS PRACTICAL, P15; Bowen RL, 2004, GERONTOLOGY, V50, P265, DOI 10.1159/000079125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1974, GENETICS, V77, P71; Cappitelli F, 2005, MACROMOL BIOSCI, V5, P49, DOI 10.1002/mabi.200400134; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Chavez V, 2007, GENETICS, V176, P1567, DOI 10.1534/genetics.107.072587; Chen YH, 2004, J GEN APPL MICROBIOL, V50, P183, DOI 10.2323/jgam.50.183; Christensen BM, 2005, TRENDS PARASITOL, V21, P192, DOI 10.1016/j.pt.2005.02.007; Cronin CJ, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-5; DAVIS BO, 1982, BIOCHEMISTRY-US, V21, P4089, DOI 10.1021/bi00260a027; Donko A, 2005, PHILOS T R SOC B, V360, P2301, DOI 10.1098/rstb.2005.1767; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Fisher AL, 2008, J BIOL CHEM, V283, P9127, DOI 10.1074/jbc.M708341200; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; Flatmark T, 1999, CHEM REV, V99, P2137, DOI 10.1021/cr980450y; FLATMARK T, 1980, ANAL BIOCHEM, V107, P71, DOI 10.1016/0003-2697(80)90494-7; Fossbakk A, 2005, ANAL BIOCHEM, V343, P100, DOI 10.1016/j.ab.2005.04.043; Gerstbrein B, 2005, AGING CELL, V4, P127, DOI 10.1111/j.1474-9726.2005.00153.x; Hagen MEK, 2002, BBA-MOL BASIS DIS, V1586, P344, DOI 10.1016/S0925-4439(01)00112-0; Honda Y, 2002, ANN NY ACAD SCI, V959, P466, DOI 10.1111/j.1749-6632.2002.tb02117.x; Ikemoto K, 2002, BIOL CHEM, V383, P325, DOI 10.1515/BC.2002.035; Infanger LC, 2004, INSECT BIOCHEM MOLEC, V34, P1329, DOI 10.1016/j.ibmb.2004.09.004; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KNAPPSKOG PM, 1995, BIOCHEMISTRY-US, V34, P11790, DOI 10.1021/bi00037a017; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lints R, 1999, DEVELOPMENT, V126, P5819; LOER C, 2002, SOC NEUR ABSTR, V28, P231; Loer CM, 1999, J NEUROGENET, V13, P157, DOI 10.3109/01677069909083472; Malencik DA, 2003, AMINO ACIDS, V25, P233, DOI 10.1007/s00726-003-0014-z; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Meredith P, 2006, PIGM CELL RES, V19, P572, DOI 10.1111/j.1600-0749.2006.00345.x; MITNAUL LJ, 1995, P NATL ACAD SCI USA, V92, P885, DOI 10.1073/pnas.92.3.885; Nighswander-Rempel SP, 2006, BIOPOLYMERS, V82, P631, DOI 10.1002/bip.20518; O'Rourke D, 2006, GENOME RES, V16, P1005, DOI 10.1101/gr.50823006; Page AP, 2007, WORMBOOK, DOI [10.1895/wormbook.1.138.1, DOI 10.1895/W0RMB00K.1.138.1]; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; Pardridge WM, 1998, NEUROCHEM RES, V23, P635, DOI 10.1023/A:1022482604276; Pey AL, 2007, AM J HUM GENET, V81, P1006, DOI 10.1086/521879; Pey AL, 2006, FASEB J, V20, P2130, DOI 10.1096/fj.06-5835fje; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P3836, DOI 10.1021/bi00312a007; Plonka PM, 2006, ACTA BIOCHIM POL, V53, P429, DOI 10.18388/abp.2006_3314; Potterf SB, 1996, J BIOL CHEM, V271, P4002; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; Riesz J, 2006, J PHYS CHEM B, V110, P13985, DOI 10.1021/jp0548691; Schallreuter KU, 2005, MOL GENET METAB, V86, pS27, DOI 10.1016/j.ymgme.2005.07.023; SCRIVER CR, 1994, ANNU REV GENET, V28, P141; Scriver CR, 2003, HUM MUTAT, V21, P333, DOI 10.1002/humu.10200; SILVA FJ, 1992, BIOCHEM J, V287, P85, DOI 10.1042/bj2870085; Sze JY, 2000, NATURE, V403, P560, DOI 10.1038/35000609; Teigen K, 2007, CURR MED CHEM, V14, P455, DOI 10.2174/092986707779941023; Thorolfsson M, 2003, BIOCHEMISTRY-US, V42, P3419, DOI 10.1021/bi034021s; Thorolfsson M, 2002, BIOCHEMISTRY-US, V41, P7573, DOI 10.1021/bi0160720; van Spronsen FJ, 2001, J INHERIT METAB DIS, V24, P1, DOI 10.1023/A:1005689232358; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Veljkovic E, 2004, J BIOL CHEM, V279, P49268, DOI 10.1074/jbc.M404470200; Watts JL, 2003, GENETICS, V163, P581; Werner-Felmayer G, 2002, CURR DRUG METAB, V3, P159, DOI 10.2174/1389200024605073; Wheeler JM, 2006, GENETICS, V174, P1327, DOI 10.1534/genetics.106.059089; Wiens M, 1998, DEV COMP IMMUNOL, V22, P469, DOI 10.1016/S0145-305X(98)00034-2; WRIGHT TRF, 1987, ADV GENET, V24, P127, DOI 10.1016/s0065-2660(08)60008-5	69	26	30	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					3046	3058		10.1096/fj.08-108522	http://dx.doi.org/10.1096/fj.08-108522			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18460651				2022-12-28	WOS:000258089300044
J	Hartz, AMS; Bauer, B; Block, ML; Hong, JS; Miller, DS				Hartz, Anika M. S.; Bauer, Bjoern; Block, Michelle L.; Hong, Jau-Shyong; Miller, David S.			Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier	FASEB JOURNAL			English	Article						NADPH oxidase; reactive oxygen species; TNF-alpha; TNF-receptor 1; JNK	NECROSIS-FACTOR-ALPHA; AIR-POLLUTION; EFFLUX TRANSPORTERS; DRUG-THERAPY; IN-VIVO; KAPPA-B; ACTIVATION; MACROPHAGE; EXPRESSION; PATHOLOGY	Here, we report that diesel exhaust particles (DEPs), a major constituent of urban air pollution, affect blood-brain barrier function at the tissue, cellular, and molecular levels. Isolated rat brain capillaries exposed to DEPs showed increased expression and transport activity of the key drug efflux transporter, P-glycoprotein (6 h EC(50) was similar to 5 mu g/ml). Upregulation of P-glycoprotein was abolished by blocking transcription or protein synthesis. Inhibition of NADPH oxidase or pretreatment of capillaries with radical scavengers ameliorated DEP-induced P-glycoprotein up-regulation, indicating a role for reactive oxygen species in signaling. DEP exposure also increased brain capillary tumor necrosis factor-alpha (TNF-alpha) levels. DEP-induced P-glycoprotein up-regulation was abolished when TNF-receptor 1 (TNF-R1) was blocked and was not evident in experiments with capillaries from TNF-R1 knockout mice. Inhibition of JNK, but not NF-kappa B, blocked DEP-induced P-glycoprotein up-regulation, indicating a role for AP-1 in the signaling pathway. Consistent with this, DEPs increased phosphorylation of c-jun. Together, our results show for the first time that a component of air pollution, DEPs, alters blood-brain barrier function through oxidative stress and proinflammatory cytokine production. These experiments disclose a novel blood-brain barrier signaling pathway, with clear implications for environmental toxicology, CNS pathology, and the pharmacotherapy of CNS disorders.	[Hartz, Anika M. S.; Bauer, Bjoern; Block, Michelle L.; Hong, Jau-Shyong; Miller, David S.] NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; [Hartz, Anika M. S.] Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Duluth, MN 55812 USA; [Bauer, Bjoern] Univ Minnesota, Coll Pharm, Dept Pharmaceut Sci, Duluth, MN 55812 USA; [Block, Michelle L.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; Virginia Commonwealth University	Miller, DS (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	miller@niehs.nih.gov	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914	Intramural NIH HHS Funding Source: Medline; NIEHS NIH HHS [R00 ES015409, R00 ES015409-02, R00ES015409] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090082, R00ES015409, Z01ES080060, Z01ES080048] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 2002, EPA600890057F NAT CT; Bauer B, 2005, EXP BIOL MED, V230, P118; Bauer B, 2004, MOL PHARMACOL, V66, P413; Bauer B, 2007, MOL PHARMACOL, V71, P667, DOI 10.1124/mol.106.029512; Bauer B, 2006, MOL PHARMACOL, V70, P1212, DOI 10.1124/mol.106.023796; Block ML, 2004, FASEB J, V18, P1618, DOI 10.1096/fj.04-1945fje; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Calderon-Garciduenas L, 2004, TOXICOL PATHOL, V32, P650, DOI 10.1080/01926230490520232; Calderon-Garciduenas L, 2003, TOXICOL PATHOL, V31, P524, DOI 10.1080/01926230390226645; Calderon-Garciduenas L, 2007, TOXICOL PATHOL, V35, P154, DOI 10.1080/01926230601059985; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Dazert P, 2006, NEUROSCIENCE, V142, P1071, DOI 10.1016/j.neuroscience.2006.07.056; Demeule M, 2002, VASC PHARMACOL, V38, P339, DOI 10.1016/S1537-1891(02)00201-X; Desai BS, 2007, CELL TRANSPLANT, V16, P285, DOI 10.3727/000000007783464731; DRAPER WM, 1986, CHEMOSPHERE, V15, P437, DOI 10.1016/0045-6535(86)90537-0; Fellner S, 2002, J CLIN INVEST, V110, P1309, DOI 10.1172/JCI200215451; GREENE G, 1994, ENVIRONMENT, V36, P25, DOI 10.1080/00139157.1994.9929182; Hartz AMS, 2006, MOL PHARMACOL, V69, P462, DOI 10.1124/mol.105.017954; Hartz AMS, 2005, CURR NANOSCI, V1, P203, DOI 10.2174/157341305774642948; Hartz AMS, 2004, MOL PHARMACOL, V66, P387, DOI 10.1124/mol.104.001503; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JETTE L, 1993, ADV EXP MED BIOL, V331, P121; JOO F, 1986, NATURE, V321, P197, DOI 10.1038/321197a0; Kim RB, 2002, DRUG METAB REV, V34, P47, DOI 10.1081/DMR-120001389; Kyriakis JM, 2001, NATURE, V414, P265, DOI 10.1038/35104735; Lin JH, 2003, DRUG METAB REV, V35, P417, DOI 10.1081/DMR-120026871; Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728; Miller DS, 2000, MOL PHARMACOL, V58, P1357, DOI 10.1124/mol.58.6.1357; *NAT I STAND TECHN, 2000, CERT AN STAND REF MA; National Institute of Standards and Technology, 2006, MAT SAF DAT SHEET SR; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Peters A, 2006, PART FIBRE TOXICOL, V3, DOI 10.1186/1743-8977-3-13; Rao KMK, 2005, ENVIRON HEALTH PERSP, V113, P612, DOI 10.1289/ehp.7696; SCHRAMM U, 1995, AM J PHYSIOL-RENAL, V268, pF46, DOI 10.1152/ajprenal.1995.268.1.F46; SCHUETZLE D, 1983, ENVIRON HEALTH PERSP, V47, P65, DOI 10.2307/3429500; Singh P, 2004, ENVIRON HEALTH PERSP, V112, P820, DOI 10.1289/ehp.6579; Sugamata M, 2006, J HEALTH SCI, V52, P82, DOI 10.1248/jhs.52.82; Taylor EM, 2002, CLIN PHARMACOKINET, V41, P81, DOI 10.2165/00003088-200241020-00001; *UN ENV PROGR WHO, 1994, ENVIRONMENT, V36, P2; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang MY, 2005, ELECTROPHORESIS, V26, P2092, DOI 10.1002/elps.200410428; Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200	46	197	203	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2723	2733		10.1096/fj.08-106997	http://dx.doi.org/10.1096/fj.08-106997			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18474546	Green Published			2022-12-28	WOS:000258089300012
J	Noda, K; She, H; Nakazawa, T; Hisatomi, T; Nakao, S; Almulki, L; Zandi, S; Miyahara, S; Ito, Y; Thomas, KL; Garland, RC; Miller, JW; Gragoudas, ES; Mashima, Y; Hafezi-Moghadam, A				Noda, Kousuke; She, Haicheng; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Almulki, Lama; Zandi, Souska; Miyahara, Shinsuke; Ito, Yasuhiro; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Mashima, Yukihiko; Hafezi-Moghadam, Ali			Vascular adhesion protein-1 blockade suppresses choroidal neovascularization	FASEB JOURNAL			English	Article						age-related macular degeneration; leukocyte recruitment; macrophage; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; GENE-EXPRESSION; BRUCHS MEMBRANE; INFLAMMATION; MACROPHAGES; ANGIOGENESIS; PATHOGENESIS; INDUCTION; MOLECULES	Vascular adhesion protein-1 (VAP-1) is an endothelial cell adhesion molecule involved in leukocyte recruitment. Leukocytes and, in particular, macrophages play an important role in the development of choroidal neovascularization (CNV), an integral component of age-related macular degeneration (AMD). Previously, we showed a role for VAP-1 in ocular inflammation. Here, we investigate the expression of VAP-1 in the choroid and its role in CNV development. VAP-1 was expressed in the choroid, exclusively in the vessels, and colocalized in the vessels of the CNV lesions. VAP-1 blockade with a novel and specific inhibitor significantly decreased CNV size, fluorescent angiographic leakage, and the accumulation of macrophages in the CNV lesions. Furthermore, VAP-1 blockade significantly reduced the expression of inflammation-associated molecules such as tumor necrosis factor (TNF)-alpha, monocyte chemoattractant protein (MCP)-1, and intercellular adhesion molecule (ICAM) - 1. This work provides evidence for an important role of VAP-1 in the recruitment of macrophages to CNV lesions, establishing a novel link between VAP-1 and angiogenesis. Inhibition of VAP-1 may become a new therapeutic strategy in the treatment of AMD.	[Noda, Kousuke; She, Haicheng; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Almulki, Lama; Zandi, Souska; Miyahara, Shinsuke; Ito, Yasuhiro; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA; [Noda, Kousuke; She, Haicheng; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Almulki, Lama; Zandi, Souska; Miyahara, Shinsuke; Ito, Yasuhiro; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; [Mashima, Yukihiko] R Tech Ueno Ltd, Tokyo, Japan	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School	Hafezi-Moghadam, A (corresponding author), Massachusetts Eye & Ear Infirm, Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.	Ali_Hafezi-Moghadam@meei.harvard.edu		Miller, Joan/0000-0003-2046-3996; Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam, Ali/0000-0002-5336-0697; Zandi, Souska/0000-0001-9351-4278	NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY014104, EY14104] Funding Source: Medline; NHLBI NIH HHS [R01 HL086933, HL086933] Funding Source: Medline; NIAID NIH HHS [K08 AI050775, AI050775] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akin E, 2001, INFECT IMMUN, V69, P1774, DOI 10.1128/IAI.69.3.1774-1780.2001; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353; Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013; DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045; Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V271, P726, DOI 10.1006/bbrc.2000.2716; ELNER SG, 1991, LAB INVEST, V64, P819; ELNER VM, 1990, AM J PATHOL, V136, P745; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914; Grossniklaus HE, 2002, MOL VIS, V8, P119; Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625; HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010; Jaakkola K, 2000, J AM COLL CARDIOL, V36, P122, DOI 10.1016/S0735-1097(00)00706-3; KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86; Koskinen K, 2004, BLOOD, V103, P3388, DOI 10.1182/blood-2003-09-3275; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; Lehr HA, 1999, J HISTOCHEM CYTOCHEM, V47, P119, DOI 10.1177/002215549904700113; Lehr HA, 1997, J HISTOCHEM CYTOCHEM, V45, P1559, DOI 10.1177/002215549704501112; Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058; Martelius T, 2000, AM J PATHOL, V157, P1229, DOI 10.1016/S0002-9440(10)64638-X; Matyus P, 2004, CURR MED CHEM, V11, P1285, DOI 10.2174/0929867043365305; Merinen M, 2005, AM J PATHOL, V166, P793, DOI 10.1016/S0002-9440(10)62300-0; Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe; Noda K, 2008, FASEB J, V22, P1094, DOI 10.1096/fj.07-9377com; Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891; PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097; SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341; SALMI M, 1993, J EXP MED, V178, P2255, DOI 10.1084/jem.178.6.2255; SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983; She HC, 2007, INVEST OPHTH VIS SCI, V48, P2268, DOI 10.1167/iovs.06-0979; Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063; Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007; Singh B, 2003, VIRCHOWS ARCH, V442, P491, DOI 10.1007/s00428-003-0802-6; Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436; WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145; Yamashiro K, 2001, INVEST OPHTH VIS SCI, V42, P1553; Zambarakji HJ, 2006, INVEST OPHTH VIS SCI, V47, P2623, DOI 10.1167/iovs.05-0855; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598	45	53	59	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2928	2935		10.1096/fj.07-105346	http://dx.doi.org/10.1096/fj.07-105346			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18436961	Green Published			2022-12-28	WOS:000258089300033
J	Ottenheijm, CAC; Fong, C; Vangheluwe, P; Wuytack, F; Babu, GJ; Periasamy, M; Witt, CC; Labeit, S; Granzier, H				Ottenheijm, Coen A. C.; Fong, Chi; Vangheluwe, Peter; Wuytack, Frank; Babu, Gopal J.; Periasamy, Muthu; Witt, Christian C.; Labeit, Siegfried; Granzier, Henk			Sarcoplasmic reticulum calcium uptake and speed of relaxation are depressed in nebulin-free skeletal muscle	FASEB JOURNAL			English	Article						sarcolipin; SERCA function; muscle contractility; nebulin KO model	CONTRACTILE FUNCTION; CARDIAC-FUNCTION; DEFICIENT MICE; CA2+ AFFINITY; SARCOLIPIN; OVEREXPRESSION; TRANSPORT; DISEASE; FIBERS; PHOSPHOLAMBAN	Previous work suggested that altered Ca2+ homeostasis might contribute to dysfunction of nebulin-free muscle, as gene expression analysis revealed that the sarco(endo) plasmic reticulum Ca2+-ATPase (SERCA)-inhibitor sarcolipin (SLN) is up-regulated > 70-fold in nebulin knockout mice, and here we tested this proposal. We investigated SLN protein expression in nebulin-free and wild-type skeletal muscle, as well as expression of other Ca2+-handling proteins. Ca2+ uptake capacity was determined in isolated sarcoplasmic reticulum vesicles and in intact myofibers by measuring Ca2+ transients. Muscle contractile performance was determined in skinned muscle activated with exogenous Ca2+, as well as in electrically stimulated intact muscle. We found profound up-regulation of SLN protein in nebulin-free skeletal muscle, whereas expression of other Ca2+-handling proteins was not (calsequestrin and phospholamban) or was minimally (SERCA) affected. Speed of Ca2(+) uptake was > 3-fold decreased in sarcoplasmic reticulum vesicles isolated from nebulin-free muscle as well as in nebulin-free intact myofibers. Ca2+-activated stress in skinned muscle and stress produced by intact nebulin-free muscle were reduced to a similar extent compared with wild type. Half-relaxation time was significantly longer in nebulin-free compared with wild-type muscle. Thus, the present study demonstrates for the first time that nebulin might also be involved in physiological Ca2+ handling of the SR-myofibrillar system.	[Ottenheijm, Coen A. C.; Fong, Chi; Granzier, Henk] Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; [Vangheluwe, Peter; Wuytack, Frank] Katholieke Univ Leuven, Lab Ca2 Transport ATPases, Leuven, Belgium; [Babu, Gopal J.; Periasamy, Muthu] Ohio State Univ, Med Ctr, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; [Witt, Christian C.; Labeit, Siegfried] Univ Hosp Mannheim, Inst Anaesthesiol & Intens Care, Mannheim, Germany	University of Arizona; KU Leuven; University System of Ohio; Ohio State University; Ruprecht Karls University Heidelberg	Granzier, H (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, POB 245217, Tucson, AZ 85724 USA.	granzier@email.arizona.edu	Babu, Gopal/AAB-7787-2021; Vangheluwe, Peter/P-5476-2017	Babu, Gopal/0000-0001-7833-5300; Vangheluwe, Peter/0000-0002-7822-2944; Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053897] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL062881, HL-062881] Funding Source: Medline; NIAMS NIH HHS [R01 AR053897, AR-053897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Asahi M, 2004, P NATL ACAD SCI USA, V101, P9199, DOI 10.1073/pnas.0402596101; Babu GJ, 2006, J BIOL CHEM, V281, P3972, DOI 10.1074/jbc.M508998200; Babu GJ, 2007, P NATL ACAD SCI USA, V104, P17867, DOI 10.1073/pnas.0707722104; Babu GJ, 2007, J MOL CELL CARDIOL, V43, P215, DOI 10.1016/j.yjmcc.2007.05.009; Bang ML, 2006, J CELL BIOL, V173, P905, DOI 10.1083/jcb.200603119; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Bruton JD, 2003, J PHYSIOL-LONDON, V552, P393, DOI 10.1113/jphysiol.org; Capote J, 2005, J PHYSIOL-LONDON, V564, P451, DOI 10.1113/jphysiol.2004.081034; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Han RZ, 2006, CELL CALCIUM, V40, P299, DOI 10.1016/j.ceca.2006.04.016; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; MacLennan DH, 2003, ANN NY ACAD SCI, V986, P472, DOI 10.1111/j.1749-6632.2003.tb07231.x; McElhinny AS, 2003, TRENDS CARDIOVAS MED, V13, P195, DOI 10.1016/S1050-1738(03)00076-8; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Ottenheijm CAC, 2006, AM J PHYSIOL-LUNG C, V290, pL127, DOI 10.1152/ajplung.00073.2005; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; Periasamy M, 2007, MUSCLE NERVE, V35, P430, DOI 10.1002/mus.20745; Pinniger G, 2005, J MUSCLE RES CELL M, V26, P135, DOI 10.1007/s10974-005-2679-2; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; Vangheluwe P, 2006, BBA-MOL CELL RES, V1763, P1216, DOI 10.1016/j.bbamcr.2006.08.025; Vangheluwe P, 2005, BIOCHEM J, V389, P151, DOI 10.1042/BJ20050068; Vangheluwe P, 2006, J MOL CELL CARDIOL, V41, P308, DOI 10.1016/j.yjmcc.2006.05.014; Wang K, 1996, J BIOL CHEM, V271, P4304; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; Wang ZM, 2002, BIOPHYS J, V82, P1338, DOI 10.1016/S0006-3495(02)75489-1; Witt CC, 2006, EMBO J, V25, P3843, DOI 10.1038/sj.emboj.7601242	26	50	50	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2912	2919		10.1096/fj.07-104372	http://dx.doi.org/10.1096/fj.07-104372			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18434434	Green Published			2022-12-28	WOS:000258089300031
J	Sanderson-Smith, ML; Dinkla, K; Cole, JN; Cork, AJ; Maamary, PG; McArthur, JD; Chhatwal, GS; Walker, MJ				Sanderson-Smith, M. L.; Dinkla, K.; Cole, J. N.; Cork, A. J.; Maamary, P. G.; McArthur, J. D.; Chhatwal, G. S.; Walker, M. J.			M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate	FASEB JOURNAL			English	Article						plasmin; group A streptococcus; innate immunity	GROUP-A STREPTOCOCCI; SERUM OPACITY FACTOR; SURFACE PROTEIN; MOLECULAR EPIDEMIOLOGY; HISTIDINE-RESIDUES; BACTERIAL SURFACE; STREPTOKINASE; INFECTION; FIBRINOGEN; GENE	The human protease plasmin plays a crucial role in the capacity of the group A streptococcus (GAS; Streptococus pyogenes) to initiate invasive disease. The GAS strain NS88.2 was isolated from a case of bacteremia from the Northern Territory of Australia, a region with high rates of GAS invasive disease. Mutagenesis of the NS88.2 plasminogen binding M protein Prp was undertaken to examine the contribution of plasminogen binding and cell surface plasmin acquisition to virulence. The isogenic mutant NS88.2prp was engineered whereby four amino acid residues critical for plasminogen binding were converted to alanine codons in the GAS genome sequence. The mutated residues were reverse complemented to the wild-type sequence to construct GAS strain NS88.2prpRC. In comparison to NS88.2 and NS88.2prpRC, the NS88.2prp mutant exhibited significantly reduced ability to bind human plasminogen and accumulate cell surface plasmin activity during growth in human plasma. Utilizing a humanized plasminogen mouse model of invasive infection, we demonstrate that the capacity to bind plasminogen and accumulate surface plasmin activity plays an essential role in GAS virulence.	[Sanderson-Smith, M. L.; Cole, J. N.; Cork, A. J.; Maamary, P. G.; McArthur, J. D.; Walker, M. J.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; [Sanderson-Smith, M. L.; Dinkla, K.; Chhatwal, G. S.] Helmholtz Ctr Infect Res, Dept Microbial Pathogenesis, Braunschweig, Germany	University of Wollongong; Helmholtz Association; Helmholtz-Center for Infection Research	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Cork, Amanda/C-3830-2012; Sanderson-Smith, Martina/O-9387-2019; Sanderson-Smith, Martina L/H-9614-2013; Walker, Mark J./F-6940-2011	Cork, Amanda/0000-0003-2207-6877; Sanderson-Smith, Martina L/0000-0002-6366-4993; Walker, Mark/0000-0001-7423-2769				Ashbaugh CD, 2001, INFECT IMMUN, V69, P6683, DOI 10.1128/IAI.69.11.6683-6686.2001; BAJAJ SP, 1977, J BIOL CHEM, V252, P492; Baldassarri L, 2007, J CLIN MICROBIOL, V45, P1284, DOI 10.1128/JCM.02119-06; BENNASR A, 1994, EUR J BIOCHEM, V222, P267, DOI 10.1111/j.1432-1033.1994.tb18865.x; BERGE A, 1993, J BIOL CHEM, V268, P25417; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carapetis JR, 1999, EPIDEMIOL INFECT, V122, P59, DOI 10.1017/S0950268898001952; Carlsson F, 2005, MOL MICROBIOL, V56, P28, DOI 10.1111/j.1365-2958.2005.04527.x; Chaffin DO, 2000, J BACTERIOL, V182, P4466, DOI 10.1128/JB.182.16.4466-4477.2000; Cole JN, 2006, FASEB J, V20, P1745, DOI 10.1096/fj.06-5804fje; Courtney HS, 2006, MOL MICROBIOL, V59, P936, DOI 10.1111/j.1365-2958.2005.04977.x; Courtney HS, 1999, MOL MICROBIOL, V32, P89, DOI 10.1046/j.1365-2958.1999.01328.x; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Delvecchio A, 2002, EPIDEMIOL INFECT, V128, P391, DOI 10.1017/S0950268802006787; Dinkla K, 2007, MICROBES INFECT, V9, P922, DOI 10.1016/j.micinf.2007.03.011; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; Gardiner D, 1997, ADV EXP MED BIOL, V418, P317; Gardiner DL, 1996, J CLIN MICROBIOL, V34, P1448, DOI 10.1128/JCM.34.6.1448-1452.1996; HOLLINGSHEAD SK, 1993, MOL MICROBIOL, V8, P707, DOI 10.1111/j.1365-2958.1993.tb01614.x; Johnson DR., 1996, LAB DIAGNOSIS GROUP; Kalia A, 2004, J BACTERIOL, V186, P110, DOI 10.1128/JB.186.1.110-121.2004; Khil J, 2003, J INFECT DIS, V188, P497, DOI 10.1086/377100; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; McArthur JD, 2006, MOL MICROBIOL, V59, P1, DOI 10.1111/j.1365-2958.2005.04967.x; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Ramachandran V, 2004, J BACTERIOL, V186, P7601, DOI 10.1128/JB.186.22.7601-7609.2004; Ranson M, 2003, FRONT BIOSCI, V8, pS294, DOI 10.2741/1044; Ringdahl U, 1998, J BIOL CHEM, V273, P6424, DOI 10.1074/jbc.273.11.6424; Ringdahl U, 2000, METHODS, V21, P143, DOI 10.1006/meth.2000.0985; Sanderson-Smith M, 2006, J BIOL CHEM, V281, P3217, DOI 10.1074/jbc.M508758200; Sanderson-Smith ML, 2007, J BACTERIOL, V189, P1435, DOI 10.1128/JB.01218-06; Sanderson-Smith ML, 2006, J BIOL CHEM, V281, P25965, DOI 10.1074/jbc.M603846200; SIMON D, 1991, FEMS MICROBIOL LETT, V82, P219, DOI 10.1016/0378-1097(91)90336-9; Staali L, 2003, CELL MICROBIOL, V5, P253, DOI 10.1046/j.1462-5822.2003.00272.x; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Svensson MD, 1999, INFECT IMMUN, V67, P3915, DOI 10.1128/IAI.67.8.3915-3920.1999; Svensson MD, 2002, MICROBIOL-SGM, V148, P3933, DOI 10.1099/00221287-148-12-3933; Tart AH, 2007, TRENDS MICROBIOL, V15, P318, DOI 10.1016/j.tim.2007.05.001; Terao Y, 2001, MOL MICROBIOL, V42, P75, DOI 10.1046/j.1365-2958.2001.02579.x; Timmer AM, 2006, MOL MICROBIOL, V62, P15, DOI 10.1111/j.1365-2958.2006.05337.x; Walker MJ, 2007, NAT MED, V13, P981, DOI 10.1038/nm1612; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WANG H, 1995, MICROB PATHOGENESIS, V18, P153, DOI 10.1016/S0882-4010(95)90013-6; WANG H, 1995, J INFECT DIS, V171, P85, DOI 10.1093/infdis/171.1.85; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x; Wistedt AC, 1998, J BIOL CHEM, V273, P24420, DOI 10.1074/jbc.273.38.24420	52	61	64	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2715	2722		10.1096/fj.07-105643	http://dx.doi.org/10.1096/fj.07-105643			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18467595	Green Submitted			2022-12-28	WOS:000258089300011
J	Parasassi, T; De Spirito, M; Mei, G; Brunelli, R; Greco, G; Lenzi, L; Maulucci, G; Nicolai, E; Papi, M; Arcovito, G; Tosatto, SCE; Ursini, F				Parasassi, Tiziana; De Spirito, Marco; Mei, Giampiero; Brunelli, Roberto; Greco, Giulia; Lenzi, Laura; Maulucci, Giuseppe; Nicolai, Eleonora; Papi, Massimiliano; Arcovito, Giuseppe; Tosatto, Silvio C. E.; Ursini, Fulvio			Low density lipoprotein misfolding and amyloidogenesis	FASEB JOURNAL			English	Article						amyloidoses; atherogenesis; computational analysis; electronegative LDL; nucleation	HUMAN ATHEROSCLEROTIC LESIONS; ELECTRONEGATIVE LDL; PROTEIN AGGREGATION; SECONDARY STRUCTURE; HUMAN-DISEASE; PARTICLES; PREDICTION; MODEL; MECHANISMS; RETENTION	In early atherogenesis, subendothelial retention of lipidic droplets is associated with an inflammatory response-to-injury, culminating in the formation of foam cells and plaque. Low density lipoprotein (LDL) is the main constituent of subendothelial lipidic droplets. The process is believed to occur following LDL modification. Searching for a modified LDL in plasma, electronegative LDL [ LDL( -)] was identified and found to be associated with major risk biomarkers. The apoprotein in LDL( -) is misfolded, and we show here that this modification primes the aggregation of native LDL, conforming to the typical pattern of protein amyloidogenesis. After a lag phase, whose length depends on LDL( -) concentration, light scattering and atomic force microscopy reveal early exponential growth of intermediate globules, which evolve into fibrils. These globules are remarkably similar to subendothelial droplets in atheromatous lesions and different from those produced by oxidation or biochemical manipulation. During aggregation, ellipticity and tryptophan fluorescence measurements reveal a domino-style spread of apoprotein misfolding from LDL( -) to all of the LDL. Computational analysis of the apoprotein primary sequence predicts an unstable, aggregation-prone domain in the regulatory alpha 2 region. Apoprotein misfolding well represents an LDL modification able to transform this cholesterol carrier into a trigger for a response-to-injury in the artery wall.	[Parasassi, Tiziana; Greco, Giulia; Lenzi, Laura] CNR, Ist Neurobiol Med Mol, I-00133 Rome, Italy; [De Spirito, Marco; Maulucci, Giuseppe; Papi, Massimiliano; Arcovito, Giuseppe] Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Ist Fis, Rome, Italy; [Mei, Giampiero; Nicolai, Eleonora] Univ Roma Tor Vergata, Dipartimento Med Sperimentale & Sci Biochim, Rome, Italy; [Brunelli, Roberto] Univ Roma La Sapienza, Dipartimento Sci Ginecol Perinatol & Puericultura, Rome, Italy; [Tosatto, Silvio C. E.] Univ Padua, Dipartimento Biol, Padua, Italy; [Tosatto, Silvio C. E.] Univ Padua, Ctr Biotecnol Innovat CRIBI, Padua, Italy; [Ursini, Fulvio] Univ Padua, Dipartimento Chim Biol, Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Rome Tor Vergata; Sapienza University Rome; University of Padua; University of Padua; University of Padua	Parasassi, T (corresponding author), CNR, Ist Neurobiol Med Mol, Via Fosso Cavaliere 100, I-00133 Rome, Italy.	t.parasassi@inmm.cnr.it	Papi, Massimiliano/B-3168-2012; De Spirito, Marco/U-3817-2019; Nicolai, Eleonora/AAR-4554-2020; De Spirito, Marco/C-5386-2008; Maulucci, Giuseppe/C-7400-2009; Papi, Massimiliano/AAC-3657-2022; Tosatto, Silvio/B-2840-2009	De Spirito, Marco/0000-0003-4260-5107; Nicolai, Eleonora/0000-0003-1415-9808; De Spirito, Marco/0000-0003-4260-5107; Maulucci, Giuseppe/0000-0002-2154-319X; Papi, Massimiliano/0000-0002-0029-1309; Tosatto, Silvio/0000-0003-4525-7793; Parasassi, Tiziana/0000-0002-9795-0568				Albrecht M, 2003, PROTEIN ENG, V16, P459, DOI 10.1093/protein/gzg063; Bader R, 2006, J MOL BIOL, V356, P189, DOI 10.1016/j.jmb.2005.11.034; Baglioni S, 2006, J NEUROSCI, V26, P8160, DOI 10.1523/JNEUROSCI.4809-05.2006; CHAO FF, 1990, AM J PATHOL, V136, P169; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; De Spirito M, 2006, BIOPHYS J, V90, P4239, DOI 10.1529/biophysj.105.075788; Demuth K, 1996, ARTERIOSCL THROM VAS, V16, P773, DOI 10.1161/01.ATV.16.6.773; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; Krisko A, 2007, PROTEINS, V66, P342, DOI 10.1002/prot.21229; Lee CC, 2007, BIOPHYS J, V92, P3448, DOI 10.1529/biophysj.106.098608; LeVine H, 1999, METHOD ENZYMOL, V309, P274; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; Oorni K, 2000, J LIPID RES, V41, P1703; Oorni K, 2004, J BIOL CHEM, V279, P34776, DOI 10.1074/jbc.M310814200; Oorni K, 2007, ARTERIOSCL THROM VAS, V27, P445, DOI 10.1161/01.ATV.0000258412.58289.ee; Parasassi T, 2001, FREE RADICAL BIO MED, V31, P82, DOI 10.1016/S0891-5849(01)00555-X; Pentikainen MO, 1996, J LIPID RES, V37, P2638; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sanchez-Quesada JL, 1999, AM J CARDIOL, V84, P655, DOI 10.1016/S0002-9149(99)00411-7; Sanchez-Quesada JL, 2002, J LIPID RES, V43, P699; SanchezQuesada JL, 1996, DIABETOLOGIA, V39, P1469, DOI 10.1007/s001250050600; Segrest JP, 2001, J LIPID RES, V42, P1346; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; Sevanian A, 1999, BLOOD PURIFICAT, V17, P66, DOI 10.1159/000014378; Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Sun Y, 2005, FEBS J, V272, P2613, DOI 10.1111/j.1742-4658.2005.04708.x; TEIXEIRA J, 1988, J APPL CRYSTALLOGR, V21, P781, DOI 10.1107/S0021889888000263; Trovato A, 2006, PLOS COMPUT BIOL, V2, P1608, DOI 10.1371/journal.pcbi.0020170; Trovato A, 2007, PROTEIN ENG DES SEL, V20, P521, DOI 10.1093/protein/gzm042; Ursini F, 2002, BIOL CHEM, V383, P599, DOI 10.1515/BC.2002.062; Ursini F, 2002, TRENDS MOL MED, V8, P370, DOI 10.1016/S1471-4914(02)02382-1; Vullo A, 2006, NUCLEIC ACIDS RES, V34, pW164, DOI 10.1093/nar/gkl166; WEITZ DA, 1987, PHYSICS COMPLEX SUPE, P509; Williams KJ, 2005, ARTERIOSCL THROM VAS, V25, P1536, DOI 10.1161/01.ATV.0000174795.62387.d3	37	41	42	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2350	2356		10.1096/fj.07-097774	http://dx.doi.org/10.1096/fj.07-097774			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18292214				2022-12-28	WOS:000257292500027
J	Quinzii, CM; Lopez, LC; Von-Moltke, J; Naini, A; Krishna, S; Schuelke, M; Salviati, L; Navas, P; DiMauro, S; Hirano, M				Quinzii, Catarina M.; Lopez, Luis C.; Von-Moltke, Jakob; Naini, Ali; Krishna, Sindu; Schuelke, Markus; Salviati, Leonardo; Navas, Placido; DiMauro, Salvatore; Hirano, Michio			Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ(10) deficiency	FASEB JOURNAL			English	Article						mitochondria; reactive oxygen species; COQ2; PDSS2	COENZYME Q(10) DEFICIENCY; MITOCHONDRIAL ELECTRON-TRANSPORT; CEREBELLAR-ATAXIA; MUTATIONS; ENCEPHALOMYOPATHY; SUPEROXIDE; GENE; NEPHROPATHY; METABOLISM; CELLS	Coenzyme Q(10) (CoQ(10)) is essential for electron transport in the mitochondrial respiratory chain and antioxidant defense. Last year, we reported the first mutations in CoQ(10) biosynthetic genes, COQ2, which encodes 4-parahydroxybenzoate: polyprenyl transferase; and PDSS2, which encodes subunit 2 of decaprenyl diphosphate synthase. However, the pathogenic mechanisms of primary CoQ(10) deficiency have not been well characterized. In this study, we investigated the consequence of severe CoQ(10) deficiency on bioenergetics, oxidative stress, and antioxidant defenses in cultured skin fibroblasts harboring COQ2 and PDSS2 mutations. Defects in the first two committed steps of the CoQ(10) biosynthetic pathway produce different biochemical alterations. PDSS2 mutant fibroblasts have 12% CoQ(10) relative to control cells and markedly reduced ATP synthesis, but do not show increased reactive oxygen species (ROS) production, signs of oxidative stress, or increased antioxidant defense markers. In contrast, COQ2 mutant fibroblasts have 30% CoQ(10) with partial defect in ATP synthesis, as well as significantly increased ROS production and oxidation of lipids and proteins. On the basis of a small number of cell lines, our results suggest that primary CoQ(10) deficiencies cause variable defects of ATP synthesis and oxidative stress, which may explain the different clinical features and may lead to more rational therapeutic strategies.	[Quinzii, Catarina M.; Lopez, Luis C.; Von-Moltke, Jakob; Naini, Ali; Krishna, Sindu; DiMauro, Salvatore; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA; [Schuelke, Markus] Charite Virchow Univ Hosp, Dept Neuropediat, Berlin, Germany; [Salviati, Leonardo] Univ Padua, Dept Pediat, Serv Genet Clin Epidemiol, Padua, Italy; [Navas, Placido] Univ Pablo Olavide, CSIC, Inst Salud Carlos III, Ctr Andaluz Biol Desarrollo, Seville, Spain; [Navas, Placido] Univ Pablo Olavide, CSIC, Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras, Seville, Spain	Columbia University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Padua; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III; Universidad Pablo de Olavide	Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 1150 St Nicholas Ave,Russ Berrie Med Sci Pavil,Rm, New York, NY 10032 USA.	mh29@columbia.edu	Lopez, Luis Carlos/AAP-9411-2020; NAVAS, PLACIDO/R-5943-2019; Lopez, Luis Carlos/L-5129-2014	Lopez, Luis Carlos/0000-0003-3355-0298; NAVAS, PLACIDO/0000-0002-4115-7966; Lopez, Luis Carlos/0000-0003-3355-0298; Schuelke, Markus/0000-0003-2824-3891	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057543, P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, P50NS011766] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD057543-02, R01 HD057543-01, HD-32062, R01 HD057543, P01 HD032062] Funding Source: Medline; NINDS NIH HHS [NS-11766, P01 NS011766] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Artuch R, 2006, J NEUROL SCI, V246, P153, DOI 10.1016/j.jns.2006.01.021; Aure K, 2004, NEUROLOGY, V63, P727, DOI 10.1212/01.WNL.0000134607.76780.B2; Baracca A, 2007, BBA-BIOENERGETICS, V1767, P913, DOI 10.1016/j.bbabio.2007.05.005; Bentinger M, 2007, MITOCHONDRION, V7, pS41, DOI 10.1016/j.mito.2007.02.006; Boitier E, 1998, J NEUROL SCI, V156, P41, DOI 10.1016/S0022-510X(98)00006-9; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515; DiMauro S, 2007, J CLIN INVEST, V117, P587, DOI 10.1172/JCI31423; Diomedi-Camassei F, 2007, J AM SOC NEPHROL, V18, P2773, DOI 10.1681/ASN.2006080833; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103; Floreani M, 2005, FEBS J, V272, P1124, DOI 10.1111/j.1742-4658.2004.04542.x; Geromel V, 2001, FREE RADICAL RES, V35, P11, DOI 10.1080/10715760100300551; Gironi M, 2004, NEUROLOGY, V62, P818, DOI 10.1212/01.WNL.0000113719.67643.B7; Gonzalez-Aragon D, 2005, BIOFACTORS, V25, P31, DOI 10.1002/biof.5520250105; Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968; Hirano M, 2006, MITOCHONDRIAL MED, P27; Horvath R, 2006, NEUROLOGY, V66, P253, DOI 10.1212/01.wnl.0000194241.35115.7c; Iuso A, 2006, J BIOL CHEM, V281, P10374, DOI 10.1074/jbc.M513387200; Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317; Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC; Le Ber I, 2007, NEUROLOGY, V68, P295, DOI 10.1212/01.wnl.0000252366.10731.43; Lenaz G, 2007, MITOCHONDRION, V7, pS8, DOI 10.1016/j.mito.2007.03.009; Lopez LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023; Lopez-Martin JM, 2007, HUM MOL GENET, V16, P1091, DOI 10.1093/hmg/ddm058; Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3; Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089; Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849; Navas P, 2007, MITOCHONDRION, V7, pS34, DOI 10.1016/j.mito.2007.02.010; Nohl H, 2005, REDOX REP, V10, P199, DOI 10.1179/135100005X70170; OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379; Pallotti F, 2004, BIOCHEM J, V384, P287, DOI 10.1042/BJ20040561; PASQUALI P, 1981, J BIOENERG BIOMEMBR, V13, P141, DOI 10.1007/BF00763836; Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092; Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58; Rahman S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/mpd.2001.117575; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; Rotig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9; Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238; SODERBERG K, 1980, J CELL PHYSIOL, V103, P169, DOI 10.1002/jcp.1041030121; Solans A, 2006, HUM MOL GENET, V15, P3063, DOI 10.1093/hmg/ddl248; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; Uchida N, 2000, J BACTERIOL, V182, P6933, DOI 10.1128/JB.182.24.6933-6939.2000	51	114	120	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1874	1885		10.1096/fj.07-100149	http://dx.doi.org/10.1096/fj.07-100149			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230681	Green Accepted, Green Submitted			2022-12-28	WOS:000256352700027
J	Stephan, A; Mateos, JM; Kozlov, SV; Cinelli, P; Kistler, AD; Hettwer, S; Rulicke, T; Streit, P; Kunz, B; Sonderegger, P				Stephan, Alexander; Mateos, Jose Maria; Kozlov, Serguei V.; Cinelli, Paolo; Kistler, Andreas David; Hettwer, Stefan; Ruelicke, Thomas; Streit, Peter; Kunz, Beat; Sonderegger, Peter			Neurotrypsin cleaves agrin locally at the synapse	FASEB JOURNAL			English	Article						extracellular proteolysis; mental retardation; cognitive function; synaptic plasticity; synaptosomes	NEURONS; BINDING; GROWTH; EXPRESSION; FILOPODIA; ROLES; LOCALIZATION; DYSTROGLYCAN; MODULATION; MATURATION	The synaptic serine protease neurotrypsin is considered to be essential for the establishment and maintenance of cognitive brain functions, because humans lacking functional neurotrypsin suffer from severe mental retardation. Neurotrypsin cleaves agrin at two homologous sites, liberating a 90-kDa and a C-terminal 22-kDa fragment from the N-terminal moiety of agrin. Morphological analyses indicate that neurotrypsin is contained in presynaptic terminals and externalized in association with synaptic activity, while agrin is localized to the extracellular space at or in the vicinity of the synapse. Here, we present a detailed biochemical analysis of neurotrypsin-mediated agrin cleavage in the murine brain. In brain homogenates, we found that neurotrypsin exclusively cleaves glycanated variants of agrin. Studies with isolated synaptosomes obtained by subcellular fractionation from brains of wild-type and neurotrypsin-overexpressing mice revealed that neurotrypsin-dependent cleavage of agrin was concentrated at synapses, where the most heavily glycanated variants of agrin predominate. Because agrin has been shown to play an important role in the formation and the maintenance of excitatory synapses in the central nervous system, its local cleavage at the synapse implicates the neurotrypsin/agrin system in the regulation of adaptive reorganizations of the synaptic circuitry in the context of cognitive functions, such as learning and memory.	[Stephan, Alexander; Kozlov, Serguei V.; Cinelli, Paolo; Kistler, Andreas David; Kunz, Beat; Sonderegger, Peter] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; [Ruelicke, Thomas] Univ Zurich, Inst Lab Anim Sci, CH-8057 Zurich, Switzerland; [Mateos, Jose Maria; Streit, Peter] Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; [Mateos, Jose Maria] Neurotune AG, Schlieren, Switzerland	University of Zurich; University of Zurich; University of Zurich	Sonderegger, P (corresponding author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	peter.sonderegger@bioc.uzh.ch		Mateos, Jose Maria/0000-0002-3675-6198; Cinelli, Paolo/0000-0002-0163-9055; Kistler, Andreas/0000-0002-4114-9560				Annies M, 2006, MOL CELL NEUROSCI, V31, P515, DOI 10.1016/j.mcn.2005.11.005; Baker KA, 2006, CURR OPIN NEUROBIOL, V16, P529, DOI 10.1016/j.conb.2006.08.002; Barber AJ, 1997, DEV DYNAM, V208, P62, DOI 10.1002/(SICI)1097-0177(199701)208:1<62::AID-AJA6>3.0.CO;2-#; Bezakova G, 2003, NAT REV MOL CELL BIO, V4, P295, DOI 10.1038/nrm1074; Burgess RW, 2002, J NEUROCHEM, V83, P271, DOI 10.1046/j.1471-4159.2002.01102.x; Caroni P, 1997, J NEUROSCI METH, V71, P3, DOI 10.1016/S0165-0270(96)00121-5; Clegg DO, 2003, FRONT BIOSCI-LANDMRK, V8, pD723, DOI 10.2741/1020; Cohen NA, 1997, NEUROSCIENCE, V76, P581, DOI 10.1016/S0306-4522(96)00345-4; FRISCHKNECHT R, 2007, J NEUROSCI IN PRESS; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; Halfter W, 1997, J COMP NEUROL, V383, P1; Hilgenberg LGW, 2006, CELL, V125, P359, DOI 10.1016/j.cell.2006.01.052; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; Hoover CL, 2003, J CELL BIOL, V161, P923, DOI 10.1083/jcb.200301013; Jontes JD, 2000, NEURON, V27, P11, DOI 10.1016/S0896-6273(00)00003-9; Kappler J, 2000, BIOCHEM BIOPH RES CO, V271, P287, DOI 10.1006/bbrc.2000.2583; Kim JH, 2007, NAT NEUROSCI, V10, P196, DOI 10.1038/nn1839; Knott GW, 2006, NAT NEUROSCI, V9, P1117, DOI 10.1038/nn1747; Koulen P, 1999, EUR J NEUROSCI, V11, P4188, DOI 10.1046/j.1460-9568.1999.00848.x; Kroger S, 2002, NEWS PHYSIOL SCI, V17, P207, DOI 10.1152/01390.2002; Ksiazek I, 2007, J NEUROSCI, V27, P7183, DOI 10.1523/JNEUROSCI.1609-07.2007; Kummer TT, 2006, CURR OPIN NEUROBIOL, V16, P74, DOI 10.1016/j.conb.2005.12.003; Li Z, 1997, NEUROSCIENCE, V79, P191, DOI 10.1016/S0306-4522(96)00654-9; Matus A, 2005, CURR OPIN NEUROBIOL, V15, P67, DOI 10.1016/j.conb.2005.01.015; McCroskery S, 2006, MOL CELL NEUROSCI, V33, P15, DOI 10.1016/j.mcn.2006.06.004; Molinari F, 2002, SCIENCE, V298, P1779, DOI 10.1126/science.1076521; Neuhuber B, 2003, MOL CELL NEUROSCI, V24, P1180, DOI 10.1016/j.mcn.2003.08.008; PHELAN P, 1997, ISOLATION SYNAPTOSOM; Proba K, 1998, BBA-GENE STRUCT EXPR, V1396, P143, DOI 10.1016/S0167-4781(97)00205-4; Reif R, 2007, FASEB J, V21, P3468, DOI 10.1096/fj.07-8800com; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Rulicke T, 2004, METH MOL B, V254, P165; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Taguchi K, 2007, NEUROSCI LETT, V413, P42, DOI 10.1016/j.neulet.2006.11.061; Toni N, 2007, NAT NEUROSCI, V10, P727, DOI 10.1038/nn1908; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Xia B, 2002, MOL CELL NEUROSCI, V19, P539, DOI 10.1006/mcne.2001.1095; Yamaguchi Y, 2002, BBA-GEN SUBJECTS, V1573, P369, DOI 10.1016/S0304-4165(02)00405-1	43	92	98	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1861	1873		10.1096/fj.07-100008	http://dx.doi.org/10.1096/fj.07-100008			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230682				2022-12-28	WOS:000256352700026
J	Wells, RD				Wells, Robert D.			DNA triplexes and Friedreich ataxia	FASEB JOURNAL			English	Review						sticky DNA; GAA; TTC; transcription silencing; non-B DNA conformations; genetic instability; polyamides	DOT-TTC REPEATS; MYOTONIC-DYSTROPHY TYPE-1; ALLEVIATE TRANSCRIPTION INHIBITION; FRAGILE-X-SYNDROME; STICKY DNA; IN-VITRO; GENETIC INSTABILITY; MENTAL-RETARDATION; FORMING SEQUENCES; HAIRPIN FORMATION	Friedreich ataxia, the most common inherited ataxia, is caused by the transcriptional silencing of the FXN gene, which codes for the 210 amino acid frataxin, a mitochondrial protein involved in iron-sulfur cluster biosynthesis. The expansion of the GAA center dot TTC tract in intron 1 to as many as 1700 repeats elicits the transcriptional silencing by the formation of non-B DNA structures (triplexes or sticky DNA), the formation of a persistent DNA center dot RNA hybrid, or heterochromatin formation. The triplex (sticky DNA) adopted by the long repeat sequence also elicits profound mutagenic, genetic instability, and recombination behaviors. Early stage therapeutic investigations involving polyamides or histone deacetylase inhibitors are being pursued. Friedreich ataxia may be one of the most thoroughly studied hereditary neurological disease from a pathophysiological standpoint.	Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Genome Res,Texas Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Wells, RD (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Genome Res,Texas Med Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamhsc.edu			NIEHS NIH HHS [ES11347] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Babady NE, 2007, MOL GENET METAB, V92, P23, DOI 10.1016/j.ymgme.2007.05.009; Bacolla A, 2004, J BIOL CHEM, V279, P47411, DOI 10.1074/jbc.R400028200; Bacolla A, 2004, P NATL ACAD SCI USA, V101, P14162, DOI 10.1073/pnas.0405974101; Bacolla A, 2006, DNA REPAIR, V5, P1161, DOI 10.1016/j.dnarep.2006.05.032; Bacolla A, 2006, NUCLEIC ACIDS RES, V34, P2663, DOI 10.1093/nar/gkl354; Bencze KZ, 2006, CRIT REV BIOCHEM MOL, V41, P269, DOI 10.1080/10409230600846058; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; Burnett R, 2006, P NATL ACAD SCI USA, V103, P11497, DOI 10.1073/pnas.0604939103; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Chin JY, 2007, FRONT BIOSCI-LANDMRK, V12, P4288, DOI 10.2741/2388; Cleary JD, 2003, CYTOGENET GENOME RES, V100, P25, DOI 10.1159/000072837; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; De Biase I, 2007, GENOMICS, V90, P1, DOI 10.1016/j.ygeno.2007.04.001; DEBIASE I, 2006, GENETIC INSTABILITIE, P305; Dere R, 2006, J MOL BIOL, V360, P21, DOI 10.1016/j.jmb.2006.05.012; Di Prospero NA, 2005, NAT REV GENET, V6, P756, DOI 10.1038/nrg1690; Festenstein R, 2006, NAT CHEM BIOL, V2, P512, DOI 10.1038/nchembio1006-512; Filla A, 1996, AM J HUM GENET, V59, P554; Fogel BL, 2007, LANCET NEUROL, V6, P245, DOI 10.1016/S1474-4422(07)70054-6; Godde JS, 1996, J BIOL CHEM, V271, P24325, DOI 10.1074/jbc.271.40.24325; Gottesfeld JM, 2007, PHARMACOL THERAPEUT, V116, P236, DOI 10.1016/j.pharmthera.2007.06.014; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; Grabczyk E, 2007, NUCLEIC ACIDS RES, V35, P5351, DOI 10.1093/nar/gkm589; Greene E, 2003, CYTOGENET GENOME RES, V100, P65, DOI 10.1159/000072839; Greene E, 2007, NUCLEIC ACIDS RES, V35, P3383, DOI 10.1093/nar/gkm271; Guieysse AL, 1996, NUCLEIC ACIDS RES, V24, P4210, DOI 10.1093/nar/24.21.4210; HEBERT MD, 2007, CELL MOL LIFE SCI, DOI DOI 10.1007/S0018-007-7293-6; Heidenfelder BL, 2003, J BIOL CHEM, V278, P2425, DOI 10.1074/jbc.M210643200; Herman D, 2006, NAT CHEM BIOL, V2, P551, DOI 10.1038/nchembio815; KANG S, 1992, J BIOL CHEM, V267, P19435; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; Kosmider B, 2006, NUCLEIC ACIDS RES, V34, P5369, DOI 10.1093/nar/gkl612; Kosynider B, 2007, DNA REPAIR, V6, P1850, DOI 10.1016/j.dnarep.2007.07.014; Krasilnikova MM, 2007, NUCLEIC ACIDS RES, V35, P1075, DOI 10.1093/nar/gkl1140; Krasilnikova MM, 2004, MOL CELL BIOL, V24, P2286, DOI 10.1128/MCB.24.6.2286-2295.2004; LeProust EM, 2000, J MOL BIOL, V302, P1063, DOI 10.1006/jmbi.2000.4073; Melander C, 2004, J BIOTECHNOL, V112, P195, DOI 10.1016/j.jbiotec.2004.03.018; Meservy JL, 2003, MOL CELL BIOL, V23, P3152, DOI 10.1128/MCB.23.9.3152-3162.2003; Mirkin SM, 2007, NATURE, V447, P932, DOI 10.1038/nature05977; Mirkin SM, 2006, CURR OPIN STRUC BIOL, V16, P351, DOI 10.1016/j.sbi.2006.05.004; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; Napierala M, 2005, J BIOL CHEM, V280, P37366, DOI 10.1074/jbc.M508065200; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Napierala M, 2004, J BIOL CHEM, V279, P6444, DOI 10.1074/jbc.M309596200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Orr HT, 2007, ANNU REV NEUROSCI, V30, P575, DOI 10.1146/annurev.neuro.29.051605.113042; Pandolfo M, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P373; Pandolfo M, 2006, J NEURAL TRANSM-SUPP, P143; Pandolfo M, 1998, NEUROMUSCULAR DISORD, V8, P409, DOI 10.1016/S0960-8966(98)00039-X; Pandolfo M, 2001, MOVEMENT DISORD, V16, P815, DOI 10.1002/mds.1162; Pandolfo M., 2006, GENETIC INSTABILITIE, P277; Parniewski P, 2002, ADV EXP MED BIOL, V516, P1; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Pollard LM, 2004, NUCLEIC ACIDS RES, V32, P5962, DOI 10.1093/nar/gkh933; Puccio H, 2007, Handb Exp Pharmacol, P365; PUCCIO H, 2006, GENETIC INSTABILITIE, P321; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Saveliev A, 2003, NATURE, V422, P909, DOI 10.1038/nature01596; Sharma R, 2004, ANN NEUROL, V56, P898, DOI 10.1002/ana.20333; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Son LS, 2006, J MOL BIOL, V360, P267, DOI 10.1016/j.jmb.2006.05.025; SON LS, 2006, GENETIC INSTABILITIE, P327; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; Suen IS, 1999, BBA-GENE STRUCT EXPR, V1444, P14, DOI 10.1016/S0167-4781(98)00267-X; Trushina E, 2007, NEUROSCIENCE, V145, P1233, DOI 10.1016/j.neuroscience.2006.10.056; Tsai SM, 2007, NUCLEIC ACIDS RES, V35, P307, DOI 10.1093/nar/gkl1025; USSERY DW, 1993, BIOCHEMISTRY-US, V32, P6206, DOI 10.1021/bi00075a013; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Vetcher AA, 2004, J BIOL CHEM, V279, P6434, DOI 10.1074/jbc.M309595200; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Vetcher AA, 2002, J BIOL CHEM, V277, P39228, DOI 10.1074/jbc.M205210200; Wang GL, 2006, P NATL ACAD SCI USA, V103, P2677, DOI 10.1073/pnas.0511084103; Wang GL, 2004, P NATL ACAD SCI USA, V101, P13448, DOI 10.1073/pnas.0405116101; Wang GL, 2006, MUTAT RES-FUND MOL M, V598, P103, DOI 10.1016/j.mrfmmm.2006.01.019; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wang YH, 1996, J MOL BIOL, V263, P511, DOI 10.1006/jmbi.1996.0593; Wang YH, 2007, FRONT BIOSCI-LANDMRK, V12, P4731, DOI 10.2741/2422; Wells R.D., 2006, GENETIC INSTABILITIE; Wells RD, 2005, NUCLEIC ACIDS RES, V33, P3785, DOI 10.1093/nar/gki697; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; Wells RD, 2007, TRENDS BIOCHEM SCI, V32, P271, DOI 10.1016/j.tibs.2007.04.003; WILSON RB, 2006, SEMIN PEDIAT NEUROL, V3, P166, DOI DOI 10.1016/J.SPEN.2006.08.005; WILSON RB, 2006, GENETIC INSTABILITIE, P297; Wojciechowska M, 2005, J BIOL CHEM, V280, P941, DOI 10.1074/jbc.M410427200; Wojciechowska M, 2006, J BIOL CHEM, V281, P24531, DOI 10.1074/jbc.M603888200	98	107	110	0	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1625	1634		10.1096/fj.07-097857	http://dx.doi.org/10.1096/fj.07-097857			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18211957				2022-12-28	WOS:000256352700004
J	Ji, SR; Ma, L; Bai, CJ; Shi, JM; Li, HY; Potempa, LA; Filep, JG; Zhao, J; Wu, Y				Ji, Shang-Rong; Ma, Le; Bai, Cai-Juan; Shi, Jing-Ming; Li, Hai-Yun; Potempa, Lawrence A.; Filep, Janos G.; Zhao, Jing; Wu, Yi			Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains	FASEB JOURNAL			English	Article						atherosclerosis; inflammation; protein-membrane interaction	INTEGRAL MEMBRANE-PROTEIN; HUMAN NEUTROPHILS; PENTAMERIC SYMMETRY; CAVEOLAE; ATHEROSCLEROSIS; EXPRESSION; RECEPTORS; ADHESION; DOMAIN; MICE	Emerging evidence indicates that in addition to native pentameric C-reactive protein (CRP), monomeric CRP (mCRP) also plays an active role in inflammation associated with cardiovascular diseases. mCRP activates endothelial cells, one of the critical events in cardiovascular diseases; however, the underlying molecular mechanisms are incompletely understood. Here we report that association of mCRP with human aortic and coronary artery endothelial cells is predominantly due to membrane insertion rather than binding to the surface proteins Fc gamma Rs and proteoglycans. We identify lipid rafts as the preferential membrane microdomains for mCRP anchorage. mCRP binding depends on membrane cholesterol content and is synergistically mediated by the putative cholesterol binding consensus sequence of CRP (aa 35-47) and the C-terminal octapeptide ( aa 199-206). Conversely, disrupting lipid rafts with methyl-beta cyclodextrin or nystatin abrogated mCRP-induced cytokine release, reactive oxygen species generation, and adhesion molecule expression in endothelial cells. Furthermore, ex vivo treatment of rabbit thoracic aorta and carotid artery segments with nystatin prevented mCRP-induced IL-8 release. Our data identify mCRP-lipid raft interaction as an important mechanism in mediating cellular responses to mCRP and lend further support to the notion of mCRP regulation of endothelial cell function during inflammation.-Ji, S.-R., Ma, L., Bai, C.-J., Shi, J.-M., Li, H.-Y., Potempa, L. A., Filep, J. G., Zhao, J., Wu, Y. Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB J. 23, 1806-1816 (2009)	[Ji, Shang-Rong; Ma, Le; Bai, Cai-Juan; Shi, Jing-Ming; Li, Hai-Yun; Zhao, Jing; Wu, Yi] Lanzhou Univ, Inst Biophys, MOE Key Lab Arid & Grassland Ecol, Lanzhou 730000, Peoples R China; [Potempa, Lawrence A.] Acphazin Inc, Deerfield, IL USA; [Filep, Janos G.] Univ Montreal, Res Ctr, Maisonneuve Rosemont Hosp, Montreal, PQ, Canada	Lanzhou University; Universite de Montreal	Wu, Y (corresponding author), Lanzhou Univ, Inst Biophys, MOE Key Lab Arid & Grassland Ecol, Life Sci Bldg,Room 227, Lanzhou 730000, Peoples R China.	wuy@lzu.edu.cn	Shi, Jing-Ming/ACS-3321-2022	Shi, Jing-Ming/0000-0002-8185-3130; Wu, Yi/0000-0003-0365-5590; Li, Haiyun/0000-0002-7458-7399; Ji, Shang-Rong/0000-0001-8595-3756	National Natural Science Foundation of China [30500087, 30670475, 30770451, 30870495]; National Natural Science Foundation of China; Canadian Institutes of Health Research [30711120578]; Fonds de la Recherche en Sante du Quebec; National Natural Science Foundation; Research Fund for the Doctoral Program of Higher Education [20070730015]; Program for New Century Excellent Talents in University [NCET-070392, NCET-05-0884]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education(Research Fund for the Doctoral Program of Higher Education of China (RFDP)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	This work was supported by grants from the National Natural Science Foundation of China (30500087, 30670475, 30770451, 30870495), National Natural Science Foundation of China-Canadian Institutes of Health Research (30711120578), Fonds de la Recherche en Sante du Quebec-National Natural Science Foundation, the Research Fund for the Doctoral Program of Higher Education (20070730015), and Program for New Century Excellent Talents in University (NCET-070392, NCET-05-0884).	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Ciubotaru I, 2005, EXP BIOL MED, V230, P762, DOI 10.1177/153537020523001010; Derham BK, 2002, BIOCHEM J, V368, P865, DOI 10.1042/BJ20020924; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Epand RM, 2005, J MOL BIOL, V345, P339, DOI 10.1016/j.jmb.2004.10.064; FRA AM, 1994, J BIOL CHEM, V269, P30745; Girard-Egrot A, 2004, J MOL BIOL, V335, P321, DOI 10.1016/j.jmb.2003.10.028; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Heuertz RM, 2005, INT J BIOCHEM CELL B, V37, P320, DOI 10.1016/j.biocel.2004.07.002; Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com; Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73; Ji SR, 2006, INT J BIOCHEM CELL B, V38, P648, DOI 10.1016/j.biocel.2005.11.004; Khreiss T, 2004, CIRCULATION, V110, P2713, DOI 10.1161/01.CIR.0000146846.00816.DD; Khreiss T, 2005, CIRC RES, V97, P690, DOI 10.1161/01.RES.0000183881.11739.CB; Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68; Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; Schwedler SB, 2006, AM J KIDNEY DIS, V47, P212, DOI 10.1053/j.ajkd.2005.10.028; Schwedler SB, 2005, CIRCULATION, V112, P1016, DOI 10.1161/CIRCULATIONAHA.105.556530; Schwedler SB, 2003, NEPHROL DIAL TRANSPL, V18, P2300, DOI 10.1093/ndt/gfg407; Sengelov H, 1998, J LEUKOCYTE BIOL, V63, P563, DOI 10.1002/jlb.63.5.563; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Singh SK, 2008, ANN MED, V40, P110, DOI 10.1080/07853890701749225; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tamai R, 2005, INFECT IMMUN, V73, P6290, DOI 10.1128/IAI.73.10.6290-6298.2005; Taylor KE, 2007, IMMUNOLOGY, V120, P404, DOI 10.1111/j.1365-2567.2006.02516.x; Verma S, 2006, CIRCULATION, V113, P2135; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Wu Y, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1377, DOI 10.1023/A:1021862027061; YING SC, 1992, MOL IMMUNOL, V29, P677, DOI 10.1016/0161-5890(92)90205-C	35	102	113	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1806	1816		10.1096/fj.08-116962	http://dx.doi.org/10.1096/fj.08-116962			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19136614				2022-12-28	WOS:000266652400021
J	De Proost, I; Pintelon, I; Wilkinson, WJ; Goethals, S; Brouns, I; Van Nassauw, L; Riccardi, D; Timmermans, JP; Kemp, PJ; Adriaensen, D				De Proost, Ian; Pintelon, Isabel; Wilkinson, William J.; Goethals, Sofie; Brouns, Inge; Van Nassauw, Luc; Riccardi, Daniela; Timmermans, Jean-Pierre; Kemp, Paul J.; Adriaensen, Dirk			Purinergic signaling in the pulmonary neuroepithelial body microenvironment unraveled by live cell imaging	FASEB JOURNAL			English	Article						ATP; NEB; Clara-like cells; mouse; lung	AIRWAY CHEMORECEPTORS; NADPH-OXIDASE; NEUROENDOCRINE CELLS; ATP RELEASE; STEM-CELLS; K+ CURRENT; BODIES; LUNG; RECEPTORS; ACTIVATION	Pulmonary neuroepithelial bodies (NEBs) are densely innervated groups of complex sensory airway receptors involved in the regulation of breathing. Together with their surrounding Clara-like cells, they exhibit stem cell potential through their capacity to regenerate depopulated areas of the epithelium following lung injury. We have employed confocal live cell imaging microscopy and novel electrophysiological techniques in a new ex vivo lung slice model to unravel potential purinergic signaling pathways within the NEB microenvironment. Quinacrine histochemistry indicated high amounts of vesicular ATP in NEB cells. Using a "reporter-patching" method adapted to create a uniquely sensitive and selective biosensor for the direct detection of ATP release from NEBs ex vivo, we demonstrated quantal ATP release from NEBs following their depolarization. Enhancing enzymatic extracellular ATP hydrolysis or inhibiting P2 receptors confirmed the central role of ATP in paracrine interactions between NEB cells and Clara-like cells. Combined calcium imaging, pharmacology, and immunohistochemistry showed that ligand-binding to functional P2Y(2) receptors underpins the activation of Clara-like cells. Hence, NEB cells communicate with their cellular neighbors in the NEB microenvironment by releasing ATP, which rapidly evokes purinergic activation of surrounding Clara-like cells. Besides ATP acting on the P2X(3) receptor expressing vagal sensory nerve terminals between NEB cells, local paracrine purinergic signaling within this potential stem cell niche may be important to both normal airway function, airway epithelial regeneration after injury, and/or the pathogenesis of small cell lung carcinomas.-De Proost, I., Pintelon, I., Wilkinson, W. J., Goethals, S., Brouns, I., Van Nassauw, L., Riccardi, D., Timmermans, J.-P., Kemp, P. J., Adriaensen, D. Purinergic signaling in the pulmonary neuroepithelial body microenvironment unraveled by live cell imaging. FASEB J. 23, 1153-1160 (2009)	[De Proost, Ian; Pintelon, Isabel; Goethals, Sofie; Brouns, Inge; Van Nassauw, Luc; Timmermans, Jean-Pierre; Adriaensen, Dirk] Univ Antwerp, Dept Vet Sci, Cell Biol & Histol Lab, B-2020 Antwerp, Belgium; [De Proost, Ian; Wilkinson, William J.; Riccardi, Daniela; Kemp, Paul J.] Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales	University of Antwerp; Cardiff University	Adriaensen, D (corresponding author), Univ Antwerp, Dept Vet Sci, Cell Biol & Histol Lab, Groenenborgerlaan 171, B-2020 Antwerp, Belgium.	dirk.adriaensen@ua.ac.be	Riccardi, Daniela/A-4674-2010; Wilkinson, William/A-1259-2011; Brouns, Inge/GZM-7277-2022; Kemp, Paul/A-4634-2010; van Nassauw, Luc/A-6735-2015	Riccardi, Daniela/0000-0002-7322-3163; Kemp, Paul/0000-0003-2773-973X; van Nassauw, Luc/0000-0001-7235-5730; Timmermans, Jean-Pierre/0000-0003-2506-6252	Fund for Scientific Research-Flanders [G.0085.04, G.0081.08]; University of Antwerp [NOI-BOF 2003, GOA-BOF 2007, KP-BOF 2006]; BBSRC; BHF; MRC; MRC [G0600821] Funding Source: UKRI; Medical Research Council [G0600821] Funding Source: researchfish	Fund for Scientific Research-Flanders(FWO); University of Antwerp; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BHF(British Heart Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the following research grants: Fund for Scientific Research-Flanders (G.0085.04 and G.0081.08 to D. A.); NOI-BOF 2003 and GOA-BOF 2007 (to D. A.), and KP-BOF 2006 (to I. B.) from the University of Antwerp; BBSRC, BHF, and MRC grants (to D. R. and P. J. K.). We especially thank Profs. J.-M. Boeynaems and B. Robaye (Universite Libre de Bruxelles, Brussels, Belgium) for the stimulating discussions about purinergic signaling. We thank J. Van Daele and D. De Rijck for help with microscopy, imaging and illustrations, and S. Kockelberg and H. De Pauw for administrative help.	ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; ADRIAENSEN D, 1993, ANAT RECORD, V236, P70, DOI 10.1002/ar.1092360111; Adriaensen D, 2003, ANAT REC PART A, V270A, P25, DOI 10.1002/ar.a.10007; Adriaensen D, 2006, J APPL PHYSIOL, V101, P960, DOI 10.1152/japplphysiol.00267.2006; Allen TGJ, 1997, TRENDS NEUROSCI, V20, P192, DOI 10.1016/S0166-2236(96)01039-9; Aubrey KR, 2007, J NEUROSCI, V27, P6273, DOI 10.1523/JNEUROSCI.1024-07.2007; Bishop AE, 2004, CELL PROLIFERAT, V37, P89, DOI 10.1111/j.1365-2184.2004.00302.x; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Brouns I, 2000, AM J RESP CELL MOL, V23, P52, DOI 10.1165/ajrcmb.23.1.3936; Brouns I, 2009, HISTOCHEM CELL BIOL, V131, P55, DOI 10.1007/s00418-008-0495-7; Brown P, 2002, J PHYSIOL-LONDON, V540, P851; Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; Cutz E, 1999, RESP PHYSIOL, V115, P201, DOI 10.1016/S0034-5687(99)00018-3; CUTZ F, 2003, LUNG OXYGEN SENSING, P567; De Proost I, 2008, AM J RESP CELL MOL, V39, P180, DOI 10.1165/rcmb.2008-0011OC; De Proost I, 2007, HISTOCHEM CELL BIOL, V128, P301, DOI 10.1007/s00418-007-0318-2; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Fu XW, 2004, BIOL CHEM, V385, P275, DOI 10.1515/BC.2004.022; Fu XW, 2002, J PHYSIOL-LONDON, V539, P503, DOI 10.1113/jphysiol.2001.013071; Giangreco A, 2007, AM J RESP CRIT CARE, V175, P547, DOI 10.1164/rccm.200607-984PP; HALLER CJ, 1994, MICRON, V25, P527, DOI 10.1016/0968-4328(94)90015-9; Hong KU, 2001, AM J RESP CELL MOL, V24, P671, DOI 10.1165/ajrcmb.24.6.4498; HUNG KS, 1982, ANAT RECORD, V203, P285, DOI 10.1002/ar.1092030210; Kemp PJ, 2003, ANAT REC PART A, V270A, P41, DOI 10.1002/ar.a.10008; Kishore BK, 2000, AM J PHYSIOL-RENAL, V278, pF43, DOI 10.1152/ajprenal.2000.278.1.F43; LAUWERYN.MJ, 1972, ANAT RECORD, V172, P471, DOI 10.1002/ar.1091720301; Linnoila RI, 2006, LAB INVEST, V86, P425, DOI 10.1038/labinvest.3700412; O'Kelly I, 1999, AM J PHYSIOL-LUNG C, V276, pL96, DOI 10.1152/ajplung.1999.276.1.L96; O'Kelly I, 2000, J BIOL CHEM, V275, P7684, DOI 10.1074/jbc.275.11.7684; PEARSALL AD, 1985, ANAT RECORD, V212, P132, DOI 10.1002/ar.1092120206; Pintelon I, 2005, CELL TISSUE RES, V321, P21, DOI 10.1007/s00441-005-1111-y; Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X; Reynolds SD, 2000, AM J PHYSIOL-LUNG C, V278, pL1256, DOI 10.1152/ajplung.2000.278.6.L1256; SCHEUERMANN DW, 1987, INT REV CYTOL, V106, P35, DOI 10.1016/S0074-7696(08)61710-6; Silinsky EM, 1996, J PHYSIOL-LONDON, V492, P815, DOI 10.1113/jphysiol.1996.sp021348; Sorokin SP, 1989, LUNG CELL BIOL, P191; STAHLMAN MT, 1984, LAB INVEST, V51, P449; Taylor SC, 2000, J NEUROCHEM, V75, P1583, DOI 10.1046/j.1471-4159.2000.0751583.x; VANSCOTT MR, 1995, AM J PHYSIOL-LUNG C, V269, pL30, DOI 10.1152/ajplung.1995.269.1.L30; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Wang DS, 1996, P NATL ACAD SCI USA, V93, P13182, DOI 10.1073/pnas.93.23.13182; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; Zhang X, 2007, P NATL ACAD SCI USA, V104, P9864, DOI 10.1073/pnas.0611048104	45	32	33	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1153	1160		10.1096/fj.08-109579	http://dx.doi.org/10.1096/fj.08-109579			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19050048				2022-12-28	WOS:000266651600019
J	Gonnord, P; Delarasse, C; Auger, R; Benihoud, K; Prigent, M; Cuif, MH; Lamaze, C; Kanellopoulos, JM				Gonnord, P.; Delarasse, C.; Auger, R.; Benihoud, K.; Prigent, M.; Cuif, M. H.; Lamaze, C.; Kanellopoulos, J. M.			Palmitoylation of the P2X7 receptor, an ATP-gated channel, controls its expression and association with lipid rafts	FASEB JOURNAL			English	Article						degradation; membrane microdomains; posttranslational modification	ESCHERICHIA-COLI HEMOLYSIN; CELL-SURFACE EXPRESSION; RAT SUBMANDIBULAR-GLAND; MEMBRANE DOMAINS; P2X(7) RECEPTOR; ENDOPLASMIC-RETICULUM; PORE FORMATION; PROTEIN PALMITOYLATION; CYSTEINE RESIDUES; PLASMA-MEMBRANE	The P2X7 receptor (P2X7R) is an ATP-gated cationic channel expressed by hematopoietic, epithelial, and neuronal cells. Prolonged ATP exposure leads to the formation of a nonselective pore, which can result in cell death. We show that P2X7R is associated with detergent-resistant membranes (DRMs) in both transfected human embryonic kidney (HEK) cells and primary macrophages independently from ATP binding. The DRM association requires the posttranslational modification of P2X7R by palmitic acid. Treatment of cells with the palmitic acid analog 2-bromopalmitate as well as mutations of cysteine to alanine residues abolished P2X7R palmitoylation. Substitution of the 17 intracellular cysteines of P2X7R revealed that 4 regions of the carboxyl terminus domain are involved in palmitoylation. Palmitoylation-defective P2X7R mutants showed a dramatic decrease in cell surface expression because of their retention in the endoplasmic reticulum and proteolytic degradation. Taken together, our data demonstrate that P2X7R palmitoylation plays a critical role in its association with the lipid microdomains of the plasma membrane and in the regulation of its half-life.-Gonnord, P., Delarasse, C., Auger, R., Benihoud, K., Prigent, M., Cuif, M. H., Lamaze, C., Kanellopoulos, J. M. Palmitoylation of the P2X7 receptor, an ATP-gated channel, controls its expression and association with lipid rafts. FASEB J. 23, 795-805 (2009)	[Gonnord, P.; Delarasse, C.; Auger, R.; Benihoud, K.; Kanellopoulos, J. M.] Univ Paris Sud, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619, Paris, France; [Prigent, M.; Cuif, M. H.] Univ Paris Sud, Inst Genet & Microbiol, CNRS, UMR 8621, Paris, France; [Lamaze, C.] CNRS, UMR 144, Lab Traf Signalisat & Ciblage Intracellulaires, Inst Curie,Ctr Rech, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Lamaze, C (corresponding author), Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619, F-91405 Orsay, France.	christophe.lamaze@curie.fr; kanellopoulos@u-psud.fr	Delarasse, Cecile/K-8234-2017; , BENIHOUD/O-4334-2019; Lamaze, Christophe/M-4912-2017	Delarasse, Cecile/0000-0001-9739-4306; LAMAZE, Christophe/0000-0001-5430-2707	CNRS; Gefluc; Fondation pour la Recherche Medicale; Association pour la Recherche sur le Cancer (ARC) [3143]; Agence Nationale de la Recherche [BLAN0211]	CNRS(Centre National de la Recherche Scientifique (CNRS)); Gefluc; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Agence Nationale de la Recherche(French National Research Agency (ANR))	We are grateful to Keith Mitchell for his advice and help during DRM preparation. We warmly thank Dr. David Holowka and Dr. Yann Percherancier for critical review of our manuscript. This work was supported by CNRS and Gefluc. P. G. was supported by a grant from the Fondation pour la Recherche Medicale. Work in C.L.'s laboratory was supported by grants from the Association pour la Recherche sur le Cancer (ARC no. 3143) and Agence Nationale de la Recherche (no. BLAN0211).	Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; Auger R, 2005, J BIOL CHEM, V280, P28142, DOI 10.1074/jbc.M501290200; Barnes NC, 2006, IMMUNOL LETT, V104, P118, DOI 10.1016/j.imlet.2005.11.007; Barth K, 2007, FEBS J, V274, P3021, DOI 10.1111/j.1742-4658.2007.05830.x; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; Chakrabandhu K, 2007, EMBO J, V26, P209, DOI 10.1038/sj.emboj.7601456; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Chen BJ, 2005, J VIROL, V79, P13673, DOI 10.1128/JVI.79.21.13673-13684.2005; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Gao ZH, 1999, BIOCHEM J, V342, P387, DOI 10.1042/0264-6021:3420387; Garcia-Marcos M, 2006, J LIPID RES, V47, P705, DOI 10.1194/jlr.M500408-JLR200; Garcia-Marcos M, 2006, BBA-BIOMEMBRANES, V1758, P796, DOI 10.1016/j.bbamem.2006.05.008; Gubitosi-Klug RA, 2005, P NATL ACAD SCI USA, V102, P5964, DOI 10.1073/pnas.0501999102; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Michelsen K, 2005, EMBO REP, V6, P717, DOI 10.1038/sj.embor.7400480; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Renner U, 2007, MOL PHARMACOL, V72, P502, DOI 10.1124/mol.107.037085; Resh MD, 2006, METHODS, V40, P191, DOI 10.1016/j.ymeth.2006.04.013; RESH MD, 2006, SCI STKE, pRE14, DOI DOI 10.1126/STKE.3592006RE14; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; SEDWICK CE, 2002, SCI STKE, pRE2; Sengupta P, 2007, SEMIN CELL DEV BIOL, V18, P583, DOI 10.1016/j.semcdb.2007.07.010; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; Vacca F, 2004, J NEUROSCI RES, V76, P653, DOI 10.1002/jnr.20069; Valdez-Taubas J, 2005, EMBO J, V24, P2524, DOI 10.1038/sj.emboj.7600724; Vial C, 2005, J BIOL CHEM, V280, P30705, DOI 10.1074/jbc.M504256200; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	53	97	99	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					795	805		10.1096/fj.08-114637	http://dx.doi.org/10.1096/fj.08-114637			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18971257				2022-12-28	WOS:000265506300015
J	Lippuner, C; Paape, D; Paterou, A; Brand, J; Richardson, M; Smith, AJ; Hoffmann, K; Brinkmann, V; Blackburn, C; Aebischer, T				Lippuner, Christoph; Paape, Daniel; Paterou, Athina; Brand, Janko; Richardson, Melville; Smith, Andrew J.; Hoffmann, Kirstin; Brinkmann, Volker; Blackburn, Clare; Aebischer, Toni			Real-time imaging of Leishmania mexicana-infected early phagosomes: a study using primary macrophages generated from green fluorescent protein-Rab5 transgenic mice	FASEB JOURNAL			English	Article						embryonic stem cells; inducible gene expression; doxycycline; wortmannin; reverse tetracycline transactivator; lipophosphoglycan	EMBRYONIC STEM-CELLS; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PARASITOPHOROUS VACUOLES; MURINE MACROPHAGES; GLYCOPROTEIN GP63; PHAGOCYTOSIS; MATURATION; LIPOPHOSPHOGLYCAN	The small GTPase Rab5 is a key regulator of endosome/phagosome maturation and in intravesicular infections marks a phagosome stage at which decisions over pathogen replication or destruction are integrated. It is currently unclear whether Leishmania-infected phagosomes uniformly pass through a Rab5(+) stage on their intracellular path to compartments with late endosomal/early lysosomal characteristics. Differences in routes and final compartments could have consequences for accessibility to antileishmanial drugs. Here, we generated a unique gfp-rab5 transgenic mouse model to visualize Rab5 recruitment to early parasite-containing phagosomes in primary host cells. Using real-time fluorescence imaging of phagosomes carrying Leishmania mexicana, we determined that parasite-infested phagosomes follow a uniform sequence of transient Rab5 recruitment. Residence in Rab5(+) compartments was much shorter compared with phagosomes harboring latex beads. Furthermore, a comparative analysis of parasite life-cycle stages and mutants deficient in lpg1, the gene encoding the enzyme required for synthesis of the dominant surface lipophosphoglycan, indicated that parasite surface ligands and host cell receptors modulate pathogen residence times in Rab5(+) phagosomes, but, as far as tested, had no significant effect on intracellular L. mexicana survival or replication. - Lippuner, C., Paape, D., Paterou, A., Brand, J., Richardson, M., Smith, A. J., Hoffmann, K., Brinkmann, V., Blackburn, C., Aebischer, T. Real-time imaging of Leishmania mexicana-infected early phagosomes: a study using primary macrophages generated from green fluorescent protein-Rab5 transgenic mice. FASEB J. 23, 483-491 (2009)	[Paape, Daniel; Paterou, Athina; Aebischer, Toni] Univ Edinburgh, Marie Curie Team Pathogen Habitats, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland; [Lippuner, Christoph; Paape, Daniel; Brand, Janko; Hoffmann, Kirstin; Aebischer, Toni] Max Planck Inst Infect Biol, Dept Mol Biol, Berlin, Germany; [Brinkmann, Volker] Max Planck Inst Infect Biol, Cent Microscopy Unit, Berlin, Germany; [Richardson, Melville; Smith, Andrew J.; Blackburn, Clare] Univ Edinburgh, Inst Stem Cell Res, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh; Max Planck Society; Max Planck Society; University of Edinburgh	Aebischer, T (corresponding author), Univ Edinburgh, Marie Curie Team Pathogen Habitats, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland.	toni.aebischer@ed.ac.uk	Blackburn, Clare/AAM-7954-2020; Blackburn, Clare/B-2847-2009; Brinkmann, Volker/A-6015-2009; Paape, Daniel/G-1665-2015	Blackburn, Clare/0000-0002-6326-640X; Blackburn, Clare/0000-0002-6326-640X; Paape, Daniel/0000-0003-4355-8058; Aebischer, Toni/0000-0002-4875-8457; Lippuner, Christoph/0000-0003-2872-9381	Deutsche Forschungsgemeinschaft [Ae16/3-1]; European Molecular Biology Organization [ASTF 171-2002]; Marie Curie Excellence Award; Boehringer Ingelheim Foundation; Medical Research Council [G0700711B] Funding Source: researchfish	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); Marie Curie Excellence Award(European Commission); Boehringer Ingelheim Foundation(Boehringer Ingelheim); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank J. Nichols for blastocyst injections; S. Moese (Max Planck Institute for Infection Biology, Berlin, Germany), S. Bronson (University of North Carolina, Chapel Hill, NC, USA), A. Galmiche (Max Planck Institute for Infection Biology), D. Colby (University of Edinburgh, Edinburgh, UK), and D. Hills (University of Edinburgh) for DNA constructs and reagents; U. Klemm for continuous advice on ES cell cultures; and U. Schaible and M. Drab for helpful comments on the manuscript. The study was supported by grants from the Deutsche Forschungsgemeinschaft (Ae16/3-1) and the European Molecular Biology Organization (ASTF 171-2002) and by a Marie Curie Excellence Award to T. A. C. L. was supported by the Boehringer Ingelheim Foundation. Finally, we also acknowledge the continuous support of T. F. Meyer. The authors have no conflicting commercial interests.	Aderem A, 2003, J INFECT DIS, V187, pS340, DOI 10.1086/374747; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Aebischer T, 2005, EUR J IMMUNOL, V35, P476, DOI 10.1002/eji.200425674; Alvarez-Dominguez C, 1998, J BIOL CHEM, V273, P33901, DOI 10.1074/jbc.273.51.33901; Alvarez-Dominguez C, 1999, J BIOL CHEM, V274, P11459, DOI 10.1074/jbc.274.17.11459; Antoine JC, 2004, ADV PARASIT, V58, P1, DOI 10.1016/S0065-308X(04)58001-6; Antoine JC, 1998, TRENDS MICROBIOL, V6, P392, DOI 10.1016/S0966-842X(98)01324-9; BAHR V, 1993, MOL BIOCHEM PARASIT, V58, P107, DOI 10.1016/0166-6851(93)90095-F; Becker I, 2003, MOL BIOCHEM PARASIT, V130, P65, DOI 10.1016/S0166-6851(03)00160-9; Bennett CL, 2001, EUR J IMMUNOL, V31, P876, DOI 10.1002/1521-4141(200103)31:3&lt;876::AID-IMMU876&gt;3.0.CO;2-I; BLACKWELL JM, 1985, IMMUNOL LETT, V11, P227, DOI 10.1016/0165-2478(85)90172-5; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103; Courret N, 2002, J CELL SCI, V115, P2303; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; de Veer MJ, 2003, EUR J IMMUNOL, V33, P2822, DOI 10.1002/eji.200324128; Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Duclos S, 2000, CELL MICROBIOL, V2, P365, DOI 10.1046/j.1462-5822.2000.00066.x; Fitzer-Attas CJ, 2000, J EXP MED, V191, P669, DOI 10.1084/jem.191.4.669; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUY RA, 1993, INFECT IMMUN, V61, P1553, DOI 10.1128/IAI.61.4.1553-1558.1993; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; Henry RM, 2004, J CELL BIOL, V164, P185, DOI 10.1083/jcb.200307080; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; Kima PE, 2000, J EXP MED, V191, P1063, DOI 10.1084/jem.191.6.1063; Lindmark H, 2004, EXP CELL RES, V300, P335, DOI 10.1016/j.yexcr.2004.06.025; Lodge R, 2005, CLIN IMMUNOL, V114, P256, DOI 10.1016/j.clim.2004.07.018; Love DC, 1998, EXP PARASITOL, V88, P161, DOI 10.1006/expr.1998.4232; MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063; Morehead J, 2002, INFECT IMMUN, V70, P4571, DOI 10.1128/IAI.70.8.4571-4580.2002; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; PETERS C, 1995, J CELL SCI, V108, P3715; Pizarro-Cerda J, 2004, NAT CELL BIOL, V6, P1026, DOI 10.1038/ncb1104-1026; Russell DG, 2007, CELL MICROBIOL, V9, P849, DOI 10.1111/j.1462-5822.2007.00920.x; Russell DG, 2007, NAT IMMUNOL, V8, P217, DOI 10.1038/ni0307-217a; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; RUSSELL DG, 1987, EUR J BIOCHEM, V164, P213, DOI 10.1111/j.1432-1033.1987.tb11013.x; Schaible UE, 1998, J IMMUNOL, V160, P1290; Scott CC, 2003, J MEMBRANE BIOL, V193, P137, DOI 10.1007/s00232-002-2008-2; Scott CC, 2005, J CELL BIOL, V169, P139, DOI 10.1083/jcb.200412162; Sorensen M, 2003, FEBS LETT, V552, P110, DOI 10.1016/S0014-5793(03)00856-1; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Stuart LM, 2005, IMMUNITY, V22, P539, DOI 10.1016/j.immuni.2005.05.002; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2; Vieira OV, 2003, MOL CELL BIOL, V23, P2501, DOI 10.1128/MCB.23.7.2501-2514.2003; Yao CQ, 2003, MOL BIOCHEM PARASIT, V132, P1, DOI 10.1016/S0166-6851(03)00211-1; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	54	18	18	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					483	491		10.1096/fj.08-108712	http://dx.doi.org/10.1096/fj.08-108712			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18927250	Green Submitted			2022-12-28	WOS:000262892900020
J	Zhu, SY; Gao, B				Zhu, Shunyi; Gao, Bin			A fossil antibacterial peptide gives clues to structural diversity of cathelicidin-derived host defense peptides	FASEB JOURNAL			English	Article						functional divergence; gene duplication; innate immunity; exon shuffling; Cetartiodactyla; sequence remodeling	ANTIMICROBIAL PEPTIDES; EVOLUTION; DIVERGENCE; PROTEINS; SEQUENCE; FAMILY; GENES; DUPLICATION; MECHANISMS; MEMBRANE	Cathelicidins, a group of vertebrate-specific immune effector molecules, developed into a multigene family through gene duplication in the Cetartiodactyla lineage, in which structural changes of the antimicrobial domains (AMDs) among paralogs during evolution are clearly associated with functional diversification of cathelicidins. However, the evolutionary mechanism for such structural diversity remains largely unsolved. Although at the genomic level, the 3'-exon alone encoding the variable AMD repertoire would favor a role of exon shuffling, the observation that two structurally unrelated subfamilies of AMDs (protegrins and prophenins) display high similarity in some nucleotide regions of the 3'-exons of their genes provides evidence for postduplication sequence remodeling. This opinion is further strengthened by finding a proline-arginine-rich antibacterial peptide of 38 residues (named PR-38) encoded by an open reading frame located in the 3' untranslated region of protegrins, which is in frame with prophenins. The latter appears to have undergone internal motif repeats in the region corresponding to PR-38. PR-38 exhibits similar amino acid sequence and carboxyl-terminal amidation feature to PR-39s, a subfamily of cathelicidin peptides conserved across Cetartiodactyla. Functional assays of the chemically synthesized PR-38 confirmed its antibacterial activity with a similar action mode to PR-39 against both gram-positive and gram-negative bacteria at micromolar concentrations, supporting an ancient functional link among cathelicidin members belonging to different subfamilies. Resurrecting the fossil peptide highlights the evolutionary position of PR-39 in generating structurally variable subfamilies of porcine cathelicidins through postduplication sequence remodeling.-Zhu, S., Gao, B. A fossil antibacterial peptide gives clues to structural diversity of cathelicidin-derived host defense peptides. FASEB J. 23, 13-20 (2009)	[Zhu, Shunyi; Gao, Bin] Chinese Acad Sci, Inst Zool, Grp Anim Innate Immun, State Key Lab Integrated Management Pest Insects, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS	Zhu, SY (corresponding author), Datun Rd, Beijing 100101, Peoples R China.	zhusy@ioz.ac.cn			Chinese Academy of Sciences	Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by the Bairen Plan from the Chinese Academy of Sciences to S.Z.	AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; Amino R, 2002, J BIOL CHEM, V277, P6207, DOI 10.1074/jbc.M109874200; Arguello J. R., 2007, V3, P131, DOI 10.1159/000107608; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Bowdish DME, 2006, CURR TOP MICROBIOL, V306, P27; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Chan YR, 2001, J INVEST DERMATOL, V116, P230, DOI 10.1046/j.1523-1747.2001.01231.x; Chothia C, 2003, SCIENCE, V300, P1701, DOI 10.1126/science.1085371; de la Vega RCR, 2005, TRENDS GENET, V21, P330, DOI 10.1016/j.tig.2005.03.009; Froy O, 2003, TRENDS GENET, V19, P684, DOI 10.1016/j.tig.2003.10.010; GUDMUNDSSON GH, 1995, P NATL ACAD SCI USA, V92, P7085, DOI 10.1073/pnas.92.15.7085; Hale JD, 2007, EXPERT REV ANTI-INFE, V5, P951, DOI 10.1586/14787210.5.6.951; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Huang LC, 2007, INVEST OPHTH VIS SCI, V48, P4498, DOI 10.1167/iovs.07-0274; Hultmark D., 1998, TECHNIQUES INSECT IM, P103; Lai JR, 2002, BIOCHEMISTRY-US, V41, P12835, DOI 10.1021/bi026127d; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; Long M, 2003, NAT REV GENET, V4, P865, DOI 10.1038/nrg1204; Lynn DJ, 2004, MOL BIOL EVOL, V21, P819, DOI 10.1093/molbev/msh084; Maxwell AI, 2003, MOL IMMUNOL, V40, P413, DOI 10.1016/S0161-5890(03)00160-3; NICOLAS M, 2002, EUR J BIOCHEM, V269, P1190; Nizet V, 2003, SCAND J INFECT DIS, V35, P670, DOI 10.1080/00365540310015629; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Otvos L, 2002, CELL MOL LIFE SCI, V59, P1138, DOI 10.1007/s00018-002-8493-8; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; Raes J, 2005, TRENDS GENET, V21, P428, DOI 10.1016/j.tig.2005.05.013; SHAFER WM, 1997, ANTIBACTERIAL PEPTID; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Taylor JS, 2004, ANNU REV GENET, V38, P615, DOI 10.1146/annurev.genet.38.072902.092831; Tomasinsig L, 2005, CURR PROTEIN PEPT SC, V6, P23, DOI 10.2174/1389203053027520; Tompa P, 2003, BIOESSAYS, V25, P847, DOI 10.1002/bies.10324; Yeaman MR, 2007, NAT REV MICROBIOL, V5, P727, DOI 10.1038/nrmicro1744; Yeaman MR, 1998, J CLIN INVEST, V101, P178, DOI 10.1172/JCI562; Zanetti M, 2005, CURR ISSUES MOL BIOL, V7, P179, DOI 10.21775/cimb.007.179; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang JZ, 2003, TRENDS ECOL EVOL, V18, P292, DOI 10.1016/S0169-5347(03)00033-8; ZHAO CQ, 1994, FEBS LETT, V346, P285, DOI 10.1016/0014-5793(94)00493-5; Zhu S, 2008, CELL MOL LIFE SCI, V65, P1285, DOI 10.1007/s00018-008-8070-x; Zhu SY, 2008, TRENDS MICROBIOL, V16, P353, DOI 10.1016/j.tim.2008.05.007; Zhu SY, 2008, MOL IMMUNOL, V45, P2531, DOI 10.1016/j.molimm.2008.01.007	41	21	22	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					13	20		10.1096/fj.08-114579	http://dx.doi.org/10.1096/fj.08-114579			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18796560				2022-12-28	WOS:000262095500004
J	Atanasov, AG; Leiser, D; Roesselet, C; Noti, M; Corazza, N; Schoonjans, K; Brunner, T				Atanasov, Atanas G.; Leiser, Dominic; Roesselet, Corinne; Noti, Mario; Corazza, Nadia; Schoonjans, Kristina; Brunner, Thomas			Cell cycle-dependent regulation of extra-adrenal glucocorticoid synthesis in murine intestinal epithelial cells	FASEB JOURNAL			English	Article						liver receptor homologue-1; nuclear receptors; steroidogenesis; mucosal immunology	INFLAMMATORY-BOWEL-DISEASE; RETINOBLASTOMA PROTEIN; RECEPTOR COACTIVATOR; NUCLEAR RECEPTORS; T-CELLS; IN-VIVO; ACTIVATION; EXPRESSION; LIGAND; LRH-1	Glucocorticoids are anti-inflammatory steroids with important applications in the treatment of inflammatory diseases. Endogenous glucocorticoids are mainly produced by the adrenal glands, although there is increasing evidence for extra-adrenal sources. Recent findings show that intestinal crypt cells produce glucocorticoids, which contribute to the maintenance of intestinal immune homeostasis. Intestinal glucocorticoid synthesis is critically regulated by the transcription factor liver receptor homologue-1 (LRH-1). As expression of steroidogenic enzymes and LRH-1 is restricted to the proliferating cells of the crypts, we aimed to investigate the role of the cell cycle in the regulation of LRH-1 activity and intestinal glucocorticoid synthesis. We here show that either pharmacological or molecular modulation of cell cycle progression significantly inhibited expression of steroidogenic enzymes and synthesis of glucocorticoids in intestinal epithelial cells. Synchronization of intestinal epithelial cells in the cell cycle revealed that expression of steroidogenic enzymes is preferentially induced at the G(1)/S stage. Differentiation of immature intestinal epithelial cells to mature nonproliferating cells also resulted in reduced expression of steroidogenic enzymes. This cell cycle-related effect on intestinal steroidogenesis was found to be mediated through the regulation of LRH-1 transcriptional activity. This mechanism may restrict intestinal glucocorticoid synthesis to the proliferating cells of the crypts.	[Atanasov, Atanas G.; Leiser, Dominic; Roesselet, Corinne; Noti, Mario; Corazza, Nadia; Brunner, Thomas] Univ Bern, Div Immunopathol, Inst Pathol, CH-3010 Bern, Switzerland; [Schoonjans, Kristina] ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France	University of Bern; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Brunner, T (corresponding author), Univ Bern, Div Immunopathol, Inst Pathol, Murtenstr 31, CH-3010 Bern, Switzerland.	tbrunner@pathology.unibe.ch	Noti, Mario/I-6581-2019; Atanasov, Atanas G./C-5535-2013	Noti, Mario/0000-0001-9386-1245; Atanasov, Atanas G./0000-0003-2545-0967; Schoonjans, Kristina/0000-0003-1247-4265	Swiss National Science Foundation; Crohn's and Colitis Foundation of America	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Crohn's and Colitis Foundation of America	The authors thank Seamus Martin (Trinity College, Dublin, Ireland), Robert Whitehead (Vanderbilt University, Nashville, TN, USA), and Ed Harlow (Massachusetts General Hospital Cancer Center, Charlestown, MA, USA) for valuable reagents, and the members of the Brunner Laboratory for helpful advice and input. This work was supported by grants from the Swiss National Science Foundation, the Crohn's and Colitis Foundation of America, and the Bernese Cancer League to T. B.	Batsche E, 2005, J BIOL CHEM, V280, P19746, DOI 10.1074/jbc.M413428200; Bens M, 1996, AM J PHYSIOL-CELL PH, V270, pC1666, DOI 10.1152/ajpcell.1996.270.6.C1666; Boivin MA, 2007, AM J PHYSIOL-GASTR L, V292, pG590, DOI 10.1152/ajpgi.00252.2006; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Cima I, 2004, J EXP MED, V200, P1635, DOI 10.1084/jem.20031958; Cole TJ, 2006, BIOTECHNOL ANN REV, V12, P269, DOI 10.1016/S1387-2656(06)12008-6; Coste A, 2007, P NATL ACAD SCI USA, V104, P13098, DOI 10.1073/pnas.0702440104; Farrell RJ, 2003, J ENDOCRINOL, V178, P339, DOI 10.1677/joe.0.1780339; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; GONZALO JA, 1993, J EXP MED, V177, P1239, DOI 10.1084/jem.177.5.1239; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Lange CA, 2004, MOL ENDOCRINOL, V18, P269, DOI 10.1210/me.2003-0331; Lee YK, 2006, J BIOL CHEM, V281, P7850, DOI 10.1074/jbc.M509115200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller C, 1999, J BIOL CHEM, V274, P38112, DOI 10.1074/jbc.274.53.38112; Mueller M, 2007, ENDOCRINOLOGY, V148, P1445, DOI 10.1210/en.2006-0591; Mueller M, 2006, J EXP MED, V203, P2057, DOI 10.1084/jem.20060357; Nachbur U, 2006, BLOOD, V107, P2790, DOI 10.1182/blood-2005-07-2744; Narayanan R, 2005, MOL CELL BIOL, V25, P264, DOI 10.1128/MCB.25.1.264-277.2005; Parker KL, 2002, RECENT PROG HORM RES, V57, P19, DOI 10.1210/rp.57.1.19; Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102; Schoonjans K, 2002, EMBO REP, V3, P1181, DOI 10.1093/embo-reports/kvf238; Siu WY, 1999, FEBS LETT, V461, P299, DOI 10.1016/S0014-5793(99)01481-7; Stasik I, 2007, BBA-MOL CELL RES, V1773, P1483, DOI 10.1016/j.bbamcr.2007.05.011; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Torgler R, 2004, J BIOL CHEM, V279, P37334, DOI 10.1074/jbc.M406913200; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018	31	29	29	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4117	4125		10.1096/fj.08-114157	http://dx.doi.org/10.1096/fj.08-114157			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18711026	Green Submitted			2022-12-28	WOS:000261254800011
J	Cerra, MC; Gallo, MP; Angelone, T; Quintieri, AM; Pulera, E; Filice, E; Guerold, B; Shooshtarizadeh, P; Levi, R; Ramella, R; Brero, A; Boero, O; Metz-Boutigue, MH; Tota, B; Alloatti, G				Cerra, M. C.; Gallo, M. P.; Angelone, T.; Quintieri, A. M.; Pulera, E.; Filice, E.; Guerold, B.; Shooshtarizadeh, P.; Levi, R.; Ramella, R.; Brero, A.; Boero, O.; Metz-Boutigue, M. H.; Tota, B.; Alloatti, G.			The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide	FASEB JOURNAL			English	Article						endocrine heart; peptide hormones; endothelial cells; stress response	N-TERMINAL DOMAIN; SECRETORY GRANULES; PEPTIDES; PROTEIN; VASOSTATIN-1; PROHORMONE; CELLS; IDENTIFICATION; EXPRESSION; FRAGMENTS	Chromogranin A (CGA), produced by human and rat myocardium, generates several biologically active peptides processed at specific proteolytic cleavage sites. A highly conserved cleavage N-terminal site is the bond 64-65 that reproduces the native rat CGA sequence (rCGA1-64), corresponding to human N-terminal CGA-derived vasostatin-1. rCGA1-64 cardiotropic activity has been explored in rat cardiac preparations. In Langendorff perfused rat heart, rCGA1-64 (from 33 nM) induced negative inotropism and lusitropism as well as coronary dilation, counteracting isoproterenol (Iso) - and endothelin-1 (ET-1) - induced positive inotropic effects and ET-1-dependent coronary constriction. rCGA1-64 also depressed basal and Iso-induced contractility on rat papillary muscles, without affecting calcium transients on isolated ventricular cells. Structure-function analysis using three modified peptides on both rat heart and papillary muscles revealed the disulfide bridge requirement for the cardiotropic action. A decline in Iso intrinsic activity in the presence of the peptides indicates a noncompetitive antagonistic action. Experiments on rat isolated cardiomyocytes and bovine aortic endothelial cells indicate that the negative inotropism observed in rat papillary muscle is probably due to an endothelial phosphatidylinositol 3-kinase-dependent nitric oxide release, rather than to a direct action on cardiomyocytes. Taken together, our data strongly suggest that in the rat heart the homologous rCGA1-64 fragment exerts an autocrine/paracrine modulation of myocardial and coronary performance acting as stabilizer against intense excitatory stimuli.-Cerra, M. C., Gallo, M. P., Angelone, T., Quintieri, A. M., Pulera, E., Filice, E., Guerold, B., Shooshtarizadeh, P., Levi, R., Ramella, R., Brero, A., Boero, O., Metz-Boutigue, M. H., Tota, B., Alloatti, G. The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. FASEB J. 22, 3992 - 4004 (2008)	[Cerra, M. C.; Angelone, T.; Tota, B.] Univ Calabria, Dept Cell Biol, I-87030 Calabria, Italy; [Cerra, M. C.; Quintieri, A. M.; Pulera, E.; Filice, E.] Univ Calabria, Dept Pharmacobiol, I-87030 Calabria, Italy; [Gallo, M. P.; Levi, R.; Ramella, R.; Brero, A.; Boero, O.; Alloatti, G.] Univ Turin, Dept Anim & Human Biol, Turin, Italy; [Guerold, B.; Shooshtarizadeh, P.; Metz-Boutigue, M. H.] Univ Strasbourg, Unity INSERM 575, Strasbourg, France	University of Calabria; University of Calabria; University of Turin; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Alloatti, G (corresponding author), Univ Calabria, Dept Cell Biol, I-87030 Calabria, Italy.	giuseppe.alloatti@unito.it	Gallo, Mariana C/J-2832-2014; Angelone, Tommaso/AAM-1230-2020	Angelone, Tommaso/0000-0001-7797-7862; Gallo, Maria Pia/0000-0002-0382-7607; Cerra, Maria Carmela/0000-0002-2091-928X	Fondazione Cassa di Risparmio di Calabria e Lucania; Italian Ministry of University and Research; Dottorato di Fisiologia, University of Turin; Istituto Nazionale di Ricerca Cardiovascolare, and Compagnia San Paolo, Italy; Regione Piemonte	Fondazione Cassa di Risparmio di Calabria e Lucania; Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Dottorato di Fisiologia, University of Turin; Istituto Nazionale di Ricerca Cardiovascolare, and Compagnia San Paolo, Italy(Compagnia di San Paolo); Regione Piemonte(Regione Piemonte)	This work was supported by Fondazione Cassa di Risparmio di Calabria e Lucania, research project Cuore-cervello: nuovi orizzonti biomedici nello studio di neuropeptidi ad attivita cardiovascolare (B. T., M. C. C., and T. A.); the Italian Ministry of University and Research (MURST ex 60%: B. T., G. A., and M. C. C.); and the Dottorato di Fisiologia, University of Turin, the Istituto Nazionale di Ricerca Cardiovascolare, and Compagnia San Paolo, Italy (A. M. Q.). O.B. was the recipient of research funds from Regione Piemonte (2004).	AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; Abi-Gerges N, 2001, J PHYSIOL-LONDON, V531, P117, DOI 10.1111/j.1469-7793.2001.0117j.x; Angelone T, 2006, J PHARMACOL EXP THER, V318, P336, DOI 10.1124/jpet.106.102103; Atherton E., 1990, SOLID PHASE PEPTIDE; BAYDOUN AR, 1989, J CARDIOVASC PHARM, V13, pS193, DOI 10.1097/00005344-198900135-00054; Beinfeld MC, 1998, ENDOCRINE, V8, P1, DOI 10.1385/ENDO:8:1:1; Brekke JF, 2002, REGUL PEPTIDES, V105, P93, DOI 10.1016/S0167-0115(02)00004-6; BRUNNER F, 2006, PHARMACOL THERAPEUT, V26, P364; BRUTSAERT DL, 1989, PHYSIOL REV, V69, P1228, DOI 10.1152/physrev.1989.69.4.1228; Cappello S, 2007, AM J PHYSIOL-HEART C, V293, pH719, DOI 10.1152/ajpheart.01352.2006; Ceconi C, 2002, EUR HEART J, V23, P967, DOI 10.1053/euhj.2001.2977; Cerra MC, 2006, BASIC RES CARDIOL, V101, P43, DOI 10.1007/s00395-005-0547-2; Corti A, 2000, ADV EXP MED BIOL, V482, P351; Courel M, 2006, J BIOL CHEM, V281, P38038, DOI 10.1074/jbc.M604037200; Danser AHJ, 2002, J MOL CELL CARDIOL, V34, P1463, DOI 10.1006/jmcc.2002.2078; DEAKIN H, 1963, BIOCHEM J, V89, P296, DOI 10.1042/bj0890296; EIDEN LE, 1987, NATURE, V325, P301, DOI 10.1038/325301a0; Ferrero E, 2004, FASEB J, V18, P554, DOI 10.1096/fj.03-0922fje; Gallo MP, 2007, AM J PHYSIOL-HEART C, V292, pH2906, DOI 10.1152/ajpheart.01253.2006; Georget M, 2003, FASEB J, V17, P1380, DOI 10.1096/fj.02-0784com; Glattard E, 2006, FEBS J, V273, P3311, DOI 10.1111/j.1742-4658.2006.05334.x; Goumon Y, 2000, J BIOL CHEM, V275, P38355, DOI 10.1074/jbc.M007557200; HALBAN PA, 1994, BIOCHEM J, V299, P1; Hartell NA, 2005, BIOCHEM PHARMACOL, V69, P781, DOI 10.1016/j.bcp.2004.11.022; Helle KB, 2007, CELL MOL LIFE SCI, V64, P2863, DOI 10.1007/s00018-007-7254-0; Helle KB, 2000, ADV EXP MED BIOL, V482, P389; Hong SJ, 1998, BRIT J PHARMACOL, V124, P849, DOI 10.1038/sj.bjp.0701898; HoveMadsen L, 1996, BASIC RES CARDIOL, V91, P1, DOI 10.1007/BF00795355; HSIAO RJ, 1990, KIDNEY INT, V37, P955, DOI 10.1038/ki.1990.71; HUTTON JC, 1988, ENDOCRINOLOGY, V122, P1014, DOI 10.1210/endo-122-3-1014; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; Koeslag JH, 1999, J PHYSIOL-LONDON, V517, P643, DOI 10.1111/j.1469-7793.1999.0643s.x; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Mahapatra NR, 2006, J HYPERTENS, V24, P895, DOI 10.1097/01.hjh.0000222760.99852.e0; Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354; Maniatis NA, 2006, CIRC RES, V99, P870, DOI 10.1161/01.RES.0000245187.08026.47; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MISEREZ B, 1992, FEBS LETT, V314, P122, DOI 10.1016/0014-5793(92)80956-H; Muth E, 2004, BBA-PROTEINS PROTEOM, V1699, P263, DOI 10.1016/j.bbapap.2004.03.007; NOBELS FRE, 1994, EUR J ENDOCRINOL, V131, P589, DOI 10.1530/eje.0.1310589; O'Connor DT, 1999, BLOOD PRESSURE, V8, P285, DOI 10.1080/080370599439508; Omland T, 2003, AM J MED, V114, P25, DOI 10.1016/S0002-9343(02)01425-0; PIERONI M, 2007, EUR HEART J, V28, P1052; Samuels MA, 2007, CIRCULATION, V116, P77, DOI 10.1161/CIRCULATIONAHA.106.678995; Shah AM, 1996, CARDIOVASC RES, V31, P847; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Shaul PW, 2002, AM J PHYSIOL-LUNG C, V283, pL1192, DOI 10.1152/ajplung.00112.2002; STEINER HJ, 1990, J HISTOCHEM CYTOCHEM, V38, P845, DOI 10.1177/38.6.2139887; STRIDSBERG M, 1995, J ENDOCRINOL, V144, P49, DOI 10.1677/joe.0.1440049; Tota B, 2003, REGUL PEPTIDES, V114, P123, DOI 10.1016/S0167-0115(03)00112-5; Tota B, 2007, COMP BIOCHEM PHYS A, V147, P11, DOI 10.1016/j.cbpa.2006.05.016; VITTONE L, 1994, J PHARMACOL TOX MET, V32, P7, DOI 10.1016/1056-8719(94)90011-6; Weiergraber M, 2000, J HISTOCHEM CYTOCHEM, V48, P807, DOI 10.1177/002215540004800609	53	41	42	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3992	4004		10.1096/fj.08-110239	http://dx.doi.org/10.1096/fj.08-110239			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18697842				2022-12-28	WOS:000260503000027
J	Yang, JL; Siqueira, MF; Behl, Y; Alikhani, M; Graves, DT				Yang, Julia; Siqueira, Michelle F.; Behl, Yugal; Alikhani, Mani; Graves, Dana T.			The transcription factor ST18 regulates proapoptotic and proinflammatory gene expression in fibroblasts	FASEB JOURNAL			English	Article						cytokines; cell death; inflammation; mRNA profiling; microarray	FACTOR-KAPPA-B; TUMOR-NECROSIS-FACTOR; PRO-APOPTOTIC GENES; RHEUMATOID-ARTHRITIS; CHEMOTHERAPY; THERAPY; CANCER; P53; IDENTIFICATION; NETWORKS	Suppression of tumorigenicity 18 (ST18) and the homologues neural zinc-finger protein-3 (NZF3) and myelin transcription factor 3 (Myt3) are transcription factors with unknown function. Previous studies have established that they repress transcription of a synthetic reporter construct consisting of the consensus sequence AAAGTTT linked to the thymidine kinase promoter. In addition, ST18 exhibits significantly reduced expression in breast cancer and breast cancer cell lines. We report here for the first time evidence that ST18 mediates tumor necrosis factor (TNF) -alpha induced mRNA levels of proapoptotic and proinflammatory genes in fibroblasts by mRNA profiling and silencing with ST18 small interfering RNA ( siRNA). Gene set enrichment analysis and mRNA profiling support this conclusion by identifying several apoptotic and inflammatory pathways that are down-regulated by ST18 siRNA. In addition, ST18 siRNA reduces TNF-induced fibroblast apoptosis and caspase3/7 activity. Fibroblasts that overexpress ST18 by transient transfection exhibit significantly increased apoptosis and increased expression of TNF-alpha, interleukin (IL) -1 alpha, and IL-6. In addition, cotransfection of ST18 and a TNF-alpha or IL-1 alpha reporter construct demonstrates that ST18 overexpression in fibroblasts significantly enhanced promoter activity of these genes. Taken together, these studies demonstrate that the transcription factor ST18/NZF3 regulates the mRNA levels of proapoptotic and proinflammatory genes in revealing a previously unrecognized function. -Yang, J., Siqueira, M. F., Behl, Y., Alikhani, M., and Graves, D. T. The transcription factor ST18 regulates proapoptotic and proinflammatory gene expression in fibroblasts. FASEB J. 22, 3956-3967 (2008)	[Yang, Julia; Siqueira, Michelle F.; Behl, Yugal; Graves, Dana T.] Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA; [Alikhani, Mani] NYU, Coll Dent, Dept Orthodont, New York, NY USA	Boston University; New York University	Graves, DT (corresponding author), Boston Univ, Sch Dent Med, Dept Periodontol & Oral Biol, 700 Albany St W-202 D, Boston, MA 02118 USA.	dgraves@bu.edu			U. S. National Institute of Health [DE07559, DE17732]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE017732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011254, R01DE007559, R23DE007559] Funding Source: NIH RePORTER	U. S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Alicia Ruff for help in preparing this manuscript. This work was supported by U. S. National Institute of Health grants DE07559 and DE17732.	Alikhani M, 2004, J CELL PHYSIOL, V201, P341, DOI 10.1002/jcp.20067; Alikhani ZB, 2005, J BIOL CHEM, V280, P12087, DOI 10.1074/jbc.M406313200; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Chen F, 1999, CLIN CHEM, V45, P7; Choisy-Rossi C, 1998, TOXICOL LETT, V103, P491, DOI 10.1016/S0378-4274(98)00238-0; Darby IA, 1997, INT J BIOCHEM CELL B, V29, P191, DOI 10.1016/S1357-2725(96)00131-8; de Winther MPJ, 2005, ARTERIOSCL THROM VAS, V25, P904, DOI 10.1161/01.ATV.0000160340.72641.87; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Graves DT, 2001, J DENT RES, V80, P1875, DOI 10.1177/00220345010800100301; Jandrig B, 2004, ONCOGENE, V23, P9295, DOI 10.1038/sj.onc.1208131; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; Kane CD, 2000, WOUND REPAIR REGEN, V8, P45, DOI 10.1046/j.1524-475x.2000.00045.x; Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991; Lavon I, 2003, CANCER RES, V63, P25; Liu HT, 2003, CURR OPIN PHARMACOL, V3, P317, DOI 10.1016/S1471-4892(03)00037-7; Matt T, 2002, ACTA MED AUST, V29, P77, DOI 10.1046/j.1563-2571.2002.02010.x; Monks NR, 2004, J CELL BIOCHEM, V92, P646, DOI 10.1002/jcb.20080; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Steinbach D, 2006, CLIN CANCER RES, V12, P2434, DOI 10.1158/1078-0432.CCR-05-2552; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang XR, 2003, P NATL ACAD SCI USA, V100, P4096, DOI 10.1073/pnas.0630562100; Taylor PC, 2001, MOL BIOTECHNOL, V19, P153, DOI 10.1385/MB:19:2:153; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wong DJ, 2005, J INVEST DERMATOL, V125, P175, DOI 10.1111/j.0022-202X.2005.23827.x; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; Yi S, 2006, MOL CARCINOGEN, V45, P409, DOI 10.1002/mc.20231	33	55	57	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3956	3967		10.1096/fj.08-111013	http://dx.doi.org/10.1096/fj.08-111013			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18676404	Green Published			2022-12-28	WOS:000260503000024
J	Cuchillo-Ibanez, I; Seereeram, A; Byers, HL; Leung, KY; Ward, MA; Anderton, BH; Hanger, DP				Cuchillo-Ibanez, Inmaculada; Seereeram, Anjan; Byers, Helen L.; Leung, Kit-Yi; Ward, Malcolm A.; Anderton, Brian H.; Hanger, Diane P.			Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin	FASEB JOURNAL			English	Article						GSK-3; mass spectrometry; lithium	GLYCOGEN-SYNTHASE KINASE-3; CYCLIN-DEPENDENT KINASE-5; DISEASE-LIKE PHOSPHORYLATION; HELICAL FILAMENT-TAU; MASS-SPECTROMETRY; PROTEIN-TAU; SITES; LITHIUM; INHIBITION; NEURONS	Defective axonal transport has been proposed as an underlying mechanism that may give rise to neurodegeneration. We investigated the effect of phosphorylation on the axonal transport of tau, a neuronal protein that stabilizes microtubules and is hyperphosphorylated and mislocalized in Alzheimer's disease. We report here that specific inhibition of glycogen synthase kinase-3 (GSK-3) reduces tau phosphorylation and significantly decreases the overall rate of axonal transport of tau in rat cortical neurons. Tau mutants, with serine/threonine targets of GSK-3 mutated to glutamate to mimic a permanent state of phosphorylation, were transported at a significantly increased rate compared to wild-type tau. Conversely, tau mutants, in which alanine replaced serine/threonine to mimic permanent dephosphorylation, were transported at a decreased rate compared to wild-type tau. We also found that tau interacts with the light chain of kinesin-1 and that this is dependent on the phosphorylation state of tau. Tau phosphorylation by GSK-3 increased binding, and dephosphorylated tau exhibited a reduced association with kinesin-1. We conclude that GSK-3 phosphorylation of tau modulates its axonal transport by regulating binding to kinesin-1. Hyperphosphorylated tau in Alzheimer's disease appearing first in distal portions of axons may result from aberrant axonal transport of phosphorylated tau reported here.	[Cuchillo-Ibanez, Inmaculada; Seereeram, Anjan; Anderton, Brian H.; Hanger, Diane P.] Kings Coll London, Inst Psychiat, MRC Ctr Neurodegenerat Res, London SE5 8AF, England	University of London; King's College London	Cuchillo-Ibanez, I (corresponding author), Kings Coll London, Inst Psychiat P037, MRC Ctr Neurodegenerat Res, De Crespigny Pk, London SE5 8AF, England.	spneici@iop.kcl.ac.uk	Hanger, Diane/C-5697-2009; cuchillo, inmaculada/P-2975-2019	Hanger, Diane/0000-0002-3044-9816; /0000-0002-3689-5518; Ward, Malcolm/0000-0003-2164-6938	Wellcome Trust; Alzheimer's Society; UK Medical Research Council; MRC [G0300408] Funding Source: UKRI; Medical Research Council [G0300408] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Alzheimer's Society; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Wellcome Trust, the Alzheimer's Society, and the UK Medical Research Council. Plasmids expressing 2N4R tau, E18tau, and E27tau were kind gifts from M. Goedert (Medical Research Council Laboratory of Molecular Biology, Cambridge, UK).	Ackerley S, 2003, J CELL BIOL, V161, P489, DOI 10.1083/jcb.200303138; Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Anderton BH, 2001, BIOCHEM SOC SYMP, V67, P73; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Crosby AH, 2003, LANCET NEUROL, V2, P311, DOI 10.1016/S1474-4422(03)00383-1; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Derkinderen P, 2005, J NEUROSCI, V25, P6584, DOI 10.1523/JNEUROSCI.1487-05.2005; Dubey M, 2008, CELL MOTIL CYTOSKEL, V65, P89, DOI 10.1002/cm.20243; Eidenmuller J, 2001, BIOCHEM J, V357, P759, DOI 10.1042/0264-6021:3570759; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Gibb GM, 2000, FEBS LETT, V485, P99, DOI 10.1016/S0014-5793(00)02196-7; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; Haase C, 2004, J NEUROCHEM, V88, P1509, DOI 10.1046/j.1471-4159.2003.02287.x; Hallows JL, 2003, J NEUROSCI, V23, P10633; Hanger DP, 2007, J BIOL CHEM, V282, P23645, DOI 10.1074/jbc.M703269200; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; ISHIGURO K, 1992, NEUROSCI LETT, V148, P202, DOI 10.1016/0304-3940(92)90839-Y; Jancsik V, 1996, Neurobiology (Bp), V4, P417; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOZACK S, 2007, J NEUROSCI, V12, P9916; Lazarov O, 2007, J NEUROSCI, V27, P7011, DOI 10.1523/JNEUROSCI.4272-06.2007; Leger J, 1997, J BIOL CHEM, V272, P8441, DOI 10.1074/jbc.272.13.8441; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1997, NEUROSCIENCE, V78, P309; Ma DL, 2000, J NEUROSCI, V20, P2112; MacAulay K, 2003, EUR J BIOCHEM, V270, P3829, DOI 10.1046/j.1432-1033.2003.03777.x; Moran CM, 2005, MOL BRAIN RES, V134, P338, DOI 10.1016/j.molbrainres.2004.10.035; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; Morfini G, 2004, EMBO J, V23, P2235, DOI 10.1038/sj.emboj.7600237; MORISHIMAKAWASHIMA M, 1995, NEUROBIOL AGING, V16, P365, DOI 10.1016/0197-4580(95)00027-C; Motil J, 2006, CELL MOTIL CYTOSKEL, V63, P266, DOI 10.1002/cm.20122; Munoz-Montano Juan Ramon, 1999, J Alzheimers Dis, V1, P361; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Owen R, 2003, MOL CELL NEUROSCI, V23, P626, DOI 10.1016/S1044-7431(03)00095-2; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Pigino G, 2003, J NEUROSCI, V23, P4499; Plattner F, 2006, J BIOL CHEM, V281, P25457, DOI 10.1074/jbc.M603469200; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Sang HC, 2001, NEUROSCI LETT, V312, P141, DOI 10.1016/S0304-3940(01)02206-6; Sengupta A, 2006, FEBS LETT, V580, P5925, DOI 10.1016/j.febslet.2006.09.060; Shea TB, 2000, J NEUROCYTOL, V29, P873, DOI 10.1023/A:1010951626090; Smith KDB, 2007, NEUROIMAGE, V35, P1401, DOI 10.1016/j.neuroimage.2007.01.046; Smith MJ, 2000, FEBS LETT, V484, P265, DOI 10.1016/S0014-5793(00)02169-4; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Takahashi M, 1999, J NEUROCHEM, V73, P2073; Terwel D, 2002, NEUROMOL MED, V2, P151, DOI 10.1385/NMM:2:2:151; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; Utton MA, 2005, J CELL SCI, V118, P4645, DOI 10.1242/jcs.02558; Utton MA, 2002, J NEUROSCI, V22, P6394; Utton MA, 1997, BIOCHEM J, V323, P741, DOI 10.1042/bj3230741; Williams DR, 2006, INTERN MED J, V36, P652, DOI 10.1111/j.1445-5994.2006.01153.x; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4	59	123	126	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3186	3195		10.1096/fj.08-109181	http://dx.doi.org/10.1096/fj.08-109181			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18511549				2022-12-28	WOS:000258761300011
J	Besaratinia, A; Kim, SI; Pfeifer, GP				Besaratinia, Ahmad; Kim, Sang-in; Pfeifer, Gerd P.			Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells	FASEB JOURNAL			English	Review						DNA damage; mutations; skin cancer; ultraviolet radiation	CYCLOBUTANE PYRIMIDINE DIMERS; OXIDATIVE DNA-DAMAGE; CUTANEOUS MALIGNANT-MELANOMA; NUCLEOTIDE EXCISION-REPAIR; HUMAN SKIN CELLS; DEFICIENT XERODERMA-PIGMENTOSUM; CANCER MUTATIONAL HOTSPOTS; ULTRAVIOLET-A RADIATION; TO-T TRANSVERSIONS; MAMMALIAN-CELLS	Despite the predominance of ultraviolet A (UVA) relative to UVB in terrestrial sunlight, solar mutagenesis in humans and rodents is characterized by mutations specific for UVB. We have investigated the kinetics of repair of UVA- and UVB-induced DNA lesions in relation to mutagenicity in transgenic mouse fibroblasts irradiated with equilethal doses of UVA and UVB in comparison to simulated-sunlight UV(SSL). We have also analyzed mutagenesis-derived carcinogenesis in sunlight-associated human skin cancers by compiling the published data on mutation types found in crucial genes in nonmelanoma and melanoma skin cancers. Here, we demonstrate a resistance to repair of UVB-induced cis-syn cyclobutane pyrimidine-dimers (CPDs) together with rapid removal of UVA- induced oxidized purines in the genome overall and in the cII transgene of SSL-irradiated cells. The spectra of mutation induced by both UVB and SSL irradiation in this experimental system are characterized by significant increases in relative frequency of C -> T transitions at dipyrimidines, which are the established signature mutation of CPDs. This type of mutation is also the predominant mutation found in human nonmelanoma and melanoma tumor samples in the TP53, CDKN2, PTCH, and protein kinase genes. The prevailing role of UVB over UVA in solar mutagenesis in our test system can be ascribed to different kinetics of repair for lesions induced by the respective UV irradiation.	[Besaratinia, Ahmad; Kim, Sang-in; Pfeifer, Gerd P.] City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Besaratinia, A (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	ania@coh.org		Besaratinia, Ahmad/0000-0001-7231-228X	NIEHS NIH HHS [ES06070, R37 ES006070-16, R01 ES006070, R37 ES006070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3; Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Avery AM, 1999, NUCLEIC ACIDS RES, V27, P2256, DOI 10.1093/nar/27.11.2256; Besaratinia A, 2005, P NATL ACAD SCI USA, V102, P10058, DOI 10.1073/pnas.0502311102; Besaratinia A, 2004, BIOCHEMISTRY-US, V43, P15557, DOI 10.1021/bi048717c; Besaratinia A, 2004, BIOCHEMISTRY-US, V43, P8169, DOI 10.1021/bi049761v; Besaratinia A, 2002, CANCER RES, V62, P4331; Besaratinia A, 2007, P NATL ACAD SCI USA, V104, P5953, DOI 10.1073/pnas.0610534104; Besaratinia A, 2006, CARCINOGENESIS, V27, P1526, DOI 10.1093/carcin/bgi311; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; Busuttil RA, 2006, DNA REPAIR, V5, P52, DOI 10.1016/j.dnarep.2005.07.006; Busuttil RA, 2003, AGING CELL, V2, P287, DOI 10.1046/j.1474-9728.2003.00066.x; Buterin T, 2002, CANCER RES, V62, P4229; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; Cadet J, 2006, PHOTOCHEM PHOTOBIOL, V82, P1219, DOI 10.1562/2006-06-09-IR-914; Castellano M, 1997, CANCER RES, V57, P4868; Courdavault S, 2005, DNA REPAIR, V4, P836, DOI 10.1016/j.dnarep.2005.05.001; Courdavault S, 2004, MUTAT RES-FUND MOL M, V556, P135, DOI 10.1016/j.mrfmmm.2004.07.011; Courdavault S, 2004, PHOTOCHEM PHOTOBIOL, V79, P145, DOI 10.1562/0031-8655(2004)079<0145:UCPDDN>2.0.CO;2; D'Errico M, 2000, ONCOGENE, V19, P463, DOI 10.1038/sj.onc.1203313; D'Errico M, 2006, EMBO J, V25, P4305, DOI 10.1038/sj.emboj.7601277; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEMARINI DM, 1995, MUTAT RES-FUND MOL M, V327, P131, DOI 10.1016/0027-5107(94)00179-9; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Douki T, 2003, BIOCHEMISTRY-US, V42, P9221, DOI 10.1021/bi034593c; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; Dutt A, 2006, CLIN CANCER RES, V12, p4396S, DOI 10.1158/1078-0432.CCR-06-0414; Emmert S, 2000, P NATL ACAD SCI USA, V97, P2151, DOI 10.1073/pnas.040559697; Evans T, 2000, HUM MUTAT, V16, P43, DOI 10.1002/1098-1004(200007)16:1<43::AID-HUMU8>3.3.CO;2-Z; Feng ZH, 2002, J NATL CANCER I, V94, P1527; Flores JF, 1996, CANCER RES, V56, P5023; FORD JM, 1994, MOL CARCINOGEN, V10, P105, DOI 10.1002/mc.2940100208; FRANKLIN WA, 1985, NUCLEIC ACIDS RES, V13, P5317, DOI 10.1093/nar/13.14.5317; Fujimoto A, 1999, ONCOGENE, V18, P2527, DOI 10.1038/sj.onc.1202803; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GALE JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P411, DOI 10.1111/j.1751-1097.1990.tb01732.x; Green A, 2007, INT J CANCER, V120, P1116, DOI 10.1002/ijc.22453; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grishko VI, 1997, MUTAT RES-DNA REPAIR, V384, P73, DOI 10.1016/S0921-8777(97)00017-7; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Heitzer E, 2007, J INVEST DERMATOL, V127, P2872, DOI 10.1038/sj.jid.5700923; Herbst RA, 1997, J INVEST DERMATOL, V108, P950, DOI 10.1111/1523-1747.ep12296624; Hollenbach S, 1999, CARCINOGENESIS, V20, P1863, DOI 10.1093/carcin/20.9.1863; Ikehata H, 2003, MUTAGENESIS, V18, P511, DOI 10.1093/mutage/geg030; IZUMIZAWA Y, 2000, NUCL ACIDS S SER, V73; Jakubczak JL, 1996, P NATL ACAD SCI USA, V93, P9073, DOI 10.1073/pnas.93.17.9073; KANJILAL S, 1993, CANCER RES, V53, P2961; Kanno S, 1999, NUCLEIC ACIDS RES, V27, P3096, DOI 10.1093/nar/27.15.3096; Kappes UP, 2006, J INVEST DERMATOL, V126, P667, DOI 10.1038/sj.jid.5700093; Kappes UP, 2005, RADIAT RES, V164, P440, DOI 10.1667/RR3434.1; KELFKENS G, 1990, PHOTOCHEM PHOTOBIOL, V52, P819, DOI 10.1111/j.1751-1097.1990.tb08687.x; Kim SI, 2007, CANCER RES, V67, P11640, DOI 10.1158/0008-5472.CAN-07-2528; Kim SI, 2007, MUTAT RES-FUND MOL M, V617, P71, DOI 10.1016/j.mrfmmm.2006.12.003; Kim SH, 2002, DYES PIGMENTS, V53, P1, DOI 10.1016/S0143-7208(02)00015-3; Kobayashi T, 1998, NUCLEIC ACIDS RES, V26, P4662, DOI 10.1093/nar/26.20.4662; Koehler DR, 1996, J BACTERIOL, V178, P1347, DOI 10.1128/jb.178.5.1347-1350.1996; Kozmin S, 2005, P NATL ACAD SCI USA, V102, P13538, DOI 10.1073/pnas.0504497102; Kumar R, 1998, INT J CANCER, V75, P193, DOI 10.1002/(SICI)1097-0215(19980119)75:2<193::AID-IJC5>3.3.CO;2-5; Lambert LB, 2005, MUTAT RES-REV MUTAT, V590, P1, DOI 10.1016/j.mrrev.2005.04.002; Lamperska K, 2002, ACTA BIOCHIM POL, V49, P369; Lan L, 2004, P NATL ACAD SCI USA, V101, P13738, DOI 10.1073/pnas.0406048101; Ley RD, 1997, CANCER RES, V57, P3682; LOMMEL L, 1993, MOL CELL BIOL, V13, P970, DOI 10.1128/MCB.13.2.970; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mathonnet R, 2003, P NATL ACAD SCI USA, V100, P7219, DOI 10.1073/pnas.123216100; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1990, J BIOL CHEM, V265, P5353; Mitchell DL, 2001, J INVEST DERMATOL, V116, P209, DOI 10.1046/j.1523-1747.2001.01192.x; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Mouret S, 2006, P NATL ACAD SCI USA, V103, P13765, DOI 10.1073/pnas.0604213103; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Otoshi E, 2000, CANCER RES, V60, P1729; Palmer CM, 1997, PHOTOCHEM PHOTOBIOL, V65, P543, DOI 10.1111/j.1751-1097.1997.tb08602.x; Pascucci B, 1997, J MOL BIOL, V273, P417, DOI 10.1006/jmbi.1997.1268; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; Perdiz D, 2000, J BIOL CHEM, V275, P26732; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; PFLAUM M, 1994, CARCINOGENESIS, V15, P297, DOI 10.1093/carcin/15.2.297; Piccinin S, 1997, INT J CANCER, V74, P26, DOI 10.1002/(SICI)1097-0215(19970220)74:1<26::AID-IJC5>3.0.CO;2-2; Platz A, 1996, BRIT J CANCER, V73, P344, DOI 10.1038/bjc.1996.59; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; RAO SN, 1985, PHOTOCHEM PHOTOBIOL, V42, P465, DOI 10.1111/j.1751-1097.1985.tb01596.x; Ratner D, 2001, J AM ACAD DERMATOL, V44, P293, DOI 10.1067/mjd.2001.112361; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Riou L, 2004, CANCER RES, V64, P889, DOI 10.1158/0008-5472.CAN-03-2070; Robert C, 1996, J INVEST DERMATOL, V106, P721, DOI 10.1111/1523-1747.ep12345616; Rochette PJ, 2003, NUCLEIC ACIDS RES, V31, P2786, DOI 10.1093/nar/gkg402; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Ruiz A, 1998, INT J CANCER, V76, P312, DOI 10.1002/(SICI)1097-0215(19980504)76:3<312::AID-IJC4>3.3.CO;2-B; RUVEN HJT, 1994, ONCOGENE, V9, P3427; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; Spencer JPE, 1996, BIOCHEM BIOPH RES CO, V224, P17, DOI 10.1006/bbrc.1996.0977; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; Tommasi S, 1997, CANCER RES, V57, P4727; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; Tung BS, 1996, MUTAT RES-DNA REPAIR, V362, P65, DOI 10.1016/0921-8777(95)00034-8; Unden AB, 1996, CANCER RES, V56, P4562; van der Wees CGC, 2003, DNA REPAIR, V2, P1297, DOI 10.1016/j.dnarep.2003.06.001; vanElsas A, 1996, AM J PATHOL, V149, P883; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VREESWIJK MPG, 1994, J BIOL CHEM, V269, P31858; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Wolter M, 1997, CANCER RES, V57, P2581; Woodhead A D, 1999, J Epidemiol, V9, pS102; Woollons A, 1999, BRIT J DERMATOL, V140, P1023; Xie JW, 1997, CANCER RES, V57, P2369; YAJIMA H, 1995, EMBO J, V14, P2393, DOI 10.1002/j.1460-2075.1995.tb07234.x; Yoon JH, 2004, CANCER RES, V64, P7321, DOI 10.1158/0008-5472.CAN-04-1094; Yoon JH, 2001, CANCER RES, V61, P7110; Zhang H, 2001, AM J PATHOL, V158, P381, DOI 10.1016/S0002-9440(10)63980-6	123	55	56	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2379	2392		10.1096/fj.07-105437	http://dx.doi.org/10.1096/fj.07-105437			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18326785	Green Accepted			2022-12-28	WOS:000257292500030
J	Herczenik, E; Gebbink, MFBG				Herczenik, Eszter; Gebbink, Martijn F. B. G.			Molecular and cellular aspects of protein misfolding and disease	FASEB JOURNAL			English	Review						protein structure; aggregation; amyloid; Alzheimer's disease; atherosclerosis; therapy	AMYLOID-P-COMPONENT; LOW-DENSITY-LIPOPROTEIN; TISSUE-PLASMINOGEN-ACTIVATOR; GLYCATION END-PRODUCTS; RECEPTOR-RELATED PROTEIN; EXTRACELLULAR CHAPERONE CLUSTERIN; TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; PHOSPHATIDYLSERINE-CONTAINING MEMBRANES; HEREDITARY CEREBRAL-HEMORRHAGE; AMYOTROPHIC-LATERAL-SCLEROSIS	Proteins are essential elements for life. They are building blocks of all organisms and the operators of cellular functions. Humans produce a repertoire of at least 30,000 different proteins, each with a different role. Each protein has its own unique sequence and shape (native conformation) to fulfill its specific function. The appearance of incorrectly shaped (misfolded) proteins occurs on exposure to environmental changes. Protein misfolding and the subsequent aggregation is associated with various, often highly debilitating, diseases for which no sufficient cure is available yet. In the first part of this review we summarize the structural composition of proteins and the current knowledge of underlying forces that lead proteins to lose their native structure. In the second and third parts we describe the molecular and cellular mechanisms that are associated with protein misfolding in disease. Finally, in the last part we portray recent efforts to develop treatments for protein misfolding diseases.	[Herczenik, Eszter; Gebbink, Martijn F. B. G.] Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Lab Thrombosis & Haemostasis, NL-3584 CX Utrecht, Netherlands; [Gebbink, Martijn F. B. G.] Crossbeta Biosci BV, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Gebbink, MFBG (corresponding author), Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Lab Thrombosis & Haemostasis, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	m.gebbink@umcutrecht.nl						Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; Aguzzi A, 2006, NAT REV MICROBIOL, V4, P765, DOI 10.1038/nrmicro1492; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; ASTBURY WILLIAM THOMAS, 1935, BIOCHEM JOUR, V29, P2351; Azuaga AI, 2002, EUR J BIOCHEM, V269, P4121, DOI 10.1046/j.1432-1033.2002.03107.x; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Belcher P. R., 2006, Cardiovascular & Hematological Disorders - Drug Targets, V6, P43; Benson MD, 2001, GENOMICS, V72, P272, DOI 10.1006/geno.2000.6499; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; BETSUYAKU T, 1993, INTERNAL MED, V32, P391, DOI 10.2169/internalmedicine.32.391; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Blanquet-Grossard F, 2005, BIOCHEMISTRY-US, V44, P4349, DOI 10.1021/bi047370a; Bouma B, 2003, J BIOL CHEM, V278, P41810, DOI 10.1074/jbc.M303925200; BOWLING AC, 1995, J NEUROCHEM, V64, P2366; Broytman O, 2004, J NEUROSCI RES, V75, P301, DOI 10.1002/jnr.10876; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bucciantini M, 2004, FASEB J, V18, P437, DOI 10.1096/fj.04-3086fje; Butko P, 2001, BIOCHEM BIOPH RES CO, V280, P212, DOI 10.1006/bbrc.2000.4098; Buxbaum Joel N., 2004, Current Opinion in Rheumatology, V16, P67, DOI 10.1097/00002281-200401000-00013; Cacquevel M, 2007, NEUROBIOL DIS, V27, P164, DOI 10.1016/j.nbd.2007.04.004; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Carneiro FA, 2001, J BIOL CHEM, V276, P62, DOI 10.1074/jbc.M008753200; Carroll L, 2006, WIEN MED WOCHENSCHR, V156, P42, DOI 10.1007/s10354-005-0242-9; Casserly I, 2004, LANCET, V363, P1139, DOI 10.1016/S0140-6736(04)15900-X; Chan JCC, 2005, BIOCHEMISTRY-US, V44, P10669, DOI 10.1021/bi050724t; Chaney MO, 1998, PROTEIN ENG, V11, P761, DOI 10.1093/protein/11.9.761; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Chen MJ, 2002, PHARMACOL THERAPEUT, V95, P89, DOI 10.1016/S0163-7258(02)00236-X; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; ChoiMiura NH, 1996, NEUROBIOL AGING, V17, P717; Ciabattoni G, 2007, NEUROBIOL AGING, V28, P336, DOI 10.1016/j.neurobiolaging.2005.12.011; Cohen I, 1979, Methods Achiev Exp Pathol, V9, P40; COYNE JD, 1993, HISTOPATHOLOGY, V22, P173, DOI 10.1111/j.1365-2559.1993.tb00098.x; Davies TA, 2000, AMYLOID, V7, P153, DOI 10.3109/13506120009146830; De Felice FG, 2004, FASEB J, V18, P1099, DOI 10.1096/fj.03-1072fje; de Haas CJC, 2000, INFECT IMMUN, V68, P1753, DOI 10.1128/IAI.68.4.1753-1759.2000; de Haas CJC, 1999, FEMS IMMUNOL MED MIC, V26, P197, DOI 10.1016/S0928-8244(99)00148-0; De Jong KL, 2006, BIOPHYS J, V91, P1905, DOI 10.1529/biophysj.105.077438; Deane R, 2004, STROKE, V35, P2628, DOI 10.1161/01.STR.0000143452.85382.d1; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Doyle R, 1997, PROTEINS, V29, P282, DOI 10.1002/(SICI)1097-0134(199711)29:3<282::AID-PROT3>3.0.CO;2-D; DuClos TW, 1996, MOL BIOL REP, V23, P253, DOI 10.1007/BF00351177; Duerrschmidt N, 2006, ENDOCRINOLOGY, V147, P3851, DOI 10.1210/en.2006-0088; Duryee MJ, 2005, MOL PHARMACOL, V68, P1423, DOI 10.1124/mol.105.016121; East E, 2005, AM J PATHOL, V167, P545, DOI 10.1016/S0002-9440(10)62996-3; Eisenberg D, 2006, ACCOUNTS CHEM RES, V39, P568, DOI 10.1021/ar0500618; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; EULITZ M, 1990, P NATL ACAD SCI USA, V87, P6542, DOI 10.1073/pnas.87.17.6542; Famularo G, 2007, WORLD J GASTROENTERO, V13, P1286, DOI 10.3748/wjg.v13.i8.1286; Fan HH, 2007, MOL PHARMACEUT, V4, P232, DOI 10.1021/mp060097h; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Febbraio M, 2007, INT J BIOCHEM CELL B, V39, P2012, DOI 10.1016/j.biocel.2007.03.012; Finch CE, 2007, CURR ALZHEIMER RES, V4, P185, DOI 10.2174/156720507780362254; Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004; Fowler DM, 2007, TRENDS BIOCHEM SCI, V32, P217, DOI 10.1016/j.tibs.2007.03.003; Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024; Fukuhara-Takaki K, 2005, J BIOL CHEM, V280, P3355, DOI 10.1074/jbc.M408715200; Galle J, 2006, ATHEROSCLEROSIS, V185, P219, DOI 10.1016/j.atherosclerosis.2005.10.005; Gebbink MFBG, 2005, NAT REV MICROBIOL, V3, P333, DOI 10.1038/nrmicro1127; Genschel J, 1998, FEBS LETT, V430, P145, DOI 10.1016/S0014-5793(98)00668-1; Geroldi D, 2006, CURR MED CHEM, V13, P1971, DOI 10.2174/092986706777585013; GERTZ HJ, 1994, BRAIN RES, V637, P339, DOI 10.1016/0006-8993(94)91257-2; Gertz MA, 2004, BLOOD REV, V18, P17, DOI 10.1016/S0268-960X(03)00027-4; Gertz Morie A, 2002, Curr Treat Options Oncol, V3, P261, DOI 10.1007/s11864-002-0016-1; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; Giri K, 2007, BIOPHYS J, V92, P293, DOI 10.1529/biophysj.106.091769; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Golde Todd E., 2006, Current Alzheimer Research, V3, P421, DOI 10.2174/156720506779025189; Goni F, 2005, NEUROSCIENCE, V133, P413, DOI 10.1016/j.neuroscience.2005.02.031; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Graff-Radford NR, 2007, SEMIN NEUROL, V27, P48, DOI 10.1055/s-2006-956755; Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200; Greenberg ME, 2006, J EXP MED, V203, P2613, DOI 10.1084/jem.20060370; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Grimm MOW, 2005, NAT CELL BIOL, V7, P1118, DOI 10.1038/ncb1313; GUDMUNDSSON G, 1972, BRAIN, V95, P387, DOI 10.1093/brain/95.2.387; Hainfellner JA, 1999, ACTA NEUROPATHOL, V98, P458, DOI 10.1007/s004010051109; Halligan CS, 2006, AMYLOID, V13, P31, DOI 10.1080/13506120500537285; HAMIDI AL, 1997, BLOOD, V90, P4799; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Harrison RS, 2007, REV PHYSIOL BIOCH P, V159, P1, DOI 10.1007/112_2007_0701; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HASEGAWA M, 1995, NEPHRON, V69, P380, DOI 10.1159/000188506; Hausfater P, 2005, SCAND J RHEUMATOL, V34, P315, DOI 10.1080/03009740510015203; Hawkins PN, 2003, J NEPHROL, V16, P443; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; Hazenberg BPC, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.08.043; Head E, 2004, CURR OPIN NEUROL, V17, P95, DOI 10.1097/00019052-200404000-00003; Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017; Herczenik E, 2007, ARTERIOSCL THROM VAS, V27, P1657, DOI 10.1161/ATVBAHA.107.143479; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Hoffner G, 2002, BIOCHIMIE, V84, P273, DOI 10.1016/S0300-9084(02)01398-6; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; HOLMSEN H, 1989, ANN MED, V21, P23, DOI 10.3109/07853898909149178; Holton JL, 2002, J NEUROPATH EXP NEUR, V61, P254, DOI 10.1093/jnen/61.3.254; Holton JL, 2001, AM J PATHOL, V158, P515, DOI 10.1016/S0002-9440(10)63993-4; Horiuchi S, 2003, AMINO ACIDS, V25, P283, DOI 10.1007/s00726-003-0029-5; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Hou X, 2007, FEBS J, V274, P1637, DOI 10.1111/j.1742-4658.2007.05712.x; Howlett GJ, 2006, CURR OPIN LIPIDOL, V17, P541, DOI 10.1097/01.mol.0000245260.63505.4f; Huang THJ, 2000, J BIOL CHEM, V275, P36436, DOI 10.1074/jbc.M005698200; Humphries SE, 2004, LANCET NEUROL, V3, P227, DOI 10.1016/S1474-4422(04)00708-2; Husmann M, 2007, EXPERT OPIN INV DRUG, V16, P563, DOI 10.1517/13543784.16.5.563; Iametti S, 1996, EUR J BIOCHEM, V237, P106, DOI 10.1111/j.1432-1033.1996.0106n.x; Imbimbo BP, 2002, ANN NEUROL, V51, P794, DOI 10.1002/ana.10218; Ishino S, 2007, ATHEROSCLEROSIS, V195, P48, DOI 10.1016/j.atherosclerosis.2006.11.031; Iwatsubo T, 2003, J NEUROL, V250, P11, DOI 10.1007/s00415-003-1303-x; Jahn TR, 2005, FEBS J, V272, P5962, DOI 10.1111/j.1742-4658.2005.05021.x; Jansen R, 2004, J MOL BIOL, V338, P203, DOI 10.1016/j.jmb.2004.02.056; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; JIANG HX, 1994, J IMMUNOL, V152, P5050; JOHNSON KH, 1989, NEW ENGL J MED, V321, P513; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; Jurk K, 2005, SEMIN THROMB HEMOST, V31, P381, DOI 10.1055/s-2005-916671; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P1, DOI 10.1016/j.coi.2006.11.018; KACZMAREK E, 1993, J BIOL CHEM, V268, P2474; Kakutani M, 2000, P NATL ACAD SCI USA, V97, P360, DOI 10.1073/pnas.97.1.360; Kallijarvi J, 2001, BIOCHEMISTRY-US, V40, P10032, DOI 10.1021/bi002095n; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly JW, 2003, J CELL BIOL, V161, P461, DOI 10.1083/jcb.200304074; Kenney JM, 2002, EUR J BIOCHEM, V269, P4159, DOI 10.1046/j.1432-1033.2002.03112.x; Khurana R, 2004, ENDOCRINOLOGY, V145, P5465, DOI 10.1210/en.2004-0780; KIEFFER N, 1988, BIOCHIM BIOPHYS ACTA, V967, P408, DOI 10.1016/0304-4165(88)90104-3; Kirfel G, 2002, EUR J CELL BIOL, V81, P664, DOI 10.1078/0171-9335-00284; Kisilevsky R, 2007, AMYLOID, V14, P21, DOI 10.1080/13506120601116419; Kiuru S, 1998, AMYLOID, V5, P55, DOI 10.3109/13506129809007291; Klintworth GK, 1997, INVEST OPHTH VIS SCI, V38, P2756; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; Koga H, 2006, EUR HEART J, V27, P817, DOI 10.1093/eurheartj/ehi746; Korporaal SJA, 2005, ARTERIOSCL THROM VAS, V25, P867, DOI 10.1161/01.ATV.0000158381.02640.4b; Kourie JI, 2002, CLIN EXP PHARMACOL P, V29, P741, DOI 10.1046/j.1440-1681.2002.03737.x; KOWALSKA MA, 1994, BIOCHEM BIOPH RES CO, V205, P1829, DOI 10.1006/bbrc.1994.2883; Kranenburg O, 2005, NEUROSCIENCE, V131, P877, DOI 10.1016/j.neuroscience.2004.11.044; Kranenburg O, 2002, CURR BIOL, V12, P1833, DOI 10.1016/S0960-9822(02)01224-1; Kudryashova EV, 2003, EUR BIOPHYS J BIOPHY, V32, P553, DOI 10.1007/s00249-003-0301-3; Kujiraoka T, 2006, J ATHEROSCLER THROMB, V13, P314, DOI 10.5551/jat.13.314; Kumita JR, 2007, J MOL BIOL, V369, P157, DOI 10.1016/j.jmb.2007.02.095; Lahera V, 2007, CURR MED CHEM, V14, P243, DOI 10.2174/092986707779313381; Laidman J, 2006, ACCOUNTS CHEM RES, V39, P576, DOI 10.1021/ar050017s; Lam MCW, 2004, ATHEROSCLEROSIS, V177, P313, DOI 10.1016/j.atherosclerosis.2004.08.003; Lashuel H. A., 2005, SCI AGING KNOWLEDGE, V2005, pe28; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; LEOPOLD PE, 1992, P NATL ACAD SCI USA, V89, P8721, DOI 10.1073/pnas.89.18.8721; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LI XA, 1995, ARTERIOSCL THROM VAS, V15, P252, DOI 10.1161/01.ATV.15.2.252; Li Y, 2001, AM J PHYSIOL-HEART C, V280, pH1480, DOI 10.1152/ajpheart.2001.280.4.H1480; Liang CP, 2007, CIRC RES, V100, P1546, DOI 10.1161/CIRCRESAHA.107.152165; Liko I, 2007, NEUROSCI LETT, V412, P51, DOI 10.1016/j.neulet.2006.10.052; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Linding R, 2004, J MOL BIOL, V342, P345, DOI 10.1016/j.jmb.2004.06.088; Lindorff-Larsen K, 2005, TRENDS BIOCHEM SCI, V30, P13, DOI 10.1016/j.tibs.2004.11.008; Linke RP, 2005, J LAB CLIN MED, V145, P187, DOI 10.1016/j.lab.2005.02.002; Litvinovich SV, 1998, J MOL BIOL, V280, P245, DOI 10.1006/jmbi.1998.1863; Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; Manuelidis L, 1997, SCIENCE, V277, P94, DOI 10.1126/science.277.5322.94; Matsubara E, 2002, ANN NY ACAD SCI, V977, P340, DOI 10.1111/j.1749-6632.2002.tb04836.x; Medina MG, 2005, EMBO J, V24, P1706, DOI 10.1038/sj.emboj.7600650; Meehan S, 2004, J BIOL CHEM, V279, P3413, DOI 10.1074/jbc.M308203200; Melchor JP, 2005, THROMB HAEMOSTASIS, V93, P655, DOI 10.1160/TH04-12-0838; Meredith SC, 2005, ANN NY ACAD SCI, V1066, P181, DOI 10.1196/annals.1363.030; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Merlini G, 2001, CLIN CHEM LAB MED, V39, P1065, DOI 10.1515/CCLM.2001.172; Messier C, 1996, BEHAV BRAIN RES, V75, P1, DOI 10.1016/0166-4328(95)00153-0; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; Misra A, 2000, J CARDIOVASC RISK, V7, P215; Mitchell MD, 2007, AM J PHYSIOL-HEART C, V292, pH1139, DOI 10.1152/ajpheart.00881.2005; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; Miyazaki A, 2002, TRENDS CARDIOVAS MED, V12, P258, DOI 10.1016/S1050-1738(02)00171-8; Morais-de-Sa E, 2006, ACTA CRYSTALLOGR D, V62, P512, DOI 10.1107/S0907444906006962; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Mukaetova-Ladinska EB, 2000, J NEUROPATH EXP NEUR, V59, P408, DOI 10.1093/jnen/59.5.408; Murayama M, 1972, Adv Exp Med Biol, V28, P243; Necula M, 2007, J BIOL CHEM, V282, P10311, DOI 10.1074/jbc.M608207200; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Obici L, 2005, BBA-PROTEINS PROTEOM, V1753, P11, DOI 10.1016/j.bbapap.2005.08.014; Ohashi K, 2001, PATHOL INT, V51, P1, DOI 10.1046/j.1440-1827.2001.01156.x; Ohhashi Y, 2005, J BIOL CHEM, V280, P32843, DOI 10.1074/jbc.M506501200; Okamura DM, 2007, AM J PHYSIOL-RENAL, V293, pF575, DOI 10.1152/ajprenal.00063.2007; ONO K, 1994, NEPHRON, V66, P404, DOI 10.1159/000187854; Palladini G, 2006, SWISS MED WKLY, V136, P715; Palsdottir A, 2006, BRAIN PATHOL, V16, P55; Partridge SR, 1996, INFECT IMMUN, V64, P4324, DOI 10.1128/IAI.64.10.4324-4329.1996; PEPYS MB, 1994, CLIN EXP IMMUNOL, V97, P152; PETERSEN LC, 1994, FEBS LETT, V338, P53, DOI 10.1016/0014-5793(94)80115-0; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Platt N, 1999, IMMUNOL LETT, V65, P15, DOI 10.1016/S0165-2478(98)00118-7; Raghuraman H, 2006, BIOPOLYMERS, V83, P111, DOI 10.1002/bip.20536; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Rattan SIS, 2004, ANN NY ACAD SCI, V1019, P554, DOI 10.1196/annals.1297.103; Ridker, 1994, J Thromb Thrombolysis, V1, P35, DOI 10.1007/BF01061993; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rocken C, 2006, ARTERIOSCL THROM VAS, V26, P676, DOI 10.1161/01.ATV.0000201930.10103.be; Roher AE, 2000, BBA-MOL BASIS DIS, V1502, P31, DOI 10.1016/S0925-4439(00)00030-2; Rostagno A, 2007, J NEUROL SCI, V257, P88, DOI 10.1016/j.jns.2007.01.050; Rousseau F, 2006, CURR OPIN STRUC BIOL, V16, P118, DOI 10.1016/j.sbi.2006.01.011; Ruben GC, 1997, SYNAPSE, V27, P208, DOI 10.1002/(SICI)1098-2396(199711)27:3<208::AID-SYN7>3.0.CO;2-H; RUDALL KM, 1952, ADV PROTEIN CHEM, V7, P253, DOI 10.1016/S0065-3233(08)60020-0; Sawaya MR, 2007, NATURE, V447, P453, DOI 10.1038/nature05695; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schladitz C, 1999, BIOPHYS J, V77, P3305, DOI 10.1016/S0006-3495(99)77161-4; Schmidt A M, 2000, Curr Atheroscler Rep, V2, P430, DOI 10.1007/s11883-000-0082-4; Schmitt HP, 2006, MED HYPOTHESES, V66, P898, DOI 10.1016/j.mehy.2005.11.016; Schmitz A, 2002, HISTOCHEM CELL BIOL, V117, P171, DOI 10.1007/s00418-001-0351-5; Shimaoka T, 2001, J IMMUNOL, V166, P5108, DOI 10.4049/jimmunol.166.8.5108; Siddiqui FA, 2002, PLATELETS, V13, P247, DOI 10.1080/09537100220146398; Sigurdsson EM, 2002, AM J PATHOL, V161, P13, DOI 10.1016/S0002-9440(10)64151-X; Skoog I, 2006, NEUROL RES, V28, P605, DOI 10.1179/016164106X130506; Skovronsky DM, 2001, J BIOL CHEM, V276, P17036, DOI 10.1074/jbc.M006285200; Solomon B, 2000, DRUGS TODAY, V36, P655, DOI 10.1358/dot.2000.36.9.593782; Solomon B, 2007, EXPERT OPIN INV DRUG, V16, P819, DOI 10.1517/13543784.16.6.819; Sorci G, 2004, J CELL PHYSIOL, V199, P274, DOI 10.1002/jcp.10462; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Sousa MM, 2001, AM J PATHOL, V159, P1993; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; Sparatore B, 2002, BIOCHEM J, V363, P529, DOI 10.1042/0264-6021:3630529; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stewart CR, 2007, BIOCHEMISTRY-US, V46, P5552, DOI 10.1021/bi602554z; Stewart CR, 2005, BIOCHEMISTRY-US, V44, P9108, DOI 10.1021/bi050497v; Stewart EM, 2007, BIOCHEMISTRY-US, V46, P1412, DOI 10.1021/bi062082v; Stix B, 2001, AM J PATHOL, V159, P561, DOI 10.1016/S0002-9440(10)61727-0; Stohs S J, 1995, J Basic Clin Physiol Pharmacol, V6, P205; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SUGIHARA K, 1992, BLOOD, V80, P2634; Suji G, 2004, BIOGERONTOLOGY, V5, P365, DOI 10.1007/s10522-004-3189-0; SUZUKI E, 1973, J MOL BIOL, V73, P275, DOI 10.1016/0022-2836(73)90329-X; Swift B, 2002, DIABETIC MED, V19, P881, DOI 10.1046/j.1464-5491.2002.07581.x; Tacnet-Delorme P, 2001, J IMMUNOL, V167, P6374, DOI 10.4049/jimmunol.167.11.6374; Tan KT, 2005, DIABETIC MED, V22, P1657, DOI 10.1111/j.1464-5491.2005.01707.x; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; Thomas CA, 2000, J EXP MED, V191, P147, DOI 10.1084/jem.191.1.147; Thorne RF, 2007, FEBS LETT, V581, P1227, DOI 10.1016/j.febslet.2007.02.043; Tiwari A, 2006, EXPERT OPIN DRUG SAF, V5, P651, DOI 10.1517/14740338.5.5.651; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Tserentsoodol N, 2006, MOL VIS, V12, P1319; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsubuki S, 2003, LANCET, V361, P1957, DOI 10.1016/S0140-6736(03)13555-6; Tucker HM, 2000, J NEUROCHEM, V75, P2172, DOI 10.1046/j.1471-4159.2000.0752172.x; Tucker HM, 2000, J NEUROSCI, V20, P3937; Urbanyi Z, 2003, BRAIN RES, V988, P69, DOI 10.1016/S0006-8993(03)03345-6; Ursini F, 2002, TRENDS MOL MED, V8, P370, DOI 10.1016/S1471-4914(02)02382-1; van OOsten M, 2001, J ENDOTOXIN RES, V7, P381, DOI 10.1177/09680519010070050601; Veerhuis R, 2005, CNS NEUROL DISORD-DR, V4, P235, DOI 10.2174/1568007054038184; Vetri V, 2007, BIOPHYS CHEM, V125, P184, DOI 10.1016/j.bpc.2006.07.012; Vieira MNN, 2006, CELL BIOCHEM BIOPHYS, V44, P549, DOI 10.1385/CBB:44:3:549; Westergaard UB, 2003, EUR J BIOCHEM, V270, P1850, DOI 10.1046/j.1432-1033.2003.03549.x; Wetzel R, 2006, ACCOUNTS CHEM RES, V39, P671, DOI 10.1021/ar050069h; White JT, 2001, P NATL ACAD SCI USA, V98, P13019, DOI 10.1073/pnas.241406698; Wickner RB, 2007, NAT REV MICROBIOL, V5, P611, DOI 10.1038/nrmicro1708; Wilcock DM, 2006, NAT PROTOC, V1, P1591, DOI 10.1038/nprot.2006.277; Williams Michael D, 2007, Curr Diab Rep, V7, P242, DOI 10.1007/s11892-007-0038-y; Yan SD, 2000, NAT MED, V6, P643, DOI 10.1038/76216; Yan SD, 1998, RESTOR NEUROL NEUROS, V12, P167; Yan Shi Fang, 2006, Curr Atheroscler Rep, V8, P232, DOI 10.1007/s11883-006-0078-9; Yang G, 2004, CANCER RES, V64, P2076, DOI 10.1158/0008-5472.CAN-03-4072; Yerbury JJ, 2007, FASEB J, V21, P2312, DOI 10.1096/fj.06-7986com; Zahedi K, 1997, J BIOL CHEM, V272, P2143; Zerbinatti CV, 2005, REV NEUROSCIENCE, V16, P123; Zhao HX, 2005, BIOCHEMISTRY-US, V44, P2857, DOI 10.1021/bi048510j; Zhao HX, 2004, BIOCHEMISTRY-US, V43, P10302, DOI 10.1021/bi049002c; Zhou YN, 2006, BIOCHEM BIOPH RES CO, V350, P860, DOI 10.1016/j.bbrc.2006.09.103; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200; Zhu X, 2007, CELL MOL LIFE SCI, V64, P2202, DOI 10.1007/s00018-007-7218-4	278	142	144	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2115	2133		10.1096/fj.07-099671	http://dx.doi.org/10.1096/fj.07-099671			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18303094				2022-12-28	WOS:000257292500004
J	Shin, DM; Jeon, JH; Kim, CW; Cho, SY; Lee, HJ; Jang, GY; Jeong, EM; Lee, DS; Kang, JH; Melino, G; Park, SC; Kim, IG				Shin, Dong-Myung; Jeon, Ju-Hong; Kim, Chai-Wan; Cho, Sung-Yup; Lee, Hye-Jin; Jang, Gi-Yong; Jeong, Eui Man; Lee, Dong-Sup; Kang, Ja-Heon; Melino, Gerry; Park, Sang-Chul; Kim, In-Gyu			TGF beta mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation	FASEB JOURNAL			English	Article						aging; cataract; protein modification	GROWTH-FACTOR-BETA; CROSS-LINKING ENZYMES; TRANSFORMING GROWTH-FACTOR-BETA-1; SIGNALING PATHWAY; SMAD PROTEINS; CELL-DEATH; CATARACT; INHIBITION; DISRUPTION; MECHANISMS	Transglutaminase 2 (TGase2) is a ubiquitously expressed enzyme that catalyzes irreversible post-translational modification of protein, forming cross-linked protein aggregates. We previously reported that intracellular TGase2 is activated by oxidative stress. To elucidate the functional role of TGase2 activation in cells under the oxidatively stressed condition, we identified the mediator that activates TGase2. In this study, we showed that low levels of oxidative stress trigger the release of TGF beta, which subsequently activates TGase2 through the nuclear translocation of Smad3. Analysis of substrate proteins reveals that TGase2-mediated protein modification results in a decrease of protein solubility and a collapse of intermediate filament network, which leads to aggregation of proteins. We confirm these results using lens tissues from TGase2-deficient mice. Among several antioxidants tried, only N-acetylcysteine effectively inhibits TGF beta-mediated activation of TGase2. These results indicate that TGF beta mediates oxidative stress-induced protein aggregation through activation of TGase2 and suggest that the formation of protein aggregation may not be a passive process of self-assembly of oxidatively damaged proteins but may be an active cellular response to oxidative stress. Therefore, TGF beta-TGase2 pathway may have implications for both the pathogenesis of age-related degenerative diseases and the development of pharmaceutics.	[Shin, Dong-Myung; Kim, Chai-Wan; Cho, Sung-Yup; Lee, Hye-Jin; Jang, Gi-Yong; Jeong, Eui Man; Park, Sang-Chul; Kim, In-Gyu] Seoul Natl Univ, Coll Med, AARC, Dept Biochem & Mol Biol, Seoul 110799, South Korea; [Jeon, Ju-Hong] Seoul Natl Univ, Coll Med, Dept Physiol & Biophys, Seoul 110799, South Korea; [Lee, Hye-Jin] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea; [Kang, Ja-Heon] Kyung Hee Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea; [Melino, Gerry] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Kyung Hee University; University of Rome Tor Vergata	Kim, IG (corresponding author), Seoul Natl Univ, Coll Med, AARC, Dept Biochem & Mol Biol, 28 Yongon Dong, Seoul 110799, South Korea.	igkim@plaza.snu.ac.kr	Jeon, Ju-Hong/D-5740-2012; Lee, Dong-Sup/J-2777-2012; Kim, In-Gyu/J-2747-2012	Jeon, Ju-Hong/0000-0002-5603-2955; Kim, Chai-Wan/0000-0001-5105-2829; Jeong, Eui Man/0000-0003-0692-2033	MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chiarelli F, 2000, HORM RES, V53, P53, DOI 10.1159/000023515; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Debacq-Chainlaux F, 2005, J CELL SCI, V118, P743, DOI 10.1242/jcs.01651; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Guh JY, 2003, KIDNEY INT, V64, P2041, DOI 10.1046/j.1523-1755.2003.00330.x; Haddad JJ, 2002, BIOCHEM BIOPH RES CO, V296, P847, DOI 10.1016/S0006-291X(02)00947-6; Hagiwara S, 2000, AM J RESP CRIT CARE, V162, P225, DOI 10.1164/ajrccm.162.1.9903129; HALES AM, 1995, INVEST OPHTH VIS SCI, V36, P1709; Hammond CJ, 2000, NEW ENGL J MED, V342, P1786, DOI 10.1056/NEJM200006153422404; Hoehenwarter W, 2006, AMINO ACIDS, V30, P369, DOI 10.1007/s00726-005-0283-9; Ichinose A, 2001, THROMB HAEMOSTASIS, V86, P57; Jeon JH, 2004, EXP MOL MED, V36, P576, DOI 10.1038/emm.2004.74; Jeon JH, 2003, EMBO J, V22, P5273, DOI 10.1093/emboj/cdg495; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Menko AS, 2002, EXP EYE RES, V75, P485, DOI 10.1006/exer.2002.2057; Miller BA, 2006, J MEMBRANE BIOL, V209, P31, DOI 10.1007/s00232-005-0839-3; MUKHERJEE DC, 1983, SCIENCE, V219, P989, DOI 10.1126/science.6130601; O'Brian CA, 2005, FREE RADICAL RES, V39, P471, DOI 10.1080/10715760500073931; Park BJ, 2000, CANCER RES, V60, P3031; Robman L, 2005, EYE, V19, P1074, DOI 10.1038/sj.eye.6701964; Saika S, 2006, LAB INVEST, V86, P106, DOI 10.1038/labinvest.3700375; Sanderson J, 2000, INVEST OPHTH VIS SCI, V41, P2255; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shin Joo-Ho, 2004, Proteome Sci, V2, P2, DOI 10.1186/1477-5956-2-2; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; Srinivasan Y, 1998, J CLIN INVEST, V101, P625, DOI 10.1172/JCI1360; Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003	41	52	52	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2498	2507		10.1096/fj.07-095455	http://dx.doi.org/10.1096/fj.07-095455			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18353867				2022-12-28	WOS:000257292500041
J	Nishida, K; Kamizato, M; Kawai, T; Masuda, K; Takeo, K; Teshima-Kondo, S; Tanahashi, T; Rokutan, K				Nishida, Kensei; Kamizato, Mai; Kawai, Tomoko; Masuda, Kiyoshi; Takeo, Keiko; Teshima-Kondo, Shigetada; Tanahashi, Toshihito; Rokutan, Kazuhito			Interleukin-18 is a crucial determinant of vulnerability of the mouse rectum to psychosocial stress	FASEB JOURNAL			English	Article						intestinal mucosal barrier; goblet cells; MUC2; inflammatory cytokines; Notch 1	IRRITABLE-BOWEL-SYNDROME; INDUCED COLITIS; CELLS; MUC2; INFLAMMATION; COLON; IL-18; DIFFERENTIATION; CANCER; CORTICOSTERONE	Psychosocial factors are important determinants of disease manifestations, treatment efficacy, and prognosis of functional and inflammatory bowel disorders. Isolation of C57BL/6J mice from their 4 brothers growing in the same cage reduced goblet cells and MUC2 expression with a peak on day 8 in the rectum, but not in the colon. Gene expression analysis using a whole mouse genome microarray showed that the stress induced a 10-fold larger change in the gene expression in the rectum (722 genes) than in the colon (72 genes). The Ingenuity Pathway Analysis (IPA) application organized the rectum-specific 711 genes into stress response-related pathways. Nuclear factor-kappa B-related cytokine networks constructed with IPA showed selective up-regulation of interleukin (IL)-18 mRNA expression, which was also confirmed by real-time polymerase chain reaction. The stress produced active forms of caspase 1, IL-18, and a negative regulator for goblet cells, Notch 1, only in the rectum. IL-18-knockout mouse rectum had significantly increased goblet cells and MUC2 mucin, compared with wild-type mouse rectum. The absence of IL-18 completely blocked the stress-induced changes in gene expression and the goblet cell responses in the rectum. Thus, IL-18 may be a crucial determinant for the vulnerability of the rectum to psychosocial stress.-Nishida, K., Kamizato, M., Kawai, T., Masuda, K., Takeo, K., Teshima-Kondo, S., Tanahashi, T., Rokutan, K. Interleukin-18 is a crucial determinant of vulnerability of the mouse rectum to psychosocial stress. FASEB J. 23, 1797-1805 (2009)	[Nishida, Kensei; Kamizato, Mai; Kawai, Tomoko; Masuda, Kiyoshi; Takeo, Keiko; Teshima-Kondo, Shigetada; Tanahashi, Toshihito; Rokutan, Kazuhito] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Stress Sci, Tokushima 7708503, Japan	Tokushima University	Rokutan, K (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Stress Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	rokutan16@basic.med.tokushima-u.ac.jp	Nishida, Kensei/AAF-2829-2020	Kawai, Tomoko/0000-0001-8137-0334; Nishida, Kensei/0000-0003-2314-785X				Bitton A, 2008, GUT, V57, P1386, DOI 10.1136/gut.2007.134817; Boraschi D, 2006, EUR CYTOKINE NETW, V17, P224; Bowers SL, 2008, BRAIN BEHAV IMMUN, V22, P105, DOI 10.1016/j.bbi.2007.07.012; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Castagliuolo I, 1998, AM J PHYSIOL-GASTR L, V274, pG1094, DOI 10.1152/ajpgi.1998.274.6.G1094; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Gareau MG, 2007, GUT, V56, P1522, DOI 10.1136/gut.2006.117176; HATCH A, 1963, SCIENCE, V142, P507, DOI 10.1126/science.142.3591.507; Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Ishikura T, 2003, J GASTROEN HEPATOL, V18, P960, DOI 10.1046/j.1440-1746.2003.03097.x; Katz JP, 2002, DEVELOPMENT, V129, P2619; Kawahara T, 2004, J IMMUNOL, V172, P3051, DOI 10.4049/jimmunol.172.5.3051; Kraneveld AD, 2008, EUR J PHARMACOL, V585, P361, DOI 10.1016/j.ejphar.2008.02.095; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; Ludwiczek O, 2005, EUR CYTOKINE NETW, V16, P27; Mawdsley JE, 2005, GUT, V54, P1481, DOI 10.1136/gut.2005.064261; Mawdsley JE, 2006, GASTROENTEROLOGY, V131, P410, DOI 10.1053/j.gastro.2006.05.017; Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Pfeiffer CJ, 2001, J PHYSIOLOGY-PARIS, V95, P81, DOI 10.1016/S0928-4257(01)00012-2; Ricci-Vitiani L, 2008, GUT, V57, P538, DOI 10.1136/gut.2007.127837; ROBERTSON DAF, 1989, GUT, V30, P623, DOI 10.1136/gut.30.5.623; Sekiyama A, 2005, IMMUNITY, V22, P669, DOI 10.1016/j.immuni.2005.04.006; Sivakumar PV, 2002, GUT, V50, P812, DOI 10.1136/gut.50.6.812; SOWDEN J, 1993, DIFFERENTIATION, V53, P67, DOI 10.1111/j.1432-0436.1993.tb00647.x; Spiller R, 2007, GUT, V56, P1770, DOI 10.1136/gut.2007.119446; Sugama S, 2008, BRAIN RES REV, V58, P85, DOI 10.1016/j.brainresrev.2007.11.003; Ten Hove T, 2001, GASTROENTEROLOGY, V121, P1372, DOI 10.1053/gast.2001.29579; Tytgat KMAJ, 1996, BIOCHEM BIOPH RES CO, V224, P397, DOI 10.1006/bbrc.1996.1039; Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Van Klinken BJW, 1999, GUT, V44, P387, DOI 10.1136/gut.44.3.387; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Wallon C, 2008, GUT, V57, P50, DOI 10.1136/gut.2006.117549; Wei EK, 2004, INT J CANCER, V108, P433, DOI 10.1002/ijc.11540; Weiss IC, 2004, BEHAV BRAIN RES, V152, P279, DOI 10.1016/j.bbr.2003.10.015; Wiercinska-Drapalo A, 2005, WORLD J GASTROENTERO, V11, P605, DOI 10.3748/wjg.v11.i4.605; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718	42	13	13	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1797	1805		10.1096/fj.08-125005	http://dx.doi.org/10.1096/fj.08-125005			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19141531				2022-12-28	WOS:000266652400020
J	Reddy, MK; Labhasetwar, V				Reddy, Maram K.; Labhasetwar, Vinod			Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury	FASEB JOURNAL			English	Article						antioxidant enzymes; blood-brain barrier; biodegradable polymers; sustained release; nanomedicine	FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; ARTERY OCCLUSION; RAT; PATHOPHYSIOLOGY; INFLAMMATION; THERAPY; ISCHEMIA/REPERFUSION; OVEREXPRESSION; ANTIOXIDANTS	Excessive production of reactive oxygen species (ROS) after cerebral ischemia and reperfusion is implicated in brain damage through different cellular and molecular mechanisms, and it is further aggravated by impaired cellular antioxidant defense systems under ischemic conditions. Therapeutic strategies based on exogenous delivery of the native form of superoxide dismutase (SOD), a free radical scavenger, are limited because of its short half-life (similar to 6 min) in vivo and poor permeability across the blood-brain-barrier (BBB). We encapsulated SOD in biodegradable poly(D, L-lactide co-glycolide) nanoparticles (SOD-NPs) and tested their efficacy in a rat focal cerebral ischemia-reperfusion injury model. We hypothesized that localized brain delivery of SOD-NPs would sustain the protective effect of SOD by neutralizing the deleterious effects of ROS formed following ischemia-reperfusion. SOD-NPs were administered at the time of reperfusion via the intracarotid route to maximize their localization in the brain. Animals receiving SOD-NPs (10,000 U of SOD/kg) demonstrated a 65% reduction in infarct volume, whereas an equivalent dose of SOD in solution (SOD-Sol) increased it by 25% over saline control (P<0.001; data at 6 h following reperfusion). Control NPs alone or mixed with SOD-Sol were ineffective in reducing infract volume, with results similar to saline control, indicating the protective effect of the encapsulated enzyme. SOD-NPs maintained BBB integrity, thereby preventing edema, reduced the level of ROS formed following reperfusion, and protected neurons from undergoing apoptosis. Animals treated with SOD-NPs demonstrated greater survival than those with saline control (75% vs. 0% at 28 days) and later regained most vital neurological functions. SOD-NPs may be an effective treatment option in conjunction with a thrombolytic agent for stroke patients.-Reddy, M. K., Labhasetwar, V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J. 23, 1384-1395 (2009)	[Reddy, Maram K.; Labhasetwar, Vinod] Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA; [Labhasetwar, Vinod] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA	Cleveland Clinic Foundation; University of Nebraska System; University of Nebraska Medical Center	Labhasetwar, V (corresponding author), Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, ND-20,9500 Euclid Ave, Cleveland, OH 44195 USA.	labhasv@ccf.org	Labhasetwar, Vinod/J-9660-2016	Labhasetwar, Vinod/0000-0001-7950-1542	University of Nebraska Medical Center, Omaha, NE	University of Nebraska Medical Center, Omaha, NE	This work was supported by grants from the Cleveland Clinic and a Technology Advancement grant from the University of Nebraska Medical Center, Omaha, NE (to V. L.). We thank Ms. Melissa Jedlicka for proofreading the manuscript.	Anderson HA, 2002, CELL DEATH DIFFER, V9, P616, DOI 10.1038/sj.cdd.4401013; Buonocore G, 2007, SEMIN FETAL NEONAT M, V12, P287, DOI 10.1016/j.siny.2007.01.020; Collard CD, 2001, ANESTHESIOLOGY, V94, P1133, DOI 10.1097/00000542-200106000-00030; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Davda J, 2002, INT J PHARM, V233, P51, DOI 10.1016/S0378-5173(01)00923-1; Davda J, 2005, J BIOMED NANOTECHNOL, V1, P74, DOI 10.1166/jbn.2005.010; Francis JW, 1997, EXP NEUROL, V146, P435, DOI 10.1006/exnr.1997.6547; Goldstein LB, 2007, CIRCULATION, V116, P1504, DOI 10.1161/CIRCULATIONAHA.106.670885; Goto H, 2007, J NEUROTRAUM, V24, P745, DOI 10.1089/neu.2006.0183; Gursoy-Ozdemir Y, 2000, STROKE, V31, P1974, DOI 10.1161/01.STR.31.8.1974; HAUN SE, 1991, STROKE, V22, P655, DOI 10.1161/01.STR.22.5.655; HE YY, 1993, AM J PHYSIOL, V265, pH252, DOI 10.1152/ajpheart.1993.265.1.H252; Heiss WD, 1999, STROKE, V30, P1486, DOI 10.1161/01.STR.30.7.1486; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; Juttler E, 2006, NAT CLIN PRACT CARD, V3, P656, DOI 10.1038/ncpcardio0721; Kim DW, 2005, MOL CELLS, V19, P88; Kitagawa K, 2001, J CEREBR BLOOD F MET, V21, P1199, DOI 10.1097/00004647-200110000-00008; Kuroda S, 1997, CLIN NEUROSCI, V4, P199; LABHASETWAR V, 2008, Patent No. 7332159; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Maier CM, 2006, ANN NEUROL, V59, P929, DOI 10.1002/ana.20850; Margaill I, 2005, FREE RADICAL BIO MED, V39, P429, DOI 10.1016/j.freeradbiomed.2005.05.003; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Muhl D, 2006, J THROMB THROMBOLYS, V22, P221, DOI 10.1007/s11239-006-9035-2; Pan J, 2007, NEURORADIOLOGY, V49, P93, DOI 10.1007/s00234-006-0183-z; Perera MN, 2006, J CLIN NEUROSCI, V13, P1, DOI 10.1016/j.jocn.2005.07.005; Plekhanova OS, 2006, B EXP BIOL MED+, V142, P304, DOI 10.1007/s10517-006-0352-4; Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378-5173(02)00315-0; Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004; Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; Saleh A, 2004, BRAIN, V127, P1670, DOI 10.1093/brain/awh191; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; Shimamura M, 2004, CIRCULATION, V109, P424, DOI 10.1161/01.CIR.0000109496.82683.49; Sinha J, 2001, BIOMED PHARMACOTHER, V55, P264, DOI 10.1016/S0753-3322(01)00060-9; SLIVKA A, 1995, STROKE, V26, P1061, DOI 10.1161/01.STR.26.6.1061; Smi CK, 2004, DEV BRAIN RES, V152, P11, DOI [10.1016/j.devbrainres.2004.05.004, 10.1016/j.debrainres.2004.05.004]; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Tsubokawa T, 2007, STROKE, V38, P1057, DOI 10.1161/01.STR.0000257978.70312.1d; Veronese FM, 2002, ADV DRUG DELIVER REV, V54, P587, DOI 10.1016/S0169-409X(02)00029-7; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Yasui K, 2006, INFLAMM RES, V55, P359, DOI 10.1007/s00011-006-5195-y; Zambaux MF, 1998, J CONTROL RELEASE, V50, P31, DOI 10.1016/S0168-3659(97)00106-5	46	199	214	3	63	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1384	1395		10.1096/fj.08-116947	http://dx.doi.org/10.1096/fj.08-116947			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19124559				2022-12-28	WOS:000266651700015
J	Sharkey, D; Gardner, DS; Fainberg, HP; Sebert, S; Bos, P; Wilson, V; Bell, R; Symonds, ME; Budge, H				Sharkey, Don; Gardner, David S.; Fainberg, Hernan P.; Sebert, Sylvain; Bos, Petra; Wilson, Vicky; Bell, Rhonda; Symonds, Michael E.; Budge, Helen			Maternal nutrient restriction during pregnancy differentially alters the unfolded protein response in adipose and renal tissue of obese juvenile offspring	FASEB JOURNAL			English	Article						endoplasmic reticulum; inflammation; fetus; metabolic syndrome	ENDOPLASMIC-RETICULUM STRESS; METABOLIC SYNDROME; DEVELOPMENTAL ORIGINS; MACROPHAGE INFILTRATION; GLUCOSE-HOMEOSTASIS; ADIPOCYTE DEATH; KIDNEY-DISEASE; ER STRESS; EXPRESSION; DIET	Maternal diet during pregnancy can program an offspring's risk of disease in later life. Obesity adversely alters renal and adipose tissue function, resulting in chronic kidney disease and insulin resistance, respectively, the latter associated with dysregulation of the unfolded protein response (UPR). In view of the current obesity epidemic, we explored the combined effects of in utero early-to midgestational nutrient restriction and postnatal obesity on the UPR in ovine juvenile offspring. Nutrient restriction was coincident with fetal kidney development but prior to exponential adipose tissue deposition. Nutrient restricted (NR) and normal diet (control) offspring were exposed to an obesogenic environment throughout adolescence, resulting in similar degrees of juvenile obesity. NR offspring showed enhanced adipose tissue dysregulation characterized by activation of the UPR, perturbed insulin signaling, and marked inflammation, as demonstrated by increased abundance of crownlike structures and proinflammatory genes. Conversely, in renal tissue NR offspring had marked attenuation of cellular stress and inflammation evident as reduced activation of the UPR, down-regulation of proinflammatory genes, and less histological damage. In conclusion, obesity-related activation of the UPR can be determined by the in utero nutritional environment, demonstrating organ-specific effects dependent on the developmental phase targeted within the fetus.-Sharkey, D., Gardner, D. S., Fainberg, H. P., Sebert, S., Bos, P., Wilson, V., Bell, R., Symonds, M. E., Budge, H. Maternal nutrient restriction during pregnancy differentially alters the unfolded protein response in adipose and renal tissue of obese juvenile offspring. FASEB J. 23, 1314-1324 (2009)	[Sharkey, Don; Fainberg, Hernan P.; Sebert, Sylvain; Bos, Petra; Wilson, Vicky; Symonds, Michael E.; Budge, Helen] Univ Nottingham, Inst Clin Res, Ctr Reprod & Early Life, Nottingham NG7 2RD, England; [Gardner, David S.] Univ Nottingham, Sch Vet Med & Sci, Loughborough, England; [Bell, Rhonda] Univ Alberta, Alberta Inst Human Nutr, Edmonton, AB, Canada	University of Nottingham; University of Nottingham; University of Alberta	Symonds, ME (corresponding author), Univ Hosp, Sch Clin Sci, Div Human Dev, E Floor E Block,Derby Rd, Nottingham NG7 2UH, England.	michael.symonds@nottingham.ac.uk	Gardner, David S/A-7484-2010; Fainberg, Hernan P/A-2449-2012; Fainberg, Hernan/GQZ-6651-2022	Gardner, David S/0000-0002-6490-2412; Sebert, Sylvain/0000-0001-6681-6983; Sharkey, Don/0000-0002-4989-8697; Fainberg, Hernan Pablo/0000-0001-9330-9047; Symonds, Michael/0000-0001-9649-8963; Bell, Rhonda C./0000-0002-4298-9641	British Heart Foundation [FS/05/098/19942, BS/03/01]; European Union Sixth Framework for Research and Technical Development of the European Community [FOOD-CT-2005-007036]; National Institute for Health Research [CL-2006-12-003] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); European Union Sixth Framework for Research and Technical Development of the European Community(European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was support by a British Heart Foundation clinical fellowship (D. S., FS/05/098/19942) and lectureship (D. S. G., BS/03/01) and the European Union Sixth Framework for Research and Technical Development of the European Community, the Early Nutrition Programming Project (FOOD-CT-2005-007036).	Alderman G., 1993, ENERGY PROTEIN REQUI; Bedard K, 2004, BASIC CLIN PHARMACOL, V94, P124, DOI 10.1111/j.1742-7843.2004.pto940305.x; Boden G, 2008, DIABETES, V57, P2438, DOI 10.2337/db08-0604; Bogacka I, 2005, DIABETES, V54, P1392, DOI 10.2337/diabetes.54.5.1392; Cameron AJ, 2004, ENDOCRIN METAB CLIN, V33, P351, DOI 10.1016/j.ecl.2004.03.005; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Dunphy J, 2001, VET IMMUNOL IMMUNOP, V82, P153, DOI 10.1016/S0165-2427(01)00356-7; Eckersall PD, 2008, BMC VET RES, V4, DOI 10.1186/1746-6148-4-1; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Gopalakrishnan GS, 2005, BRIT J NUTR, V94, P938, DOI 10.1079/BJN20051559; Gregor MF, 2007, J LIPID RES, V48, P1905, DOI 10.1194/jlr.R700007-JLR200; Hall JE, 1999, ANN NY ACAD SCI, V892, P91, DOI 10.1111/j.1749-6632.1999.tb07788.x; Harman-Boehm I, 2007, J CLIN ENDOCR METAB, V92, P2240, DOI 10.1210/jc.2006-1811; Henegar JR, 2001, J AM SOC NEPHROL, V12, P1211, DOI 10.1681/ASN.V1261211; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Inagi R, 2005, KIDNEY INT, V68, P2639, DOI 10.1111/j.1523-1755.2005.00736.x; Inagi R, 2008, J AM SOC NEPHROL, V19, P915, DOI 10.1681/ASN.2007070745; Ingelfinger JR, 2005, J AM SOC NEPHROL, V16, P2533, DOI 10.1681/ASN.2005060622; Johann AM, 2007, FASEB J, V21, P2704, DOI 10.1096/fj.06-7815com; Kaaman M, 2007, DIABETOLOGIA, V50, P2526, DOI 10.1007/s00125-007-0818-6; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kelishadi R, 2007, CLIN CHEM, V53, P456, DOI 10.1373/clinchem.2006.073668; KELLY T, 2008, INT J OBES IN PRESS; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Koh EH, 2007, DIABETES, V56, P2973, DOI 10.2337/db07-0510; Lomax MA, 2007, ENDOCRINOLOGY, V148, P461, DOI 10.1210/en.2006-0918; Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; Moritz KM, 2003, BIOESSAYS, V25, P212, DOI 10.1002/bies.10240; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Ozanne SE, 2007, NAT CLIN PRACT ENDOC, V3, P539, DOI 10.1038/ncpendmet0531; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pan Y, 2008, J AM DIET ASSOC, V108, P276, DOI 10.1016/j.jada.2007.10.049; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Plisov SY, 2000, GENESIS, V27, P22, DOI 10.1002/1526-968X(200005)27:1<22::AID-GENE40>3.3.CO;2-M; SEBERT SP, 2008, ENDOCRINOLO IN PRESS; Serra A, 2008, KIDNEY INT, V73, P947, DOI 10.1038/sj.ki.5002796; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Strissel KJ, 2007, DIABETES, V56, P2910, DOI 10.2337/db07-0767; Symonds ME, 2003, J ENDOCRINOL, V179, P293, DOI 10.1677/joe.0.1790293; Taylor PD, 2005, AM J PHYSIOL-REG I, V288, pR134, DOI 10.1152/ajpregu.00355.2004; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049; Westerbacka J, 2008, AM J PHYSIOL-ENDOC M, V294, pE841, DOI 10.1152/ajpendo.00653.2006; Williams PJ, 2007, KIDNEY INT, V72, P279, DOI 10.1038/sj.ki.5002276; Wood CE, 2005, AM J PHYSIOL-REG I, V289, pR613, DOI 10.1152/ajpregu.00722.2004; Zandi-Nejad K, 2006, HYPERTENSION, V47, P502, DOI 10.1161/01.HYP.0000198544.09909.1a; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	49	38	39	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1314	1324		10.1096/fj.08-114330	http://dx.doi.org/10.1096/fj.08-114330			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19103646				2022-12-28	WOS:000266651700008
J	Chandler, RJ; Zerfas, PM; Shanske, S; Sloan, J; Hoffmann, V; DiMauro, S; Venditti, CP				Chandler, Randy J.; Zerfas, Patricia M.; Shanske, Sara; Sloan, Jennifer; Hoffmann, Victoria; DiMauro, Salvatore; Venditti, Charles P.			Mitochondrial dysfunction in mut methylmalonic acidemia	FASEB JOURNAL			English	Article						methylmalonyl-CoA mutase; cytochrome c oxidase; glutathione; oxidant stress; vitamin B12	LIVER-KIDNEY TRANSPLANTATION; RESPIRATORY-CHAIN; ORGANIC ACIDEMIAS; GLOBUS-PALLIDUS; KNOCKOUT MICE; INBORN ERROR; ACIDURIA; DEFICIENCY; METABOLISM; MANAGEMENT	Methylmalonic acidemia is an autosomal recessive inborn error of metabolism caused by defective activity of methylmalonyl-CoA mutase (MUT) that exhibits multiorgan system pathology. To examine whether mitochondrial dysfunction is a feature of this organic acidemia, a background-modified Mut-knockout mouse model was constructed and used to examine mitochondrial ultrastructure and respiratory chain function in the tissues that manifest pathology in humans. In parallel, the liver from a patient with mut methylmalonic acidemia was studied in a similar fashion. Megamitochondria formed early in life in the hepatocytes of the Mut(-/-) animals and progressively enlarged. Liver extracts prepared from the mutants at multiple time points displayed respiratory chain dysfunction, with diminished cytochrome c oxidase activity and reduced intracellular glutathione compared to control littermates. Over time, the exocrine pancreas and proximal tubules of the kidney also exhibited megamitochondria, and older mutant mice eventually developed tubulointerstitial renal disease. The patient liver displayed similar morphological and enzymatic findings as observed in the murine tissues. These murine and human studies establish that megamitochondria formation with respiratory chain dysfunction occur in a tissue-specific fashion in methylmalonic acidemia and suggest treatment approaches based on improving mitochondrial function and ameliorating the effects of oxidative stress.-Chandler, R. J., Zerfas, P. M., Shanske, S., Sloan, J., Hoffmann, V., DiMauro, S., Venditti, C. P. Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J. 23, 1252-1261 (2009)	[Chandler, Randy J.; Sloan, Jennifer; Venditti, Charles P.] NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; [Zerfas, Patricia M.; Hoffmann, Victoria] NIH, Div Vet Resources, Off Res Serv, Bethesda, MD 20892 USA; [Shanske, Sara; DiMauro, Salvatore] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; Columbia University	Venditti, CP (corresponding author), NHGRI, Genet Dis Res Branch, NIH, Bldg 49 Rm 4A62A, Bethesda, MD 20892 USA.	venditti@mail.nih.gov	Chandler, Randy Joseph/Y-1164-2019	Chandler, Randy Joseph/0000-0002-6047-5230	Intramural NIH HHS [Z99 HG999999, Z01 HG200318-05, Z01 HG200318-04] Funding Source: Medline; NICHD NIH HHS [P01 HD032062, HD32062] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200318] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALLEN RH, 1993, METABOLISM, V42, P978, DOI 10.1016/0026-0495(93)90010-L; ANDO T, 1972, P NATL ACAD SCI USA, V69, P2807, DOI 10.1073/pnas.69.10.2807; BAUMGARTER ER, 1995, J INHERIT METAB DIS, V18, P138, DOI 10.1007/BF00711749; BRASS EP, 1990, BIOCHEM J, V266, P809; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chandler RJ, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-64; Chandler RJ, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-24; Chandler RJ, 2008, HUM GENE THER, V19, P53, DOI 10.1089/hum.2007.0118; de Baulny HO, 2005, J INHERIT METAB DIS, V28, P415, DOI 10.1007/s10545-005-7056-1; DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; Dionisi-Vici C, 2006, J INHERIT METAB DIS, V29, P383, DOI 10.1007/s10545-006-0278-z; Fenton WA, 2001, METABOLIC MOL BASES, P2165; FENTON WA, 2001, METABOLIC MOL BASES, P3897; HAYASAKA K, 1982, TOHOKU J EXP MED, V137, P329, DOI 10.1620/tjem.137.329; HEIDENREICH R, 1988, J PEDIATR-US, V113, P1022, DOI 10.1016/S0022-3476(88)80574-2; Horster F, 2007, PEDIATR RES, V62, P225; KAHLER SG, 1994, J PEDIATR-US, V124, P239, DOI 10.1016/S0022-3476(94)70311-6; Kaplan P, 2006, MOL GENET METAB, V88, P322, DOI 10.1016/j.ymgme.2006.04.003; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Kolker S, 2003, J BIOL CHEM, V278, P47388, DOI 10.1074/jbc.M308861200; KORF B, 1986, ANN NEUROL, V20, P364, DOI 10.1002/ana.410200317; KRAHENBUHL S, 1990, J CLIN INVEST, V86, P2054, DOI 10.1172/JCI114942; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Leonard JV, 2001, J INHERIT METAB DIS, V24, P309, DOI 10.1023/A:1010395724012; Li H, 2000, P NATL ACAD SCI USA, V97, P3467, DOI 10.1073/pnas.97.7.3467; LINDBLAD B, 1968, ACTA PAEDIATR SCAND, V57, P417, DOI 10.1111/j.1651-2227.1968.tb07314.x; MATSUI SM, 1983, NEW ENGL J MED, V308, P857, DOI 10.1056/NEJM198304143081501; MORROW G, 1969, J PEDIATR, V74, P680, DOI 10.1016/S0022-3476(69)80130-7; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Nagarajan S, 2005, J INHERIT METAB DIS, V28, P517, DOI 10.1007/s10545-005-0517-8; Nicolaides P, 1998, ARCH DIS CHILD, V78, P508, DOI 10.1136/adc.78.6.508; OBERHOLZ.VG, 1967, ARCH DIS CHILD, V42, P492, DOI 10.1136/adc.42.225.492; Okun JG, 2002, J BIOL CHEM, V277, P14674, DOI 10.1074/jbc.M200997200; Peters H, 2003, J BIOL CHEM, V278, P52909, DOI 10.1074/jbc.M310533200; Pettenuzzo LF, 2006, INT J DEV NEUROSCI, V24, P45, DOI 10.1016/j.ijdevneu.2005.10.005; Richard E, 2007, J PATHOL, V213, P453, DOI 10.1002/path.2248; Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1; STABLER SP, 1991, J CLIN INVEST, V87, P1422, DOI 10.1172/JCI115148; STOKKE O, 1967, SCAND J CLIN LAB INV, V20, P313, DOI 10.3109/00365516709076961; TANDLER B, 1991, ANAT RECORD, V231, P1, DOI 10.1002/ar.1092310102; Treacy E, 1996, J PEDIATR-US, V129, P445, DOI 10.1016/S0022-3476(96)70080-X; van't Hoff WG, 1998, J PEDIATR-US, V132, P1043, DOI 10.1016/S0022-3476(98)70407-X; VANDERMEER SB, 1994, J PEDIATR-US, V125, P903, DOI 10.1016/S0022-3476(05)82005-0; Wakabayashi T, 2002, J CELL MOL MED, V6, P497, DOI 10.1111/j.1582-4934.2002.tb00452.x; WALTER JH, 1989, EUR J PEDIATR, V148, P344, DOI 10.1007/BF00444131; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510	47	131	133	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1252	1261		10.1096/fj.08-121848	http://dx.doi.org/10.1096/fj.08-121848			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19088183	Green Published			2022-12-28	WOS:000266651600029
J	Klimova, TA; Bell, EL; Shroff, EH; Weinberg, FD; Snyder, CM; Dimri, GP; Schumacker, PT; Budinger, GRS; Chandel, NS				Klimova, Tatyana A.; Bell, Eric L.; Shroff, Emelyn H.; Weinberg, Frank D.; Snyder, Colleen M.; Dimri, Goberdan P.; Schumacker, Paul T.; Budinger, G. R. Scott; Chandel, Navdeep S.			Hyperoxia-induced premature senescence requires p53 and pRb, but not mitochondrial matrix ROS	FASEB JOURNAL			English	Article						AMPK; cell cycle; telomerase	REPLICATIVE LIFE-SPAN; FLUORESCENT PROTEIN INDICATORS; DIPLOID FIBROBLAST CELLS; OXIDATIVE DNA-DAMAGE; CELLULAR SENESCENCE; RETINOBLASTOMA PROTEIN; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; C-MYC; EXPRESSION	Senescence is a potential tumor-suppressing mechanism and a commonly used model of cellular aging. One current hypothesis to explain senescence, based in part on the correlation of oxygen with senescence, postulates that it is caused by oxidative damage from reactive oxygen species (ROS). Here, we further test this theory by determining the mechanisms of hyperoxia-induced senescence. Exposure to 70% O-2 led to stress-induced, telomere-independent senescence. Although hyperoxia elevated mitochondrial ROS production, overexpression of antioxidant proteins was not sufficient to prevent hyperoxia-induced senescence. Hyperoxia activated AMPK; however, overexpression of a kinase-dead mutant of LKB1, which prevented AMPK activation, did not prevent hyperoxia-induced senescence. Knocking down p21 via shRNA, or suppression of the p16/pRb pathway by either BMI1 or HPV16-E7 overexpression, was also insufficient to prevent hyperoxia-induced senescence. However, suppressing p53 function resulted in partial rescue from senescence, suggesting that hyperoxia-induced senescence involves p53. Suppressing both the p53 and pRb pathways resulted in almost complete protection, indicating that both pathways cooperate in hyperoxia-induced senescence. Collectively, these results indicate a ROS-independent but p53/pRb-dependent senescence mechanism during hyperoxia.-Klimova, T. A., Bell, E. L., Shroff, E. H., Weinberg, F. D., Snyder, C. M., Dimri, G. P., Schumacker, P. T., Budinger, G. R. S., Chandel, N. S. Hyperoxia-induced premature senescence requires p53 and pRb, but not mitochondrial matrix ROS. FASEB J. 23, 783-794 (2009)	[Klimova, Tatyana A.; Bell, Eric L.; Shroff, Emelyn H.; Weinberg, Frank D.; Snyder, Colleen M.; Budinger, G. R. Scott; Chandel, Navdeep S.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Schumacker, Paul T.] Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; [Dimri, Goberdan P.] Evanston NW Hosp, Res Inst, Div Canc Biol, Evanston, IL USA; [Dimri, Goberdan P.] Evanston NW Hosp, Res Inst, Dept Med, Evanston, IL USA; [Dimri, Goberdan P.; Chandel, Navdeep S.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Evanston, IL USA	Northwestern University; Northwestern University; NorthShore University Health System; NorthShore University Health System; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Chandel, NS (corresponding author), 240 E Huron Ave,Rm M-334, Chicago, IL 60611 USA.	nav@northwestern.edu	Bell, Eric/F-6368-2012; Weinberg, Frank/AAC-9915-2020	Schumacker, Paul T/0000-0001-9591-2034	U.S. National Institutes of Health [GM60472-09, P01HL071643-03004, R21AG027093]; American Heart Association [0715708Z]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071643] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG027093] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr. Laimonis A. Laimins (Northwestern University) for his kind gift of packaging cells expressing HPV-E7 WT and mutant, and HPV-E6 and E7 in combination. This work was supported in part by U.S. National Institutes of Health grants to N.S.C. (GM60472-09, P01HL071643-03004, R21AG027093). T.A.K. is supported by an American Heart Association predoctoral grant (0715708Z).	Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bell EL, 2007, MOL CELL BIOL, V27, P5737, DOI 10.1128/MCB.02265-06; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond J, 2004, EXP CELL RES, V292, P151, DOI 10.1016/j.yexcr.2003.09.021; Boyer SN, 1996, CANCER RES, V56, P4620; Budinger GRS, 2002, J BIOL CHEM, V277, P15654, DOI 10.1074/jbc.M109317200; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; Dooley CT, 2004, J BIOL CHEM, V279, P22284, DOI 10.1074/jbc.M312847200; Fridovich I, 1998, J EXP BIOL, V201, P1203; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Hanson GT, 2004, J BIOL CHEM, V279, P13044, DOI 10.1074/jbc.M312846200; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Herbert KE, 2008, CIRC RES, V102, P201, DOI 10.1161/CIRCRESAHA.107.158626; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; KIMURA RE, 1983, J APPL PHYSIOL, V55, P1501, DOI 10.1152/jappl.1983.55.5.1501; Li CH, 2005, J BIOL CHEM, V280, P26193, DOI 10.1074/jbc.M501371200; Liu L, 2006, ONCOGENE, V25, P4370, DOI 10.1038/sj.onc.1209454; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Ruchko M, 2005, AM J PHYSIOL-LUNG C, V288, pL530, DOI 10.1152/ajplung.00255.2004; SAITO H, 1995, EXP CELL RES, V217, P272, DOI 10.1006/excr.1995.1087; Saretzki G, 1998, J GERONTOL A-BIOL, V53, pB438, DOI 10.1093/gerona/53A.6.B438; Saretzki G, 2003, AGING CELL, V2, P141, DOI 10.1046/j.1474-9728.2003.00040.x; Sasaki M, 2001, MECH AGEING DEV, V122, P1695, DOI 10.1016/S0047-6374(01)00281-0; Sasaki M, 2006, AM J PATHOL, V169, P831, DOI 10.2353/ajpath.2006.051237; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHOONEN WGEJ, 1990, MUTAT RES, V237, P173; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Stockl P, 2007, FREE RADICAL BIO MED, V43, P947, DOI 10.1016/j.freeradbiomed.2007.06.005; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang WG, 2003, J BIOL CHEM, V278, P27016, DOI 10.1074/jbc.M300318200; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446	47	50	52	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					783	794		10.1096/fj.08-114256	http://dx.doi.org/10.1096/fj.08-114256			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18948382	Green Published			2022-12-28	WOS:000265506300014
J	Jakubowski, H; Boers, GHJ; Strauss, KA				Jakubowski, Hieronim; Boers, Godfried H. J.; Strauss, Kevin A.			Mutations in cystathionine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans	FASEB JOURNAL			English	Article						genetic hyperhomocysteinemia; homocysteine thiolactone; fibrinogen; atherothrombosis	MOLECULAR-BASIS; PATHOLOGICAL CONSEQUENCES; POSSIBLE MECHANISM; HUMAN FIBRINOGEN; THIOLACTONE; AUTOANTIBODIES; HOMOCYSTINURIA; DEFICIENCY; RESISTANCE; DISEASE	Severely elevated plasma homocysteine (Hcy) levels observed in genetic disorders of Hcy metabolism are associated with pathologies in multiple organs and lead to premature death due to vascular complications. In addition to elevating plasma Hcy, mutations in cystathionine beta-synthase (CBS) or methylenetetrahydrofolate reductase (MTHFR) gene lead to markedly elevated levels of circulating Hcy-thiolactone. The thiooester chemistry of Hcy-thiolactone underlies its ability to form isopeptide bonds with protein lysine residues (N-Hcy-protein), which may impair or alter the protein's function. However, it was not known whether genetic deficiencies in Hcy metabolism affect N-Hcy-protein levels in humans. Here we show that plasma N-Hcy-protein levels are significantly elevated in CBS- and MTHFR-deficient patients. We also show that CBS-deficient patients have significantly elevated plasma levels of prothrombotic N-Hcy-fibrinogen. These results provide a possible explanation for increased atherothrombosis observed in CBS-deficient patients.	[Jakubowski, Hieronim] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07101 USA; [Jakubowski, Hieronim] Polish Acad Sci, Inst Bioorgan Chem, Poznan, Poland; [Boers, Godfried H. J.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands; [Strauss, Kevin A.] Clin Special Children, Strasburg, PA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Radboud University Nijmegen	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409	American Heart Association; Ministry of Science and Higher Education, Poland	American Heart Association(American Heart Association); Ministry of Science and Higher Education, Poland(Ministry of Science and Higher Education, Poland)	This work was supported in part by grants from the American Heart Association and the Ministry of Science and Higher Education, Poland.	Chwatko G, 2005, CLIN CHEM, V51, P408, DOI 10.1373/clinchem.2004.042531; Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035; Chwatko G, 2007, FASEB J, V21, P1707, DOI 10.1096/fj.06-7435com; de las Casas CM, 2003, BIRTH DEFECTS RES A, V67, P35, DOI 10.1002/bdra.10014; Endo N, 2006, BRIT J NUTR, V95, P1088, DOI 10.1079/BJN20061764; Goyette P, 1996, AM J HUM GENET, V59, P1268; Hanss M, 2001, ANN NY ACAD SCI, V936, P89; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2005, CLIN CHEM LAB MED, V43, P1011, DOI 10.1515/CCLM.2005.177; Jakubowski H, 2004, CELL MOL LIFE SCI, V61, P470, DOI 10.1007/s00018-003-3204-7; Jakubowski H, 2002, J BIOL CHEM, V277, P30425, DOI 10.1074/jbc.C200267200; Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5; Jakubowski H, 2001, BIOMED PHARMACOTHER, V55, P443, DOI 10.1016/S0753-3322(01)00085-3; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; Jakubowski H, 2008, ANAL BIOCHEM, V380, P257, DOI 10.1016/j.ab.2008.05.049; Jakubowski H, 2007, CLIN CHEM LAB MED, V45, P1704, DOI 10.1515/CCLM.2007.338; Jakubowski H, 2007, ANAL BIOCHEM, V370, P124, DOI 10.1016/j.ab.2007.05.030; Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S; Kluijtmans LAJ, 1999, AM J HUM GENET, V65, P59, DOI 10.1086/302439; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; MUDD SH, 2001, METABOLIC MOL BASES, V2, P2007; Perla-Kajan J, 2008, BIOMED PHARMACOTHER, V62, P473, DOI 10.1016/j.biopha.2008.04.001; Rosenblatt D. S., 2001, METABOLIC MOL BASES, V8th, P3897; Sauls DL, 2006, BIOCHEMISTRY-US, V45, P2480, DOI 10.1021/bi052076j; Strauss KA, 2007, MOL GENET METAB, V91, P165, DOI 10.1016/j.ymgme.2007.02.012; Undas A, 2005, THROMB HAEMOSTASIS, V93, P346, DOI 10.1160/TH04-08-0493; Undas A, 2004, STROKE, V35, P1299, DOI 10.1161/01.STR.0000128412.59768.6e; Undas A, 2006, ARTERIOSCL THROM VAS, V26, P1397, DOI 10.1161/01.ATV.0000219688.43572.75; Yap S, 2001, ARTERIOSCL THROM VAS, V21, P2080, DOI 10.1161/hq1201.100225	33	77	87	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4071	4076		10.1096/fj.08-112086	http://dx.doi.org/10.1096/fj.08-112086			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18708589				2022-12-28	WOS:000261254800006
J	Jing, Y; Mal, N; Williams, PS; Mayorga, M; Penn, MS; Chalmers, JJ; Zborowski, M				Jing, Ying; Mal, Niladri; Williams, P. Stephen; Mayorga, Maritza; Penn, Marc S.; Chalmers, Jeffrey J.; Zborowski, Maciej			Quantitative intracellular magnetic nanoparticle uptake measured by live cell magnetophoresis	FASEB JOURNAL			English	Article						intracellular MRI contrast; stem cell tracking; SPIO; transfection agent; intracellular iron; particle tracking velocimetry	MR CONTRAST AGENTS; TRACKING VELOCIMETRY; STEM-CELLS; INDUCED VELOCITY; EXTERNAL FIELDS; GENE DELIVERY; RAT-BRAIN; IRON; QUANTIFICATION; EXPRESSION	Superparamagnetic iron oxide (SPIO) particles have been used successfully as an intracellular contrast agent for nuclear MRI cell tracking in vivo. We present a method of detecting intracellular SPIO colloid uptake in live cells using cell magnetophoresis, with potential applications in measuring intracellular MRI contrast uptake. The method was evaluated by measuring shifts in mean and distribution of the cell magnetophoretic mobility, and the concomitant changes in population frequency of the magnetically positive cells when compared to the unmanipulated negative control. Seven different transfection agent (TA) -SPIO complexes based on dendrimer, lipid, and polyethylenimine compounds were used as test standards, in combination with 3 different cell types: mesenchymal stem cells, cardiac fibroblasts, and cultured KG-1a hematopoietic stem cells. Transfectol (TRA) -SPIO incubation resulted in the highest frequency of magnetically positive cells (> 90%), and Fugene 6 (FUG) -SPIO incubation the lowest, below that when using SPIO alone. A highly regular process of cell magnetophoresis was amenable to intracellular iron mass calculations. The results were consistent in all the cell types studied and with other reports. The cell magnetophoresis depends on the presence of high- spin iron species and is therefore expected to be directly related to the cell MRI contrast level.	[Jing, Ying; Williams, P. Stephen; Zborowski, Maciej] Cleveland Clin, Dept Biomed Engn ND20, Lerner Res Inst, Cleveland, OH 44195 USA; [Mal, Niladri; Mayorga, Maritza; Penn, Marc S.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA; [Jing, Ying; Chalmers, Jeffrey J.] Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Zborowski, M (corresponding author), Cleveland Clin, Dept Biomed Engn ND20, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	zborowm@ccf.org	Chalmers, Jeffrey J/D-2305-2009; Williams, Philip/C-2774-2008	Williams, Philip/0000-0002-5951-2612	U.S. National Institutes of Health [CA62349]; National Science Foundation [BES-0124897]; NATIONAL CANCER INSTITUTE [R01CA062349] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thankfully acknowledge support by the U.S. National Institutes of Health (CA62349 to M.Z.) and the National Science Foundation (BES-0124897 to J J.C.).	Arbab Ali Syed, 2004, Mol Imaging, V3, P24, DOI 10.1162/153535004773861697; Arbab AS, 2003, RADIOLOGY, V229, P838, DOI 10.1148/radiol.2293021215; Arbab AS, 2004, HUM GENE THER, V15, P351, DOI 10.1089/104303404322959506; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Bulte JWM, 1996, ACAD RADIOL, V3, pS301, DOI 10.1016/S1076-6332(96)80564-2; Chalmers JJ, 1999, J MAGN MAGN MATER, V194, P231, DOI 10.1016/S0304-8853(98)00557-5; Chalmers JJ, 1999, BIOTECHNOL BIOENG, V64, P519, DOI 10.1002/(SICI)1097-0290(19990905)64:5<519::AID-BIT2>3.3.CO;2-M; Chalmers JJ, 1999, BIOTECHNOL BIOENG, V64, P509, DOI 10.1002/(SICI)1097-0290(19990905)64:5<509::AID-BIT1>3.0.CO;2-Z; Dyer PA, 1998, PRACT APPROACH SER, V193, P191; Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; Frank JA, 2002, ACAD RADIOL, V9, pS484, DOI 10.1016/S1076-6332(03)80271-4; Gee A.P., 1997, CELL SEP METHODS APP, P175; GUEZENNEC YG, 1994, EXP FLUIDS, V17, P209, DOI 10.1007/BF00203039; Hafeli UO, 2006, SMART NANOPARTICLES, V8, P77; Hecker JG, 2001, MOL THER, V3, P375, DOI 10.1006/mthe.2001.0272; Hergt R, 2004, J MAGN MAGN MATER, V270, P345, DOI 10.1016/j.jmmm.2003.09.001; Jing Y, 2007, EXP HEMATOL, V35, P662, DOI 10.1016/j.exphem.2006.12.009; JUNG CW, 1995, MAGN RESON IMAGING, V13, P661, DOI 10.1016/0730-725X(95)00024-B; Kalish H, 2003, MAGN RESON MED, V50, P275, DOI 10.1002/mrm.10556; Kantor A.B., 1998, CELL SEP METHODS APP, V1, P153; Leigh DR, 2005, CYTOM PART A, V66A, P103, DOI 10.1002/cyto.a.20155; LIBERTI PA, 1991, ACS SYM SER, V464, P268; McCloskey KE, 2000, CYTOMETRY, V40, P307, DOI 10.1002/1097-0320(20000801)40:4<307::AID-CYTO6>3.0.CO;2-H; Mills WR, 2007, J MOL CELL CARDIOL, V42, P304, DOI 10.1016/j.yjmcc.2006.09.011; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; MOLDAY RS, 1982, J IMMUNOL METHODS, V52, P353, DOI 10.1016/0022-1759(82)90007-2; Moore LR, 2006, FASEB J, V20, P747, DOI 10.1096/fj.05-5122fje; Moore LR, 2000, J BIOCHEM BIOPH METH, V44, P115, DOI 10.1016/S0165-022X(00)00085-3; Moore LR, 2004, ANAL CHEM, V76, P3899, DOI 10.1021/ac049910f; Nakamura M, 2001, EXP FLUIDS, V30, P371, DOI 10.1007/s003480000211; Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201; Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4; Schenk S, 2007, STEM CELLS, V25, P245, DOI 10.1634/stemcells.2006-0293; Schneider T, 2006, J BIOCHEM BIOPH METH, V68, P1, DOI 10.1016/j.jbbm.2006.02.011; Sipe JC, 1999, MAGN RESON IMAGING, V17, P1521, DOI 10.1016/S0730-725X(99)00085-5; Stroh A, 2005, NEUROIMAGE, V24, P635, DOI 10.1016/j.neuroimage.2004.09.014; UGELSTAD J, 1993, BLOOD PURIFICAT, V11, P349, DOI 10.1159/000170129; Wilhelm C, 2002, EUR BIOPHYS J BIOPHY, V31, P118, DOI 10.1007/s00249-001-0200-4; WINOTOMORBACH S, 1994, J CLIN LAB ANAL, V8, P400, DOI 10.1002/jcla.1860080610; WINOTOMORBACH S, 1995, J CLIN LAB ANAL, V9, P42, DOI 10.1002/jcla.1860090108; Zborowski M, 2003, BIOPHYS J, V84, P2638, DOI 10.1016/S0006-3495(03)75069-3; Zborowski M, 2008, LAB TECH BIOCHEM MOL, V32, P1; Zhang HD, 2005, ANALYST, V130, P514, DOI 10.1039/b412723d; Zhang M, 2007, FASEB J, V21, P3197, DOI 10.1096/fj.06-6558com	44	61	62	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4239	4247		10.1096/fj.07-105544	http://dx.doi.org/10.1096/fj.07-105544			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18725459	Green Published			2022-12-28	WOS:000261254800023
J	Ng, AKL; Zhang, HM; Tan, KM; Li, ZL; Liu, JH; Chan, PKS; Li, SM; Chan, WY; Au, SWN; Joachimiak, A; Walz, T; Wang, JH; Shaw, PC				Ng, Andy Ka-Leung; Zhang, Hongmin; Tan, Kemin; Li, Zongli; Liu, Jin-Huan; Chan, Paul Kay-Sheung; Li, Sui-Mui; Chan, Wood-Yee; Au, Shannon Wing-Ngor; Joachimiak, Andrzej; Walz, Thomas; Wang, Jia-Huai; Shaw, Pang-Chui			Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design	FASEB JOURNAL			English	Article						protein-RNA interaction; crystal structure; trimerization	CYTOTOXIC T-LYMPHOCYTES; LIMIT ESCAPE; POLYMERASE; IDENTIFICATION; TRANSCRIPTION; ROLES; MODEL	The threat of a pandemic outbreak of influenza virus A H5N1 has become a major concern worldwide. The nucleoprotein (NP) of the virus binds the RNA genome and acts as a key adaptor between the virus and the host cell. It, therefore, plays an important structural and functional role and represents an attractive drug target. Here, we report the 3.3-angstrom crystal structure of H5N1 NP, which is composed of a head domain, a body domain, and a tail loop. Our structure resolves the important linker segments (residues 397401, 429-437) that connect the tail loop with the remainder of the molecule and a flexible, basic loop (residues 73-91) located in an arginine-rich groove surrounding Arg150. Using surface plasmon resonance, we found the basic loop and arginine-rich groove, but mostly a protruding element containing Arg174 and Arg175, to be important in RNA binding by NP. We also used our crystal structure to build a ring-shaped assembly of nine NP subunits to model the miniribonucleo-protein particle previously visualized by electron microscopy. Our study of H5N1 NP provides insight into the oligomerization interface and the RNA-binding groove, which are attractive drug targets, and it identifies the epitopes that might be used for universal vaccine development.	[Ng, Andy Ka-Leung; Li, Sui-Mui; Au, Shannon Wing-Ngor; Shaw, Pang-Chui] Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China; [Ng, Andy Ka-Leung; Shaw, Pang-Chui] Chinese Univ Hong Kong, Mol Biotechnol Program, Shatin, Hong Kong, Peoples R China; [Ng, Andy Ka-Leung; Li, Sui-Mui; Au, Shannon Wing-Ngor; Shaw, Pang-Chui] Chinese Univ Hong Kong, Ctr Prot Sci & Crystallog, Shatin, Hong Kong, Peoples R China; [Chan, Paul Kay-Sheung] Chinese Univ Hong Kong, Dept Microbiol, Shatin, Hong Kong, Peoples R China; [Chan, Wood-Yee] Chinese Univ Hong Kong, Dept Anat, Shatin, Hong Kong, Peoples R China; [Li, Zongli; Walz, Thomas] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Tan, Kemin; Joachimiak, Andrzej] Argonne Natl Lab, Midwest Ctr Struct Genom, Argonne, IL 60439 USA; [Tan, Kemin; Joachimiak, Andrzej] Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA; [Zhang, Hongmin; Liu, Jin-Huan; Wang, Jia-Huai] Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Sch Med,Dept Pediat,Dept Biol Chem & Mol Pharmaco, Boston, MA 02115 USA	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Shaw, PC (corresponding author), Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China.	pcshaw@cuhk.edu.hk	Chan, Paul KS/J-9360-2013; Chan, Wood Yee/R-6692-2018; Li, Zongli/AAB-9100-2020; Zhang, Hongmin/C-4503-2009; Zhang, Hongmin/S-9953-2017	Chan, Paul KS/0000-0002-6360-4608; Chan, Wood Yee/0000-0002-7114-1463; Zhang, Hongmin/0000-0001-6357-4106; Zhang, Hongmin/0000-0003-4356-3615; Walz, Thomas/0000-0003-2606-2835	Chinese University [CUHK 472808]; HK-SAR; National Institutes of Health (NIH); Giovanni Armenise Harvard Center for Strucutural Biology	Chinese University; HK-SAR; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Giovanni Armenise Harvard Center for Strucutural Biology	This work was supported by a Direct Research grant from the Chinese University and a General Research Fund grant (CUHK 472808) from the Research Grants Council of HK-SAR (P.-C.S.), a subcontracted National Institutes of Health (NIH) grant, and the Claudia Adams Barr Program in Cancer Research (J.-H.W.). The molecular EM facility at Harvard Medical School was established with it generous donation from the Giovanni Armenise Harvard Center for Strucutural Biology and is maintained with funds from NIH (T.W.), The authors (flank Professor Ming Luo for advice on the manuscript.	Albertini AAV, 2006, SCIENCE, V313, P360, DOI 10.1126/science.1125280; Area E, 2004, P NATL ACAD SCI USA, V101, P308, DOI 10.1073/pnas.0307127101; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAUDIN F, 1994, EMBO J, V13, P3158, DOI 10.1002/j.1460-2075.1994.tb06614.x; Berkhoff EGM, 2006, VACCINE, V24, P6594, DOI 10.1016/j.vaccine.2006.05.051; Berkhoff EGM, 2005, J VIROL, V79, P11239, DOI 10.1128/JVI.79.17.11239-11246.2005; BISHOP DHL, 1971, J VIROL, V8, P66, DOI 10.1128/JVI.8.1.66-73.1971; Biswas SK, 1998, J VIROL, V72, P5493, DOI 10.1128/JVI.72.7.5493-5501.1998; Boon ACM, 2006, J VIROL, V80, P6024, DOI 10.1128/JVI.00009-06; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano WL, 2002, PYMOL USERS MANUAL; Elton D, 1999, VIROLOGY, V260, P190, DOI 10.1006/viro.1999.9818; Elton D, 1999, J VIROL, V73, P7357, DOI 10.1128/JVI.73.9.7357-7367.1999; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Epstein SL, 2005, VACCINE, V23, P5404, DOI 10.1016/j.vaccine.2005.04.047; Fernandez-Fuentes N, 2006, NUCLEIC ACIDS RES, V34, pW173, DOI 10.1093/nar/gkl113; Gerhard W, 2006, EMERG INFECT DIS, V12, P569, DOI 10.3201/eid1204.051020; Green TJ, 2006, SCIENCE, V313, P357, DOI 10.1126/science.1126953; Gschoesser C, 2002, VACCINE, V20, P3731, DOI 10.1016/S0264-410X(02)00355-9; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Klumpp K, 1997, EMBO J, V16, P1248, DOI 10.1093/emboj/16.6.1248; KOBAYASHI M, 1994, J VIROL, V68, P8433, DOI 10.1128/JVI.68.12.8433-8436.1994; Kreijtz JHCM, 2008, J VIROL, V82, P5161, DOI 10.1128/JVI.02694-07; Livingston BD, 2006, BIODRUGS, V20, P335, DOI 10.2165/00063030-200620060-00003; Luo M, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-72; Martin-Benito J, 2001, EMBO REP, V2, P313, DOI 10.1093/embo-reports/kve063; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Normile D, 2006, SCIENCE, V311, P315, DOI 10.1126/science.311.5759.315; Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70; Ortega J, 2000, J VIROL, V74, P156, DOI 10.1128/JVI.74.1.156-163.2000; Portela A, 2002, J GEN VIROL, V83, P723, DOI 10.1099/0022-1317-83-4-723; Prokudina EN, 2004, VIRUS RES, V99, P169, DOI 10.1016/j.virusres.2003.11.008; ProkudinaKantorovich EN, 1996, VIROLOGY, V223, P51, DOI 10.1006/viro.1996.0454; Rimmelzwaan GF, 2004, VIRUS RES, V103, P97, DOI 10.1016/j.virusres.2004.02.020; Roti M, 2008, J IMMUNOL, V180, P1758, DOI 10.4049/jimmunol.180.3.1758; SHU LL, 1993, J VIROL, V67, P2723, DOI 10.1128/JVI.67.5.2723-2729.1993; SKORKO R, 1991, VIROLOGY, V180, P668, DOI 10.1016/0042-6822(91)90080-U; TILEY LS, 1994, J VIROL, V68, P5108, DOI 10.1128/JVI.68.8.5108-5116.1994; Yager EJ, 2008, J EXP MED, V205, P711, DOI 10.1084/jem.20071140; Ye QZ, 2006, NATURE, V444, P1078, DOI 10.1038/nature05379	40	175	187	1	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3638	3647		10.1096/fj.08-112110	http://dx.doi.org/10.1096/fj.08-112110			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18614582	Green Published			2022-12-28	WOS:000259642600025
J	Troeberg, L; Fushimi, K; Khokha, R; Emonard, H; Ghosh, P; Nagase, H				Troeberg, Linda; Fushimi, Kazunari; Khokha, Rama; Emonard, Herve; Ghosh, Peter; Nagase, Hideaki			Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases	FASEB JOURNAL			English	Article						ADAMTS; LRP; osteoarthitis; cartilage destruction; proteoglycan	MATRIX-METALLOPROTEINASE; TISSUE INHIBITOR; ARTICULAR-CARTILAGE; SULFATED GLYCOSAMINOGLYCANS; PROTEOLYTIC ACTIVITIES; MONOCLONAL-ANTIBODIES; ADAMTS4 AGGRECANASE-1; TIMP-3; OSTEOARTHRITIS; DEGRADATION	Degradation of the cartilage proteoglycan aggrecan is a key early event in the development of osteoarthritis. Adamalysin with thrombospondin motifs (ADAMTS) A and ADAMTS-5 are considered to be the main enzymes responsible for aggrecan breakdown, making them attractive drugs targets. Here we show that calcium pentosan polysulfate (CaPPS), a chemically sulfated xylanopyranose from beechwood, is a multifaceted exosite inhibitor of the aggrecanases and protects cartilage against aggrecan degradation. CaPPS interacts with the noncatalytic spacer domain of ADAMTS4 and the cysteine-rich domain of ADAMTS-5, blocking activity against their natural substrate aggrecan with inhibitory concentration 50 values of 10-40 nM but only weakly inhibiting hydrolysis of a nonglycosylated recombinant protein substrate. In addition, CaPPS increased cartilage levels of tissue inhibitor of metalloproteinases-3 (TIMP-3), an endogenous inhibitor of ADAMTS-4 and -5. This was due to the ability of CaPPS to block endocytosis of TIMP-3 mediated by low-density lipoprotein receptor-related protein. CaPPS also increased the affinity of TIMP-3 for ADAMTS-4 and -5 by more than 100-fold, improving the efficacy of TIMP-3 as an aggrecanase inhibitor. Studies with TIMP-3-null mouse cartilage indicated that CaPPS inhibition of aggrecan degradation is TIMP-3 dependent. These unique properties make CaPPS a prototypic disease-modifying agent for osteoarthritis.	[Troeberg, Linda; Fushimi, Kazunari; Nagase, Hideaki] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, London W6 8LH, England; [Khokha, Rama] Univ Toronto, Ontario Canc Res, Toronto, ON, Canada; [Emonard, Herve] Univ Reims, Fac Med, Reims, France; [Ghosh, Peter] Inst Nutraceut Res, Sydney, NSW, Australia	Imperial College London; University of Oxford; University of Toronto; Universite de Reims Champagne-Ardenne	Nagase, H (corresponding author), Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, 65 Aspenlea Rd, London W6 8LH, England.	h.nagase@imperial.ac.uk	Emonard, Herve/R-9718-2019; Emonard, Hervé/AAD-5432-2019; Fushimi, Kazunari/AAN-8382-2021	Fushimi, Kazunari/0000-0003-0884-1990; Khokha, Rama/0000-0002-6028-1524; /0000-0003-0939-4651	Wellcome Trust [057508]; National Institutes of Health [AR40994]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by Wellcome Trust grant. 057508 and U.S. National Institutes of Health grant AR40994 to H.N. We thank Shi-Lu Chia (Kennedy Institute of Rheumatology) for help with mouse explant culture and Bruce Caterson and Clare Hughes of the University of Cardiff (Cardiff, UK) for provision of 2-B-6, BC3, and BC 14 monoclonal antibodies. We are grateful to Jonathan Jones (Heatherwood and Wexham Park Hospitals, Slough, UK) and the Orthopaedic Surgery Department of Charing Cross Hospital (London, UK) for providing human cartilage.	Arris CE, 2003, BBA-MOL BASIS DIS, V1638, P20, DOI 10.1016/S0925-4439(03)00036-X; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; Bursavich MG, 2007, BIOORG MED CHEM LETT, V17, P5630, DOI 10.1016/j.bmcl.2007.07.048; Bursavich MG, 2007, BIOORG MED CHEM LETT, V17, P1185, DOI 10.1016/j.bmcl.2006.12.027; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; CATERSON B, 1985, FED PROC, V44, P386; Caterson B, 1995, ACTA ORTHOP SCAND, V66, P121, DOI 10.3109/17453679509157666; Edelman J., 1994, OSTEOARTHR CARTIL, V2, P35; Emonard H, 2004, J BIOL CHEM, V279, P54944, DOI 10.1074/jbc.M406792200; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Fushimi K, 2008, J BIOL CHEM, V283, P6706, DOI 10.1074/jbc.M708647200; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gendron C, 2003, FEBS LETT, V555, P431, DOI 10.1016/S0014-5793(03)01295-X; Gendron C, 2007, J BIOL CHEM, V282, P18294, DOI 10.1074/jbc.M701523200; Ghosh P, 2005, CURR THER RES CLIN E, V66, P552, DOI 10.1016/j.curtheres.2005.12.012; Ghosh P, 1999, SEMIN ARTHRITIS RHEU, V28, P211, DOI 10.1016/S0049-0172(99)80021-3; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Itoh Y, 1998, J BIOL CHEM, V273, P24360, DOI 10.1074/jbc.273.38.24360; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; Lauer-Fields JL, 2008, ANAL BIOCHEM, V373, P43, DOI 10.1016/j.ab.2007.09.014; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; Milner Jennifer M., 2005, Current Drug Targets - Inflammation and Allergy, V4, P363, DOI 10.2174/1568010054022141; Munteanu SE, 2000, ARTHRITIS RHEUM, V43, P2211, DOI 10.1002/1529-0131(200010)43:10<2211::AID-ANR8>3.0.CO;2-D; Murphy G, 2008, NAT CLIN PRACT RHEUM, V4, P128, DOI 10.1038/ncprheum0727; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OLSON ST, 1992, J BIOL CHEM, V267, P12528; Sahebjam S, 2007, ARTHRITIS RHEUM, V56, P905, DOI 10.1002/art.22427; Sandy JD, 2006, OSTEOARTHR CARTILAGE, V14, P95, DOI 10.1016/j.joca.2005.09.004; Song RH, 2007, ARTHRITIS RHEUM-US, V56, P575, DOI 10.1002/art.22334; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Struglics A, 2006, OSTEOARTHR CARTILAGE, V14, P101, DOI 10.1016/j.joca.2005.07.018; Takizawa M, 2000, ARTHRITIS RHEUM, V43, P812, DOI 10.1002/1529-0131(200004)43:4<812::AID-ANR11>3.0.CO;2-Y; Wang WM, 2006, BIOCHEM J, V398, P515, DOI 10.1042/BJ20060630; Wayne GJ, 2007, J BIOL CHEM, V282, P20991, DOI 10.1074/jbc.M610721200; Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	47	85	87	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3515	3524		10.1096/fj.08-112680	http://dx.doi.org/10.1096/fj.08-112680			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18632849	Green Published			2022-12-28	WOS:000259642600014
J	Kukley, M; Kiladze, M; Tognatta, R; Hans, M; Swandulla, D; Schramm, J; Dietrich, D				Kukley, Maria; Kiladze, Maia; Tognatta, Reshmi; Hans, Michael; Swandulla, Dieter; Schramm, Johannes; Dietrich, Dirk			Glial cells are born with synapses	FASEB JOURNAL			English	Article						NG2; proliferation; mitosis; GABA; glutamate; patch clamp	OLIGODENDROCYTE PRECURSOR CELLS; CENTRAL-NERVOUS-SYSTEM; PROGENITOR CELLS; WHITE-MATTER; GABAERGIC INTERNEURONS; SUBVENTRICULAR ZONE; NG2 PROTEOGLYCAN; OLFACTORY-BULB; BRAIN; CNS	In postnatal rodent brain, certain NG2-expressing oligodendroglial precursor cells (OPCs) are contacted by synaptic terminals from local neurons. However, it has remained elusive whether and when NG(2+) cells are integrated into neuronal circuits. Here we use patch-clamp recordings from mitotic cells in murine brain slices to show that, unlike any other cell in the central nervous system (CNS), cortical NG(2+) cells divide and relocate while being linked to synaptic junctions. Together with bromodeoxyuridine (BrdU) labeling, our recordings imply that cellular processes that bear synaptic junctions are surprisingly kept during cytokinesis and are inherited by the daughter cells. Cell cycle time (78 h) and relocation speed (5 mu m/day) are slowed, and NG(2+) cells largely divide symmetrically. Inheritance of synapses enables newborn glial cells to establish synaptic connections much faster than newborn neurons and ensures that the entire population of NG(2+) cells is exposed to synaptic signals from local axons. The results suggest that synapses do not only transmit neuronal activity but also act as environmental cues for the development of glial cells. Inheritance of synapses allows for the direct transfer of environmental interactions to clonal descendants of OPCs, which might be important for effective colonization and myelination of the developing brain.	[Hans, Michael; Swandulla, Dieter] Univ Bonn, Dept Physiol, D-5300 Bonn, Germany; [Kukley, Maria; Kiladze, Maia; Tognatta, Reshmi; Schramm, Johannes; Dietrich, Dirk] Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany	University of Bonn; University of Bonn	Kukley, M (corresponding author), Univ Clin Bonn, Dept Neurosurg, NCH U1 R035,Sigmund Freud Str 25, D-53105 Bonn, Germany.	maria.kukley@gmx.de; dirk.dietrich@ukb.uni-bonn.de	Messier, Claude/A-2322-2008; Kukley, Maria/I-4064-2017	Messier, Claude/0000-0002-4791-1763; Kukley, Maria/0000-0002-4567-1241; Kiladze, Maia/0000-0002-0656-0821				Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; BERGER T, 1991, J NEUROSCI, V11, P3008; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Brazel CY, 2003, PROG NEUROBIOL, V69, P49, DOI 10.1016/S0301-0082(03)00002-9; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Carleton A, 2003, NAT NEUROSCI, V6, P507, DOI 10.1038/nn1048; Cherubini E, 2001, TRENDS NEUROSCI, V24, P155, DOI 10.1016/S0166-2236(00)01724-0; Chittajallu R, 2004, J PHYSIOL-LONDON, V561, P109, DOI 10.1113/jphysiol.2004.074252; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Dayer AG, 2005, J CELL BIOL, V168, P415, DOI 10.1083/jcb.200407053; Dietrich D, 2003, NEURON, V39, P483, DOI 10.1016/S0896-6273(03)00430-6; Doetsch F, 2005, CURR OPIN NEUROBIOL, V15, P121, DOI 10.1016/j.conb.2005.01.018; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Goda Y, 2003, NEURON, V40, P243, DOI 10.1016/S0896-6273(03)00608-1; Horner PJ, 2002, J NEUROCYTOL, V31, P469, DOI 10.1023/A:1025739630398; Kessaris N, 2006, NAT NEUROSCI, V9, P173, DOI 10.1038/nn1620; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kukley M, 2004, J NEUROSCI, V24, P7128, DOI 10.1523/JNEUROSCI.2093-04.2004; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; Lin SC, 2005, NEURON, V46, P773, DOI 10.1016/j.neuron.2005.04.025; Lin SC, 2004, NAT NEUROSCI, V7, P24, DOI 10.1038/nn1162; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; Miller RH, 2002, PROG NEUROBIOL, V67, P451, DOI 10.1016/S0301-0082(02)00058-8; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; Nishiyama A, 2007, NEUROSCIENTIST, V13, P62, DOI 10.1177/1073858406295586; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Petreanu L, 2002, J NEUROSCI, V22, P6106; QUASTLER H, 1959, EXP CELL RES, V17, P420, DOI 10.1016/0014-4827(59)90063-1; Reynolds R, 1997, J NEUROSCI RES, V47, P455, DOI 10.1002/(SICI)1097-4547(19970301)47:5<455::AID-JNR1>3.0.CO;2-G; SASAKI K, 1993, CYTOMETRY, V14, P876, DOI 10.1002/cyto.990140805; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Trapp BD, 1997, J CELL BIOL, V137, P459, DOI 10.1083/jcb.137.2.459; Yuan XQ, 1998, DEVELOPMENT, V125, P2901; ZAJICEK J, 1994, BRAIN, V117, P1333, DOI 10.1093/brain/117.6.1333; Zhu XQ, 2008, DEVELOPMENT, V135, P145, DOI 10.1242/dev.004895; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	46	96	99	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2957	2969		10.1096/fj.07-090985	http://dx.doi.org/10.1096/fj.07-090985			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18467596				2022-12-28	WOS:000258089300036
J	Qin, K; Sethi, PR; Lambert, NA				Qin, Kou; Sethi, Pooja R.; Lambert, Nevin A.			Abundance and stability of complexes containing inactive G protein-coupled receptors and G proteins	FASEB JOURNAL			English	Article						FRAP; heterotrimers; precoupling; collision	RESONANCE ENERGY-TRANSFER; BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; 3RD-INTRACELLULAR LOOP; PLASMA-MEMBRANE; GIRK CHANNELS; GAMMA COMPLEX; IN-VIVO; BINDING; AGONIST	G protein-coupled receptors (GPCRs) interact directly with heterotrimeric G proteins to transduce physiological signals. Early studies of this interaction concluded that GPCRs (R) and G proteins (G) collide with each other randomly after receptor activation and that R-G complexes are transient. More recent studies have suggested that inactive R and G are preassembled (precoupled) as stable R-G complexes. Here we examine the stability of complexes formed between cyan fluorescent protein-labeled alpha(2A)-adrenore-ceptors (C-alpha 2ARs) and G proteins in cells using fluorescence recovery after photobleaching (FRAP). Labeled G proteins diffused in the plasma membrane with equal mobility in the absence and presence of immobile C-alpha 2ARs. Immobile C-alpha 2ARs activated labeled G proteins, demonstrating functional coupling without stable physical association. In contrast, a stable R-G interaction was detected when G proteins were deprived of nucleotides and C-alpha 2ARs were active, as predicted by the ternary complex model. Overexpression of regulator of G protein signaling 4 (RGS4) accelerated the onset of effector activation but did not detectably alter the interaction between C-alpha 2ARs and G proteins. We conclude that at most a small fraction of C-alpha 2ARs and G proteins exist as R-G complexes at any moment.	[Qin, Kou] Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30809 USA; Med Coll Georgia, Grad Program Neurosci, Augusta, GA 30809 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Qin, K (corresponding author), Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30809 USA.	nlambert@mcg.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078319] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akgoz M, 2004, J BIOL CHEM, V279, P51541, DOI 10.1074/jbc.M410639200; Akgoz M, 2006, CELL SIGNAL, V18, P1758, DOI 10.1016/j.cellsig.2006.01.016; Ayoub MA, 2007, MOL PHARMACOL, V71, P1329, DOI 10.1124/mol.106.030304; Azpiazu I, 2004, J BIOL CHEM, V279, P27709, DOI 10.1074/jbc.M403712200; Benians A, 2005, J BIOL CHEM, V280, P13383, DOI 10.1074/jbc.M410163200; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Carrero G, 2003, METHODS, V29, P14, DOI 10.1016/S1046-2023(02)00288-8; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Digby GJ, 2006, P NATL ACAD SCI USA, V103, P17789, DOI 10.1073/pnas.0607116103; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Dushek O, 2008, J BIOCHEM BIOPH METH, V70, P1224, DOI 10.1016/j.jbbm.2007.07.002; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Fernandez-Fernandez JM, 2001, EUR J NEUROSCI, V14, P283, DOI 10.1046/j.0953-816x.2001.01642.x; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAESER D, 1993, MOL PHARMACOL, V43, P434; Hague C, 2005, J BIOL CHEM, V280, P27289, DOI 10.1074/jbc.M502365200; Hein P, 2005, EMBO J, V24, P4106, DOI 10.1038/sj.emboj.7600870; Hynes TR, 2004, J BIOL CHEM, V279, P30279, DOI 10.1074/jbc.M401432200; Jeong SW, 2001, J PHYSIOL-LONDON, V535, P335, DOI 10.1111/j.1469-7793.2001.00335.x; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NEUBIG RR, 1988, BIOCHEMISTRY-US, V27, P2374, DOI 10.1021/bi00407a019; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; Phair RD, 2004, METHOD ENZYMOL, V375, P393; Philip F, 2007, J BIOL CHEM, V282, P19203, DOI 10.1074/jbc.M701558200; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Sprague BL, 2005, TRENDS CELL BIOL, V15, P84, DOI 10.1016/j.tcb.2004.12.001; Sprague BL, 2004, BIOPHYS J, V86, P3473, DOI 10.1529/biophysj.103.026765; TOLKOVSKY AM, 1978, BIOCHEMISTRY-US, V17, P3795, DOI 10.1021/bi00611a020; Vogel Steven S, 2006, Sci STKE, V2006, pre2; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151	39	50	50	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2920	2927		10.1096/fj.08-105775	http://dx.doi.org/10.1096/fj.08-105775			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18434433	Green Published, Green Accepted			2022-12-28	WOS:000258089300032
J	Yuan, SP; Fu, Y; Wang, XF; Shi, HB; Huang, YJ; Song, XM; Li, L; Song, N; Luo, YZ				Yuan, Shaopeng; Fu, Yan; Wang, Xiaofeng; Shi, Hubing; Huang, Yujie; Song, Xiaomin; Li, Ling; Song, Nan; Luo, Yongzhang			Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis	FASEB JOURNAL			English	Article						angiogenesis; endothelium; hexokinase; mitochondria; metabolism	PERMEABILITY TRANSITION PORE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CYTOCHROME-C RELEASE; HEXOKINASE-II; MITOCHONDRIAL BINDING; TUMOR ANGIOGENESIS; IN-VIVO; KINASE; GROWTH; DEATH	in endothelial cells, but the exact mechanism remains controversial. In the present study, we elucidate the mechanism of ES-induced endothelial cell apoptosis. Our results indicate that ES induces cytochrome c release and caspase-9 activation in human microvascular endothelial cells (HMECs) at the concentration of 1 mu M for 24 h, which initiates the apoptosis process. Further, ATP production, mitochondrial membrane potential, and tubule formation assays showed that ES promotes the mitochondrial permeability transition pore (mPTP) opening via voltage-dependent anion channel 1 (VDAC1), a major component of mitochondrial outer membrane. Knocking down VDAC1 by small interfering RNA attenuates ES-induced apoptosis, while overexpression of VDAC1 enhances the sensitivity of endothelial cells to ES. Moreover, we reveal that ES induces the reduction of hexokinase 2 (HK2), which, in turn, promotes VDAC1 phosphorylation and accumulation. Data from two-dimensional electrophoresis, immunoprecipitation, mPTP opening, and caspase-3 activation assays indicate that two serine residues of VDAC1, Ser-12 and Ser-103, can modulate VDAC1 protein level and thus the sensitivity to apoptosis stimuli. On the basis of these findings, we conclude that VDAC1 plays a vital role in modulating ES-induced endothelial cell apoptosis.	[Yuan, Shaopeng; Fu, Yan; Wang, Xiaofeng; Shi, Hubing; Huang, Yujie; Song, Xiaomin; Li, Ling; Song, Nan; Luo, Yongzhang] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing Key Lab Prot Therapeut, Prot Chem Lab, Beijing 100084, Peoples R China	Tsinghua University	Luo, YZ (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing Key Lab Prot Therapeut, Prot Chem Lab, Beijing 100084, Peoples R China.	protein@tsinghua.edu.cn	Song, Nan/T-9778-2018; Shi, Hubing/B-8445-2014	Song, Nan/0000-0002-7442-7475; Song, Xiaomin/0000-0002-2586-9285				Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Abu-Hamad S, 2006, P NATL ACAD SCI USA, V103, P5787, DOI 10.1073/pnas.0600103103; Adachi M, 2004, AM J PHYSIOL-GASTR L, V287, pG695, DOI 10.1152/ajpgi.00415.2003; Addison CL, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-38; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Banerjee J, 2006, J NEUROCHEM, V98, P670, DOI 10.1111/j.1471-4159.2006.03853.x; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Davidson SM, 2007, CIRC RES, V100, P1128, DOI 10.1161/01.RES.0000261970.18328.1d; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Distler AM, 2007, BBA-PROTEINS PROTEOM, V1774, P628, DOI 10.1016/j.bbapap.2007.03.012; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Don AS, 2003, CANCER CELL, V3, P497, DOI 10.1016/S1535-6108(03)00109-0; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HEIDEN, 2000, P NATL ACAD SCI USA, V97, P4666; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Jacotot E, 1999, ANN NY ACAD SCI, V887, P18, DOI 10.1111/j.1749-6632.1999.tb07919.x; Jiang LW, 2001, AM J PHYSIOL-CELL PH, V280, pC1140, DOI 10.1152/ajpcell.2001.280.5.C1140; Kang HY, 2006, J BIOCHEM MOL BIOL, V39, P97; Khan ZA, 2006, BLOOD, V108, P915, DOI 10.1182/blood-2006-03-006478; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Le Mellay V, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-14; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Shi HB, 2007, BLOOD, V110, P2899, DOI 10.1182/blood-2007-01-064428; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Skovseth DK, 2005, BLOOD, V105, P1044, DOI 10.1182/blood-2004-03-1164; Sun L, 2008, MOL CELL BIOL, V28, P1007, DOI 10.1128/MCB.00224-07; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Walter DH, 1998, CIRCULATION, V98, P1153, DOI 10.1161/01.CIR.98.12.1153; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yasuda S, 2004, J HEPATOL, V40, P117, DOI 10.1016/S0168-8278(03)00503-8; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205	47	122	132	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2809	2820		10.1096/fj.08-107417	http://dx.doi.org/10.1096/fj.08-107417			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18381814				2022-12-28	WOS:000258089300021
J	Lavigne, MD; Yates, L; Coxhead, P; Gorecki, DC				Lavigne, Matthieu D.; Yates, Laura; Coxhead, Peter; Gorecki, Dariusz C.			Nuclear-targeted chimeric vector enhancing nonviral gene transfer into skeletal muscle of Fabry mice in vivo	FASEB JOURNAL			English	Article						cell penetration peptides; gene therapy; TAT; pluronic	ALPHA-GALACTOSIDASE-A; PROTEIN TRANSDUCTION DOMAIN; INTRACELLULAR DELIVERY; ENZYME REPLACEMENT; HIV TAT; DNA; EXPRESSION; PEPTIDE; TRANSPORT; POLYMERS	Poor nuclear entry, especially into nondividing cells, is a limiting factor in nonviral gene delivery. We have engineered a novel chimeric vector relying on the controlled assembly of a TAT-tagged multisubunit DNA binding protein (EcoR124I) with expression plasmids containing the EcoR124I recognition site. Molecular interactions of this molecular assembly were studied by electrophoretic mobility shift assay and atomic force microscopy. Maintenance of nanocomplexes in an appropriate stoichiometric ratio was both necessary and sufficient to produce a significant (> 8-fold) increase in the activity of the therapeutic alpha-galactosidase A enzyme after intramuscular administration in the mouse model of Fabry disease. To our knowledge, this is the first molecular targeting system significantly enhancing plasmid-based expression in skeletal muscle. Coinjection with pluronic SP1017 produced further enhancement of gene expression, demonstrating cumulative effects of the increased nuclear delivery by TAT chimeras and transcription activation by the pluronic. Cell penetration peptides (CPP), such as TAT, have been shown to improve delivery of macromolecules, when linked directly. However, in our system TAT-enhanced targeting took place even though it was linked to the plasmid DNA molecule indirectly via two noncovalent bonds. Therefore, this proof-of principle result indicates that TAT (and potentially other CPP) can be used for targeting modular chimeric vectors and therapeutic nanodevices.	[Lavigne, Matthieu D.; Yates, Laura; Gorecki, Dariusz C.] Univ Portsmouth, Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England; [Coxhead, Peter] Univ Portsmouth, Inst Biomed & Biomol Sci, Sch Biol Sci, Portsmouth PO1 2DT, Hants, England	University of Portsmouth; University of Portsmouth	Gorecki, DC (corresponding author), Univ Portsmouth, Inst Biomed & Biomol Sci, Sch Pharm & Biomed Sci, St Michaels Bldg,White Swan Rd, Portsmouth PO1 2DT, Hants, England.	darek.gorecki@port.ac.uk		Lavigne, Matthieu/0000-0003-1543-8745; Coxhead, Peter/0000-0001-7550-0235; Yates, Laura/0000-0002-1620-1603; Gorecki, Dariusz/0000-0003-3584-1654	Wellcome Trust [067484] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beck M, 2007, HUM GENET, V121, P1, DOI 10.1007/s00439-006-0280-4; Benenson Y, 2004, NATURE, V429, P423, DOI 10.1038/nature02551; Cardarelli F, 2007, MOL THER, V15, P1313, DOI 10.1038/sj.mt.6300172; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635; Chan CK, 1999, HUM GENE THER, V10, P1695, DOI 10.1089/10430349950017699; Chang CW, 2007, J CONTROL RELEASE, V118, P245, DOI 10.1016/j.jconrel.2006.11.025; Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031; Chen L, 2007, BIOCHEM SOC T, V35, P821, DOI 10.1042/BST0350821; Dean DA, 2005, GENE THER, V12, P881, DOI 10.1038/sj.gt.3302534; Desnick RJ, 2003, ANN INTERN MED, V138, P338, DOI 10.7326/0003-4819-138-4-200302180-00014; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Gorecki Dariusz C, 2006, Discov Med, V6, P191; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Ioannou YA, 2001, AM J HUM GENET, V68, P14, DOI 10.1086/316953; Janscak P, 1996, J MOL BIOL, V257, P977, DOI 10.1006/jmbi.1996.0217; Lavigne MD, 2007, J GENE MED, V9, P44, DOI 10.1002/jgm.992; Lavigne MD, 2005, MOL THER, V12, P985, DOI 10.1016/j.ymthe.2005.02.032; Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Mernagh DR, 1998, BIOL CHEM, V379, P497, DOI 10.1515/bchm.1998.379.4-5.497; Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900; Novo FJ, 1997, GENE THER, V4, P488, DOI 10.1038/sj.gt.3300410; Ohshima T, 1997, P NATL ACAD SCI USA, V94, P2540, DOI 10.1073/pnas.94.6.2540; PATEL J, 1992, GENE, V112, P21, DOI 10.1016/0378-1119(92)90298-4; Pennadam SS, 2007, LANGMUIR, V23, P41, DOI 10.1021/la061992a; Pennadam Sivanand S, 2004, J Nanobiotechnology, V2, P8, DOI 10.1186/1477-3155-2-8; Pennadam SS, 2004, J AM CHEM SOC, V126, P13208, DOI 10.1021/ja045275j; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Rajagopalan R, 2007, J GENE MED, V9, P275, DOI 10.1002/jgm.1014; Ramaswami U, 2007, ACTA PAEDIATR, V96, P122, DOI 10.1111/j.1651-2227.2007.00029.x; Ratanamart J, 2006, CURR GENE THER, V6, P93, DOI 10.2174/156652306775515583; Renigunta A, 2006, BIOCONJUGATE CHEM, V17, P327, DOI 10.1021/bc050263o; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seelig G, 2006, SCIENCE, V314, P1585, DOI 10.1126/science.1132493; Seidel R, 2004, NAT STRUCT MOL BIOL, V11, P838, DOI 10.1038/nsmb816; Seidel R, 2007, CURR OPIN STRUC BIOL, V17, P80, DOI 10.1016/j.sbi.2006.12.003; Sloots A, 2005, FEBS J, V272, P4221, DOI 10.1111/j.1742-4658.2005.04834.x; Sriadibhatla S, 2006, MOL THER, V13, P804, DOI 10.1016/j.ymthe.2005.07.701; Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013; TAYLOR I, 1992, NUCLEIC ACIDS RES, V20, P179, DOI 10.1093/nar/20.2.179; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Torchinsky A, 2006, AM J REPROD IMMUNOL, V55, P36, DOI 10.1111/j.1600-0897.2005.00321.x; Torchinsky Arkady, 2002, BMC Dev Biol, V2, P2, DOI 10.1186/1471-213X-2-2; Toro A, 2006, J CLIN INVEST, V116, P2717, DOI 10.1172/JCI25052; Trollet C, 2006, CURR GENE THER, V6, P561, DOI 10.2174/156652306778520656; Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com; Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1; Twaites BR, 2005, J CONTROL RELEASE, V108, P472, DOI 10.1016/j.jconrel.2005.08.009; Twaites BR, 2004, J CONTROL RELEASE, V97, P551, DOI 10.1016/j.jconrel.2004.03.032; Utvik JK, 1999, HUM GENE THER, V10, P291, DOI 10.1089/10430349950019075; Vaysse L, 2006, J GENE MED, V8, P754, DOI 10.1002/jgm.883; Volcke C, 2006, J BIOTECHNOL, V125, P11, DOI 10.1016/j.jbiotec.2006.02.010; Wagstaff KM, 2007, MOL THER, V15, P721, DOI 10.1038/sj.mt.6300093; Yoshimitsu M, 2006, CIRC J, V70, P1503, DOI 10.1253/circj.70.1503; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Ziegler RJ, 2004, MOL THER, V9, P231, DOI 10.1016/j.ymthe.2003.11.015; Zinkevich V, 1997, NUCLEIC ACIDS RES, V25, P503, DOI 10.1093/nar/25.3.503	60	17	20	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2097	2107		10.1096/fj.07-093765	http://dx.doi.org/10.1096/fj.07-093765			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18202142				2022-12-28	WOS:000256352700049
J	Tozuka, Y; Wada, E; Wada, K				Tozuka, Yusuke; Wada, Etsuko; Wada, Keiji			Diet-induced obesity in female mice leads to peroxidized lipid accumulations and impairment of hippocampal neurogenesis during the early life of their offspring	FASEB JOURNAL			English	Article						lactation; neural progenitor cells; hight-fat diet; metabolic abnormalities; oxidative stress; brain development	NEURAL PRECURSOR CELLS; HIGH-FAT DIET; SYNAPTIC PLASTICITY; ADULT NEUROGENESIS; INSULIN-RESISTANCE; OXIDATIVE STRESS; CHOLINE AVAILABILITY; CIRCULATING LEVELS; PROGENITOR CELLS; MILK-COMPOSITION	Maternal obesity may affect the child's long-term development and health. However, there is little information about the involvement of maternal obesity in the brain development of offspring. Here, we investigated the effects of maternal obesity on the hippocampal formation of offspring. Adult female mice were fed either a normal diet (ND, 4% fat) or a high-fat diet (HFD, 32% fat) 6 wk before mating and throughout pregnancy and the majority of lactation. We found that infants from HFD-fed dams (HFD offspring) showed obesity and hyperlipidemia during suckling. In HFD offspring, lipid peroxidation was promoted in serum and the hippocampal dentate gyrus, where neurogenesis takes place throughout postnatal life. Using a BrdU-pulse labeling study, we showed that malondialdehyde, a product of peroxidized lipids, reduced the proliferation of hippocampal progenitor cells in vitro and that neurogenesis in HFD offspring during postnatal development was similarly lowered relative to the ND animals. These results indicated that maternal obesity impairs hippocampal progenitor cell division and neuronal production in young offspring possibly due to metabolic and oxidative changes.-Tozuka, Y., Wada, E., Wada, K. Diet-induced obesity in female mice leads to peroxidized lipid accumulations and impairment of hippocampal neurogenesis during the early life of their offspring. FASEB J. 23, 1920-1934 (2009)	[Tozuka, Yusuke; Wada, Etsuko; Wada, Keiji] Natl Ctr Neurol & Psychiat, Dept Degenerat Neurol Dis, Natl Inst Neurosci, Tokyo 1878502, Japan; [Tozuka, Yusuke] Japan Assoc Adv Med Equipment, Tokyo, Japan; [Tozuka, Yusuke; Wada, Etsuko; Wada, Keiji] Japan Sci & Technol Agcy, Saitama, Japan	National Center for Neurology & Psychiatry - Japan; Japan Science & Technology Agency (JST)	Wada, K (corresponding author), Natl Ctr Neurol & Psychiat, Dept Degenerat Neurol Dis, Natl Inst Neurosci, 4-1-1 Ogawahigasi, Tokyo 1878502, Japan.	wada@ncnp.go.jp			Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Masayuki Sekiguchi (NCNP), Satoshi Nagamine (NCNP), Tomohiro Kabuta (NCNP), H. Akiko Popiel (NCNP), Daisuke Yamada (CNP), and Motoko Maekawa (RIKEN) for informative discussions and insightful comments. We are also grateful to Hisae Kikuchi ( NCNP), Mami Kumon (NCNP), and Noboru Ohsawa (Waseda University) for technical assistance. This work was supported in part by grants-in-aid for scientific research from the Ministry of Health, Labour and Welfare of Japan; grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation; and a grant from the Japan Science and Technology Agency.	Andersen RE, 2000, CAN MED ASSOC J, V163, P1461; Bergami M, 2008, P NATL ACAD SCI USA, V105, P15570, DOI 10.1073/pnas.0803702105; Bick-Sander A, 2006, P NATL ACAD SCI USA, V103, P3852, DOI 10.1073/pnas.0502644103; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; Casolini P, 2007, J NEUROSCI, V27, P7041, DOI 10.1523/JNEUROSCI.1074-07.2007; Cerf ME, 2005, AM J PHYSIOL-REG I, V288, pR1122, DOI 10.1152/ajpregu.00335.2004; Cetina I, 2008, CURR OPIN CLIN NUTR, V11, P297, DOI 10.1097/MCO.0b013e3282f795e6; Chan O, 2001, ENDOCRINOLOGY, V142, P4872, DOI 10.1210/en.142.11.4872; Chang GQ, 2008, J NEUROSCI, V28, P12107, DOI 10.1523/JNEUROSCI.2642-08.2008; CHAPMAN RH, 1979, DEV PSYCHOBIOL, V12, P255, DOI 10.1002/dev.420120309; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; Cserjesi R, 2007, APPETITE, V49, P675, DOI 10.1016/j.appet.2007.04.001; DACOSTA THM, 1993, BIOCHEM J, V290, P557, DOI 10.1042/bj2900557; DelPrado M, 1997, J NUTR, V127, P458, DOI 10.1093/jn/127.3.458; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Farioli-Vecchioli S, 2008, PLOS BIOL, V6, P2188, DOI 10.1371/journal.pbio.0060246; Ferezou-Viala J, 2007, AM J PHYSIOL-REG I, V293, pR1056, DOI 10.1152/ajpregu.00117.2007; Fukuda S, 2003, J NEUROSCI, V23, P9357; Giedzinski E, 2005, RADIAT RES, V164, P540, DOI 10.1667/RR3369.1; Glenn MJ, 2007, EUR J NEUROSCI, V25, P2473, DOI 10.1111/j.1460-9568.2007.05505.x; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Herrera DG, 2003, P NATL ACAD SCI USA, V100, P7919, DOI 10.1073/pnas.1230907100; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Innis SM, 2005, PLACENTA, V26, pS70, DOI 10.1016/j.placenta.2005.01.005; Jones HN, 2007, PLACENTA, V28, P763, DOI 10.1016/j.placenta.2007.05.002; Jones HN, 2009, FASEB J, V23, P271, DOI 10.1096/fj.08-116889; Kabuta T, 2006, J BIOL CHEM, V281, P30524, DOI 10.1074/jbc.M603337200; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Lee HH, 2006, BRAIN DEV-JPN, V28, P147, DOI 10.1016/j.braindev.2005.05.007; Limoli CL, 2004, RADIAT RES, V161, P17, DOI 10.1667/RR3112; Lindqvist A, 2006, EUR J NEUROL, V13, P1385, DOI 10.1111/j.1468-1331.2006.01500.x; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Maekawa M, 2005, GENES CELLS, V10, P1001, DOI 10.1111/j.1365-2443.2005.00893.x; Manganas LN, 2007, SCIENCE, V318, P980, DOI 10.1126/science.1147851; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mirescu C, 2004, NAT NEUROSCI, V7, P841, DOI 10.1038/nn1290; Mohn A, 2005, J CLIN ENDOCR METAB, V90, P2653, DOI 10.1210/jc.2004-2178; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Muhlhausler BS, 2006, FASEB J, V20, P1257, DOI 10.1096/fj.05-5241fje; NAEYE RL, 1990, AM J CLIN NUTR, V52, P273, DOI 10.1093/ajcn/52.2.273; NICHOLAS KR, 1991, COMP BIOCHEM PHYS A, V98, P535, DOI 10.1016/0300-9629(91)90443-G; Nishimoto M, 2007, GLIA, V55, P317, DOI 10.1002/glia.20461; Nixon K, 2004, J NEUROSCI, V24, P9714, DOI 10.1523/JNEUROSCI.3063-04.2004; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Oike Y, 2005, NAT MED, V11, P400, DOI 10.1038/nm1214; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Samuelsson AM, 2008, HYPERTENSION, V51, P383, DOI 10.1161/HYPERTENSIONAHA.107.101477; Sarafidis PA, 2007, J HUM HYPERTENS, V21, P12, DOI 10.1038/sj.jhh.1002103; Sava V, 2007, TOXICOL SCI, V98, P187, DOI 10.1093/toxsci/kfm093; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Shankar K, 2008, AM J PHYSIOL-REG I, V294, pR528, DOI 10.1152/ajpregu.00316.2007; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; Srinivasan M, 2006, AM J PHYSIOL-ENDOC M, V291, pE792, DOI 10.1152/ajpendo.00078.2006; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; Stranahan AM, 2008, NAT NEUROSCI, V11, P309, DOI 10.1038/nn2055; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Sun AY, 2001, J BIOMED SCI, V8, P37, DOI 10.1007/BF02255969; Tanaka Y, 2009, CEREB CORTEX, V19, P2181, DOI 10.1093/cercor/bhn238; Tozuka Y, 2005, NEURON, V47, P803, DOI 10.1016/j.neuron.2005.08.023; Tripathy D, 2003, DIABETES, V52, P2882, DOI 10.2337/diabetes.52.12.2882; Trottier G, 1998, ENDOCRINOLOGY, V139, P3704, DOI 10.1210/en.139.9.3704; Wong-Goodrich SJE, 2008, NEUROBIOL DIS, V30, P255, DOI 10.1016/j.nbd.2008.01.008; Wong-Goodrich SJE, 2008, BRAIN RES, V1237, P153, DOI 10.1016/j.brainres.2008.08.074; Woollett LA, 2005, AM J CLIN NUTR, V82, P1155, DOI 10.1093/ajcn/82.6.1155; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Yamaguchi Y, 2006, NITRIC OXIDE-BIOL CH, V15, P380, DOI 10.1016/j.niox.2006.04.264; Yamato M, 2007, FEBS J, V274, P3855, DOI 10.1111/j.1742-4658.2007.05914.x; Yang JL, 2006, HIPPOCAMPUS, V16, P431, DOI 10.1002/hipo.20181; YOGMAN MW, 1985, AM J CLIN NUTR, V42, P352, DOI 10.1093/ajcn/42.2.352; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562; Zhang WJ, 2008, ACTA NEUROL SCAND, V117, P205, DOI 10.1111/j.1600-0404.2007.00928.x	76	126	129	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1920	1934		10.1096/fj.08-124784	http://dx.doi.org/10.1096/fj.08-124784			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19158155				2022-12-28	WOS:000266652400031
J	van Schothorst, EM; Bunschoten, A; Schrauwen, P; Mensink, RP; Keijer, J				van Schothorst, Evert M.; Bunschoten, Annelies; Schrauwen, Patrick; Mensink, Ronald P.; Keijer, Jaap			Effects of a high-fat, low- versus high-glycemic index diet: retardation of insulin resistance involves adipose tissue modulation	FASEB JOURNAL			English	Article						carbohydrate; adipokines; glucose tolerance	LIPID-METABOLISM; STARCH PROMOTES; GLUCOSE; OBESITY; CARBOHYDRATE; PROTEIN; LEPTIN; RAT; ADIPONECTIN; ADIPOCYTES	Beneficial effects of low glycemic index (GI) diets in rodents have been studied using healthy low-fat diets, while the effects might be different on high-fat diets inducing progression of insulin resistance. We fed C57BL/6J male mice high-fat low/high-GI (LGI/HGI) diets for 13 wk. Glucose and insulin tolerance and serum substrates, including adipokines, were measured longitudinally. The LGI group showed a significantly higher glucose tolerance from wk 2 onwards, which was supported by lower serum insulin and free fatty acids levels at 8 wk, and a tendency for lower leptin levels, while resistin levels remained similar. At 11 wk, when differences in serum resistin started to increase, differences in serum insulin were diminished. Although food intake was similar throughout the study, body weights and epididymal adipose tissue mass became significantly lower in the LGI group at necropsy. Several serum substrates and adipose tissue leptin mRNA levels, as analyzed by Q-PCR, were, again, significantly lower, whereas adiponectin mRNA levels were higher. Taken together, an LGI high-fat diet maintains higher glucose tolerance and insulin sensitivity via adipose tissue modulation solely because of a difference in the type of carbohydrate, supporting a nutritional approach in the fight against insulin resistance.-Van Schothorst, E. M., Bunschoten, A., Schrauwen, P., Mensink, R. P., Keijer, J. Effects of a high-fat, low versus high glycemic index diet: retardation of insulin resistance involves adipose tissue modulation. FASEB J. 23, 1092-1101 (2009)	[van Schothorst, Evert M.; Bunschoten, Annelies; Keijer, Jaap] Wageningen Univ, NL-6700 AH Wageningen, Netherlands; [van Schothorst, Evert M.; Bunschoten, Annelies; Schrauwen, Patrick; Mensink, Ronald P.; Keijer, Jaap] Top Inst Food & Nutr, Wageningen, Netherlands; [van Schothorst, Evert M.; Bunschoten, Annelies; Keijer, Jaap] Univ Wageningen & Res Ctr, RIKILT, Inst Food Safety, Wageningen, Netherlands; [Schrauwen, Patrick; Mensink, Ronald P.] Maastricht Univ, Dept Human Biol, Maastricht, Netherlands	Wageningen University & Research; Top Institute Food & Nutrition; Wageningen University & Research; Maastricht University	van Schothorst, EM (corresponding author), Wageningen Univ, Marijkeweg 40,POB 338, NL-6700 AH Wageningen, Netherlands.	evert.vanschothorst@wur.nl	Keijer, Jaap/J-8089-2013	Keijer, Jaap/0000-0002-9720-7491; van Schothorst, Evert/0000-0002-3036-5903; schrauwen, patrick/0000-0002-0973-847X				Anderwald C, 2007, EUR J CLIN INVEST, V37, P774, DOI 10.1111/j.1365-2362.2007.01858.x; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Brand-Miller JC, 2003, DIABETES CARE, V26, P3363, DOI 10.2337/diacare.26.12.3363; Browning LM, 2006, DIABETES TECHNOL THE, V8, P45, DOI 10.1089/dia.2006.8.45; Bullen JW, 2007, AM J PHYSIOL-ENDOC M, V292, pE1079, DOI 10.1152/ajpendo.00245.2006; BYRNES SE, 1995, J NUTR, V125, P1430; de Boer VCJ, 2006, CELL MOL LIFE SCI, V63, P2847, DOI 10.1007/s00018-006-6316-z; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Herrmann TS, 2001, EXP BIOL MED, V226, P1037, DOI 10.1177/153537020122601111; Higgins JA, 1996, J NUTR, V126, P596, DOI 10.1093/jn/126.3.596; James PT, 2004, CLIN DERMATOL, V22, P276, DOI 10.1016/j.clindermatol.2004.01.010; JENKINS DJA, 1978, BRIT MED J, V1, P1392, DOI 10.1136/bmj.1.6124.1392; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; Jensen L, 2008, AM J CLIN NUTR, V87, P97, DOI 10.1093/ajcn/87.1.97; Kabir M, 1998, J NUTR, V128, P1878, DOI 10.1093/jn/128.11.1878; Kabir M, 1998, J NUTR, V128, P35, DOI 10.1093/jn/128.1.35; Kabir M, 2000, METABOLISM, V49, P764, DOI 10.1053/meta.2000.6258; Keijer J, 2008, CURR OPIN LIPIDOL, V19, P4, DOI 10.1097/MOL.0b013e3282f39f95; Kiens B, 1996, AM J CLIN NUTR, V63, P47, DOI 10.1093/ajcn/63.1.47; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; KREIJL CFK, 2004, OUR FOOD OUR HLTH HL; Lazar MA, 2007, HORM METAB RES, V39, P710, DOI 10.1055/s-2007-985897; Lee JH, 2005, AM J PHYSIOL-ENDOC M, V288, pE625, DOI 10.1152/ajpendo.00184.2004; LererMetzger M, 1996, BRIT J NUTR, V75, P723, DOI 10.1079/BJN19960176; Lockridge JB, 2008, J LIPID RES, V49, P1395, DOI 10.1194/jlr.M700517-JLR200; Ludwig DS, 2007, LANCET, V369, P890, DOI 10.1016/S0140-6736(07)60427-9; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Muurling M, 2003, J NUTR, V133, P3350, DOI 10.1093/jn/133.11.3350; Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7; Pawlak DB, 2001, J NUTR, V131, P99, DOI 10.1093/jn/131.1.99; Petro AE, 2004, METABOLISM, V53, P454, DOI 10.1016/j.metabol.2003.11.018; Pravenec M, 2003, J BIOL CHEM, V278, P45209, DOI 10.1074/jbc.M304869200; Rocca AS, 2001, ENDOCRINOLOGY, V142, P1148, DOI 10.1210/en.142.3.1148; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Scribner KB, 2007, OBESITY, V15, P2190, DOI 10.1038/oby.2007.260; Stienstra R, 2007, ENDOCRINOLOGY, V148, P2753, DOI 10.1210/en.2007-0014; Taketani Yutaka, 2007, J Med Invest, V54, P359, DOI 10.2152/jmi.54.359; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Van Schothorst EM, 2005, OBES RES, V13, P1031, DOI 10.1038/oby.2005.121; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Waki H, 2007, ANNU REV PATHOL-MECH, V2, P31, DOI 10.1146/annurev.pathol.2.010506.091859; Walker CG, 2002, HORM METAB RES, V34, P176, DOI 10.1055/s-2002-26707; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; Wang P, 2008, J CELL PHYSIOL, V216, P3, DOI 10.1002/jcp.21386; WRIGHT JD, 2003, ADV DATA VITAL HLTH, V334; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	51	41	41	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1092	1101		10.1096/fj.08-117119	http://dx.doi.org/10.1096/fj.08-117119			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19029198	Green Submitted			2022-12-28	WOS:000266651600013
J	Yakar, S; Rosen, CJ; Bouxsein, ML; Sun, H; Mejia, W; Kawashima, Y; Wu, YJ; Emerton, K; Williams, V; Jepsen, K; Schaffler, MB; Majeska, RJ; Gavrilova, O; Gutierrez, M; Hwang, D; Pennisi, P; Frystyk, J; Boisclair, Y; Pintar, J; Jasper, H; Domene, H; Cohen, P; Clemmons, D; LeRoith, D				Yakar, Shoshana; Rosen, Clifford J.; Bouxsein, Mary L.; Sun, Hui; Mejia, Wilson; Kawashima, Yuki; Wu, Yingjie; Emerton, Kelly; Williams, Valerie; Jepsen, Karl; Schaffler, Mitchell B.; Majeska, Robert J.; Gavrilova, Oksana; Gutierrez, Mariana; Hwang, David; Pennisi, Patricia; Frystyk, Jan; Boisclair, Yves; Pintar, John; Jasper, Hector; Domene, Horacio; Cohen, Pinchas; Clemmons, David; LeRoith, Derek			Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism	FASEB JOURNAL			English	Article						cortical bone; trabecular bone; osteoblast; osteoclast; ternary complex; binary complex	ACID-LABILE SUBUNIT; FACTOR-BINDING PROTEIN-5; TYPE-1 IGF RECEPTOR; BONE-MINERAL DENSITY; BREAST-CANCER CELLS; TRANSGENIC MICE; SECRETING CELLS; FACTOR SYSTEM; GENE; HORMONE	Serum insulin-like growth factor (IGF)-1 is secreted mainly by the liver and circulates bound to IGF-binding proteins (IGFBPs), either as binary complexes or ternary complexes with IGFBP-3 or IGFBP-5 and an acid-labile subunit (ALS). The purpose of this study was to genetically dissect the role of IGF-1 circulatory complexes in somatic growth, skeletal integrity, and metabolism. Phenotypic comparisons of controls and four mouse lines with genetic IGF-1 deficits liver-specific IGF-1 deficiency (LID), ALS knockout (ALSKO), IGFBP-3 (BP3) knockout, and a triply deficient LID/ALSKO/BP3 line-produced several novel findings. 1) All deficient strains had decreased serum IGF-1 levels, but this neither predicted growth potential or skeletal integrity nor defined growth hormone secretion or metabolic abnormalities. 2) IGF-1 deficiency affected development of both cortical and trabecular bone differently, effects apparently dependent on the presence of different circulating IGF-1 complexes. 3) IGFBP-3 deficiency resulted in increased linear growth. In summary, each IGF-1 complex constituent appears to play a distinct role in determining skeletal phenotype, with different effects on cortical and trabecular bone compartments.-Yakar, S., Rosen, C. J., Bouxsein, M. L., Sun, H., Mejia, W., Kawashima, Y., Wu, Y., Emerton, K., Williams, V., Jepsen, K., Schaffler, M. B., Majeska, R. J., Gavrilova, O., Gutierrez, M., Hwang, D., Pennisi, P., Frystyk, J., Boisclair, Y., Pintar, J., Jasper, H., Domene, H., Cohen, P., Clemmons, D., LeRoith, D. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J. 23, 709-719 (2009)	[Yakar, Shoshana; Sun, Hui; Mejia, Wilson; Kawashima, Yuki; Wu, Yingjie; Emerton, Kelly; Williams, Valerie; Jepsen, Karl; Schaffler, Mitchell B.; Majeska, Robert J.; LeRoith, Derek] Mt Sinai Sch Med, Div Endocrine, New York, NY 10029 USA; [Yakar, Shoshana; Sun, Hui; Mejia, Wilson; Kawashima, Yuki; Wu, Yingjie; Emerton, Kelly; Williams, Valerie; Jepsen, Karl; Schaffler, Mitchell B.; Majeska, Robert J.; LeRoith, Derek] Mt Sinai Sch Med, Orthoped Div, New York, NY 10029 USA; [Rosen, Clifford J.] Maine Med Ctr, Res Inst, Scarborough, ME USA; [Bouxsein, Mary L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Orthoped Biomech Lab, Boston, MA 02215 USA; [Gavrilova, Oksana; Pennisi, Patricia] NIDDK, NIH, Bethesda, MD USA; [Gutierrez, Mariana; Jasper, Hector; Domene, Horacio] R Gutierrez Childrens Hosp, Div Endocrinol, Endocrinol Res Ctr, Buenos Aires, DF, Argentina; [Hwang, David; Cohen, Pinchas] Mattel Hosp Children, David Geffen Sch Med, Div Pediat Endocrinol, Los Angeles, CA USA; [Frystyk, Jan] Aarhus Univ Hosp, Inst Clin, Med Res Labs, DK-8000 Aarhus, Denmark; [Frystyk, Jan] Aarhus Univ Hosp, Med Dept M Diabet & Endocrinol, DK-8000 Aarhus, Denmark; [Boisclair, Yves] Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA; [Pintar, John] Univ Med & Dent New Jersey, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; [Clemmons, David] Univ N Carolina, Div Endocrinol, Chapel Hill, NC USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Maine Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Hospital de Ninos Doctor Ricardo Gutierrez; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Aarhus University; Aarhus University; Cornell University; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Yakar, S (corresponding author), Mt Sinai Sch Med, Div Endocrine, 1 Gustave L Levy Pl,Box 1055, New York, NY 10029 USA.	shoshana.yakar@mssm.edu		Frystyk, Jan/0000-0002-5379-0961; Pennisi, Patricia/0000-0001-5179-7353; Jasper, Hector/0000-0002-3451-8647	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041210, R01AR054919, R01AR045433, R01AR055141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZICDK070002] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR017868] Funding Source: Medline; NIAMS NIH HHS [AR45433, R01 AR041210, R01 AR054919, 1R01AR055141-01, AR054919-01A, R01 AR055141, R01 AR045433] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMO ML, 1993, ADV EXP MED BIOL, V343, P1; Banerjee I, 2008, EUR J ENDOCRINOL, V158, P473, DOI 10.1530/EJE-07-0769; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; Boisclair YR, 2001, J ENDOCRINOL, V170, P63, DOI 10.1677/joe.0.1700063; Boisclair YR, 2000, PEDIATR NEPHROL, V14, P562, DOI 10.1007/s004670000333; Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307; Bouxsein ML, 2002, J BONE MINER RES, V17, P570, DOI 10.1359/jbmr.2002.17.4.570; Butt AJ, 2005, ENDOCRINOLOGY, V146, P3113, DOI 10.1210/en.2004-1408; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Chen JW, 2005, J CLIN ENDOCR METAB, V90, P366, DOI 10.1210/jc.2004-0039; Chen XY, 2006, GROWTH HORM IGF RES, V16, P41, DOI 10.1016/j.ghir.2005.09.003; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; Daughaday WH, 2004, NEW ENGL J MED, V350, P1906; DE W, 1995, MOL CELL ENDOCRINOL, V114, P43, DOI 10.1016/0303-7207(95)03640-S; Domene H M, 2005, J Endocrinol Invest, V28, P43; Domene HM, 2004, NEW ENGL J MED, V350, P570, DOI 10.1056/NEJMoa013100; Domene HM, 2007, J CLIN ENDOCR METAB, V92, P4444, DOI 10.1210/jc.2007-1152; Domene HM, 2007, HORM RES, V67, P243, DOI 10.1159/000098479; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Haluzik M, 2003, DIABETES, V52, P2483, DOI 10.2337/diabetes.52.10.2483; Hedstrom M, 2004, ACTA ORTHOP SCAND, V75, P394, DOI 10.1080/00016470410001141-1; Hill DJ, 1999, J ENDOCRINOL, V160, P305, DOI 10.1677/joe.0.1600305; Holly J, 2006, NEUROENDOCRINOLOGY, V83, P154, DOI 10.1159/000095523; Hwa V, 2006, J CLIN ENDOCR METAB, V91, P1826, DOI 10.1210/jc.2005-2842; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; Joseph Cherian, 2005, Molecular Aspects of Medicine, V26, P181, DOI 10.1016/j.mam.2005.01.004; Kanatani M, 2000, J BONE MINER RES, V15, P902, DOI 10.1359/jbmr.2000.15.5.902; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007-0038; Maitra A, 2003, CLIN CANCER RES, V9, P5988; Marsell R, 2007, ACTA ORTHOP, V78, P39, DOI 10.1080/17453670610013402; Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456; Modric T, 2001, ENDOCRINOLOGY, V142, P1958, DOI 10.1210/en.142.5.1958; MOHAN S, 1991, CLIN ORTHOP RELAT R, P30; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; MohseniZadeh S, 1997, ENDOCRINOLOGY, V138, P5645, DOI 10.1210/en.138.12.5645; Murphy Liam J., 1995, Progress in Growth Factor Research, V6, P425, DOI 10.1016/0955-2235(95)00026-7; MURPHY LJ, 1995, J MOL ENDOCRINOL, V15, P293, DOI 10.1677/jme.0.0150293; Ning Y, 2006, MOL ENDOCRINOL, V20, P2173, DOI 10.1210/me.2005-0196; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Ricort JM, 2001, ENDOCRINOLOGY, V142, P108, DOI 10.1210/en.142.1.108; Rosen CJ, 2004, BEST PRACT RES CL EN, V18, P423, DOI 10.1016/j.beem.2004.02.007; Schneider MR, 2000, FASEB J, V14, P629, DOI 10.1096/fasebj.14.5.629; Shim ML, 2004, GROWTH HORM IGF RES, V14, P216, DOI 10.1016/j.ghir.2003.12.009; Silha JV, 2005, ENDOCRINOLOGY, V146, P1523, DOI 10.1210/en.2004-0905; Silha JV, 2003, J BONE MINER RES, V18, P1834, DOI 10.1359/jbmr.2003.18.10.1834; Silha JV, 2001, ENDOCRINOLOGY, V142, P4305, DOI 10.1210/en.142.10.4305; Taniguchi T, 2003, INJURY, V34, P477, DOI 10.1016/S0020-1383(02)00380-7; Trejo JL, 2005, ADV EXP MED BIOL, V567, P27; Twigg SM, 2000, ENDOCRINOLOGY, V141, P454, DOI 10.1210/en.141.1.454; Ueki I, 2000, P NATL ACAD SCI USA, V97, P6868, DOI 10.1073/pnas.120172697; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Van Den Dolder J, 2006, TISSUE ENG, V12, P3067, DOI 10.1089/ten.2006.12.3067; Wang DS, 1999, ENDOCR J, V46, P125, DOI 10.1507/endocrj.46.125; Wang L, 2000, ENDOCRINOLOGY, V141, P1118, DOI 10.1210/en.141.3.1118; Wiren KM, 2008, BONE, V43, P440, DOI 10.1016/j.bone.2008.04.026; Wood TL, 2000, MOL ENDOCRINOL, V14, P1472, DOI 10.1210/me.14.9.1472; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463; Yakar S, 2004, J CLIN INVEST, V113, P96, DOI 10.1172/JCI200417763; Yakar S, 2001, DIABETES, V50, P1110, DOI 10.2337/diabetes.50.5.1110; Yakar S, 2006, J ENDOCRINOL, V189, P289, DOI 10.1677/joe.1.06657	64	75	80	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2009	23	3					709	719		10.1096/fj.08-118976	http://dx.doi.org/10.1096/fj.08-118976			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18952711	Green Published			2022-12-28	WOS:000265506300007
J	Cohen, TJ; Barrientos, T; Hartman, ZC; Garvey, SM; Cox, GA; Yao, TP				Cohen, Todd J.; Barrientos, Tomasa; Hartman, Zachary C.; Garvey, Sean M.; Cox, Gregory A.; Yao, Tso-Pang			The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity	FASEB JOURNAL			English	Article						neuromuscular disease; remodeling; pathological induction; muscle integrity	AMYOTROPHIC-LATERAL-SCLEROSIS; MUSCULAR-ATROPHY; SKELETAL-MUSCLE; PROMOTER; MEF2; ACTIVATION; MYOTILIN; FIBERS; MICE; BOX	Histone deacetylase 4 (HDAC4) binds and inhibits activation of the critical muscle transcription factor myocyte enhancer factor-2 (MEF2). However, the physiological significance of the HDAC4-MEF2 complex in skeletal muscle has not been established. Here we show that in skeletal muscle, HDAC4 is a critical modulator of MEF2-dependent structural and contractile gene expression in response to neural activity. We present evidence that loss of neural input leads to concomitant nuclear accumulation of HDAC4 and transcriptional reduction of MEF2-regulated gene expression. Cell-based assays show that HDAC4 represses structural gene expression via direct binding to AT-rich MEF2 response elements. Notably, using both surgical denervation and the neuromuscular disease amyotrophic lateral sclerosis (ALS) model, we found that elevated levels of HDAC4 are required for efficient repression of MEF2-dependent structural gene expression, indicating a link between the pathological induction of HDAC4 and subsequent MEF2 target gene suppression. Supporting this supposition, we show that ectopic expression of HDAC4 in muscle fibers is sufficient to induce muscle damage in mice. Our study identifies HDAC4 as an activity-dependent regulator of MEF2 function and suggests that activation of HDAC4 in response to chronically reduced neural activity suppresses MEF2-dependent gene expression and contributes to progressive muscle dysfunction observed in neuromuscular diseases.-Cohen, T. J., Barrientos, T., Hartman, Z. C., Garvey, S. M., Cox, G. A., Yao, T.- P. The deacetylase HDAC4 controls myocyte enhancing factor-2 dependent structural gene expression in response to neural activity. FASEB J. 23, 99-106 (2009)	[Yao, Tso-Pang] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Hartman, Zachary C.] Duke Univ, Dept Surg, Durham, NC 27710 USA; [Garvey, Sean M.] Univ Virginia, Robert M Berne Cardiovasc Res Ctr, Charlottesville, VA USA; [Cox, Gregory A.] Jackson Lab, Bar Harbor, ME 04609 USA	Duke University; Duke University; University of Virginia; Jackson Laboratory	Yao, TP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	yao00001@mc.duke.edu		Garvey, Sean/0000-0003-1013-7871	Leukemia and Lymphoma Society [AR055613]; U.S. National Institutes of Health; ALS Association; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR055613] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ALS Association; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Tim Bolger, Xuan Zhao, and Chun Lai for technical assistance. We thank Satoru Noguchi (National Institute of Neuroscience, Tokyo, Japan) and Olli Carpen (University of Helsinki, Helsinki, Finland) for kindly providing mouse gamma-sarcoglycan and mouse myotilin reporter constructs and Mike Hauser (Duke University, Durham, NC, USA) for providing myotilin antibody. This work was supported by the Leukemia and Lymphoma Society and grant AR055613 (to T.-P.Y), and the U.S. National Institutes of Health and the ALS Association (to G.A.C.).	Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Brichta L, 2006, ANN NEUROL, V59, P970, DOI 10.1002/ana.20836; Cohen TJ, 2007, J BIOL CHEM, V282, P33752, DOI 10.1074/jbc.M706268200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Delgado-Olguin P, 2006, BBA-GENE STRUCT EXPR, V1759, P240, DOI 10.1016/j.bbaexp.2006.04.007; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DRACHMAN DB, 1967, ARCH NEUROL-CHICAGO, V16, P14, DOI 10.1001/archneur.1967.00470190018002; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; FIDZIANSKA A, 1976, ACTA NEUROPATHOL, V34, P321, DOI 10.1007/BF00696561; Garvey SM, 2006, HUM MOL GENET, V15, P2348, DOI 10.1093/hmg/ddl160; Hinits Y, 2007, DEVELOPMENT, V134, P2511, DOI 10.1242/dev.007088; Klamut HJ, 1997, NUCLEIC ACIDS RES, V25, P1618, DOI 10.1093/nar/25.8.1618; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Mejat A, 2005, NAT NEUROSCI, V8, P313, DOI 10.1038/nn1408; Minamiyama M, 2004, HUM MOL GENET, V13, P1183, DOI 10.1093/hmg/ddh131; Mologni L, 2005, BIOCHEM BIOPH RES CO, V329, P1001, DOI 10.1016/j.bbrc.2005.02.074; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Potthoff MJ, 2007, MOL CELL BIOL, V27, P8143, DOI 10.1128/MCB.01187-07; Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960; Raffaello A, 2006, PHYSIOL GENOMICS, V25, P60, DOI 10.1152/physiolgenomics.00051.2005; Ryu H, 2005, J NEUROCHEM, V93, P1087, DOI 10.1111/j.1471-4159.2005.03077.x; Wakabayashi-Takai E, 2001, EUR J BIOCHEM, V268, P948, DOI 10.1046/j.1432-1327.2001.01954.x; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005	24	63	66	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					99	106		10.1096/fj.08-115931	http://dx.doi.org/10.1096/fj.08-115931			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18780762	Green Published			2022-12-28	WOS:000262095500012
J	Errasti-Murugarren, E; Molina-Arcas, M; Casado, FJ; Pastor-Anglada, M				Errasti-Murugarren, Ekaitz; Molina-Arcas, Miriam; Casado, Fco Javier; Pastor-Anglada, Marcal			A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum	FASEB JOURNAL			English	Article						alternative splicing; CNT; protein turnover	CHRONIC LYMPHOCYTIC-LEUKEMIA; FUNCTIONAL-CHARACTERIZATION; RAT-LIVER; SUBCELLULAR-LOCALIZATION; MAMMALIAN-CELLS; PLASMA-MEMBRANE; EXPRESSION; COTRANSPORTER; DIFFERENTIATION; IDENTIFICATION	Nucleoside transporters are plasma membrane proteins essential for nucleoside salvage. Among them, human concentrative nucleoside transporter 3 (hCNT3, SLC28A3) plays an essential role in this process because of its broader substrate selectivity and higher concentrative ability than the other members of the SLC28 protein family, hCNT1 and hCNT2. The aim of this study was to characterize an isoform of hCNT3, encoded by an alternatively spliced SLC28A3-related mRNA, the first identified for a CNT protein. This variant, named hCNT3ins, is the result of the insertion of 176 bp corresponding to an intron located between exons 2 and 3 of the gene. This insertion results in a shift of the reading frame, yielding a protein lacking 69 residues of the N terminus. hCNT3 and hCNT3ins mRNAs are simultaneously expressed both in normal and transformed cells and are differentially regulated by activation and differentiation. Because of the N-terminal deletion, hCNT3ins is retained in the endoplasmic reticulum, where it shows a typical hCNT3-related activity. hCNT3ins exhibits a shorter half-life than its plasma membrane counterpart, being degraded via a proteasome-dependent pathway. We suggest that this novel hCNT3 isoform would be involved in the salvage of intracellular nucleosides from the lumen of the endoplasmic reticulum to the cytoplasm.-Errasti-Murugarren, E., Molina-Arcas, M., Casado, F. J., Pastor-Anglada, M. A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum. FASEB J. 23, 172-182 (2009)	[Errasti-Murugarren, Ekaitz; Molina-Arcas, Miriam; Casado, Fco Javier; Pastor-Anglada, Marcal] Univ Barcelona, Dept Bioquim & Biol Mol, Fac Biol, Inst Biomed,CIBER EHD, E-08028 Barcelona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona	Pastor-Anglada, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Fac Biol, Inst Biomed,CIBER EHD, Avda Diagonal 645, E-08028 Barcelona, Spain.	mpastor@ub.edu	Molina-Arcas, Miriam/R-4908-2019; Errasti-Murugarren, Ekaitz/G-9723-2015; Pastor Anglada, Marcal/C-3730-2017	Molina-Arcas, Miriam/0000-0002-8176-8948; Errasti-Murugarren, Ekaitz/0000-0002-6054-7900; Pastor Anglada, Marcal/0000-0003-3712-1773; Casado Merediz, Francisco Javier/0000-0003-0192-841X	Fondo de Investigaciones Sanitarias; Ministerio de Sanidad y Consumo [PI-020934]; Ministerio de Educacion y Ciencia [BFU2006-07556/BFI]; Fundacion Ramon Areces; Ministerio de Educacion y Ciencia e Innovacion [SAF2005-01259, SAF2008-00577]; Fundacion para la Investigacion y la Prevencion del SIDA en Espana (FIPSE); Centro de Investigacion Biomedica en Red (CIBER-EHD); Ministerio de Sanidad y Consumo, and Departament d'Universitats, Recerca i Socitat de la Informacio (DURSI); Generalitat de Catalunya [2005SGR00315]; Ministerio de Educacion y Ciencia	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Ministerio de Sanidad y Consumo(Instituto de Salud Carlos III); Ministerio de Educacion y Ciencia(Spanish Government); Fundacion Ramon Areces; Ministerio de Educacion y Ciencia e Innovacion(Spanish Government); Fundacion para la Investigacion y la Prevencion del SIDA en Espana (FIPSE); Centro de Investigacion Biomedica en Red (CIBER-EHD); Ministerio de Sanidad y Consumo, and Departament d'Universitats, Recerca i Socitat de la Informacio (DURSI); Generalitat de Catalunya(Generalitat de Catalunya); Ministerio de Educacion y Ciencia(Spanish Government)	This work was supported by grants from Fondo de Investigaciones Sanitarias, Ministerio de Sanidad y Consumo (PI-020934), Ministerio de Educacion y Ciencia (BFU2006-07556/BFI), and Fundacion Ramon Areces to F.J.C.; and from Ministerio de Educacion y Ciencia e Innovacion (SAF2005-01259 and SAF2008-00577), Fundacion para la Investigacion y la Prevencion del SIDA en Espana (FIPSE), Centro de Investigacion Biomedica en Red (CIBER-EHD), Ministerio de Sanidad y Consumo, and Departament d'Universitats, Recerca i Socitat de la Informacio (DURSI), Generalitat de Catalunya (2005SGR00315) to M.P.-A. E.E.-M. was the recipient of a Formacion de Profesorado Universitario (FPU) fellowship from Ministerio de Educacion y Ciencia.	Alfalah M, 2006, J BIOL CHEM, V281, P11894, DOI 10.1074/jbc.M511364200; Ayalon-Soffer M, 1999, FEBS LETT, V460, P112, DOI 10.1016/S0014-5793(99)01321-6; Badagnani I, 2005, PHARMACOGENOMICS J, V5, P157, DOI 10.1038/sj.tpj.6500303; Baldwin SA, 2005, J BIOL CHEM, V280, P15880, DOI 10.1074/jbc.M414337200; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Bidaux G, 2007, J CLIN INVEST, V117, P1647, DOI 10.1172/JCI30168; BISCHOFF E, 1975, EUR J BIOCHEM, V51, P353, DOI 10.1111/j.1432-1033.1975.tb03935.x; BISCHOFF E, 1976, EUR J BIOCHEM, V62, P279, DOI 10.1111/j.1432-1033.1976.tb10158.x; Damaraju S, 2005, PHARMACOGENET GENOM, V15, P173, DOI 10.1097/01213011-200503000-00006; Duflot S, 2004, MOL CELL BIOL, V24, P2710, DOI 10.1128/MCB.24.7.2710-2719.2004; Duflot S, 2002, EXP CELL RES, V281, P77, DOI 10.1006/excr.2002.5641; Errasti-Murugarren E, 2008, MOL PHARMACOL, V73, P379, DOI 10.1124/mol.107.041848; Failer BU, 2002, J BIOL CHEM, V277, P36978, DOI 10.1074/jbc.M201656200; Fernandez-Veledo S, 2006, BIOCHEM J, V395, P337, DOI 10.1042/BJ20051232; FRANCO R, 1986, NEUROCHEM RES, V11, P407, DOI 10.1007/BF00965015; Gloeckner-Hofmann K, 2006, ONCOLOGY-BASEL, V70, P238, DOI 10.1159/000094541; GOLDFISC.S, 1971, J HISTOCHEM CYTOCHEM, V19, P349, DOI 10.1177/19.6.349; Gorner K, 2004, J BIOL CHEM, V279, P6943, DOI 10.1074/jbc.M309204200; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; Handa M, 2001, GENE, V262, P301, DOI 10.1016/S0378-1119(00)00555-2; Harris MJ, 2004, J GASTROEN HEPATOL, V19, P819, DOI 10.1111/j.1440-1746.2004.03347.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hu HK, 2006, MOL PHARMACOL, V69, P1542, DOI 10.1124/mol.105.018945; Kabuss R, 2005, GLYCOBIOLOGY, V15, P905, DOI 10.1093/glycob/cwi085; Kapetanovich L, 2005, MOL BIOL CELL, V16, P835, DOI 10.1091/mbc.e04-09-0785; Lai YR, 2004, J BIOL CHEM, V279, P4490, DOI 10.1074/jbc.M307938200; Leuzzi R, 2001, BIOCHEM J, V357, P557, DOI 10.1042/0264-6021:3570557; Loewen SK, 2004, MOL MEMBR BIOL, V21, P1, DOI 10.1080/0968768031000140836; Mackey JR, 2005, BLOOD, V105, P767, DOI 10.1182/blood-2004-03-1046; Mangravite LM, 2003, AM J PHYSIOL-RENAL, V284, pF902, DOI 10.1152/ajprenal.00215.2002; Mani RS, 1998, J BIOL CHEM, V273, P30818, DOI 10.1074/jbc.273.46.30818; Minuesa G, 2008, J PHARMACOL EXP THER, V324, P558, DOI 10.1124/jpet.107.131482; Molina-Arcas M, 2003, BLOOD, V101, P2328, DOI 10.1182/blood-2002-07-2236; Molina-Arcas M, 2005, LEUKEMIA, V19, P64, DOI 10.1038/sj.leu.2403582; Monni M, 2001, EUR J BIOCHEM, V268, P2020, DOI 10.1046/j.1432-1327.2001.02079.x; Ngo LY, 2001, AM J PHYSIOL-GASTR L, V280, pG475, DOI 10.1152/ajpgi.2001.280.3.G475; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; REESJONES R, 1984, BIOCHEMISTRY-US, V23, P2236, DOI 10.1021/bi00305a022; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Rodriguez-Mulero S, 2005, KIDNEY INT, V68, P665, DOI 10.1111/j.1523-1755.2005.00444.x; Rubio-Aliaga I, 2004, J BIOL CHEM, V279, P2754, DOI 10.1074/jbc.M305556200; RUIZMONTASELL B, 1992, J MEMBRANE BIOL, V128, P227; Slugoski MD, 2008, J BIOL CHEM, V283, P24922, DOI 10.1074/jbc.M801793200; Smith KM, 2005, J BIOL CHEM, V280, P25436, DOI 10.1074/jbc.M409454200; Spratlin J, 2004, CLIN CANCER RES, V10, P6956, DOI 10.1158/1078-0432.CCR-04-0224; Toan SV, 2003, PFLUG ARCH EUR J PHY, V447, P195, DOI 10.1007/s00424-003-1166-0; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; WACHSTEIN M, 1964, J HISTOCHEM CYTOCHEM, V12, P40, DOI 10.1177/12.1.40; Wang YJ, 2003, J CELL BIOCHEM, V88, P1012, DOI 10.1002/jcb.10451; Wu SK, 2005, J DRUG TARGET, V13, P521, DOI 10.1080/10611860500403099	52	33	33	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					172	182		10.1096/fj.08-113902	http://dx.doi.org/10.1096/fj.08-113902			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18827020				2022-12-28	WOS:000262095500020
J	Falagas, ME; Ierodiakonou, V; Alexiou, VG				Falagas, Matthew E.; Ierodiakonou, Vrettos; Alexiou, Vangelis G.			At what age do biomedical scientists do their best work?	FASEB JOURNAL			English	Article						creative productivity; scientific workforce; research performance; age distribution; scientific literature		Several human characteristics that influence scientific research performance, including set goals, mental and physical abilities, education, and experience, may vary considerably during the life cycle of scientists. We sought to answer the question of whether high-quality research productivity is associated with investigator's age. We randomly selected 300 highly cited scientists (50 from each of 6 different biomedical fields, specifically immunology, microbiology, neuroscience, psychology-psychiatry, clinical medicine, and biology-biochemistry). Then, we identified the top 5 highly cited articles (within 10 yr after publication adjusted for the expansion of the literature) as first author of each of them. Subsequently, we plotted the distribution of the 1500 analyzed articles of the 300 studied scientists in the eight 5-year intervals of investigator's age during the year of article publication (21-25 to 55-60 yr of age), adjusted for person-years of contribution of each scientist in the various age groups. Highly cited research productivity plotted a curve that peaked at the age group of 31-35 yr of age and then gradually decreased with advancing age. However, a considerable proportion of this highly cited research was produced by older scientists (in almost 20% of the analyzed articles, researchers were older than 50 yr). The results were similar in another analysis of the single most cited article of each studied scientist. In conclusion, high-quality scientific productivity in the biomedical fields as a function of investigator's age plots an inverted U-shaped curve, in which significant decreases take place from around 40 yr of age and beyond.	[Falagas, Matthew E.; Ierodiakonou, Vrettos; Alexiou, Vangelis G.] Alfa Inst Biomed Sci, Athens 15123, Greece; [Falagas, Matthew E.] Henry Dunant Hosp, Dept Med, Athens, Greece; [Falagas, Matthew E.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Alfa Institute Of Biomedical Sciences; Henry Dunant Hospital; Tufts University	Falagas, ME (corresponding author), Alfa Inst Biomed Sci, 9 Neapoleos St, Athens 15123, Greece.	m.falagas@aibs.gr	Alexiou, Vangelis/GLR-9050-2022					AVOLIO BJ, 1994, PSYCHOL AGING, V9, P430, DOI 10.1037/0882-7974.9.3.430; Bass S., 1993, ACHIEVING PRODUCTIVE; Falagas ME, 2008, AM J MED SCI, V335, P188, DOI 10.1097/MAJ.0b013e318145abb9; Herskovic JR, 2007, J BIOMED INFORM, V40, P93, DOI 10.1016/j.jbi.2005.12.007; MARCHETTI C, 2002, PRODUCTIVITY VERSUS; Stephan P., 1988, HDB QUANTITATIVE STU, P31; Tsay MY, 2004, J AM SOC INF SCI TEC, V55, P64, DOI 10.1002/asi.10346; VEGARD S, 2003, AGE INDIVIDUAL PRODU; Verhaeghen P, 1997, PSYCHOL BULL, V122, P231, DOI 10.1037/0033-2909.122.3.231	9	20	21	4	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4067	4070		10.1096/fj.08-117606	http://dx.doi.org/10.1096/fj.08-117606			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18753247				2022-12-28	WOS:000261254800005
J	Michailidou, Z; Carter, RN; Marshall, E; Sutherland, HG; Brownstein, DG; Owen, E; Cockett, K; Kelly, V; Ramage, L; Al-Dujaili, EAS; Ross, M; Maraki, I; Newton, K; Holmes, MC; Seckl, JR; Morton, NM; Kenyon, CJ; Chapman, KE				Michailidou, Z.; Carter, R. N.; Marshall, E.; Sutherland, H. G.; Brownstein, D. G.; Owen, E.; Cockett, K.; Kelly, V.; Ramage, L.; Al-Dujaili, E. A. S.; Ross, M.; Maraki, I.; Newton, K.; Holmes, M. C.; Seckl, J. R.; Morton, N. M.; Kenyon, C. J.; Chapman, K. E.			Glucocorticoid receptor haploinsufficiency causes hypertension and attenuates hypothalamic-pituitary-adrenal axis and blood pressure adaptions to high-fat diet	FASEB JOURNAL			English	Article						HPA axis; diet-induced obesity; NR3C1; glucose and lipid homeostasis	BODY-MASS INDEX; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; TRIGLYCERIDE-METABOLISM; TARGETED MUTATIONS; DIABETES-MELLITUS; INDUCED OBESITY; MICE BEARING; GENE; EXPRESSION; SYSTEM	Glucocorticoid hormones are critical to respond and adapt to stress. Genetic variations in the glucocorticoid receptor (GR) gene alter hypothalamic-pituitary-adrenal (HPA) axis activity and associate with hypertension and susceptibility to metabolic disease. Here we test the hypothesis that reduced GR density alters blood pressure and glucose and lipid homeostasis and limits adaption to obesogenic diet. Heterozygous GR(beta geo/+) mice were generated from embryonic stem (ES) cells with a gene trap integration of a beta-galactosidase-neomycin phosphotransferase (beta geo) cassette into the GR gene creating a transcriptionally inactive GR fusion protein. Although GR(beta geo/+) mice have 50% less functional GR, they have normal lipid and glucose homeostasis due to compensatory HPA axis activation but are hypertensive due to activation of the renin-angiotensin-aldosterone system (RAAS). When challenged with a high-fat diet, weight gain, adiposity, and glucose intolerance were similarly increased in control and GR(beta geo/+) mice, suggesting preserved control of intermediary metabolism and energy balance. However, whereas a high-fat diet caused HPA activation and increased blood pressure in control mice, these adaptions were attenuated or abolished in GR(beta geo/+) mice. Thus, reduced GR density balanced by HPA activation leaves glucocorticoid functions unaffected but mineralocorticoid functions increased, causing hypertension. Importantly, reduced GR limits HPA and blood pressure adaptions to obesogenic diet. -Michailidou, Z., Carter, R. N., Marshall, E., Sutherland, H. G., Brownstein, D. G., Owen, E., Cockett, K., Kelly, V., Ramage, L., Al-Dujaili, E. A. S., Ross, M., Maraki, I., Newton, K., Holmes, M. C., Seckl, J. R., Morton, N. M., Kenyon, C. J., Chapman, K. E. Glucocorticoid receptor haploinsufficiency causes hypertension and attenuates hypothalamic-pituitary-adrenal axis and blood pressure adaptions to high-fat diet. FASEB J. 22, 3896-3907 (2008)	[Chapman, K. E.] Univ Edinburgh, Endocrinol Unit, Ctr Cardiovasc Sci, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland; [Sutherland, H. G.; Newton, K.] MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland; [Al-Dujaili, E. A. S.] Queen Margaret Univ, Musselburgh, East Lothian, Scotland	University of Edinburgh; University of Edinburgh; Queen Margaret University	Chapman, KE (corresponding author), Univ Edinburgh, Endocrinol Unit, Ctr Cardiovasc Sci, Queens Med Res Inst, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	karen.chapman@ed.ac.uk	Seckl, Jonathan R/C-3555-2013; Morton, NICHOLAS/ABF-3774-2020	Chapman, Karen/0000-0001-7777-6817; Sutherland, Heidi/0000-0002-8512-1498	Wellcome Trust PhD Studentship; British Heart Foundation; Wellcome Trust Programme; Wellcome Trust Project; Medical Research Council Programme; Wellcome Trust Research Career Development Fellowship; Medical Research Council [G0500026] Funding Source: researchfish; MRC [G0500026] Funding Source: UKRI	Wellcome Trust PhD Studentship(Wellcome Trust); British Heart Foundation(British Heart Foundation); Wellcome Trust Programme(Wellcome Trust); Wellcome Trust Project(Wellcome Trust); Medical Research Council Programme(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust Research Career Development Fellowship(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Mark Danielsen (Georgetown University School of Medicine, Washington, DC, USA) for kindly providing the SV2wrec plasmid encoding mouse GR cDNA and David Pearce (University of California, San Francisco, Department of Medicine, San Francisco, CA, USA) for providing the rPNMT-998/-466 Luc plasmid. We thank the Biomedical Research Resources facility, University of Edinburgh, facility for assistance with animal care and members of the Endocrinology Unit for helpful discussions and advice. This work was supported by a Wellcome Trust PhD Studentship (to Z.M.), a British Heart Foundation Project Grant (to K.E.C., C.J.K., N.M.M., and J.R.S.), a Wellcome Trust Programme Grant (to J.R.S. and K.E.C.), a Wellcome Trust Project Grant (to M.C.H and J.R.S.), and a Medical Research Council Programme Grant (to C.J.K.). N.M.M. is supported by a Wellcome Trust Research Career Development Fellowship.	Adams M, 2003, MOL ENDOCRINOL, V17, P2583, DOI 10.1210/me.2002-0305; Al-Dujaili EAS, 2006, CLIN CHIM ACTA, V364, P172, DOI 10.1016/j.cccn.2005.06.019; ALDUJAILI EAS, 1981, CLIN CHIM ACTA, V116, P277, DOI 10.1016/0009-8981(81)90047-4; BALLARD PL, 1974, ENDOCRINOLOGY, V94, P998, DOI 10.1210/endo-94-4-998; BARTLETT SM, 1988, BIOCHEM J, V249, P37, DOI 10.1042/bj2490037; Boyle MP, 2005, P NATL ACAD SCI USA, V102, P473, DOI 10.1073/pnas.0406458102; CARROLL K. K., 1952, ENDOCRINOLOGY, V51, P476; CHAPMAN KE, 2007, NEUROCHEM RES; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Coll AP, 2004, ENDOCRINOLOGY, V145, P4721, DOI 10.1210/en.2004-0491; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; Di Blasio AM, 2003, CLIN ENDOCRINOL, V59, P68, DOI 10.1046/j.1365-2265.2003.01798.x; EVANS AL, 1994, MED BIOL ENG COMPUT, V32, P101, DOI 10.1007/BF02512487; Finotto S, 1999, DEVELOPMENT, V126, P2935; FREDERICH RC, 1992, HYPERTENSION, V19, P339, DOI 10.1161/01.HYP.19.4.339; Gass P, 2001, PHYSIOL BEHAV, V73, P811, DOI 10.1016/S0031-9384(01)00518-2; Harris HJ, 2001, ENDOCRINOLOGY, V142, P114, DOI 10.1210/en.142.1.114; Harrison PA, 2001, J CHILD ADOLES SUBST, V11, P1, DOI 10.1300/J029v11n02_01; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Howell MP, 2006, FRONT NEUROENDOCRIN, V27, P275, DOI 10.1016/j.yfrne.2006.05.001; KASAI Y, 1990, FEBS LETT, V274, P99, DOI 10.1016/0014-5793(90)81339-P; KAUFMAN LN, 1993, AM J PHYSIOL, V265, pR1, DOI 10.1152/ajpregu.1993.265.1.R1; Kellendonk C, 2002, ENDOCRINOLOGY, V143, P2333, DOI 10.1210/en.143.6.2333; Kino T, 2002, ANN NY ACAD SCI, V970, P101, DOI 10.1111/j.1749-6632.2002.tb04416.x; Kino T, 2001, J ENDOCRINOL, V169, P437, DOI 10.1677/joe.0.1690437; KIRK CJ, 1976, BIOCHEM J, V156, P593, DOI 10.1042/bj1560593; KLAUSNER H, 1967, AM J PHYSIOL, V212, P1236, DOI 10.1152/ajplegacy.1967.212.6.1236; Kleiman A, 2007, MOL CELL ENDOCRINOL, V275, P98, DOI 10.1016/j.mce.2007.05.009; Korte SM, 2005, NEUROSCI BIOBEHAV R, V29, P3, DOI 10.1016/j.neubiorev.2004.08.009; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; Magiakou MA, 2006, BEST PRACT RES CL EN, V20, P467, DOI 10.1016/j.beem.2006.07.006; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mantha L, 1999, AM J PHYSIOL-REG I, V277, pR455, DOI 10.1152/ajpregu.1999.277.2.R455; Mantha L, 2000, AM J PHYSIOL-REG I, V278, pR1424, DOI 10.1152/ajpregu.2000.278.6.R1424; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILLS E, 1993, AM J PHYSIOL, V264, pR73, DOI 10.1152/ajpregu.1993.264.1.R73; Morton NM, 2005, DIABETES, V54, P3371, DOI 10.2337/diabetes.54.12.3371; NAKAMURA N, 1985, HYPERTENSION, V7, P855, DOI 10.1161/01.HYP.7.6.855; Opherk C, 2004, MOL ENDOCRINOL, V18, P1346, DOI 10.1210/me.2003-0283; Panarelli M, 1998, J CLIN ENDOCR METAB, V83, P1846, DOI 10.1210/jc.83.6.1846; Pazirandeh A, 2002, FASEB J, V16, P727, DOI 10.1096/fj.01-0891fje; PEPIN MC, 1992, NATURE, V355, P725, DOI 10.1038/355725a0; Ramdas J, 1999, CANCER RES, V59, P1378; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; RICHARD D, 1993, AM J PHYSIOL, V265, pR146, DOI 10.1152/ajpregu.1993.265.1.R146; Ridder S, 2005, J NEUROSCI, V25, P6243, DOI 10.1523/JNEUROSCI.0736-05.2005; Rosmond R, 2000, OBES RES, V8, P211, DOI 10.1038/oby.2000.24; Sainte-Marie Y, 2007, FASEB J, V21, P3133, DOI 10.1096/fj.07-8357com; SECKL JR, 1994, J HYPERTENS, V12, P105; SECKL JR, 1990, J NEUROENDOCRINOL, V2, P911, DOI 10.1111/j.1365-2826.1990.tb00659.x; Seckl JR, 2001, MOL CELL ENDOCRINOL, V185, P61, DOI 10.1016/S0303-7207(01)00633-5; Sutherland HGE, 2001, HUM MOL GENET, V10, P1995, DOI 10.1093/hmg/10.18.1995; Takami S, 1999, AM J PHYSIOL-HEART C, V276, pH1379, DOI 10.1152/ajpheart.1999.276.4.H1379; Tannenbaum BM, 1997, AM J PHYSIOL-ENDOC M, V273, pE1168, DOI 10.1152/ajpendo.1997.273.6.E1168; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; van Rossum EFC, 2004, RECENT PROG HORM RES, V59, P333, DOI 10.1210/rp.59.1.333; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; WATT GCM, 1992, J HYPERTENS, V10, P473, DOI 10.1097/00004872-199205000-00011; WHITWORTH JA, 1995, STEROIDS, V60, P76, DOI 10.1016/0039-128X(94)00033-9; Williams TD, 2003, CLIN EXP PHARMACOL P, V30, P769, DOI 10.1046/j.1440-1681.2003.t01-1-03808.x; Yau JLW, 2007, NEUROPSYCHOPHARMACOL, V32, P2520, DOI 10.1038/sj.npp.1301389	63	41	43	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2008	22	11					3896	3907		10.1096/fj.08-111914	http://dx.doi.org/10.1096/fj.08-111914			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18697839	Green Published, hybrid			2022-12-28	WOS:000260503000018
J	Niclou, SP; Danzeisen, C; Eikesdal, HP; Wiig, H; Brons, NHC; Poli, AMF; Svendsen, A; Torsvik, A; Enger, PO; Terzis, JA; Bjerkvig, R				Niclou, Simone P.; Danzeisen, Claude; Eikesdal, Hans P.; Wiig, Helge; Brons, Nicolaas H. C.; Poli, Aurelie M. F.; Svendsen, Agnete; Torsvik, Anja; Enger, Per Oyvind; Terzis, Jorge A.; Bjerkvig, Rolf			A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions	FASEB JOURNAL			English	Article						xenograft; in vivo imaging; vascular mimicry; cell fusion; tumor microenvironment; glioma	STEM-CELLS; CANCER; GLIOMAS; ANGIOGENESIS; MICE	A NOD/Scid mouse expressing enhanced green fluorescent protein (eGFP) is described, in which human and mouse tumors marked with red fluorescent protein can be established in vivo, both at subcutaneous and orthotopic locations. Using light microscopy as well as multiphoton confocal microscopy techniques, we visualized in detail the intricate colocalization of tumor and host cells in situ. Moreover, using fluorescence-activated cell sorting (FACS), we were able to completely separate the host cells from the tumor cells, thus providing a system for detailed cellular and molecular analysis of tumor-host cell interactions. The fact that tumor and host cells can be reliably identified also allowed us to detect double-positive cells, possibly arising from cell fusion events or horizontal gene transfer. Similarly, the model can be applied for the detection of circulating metastatic cells and for detailed studies on the vascular compartments within tumors, including vasculogenic mimicry. Thus, the model described should provide significant insight into how tumor cells communicate with their microenvironment.	[Niclou, Simone P.; Danzeisen, Claude; Terzis, Jorge A.; Bjerkvig, Rolf] CRP Sante, NorLux Neurooncol Lab, L-1526 Luxembourg, Luxembourg; [Brons, Nicolaas H. C.] CRP Sante, Core Facil Flowcytometry, L-1526 Luxembourg, Luxembourg; [Poli, Aurelie M. F.] CRP Sante, Lab Immunogenet & Allergol LIGA, L-1526 Luxembourg, Luxembourg; [Eikesdal, Hans P.; Wiig, Helge; Svendsen, Agnete; Torsvik, Anja; Enger, Per Oyvind; Bjerkvig, Rolf] Univ Bergen, Dept Biomed, Bergen, Norway	Luxembourg Institute of Health; Luxembourg Institute of Health; Luxembourg Institute of Health; University of Bergen	Niclou, SP (corresponding author), CRP Sante, NorLux Neurooncol Lab, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.	simone.niclou@crp-sante.lu	Niclou, Simone/P-2304-2018; Engelsen, Agnete Svendsen Tenfjord/AAB-6652-2020; Eikesdal, Hans Petter/AAG-3228-2020	Niclou, Simone/0000-0002-3417-9534; Engelsen, Agnete Svendsen Tenfjord/0000-0003-0375-3406; Eikesdal, Hans Petter/0000-0003-4086-0147; Wiig, Helge/0000-0002-7740-8210; Torsvik, Anja/0000-0001-8638-8357; Poli, Aurelie/0000-0002-7986-0761	Norwegian Cancer Society; Norwegian Research Council; Innovest AS; Western Norway Regional Health Authority; Haukeland University Hospital, Bergen, Norway; Bergen Translational Research Programme; Centre de Recherche Public de la Sante (CRP-Sante); European Commission 6th Framework Program [504743]	Norwegian Cancer Society(Norwegian Cancer Society); Norwegian Research Council(Research Council of NorwayEuropean Commission); Innovest AS; Western Norway Regional Health Authority; Haukeland University Hospital, Bergen, Norway; Bergen Translational Research Programme; Centre de Recherche Public de la Sante (CRP-Sante); European Commission 6th Framework Program(European CommissionEuropean Commission Joint Research Centre)	This work was supported by the Norwegian Cancer Society; the Norwegian Research Council; Innovest AS; the Western Norway Regional Health Authority; Haukeland University Hospital, Bergen, Norway; The Bergen Translational Research Programme; the Centre de Recherche Public de la Sante (CRP-Sante) through a grant from the Research Ministry in Luxembourg; and the European Commission 6th Framework Program (contract 504743). The technical assistance of Vanessa Barthelemy, Virginie Baus, and Lene Nybo is greatly appreciated.	Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Axelrod R, 2006, P NATL ACAD SCI USA, V103, P13474, DOI 10.1073/pnas.0606053103; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; BJERKVIG R, 1990, J NEUROSURG, V72, P463, DOI 10.3171/jns.1990.72.3.0463; Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Duelli D, 2007, NAT REV CANCER, V7, P968, DOI 10.1038/nrc2272; Glinsky GV, 2006, CELL CYCLE, V5, P191, DOI 10.4161/cc.5.2.2320; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; GREINER DL, 1992, IMMUNOL TODAY, V13, P116, DOI 10.1016/0167-5699(92)90104-F; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hillen F, 2007, CANCER METAST REV, V26, P489, DOI 10.1007/s10555-007-9094-7; Hoffman RM, 2006, NAT PROTOC, V1, P1429, DOI 10.1038/nprot.2006.223; Holmgren L, 2002, VOX SANG, V83, P305, DOI 10.1111/j.1423-0410.2002.tb05323.x; *JACKS LAB, 2006, JAX NOT, V501; *JACKS LAB, 1999, JAX NOT, V476; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Langley RR, 2007, ENDOCR REV, V28, P297, DOI 10.1210/er.2006-0027; Munshi HG, 2006, CANCER METAST REV, V25, P45, DOI 10.1007/s10555-006-7888-7; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Sakariassen PO, 2006, P NATL ACAD SCI USA, V103, P16466, DOI 10.1073/pnas.0607668103; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Tysnes BB, 2007, BBA-REV CANCER, V1775, P283, DOI 10.1016/j.bbcan.2007.01.001; Yang M, 2004, CANCER RES, V64, P8651, DOI 10.1158/0008-5472.CAN-04-3118; Yang M, 2003, P NATL ACAD SCI USA, V100, P14259, DOI 10.1073/pnas.2436101100	29	51	55	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3120	3128		10.1096/fj.08-109611	http://dx.doi.org/10.1096/fj.08-109611			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18495755	Green Published			2022-12-28	WOS:000258761300004
J	Tapia-Paez, I; Tammimies, K; Massinen, S; Roy, AL; Kere, J				Tapia-Paez, Isabel; Tammimies, Kristiina; Massinen, Satu; Roy, Ananda L.; Kere, Juha			The complex of TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene implicated in neuronal migration and dyslexia	FASEB JOURNAL			English	Article						complex disease; regulation of transcription; learning disability; reading impairment	FAMILY-BASED ASSOCIATION; DEVELOPMENTAL DYSLEXIA; CANDIDATE GENE; SUSCEPTIBILITY LOCUS; READING-DISABILITY; INITIATOR ELEMENT; CHROMOSOME 15Q; TERM-MEMORY; EXPRESSION; SUPPORT	DYX1C1 was first identified as a candidate gene for dyslexia susceptibility, and its role in controlling neuronal migration during embryogenesis and effect on learning in rodents have been verified. In contrast, genetic association studies have been ambiguous in replicating its effects on dyslexia. To better understand the regulation of DYX1C1 and the possible functional role of genetic variation in the promoter of DYX1C1, we selected three single-nucleotide polymorphisms (SNPs) with predicted functional consequences or suggested associations to dyslexia for detailed study. Electrophoretic mobility shift assays suggested the allele-specific binding of the transcription factors TFII-I (to rs3743205) and Sp1 (to rs16787 and rs12899331) that could be verified by competition assays. In addition, we purified a complex of protein factors binding to the previously suggested dyslexia-related SNP, -3G/A (rs3743205). Three proteins, TFII-I, PARP1, and SFPQ, were unambiguously identified by mass spectrometry and protein sequencing. Two SNPs, rs16787 and rs3743205, showed significant allelic differences in luciferase assays. Our results show that TFII-I, PARP1, and SFPQ proteins, each previously implicated in gene regulation, form a complex controlling transcription of DYX1C1. Furthermore, allelic differences in the promoter or 5' untranslated region of DYX1C1 may affect factor binding and thus regulation of the gene.	[Massinen, Satu; Kere, Juha] Univ Helsinki, Dept Med Genet, Helsinki, Finland; [Roy, Ananda L.] Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; [Tapia-Paez, Isabel; Tammimies, Kristiina; Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden	University of Helsinki; Tufts University; Karolinska Institutet	Kere, J (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Halsovagen 7-9, S-14157 Stockholm, Sweden.	juha.kere@biosci.ki.se	Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008; Tapia-Páez, Isabel/N-1210-2013; Tapia-Páez, Isabel/ABD-7197-2021	Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Tapia-Paez, Isabel/0000-0002-0535-4233; Tammimies, Kristiina/0000-0002-8324-4697	NICHD NIH HHS [R01 HD046034, HD046034] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD046034] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akterin S, 2006, CELL DEATH DIFFER, V13, P1454, DOI 10.1038/sj.cdd.4401818; Anthoni H, 2007, HUM MOL GENET, V16, P667, DOI 10.1093/hmg/ddm009; Bellini G, 2005, J MOL NEUROSCI, V27, P311, DOI 10.1385/JMN:27:3:311; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caceres M, 2003, P NATL ACAD SCI USA, V100, P13030, DOI 10.1073/pnas.2135499100; Chanas-Sacre G, 1999, J NEUROSCI RES, V57, P62, DOI 10.1002/(SICI)1097-4547(19990701)57:1<62::AID-JNR7>3.0.CO;2-Y; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Cohen-Armon M, 2004, SCIENCE, V304, P1820, DOI 10.1126/science.1096775; Cope NA, 2005, MOL PSYCHIATR, V10, P237, DOI 10.1038/sj.mp.4001596; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; GALABURDA AM, 1979, ANN NEUROL, V6, P94, DOI 10.1002/ana.410060203; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; Grigorenko EL, 2003, P NATL ACAD SCI USA, V100, P11190, DOI 10.1073/pnas.2134926100; Grigorenko EL, 1997, AM J HUM GENET, V60, P27; Grigorenko EL, 2001, AM J MED GENET, V105, P120, DOI 10.1002/1096-8628(20010108)105:1<120::AID-AJMG1075>3.3.CO;2-K; Hannula-Jouppi K, 2005, PLOS GENET, V1, P467, DOI 10.1371/journal.pgen.0010050; Hatakeyama S, 2004, GENES CELLS, V9, P533, DOI 10.1111/j.1356-9597.2004.00742.x; Hatip-Al-Khatib I, 2004, LIFE SCI, V75, P1967, DOI 10.1016/j.lfs.2004.05.014; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lowery LA, 2007, DEV DYNAM, V236, P1347, DOI 10.1002/dvdy.21132; Marino C, 2007, GENES BRAIN BEHAV, V6, P640, DOI 10.1111/j.1601-183X.2006.00291.x; Marino C, 2005, EUR J HUM GENET, V13, P491, DOI 10.1038/sj.ejhg.5201356; Meng HY, 2005, P NATL ACAD SCI USA, V102, P17053, DOI 10.1073/pnas.0508591102; Miscimarra L, 2007, HUM HERED, V63, P47, DOI 10.1159/000098727; Morris DW, 2000, HUM MOL GENET, V9, P843, DOI 10.1093/hmg/9.5.843; Nopola-Hemmi J, 2000, J MED GENET, V37, P771, DOI 10.1136/jmg.37.10.771; Ogura Y, 2006, GENES CELLS, V11, P373, DOI 10.1111/j.1365-2443.2006.00952.x; Paracchini S, 2006, HUM MOL GENET, V15, P1659, DOI 10.1093/hmg/ddl089; Preuss TM, 2004, NAT REV GENET, V5, P850, DOI 10.1038/nrg1469; RABIN M, 1993, LANCET, V342, P178, DOI 10.1016/0140-6736(93)91384-X; Rico-Bautista E, 2004, EXP CELL RES, V294, P269, DOI 10.1016/j.yexcr.2003.11.017; Rosen GD, 2007, CEREB CORTEX, V17, P2562, DOI 10.1093/cercor/bhl162; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Sambrook J., 2001, MOL CLONING LAB MANU; Scerri TS, 2004, J MED GENET, V41, P853, DOI 10.1136/jmg.2004.018341; Schulte-Korne G, 1998, AM J HUM GENET, V63, P279, DOI 10.1086/301919; Schumacher J, 2006, AM J HUM GENET, V78, P52, DOI 10.1086/498992; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Taipale M, 2003, P NATL ACAD SCI USA, V100, P11553, DOI 10.1073/pnas.1833911100; Temple CM, 2003, J NEUROLINGUIST, V16, P457, DOI 10.1016/S0911-6044(01)00044-6; Threlkeld SW, 2007, BRAIN RES BULL, V71, P508, DOI 10.1016/j.brainresbull.2006.11.005; Tzenova J, 2004, AM J MED GENET B, V127B, P117, DOI 10.1002/ajmg.b.20139; Wang Y, 2006, NEUROSCIENCE, V143, P515, DOI 10.1016/j.neuroscience.2006.08.022; Wigg KG, 2004, MOL PSYCHIATR, V9, P1111, DOI 10.1038/sj.mp.4001543; YULE W, 1974, BRIT J EDUC PSYCHOL, V44, P1, DOI 10.1111/j.2044-8279.1974.tb00760.x	46	60	61	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					3001	3009		10.1096/fj.07-104455	http://dx.doi.org/10.1096/fj.07-104455			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18445785	Green Published			2022-12-28	WOS:000258089300040
J	Carmody, LC; Baucum, AJ; Bass, MA; Colbran, RJ				Carmody, Leigh C.; Baucum, Anthony J., II; Bass, Martha A.; Colbran, Roger J.			Selective targeting of the gamma 1 isoform of protein phosphatase 1 to F-actin in intact cells requires multiple domains in spinophilin and neurabin	FASEB JOURNAL			English	Article						subcellular targeting; cytoskeleton; dendritic spine; synaptic plasticity	PROTEIN PHOSPHATASE 1; PRIMATE PREFRONTAL CORTEX; FILAMENT-BINDING PROTEIN; P70 S6 KINASE; DENDRITIC SPINES; CATALYTIC SUBUNIT; SUBCELLULAR-DISTRIBUTION; STRUCTURAL BASIS; PHOSPHORYLATION; LOCALIZATION	Protein phosphatase 1 (PP1) catalytic subunits dephosphorylate specific substrates in discrete subcellular compartments to modulate many cellular processes. Canonical PP1-binding motifs (R/K-V/I-X-F) in a family of proteins mediate subcellular targeting, and the amino acids that form the binding pocket for the canonical motif are identical in all PP1 isoforms. However, PP1 gamma 1 but not PP1 beta is selectively localized to F-actin-rich dendritic spines in neurons. Although the F-actin-binding proteins neurabin I and spinophilin (neurabin II) also bind PP1, their role in PP1 isoform selective targeting in intact cells is poorly understood. We show here that spinophilin selectively targets PP1 gamma 1, but not PP1 beta, to F-actin-rich cortical regions of intact cells. Mutation of a PP1 gamma 1 selectivity determinant (N(464)EDYDRR (470) in spinophilin: conserved as residues 473 -479 in neurabin) to VKDYDTW severely attenuated PP1 gamma 1 interactions with neurabins in vitro and in cells and disrupted PP1 gamma 1 targeting to F-actin. This domain is not involved in the weaker interactions of neurabins with PP1 beta. In contrast, mutation of the canonical PP1-binding motif attenuated interactions of neurabins with both isoforms. Thus, selective targeting of PP1 gamma 1 to F-actin by neurabins in intact cells requires both the canonical PP1-binding motif and an auxiliary PP1 gamma 1-selectivity determinant.	[Carmody, Leigh C.; Baucum, Anthony J., II; Bass, Martha A.; Colbran, Roger J.] Vanderbilt Univ, Med Ctr, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Baucum, Anthony J., II; Colbran, Roger J.] Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; [Baucum, Anthony J., II; Colbran, Roger J.] Vanderbilt Univ, Sch Med, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Mol Physiol & Biophys, Robinson Res Bldg,Room 724, Nashville, TN 37232 USA.	roger.colbran@vanderbilt.edu	Colbran, Roger/AAU-7708-2021; Baucum, Anthony/I-5109-2013	Colbran, Roger/0000-0001-7401-8244; Baucum, Anthony/0000-0002-4756-9865; Carmody, Leigh/0000-0001-7941-2961	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD015052] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U2CDK059637, P60DK020593, U24DK059637, P30DK058404, P30DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH065215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044282] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA068485, CA68485] Funding Source: Medline; NEI NIH HHS [EY08126, P30 EY008126] Funding Source: Medline; NICHD NIH HHS [P30 HD015052, HD15052] Funding Source: Medline; NIDDK NIH HHS [DK58404, P60 DK020593, P30 DK020593, DK59637, P30 DK058404, U24 DK059637, DK20593] Funding Source: Medline; NIMH NIH HHS [T32-MH65215, T32 MH065215] Funding Source: Medline; NINDS NIH HHS [P01 NS044282, P01-NS44282, P01 NS044282-010002] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; Allen PB, 2006, NEUROSCIENCE, V140, P897, DOI 10.1016/j.neuroscience.2006.02.067; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Bordelon JR, 2005, CEREB CORTEX, V15, P1928, DOI 10.1093/cercor/bhi070; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Carmody LC, 2004, J BIOL CHEM, V279, P21714, DOI 10.1074/jbc.M402261200; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Cohen PTW, 2002, J CELL SCI, V115, P241; Colbran RJ, 2003, METHOD ENZYMOL, V366, P156; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Grossman SD, 2004, J NEUROCHEM, V90, P317, DOI 10.1111/j.1471-4159.2004.02491.x; Haneji T, 1998, BIOCHEM BIOPH RES CO, V248, P39, DOI 10.1006/bbrc.1998.8913; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Hsieh-Wilson LC, 2003, J BIOL CHEM, V278, P1186, DOI 10.1074/jbc.M205754200; Hu XD, 2006, J NEUROCHEM, V98, P1841, DOI 10.1111/j.1471-4159.2006.04070.x; Huang HS, 2005, ARCH BIOCHEM BIOPHYS, V443, P33, DOI 10.1016/j.abb.2005.08.021; Lanner C, 2001, ARCH BIOCHEM BIOPHYS, V388, P135, DOI 10.1006/abbi.2001.2283; Lesage B, 2004, J BIOL CHEM, V279, P55978, DOI 10.1074/jbc.M411911200; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; Meiselbach H, 2006, CHEM BIOL, V13, P49, DOI 10.1016/j.chembiol.2005.10.009; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; Muly EC, 2004, J COMP NEUROL, V469, P185, DOI 10.1002/cne.11001; Muly EC, 2004, CEREB CORTEX, V14, P1398, DOI 10.1093/cercor/bhh101; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Ouimet CC, 2004, J COMP NEUROL, V479, P374, DOI 10.1002/cne.20313; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Ryan XZP, 2005, NEURON, V47, P85, DOI 10.1016/j.neuron.2005.05.013; Sarrouilhe D, 2006, BIOCHIMIE, V88, P1099, DOI 10.1016/j.biochi.2006.04.010; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Strack S, 1999, J COMP NEUROL, V413, P373; Terrak M, 2004, NATURE, V429, P780, DOI 10.1038/nature02582; Terry-Lorenzo RT, 2005, MOL BIOL CELL, V16, P2349, DOI 10.1091/mbc.E04-12-1054; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Tsukada M, 2005, J BIOL CHEM, V280, P11361, DOI 10.1074/jbc.M405525200; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110; Zito K, 2004, NEURON, V44, P321, DOI 10.1016/j.neuron.2004.09.022	54	25	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1660	1671		10.1096/fj.07-092841	http://dx.doi.org/10.1096/fj.07-092841			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18216290	Green Accepted			2022-12-28	WOS:000256352700007
J	Gong, ZD; Niklason, LE				Gong, Zhaodi; Niklason, Laura E.			Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs)	FASEB JOURNAL			English	Article						smooth muscle cell; bioreactor; cyclic strain; extracellular matrix; soluble factors	SMOOTH-MUSCLE-CELL; GROWTH FACTOR-BB; PROGENITOR CELLS; BLOOD-VESSELS; ENDOTHELIAL-CELLS; STROMAL CELLS; TGF-BETA; DIFFERENTIATION; TISSUE; EXPRESSION	Using biodegradable scaffold and a biomimetic perfusion system, our lab has successfully engineered small-diameter vessel grafts using endothelial cells ( ECs) and smooth muscle cells (SMCs) obtained from vessels in various species. However, translating this technique into humans has presented tremendous obstacles due to species and age differences. SMCs from elderly persons have limited proliferative capacity and a reduction in collagen production, which impair the mechanical strength of engineered vessels. As an alternative cell source, adult human bone marrow-derived mesenchymal stem cells (hMSCs) were studied for their ability to differentiate into SMCs in culture plates as well as in a bioreactor system. In the former setting, immunofluorescence staining showed that MSCs, after induction for 14 days, expressed smooth muscle alpha-actin (SMA) and calponin, early and mid-SMC phenotypic markers, respectively. In the latter setting, vessel walls were constructed with MSC-derived SMCs. Various factors (i. e., matrix proteins, soluble factors, and cyclic strain) in the engineering system were further investigated for their effects on hMSC cell proliferation and differentiation into SMCs. Based on a screening of multiple factors, the engineering system was optimized by dividing the vessel culture into proliferation and differentiation phases. The vessel walls engineered under the optimized conditions were examined histologically and molecularly, and found to be substantially similar to native vessels. In conclusion, bone marrow-derived hMSCs can serve as a new cell source of SMCs in vessel engineering. Optimization of the culture conditions to drive SMC differentiation and matrix production significantly improved the quality of the hMSC-derived engineered vessel wall.	[Gong, Zhaodi; Niklason, Laura E.] Yale Univ, Sch Med, Med Ctr, Dept Anesthesiol, New Haven, CT 06520 USA	Yale University	Niklason, LE (corresponding author), Yale Univ, Sch Med, Med Ctr, Dept Anesthesiol, POB 208089, New Haven, CT 06520 USA.	laura.niklason@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083895, R01HL063766] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL063766-05, R01 HL083895-03, R01 HL063766, HL063766, R01HL083895, R01 HL083895] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCINIEGAS E, 1992, J CELL SCI, V103, P521; Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097-4644(19990301)72:3<396::AID-JCB9>3.3.CO;2-Y; Ball SG, 2004, INT J BIOCHEM CELL B, V36, P714, DOI 10.1016/j.biocel.2003.10.015; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; BIRUKOV KG, 1995, MOL CELL BIOCHEM, V144, P131, DOI 10.1007/BF00944392; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V11, P892, DOI 10.1161/01.ATV.11.4.892; CAREY DJ, 1991, ANNU REV PHYSIOL, V53, P161, DOI 10.1146/annurev.physiol.53.1.161; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; Chapman GB, 2000, AM J PHYSIOL-HEART C, V278, pH748, DOI 10.1152/ajpheart.2000.278.3.H748; CHARD RB, 1987, J THORAC CARDIOV SUR, V94, P132; Cho SW, 2005, ANN SURG, V241, P506, DOI 10.1097/01.sla.0000154268.12239.ed; CINTORINO M, 1991, INT J CANCER, V47, P843, DOI 10.1002/ijc.2910470609; CLYMAN RI, 1990, CIRC RES, V67, P175, DOI 10.1161/01.RES.67.1.175; Dandre F, 2004, AM J PHYSIOL-HEART C, V286, pH2042, DOI 10.1152/ajpheart.00625.2003; DARBY I, 1990, LAB INVEST, V63, P21; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; GALMICHE MC, 1993, BLOOD, V82, P66, DOI 10.1182/blood.V82.1.66.bloodjournal82166; Gong ZD, 2004, ALCOHOL CLIN EXP RES, V28, P468, DOI 10.1097/01.ALC.0000118315.58404.C1; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756-3282(92)90363-2; HEDIN U, 1989, DEV BIOL, V133, P489, DOI 10.1016/0012-1606(89)90052-3; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; Hoerstrup SP, 2002, CIRCULATION, V106, pI143, DOI 10.1161/01.cir.0000032872.55215.05; INGBER DE, 1994, INT REV CYTOL, V150, P173; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kadner A, 2002, EUR J CARDIO-THORAC, V21, P1055, DOI 10.1016/S1010-7940(02)00079-9; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; Kinner B, 2002, EXP CELL RES, V278, P72, DOI 10.1006/excr.2002.5561; Kurpinski Kyle, 2006, Molecular & Cellular Biomechanics, V3, P21; LI J, 1995, EXP HEMATOL, V23, P133; Li Q, 1997, Hypertens Res, V20, P217, DOI 10.1291/hypres.20.217; Li XR, 2005, J CLIN INVEST, V115, P118, DOI 10.1172/JCI200519189; Liu JY, 2007, CARDIOVASC RES, V75, P618, DOI 10.1016/j.cardiores.2007.04.018; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; Matsumura G, 2003, CIRCULATION, V108, P1729, DOI 10.1161/01.CIR.0000092165.32213.61; McKee JA, 2003, EMBO REP, V4, P633, DOI 10.1038/sj.embor.embor847; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Niklason LE, 2001, J VASC SURG, V33, P628, DOI 10.1067/mva.2001.111747; Niklason LE, 1999, SCIENCE, V286, P1493, DOI 10.1126/science.286.5444.1493; NIKLASON LE, 2002, METHODS TISSUE ENG, P905; Noth U, 2002, J ORTHOP RES, V20, P1060, DOI 10.1016/S0736-0266(02)00018-9; O'Callaghan CJ, 2000, HYPERTENSION, V36, P319, DOI 10.1161/01.HYP.36.3.319; OWENS GK, 1995, PHYSIOL REV, V75, P487; Park JS, 2004, BIOTECHNOL BIOENG, V88, P359, DOI 10.1002/bit.20250; PAULY RR, 1992, CIRCULATION, V86, P68; Perry TE, 2003, ANN THORAC SURG, V75, P761, DOI 10.1016/S0003-4975(02)03776-1; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Poh M, 2005, LANCET, V365, P2122, DOI 10.1016/S0140-6736(05)66735-9; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; Ross JJ, 2006, J CLIN INVEST, V116, P3139, DOI 10.1172/JCI28184; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SAPSFORD RN, 1981, J THORAC CARDIOV SUR, V81, P860; SAWTELL NM, 1989, J CELL BIOL, V109, P2929, DOI 10.1083/jcb.109.6.2929; Seliktar D, 2001, ANN BIOMED ENG, V29, P923, DOI 10.1114/1.1415522; Seruya M, 2004, CELL TRANSPLANT, V13, P93, DOI 10.3727/000000004773301762; Steinthorsson G, 1999, ACTA CHIR BELG, V99, P282; vanderLoop FTL, 1996, J CELL BIOL, V134, P401, DOI 10.1083/jcb.134.2.401; VEITH FJ, 1986, J VASC SURG, V3, P104; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; Wu X, 2004, AM J PHYSIOL-HEART C, V287, pH480, DOI 10.1152/ajpheart.01232.2003; Yoshida T, 2007, AM J PHYSIOL-CELL PH, V292, pC886, DOI 10.1152/ajpcell.00449.2006; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	73	249	268	1	57	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1635	1648		10.1096/fj.07-087924	http://dx.doi.org/10.1096/fj.07-087924			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18199698	Green Accepted			2022-12-28	WOS:000256352700005
J	Mattioli, B; Straface, E; Matarrese, P; Quaranta, MG; Giordani, L; Malorni, W; Viora, M				Mattioli, Benedetta; Straface, Elisabetta; Matarrese, Paola; Quaranta, Maria Giovanna; Giordani, Luciana; Malorni, Walter; Viora, Marina			Leptin as an immunological adjuvant: enhanced migratory and CD8(+) T cell stimulatory capacity of human dendritic cells exposed to leptin	FASEB JOURNAL			English	Article						chemotaxis; vaccination; cytoskeleton; CTL	CHEMOKINE RECEPTOR CCR7; UP-REGULATION; IMMUNE-RESPONSE; SERUM LEPTIN; LYMPH-NODES; RHO GTPASES; ACTIVATION; EXPRESSION; DIFFERENTIATION; MATURATION	Leptin is an adipocyte-derived hormone/cytokine that links nutrition, metabolism, and immune homeostasis and is endowed to modulate several immune responses. We previously demonstrated that both immature and mature human dendritic cells (DCs) express a functional leptin receptor, and we found that leptin activates DCs, licenses them for Th1 priming, and promotes DC survival. Moreover, we found that leptin induces rearrangement of actin microfilaments, leading to uropod and ruffle formation. Here we monitor the effects of leptin on DC migratory capacities, focusing on the intracellular signaling driving cytoskeleton rearrangement. We found that leptin increases immature DC migratory performance both by favoring cytoskeleton dynamics and by up-regulating CCR7 surface expression, thus favoring chemotactic responsiveness. We found that in immature DCs, leptin activates cofilin, favoring the turnover of actin microfilaments, and, by triggering Vav phosphorylation, promotes Rac1 activation. Finally, we found that in immature DCs, leptin up-regulates interleukin-12p70 production on CD40 stimulation and, more importantly, increases their capacity to stimulate activation of autologous CD8(+) T cells. Taken altogether, the findings herein highlight the potential use of leptin as an adjuvant tool in vaccination protocols employing ex vivo-generated autologous DCs.	[Mattioli, Benedetta; Straface, Elisabetta; Matarrese, Paola; Quaranta, Maria Giovanna; Giordani, Luciana; Malorni, Walter; Viora, Marina] Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Viora, M (corresponding author), Ist Super Sanita, Dept Drug Res & Evaluat, 299 Viale Regina Elena, I-00161 Rome, Italy.	viora@iss.it	Malorni, Walter/G-5874-2016; Matarrese, Paola/A-4369-2014	Quaranta, Maria Giovanna/0000-0002-1077-1488; matarrese, paola/0000-0001-5477-3752; malorni, walter/0000-0002-1223-7000				Adema GJ, 2005, CURR OPIN IMMUNOL, V17, P170, DOI 10.1016/j.coi.2005.01.004; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Benvenuti F, 2004, SCIENCE, V305, P1150, DOI 10.1126/science.1099159; Berard F, 2000, J EXP MED, V192, P1535, DOI 10.1084/jem.192.11.1535; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chen H, 2000, TRENDS BIOCHEM SCI, V25, P19, DOI 10.1016/S0968-0004(99)01511-X; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; de Vries IJM, 2003, CANCER RES, V63, P12; de Vries IJM, 2003, CLIN CANCER RES, V9, P5091; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; Friedman JM, 1998, NUTR REV, V56, pS38; Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578; Gainsford T, 1999, MOL BIOTECHNOL, V11, P149, DOI 10.1007/BF02915808; Gao YF, 2005, J IMMUNOL, V175, P5783, DOI 10.4049/jimmunol.175.9.5783; Giammarioli AM, 2006, FEBS LETT, V580, P3335, DOI 10.1016/j.febslet.2006.04.095; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Granucci F, 2001, EUR J IMMUNOL, V31, P2539, DOI 10.1002/1521-4141(200109)31:9<2539::AID-IMMU2539>3.0.CO;2-9; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Gutzmer R, 2003, J IMMUNOL, V171, P6363, DOI 10.4049/jimmunol.171.12.6363; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Hopken UE, 2002, BLOOD, V99, P1109, DOI 10.1182/blood.V99.4.1109; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; JONULEIT H, INT J CANC, V93, P243; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; La Cava A, 2004, J MOL MED, V82, P4, DOI 10.1007/s00109-003-0492-1; Lam QLK, 2007, J BIOL CHEM, V282, P27587, DOI 10.1074/jbc.M704579200; Lam QLK, 2006, EUR J IMMUNOL, V36, P3118, DOI 10.1002/eji.200636602; LANE P, 1995, EUR J IMMUNOL, V25, P1788, DOI 10.1002/eji.1830250646; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Luft T, 2004, BLOOD, V104, P1066, DOI 10.1182/blood-2003-12-4146; Macia L, 2006, J IMMUNOL, V177, P5997, DOI 10.4049/jimmunol.177.9.5997; MADEJ T, 1995, FEBS LETT, V373, P13, DOI 10.1016/0014-5793(95)00977-H; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; Malorni W, 2004, THROMB HAEMOSTASIS, V92, P1159, DOI 10.1055/s-0037-1614296; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Mattioli B, 2005, J IMMUNOL, V174, P6820, DOI 10.4049/jimmunol.174.11.6820; McIlroy D, 2003, CANCER IMMUNOL IMMUN, V52, P583, DOI 10.1007/s00262-003-0414-7; O'Malley D, 2005, FASEB J, V19, P1917, DOI 10.1096/fj.05-4166fje; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riol-Blanco L, 2005, J IMMUNOL, V174, P4070, DOI 10.4049/jimmunol.174.7.4070; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sanchez-Margalet V, 2003, CLIN EXP IMMUNOL, V133, P11, DOI 10.1046/j.1365-2249.2003.02190.x; Sanchez-Sanchez N, 2006, J IMMUNOL, V176, P5153, DOI 10.4049/jimmunol.176.9.5153; Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shutt DC, 2000, CELL MOTIL CYTOSKEL, V46, P200, DOI 10.1002/1097-0169(200007)46:3<200::AID-CM5>3.0.CO;2-M; Steinman R. M, 1999, FUNDAMENTAL IMMUNOLO, P547; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Turtle CJ, 2004, CURR DRUG TARGETS, V5, P17, DOI 10.2174/1389450043490640; Verdijk P, 2004, EUR J IMMUNOL, V34, P156, DOI 10.1002/eji.200324241; Weber A, 1999, MOL CELL BIOCHEM, V190, P67, DOI 10.1023/A:1006984010267; White David W., 1996, Cytokine and Growth Factor Reviews, V7, P303, DOI 10.1016/S1359-6101(96)00040-8; Zarkesh-Esfahani H, 2004, J IMMUNOL, V172, P1809, DOI 10.4049/jimmunol.172.3.1809; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao YR, 2003, BIOCHEM BIOPH RES CO, V300, P247, DOI 10.1016/S0006-291X(02)02838-3	74	42	46	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2012	2022		10.1096/fj.07-098095	http://dx.doi.org/10.1096/fj.07-098095			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18218920				2022-12-28	WOS:000256352700040
J	Xia, N; Thodeti, CK; Hunt, TP; Xu, QB; Ho, M; Whitesides, GM; Westervelt, R; Ingber, DE				Xia, Nan; Thodeti, Charles K.; Hunt, Tom P.; Xu, Qiaobing; Ho, Madelyn; Whitesides, George M.; Westervelt, Robert; Ingber, Donald E.			Directional control of cell motility through focal adhesion positioning and spatial control of Rac activation	FASEB JOURNAL			English	Article						migration; extracellular matrix; microcontact printing; cytoskeleton; mechanical; traction	COUPLING MEMBRANE PROTRUSION; ARP2/3 COMPLEX; REGULATES ADHESION; ACTIN; CDC42; LAMELLIPODIA; CHEMOTAXIS; MIGRATION; RIGIDITY; PAXILLIN	Local physical interactions between cells and extracellular matrix (ECM) influence directional cell motility that is critical for tissue development, wound repair, and cancer metastasis. Here we test the possibility that the precise spatial positioning of focal adhesions governs the direction in which cells spread and move. NIH 3T3 cells were cultured on circular or linear ECM islands, which were created using a microcontact printing technique and were 1 mu m wide and of various lengths (1 to 8 mu m) and separated by 1 to 4.5 mu m wide nonadhesive barrier regions. Cells could be driven proactively to spread and move in particular directions by altering either the interisland spacing or the shape of similar-sized ECM islands. Immunofluorescence microscopy confirmed that focal adhesions assembled preferentially above the ECM islands, with the greatest staining intensity being observed at adhesion sites along the cell periphery. Rac-FRET analysis of living cells revealed that Rac became activated within 2 min after peripheral membrane extensions adhered to new ECM islands, and this activation wave propagated outward in an oriented manner as the cells spread from island to island. A computational model, which incorporates that cells preferentially protrude membrane processes from regions near newly formed focal adhesion contacts, could predict with high accuracy the effects of six different arrangements of micropatterned ECM islands on directional cell spreading. Taken together, these results suggest that physical properties of the ECM may influence directional cell movement by dictating where cells will form new focal adhesions and activate Rac and, hence, govern where new membrane protrusions will form.	[Xia, Nan; Thodeti, Charles K.; Ho, Madelyn; Ingber, Donald E.] Childrens Hosp, Dept Pathol, Vasc Biol Program, Boston, MA 02115 USA; [Xia, Nan; Thodeti, Charles K.; Ho, Madelyn; Ingber, Donald E.] Childrens Hosp, Dept Surg, Boston, MA 02115 USA; [Xia, Nan; Thodeti, Charles K.; Ho, Madelyn; Ingber, Donald E.] Harvard Univ, Sch Med, Boston, MA USA; [Hunt, Tom P.; Westervelt, Robert] Harvard Univ, Dept Phys, Boston, MA 02115 USA; [Hunt, Tom P.; Westervelt, Robert] Harvard Univ, Div Engn & Appl Sci, Boston, MA 02115 USA; [Xu, Qiaobing; Whitesides, George M.] Harvard Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard University	Ingber, DE (corresponding author), Childrens Hosp, Dept Pathol, Vasc Biol Program, KFRL 11-127, Boston, MA 02115 USA.	donald.ingber@childrens.harvard.edu	Ingber, Donald E/AAC-5894-2019; Xia, Nan/ABG-4600-2021		NCI NIH HHS [CA45548, P01 CA045548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Brock A, 2003, LANGMUIR, V19, P1611, DOI 10.1021/la026394k; Chen CS, 2003, BIOCHEM BIOPH RES CO, V307, P355, DOI 10.1016/S0006-291X(03)01165-3; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Dubin-Thaler BJ, 2004, BIOPHYS J, V86, P1794, DOI 10.1016/S0006-3495(04)74246-0; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Jiang XY, 2005, P NATL ACAD SCI USA, V102, P975, DOI 10.1073/pnas.0408954102; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MOONEY DJ, 1995, J CELL SCI, V108, P2311; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NAKATSUJI N, 1984, NATURE, V307, P453, DOI 10.1038/307453a0; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Peyton SR, 2005, J CELL PHYSIOL, V204, P198, DOI 10.1002/jcp.20274; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Roberts C, 1998, J AM CHEM SOC, V120, P6548, DOI 10.1021/ja972467o; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Tan JL, 2004, TISSUE ENG, V10, P865, DOI 10.1089/1076327041348365; Ueda M, 2001, SCIENCE, V294, P864, DOI 10.1126/science.1063951; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365	38	120	126	1	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1649	1659		10.1096/fj.07-090571	http://dx.doi.org/10.1096/fj.07-090571			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18180334				2022-12-28	WOS:000256352700006
J	Cassar, L; Nicholls, C; Pinto, AR; Li, H; Liu, JP				Cassar, Lucy; Nicholls, Craig; Pinto, Alex R.; Li, He; Liu, Jun-Ping			RETRACTED: Bone morphogenetic protein-7 induces telomerase inhibition, telomere shortening, breast cancer cell senescence, and death via Smad3 (Retracted article. See vol 23, pg 2790, 2009)	FASEB JOURNAL			English	Article; Retracted Publication						TGFb receptor; signal transduction; cross-talk; immortalization; luciferase gene reporter	GROWTH-FACTOR-BETA; TGF-BETA; IN-VIVO; C-MYC; HTERT GENE; MESENCHYMAL TRANSITION; TUMOR-GROWTH; MOUSE CELLS; BMP7; TRANSCRIPTION	Human telomerase reverse transcriptase (hTERT) is central to maintain telomeres for continuous cell proliferation, but it remains unknown how extracellular cues regulate telomerase maintenance of telomeres. Here we report that the cytokine bone morphogenetic protein-7 (BMP7) induces Smad3 phosphorylation, nuclear translocation, and hTERT gene repression. BMP7 induces Smad3-dependent telomerase inhibition in a time- and concentration-dependent manner in breast cancer cells. Chronic exposure of breast cancer cells to BMP7 results in short telomeres, cell senescence, and apoptosis. Mutation of BMPRII receptor, but not TGF beta RII, ACTRIIA, or ACTRIIB, blocked BMP7-induced repression of the hTERT gene promoter activity, leading to increased telomerase activity, lengthened telomeres, and continued cell proliferation. Expression of hTERT inhibits BMP7-induced breast cancer cell senescence and apoptosis. Thus, our data suggest that BMP7 induces breast cancer cell aging and death by a mechanism involving inhibition of telomerase activity and telomere maintenance via BMPRII receptor- and Smad3-mediated repression of the hTERT gene.-Cassar, L., Nicholls, C., Pinto, A. R., Li, H., Liu, J.-P. Bone morphogenetic protein-7 induces telomerase inhibition, telomere shortening, breast cancer cell senescence, and death via Smad3. FASEB J. 23, 1880-1892 (2009)	[Cassar, Lucy; Nicholls, Craig; Pinto, Alex R.; Li, He; Liu, Jun-Ping] Monash Univ, Cent Eastern Clin Sch, Dept Immunol, Mol Signaling Lab, Melbourne, Vic 3004, Australia	Monash University	Li, H (corresponding author), Monash Univ, Cent Eastern Clin Sch, Dept Immunol, Commercial Rd, Prahran, Vic 3181, Australia.	he.li@med.monash.edu.au; jun-ping.liu@med.monash.edu.au	Liu, Jun-Ping/AAA-5521-2020	Liu, Jun-Ping/0000-0001-7442-2116	National Health and Medical Research Council of Australia; Australia Research Council; Cancer Council of Victoria, Australia.	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australia Research Council(Australian Research Council); Cancer Council of Victoria, Australia.(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	We thank Claude Labrie (Universite Laval, Quebec, QC, Canada) for the plasmid construct encoding BMPRII truncation and Peter Lansdorp (British Columbia Cancer Agency, Vancouver, BC, Canada) for the TFL-Telo 2.2 software program for telomere analysis. This work was supported by grants from the National Health and Medical Research Council of Australia, Australia Research Council, and Cancer Council of Victoria, Australia.	Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307; Alarmo EL, 2007, BREAST CANCER RES TR, V103, P239, DOI 10.1007/s10549-006-9362-1; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bestilny LJ, 1996, CANCER RES, V56, P3796; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Hu B, 2006, ONCOGENE, V25, P1030, DOI 10.1038/sj.onc.1209140; Jacobs JJL, 2005, CELL CYCLE, V4, P1364, DOI 10.4161/cc.4.10.2104; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Jena N, 1997, EXP CELL RES, V230, P28, DOI 10.1006/excr.1996.3411; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Li H, 2005, J NEUROCHEM, V95, P891, DOI 10.1111/j.1471-4159.2005.03439.x; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Li H, 2007, ANN NY ACAD SCI, V1114, P56, DOI 10.1196/annals.1396.016; Li H, 2006, J BIOL CHEM, V281, P25588, DOI 10.1074/jbc.M602381200; Liu XJ, 1998, CANCER RES, V58, P4752; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Ma T, 2007, BONE, V41, P386, DOI 10.1016/j.bone.2007.05.015; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Miyazaki H, 2004, ONCOGENE, V23, P9326, DOI 10.1038/sj.onc.1208127; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Notting I, 2007, INVEST OPHTH VIS SCI, V48, P4882, DOI 10.1167/iovs.07-0505; Parsch D, 2004, J MOL MED-JMM, V82, P49, DOI 10.1007/s00109-003-0506-z; Patel SR, 2005, TRENDS MOL MED, V11, P512, DOI 10.1016/j.molmed.2005.09.007; Piek E, 1999, J CELL SCI, V112, P4557; Rees JRE, 2006, CANCER RES, V66, P9583, DOI 10.1158/0008-5472.CAN-06-1842; Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386; Rothhammer Tania, 2007, Cancer Biomarkers, V3, P111; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Shay JW, 2006, NAT REV DRUG DISCOV, V5, P577, DOI 10.1038/nrd2081; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Simic P, 2006, J BIOL CHEM, V281, P25509, DOI 10.1074/jbc.M513276200; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Sugimoto H, 2007, DIABETES, V56, P1825, DOI 10.2337/db06-1226; Takakura M, 2005, MOL CELL BIOL, V25, P8037, DOI 10.1128/MCB.25.18.8037-8043.2005; Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919; Wang SN, 2004, J BIOL CHEM, V279, P23200, DOI 10.1074/jbc.M311998200; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DK, 2008, J BIOL CHEM, V283, P23567, DOI 10.1074/jbc.M800790200; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang SX, 2005, CANCER RES, V65, P5769, DOI 10.1158/0008-5472.CAN-05-0289; Yang ZY, 2001, J BIOL CHEM, V276, P4251, DOI 10.1074/jbc.M006371200; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613	57	22	22	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1880	1892		10.1096/fj.08-119529	http://dx.doi.org/10.1096/fj.08-119529			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19193721				2022-12-28	WOS:000266652400028
J	Diaz-Hernandez, M; Diez-Zaera, M; Sanchez-Nogueiro, J; Gomez-Villafuertes, R; Canals, JM; Alberch, J; Miras-Portugal, MT; Lucas, JJ				Diaz-Hernandez, Miguel; Diez-Zaera, Maria; Sanchez-Nogueiro, Jesus; Gomez-Villafuertes, Rosa; Canals, Josep M.; Alberch, Jordi; Teresa Miras-Portugal, Maria; Lucas, Jose J.			Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration	FASEB JOURNAL			English	Article						ATP; calcium; apoptosis; polyglutamine; BBG	BRILLIANT BLUE-G; CELL-DEATH; EXTRACELLULAR ATP; SYNAPTIC TERMINALS; MUTANT HUNTINGTIN; MOTOR DYSFUNCTION; P2X(7) RECEPTORS; MINOCYCLINE; NEURONS; PATHOGENESIS	The precise mechanism by which mutant huntingtin elicits its toxicity remains unknown. However, synaptic alterations and increased susceptibility to neuronal death are known contributors to Huntington's disease (HD) symptomatology. While decreased metabolism has long been associated with HD, recent findings have surprisingly demonstrated reduced neuronal apoptosis in Caenorhabditis elegans and Drosophila models of HD by drugs that diminish ATP production. Interestingly, extracellular ATP has been recently reported to elicit neuronal death through stimulation of P2X7 receptors. These are ATP-gated cation channels known to modulate neurotransmitter release from neuronal presynaptic terminals and to regulate cytokine production and release from microglia. We hypothesized that alteration in P2X7-mediated calcium permeability may contribute to HD synaptic dysfunction and increased neuronal apoptosis. Using mouse and cellular models of HD, we demonstrate increased P2X7- receptor level and altered P2X7- mediated calcium permeability in somata and terminals of HD neurons. Furthermore, cultured neurons expressing mutant huntingtin showed increased susceptibility to apoptosis triggered by P2X7receptor stimulation. Finally, in vivo administration of the P2X7-antagonist Brilliant Blue-G (BBG) to HD mice prevented neuronal apoptosis and attenuated body weight loss and motor-coordination deficits. These in vivo data strongly suggest that altered P2X7- receptor level and function contribute to HD pathogenesis and highlight the therapeutic potential of P2X7 receptor antagonists.-Diaz-Hernandez, M., Diez-Zaera, M., Sanchez-Nogueiro, J., Gomez-Villafuertes, R., Canals, J. M., Alberch, J., Miras-Portugal, M. T., Lucas, J. J. Altered P2X7- receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J. 23, 1893-1906 (2009)	[Diaz-Hernandez, Miguel; Sanchez-Nogueiro, Jesus; Lucas, Jose J.] UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain; [Diaz-Hernandez, Miguel; Canals, Josep M.; Alberch, Jordi; Lucas, Jose J.] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain; [Diaz-Hernandez, Miguel; Diez-Zaera, Maria; Sanchez-Nogueiro, Jesus; Gomez-Villafuertes, Rosa; Teresa Miras-Portugal, Maria] Univ Complutense Madrid, Fac Vet, Dept Bioquim & Biol Mol 4, Madrid, Spain; [Canals, Josep M.; Alberch, Jordi] Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi & Sunyer, Barcelona 7, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); CIBERNED; Instituto de Salud Carlos III; Complutense University of Madrid; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Lucas, JJ (corresponding author), UAM, CSIC, Ctr Biol Mol Severo Ochoa, Campus UAM Cantoblanco, Madrid 28049, Spain.	jjlucas@cbm.uam.es	Alberch, Jordi/K-5702-2014; Miras-Portugal, Maria Teresa/L-7137-2014; Canals, Josep M/M-3846-2014; Lucas, Jose J./U-6543-2019; Gomez-Villafuertes, Rosa/L-7181-2014	Alberch, Jordi/0000-0002-8684-2721; Canals, Josep M/0000-0001-6829-7670; Gomez-Villafuertes, Rosa/0000-0002-7064-0906; Lucas, Jose J./0000-0003-1597-3916; Diez Zaera, Maria/0000-0001-7062-7579; Diaz-Hernandez, Miguel/0000-0002-1952-4600	Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CiberNed); Ministerio de Educacion y Ciencia, Comunidad Autonoma de Madrid, Fundacion "La Caixa," Fundacion Marcelino Botin	Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CiberNed); Ministerio de Educacion y Ciencia, Comunidad Autonoma de Madrid, Fundacion "La Caixa," Fundacion Marcelino Botin(Spanish Government)	The authors thank Drs. M. R. Fernandez and C. Tomas for helpful discussion and comments; Dr. O. Howard for comments and style correction; and Drs. S. Finkbeiner and M. Arrasate (Gladstone Institute, San Francisco, CA, USA) for kindly providing plasmids expressing exon 1 htt fused to GFP with 17 or 72 Q repeats. The authors are also grateful to Javier Palac n, Desiree Ruiz, and Alicia Tomico for technical assistance. This work was supported by Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CiberNed) and by grants from Ministerio de Educacion y Ciencia, Comunidad Autonoma de Madrid, Fundacion "La Caixa," Fundacion Marcelino Botin, and by an institutional grant from Fundacion Ramon Areces. M.D.II. was a recipient of a "Juan de la Cierva" contract from Ministerio de Educacion y Ciencia and is currently a recipient of a "Ramon y Cajal" contract.	Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; Borrell-Pages M, 2006, CELL MOL LIFE SCI, V63, P2642, DOI 10.1007/s00018-006-6242-0; Canals JM, 2004, J NEUROSCI, V24, P7727, DOI 10.1523/JNEUROSCI.1197-04.2004; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Diaz-Hernandez M, 2005, J NEUROSCI, V25, P9773, DOI 10.1523/JNEUROSCI.3183-05.2005; Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653; Diaz-Hernandez M, 2008, J CELL SCI, V121, P3717, DOI 10.1242/jcs.034082; DiProspero NA, 2004, J NEUROCYTOL, V33, P517, DOI 10.1007/s11068-004-0514-8; Donnelly-Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265; DUBINSKY JM, 1989, J NEUROSCI, V9, P3955; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; Ferrari D, 1996, J IMMUNOL, V156, P1531; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; GROSS E, 1961, Z Krebsforsch, V64, P287, DOI 10.1007/BF00525218; Guidetti P, 2001, EXP NEUROL, V169, P340, DOI 10.1006/exnr.2000.7626; Gusella JF, 2006, TRENDS BIOCHEM SCI, V31, P533, DOI 10.1016/j.tibs.2006.06.009; Hersch S, 2003, ANN NEUROL, V54, P841, DOI 10.1002/ana.21891; Hisatomi T, 2006, ARCH OPHTHALMOL-CHIC, V124, P514, DOI 10.1001/archopht.124.4.514; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Jun DJ, 2007, J BIOL CHEM, V282, P37350, DOI 10.1074/jbc.M707915200; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; Li CM, 2002, FEBS LETT, V531, P127, DOI 10.1016/S0014-5793(02)03424-5; Li JY, 2003, TRENDS MOL MED, V9, P414, DOI 10.1016/j.molmed.2003.08.006; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Marin-Garcia P, 2008, NEUROSCIENCE, V151, P361, DOI 10.1016/j.neuroscience.2007.10.038; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; McGaraughty S, 2007, NEUROSCIENCE, V146, P1817, DOI 10.1016/j.neuroscience.2007.03.035; Miras-Portugal MT, 2003, NEUROCHEM RES, V28, P1597, DOI 10.1023/A:1025690913206; Nelson DW, 2006, J MED CHEM, V49, P3659, DOI 10.1021/jm051202e; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ortega Z, 2007, CELL MOL LIFE SCI, V64, P2245, DOI 10.1007/s00018-007-7222-8; Paxinos G., 2001, MOUSE BRAIN STEREOTA; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Reynolds N, 2007, MOVEMENT DISORD, V22, P292, DOI 10.1002/mds.21199; Riedel T, 2007, BIOPHYS J, V92, P2377, DOI 10.1529/biophysj.106.091413; Riley BE, 2006, GENE DEV, V20, P2183, DOI 10.1101/gad.1436506; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Sanchez-Nogueiro J, 2005, FEBS LETT, V579, P3783, DOI 10.1016/j.febslet.2005.05.073; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Tsukimoto M, 2006, J IMMUNOL, V177, P2842, DOI 10.4049/jimmunol.177.5.2842; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Varma H, 2007, P NATL ACAD SCI USA, V104, P14525, DOI 10.1073/pnas.0704482104; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P55, DOI 10.1007/s00401-007-0306-6; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yu Y, 2008, BRAIN RES, V1194, P45, DOI 10.1016/j.brainres.2007.11.064	59	179	197	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1893	1906		10.1096/fj.08-122275	http://dx.doi.org/10.1096/fj.08-122275			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19171786				2022-12-28	WOS:000266652400029
J	Maselli, A; Matarrese, P; Straface, E; Canu, S; Franconi, F; Malorni, W				Maselli, Angela; Matarrese, Paola; Straface, Elisabetta; Canu, Silvia; Franconi, Flavia; Malorni, Walter			Cell sex: a new look at cell fate studies	FASEB JOURNAL			English	Review						estrogen; oxidative stress; ROS; mitochondria	NF-KAPPA-B; VASCULAR ENDOTHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; ANTIOXIDANT ENZYME EXPRESSION; CORONARY-HEART-DISEASE; ALZHEIMERS-DISEASE; ESTROGEN-RECEPTOR; INDUCED APOPTOSIS; OXIDATIVE STRESS; TNF-ALPHA	Cell death processes have been widely investigated in recent years in order to elucidate the different pathways involved in the complex machinery implicated in determining cell fate. Different forms of cell death have been described: Apart from the classical form of death known as necrosis, a well-characterized traumatic injury of the cell, several additional forms of cell death have been identified. Of these, apoptosis has been characterized in the greatest detail. Defects in the mechanisms of cell demise (that is, an excess of or decrease in apoptosis) have been associated with the pathogenesis of a number of human diseases. Here we review some new aspects derived from recent insights into this field, particularly the hypothesis that cells of males and females could display several different features, including those determining their fate.-Maselli, A., Matarrese, P., Straface, E., Canu, S., Franconi, F., Malorni, W. Cell sex: a new look at cell fate studies. FASEB J. 23, 978-984 (2009)	[Maselli, Angela; Matarrese, Paola; Straface, Elisabetta; Malorni, Walter] Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy; [Canu, Silvia; Franconi, Flavia] Univ Sassari, Dept Pharmacol, I-07100 Sassari, Italy; [Canu, Silvia; Franconi, Flavia] Univ Sassari, Dev Ctr Biotechnol, I-07100 Sassari, Italy; [Maselli, Angela; Franconi, Flavia] Natl Inst Biostruct & Biosyst, Natl Lab, Osilo, Italy	Istituto Superiore di Sanita (ISS); University of Sassari; University of Sassari	Malorni, W (corresponding author), Ist Super Sanita, Sect Cell Aging & Degenerat, Dept Therapeut Res & Med Evaluat, Viale Regina Elena 299, I-00161 Rome, Italy.	malorni@iss.it	Malorni, Walter/G-5874-2016; Matarrese, Paola/A-4369-2014	matarrese, paola/0000-0001-5477-3752; malorni, walter/0000-0002-1223-7000	Telethon; MIUR	Telethon(Fondazione Telethon); MIUR(Ministry of Education, Universities and Research (MIUR))	This work was partially supported by grants from Telethon and MIUR to W. M.	Adlercreutz H, 2004, BIOFACTORS, V22, P229, DOI 10.1002/biof.5520220146; Alvarez RJ, 1997, BIOCHEM BIOPH RES CO, V237, P372, DOI 10.1006/bbrc.1997.7085; Barchiesi F, 2006, CIRC RES, V99, P266, DOI 10.1161/01.RES.0000233318.85181.2e; Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429; Borras C, 2005, AGING CELL, V4, P113, DOI 10.1111/j.1474-9726.2005.00151.x; Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4; Buja LM, 2008, CARDIOVASC PATHOL, V17, P349, DOI 10.1016/j.carpath.2008.02.004; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; Carruba G, 2003, J CELL BIOCHEM, V90, P187, DOI 10.1002/jcb.10607; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432; Coto-Montes A, 2006, AUTOPHAGY, V2, P126, DOI 10.4161/auto.2.2.2351; Cutolo M, 2005, ARTHRITIS RES THER, V7, pR1124, DOI 10.1186/ar1791; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Dykens JA, 2005, ANN NY ACAD SCI, V1052, P116, DOI 10.1196/annals.1347.008; Florian M, 2008, STEROIDS, V73, P47, DOI 10.1016/j.steroids.2007.08.010; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Ghanbari HA, 2004, AGING CELL, V3, P41, DOI 10.1111/j.1474-9728.2004.00083.x; Giovannetti A, 2008, CURR PHARM DESIGN, V14, P253; Gompel A, 2004, MATURITAS, V49, P16, DOI 10.1016/j.maturitas.2004.06.009; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Haeger P, 2006, J NEUROSCI, V26, P4908, DOI 10.1523/JNEUROSCI.0476-06.2006; Hirakawa Y, 2007, INTERNAL MED, V46, P361, DOI 10.2169/internalmedicine.46.6137; Hirano S, 2007, AM J PHYSIOL-REG I, V292, pR1465, DOI 10.1152/ajpregu.00778.2006; Huber JC, 2002, MATURITAS, V42, P1, DOI 10.1016/S0378-5122(02)00021-X; Jenkins JK, 2001, INT IMMUNOPHARMACOL, V1, P1897, DOI 10.1016/S1567-5769(01)00114-X; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Kublickiene K, 2008, J CLIN ENDOCR METAB, V93, P1874, DOI 10.1210/jc.2007-2651; Legato Marianne J, 2004, Gend Med, V1, P61, DOI 10.1016/S1550-8579(04)80011-1; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Ling SH, 2002, ENDOCRINOLOGY, V143, P1119, DOI 10.1210/en.143.3.1119; Ling SH, 2006, STEROIDS, V71, P799, DOI 10.1016/j.steroids.2006.05.010; Lloret A, 2008, FREE RADICAL BIO MED, V44, P2019, DOI 10.1016/j.freeradbiomed.2008.02.017; Lovekamp-Swan T, 2007, NEUROSCIENCE, V148, P644, DOI 10.1016/j.neuroscience.2007.06.046; Lu AL, 2007, AM J PHYSIOL-ENDOC M, V292, pE585, DOI 10.1152/ajpendo.00413.2006; Lund LH, 2004, MED CLIN N AM, V88, P1321, DOI 10.1016/j.mcna.2004.03.003; Malorni W, 2008, FEBS LETT, V582, P635, DOI 10.1016/j.febslet.2008.01.034; Malorni W, 2007, ANTIOXID REDOX SIGN, V9, P1779, DOI 10.1089/ars.2007.1596; Martinet W, 2007, TRENDS MOL MED, V13, P482, DOI 10.1016/j.molmed.2007.08.004; Matarrese P, 2008, CURR PHARM DESIGN, V14, P245; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mori-Abe A, 2003, J ENDOCRINOL, V178, P417, DOI 10.1677/joe.0.1780417; Moutsatsou Paraskevi, 2007, Hormones (Athens), V6, P173; Narula J, 2000, CURR OPIN CARDIOL, V15, P183, DOI 10.1097/00001573-200005000-00011; Nijboer CHA, 2007, J CEREBR BLOOD F MET, V27, P282, DOI 10.1038/sj.jcbfm.9600342; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Nilsen J, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-74; Nilsen J, 2004, CNS NEUROL DISORD-DR, V3, P297, DOI 10.2174/1568007043337193; Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2; Patten RD, 2006, TRENDS CARDIOVAS MED, V16, P69, DOI 10.1016/j.tcm.2006.01.002; Petraki CD, 2007, HISTOL HISTOPATHOL, V22, P107, DOI 10.14670/HH-22.107; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Rashedi I, 2007, CURR MED CHEM, V14, P3139, DOI 10.2174/092986707782793952; Raynaud JP, 2006, J STEROID BIOCHEM, V102, P261, DOI 10.1016/j.jsbmb.2006.09.032; Ren J, 2007, CLIN EXP PHARMACOL P, V34, P432, DOI 10.1111/j.1440-1681.2007.04591.x; Roy D, 2007, J TOXICOL ENV HEAL B, V10, P235, DOI 10.1080/15287390600974924; Rubio MF, 2006, ONCOGENE, V25, P1367, DOI 10.1038/sj.onc.1209176; Satoh M, 2007, CIRCULATION, V115, P3197, DOI 10.1161/CIRCULATIONAHA.106.657981; Seli E, 2006, J CLIN ENDOCR METAB, V91, P4995, DOI 10.1210/jc.2006-1225; Somai S, 2003, INT J CANCER, V105, P607, DOI 10.1002/ijc.11147; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Subramanian M, 2007, J IMMUNOL, V179, P2330, DOI 10.4049/jimmunol.179.4.2330; Thongngarm T, 2003, AM J REPROD IMMUNOL, V49, P129, DOI 10.1034/j.1600-0897.2003.00015.x; Tinari A, 2008, AUTOPHAGY, V4, P128, DOI 10.4161/auto.5174; Urata Y, 2006, J BIOL CHEM, V281, P13092, DOI 10.1074/jbc.M601984200; Valentim L, 2006, J MOL CELL CARDIOL, V40, P846, DOI 10.1016/j.yjmcc.2006.03.428; van Oers NSC, 2005, SCIENCE, V308, P65, DOI 10.1126/science.1110902; Vegeto E, 1999, FASEB J, V13, P793, DOI 10.1096/fasebj.13.8.793; Vicencio JM, 2008, GERONTOLOGY, V54, P92, DOI 10.1159/000129697; Vina J, 2007, J ALZHEIMERS DIS, V11, P175; Wang C, 2008, MOL ENDOCRINOL, V22, P636, DOI 10.1210/me.2007-0359; Yager JD, 2007, TRENDS ENDOCRIN MET, V18, P89, DOI 10.1016/j.tem.2007.02.006; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yang ZH, 2007, INT J CARDIOL, V118, P381, DOI 10.1016/j.ijcard.2006.07.049; Yao MZ, 2007, J NEUROSCI, V27, P1422, DOI 10.1523/JNEUROSCI.2382-06.2007; Yavuz S, 2007, CLIN EXP RHEUMATOL, V25, pS46	79	33	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					978	984		10.1096/fj.08-114348	http://dx.doi.org/10.1096/fj.08-114348			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19074513				2022-12-28	WOS:000266651600002
J	Chang, EI; Bonillas, RG; El-ftesi, S; Chang, EI; Ceradini, DJ; Vial, IN; Chan, DA; Michaels, J; Gurtner, GC				Chang, Edward I.; Bonillas, Robert G.; El-ftesi, Samyra; Chang, Eric I.; Ceradini, Daniel J.; Vial, Ivan N.; Chan, Denise A.; Michaels, Joseph, V; Gurtner, Geoffrey C.			Tissue engineering using autologous microcirculatory beds as vascularized bioscaffolds	FASEB JOURNAL			English	Article						stem cells; bioreactor; gene therapy	MESENCHYMAL STEM-CELLS; PROGENITOR CELLS; SKELETAL-MUSCLE; IN-VIVO; ADULT; PERFUSION; LIVER; FLAP; RAT; TRANSPLANTATION	Classic tissue engineering paradigms are limited by the incorporation of a functional vasculature and a reliable means for reimplantation into the host circulation. We have developed a novel approach to overcome these obstacles using autologous explanted microcirculatory beds (EMBs) as bioscaffolds for engineering complex three-dimensional constructs. In this study, EMBs consisting of an afferent artery, capillary beds, efferent vein, and surrounding parenchymal tissue are explanted and maintained for 24 h ex vivo in a bioreactor that preserves EMB viability and function. Given the rapidly advancing field of stem cell biology, EMBs were subsequently seeded with three distinct stem cell populations, multipotent adult progenitor cells (MAPCs), and bone marrow and adipose tissuederived mesenchymal stem cells (MSCs). We demonstrate MAPCs, as well as MSCs, are able to egress from the microcirculation into the parenchymal space, forming proliferative clusters. Likewise, human adipose tissuederived MSCs were also found to egress from the vasculature and seed into the EMBs, suggesting feasibility of this technology for clinical applications. We further demonstrate that MSCs can be transfected to express a luciferase protein and continue to remain viable and maintain luciferase expression in vivo. By using the vascular network of EMBs, EMBs can be perfused ex vivo and seeded with stem cells, which can potentially be directed to differentiate into neoorgans or transfected to replace failing organs and deficient proteins.-Chang, E. I., Bonillas, R. G., Elftesi, S., Chang, E. I., Ceradini, D. J., Vial, I. N., Chan, D. A., Michaels, J., V, Gurtner, G. C. Tissue engineering using autologous microcirculatory beds as vascularized bioscaffolds. FASEB J. 23, 906-915 (2009)	[Gurtner, Geoffrey C.] Stanford Univ, Med Ctr, Dept Surg, Div Plast Surg, Stanford, CA 94305 USA; [Chan, Denise A.] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA; [Ceradini, Daniel J.; Michaels, Joseph, V] NYU, Dept Surg, Sch Med, New York, NY 10016 USA	Stanford University; Stanford University; New York University	Gurtner, GC (corresponding author), Stanford Univ, Med Ctr, Dept Surg, Div Plast Surg, 257 Campus Dr,GK-201, Stanford, CA 94305 USA.	ggurtner@stanford.edu	/ABE-5226-2021		National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering [EB-02265]; National Institutes of Health Loan Repayment Program; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB002265] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); National Institutes of Health Loan Repayment Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	Human adipo-derived MSCs were a generous gift from Dr. Michael T. Longaker (Department of Surgery, Stanford University, Stanford, CA, USA). This research was supported by National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering grant EB-02265 (G. C. G.) and the National Institutes of Health Loan Repayment Program (Edward I. Chang).	Armstrong MB, 2001, CLIN PLAST SURG, V28, P671; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Babensee JE, 1998, ADV DRUG DELIVER REV, V33, P111, DOI 10.1016/S0169-409X(98)00023-4; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; Buncke HJ, 1996, PLAST RECONSTR SURG, V98, P1122, DOI 10.1097/00006534-199611000-00052; Butler AJ, 2002, TRANSPLANTATION, V73, P1212, DOI 10.1097/00007890-200204270-00005; Callan MB, 2003, VET CLIN N AM-SMALL, V33, P1277, DOI 10.1016/S0195-5616(03)00119-0; Dempsey MP, 2008, PLAST RECONSTR SURG, V121, P1541, DOI 10.1097/PRS.0b013e31816ff6aa; Dolderer JH, 2007, TISSUE ENG, V13, P673, DOI 10.1089/ten.2006.0212; Fiegel HC, 2008, J CELL MOL MED, V12, P56, DOI 10.1111/j.1582-4934.2007.00162.x; Hickey MJ, 1996, AM J PHYSIOL-HEART C, V271, pH1277, DOI 10.1152/ajpheart.1996.271.4.H1277; Hoganson DM, 2008, PEDIATR RES, V63, P520, DOI 10.1203/01.pdr.0000305879.38476.0c; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jori FP, 2005, J CELL BIOCHEM, V94, P645, DOI 10.1002/jcb.20315; Kaihara S, 1999, ARCH SURG-CHICAGO, V134, P1184, DOI 10.1001/archsurg.134.11.1184; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Lokmic Z, 2007, FASEB J, V21, P511, DOI 10.1096/fj.06-6614com; Matsumoto T, 2008, BONE, V43, P434, DOI 10.1016/j.bone.2008.05.001; McGuigan AP, 2006, P NATL ACAD SCI USA, V103, P11461, DOI 10.1073/pnas.0602740103; Melero-Martin JM, 2008, CIRC RES, V103, P194, DOI 10.1161/CIRCRESAHA.108.178590; Messina A, 2005, FASEB J, V19, P1570, DOI 10.1096/fj.04-3241fje; Michaels J, 2006, PLAST RECONSTR SURG, V118, P54, DOI 10.1097/01.prs.0000220466.27521.22; Morritt AN, 2007, CIRCULATION, V115, P353, DOI 10.1161/CIRCULATIONAHA.106.657379; Ochoa ER, 2002, ANN NY ACAD SCI, V979, P10, DOI 10.1111/j.1749-6632.2002.tb04863.x; Ott Harald C, 2007, Nat Clin Pract Cardiovasc Med, V4 Suppl 1, pS27, DOI 10.1038/ncpcardio0771; Pantazi G, 2000, ANN PLAS SURG, V44, P304, DOI 10.1097/00000637-200044030-00009; PETRY JJ, 1984, PLAST RECONSTR SURG, V74, P410, DOI 10.1097/00006534-198409000-00014; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Schaffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006-0589; Sekine H, 2006, CIRCULATION, V114, pI87, DOI 10.1161/CIRCULATIONAHA.105.000273; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; Sipowicz MA, 1997, AM J PATHOL, V151, P933; Stock UA, 2001, ANNU REV MED, V52, P443, DOI 10.1146/annurev.med.52.1.443; Tae SK, 2006, BIOMED MATER, V1, P63, DOI 10.1088/1748-6041/1/2/003; TAYLOR GI, 1987, BRIT J PLAST SURG, V40, P113, DOI 10.1016/0007-1226(87)90185-8; TOMINO Y, 1994, NEPHRON, V68, P207, DOI 10.1159/000188258; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; Zacharowski K, 1999, ARTERIOSCL THROM VAS, V19, P2276, DOI 10.1161/01.ATV.19.9.2276; Zhang F, 2001, J RECONSTR MICROSURG, V17, P211, DOI 10.1055/s-2001-14353	43	40	40	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					906	915		10.1096/fj.08-114868	http://dx.doi.org/10.1096/fj.08-114868			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19001054	Green Published			2022-12-28	WOS:000265506300026
J	Magnusson, SE; Pejler, G; Kleinau, S; Abrink, M				Magnusson, Sofia E.; Pejler, Gunnar; Kleinau, Sandra; Abrink, Magnus			Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis	FASEB JOURNAL			English	Article						protease and knockout mice; innate immune cell	COLLAGEN-INDUCED ARTHRITIS; FC-GAMMA RECEPTORS; RHEUMATOID-ARTHRITIS; INFLAMMATORY ARTHRITIS; ANGIOTENSIN-II; BETA-CHYMASES; C5A RECEPTOR; KEY ROLE; ACTIVATION; MICE	Mast cells are implicated in rheumatoid arthritis, but the mechanism by which they contribute to disease progression is not clarified. Here we investigated whether mouse mast cell protease-4 (mMCP-4), a chymase present in the mast cell secretory granule, contributes to experimental arthritis. Two models of arthritis were investigated in mMCP-4(+/+) and mMCP-4(-/-) DBA/1 mice: collagen-induced arthritis ( CIA) was induced by immunization with collagen II (CII) in Freund's complete adjuvant, and a passive model of arthritis was induced by administration of anti-CII antibodies. The clinical scores were significantly reduced in the mMCP-4(-/-) animals as compared to mMCP-4(+/+) controls in both arthritis models. In CIA, the number of affected paws was lower in the CII-immunized mMCP-4(-/-) mice, with less cartilage destruction, pannus formation, and mononuclear cell and mast cell influx in the mMCP-4(-/-) joints. Interestingly, the lower clinical scores in the CII-immunized mMCP-4(-/-) mice coincided with lower serum levels of immunoglobulin G anti-CII antibodies. Our findings identify a pathogenic role of mMCP-4 in autoimmune arthritis.-Magnusson, S. E., Pejler, G., Kleinau, S., Abrink, M. Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis. FASEB J. 23, 875-882 (2009)	[Kleinau, Sandra] Uppsala Univ, Dept Cell & Mol Biol, Program Mol Immunol, Biomed Ctr, SE-75124 Uppsala, Sweden; [Abrink, Magnus] Uppsala Univ, Dept Med Biochem & Microbiol, SE-75124 Uppsala, Sweden; [Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden	Uppsala University; Uppsala University; Swedish University of Agricultural Sciences	Kleinau, S (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Program Mol Immunol, Biomed Ctr, Box 596, SE-75124 Uppsala, Sweden.	sandra.kleinau@icm.uu.se; magnus.abrink@imbim.uu.se	Kleinau, Sandra/C-9545-2013; Åbrink, Magnus/AAK-8346-2020	Kleinau, Sandra/0000-0002-9729-2286; Abrink, Magnus/0000-0002-1335-3927	Swedish Research Council; King Gustaf V 80-Year Foundation; Swedish Rheumatism Association; Goran Gustafsson Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); King Gustaf V 80-Year Foundation; Swedish Rheumatism Association; Goran Gustafsson Foundation	This study was supported by the Swedish Research Council, King Gustaf V 80-Year Foundation, The Swedish Rheumatism Association, and the Goran Gustafsson Foundation.	Andersson MK, 2008, MOL IMMUNOL, V45, P766, DOI 10.1016/j.molimm.2007.06.360; Berahovich RD, 2005, J IMMUNOL, V174, P7341, DOI 10.4049/jimmunol.174.11.7341; Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Chen RY, 2001, J CLIN INVEST, V108, P1151, DOI 10.1172/jci11494; DIAZ DS, 2002, EUR J IMMUNOL, V32, P2915; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; Grant EP, 2002, J EXP MED, V196, P1461, DOI 10.1084/jem.20020205; Haringman JJ, 2006, ANN RHEUM DIS, V65, P294, DOI 10.1136/ard.2005.037176; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643; Johnston B, 1998, AM J PATHOL, V152, P555; Kakizoe E, 1999, INFLAMM RES, V48, P318, DOI 10.1007/s000110050467; KIDO H, 1985, BIOCHEM INT, V10, P863; Kleinau S, 2000, J EXP MED, V191, P1611, DOI 10.1084/jem.191.9.1611; Kleinau S, 1999, J IMMUNOL, V162, P4266; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Lundequist A, 2004, J BIOL CHEM, V279, P32339, DOI 10.1074/jbc.M405576200; Maruotti N, 2007, CLIN RHEUMATOL, V26, P1, DOI 10.1007/s10067-006-0305-3; McNeil HP, 2008, ARTHRITIS RHEUM-US, V58, P2338, DOI 10.1002/art.23639; Nandakumar KS, 2003, EUR J IMMUNOL, V33, P2269, DOI 10.1002/eji.200323810; Nigrovic PA, 2007, P NATL ACAD SCI USA, V104, P2325, DOI 10.1073/pnas.0610852103; Paniagua RT, 2006, J CLIN INVEST, V116, P2633, DOI 10.1172/JCI28546; Pejler G, 2007, ADV IMMUNOL, V95, P167, DOI 10.1016/S0065-2776(07)95006-3; Rioja I, 2008, ARTHRITIS RHEUM-US, V58, P2257, DOI 10.1002/art.23667; SCHICK B, 1984, J IMMUNOL, V132, P2571; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Shin K, 2006, ARTHRITIS RHEUM-US, V54, P2863, DOI 10.1002/art.22058; Soruri A, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-29; Sylvestre DL, 1996, IMMUNITY, V5, P387, DOI 10.1016/S1074-7613(00)80264-2; Tani K, 2000, J LEUKOCYTE BIOL, V67, P585, DOI 10.1002/jlb.67.4.585; Tchougounova E, 2005, J BIOL CHEM, V280, P9291, DOI 10.1074/jbc.M410396200; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Terakawa M, 2006, EUR J PHARMACOL, V538, P175, DOI 10.1016/j.ejphar.2006.03.053; Tkaczyk C, 2004, INT ARCH ALLERGY IMM, V133, P305, DOI 10.1159/000077213; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; Yoshikawa T, 2001, IMMUNOLOGY, V104, P333, DOI 10.1046/j.1365-2567.2001.01320.x	37	46	47	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					875	882		10.1096/fj.08-120394	http://dx.doi.org/10.1096/fj.08-120394			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19010978				2022-12-28	WOS:000265506300023
J	Mosig, S; Rennert, K; Krause, S; Kzhyshkowska, J; Neunubel, K; Heller, R; Funke, H				Mosig, Sandy; Rennert, Knut; Krause, Siegfried; Kzhyshkowska, Julia; Neunuebel, Kerstin; Heller, Regine; Funke, Harald			Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14(+)CD16(+) monocytes in detoxification of oxidized LDL	FASEB JOURNAL			English	Article						atherosclerosis; lipoprotein uptake; adhesion; phagocytosis; macrophage surface markers	LOW-DENSITY-LIPOPROTEIN; HUMAN PERIPHERAL-BLOOD; SMOOTH-MUSCLE-CELLS; DENDRITIC CELLS; SCAVENGER RECEPTOR; HUMAN MACROPHAGES; APOPTOTIC CELLS; IN-VITRO; ATHEROSCLEROSIS; ADHESION	The study was undertaken to investigate whether the two major monocyte subsets defined by the surface markers CD14(+)CD16(+) and CD14(++)CD16(-) show differences in their responses to hypercholesterolemia. Monocytes were rapidly isolated from the blood of hypercholesterolemic, low-density lipoprotein (LDL) receptor-defective familial hypercholesterolemia (FH) patients and from control persons. Using flow cytometry and uptake, adhesion, and phagocytosis assays as well as laser scanning microscopy, we found significant differences between the monocyte subsets. FH-CD14(+)CD16(+) monocytes exhibit an increased uptake of oxidized LDL (oxLDL) via CD36, whereas FH-CD14(++)CD16(-) monocytes preferentially take up native LDL (nLDL). FH-CD14(+)CD16(+) monocytes have an increased expression of surface proteins CD68, stabilin-1, and CD11c and a higher adherence to activated endothelial cells in response to oxLDL and nLDL stimulation. In addition, all CD14(+)CD16(+) monocytes have an increased ability for phagocytosis and a higher resistance to phagocytosis impairment by oxLDL compared with CD14(++)CD16(-) monocytes. We conclude that FH-CD14(+)CD16(+) monocytes have specialized functions in the uptake of oxLDL at activated endothelial cell surfaces, and we hypothesize that these functions are critical for the clearance of oxLDL deposits and apoptotic cells from the vessel wall under hyperlipidemic conditions.-Mosig, S., Rennert, K., Krause, S., Kzhyshkowska, J., Neunubel, K., Heller, R., Funke, H. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14(+)CD16(+) monocytes in detoxification of oxidized LDL. FASEB J. 23, 866-874 (2009)	[Krause, Siegfried; Heller, Regine] Univ Jena, Inst Mol Cell Biol, Jena, Germany; [Kzhyshkowska, Julia] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol, D-6800 Mannheim, Germany	Friedrich Schiller University of Jena; Ruprecht Karls University Heidelberg	Mosig, S (corresponding author), Bachstr 18, D-07743 Jena, Germany.	sandy.mosig@mti.uni-jena.de	Heller, Regine/AAC-9353-2019; Mosig, Alexander S./D-9620-2015; Kzhyshkowska, Julia G./J-5835-2016	Mosig, Alexander S./0000-0002-5687-2444; 	German Federal Ministry of Education and Research	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	This study was supported by research funding from the German Federal Ministry of Education and Research to H. F. We thank all patients participating in the study and Prof. K. Oette, Prof. H. Borberg, Dr. T. Schreiber, and the staff of the German Hemapheresis Center in Cologne for help in recruiting FH patients and blood processing. We also thank Dr. M. Blaha and his department of the Charles University Hospital (Hradec Kralove, Czech Republic) for gaining access to FH patients.	Ammon C, 2000, IMMUNOLOGY, V100, P364, DOI 10.1046/j.1365-2567.2000.00056.x; Ancuta P, 2004, IMMUNOBIOLOGY, V209, P11, DOI 10.1016/j.imbio.2004.04.001; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Barlic J, 2006, CIRCULATION, V114, P807, DOI 10.1161/CIRCULATIONAHA.105.602359; Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536; Bobryshev YV, 2005, EUR HEART J, V26, P1700, DOI 10.1093/eurheartj/ehi282; Cho HJ, 2007, PHYSIOL GENOMICS, V29, P149, DOI 10.1152/physiolgenomics.00051.2006; DOHERTY DE, 1989, J IMMUNOL, V143, P3673; Fogg DK, 2006, SCIENCE, V311, P83, DOI 10.1126/science.1117729; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Grabner R, 2000, CYTOMETRY, V40, P238, DOI 10.1002/1097-0320(20000701)40:3<238::AID-CYTO9>3.0.CO;2-3; Hakkinen T, 2000, VIRCHOWS ARCH, V437, P396, DOI 10.1007/s004280000239; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hayden JM, 2002, J LIPID RES, V43, P26; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOLNESS CL, 1993, BLOOD, V81, P1607; Imaizumi Tadaatsu, 2004, J Atheroscler Thromb, V11, P15; ISSEKUTZ TB, 1995, J IMMUNOL, V154, P6533; Kashiwakura Y, 2004, CIRCULATION, V110, P3329, DOI 10.1161/01.CIR.0000147828.86593.85; Kounalakis NS, 2006, J SURG RES, V135, P137, DOI 10.1016/j.jss.2005.12.018; Kzhyshkowska J, 2004, J LEUKOCYTE BIOL, V76, P1151, DOI 10.1189/jlb.0504300; Kzhyshkowska J, 2006, J CELL MOL MED, V10, P635, DOI 10.1111/j.1582-4934.2006.tb00425.x; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Miller YI, 2003, J BIOL CHEM, V278, P1561, DOI 10.1074/jbc.M209634200; Namgaladze D, 2008, J LIPID RES, V49, P58, DOI 10.1194/jlr.M700100-JLR200; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Radhika A, 2007, MOL CELL BIOCHEM, V305, P133, DOI 10.1007/s11010-007-9536-0; Randolph GJ, 2002, J EXP MED, V196, P517, DOI 10.1084/jem.20011608; Saederup N, 2008, CIRCULATION, V117, P1642, DOI 10.1161/CIRCULATIONAHA.107.743872; Schledzewski K, 2006, J PATHOL, V209, P67, DOI 10.1002/path.1942; Schrijvers DM, 2005, ARTERIOSCL THROM VAS, V25, P1256, DOI 10.1161/01.ATV.0000166517.18801.a7; Shih PT, 1999, J CLIN INVEST, V103, P613, DOI 10.1172/JCI5710; Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Tacke F, 2006, IMMUNOBIOLOGY, V211, P609, DOI 10.1016/j.imbio.2006.05.025; VANFURTH R, 1968, J EXP MED, V128, P415, DOI 10.1084/jem.128.3.415; WHITELAW DM, 1972, CELL TISSUE KINET, V5, P311, DOI 10.1111/j.1365-2184.1972.tb00369.x; Wintergerst ES, 2000, EUR J BIOCHEM, V267, P6050, DOI 10.1046/j.1432-1327.2000.01682.x; Ziegler-Heitbrock L, 2007, J LEUKOCYTE BIOL, V81, P584, DOI 10.1189/jlb.0806510; ZIEGLERHEITBROCK HWL, 1988, HYBRIDOMA, V7, P521, DOI 10.1089/hyb.1988.7.521; ZIEGLERHEITBROCK HWL, 1993, EUR J IMMUNOL, V23, P2053, DOI 10.1002/eji.1830230902	47	92	99	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					866	874		10.1096/fj.08-118240	http://dx.doi.org/10.1096/fj.08-118240			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19001052				2022-12-28	WOS:000265506300022
J	Han, PP; Yuan, YJ				Han, Pei-pei; Yuan, Ying-jin			Lipidomic analysis reveals activation of phospholipid signaling in mechanotransduction of Taxus cuspidata cells in response to shear stress	FASEB JOURNAL			English	Article						phospholipase; phosphatidic acid; mechanical stress; plant cell culture; metabolomics; LC; MS/MS	PHOSPHATIDIC-ACID ACCUMULATION; METHYL JASMONATE; NITRIC-OXIDE; BACCATIN-III; PACLITAXEL; INTEGRINS	Lipid signaling involved in mechanotransduction processes in response to shear stress in plants remained elusive. To understand the responses of phospholipids in shear stress-induced mechanotransduction, a lipidomic approach was employed to profile phospholipid species of Taxus cuspidata cells under laminar shear stress. A total of 99 phospholipid species were profiled quantitatively, using the LC/ESI/MSn procedure. Potential biomarkers were found by the principal component analysis (PCA) as well as partial least squares (PLS) combined with variable influence in the projection (VIP). Phosphatidic acid (PA) and lysophosphatidylcholine (LysoPC) were two important lipid groups that were responsible for the discrimination between shear stress induced and control cells. Further research revealed that shear stress enhanced the activation of phospholipase D (PLD) and phospholipase C (PLC) compared with control cells and consequently increased PA content in shear stress induced T. cuspidata cells. These results demonstrate that phospholipids and related phospholipases play important roles in mechanotransduction of T. cuspidata cells in response to shear stress.-Han, P.-P., Yuan, Y.-J. Lipidomic analysis reveals activation of phospholipid signaling in mechanotransduction of Taxus cuspidata cells in response to shear stress. FASEB J. 23, 623-630 (2009)	[Yuan, Ying-jin] Tianjin Univ, Key Lab Syst Bioengn, Minist Educ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China; Tianjin Univ, Dept Pharmaceut Engn, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China	Tianjin University; Tianjin University	Yuan, YJ (corresponding author), Tianjin Univ, Key Lab Syst Bioengn, Minist Educ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.	yjyuan@tju.edu.cn			National Science Fund of China [20425620]; Key Program grant [20736006]; National Basic Research Program of China [2007CB714301]	National Science Fund of China(National Natural Science Foundation of China (NSFC)); Key Program grant; National Basic Research Program of China(National Basic Research Program of China)	This work was funded by a National Science Fund of China for Distinguished Young Scholars grant (project 20425620), a Key Program grant (project 20736006), and the National Basic Research Program of China ("973" Program: 2007CB714301).	Baumert BM, 1999, J NON-NEWTON FLUID, V83, P33, DOI 10.1016/S0377-0257(98)00132-3; BHAGYALAKSHMI A, 1992, J VASC RES, V29, P443, DOI 10.1159/000158963; Blee E, 2002, TRENDS PLANT SCI, V7, P315, DOI 10.1016/S1360-1385(02)02290-2; Bogre L, 1996, NATURE, V383, P489, DOI 10.1038/383489a0; Cazzolli R, 2006, IUBMB LIFE, V58, P457, DOI 10.1080/15216540600871142; Chachisvilis M, 2006, P NATL ACAD SCI USA, V103, P15463, DOI 10.1073/pnas.0607224103; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; de Jong CF, 2004, PLANT J, V39, P1, DOI 10.1111/j.1365-313X.2004.02110.x; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Distefano AM, 2008, PLANT CELL ENVIRON, V31, P187, DOI 10.1111/j.1365-3040.2007.01756.x; Drissner D, 2007, SCIENCE, V318, P265, DOI 10.1126/science.1146487; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; Gao H, 2007, BIOTECHNOL PROGR, V23, P673, DOI 10.1021/bp060329+; Gomez-Merino FC, 2004, J BIOL CHEM, V279, P8230, DOI 10.1074/jbc.M312187200; Gong YW, 2006, J BIOTECHNOL, V123, P185, DOI 10.1016/j.jbiotec.2005.11.003; Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515; Gus-Mayer S, 1998, P NATL ACAD SCI USA, V95, P8398, DOI 10.1073/pnas.95.14.8398; Han RB, 2004, BIOTECHNOL PROGR, V20, P507, DOI 10.1021/bp034242p; Hornberger TA, 2006, P NATL ACAD SCI USA, V103, P4741, DOI 10.1073/pnas.0600678103; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; Lagarde M, 2003, BBA-MOL CELL BIOL L, V1634, P61, DOI 10.1016/j.bbalip.2003.11.002; Laxalt AM, 2002, CURR OPIN PLANT BIOL, V5, P332, DOI 10.1016/S1369-5266(02)00268-6; Laxalt AM, 2007, J BIOL CHEM, V282, P21160, DOI 10.1074/jbc.M701212200; Lee S, 2001, PLANT J, V26, P479, DOI 10.1046/j.1365-313x.2001.01037.x; Martinac B, 2004, J CELL SCI, V117, P2449, DOI 10.1242/jcs.01232; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Nakagawa Y, 2007, P NATL ACAD SCI USA, V104, P3639, DOI 10.1073/pnas.0607703104; Palazon J, 2003, J BIOTECHNOL, V101, P157, DOI 10.1016/S0168-1656(02)00318-8; Ruelland E, 2002, PLANT PHYSIOL, V130, P999, DOI 10.1104/pp.006080; Sang YM, 2001, PLANT PHYSIOL, V126, P1449, DOI 10.1104/pp.126.4.1449; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Skinner DZ, 2005, CROP SCI, V45, P1858, DOI 10.2135/cropsci2004.0721; Song K, 2004, IEEE SYS MAN CYBERN, P1354; TAKAHASHI H, 1984, PHYSIOL PLANTARUM, V61, P405, DOI 10.1111/j.1399-3054.1984.tb06347.x; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; Wakelam MJO, 2007, METHOD ENZYMOL, V432, P233, DOI 10.1016/S0076-6879(07)32010-7; Wang XL, 2007, PROTEOMICS, V7, P588, DOI 10.1002/pmic.200600568; Wang XM, 2006, PROG LIPID RES, V45, P250, DOI 10.1016/j.plipres.2006.01.005; Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P131, DOI 10.1016/S0169-7439(01)00156-3; Yang RYK, 2003, J BIOTECHNOL, V100, P13, DOI 10.1016/S0168-1656(02)00226-2; Yang S, 2008, BBA-MOL CELL BIOL L, V1781, P123, DOI 10.1016/j.bbalip.2007.11.005; Yang S, 2007, BBA-MOL CELL BIOL L, V1771, P600, DOI 10.1016/j.bbalip.2007.02.011; Yukimune Y, 1996, NAT BIOTECHNOL, V14, P1129, DOI 10.1038/nbt0996-1129; Zhang WH, 2003, PLANT CELL, V15, P2285, DOI 10.1105/tpc.013961; Zhao J, 2005, BIOTECHNOL ADV, V23, P283, DOI 10.1016/j.biotechadv.2005.01.003	50	24	25	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					623	630		10.1096/fj.08-119362	http://dx.doi.org/10.1096/fj.08-119362			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18922880				2022-12-28	WOS:000262892900033
J	de Jong, EK; Vinet, J; Stanulovic, VS; Meijer, M; Wesseling, E; Sjollema, K; Boddeke, HWGM; Biber, K				de Jong, Eiko K.; Vinet, Jonathan; Stanulovic, Vesna S.; Meijer, Michel; Wesseling, Evelyn; Sjollema, Klaas; Boddeke, Hendrikus W. G. M.; Biber, Knut			Expression, transport, and axonal sorting of neuronal CCL21 in large dense-core vesicles	FASEB JOURNAL			English	Article						chemokines; neuroimmunology; vesicles; microglia; neuronal injury; neuron-glia communication	REGULATED SECRETORY PATHWAY; NERVOUS-SYSTEM; GROWTH-FACTOR; PC12 CELLS; RAT-BRAIN; MICROGLIA; CHEMOKINES; GRANULES; NEUROPEPTIDES; MOTOR	Neurons are highly polarized cells, and neuron-neuron communication is based on directed transport and release of neurotransmitters, neuropeptides, and neurotrophins. Directed communication may also be attributed to neuron-microglia signaling, since neuronal damage can induce a microglia reaction at specific sites only. However, the mechanism underlying this site-specific microglia reaction is not yet understood. Neuronal CCL21 is a microglia-activating chemokine, which in brain is solely found in endangered neurons and is therefore a candidate for neuron-microglia signaling. Here we present that neuronal CCL21 is sorted into large dense-core vesicles, the secretory granules of the regulated release pathway of neurons. Live-cell imaging studies show preferential sorting of CCL21-containing vesicles into axons, indicating its directed transport. Thus, mouse neurons express and transport a microglia activating factor very similar to signaling molecules used in neuron-neuron communication. These data show for the first time the directed transport of a microglia activating factor in neurons and corroborate the function of neuronal CCL21 in directed neuron-microglia communication.	[de Jong, Eiko K.; Vinet, Jonathan; Stanulovic, Vesna S.; Meijer, Michel; Wesseling, Evelyn; Boddeke, Hendrikus W. G. M.; Biber, Knut] Univ Groningen, Dept Med Physiol, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands; [Sjollema, Klaas] Univ Groningen, Univ Med Imaging Ctr, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands	University of Groningen; University of Groningen	Biber, K (corresponding author), Univ Groningen, Dept Med Physiol, Univ Med Ctr Groningen, Ant Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	k.p.h.biber@med.umcg.nl	Vinet, Jonathan/O-2934-2015; de Jong, Eiko/P-3407-2015	Vinet, Jonathan/0000-0001-9011-6207; de Jong, Eiko/0000-0001-6520-0407; Sjollema, Klaas/0000-0001-8840-2087	NWO-Vidi	NWO-Vidi(Netherlands Organization for Scientific Research (NWO))	The authors thank Dr. R. Toonen and Prof. M. Verhage (VUMC, Amsterdam, The Netherlands) for providing pmRFP-N1, pNPY-mRFP, and pVAMP-mRFP plasmids, and Dr. S. Carra and N. Bouwer for technical support. The work of K.B., J.V., and V.S. is supported by an NWO-Vidi grant to K.B.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Adler MW, 2005, AAPS J, V7, pE865, DOI 10.1208/aapsj070484; Banati RB, 2002, J PHYSIOLOGY-PARIS, V96, P289, DOI 10.1016/S0928-4257(02)00018-9; Banisadr G, 2005, J COMP NEUROL, V489, P275, DOI 10.1002/cne.20598; Barkus RV, 2008, MOL BIOL CELL, V19, P274, DOI 10.1091/mbc.E07-03-0261; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bhattacharyya BJ, 2008, J NEUROSCI, V28, P6720, DOI 10.1523/JNEUROSCI.1677-08.2008; Biber K, 2006, CURR DRUG TARGETS, V7, P29, DOI 10.2174/138945006775270196; Biber K, 2001, GLIA, V34, P121, DOI 10.1002/glia.1047; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Borgonovo B, 2006, CURR OPIN CELL BIOL, V18, P365, DOI 10.1016/j.ceb.2006.06.010; Brigadski T, 2005, J NEUROSCI, V25, P7601, DOI 10.1523/JNEUROSCI.1776-05.2005; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Copray JCVM, 2001, J NEUROIMMUNOL, V118, P203, DOI 10.1016/S0165-5728(01)00324-1; de Haas AH, 2007, MOL NEUROBIOL, V36, P137, DOI 10.1007/s12035-007-0036-8; de Jong EK, 2005, J NEUROSCI, V25, P7548, DOI 10.1523/JNEUROSCI.1019-05.2005; de Wit H, 2001, MOL BIOL CELL, V12, P3703, DOI 10.1091/mbc.12.11.3703; de Wit J, 2006, TRAFFIC, V7, P1060, DOI 10.1111/j.1600-0854.2006.00442.x; Dijkstra IM, 2004, J IMMUNOL, V172, P2744, DOI 10.4049/jimmunol.172.5.2744; Dikeakos JD, 2007, J CELL BIOL, V177, P191, DOI 10.1083/jcb.200701024; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Hirokawa N, 2004, EXP CELL RES, V301, P50, DOI 10.1016/j.yexcr.2004.08.010; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Juttler E, 2002, NEUROSCIENTIST, V8, P268, DOI 10.1177/1073858402008003012; Kayadjanian N, 2007, MOL CELL NEUROSCI, V34, P219, DOI 10.1016/j.mcn.2006.11.001; Lessmann V, 2003, PROG NEUROBIOL, V69, P341, DOI 10.1016/S0301-0082(03)00019-4; Li HY, 2005, NEURON, V48, P619, DOI 10.1016/j.neuron.2005.09.033; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Meldolesi J, 2004, TRENDS CELL BIOL, V14, P13, DOI 10.1016/j.tcb.2003.11.006; Minami M, 2005, NEUROMOL MED, V7, P149, DOI 10.1385/NMM:7:1-2:149; Moller JC, 2006, NEUROSCI LETT, V400, P75, DOI 10.1016/j.neulet.2006.02.018; Mowla SJ, 1999, J NEUROSCI, V19, P2069; Nakata T, 2003, J CELL BIOL, V162, P1045, DOI 10.1083/jcb.200302175; PELLETIER G, 1984, NEUROPEPTIDES, V4, P319, DOI 10.1016/0143-4179(84)90006-4; Rappert A, 2002, J IMMUNOL, V168, P3221, DOI 10.4049/jimmunol.168.7.3221; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Rasband W.S., 2006, IMAGEJ; Rebenko-Moll NM, 2006, CURR OPIN IMMUNOL, V18, P683, DOI 10.1016/j.coi.2006.09.005; Salio C, 2006, CELL TISSUE RES, V326, P583, DOI 10.1007/s00441-006-0268-3; Specht H, 2003, MOL CELL NEUROSCI, V22, P75, DOI 10.1016/S1044-7431(02)00023-4; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; Thomas K, 2005, CURR BIOL, V15, pR262, DOI 10.1016/j.cub.2005.03.023; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; von Gersdorff H, 1999, ANNU REV PHYSIOL, V61, P725, DOI 10.1146/annurev.physiol.61.1.725; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180	48	45	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4136	4145		10.1096/fj.07-101907	http://dx.doi.org/10.1096/fj.07-101907			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18697841				2022-12-28	WOS:000261254800013
J	Leoni, G; Patel, HB; Sampaio, ALF; Gavins, FNE; Murray, JF; Grieco, P; Getting, SJ; Perretti, M				Leoni, Giovanna; Patel, Hetal B.; Sampaio, Andre L. F.; Gavins, Felicity N. E.; Murray, Joanne F.; Grieco, Paolo; Getting, Stephen J.; Perretti, Mauro			Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion	FASEB JOURNAL			English	Article						intravital microscopy; cell trafficking; GPCR	MELANOCYTE-STIMULATING HORMONE; EXPERIMENTAL HEART-TRANSPLANTATION; SPLANCHNIC ARTERY-OCCLUSION; YELLOW E/E MOUSE; NF-KAPPA-B; ALPHA-MSH; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; NEUTROPHIL MIGRATION; INDUCED INFLAMMATION	The existence of anti-inflammatory circuits centered on melanocortin receptors (MCRs) has been supported by the inhibitory properties displayed by melanocortin peptides in models of inflammation and tissue injury. Here we addressed the pathophysiological effect that one MCR, MCR type 3 (MC3R), might have on vascular inflammation. After occlusion (35 min) and reopening of the superior mesenteric artery, MC3R-null mice displayed a higher degree of plasma extravasation (45 min postreperfusion) and cell adhesion and emigration (90 min postreperfusion). These cellular alterations were complemented by higher expression of mesenteric tissue CCL2 and CXCL1 (mRNA and protein) and myeloperoxydase, as compared with wild-type animals. MC1R and MC3R mRNA and protein were both expressed in the inflamed mesenteric tissue; however, no changes in vascular responses were observed in a mouse colony bearing an inactive MC1R. Pharmacological treatment of animals with a selective MC3R agonist ([D-Trp(8)]-gamma- melanocyte-stimulating hormone; 10 mu g i.v.) produced marked attenuation of cell adhesion, emigration, and chemokine generation; such effects were absent in MC3R-null mice. These new data reveal the existence of a tonic inhibitory signal provided by MC3R in the mesenteric microcirculation of the mouse, acting to down-regulate cell trafficking and local mediator generation.	[Leoni, Giovanna; Patel, Hetal B.; Sampaio, Andre L. F.; Gavins, Felicity N. E.; Perretti, Mauro] Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England; [Grieco, Paolo] Univ Naples Federico 2, Dept Pharmaceut Chem & Toxicol, Naples, Italy; [Murray, Joanne F.; Getting, Stephen J.] Univ Westminster, Sch Biosci, London W1R 8AL, England	University of London; Queen Mary University London; University of Naples Federico II; University of Westminster	Perretti, M (corresponding author), Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	m.perretti@qmul.ac.uk	Murray, Joanne F/P-7034-2016; Gavins, Felicity N. E./AAU-6010-2020; Grieco, Paolo/AAB-9034-2019	Murray, Joanne F/0000-0003-4884-9153; Gavins, Felicity N. E./0000-0001-7008-5423; Grieco, Paolo/0000-0002-6854-8123	British Heart Foundation [FS/05/078/19406]; CNPq Brasil [201172/2004-06]	British Heart Foundation(British Heart Foundation); CNPq Brasil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study was funded by the British Heart Foundation (studentship FS/05/078/19406). A.L.F.S. is a Fellow of CNPq Brasil (201172/2004-06).	Artuc M, 2006, J INVEST DERMATOL, V126, P1976, DOI 10.1038/sj.jid.5700318; Bazzani C, 2001, J PHARMACOL EXP THER, V297, P1082; Butler AA, 2002, NEUROPEPTIDES, V36, P77, DOI 10.1054/npep.2002.0890; Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1; Catania A, 2000, TRENDS ENDOCRIN MET, V11, P304, DOI 10.1016/S1043-2760(00)00296-4; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Chiao H, 1996, J CLIN INVEST, V97, P2038, DOI 10.1172/JCI118639; Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272; Colombo G, 2005, J IMMUNOL, V175, P3391, DOI 10.4049/jimmunol.175.5.3391; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; Damazo AS, 2006, J IMMUNOL, V176, P4410, DOI 10.4049/jimmunol.176.7.4410; Di Filippo C, 2004, J PHARMACOL EXP THER, V310, P1133, DOI 10.1124/jpet.104.068726; Ellacott KLJ, 2007, ENDOCRINOLOGY, V148, P6186, DOI 10.1210/en.2007-0699; Gantz I, 2003, AM J PHYSIOL-ENDOC M, V284, pE468, DOI 10.1152/ajpendo.00434.2002; Gatti S, 2002, TRANSPLANTATION, V74, P1678, DOI 10.1097/01.TP.0000038865.87650.E8; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Getting SJ, 2004, J LEUKOCYTE BIOL, V76, P845, DOI 10.1189/jlb.0306175; Getting SJ, 2002, ARTHRITIS RHEUM, V46, P2765, DOI 10.1002/art.10526; Getting SJ, 1999, J IMMUNOL, V162, P7446; Getting SJ, 2003, J IMMUNOL, V170, P3323, DOI 10.4049/jimmunol.170.6.3323; Getting SJ, 2006, MOL PHARMACOL, V70, P1850, DOI 10.1124/mol.106.028878; Getting SJ, 2006, FASEB J, V20, P2234, DOI 10.1096/fj.06-6339com; Getting SJ, 2006, PHARMACOL THERAPEUT, V111, P1, DOI 10.1016/j.pharmthera.2005.06.022; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gonzalez-Rey E, 2007, NAT REV IMMUNOL, V7, P52, DOI 10.1038/nri1984; Grieco P, 2000, J MED CHEM, V43, P4998, DOI 10.1021/jm000211e; Guarini S, 2002, N-S ARCH PHARMACOL, V366, P177, DOI 10.1007/s00210-002-0572-8; Kalden DH, 1999, ANN NY ACAD SCI, V885, P254; Lam CW, 2006, PEPTIDES, V27, P404, DOI 10.1016/j.peptides.2005.01.031; Lam CW, 2005, J IMMUNOL, V174, P2297, DOI 10.4049/jimmunol.174.4.2297; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Luger TA, 2003, ANN NY ACAD SCI, V994, P133, DOI 10.1111/j.1749-6632.2003.tb03172.x; Luger TA, 2007, ANN RHEUM DIS, V66, P52, DOI 10.1136/ard.2007.079780; Lyons PD, 1997, J NEUROIMMUNOL, V78, P47, DOI 10.1016/S0165-5728(97)00081-7; Maaser C, 2006, GUT, V55, P1415, DOI 10.1136/gut.2005.083634; Manna SK, 1998, J IMMUNOL, V161, P2873; Mioni C, 2003, EUR J PHARMACOL, V477, P227, DOI 10.1016/S0014-2999(03)02184-8; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Paul-Clark M, 2000, BRIT J PHARMACOL, V131, P1345, DOI 10.1038/sj.bjp.0703704; Perretti M, 1997, TRENDS PHARMACOL SCI, V18, P418; RITTER J, 1994, J RHEUMATOL, V21, P696; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Squadrito F, 1999, BRIT J PHARMACOL, V128, P816, DOI 10.1038/sj.bjp.0702848; Wainwright CL, 2004, CURR OPIN PHARMACOL, V4, P132, DOI 10.1016/j.coph.2004.01.001	47	36	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4228	4238		10.1096/fj.08-113886	http://dx.doi.org/10.1096/fj.08-113886			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18757499	hybrid, Green Published			2022-12-28	WOS:000261254800022
J	Marathe, DD; Chandrasekaran, EV; Lau, JTY; Matta, KL; Neelamegham, S				Marathe, Dhananjay D.; Chandrasekaran, E. V.; Lau, Joseph T. Y.; Matta, Khushi L.; Neelamegham, Sriram			Systems-level studies of glycosyltransferase gene expression and enzyme activity that are associated with the selectin binding function of human leukocytes	FASEB JOURNAL			English	Article						systems biology; glycan; PSGL-1; inflammation; hydroxyurea	SIALYL-LEWIS-X; P-SELECTIN; HL-60 CELLS; GLYCOPROTEIN LIGAND-1; O-GLYCANS; GRANULOCYTIC DIFFERENTIATION; MOLECULAR-CLONING; RETINOIC ACID; MUCIN CORE-2; IN-VITRO	The application of systems biology methods in the emerging field of glycomics requires the collection and integration of glycosyltransferase data at the gene and enzyme level for the purpose of hypothesis generation. We systematically examined the relationship between gene expression, glycosyltransferase activity, glycan expression, and selectin-binding function in different systems, including human neutrophils, undifferentiated HL-60 (human promyelocytic cells), differentiated HL-60, and HL-60 synchronized in specific growth phases. Results demonstrate that 1) the sLe(X) (sialyl-Lewis-X) epitope is expressed in P-selectin glycoprotein ligand-1 (PSGL-1) from neutrophils at higher levels compared with HL-60. This variation may be due to differences in the relative activities of alpha 1,3-fucosyltransferases and alpha 2,3-sialyltransferases in these two cell types. 2) HL-60 cell differentiation along granulocyte lineage increased the activity of beta 1,4GalT and beta 1,3GlcNAcT by 1.6- to 3.2-fold. This may contribute to LacNAc chain extension as evidenced by the 1.7-fold increase in DSA-lectin (lectin recognizing LacNAc) binding to cells after differentiation. 3) The activity of enzymes contributing to sLeX formation in leukocytes likely varies as ST3[Gal beta 1,4GlcNAc] <= alpha 1,3FT[sialyl-LacNAc] < beta 1,3GlcNAcT. 4) O-glycan specific glycosyltransferase activity does not undergo periodic variation with cell cycle phases. Overall, gene expression and enzyme activity data combined with knowledge of biochemistry can predict the resulting glycan structures and yield viable experimentally testable hypothesis.	[Neelamegham, Sriram] SUNY Buffalo, New York State Ctr Excellence Bioinformat & Life, Buffalo, NY 14260 USA; [Chandrasekaran, E. V.; Matta, Khushi L.] Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA; [Lau, Joseph T. Y.] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Neelamegham, S (corresponding author), SUNY Buffalo, New York State Ctr Excellence Bioinformat & Life, Buffalo, NY 14260 USA.	neel@eng.buffalo.edu		Neelamegham, Sriram/0000-0002-1371-8500; Marathe, Dhananjay/0000-0003-0238-2252	National Institutes of Health [HL63014, HL76211, CA35329, AI56082]; NATIONAL CANCER INSTITUTE [R01CA035329] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL076211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056082] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from the National Institutes of Health (HL63014 and HL76211 to S.N., CA35329 to K.L.M. and AI56082 to J.T.Y.L.). Carbohydrate acceptors used in this work were synthesized by various members of Matta Laboratory.	Aeed PA, 1998, GLYCOCONJUGATE J, V15, P975, DOI 10.1023/A:1006985825141; Beauharnois Mark E., 2006, V347, P343; Beauharnois ME, 2005, BIOCHEMISTRY-US, V44, P9507, DOI 10.1021/bi0507130; Benkerrou M, 2002, BLOOD, V99, P2297, DOI 10.1182/blood.V99.7.2297; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; Chandrasekaran EV, 2005, BIOCHEMISTRY-US, V44, P15619, DOI 10.1021/bi050246m; Chandrasekaran EV, 2004, J BIOL CHEM, V279, P10032, DOI 10.1074/jbc.M311989200; Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8925, DOI 10.1021/bi952194e; CHANDRASEKARAN EV, 1992, J BIOL CHEM, V267, P19929; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; Ellies LG, 2002, BLOOD, V100, P3618, DOI 10.1182/blood-2002-04-1007; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; Giraudo CG, 2003, J BIOL CHEM, V278, P40262, DOI 10.1074/jbc.M305455200; Guo HB, 2000, BBA-MOL CELL RES, V1495, P297, DOI 10.1016/S0167-4889(99)00157-3; Hillery CA, 2000, BRIT J HAEMATOL, V109, P322, DOI 10.1046/j.1365-2141.2000.02040.x; Kawano S, 2005, BIOINFORMATICS, V21, P3976, DOI 10.1093/bioinformatics/bti666; Krambeck FJ, 2005, BIOTECHNOL BIOENG, V92, P711, DOI 10.1002/bit.20645; LEE N, 1990, J BIOL CHEM, V265, P20476; LeMarer N, 1997, GLYCOBIOLOGY, V7, P357; Leppanen A, 2002, J BIOL CHEM, V277, P39749, DOI 10.1074/jbc.M206281200; Li X, 2001, J LEUKOCYTE BIOL, V69, P565; Liu AH, 1998, CELL BIOL INT, V22, P545, DOI 10.1006/cbir.1998.0293; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Nakayama F, 2001, J BIOL CHEM, V276, P16100, DOI 10.1074/jbc.M007272200; Nasirikenari M, 2006, BLOOD, V108, P3397, DOI 10.1182/blood-2006-04-014779; Neelamegham S, 2004, CELL COMMUN ADHES, V11, P35, DOI 10.1080/15419060490471793; Ogawa J, 1997, CANCER, V79, P1678, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1678::AID-CNCR7>3.0.CO;2-8; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; Pratt MR, 2004, CHEM BIOL, V11, P1009, DOI 10.1016/j.chembiol.2004.05.009; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Sjogren F, 2000, INFLAMMATION, V24, P21, DOI 10.1023/A:1006983824890; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2006, EUR J IMMUNOL, V36, P3207, DOI 10.1002/eji.200636157; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Watson RWG, 1997, FEBS LETT, V412, P603, DOI 10.1016/S0014-5793(97)00779-5; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Xiao ZH, 2006, BIOPHYS J, V90, P2221, DOI 10.1529/biophysj.105.065789; Young WW, 2004, J MEMBRANE BIOL, V198, P1, DOI 10.1007/s00232-004-0656-5	41	38	39	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4154	4167		10.1096/fj.07-104257	http://dx.doi.org/10.1096/fj.07-104257			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18716032	Green Published			2022-12-28	WOS:000261254800015
J	Brown, K; Sacks, SH; Wong, W				Brown, Kathryn; Sacks, Steven H.; Wong, Wilson			Extensive and bidirectional transfer of major histocompatibility complex class II molecules between donor and recipient cells in vivo following solid organ transplantation	FASEB JOURNAL			English	Article						antigen presentation; molecular exchange; surface molecules	CD4(+) T-CELLS; MHC-CLASS-II; ANTIGEN-PRESENTING CELLS; DENDRITIC-CELLS; INTERCELLULAR TRANSFER; IMMUNOLOGICAL SYNAPSE; CARDIAC ALLOGRAFTS; RENAL-ALLOGRAFTS; CUTTING EDGE; LIVE CELLS	Intercellular transfer of surface molecules has been demonstrated in vitro, or in vivo under artificial situations. Transplantation is a unique clinical situation in which foreign major histocompatibility complex (MHC) molecules are deliberately introduced. This provides a model to study intercellular MHC transfer because donor MHC molecules can easily be tracked. Here we describe the bidirectional transfer of MHC class II molecules between donor and recipient cells after transplantation of vascularized kidney and cardiac allografts in mice. Cells that are positive for both donor and recipient MHC class II accounted for up to 30% of the donor MHC class II+ population, suggesting that they play a significant role in the antigen presentation process. The majority of these cells were dendritic cells, but macrophages and B cells were also able to acquire foreign MHC molecules. Most double-positive cells were also positive for costimulatory molecules, indicating a capability to elicit a T-cell response. This transfer of MHC molecules between donor and recipient cells provides a link between the direct and indirect pathways of alloantigen presentation and suggests that MHC transfer is also likely to occur under normal physiological conditions, which has implications in the fields of infection, vaccination, and tumor immunology.-Brown, K., Sacks, S. H., Wong, W. Extensive and bidirectional transfer of major histocompatibility complex class II molecules between donor and recipient cells in vivo following solid organ transplantation. FASEB J. 22, 3776-3784 (2008)	[Brown, Kathryn; Sacks, Steven H.; Wong, Wilson] Kings Coll London, Guys Kings & St Thomas Hosp, MRC, Ctr Transplant,Sch Med, London, England	University of London; King's College London	Wong, W (corresponding author), Guys Hosp, MRC, Ctr Transplantat, 5th Floor,Tower Wing,Great Maze Pond, London SE1 9RT, England.	wilson.wong@kcl.ac.uk		Sacks, Steven/0000-0001-6361-9095	Genzyme renal innovative program; Medical Research Council, UK; Medical Research Council [G0600698B] Funding Source: researchfish	Genzyme renal innovative program(Sanofi-AventisGenzyme Corporation); Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Genzyme renal innovative program and the Medical Research Council, UK.	Arnold PY, 1997, EUR J IMMUNOL, V27, P3198, DOI 10.1002/eji.1830271217; Baba E, 2001, J IMMUNOL, V167, P875, DOI 10.4049/jimmunol.167.2.875; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Bickerstaff AA, 2001, J IMMUNOL, V167, P4821, DOI 10.4049/jimmunol.167.9.4821; Brown K, 2007, AM J PATHOL, V171, P1915, DOI 10.2353/ajpath.2007.070396; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; Davis DM, 2004, TRENDS IMMUNOL, V25, P323, DOI 10.1016/j.it.2004.03.007; Dolan BP, 2006, J IMMUNOL, V176, P1447, DOI 10.4049/jimmunol.176.3.1447; Dolan BP, 2006, J IMMUNOL, V177, P6018, DOI 10.4049/jimmunol.177.9.6018; Han WR, 1999, MICROSURG, V19, P272, DOI 10.1002/(SICI)1098-2752(1999)19:6<272::AID-MICR3>3.0.CO;2-L; Harshyne LA, 2001, J IMMUNOL, V166, P3717, DOI 10.4049/jimmunol.166.6.3717; Harshyne LA, 2003, J IMMUNOL, V170, P2302, DOI 10.4049/jimmunol.170.5.2302; Herrera OB, 2004, J IMMUNOL, V173, P4828, DOI 10.4049/jimmunol.173.8.4828; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Hwang I, 2000, J EXP MED, V191, P1137, DOI 10.1084/jem.191.7.1137; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511; PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942; Patel DM, 1999, J IMMUNOL, V163, P5201; Patel DM, 2001, CELL IMMUNOL, V214, P165, DOI 10.1006/cimm.2001.1897; Russo V, 2000, BLOOD, V95, P3473, DOI 10.1182/blood.V95.11.3473.011k06_3473_3477; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; SCHRIER SL, 1971, BIOCHIM BIOPHYS ACTA, V233, P26, DOI 10.1016/0005-2736(71)90354-3; Sjostrom A, 2001, J EXP MED, V194, P1519, DOI 10.1084/jem.194.10.1519; Smyth LA, 2007, AM J TRANSPLANT, V7, P1442, DOI 10.1111/j.1600-6143.2007.01816.x; Tsang JYS, 2002, TRANSPLANT P, V34, P2849, DOI 10.1016/S0041-1345(02)03532-7; Wetzel SA, 2005, J IMMUNOL, V174, P80, DOI 10.4049/jimmunol.174.1.80; Yamada A, 2001, J IMMUNOL, V167, P5522, DOI 10.4049/jimmunol.167.10.5522	28	38	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2008	22	11					3776	3784		10.1096/fj.08-107441	http://dx.doi.org/10.1096/fj.08-107441			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18632850				2022-12-28	WOS:000260503000006
J	Cen, H; Mao, F; Aronchik, I; Fuentes, RJ; Firestone, GL				Cen, Hui; Mao, Fei; Aronchik, Ida; Fuentes, Rholinelle Joy; Firestone, Gary L.			DEVD-NucView488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells	FASEB JOURNAL			English	Article						apoptosis; fluorescence; imaging; nucleic acid; nucleus	THIAZOLE ORANGE; APOPTOSIS; DNA; ACTIVATION; EXPRESSION; BINDING; CALCIUM; DYE	Live-cell detection of intracellular enzyme activity requires that substrates are cell-permeable and that the generated products are easily detected and retained in cells. Our objective was to create a novel fluorogenic substrate that could be used for real-time detection of apoptosis in living cells. We have synthesized a highly cell-permeable caspase-3 substrate, DEVD-NucView488, by linking a fluorogenic DNA-binding dye to the caspase-3 recognition sequence that renders the dye nonfunctional. On substrate cleavage, the dye is released and becomes highly fluorescent on binding to DNA. DEVD-NucView488 detected caspase-3 activation within a live-cell population much earlier and with higher sensitivity compared with other apoptosis reagents that are currently available. Furthermore, cells incubated with DEVD-NucView488 exhibited no toxicity and normal apoptotic progression. DEVD-NucView488 is an ideal substrate for kinetic studies of caspase-3 activation because it detects caspase-3 activity in real-time and also efficiently labels DNA in nuclei of caspase-3-activated cells for real-time fluorescent visualization of apoptotic morphology. The strategy utilized in the design of this fluorogenic substrate can be applied in future endeavors to develop substrates for detecting real-time intracellular enzyme activity.	[Cen, Hui; Mao, Fei; Fuentes, Rholinelle Joy] Biotium Inc, Hayward, CA 94545 USA; [Aronchik, Ida; Firestone, Gary L.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Cen, H (corresponding author), Biotium Inc, 3423 Investment Blvd,Ste 8, Hayward, CA 94545 USA.	dcen@biotium.com			NATIONAL CANCER INSTITUTE [R01CA102360] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102360, R01 CA102360-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armitage BA, 2005, TOP CURR CHEM, V253, P55, DOI 10.1007/b100442; Bedner E, 2000, EXP CELL RES, V259, P308, DOI 10.1006/excr.2000.4955; Benetti L, 2007, J VIROL, V81, P10242, DOI 10.1128/JVI.00820-07; Bonnesen C, 2001, CANCER RES, V61, P6120; BORLE AB, 1982, SCIENCE, V217, P252, DOI 10.1126/science.6806904; Bosch M, 2007, P NATL ACAD SCI USA, V104, P18327, DOI 10.1073/pnas.0705826104; Cai SX, 2001, BIOORG MED CHEM LETT, V11, P39, DOI 10.1016/S0960-894X(00)00590-4; Carreon JR, 2004, ORG LETT, V6, P517, DOI 10.1021/ol0362818; GRASSMANN A, 1971, H-S Z PHYSIOL CHEM, V352, P527, DOI 10.1515/bchm2.1971.352.1.527; Hawkins RB, 2005, INT J RADIAT ONCOL, V63, P529, DOI 10.1016/j.ijrobp.2005.05.055; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEE LG, 1986, CYTOMETRY, V7, P508, DOI 10.1002/cyto.990070603; Liu LZ, 2002, NAT MED, V8, P185, DOI 10.1038/nm0202-185; Messerli SM, 2004, NEOPLASIA, V6, P95, DOI 10.1593/neo.03214; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Paez PM, 2007, J NEUROSCI, V27, P12690, DOI 10.1523/JNEUROSCI.2381-07.2007; Smolewski P, 2002, CYTOMETRY, V47, P143, DOI 10.1002/cyto.10062; TENG H, 2007, J CEREB BLOOD FLOW M; Vuorinen K, 2007, EXP LUNG RES, V33, P357, DOI 10.1080/01902140701634827; Zhang HZ, 2003, BIOCONJUGATE CHEM, V14, P458, DOI 10.1021/bc0256188; ZHANG YZ, 1991, FASEB J, V5, P3108, DOI 10.1096/fasebj.5.15.1720751	21	62	66	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2243	2252		10.1096/fj.07-099234	http://dx.doi.org/10.1096/fj.07-099234			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263700				2022-12-28	WOS:000257292500017
J	Gunning, AP; Chambers, S; Pin, C; Man, AL; Morris, VJ; Nicoletti, C				Gunning, A. Patrick; Chambers, Stephen; Pin, Carmen; Man, Angela L.; Morris, Victor J.; Nicoletti, Claudio			Mapping specific adhesive interactions on living human intestinal epithelial cells with atomic force microscopy	FASEB JOURNAL			English	Article						AFM; caco-2; force mapping; lectin-carbohydrate interactions	COLLOID PROBE; SPECTROSCOPY; RECEPTOR; CACO-2; GUT; ANTIBODIES; MEMBRANES; STRENGTH; ANTIGEN; BINDING	Specific molecular-receptor interactions with gut epithelium cells are important in understanding bioactivity of food components and drugs, binding of commensal microflora, attachment and initiation of defense mechanisms against pathogenic bacteria and for development of targeted delivery systems to the gut. However, methods for probing such interactions are lacking. Methodology has been developed and validated to measure specific molecular-receptor interactions on living human colorectal cancer cells as in vitro models for the gut epithelium. Atomic force microscopy (AFM) was used to measure ligand-receptor interactions and to map receptor locations on cell surfaces. Measurements were made using silica beads attached to the AFM tip- cantilever assembly, which were functionalized by coupling of ligands to the bead surface. Wheat germ agglutinin (WGA) binds to the glycosylated extracellular domain III of the epidermal growth factor receptor. Methodology was tested by measuring binding of WGA to the surface of confluent monolayers of living Caco-2 human intestinal epithelial cells. The measured modal detachment force of 125 pN is typical of values expected for single molecule interactions. Adhesive events were used to map the location of binding sites on the cell surface revealing heterogeneity in their distribution within and between cells within the monolayer.			Gunning, AP (corresponding author), Inst Food Res, Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	patrick.gunning@bbsrc.ac.uk	pin, carmen/C-8959-2014	Man, Angela/0000-0002-9596-0068	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000; BHATIA SK, 1989, ANAL BIOCHEM, V178, P408, DOI 10.1016/0003-2697(89)90662-3; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUTT HJ, 1995, NANOTECHNOLOGY, V6, P1, DOI 10.1088/0957-4484/6/1/001; CHAMOW SM, 1992, J BIOL CHEM, V267, P15916; Dammer U, 1996, BIOPHYS J, V70, P2437, DOI 10.1016/S0006-3495(96)79814-4; Didierlaurent A, 2002, CELL MICROBIOL, V4, P61, DOI 10.1046/j.1462-5822.2002.00177.x; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Foster N, 2005, ADV DRUG DELIVER REV, V57, P431, DOI 10.1016/j.addr.2004.09.009; Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045; Gabor F, 1998, J CONTROL RELEASE, V55, P131, DOI 10.1016/S0168-3659(98)00043-1; Gabor F, 2002, INT J PHARM, V237, P227, DOI 10.1016/S0378-5173(02)00049-2; HAN T, 1995, ANAL CHIM ACTA, V307, P365, DOI 10.1016/0003-2670(94)00671-8; Kaiserlian D, 1999, CURR TOP MICROBIOL, V236, P55; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; Lochner N, 2003, PHARM RES-DORDR, V20, P833, DOI 10.1023/A:1023406224028; MADARA JL, 1990, J MEMBRANE BIOL, V116, P117; McNamee CE, 2006, BIOPHYS J, V91, P1960, DOI 10.1529/biophysj.106.082420; McNamee CE, 2006, COLLOID SURFACE B, V48, P176, DOI 10.1016/j.colsurfb.2006.01.014; McNamee CE, 2006, COLLOID SURFACE B, V47, P85, DOI 10.1016/j.colsurfb.2005.11.023; MEYER G, 1988, APPL PHYS LETT, V53, P1045, DOI 10.1063/1.100061; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; PETERSON MD, 1993, J CELL SCI, V105, P445; PINTO, 1983, BIOL CELL, V47, P322; Puntheeranurak T, 2006, J CELL SCI, V119, P2960, DOI 10.1242/jcs.03035; Shao L, 2001, SEMIN IMMUNOL, V13, P163, DOI 10.1006/smim.2000.0311; Sulchek T, 2006, BIOPHYS J, V90, P4686, DOI 10.1529/biophysj.105.080291; Touhami A, 2003, MICROBIOL-SGM, V149, P2873, DOI 10.1099/mic.0.26431-0; Touhami A, 2003, LANGMUIR, V19, P1745, DOI 10.1021/la026145w; Williams JM, 1996, LANGMUIR, V12, P1291, DOI 10.1021/la950500j; Williams PM, 2003, ANAL CHIM ACTA, V479, P107, DOI 10.1016/S0003-2670(02)01569-6; Zhang XH, 2004, AM J PHYSIOL-HEART C, V286, pH359, DOI 10.1152/ajpheart.00491.2003; Zhang XH, 2002, BIOPHYS J, V83, P2270, DOI 10.1016/S0006-3495(02)73987-8	36	29	30	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2331	2339		10.1096/fj.07-100578	http://dx.doi.org/10.1096/fj.07-100578			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263697				2022-12-28	WOS:000257292500025
J	Varady, KA; Roohk, DJ; McEvoy-Hein, BK; Gaylinn, BD; Thorner, MO; Hellerstein, MK				Varady, K. A.; Roohk, D. J.; McEvoy-Hein, B. K.; Gaylinn, B. D.; Thorner, M. O.; Hellerstein, M. K.			Modified alternate-day fasting regimens reduce cell proliferation rates to a similar extent as daily calorie restriction in mice	FASEB JOURNAL			English	Article						cancer; insulin-like growth factor-1; insulin-like growth factor binding protein-3	GROWTH-FACTOR-I; SPONTANEOUS TUMORIGENESIS; MAMMARY CARCINOGENESIS; DIETARY RESTRICTION; ENERGY RESTRICTION; BINDING PROTEIN-3; DNA-SYNTHESIS; CANCER; GHRELIN; INSULIN	Calorie restriction (CR) and alternate-day fasting (ADF) reduce cancer risk and reduce cell proliferation rates. Whether modified ADF regimens (i.e., allowing a portion of energy needs to be consumed on the fast day) work, as well as true ADF or CR to reduce global cell proliferation rates, remains unresolved. Here, we measured the effects of true ADF, modified ADF, and daily CR on cell proliferation rates in mice. Thirty female C57BL/6J mice were randomized to one of five interventions for 4 wk: 1) CR-25% (25% reduction in daily energy intake), 2) ADF-75% (75% reduction on fast day), 3) ADF-85% (85% reduction on fast day), 4) ADF-100% (100% reduction on fast day), and 5) control (ad libitum intake). Body weights of the ADF groups did not differ from controls, whereas the CR-25% group weighed less than all other groups posttreatment. Epidermal cell proliferation decreased (P < 0.01) by 29, 20, and 31% in the CR-25%, ADF-85% and ADF-100% groups, respectively, relative to controls. Proliferation rates of splenic T cells were reduced (P < 0.01) by 37, 32, and 31% in the CR- 25%, ADF-85%, and ADF-100% groups, respectively, and mammary epithelial cell proliferation was 70, 65, and 62% lower (P < 0.01), compared with controls. Insulin-like growth factor-1 levels were reduced (P < 0.05) in the CR- 25% and ADF-100% groups only. In summary, modified ADF, allowing the consumption of 15% of energy needs on the restricted intake day, decreases global cell proliferation similarly as true ADF and daily CR without reducing body weight.	[Varady, K. A.; Roohk, D. J.; McEvoy-Hein, B. K.; Hellerstein, M. K.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; [Gaylinn, B. D.; Thorner, M. O.] Univ Virginia, Div Endocrinol & Metab, Dept Internal Med, Charlottesville, VA USA	University of California System; University of California Berkeley; University of Virginia	Varady, KA (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Morgan Hall,Rm 308, Berkeley, CA 94720 USA.	kvarady@nature.berkeley.edu; march@nture.berkeley.edu	Gaylinn, Bruce/AAD-4663-2020	Gaylinn, Bruce/0000-0003-1195-0864	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076037] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK076037, R01 DK076037-04] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Collins ML, 2003, J APPL PHYSIOL, V94, P2203, DOI 10.1152/japplphysiol.00691.2002; Fontana L, 2007, JAMA-J AM MED ASSOC, V297, P986, DOI 10.1001/jama.297.9.986; Giovannucci E, 1999, HORM RES, V51, P34, DOI 10.1159/000053160; Gualillo O, 2002, OBES RES, V10, P682, DOI 10.1038/oby.2002.92; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Heilbronn LK, 2005, OBES RES, V13, P574, DOI 10.1038/oby.2005.61; Heilbronn LK, 2005, AM J CLIN NUTR, V81, P69; Higgins SC, 2007, ANN MED, V39, P116, DOI 10.1080/07853890601149179; Hsieh EA, 2005, AM J PHYSIOL-ENDOC M, V288, pE965, DOI 10.1152/ajpendo.00368.2004; Hsieh EA, 2004, J INVEST DERMATOL, V123, P530, DOI 10.1111/j.0022-202X.2004.23303.x; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Ikeyama S, 2003, EXP GERONTOL, V38, P431, DOI 10.1016/S0531-5565(02)00239-5; Jenkins PJ, 2004, EUR J ENDOCRINOL, V151, pS17, DOI 10.1530/eje.0.151S017; Jolly CA, 2005, CURR OPIN CLIN NUTR, V8, P382, DOI 10.1097/01.mco.0000172577.56396.7a; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lawrence CB, 2002, ENDOCRINOLOGY, V143, P155, DOI 10.1210/en.143.1.155; Lev-Ran A, 1998, MECH AGEING DEV, V102, P95, DOI 10.1016/S0047-6374(98)00027-X; Liu Jianhua, 2004, Growth Hormone & IGF Research, V14, P131; LOK E, 1988, CANCER LETT, V38, P249, DOI 10.1016/0304-3835(88)90016-X; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; Mai V, 2003, CANCER RES, V63, P1752; MERRY B, 1994, EFFECTS DIET AGING; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Neese RA, 2002, P NATL ACAD SCI USA, V99, P15345, DOI 10.1073/pnas.232551499; Neese RA, 2001, ANAL BIOCHEM, V298, P189, DOI 10.1006/abio.2001.5375; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; Patel AC, 2004, J NUTR, V134, p3394S, DOI 10.1093/jn/134.12.3394S; Rocha NS, 2002, TERATOGEN CARCIN MUT, V22, P129, DOI 10.1002/tcm.10005; SIEGEL I, 1988, CANCER INVEST, V6, P677, DOI 10.3109/07357908809078034; Stewart JW, 2005, CARCINOGENESIS, V26, P1077, DOI 10.1093/carcin/bgi051; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Varady KA, 2007, J LIPID RES, V48, P2212, DOI 10.1194/jlr.M700223-JLR200; Varady KA, 2007, J APPL PHYSIOL, V103, P547, DOI 10.1152/japplphysiol.00209.2007; Yakar S, 2005, CYTOKINE GROWTH F R, V16, P407, DOI 10.1016/j.cytogfr.2005.01.010; Zhu ZJ, 1999, CARCINOGENESIS, V20, P1721, DOI 10.1093/carcin/20.9.1721	39	28	28	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2090	2096		10.1096/fj.07-098178	http://dx.doi.org/10.1096/fj.07-098178			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18184721	Green Accepted			2022-12-28	WOS:000256352700048
J	Liao, JJ; Huang, MC; Fast, K; Gundling, K; Yadav, M; Van Brocklyn, JR; Wabl, MR; Goetzl, EJ				Liao, Jia-Jun; Huang, Mei-Chuan; Fast, Katharine; Gundling, Katherine; Yadav, Mahesh; Van Brocklyn, James R.; Wabl, Matthias R.; Goetzl, Edward J.			Immunosuppressive human anti-lymphocyte autoantibodies specific for the type 1 sphingosine 1-phosphate receptor	FASEB JOURNAL			English	Article						inflammation; chemotaxis; sphingolipid; G protein-coupled	LYMPHOCYTE EGRESS; ANTIBODIES; SPHINGOSINE-1-PHOSPHATE; S1P; ACTIVATION; IDENTIFICATION; SPHINGOLIPIDS; AGONIST; CELLS	Anti-lymphocyte antibodies (Abs) that suppress T-cell chemotactic and other responses to sphingosine 1-phosphate (S1P), but not to chemokines, were found in a lymphopenic patient with recurrent infections. Lymphocyte type 1 S1P receptor (S1P(1)) that transduces S1P chemotactic stimulation was recognized by patient Abs in Western blots of T cells, S1P(1) transfectants, and S1P(1)-hemagglutinin purified by monoclonal anti-hemagglutinin Ab absorption. The amino terminus of S1P(1), but not any extracellular loop, prevented anti-S1P(1) Ab suppression of S1P(1) signaling and T-cell chemotaxis to S1P. Human purified anti-S1P(1) Abs decreased mouse blood lymphocyte levels by a mean of 72%, suppressed mouse T-cell chemotaxis to S1P in vivo, and significantly reduced the severity of dextran sodium sulfate-induced colitis in mice. Human Abs to the amino terminus of S1P(1) suppress T-cell trafficking sufficiently to impair host defense and provide therapeutic immunosuppression.-Liao, J.- J., Huang, M.-C., Fast, K., Gundling, K., Yadav, M., Van Brocklyn, J. R., Wabl, M. R., Goetzl, E. J. Immunosuppressive human anti-lymphocyte autoantibodies specific for the type 1 sphingosine 1-phosphate receptor. FASEB J. 23, 1786-1796 (2009)	[Goetzl, Edward J.] Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; [Wabl, Matthias R.; Goetzl, Edward J.] Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA; [Van Brocklyn, James R.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Ohio; Ohio State University	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, Rm UB8B,UCSF Box 0711,533 Parnassus & 4th Ave, San Francisco, CA 94143 USA.	edward.goetzl@ucsf.edu	Van Brocklyn, Jim/A-9733-2010		National Institutes of Health (NIH) [RO-1, HL-31809, RO1 AI041570]; Rainin Post-Doctoral Training Fund; NIH [T32 AG000212]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000212] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rainin Post-Doctoral Training Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	These studies were made possible by RO-1 grant HL-31809 from the National Institutes of Health (NIH) (E.J.G.), NIH grant RO1 AI041570 (M.R.W.), and the Rainin Post-Doctoral Training Fund (M.Y.). K. F. is supported by the UCSF Geriatric Program Training Grant T32 AG000212 from NIH.	Chun J, 2007, SCIENCE, V316, P208, DOI 10.1126/science.1142239; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Fieger CB, 2005, FASEB J, V19, P1926, DOI 10.1096/fj.05-4476fje; Fina D, 2008, GASTROENTEROLOGY, V134, P1038, DOI 10.1053/j.gastro.2008.01.041; Fujiwara Y, 2007, J BIOL CHEM, V282, P2374, DOI 10.1074/jbc.M609648200; GILBREATH MJ, 1983, CLIN EXP IMMUNOL, V51, P232; Gonzalez-Cabrera PJ, 2008, MOL PHARMACOL, V74, P1308, DOI 10.1124/mol.108.049783; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; Grahler MH, 2005, J IMMUNOL, V174, P1997; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; GRIGGI T, 1994, SCAND J IMMUNOL, V40, P77, DOI 10.1111/j.1365-3083.1994.tb03436.x; Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com; Hale JJ, 2004, BIOORG MED CHEM LETT, V14, P3351, DOI 10.1016/j.bmcl.2004.02.106; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Kohno T, 2002, FASEB J, V16, P983, DOI 10.1096/fj.01-0809com; Lebman DA, 2008, J LIPID RES, V49, P1388, DOI 10.1194/jlr.R800008-JLR200; Li X, 2008, BLOOD, V111, P3489, DOI 10.1182/blood-2007-05-092148; Lobo PI, 2008, J IMMUNOL, V180, P1780, DOI 10.4049/jimmunol.180.3.1780; LOBO PI, 1981, TRANSPLANTATION, V32, P233, DOI 10.1097/00007890-198109000-00010; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; MIMURA T, 1990, J EXP MED, V172, P653, DOI 10.1084/jem.172.2.653; MINOTA S, 1987, J IMMUNOL, V139, P3644; Olivera A, 2005, J IMMUNOL, V174, P1153, DOI 10.4049/jimmunol.174.3.1153; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Przybylowski P, 1999, TRANSPLANTATION, V67, P258, DOI 10.1097/00007890-199901270-00012; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; STRICKER RB, 1987, NATURE, V327, P710, DOI 10.1038/327710a0; Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113; Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080; WARREN RQ, 1988, CLIN EXP IMMUNOL, V73, P168; Wei SH, 2005, NAT IMMUNOL, V6, P1228, DOI 10.1038/ni1269; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41	36	12	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1786	1796		10.1096/fj.08-124891	http://dx.doi.org/10.1096/fj.08-124891			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19158154	Green Published			2022-12-28	WOS:000266652400019
J	Fustin, JM; Dardente, H; Wagner, GC; Carter, DA; Johnston, JD; Lincoln, GA; Hazlerigg, DG				Fustin, J. M.; Dardente, H.; Wagner, G. C.; Carter, D. A.; Johnston, J. D.; Lincoln, G. A.; Hazlerigg, D. G.			Egr1 involvement in evening gene regulation by melatonin	FASEB JOURNAL			English	Article						pars tuberalis; clock gene; cryptochrome; photoperiod; circadian	HORMONE-BETA-GENE; DECODING PHOTOPERIODIC TIME; EARLY GROWTH RESPONSE-1; STEROIDOGENIC FACTOR-I; OVINE PARS TUBERALIS; PITUITARY HOMEOBOX 1; NGFI-A; SUPRACHIASMATIC NUCLEUS; TRANSCRIPTION FACTORS; BINDING-SITES	Seasonal photoperiodic responses in mammals depend on the pineal hormone melatonin. The pars tuberalis (PT) region of the anterior pituitary has emerged as a principal melatonin target tissue, controlling endocrine responses. Rising melatonin levels acutely influence the expression of a small cluster of genes either positively (exemplified by cryptochrome-1, cry1) or negatively (exemplified by the type 1 melatonin receptor, mt1). The purpose of this study was to characterize the pathways through which these evening actions of melatonin are mediated. In vitro experiments showed that cAMP signaling in the PT directly influences mt1 but not cry1 expression. Analysis of nuclear extracts from sheep PT tissue collected 90 min after melatonin or saline control injections highlighted the response element for the immediate early gene egr1 (EGR1-RE) as a candidate for acute melatonin-dependent transcriptional regulation. We identified putative EGR1-RE's in the proximal promoter regions of the ovine cry1 and mt1 genes, and confirmed their functionality in luciferase reporter assays. Egr1 expression is suppressed by melatonin in PT cell cultures, and is rhythmic in the ovine PT with a nadir in the early night. We propose that melatonin-dependent effects on EGR1-RE's contribute to evening gene expression profiles in this pituitary melatonin target tissue.-Fustin J. M., Dardente H., Wagner G. C., Carter D. A., Johnston J. D., Lincoln G. A., Hazlerigg D. G. Egr1 involvement in evening gene regulation by melatonin. FASEB J. 23, 764-773 (2009)	[Fustin, J. M.; Dardente, H.; Wagner, G. C.; Hazlerigg, D. G.] Univ Aberdeen, Sch Biol Sci, Dept Zool, Aberdeen AB24 2TZ, Scotland; [Johnston, J. D.] Univ Surrey, Guildford GU2 5XH, Surrey, England; [Lincoln, G. A.] Univ Edinburgh, Ctr Reprod Biol, Queens Med Res Inst, Edinburgh EH3 9EW, Midlothian, Scotland	University of Aberdeen; University of Surrey; University of Edinburgh	Hazlerigg, DG (corresponding author), Univ Aberdeen, Sch Biol Sci, Dept Zool, Tillydrone Ave, Aberdeen AB24 2TZ, Scotland.	d.hazlerigg@abdn.ac.uk	Fustin, Jean-Michel/R-6621-2019; DARDENTE, Hugues/ABI-5590-2020; Carter, David/A-4479-2010; Johnston, Jonathan D/H-6363-2011; Johnston, Jonathan/AAS-6969-2021	Fustin, Jean-Michel/0000-0002-6200-6075; DARDENTE, Hugues/0000-0001-7209-5940; Carter, David/0000-0002-8419-3975; Johnston, Jonathan D/0000-0001-8083-9794; 	Aberdeen University College of Life Science and Medicine; UK Biotechnology and Biological Sciences Research Council; MRC [G0600678, G9724886] Funding Source: UKRI; Medical Research Council [G0600678, G9724886] Funding Source: researchfish	Aberdeen University College of Life Science and Medicine; UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors thank the Aberdeen University College of Life Science and Medicine and the UK Biotechnology and Biological Sciences Research Council for financial support, and Jacques Tremblay (Laval University, Quebec, QC, Canada) for the PITX1 expression vector. The authors thank the Marshall Building animal care staff and Mr. M. Birnie for excellent technical support.	Barrett P, 1997, BBA-MOL CELL RES, V1356, P299, DOI 10.1016/S0167-4889(96)00179-6; Barrett P, 2003, J PINEAL RES, V35, P221, DOI 10.1034/j.1600-079X.2003.00090.x; Barrett P, 1996, MOL ENDOCRINOL, V10, P892, DOI 10.1210/me.10.7.892; Dardente H, 2003, MOL BRAIN RES, V114, P101, DOI 10.1016/S0169-328X(03)00134-7; Donovan MJ, 1999, DEV GENET, V24, P252, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<252::AID-DVG8>3.0.CO;2-K; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; Drouin J, 1998, MOL CELL ENDOCRINOL, V140, P31, DOI 10.1016/S0303-7207(98)00026-4; Dupre SM, 2008, ENDOCRINOLOGY, V149, P5527, DOI 10.1210/en.2008-0834; Esumi N, 2007, J BIOL CHEM, V282, P1838, DOI 10.1074/jbc.M609517200; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; Hazlerigg DG, 2001, J BIOL RHYTHM, V16, P326, DOI 10.1177/074873001129002042; HAZLERIGG DG, 1993, ENDOCRINOLOGY, V132, P285, DOI 10.1210/en.132.1.285; Johnston JD, 2006, ENDOCRINOLOGY, V147, P959, DOI 10.1210/en.2005-1100; Johnston JD, 2003, P NATL ACAD SCI USA, V100, P2831, DOI 10.1073/pnas.0436184100; Johnston JD, 2007, MOL CELL ENDOCRINOL, V268, P59, DOI 10.1016/j.mce.2007.01.015; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; Kilduff TS, 1998, J BIOL RHYTHM, V13, P347, DOI 10.1177/074873098129000174; Knapska E, 2004, PROG NEUROBIOL, V74, P183, DOI 10.1016/j.pneurobio.2004.05.007; Lanctot C, 1999, ENDOCRINOLOGY, V140, P1416, DOI 10.1210/en.140.3.1416; Lawson MA, 2007, MOL ENDOCRINOL, V21, P1175, DOI 10.1210/me.2006-0392; Lin JT, 1997, MOL BRAIN RES, V46, P303, DOI 10.1016/S0169-328X(97)00005-3; Lincoln G, 2002, P NATL ACAD SCI USA, V99, P13890, DOI 10.1073/pnas.212517599; Lincoln GA, 2006, SCIENCE, V314, P1941, DOI 10.1126/science.1132009; Messager S, 2001, NEUROREPORT, V12, P579, DOI 10.1097/00001756-200103050-00029; Messager S, 1999, P NATL ACAD SCI USA, V96, P9938, DOI 10.1073/pnas.96.17.9938; Morgan PJ, 1998, J NEUROENDOCRINOL, V10, P319, DOI 10.1046/j.1365-2826.1998.00232.x; MORGAN PJ, 1995, J NEUROENDOCRINOL, V7, P361, DOI 10.1111/j.1365-2826.1995.tb00770.x; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Simonneaux V, 2003, PHARMACOL REV, V55, P325, DOI 10.1124/pr.55.2.2; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Tanaka M, 1999, EUR J NEUROSCI, V11, P3178, DOI 10.1046/j.1460-9568.1999.00739.x; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; Wagner GC, 2008, ENDOCRINOLOGY, V149, P32, DOI 10.1210/en.2007-0658	36	25	26	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					764	773		10.1096/fj.08-121467	http://dx.doi.org/10.1096/fj.08-121467			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19019852				2022-12-28	WOS:000265506300012
J	Kerrick, WGL; Kazmierczak, K; Xu, YY; Wang, YC; Szczesna-Cordary, D				Kerrick, W. Glenn L.; Kazmierczak, Katarzyna; Xu, Yuanyuan; Wang, Yingcai; Szczesna-Cordary, Danuta			Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice	FASEB JOURNAL			English	Article						phosphorylation; calcium and force transients; cross-bridge dissociation rate; energy cost; ATPase-pCa dependence	RABBIT PSOAS FIBERS; SKELETAL-MUSCLE; CROSS-BRIDGES; FORCE TRANSIENTS; CARDIAC-MUSCLE; E22K MUTATION; GENETIC-BASIS; CA2+ BINDING; TROPONIN-C; PHOSPHORYLATION	Transgenic (Tg) mice expressing similar to 95% of the D166V (aspartic acid to valine) mutation in the ventricular myosin regulatory light chain (RLC) shown to cause a malignant familial hypertrophic cardiomyopathy (FHC) phenotype were generated, and the skinned and intact papillary muscle fibers from the Tg-D166V mice were examined using a Guth muscle research system. A large increase in the Ca2+ sensitivity of force and ATPase (Delta pCa(50)>0.25) and a significant decrease in maximal force and ATPase were observed in skinned muscle fibers from Tg-D166V mice compared with control mice. The cross-bridge dissociation rate g was dramatically decreased, whereas the energy cost (ATPase/force) was slightly increased in Tg-D166V fibers compared with controls. The calculated average force per D166V cross-bridge was also reduced. Intact papillary muscle data demonstrated prolonged force transients with no change in calcium transients in Tg-D166V fibers compared with control fibers. Histopathological examination revealed fibrotic lesions in the hearts of the older D166V mice. Our results suggest that a charge effect of the D166V mutation and/or a mutation-dependent decrease in RLC phosphorylation could initiate the slower kinetics of the D166V cross-bridges and ultimately affect the regulation of cardiac muscle contraction. Profound cellular changes observed in Tg-D166V myocardium when placed in vivo could trigger a series of pathological responses and result in poor prognosis for D166V-positive patients.-Kerrick, W. G. L., Kazmierczak, K., Xu, Y., Wang, Y., Szczesna-Cordary, D. Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice. FASEB J. 23, 855-865 (2009)	[Kazmierczak, Katarzyna; Wang, Yingcai; Szczesna-Cordary, Danuta] Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol R189, Miami, FL 33101 USA; [Kerrick, W. Glenn L.; Xu, Yuanyuan] Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33101 USA	University of Miami; University of Miami	Szczesna-Cordary, D (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol R189, POB 016189,1600 NW 10th Ave,Room 6113, Miami, FL 33101 USA.	dszczesna@med.miami.edu			NIH [HL071778]; American Heart Association [0555320B]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071778] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors gratefully acknowledge Dr. Neal Epstein at the National Heart, Lung, and Blood Institute, NIH, for the gift of + P-human RLC antibodies. We thank Georgianna Guzman and Zoraida Diaz-Perez for their excellent technical assistance. This work was supported by NIH grant HL071778 (D.S.-C.) and American Heart Association grant 0555320B (D.S.-C.).	Alcalai R, 2008, J CARDIOVASC ELECTR, V19, P104, DOI 10.1111/j.1540-8167.2007.00965.x; Allen K, 2000, J APPL PHYSIOL, V88, P180, DOI 10.1152/jappl.2000.88.1.180; Baylor SM, 2000, NEWS PHYSIOL SCI, V15, P19; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; Davis JS, 2002, COLD SPRING HARB SYM, V67, P345, DOI 10.1101/sqb.2002.67.345; Davis JS, 2001, CELL, V107, P631, DOI 10.1016/S0092-8674(01)00586-4; Dias FAL, 2006, J MOL CELL CARDIOL, V41, P330, DOI 10.1016/j.yjmcc.2006.05.012; Doolittle RF, 2007, BIOCHEMISTRY-US, V46, P10033, DOI 10.1021/bi7010916; FERENCZI MA, 1984, J PHYSIOL-LONDON, V352, P575, DOI 10.1113/jphysiol.1984.sp015311; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; Geeves Michael A, 2002, Results Probl Cell Differ, V36, P111; Gomes AV, 2005, J MOL CELL CARDIOL, V39, P754, DOI 10.1016/j.yjmcc.2005.05.013; GUTH K, 1987, J BIOL CHEM, V262, P13627; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HOFMANN PA, 1990, J GEN PHYSIOL, V95, P477, DOI 10.1085/jgp.95.3.477; Hougs L, 2005, EUR J HUM GENET, V13, P161, DOI 10.1038/sj.ejhg.5201310; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Huxley AF, 2000, J BIOMECH, V33, P1189, DOI 10.1016/S0021-9290(00)00060-9; Kabaeva ZT, 2002, EUR J HUM GENET, V10, P741, DOI 10.1038/sj.ejhg.5200872; KABAEVA ZT, 2002, THESIS HUMBOLDT U BE; Kerrick WGL, 2004, J MUSCLE RES CELL M, V25, P107, DOI 10.1023/B:JURE.0000035841.04314.16; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2000, CIRCULATION, V102, P858; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; Mogensen J, 2001, J MED GENET, V38, P193, DOI 10.1136/jmg.38.3.193; Morner S, 2003, J MOL CELL CARDIOL, V35, P841, DOI 10.1016/S0022-2828(03)00146-9; Omote H, 2004, BIOCHEMISTRY-US, V43, P3917, DOI 10.1021/bi035365l; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Prakash YS, 1999, J MUSCLE RES CELL M, V20, P717, DOI 10.1023/A:1005585807179; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; Robinson JM, 2002, J MOL BIOL, V322, P1065, DOI 10.1016/S0022-2836(02)00855-0; Sanbe A, 2000, CIRC RES, V87, P296, DOI 10.1161/01.RES.87.4.296; Seidman CE, 1998, BASIC RES CARDIOL, V93, P13; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Stelzer JE, 2006, J GEN PHYSIOL, V128, P261, DOI 10.1085/jgp.200609547; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Szczesna D, 2002, J APPL PHYSIOL, V92, P1661, DOI 10.1152/japplphysiol.00858.2001; Szczesna D, 2001, J BIOL CHEM, V276, P7086, DOI 10.1074/jbc.M009823200; Szczesna Danuta, 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P187, DOI 10.2174/1568006033481474; Szczesna-Cordary D, 2005, J CELL SCI, V118, P3675, DOI 10.1242/jcs.02492; Szczesna-Cordary D, 2004, J BIOL CHEM, V279, P3535, DOI 10.1074/jbc.M307092200; Szczesna-Cordary D, 2007, FASEB J, V21, P3974, DOI 10.1096/fj.07-8630com; Troughton RW, 2004, CIRCULATION, V109, pE325; Wang Y, 1999, J MUSCLE RES CELL M, V20, P645, DOI 10.1023/A:1005559613516; Wang Y, 2006, J MOL BIOL, V361, P286, DOI 10.1016/j.jmb.2006.06.018; Wen YH, 2008, J BIOL CHEM, V283, P20484, DOI 10.1074/jbc.M801661200	49	51	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					855	865		10.1096/fj.08-118182	http://dx.doi.org/10.1096/fj.08-118182			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18987303	Green Published			2022-12-28	WOS:000265506300021
J	Luker, KE; Gupta, M; Luker, GD				Luker, Kathryn E.; Gupta, Mudit; Luker, Gary D.			Imaging chemokine receptor dimerization with firefly luciferase complementation	FASEB JOURNAL			English	Article						bioluminescence; seven-transmembrane receptors	RESONANCE ENERGY-TRANSFER; PROTEIN-PROTEIN INTERACTIONS; BREAST-CANCER; T-LYMPHOCYTES; TUMOR-GROWTH; CXCR4; CELLS; HETERODIMERS; CXCL12/SDF-1; ANTAGONISTS	Seven-transmembrane (G-protein coupled) receptors are key regulators of normal physiology and a large number of diseases, and this family of receptors is the target for almost half of all drugs. Cell culture models suggest that homodimerization and heterodimerization of 7-transmembrane receptors regulate processes including specificity of ligand binding and activation of downstream signaling pathways, making receptor dimerization a critical determinant of receptor biology and a promising new therapeutic target. To monitor receptor dimerization in cell-based assays and living animals, we developed a protein fragment complementation assay based on firefly luciferase to investigate dimerization of chemokine receptors CXCR4 and CXCR7, two 7-transmembrane receptors with central functions in normal development, cancer, and other diseases. Treatment with chemokine ligands and pharmacologic agents produced time- and dose-dependent changes in reporter signal. Chemokines regulated reporter bioluminescence for CXCR4 or CXCR7 homodimers without affecting signals from receptor heterodimers. In a tumor xenograft model of breast cancer, we used bioluminescence imaging to measure changes in receptor homodimerization in response to pharmacologic agents. This technology should be valuable for analyzing function and therapeutic modulation of receptor dimerization in intact cells and living mice.-Luker, K. E., Gupta, M., Luker, G. D. Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J. 23, 823-834 (2009)	[Luker, Kathryn E.; Gupta, Mudit; Luker, Gary D.] Univ Michigan, Sch Med, Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI 48109 USA; [Luker, Gary D.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Sch Med, Ctr Mol Imaging, Dept Radiol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.	gluker@umich.edu		luker, gary/0000-0001-6832-2581	Susan G. Komen Foundation [BCTR0503550]; U.S. National Institutes of Health (NIH) [P50CA093990, R24CA083099]; NATIONAL CANCER INSTITUTE [P50CA093990, R24CA083099] Funding Source: NIH RePORTER	Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grant BCTR0503550 from the Susan G. Komen Foundation and U.S. National Institutes of Health (NIH) grants P50CA093990 and R24CA083099 for the University of Michigan Small Animal Imaging Resource. Experiments were performed and analyzed by all authors. K. E. L. and G. D. L. wrote the manuscript. The authors declare no conflicts of interest.	Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; De A, 2005, FASEB J, V19, P2017, DOI 10.1096/fj.05-4628fje; De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134; Ding ZQ, 2003, BLOOD, V101, P4245, DOI 10.1182/blood-2002-06-1782; Drake MT, 2006, CIRC RES, V99, P570, DOI 10.1161/01.RES.0000242563.47507.ce; Gupta A, 2006, AAPS J, V8, pE153, DOI 10.1208/aapsj080118; Hartmann TN, 2008, J LEUKOCYTE BIOL, V84, P1130, DOI 10.1189/jlb.0208088; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; James JR, 2006, NAT METHODS, V3, P1001, DOI 10.1038/nmeth978; Lagane B, 2008, BLOOD, V112, P34, DOI 10.1182/blood-2007-07-102103; Lee CH, 2006, MOL CANCER THER, V5, P2592, DOI 10.1158/1535-7163.MCT-06-0310; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Luker GD, 1997, BIOCHEMISTRY-US, V36, P14218, DOI 10.1021/bi971931z; Luker GD, 2002, J VIROL, V76, P12149, DOI 10.1128/JVI.76.23.12149-12161.2002; Luker KE, 2008, ANAL CHEM, V80, P5565, DOI 10.1021/ac8005457; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Luker KE, 2004, P NATL ACAD SCI USA, V101, P12288, DOI 10.1073/pnas.0404041101; Luker KE, 2001, CANCER RES, V61, P6540; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Sohy D, 2007, J BIOL CHEM, V282, P30062, DOI 10.1074/jbc.M705302200; Springael JY, 2007, PHARMACOL THERAPEUT, V115, P410, DOI 10.1016/j.pharmthera.2007.06.004; Tamamura H, 2003, ORG BIOMOL CHEM, V1, P3663, DOI 10.1039/b306613b; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Toth PT, 2004, J PHARMACOL EXP THER, V310, P8, DOI 10.1124/jpet.103.064956; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200	35	94	99	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					823	834		10.1096/fj.08-116749	http://dx.doi.org/10.1096/fj.08-116749			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19001056	Green Submitted, Green Published			2022-12-28	WOS:000265506300018
J	Sun, DX; Martinez, CO; Ochoa, O; Ruiz-Willhite, L; Bonilla, JR; Centonze, VE; Waite, LL; Michalek, JE; McManus, LM; Shireman, PK				Sun, Dongxu; Martinez, Carlo O.; Ochoa, Oscar; Ruiz-Willhite, Lourdes; Bonilla, Jose R.; Centonze, Victoria E.; Waite, Lindsay L.; Michalek, Joel E.; McManus, Linda M.; Shireman, Paula K.			Bone marrow-derived cell regulation of skeletal muscle regeneration	FASEB JOURNAL			English	Article						CC chemokine receptor 2; CCR2; chimera; inflammation; monocyte/macrophage; myogenic progenitor cell	HEMATOPOIETIC STEM-CELLS; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CC-CHEMOKINE RECEPTOR-2; SATELLITE CELLS; IN-VIVO; PROGENITOR CELLS; CCR2-/-MICE; ALTERED INFLAMMATION; TUMOR ANGIOGENESIS; ENDOTHELIAL-CELLS	Limb regeneration requires the coordination of multiple stem cell populations to recapitulate the process of tissue formation. Therefore, bone marrow (BM) -derived cell regulation of skeletal muscle regeneration was examined in mice lacking the CC chemokine receptor 2 (CCR2). Myofiber size, numbers of myogenic progenitor cells (MPCs), and recruitment of BM-derived cells and macrophages were assessed after cardiotoxin-induced injury of chimeric mice produced by transplanting BM from wild-type (WT) or CCR2(-/-) mice into irradiated WT or CCR2(-/-) host mice. Regardless of the host genotype, muscle regeneration and recruitment of BM-derived cells and macrophages were similar in mice replenished with WT BM, whereas BM-derived cells and macrophage accumulation were decreased and muscle regeneration was impaired in all animals receiving CCR2(-/-) BM. Furthermore, numbers of MPCs (CD34(+)/Sca-1(-)/CD45(-) cells) were significantly increased in mice receiving CCR2(-/-) BM despite the decreased size of regenerated myofibers. Thus, the expression of CCR2 on BM-derived cells regulated macrophage recruitment into injured muscle, numbers of MPC, and the extent of regenerated myofiber size, all of which were independent of CCR2 expression on host-derived cells. Future studies in regenerative medicine must include consideration of the role of BM-derived cells, possibly macrophages, in CCR2-dependent events that regulate effective skeletal muscle regeneration. - Sun, D., Martinez, C. O., Ochoa, O., Ruiz-Willhite, L., Bonilla, J. R., Centonze, V. E., Waite, L. L., Michalek, J. E., McManus, L. M., Shireman, P. K. Bone marrow-derived cell regulation of skeletal muscle regeneration. FASEB J. 23, 382-395 (2009)	[Sun, Dongxu; Martinez, Carlo O.; Ochoa, Oscar; Ruiz-Willhite, Lourdes; Bonilla, Jose R.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA; [Centonze, Victoria E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA; [Waite, Lindsay L.; Michalek, Joel E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA; [McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA; [Shireman, Paula K.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Shireman, PK (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA.	shireman@uthscsa.edu		SHIREMAN, PAULA/0000-0002-9701-5422; Jones, Lindsay/0000-0002-4219-8356	UTHSCSA; San Antonio Cancer Institute [CA54174]; Nathan Shock Center [AG013319]; Veterans Administration Merit Review; San Antonio Area Foundation [Sun-UTHSCSA-060104]; National Institutes of Health, National Heart, Lung, and Blood Institute [R01HL074236, F32HL090196];  [AG19316]; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL090196, R01HL074236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013319, P01AG019316] Funding Source: NIH RePORTER	UTHSCSA; San Antonio Cancer Institute; Nathan Shock Center; Veterans Administration Merit Review(US Department of Veterans Affairs); San Antonio Area Foundation; National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We acknowledge the expert technical assistance of Michael D. Wetzel and Jimmy Wewer in these studies. A portion of the statistical analyses was expertly performed by Lee Ann Zarzabal. The flow cytometry portion of this work was performed at the Institutional Flow Cytometry Core of the University of Texas Health Science Center, San Antonio (UTHSCSA). Images were generated in the UTHSCSA Core Optical Imaging Facility, which is supported by UTHSCSA, CA54174 (San Antonio Cancer Institute), AG013319 (Nathan Shock Center), and AG19316. These studies were supported, in part, by a Veterans Administration Merit Review grant, the San Antonio Area Foundation (Sun-UTHSCSA-060104), and the National Institutes of Health (R01HL074236 and F32HL090196) from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors have no relationships that pose a conflict of interest for these studies.	Amano H, 2004, J IMMUNOL, V172, P398, DOI 10.4049/jimmunol.172.1.398; Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Bartoli C, 2001, ACTA NEUROPATHOL, V102, P385; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Belperio JA, 2001, J CLIN INVEST, V108, P547, DOI 10.1172/JCI12214; CANTINI M, 1994, BIOCHEM BIOPH RES CO, V202, P1688, DOI 10.1006/bbrc.1994.2129; CANTINI M, 1995, J NEUROPATH EXP NEUR, V54, P121, DOI 10.1097/00005072-199501000-00014; Cantini M, 2002, NEUROL SCI, V23, P189, DOI 10.1007/s100720200060; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; Carulli MT, 2005, ARTHRITIS RHEUM-US, V52, P3772, DOI 10.1002/art.21396; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17; Chazaud B, 2003, J CELL BIOL, V163, P1133, DOI 10.1083/jcb.200212046; Contreras-Shannon V, 2007, AM J PHYSIOL-CELL PH, V292, pC953, DOI 10.1152/ajpcell.00154.2006; Cotter MJ, 2001, AM J PATHOL, V159, P473, DOI 10.1016/S0002-9440(10)61719-1; Day K, 2007, DEV BIOL, V304, P246, DOI 10.1016/j.ydbio.2006.12.026; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Dreyfus PA, 2004, AM J PATHOL, V164, P773, DOI 10.1016/S0002-9440(10)63165-3; Dzenko KA, 2005, MICROVASC RES, V70, P53, DOI 10.1016/j.mvr.2005.04.005; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Grounds MD, 1998, ANN NY ACAD SCI, V854, P78, DOI 10.1111/j.1749-6632.1998.tb09894.x; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hayes IM, 1998, ARTERIOSCL THROM VAS, V18, P397, DOI 10.1161/01.ATV.18.3.397; Heil M, 2004, CIRC RES, V94, P671, DOI 10.1161/01.RES.0000122041.73808.B5; Hilbe W, 2004, J CLIN PATHOL, V57, P965, DOI 10.1136/jcp.2004.016444; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Kurihara T, 1996, J BIOL CHEM, V271, P11603, DOI 10.1074/jbc.271.20.11603; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Layland J, 2005, FASEB J, V19, P1137, DOI 10.1096/fj.04-2519fje; Lee S, 2006, FREE RADICAL BIO MED, V41, P1174, DOI 10.1016/j.freeradbiomed.2006.07.005; Li HQ, 2004, CANCER RES, V64, P6137, DOI 10.1158/0008-5472.CAN-04-1287; Li P, 2005, AM J PATHOL, V167, P637, DOI 10.1016/S0002-9440(10)62039-1; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Massimino ML, 1997, BIOCHEM BIOPH RES CO, V235, P754, DOI 10.1006/bbrc.1997.6823; Maus U, 2002, AM J RESP CRIT CARE, V166, P268, DOI 10.1164/rccm.2112012; Maus UA, 2005, AM J PHYSIOL-LUNG C, V288, pL350, DOI 10.1152/ajplung.00061.2004; Merly F, 1999, MUSCLE NERVE, V22, P724, DOI 10.1002/(SICI)1097-4598(199906)22:6<724::AID-MUS9>3.0.CO;2-O; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Moore BB, 2006, AM J RESP CELL MOL, V35, P175, DOI 10.1165/rcmb.2005-0239OC; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nguyen HX, 2005, J PHYSIOL-LONDON, V565, P403, DOI 10.1113/jphysiol.2005.085506; Ochoa O, 2007, AM J PHYSIOL-REG I, V293, pR651, DOI 10.1152/ajpregu.00069.2007; Okuma T, 2004, J PATHOL, V204, P594, DOI 10.1002/path.1667; PimoradyEsfahani A, 1997, MUSCLE NERVE, V20, P158, DOI 10.1002/(SICI)1097-4598(199702)20:2<158::AID-MUS4>3.0.CO;2-B; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Rajantie I, 2004, BLOOD, V104, P2084, DOI 10.1182/blood-2004-01-0336; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Reyes M, 2005, BLOOD, V106, P3646, DOI 10.1182/blood-2004-12-4603; ROBERTSON TA, 1993, EXP CELL RES, V207, P321, DOI 10.1006/excr.1993.1199; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; Schober A, 2004, CIRC RES, V95, P1125, DOI 10.1161/01.RES.0000149518.86865.3e; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Shireman PK, 2007, J VASC SURG, V45, p48A, DOI 10.1016/j.jvs.2007.02.030; Shireman PK, 2006, J SURG RES, V134, P145, DOI 10.1016/j.jss.2005.12.003; Shirernan PK, 2007, J LEUKOCYTE BIOL, V81, P775, DOI 10.1189/jlb.0506356; Sonnet C, 2006, J CELL SCI, V119, P2497, DOI 10.1242/jcs.02988; Spring H, 2005, P NATL ACAD SCI USA, V102, P18111, DOI 10.1073/pnas.0507158102; Summan M, 2006, AM J PHYSIOL-REG I, V290, pR1488, DOI 10.1152/ajpregu.00465.2005; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Tidball JG, 2007, J PHYSIOL-LONDON, V578, P327, DOI 10.1113/jphysiol.2006.118265; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; Wareing MD, 2007, J LEUKOCYTE BIOL, V81, P793, DOI 10.1189/jlb.0506299; Wilson A, 2007, ANN NY ACAD SCI, V1106, P64, DOI 10.1196/annals.1392.021; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Yang XQ, 2006, INT J CANCER, V118, P335, DOI 10.1002/ijc.21371; Zammit PS, 2001, DIFFERENTIATION, V68, P193, DOI 10.1046/j.1432-0436.2001.680407.x; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	71	78	78	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					382	395		10.1096/fj.07-095901	http://dx.doi.org/10.1096/fj.07-095901			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18827026	Green Published, hybrid			2022-12-28	WOS:000262892900010
J	Liu, WT; Li, HC; Song, XS; Huang, ZJ; Song, XJ				Liu, Wen-Tao; Li, Hao-Chuan; Song, Xue-Song; Huang, Zhi-Jiang; Song, Xue-Jun			EphB receptor signaling in mouse spinal cord contributes to physical dependence on morphine	FASEB JOURNAL			English	Article						opiate withdrawal; NR2B; ERK; CREB; c-Fos	D-ASPARTATE RECEPTOR; PROTEIN-KINASE-II; PERIPHERAL-NERVE INJURY; NEURAL CREST MIGRATION; DORSAL-ROOT GANGLION; GENE-RELATED PEPTIDE; SYNAPTIC PLASTICITY; NEUROPATHIC PAIN; PRECIPITATED WITHDRAWAL; CELLULAR MECHANISMS	Cellular and molecular mechanisms underlying opioid tolerance and dependence remain elusive. We investigated roles of EphB receptor tyrosine kinases which play important roles in synaptic connection and plasticity during development and in the matured nervous system-in development and maintenance of physical dependence on morphine in the mouse spinal cord (SC). Spinal administration of an EphB receptor blocking reagent EphB2-Fc prevents and/or suppresses behavioral responses to morphine withdrawal and associated induction of c-Fos and depletion of calcitonin gene-related peptide. Western blotting and immunohistochemical fluorescence staining demonstrates that EphB1 receptor protein is significantly up-regulated in the spinal dorsal horn following escalating morphine treatment. Chronic morphine exposure and withdrawal significantly increased phosphorylation of N-methyl-D-aspartate receptor subunit NR2B as well as the activated forms of extracellular signal-regulated kinase and the cAMP response element binding protein in SC. The increased levels of phosphorylation of these molecules, however, are significantly inhibited by the EphB receptor blocker. These findings indicate that EphB receptor signaling, probably by interacting with NR2B in SC, contributes to the development of opioid physical dependence and withdrawal effects. This novel role for EphB receptor signaling suggests that these molecules may be useful therapeutic targets for preventing, minimizing, or reversing the development of opiate dependence.-Liu,W.-T., Li, H.-C., Song, X.-S., Huang, Z.-J., Song, X.-J. EphB receptor signaling in mouse spinal cord contributes to physical dependence on morphine. FASEB J. 23, 90-98 (2009)	[Liu, Wen-Tao; Li, Hao-Chuan; Song, Xue-Song; Huang, Zhi-Jiang; Song, Xue-Jun] Parker Univ, Res Inst, Dept Neurobiol, Dallas, TX 75229 USA; [Song, Xue-Jun] Xuzhou Med Coll, Jiangsu Prov Key Lab Anesthesiol, Xuzhou, Jiangsu, Peoples R China; [Song, Xue-Jun] Xuzhou Med Coll, Ctr Pain Res & Treatment, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University	Song, XJ (corresponding author), Parker Univ, Res Inst, Dept Neurobiol, 2500 Walnut Hill Lane, Dallas, TX 75229 USA.	song@parkercc.edu	HUANG, ZHI-JIANG/F-9443-2010		Parker Research Foundation [PCCRF-BSR0703, PCCRF-BSR0804]; National Natural Science Foundation of China [NSFC-30628027]	Parker Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr. Edgar T. Walters for his helpful comment on the manuscript, Dr. Ronald L. Rupert for his general support as Dean of Research, and Maria Dominguez for her assistance in laboratory management. Supported by grants from Parker Research Foundation (PCCRF-BSR0703 and PCCRF-BSR0804) and National Natural Science Foundation of China (NSFC-30628027).	Bailey CP, 2005, CURR OPIN PHARMACOL, V5, P60, DOI 10.1016/j.coph.2004.08.012; Bajo M, 2006, J NEUROSCI RES, V83, P532, DOI 10.1002/jnr.20756; Barrot M, 2002, P NATL ACAD SCI USA, V99, P11435, DOI 10.1073/pnas.172091899; Battaglia AA, 2003, NAT NEUROSCI, V6, P339, DOI 10.1038/nn1034; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Boyce S, 1999, NEUROPHARMACOLOGY, V38, P611, DOI 10.1016/S0028-3908(98)00218-4; Bundesen LQ, 2003, J NEUROSCI, V23, P7789; Cao JL, 2005, PAIN, V118, P336, DOI 10.1016/j.pain.2005.09.006; Chen ZL, 2007, ANNU REV NEUROSCI, V30, P209, DOI 10.1146/annurev.neuro.30.051606.094337; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Fan GH, 1999, MOL PHARMACOL, V56, P39, DOI 10.1124/mol.56.1.39; Grunwald IC, 2004, NAT NEUROSCI, V7, P33, DOI 10.1038/nn1164; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Hamdy MM, 2004, BEHAV BRAIN RES, V152, P263, DOI 10.1016/j.bbr.2003.10.014; Henderson JT, 2001, NEURON, V32, P1041, DOI 10.1016/S0896-6273(01)00553-0; Inoue M, 2003, J NEUROSCI, V23, P6529; Inturrisi CE, 2002, CLIN J PAIN, V18, pS3, DOI 10.1097/00002508-200207001-00002; Jassen AK, 2006, MOL PHARMACOL, V70, P71, DOI 10.1124/mol.105.021998; Jhamandas KH, 1996, J NEUROSCI, V16, P2758; Kerr BJ, 2000, EUR J NEUROSCI, V12, P793, DOI 10.1046/j.1460-9568.2000.00967.x; King M, 2001, NAT NEUROSCI, V4, P268, DOI 10.1038/85115; Kobayashi H, 2007, SPINE, V32, P1592, DOI 10.1097/BRS.0b013e318074d46a; KOLESNIKOV YA, 1993, P NATL ACAD SCI USA, V90, P5162, DOI 10.1073/pnas.90.11.5162; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Liang D, 2004, NEUROSCIENCE, V123, P769, DOI 10.1016/j.neuroscience.2003.10.007; Lu L, 2000, NEUROSCI LETT, V291, P191, DOI 10.1016/S0304-3940(00)01352-5; Ma WY, 2001, EUR J NEUROSCI, V14, P1091, DOI 10.1046/j.0953-816x.2001.01731.x; Mao JR, 2002, J NEUROSCI, V22, P8312; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; Mao JR, 2001, ANN NY ACAD SCI, V933, P175; MARSHALL DC, 1985, EXPERIENTIA, V41, P1151, DOI 10.1007/BF01951703; Mayer DJ, 1999, P NATL ACAD SCI USA, V96, P7731, DOI 10.1073/pnas.96.14.7731; Murai KK, 2004, NEUROSCIENTIST, V10, P304, DOI 10.1177/1073858403262221; Muscoli C, 2007, J CLIN INVEST, V117, P3530, DOI 10.1172/JCI32420; Nagy GG, 2004, EUR J NEUROSCI, V20, P3301, DOI 10.1111/j.1460-9568.2004.03798.x; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nateri AS, 2007, EMBO J, V26, P4891, DOI 10.1038/sj.emboj.7601911; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Noda Y, 2004, EUR J PHARMACOL, V500, P121, DOI 10.1016/j.ejphar.2004.07.017; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Pasternak GW, 2007, J CLIN INVEST, V117, P3185, DOI 10.1172/JCI34035; PASTERNAK GW, 2005, CONT CLIN NEUROSCIEN, P409; Prybylowski K, 2004, J BIOL CHEM, V279, P9673, DOI 10.1074/jbc.R300029200; Ren X, 2004, BEHAV BRAIN RES, V152, P243, DOI 10.1016/j.bbr.2003.10.013; Rohde DS, 1998, J NEUROSCI, V18, P4393; Rohde DS, 1997, BRAIN RES, V745, P83, DOI 10.1016/S0006-8993(96)01132-8; Rohde DS, 1996, NEUROSCIENCE, V72, P233, DOI 10.1016/0306-4522(95)00529-3; Shaw-Lutchman TZ, 2002, J NEUROSCI, V22, P3663; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Song XJ, 2008, PAIN, V139, P168, DOI 10.1016/j.pain.2008.03.019; Song XJ, 2008, EUR J PAIN, V12, P1031, DOI 10.1016/j.ejpain.2008.01.011; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Trang T, 2003, BRIT J PHARMACOL, V140, P295, DOI 10.1038/sj.bjp.0705440; Trang T, 2006, PAIN, V126, P256, DOI 10.1016/j.pain.2006.07.008; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WATSON A, 1995, J BIOL CHEM, V270, P9655, DOI 10.1074/jbc.270.16.9655; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Zachariou V, 2003, P NATL ACAD SCI USA, V100, P13656, DOI 10.1073/pnas.2232594100; Zhu HB, 2001, SYNAPSE, V40, P282, DOI 10.1002/syn.1051	65	28	33	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					90	98		10.1096/fj.08-114462	http://dx.doi.org/10.1096/fj.08-114462			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18772347				2022-12-28	WOS:000262095500011
J	Ripps, H				Ripps, Harris			The color purple: milestones in photochemistry	FASEB JOURNAL			English	Editorial Material							RHODOPSIN; BOLLS		[Ripps, Harris] Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA; [Ripps, Harris] Marine Biol Lab, Woods Hole, MA 02543 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Marine Biological Laboratory - Woods Hole	Ripps, H (corresponding author), Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci, 1855 W Taylor St M-C 648, Chicago, IL 60612 USA.	harrripp@uic.edu						BAUMANN C, 1977, VISION RES, V17, P1325, DOI 10.1016/0042-6989(77)90116-X; BOLL F, 1977, Vision Research, V17, P1253; Boll F., 1876, MONATSBERICHTE KONIG, P783; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; Crescitelli F, 1977, Vision Res, V17, P1317, DOI 10.1016/0042-6989(77)90115-8; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; Dowling JE, 2002, P AM PHILOS SOC, V146, P431; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; HUBBARD R, 1951, P NATL ACAD SCI USA, V37, P69, DOI 10.1073/pnas.37.2.69; HUBBARD R, 1977, VISION RES, V17, P1247, DOI 10.1016/0042-6989(77)90111-0; HUBBARD R, 1952, J GEN PHYSIOL, V36, P269, DOI 10.1085/jgp.36.2.269; K?hne W., 1877, UNTERSUCH PHYSL I U, V1, P15; Kuhne W., 1878, PHOTOCHEMISTRY RETIN, P1; KUHNE W, 1877, UNTERS PHYSL I U HEI, V1, P1; MARMOR MF, 1978, SURV OPHTHALMOL, V22, P279, DOI 10.1016/0039-6257(78)90074-7; RANDO RR, 1991, PROGR RETINAL RES, V10, P161; RIPPS H, 1969, NATURE, V222, P775, DOI 10.1038/222775a0; RIPPS H, 1965, NATURE, V205, P52, DOI 10.1038/205052a0; RIPPS H, 1982, INVEST OPHTH VIS SCI, V23, P588; WALD G, 1958, Exp Cell Res, V14, P389; WARLOMONT E, 1877, ANN OCUL, V77, P77	22	6	6	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4038	4043		10.1096/fj.08-1202ufm	http://dx.doi.org/10.1096/fj.08-1202ufm			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	19047069				2022-12-28	WOS:000261254800002
J	Szklarczyk, A; Ewaleifoh, O; Beique, JC; Wang, Y; Knorr, D; Haughey, N; Malpica, T; Mattson, MP; Huganir, R; Conant, K				Szklarczyk, Arek; Ewaleifoh, Osefame; Beique, Jean-Claude; Wang, Yue; Knorr, David; Haughey, Norman; Malpica, Tanya; Mattson, Mark P.; Huganir, Richard; Conant, Katherine			MMP-7 cleaves the NR1 NMDA receptor subunit and modifies NMDA receptor function	FASEB JOURNAL			English	Article						matrilysin; glutamate; synapse; proteolysis	MATRIX-METALLOPROTEINASE ACTIVITY; AMYLOID PROTEIN-PRECURSOR; FOCAL CEREBRAL-ISCHEMIA; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; SPINAL-CORD; CELL-DEATH; CALCIUM DYSREGULATION; HIPPOCAMPAL SYNAPSES; SYNAPTIC PLASTICITY	Matrix metalloproteinases (MMPs) are zinc-dependent enzymes that play a role in the inflammatory response. These enzymes have been well studied in the context of cancer biology and inflammation. Recent studies, however, suggest that these enzymes also play roles in brain development and neurodegenerative disease. Select MMPs can target proteins critical to synaptic structure and neuronal survival, including integrins and cadherins. Here, we show that one member of the MMP family, MMP-7, which may be released from cells, including microglia, can target a protein critical to synaptic function. Through analysis of extracts from murine cortical slice preparations, we show that MMP-7 cleaves the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor to generate an N-terminal fragment of similar to 65 kDa. Moreover, studies with recombinant protein show that MMP-7-mediated cleavage of NR1 occurs at amino acid 517, which is extracellular and just distal to the first transmembrane domain. Data suggest that NR2A, which shares sequence homology with NR1, is also cleaved following treatment of slices with MMP-7, while select AMPA receptor subunits are not. Consistent with a potential effect of MMP-7 on ligand binding, additional experiments demonstrate that NMDA-mediated calcium flux is significantly diminished by MMP-7 pretreatment of cultures. In addition, the AMPA/NMDA ratio is increased by MMP-7 pretreatment. These data suggest that synaptic function may be altered in neurological conditions associated with increased levels of MMP-7.-Szklarczyk, A., Ewaleifoh, O., Beique, J.-C., Wang, Y., Knorr, D., Haughey, N., Malpica, T., Mattson, M. P., Huganir, R., Conant, K. MMP-7 cleaves the NR1 NMDA receptor subunit and modifies NMDA receptor function. FASEB J. 22, 3757-3767 (2008)	[Conant, Katherine] Johns Hopkins Univ, Dept Neurol, Sch Med, Baltimore, MD 21287 USA; [Beique, Jean-Claude; Mattson, Mark P.; Huganir, Richard] Johns Hopkins Univ, Dept Neurosci, Sch Med, Baltimore, MD 21287 USA; [Beique, Jean-Claude; Huganir, Richard] Howard Hughes Med Inst, Chevy Chase, MD USA; [Wang, Yue; Mattson, Mark P.] NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Conant, K (corresponding author), Johns Hopkins Univ, Dept Neurol, Sch Med, Pathol Bldg Rm 625,600 N Wolfe St, Baltimore, MD 21287 USA.	kconant@mail.jhmi.edu	Mattson, Mark P/F-6038-2012		National Institutes of Health [NS052580, DA024447]; Alzheimer's Association; Howard Hughes Medical Institute; NARSAD; National Institute on Aging Intramural Research Program; NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH072534, R01MH077542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS052580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023471, R21AG034849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA024447] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer's Association(Alzheimer's Association); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NARSAD(NARSAD); National Institute on Aging Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank Jenny Ryu and Jackie Mann for expert technical assistance. We also thank Dr. Yuri Kim and Kee Jun Kim for helpful comments. And we thank Marc Mayer and Yongneng Yao for the NR1 S1/S2 construct. This work was supported, in part, by the National Institutes of Health (NS052580 and DA024447 to K. C.), the Alzheimer's Association (K.C.), the Howard Hughes Medical Institute (J.C.B. and R.H.), NARSAD (J.C.B.), and the National Institute on Aging Intramural Research Program.	Alvarez VA, 2007, J NEUROSCI, V27, P7365, DOI 10.1523/JNEUROSCI.0956-07.2007; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Beique JC, 2006, P NATL ACAD SCI USA, V103, P19535, DOI 10.1073/pnas.0608492103; Bernard-Trifilo JA, 2005, J NEUROCHEM, V93, P834, DOI 10.1111/j.1471-4159.2005.03062.x; Bilousova TV, 2006, J NEUROCHEM, V97, P44, DOI 10.1111/j.1471-4159.2006.03701.x; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Brule S, 2006, GLYCOBIOLOGY, V16, P488, DOI 10.1093/glycob/cwj098; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Campbell SJ, 2004, J NEUROCHEM, V89, P1378, DOI 10.1111/j.1471-4159.2004.02441.x; Chapman GA, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0004.2000; COLLINGRIDGE GL, 1992, CIBA F SYMP, V164, P172; COLLINGRIDGE GL, 1992, CIBA F SYMP, V164, P162; Conant K, 2004, J BIOL CHEM, V279, P8056, DOI 10.1074/jbc.M307051200; Conant K, 1999, ANN NEUROL, V46, P391, DOI 10.1002/1531-8249(199909)46:3<391::AID-ANA15>3.0.CO;2-0; Cossins JA, 1997, ACTA NEUROPATHOL, V94, P590, DOI 10.1007/s004010050754; Cui ZZ, 2004, NEURON, V41, P781, DOI 10.1016/S0896-6273(04)00072-8; Cull-Candy Stuart G, 2004, Sci STKE, V2004, pre16, DOI 10.1126/stke.2552004re16; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Fernandez-Monreal M, 2004, J BIOL CHEM, V279, P50850, DOI 10.1074/jbc.M407069200; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; George SJ, 2004, TRENDS CARDIOVAS MED, V14, P100, DOI 10.1016/j.tcm.2003.12.008; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; GROSSHANS DR, 2002, SCI STKE, pPL8; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Haughey NJ, 1999, J NEUROCHEM, V73, P1363, DOI 10.1046/j.1471-4159.1999.0731363.x; Haughey NJ, 2002, JAIDS-J ACQ IMM DEF, V31, pS55, DOI 10.1097/00126334-200210012-00005; Inanobe A, 2005, NEURON, V47, P71, DOI 10.1016/j.neuron.2005.05.022; Jourquin J, 2003, EUR J NEUROSCI, V18, P1507, DOI 10.1046/j.1460-9568.2003.02876.x; Kalbaugh TL, 2004, MOL PHARMACOL, V66, P209, DOI 10.1124/mol.66.2.209; Larsen PH, 2006, J NEUROSCI, V26, P2207, DOI 10.1523/JNEUROSCI.1880-05.2006; Leake A, 2000, NEUROSCI LETT, V291, P201, DOI 10.1016/S0304-3940(00)01418-X; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lim GP, 1996, J NEUROCHEM, V67, P251; Lorenzl S, 2003, NEUROCHEM INT, V43, P191, DOI 10.1016/S0197-0186(03)00004-4; Mattson MP, 2007, AGING CELL, V6, P337, DOI 10.1111/j.1474-9726.2007.00275.x; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Meighan PC, 2007, J NEUROCHEM, V102, P2085, DOI 10.1111/j.1471-4159.2007.04682.x; Meighan SE, 2006, J NEUROCHEM, V96, P1227, DOI 10.1111/j.1471-4159.2005.03565.x; Michaluk P, 2007, J BIOL CHEM, V282, P16036, DOI 10.1074/jbc.M700641200; Monea S, 2006, J NEUROSCI, V26, P2300, DOI 10.1523/JNEUROSCI.3521-05.2006; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Noble LJ, 2002, J NEUROSCI, V22, P7526; Nunan J, 2003, J NEUROSCI RES, V74, P378, DOI 10.1002/jnr.10646; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; Raymond LA, 1996, MOL CELL NEUROSCI, V7, P102, DOI 10.1006/mcne.1996.0008; Robbins TW, 2006, TRENDS PHARMACOL SCI, V27, P141, DOI 10.1016/j.tips.2006.01.009; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Schulz B, 2008, CIRC RES, V102, P1192, DOI 10.1161/CIRCRESAHA.107.169805; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Tomimatsu Y, 2002, LIFE SCI, V72, P355, DOI 10.1016/S0024-3205(02)02285-3; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Turgeon VL, 1998, J NEUROSCI, V18, P6882; Vaillant C, 2003, MOL CELL NEUROSCI, V24, P395, DOI 10.1016/S1044-7431(03)00196-9; Vos CMP, 2000, EXP NEUROL, V163, P324, DOI 10.1006/exnr.2000.7388; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200; Yao DY, 2002, MOL BIOL CELL, V13, P4001, DOI 10.1091/mbc.02-07-0104; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Zhang JW, 1998, EUR J NEUROSCI, V10, P3358, DOI 10.1046/j.1460-9568.1998.00347.x; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zhang X, 2004, INVEST OPHTH VIS SCI, V45, P2374, DOI 10.1167/iovs.03-1239	66	40	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3757	3767		10.1096/fj.07-101402	http://dx.doi.org/10.1096/fj.07-101402			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18644839	Green Published			2022-12-28	WOS:000260503000004
J	Walsh, CT; Radeff-Huang, J; Matteo, R; Hsiao, A; Subramaniam, S; Stupack, D; Brown, JH				Walsh, Colin T.; Radeff-Huang, Julie; Matteo, Rosalia; Hsiao, Albert; Subramaniam, Shankar; Stupack, Dwayne; Brown, Joan Heller			Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61	FASEB JOURNAL			English	Article						G-protein; S1P receptor; PAR1; matricellular protein; glioblastoma	IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; PRO-ANGIOGENIC ACTIVITIES; BREAST-CANCER; EXTRACELLULAR-MATRIX; BINDING-SITE; FAMILY GTPASES; DNA-SYNTHESIS; CCN1 CYR61; C-JUN	A subset of G-protein coupled receptors (GPCRs), including the thrombin receptor (PAR1), elicits mitogenic responses. Thrombin also activates Ras homolog gene family member A (RhoA) and activating protein (AP-1) -mediated gene expression in 1321N1 astrocytoma cells, whereas the nonmitogenic agonist carbachol does not. Transcriptomic analysis was used to explore differential gene induction by these agonists and revealed that the matricellular protein cysteine-rich 61 (Cyr61/CCN1) is selectively induced by thrombin. The ability of GPCR agonists to induce Cyr61 parallels their ability to activate RhoA; agonist-stimulated Cyr61 expression is inhibited by C3 toxin. When Cyr61 is down-regulated using short interfering RNA (siRNA) or short-hairpin RNA (shRNA), thrombin-induced DNA synthesis is significantly attenuated. When Cyr61 expression is induced, it appears in the extracellular compartment and on the cell surface. Extracellular Cyr61 interacts with alpha(5), alpha(6), and beta(1) integrins on these cells, and monoclonal antibodies directed against alpha(5) and beta(1) integrins inhibit thrombin-induced DNA synthesis. Functional blockade of Cyr61 with soluble heparin or anti-Cyr61 antibodies also inhibits thrombin-induced DNA synthesis. Thus Cyr61 is a highly inducible, secreted extracellular factor through which GPCR and RhoA signaling pathways engage integrins that contribute to GPCR-mediated proliferation.-Walsh, C. T., Radeff-Huang, J., Matteo, R., Hsiao, A., Subramaniam, S., Stupack, D., and Brown, J. H. Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61. FASEB J. 22, 4011-4021 (2008)	[Walsh, Colin T.; Radeff-Huang, Julie; Matteo, Rosalia; Brown, Joan Heller] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Hsiao, Albert; Subramaniam, Shankar] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; [Stupack, Dwayne] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Stupack, Dwayne] Univ Calif San Diego, John & Rebecca Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr-0636, La Jolla, CA 92093 USA.	jhbrown@ucsd.edu		Hsiao, Albert/0000-0002-9412-1369	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA218859] Funding Source: Medline; NIGMS NIH HHS [R01 GM036927] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; An DS, 1999, J VIROL, V73, P7671, DOI 10.1128/JVI.73.9.7671-7677.1999; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Arora P, 2007, J CELL SCI, V120, P921, DOI 10.1242/jcs.03409; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Bleau AM, 2005, FRONT BIOSCI-LANDMRK, V10, P998, DOI 10.2741/1594; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen CC, 2007, EMBO J, V26, P1257, DOI 10.1038/sj.emboj.7601596; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Citro S, 2007, P NATL ACAD SCI USA, V104, P15543, DOI 10.1073/pnas.0702943104; Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538-7836.2005.01377.x; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JS, 2003, EUR J BIOCHEM, V270, P3408, DOI 10.1046/j.1432-1033.2003.03723.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hsiao A, 2005, NUCLEIC ACIDS RES, V33, pW627, DOI 10.1093/nar/gki443; Hsiao A, 2004, BIOINFORMATICS, V20, P3108, DOI 10.1093/bioinformatics/bth371; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; Lau LF, 2005, CCN PROTEINS: A NEW FAMILY OF CELL GROWTH AND DIFFERENTIATION REGULATORS, P61, DOI 10.1142/9781860946899_0003; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Liang YB, 2003, J BIOL CHEM, V278, P27267, DOI 10.1074/jbc.M301009200; Lin BR, 2007, MOL CANCER RES, V5, P1111, DOI 10.1158/1541-7786.MCR-06-0289; Lin MT, 2007, J BIOL CHEM, V282, P34594, DOI 10.1074/jbc.M706600200; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; McLaughlin JN, 2005, J BIOL CHEM, V280, P25048, DOI 10.1074/jbc.M414090200; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082; Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Pendurthi UR, 2002, ARTERIOSCL THROM VAS, V22, P1421, DOI 10.1161/01.ATV.0000030200.59331.3F; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; QUI RG, 1995, NATURE, V374, P457; Radeff-Huang J, 2007, J BIOL CHEM, V282, P863, DOI 10.1074/jbc.M601698200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sakamoto S, 2004, ENDOCRINOLOGY, V145, P2929, DOI 10.1210/en.2003-1350; Schober JM, 2003, J BIOL CHEM, V278, P25808, DOI 10.1074/jbc.M301534200; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; Seasholtz TM, 2004, MOL INTERV, V4, P348, DOI 10.1124/mi.4.6.8; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Tamura I, 2001, AM J PHYSIOL-CELL PH, V281, pC1524, DOI 10.1152/ajpcell.2001.281.5.C1524; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Wiedmaier N, 2008, INT J MED MICROBIOL, V298, P231, DOI 10.1016/j.ijmm.2007.06.001; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102; Young N, 2007, EXP CELL RES, V313, P1615, DOI 10.1016/j.yexcr.2007.02.009; Zhou DM, 2005, J APPL PHYSIOL, V98, P2344, DOI 10.1152/japplphysiol.01093.2004	77	37	37	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					4011	4021		10.1096/fj.08-113266	http://dx.doi.org/10.1096/fj.08-113266			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18687805	Green Published			2022-12-28	WOS:000260503000029
J	Raucci, A; Cugusi, S; Antonelli, A; Barabino, SM; Monti, L; Bierhaus, A; Reiss, K; Saftig, P; Bianchi, ME				Raucci, Angela; Cugusi, Simona; Antonelli, Antonella; Barabino, Silvia M.; Monti, Lucilla; Bierhaus, Angelika; Reiss, Karina; Saftig, Paul; Bianchi, Marco E.			A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)	FASEB JOURNAL			English	Article						cytokines; HMGB1; inflammation; receptor shedding; atherosclerosis; diabetes	CELL-CELL ADHESION; END-PRODUCTS; MIGRATION; PROTEIN; ATHEROSCLEROSIS; INFLAMMATION; ACTIVATION; EXPRESSION; CADHERIN; PATHWAY	The receptor for advanced glycation endproducts (RAGE) mediates responses to cell danger and stress. When bound by its many ligands (which include advanced glycation endproducts, certain members of the S100/calgranulin family, extracellular high-mobility group box 1, the integrin Mac-1, amyloid (beta-peptide and fibrils), RAGE activates programs responsible for acute and chronic inflammation. RAGE is therefore also involved in cancer progression, diabetes, atherosclerosis, and Alzheimer's disease. RAGE has several isoforms deriving from alternative splicing, including a soluble form called endogenous secretory RAGE (esRAGE). We show here that most soluble RAGE, either produced by cell lines or present in human blood, is not recognized by an anti-esRAGE antibody. Cells transfected with the cDNA for full-length RAGE, and thus not expressing esRAGE, produce a form of soluble RAGE, cleaved RAGE (cRAGE) that derives from proteolytic cleavage of the membrane-bound molecules and acts as a decoy receptor. By screening chemical inhibitors and genetically modified mouse embryonic fibroblasts (MEFs), we identify the sheddase ADAM10 as a membrane protease responsible for RAGE cleavage. Binding of its ligand HMGB1 promotes RAGE shedding. Our data do not disprove the interpretation that high levels of soluble forms of RAGE protect against chronic inflammation, but rather suggest that they correlate with high levels of ongoing inflammation.	[Bianchi, Marco E.] Univ Vita Salute San Raffaele, I-20132 Milan, Italy; [Raucci, Angela; Antonelli, Antonella; Monti, Lucilla] Ist Sci San Raffaele, I-20132 Milan, Italy; [Cugusi, Simona; Barabino, Silvia M.] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy; [Bierhaus, Angelika] Heidelberg Univ, Dept Med & Clin Chem 1, Heidelberg, Germany; [Reiss, Karina; Saftig, Paul] Univ Kiel, Inst Biochem, D-2300 Kiel, Germany	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milano-Bicocca; Ruprecht Karls University Heidelberg; University of Kiel	Bianchi, ME (corresponding author), Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.	bianchi.marco@hsr.it	Saftig, Paul/A-7966-2010; Bianchi, Marco Emilio/K-3417-2018; Reiss, Karina/B-3175-2010; Barabino, Silvia/AAC-4674-2021; Monti, Lucilla/AAN-3716-2020; Raucci, Angela/K-3722-2018; Antonelli, Antonella/AAN-1856-2020; ANTONELLI, ANTONELLA/C-6238-2011	Bianchi, Marco Emilio/0000-0002-5329-6445; Raucci, Angela/0000-0003-1333-9671; Antonelli, Antonella/0000-0003-1497-3586	Associazione Italiana Ricerca sul Cancro; Fondazione Cariplo; Italian Ministry of Health; Deutsche Forschungsgemeinschaft [SFB415B9, SFB405]	Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariplo(Fondazione Cariplo); Italian Ministry of Health(Ministry of Health, Italy); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Dr. Hiroshi Yamamoto (Kanazawa University. K Kanazawa, Japan) for providing the anti-esRAGE antibody. Gianluca Varetti (European Institute of Oncology, Milan. Italy) for construction of pcDNA/FL-RAGE-myc vector. Francesca Sanvito (San Raffaele Scientific Institute, Milan. Italy) for providing human samples, anti Grazisa Rossetti for the helpful discussion. A.R. was supported by a fellowship from Federazione Italiana Ricerca Cancro (FIRC), A.A. 1) v the Ingenio program, and S.C. by Fondazione Cariplo. This work leas been supported by grants from Associazione Italiana Ricerca sul Cancro, Fondazione Cariplo, the Italian Ministry of Health, the 'Targeting Cell Migration in Chronic Inflammationcytokines HMGB1 inflammation receptor shedding atherosclerosis diabetes Network of Excellence, the Deutsche Forschungsgemeinschaft (SFB415B9 and SFB405). and the Belgian Inter-university Attraction Poles Programme. The authors declare no direct financial interest. However, M.E.B. is founder and part owner of HMGBiotech, it company that provides goods and services related to HMGB proteins.	Basta G, 2008, ATHEROSCLEROSIS, V196, P9, DOI 10.1016/j.atherosclerosis.2007.07.025; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; BRETT J, 1993, AM J PATHOL, V143, P1699; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Dattilo BM, 2007, BIOCHEMISTRY-US, V46, P6957, DOI 10.1021/bi7003735; Demling N, 2006, CELL TISSUE RES, V323, P475, DOI 10.1007/s00441-005-0069-0; Garton KJ, 2006, J LEUKOCYTE BIOL, V79, P1105, DOI 10.1189/jlb.0106038; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Geroldi D, 2005, J HYPERTENS, V23, P1725, DOI 10.1097/01.hjh.0000177535.45785.64; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Hanford LE, 2004, J BIOL CHEM, V279, P50019, DOI 10.1074/jbc.M409782200; Harashima A, 2006, BIOCHEM J, V396, P109, DOI 10.1042/BJ20051573; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Herold K, 2007, J LEUKOCYTE BIOL, V82, P204, DOI 10.1189/jlb.1206751; Hofmann MA, 2002, GENES IMMUN, V3, P123, DOI 10.1038/sj.gene.6363861; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Humpert PM, 2006, DIABETES CARE, V29, P1111, DOI 10.2337/dc05-2478; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Malherbe P, 1999, MOL BRAIN RES, V71, P159, DOI 10.1016/S0169-328X(99)00174-6; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552; Ostendorp T, 2007, EMBO J, V26, P3868, DOI 10.1038/sj.emboj.7601805; Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135; Palumbo R, 2007, J CELL BIOL, V179, P33, DOI 10.1083/jcb.200704015; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Reiss K, 2006, PHARMACOL THERAPEUT, V111, P985, DOI 10.1016/j.pharmthera.2006.02.009; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlueter C, 2003, BBA-GENE STRUCT EXPR, V1630, P1, DOI 10.1016/j.bbaexp.2003.08.008; Uchida T, 2006, AM J RESP CRIT CARE, V173, P1008, DOI 10.1164/rccm.200509-1477OC; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371	34	441	453	2	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3716	3727		10.1096/fj.08-109033	http://dx.doi.org/10.1096/fj.08-109033			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18603587				2022-12-28	WOS:000259642600032
J	Westerlund, M; Belin, AC; Anvret, A; Hakansson, A; Nissbrandt, H; Lind, C; Sydow, O; Olson, L; Galter, D				Westerlund, Marie; Belin, Andrea Carmine; Anvret, Anna; Hakansson, Anna; Nissbrandt, Hans; Lind, Charlotta; Sydow, Olof; Olson, Lars; Galter, Dagmar			Cerebellar alpha-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material	FASEB JOURNAL			English	Article						NACP; PARK1; PD1; Western blot	MESSENGER-RNA EXPRESSION; LEWY BODY; GENE; MUTATION; VARIABILITY; DUPLICATION; BRAIN	Alterations of brain and plasma a-synuclein levels and SNCA gene variability have been implicated in the pathogenesis of Parkinson's disease (PD). We therefore measured a-synuclein protein levels in postmortem PD and control cerebellum tissue using Western blot and investigated whether the levels correlated to SNCA genotype. We found markedly decreased a-synuclein levels in PD patients (n=16) compared to gender- and age-matched controls (n=14; P=0.004) normalized to a-tubulin. We also performed an association study of the noncoding polymorphisms rs2737029 (A/G) and rs356204 (A/G) (intron 4), and of rs356219 (T/C) (3'-region) of SNCA in a Swedish PD case-control material. Using a two-sided chi(2) test, we found significant association of rs2737029 (P=0.003; chi(2)=9.07) and rs356204 (P=0.048; chi(2)=3.91) with disease, strengthening the involvement of SNCA polymorphisms in sporadic PD. Stratification of the human postmortem brain material by genotype of the three investigated polymorphisms, did not indicate any influence of genotype on alpha-synuclein protein levels when comparing PD with controls. Taken together, our findings demonstrate that the investigated Parkinson patients have markedly reduced levels of a-synuclein in cerebellum, and that this reduction is general, rather then correlated to the investigated polymorphisms, although two of the polymorphisms also associated with disease in a Swedish material.	[Westerlund, Marie; Belin, Andrea Carmine; Anvret, Anna; Olson, Lars; Galter, Dagmar] Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; [Hakansson, Anna; Nissbrandt, Hans] Univ Gothenburg, Dept Pharmacol, Sahlgrenska Acad, Gothenburg, Sweden; [Lind, Charlotta; Sydow, Olof] Karolinska Univ Hosp, Dept Clin Neurosci, Neurol Sect, Stockholm, Sweden	Karolinska Institutet; University of Gothenburg; Karolinska Institutet; Karolinska University Hospital	Galter, D (corresponding author), Karolinska Inst, Dept Neurosci, Retziusvag 8, S-17177 Stockholm, Sweden.	dagmar.galter@ki.se	Galter, Dagmar/C-4826-2011; Belin, Andrea Carmine/AAV-9933-2021	Galter, Dagmar/0000-0001-6485-6244; Belin, Andrea Carmine/0000-0001-6668-3172; Sydow, Olof/0000-0001-7798-8297	Swedish Research Council; Swedish Brain Foundation; Hallstens Forskningsstiftelse; Swedish Parkinson Foundation; Swedish Brain Power; U.S. Public Health Service; Ahlen's Foundation; Karolinska Institutet Funds	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Brain Foundation; Hallstens Forskningsstiftelse; Swedish Parkinson Foundation; Swedish Brain Power; U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Ahlen's Foundation; Karolinska Institutet Funds	We thank Silvia Paddock for technical advice and Ann-Christin Thelander, Karin Lundstromer, and Caroline Ran for technical assistance. This work was supported by the Swedish Research Council, Swedish Brain Foundation and Hallstens Forskningsstiftelse, the Swedish Parkinson Foundation, Swedish Brain Power, U.S. Public Health Service grants, the Ahlen's Foundation, and Karolinska Institutet Funds. Human brain tissue samples were provided by the Queen Square Brain Bank for Neurological Disorders (London, UK).	Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Chiba-Falek O, 2006, MOVEMENT DISORD, V21, P1703, DOI 10.1002/mds.21007; Cookson MR, 2008, EXP NEUROL, V209, P5, DOI 10.1016/j.expneurol.2007.05.022; Dachsel JC, 2007, MOVEMENT DISORD, V22, P293, DOI 10.1002/mds.21223; Daniel S E, 1993, J Neural Transm Suppl, V39, P165; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Fahn S, 2005, J NEUROL, V252, P37, DOI 10.1007/s00415-005-4008-5; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Fuchs J, 2008, FASEB J, V22, P1327, DOI 10.1096/fj.07-9348com; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Kingsbury AE, 2004, MOVEMENT DISORD, V19, P162, DOI 10.1002/mds.10683; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Li QX, 2007, EXP NEUROL, V204, P583, DOI 10.1016/j.expneurol.2006.12.006; Maraganore DM, 2006, JAMA-J AM MED ASSOC, V296, P661, DOI 10.1001/jama.296.6.661; Mizuta I, 2006, HUM MOL GENET, V15, P1151, DOI 10.1093/hmg/ddl030; Mueller JC, 2005, ANN NEUROL, V57, P535, DOI 10.1002/ana.20438; Neystat M, 1999, MOVEMENT DISORD, V14, P417, DOI 10.1002/1531-8257(199905)14:3<417::AID-MDS1005>3.0.CO;2-X; Papapetropoulos S, 2007, MOVEMENT DISORD, V22, P1057, DOI 10.1002/mds.21466; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rockenstein E, 2001, BRAIN RES, V914, P48, DOI 10.1016/S0006-8993(01)02772-X; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Solano SM, 2000, ANN NEUROL, V47, P201, DOI 10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tokuda T, 2006, BIOCHEM BIOPH RES CO, V349, P162, DOI 10.1016/j.bbrc.2006.08.024; Wang G, 2008, AM J HUM GENET, V82, P283, DOI 10.1016/j.ajhg.2007.09.021; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	28	28	29	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2008	22	10					3509	3514		10.1096/fj.08-110148	http://dx.doi.org/10.1096/fj.08-110148			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18606870				2022-12-28	WOS:000259642600013
J	Masini, E; Vannacci, A; Failli, P; Mastroianni, R; Giannini, L; Vinci, MC; Uliva, C; Motterlini, R; Mannaioni, PF				Masini, Emanuela; Vannacci, Alfredo; Failli, Paola; Mastroianni, Rosanna; Giannini, Lucia; Vinci, Maria Cristina; Uliva, Caterina; Motterlini, Roberto; Mannaioni, Pier Francesco			A carbon monoxide-releasing molecule (CORM-3) abrogates polymorphonuclear granulocyte-induced activation of endothelial cells and mast cells	FASEB JOURNAL			English	Article						neutrophils; formyl-methionyl peptides; integrins; ICAM-1; reactive oxygen species	FORMYLMETHIONYL-LEUCYL-PHENYLALANINE; HISTAMINE-RELEASE; HUMAN-NEUTROPHILS; SUPEROXIDE ANION; HEME OXYGENASE-1; NITRIC-OXIDE; EXPRESSION; CO; MODULATION; ADHESION	We hypothesized that circulating polymorphonuclear granulocytes (PMNs), vascular endothelial cells (ECs), and perivascular mast cells (MCs) may initiate and sustain the inflammatory response through the generation of the superoxide anion (O-2 center dot(-)) by PMNs primed by inflammatory stimuli, which in turn evoked the overexpression of adhesion molecules from ECs and release of histamine by MCs. To pin-point the role of carbon monoxide (CO) in curbing vascular inflammation, we studied the effect of a water-soluble CO-releasing molecule [tricarbonylchloro-glycinate-ruthenium (II); CORM-3] on an experimental model of vascular inflammation. The model consists of coincubating formyl-methionyl peptide (fMLP)-primed human PMNs with rat ECs or with rat MCs. The effects of CORM-3 were evaluated by measuring the generation of O-2 center dot(-) and the expression of CD11b in fMLP-primed PMNs; the expression of ICAM-1 and CD203c in ECs and MCs, respectively; and the release of histamine from MCs. Our results show that the chemotactic peptide fMLP primes PMNs to generate O-2 center dot(-) and overexpress CD11b, both events being central to the inflammatory process, while CORM-3 significantly decreases these events (IC50 = 1.66 mu M for O-2 center dot(-) production; 1.20 mu M for CD11b expression in human PMNs). The experiments also show that fMLP-primed PMNs increase the CD54 expression by coincubated ECs, and the expression of CD203c and the release of histamine by coincubated MCs. Once again, CORM-3 abolishes these events (IC50 = 6.78 mu M for CD54 expression in ECs; 1.18 mu M for CD203 expression; 1.15 mu M for histamine release in MCs). Thus, CORM-3 exerts a powerful anti-inflammatory action by down-regulating the oxidative burst in PMNs, the overexpression of adhesion molecules in PMNs and ECs, the release of histamine, and the overexpression of an activation marker by MCs.	[Masini, Emanuela; Vannacci, Alfredo; Failli, Paola; Mastroianni, Rosanna; Giannini, Lucia; Vinci, Maria Cristina; Uliva, Caterina; Mannaioni, Pier Francesco] Univ Florence, Dept Preclin & Clin Pharmacol, I-50139 Florence, Italy; [Motterlini, Roberto] Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow, Middx, England	University of Florence; Imperial College London	Mannaioni, PF (corresponding author), Univ Florence, Dept Preclin & Clin Pharmacol, Viale G Pieraccini 6, I-50139 Florence, Italy.	pierfrancesco.mannaioni@unifi.it	Motterlini, Roberto/Q-1890-2019; Motterlini, Roberto/G-2489-2013; Vinci, Maria Cristina/E-7401-2016; Vannacci, Alfredo/A-1708-2008	Motterlini, Roberto/0000-0003-2684-2612; Motterlini, Roberto/0000-0003-2684-2612; Vinci, Maria Cristina/0000-0001-6323-147X; Vannacci, Alfredo/0000-0001-5259-2026; Failli, Paola/0000-0003-3879-9068	Ente Cassa di Risparmio, Florence, Italy	Ente Cassa di Risparmio, Florence, Italy	These investigations were supported by a grant from Ente Cassa di Risparmio, Florence, Italy.	Abraham NG, 2002, HEME OXYGENASE BIOL; Andersson JA, 2002, ALLERGY, V57, P718, DOI 10.1034/j.1398-9995.2002.23593.x; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; Bani-Hani MG, 2006, J PHARMACOL EXP THER, V318, P1315, DOI 10.1124/jpet.106.104729; BLANDINA P, 1980, J PHYSIOL-LONDON, V301, P281, DOI 10.1113/jphysiol.1980.sp013205; Boczkowski J, 2006, TRENDS BIOCHEM SCI, V31, P614, DOI 10.1016/j.tibs.2006.09.001; Chlopicki S, 2006, CARDIOVASC RES, V71, P393, DOI 10.1016/j.cardiores.2006.03.011; Cines DB, 1998, BLOOD, V91, P3527; Cirillo P, 2007, J VASC RES, V44, P460, DOI 10.1159/000106464; Clark JE, 2003, CIRC RES, V93, pE2, DOI 10.1161/01.RES.0000084381.86567.08; Di Pascoli M, 2006, BIOCHEM BIOPH RES CO, V340, P935, DOI 10.1016/j.bbrc.2005.12.082; Failli P, 2000, BRIT J PHARMACOL, V130, P1468, DOI 10.1038/sj.bjp.0703453; FANTOZZI R, 1983, AGENTS ACTIONS, V13, P218, DOI 10.1007/BF01967336; FANTOZZI R, 1984, AGENTS ACTIONS, V14, P441, DOI 10.1007/BF01973846; FANTOZZI R, 1985, AGENTS ACTIONS, V16, P260, DOI 10.1007/BF01983155; FANTOZZI R, 1986, AGENTS ACTIONS, V18, P155, DOI 10.1007/BF01988009; Foresti R, 2004, BRIT J PHARMACOL, V142, P453, DOI 10.1038/sj.bjp.0705825; Freitas A, 2006, BRIT J PHARMACOL, V149, P345, DOI 10.1038/sj.bjp.0706882; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Jaggar JH, 2002, CIRC RES, V91, P610, DOI 10.1161/01.RES.0000036900.76780.95; Johnson TR, 2003, ANGEW CHEM INT EDIT, V42, P3722, DOI 10.1002/anie.200301634; Kim HP, 2006, ANNU REV PHARMACOL, V46, P411, DOI 10.1146/annurev.pharmtox.46.120604.141053; KREMZNER LT, 1961, BIOCHIM BIOPHYS ACTA, V50, P364, DOI 10.1016/0006-3002(61)90339-0; Mannaioni PF, 2006, INFLAMM RES, V55, P261, DOI 10.1007/s00011-006-0084-y; MANNAIONI PF, 1988, FREE RADICAL BIO MED, V5, P177, DOI 10.1016/0891-5849(88)90080-9; Masini E, 2004, ENDOCRINOLOGY, V145, P1106, DOI 10.1210/en.2003-0833; Milovanova T, 2006, AM J PHYSIOL-CELL PH, V290, pC66, DOI 10.1152/ajpcell.00094.2005; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; Motterlini R, 2005, EXPERT OPIN INV DRUG, V14, P1305, DOI 10.1517/13543784.14.11.1305; Motterlini R, 2002, CIRC RES, V90, pE17, DOI 10.1161/hh0202.104530; Mugnai S, 1997, BRIT J PHARMACOL, V122, P1345, DOI 10.1038/sj.bjp.0701521; Ndisang JF, 2001, BRIT J PHARMACOL, V134, P1689, DOI 10.1038/sj.bjp.0704427; Ndisang JF, 1999, IMMUNOPHARMACOLOGY, V43, P65, DOI 10.1016/S0162-3109(99)00045-4; Neto JS, 2006, AM J PHYSIOL-RENAL, V290, pF324, DOI 10.1152/ajprenal.00026.2005; Ning W, 2005, AM J PHYSIOL-LUNG C, V289, pL268, DOI 10.1152/ajplung.00168.2004; OHMORI H, 1979, BIOCHEM PHARMACOL, V28, P333, DOI 10.1016/0006-2952(79)90524-0; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Rucker M, 2001, SURGERY, V129, P292, DOI 10.1067/msy.2001.111079; Sawle P, 2006, J PHARMACOL EXP THER, V318, P403, DOI 10.1124/jpet.106.101758; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Srisook K, 2006, BIOCHEM PHARMACOL, V71, P307, DOI 10.1016/j.bcp.2005.10.042; Stein AB, 2005, J MOL CELL CARDIOL, V38, P127, DOI 10.1016/j.yjmcc.2004.10.006; Taille C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200; Uemura K, 2005, BIOCHEM BIOPH RES CO, V334, P661, DOI 10.1016/j.bbrc.2005.06.142; Vachharajani TJ, 2000, AM J PHYSIOL-HEART C, V278, pH1613, DOI 10.1152/ajpheart.2000.278.5.H1613; Vannacci A, 2004, INFLAMM RES, V53, pS9, DOI 10.1007/s00011-003-0303-8; Vannacci A, 2003, EUR J PHARMACOL, V465, P289, DOI 10.1016/S0014-2999(03)01489-4; Vera T, 2005, J AM SOC NEPHROL, V16, P950, DOI 10.1681/ASN.2004090736; Vinci MC, 2004, BIOCHEM PHARMACOL, V67, P277, DOI 10.1016/j.bcp.2003.09.007; WONG K, 1981, CAN J PHYSIOL PHARM, V59, P915, DOI 10.1139/y81-141; Wu LY, 2005, PHARMACOL REV, V57, P585, DOI 10.1124/pr.57.4.3; Yu HP, 2006, AM J PHYSIOL-LUNG C, V291, pL400, DOI 10.1152/ajplung.00537.2005	52	25	27	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3380	3388		10.1096/fj.08-107110	http://dx.doi.org/10.1096/fj.08-107110			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18556460				2022-12-28	WOS:000258761300030
J	Orso, F; Penna, E; Cimino, D; Astanina, E; Maione, F; Valdembri, D; Giraudo, E; Serini, G; Sismondi, P; De Bortoli, M; Taverna, D				Orso, Francesca; Penna, Elisa; Cimino, Daniela; Astanina, Elena; Maione, Federica; Valdembri, Donatella; Giraudo, Enrico; Serini, Guido; Sismondi, Piero; De Bortoli, Michele; Taverna, Daniela			AP-2 alpha and AP-2 gamma regulate tumor progression via specific genetic programs	FASEB JOURNAL			English	Article						transcription factor; migration; microarray	TRANSCRIPTION FACTOR AP-2; ACTIVATOR PROTEIN 2-ALPHA; BREAST-CANCER; EPITHELIAL-CELLS; PROSTATE-CANCER; DOWN-REGULATION; MAMMARY-CARCINOMA; DNA-BINDING; EXPRESSION; METASTASIS	The events occurring during tumor formation and progression display similarities to some of the steps in embryonic morphogenesis. The family of AP-2 proteins consists of five different transcription factors ( alpha,beta,gamma,delta, and epsilon) that play relevant roles in embryonic development, as demonstrated by the phenotypes of the corresponding knockout mice. Here, we show that AP-2 alpha and AP-2 gamma proteins play an essential role in tumorigenesis. Down-modulation of AP-2 expression in tumor cells by RNA interference (RNAi) led to enhanced tumor growth and reduced chemotherapy-induced cell death, as well as migration and invasion. Most of these biological modulations were rescued by AP-2 overexpression. We observed that increased xeno-transplant growth was mostly due to highly enhanced proliferation of the tumor cells together with reduced innate immune cell recruitment. Moreover, we showed that migration impairment was mediated, at least in part, by secreted factors. To identify the genetic programs involved in tumorigenesis, we performed whole genome microarray analysis of AP-2 alpha knockdown cells and observed that AP-2 alpha regulates specific genes involved in cell cycle, cell death, adhesion, and migration. In particular, we showed that ESDN, EREG, and CXCL2 play a major role in AP-2 controlled migration, as ablation of any of these genes severely altered migration.	[Orso, Francesca; Penna, Elisa; Cimino, Daniela; Taverna, Daniela] Univ Turin, Dept Oncol Sci, Ctr Mol Biotechnol, I-10126 Turin, Italy; [Orso, Francesca; Penna, Elisa; Cimino, Daniela; Astanina, Elena; Maione, Federica; Valdembri, Donatella; Giraudo, Enrico; Serini, Guido; Sismondi, Piero; De Bortoli, Michele; Taverna, Daniela] Univ Turin, Dept Oncol Sci, Inst Canc Res & Treatment, I-10126 Turin, Italy; [Giraudo, Enrico; Serini, Guido; De Bortoli, Michele; Taverna, Daniela] Univ Turin, Ctr Complex Syst Mol Biol & Med, I-10126 Turin, Italy	University of Turin; University of Turin; University of Turin	Taverna, D (corresponding author), Univ Turin, Dept Oncol Sci, Ctr Mol Biotechnol, Via Nizza 52, I-10126 Turin, Italy.	daniela.taverna@unito.it	Serini, Guido/AAF-2873-2021; taverna, daniela/J-8358-2016; De Bortoli, Michele/B-5418-2013; Giraudo, Enrico/K-3192-2016; Maione, Federica/K-6679-2016; Giraudo, Enrico/K-6441-2019; Orso, Francesca/B-1985-2014	Serini, Guido/0000-0002-3502-8367; taverna, daniela/0000-0002-6365-527X; De Bortoli, Michele/0000-0002-6666-9052; Giraudo, Enrico/0000-0003-4128-4786; Maione, Federica/0000-0003-2789-799X; Giraudo, Enrico/0000-0003-4128-4786; Valdembri, Donatella/0000-0003-4590-417X; Sismondi, Piero/0000-0002-2505-5716; Orso, Francesca/0000-0003-4706-6464	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chiorino G, 2004, EUR J CANCER, V40, P2592, DOI 10.1016/j.ejca.2004.07.029; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Jager R, 2005, BREAST CANCER RES TR, V90, P273, DOI 10.1007/s10549-004-4815-x; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lazzarato F, 2004, BIOINFORMATICS, V20, P2848, DOI 10.1093/bioinformatics/bth287; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Nagai H, 2007, ONCOGENE, V26, P4025, DOI 10.1038/sj.onc.1210183; Nyormoi O, 2003, CLIN EXP METASTAS, V20, P251, DOI 10.1023/A:1022991302172; Orso F, 2004, BIOCHEM J, V377, P429, DOI 10.1042/BJ20031133; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pellikainen J, 2002, CLIN CANCER RES, V8, P3487; Pellikainen JM, 2007, INT J CANCER, V120, P2061, DOI 10.1002/ijc.22648; Perissi V, 2000, ONCOGENE, V19, P280, DOI 10.1038/sj.onc.1203303; Rasola A, 2001, CYTOMETRY, V45, P151, DOI 10.1002/1097-0320(20011001)45:2<151::AID-CYTO1157>3.0.CO;2-I; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SUYAMA E, 2002, NUCL ACIDS RES S, V2, P247; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Wajapeyee N, 2005, CANCER RES, V65, P8628, DOI 10.1158/0008-5472.CAN-05-1059; Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; Werling U, 2002, MOL CELL BIOL, V22, P3149, DOI 10.1128/MCB.22.9.3149-3156.2002; Werling Uwe, 2002, Genesis The Journal of Genetics and Development, V32, P127, DOI 10.1002/gene.10057; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	50	59	59	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2702	2714		10.1096/fj.08-106492	http://dx.doi.org/10.1096/fj.08-106492			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18443366				2022-12-28	WOS:000258089300010
J	Loukin, S; Zhou, XL; Kung, C; Saimi, Y				Loukin, Stephen; Zhou, Xinliang; Kung, Ching; Saimi, Yoshiro			A genome-wide survey suggests an osmoprotective role for vacuolar Ca2+ release in cell wall-compromised yeast	FASEB JOURNAL			English	Article						Saccharomyces cerevisiae; Yvc1; TRPY1; transient receptor potential ion channel; CCH1; calcineurin	SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; INTEGRITY PATHWAY; ANCHORED PROTEINS; HYPERTONIC SHOCK; PLASMA-MEMBRANE; HYPOTONIC SHOCK; ION-CHANNEL; GENE; CALCINEURIN	In yeast, osmotic upshock causes a release of vacuolar Ca2+ through the mechanosensitive transient receptor potential channel, Yvc1. We screened the collection of 4810 yeast gene deletants twice for alterations in this response in an attempt to find elements that regulate the amount of vacuolar Ca2+ or the Yvc1 channel. Severe overresponders and underresponders to upshock were further scrutinized for their calcium content with Ca-45 and their Yvc1 electrophysiological activities under patch-clamp. The severe underresponders have lower calcium content but no change in Yvc1 activity. The strong overresponders, most of which are deleted of genes involved in cell wall metabolism, have higher calcium content. Wall mutations are known to up-regulate Ca2+ -calcineurin-dependent genes. It appears that stress on the cell wall induces Ca2+ accumulation, adaptively anticipating the need in defense or repair against future stress, including osmotic stress.	[Loukin, Stephen; Zhou, Xinliang; Kung, Ching; Saimi, Yoshiro] Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; [Kung, Ching] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Loukin, S (corresponding author), Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA.	shloukin@wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047856] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47856, GM54867] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; EILAM Y, 1985, J GEN MICROBIOL, V131, P623; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; Fujita M, 2006, MOL BIOL CELL, V17, P834, DOI 10.1091/mbc.E05-05-0443; Fujita M, 2006, MOL BIOL CELL, V17, P5253, DOI 10.1091/mbc.E06-08-0715; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; HOFMANN M, 1994, EUR J BIOCHEM, V221, P741, DOI 10.1111/j.1432-1033.1994.tb18787.x; HONG Z, 1994, MOL CELL BIOL, V14, P1017, DOI 10.1128/MCB.14.2.1017; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lesage G, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-8; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; Loukin SH, 2007, FASEB J, V21, P1813, DOI 10.1096/fj.06-7898com; Martin-Yken H, 2003, MOL MICROBIOL, V49, P23, DOI 10.1046/j.1365-2958.2003.03541.x; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; Nass R, 1999, MICROBIOL-SGM, V145, P3221, DOI 10.1099/00221287-145-11-3221; Palmer CP, 2005, BIOCHEM J, V387, P211, DOI 10.1042/BJ20041710; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013; Zhou XL, 2003, P NATL ACAD SCI USA, V100, P7105, DOI 10.1073/pnas.1230540100	36	11	11	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2405	2415		10.1096/fj.07-101410	http://dx.doi.org/10.1096/fj.07-101410			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18323404				2022-12-28	WOS:000257292500032
J	Zhao, DW; Richer, E; Antich, PP; Mason, RP				Zhao, Dawen; Richer, Edmond; Antich, Peter P.; Mason, Ralph P.			Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI	FASEB JOURNAL			English	Article						breast tumor; vascular targeting agent; vascular disrupting agent; pharmacodynamics	VASCULAR-TARGETING AGENTS; QUANTITATIVE ASSESSMENT; NORMAL-TISSUES; A-4 PHOSPHATE; LUNG-CANCER; TUMOR; RAT; THERAPIES; INHIBITION; EXPRESSION	Bioluminescence imaging (BLI) has found significant use in evaluating long-term cancer therapy in small animals. We have now tested the feasibility of using BLI to assess acute effects of the vascular disrupting agent combretastatin A4 phosphate (CA4P) on luciferase-expressing MDA-MB-231 human breast tumor cells growing as xenografts in mice. Following administration of luciferin substrate, there is a rapid increase in light emission reaching a maximum after about 6 min, which gradually decreases over the following 20 min. The kinetics of light emission are highly reproducible; however, following i.p. administration of CA4P (120 mg/kg), the detected light emission was decreased between 50 and 90%, and time to maximum was significantly delayed. Twenty-four hours later, there was some recovery of light emission following further administration of luciferin substrate. Comparison with dynamic contrast-enhanced MRI based on the paramagnetic contrast agent Omniscan showed comparable changes in the tumors consistent with the previous literature. Histology also confirmed shutdown of tumor vascular perfusion. We believe this finding provides an important novel application for BLI that could have widespread application in screening novel therapeutics expected to cause acute vascular changes in tumors.	Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; Univ Texas SW Med Ctr Dallas, Simmons Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Mason, RP (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Radiol, 5523 Harry Hines, Dallas, TX 75390 USA.	ralph.mason@utsouthwestern.edu	Mason, Ralph/C-8472-2012	Mason, Ralph/0000-0001-7517-3721	NATIONAL CANCER INSTITUTE [U24CA126608, P20CA086354] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA086354-03, U24 CA126608-01, P20 CA086354, U24 CA126608] Funding Source: Medline; NCRR NIH HHS [P41 RR002584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson HL, 2003, J CLIN ONCOL, V21, P2823, DOI 10.1200/JCO.2003.05.186; Beauregard DA, 2002, NMR BIOMED, V15, P99, DOI 10.1002/nbm.723; BOLLINGER RA, 2006, THESIS U TEXAS SW; Chen CC, 2007, NUCL INSTRUM METH A, V571, P437, DOI 10.1016/j.nima.2006.10.129; Contag CH, 2002, J MAGN RESON IMAGING, V16, P378, DOI 10.1002/jmri.10178; Dark GG, 1997, CANCER RES, V57, P1829; DENEKAMP J, 1990, CANCER METAST REV, V9, P267, DOI 10.1007/BF00046365; Dikmen ZG, 2005, CANCER RES, V65, P7866, DOI 10.1158/0008-5472.CAN-05-1215; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; Galbraith SM, 2003, J CLIN ONCOL, V21, P2831, DOI 10.1200/JCO.2003.05.187; Goertz DE, 2002, CANCER RES, V62, P6371; Horsman MR, 2006, CANCER RES, V66, P11520, DOI 10.1158/0008-5472.CAN-06-2848; Hsu AR, 2007, J NUCL MED, V48, P445; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P745, DOI 10.1023/B:CLIN.0000006817.25962.87; KIM JG, 2006, BIOM OPT TOP M FORT, P19; Kragh M, 2002, NEOPLASIA, V4, P263, DOI 10.1038/sj.neo.7900230; Ley CD, 2007, NEOPLASIA, V9, P108, DOI 10.1593/neo.06733; Li JZ, 2005, J GENE MED, V7, P792, DOI 10.1002/jgm.720; Lipshutz GS, 2001, MOL THER, V3, P284, DOI 10.1006/mthe.2001.0267; Maxwell RJ, 2002, NMR BIOMED, V15, P89, DOI 10.1002/nbm.754; McIntyre DJO, 2004, NEOPLASIA, V6, P150, DOI 10.1593/neo.03247; Mi J, 2006, J SURG RES, V131, P97, DOI 10.1016/j.jss.2005.09.008; Ng QS, 2007, INT J RADIAT ONCOL, V67, P1375, DOI 10.1016/j.ijrobp.2006.11.028; Padhani AR, 2003, BRIT J RADIOL, V76, pS60, DOI 10.1259/bjr/15334380; Paroo Z, 2004, MOL IMAGING, V3, P117, DOI 10.1162/1535350041464865; Prise VE, 2002, INT J ONCOL, V21, P717; Rehemtulla A, 2000, NEOPLASIA, V2, P491, DOI 10.1038/sj.neo.7900121; Rice BW, 2001, J BIOMED OPT, V6, P432, DOI 10.1117/1.1413210; Robinson SP, 2003, BRIT J CANCER, V88, P1592, DOI 10.1038/sj.bjc.6600926; Rustin GJS, 2003, J CLIN ONCOL, V21, P2815, DOI 10.1200/JCO.2003.05.185; Siemann DW, 2005, CLIN CANCER RES, V11, P416; Szentirmai O, 2006, NEUROSURGERY, V58, P365, DOI 10.1227/01.NEU.0000195114.24819.4F; Thorne SH, 2005, P IEEE, V93, P750, DOI 10.1109/JPROC.2005.844261; Thorpe PE, 2004, CLIN CANCER RES, V10, P415, DOI 10.1158/1078-0432.CCR-0642-03; Tozer GM, 1999, CANCER RES, V59, P1626; Tozer GM, 2001, CANCER RES, V61, P6413; Verneris MR, 2005, CLIN CANCER RES, V11, P4561, DOI 10.1158/1078-0432.CCR-05-0157; Wang Y, 2007, BIOTECHNOL LETT, V29, P1665, DOI 10.1007/s10529-007-9452-0; Zhao DW, 2005, INT J RADIAT ONCOL, V62, P872, DOI 10.1016/j.ijrobp.2005.03.009	39	55	59	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2445	2451		10.1096/fj.07-103713	http://dx.doi.org/10.1096/fj.07-103713			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263704	Green Accepted			2022-12-28	WOS:000257292500036
J	Zuo, XS; Shen, L; Issa, JP; Moy, O; Morris, JS; Lippman, SM; Shureiqi, I				Zuo, Xiangsheng; Shen, Lanlan; Issa, Jean-Pierre; Moy, Ofir; Morris, Jeffrey S.; Lippman, Scott M.; Shureiqi, Imad			15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation	FASEB JOURNAL			English	Article						colon cancer; transcriptional regulation; histone deacetylase inhibitor; DNMT-1 hypomorph protein	COLORECTAL-CANCER CELLS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HISTONE METHYLTRANSFERASE; PROMOTER METHYLATION; INDUCED APOPTOSIS; INDUCE APOPTOSIS; GENE PROMOTER; EXPRESSION; INFLAMMATION; DNMT1	Methylation of promoter DNA contributes to transcriptional silencing of various tumor-suppressor genes in cancer. Transcriptional silencing of 15-lipoxygenase-1 (15-LOX-1) promotes tumorigenesis. Methylation of 15-LOX-1 promoter DNA occurs in some cancers, but its mechanistic role in 15-LOX-1 transcriptional silencing is unclear. We examined the mechanistic role of 15-LOX-1 promoter DNA methylation in 15-LOX-1 transcriptional regulation in human colorectal cancers. 15-LOX-1 promoter methylation occurred in colorectal cancer cells in vitro, in 36% of tumor tissue samples of colorectal cancer patients, and in virtually no normal colonic mucosa samples of 50 human subjects with no history of colorectal cancer or polyps. 15-LOX-1 promoter DNA methylation levels, however, did not correlate with 15-LOX-1 expression levels (Spearman's r=0.21; P=0.38). We employed siRNA knockdown and genetic disruption models of DNA methyltransferases (DNMTs) to study the effects of this methylation on 15-LOX-1 expression in colon cancer cells. 15-LOX-1 promoter demethylation was insufficient to reestablish 15-LOX-1 expression. 15-LOX-1 transcription was activated by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) only after DNMT-1 dissociation from the 15-LOX- 1 promoter and without altering 15-LOX-1 promoter DNA methylation. DNMT-1 protein hypomorphism impaired DNMT-1 recruitment to the 15-LOX-1 promoter, which allowed 15-LOX-1 transcription activation by SAHA. DNMT-1 has a direct suppressive role in 15-LOX-1 transcriptional silencing that is independent of 15-LOX-1 promoter DNA methylation.	[Zuo, Xiangsheng; Moy, Ofir; Lippman, Scott M.; Shureiqi, Imad] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA; [Shen, Lanlan; Issa, Jean-Pierre] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Morris, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; [Lippman, Scott M.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Shureiqi, Imad] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shureiqi, I (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ishureiqi@mdanderson.org	Shureiqi, imad/T-6214-2019	Zuo, Xiangsheng/0000-0002-8593-1132; Shureiqi, Imad/0000-0003-2019-938X; Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [R01 CA106577-01A1, K07 CA086970-05, K07 CA086970-03, K07 CA086970-02, R01 CA106577, K07 CA086970, N02-CB-07008, K07 CA086970-06, R01 CA106577-03, K07 CA086970-04, K07 CA086970-01, R01 CA106577-02, K07 CA86970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA086970, R01CA106577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariel A, 2005, J BIOL CHEM, V280, P43079, DOI 10.1074/jbc.M509796200; Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007; BAER AN, 1991, BIOCHEM BIOPH RES CO, V180, P98, DOI 10.1016/S0006-291X(05)81260-4; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Damelin M, 2007, MOL CELL BIOL, V27, P3891, DOI 10.1128/MCB.00036-07; Deguchi A, 2005, CANCER RES, V65, P8442, DOI 10.1158/0008-5472.CAN-05-1109; Egger G, 2006, P NATL ACAD SCI USA, V103, P14080, DOI 10.1073/pnas.0604602103; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hennig R, 2007, NEOPLASIA, V9, P917, DOI 10.1593/neo.07565; Heslin MJ, 2005, ANN SURG, V241, P941, DOI 10.1097/01.sla.0000164177.95620.c1; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Hsi LC, 2004, CANCER RES, V64, P8778, DOI 10.1158/0008-5472.CAN-04-1867; Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P235, DOI 10.1016/j.plefa.2006.01.009; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; Kelavkar U, 1998, MOL BIOL REP, V25, P173, DOI 10.1023/A:1006813009006; Kelavkar UP, 2007, PROSTAG OTH LIPID M, V82, P185, DOI 10.1016/j.prostaglandins.2006.05.015; Kuhn H, 2006, PROG LIPID RES, V45, P334, DOI 10.1016/j.plipres.2006.02.003; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Liu C, 2004, EXP CELL RES, V297, P61, DOI 10.1016/j.yexcr.2004.02.014; Makar KW, 2003, NAT IMMUNOL, V4, P1183, DOI 10.1038/ni1004; Martinez ME, 1997, GASTROENTEROLOGY, V113, P423, DOI 10.1053/gast.1997.v113.pm9247459; MARTINEZ ME, 1995, CANCER EPIDEM BIOMAR, V4, P703; Massaro M, 2006, P NATL ACAD SCI USA, V103, P15184, DOI 10.1073/pnas.0510086103; Munger KA, 1999, P NATL ACAD SCI USA, V96, P13375, DOI 10.1073/pnas.96.23.13375; Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Serhan CN, 2003, J IMMUNOL, V171, P6856, DOI 10.4049/jimmunol.171.12.6856; Shu JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008-5472.CAN-05-2629; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2005, CANCER RES, V65, P11486, DOI 10.1158/0008-5472.CAN-05-2180; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Shureiqi I, 2001, CANCER RES, V61, P4879; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Wu J, 2003, CARCINOGENESIS, V24, P243, DOI 10.1093/carcin/24.2.243; Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549; Zuo X, 2006, ONCOGENE, V25, P1225, DOI 10.1038/sj.onc.1209160	50	20	21	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1981	1992		10.1096/fj.07-098301	http://dx.doi.org/10.1096/fj.07-098301			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198215	Green Accepted			2022-12-28	WOS:000256352700037
J	Di Gennaro, A; Kenne, E; Wan, M; Soehnlein, O; Lindbom, L; Haeggstrom, JZ				Di Gennaro, Antonio; Kenne, Ellinor; Wan, Min; Soehnlein, Oliver; Lindbom, Lennart; Haeggstrom, Jesper Z.			Leukotriene B-4-induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin)	FASEB JOURNAL			English	Article						inflammation; antimicrobial peptides; eicosanoid	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; SRC FAMILY KINASES; ENDOTHELIAL-CELLS; ACTIVATION; B-4; DEGRANULATION; BIOSYNTHESIS; INFLAMMATION; SECRETION; RECEPTOR	In humans, heparin-binding protein (HBP) and the potent chemotactic lipid leukotriene B-4 (LTB4) are important mediators of innate immune reponses. Here we show that human neutrophils (PMNs) challenged with LTB4 (30 s to 5 min) release HBP as determined by Western blot analysis. This response peaks at 100 nM of agonist and is mediated by the BLT1 receptor. Protein phosphatase-1 (30 mu M) and wortmannin (0.5 mu M) block the LTB4-mediated HBP release from PMNs, which suggests involvement of the 1-phosphatidylinositol 3-kinase intracellular pathway during degranulation. Furthermore, postsecretory supernatants from LTB4-stimulated PMNs induce intracellular calcium mobilization in endothelial cells in vitro and increase in vascular permeability in vivo, as assessed in a mouse model of pleurisy. Selective removal of HBP from the supernatant significantly reduces these activities attributing a key role to HBP in the LTB4-induced change in vascular permeability. This lipid-protein axis could offer novel opportunities for pharmacological intervention in key steps of the vascular response to inflammation.-Di Gennaro, A., Kenne, E., Wan, M., Soehnlein, O., Lindbom, L., Haeggstrom, J. Z. Leukotriene B-4-induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin). FASEB J. 23, 1750-1757 (2009)	[Di Gennaro, Antonio; Wan, Min; Haeggstrom, Jesper Z.] Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; [Kenne, Ellinor; Soehnlein, Oliver; Lindbom, Lennart] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Haeggstrom, JZ (corresponding author), Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	lennart.lindbom@ki.se; jesper.haeggstrom@ki.se	Kenne, Ellinor/HCH-1218-2022	Lindbom, Lennart/0000-0001-9243-257X; Kenne, Ellinor/0000-0002-2784-5244	Swedish Research Council [10350, 04342, 20854]; CERIC; EICOSANOX [005033]; Atheroremo [201668]; Swedish Heart-Lung Foundation; CIDaT; Italian Ministry of University and Research; Deutsche Forschungsgemeinschaft [SO876/1-1]	Swedish Research Council(Swedish Research CouncilEuropean Commission); CERIC; EICOSANOX; Atheroremo; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); CIDaT; Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Swedish Research Council (10350, 04342, 20854, and Linneus Grant CERIC), the EU integrated projects EICOSANOX (005033) and Atheroremo (201668), the Swedish Heart-Lung Foundation, the CIDaT consortium (Vinnova), and the Italian Ministry of University and Research (MIUR, "Internazionalizzazione del Sistema Universitario"). O.S. is recipient of a postdoctorate grant from the Deutsche Forschungsgemeinschaft (SO876/1-1). This publication reflects only the authors' point of view. The European Commission is not liable for any use that may be made of information herein. The authors thank Antonio G. Rothfuchs (NIH, Bethesda, MD, USA) for donation of mAb RB6-8C5 and Hans Flodgaard (Leukotech, Copenhagen) for gift of HBP antibody. The authors disclose that there are no conflicts of interest.	Almeida RP, 1996, PROTEIN EXPRES PURIF, V7, P355, DOI 10.1006/prep.1996.0053; BJORK J, 1982, INFLAMMATION, V6, P189, DOI 10.1007/BF00916243; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; Chen M, 2006, J EXP MED, V203, P837, DOI 10.1084/jem.20052371; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gaudreault E, 2005, J IMMUNOL, V174, P3617, DOI 10.4049/jimmunol.174.6.3617; Gautam N, 2001, NAT MED, V7, P1123, DOI 10.1038/nm1001-1123; Gautam N, 2000, J EXP MED, V191, P1829, DOI 10.1084/jem.191.11.1829; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Heimburger M, 1996, CLIN EXP IMMUNOL, V103, P454; Iizuka Y, 2005, J BIOL CHEM, V280, P24816, DOI 10.1074/jbc.M413257200; Lee TD, 2003, MICROVASC RES, V66, P38, DOI 10.1016/S0026-2862(03)00010-4; Levy O, 2004, J LEUKOCYTE BIOL, V76, P909, DOI 10.1189/jlb.0604320; Lindmark A, 1999, J LEUKOCYTE BIOL, V66, P634, DOI 10.1002/jlb.66.4.634; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Mocsai A, 1999, J IMMUNOL, V162, P1120; Nanamori M, 2007, J IMMUNOL, V178, P416, DOI 10.4049/jimmunol.178.1.416; Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671; PALMBLAD J, 1994, J IMMUNOL, V152, P262; Penrose JF, 1999, CLIN REV ALLERG IMMU, V17, P133, DOI 10.1007/BF02737601; PETERSON MW, 1987, J APPL PHYSIOL, V62, P1521, DOI 10.1152/jappl.1987.62.4.1521; Provost P, 1998, BRIT J PHARMACOL, V123, P251, DOI 10.1038/sj.bjp.0701611; Qiu H, 2006, P NATL ACAD SCI USA, V103, P8161, DOI 10.1073/pnas.0602414103; ROSENGREN S, 1991, J APPL PHYSIOL, V71, P1322, DOI 10.1152/jappl.1991.71.4.1322; ROSENGREN S, 1991, INFLAMMATION, V15, P159, DOI 10.1007/BF00918643; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serezani CHC, 2005, BLOOD, V106, P1067, DOI 10.1182/blood-2004-08-3323; SERHAN CN, 1983, ADV PROSTAG THROMB L, V11, P53; SMITH MJH, 1980, J PHARM PHARMACOL, V32, P517, DOI 10.1111/j.2042-7158.1980.tb12985.x; Soehnlein O, 2005, J IMMUNOL, V174, P6399, DOI 10.4049/jimmunol.174.10.6399; Soehnlein O, 2008, J CLIN INVEST, V118, P3491, DOI 10.1172/JCI35740; Soehnlein O, 2008, BLOOD, V112, P1461, DOI 10.1182/blood-2008-02-139634; SUMIMOTO H, 1984, BIOCHIM BIOPHYS ACTA, V803, P271, DOI 10.1016/0167-4889(84)90117-4; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; Tager AM, 2003, PROSTAG LEUKOTR ESS, V69, P123, DOI 10.1016/S0952-3278(03)00073-5; Tapper H, 2002, BLOOD, V99, P1785, DOI 10.1182/blood.V99.5.1785; Wan M, 2007, FASEB J, V21, P2897, DOI 10.1096/fj.06-7974com; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	44	56	56	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2009	23	6					1750	1757		10.1096/fj.08-121277	http://dx.doi.org/10.1096/fj.08-121277			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19151333				2022-12-28	WOS:000266652400015
J	Rothmeier, AS; Ischenko, I; Joore, J; Garczarczyk, D; Furst, R; Bruns, CJ; Vollmar, AM; Zahler, S				Rothmeier, Andrea S.; Ischenko, Ivan; Joore, Jos; Garczarczyk, Dorota; Fuerst, Robert; Bruns, Christiane J.; Vollmar, Angelika M.; Zahler, Stefan			Investigation of the marine compound spongistatin 1 links the inhibition of PKC alpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis	FASEB JOURNAL			English	Article						angiogenesis; microtubules; chemotaxis; protein kinase C	PROTEIN-KINASE-C; ENDOTHELIAL GROWTH-FACTOR; MICROTUBULE-TARGETING AGENTS; VASCULAR DISRUPTING AGENTS; CANCER-TREATMENT; CELLS; DRUGS; ACTIVATION; MECHANISMS; MIGRATION	The aims of the study were to meet the demand of new tubulin antagonists with fewer side effects by characterizing the antiangiogenic properties of the experimental compound spongistatin 1, and to elucidate nonmitotic mechanisms by which tubulin antagonists inhibit angiogenesis. Although tubulin-inhibiting drugs and their antiangiogenic properties have been investigated for a long time, surprisingly little is known about their underlying mechanisms of action. Antiangiogenic effects of spongistatin 1 were investigated in endothelial cells in vitro, including functional cell-based assays, live-cell imaging, and a kinome array, and in the mouse cornea pocket assay in vivo. Spongistatin 1 inhibited angiogenesis at nanomolar concentrations (IC50: cytotoxicity > 50 nM, proliferation 100 pM, migration 1.0 nM, tube formation 1.0 nM, chemotaxis 1.0 nM, aortic ring sprouting 500 pM, neovascularization in vivo 10 mu g/kg). Further, a kinome array and validating data showed that spongistatin 1 inhibits the phosphorylation activity of protein kinase C alpha (PKC alpha), an essential kinase in angiogenesis, and its translocation to the membrane. Thus, we conclude that PKC alpha might be an important target for the antiangiogenic effects of tubulin antagonism. In addition, the data from the kinase array suggest that different tubulin antagonists might have individual intracellular actions.-Rothmeier, A. S., Ischenko, I., Joore, J., Garczarczyk, D., Furst, R., Bruns, C. J., Vollmar, A. M., Zahler, S. Investigation of the marine compound spongistatin 1 links the inhibition of PKC alpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J. 23, 1127-1137 (2009)	[Rothmeier, Andrea S.; Fuerst, Robert; Vollmar, Angelika M.; Zahler, Stefan] Univ Munich, Dept Pharm, Ctr Drug Res, D-81377 Munich, Germany; [Ischenko, Ivan; Bruns, Christiane J.] Univ Munich, Dept Surg, Klinikum Grosshadern, D-81377 Munich, Germany; [Joore, Jos] Pepscan Syst BV, Lelystad, Netherlands; [Garczarczyk, Dorota] Innsbruck Med Univ, Div Med Biochem, Innsbruck, Austria	University of Munich; University of Munich; Pepscan Therapeutics B.V.; Medical University of Innsbruck	Zahler, S (corresponding author), Univ Munich, Dept Pharm, Ctr Drug Res, Butenandtstr 5-13, D-81377 Munich, Germany.	stefan.zahler@cup.uni-muenchen.de	Fuerst, Robert/B-5815-2011; Ischenko, Ivan/A-4591-2011	Zahler, Stefan/0000-0002-5140-7287; Furst, Robert/0000-0002-9926-7578; Joore, Jos/0000-0002-2744-4862	European Community [LSHB-CT-2004-503467]	European Community(European Commission)	This work has been partially supported by the European Community (FP6-2002-Life Science & Health, Prokinase Research Project, project no. LSHB-CT-2004-503467).	Attard G, 2006, PATHOL BIOL, V54, P72, DOI 10.1016/j.patbio.2005.03.003; BAI RL, 1995, BIOCHEMISTRY-US, V34, P9714, DOI 10.1021/bi00030a009; BAI RL, 1993, MOL PHARMACOL, V44, P757; Battistella-Patterson AS, 2000, ACTA PHYSIOL SCAND, V170, P87, DOI 10.1046/j.1365-201x.2000.00755.x; Bijman MNA, 2006, MOL CANCER THER, V5, P2348, DOI 10.1158/1535-7163.MCT-06-0242; Broxterman HJ, 2005, DRUG RESIST UPDATE, V8, P183, DOI 10.1016/j.drup.2005.07.002; Cai SX, 2007, RECENT PAT ANTI-CANC, V2, P79, DOI 10.2174/157489207779561462; Diks SH, 2004, J BIOL CHEM, V279, P49206, DOI 10.1074/jbc.M405028200; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gliki G, 2002, CELL BIOL INT, V26, P751, DOI 10.1016/S1065-6995(02)90926-1; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; Hinnen P, 2007, BRIT J CANCER, V96, P1159, DOI 10.1038/sj.bjc.6603694; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; KOBAYASHI M, 1993, TETRAHEDRON LETT, V34, P2795, DOI 10.1016/S0040-4039(00)73564-7; Li HG, 1998, MOL PHARMACOL, V53, P630, DOI 10.1124/mol.53.4.630; Meissner M, 2008, J INVEST DERMATOL, V128, P2084, DOI 10.1038/jid.2008.37; Mwanjewe J, 2001, BIOCHEM J, V359, P211, DOI 10.1042/0264-6021:3590211; Nakhost A, 2002, J BIOL CHEM, V277, P40633, DOI 10.1074/jbc.M205099200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Omelchenko T, 2002, P NATL ACAD SCI USA, V99, P10452, DOI 10.1073/pnas.152339899; Pasquier E, 2007, CURR CANCER DRUG TAR, V7, P566, DOI 10.2174/156800907781662266; Pasquier E, 2006, DRUG RESIST UPDATE, V9, P74, DOI 10.1016/j.drup.2006.04.003; PETTIT GR, 1993, J ORG CHEM, V58, P1302, DOI 10.1021/jo00058a004; Rask-Madsen C, 2008, ARTERIOSCL THROM VAS, V28, P919, DOI 10.1161/ATVBAHA.108.162842; Schyschka L, 2008, LEUKEMIA, V22, P1737, DOI 10.1038/leu.2008.146; Siegrist SE, 2007, GENE DEV, V21, P483, DOI 10.1101/gad.1511207; Taylor Caroline J., 2006, Angiogenesis, V9, P39, DOI 10.1007/s10456-006-9028-y; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038/nrc1628; UEDA M, 1994, J CELL SCI, V107, P2071; van Baal JWPM, 2006, CANCER RES, V66, P11605, DOI 10.1158/0008-5472.CAN-06-1370; Vincent L, 2005, J CLIN INVEST, V115, P2992, DOI 10.1172/JCI24586; Wang AH, 2002, CIRC RES, V90, P609, DOI 10.1161/01.RES.0000012503.30315.E8; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Xu H, 2008, CARDIOVASC RES, V78, P349, DOI 10.1093/cvr/cvm085	36	28	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1127	1137		10.1096/fj.08-117127	http://dx.doi.org/10.1096/fj.08-117127			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19056838	Green Submitted			2022-12-28	WOS:000266651600016
J	Caiafa, P; Guastafierro, T; Zampieri, M				Caiafa, Paola; Guastafierro, Tiziana; Zampieri, Michele			Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns	FASEB JOURNAL			English	Review						imprinting; CTCF; Dnmt1; CpG islands	INSULATOR PROTEIN CTCF; DNA TOPOISOMERASE-I; QUANTITATIVE-ANALYSIS; CPG ISLANDS; CHROMATIN; BINDING; DOMAINS; CANCER; HYPERMETHYLATION; HYPOMETHYLATION	In the postgenome era, attention is being focused on those epigenetic modifications that modulate chromatin structure to guarantee that information present on DNA is read correctly and at the most appropriate time to meet cellular requirements. Data reviewed show that along the chain of events that induce DNA methylation-dependent chromatin condensation/decondensation, a postsynthetic modification other than histone acetylation, phosphorylation, and methylation-namely poly(ADP-ribosyl)ation (PARylation)-participates in the establishment and maintenance of a genome methylation pattern. We hypothesize that the right nuclear balance between unmodified and PARylated poly(ADP-ribose) polymerase 1 (PARP-1), which depends on the dynamics of PARPs/PARG activity, is key to maintaining genomic methylation pattern. According to our data, decreased or increased levels of PARylated PARP-1 are responsible for diffuse hypermethylation or hypomethylation of DNA, respectively. In our model, polymers present on PARP-1 interact noncovalently with DNA methyltransferase 1 (Dnmt1), preventing its enzymatic activity. In the absence of PARylated PARP-1, Dnmt1 is free to methylate DNA; if, in contrast, high levels of PARylated PARP-1 persist, Dnmt1 will be stably inhibited, preventing DNA methylation.-Caiafa, P., Guastafierro, T., Zampieri, M. Epigenetics: poly(ADP-ribosyl) ation of PARP-1 regulates genomic methylation patterns. FASEB J. 23, 672-678 (2009)	[Caiafa, Paola] Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, Fac Med & Surg 2, I-00161 Rome, Italy; Inst Pasteur, Fdn Cenci Bolognetti, Rome, Italy	Sapienza University Rome; Fondazione Cenci Bolognetti	Caiafa, P (corresponding author), Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, Fac Med & Surg 2, Viale Regina Elena 324, I-00161 Rome, Italy.	caiafa@bce.uniroma1.it	guastafeierro, tiziana/J-8006-2016; Zampieri, Michele/F-7099-2013; Zampieri, Michele/AGF-5460-2022	guastafeierro, tiziana/0000-0001-9433-2759; Zampieri, Michele/0000-0002-6799-2492; Zampieri, Michele/0000-0002-6799-2492	Ministero Italiano dell'Istruzione; dell'Universita e della Ricerca; Ministero Italiano della Salute	Ministero Italiano dell'Istruzione(Ministry of Education, Universities and Research (MIUR)); dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Ministero Italiano della Salute(Ministry of Health, Italy)	This work was supported by Ministero Italiano dell'Istruzione, dell'Universita e della Ricerca, and by Ministero Italiano della Salute.	ALTHAUS FR, 1995, BIOCHIMIE, V77, P423, DOI 10.1016/0300-9084(96)88155-7; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Burkle A, 2006, FREE RADICAL RES, V40, P1295, DOI 10.1080/10715760600915288; Caiafa P, 2005, J CELL BIOCHEM, V94, P257, DOI 10.1002/jcb.20325; Chen TP, 2007, NAT GENET, V39, P391, DOI 10.1038/ng1982; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; De Capoa A, 1999, FASEB J, V13, P89; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fahrer J, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm944; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Guastafierro T, 2008, J BIOL CHEM, V283, P21873, DOI 10.1074/jbc.M801170200; Hassa PO, 2008, FRONT BIOSCI-LANDMRK, V13, P3046, DOI 10.2741/2909; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JUAREZSALINAS H, 1982, J BIOL CHEM, V257, P607; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; Klenova E, 2005, CELL CYCLE, V4, P96, DOI 10.4161/cc.4.1.1398; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Koh DW, 2004, P NATL ACAD SCI USA, V101, P17699, DOI 10.1073/pnas.0406182101; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Malanga M, 2005, BIOCHEM CELL BIOL, V83, P354, DOI 10.1139/o05-038; Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200; Malanga M, 2008, J BIOL CHEM, V283, P19991, DOI 10.1074/jbc.M709495200; Pant V, 2003, GENE DEV, V17, P586, DOI 10.1101/gad.254903; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Reale A, 2005, ONCOGENE, V24, P13, DOI 10.1038/sj.onc.1208005; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Schoenherr CJ, 2003, NAT GENET, V33, P66, DOI 10.1038/ng1057; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Szyf M, 2008, CURR ONCOL, V15, P72; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Wallace JA, 2007, CURR OPIN GENET DEV, V17, P400, DOI 10.1016/j.gde.2007.08.005; Xie XH, 2007, P NATL ACAD SCI USA, V104, P7145, DOI 10.1073/pnas.0701811104; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426; Zardo G, 1999, FASEB J, V13, P1518, DOI 10.1096/fasebj.13.12.1518; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s	50	133	145	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2009	23	3					672	678		10.1096/fj.08-123265	http://dx.doi.org/10.1096/fj.08-123265			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19001527				2022-12-28	WOS:000265506300002
J	Hohensinner, PJ; Kaun, C; Rychli, K; Niessner, A; Pfaffenberger, S; Rega, G; Furnkranz, A; Uhrin, P; Zaujec, J; Afonyushkin, T; Bochkov, VN; Maurer, G; Huber, K; Wojta, J				Hohensinner, P. J.; Kaun, C.; Rychli, K.; Niessner, A.; Pfaffenberger, S.; Rega, G.; Furnkranz, A.; Uhrin, P.; Zaujec, J.; Afonyushkin, T.; Bochkov, V. N.; Maurer, G.; Huber, K.; Wojta, J.			The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells	FASEB JOURNAL			English	Article						cytokine; heart	ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; MYOCARDIAL-INFARCTION; FACTOR EXPRESSION; TISSUE INHIBITOR; UP-REGULATION; STEM-CELLS; HEART; FIBROBLASTS; MYOCYTES	Stromal derived factor 1 (SDF-1) is a CXC chemokine important in the homing process of stem cells to injured tissue. It has been implicated in healing and tissue repair. Growing evidence suggests that the glycoprotein-130 (gp130) ligand family is involved in repair processes in the heart. The aim of our study was to determine whether gp130 ligands could affect SDF-1 expression in cardiac cells. Human adult cardiac myocytes (HACMs) and fibroblasts (HACFs) were treated with gp130 ligands. Protein and mRNA levels of SDF-1 were determined using ELISA and RT-PCR, respectively. mRNA levels of SDF-1 were determined in human and mouse heart samples by RT-PCR. HACMs and HACFs constitutively express SDF-1, which was significantly up-regulated by the gp130 ligand oncostatin M (OSM). This effect was counteracted by a p38 inhibitor and to a lesser extent by a PI3K inhibitor. mRNA expression of SDF-1 in hearts of mice injected with OSM increased significantly. Levels of OSM and SDF-1 mRNA correlated significantly in human failing hearts. Our data, showing that OSM induces SDF-1 protein secretion in human cardiac cells in vitro and murine hearts in vivo, suggest that OSM via the induction of SDF-1 might play a key role in repair and tissue regeneration.-Hohensinner, P. J., Kaun, C., Rychli, K., Niessner, A., Pfaffenberger, S., Rega, G., Furnkranz, A., Uhrin, P., Zaujec, J., Afonyushkin, T., Bochkov, V. N., Maurer, G., Huber, K., Wojta, J. The inflammatory mediator oncostatin M induces stromal derived factor-1 in human adult cardiac cells. FASEB J. 23, 774-782 (2009)	[Hohensinner, P. J.; Kaun, C.; Rychli, K.; Niessner, A.; Pfaffenberger, S.; Rega, G.; Maurer, G.; Wojta, J.] Med Univ Vienna, Dept Internal Med 2, Vienna, Austria; [Uhrin, P.; Zaujec, J.; Afonyushkin, T.; Bochkov, V. N.] Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, Vienna, Austria; [Hohensinner, P. J.; Wojta, J.] Ludwig Boltzmann Cluster Cardiovasc Res, Vienna, Austria; [Furnkranz, A.; Huber, K.] Wilhelminenhosp, Dept Med 3, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Ludwig Boltzmann Institute; Wilhelminenspital	Wojta, J (corresponding author), Med Univ Vienna, Dept Internal Med 2, Waehringer Guertel 18-20, Vienna, Austria.	johann.wojta@meduniwien.ac.at	Kaun, Christoph/L-7543-2015; Wojta, Johann/AAC-8433-2020	Kaun, Christoph/0000-0003-3873-7246; Wojta, Johann/0000-0002-1282-9276; Maurer, Gerald/0000-0002-9043-7657; Kober-Rychli, Kathrin/0000-0001-6147-577X; Hohensinner, Philipp/0000-0003-4819-3190; Rega-Kaun, Gersina/0000-0002-3110-481X; Uhrin, Pavel/0000-0002-9792-3420	Fund for the Promotion of Scientific Research [S9409-B11]; Association for the Promotion of Research in Arteriosclerosis, Thrombosis, and Vascular Biology; Austrian Cardiologic Society	Fund for the Promotion of Scientific Research(Austrian Science Fund (FWF)); Association for the Promotion of Research in Arteriosclerosis, Thrombosis, and Vascular Biology; Austrian Cardiologic Society	This work was supported by the Fund for the Promotion of Scientific Research ( grant S9409-B11) and by the Association for the Promotion of Research in Arteriosclerosis, Thrombosis, and Vascular Biology. P.J.H. received a scholarship from the Austrian Cardiologic Society.	Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Amin MA, 2007, ARTHRITIS RHEUM-US, V56, P1787, DOI 10.1002/art.22705; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Brar BK, 2001, CYTOKINE, V16, P93, DOI 10.1006/cyto.2001.0951; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Cohen EBT, 2007, BIOCHEM PHARMACOL, V73, P77, DOI 10.1016/j.bcp.2006.09.007; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Demyanets S, 2006, THROMB HAEMOSTASIS, V95, P107, DOI 10.1160/TH05-05-0333; Demyanets S, 2007, AM J PHYSIOL-HEART C, V293, pH1962, DOI 10.1152/ajpheart.01366.2006; Ebelt H, 2007, STEM CELLS, V25, P236, DOI 10.1634/stemcells.2006-0374; Elmadbouh I, 2007, J MOL CELL CARDIOL, V42, P792, DOI 10.1016/j.yjmcc.2007.02.001; Fedyk ER, 2001, J IMMUNOL, V166, P5749, DOI 10.4049/jimmunol.166.9.5749; Fischer P, 2007, BASIC RES CARDIOL, V102, P279, DOI 10.1007/s00395-007-0658-z; Freed DH, 2003, MOL CELL BIOCHEM, V254, P247, DOI 10.1023/A:1027332504861; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Guan K, 2007, J MOL CELL CARDIOL, V43, P377, DOI 10.1016/j.yjmcc.2007.07.056; Gwechenberger M, 1999, CIRCULATION, V99, P546, DOI 10.1161/01.CIR.99.4.546; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hitchon C, 2002, ARTHRITIS RHEUM, V46, P2587, DOI 10.1002/art.10520; Hohensinner PJ, 2007, J THROMB HAEMOST, V5, P2520, DOI 10.1111/j.1538-7836.2007.02784.x; Hu XF, 2007, CIRCULATION, V116, P654, DOI 10.1161/CIRCULATIONAHA.106.672451; Kim KW, 2007, ARTHRITIS RHEUM-US, V56, P1076, DOI 10.1002/art.22439; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Lafontant PJ, 2006, AM J PHYSIOL-CELL PH, V291, pC18, DOI 10.1152/ajpcell.00322.2005; Lee MJ, 2007, INT J BIOCHEM CELL B, V39, P650, DOI 10.1016/j.biocel.2006.11.003; Leone AM, 2006, INT J CARDIOL, V111, P202, DOI 10.1016/j.ijcard.2005.06.043; Ma N, 2005, CARDIOVASC RES, V66, P45, DOI 10.1016/j.cardiores.2004.12.013; Macfelda K, 2002, J MOL CELL CARDIOL, V34, P1681, DOI 10.1006/jmcc.2002.2117; Minehata K, 2006, INT J HEMATOL, V84, P319, DOI 10.1532/IJH97.06090; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Ono K, 1998, CIRCULATION, V98, P149, DOI 10.1161/01.CIR.98.2.149; Pillarisetti K, 2001, INFLAMMATION, V25, P293, DOI 10.1023/A:1012808525370; Salvucci O, 2004, J LEUKOCYTE BIOL, V76, P217, DOI 10.1189/jlb.1203609; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Segret A, 2007, J HISTOCHEM CYTOCHEM, V55, P141, DOI 10.1369/jhc.6A7050.2006; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Sohara N, 2002, J HEPATOL, V36, P191, DOI 10.1016/S0168-8278(01)00265-3; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; Vandervelde S, 2005, J MOL CELL CARDIOL, V39, P363, DOI 10.1016/j.yjmcc.2005.05.012; Wang F, 2002, J MOL CELL CARDIOL, V34, P1309, DOI 10.1006/jmcc.2002.2059; Weiss TW, 2005, J MOL CELL CARDIOL, V39, P545, DOI 10.1016/j.yjmcc.2005.03.015; Weiss TW, 2004, J MOL CELL CARDIOL, V36, P539, DOI 10.1016/j.yjmcc.2004.02.001; Weiss TW, 2003, CARDIOVASC RES, V59, P628, DOI 10.1016/S0008-6363(03)00463-2; Yamani MH, 2005, J AM COLL CARDIOL, V46, P1029, DOI 10.1016/j.jacc.2005.04.059; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250; Zhang M, 2007, FASEB J, V21, P3197, DOI 10.1096/fj.06-6558com	51	28	29	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					774	782		10.1096/fj.08-108035	http://dx.doi.org/10.1096/fj.08-108035			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19019853				2022-12-28	WOS:000265506300013
J	Ogunniyi, AD; Grabowicz, M; Mahdi, LK; Cook, J; Gordon, DL; Sadlon, TA; Paton, JC				Ogunniyi, Abiodun D.; Grabowicz, Marcin; Mahdi, Layla K.; Cook, Jan; Gordon, David L.; Sadlon, Tania A.; Paton, James C.			Pneumococcal histidine triad proteins are regulated by the Zn2+-dependent repressor AdcR and inhibit complement deposition through the recruitment of complement factor H	FASEB JOURNAL			English	Article						Streptococcus pneumoniae; virulence; gene expression; innate immunity; protein vaccines	STREPTOCOCCUS-PNEUMONIAE INFECTION; VIRULENCE PROTEINS; SURFACE PROTEIN; GENE-EXPRESSION; ZINC; PROTECTION; MICE; DISEASE; VACCINE; FAMILY	The pneumococcal histidine triad (Pht) proteins are a recently recognized family of surface proteins, comprising 4 members: PhtA, PhtB, PhtD, and PhtE. They are being promoted for inclusion in a multicomponent pneumococcal protein vaccine currently under development, but to date, their biological functions and their relative contributions to pathogenesis have not been clarified. In this study, the involvement of these proteins in pneumococcal virulence was investigated in murine models of sepsis and pneumonia by using defined, nonpolar mutants of the respective genes in Streptococcus pneumoniae D39. In either challenge model, mutagenesis of all 4 genes was required to completely abolish virulence relative to the wild-type, suggesting significant functional redundancy among Pht proteins. The in vivo expression of pht genes was significantly up-regulated in the nasopharynx and lungs compared with blood. We provide unequivocal molecular evidence for Zn2+-dependent, AdcR-mediated, regulation of pht gene expression by real-time reverse transcriptase-polymerase chain reaction, Western blotting, and electrophoretic mobility-shift assays. We also present the first direct evidence for the biological function of this protein family by demonstrating that Pht proteins are required for inhibition of complement deposition on the pneumococcal surface through the recruitment of complement factor H.-Ogunniyi, A. D., Grabowicz, M., Mahdi, L. K., Cook, J., Gordon, D. L., Sadlon, T. A., Paton, J. C. Pneumococcal histidine triad proteins are regulated by the Zn2+-dependent repressor AdcR and inhibit complement deposition through the recruitment of complement factor H. FASEB J. 23, 731-738 (2009)	[Ogunniyi, Abiodun D.; Grabowicz, Marcin; Mahdi, Layla K.; Cook, Jan; Paton, James C.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia; [Gordon, David L.; Sadlon, Tania A.] Flinders Med Ctr, Dept Microbiol, Adelaide, SA, Australia; [Gordon, David L.; Sadlon, Tania A.] Flinders Med Ctr, Dept Infect Dis, Adelaide, SA, Australia; [Gordon, David L.; Sadlon, Tania A.] Flinders Univ S Australia, Adelaide, SA, Australia	University of Adelaide; Flinders Medical Centre; Flinders Medical Centre; Flinders University South Australia	Paton, JC (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	james.paton@adelaide.edu.au	Paton, James C/A-9920-2008; Johnson, Michael D. L./B-4352-2012	Mahdi, Layla/0000-0002-5878-8385; Grabowicz, Marcin/0000-0001-8000-2222; Gordon, David/0000-0003-3276-9685; Ogunniyi, Abiodun/0000-0001-9308-5629	National Health and Medical Research Council of Australia (NHMRC) [284214]	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	We thank U. Stroeher and L. Purins for assistance with EMSA, H. Wang for assistance with flow cytometry, U. Talbot for assistance with purification of PhtA and PhtD, G. Bull for assistance with atomic absorption spectroscopy, L. Dent for helpful discussions, and Mohamed Daha (Leiden University Medical Centre, Leiden, The Netherlands) for generously supplying rabbit anti-mouse C3 antibody. This work was supported by the National Health and Medical Research Council of Australia (NHMRC) Program, grant 284214. J.C.P. is an NHMRC Australia Fellow. The authors have declared that no competing interests exist.	Adamou JE, 2001, INFECT IMMUN, V69, P949, DOI 10.1128/IAI.69.2.949-958.2001; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Berry AM, 2000, INFECT IMMUN, V68, P133, DOI 10.1128/IAI.68.1.133-140.2000; Brenot A, 2007, MOL MICROBIOL, V63, P1185, DOI 10.1111/j.1365-2958.2006.05577.x; BROWN EJ, 1983, REV INFECT DIS, V5, pS797; Brown JS, 2002, P NATL ACAD SCI USA, V99, P16969, DOI 10.1073/pnas.012669199; BROWN MGM, 1979, FEMS MICROBIOL LETT, V5, P219; BUNKER VW, 1984, AM J CLIN NUTR, V40, P1096, DOI 10.1093/ajcn/40.5.1096; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; Cognet I, 2003, J IMMUNOL METHODS, V272, P199, DOI 10.1016/S0022-1759(02)00506-9; Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001; Dintilhac A, 1997, RES MICROBIOL, V148, P119, DOI 10.1016/S0923-2508(97)87643-7; Dintilhac A, 1997, MOL MICROBIOL, V25, P727, DOI 10.1046/j.1365-2958.1997.5111879.x; Duthy TG, 2002, INFECT IMMUN, V70, P5604, DOI 10.1128/IAI.70.10.5604-5611.2002; Giammarinaro P, 2002, INFECT IMMUN, V70, P5454, DOI 10.1128/IAI.70.10.5454-5461.2002; Hamel J, 2004, INFECT IMMUN, V72, P2659, DOI 10.1128/IAI.72.5.2659-2670.2004; Harlyk C, 1997, J TRACE ELEM MED BIO, V11, P137, DOI 10.1016/S0946-672X(97)80040-5; Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.03106.x; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; Hostetter MK, 1999, MICROB DRUG RESIST, V5, P85, DOI 10.1089/mdr.1999.5.85; Kloosterman TG, 2007, MOL MICROBIOL, V65, P1049, DOI 10.1111/j.1365-2958.2007.05849.x; LACKS S, 1960, BIOCHIM BIOPHYS ACTA, V39, P508, DOI 10.1016/0006-3002(60)90205-5; LeMessurier KS, 2006, MICROBIOL-SGM, V152, P305, DOI 10.1099/mic.0.28438-0; Li J, 2007, INFECT IMMUN, V75, P5877, DOI 10.1128/IAI.00839-07; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lynch JP, 2005, SEMIN RESP CRIT CARE, V26, P575, DOI 10.1055/s-2005-925524; Lysenko ES, 2005, PLOS PATHOG, V1, P3, DOI 10.1371/journal.ppat.0010001; Mahdi LK, 2008, INFECT IMMUN, V76, P646, DOI 10.1128/IAI.01161-07; McAllister LJ, 2004, MOL MICROBIOL, V53, P889, DOI 10.1111/j.1365-2958.2004.04164.x; McGeer A, 2003, NAT MED, V9, P390, DOI 10.1038/nm0403-390; Morona JK, 2004, J INFECT DIS, V189, P1905, DOI 10.1086/383352; Ogunniyi AD, 2007, INFECT IMMUN, V75, P350, DOI 10.1128/IAI.01103-06; Ogunniyi AD, 2000, INFECT IMMUN, V68, P3028, DOI 10.1128/IAI.68.5.3028-3033.2000; Ogunniyi AD, 2001, INFECT IMMUN, V69, P5997, DOI 10.1128/IAI.69.10.5997-6003.2001; Panina EM, 2003, P NATL ACAD SCI USA, V100, P9912, DOI 10.1073/pnas.1733691100; Paton JC, 2004, PNEUMOCCOCUS, P382; Paton JC, 1998, TRENDS MICROBIOL, V6, P85, DOI 10.1016/S0966-842X(98)01220-7; Riboldi-Tunnicliffe A, 2005, FEBS LETT, V579, P5353, DOI 10.1016/j.febslet.2005.08.066; Standish AJ, 2005, P NATL ACAD SCI USA, V102, P7701, DOI 10.1073/pnas.0409377102; VERSIECK J, 1985, CRC CR REV CL LAB SC, V22, P97, DOI 10.3109/10408368509165788; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; Wizemann TM, 2001, INFECT IMMUN, V69, P1593, DOI 10.1128/IAI.69.3.1593-1598.2001; Zhang Y, 2001, INFECT IMMUN, V69, P3827, DOI 10.1128/IAI.69.6.3827-3836.2001	44	94	100	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					731	738		10.1096/fj.08-119537	http://dx.doi.org/10.1096/fj.08-119537			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18971260				2022-12-28	WOS:000265506300009
J	Abramowitz, J; Birnbaumer, L				Abramowitz, Joel; Birnbaumer, Lutz			Physiology and pathophysiology of canonical transient receptor potential channels	FASEB JOURNAL			English	Review						calcium; cardiovascular system; epithelium; lung; neuron	CAPACITATIVE CA2+ ENTRY; ARTERIAL SMOOTH-MUSCLE; METABOTROPIC GLUTAMATE RECEPTORS; CA2+-PERMEABLE CATION CHANNEL; INTESTINAL EPITHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM-INDUCED DIFFERENTIATION; GLOMERULAR MESANGIAL CELLS; CHRONIC LITHIUM TREATMENT	The existence of a mammalian family of TRPC ion channels, direct homologues of TRP, the visual transduction channel of flies, was discovered during 1995-1996 as a consequence of research into the mechanism by which the stimulation of the receptor-Gq-phospholipase C beta signaling pathway leads to sustained increases in intracellular calcium. Mammalian TRPs, TRPCs, turned out to be nonselective, calcium-permeable cation channels, which cause both a collapse of the cell's membrane potential and entry of calcium. The family comprises 7 members and is widely expressed. Many cells and tissues express between 3 and 4 of the 7 TRPCs. Despite their recent discovery, a wealth of information has accumulated, showing that TRPCs have widespread roles in almost all cells studied, including cells from excitable and nonexcitable tissues, such as the nervous and cardiovascular systems, the kidney and the liver, and cells from endothelia, epithelia, and the bone marrow compartment. Disruption of TRPC function is at the root of some familial diseases. More often, TRPCs are contributing risk factors in complex diseases. The present article reviews what has been uncovered about physiological roles of mammalian TRPC channels since the time of their discovery. This analysis reveals TRPCs as major and unsuspected gates of Ca2+ entry that contribute, depending on context, to activation of transcription factors, apoptosis, vascular contractility, platelet activation, and cardiac hypertrophy, as well as to normal and abnormal cell proliferation. TRPCs emerge as targets for a thus far nonexistent field of pharmacological intervention that may ameliorate complex diseases. - Abramowitz, J., Birnbaumer, L. Physiology and pathophysiology of canonical transient receptor potential channels. FASEB J. 23, 297 - 328 ( 2009)	[Abramowitz, Joel; Birnbaumer, Lutz] NIEHS, Transmembrane Signaling Grp, Neurobiol Lab, NIH,Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Abramowitz, J (corresponding author), NIEHS, Transmembrane Signaling Grp, Neurobiol Lab, NIH,Dept Hlth & Human Serv, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	abramow1@niehs.nih.gov; birnbau1@niehs.nih.gov	Abramowitz, Joel/A-2620-2015		Intramural Research Program of the NIH, National Institute of Environmental Health Sciences [Z01 ES101684]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101684, ZIGES101684] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (project Z01 ES101684).	Abramowitz J., 2007, V179, P379; Adachi N, 2008, J BIOL CHEM, V283, P19854, DOI 10.1074/jbc.M801492200; Ahmmed GU, 2005, PFLUG ARCH EUR J PHY, V451, P131, DOI 10.1007/s00424-005-1461-z; Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200; Albert AP, 2006, J PHYSIOL-LONDON, V571, P361, DOI 10.1113/jphysiol.2005.102780; Amaral MD, 2007, J NEUROPHYSIOL, V98, P2476, DOI 10.1152/jn.00797.2007; Amaral MD, 2007, J NEUROSCI, V27, P5179, DOI 10.1523/JNEUROSCI.5499-06.2007; AMRANI Y, 1995, BRIT J PHARMACOL, V114, P4, DOI 10.1111/j.1476-5381.1995.tb14896.x; Andreopoulos S, 2004, PHARMACOGENOMICS J, V4, P365, DOI 10.1038/sj.tpj.6500266; Antoniotti S, 2002, FEBS LETT, V510, P189, DOI 10.1016/S0014-5793(01)03256-2; Atherton JF, 2005, J NEUROSCI, V25, P8272, DOI 10.1523/JNEUROSCI.1475-05.2005; Babich LG, 2004, BIOL REPROD, V70, P919, DOI 10.1095/biolreprod.103.023325; Babu KS, 2004, IMMUNOL ALLERGY CLIN, V24, P583, DOI 10.1016/j.iac.2004.06.010; Bae YM, 2007, J HYPERTENS, V25, P809, DOI 10.1097/HJH.0b013e3280148312; Baldi C, 2003, J CELL BIOCHEM, V90, P197, DOI 10.1002/jcb.10612; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Basora N, 2003, J BIOL CHEM, V278, P31709, DOI 10.1074/jbc.M304437200; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; Beck B, 2008, CELL CALCIUM, V43, P492, DOI 10.1016/j.ceca.2007.08.005; Beech D. J., 2007, V179, P109; Beech DJ, 2003, CELL CALCIUM, V33, P433, DOI 10.1016/S0143-4160(03)00054-X; Berg AP, 2007, J NEUROSCI, V27, P8845, DOI 10.1523/JNEUROSCI.0551-07.2007; Bergdahl A, 2005, AM J PHYSIOL-CELL PH, V288, pC872, DOI 10.1152/ajpcell.00334.2004; Bergdahl A, 2003, CIRC RES, V93, P839, DOI 10.1161/01.RES.0000100367.45446.A3; Beskina O, 2007, AM J PHYSIOL-CELL PH, V293, pC1103, DOI 10.1152/ajpcell.00249.2007; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Bird IM, 2003, AM J PHYSIOL-REG I, V284, pR245, DOI 10.1152/ajpregu.00108.2002; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BIRNBAUMER L, 2009, ANN REV PHA IN PRESS; Birnbaumer L, 2006, RES PERSPECT END INT, P1, DOI 10.1007/3-540-34447-0_1; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; Bollimuntha S, 2005, J BIOL CHEM, V280, P2132, DOI 10.1074/jbc.M407384200; Bollimuntha S, 2006, BRAIN RES, V1099, P141, DOI 10.1016/j.brainres.2006.04.104; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Brann JH, 2006, J EXP BIOL, V209, P1914, DOI 10.1242/jeb.02206; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Brown RD, 2005, ANNU REV PHARMACOL, V45, P657, DOI 10.1146/annurev.pharmtox.45.120403.095802; BURGE SM, 1992, J AM ACAD DERMATOL, V27, P40, DOI 10.1016/0190-9622(92)70154-8; Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817; Bush EW, 2006, J BIOL CHEM, V281, P33487, DOI 10.1074/jbc.M605536200; Cai SW, 2006, PFLUG ARCH EUR J PHY, V452, P43, DOI 10.1007/s00424-005-0001-1; Cai SW, 2005, J DERMATOL SCI, V40, P21, DOI 10.1016/j.jdermsci.2005.06.005; Caraveo G, 2006, SCIENCE, V314, P122, DOI 10.1126/science.1127815; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Chaudhuri P, 2003, ARTERIOSCL THROM VAS, V23, P218, DOI 10.1161/01.ATV.0000052673.77316.01; Chaudhuri P, 2008, MOL BIOL CELL, V19, P3203, DOI 10.1091/mbc.E07-08-0765; Chen DH, 2003, AM J HUM GENET, V72, P839, DOI 10.1086/373883; Chen JL, 2003, BIOCHEM J, V373, P327, DOI 10.1042/BJ20021904; Cheng HW, 2006, ARTERIOSCL THROM VAS, V26, P1768, DOI 10.1161/01.ATV.0000231518.86795.0f; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; Cioffi DL, 2005, CIRC RES, V97, P1164, DOI 10.1161/01.RES.0000193597.65217.00; Dalrymple A, 2007, MOL HUM REPROD, V13, P171, DOI 10.1093/molehr/gal110; Dalrymple A, 2004, J CLIN ENDOCR METAB, V89, P1291, DOI 10.1210/jc.2003-031428; Dalrymple A, 2002, MOL HUM REPROD, V8, P946, DOI 10.1093/molehr/8.10.946; Daskalakis N, 2006, CELL MOL LIFE SCI, V63, P2506, DOI 10.1007/s00018-006-6171-y; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005; Dietrich A, 2007, PFLUG ARCH EUR J PHY, V455, P465, DOI 10.1007/s00424-007-0314-3; Du J, 2007, J AM SOC NEPHROL, V18, P1437, DOI 10.1681/ASN.2006091067; Dulac C, 2007, CURR OPIN NEUROBIOL, V17, P675, DOI 10.1016/j.conb.2008.01.009; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V270, pF623, DOI 10.1152/ajprenal.1996.270.4.F623; El Boustany C, 2008, HEPATOLOGY, V47, P2068, DOI 10.1002/hep.22263; Elg S, 2007, J COMP NEUROL, V503, P35, DOI 10.1002/cne.21351; Epperson A, 2000, AM J PHYSIOL-CELL PH, V279, pC529, DOI 10.1152/ajpcell.2000.279.2.C529; Estacion M, 2006, J PHYSIOL-LONDON, V572, P359, DOI 10.1113/jphysiol.2005.103143; Estacion M, 2004, J BIOL CHEM, V279, P22047, DOI 10.1074/jbc.M402320200; Everett KV, 2008, AM J HUM GENET, V82, P756, DOI 10.1016/j.ajhg.2007.12.023; Faber ESL, 2006, NEUROSCIENCE, V137, P781, DOI 10.1016/j.neuroscience.2005.09.027; Fabian A, 2008, PFLUG ARCH EUR J PHY, V457, P475, DOI 10.1007/s00424-008-0515-4; Fang Y, 2000, NEUROCHEM RES, V25, P931, DOI 10.1023/A:1007596223484; Fang Y, 2002, J NEUROSCI RES, V69, P669, DOI 10.1002/jnr.10333; Fantozzi I, 2003, AM J PHYSIOL-LUNG C, V285, pL1233, DOI 10.1152/ajplung.00445.2002; Fauconnier J, 2007, CARDIOVASC RES, V73, P376, DOI 10.1016/j.cardiores.2006.10.018; Fegley AJ, 2003, J SURG RES, V113, P32, DOI 10.1016/S0022-4804(03)00120-3; Ferroni P, 2004, J THROMB HAEMOST, V2, P1282, DOI 10.1111/j.1538-7836.2004.00836.x; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Fleming I, 2007, ARTERIOSCL THROM VAS, V27, P2612, DOI 10.1161/ATVBAHA.107.152074; Flemming PK, 2006, J BIOL CHEM, V281, P4977, DOI 10.1074/jbc.M510301200; FLOCKERZI V, 2007, TRANSIENT RECEPTOR P; Foller M, 2008, CELL PHYSIOL BIOCHEM, V21, P183, DOI 10.1159/000113760; Foller M, 2006, CELL PHYSIOL BIOCHEM, V17, P201, DOI 10.1159/000094125; FOREMAN JC, 1977, J PHYSIOL-LONDON, V271, P233, DOI 10.1113/jphysiol.1977.sp011998; Fowler MA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000573; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Fujii T, 2005, J BIOL CHEM, V280, P23041, DOI 10.1074/jbc.M409397200; Gervasio OL, 2008, J CELL SCI, V121, P2246, DOI 10.1242/jcs.032003; Gifford SM, 2006, J ENDOCRINOL, V190, P385, DOI 10.1677/joe.1.06773; Gifford SM, 2006, J ENDOCRINOL, V190, P373, DOI 10.1677/joe.1.06635; Goel M, 2007, AM J PHYSIOL-RENAL, V293, pF1476, DOI 10.1152/ajprenal.00186.2007; Golovina VA, 2001, AM J PHYSIOL-HEART C, V280, pH746, DOI 10.1152/ajpheart.2001.280.2.H746; Gottlieb P, 2008, PFLUG ARCH EUR J PHY, V455, P1097, DOI 10.1007/s00424-007-0359-3; Graham S, 2007, AM J PHYSIOL-RENAL, V293, pF1381, DOI 10.1152/ajprenal.00185.2007; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Guilbert A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-125; Hartmann J, 2008, NEURON, V59, P392, DOI 10.1016/j.neuron.2008.06.009; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hough C, 1999, BIOL PSYCHIAT, V46, P247, DOI 10.1016/S0006-3223(98)00308-4; Huber TB, 2006, P NATL ACAD SCI USA, V103, P17079, DOI 10.1073/pnas.0607465103; Hui H, 2006, J PHYSIOL-LONDON, V572, P165, DOI 10.1113/jphysiol.2005.102889; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Jia YC, 2007, NAT NEUROSCI, V10, P559, DOI 10.1038/nn1870; Jung C, 2008, CARDIOVASC RES, V77, P766, DOI 10.1093/cvr/cvm089; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kang PM, 2003, TRENDS MOL MED, V9, P177, DOI 10.1016/S1471-4914(03)00025-X; Kanki H, 2001, MOL PHARMACOL, V60, P989, DOI 10.1124/mol.60.5.989; Kaplan J, 2002, CELL, V111, P603, DOI 10.1016/S0092-8674(02)01164-9; Kawasaki BT, 2006, P NATL ACAD SCI USA, V103, P335, DOI 10.1073/pnas.0508030102; Kim JH, 2006, J BIOL CHEM, V281, P26144, DOI 10.1074/jbc.M603636200; Kim SJ, 2003, NATURE, V426, P285, DOI 10.1038/nature02162; Kimchi T, 2007, NATURE, V448, P1009, DOI 10.1038/nature06089; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Koyama T, 2002, LIFE SCI, V72, P511, DOI 10.1016/S0024-3205(02)02246-4; Kumar B, 2006, CIRC RES, V98, P557, DOI 10.1161/01.RES.0000204724.29685.db; Kunichika N, 2004, AM J RESP CRIT CARE, V170, P1101, DOI 10.1164/rccm.200312-1668OC; Kunichika N, 2004, AM J PHYSIOL-LUNG C, V287, pL962, DOI 10.1152/ajplung.00452.2003; Kunzelmann-Marche C, 2002, J BIOL CHEM, V277, P19876, DOI 10.1074/jbc.M200324200; Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702; Lang F, 2006, ANTIOXID REDOX SIGN, V8, P1183, DOI 10.1089/ars.2006.8.1183; Larsson KP, 2005, J BIOL CHEM, V280, P1771, DOI 10.1074/jbc.M406073200; Lee EH, 2006, J BIOL CHEM, V281, P10042, DOI 10.1074/jbc.M600981200; Lee KP, 2005, MOL CELLS, V20, P435; Leuner K, 2007, FASEB J, V21, P4101, DOI 10.1096/fj.07-8110com; Leypold BG, 2002, P NATL ACAD SCI USA, V99, P6376, DOI 10.1073/pnas.082127599; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; LI LW, 1995, J CELL PHYSIOL, V163, P105, DOI 10.1002/jcp.1041630112; Li Y, 2005, NATURE, V434, P894, DOI 10.1038/nature03477; Liao Y, 2008, P NATL ACAD SCI USA, V105, P2895, DOI 10.1073/pnas.0712288105; Liao Y, 2007, P NATL ACAD SCI USA, V104, P4682, DOI 10.1073/pnas.0611692104; Liedtke Wolfgang B., 2007, P303; Lievremont JP, 2005, J BIOL CHEM, V280, P35346, DOI 10.1074/jbc.M507606200; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Liman ER, 2003, P NATL ACAD SCI USA, V100, P3328, DOI 10.1073/pnas.0636123100; Lin MJ, 2004, CIRC RES, V95, P496, DOI 10.1161/01.RES.0000138952.16382.ad; Lindsey SH, 2008, LIFE SCI, V83, P29, DOI 10.1016/j.lfs.2008.04.013; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu CL, 2006, ACTA PHARMACOL SIN, V27, P981, DOI 10.1111/j.1745-7254.2006.00354.x; Liu DY, 2007, AM J HYPERTENS, V20, P1111, DOI 10.1016/j.amjhyper.2007.04.004; Liu DY, 2007, J HYPERTENS, V25, P799, DOI 10.1097/HJH.0b013e32803cae2b; Liu DY, 2006, J HYPERTENS, V24, P1105, DOI 10.1097/01.hjh.0000226201.73065.14; Liu DY, 2008, ARTERIOSCL THROM VAS, V28, P746, DOI 10.1161/ATVBAHA.108.162222; Liu DY, 2005, AM J HYPERTENS, V18, P1503, DOI 10.1016/j.amjhyper.2005.05.033; Liu XB, 2007, P NATL ACAD SCI USA, V104, P17542, DOI 10.1073/pnas.0701254104; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Lopez-Revilla R, 2004, NEUROPATHOLOGY, V24, P30, DOI 10.1111/j.1440-1789.2003.00536.x; Lucas P, 2003, NEURON, V40, P551, DOI 10.1016/S0896-6273(03)00675-5; Ma HT, 2008, J IMMUNOL, V180, P2233, DOI 10.4049/jimmunol.180.4.2233; Malarkey EB, 2008, GLIA, V56, P821, DOI 10.1002/glia.20656; Marasa BS, 2008, AM J PHYSIOL-CELL PH, V294, pC1277, DOI 10.1152/ajpcell.90635.2007; Marasa BS, 2006, BIOCHEM J, V397, P77, DOI 10.1042/BJ20060124; Maric D, 2000, CEREB CORTEX, V10, P561, DOI 10.1093/cercor/10.6.561; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; Maruyama Y, 2006, CIRC RES, V98, P1520, DOI 10.1161/01.RES.0000226495.34949.28; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Menco BPM, 2001, J COMP NEUROL, V438, P468, DOI 10.1002/cne.1329; Merlin LR, 1997, J NEUROPHYSIOL, V78, P539, DOI 10.1152/jn.1997.78.1.539; Moeller CC, 2007, J AM SOC NEPHROL, V18, P29, DOI 10.1681/ASN.2006091010; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Muller WE, 2003, PHARMACOL RES, V47, P101, DOI 10.1016/S1043-6618(02)00266-9; Munsch T, 2003, P NATL ACAD SCI USA, V100, P16065, DOI 10.1073/pnas.2535311100; Mwanjewe J, 2004, BIOCHEM J, V378, P975, DOI 10.1042/BJ20031187; Nagamatsu Y, 2006, J PHARMACOL SCI, V101, P144, DOI 10.1254/jphs.FP0051036; Nakayama H, 2006, FASEB J, V20, P1660, DOI 10.1096/fj.05-5560com; Nasman J, 2006, J NEUROSCI, V26, P10658, DOI 10.1523/JNEUROSCI.2609-06.2006; Niehof M, 2008, DIABETES, V57, P1069, DOI 10.2337/db07-1065; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Nishikawa Masaru, 2007, Japanese Journal of Systematic Entomology, V13, P1; Nodari F, 2008, J NEUROSCI, V28, P6407, DOI 10.1523/JNEUROSCI.1425-08.2008; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Odell AF, 2008, J BIOL CHEM, V283, P4395, DOI 10.1074/jbc.M709729200; Odell AF, 2005, J BIOL CHEM, V280, P37974, DOI 10.1074/jbc.M503646200; Oh EJ, 2003, J NEUROPHYSIOL, V90, P2069, DOI 10.1152/jn.00026.2003; Ohba T, 2007, J MOL CELL CARDIOL, V42, P498, DOI 10.1016/j.yjmcc.2006.10.020; Ohta T, 2004, NEUROSCI LETT, V358, P161, DOI 10.1016/j.neulet.2004.01.028; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Ong HL, 2007, J BIOL CHEM, V282, P9105, DOI 10.1074/jbc.M608942200; Onohara N, 2006, EMBO J, V25, P5305, DOI 10.1038/sj.emboj.7601417; Ordaz B, 2005, J BIOL CHEM, V280, P30788, DOI 10.1074/jbc.M504745200; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Panda S, 2005, SCIENCE, V307, P600, DOI 10.1126/science.1105121; Pani B, 2006, MOL BIOL CELL, V17, P4446, DOI 10.1091/mbc.E06-03-0251; Paria BC, 2004, AM J PHYSIOL-LUNG C, V287, pL1303, DOI 10.1152/ajplung.00240.2004; Paria BC, 2006, J BIOL CHEM, V281, P20715, DOI 10.1074/jbc.M600722200; Peppiatt-Wildman CM, 2007, J PHYSIOL-LONDON, V580, P755, DOI 10.1113/jphysiol.2006.126656; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Philipp S, 2003, J BIOL CHEM, V278, P26629, DOI 10.1074/jbc.M304044200; Pinto YM, 1998, CARDIOVASC RES, V39, P77, DOI 10.1016/S0008-6363(98)00077-7; Pla AF, 2005, J NEUROSCI, V25, P2687, DOI 10.1523/JNEUROSCI.0951-04.2005; Pocock TM, 2004, AM J PHYSIOL-HEART C, V286, pH1015, DOI 10.1152/ajpheart.00826.2003; Poteser M, 2006, J BIOL CHEM, V281, P13588, DOI 10.1074/jbc.M512205200; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Qiu XD, 2005, NATURE, V433, P745, DOI 10.1038/nature03345; Rao JN, 2006, AM J PHYSIOL-GASTR L, V290, pG782, DOI 10.1152/ajpgi.00441.2005; Raptis AE, 2001, EXP CLIN ENDOCR DIAB, V109, pS424, DOI 10.1055/s-2001-18600; Raybould NP, 2007, J PHYSIOL-LONDON, V579, P101, DOI 10.1113/jphysiol.2006.122929; Reading SA, 2005, AM J PHYSIOL-HEART C, V288, pH2055, DOI 10.1152/ajpheart.00861.2004; Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; Rodriguez-Santiago M, 2007, BIOCHEM BIOPH RES CO, V360, P874, DOI 10.1016/j.bbrc.2007.06.150; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Saleh SN, 2006, J PHYSIOL-LONDON, V577, P479, DOI 10.1113/jphysiol.2006.119305; Sanders KM, 1996, GASTROENTEROLOGY, V111, P492, DOI 10.1053/gast.1996.v111.pm8690216; Sandoval R, 2001, AM J PHYSIOL-LUNG C, V280, pL239, DOI 10.1152/ajplung.2001.280.2.L239; Sato Y, 2005, J NEUROSCI, V25, P4889, DOI 10.1523/JNEUROSCI.0679-05.2005; Satoh S, 2007, MOL CELL BIOCHEM, V294, P205, DOI 10.1007/s11010-006-9261-0; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129; Semtner M, 2007, J BIOL CHEM, V282, P33868, DOI 10.1074/jbc.M702577200; Seth M, 2004, P NATL ACAD SCI USA, V101, P16683, DOI 10.1073/pnas.0407537101; Shan D, 2008, AM J PHYSIOL-CELL PH, V294, pC833, DOI 10.1152/ajpcell.00313.2007; SHAPIRO BM, 1985, CURR TOP CELL REGUL, V26, P97; Shim S, 2005, NAT NEUROSCI, V8, P730, DOI 10.1038/nn1459; Shlykov SG, 2003, BIOL REPROD, V69, P647, DOI 10.1095/biolreprod.103.015396; SILEN W, 1985, ANNU REV PHYSIOL, V47, P217; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Singh I, 2007, J BIOL CHEM, V282, P7833, DOI 10.1074/jbc.M608288200; Smyth JT, 2006, J BIOL CHEM, V281, P11712, DOI 10.1074/jbc.M510541200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P16586, DOI 10.1073/pnas.0606894103; Stamboulian S, 2005, DEV BIOL, V286, P326, DOI 10.1016/j.ydbio.2005.08.006; Stankunas K, 1999, COLD SPRING HARB SYM, V64, P505, DOI 10.1101/sqb.1999.64.505; Steinborn A, 1996, J PERINAT MED, V24, P381, DOI 10.1515/jpme.1996.24.4.381; Stenmark KR, 2006, CIRC RES, V99, P675, DOI 10.1161/01.RES.0000243584.45145.3f; Stiber JA, 2008, MOL CELL BIOL, V28, P2637, DOI 10.1128/MCB.01601-07; Stockand JD, 1998, PHYSIOL REV, V78, P723, DOI 10.1152/physrev.1998.78.3.723; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Sutton KA, 2004, DEV BIOL, V274, P426, DOI 10.1016/j.ydbio.2004.07.031; Sweeney M, 2002, AM J PHYSIOL-LUNG C, V283, pL144, DOI 10.1152/ajplung.00412.2001; Tabata H, 2002, BIOCHEM BIOPH RES CO, V298, P398, DOI 10.1016/S0006-291X(02)02455-5; Tai YL, 2008, J CELL SCI, V121, P2301, DOI 10.1242/jcs.026906; Takahashi Y, 2007, ATHEROSCLEROSIS, V195, P287, DOI 10.1016/j.atherosclerosis.2006.12.033; Takamori M, 2008, J NEUROIMMUNOL, V200, P142, DOI 10.1016/j.jneuroim.2008.06.001; Tempia F, 1998, J NEUROPHYSIOL, V80, P520, DOI 10.1152/jn.1998.80.2.520; Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376; Thebault S, 2005, J CELL PHYSIOL, V204, P320, DOI 10.1002/jcp.20301; Thilo F, 2008, ARCH BIOCHEM BIOPHYS, V471, P57, DOI 10.1016/j.abb.2007.12.006; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Tong Q, 2008, J BIOL CHEM, V283, P10385, DOI 10.1074/jbc.M710231200; Torihashi S, 2002, J BIOL CHEM, V277, P19191, DOI 10.1074/jbc.M201728200; Treves S, 2004, J CELL BIOL, V166, P537, DOI 10.1083/jcb.200404079; Tribe RM, 2003, BIOL REPROD, V68, P1842, DOI 10.1095/biolreprod.102.011403; Tseng PH, 2004, BIOCHEMISTRY-US, V43, P11701, DOI 10.1021/bi049349f; Tutdibi O, 1999, J PHYSIOL-LONDON, V515, P859, DOI 10.1111/j.1469-7793.1999.859ab.x; Valenti G, 2005, ENDOCRINOLOGY, V146, P5063, DOI 10.1210/en.2005-0868; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Vandebrouck A, 2007, FASEB J, V21, P608, DOI 10.1096/fj.06-6683com; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Veliceasa D, 2007, FEBS J, V274, P6365, DOI 10.1111/j.1742-4658.2007.06159.x; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Wang GX, 2005, NATURE, V434, P898, DOI 10.1038/nature03478; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Wang J, 2006, CIRC RES, V98, P1528, DOI 10.1161/01.RES.0000227551.68124.98; Wang M, 2007, J NEUROCHEM, V101, P411, DOI 10.1111/j.1471-4159.2006.04377.x; Wasserman MJ, 2004, NEUROPSYCHOPHARMACOL, V29, P759, DOI 10.1038/sj.npp.1300400; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; Weissmann N, 2006, P NATL ACAD SCI USA, V103, P19093, DOI 10.1073/pnas.0606728103; Welsh DG, 2002, CIRC RES, V90, P248, DOI 10.1161/hh0302.105662; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; White TA, 2006, AM J RESP CELL MOL, V35, P243, DOI 10.1165/rcmb.2006-0003OC; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Williams IA, 2007, AM J PHYSIOL-HEART C, V293, pH1969, DOI 10.1152/ajpheart.00489.2007; Williams IA, 2007, AM J PHYSIOL-HEART C, V292, pH846, DOI 10.1152/ajpheart.00688.2006; Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215; Wissenbach U, 1998, FEBS LETT, V429, P61, DOI 10.1016/S0014-5793(98)00561-4; Woo JS, 2008, BIOCHEM J, V411, P399, DOI [10.1042/BJ20071504, 10.1042/bj20071504]; Wray S, 2001, EXP PHYSIOL, V86, P239, DOI 10.1113/eph8602114; Wu D, 2008, J BIOL CHEM, V283, P416, DOI 10.1074/jbc.M703177200; Wu DS, 2007, EXP NEUROL, V204, P66, DOI 10.1016/j.expneurol.2006.09.017; Wu GS, 2007, J NEUROSCI, V27, P7447, DOI 10.1523/JNEUROSCI.4266-06.2007; Wu SW, 2001, J CELL BIOL, V154, P1225, DOI 10.1083/jcb.200106156; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Xi Q, 2008, CIRC RES, V102, P1118, DOI 10.1161/CIRCRESAHA.108.173948; Xie A, 2007, J CEREBR BLOOD F MET, V27, P1692, DOI 10.1038/sj.jcbfm.9600471; Xu SZ, 2008, NATURE, V451, P69, DOI 10.1038/nature06414; Xu SZ, 2006, CIRC RES, V98, P1381, DOI 10.1161/01.RES.0000225284.36490.a2; Yang H, 2005, J BIOL CHEM, V280, P32230, DOI 10.1074/jbc.M504553200; Yang H, 2003, J MEMBRANE BIOL, V194, P47, DOI 10.1007/s00232-003-2025-9; Yang M, 2002, BIOL REPROD, V67, P988, DOI 10.1095/biolreprod.102.004119; Yetik-Anacak G, 2006, VASC PHARMACOL, V45, P268, DOI 10.1016/j.vph.2006.08.002; Yildirim E, 2003, P NATL ACAD SCI USA, V100, P2220, DOI 10.1073/pnas.0438036100; Yildirim E., 2007, V179, P53; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang JZ, 2003, P NATL ACAD SCI USA, V100, P8337, DOI 10.1073/pnas.1331721100; Zhang S, 2004, AM J PHYSIOL-CELL PH, V287, pC1192, DOI 10.1152/ajpcell.00158.2004; Zhang S, 2007, AM J PHYSIOL-LUNG C, V292, pL1202, DOI 10.1152/ajplung.00214.2006; Zhang T, 2001, INFORM RETRIEVAL, V4, P5, DOI 10.1023/A:1011441423217; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhou FW, 2008, J NEUROSCI, V28, P473, DOI 10.1523/JNEUROSCI.3978-07.2008; Zhou J, 2008, NAT NEUROSCI, V11, P741, DOI 10.1038/nn.2127; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; 2007, BIOCH BIOPHYS ACTA, V1772, P805	321	253	268	1	41	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					297	328		10.1096/fj.08-119495	http://dx.doi.org/10.1096/fj.08-119495			32	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18940894	Green Published			2022-12-28	WOS:000262892900004
J	Monahan, TS; Andersen, ND; Martin, MC; Malek, JY; Shrikhande, GV; Pradhan, L; Ferran, C; LoGerfo, FW				Monahan, Thomas S.; Andersen, Nicholas D.; Martin, Michelle C.; Malek, Junaid Y.; Shrikhande, Gautam V.; Pradhan, Leena; Ferran, Christiane; LoGerfo, Frank W.			MARCKS silencing differentially affects human vascular smooth muscle and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein	FASEB JOURNAL			English	Article						bypass graft; RNA interference; small interfering RNA; gene therapy; transfection; protein kinase C	PROTEIN-KINASE-C; BYPASS GRAFTS; ARTERIAL INJURY; ORGAN-CULTURE; GROWTH-FACTOR; RAT AORTA; IN-VITRO; PROLIFERATION; MIGRATION; EXPRESSION	Intimal hyperplasia (IH) limits the patency of all cardiovascular vein bypass grafts. We previously found the myristoylated alanine-rich C kinase substrate (MARCKS), a key protein kinase C (PKC) substrate, to be up-regulated in canine models of IH. Here, we further characterize the role of MARCKS in IH and examine the phenotypic consequences of MARCKS silencing by small interfering RNA (siRNA) transfection in human vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) in vitro and use a rapid 10-min nonviral siRNA transfection technique to determine the effects of MARCKS silencing in human saphenous vein cultured ex vivo. We demonstrate MARCKS silencing attenuates VSMC migration and arrests VSMC proliferation in part through the up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). Conversely, MARCKS silencing had little or no effect on EC migration or proliferation. These phenotypic changes culminated in reduced neointimal formation in cultured human saphenous vein. These data identify MARCKS as a pathogenic contributor to IH and indicate therapeutic MARCKS silencing could selectively suppress the "atherogenic," proliferative phenotype of VSMCs without collateral harm to the endothelium. This approach could be readily translated to the clinic to silence MARCKS in vein bypass grafts prior to implantation.-Monahan, T. S., Andersen, N. D., Martin, M. C., Malek, J. Y., Shrikhande, G. V., Pradhan, L., Ferran, C., LoGerfo, F. W. MARCKS silencing differentially affects human vascular smooth muscle and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein. FASEB J. 23, 557-564 (2009)	[Monahan, Thomas S.; Andersen, Nicholas D.; Martin, Michelle C.; Malek, Junaid Y.; Shrikhande, Gautam V.; Pradhan, Leena; Ferran, Christiane; LoGerfo, Frank W.] Beth Israel Deaconess Med Ctr, Div Vasc Surg, Dept Surg, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center	Andersen, ND (corresponding author), Beth Israel Deaconess Med Ctr, Div Vasc Surg, Dept Surg, 4 Blackfan Cir,HIM Bldg,Rm 131, Boston, MA 02115 USA.	nicholas.andersen@duke.edu		Andersen, Nicholas/0000-0002-0905-1694	National Institutes of Health (NIH) [T32, HL021796, HL086741, HL080130, HL007734]; Howard Hughes Medical Institute; von Liebig Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086741, T32HL007734, R01HL080130, R01HL021796] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); von Liebig Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The authors are grateful to Ian Driscoll, Faramarz Edalat, Monica Jain, and Lena Caron for help with transfection experiments, and Scott Damrauer for careful reading of the manuscript. This work was supported by National Institutes of Health (NIH) T32 Harvard-Longwood Research Training in Vascular Surgery grant HL007734 ( to T. S. M., M. C. M., J.Y.M., and G. V. M.); a Howard Hughes Medical Institute Research Training Fellowship for Medical Students (to N.D.A.); NIH R01 grants HL021796, HL086741 (to C. F., and F. W. L.), and HL080130 (to C. F.); and the von Liebig Foundation (to L. P. and F. W. L.).	Abid MR, 2005, J BIOL CHEM, V280, P29864, DOI 10.1074/jbc.M502149200; Allaire E, 1997, ANN THORAC SURG, V63, P582; Andersen ND, 2007, J AM COLL SURGEONS, V204, P399, DOI 10.1016/j.jamcollsurg.2006.12.029; Andrassy M, 2005, CIRC RES, V96, P476, DOI 10.1161/01.RES.0000156903.37007.d1; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; BOERBOOM LE, 1985, J THORAC CARDIOV SUR, V90, P756; Castro C, 2003, J BIOL CHEM, V278, P4482, DOI 10.1074/jbc.M204716200; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; CLOWES AW, 1983, LAB INVEST, V49, P327; Conte MS, 2007, J VASC SURG, V45, p74A, DOI 10.1016/j.jvs.2007.02.031; DAVIES MG, 1995, EUR J VASC ENDOVASC, V9, P7, DOI 10.1016/S1078-5884(05)80218-7; Disatnik MH, 2004, J CELL SCI, V117, P4469, DOI 10.1242/jcs.01309; Disatnik MH, 2002, J CELL SCI, V115, P2151; Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044; Dulong S, 2004, BIOCHEM J, V382, P1015, DOI 10.1042/BJ20040347; Gallant C, 2005, J CELL SCI, V118, P3595, DOI 10.1242/jcs.02493; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; Hall JL, 2000, CIRC RES, V87, P574, DOI 10.1161/01.RES.87.7.574; Herbert JM, 1996, J BIOL CHEM, V271, P25928; Holderfield MT, 2008, CIRC RES, V102, P637, DOI 10.1161/CIRCRESAHA.107.167171; Hoofnagle MH, 2006, ARTERIOSCL THROM VAS, V26, P2579, DOI 10.1161/01.ATV.0000249623.79871.bc; Itoh H, 2001, AM J PHYSIOL-HEART C, V281, pH359, DOI 10.1152/ajpheart.2001.281.1.H359; Izzard TD, 2002, CARDIOVASC RES, V53, P242, DOI 10.1016/S0008-6363(01)00444-8; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P490, DOI 10.1161/01.ATV.17.3.490; Kalish JA, 2004, J VASC SURG, V39, P645, DOI 10.1016/j.jvs.2003.10.049; Kirkeby S, 2005, J IMMUNOL METHODS, V301, P102, DOI 10.1016/j.jim.2005.04.006; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LOGERFO FW, 1981, SURGERY, V90, P1015; Mann MJ, 1999, LANCET, V354, P1493, DOI 10.1016/S0140-6736(99)09405-2; Mann MJ, 1999, P NATL ACAD SCI USA, V96, P6411, DOI 10.1073/pnas.96.11.6411; Monahan TS, 2007, J VASC SURG, V45, P581, DOI 10.1016/j.jvs.2006.12.016; Porter KE, 1996, EUR J VASC ENDOVASC, V11, P48, DOI 10.1016/S1078-5884(96)80134-1; RAMOS JR, 1976, ANN SURG, V183, P205, DOI 10.1097/00000658-197603000-00001; Raptis AE, 2001, EXP CLIN ENDOCR DIAB, V109, pS424, DOI 10.1055/s-2001-18600; Schonwasser DC, 1996, FEBS LETT, V395, P1; Schwartz SM, 1997, J CLIN INVEST, V100, pS87; SOYOMBO AA, 1995, J THORAC CARDIOV SUR, V109, P2, DOI 10.1016/S0022-5223(95)70415-9; SOYOMBO AA, 1990, AM J PATHOL, V137, P1401; Stegemann JP, 2003, ANN BIOMED ENG, V31, P391, DOI 10.1114/1.1558031; Stone D, 2002, J BIOMED MATER RES, V59, P160, DOI 10.1002/jbm.1229; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; TSOPANOGLOU NE, 1993, J VASC RES, V30, P202, DOI 10.1159/000158995; Tzima E, 2006, CIRC RES, V98, P176, DOI 10.1161/01.RES.0000200162.94463.d7; Willis DJ, 2004, J SURG RES, V120, P27, DOI 10.1016/j.jss.2003.12.014; Zhao Y, 2000, AM J PHYSIOL-CELL PH, V279, pC1611, DOI 10.1152/ajpcell.2000.279.5.C1611	45	24	24	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					557	564		10.1096/fj.08-114173	http://dx.doi.org/10.1096/fj.08-114173			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18940893	Green Published			2022-12-28	WOS:000262892900027
J	Verhoef, LGGC; Heinen, C; Selivanova, A; Halff, EF; Salomons, FA; Dantuma, NP				Verhoef, Lisette G. G. C.; Heinen, Christian; Selivanova, Alexandra; Halff, Els F.; Salomons, Florian A.; Dantuma, Nico P.			Minimal length requirement for proteasomal degradation of ubiquitin-dependent substrates	FASEB JOURNAL			English	Article						ubiquitin fusion degradation; UBB+1; neurodegeneration; conformational diseases; Alzheimer; protein degradation	MUTANT UBIQUITIN; 26S PROTEASOME; AGGREGATE FORMATION; INHIBITION; PROTEINS; ALZHEIMERS; SYSTEM; ACCUMULATION; RAD23; RECOGNITION	An erroneous transcriptional process, known as molecular misreading, gives rise to an alternative transcript of the ubiquitin B (UBB) gene. This transcript encodes the protein UBB+1, which comprises a ubiquitin moiety and a 19-aa C-terminal extension. UBB+1 is found in affected neurons in neurodegenerative diseases and behaves as an atypical ubiquitin fusion degradation (UFD) proteasome substrate that is poorly degraded and impedes the ubiquitin/proteasome system. Here, we show that the limited length of UBB+1 is responsible for its inefficient degradation and inhibitory activity. Designed UFD substrates with an equally short 19-aa or a 20-aa C-terminal extension were also poorly degraded and had a general inhibitory activity on the ubiquitin/proteasome system in two unrelated cell lines. Extending the polypeptide to 25 aa sufficed to convert the protein into an efficiently degraded proteasome substrate that lacked inhibitory activity. A similar length dependency was found for degradation of two UFD substrates in Saccharomyces cerevisiae, which suggests that the mechanisms underlying this length constraint are highly conserved. Extending UBB+1 also converted this protein into an efficient substrate of the proteasome. These observations provide an explanation for the accumulation of UBB+1 in neurodegenerative disorders and offers new insights into the physical constraints determining proteasomal degradation.-Verhoef, L. G. G. C., Heinen, C., Selivanova, A., Halff, E. F., Salomons, F. A., Dantuma, N. P. Minimal length requirement for proteasomal degradation of ubiquitin-dependent substrates. FASEB J. 23, 123-133 (2009)	[Verhoef, Lisette G. G. C.; Heinen, Christian; Halff, Els F.; Salomons, Florian A.; Dantuma, Nico P.] Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; [Selivanova, Alexandra] Karolinska Inst, Dept Neurobiol Hlth Care Sci & Soc, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Dantuma, NP (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, Von Eulers Vag 3, S-17177 Stockholm, Sweden.	nico.dantuma@ki.se	Halff, Els F/M-9110-2015	Halff, Els F/0000-0001-5814-0899; Dantuma, Nico/0000-0002-6090-4170	Swedish Research Council; Swedish Cancer Society; Wallenberg foundation; Hereditary Disease Foundation; Nordic Center of Excellence Neurodegeneration; Marie Curie Research Training Network [MRTN-CT-2004-512585]; Karolinska Institute; Prinses Beatrix Fonds	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Wallenberg foundation(European Commission); Hereditary Disease Foundation; Nordic Center of Excellence Neurodegeneration; Marie Curie Research Training Network(European Commission); Karolinska Institute(Karolinska Institutet); Prinses Beatrix Fonds	We thank Drs. Michael Glickman and Dasha Krutauz for stimulating discussions and critical reading of the manuscript, Dr. J. Neefjes (Netherlands Cancer Institute, Amsterdam) for the CD8 alpha expression plasmid, Dr. F. van Leeuwen (Maastricht University, Maastricht, The Netherlands) for the UBB<SUP>+1</SUP> antibody, and the members of the Dantuma lab for helpful suggestions. The work in the Dantuma lab was supported by the Swedish Research Council, Swedish Cancer Society, the Wallenberg foundation, the Hereditary Disease Foundation, the Nordic Center of Excellence Neurodegeneration, the Marie Curie Research Training Network (MRTN-CT-2004-512585), and the Karolinska Institute. N.P.D. is supported by the Swedish Research Council. E.F.H. received financial support from the Prinses Beatrix Fonds.	Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Dantuma NP, 2002, FEBS LETT, V529, P22, DOI 10.1016/S0014-5793(02)03252-0; de Pril R, 2004, HUM MOL GENET, V13, P1803, DOI 10.1093/hmg/ddh188; De Vrij FMS, 2001, FASEB J, V15, P2680, DOI 10.1096/fj.01-0438com; Finney N, 2003, J BIOL CHEM, V278, P16054, DOI 10.1074/jbc.C300051200; Fischer DF, 2003, FASEB J, V17, P2014, DOI 10.1096/fj.03-0205com; Flick K, 2006, NAT CELL BIOL, V8, P509, DOI 10.1038/ncb1402; Fratta P, 2004, NEUROLOGY, V63, P1114, DOI 10.1212/01.WNL.0000138574.56908.5D; French BA, 2001, EXP MOL PATHOL, V71, P241, DOI 10.1006/exmp.2001.2401; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Heessen S, 2005, MOL CELL, V18, P225, DOI 10.1016/j.molcel.2005.03.015; Hope AD, 2003, J NEUROCHEM, V86, P394, DOI 10.1046/j.1471-4159.2003.01844.x; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lambertson D, 2003, CURR GENET, V42, P199, DOI 10.1007/s00294-002-0350-7; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; Lindsten K, 2002, J CELL BIOL, V157, P417, DOI 10.1083/jcb.200111034; Liu C, 2007, BIOTECHNIQUES, V42, P156, DOI 10.2144/000112389; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Menendez-Benito V, 2005, HUM MOL GENET, V14, P2787, DOI 10.1093/hmg/ddi312; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Shabek N, 2007, BIOCHEM BIOPH RES CO, V363, P425, DOI 10.1016/j.bbrc.2007.08.185; Smith DM, 2005, MOL CELL, V20, P687, DOI 10.1016/j.molcel.2005.10.019; Song S, 2003, MOL CELL, V12, P553, DOI 10.1016/j.molcel.2003.08.005; Stack JH, 2000, NAT BIOTECHNOL, V18, P1298, DOI 10.1038/82422; Takeuchi J, 2007, EMBO J, V26, P123, DOI 10.1038/sj.emboj.7601476; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; van Leeuwen FW, 2006, BIOCHEM SOC T, V34, P738, DOI 10.1042/BST0340738; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Tijn P, 2007, J CELL SCI, V120, P1615, DOI 10.1242/jcs.03438; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Verhoef LGGC, 2002, HUM MOL GENET, V11, P2689, DOI 10.1093/hmg/11.22.2689; Wu SS, 2002, PEDIATR DEVEL PATHOL, V5, P293, DOI 10.1007/s10024-001-0202-3; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	44	40	40	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					123	133		10.1096/fj.08-115055	http://dx.doi.org/10.1096/fj.08-115055			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18796559				2022-12-28	WOS:000262095500015
J	Leveille, F; El Gaamouch, F; Gouix, E; Lecocq, M; Lobner, D; Nicole, O; Buisson, A				Leveille, F.; El Gaamouch, F.; Gouix, E.; Lecocq, M.; Lobner, D.; Nicole, O.; Buisson, A.			Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors	FASEB JOURNAL			English	Article						excitotoxicity; glutamate uptake; memantine; ERK signaling	LONG-TERM POTENTIATION; MOLECULAR-MECHANISMS; CALCIUM; EXCITOTOXICITY; ROLES; NEUROTOXICITY; SUBUNITS; SUBTYPES; DEATH; CA2+	N-methyl-D-aspartate receptors (NMDARs) are critical for synaptic plasticity that underlies learning and memory. But, they have also been described as a common source of neuronal damage during stroke and neurodegenerative diseases. Several studies have suggested that cellular location of NMDARs (synaptic or extrasynaptic) is a key parameter controlling their effect on neuronal viability. The aim of the study was to understand the relation between these two pools of receptors and to determine their implication in both beneficial and/or deleterious events related to NMDAR activation. We demonstrated that selective extrasynaptic NMDAR activation, as well as NMDA bath application, does not activate extracellular signal-regulated kinase (ERK) pathways, but induces mitochondrial membrane potential breakdown and triggers cell body and dendrite damages, whereas synaptic NMDAR activation is innocuous and induces a sustained ERK activation. The functional dichotomy between these two NMDAR pools is tightly controlled by glutamate uptake systems. Finally, we demonstrated that the only clinically approved NMDAR antagonist, memantine, preferentially antagonizes extrasynaptic NMDARs. Together, these results suggest that extrasynaptic NMDAR activation contributes to excitotoxicity and that a selective targeting of the extrasynaptic NMDARs represents a promising therapeutic strategy for brain injuries.	[Leveille, F.; El Gaamouch, F.; Gouix, E.; Lecocq, M.; Nicole, O.; Buisson, A.] Univ Caen, CNRS, UMR 6232, GIP CYCERON,CEA, F-14074 Caen, France; [Lobner, D.] Marquette Univ, Dept Physiol & Neurobiol, Milwaukee, WI 53233 USA	CEA; Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie; Marquette University	Buisson, A (corresponding author), Univ Caen, CNRS, UMR 6232, GIP CYCERON,CEA, Bd Henri Becquerel,BP 5229, F-14074 Caen, France.	buisson@cyceron.fr	Nicole, Olivier/AAZ-2865-2020; buisson, alain/AAI-8218-2020	Nicole, Olivier/0000-0001-9981-1820; buisson, alain/0000-0002-4281-7911	Association France Alzheimer et Maladies Apparentees; Institut Paul Hamel	Association France Alzheimer et Maladies Apparentees; Institut Paul Hamel	This work was supported by grants from the Association France Alzheimer et Maladies Apparentees and the Institut Paul Hamel.	Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; Bengtson CP, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-11; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Butterfield DA, 2003, CNS DRUGS, V17, P641, DOI 10.2165/00023210-200317090-00004; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; Dingledine R, 1999, PHARMACOL REV, V51, P7; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Groc L, 2004, NAT NEUROSCI, V7, P695, DOI 10.1038/nn1270; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Harris AZ, 2008, J NEUROPHYSIOL, V99, P524, DOI 10.1152/jn.01169.2007; Harris AZ, 2007, J PHYSIOL-LONDON, V584, P509, DOI 10.1113/jphysiol.2007.137679; Hasbani MJ, 2001, J NEUROSCI, V21, P2393, DOI 10.1523/JNEUROSCI.21-07-02393.2001; HORI N, 1994, EXP NEUROL, V129, P279, DOI 10.1006/exnr.1994.1170; IKONOMIDOU C, 1989, J NEUROSCI, V9, P1693; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Neyton J, 2006, J NEUROSCI, V26, P1331, DOI 10.1523/JNEUROSCI.5242-05.2006; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; OLNEY JW, 1971, J NEUROPATH EXP NEUR, V30, P75, DOI 10.1097/00005072-197101000-00008; OLNEY JW, 1979, BRAIN RES, V176, P91, DOI 10.1016/0006-8993(79)90872-2; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Rose K, 1993, IN VITRO BIOL METHOD, P46; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Rumbaugh G, 1999, J NEUROSCI, V19, P10603, DOI 10.1523/JNEUROSCI.19-24-10603.1999; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Thomas CG, 2006, J NEUROPHYSIOL, V95, P1727, DOI 10.1152/jn.00771.2005; Tovar KR, 2002, NEURON, V34, P253; Triller A, 2005, TRENDS NEUROSCI, V28, P133, DOI 10.1016/j.tins.2005.01.001; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; White RJ, 1996, J NEUROSCI, V16, P5688; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025; Zhao J, 2008, J NEUROSCI, V28, P3060, DOI 10.1523/JNEUROSCI.5450-07.2008	50	191	192	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4258	4271		10.1096/fj.08-107268	http://dx.doi.org/10.1096/fj.08-107268			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18711223				2022-12-28	WOS:000261254800025
J	Scanu, AM; Edelstein, C				Scanu, Angelo M.; Edelstein, Celina			HDL: bridging past and present with a look at the future	FASEB JOURNAL			English	Review						apoA-I; apoA-II; ATP-binding cassette transporter; lecithin-cholesterol acyl transferase; paraoxonase	APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEINS; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; AIR-WATER-INTERFACE; AMINO-ACID SEQUENCE; HUMAN APOA-I; SPHINGOSINE 1-PHOSPHATE; SERUM-LIPOPROTEINS; SELF-ASSOCIATION; HUMAN-PLASMA	Clinical and epidemiological studies have shown that HDLs, a class of plasma lipoproteins, heterogeneous in size and density, have an atheroprotective role attributed, for years, to their capacity to promote the efflux of cholesterol from activated cholesterol-loaded arterial macrophages. Recent studies, however, have recognized that the physical heterogeneity of HDLs is associated with multiple functions that involve both the protein and the lipid components of these particles. ApoA-I, quantitatively the major protein constituent, has an amphipathic structure suited for transport of lipids. It readily interacts with the ATP-binding cassette transporter ABCA1, the SR-B1 scavenger receptor; activates the enzyme lecithin-cholesterol acyl transferase (LCAT), which is critical for HDL maturation. It also has antioxidant and antiinflammatory properties, along with the HDL-associated enzymes paraoxonase, platelet activating factor acetylhydrolase (PAF), and glutathione peroxidase. Regarding the lipid moiety, an atheroprotective role has been recognized for lysosphingolipids, particularly sphingosine-1-phosphate (S1P). All of these atheroprotective functions are lost in the post-translational dependent dysfunctional plasma HDLs of subjects with systemic inflammation, coronary heart disease, diabetes, and chronic renal disease. The emerging notion that particle quality has more predictive power than quantity has stimulated further exploration of the HDL proteome, already revealing unsuspected pro- or antiatherogenic proteins/peptides associated with HDL.	[Scanu, Angelo M.; Edelstein, Celina] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Scanu, Angelo M.] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Scanu, AM (corresponding author), Univ Chicago, Dept Med, MC5041,5841 S Maryland Ave, Chicago, IL 60637 USA.	ascanu@medicine.bsd.uchicago.edu			National Heart, Lung, and Blood Institute; National Institutes of Health [HL 63209]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063209] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr. Trudy Forte for providing the electron micrographs. We also acknowledge the support from the National Heart, Lung, and Blood Institute, National Institutes of Health grant HL 63209.	Ajees AA, 2006, P NATL ACAD SCI USA, V103, P2126, DOI 10.1073/pnas.0506877103; Anantharamaiah GM, 2007, J LIPID RES, V48, P1915, DOI 10.1194/jlr.R700010-JLR200; ANANTHARAMAIAH GM, 1988, J LIPID RES, V29, P309; Argraves KM, 2007, J LIPID RES, V48, P2325, DOI 10.1194/jlr.R700011-JLR200; BARBEAU DL, 1977, J BIOL CHEM, V252, P6745; Benoit P, 1999, CIRCULATION, V99, P105, DOI 10.1161/01.CIR.99.1.105; Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; Bhat S, 2005, J BIOL CHEM, V280, P33015, DOI 10.1074/jbc.M505081200; Blanco-Vaca F, 2001, J LIPID RES, V42, P1727; Bloedon LT, 2008, J LIPID RES, V49, P1344, DOI 10.1194/jlr.P800003-JLR200; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Castellani LW, 2008, J BIOL CHEM, V283, P11633, DOI 10.1074/jbc.M708995200; Castellani LW, 2001, DIABETES, V50, P643, DOI 10.2337/diabetes.50.3.643; Clay MA, 2000, J BIOL CHEM, V275, P9019, DOI 10.1074/jbc.275.12.9019; Corella D, 2007, CLIN CHEM, V53, P1144, DOI 10.1373/clinchem.2006.084863; DAWSON G, 1976, J LIPID RES, V17, P125; Deigner HP, 2008, CURR OPIN LIPIDOL, V19, P289, DOI 10.1097/MOL.0b013e3282fe1d0e; Durbin DM, 1999, J LIPID RES, V40, P2293; EDELSTEIN C, 1982, J BIOL CHEM, V257, P7189; EDELSTEIN C, 1972, J BIOL CHEM, V247, P5842; EDELSTEIN C, 1973, J BIOL CHEM, V248, P7653; EDELSTEIN C, 1980, J BIOL CHEM, V255, P5747; FUKUSHIMA D, 1979, J AM CHEM SOC, V101, P3703, DOI 10.1021/ja00507a068; Gharavi NM, 2007, ARTERIOSCL THROM VAS, V27, P1346, DOI 10.1161/ATVBAHA.107.141283; GOFMAN JW, 1949, J BIOL CHEM, V179, P973; Gong EL, 1996, J BIOL CHEM, V271, P5984, DOI 10.1074/jbc.271.11.5984; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; Gursky O, 1996, PROTEIN SCI, V5, P1874, DOI 10.1002/pro.5560050913; Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com; HARA A, 1987, J BIOCHEM-TOKYO, V102, P83, DOI 10.1093/oxfordjournals.jbchem.a122044; Hoang A, 2007, DIABETOLOGIA, V50, P1770, DOI 10.1007/s00125-007-0718-9; Hortin GL, 2006, BIOCHEM BIOPH RES CO, V340, P909, DOI 10.1016/j.bbrc.2005.12.098; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; Ito K, 2007, BIOCHEM BIOPH RES CO, V357, P212, DOI 10.1016/j.bbrc.2007.03.123; Jayaraman S, 2008, BIOCHEMISTRY-US, V47, P3875, DOI 10.1021/bi7023783; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Kimura T, 2003, ARTERIOSCL THROM VAS, V23, P1283, DOI 10.1161/01.ATV.0000079011.67194.5A; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; Kumar MS, 2002, BIOCHEMISTRY-US, V41, P11681, DOI 10.1021/bi026069w; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; Li HH, 2002, J BIOL CHEM, V277, P39093, DOI 10.1074/jbc.M206770200; Li Y, 2006, BIOPHYS J, V91, P3819, DOI 10.1529/biophysj.106.087072; MASSEY JB, 1980, J BIOL CHEM, V255, P167; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V794, P137, DOI 10.1016/0005-2760(84)90306-0; Moore RE, 2003, ARTERIOSCL THROM VAS, V23, P1914, DOI 10.1161/01.ATV.0000092328.66882.F5; Navab M, 2004, CIRCULATION, V109, P3215, DOI 10.1161/01.CIR.0000134275.90823.87; Navab M, 2006, NAT CLIN PRACT CARD, V3, P540, DOI 10.1038/ncpcardio0661; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; PORN MI, 1991, BIOCHEM J, V279, P29; Reilly MP, 2007, J CLIN INVEST, V117, P595, DOI 10.1172/JCI31608; RITTER MC, 1977, J BIOL CHEM, V252, P1208; RITTER MC, 1979, J BIOL CHEM, V254, P2517; RYE KA, 1994, J BIOL CHEM, V269, P10298; Rye KA, 2003, J BIOL CHEM, V278, P22530, DOI 10.1074/jbc.M213250200; Rye KA, 1997, J BIOL CHEM, V272, P3953, DOI 10.1074/jbc.272.7.3953; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; SCANU A, 1970, BIOCHEMISTRY-US, V9, P1327, DOI 10.1021/bi00808a005; SCANU A, 1965, P NATL ACAD SCI USA, V54, P1699, DOI 10.1073/pnas.54.6.1699; SCANU A, 1958, ARCH BIOCHEM BIOPHYS, V74, P390, DOI 10.1016/0003-9861(58)90009-2; SCANU A., 1954, RIV IST SIEROTERAP ITAL, V29, P276; SCANU A, 1968, Progress in Biochemical Pharmacology, V4, P153; SCANU A, 1968, P NATL ACAD SCI USA, V59, P890, DOI 10.1073/pnas.59.3.890; SCANU A, 1960, J BIOL CHEM, V235, P2876; SCANU AM, 1972, ANNU REV BIOCHEM, V41, P703, DOI 10.1146/annurev.bi.41.070172.003415; SCANU AM, 1984, CLIN PHYSIOL BIOCH, V2, P111; SCANU AM, 1974, BIOCHIM BIOPHYS ACTA, V351, P341, DOI 10.1016/0005-2795(74)90197-4; SCANU AM, 1972, J BIOL CHEM, V247, P5850; SCANU AM, 1975, PAABS REV, V4, P1; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1992, J LIPID RES, V33, P141; Shao BH, 2008, METHOD ENZYMOL, V440, P33, DOI 10.1016/S0076-6879(07)00803-8; SHEN BW, 1985, J BIOL CHEM, V260, P1032; SHEN BW, 1980, BIOCHEMISTRY-US, V19, P3643, DOI 10.1021/bi00557a001; SHOULDERS CC, 1983, NUCLEIC ACIDS RES, V11, P2827, DOI 10.1093/nar/11.9.2827; Silva RAGD, 2007, J BIOL CHEM, V282, P9713, DOI 10.1074/jbc.M610380200; SPARKS DL, 1995, J BIOL CHEM, V270, P26910, DOI 10.1074/jbc.270.45.26910; Stahlman M, 2008, J LIPID RES, V49, P481, DOI 10.1194/jlr.D700025-JLR200; TENG TL, 1978, BIOCHEMISTRY-US, V17, P17, DOI 10.1021/bi00594a003; van't Hooft FM, 2001, CIRCULATION, V104, P1223, DOI 10.1161/hc3601.095709; VITELLO LB, 1976, BIOCHEMISTRY-US, V15, P1161, DOI 10.1021/bi00650a031; VITELLO LB, 1976, J BIOL CHEM, V251, P1131; Weng W, 1996, P NATL ACAD SCI USA, V93, P14788, DOI 10.1073/pnas.93.25.14788; Yang LB, 1999, BRIT J HAEMATOL, V107, P282, DOI 10.1046/j.1365-2141.1999.01697.x; Yatomi Y, 1997, J BIOCHEM, V121, P969; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333; YUAN YP, 1995, BLOOD, V86, P4166, DOI 10.1182/blood.V86.11.4166.bloodjournal86114166; Zhan B, 2005, ATHEROSCLEROSIS, V178, P199, DOI 10.1016/j.atherosclerosis.2004.08.024; Zheng L, 2005, J BIOL CHEM, V280, P38, DOI 10.1074/jbc.M407019200; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	98	97	102	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2008	22	12					4044	4054		10.1096/fj.08-117150	http://dx.doi.org/10.1096/fj.08-117150			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18716026	Green Published			2022-12-28	WOS:000261254800003
J	Aydin, J; Shabalina, IG; Place, N; Reiken, S; Zhang, SJ; Bellinger, AM; Nedergaard, J; Cannon, B; Marks, AR; Bruton, JD; Westerblad, H				Aydin, Jan; Shabalina, Irina G.; Place, Nicolas; Reiken, Steven; Zhang, Shi-Jin; Bellinger, Andrew M.; Nedergaard, Jan; Cannon, Barbara; Marks, Andrew R.; Bruton, Joseph D.; Westerblad, Hakan			Nonshivering thermogenesis protects against defective calcium handling in muscle	FASEB JOURNAL			English	Article						muscle contraction; ryanodine receptor; temperature control; increased beta-adrenergic activity	SKELETAL-MUSCLE; RYANODINE RECEPTOR; INTACT FIBERS; COLD; MOUSE; SINGLE; MICE; CATECHOLAMINES; ADAPTATION; RELEASE	When acutely exposed to a cold environment, mammals shiver to generate heat. During prolonged cold exposure, shivering is replaced by adaptive adrenergic nonshivering thermogenesis with increased heat production in brown adipose tissue due to activation of uncoupling protein-1 (UCP1). This cold acclimation is associated with chronically increased sympathetic stimulation of skeletal muscle, which may increase the sarcoplasmic reticulum (SR) Ca2+ leak via destabilized ryanodine receptor 1 (RyR1) channel complexes. Here, we use genetically engineered UCP1-deficient (UCP1-KO) mice that rely completely on shivering in the cold. We examine soleus muscle, which participates in shivering, and flexor digitorum brevis (FDB) muscle, a distal and superficial muscle that does not shiver. Soleus muscles of cold-acclimated UCP1-KO mice exhibited severe RyR1 PKA hyperphosphorylation and calstabin1 depletion, as well as markedly decreased SR Ca2+ release and force during contractions. In stark contrast, the RyR1 channel complexes were little affected, and Ca2+ and force were not decreased in FDB muscles of cold-acclimated UCP1-KO mice. These results indicate that activation of UCP1-mediated heat production in brown adipose tissue during cold exposure reduces the necessity for shivering and thus prevents the development of severe dysfunction in shivering muscles. Aydin, J., Shabalina, I. G., Place, N., Reiken, S., Zhang, S.-J., Bellinger, A. M., Nedergaard, J., Cannon, B., Marks, A. R., Bruton, J. D., Westerblad, H. Nonshivering thermogenesis protects against defective calcium handling in muscle. FASEB J. 22, 3919-3924 (2008)	[Aydin, Jan; Place, Nicolas; Zhang, Shi-Jin; Bruton, Joseph D.; Westerblad, Hakan] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; [Shabalina, Irina G.; Nedergaard, Jan; Cannon, Barbara] Univ Stockholm, Wenner Gren Inst, Arrhenius Labs, S-11345 Stockholm, Sweden; [Reiken, Steven; Bellinger, Andrew M.; Marks, Andrew R.] Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Karolinska Institutet; Stockholm University; Columbia University	Westerblad, H (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden.	hakan.westerblad@ki.se	Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Shabalina, Irina G/A-4225-2011; Place, Nicolas/B-3416-2018; Shabalina, Irina/AAC-3720-2019; Cannon, Barbara/B-3089-2016	Shabalina, Irina G/0000-0002-2915-6450; Place, Nicolas/0000-0001-9044-0621; Shabalina, Irina/0000-0002-2915-6450; Cannon, Barbara/0000-0001-6594-2363; Westerblad, Hakan/0000-0002-8180-3029; Nedergaard, Jan/0000-0003-2070-1587; Bruton, Joseph/0000-0002-6985-099X	Swedish Research Council; Swedish National Center for Sports Research; Karolinska Institute; U.S. Defense Advanced Research Projects Agency (DARPA); Swedish Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056180] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish National Center for Sports Research; Karolinska Institute(Karolinska Institutet); U.S. Defense Advanced Research Projects Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Swedish Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by the Swedish Research Council, the Swedish National Center for Sports Research, funds from the Karolinska Institute, and the U.S. Defense Advanced Research Projects Agency (DARPA). N.P. was supported by the Swedish Institute.	Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x; Bellinger AM, 2008, P NATL ACAD SCI USA, V105, P2198, DOI 10.1073/pnas.0711074105; BROWN GL, 1948, J PHYSIOL-LONDON, V107, P115, DOI 10.1113/jphysiol.1948.sp004255; CAIRNS SP, 1993, PFLUG ARCH EUR J PHY, V425, P150, DOI 10.1007/BF00374515; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; DULLOO AG, 1988, AM J PHYSIOL, V255, pE180, DOI 10.1152/ajpendo.1988.255.2.E180; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; Harper ME, 2001, BBA-BIOENERGETICS, V1504, P159, DOI 10.1016/S0005-2728(00)00244-9; HEMINGWAY A, 1963, PHYSIOL REV, V43, P397, DOI 10.1152/physrev.1963.43.3.397; LANNERGREN J, 1987, J PHYSIOL-LONDON, V390, P285; LEBLANC J, 1967, AM J PHYSIOL, V213, P1419, DOI 10.1152/ajplegacy.1967.213.6.1419; Liu YW, 1997, AM J PHYSIOL-CELL PH, V273, pC1915, DOI 10.1152/ajpcell.1997.273.6.C1915; MOTELICA I, 1969, ACTA PHYSIOL SCAND, V76, P393, DOI 10.1111/j.1748-1716.1969.tb04484.x; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; ROTH J, 1988, J COMP PHYSIOL B, V157, P855, DOI 10.1007/BF00691018; Ward CW, 2003, FASEB J, V17, P1517, DOI 10.1096/fj.02-1083fje; WILLIAMS JH, 1989, MUSCLE NERVE, V12, P968, DOI 10.1002/mus.880121204; Zalk R, 2007, ANNU REV BIOCHEM, V76, P367, DOI 10.1146/annurev.biochem.76.053105.094237	19	51	51	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2008	22	11					3919	3924		10.1096/fj.08-113712	http://dx.doi.org/10.1096/fj.08-113712			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18687806	Green Published			2022-12-28	WOS:000260503000020
J	Harrington, LS; Lucas, R; McMaster, SK; Moreno, L; Scadding, G; Warner, TD; Mitchell, JA				Harrington, Louise S.; Lucas, Ruth; McMaster, Shaun K.; Moreno, Laura; Scadding, Glenis; Warner, Timothy D.; Mitchell, Jane A.			COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma	FASEB JOURNAL			English	Article						nonsteroid drugs; bronchoconstriction; prostaglandins	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ARACHIDONIC-ACID; CYCLOOXYGENASE; SYNTHASE; CYCLO-OXYGENASE-2; ACETAMINOPHEN; INFLAMMATION; INHIBITION; MECHANISMS; EXPRESSION	Cyclooxygenase (COX) -1 and COX-2 are expressed in airway cells, where their activities influence functions such as airway hyperreactivity. Clinical data show that mixed COX-1/COX-2 inhibitors such as aspirin, but not COX-2 selective inhibitors such as rofecoxib, induce bronchoconstriction and asthma in sensitive individuals. This anomaly has not yet been explained. Here, we have used tissue from genetically modified mice lacking functional COX-1 (COX-1(-/-)), as well as airway tissue from "aspirin-sensitive" and control patients to address this issue. Bronchi from wild-type mice contained predominantly COX-1 immunoreactivity and contracted in vitro in response to acetylcholine and U46619. Bronchi from COX-1(-/-) mice were hyperresponsive to bronchoconstrictors. Inhibitors of COX (naproxen, diclofenac, or ibuprofen) increased bronchoconstriction in tissue from wild-type but not from COX-1(-/-) mice. Cells cultured from aspirin-sensitive or control human donors contained similar levels of COX-1 and COX-2 immunoreactivity. COX activity in cells from aspirin-sensitive or tolerant patients was inhibited by aspirin, SC560, which blocks COX-1 selectively, but not by rofecoxib, which is a selective inhibitor of COX-2. These observations show that despite the presence of COX-2, COX-1 is functionally predominant in the airways and explains clinical observations relating to drug specificity in patients with aspirin-sensitive asthma.-Harrington, L. S., Lucas, R., McMaster, S. K., Moreno, L., Scadding, G., Warner, T. D., Mitchell, J. A. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. FASEB J. 22, 4005-4010 (2008)	[Harrington, Louise S.; Lucas, Ruth; McMaster, Shaun K.; Moreno, Laura; Scadding, Glenis; Mitchell, Jane A.] Univ London Imperial Coll Sci Technol & Med, NHLI, London SW3 6LY, England; [Warner, Timothy D.] Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London, England	Imperial College London; University of London; Queen Mary University London	Mitchell, JA (corresponding author), Univ London Imperial Coll Sci Technol & Med, NHLI, Dovehouse St, London SW3 6LY, England.	j.a.mitchell@ic.ac.uk	Warner, Timothy D/A-1980-2009; Moreno, Laura/A-9433-2010; Lucas, Rut/H-6050-2015; Mackenzie, Louise/AAY-7585-2020; Mitchell, Jane A/A-1991-2009	Warner, Timothy D/0000-0003-3988-4408; Moreno, Laura/0000-0001-9028-2299; Lucas, Rut/0000-0002-4697-7832; Mackenzie, Louise/0000-0003-4271-379X; 	Wellcome Trust; European Community [LSHM-CT-2004-0050333]; Spanish Government	Wellcome Trust(Wellcome TrustEuropean Commission); European Community(European Commission); Spanish Government(Spanish GovernmentEuropean Commission)	This research was supported by the Wellcome Trust, European Community FP6 funding (Eicosanox; LSHM-CT-2004-0050333), European Community FP7 funding (Marie Currie Fellowship) and the Spanish Government. This publication reflects only the authors' views. The European Community is not liable for any use that may be made of information herein.	BishopBailey D, 1997, ARTERIOSCL THROM VAS, V17, P1644, DOI 10.1161/01.ATV.17.9.1644; Demoly P, 1998, CLIN EXP ALLERGY, V28, P278; Gray PA, 2002, BRIT J PHARMACOL, V137, P1031, DOI 10.1038/sj.bjp.0704927; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HULKOWER KI, 1993, AGENTS ACTIONS, V39, pC5, DOI 10.1007/BF01972703; Kakuyama M, 1999, AM J RESP CRIT CARE, V160, P2072, DOI 10.1164/ajrccm.160.6.9808105; Kowalski Marek L, 2007, Clin Allergy Immunol, V19, P147; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lucas R, 2005, FASEB J, V19, P635, DOI 10.1096/fj.04-2437fje; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Mitchell JA, 1997, MOL PHARMACOL, V51, P907, DOI 10.1124/mol.51.6.907; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Mitchell JA, 2006, FASEB J, V20, P2468, DOI 10.1096/fj.06-6615com; Moreno L, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-111; Parikh A, 2002, ACTA OTO-LARYNGOL, V122, P302, DOI 10.1080/000164802753648204; Picado C, 2006, CURR ALLERGY ASTHM R, V6, P198, DOI 10.1007/s11882-006-0035-2; Sampson AP, 1997, INT ARCH ALLERGY IMM, V113, P355, DOI 10.1159/000237600; Schonthal AH, 2007, BRIT J CANCER, V97, P1465, DOI 10.1038/sj.bjc.6604049; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Warner TD, 2004, J PHARMACOL EXP THER, V310, P642, DOI 10.1124/jpet.103.063875	23	40	40	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					4005	4010		10.1096/fj.08-107979	http://dx.doi.org/10.1096/fj.08-107979			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18753249	hybrid, Green Published			2022-12-28	WOS:000260503000028
J	Gottlieb, Y; Ghanim, M; Gueguen, G; Kontsedalov, S; Vavre, F; Fleury, F; Zchori-Fein, E				Gottlieb, Yuval; Ghanim, Murad; Gueguen, Gwenaelle; Kontsedalov, Svetlana; Vavre, Fabrice; Fleury, Frederic; Zchori-Fein, Einat			Inherited intracellular ecosystem: symbiotic bacteria share bacteriocytes in whiteflies	FASEB JOURNAL			English	Article						Bemisia tabaci; fluorescent in situ hybridization; spatial distribution; vertical transmission	BEMISIA-TABACI HOMOPTERA; EVOLUTIONARY RELATIONSHIPS; ENDOSYMBIOTIC BACTERIA; SCAPHOIDEUS-TITANUS; SECONDARY SYMBIONT; PEA APHID; WOLBACHIA; HEMIPTERA; PARTHENOGENESIS; ULTRASTRUCTURE	Symbiotic relationships with bacteria are common within the Arthropoda, with interactions that substantially influence the biology of both partners. The symbionts' spatial distribution is essential for understanding key aspects of this relationship, such as bacterial transmission, phenotype, and dynamics. In this study, fluorescence in situ hybridization was used to localize five secondary symbionts from various populations and biotypes of the sweet potato whitefly Bemisia tabaci: Hamiltonella, Arsenophonus, Cardinium, Wolbachia, and Rickettsia. All five symbionts were found to be located with the primary symbiont Portiera inside the bacteriocytes-cells specifically modified to house bacteria-but within these cells, they occupied various niches. The intrabacteriocyte distribution pattern of Rickettsia differed from what has been described previously. Cardinium and Wolbachia were found in other host tissues as well. Because all symbionts share the same cell, bacteriocytes in B. tabaci represent a unique intracellular ecosystem. This phenomenon may be a result of the direct enclosure of the bacteriocyte in the egg during oogenesis, providing a useful mechanism for efficient vertical transmission by "hitching a ride" with Portiera. On the other hand, cohabitation in the same cell provides ample opportunities for interactions among symbionts that can either facilitate (cooperation) or limit (warfare) symbiotic existence.	[Gottlieb, Yuval; Ghanim, Murad; Kontsedalov, Svetlana] Agr Res Org, Volcani Ctr, Dept Entomol, IL-50250 Bet Dagan, Israel; [Gueguen, Gwenaelle; Vavre, Fabrice; Fleury, Frederic] Univ Lyon 1, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, F-69622 Villeurbanne, France; [Zchori-Fein, Einat] Agr Res Org, Dept Entomol, Newe Yaar Res Ctr, Ramat Yishay, Israel	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup	Gottlieb, Y (corresponding author), Agr Res Org, Volcani Ctr, Dept Entomol, POB 6, IL-50250 Bet Dagan, Israel.	yuvalgd@yahoo.com	vavre, fabrice/N-2945-2017; Gueguen, Gwenaelle/E-9787-2011; Gottlieb, Yuval/H-6461-2013	vavre, fabrice/0000-0003-0909-2936; 				Anselme C, 2006, APPL ENVIRON MICROB, V72, P6766, DOI 10.1128/AEM.00942-06; Bao SN, 1996, J INVERTEBR PATHOL, V67, P309, DOI 10.1006/jipa.1996.0047; Baumann P, 2005, ANNU REV MICROBIOL, V59, P155, DOI 10.1146/annurev.micro.59.030804.121041; Bigliardi E, 2006, TISSUE CELL, V38, P257, DOI 10.1016/j.tice.2006.06.001; Bordenstein SR, 2005, NAT REV MICROBIOL, V3, P688, DOI 10.1038/nrmicro1233; Braendle C, 2003, PLOS BIOL, V1, P70, DOI 10.1371/journal.pbio.0000021; Buchner P., 1965, ENDOSYMBIOSIS ANIMAL; Chiel E, 2007, B ENTOMOL RES, V97, P407, DOI 10.1017/S0007485307005159; Clark ME, 2002, MECH DEVELOP, V111, P3, DOI 10.1016/S0925-4773(01)00594-9; Costa HS, 1995, PROTOPLASMA, V189, P194, DOI 10.1007/BF01280174; De Barro PJ, 2000, B ENTOMOL RES, V90, P103, DOI 10.1017/S0007485300000201; Everett KDE, 2005, INT J SYST EVOL MICR, V55, P1581, DOI 10.1099/ijs.0.63454-0; Ferree PM, 2005, PLOS PATHOG, V1, P111, DOI 10.1371/journal.ppat.0010014; Ghanim M, 2001, J MORPHOL, V248, P22, DOI 10.1002/jmor.1018; Gomez-Valero L, 2004, J BACTERIOL, V186, P6626, DOI 10.1128/JB.186.19.6626-6633.2004; Gottlieb Y, 2006, APPL ENVIRON MICROB, V72, P3646, DOI 10.1128/AEM.72.5.3646-3652.2006; Heddi A, 2005, CELL MICROBIOL, V7, P293, DOI 10.1111/j.1462-5822.2004.00461.x; Heddi A, 1999, P NATL ACAD SCI USA, V96, P6814, DOI 10.1073/pnas.96.12.6814; HUNTER MS, 2006, INSECT SYMBIOSIS, V2, P39; Hypsa V, 1997, INT J SYST BACTERIOL, V47, P1140, DOI 10.1099/00207713-47-4-1140; Ijichi N, 2002, APPL ENVIRON MICROB, V68, P4074, DOI 10.1128/AEM.68.8.4074-4080.2002; Ishikawa H, 2003, CONT T ENT, P1; Marzorati M, 2006, APPL ENVIRON MICROB, V72, P1467, DOI 10.1128/AEM.72.2.1467-1475.2006; Matalon Y, 2007, J INVERTEBR PATHOL, V96, P106, DOI 10.1016/j.jip.2007.02.010; Miller WJ, 2006, APPL ENVIRON MICROB, V72, P826, DOI 10.1128/AEM.72.1.826-835.2006; Min KT, 1997, P NATL ACAD SCI USA, V94, P10792, DOI 10.1073/pnas.94.20.10792; Mitsuhashi W, 2002, INSECT MOL BIOL, V11, P577, DOI 10.1046/j.1365-2583.2002.00368.x; Moran NA, 2005, P NATL ACAD SCI USA, V102, P16919, DOI 10.1073/pnas.0507029102; Moran NA, 2005, APPL ENVIRON MICROB, V71, P3302, DOI 10.1128/AEM.71.6.3302-3310.2005; Morin S, 1999, VIROLOGY, V256, P75, DOI 10.1006/viro.1999.9631; Oliver KM, 2003, P NATL ACAD SCI USA, V100, P1803, DOI 10.1073/pnas.0335320100; Perlman SJ, 2006, P ROY SOC B-BIOL SCI, V273, P2097, DOI 10.1098/rspb.2006.3541; Perotti MA, 2006, FASEB J, V20, P2372, DOI 10.1096/fj.06-5870fje; Perring TM, 2001, CROP PROT, V20, P725, DOI 10.1016/S0261-2194(01)00109-0; SACCHI L, 2008, TISSUE CELL IN PRESS; Stouthamer R, 1999, ANNU REV MICROBIOL, V53, P71, DOI 10.1146/annurev.micro.53.1.71; Szklarzewicz T, 2001, PROTOPLASMA, V218, P45, DOI 10.1007/BF01288359; Thao ML, 2004, APPL ENVIRON MICROB, V70, P3401, DOI 10.1128/AEM.70.6.3401-3406.2004; Thao MLL, 2004, CURR MICROBIOL, V48, P140, DOI 10.1007/s00284-003-4157-7; Tsuchida T, 2005, MICROB ECOL, V49, P126, DOI 10.1007/s00248-004-0216-2; Tsuchida T, 2002, MOL ECOL, V11, P2123, DOI 10.1046/j.1365-294X.2002.01606.x; Vautrin E, 2008, J EVOLUTION BIOL, V21, P145, DOI 10.1111/j.1420-9101.2007.01460.x; Veneti Z, 2004, APPL ENVIRON MICROB, V70, P5366, DOI 10.1128/AEM.70.9.5366-5372.2004; Weeks AR, 2003, CONT T ENT, P165; Wernegreen JJ, 2004, PLOS BIOL, V2, P307, DOI 10.1371/journal.pbio.0020068; Wu D, 2006, PLOS BIOL, V4, P1079, DOI 10.1371/journal.pbio.0040188; Zchori-Fein E, 2001, P NATL ACAD SCI USA, V98, P12555, DOI 10.1073/pnas.221467498; Zchori-Fein E, 1998, CURR MICROBIOL, V36, P1, DOI 10.1007/s002849900270; Zchori-Fein E, 2002, ANN ENTOMOL SOC AM, V95, P711, DOI 10.1603/0013-8746(2002)095[0711:DOPAWB]2.0.CO;2	49	172	183	2	69	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2591	2599		10.1096/fj.07-101162	http://dx.doi.org/10.1096/fj.07-101162			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18285399				2022-12-28	WOS:000257292500050
J	Scapa, EF; Pocai, A; Wu, MK; Gutierrez-Juarez, R; Glenz, L; Kanno, K; Li, H; Biddinger, S; Jelicks, LA; Rossetti, L; Cohen, DE				Scapa, Erez F.; Pocai, Alessandro; Wu, Michele K.; Gutierrez-Juarez, Roger; Glenz, Lauren; Kanno, Keishi; Li, Hua; Biddinger, Sudha; Jelicks, Linda A.; Rossetti, Luciano; Cohen, David E.			Regulation of energy substrate utilization and hepatic insulin sensitivity by phosphatidylcholine transfer protein/StarD2	FASEB JOURNAL			English	Article						fatty acid; triglyceride; glucose; respiratory quotient; phospholipid	STEAROYL-COA DESATURASE-1; FATTY-ACID TRANSPORT; DIET-INDUCED OBESITY; CHOLESTEROL-METABOLISM; LIPID-METABOLISM; ADIPOSE-TISSUE; DEFICIENT MICE; START DOMAIN; WEIGHT-LOSS; LIVER	Phosphatidylcholine transfer protein (PC-TP, also known as StarD2) is a highly specific intracellular lipid binding protein with accentuated expression in oxidative tissues. Here we show that decreased plasma concentrations of glucose and free fatty acids in fasting PC-TP-deficient (Pctp(-/-)) mice are attributable to increased hepatic insulin sensitivity. In hyperinsulinemic-euglycemic clamp studies, Pctp(-/-) mice exhibited profound reductions in hepatic glucose production, gluconeogenesis, glycogenolysis, and glucose cycling. These changes were explained in part by the lack of PC-TP expression in liver per se and in part by marked alterations in body fat composition. Reduced respiratory quotients in Pctp(-/-) mice were indicative of preferential fatty acid utilization for energy production in oxidative tissues. In the setting of decreased hepatic fatty acid synthesis, increased clearance rates of dietary triglycerides and increased hepatic triglyceride production rates reflected higher turnover in Pctp(-/-) mice. Collectively, these data support a key biological role for PC-TP in the regulation of energy substrate utilization.	[Scapa, Erez F.; Wu, Michele K.; Glenz, Lauren; Kanno, Keishi; Cohen, David E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol,Dept Med, Boston, MA 02115 USA; [Pocai, Alessandro; Gutierrez-Juarez, Roger; Rossetti, Luciano] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; [Pocai, Alessandro; Gutierrez-Juarez, Roger; Rossetti, Luciano] Albert Einstein Coll Med, Diabet Res Ctr, Dept Mol Pharmacol, Bronx, NY 10467 USA; [Li, Hua; Jelicks, Linda A.] Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10467 USA; [Biddinger, Sudha] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA; [Cohen, David E.] Harvard Massachusetts Inst Technol, Div Hlth & Sci & Technol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University	Cohen, DE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol,Dept Med, 75 Francis St, Boston, MA 02115 USA.	dcohen@partners.org	Jelicks, Linda/L-9740-2019	Jelicks, Linda/0000-0002-6438-1792	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056626, R37DK048873, R01DK048873, R29DK048873] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [DK-56626, R01 DK056626, DK-48873, R37 DK048873] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485; Baez JM, 2005, BIOCHEM J, V388, P57, DOI 10.1042/BJ20041899; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; de Brouwer APM, 2002, EXP CELL RES, V274, P100, DOI 10.1006/excr.2001.5460; Dolley G, 2007, ATHEROSCLEROSIS, V195, P297, DOI 10.1016/j.atherosclerosis.2007.01.002; Geijtenbeek TBH, 1996, BIOCHEM J, V316, P49; Gibbons Geoffrey F., 1994, Current Opinion in Lipidology, V5, P191, DOI 10.1097/00041433-199405030-00006; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991; Hajri T, 2002, ANNU REV NUTR, V22, P383, DOI 10.1146/annurev.nutr.22.020402.130846; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hyogo H, 2002, J BIOL CHEM, V277, P34117, DOI 10.1074/jbc.M203912200; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Ilany J, 2006, P NATL ACAD SCI USA, V103, P4481, DOI 10.1073/pnas.0511246103; Kanno K, 2007, J BIOL CHEM, V282, P30728, DOI 10.1074/jbc.M703745200; Kanno K, 2007, BBA-MOL CELL BIOL L, V1771, P654, DOI 10.1016/j.bbalip.2007.04.003; Kuriyama H, 2005, CELL METAB, V1, P41, DOI 10.1016/j.cmet.2004.11.004; Lam TKT, 2007, NAT MED, V13, P171, DOI 10.1038/nm1540; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Nakagawa Y, 2006, NAT MED, V12, P107, DOI 10.1038/nm1334; Neufeld D S, 1997, Methods Mol Biol, V75, P145; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; Okamoto H, 2005, J CLIN INVEST, V115, P1314, DOI 10.1172/JCI200523096; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Riachi M, 2004, CAN J PHYSIOL PHARM, V82, P1075, DOI [10.1139/y04-117, 10.1139/Y04-117]; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Roy S, 2005, HEPATOLOGY, V41, P887, DOI 10.1002/hep.20643; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Scherer PE, 2006, DIABETES, V55, P1537, DOI 10.2337/db06-0263; SHIMADA M, 2000, GEOMECH RES SER, V2, P1; Shoelson SE, 2007, GASTROENTEROLOGY, V132, P2169, DOI 10.1053/j.gastro.2007.03.059; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Stahl A, 2004, PFLUG ARCH EUR J PHY, V447, P722, DOI 10.1007/s00424-003-1106-z; Taniguchi CM, 2005, J CLIN INVEST, V115, P718, DOI 10.1172/JCI200523187; Tinsley FC, 2004, OBES RES, V12, P150, DOI 10.1038/oby.2004.20; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; van Helvoort A, 1999, P NATL ACAD SCI USA, V96, P11501, DOI 10.1073/pnas.96.20.11501; VanPatten S, 2004, BIOCHEM J, V379, P229, DOI 10.1042/BJ20040134; Wang WJ, 2006, J LIPID RES, V47, P2400, DOI 10.1194/jlr.M600277-JLR200; Wu MK, 2005, J LIPID RES, V46, P422, DOI 10.1194/jlr.M400387-JLR200; Wu MK, 2005, AM J PHYSIOL-GASTR L, V289, pG1067, DOI 10.1152/ajpgi.00194.2005; Wu QW, 2006, MOL CELL BIOL, V26, P3455, DOI 10.1128/MCB.26.9.3455-3467.2006	48	31	32	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2579	2590		10.1096/fj.07-105395	http://dx.doi.org/10.1096/fj.07-105395			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18347010				2022-12-28	WOS:000257292500049
J	Li, Z; Xia, F; Zhang, YQ				Li, Zhen; Xia, Feng; Zhang, Yuanqiang			RETRACTED: Polarized release of RANTES by cytotoxic T cells paints tumor targets and enhances apoptotic cell removal (Retracted Article. See vol 22, pg 3409, 2008)	FASEB JOURNAL			English	Article; Retracted Publication						chemokine; macrophage; phagocytosis	IN-VIVO; CHEMOKINE RECEPTORS; EFFECTOR-CELLS; OLIGOMERIZATION; EXPRESSION; GENE; ANTAGONISTS; DEATH	The release of regulated on activation normal T-cell expressed and secreted (RANTES) from CD8 + lymphocytes has been shown to be dependent on T-cell receptor triggering by major histocompatability complex class I/peptide complex engagement. We characterized the secretion of RANTES by human leukocyte antigen-A2-restricted tyrosinase-specific cytotoxic T lymphocyte (CTL) in the context of human melanoma cell killing. CTL contact with tumor cell targets elicited a vectorial release of the chemokine RANTES resulting in the selective deposition of RANTES on target cells but not on nontarget bystander cells or the CTL. RANTES on the surface of apoptotic cells enhanced their phagocytosis by murine macrophages. This effect appeared unique to RANTES as the related chemokines macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and monocyte chemoattractant protein-1 did not significantly affect uptake and were mediated through chemokine receptor CCR1. Oligomerization of RANTES, at least at the level of a tetramer, was required for the enhanced phagocytosis. These results suggest that the role of RANTES in inflammatory disorders might not be restricted to inducing leukocyte infiltration but could also extend to potent macrophage modulation, directly regulating inflammation.	[Li, Zhen; Zhang, Yuanqiang] Fourth Mil Med Univ, Dept Histol & Embryol, Xian 710032, Shaanxi, Peoples R China; [Xia, Feng] Fourth Mil Med Univ, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Zhang, YQ (corresponding author), Fourth Mil Med Univ, Dept Histol & Embryol, 17 Changle W Rd, Xian 710032, Shaanxi, Peoples R China.	zhangyq@fmmu.edu.cn						Anders HJ, 2006, KIDNEY INT, V69, P29, DOI 10.1038/sj.ki.5000053; Anders HJ, 2003, J IMMUNOL, V170, P5658, DOI 10.4049/jimmunol.170.11.5658; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baltus T, 2003, BLOOD, V102, P1985, DOI 10.1182/blood-2003-04-1175; Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27; Bouet-Toussaint F, 2003, CANCER IMMUNOL IMMUN, V52, P699, DOI 10.1007/s00262-003-0412-9; Catalfamo M, 2004, IMMUNITY, V20, P219, DOI 10.1016/S1074-7613(04)00027-5; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Fadok VA, 1999, J MAMMARY GLAND BIOL, V4, P203, DOI 10.1023/A:1011384009787; Fessele S, 2002, TRENDS GENET, V18, P60, DOI 10.1016/S0168-9525(02)02591-X; Henkart PA, 2004, ADV IMMUNOL, V83, P233; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Milani V, 2005, INT IMMUNOL, V17, P257, DOI 10.1093/intimm/dxh203; Murphy PM, 2002, PHARMACOL REV, V54, P227, DOI 10.1124/pr.54.2.227; Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2; Ortiz BD, 1997, IMMUNOL TODAY, V18, P468, DOI 10.1016/S0167-5699(97)01128-6; Pipkin ME, 2007, CURR OPIN IMMUNOL, V19, P301, DOI 10.1016/j.coi.2007.04.011; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; Swanson BJ, 2002, IMMUNITY, V17, P605, DOI 10.1016/S1074-7613(02)00456-9; Trapani JA, 2000, CURR OPIN IMMUNOL, V12, P323, DOI 10.1016/S0952-7915(00)00094-7; vonLuettichau I, 1996, CYTOKINE, V8, P89, DOI 10.1006/cyto.1996.0012; Voskoboinik I, 2006, NAT REV IMMUNOL, V6, P940, DOI 10.1038/nri1983; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Weber C, 2001, BLOOD, V97, P1144, DOI 10.1182/blood.V97.4.1144	30	3	3	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1748	1755		10.1096/fj.07-101212RET	http://dx.doi.org/10.1096/fj.07-101212RET			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198213				2022-12-28	WOS:000256352700015
J	McLear, JA; Lebrecht, D; Messer, A; Wolfgang, WJ				McLear, J. A.; Lebrecht, D.; Messer, A.; Wolfgang, W. J.			Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease	FASEB JOURNAL			English	Article						scFv; polyglutamine; Drosophila; neurodegenerative; disorder; chaperone protein	NEURONAL INTRANUCLEAR INCLUSIONS; MUTANT HUNTINGTIN; POLYGLUTAMINE TOXICITY; HSP90 INHIBITOR; HEAT-SHOCK; CHAPERONE SUPPRESSION; TRINUCLEOTIDE REPEAT; MOLECULAR CHAPERONES; TERMINAL HUNTINGTIN; PARKINSONS-DISEASE	Intracellular antibodies (intrabodies) and the chaperone, heat shock protein 70 (Hsp70), have each shown potential as therapeutics for neurodegenerative diseases in vitro and in vivo. Investigating combinational therapy in an established Drosophila model of Huntington's disease (HD), we show that Hsp70 and intrabody actually affect different aspects of the disease. Overexpression of human Hsp70 resulted in improved survival of HD flies to eclosion and prolonged adult life compared with intrabody treatment alone. An additive effect on adult survival was observed when the two therapies were combined. Intrabody was more successful at suppressing neurodegeneration in photoreceptors than was Hsp70. Furthermore, Hsp70 treatment alone did not block aggregation of mutant huntingtin, a process slowed by intrabody. Expression of each is restricted to the nervous system, which implies different neuronal populations respond distinctly to these treatments. Importantly, a role for endogenous Hsp70 in suppression of mutant huntingtin pathology was confirmed by a separate set of genetic studies in which HD flies deficient for Hsp70 showed significantly increased pathology. We conclude that a combinational approach of intrabody with enhanced Hsp70 expression is beneficial in addressing multiple pathologies associated with HD and has potential application for other neurodegenerative disorders.	[McLear, J. A.; Lebrecht, D.; Messer, A.; Wolfgang, W. J.] New York State Dept Hlth, Div Genet Disorders, Wadsworth Ctr, Albany, NY 12237 USA; [Lebrecht, D.; Messer, A.; Wolfgang, W. J.] SUNY Albany, Dept Biomed Sci, Albany, NY USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Messer, A (corresponding author), New York State Dept Hlth, Div Genet Disorders, Wadsworth Ctr, 120 New Scotland Ave, Albany, NY 12237 USA.	messer@wadsworth.org		Wolfgang, William/0000-0003-1769-0215	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053912] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS053912] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi H, 2003, J NEUROSCI, V23, P2203; Agashe VR, 2000, SEMIN CELL DEV BIOL, V11, P15, DOI 10.1006/scdb.1999.0347; Agrawal N, 2005, P NATL ACAD SCI USA, V102, P3777, DOI 10.1073/pnas.0500055102; Alvarez RD, 2000, CLIN CANCER RES, V6, P3081; Andresen JM, 2007, ANN HUM GENET, V71, P295, DOI 10.1111/j.1469-1809.2006.00335.x; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Bodner RA, 2006, P NATL ACAD SCI USA, V103, P4246, DOI 10.1073/pnas.0511256103; Bolivar VJ, 2004, BRAIN RES, V1005, P29, DOI 10.1016/j.brainres.2004.01.021; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Carter RJ, 1999, J NEUROSCI, V19, P3248; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chan HYE, 2002, HUM MOL GENET, V11, P2895, DOI 10.1093/hmg/11.23.2895; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; da Silva FA, 2004, J MOL BIOL, V340, P525, DOI 10.1016/j.jmb.2004.04.062; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dehay B, 2006, J BIOL CHEM, V281, P35608, DOI 10.1074/jbc.M605558200; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; FRANCESCHINI N, 1971, KYBERNETIK, V8, P1, DOI 10.1007/BF00270828; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Gong WJ, 2006, GENETICS, V172, P275, DOI 10.1534/genetics.105.048793; Gong WJ, 2004, GENETICS, V168, P1467, DOI 10.1534/genetics.104.030874; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Klucken J, 2006, FASEB J, V20, P2050, DOI 10.1096/fj.05-5422com; Kuhn A, 2007, HUM MOL GENET, V16, P1845, DOI 10.1093/hmg/ddm133; Lecerf JM, 2001, P NATL ACAD SCI USA, V98, P4764, DOI 10.1073/pnas.071058398; Lee WCM, 2004, P NATL ACAD SCI USA, V101, P3224, DOI 10.1073/pnas.0400243101; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Lynch SM, 2008, J MOL BIOL, V377, P136, DOI 10.1016/j.jmb.2007.11.096; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Messer A, 2006, BIODRUGS, V20, P327, DOI 10.2165/00063030-200620060-00002; Miller TW, 2005, NEUROBIOL DIS, V19, P47, DOI 10.1016/j.nbd.2004.11.003; Miyata Y, 2005, CURR PHARM DESIGN, V11, P1131, DOI 10.2174/1381612053507585; Murphy RC, 2004, MOL BRAIN RES, V121, P141, DOI 10.1016/j.molbrainres.2003.11.011; Naver B, 2003, NEUROSCIENCE, V122, P1049, DOI 10.1016/j.neuroscience.2003.08.053; Novoselova TV, 2005, J NEUROCHEM, V94, P597, DOI 10.1111/j.1471-4159.2005.03119.x; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Rezaval C, 2007, EUR J NEUROSCI, V25, P683, DOI 10.1111/j.1460-9568.2007.05317.x; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Smith DL, 2001, NEUROBIOL DIS, V8, P1017, DOI 10.1006/nbdi.2001.0438; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Tagawa K, 2004, J NEUROCHEM, V89, P974, DOI 10.1111/j.1471-4159.2004.02372.x; Tagawa K, 2007, J NEUROSCI, V27, P868, DOI 10.1523/JNEUROSCI.4522-06.2007; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Waza M, 2006, ANN NY ACAD SCI, V1086, P21, DOI 10.1196/annals.1377.012; Waza M, 2006, J MOL MED, V84, P635, DOI 10.1007/s00109-006-0066-0; Wheeler YRY, 2003, MOL THER, V8, P355, DOI 10.1016/S1525-0016(03)00183-7; Wolfgang WJ, 2005, P NATL ACAD SCI USA, V102, P11563, DOI 10.1073/pnas.0505321102; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zhou Y, 2004, NEUROSCIENCE, V128, P281, DOI 10.1016/j.neuroscience.2004.06.048	69	34	35	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2003	2011		10.1096/fj.07-099689	http://dx.doi.org/10.1096/fj.07-099689			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18199697				2022-12-28	WOS:000256352700039
J	Miyahara, S; Almulki, L; Noda, K; Nakazawa, T; Hisatomi, T; Nakao, S; Thomas, KL; Schering, A; Zandi, S; Frimmel, S; Tayyari, F; Garland, RC; Miller, JW; Gragoudas, ES; Masli, S; Hafezi-Moghadam, A				Miyahara, Shinsuke; Almulki, Lama; Noda, Kousuke; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Thomas, Kennard L.; Schering, Alexander; Zandi, Souska; Frimmel, Sonja; Tayyari, Faryan; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Masli, Sharmila; Hafezi-Moghadam, Ali			In vivo imaging of endothelial injury in choriocapillaris during endotoxin-induced uveitis	FASEB JOURNAL			English	Article						inflammation; adhesion molecules; subclinical diagnosis; noninvasive molecular imaging; vascular diseases	OCULAR BLOOD-FLOW; P-SELECTIN; GLYCOPROTEIN LIGAND-1; CHOROIDAL CIRCULATION; LEUKOCYTE; NEUTROPHILS; RETINA; CELLS	Early detection of ocular inflammation may prevent the occurrence of structural damage or vision loss. Here, we introduce a novel noninvasive technique for molecular imaging and quantitative evaluation of endothelial injury in the choriocapillaris of live animals, which detects disease earlier than currently possible. Using an established model of ocular inflammation, endotoxin-induced uveitis (EIU), we visualized the rolling and adhesive interaction of fluorescent microspheres conjugated to recombinant P-selectin glycoprotein ligand-Ig (rPSGL-Ig) in choriocapillaris using a scanning laser ophthalmoscope (SLO). The number of rolling microspheres in the choriocapillaris peaked 4-10 h after LPS injection. The number of the accumulated microspheres peaked 4 h after LPS injection in the temporal choriocapillaris and 4 and 36 h after LPS injection in the central areas around the optic disk. Furthermore, we semiquantified the levels of P-selectin mRNA expression in the choroidal vessels by reverse transcription-PCR and found its pattern to match the functional microsphere interactions, with a peak at 4 h after LPS injection. These results indicate that PSGL-1-conjugated fluorescent microspheres allow specific detection of endothelial P-selectin expression in vivo and noninvasive assessment of endothelial injury. This technique may help to diagnose subclinical signs of ocular inflammatory diseases.	[Miyahara, Shinsuke; Almulki, Lama; Noda, Kousuke; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Thomas, Kennard L.; Schering, Alexander; Zandi, Souska; Frimmel, Sonja; Tayyari, Faryan; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA; [Miyahara, Shinsuke; Almulki, Lama; Noda, Kousuke; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Thomas, Kennard L.; Schering, Alexander; Zandi, Souska; Frimmel, Sonja; Tayyari, Faryan; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Masli, Sharmila; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; [Masli, Sharmila] Schepens Eye Res Inst, Boston, MA USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Harvard University; Schepens Eye Research Institute	Hafezi-Moghadam, A (corresponding author), Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA.	ahm@meei.harvard.edu		Miller, Joan/0000-0003-2046-3996; Hafezi-Moghadam, Ali/0000-0002-5336-0697; Hisatomi, Toshio/0000-0003-2552-9595; Zandi, Souska/0000-0001-9351-4278	NEI NIH HHS [EY14104] Funding Source: Medline; NIAID NIH HHS [AI050775] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abiko T, 2003, DIABETES, V52, P829, DOI 10.2337/diabetes.52.3.829; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; BAATZ H, 1995, INVEST OPHTH VIS SCI, V36, P1960; BISCHOFF PM, 1995, RETINA-J RET VIT DIS, V15, P91, DOI 10.1097/00006982-199515020-00002; DORE M, 1993, BLOOD, V82, P1308; FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8; GABER AO, 2007, AM TRANSPL C; GHEZZI P, 1991, CYTOKINE, V3, P189, DOI 10.1016/1043-4666(91)90015-6; Hafezi-Moghadam A, 2007, FASEB J, V21, P464, DOI 10.1096/fj.06-6390com; Hafezi-Moghadam A, 2004, AM J PHYSIOL-CELL PH, V286, pC876, DOI 10.1152/ajpcell.00500.2003; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Hirata Y, 2006, PROG RETIN EYE RES, V25, P129, DOI 10.1016/j.preteyeres.2005.08.001; Hirata Y, 2004, INVEST OPHTH VIS SCI, V45, P1954, DOI 10.1167/iovs.03-0759; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Khoobehi B, 1997, OPHTHALMIC SURG LAS, V28, P937; Khor SP, 2000, J PHARMACOL EXP THER, V293, P618; Kuroki AM, 2002, OPHTHALMIC RES, V34, P200, DOI 10.1159/000063886; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; Mertens P, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.04.020; Miyahara S, 2004, AM J PATHOL, V164, P1697, DOI 10.1016/S0002-9440(10)63728-5; Miyahara S, 2003, STROKE, V34, P2043, DOI 10.1161/01.STR.0000083052.01361.3D; Miyamoto K, 1996, INVEST OPHTH VIS SCI, V37, P2708; Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345; Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104; Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434; Savage HI, 2004, INVEST OPHTH VIS SCI, V45, P4504, DOI 10.1167/iovs.04-0077; Schocket Lisa S., 2004, International Ophthalmology, V25, P89, DOI 10.1023/B:INTE.0000031744.93778.60; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; Suzuma K, 1997, INVEST OPHTH VIS SCI, V38, P1610; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; Yang PZ, 1997, BRIT J OPHTHALMOL, V81, P396, DOI 10.1136/bjo.81.5.396	34	13	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1973	1980		10.1096/fj.07-096891	http://dx.doi.org/10.1096/fj.07-096891			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18216288				2022-12-28	WOS:000256352700036
J	Kalea, AZ; Reiniger, N; Yang, HJ; Arriero, M; Schmidt, AM; Hudson, BI				Kalea, Anastasia Z.; Reiniger, Nina; Yang, Hojin; Arriero, Maria; Schmidt, Ann Marie; Hudson, Barry I.			Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene	FASEB JOURNAL			English	Article						DNA cloning; mRNA; soluble receptor; species-specific splicing; protein evolution	CELL-SURFACE RECEPTOR; SOLUBLE RECEPTOR; CYTOPLASMIC DOMAIN; NEURITE OUTGROWTH; PLASMA-LEVELS; HUMAN BRAIN; EXPRESSION; ATHEROSCLEROSIS; DISEASE; ACTIVATION	The alternative splicing of pre-mRNAs is a critical mechanism in genomic complexity, disease, and development. Studies of the receptor for advanced glycation end-products (RAGE) indicate that this gene undergoes a variety of splice events in humans. However, no studies have extensively analyzed the tissue distribution in other species or compared evolutionary differences of RAGE isoforms. Because the majority of studies probing RAGE function have been performed in murine models, we therefore performed studies to identify and characterize the splice variants of the murine RAGE gene, and we compared these to human isoforms. Here, using mouse tissues, we identified numerous splice variants including changes in the extracellular domain or the removal of the transmembrane and cytoplasmic domains, which produce soluble splice isoforms. Comparison of splice variants between humans and mice revealed homologous regions in the RAGE gene that undergo splicing as well as key species-specific mechanisms of splicing. Further analysis of tissue splice variant distribution in mice revealed major differences between lung, kidney, heart, and brain. To probe the potential impact of disease- like pathological states, we studied diabetic mice and report that RAGE splice variation changed dramatically, resulting in an increase in production of soluble RAGE (sRAGE) splice variants, which were not associated with detectable levels of sRAGE in murine plasma. In conclusion, we have determined that the murine RAGE gene undergoes extensive splicing with distinct splice isoforms being uniquely distributed in different tissues. These differences in RAGE splicing in both physiological and pathogenic states further expand our understanding of the biological repertoire of this receptor in health and disease.-Kalea, A. Z., Reiniger, N., Yang, H., Arriero, M., Schmidt, A. M., Hudson, B. I. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 23, 1766-1774 (2009)	[Kalea, Anastasia Z.; Reiniger, Nina; Yang, Hojin; Arriero, Maria; Schmidt, Ann Marie; Hudson, Barry I.] Columbia Univ, Dept Surg, Coll Phys & Surg, Div Surg Sci, New York, NY 10032 USA	Columbia University	Hudson, BI (corresponding author), Columbia Univ, Dept Surg, Coll Phys & Surg, Div Surg Sci, 630 W 168th St,P&S 17-401, New York, NY 10032 USA.	bh2021@columbia.edu	Hudson, Barry/B-3122-2009; Kalea, Anastasia Z./G-4053-2010	Hudson, Barry/0000-0001-7647-8121; Kalea, Anastasia Z./0000-0001-5775-3984	U.S. Public Health Service; Juvenile Diabetes Research Foundation; National Institutes of Health	U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the U.S. Public Health Service and the Juvenile Diabetes Research Foundation. B.I.H. is a recipient of a Career Development Award from the Juvenile Diabetes Research Foundation International. A.M.S. is a recipient of a Scholar Award from the Juvenile Diabetes Research Foundation International. A.Z.K. is a recipient of a postdoctoral fellowship from the Juvenile Diabetes Research Foundation International. N.R. is a recipient of a National Research Service Award from the National Institutes of Health.	Basta G, 2006, J CLIN ENDOCR METAB, V91, P4628, DOI 10.1210/jc.2005-2559; Brown LF, 2008, ANN CLIN BIOCHEM, V45, P518, DOI 10.1258/acb.2008.008043; Ding QX, 2005, NEUROSCI LETT, V373, P67, DOI 10.1016/j.neulet.2004.09.059; Emanuele E, 2005, ARCH NEUROL-CHICAGO, V62, P1734, DOI 10.1001/archneur.62.11.1734; Falcone C, 2005, ARTERIOSCL THROM VAS, V25, P1032, DOI 10.1161/01.ATV.0000160342.20342.00; Galichet A, 2008, BIOCHEM BIOPH RES CO, V370, P1, DOI 10.1016/j.bbrc.2008.02.163; Geroldi D, 2005, J HYPERTENS, V23, P1725, DOI 10.1097/01.hjh.0000177535.45785.64; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Hanford LE, 2004, J BIOL CHEM, V279, P50019, DOI 10.1074/jbc.M409782200; Harashima A, 2006, BIOCHEM J, V396, P109, DOI 10.1042/BJ20051573; Harja E, 2008, J CLIN INVEST, V118, P183, DOI 10.1172/JCI32703; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hudson BI, 2008, FASEB J, V22, P1572, DOI 10.1096/fj.07-9909com; Hudson BI, 2008, J BIOL CHEM, V283, P34457, DOI 10.1074/jbc.M801465200; Hudson BI, 2005, ANTIOXID REDOX SIGN, V7, P1588, DOI 10.1089/ars.2005.7.1588; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Katakami N, 2005, DIABETES CARE, V28, P2716, DOI 10.2337/diacare.28.11.2716; Kislinger T, 2001, ARTERIOSCL THROM VAS, V21, P905, DOI 10.1161/01.ATV.21.6.905; Koyama H, 2005, ARTERIOSCL THROM VAS, V25, P2587, DOI 10.1161/01.ATV.0000190660.32863.cd; Lareau LF, 2004, CURR OPIN STRUC BIOL, V14, P273, DOI 10.1016/j.sbi.2004.05.002; Lizotte PP, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-15; Malherbe P, 1999, MOL BRAIN RES, V71, P159, DOI 10.1016/S0169-328X(99)00174-6; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Nurtdinov RN, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-249; Nurtdinov RN, 2003, HUM MOL GENET, V12, P1313, DOI 10.1093/hmg/ddg137; Park IH, 2004, MOL IMMUNOL, V40, P1203, DOI 10.1016/j.molimm.2003.11.027; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Raucci A, 2008, FASEB J, V22, P3716, DOI 10.1096/fj.08-109033; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; Schlueter C, 2003, BBA-GENE STRUCT EXPR, V1630, P1, DOI 10.1016/j.bbaexp.2003.08.008; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; Wendt T, 2006, ATHEROSCLEROSIS, V185, P70, DOI 10.1016/j.atherosclerosis.2005.06.013; Wendt TM, 2003, AM J PATHOL, V162, P1123, DOI 10.1016/S0002-9440(10)63909-0; Xing Y, 2003, FEBS LETT, V555, P572, DOI 10.1016/S0014-5793(03)01354-1; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371	41	90	92	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1766	1774		10.1096/fj.08-117739	http://dx.doi.org/10.1096/fj.08-117739			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19164451	Green Published			2022-12-28	WOS:000266652400017
J	Suuronen, EJ; Zhang, PC; Kuraitis, D; Cao, XD; Melhuish, A; Mckee, D; Li, FF; Mesana, TG; Veinot, JP; Ruel, M				Suuronen, Erik J.; Zhang, Pingchuan; Kuraitis, Drew; Cao, Xudong; Melhuish, Angela; McKee, Daniel; Li, Fengfu; Mesana, Thierry G.; Veinot, John P.; Ruel, Marc			An acellular matrix-bound ligand enhances the mobilization, recruitment and therapeutic effects of circulating progenitor cells in a hindlimb ischemia model	FASEB JOURNAL			English	Article						tissue engineering; stem cells; angiogenesis; cell homing; paracrine effects; apoptosis	EMBRYONIC STEM-CELLS; BONE-MARROW; PERIPHERAL-BLOOD; L-SELECTIN; NEOVASCULARIZATION CAPACITY; MUSCLE; ANGIOGENESIS; REGENERATION; CONTRIBUTES; EXPRESSION	Circulating progenitor cells home to and engraft to sites of ischemia, mediated in part by the adhesion molecule L-selectin; however, accumulation in tissues such as the heart is low. In this study, an acellular collagen-based matrix containing sialyl Lewis(X) (sLe(X)), which binds L-selectin, was developed in order to enhance the endogenous progenitor cell therapeutic response. Its effect on progenitor cells and angiogenesis were assessed in vitro and using a hindlimb ischemia model with rats. In culture, the sLe(X)-collagen matrix recruited more CD133(+)CD34(+)L-selectin(+) cells than collagen-only matrix, with adhesion mediated by L-selectin binding. Increased angiogenic/chemotactic cytokine production and improved resistance to apoptosis appeared in cells cultured on sLe(X)-collagen matrix. In vivo, mobilization of endogenous circulating progenitor cells was increased, and greater recruitment of these and systemically injected human peripheral blood CXCR4(+)L-selectin(+) cells to sLe(X)-collagen treated limbs was observed compared to collagen-only. This condition was associated with differences in angiogenic/chemotactic cytokine levels, with greater arteriole density and increased perfusion in sLe(X)-collagen treated hindlimbs. With these factors taken together, we demonstrated that an acellular matrix-bound ligand approach can enhance the mobilization, recruitment, and therapeutic effects of endogenous and/or transplanted progenitor cells, possibly through paracrine and antiapoptotic mechanisms, and could be used to improve cell-based regenerative therapies.-Suuronen, E. J., Zhang, P., Kuraitis, D., Cao, X., Melhuish, A., McKee, D., Li, F., Mesana, T. G., Veinot, J. P., Ruel, M. An acellular matrix-bound ligand enhances the mobilization, recruitment and therapeutic effects of circulating progenitor cells in a hindlimb ischemia model. FASEB J. 23, 1447-1458 (2009)	[Suuronen, Erik J.; Zhang, Pingchuan; Kuraitis, Drew; McKee, Daniel; Mesana, Thierry G.; Ruel, Marc] Univ Ottawa, Inst Heart, Div Cardiac Surg, Ottawa, ON K1Y 4W7, Canada; [Suuronen, Erik J.; Kuraitis, Drew; McKee, Daniel; Ruel, Marc] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1Y 4W7, Canada; [Cao, Xudong; Melhuish, Angela] Univ Ottawa, Dept Chem Engn, Ottawa, ON K1Y 4W7, Canada; [Veinot, John P.] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; [Li, Fengfu] Ottawa Hlth Res Inst, Dept Vis, Ottawa, ON, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Suuronen, EJ (corresponding author), Univ Ottawa, Inst Heart, Div Cardiac Surg, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	esuuronen@ottawaheart.ca		RUEL, MARC/0000-0002-0487-1319	Heart and Stroke Foundation of Ontario [NA6121]; Canadian Institutes of Health Research [MOP-77536]; University of Ottawa Interfaculty research; Natural Sciences and Engineering Research Council of Canada; Lawrence Soloway Research Fellowship	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); University of Ottawa Interfaculty research; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Lawrence Soloway Research Fellowship	We thank Suzanne Crowe, Samir Hazra, Dan deVette, and Drs. Fraser Rubens and Naoshi Shinozaki for their assistance and Drs. Ross Milne and Robert Roberts for their helpful insights. This work was supported by grant NA6121 from the Heart and Stroke Foundation of Ontario (to E. S.), by grant MOP-77536 from the Canadian Institutes of Health Research (to M. R. and E. S.), by a University of Ottawa Interfaculty research grant (E. S. and X. C.) and by a Natural Sciences and Engineering Research Council of Canada Grant (to X. C.). P.Z. is recipient of the Lawrence Soloway Research Fellowship, and D. K. is supported by a master's studentship award from the Heart and Stroke Foundation of Ontario.	Abdel-Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989; Aicher A, 2005, HYPERTENSION, V45, P321, DOI 10.1161/01.HYP.0000154789.28695.ea; Arbab AS, 2008, FASEB J, V22, P3234, DOI 10.1096/fj.07-105676; Biancone L, 2004, J IMMUNOL, V173, P5268, DOI 10.4049/jimmunol.173.8.5268; Chavakis E, 2005, J EXP MED, V201, P63, DOI 10.1084/jem.20041402; Cho HJ, 2007, J EXP MED, V204, P3257, DOI 10.1084/jem.20070166; Doyle B, 2007, J NUCL MED, V48, P1708, DOI 10.2967/jnumed.107.042838; Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Hickey MJ, 2000, J IMMUNOL, V165, P7164, DOI 10.4049/jimmunol.165.12.7164; Hofmann M, 2005, CIRCULATION, V111, P2198, DOI 10.1161/01.CIR.0000163546.27639.AA; Hristov M, 2007, CIRC RES, V100, P590, DOI 10.1161/01.RES.0000259043.42571.68; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Kang HJ, 2006, CIRCULATION, V114, pI145, DOI 10.1161/CIRCULATIONAHA.105.001107; Kapila V, 2005, EXPERT OPIN INV DRUG, V14, P37, DOI 10.1517/13543784.14.1.37; Krenning G, 2009, J CELL MOL MED, V13, P2521, DOI 10.1111/j.1582-4934.2008.00479.x; Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327; Lev EI, 2005, J VASC RES, V42, P408, DOI 10.1159/000087370; Lipinski MJ, 2007, J AM COLL CARDIOL, V50, P1761, DOI 10.1016/j.jacc.2007.07.041; Martin-Rendon E, 2007, STEM CELLS, V25, P1003, DOI 10.1634/stemcells.2006-0398; Morimoto H, 2008, CARDIOVASC RES, V78, P554, DOI 10.1093/cvr/cvn035; Murry CE, 2006, J AM COLL CARDIOL, V47, P1777, DOI 10.1016/j.jacc.2006.02.002; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Oh HK, 2007, CANCER RES, V67, P4851, DOI 10.1158/0008-5472.CAN-06-2979; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Retuerto MA, 2004, J THORAC CARDIOV SUR, V127, P1041, DOI 10.1016/j.jtcvs.2003.09.049; Ruel M, 2005, J THORAC CARDIOV SUR, V130, P633, DOI 10.1016/j.jtcvs.2005.01.013; Ruel M, 2004, MOL CELL BIOCHEM, V264, P119, DOI 10.1023/B:MCBI.0000044381.01098.03; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; Schmidt-Lucke C, 2005, CIRCULATION, V111, P2981, DOI 10.1161/CIRCULATIONAHA.104.504340; Singla DK, 2007, AM J PHYSIOL-HEART C, V293, pH1590, DOI 10.1152/ajpheart.00431.2007; Skarja GA, 1997, J BIOMED MATER RES, V34, P427, DOI 10.1002/(SICI)1097-4636(19970315)34:4<427::AID-JBM4>3.3.CO;2-R; Stamenkovic I, 1995, Curr Opin Hematol, V2, P68; Steiner S, 2005, ATHEROSCLEROSIS, V181, P305, DOI 10.1016/j.atherosclerosis.2005.01.006; Suuronen EJ, 2007, J THORAC CARDIOV SUR, V134, P1249, DOI 10.1016/j.jtcvs.2007.07.028; Suuronen EJ, 2006, CIRCULATION, V114, pI138, DOI 10.1161/CIRCULATIONAHA.105.001081; Tillmanns J, 2008, P NATL ACAD SCI USA, V105, P1668, DOI 10.1073/pnas.0706315105; Torrente Y, 2003, J CELL BIOL, V162, P511, DOI 10.1083/jcb.200210006; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; van Weel V, 2007, ARTERIOSCL THROM VAS, V27, P1426, DOI 10.1161/ATVBAHA.107.139642; Walter DH, 2005, CIRC RES, V97, P1142, DOI 10.1161/01.RES.0000193596.94936.2c; Wojakowski W, 2004, CIRCULATION, V110, P3213, DOI 10.1161/01.CIR.0000147609.39780.02; Ziebart T, 2008, CIRC RES, V103, P1327, DOI 10.1161/CIRCRESAHA.108.180463; Zvibel I, 2002, CELL TRANSPLANT, V11, P621, DOI 10.3727/000000002783985404	44	41	41	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1447	1458		10.1096/fj.08-111054	http://dx.doi.org/10.1096/fj.08-111054			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19136616				2022-12-28	WOS:000266651700021
J	Foller, M; Sopjani, M; Koka, S; Gu, SC; Mahmud, H; Wang, K; Floride, E; Schleicher, E; Schulz, E; Munzel, T; Lang, F				Foeller, Michael; Sopjani, Mentor; Koka, Saisudha; Gu, Shuchen; Mahmud, Hasan; Wang, Kan; Floride, Elisa; Schleicher, Erwin; Schulz, Eberhard; Muenzel, Thomas; Lang, Florian			Regulation of erythrocyte survival by AMP-activated protein kinase	FASEB JOURNAL			English	Article						cell volume; annexin; eryptosis; calcium; phosphatidylserine	PROGRAMMED CELL-DEATH; PHOSPHATIDYLSERINE EXPOSURE; CATION CONDUCTANCE; INHIBITION; STIMULATION; MECHANISMS; APOPTOSIS; ADHESION; CHANNELS; RECEPTOR	AMP-activated protein kinase (AMPK), an energy-sensing enzyme, counteracts energy depletion by stimulation of energy production and limitation of energy utilization. On energy depletion, erythrocytes undergo suicidal death or eryptosis, triggered by an increase in cytosolic Ca2+ activity ([Ca2+](i)) and characterized by cell shrinkage and phosphatidylserine (PS) exposure at the erythrocyte surface. The present study explored whether AMPK participates in the regulation of eryptosis. Western blotting and confocal microscopy disclosed AMPK expression in erythrocytes. [Ca2+](i) (Fluo3 fluorescence), cell volume (forward scatter), and PS exposure (annexin V binding) were determined by fluorescence-activated cell sorting (FACS) analysis. Glucose removal increased [Ca2+](i), decreased cell volume, and increased PS exposure. The AMPK-inhibitor compound C (20 mu M) did not significantly modify eryptosis under glucose-replete conditions but significantly augmented the eryptotic effect of glucose withdrawal. An increase in [Ca2+](i) by Ca2+ ionophore ionomycin triggered eryptosis, an effect blunted by the AMPK activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR; 1 mM). As compared with erythrocytes from wild-type littermates (ampk(+/+)), erythrocytes from AMPK alpha 1-deficient mice (ampk(-/-)) were significantly more susceptible to the eryptotic effect of energy depletion. The ampk(-/-) mice were anemic despite excessive reticulocytosis, and they suffered from severe splenomegaly, again pointing to enhanced erythrocyte turnover. The observations disclose a critical role of AMPK in the survival of circulating erythrocytes.-Foller, M., Sopjani, M., Koka, S., Gu, S., Mahmud, H., Wang, K., Floride, E., Schleicher, E., Schulz, E., Munzel, T., Lang, F. Regulation of erythrocyte survival by AMP-activated protein kinase. FASEB J. 23, 1072-1080 (2009)	[Foeller, Michael] Univ Tubingen, Inst Physiol, Dept Physiol, D-72076 Tubingen, Germany; [Schleicher, Erwin] Univ Tubingen, Dept Endocrinol Diabet Vasc Med Nephrol & Clin Ch, D-72076 Tubingen, Germany; [Schulz, Eberhard; Muenzel, Thomas] Johannes Gutenberg Univ Mainz, Dept Cardiol, Mainz, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Johannes Gutenberg University of Mainz	Foller, M (corresponding author), Univ Tubingen, Inst Physiol, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	Munzel, Thomas/A-2912-2014; koka, Saisudha/F-2381-2012	Munzel, Thomas/0000-0001-5503-4150; Sopjani, Mentor/0000-0002-4187-7218	Carl-Zeiss-Stiftung; Deutsche Forschungsgemeinschaft [GRK 1302, SFB 773, LA 315/13-3]	Carl-Zeiss-Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We acknowledge the technical assistance of Vanessa Schnorr and Alejandro Hernandez Garcia and the meticulous preparation of the manuscript by Tanja Loch. We further thank Albrecht Pfafflin for helping to determine vitamins in murine plasma and Ulf Scheurlen for providing the animal blood counter. This study was supported by the Carl-Zeiss-Stiftung, and the Deutsche Forschungsgemeinschaft, GRK 1302, SFB 773, LA 315/13-3.	Andrews D A, 1999, Curr Opin Hematol, V6, P76, DOI 10.1097/00062752-199903000-00004; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; Boas FE, 1998, P NATL ACAD SCI USA, V95, P3077, DOI 10.1073/pnas.95.6.3077; Bookchin R M, 1987, Prog Clin Biol Res, V240, P193; Brand VB, 2003, CELL PHYSIOL BIOCHEM, V13, P347, DOI 10.1159/000075122; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; Carling David, 2007, Novartis Found Symp, V286, P72; CASKIN FS, 2007, AM J PHYSIOL-HEART C, V292, pH326; Chuang De-Maw, 2004, Critical Reviews in Neurobiology, V16, P83, DOI 10.1615/CritRevNeurobiol.v16.i12.90; Chung SM, 2007, ARTERIOSCL THROM VAS, V27, P414, DOI 10.1161/01.ATV.0000252898.48084.6a; Closse C, 1999, BRIT J HAEMATOL, V107, P300, DOI 10.1046/j.1365-2141.1999.01718.x; Daugas E, 2001, CELL DEATH DIFFER, V8, P1131, DOI 10.1038/sj.cdd.4400953; Duranton C, 2003, CELL PHYSIOL BIOCHEM, V13, P189, DOI 10.1159/000072421; Duranton C, 2002, J PHYSIOL-LONDON, V539, P847, DOI 10.1113/jphysiol.2001.013040; Evans AM, 2005, J BIOL CHEM, V280, P41504, DOI 10.1074/jbc.M510040200; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Foller M, 2007, CELL PHYSIOL BIOCHEM, V20, P1051, DOI 10.1159/000110715; Gallagher PG, 2003, BLOOD, V101, P4625, DOI 10.1182/blood-2001-12-0329; Gulbins E, 2003, PHARMACOL RES, V47, P393, DOI 10.1016/S1043-6618(03)00052-5; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Horie T, 2008, J CELL PHYSIOL, V215, P733, DOI 10.1002/jcp.21353; Huber SM, 2001, PFLUG ARCH EUR J PHY, V441, P551, DOI 10.1007/s004240000456; Jensen TE, 2007, AM J PHYSIOL-ENDOC M, V293, pE286, DOI 10.1152/ajpendo.00693.2006; Kaestner L, 2004, THROMB HAEMOSTASIS, V92, P1269, DOI 10.1160/TH04-06-0338; Kempe DS, 2006, FASEB J, V20, P368, DOI 10.1096/fj.05-4872fje; Klarl BA, 2006, AM J PHYSIOL-CELL PH, V290, pC244, DOI 10.1152/ajpcell.00283.2005; Kohno D, 2008, BIOCHEM BIOPH RES CO, V366, P388, DOI 10.1016/j.bbrc.2007.11.166; Lang KS, 2005, CELL PHYSIOL BIOCHEM, V15, P195, DOI 10.1159/000086406; Lang KS, 2004, AM J PHYSIOL-RENAL, V286, pF1046, DOI 10.1152/ajprenal.00263.2003; Lang KS, 2004, CELL DEATH DIFFER, V11, P231, DOI 10.1038/sj.cdd.4401311; Lang KS, 2003, CELL DEATH DIFFER, V10, P249, DOI 10.1038/sj.cdd.4401144; Lang PA, 2003, CELL PHYSIOL BIOCHEM, V13, P337, DOI 10.1159/000075121; Lang PA, 2003, AM J PHYSIOL-CELL PH, V285, pC1553, DOI 10.1152/ajpcell.00186.2003; Lang PA, 2006, CELL PHYSIOL BIOCHEM, V18, P151, DOI 10.1159/000095190; Lira VA, 2007, AM J PHYSIOL-ENDOC M, V293, pE1062, DOI 10.1152/ajpendo.00045.2007; LOW PS, 1993, J BIOL CHEM, V268, P14627; Mayer A, 2008, EUR J IMMUNOL, V38, P948, DOI 10.1002/eji.200738045; Mcgee SL, 2008, FRONT BIOSCI-LANDMRK, V13, P3022, DOI 10.2741/2907; Nicolay JP, 2008, PFLUG ARCH EUR J PHY, V456, P293, DOI 10.1007/s00424-007-0393-1; Nicolay JP, 2006, CELL PHYSIOL BIOCHEM, V18, P223, DOI 10.1159/000097669; Nicolay JP, 2007, CELL PHYSIOL BIOCHEM, V19, P175, DOI 10.1159/000099205; Pandolfi A, 2007, J CELL PHYSIOL, V213, P699, DOI 10.1002/jcp.21138; Schneider J, 2007, CELL PHYSIOL BIOCHEM, V20, P35, DOI 10.1159/000104151; Sell H, 2006, BIOCHEM BIOPH RES CO, V343, P700, DOI 10.1016/j.bbrc.2006.03.010; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216; Winder WW, 2007, CELL BIOCHEM BIOPHYS, V47, P332, DOI 10.1007/s12013-007-0008-7; Wood BL, 1996, BLOOD, V88, P1873; Zappulla Donatella, 2008, J Cardiometab Syndr, V3, P30, DOI 10.1111/j.1559-4572.2008.07263.x; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3	51	173	175	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1072	1080		10.1096/fj.08-121772	http://dx.doi.org/10.1096/fj.08-121772			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19050047				2022-12-28	WOS:000266651600011
J	Morand, S; Ueyama, T; Tsujibe, S; Saito, N; Korzeniowska, A; Leto, TL				Morand, Stanislas; Ueyama, Takehiko; Tsujibe, Satoshi; Saito, Naoaki; Korzeniowska, Agnieszka; Leto, Thomas L.			Duox maturation factors form cell surface complexes with Duox affecting the specificity of reactive oxygen species generation	FASEB JOURNAL			English	Article						Dual oxidase; NADPH oxidase; Nox; NIP	HYDROGEN-PEROXIDE PRODUCTION; NADPH OXIDASE; DUAL OXIDASE; GENE; IDENTIFICATION; ACTIVATION; MUTATIONS; PROTEINS; SUPEROXIDE; EXPRESSION	Dual oxidases (Duox1 and Duox2) are plasma membrane-targeted hydrogen peroxide generators that support extracellular hemoperoxidases. Duox activator 2 (Duoxa2), initially described as an endoplasmic reticulum resident protein, functions as a maturation factor needed to deliver active Duox2 to the cell surface. However, less is known about the Duox1/Duoxa1 homologues. We identified four alternatively spliced Duoxa1 variants and explored their roles in Duox subcellular targeting and reconstitution. Duox1 and Duox2 are functionally rescued by Duoxa2 or the Duoxa1 variants that contain the third coding exon. All active maturation factors are cotransported to the cell surface when coexpressed with either Duox1 or Duox2, consistent with detection of endogenous Duoxa1 on apical plasma membranes of the airway epithelium. In contrast, the Duoxa proteins are retained in the endoplasmic reticulum when expressed without Duox. Duox1/Duoxa1 alpha and Duox2/Duoxa2 pairs produce the highest levels of hydrogen peroxide, as they undergo Golgi-based carbohydrate modifications and form stable cell surface complexes. Cross-functioning pairs that do not form stable complexes produce less hydrogen peroxide and leak superoxide. These findings suggest Duox activators not only promote Duox maturation, but they function as part of the hydrogen peroxide-generating enzyme.-Morand, S., Ueyama, T., Tsujibe, S., Saito, N., Korzeniowska, A., Leto, T. L. Duox maturation factors form cell surface complexes with Duox affecting the specificity of reactive oxygen species generation. FASEB J. 23, 1205-1218 (2009)	[Morand, Stanislas; Korzeniowska, Agnieszka; Leto, Thomas L.] NIAID, Host Def Lab, NIH, Rockville, MD 20852 USA; [Ueyama, Takehiko; Tsujibe, Satoshi; Saito, Naoaki] Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Kobe, Hyogo 657, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Kobe University	Leto, TL (corresponding author), NIAID, Host Def Lab, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.	tleto@nih.gov			U.S. National Institutes of Health Intramural Research Program, National Institute of Allergy and Infectious Diseases; KAKENHI on Priority Areas and on the GlobalCOE Program in Japan; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000614, Z01AI000614] Funding Source: NIH RePORTER	U.S. National Institutes of Health Intramural Research Program, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); KAKENHI on Priority Areas and on the GlobalCOE Program in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are thankful to Dr. F. Borrego (NIAID/LIG) and Dr. J. Kabat (NIAID/RTB) for their technical assistance in flow cytometry and imaging experiments. This work was supported by the U.S. National Institutes of Health Intramural Research Program, National Institute of Allergy and Infectious Diseases, and KAKENHI on Priority Areas and on the GlobalCOE Program in Japan.	Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Ameziane-El-Hassani R, 2005, J BIOL CHEM, V280, P30046, DOI 10.1074/jbc.M500516200; BENARD B, 1971, UNION MED CAN, V100, P701; Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DE D, 2002, EXP CELL RES, V273, P187; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Donko A, 2005, PHILOS T R SOC B, V360, P2301, DOI 10.1098/rstb.2005.1767; Dupuy C, 2000, BIOCHEM BIOPH RES CO, V277, P287, DOI 10.1006/bbrc.2000.3671; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; DUPUY C, 1991, J BIOL CHEM, V266, P3739; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; El Hassani RA, 2005, AM J PHYSIOL-GASTR L, V288, pG933, DOI 10.1152/ajpgi.00198.2004; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; Forteza R, 2005, AM J RESP CELL MOL, V32, P462, DOI 10.1165/rcmb.2004-0302OC; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Grasberger H, 2007, MOL ENDOCRINOL, V21, P1408, DOI 10.1210/me.2007-0018; Grasberger H, 2006, J BIOL CHEM, V281, P18269, DOI 10.1074/jbc.C600095200; Harper RW, 2006, FEBS LETT, V580, P5150, DOI 10.1016/j.febslet.2006.08.048; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Luxen S, 2008, CANCER RES, V68, P1037, DOI 10.1158/0008-5472.CAN-07-5782; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; Nakano Y, 2007, BIOCHEM J, V403, P97, DOI 10.1042/BJ20060819; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; Qin HJ, 2004, J BIOL CHEM, V279, P11304, DOI 10.1074/jbc.M311733200; Schwarzer C, 2004, J BIOL CHEM, V279, P36454, DOI 10.1074/jbc.M404983200; Song Y, 2007, J CLIN ENDOCR METAB, V92, P3764, DOI 10.1210/jc.2007-0660; Sugawara M, 2002, EXP BIOL MED, V227, P141, DOI 10.1177/153537020222700209; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006; Varela V, 2006, CLIN CHEM, V52, P182, DOI 10.1373/clinchem.2005.058321; Vigone Maria Cristina, 2005, Hum Mutat, V26, P395; Wesley UV, 2007, J BIOL CHEM, V282, P3213, DOI 10.1074/jbc.M606533200; Wong JL, 2004, DEV CELL, V7, P801, DOI 10.1016/j.devcel.2004.10.014; Zamproni I, 2008, J CLIN ENDOCR METAB, V93, P605, DOI 10.1210/jc.2007-2020; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; Zhu YM, 2006, J BIOL CHEM, V281, P30336, DOI 10.1074/jbc.M607191200	39	126	127	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1205	1218		10.1096/fj.08-120006	http://dx.doi.org/10.1096/fj.08-120006			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19074510	Green Published			2022-12-28	WOS:000266651600025
J	Chomel, C; Cazes, A; Faye, C; Bignon, M; Gomez, E; Ardidie-Robouant, C; Barret, A; Ricard-Blum, S; Muller, L; Germain, S; Monnot, C				Chomel, Clemence; Cazes, Aurelie; Faye, Clement; Bignon, Marine; Gomez, Elisa; Ardidie-Robouant, Corinne; Barret, Alain; Ricard-Blum, Sylvie; Muller, Laurent; Germain, Stephane; Monnot, Catherine			Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity	FASEB JOURNAL			English	Article						angiogenesis; extracellular matrix; endothelial cell; hypoxia	PROPROTEIN CONVERTASES; EXTRACELLULAR-MATRIX; TUMOR ANGIOGENESIS; CELL-SURFACE; PROTEIN-4; INHIBITION; METASTASIS; METABOLISM; OLIGOMERIZATION; ACTIVATION	Angiopoietin-like 4 (ANGPTL4) is involved in angiogenesis and lipid metabolism. It is secreted by liver and adipose tissues and cleaved to generate circulating coiled-coil domain (CCD) and fibrinogen-like domain (FLD) fragments. The full-length ANGPTL4 produced by hypoxic endothelial cells interacts with the extracellular matrix (ECM). The ECM-bound and soluble forms of ANGPTL4 have antiangiogenic properties. We carried out a structure-function analysis to investigate the regulation of ANGPTL4 bioactivity in endothelial cells. We found that the recombinant CCD binds to the ECM, whereas the FLD is released into the medium. The CCD, like the full-length ANGPTL4, binds to heparan and dermatan sulfates in surface plasmon resonance assays and inhibits endothelial cell adhesion, motility, and tubule-like formation. In endothelial cells, ANGPTL4 is processed in the secretion medium after release from the ECM. This processing is altered by the proprotein convertases inhibitor alpha 1-PDX and abolished by the mutation of the 161RRKR164 cleavage site without modification of the ECM binding and release. These data suggest that the full-length form, which interacts with heparan sulfate proteoglycans via its CCD, is protected from proteolysis by proprotein convertases and constitutes the major active pool of ANGPTL4 in hypoxic endothelial cells.-Chomel, C., Cazes, A., Faye, C., Bignon, M., Gomez, E., Ardidie-Robouant, C., Barret, A., Ricard-Blum, S., Muller, L., Germain, S., Monnot, C. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. FASEB J. 23, 940-949 (2009)	[Monnot, Catherine] Coll France, INSERM, U833, F-75005 Paris, France; [Chomel, Clemence; Bignon, Marine; Gomez, Elisa; Ardidie-Robouant, Corinne; Barret, Alain; Muller, Laurent; Germain, Stephane; Monnot, Catherine] Coll France, Expt Med Unit, F-75005 Paris, France; [Cazes, Aurelie] Hop Europeen Georges Pompidou, Serv Anat Pathol, Paris, France; [Germain, Stephane] Hop Europeen Georges Pompidou, Serv Hematol Biol A, Paris, France; [Faye, Clement; Ricard-Blum, Sylvie] Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69365 Lyon, France; [Cazes, Aurelie] Fac Med Paris Descartes, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Paris Cite	Monnot, C (corresponding author), Coll France, INSERM, U833, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	catherine.monnot@college-de-france.fr	Perdiguero, Elisa Gomez/U-2120-2018; Germain, Stephane/E-2301-2016; muller, laurent/S-1990-2016; Monnot, Catherine/E-5861-2017	Perdiguero, Elisa Gomez/0000-0002-7717-7897; Germain, Stephane/0000-0001-5992-1275; muller, laurent/0000-0001-9634-4323; Monnot, Catherine/0000-0003-1334-7348; RICARD-BLUM, Sylvie/0000-0001-9263-1851	European Vascular Genomics Network [LSHMCT-2003503254]; Agence Nationale de la Recherche [ANR-06-JCJC-0160]	European Vascular Genomics Network; Agence Nationale de la Recherche(French National Research Agency (ANR))	This work was supported by the European Vascular Genomics Network (http:// www. evgn. org; contract LSHMCT-2003503254) and by a grant from the Agence Nationale de la Recherche (ANR-06-JCJC-0160). We thank Eric Etienne for technical help in confocal microscopy, videomicroscopy, and cell tracking.	Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Ge HF, 2004, J LIPID RES, V45, P2071, DOI 10.1194/jlr.M400138-JLR200; Ge HF, 2004, J BIOL CHEM, V279, P2038, DOI 10.1074/jbc.M307583200; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; Hermann LM, 2005, CLIN IMMUNOL, V115, P93, DOI 10.1016/j.clim.2004.12.002; Ito Y, 2003, CANCER RES, V63, P6651; Jin WJ, 2007, CELL METAB, V6, P129, DOI 10.1016/j.cmet.2007.07.009; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kelly T, 2003, CANCER RES, V63, P8749; Kim I, 2000, BIOCHEM J, V346, P603, DOI 10.1042/0264-6021:3460603; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Le Jan S, 2006, FEBS LETT, V580, P3395, DOI 10.1016/j.febslet.2006.05.011; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; Morimoto-Tomita M, 2005, NEOPLASIA, V7, P1001, DOI 10.1593/neo.05496; Nour N, 2005, MOL BIOL CELL, V16, P5215, DOI 10.1091/mbc.E05-06-0504; Ono M, 2003, J BIOL CHEM, V278, P41804, DOI 10.1074/jbc.M302861200; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Ricard-Blum S, 2006, J BIOL CHEM, V281, P25195, DOI 10.1074/jbc.M603096200; Scamuffa N, 2008, J CLIN INVEST, V118, P352, DOI 10.1172/JCI32040; Seidah NG, 2008, INT J BIOCHEM CELL B, V40, P1111, DOI 10.1016/j.biocel.2008.01.030; Sukonina V, 2006, P NATL ACAD SCI USA, V103, P17450, DOI 10.1073/pnas.0604026103; Tsuji A, 2003, BBA-PROTEINS PROTEOM, V1645, P95, DOI 10.1016/S1570-9639(02)00532-0; Xu AM, 2005, P NATL ACAD SCI USA, V102, P6086, DOI 10.1073/pnas.0408452102; Xu Y, 2004, CANCER RES, V64, P6119, DOI 10.1158/0008-5472.CAN-04-1054; Xu Y, 2004, J BIOL CHEM, V279, P41179, DOI 10.1074/jbc.M400292200; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200; Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776	28	71	73	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					940	949		10.1096/fj.08-115170	http://dx.doi.org/10.1096/fj.08-115170			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19019854				2022-12-28	WOS:000265506300029
J	Saslowsky, DE; Tanaka, N; Reddy, KP; Lencer, WI				Saslowsky, David E.; Tanaka, Noriyuki; Reddy, Krishna P.; Lencer, Wayne I.			Ceramide activates JNK to inhibit a cAMP-gated K+ conductance and Cl- secretion in intestinal epithelia	FASEB JOURNAL			English	Article						sphingomyelinase; sphingomyelin; potassium channel	POTASSIUM CHANNEL; ALKALINE SPHINGOMYELINASE; NEUTRAL SPHINGOMYELINASE; ACID SPHINGOMYELINASE; STAPHYLOCOCCUS-AUREUS; CHLORIDE SECRETION; PLASMA-MEMBRANE; IN-VIVO; CELLS; MODEL	Sphingomyelinases (SMases) hydrolyze membrane sphingomyelin to ceramide and are expressed by diverse host and microbial cell types populating mucosal surfaces. Exogenous bacterial SMase acts on the basolateral membrane of polarized human intestinal epithelial cells to repress the cAMP-induced Cl- secretory response, but how this occurs is unknown. We show here that SMase acts by down-regulating a cAMP-gated basolateral membrane K+ conductance. Neither phosphocholine, ceramide-1-phosphate, nor sphingosine-1-phosphate recapitulates this effect, indicating that ceramide production is the decisive factor. Basolaterally applied SMase induced the phosphorylation of c-Jun NH2-terminal kinase (JNK), and inhibition of JNK rescued the effect of SMase on cAMP-dependant secretion. SMase secreted by normal human fibroblasts specifically recapitulated the effect on cAMP-induced Cl- secretion, indicating that cell types inhabiting the subepithelial space can provide such an activity to the basolateral membrane of intestinal enterocytes in trans. Thus, conversion of sphingomyelin to ceramide in basolateral membranes of intestinal cells rapidly activates JNK to inhibit a cAMP-gated K+ conductance and thereby attenuates Cl- secretion. These results define a novel lipid-mediated pathway for regulation of salt and water homeostasis at mucosal surfaces.-Saslowsky, D. E., Tanaka, N., Reddy, K. P., Lencer, W. I. Ceramide activates JNK to inhibit a cAMP-gated K+ conductance and Cl- secretion in intestinal epithelia. FASEB J. 23, 259-270 (2009)	[Saslowsky, David E.; Lencer, Wayne I.] Childrens Hosp, GI Cell Biol, Boston, MA 02115 USA; [Saslowsky, David E.; Lencer, Wayne I.] Harvard Digest Dis Ctr, Boston, MA USA; [Saslowsky, David E.; Reddy, Krishna P.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Tanaka, Noriyuki] Teine Keijinkai Hosp, Sapporo, Hokkaido, Japan	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Teine Keijinkai Hospital	Saslowsky, DE (corresponding author), Childrens Hosp, GI Cell Biol, 300 Longwood Ave,Enders 720, Boston, MA 02115 USA.	saslowsky@childrens.harvard.edu		Lencer, Wayne/0000-0001-7346-2730	NIDDK NIH HHS [R01 DK048106, DK48106, P30 DK034854, P30 DK040561, R01 DK084424, P30 DK040561-13, K01 DK073480, R37 DK048106, DK34854] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854, P30DK040561, R01DK084424, K01DK073480, R37DK048106, R01DK048106] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ago H, 2006, J BIOL CHEM, V281, P16157, DOI 10.1074/jbc.M601089200; Bajwa PJ, 2007, AM J PHYSIOL-GASTR L, V293, pG1288, DOI 10.1152/ajpgi.00234.2007; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhalla A, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-105; Bock J, 2003, BIOCHEM BIOPH RES CO, V305, P890, DOI 10.1016/S0006-291X(03)00763-0; Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06; Bourbon NA, 2001, AM J PHYSIOL-CELL PH, V280, pC1403, DOI 10.1152/ajpcell.2001.280.6.C1403; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chapman H, 2005, J CELL SCI, V118, P5325, DOI 10.1242/jcs.02635; Cheng ZJ, 2006, MOL BIOL CELL, V17, P3197, DOI 10.1091/mbc.E05-12-1101; Chik CL, 2001, J NEUROCHEM, V79, P339, DOI 10.1046/j.1471-4159.2001.00566.x; Clarke CJ, 2006, BIOCHEMISTRY-US, V45, P11247, DOI 10.1021/bi061307z; Colina C, 2005, ARCH BIOCHEM BIOPHYS, V436, P333, DOI 10.1016/j.abb.2005.02.014; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; De Luca HE, 2006, METH MOL B, V341, P127; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; Delmas P, 2005, NAT REV NEUROSCI, V6, P850, DOI 10.1038/nrn1785; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Duan RD, 2003, J BIOL CHEM, V278, P38528, DOI 10.1074/jbc.M305437200; Duan RD, 2003, J LIPID RES, V44, P1241, DOI 10.1194/jlr.M300037-JLR200; Ella KM, 1997, ARCH BIOCHEM BIOPHYS, V340, P101, DOI 10.1006/abbi.1997.9897; Farokhzad OC, 1999, J CELL PHYSIOL, V181, P489, DOI 10.1002/(SICI)1097-4652(199912)181:3<489::AID-JCP13>3.0.CO;2-7; Fink CC, 1999, J CELL BIOL, V147, P929, DOI 10.1083/jcb.147.5.929; Finnegan CM, 2004, P NATL ACAD SCI USA, V101, P15452, DOI 10.1073/pnas.0402874101; GILBERT RJ, 1984, BIOCHEM SOC T, V12, P198, DOI 10.1042/bst0120198; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Gonzalez-Zorn B, 1999, MOL MICROBIOL, V33, P510, DOI 10.1046/j.1365-2958.1999.01486.x; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grassme H, 2007, PROG LIPID RES, V46, P161, DOI 10.1016/j.plipres.2007.03.002; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hochbaum D, 2003, J BIOL CHEM, V278, P33738, DOI 10.1074/jbc.M305208200; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Ito Y, 2004, BIOCHEM BIOPH RES CO, V324, P901, DOI 10.1016/j.bbrc.2004.09.134; Jespersen T, 2007, CARDIOVASC RES, V74, P64, DOI 10.1016/j.cardiores.2007.01.008; Lee CY, 2006, J LIPID RES, V47, P622, DOI 10.1194/jlr.M500487-JLR200; Lee JT, 2004, J CELL BIOL, V164, P123, DOI 10.1083/jcb.200307017; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; Maguy A, 2006, CARDIOVASC RES, V69, P798, DOI 10.1016/j.cardiores.2005.11.013; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Martens JR, 2004, TRENDS PHARMACOL SCI, V25, P16, DOI 10.1016/j.tips.2003.11.007; Martial S, 2008, BIOCHEM BIOPH RES CO, V366, P944, DOI 10.1016/j.bbrc.2007.12.027; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; PATEL AH, 1987, INFECT IMMUN, V55, P3103, DOI 10.1128/IAI.55.12.3103-3110.1987; Ramu Y, 2006, NATURE, V442, P696, DOI 10.1038/nature04880; Rawat SS, 2006, GLYCOCONJUGATE J, V23, P189, DOI 10.1007/s10719-006-7924-4; Ray AJ, 2003, CLIN INFECT DIS, V37, P875, DOI 10.1086/377451; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; Saslowsky DE, 2008, CELL MICROBIOL, V10, P67, DOI 10.1111/j.1462-5822.2007.01015.x; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Seebohm G, 2007, CIRC RES, V100, P686, DOI 10.1161/01.RES.0000260250.83824.8f; Si JM, 2004, WORLD J GASTROENTERO, V10, P1802; Sjoqvist U, 2002, INFLAMM BOWEL DIS, V8, P258; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Subbaiah PV, 2003, J LIPID RES, V44, P1574, DOI 10.1194/jlr.M300103-JLR200; Tabas I, 1999, CHEM PHYS LIPIDS, V102, P123, DOI 10.1016/S0009-3084(99)00080-8; Tseng HJ, 2004, BIOCHEM BIOPH RES CO, V314, P513, DOI 10.1016/j.bbrc.2003.12.125; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; VARNUM MD, 1993, P NATL ACAD SCI USA, V90, P11528, DOI 10.1073/pnas.90.24.11528; Vazquez-Boland JA, 2001, CLIN MICROBIOL REV, V14, P584, DOI 10.1128/CMR.14.3.584-640.2001; Wang HT, 2001, CANCER RES, V61, P5102; Warth R, 1999, PFLUG ARCH EUR J PHY, V438, P437, DOI 10.1007/s004240051059; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Wong ML, 2000, P NATL ACAD SCI USA, V97, P8681, DOI 10.1073/pnas.150098097; Xiao GQ, 2003, BIOCHEM BIOPH RES CO, V306, P1019, DOI 10.1016/S0006-291X(03)01095-7; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9	70	7	7	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					259	270		10.1096/fj.08-116467	http://dx.doi.org/10.1096/fj.08-116467			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18820034	Green Published			2022-12-28	WOS:000262095500028
J	Sinkkonen, A				Sinkkonen, Aki			Umbilicus as a fitness signal in humans	FASEB JOURNAL			English	Article						fetal development; honest signal; nutrition; pregnancy; symmetry	PRETERM INFANTS; CORD; CONSTRICTION; RING	Typically, mammalian umbilical cord forms a tiny, stable, and asymmetrical scar. In contrast, humans have a clearly visible umbilicus that changes with age and nutrients gathered. Based on this, I propose that umbilicus, together with the surrounding skin area, is an honest signal of individual vigour. More precisely, I suggest that the symmetry, shape, and position of umbilicus can be used to estimate the reproductive potential of fertile females, including risks of certain genetically and maternally inherited fetal anomalies. The idea is supported by a comparative study where symmetrical t-shaped and oval-shaped umbilici of fertile females were considered the most attractive. Further support comes from observations that abnormal velocity of umbilical cord has been associated with fetal brain development, diabetes, and other fitness-related properties with a strong genetically or maternally inherited component. In addition, umbilicus and the umbilical skin area may reveal nutrimental competitive ability, and need for social care in small children and pregnant females. The novel hypothesis explains why umbilicus has aesthetic value, and why umbilicus has had a distinctive role in different cultures. If further research confirms the signalling hypothesis, female umbilici may be routinely measured to detect risk pregnancies of several fetal abnormalities.	Univ Helsinki, Dept Ecol & Environm Sci, FIN-15140 Lahti, Finland	University of Helsinki	Sinkkonen, A (corresponding author), Univ Helsinki, Dept Ecol & Environm Sci, Niemenkatu 73, FIN-15140 Lahti, Finland.	aki.sinkkonen@helsinki.fi		sinkkonen, aki/0000-0002-6821-553X				Acharya G, 2006, ULTRASOUND OBST GYN, V28, P150, DOI 10.1002/uog.2711; ALIGHIERI D, 1980, COMMEDIA DIVINA; COULTER JBS, 1975, BRIT J OBSTET GYNAEC, V82, P453, DOI 10.1111/j.1471-0528.1975.tb00669.x; Craig SB, 2000, PLAST RECONSTR SURG, V105, P389, DOI 10.1097/00006534-200001000-00064; Gadelha-Costa A, 2007, EUR J OBSTET GYN R B, V132, P148, DOI 10.1016/j.ejogrb.2006.11.003; Ghezzi F, 2002, ULTRASOUND OBST GYN, V19, P235, DOI 10.1046/j.1469-0705.2002.00650.x; Groth M, 2000, PSYCHOANAL PSYCHOL, V17, P360, DOI 10.1037/0736-9735.17.2.360; HODGKINSON DJ, 1983, AESTHET PLAST SURG, V7, P221, DOI 10.1007/BF01570663; Huopio H, 2000, J CLIN INVEST, V106, P897, DOI 10.1172/JCI9804; HUTTON EK, 2007, JAMA-J AM MED ASSOC, V297, P1257; Kaukola T, 2005, AM J OBSTET GYNECOL, V193, P414, DOI 10.1016/j.ajog.2004.12.005; KONIG R, 1999, SUPER PARADISE; MARKMAN B, 1987, PLAST RECONSTR SURG, V80, P248, DOI 10.1097/00006534-198708000-00015; MAYNARD-SMITH J., 2003, ANIMAL SIGNALS; Mercer JS, 2006, PEDIATRICS, V117, P1235, DOI 10.1542/peds.2005-1706; NERET G, 1992, TAMARA LEMPICKA 1898; Olofsson P, 2004, ACTA OBSTET GYN SCAN, V83, P440, DOI 10.1111/j.0001-6349.2004.00339.x; Pettay JE, 2008, EVOLUTION, V62, P2297, DOI 10.1111/j.1558-5646.2008.00452.x; Rozen SM, 2007, PLAST RECONSTR SURG, V119, P2255, DOI 10.1097/01.prs.0000261037.69256.3e; SIMS M, 2003, A NAVEL NATURAL CULT; Skulstad SM, 2006, ULTRASOUND OBST GYN, V28, P692, DOI 10.1002/uog.3814; Thorpe SKS, 2007, SCIENCE, V316, P1328, DOI 10.1126/science.1140799; Weissman A, 1997, J ULTRAS MED, V16, P691	23	5	5	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					10	12		10.1096/fj.09-0104ufm	http://dx.doi.org/10.1096/fj.09-0104ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	19118079				2022-12-28	WOS:000262095500003
J	Jadin, L; Wu, XL; Ding, H; Frost, GI; Onclinx, C; Triggs-Raine, B; Flamion, B				Jadin, Laurence; Wu, Xiaoli; Ding, Hao; Frost, Gregory I.; Onclinx, Cecile; Triggs-Raine, Barbara; Flamion, Bruno			Skeletal and hematological anomalies in HYAL2-deficient mice: a second type of mucopolysaccharidosis IX?	FASEB JOURNAL			English	Article						hyaluronan; hyaluronidase; sinusoidal endothelial cells; hemolysis; frontonasal suture	JAAGSIEKTE SHEEP RETROVIRUS; HYALURONIC-ACID; CONGENITAL-ANOMALIES; SERUM HYALURONAN; ENDOCYTOSIS HARE; RAT-LIVER; RECEPTOR; GENES; MOUSE; TRANSFORMATION	The metabolism of hyaluronan (HA) relies on HA synthases and hyaluronidases, among which hyaluronidase-1 (HYAL1) and -2 (HYAL2) have been proposed as key actors. Congenital HYAL1 deficiency leads to mucopolysaccharidosis IX (MPS IX), a rare lysosomal storage disorder characterized by joint abnormalities. Knowledge of HYAL2 is limited. This protein displays weak in vitro hyaluronidase activity and acts as a receptor for oncogenic ovine retroviruses. We have generated HYAL2-deficient mice through a conditional Cre-lox system. Hyal2(-/-) mice are viable and fertile. They exhibit localized congenital defects in frontonasal and vertebral bone formation and suffer from mild thrombocytopenia and chronic, possibly intravascular, hemolysis. In addition, Hyal2(-/-) mice display 10-fold increases in plasma levels of HA and 2-fold increases in plasma hyaluronidase activity. Globally, there is no HA accumulation in tissues, including bones, but liver sinusoidal cells seem overloaded with undigested HA. Taken together, these elements demonstrate for the first time that murine HYAL2 has a physiological activity in vivo that is relevant for cranio-vertebral bone formation, maintenance of plasma HA concentrations, and erythrocyte and platelet homeostasis. In addition, the viability of HYAL2-deficient mice raises the possibility that a similar defect, defining a new MPS disorder, exists in humans.-Jadin, L., Wu, X., Ding, H., Frost, G. I., Onclinx, C., Triggs-Raine, B., Flamion, B. Skeletal and hematological anomalies in HYAL2-deficient mice: a second type of mucopolysaccharidosis IX? FASEB J. 22, 4316-4326 (2008)	[Jadin, Laurence; Onclinx, Cecile; Flamion, Bruno] Univ Namur, Lab Physiol & Pharmacol, URPhyM, B-5000 Namur, Belgium; [Wu, Xiaoli; Ding, Hao; Triggs-Raine, Barbara] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada; [Frost, Gregory I.] Halozyme Therapeut, San Diego, CA USA	University of Namur; University of Manitoba; Halozyme	Flamion, B (corresponding author), Univ Namur, Lab Physiol & Pharmacol, URPhyM, 61 Rue Bruxelles, B-5000 Namur, Belgium.	bruno.flamion@fundp.ac.be	Triggs-Raine, Barbara/AAF-6209-2021	Triggs-Raine, Barbara/0000-0003-4719-6779	Canadian Institutes of Health Research Innovative Technologies In Multidisciplinary Health Research Training (CIHR ITMHRT) program in Winnipeg	Canadian Institutes of Health Research Innovative Technologies In Multidisciplinary Health Research Training (CIHR ITMHRT) program in Winnipeg(Canadian Institutes of Health Research (CIHR))	During this study, Laurence Jadin was a Research Fellow from the Belgian Fonds de la Recherche Scientifique-Fonds National de la Recherche Scientifique (F.R.S.-FNRS) and a recipient of a short-term training award from the Canadian Institutes of Health Research Innovative Technologies In Multidisciplinary Health Research Training (CIHR ITMHRT) program in Winnipeg. We thank Olivier DeBacker for providing us with ES cells, Thierry VanReeth (BioVallee, Gosselies, Belgium) for PGK-Cre mice, Anirban Kundu for measurement of plasma hyaluronan and hyaluronidase samples, and Catherine Lambert for advice.	Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Chajara A, 2000, DIABETOLOGIA, V43, P387; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; DEACIUC IV, 1993, HEPATOLOGY, V17, P266, DOI 10.1002/hep.1840170217; ELLIOTT S, 1988, ARCH DIS CHILD, V63, P1484, DOI 10.1136/adc.63.12.1484; Enomoto Katsuhiko, 2004, Medical Electron Microscopy, V37, P208, DOI 10.1007/s00795-004-0261-4; FRASER JRE, 1985, CELL TISSUE RES, V242, P505; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Frost GI, 1997, ANAL BIOCHEM, V251, P263, DOI 10.1006/abio.1997.2262; Harada H, 2007, J BIOL CHEM, V282, P5597, DOI 10.1074/jbc.M608358200; Harris EN, 2004, J BIOL CHEM, V279, P36201, DOI 10.1074/jbc.M405322200; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; HENSINGER RN, 1978, ORTHOP CLIN N AM, V9, P901; Ikegami-Kawai M, 2004, GLYCOBIOLOGY, V14, P65, DOI 10.1093/glycob/cwh011; Ishii M, 2003, DEVELOPMENT, V130, P6131, DOI 10.1242/dev.00793; Jiang D, 2007, ANNU REV CELL DEV BI, V23, P435, DOI 10.1146/annurev.cellbio.23.090506.123337; JOHNSON DR, 1976, J ANAT, V121, P507; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Martin DC, 2008, HUM MOL GENET, V17, P1904, DOI 10.1093/hmg/ddn088; Mikles M, 1997, Am J Orthop (Belle Mead NJ), V26, P533; Myles DG, 1997, BIOL REPROD, V56, P320, DOI 10.1095/biolreprod56.2.320; Nagy A., 2003, MANIPULATING MOUSE E; Natowicz MR, 1996, NEW ENGL J MED, V335, P1029, DOI 10.1056/NEJM199610033351405; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Ramsden CA, 2000, J PEDIATR-US, V136, P62, DOI 10.1016/S0022-3476(00)90051-9; SHERIDAN O, 1994, J CRAN GENET DEV BIO, V14, P7; SMOKER WRK, 1994, RADIOGRAPHICS, V14, P255, DOI 10.1148/radiographics.14.2.8190952; Stern R, 2004, EUR J CELL BIOL, V83, P317, DOI 10.1078/0171-9335-00392; Stern R, 2006, EUR J CELL BIOL, V85, P699, DOI 10.1016/j.ejcb.2006.05.009; Suehiro Y, 2007, EUR J HAEMATOL, V79, P349, DOI 10.1111/j.1600-0609.2007.00909.x; Triggs-Raine B, 1999, P NATL ACAD SCI USA, V96, P6296, DOI 10.1073/pnas.96.11.6296; TRUSLOVE GM, 1952, J GENET, V51, P115, DOI 10.1007/BF02986709; Vigdorovich V, 2007, J VIROL, V81, P3124, DOI 10.1128/JVI.02177-06; Wadhwa S, 2007, BONE, V40, P861, DOI 10.1016/j.bone.2006.11.003; Weigel JA, 2003, J BIOL CHEM, V278, P9808, DOI 10.1074/jbc.M211462200; Weigel PH, 2007, J BIOL CHEM, V282, P36777, DOI 10.1074/jbc.R700036200; Zhang H, 2005, MOL REPROD DEV, V72, P404, DOI 10.1002/mrd.20360	42	68	71	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4316	4326		10.1096/fj.08-111997	http://dx.doi.org/10.1096/fj.08-111997			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18772348				2022-12-28	WOS:000261254800030
J	Wang, Q; Wang, YL; Minto, AW; Wang, JH; Shi, Q; Li, XM; Quigg, RJ				Wang, Qiang; Wang, Youli; Minto, Andrew W.; Wang, Jinhua; Shi, Qun; Li, Xinmin; Quigg, Richard J.			MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy	FASEB JOURNAL			English	Article						diabetes; microRNA; glomerulus; extracellular matrix	SUPEROXIDE-DISMUTASE; MESANGIAL CELLS; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; KIDNEY GLOMERULI; RENAL INJURY; ACTIVATION; APOPTOSIS; GLUCOSE; MECHANISM	Intrinsic glomerular cells in a diabetic milieu have transcriptional activation of genes that influence the development of diabetic nephropathy. The cellular repertoire of microRNAs can regulate translation of these expressed genes into proteins. Fibronectin is a key matrix protein accumulated in excess in diabetic nephropathy. Here, we exposed cultured human and mouse mesangial cells to high glucose and transforming growth factor-beta to simulate the diabetic milieu. In these conditions in vitro, as well as in mouse diabetic nephropathy models in vivo, microRNA-377 was consistently up-regulated relative to controls. Through a combination of computational and biological approaches, we identified relevant miR-377 target genes. Although fibronectin was induced by miR-377, it was not a direct target of miR-377. However, miR-377 led to reduced expressions of p21-activated kinase and superoxide dismutase, which enhanced fibronectin protein production. Thus, overexpression of miR-377 in diabetic nephropathy indirectly leads to increased fibronectin protein production; as such, miR-377 can have a critical role in the pathophysiology of this prevalent human disease.	[Wang, Qiang; Wang, Youli; Minto, Andrew W.; Wang, Jinhua; Shi, Qun; Li, Xinmin; Quigg, Richard J.] Univ Chicago, Nephrol Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	Quigg, RJ (corresponding author), Univ Chicago, Nephrol Sect, Dept Med, 5841 S Maryland Ave,MC5100,AMB-S523, Chicago, IL 60637 USA.	rquigg@uchicago.edu			Juvenile Diabetes Research Foundation; National Institutes of Health [R21DK057684, U24DK058820]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK057684, U24DK058820] Funding Source: NIH RePORTER	Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in its entirety by an innovation grant from the Juvenile Diabetes Research Foundation. Funding from the National Institutes of Health (R21DK057684 and U24DK058820) was essential for our earlier supporting studies in diabetic nephropathy.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Chen C, 2006, FEBS LETT, V580, P813, DOI 10.1016/j.febslet.2005.12.097; Craven PA, 2001, METABOLISM, V50, P1043, DOI 10.1053/meta.2001.25802; Craven PA, 2001, DIABETES, V50, P2114, DOI 10.2337/diabetes.50.9.2114; DeRubertis FR, 2004, DIABETES, V53, P762, DOI 10.2337/diabetes.53.3.762; DeRubertis FR, 2007, METABOLISM, V56, P1256, DOI 10.1016/j.metabol.2007.04.024; DOI T, 1990, LAB INVEST, V63, P204; Duan XY, 2006, J BIOL CHEM, V281, P36526, DOI 10.1074/jbc.M605169200; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; FROST JA, 2000, J CELL BIOL, V162, P281; Haneda M, 2003, J AM SOC NEPHROL, V14, P1374, DOI 10.1097/01.ASN.0000064500.89551.76; Ismail N, 1999, KIDNEY INT, V55, P1, DOI 10.1046/j.1523-1755.1999.00232.x; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Johnson Felicity, 2005, Molecular Aspects of Medicine, V26, P340, DOI 10.1016/j.mam.2005.07.006; Kang BPS, 2003, AM J PHYSIOL-RENAL, V284, pF455, DOI 10.1152/ajprenal.00137.2002; Kato M, 2007, P NATL ACAD SCI USA, V104, P3432, DOI 10.1073/pnas.0611192104; Kloosterman WP, 2004, NUCLEIC ACIDS RES, V32, P6284, DOI 10.1093/nar/gkh968; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; LEITER EH, 1987, AM J PATHOL, V128, P380; Lin CL, 2008, AM J NEPHROL, V28, P290, DOI 10.1159/000111142; Lin Xia, 2007, Journal of Genetics and Genomics, V34, P1, DOI 10.1016/S1673-8527(07)60001-0; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Lovis P, 2008, BIOL CHEM, V389, P305, DOI 10.1515/BC.2008.026; Mason RM, 2003, J AM SOC NEPHROL, V14, P1358, DOI 10.1097/01.ASN.0000065640.77499.D7; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Neumann M, 2006, BIOL CHEM, V387, P79, DOI 10.1515/BC.2006.011; Noor Rana, 2002, Med Sci Monit, V8, pRA210; Obernosterer G, 2007, NAT PROTOC, V2, P1508, DOI 10.1038/nprot.2007.153; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Poy MN, 2007, DIABETES OBES METAB, V9, P67, DOI 10.1111/j.1463-1326.2007.00775.x; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; QUIGG RJ, 1995, KIDNEY INT, V48, P412, DOI 10.1038/ki.1995.309; Ramakrishna V, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-22; Rychlik I, 1998, NEPHROL DIAL TRANSPL, V13, P6, DOI 10.1093/ndt/13.suppl_8.6; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Schiffer M, 2002, J AM SOC NEPHROL, V13, P2657, DOI 10.1097/01.ASN.0000033276.06451.50; Schnaper HW, 2003, AM J PHYSIOL-RENAL, V284, pF243, DOI 10.1152/ajprenal.00300.2002; Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Takemoto M, 2002, AM J PATHOL, V161, P799, DOI 10.1016/S0002-9440(10)64239-3; Uchimura K, 1999, J DIABETES COMPLICAT, V13, P264, DOI 10.1016/S1056-8727(99)00053-7; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wang Q, 2008, P NATL ACAD SCI USA, V105, P2889, DOI 10.1073/pnas.0800178105; Wu DT, 2005, J AM SOC NEPHROL, V16, P3211, DOI 10.1681/ASN.2004121055; Zhang Z, 2008, KIDNEY INT, V73, P163, DOI 10.1038/sj.ki.5002572; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638	48	327	355	1	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4126	4135		10.1096/fj.08-112326	http://dx.doi.org/10.1096/fj.08-112326			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18716028	Green Published			2022-12-28	WOS:000261254800012
J	Zeerleder, S; Zwart, B; Velthuis, HT; Stephan, F; Manoe, R; Rensink, I; Aarden, LA				Zeerleder, Sacha; Zwart, Bas; Velthuis, Henk te; Stephan, Femke; Manoe, Rishi; Rensink, Irma; Aarden, Lucien A.			Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP)	FASEB JOURNAL			English	Article						apoptosis; hyaluronan; binding protein; SLE; plasmin; monoclonal; single chain	SYSTEMIC-LUPUS-ERYTHEMATOSUS; HYALURONAN-BINDING PROTEIN; SECONDARY NECROTIC CELLS; AMYLOID-P COMPONENT; APOPTOTIC CELLS; SERINE-PROTEASE; HUMAN PLASMA; AUTOANTIGENS; PURIFICATION; MACROPHAGES	Plasma proteins such as early complement components and IgM are involved in the removal of late apoptotic or secondary necrotic (sn) cells. We have recently described how a plasma protease that could be inhibited by the protease inhibitor aprotinin was essential to remove nucleosomes from sn cells. An obvious candidate, plasmin, did indeed have nucleosome-releasing factor (NRF) activity. However, recalcified plasma (r-plasma) retained its NRF activity after plasminogen depletion, which suggests the existence of another protease responsible for NRF activity in plasma. In this study we have used size-exclusion and anion-exchange chromatography to purify the protease responsible for NRF activity in plasma. SDS-PAGE analysis of chromatography fractions containing NRF activity revealed a protein band corresponding with NRF activity. Sequence analysis showed this band to be factor VII-activating protease (FSAP). We developed monoclonal antibodies to FSAP and were able to completely inhibit NRF activity in plasma with monoclonal antibodies to FSAP. Using affinity chromatography we were able to purify single-chain (sc) FSAP from r-plasma. Purified scFSAP efficiently removes nucleosomes from sn cells. We report that factor VII-activating protease may function in cellular homeostasis by catalyzing the release of nucleosomes from secondary necrotic cells.	[Zeerleder, Sacha; Zwart, Bas; Stephan, Femke; Manoe, Rishi; Rensink, Irma; Aarden, Lucien A.] Univ Amsterdam, Acad Med Ctr, Sanquin Res CLB, Dept Immunopathol,Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands; [Velthuis, Henk te] Business Unit Reagents, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Zeerleder, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Sanquin Res CLB, Dept Immunopathol,Landsteiner Lab, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	s.zeerleder@sanquin.nl			Landsteiner Foundation for Blood Transfusion Research [LSBR 0422]; Dutch Arthritis Association [97.402.01]	Landsteiner Foundation for Blood Transfusion Research; Dutch Arthritis Association	S.Z. was supported by a grant of the Landsteiner Foundation for Blood Transfusion Research (LSBR 0422). B.Z. was supported by grant 97.402.01 of the Dutch Arthritis Association. We thank Piet Modderman for his helpful comments on the manuscript.	Amoura Z, 1997, ARTHRITIS RHEUM, V40, P2217, DOI 10.1002/art.1780401217; Bijl M, 2003, ARTHRITIS RHEUM, V48, P248, DOI 10.1002/art.10737; Boes M, 2000, P NATL ACAD SCI USA, V97, P1184, DOI 10.1073/pnas.97.3.1184; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; Cocca BA, 2002, J IMMUNOL, V169, P159, DOI 10.4049/jimmunol.169.1.159; Etscheid M, 2000, BIOL CHEM, V381, P1223, DOI 10.1515/BC.2000.150; Familian A, 2001, J IMMUNOL, V167, P647, DOI 10.4049/jimmunol.167.2.647; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Hunfeld A, 1999, FEBS LETT, V456, P290, DOI 10.1016/S0014-5793(99)00959-X; Kannemeier C, 2004, FASEB J, V18, P728, DOI 10.1096/fj.03-0898fje; Kannemeier C, 2001, EUR J BIOCHEM, V268, P3789, DOI 10.1046/j.1432-1327.2001.02285.x; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Nakazawa F, 2005, BIOCHEM J, V385, P831, DOI 10.1042/BJ20041021; Napirei M, 2004, ARTHRITIS RHEUM-US, V50, P1873, DOI 10.1002/art.20267; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Radic M, 2004, J IMMUNOL, V172, P6692, DOI 10.4049/jimmunol.172.11.6692; Romisch J, 1999, BLOOD COAGUL FIBRIN, V10, P471; Romisch J, 1999, HAEMOSTASIS, V29, P292; Romisch J, 2001, BLOOD COAGUL FIBRIN, V12, P375, DOI 10.1097/00001721-200107000-00007; RUMORE PM, 1990, J CLIN INVEST, V86, P69, DOI 10.1172/JCI114716; Sedding D, 2006, J EXP MED, V203, P2801, DOI 10.1084/jem.20052546; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; van Nieuwenhuijze AEM, 2003, ANN RHEUM DIS, V62, P10, DOI 10.1136/ard.62.1.10; Vostrov AR, 2000, J BIOL CHEM, V275, P22978, DOI 10.1074/jbc.M904640199; Zeerleder S, 2007, FEBS LETT, V581, P5382, DOI 10.1016/j.febslet.2007.10.037; Zwart B, 2004, AUTOIMMUNITY, V37, P95, DOI 10.1080/0891693042000196183	30	47	47	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2008	22	12					4077	4084		10.1096/fj.08-110429	http://dx.doi.org/10.1096/fj.08-110429			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18753248				2022-12-28	WOS:000261254800007
J	Asprodites, N; Zheng, L; Geng, D; Velasco-Gonzalez, C; Sanchez-Perez, L; Davila, E				Asprodites, Nicole; Zheng, Liqin; Geng, Degui; Velasco-Gonzalez, Cruz; Sanchez-Perez, Luis; Davila, Eduardo			Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity	FASEB JOURNAL			English	Article						T cell activation; costimulation; immunotherapy	TOLL-LIKE RECEPTORS; CELL-ACTIVATION; RHEUMATOID-ARTHRITIS; DIFFERENTIAL ROLES; DENDRITIC CELLS; CANCER-THERAPY; IFN-GAMMA; ANTIGEN; TLR2; EXPRESSION	Toll-like receptors (TLRs) are among the fundamental molecules that alert the immune system to the presence of an infection by recognizing pathogen-associated molecules. Much of our understanding regarding TLR function stems from the study of innate immune cells. Recent studies by several groups, including ours, have shown that TLRs can function as costimulatory receptors for antigen-specific T cells, resulting in enhanced T-cell survival and increased expression of effector molecules. We report that the ligation of the TLR1/2 heterodimer on OT-1 cytotoxic T-lymphocytes (CTL) but not TLR2(-/-)OT-1 T cells increased cytolytic activity in vitro and in vivo. On the basis of these data, we tested the hypothesis that TLR1/2 stimulation on CTLs would enhance antitumor activity in a therapeutic model of B16-Ova melanoma. Adoptive OT-1 T-cell transfer into wild-type and MyD88(-/-) mice, followed by injection with TLR1/2 ligand, resulted in a synergistic antitumor effect, which correlated with the induction of CD8 T cells specific to various tumor antigens. In contrast, mice receiving TLR2-/-OT-1 T cells and TLR1/2 ligand showed minimal therapeutic efficacy. These findings emphasize the physiological significance of TLR2 engagement on CTLs and could make possible new approaches for the development of effective immunotherapies by manipulating TLR signaling within CTLs.	[Davila, Eduardo] Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70112 USA; [Asprodites, Nicole; Zheng, Liqin; Geng, Degui; Davila, Eduardo] Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; [Velasco-Gonzalez, Cruz] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, New Orleans, LA 70112 USA; [Sanchez-Perez, Luis] Duke Univ, Med Ctr, Durham, NC USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Duke University	Davila, E (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, CSRB Rm 454,533 Bolivar, New Orleans, LA 70112 USA.	edavil@lsuhsc.edu			National Institutes of Health Center for Biomedical Research Center Excellence [1P20 RR021970]; Louisiana Cancer Research Consortium; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021970] Funding Source: NIH RePORTER	National Institutes of Health Center for Biomedical Research Center Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Cancer Research Consortium; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Research was supported by at National Institutes of Health Center for Biomedical Research Center Excellence grant (1P20 RR021970) and the Louisiana Cancer Research Consortium. The authors declare no competing financial interests.	Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Bendigs S, 1999, EUR J IMMUNOL, V29, P1209, DOI 10.1002/(SICI)1521-4141(199904)29:04<1209::AID-IMMU1209>3.0.CO;2-J; Buwitt-Beckmann U, 2006, J BIOL CHEM, V281, P9049, DOI 10.1074/jbc.M512525200; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; Cottalorda A, 2006, EUR J IMMUNOL, V36, P1684, DOI 10.1002/eji.200636181; Davila E, 2000, J IMMUNOL, V165, P539, DOI 10.4049/jimmunol.165.1.539; Davila E, 2005, J IMMUNOL, V174, P7292, DOI 10.4049/jimmunol.174.11.7292; Davila E, 2003, CANCER RES, V63, P3281; Davila E, 2002, BLOOD, V100, P2537, DOI 10.1182/blood-2002-02-0401; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Dudley ME, 2001, J IMMUNOTHER, V24, P363, DOI 10.1097/00002371-200107000-00012; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480; Gelman AE, 2004, J IMMUNOL, V172, P6065, DOI 10.4049/jimmunol.172.10.6065; Gelman AE, 2006, IMMUNITY, V25, P783, DOI 10.1016/j.immuni.2006.08.023; Ghosh TK, 2006, CELL IMMUNOL, V243, P48, DOI 10.1016/j.cellimm.2006.12.002; Glimcher LH, 2004, NAT REV IMMUNOL, V4, P900, DOI 10.1038/nri1490; Ingalls RR, 2000, J ENDOTOXIN RES, V6, P411, DOI 10.1177/09680519000060050301; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jahrsdorfer B, 2002, J LEUKOCYTE BIOL, V72, P83; June CH, 2007, J CLIN INVEST, V117, P1204, DOI 10.1172/JCI31446; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Kurts C, 1998, J EXP MED, V188, P409, DOI 10.1084/jem.188.2.409; Leen AM, 2007, ANNU REV IMMUNOL, V25, P243, DOI 10.1146/annurev.immunol.25.022106.141527; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Lugo-Villarino G, 2005, P NATL ACAD SCI USA, V102, P13248, DOI 10.1073/pnas.0506638102; Lugo-Villarino G, 2003, P NATL ACAD SCI USA, V100, P7749, DOI 10.1073/pnas.1332767100; Matsuguchi T, 2000, BLOOD, V95, P1378, DOI 10.1182/blood.V95.4.1378.004k08_1378_1385; Mokuno Y, 2000, J IMMUNOL, V165, P931, DOI 10.4049/jimmunol.165.2.931; Overwijk WW, 1998, J EXP MED, V188, P277, DOI 10.1084/jem.188.2.277; Pasare C, 2004, IMMUNITY, V21, P733, DOI 10.1016/j.immuni.2004.10.006; Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205; Prins RM, 2006, J IMMUNOL, V176, P157, DOI 10.4049/jimmunol.176.1.157; Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51; Schwarz K, 2003, EUR J IMMUNOL, V33, P1465, DOI 10.1002/eji.200323919; Sobek V, 2004, ARTHRITIS RES THER, V6, pR433, DOI 10.1186/ar1212; Tabiasco J, 2006, J IMMUNOL, V177, P8708, DOI 10.4049/jimmunol.177.12.8708; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Terato K, 1995, AUTOIMMUNITY, V22, P137, DOI 10.3109/08916939508995311; van der Heijden IM, 2000, ARTHRITIS RHEUM-US, V43, P593, DOI 10.1002/1529-0131(200003)43:3<593::AID-ANR16>3.0.CO;2-1; Yi AK, 1996, J IMMUNOL, V157, P4918; Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje; Zhang T, 2004, FASEB J, V18, P600, DOI 10.1096/fj.03-0881fje; Zheng LQ, 2008, BLOOD, V111, P2704, DOI 10.1182/blood-2007-07-104141	49	66	68	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3628	3637		10.1096/fj.08-108274	http://dx.doi.org/10.1096/fj.08-108274			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18587008	Green Published			2022-12-28	WOS:000259642600024
J	Furze, RC; Rankin, SM				Furze, Rebecca C.; Rankin, Sara M.			The role of the bone marrow in neutrophil clearance under homeostatic conditions in the mouse	FASEB JOURNAL			English	Article						macrophage; apoptosis; chemokine	COLONY-STIMULATING FACTOR; APOPTOTIC CELLS; CYTOKINE PRODUCTION; B-LYMPHOPOIESIS; MACROPHAGES; GRANULOCYTE; PHAGOCYTOSIS; IL-17; MICE; GRANULOPOIESIS	In humans, 10(11) neutrophils are released from the bone marrow per day, and these cells have a half-life in the blood of only similar to 6.5 h. Although it is generally believed that neutrophils are cleared from the circulation via the liver and spleen, in this study using (111)In-labeled senescent neutrophils, we show that in mice, 32% of neutrophils are cleared from the circulation via the bone marrow. We have previously shown that senescent neutrophils home to the bone marrow in a CXCR4-dependent manner, and we show here that pretreatment of neutrophils with pertussis toxin significantly inhibits neutrophil clearance via the bone marrow (75%), consistent with a role for chemokines in this process. By labeling senescent neutrophils with inert fluorescent microspheres, we have tracked their fate and shown that in vivo, they are ultimately phagocytosed by bone marrow stromal macrophages. Finally, we show that under noninflammatory conditions, circulating levels of neutrophils are regulated by granulocyte-colony stimulating factor (G-CSF), but not interleukin-17. Interestingly, we report that the uptake of apoptotic neutrophils by bone marrow macrophages stimulates their production of G-CSF in vitro. Taken together, these data provide evidence that the bone marrow represents a major site of neutrophil clearance in mice.	[Furze, Rebecca C.; Rankin, Sara M.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England	Imperial College London	Rankin, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	s.rankin@imperial.ac.uk			Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank C. A. Dewar for help with the TEM. The authors also thank R. Palframan and S. Rapecki (UCB Celltech, Slough, Berkshire, UK) for kindly providing the antimurine IL-17 and isotype control 101.4 used in this study. This work was funded by the Wellcome Trust. The authors declare no competing financial interests.	CHERVENICK PA, 1968, AM J PHYSIOL, V215, P353, DOI 10.1152/ajplegacy.1968.215.2.353; DEXTER TM, 1977, BIOMED EXPRESS, V27, P344; Dogusan Z, 2004, J IMMUNOL, V172, P4717, DOI 10.4049/jimmunol.172.8.4717; DRESCH C, 1980, J CLIN PATHOL, V33, P1110, DOI 10.1136/jcp.33.11.1110; FADOK VA, 1992, J IMMUNOL, V149, P4029; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 1998, BIOCHEM SOC T, V26, P653, DOI 10.1042/bst0260653; Forlow SB, 2001, BLOOD, V98, P3309, DOI 10.1182/blood.V98.12.3309; Hareng L, 2002, BIOL CHEM, V383, P1501, DOI 10.1515/BC.2002.172; KING AG, 1988, J IMMUNOL, V141, P2016; KITTLER ELW, 1992, BLOOD, V79, P3168; Laan M, 1999, J IMMUNOL, V162, P2347; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Lovas K, 1996, EUR J HAEMATOL, V56, P221; Lucas M, 2003, J IMMUNOL, V171, P2610, DOI 10.4049/jimmunol.171.5.2610; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; MAUER AM, 1960, J CLIN INVEST, V39, P1481, DOI 10.1172/JCI104167; Metcalf D, 1996, BLOOD, V88, P3755, DOI 10.1182/blood.V88.10.3755.bloodjournal88103755; Miyamoto M, 2003, J IMMUNOL, V170, P4665, DOI 10.4049/jimmunol.170.9.4665; Nagase H, 2002, J LEUKOCYTE BIOL, V71, P711; OSMOND DG, 1994, IMMUNOL REV, V142, P209, DOI 10.1111/j.1600-065X.1994.tb00891.x; Sadahira Y, 1999, PATHOL INT, V49, P841, DOI 10.1046/j.1440-1827.1999.00954.x; SAVERYMUTTU SH, 1985, BRIT J HAEMATOL, V61, P675, DOI 10.1111/j.1365-2141.1985.tb02882.x; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011; Suratt BT, 2001, AM J PHYSIOL-LUNG C, V281, pL913, DOI 10.1152/ajplung.2001.281.4.L913; TEMELES DS, 1993, EXP HEMATOL, V21, P388; THAKUR ML, 1977, J NUCL MED, V18, P1014; Witowski J, 2000, J IMMUNOL, V165, P5814, DOI 10.4049/jimmunol.165.10.5814; Witowski J, 2007, KIDNEY INT, V71, P514, DOI 10.1038/sj.ki.5002082; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Ye P, 2001, AM J RESP CELL MOL, V25, P335, DOI 10.1165/ajrcmb.25.3.4424	33	133	134	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3111	3119		10.1096/fj.08-109876	http://dx.doi.org/10.1096/fj.08-109876			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18509199	Green Published			2022-12-28	WOS:000258761300003
J	Pan, YH; Jing, RF; Pitre, A; Williams, BJ; Skalli, O				Pan, Yihang; Jing, Runfeng; Pitre, Aaron; Williams, Briana Jill; Skalli, Omar			Intermediate filament protein synemin contributes to the migratory properties of astrocytoma cells by influencing the dynamics of the actin cytoskeleton	FASEB JOURNAL			English	Article						glioma; invasion; alpha-actinin	ENDOTHELIAL-CELLS; COMPLEMENTARY-DNA; FOCAL ADHESIONS; ALPHA-ACTININ; CANCER-CELLS; VIMENTIN; EXPRESSION; MOTILITY; INVASION; FIBROBLASTS	We have shown previously that, in astrocytoma cells, synemin is present at the leading edge, an unusual localization for an intermediate filament (IF) protein. Here, we report that synemin down-regulation with specific small hairpin RNAs (shRNAs) sharply decreased the migration of astrocytoma cells. The presence of synemin at the leading edge also correlated with a high migratory potential, as shown by comparing astrocytoma cells to carcinoma cells without synemin at the leading edge. Synemin-silenced astrocytoma cells were smaller and spread more slowly than controls. In addition, synemin silencing reduced proliferation without increasing apoptosis. The adhesion to substratum and distribution of vinculin in focal contacts of synemin-silenced astrocytoma cells were similar to those of controls. Synemin-silenced cells, however, exhibited a reduction in the amount of filamentous (F) -actin and of alpha-actinin, but not of vinculin, associated with F-actin. Altogether, these results demonstrate that synemin is important for the malignant behavior of astrocytoma cells and that it contributes to the high motility of these cells by modulating the dynamics of alpha-actinin and actin.	[Pan, Yihang; Jing, Runfeng; Pitre, Aaron; Skalli, Omar] Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA; [Williams, Briana Jill] Louisiana State Univ, Hlth Sci Ctr, Dept Urol, Shreveport, LA 71130 USA; [Pan, Yihang; Jing, Runfeng; Pitre, Aaron; Williams, Briana Jill; Skalli, Omar] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Skalli, O (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, 1501 Kings Hwy, Shreveport, LA 71130 USA.	oskall@lsuhsc.edu	Pitre, Aaron/C-3423-2016; Skalli, Omar/D-4980-2013	Pitre, Aaron/0000-0002-3017-2140; 	National Institutes of Health [NS-35317]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035317, R29NS035317] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are thankful to Drs. Long Chen and Kathryn Llorens for assistance with the adhesion assays and confocal microscopy, respectively, and to Larry Smart for help with apoptosis assays. This work was supported by National Institutes of Health grant NS-35317 to O.S.	Beil M, 2003, NAT CELL BIOL, V5, P803, DOI 10.1038/ncb1037; Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; Bellin RM, 2001, J BIOL CHEM, V276, P32330, DOI 10.1074/jbc.M104005200; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; Capetanaki Y, 2007, EXP CELL RES, V313, P2063, DOI 10.1016/j.yexcr.2007.03.033; Carlsson L, 2000, HISTOCHEM CELL BIOL, V114, P39; Chou YH, 2007, EXP CELL RES, V313, P2236, DOI 10.1016/j.yexcr.2007.04.008; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; Chun J, 1997, J CELL PHYSIOL, V173, P361, DOI 10.1002/(SICI)1097-4652(199712)173:3<361::AID-JCP8>3.0.CO;2-L; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; Eckes B, 1998, J CELL SCI, V111, P1897; Fukushima N, 2002, MOL BIOL CELL, V13, P2692, DOI 10.1091/mbc.01-09-0465; Gilles C, 1999, J CELL SCI, V112, P4615; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Izmiryan A, 2006, GLIA, V54, P204, DOI 10.1002/glia.20378; Jing RF, 2005, GLIA, V50, P107, DOI 10.1002/glia.20158; Jing RF, 2007, J CELL SCI, V120, P1267, DOI 10.1242/jcs.03423; Kim S, 2007, GENE DEV, V21, P1581, DOI 10.1101/gad.1552107; Kleeberger W, 2007, CANCER RES, V67, P9199, DOI 10.1158/0008-5472.CAN-07-0806; Lee YJ, 2005, MOL BIOTECHNOL, V31, P1, DOI 10.1385/MB:31:1:001; Lepekhin EA, 2001, J NEUROCHEM, V79, P617, DOI 10.1046/j.1471-4159.2001.00595.x; Lohez OD, 2003, J CELL BIOL, V161, P67, DOI 10.1083/jcb.200208140; MANESS PF, 1982, CELL, V30, P253, DOI 10.1016/0092-8674(82)90031-9; MOONEY DJ, 1995, J CELL SCI, V108, P2311; MUGURUMA M, 1992, J BIOL CHEM, V267, P5621; Nakamura F, 2002, J BIOL CHEM, V277, P9148, DOI 10.1074/jbc.M111297200; Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355; Pitre A, 2007, ANAL BIOCHEM, V361, P305, DOI 10.1016/j.ab.2006.11.008; Rafelski SM, 2004, ANNU REV BIOCHEM, V73, P209, DOI 10.1146/annurev.biochem.73.011303.073844; Russell MA, 2006, ARCH BIOCHEM BIOPHYS, V456, P204, DOI 10.1016/j.abb.2006.06.010; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; Schmitt-Graeff A, 2006, HUM PATHOL, V37, P1200, DOI 10.1016/j.humpath.2006.04.017; Sultana S, 2000, GLIA, V30, P143, DOI 10.1002/(SICI)1098-1136(200004)30:2<143::AID-GLIA4>3.0.CO;2-Z; Sun N, 2008, BIOCHEM J, V409, P657, DOI 10.1042/BJ20071188; Titeux M, 2001, EUR J BIOCHEM, V268, P6435, DOI 10.1046/j.0014-2956.2001.02594.x; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Uyama N, 2006, GUT, V55, P1276, DOI 10.1136/gut.2005.078865; Wakatsuki T, 2003, J CELL SCI, V116, P1617, DOI 10.1242/jcs.00340; Ziegler WH, 2006, TRENDS CELL BIOL, V16, P453, DOI 10.1016/j.tcb.2006.07.004	45	38	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3196	3206		10.1096/fj.08-106187	http://dx.doi.org/10.1096/fj.08-106187			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18509200	Green Published			2022-12-28	WOS:000258761300012
J	Lemberger, T; Parkitna, JR; Chai, M; Schuetz, G; Engblom, D				Lemberger, Thomas; Parkitna, Jan Rodriguez; Chai, Minqiang; Schuetz, Guenther; Engblom, David			CREB has a context-dependent role in activity-regulated transcription and maintains neuronal cholesterol homeostasis	FASEB JOURNAL			English	Article						cocaine plasticity; microarray; Cre/loxP; neurodegeneration	GENOME-WIDE ANALYSIS; GENE-EXPRESSION; NERVOUS-SYSTEM; BINDING PROTEIN; CELL-SURVIVAL; IN-VIVO; PHOSPHORYLATION; STIMULATION; ACTIVATION; MUTATION	Induction of specific gene expression patterns in response to activity confers functional plasticity to neurons. A principal role in the regulation of these processes has been ascribed to the cAMP responsive element binding protein (CREB). Using genome-wide expression profiling in mice lacking CREB in the forebrain, accompanied by deletion of the cAMP responsive element modulator gene (CREM), we here show that the role of these proteins in activity-induced gene expression is surprisingly selective and highly context dependent. Thus, only a very restricted subset of activity-induced genes (i.e., Gadd45b or Nr4a2) requires these proteins for their induction in the hippocampus after kainic acid administration, while they are required for most of the cocaine-induced expression changes in the striatum. Interestingly, in the absence of CREB, CREM is able to rescue activity-regulated transcription, which strengthens the notion of overlapping functions of the two proteins. In addition, we show that cholesterol metabolism is dysregulated in the brains of mutant mice, as reflected coordinated expression changes in genes involved in cholesterol synthesis and neuronal accumulation of cholesterol. These findings provide novel insights into the role of CREB and CREM in stimulus-dependent transcription and neuronal homeostasis.	[Lemberger, Thomas; Parkitna, Jan Rodriguez; Chai, Minqiang; Schuetz, Guenther; Engblom, David] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Lemberger, Thomas; Parkitna, Jan Rodriguez; Chai, Minqiang; Schuetz, Guenther; Engblom, David] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Linkoping University	Schuetz, G (corresponding author), German Canc Res Ctr, D-69120 Heidelberg, Germany.	g.schuetz@dkfz.de	Lemberger, Thomas/A-7301-2008; Rodriguez, Jan/I-2910-2012	Lemberger, Thomas/0000-0002-2499-4025; Rodriguez, Jan/0000-0003-0367-2331				Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Cattaneo E, 1998, J NEUROSCI RES, V53, P223, DOI 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; Cooper SJ, 2007, GENOME RES, V17, P136, DOI 10.1101/gr.5875007; Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050; Fagan AM, 2000, MICROSC RES TECHNIQ, V50, P297, DOI 10.1002/1097-0029(20000815)50:4<297::AID-JEMT9>3.0.CO;2-C; Funfschilling U, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-1; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; Guzowski JF, 2002, HIPPOCAMPUS, V12, P86, DOI 10.1002/hipo.10010; Halder SK, 2002, MOL ENDOCRINOL, V16, P1853, DOI 10.1210/me.2001-0262; Han JH, 2007, SCIENCE, V316, P457, DOI [10.1126/science.1139438, 10.1126/science.1134697]; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Lanahan A, 1998, NEUROBIOL LEARN MEM, V70, P37, DOI 10.1006/nlme.1998.3836; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McClung CA, 2003, NAT NEUROSCI, V6, P1208, DOI 10.1038/nn1143; Michikawa Makoto, 2004, Current Alzheimer Research, V1, P271, DOI 10.2174/1567205043331983; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Valenza M, 2007, HUM MOL GENET, V16, P2187, DOI 10.1093/hmg/ddm170; Walton M, 1999, J NEUROCHEM, V73, P1836; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; Xu W, 2007, EMBO J, V26, P2890, DOI 10.1038/sj.emboj.7601734; Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	42	60	61	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2872	2879		10.1096/fj.08-107888	http://dx.doi.org/10.1096/fj.08-107888			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18424767				2022-12-28	WOS:000258089300027
J	Mathew, LK; Sengupta, SS; Ladu, J; Andreasen, EA; Tanguay, RL				Mathew, Lijoy K.; Sengupta, Sumitra S.; Ladu, Jane; Andreasen, Eric A.; Tanguay, Robert L.			Crosstalk between AHR and Wnt signaling through R-Spondin1 impairs tissue regeneration in zebrafish	FASEB JOURNAL			English	Article						TCDD; dioxin; fin; differentiation; LRP6	ARYL-HYDROCARBON RECEPTOR; BETA-CATENIN ACTIVATION; HEMATOPOIETIC STEM-CELL; FIN REGENERATION; CHONDROCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; R-SPONDIN; GROWTH; PATHWAY	Exposure to dioxins, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), causes a wide array of toxicities in vertebrates, which are mostly considered to be mediated through the inappropriate activation of the aryl hydrocarbon receptor (AHR) signaling pathway. Although transcriptional regulation by AHR is widely studied, the molecular mechanisms responsible for the adverse outcomes after AHR activation are largely unknown. To identify the important downstream events of AHR activation, we employed the zebrafish caudal fin regeneration model, where AHR activation blocks the regenerative process. Comparative toxicogenomic analysis revealed that both adult and larval fins respond to TCDD during regeneration with misexpression of Wnt signaling pathway members and Wnt target genes. R-Spondin1, a novel ligand for the Wnt coreceptor, was highly induced, and we hypothesized that misexpression of R-Spondin1 is necessary for AHR activation to block regeneration. Partial antisense repression of R-Spondin1 reversed the inhibitory effect of TCDD, and tissue regeneration was restored. This finding demonstrates that inhibition of regeneration by TCDD is mediated by misinduction of R-Spondin1. Because R-Spondin1 signals through the Wnt coreceptor LRP6, we further demonstrated that the TCDD-mediated block in regeneration is also LRP6 dependent. Collectively, these results indicate that inappropriate regulation of R-Spondin/LRP6 is absolutely required for TCDD to inhibit fin regeneration.	[Mathew, Lijoy K.; Sengupta, Sumitra S.; Ladu, Jane; Andreasen, Eric A.; Tanguay, Robert L.] Oregon State Univ, Dept Environm & Mol Toxicol, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA	Oregon State University	Tanguay, RL (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Environm Hlth Sci Ctr, 1007 ALS, Corvallis, OR 97331 USA.	robert.tanguay@oregonstate.edu	Sengupta, Sumitra/G-1814-2017	Sengupta, Sumitra/0000-0003-2861-5608	NIEHS NIH HHS [ES10820, ES03850, R01 ES010820, P30 ES000210, ES00210, P30 ES003850] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210, P50ES003850, R01ES010820, P30ES003850] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akimenko MA, 2003, DEV DYNAM, V226, P190, DOI 10.1002/dvdy.10248; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Andreasen EA, 2007, TOXICOL SCI, V95, P215, DOI 10.1093/toxsci/kfl119; Andreasen EA, 2006, TOXICOL SCI, V92, P254, DOI 10.1093/toxsci/kfj118; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Binnerts ME, 2007, P NATL ACAD SCI USA, V104, P14700, DOI 10.1073/pnas.0702305104; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Blaydon DC, 2006, NAT GENET, V38, P1245, DOI 10.1038/ng1883; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Chang XQ, 2007, MOL CELL BIOL, V27, P6127, DOI 10.1128/MCB.00323-07; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; HENRY EC, 1993, BIOCHEM J, V294, P95, DOI 10.1042/bj2940095; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kawakami A, 2004, DEV DYNAM, V231, P693, DOI 10.1002/dvdy.20181; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305; Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Mathew LK, 2006, MOL PHARMACOL, V69, P257, DOI 10.1124/mol.105.018044; Mitchell KA, 2006, MOL PHARMACOL, V70, P163, DOI 10.1124/mol.106.023465; Nam JS, 2006, J BIOL CHEM, V281, P13247, DOI 10.1074/jbc.M508324200; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Parma P, 2006, NAT GENET, V38, P1304, DOI 10.1038/ng1907; Poss KD, 2000, DEV DYNAM, V219, P282, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1045>3.3.CO;2-3; Puga A, 2005, BIOCHEM PHARMACOL, V69, P199, DOI 10.1016/j.bcp.2004.06.043; SANTAMARIA JA, 1991, J ANAT, V176, P9; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387; Schier AF, 1997, DEVELOPMENT, V124, P327; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Smith A, 2006, DEV BIOL, V299, P438, DOI 10.1016/j.ydbio.2006.08.016; Stoick-Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123; Thomae TL, 2005, J BIOL CHEM, V280, P12742, DOI 10.1074/jbc.M410780200; Wei Q, 2007, J BIOL CHEM, V282, P15903, DOI 10.1074/jbc.M701927200; Westerfield M, 1995, ZEBRAFISH BOOK; Yano F, 2005, BIOCHEM BIOPH RES CO, V333, P1300, DOI 10.1016/j.bbrc.2005.06.041; Zodrow JM, 2003, TOXICOL SCI, V76, P151, DOI 10.1093/toxsci/kfg205	39	65	72	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					3087	3096		10.1096/fj.08-109009	http://dx.doi.org/10.1096/fj.08-109009			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18495758	Green Published			2022-12-28	WOS:000258089300048
J	Moussaieff, A; Rimmerman, N; Bregman, T; Straiker, A; Felder, CC; Shoham, S; Kashman, Y; Huang, SM; Lee, H; Shohami, E; Mackie, K; Caterina, MJ; Walker, JM; Fride, E; Mechoulam, R				Moussaieff, Arieh; Rimmerman, Neta; Bregman, Tatiana; Straiker, Alex; Felder, Christian C.; Shoham, Shai; Kashman, Yoel; Huang, Susan M.; Lee, Hyosang; Shohami, Esther; Mackie, Ken; Caterina, Michael J.; Walker, J. Michael; Fride, Ester; Mechoulam, Raphael			Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain	FASEB JOURNAL			English	Article						Boswellia; frankincense; depression; anxiety	FORCED SWIMMING TEST; GATED ION-CHANNEL; SEXUAL DYSFUNCTION; RECEPTOR; HEAT; ANXIETY; MICE; ANTAGONISTS; AGONISTS; CURRENTS	Burning of Boswellia resin as incense has been part of religious and cultural ceremonies for millennia and is believed to contribute to the spiritual exaltation associated with such events. Transient receptor potential vanilloid (TRPV) 3 is an ion channel implicated in the perception of warmth in the skin. TRPV3 mRNA has also been found in neurons throughout the brain; however, the role of TRPV3 channels there remains unknown. Here we show that incensole acetate (IA), a Boswellia resin constituent, is a potent TRPV3 agonist that causes anxiolytic-like and antide-pressive-like behavioral effects in wild-type (WT) mice with concomitant changes in c-Fos activation in the brain. These behavioral effects were not noted in TRPV3(-/-) mice, suggesting that they are mediated via TRPV3 channels. IA activated TRPV3 channels stably expressed in HEK293 cells and in keratinocytes from TRPV3(-/-) mice. It had no effect on keratinocytes from TRPV3(-/-) mice and showed modest or no effect on TRPV1, TRPV2, and TRPV4, as well as on 24 other receptors, ion channels, and transport proteins. Our results imply that TRPV3 channels in the brain may play a role in emotional regulation. Furthermore, the biochemical and pharmacological effects of IA may provide a biological basis for deeply rooted cultural and religious traditions.	[Moussaieff, Arieh; Shohami, Esther; Mechoulam, Raphael] Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel; [Moussaieff, Arieh; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Rimmerman, Neta; Straiker, Alex; Mackie, Ken; Walker, J. Michael] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA; [Rimmerman, Neta; Straiker, Alex; Mackie, Ken; Walker, J. Michael] Indiana Univ, Gill Ctr Biomol Sci, Bloomington, IN USA; [Bregman, Tatiana; Fride, Ester] Ariel Univ Ctr Samaria, Dept Behav Sci, Ariel, Israel; [Bregman, Tatiana; Fride, Ester] Ariel Univ Ctr Samaria, Dept Mol Biol, Ariel, Israel; [Felder, Christian C.] Eli Lilly & Co, Div Neurosci, Indianapolis, IN 46285 USA; [Shoham, Shai] Herzog Mem Hosp, Res Dept, Jerusalem, Israel; [Kashman, Yoel] Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, Ramat Aviv, Israel; [Huang, Susan M.; Lee, Hyosang; Caterina, Michael J.] Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Ariel University; Ariel University; Eli Lilly; Hebrew University of Jerusalem; Herzog Medical Center; Tel Aviv University; Johns Hopkins University; Johns Hopkins Medicine	Moussaieff, A (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91120 Jerusalem, Israel.	arieh@weizmann.ac.il; mechou@cc.huji.ac.il	Mackie, Ken/E-3715-2013; Rimmerman, Neta/F-1331-2010; Mackie, Kenneth P/B-7358-2011	Mackie, Ken/0000-0001-8501-6199; , Hyosang/0000-0002-3200-8678; Felder, Christian/0000-0003-1134-8881; Moussaieff, Arieh/0000-0003-1289-4737	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA009789, R01DA020402, K05DA021696, R01DA011322] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA011322, DA020402, DA11322, P01 DA009789, R01 DA020402, K05 DA021696, DA21696, DA018244, DA9789] Funding Source: Medline; NINDS NIH HHS [R01 NS051551, NS051551] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEL I, 1991, FUNDAM CLIN PHARM, V5, P107, DOI 10.1111/j.1472-8206.1991.tb00704.x; Bandelow Borwin, 2007, Expert Rev Neurother, V7, P769, DOI 10.1586/14737175.7.7.769; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chung MK, 2005, J BIOL CHEM, V280, P15928, DOI 10.1074/jbc.M500596200; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; CHUNG MK, J BIOL CHEM, V279, P21569; CORSANO S, 1967, TETRAHEDRON, V23, P1977, DOI 10.1016/S0040-4020(01)82601-6; Crawley Jacqueline N., 2007, WHATS WRONG MY MOUSE; Dhaka A, 2006, ANNU REV NEUROSCI, V29, P135, DOI 10.1146/annurev.neuro.29.051605.112958; DRAGUNOW M, 1990, NEUROSCIENCE, V37, P287, DOI 10.1016/0306-4522(90)90399-O; ELFERINK JGR, 1983, J ETHNOPHARMACOL, V7, P111, DOI 10.1016/0378-8741(83)90084-3; Fride E, 2006, METH MOLEC MED, V123, P269; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; Guler AD, 2002, J NEUROSCI, V22, P6408; Gunther R.T., 1959, GREEK HERBAL DIOSCOR; Haberfellner EM, 2007, PHARMACOPSYCHIATRY, V40, P173, DOI 10.1055/s-2007-985881; Hamm S, 2005, PHYTOCHEMISTRY, V66, P1499, DOI 10.1016/j.phytochem.2005.04.025; Harkin A, 2004, EUR NEUROPSYCHOPHARM, V14, P274; Henry B, 2006, J NEUROSCI, V26, P9142, DOI 10.1523/JNEUROSCI.1494-06.2006; Keller MB, 2003, JAMA-J AM MED ASSOC, V289, P3152, DOI 10.1001/jama.289.23.3152; MACCULLOCH JA, ENCY RELIG ETHICS, V7, P201; Marsch R, 2007, J NEUROSCI, V27, P832, DOI 10.1523/JNEUROSCI.3303-06.2007; MENON MK, 1971, PLANTA MED, V19, P333, DOI 10.1055/s-0028-1099651; Moore PD, 2006, NATURE, V444, P829, DOI 10.1038/444829a; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; Moussaieff A, 2008, J CEREBR BLOOD F MET, V28, P1341, DOI 10.1038/jcbfm.2008.28; Moussaieff A, 2007, MOL PHARMACOL, V72, P1657, DOI 10.1124/mol.107.038810; Nurnberg HG, 2003, JAMA-J AM MED ASSOC, V289, P56, DOI 10.1001/jama.289.1.56; O'Connor KA, 2005, LIFE SCI, V78, P506, DOI 10.1016/j.lfs.2005.09.002; O'Dell DK, 2007, BIOORGAN MED CHEM, V15, P6164, DOI 10.1016/j.bmc.2007.06.032; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Petit-Demouliere B, 2005, PSYCHOPHARMACOLOGY, V177, P245, DOI 10.1007/s00213-004-2048-7; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; RICHARDS MH, 1990, BRIT J PHARMACOL, V99, P753, DOI 10.1111/j.1476-5381.1990.tb13002.x; Schultes R.E., 1980, BOT CHEM HALLUCINOGE; SHACHTER J, 1935, BABYLONIAN TALMUD, P43; Sheehan DV, 2007, PSYCHOPHARMACOL BULL, V40, P98; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; SMITH PL, 2006, J BIOL CHEM, V28; Thompson BL, 2006, NEUROPHARMACOLOGY, V50, P57, DOI 10.1016/j.neuropharm.2005.07.024; TREIT D, 1998, IN VIVO NEUROMETHODS, P89; Vogt-Eisele AK, 2007, BRIT J PHARMACOL, V151, P530, DOI 10.1038/sj.bjp.0707245; Werme M, 2000, BRAIN RES, V863, P112, DOI 10.1016/S0006-8993(00)02109-0; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; 1975, ENCY BRITANNICA, V5, P322; [No title captured]	48	111	124	2	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					3024	3034		10.1096/fj.07-101865	http://dx.doi.org/10.1096/fj.07-101865			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18492727	Green Published			2022-12-28	WOS:000258089300042
J	Brandt, N; Franke, K; Johannes, S; Buck, F; Harder, N; Hassel, B; Nitsch, R; Schumacher, S				Brandt, Nicola; Franke, Kristin; Johannes, Sascha; Buck, Friedrich; Harder, Soenke; Hassel, Burkhard; Nitsch, Robert; Schumacher, Stefan			B56 beta, a regulatory subunit of protein phosphatase 2A, interacts with CALEB/NGC-mediated dendritic branching	FASEB JOURNAL			English	Article						neuronal differentiation; dendritic tree elaboration; spine morphogenesis; Akt signaling; mass spectrometry	EGF FAMILY; BETA-CATENIN; RHO GTPASES; TENASCIN-R; MEMBER; IDENTIFICATION; EXPRESSION; DYNAMICS; SURVIVAL; 3-KINASE	The development of dendritic arbors is critical in neuronal circuit formation, as dendrites are the primary sites of synaptic input. Morphologically specialized dendritic protrusions called spines represent the main postsynaptic compartment for excitatory neuro-transmission. Recently, we demonstrated that chicken acidic leucine-rich epidermal growth factor (EGF) -like domain-containing brain protein/neuroglycanC(CALEB/ NGC), a neural member of the EGF family, mediates dendritic tree and spine complexity but that the signaling pathways in the respective processes differ. For a more detailed characterization of these signal transduction pathways, we performed a yeast two-hybrid screen to identify proteins that interact with CALEB/NGC. Our results show that B56 beta, a regulatory subunit of protein phosphatase 2A, interacts with CALEB/NGC and inhibits CALEB/NGC-mediated dendritic branching but not spine formation. Binding of B56 beta to CALEB/NGC was confirmed by several biochemical and immunocytochemical assays. Using affinity chromatography and mass spectrometry, we demonstrate that the whole protein phosphatase 2A trimer, including structural and catalytic subunits, binds to CALEB/NGC via B56 beta. We show that CALEB/NGC induces the phosphorylation of Akt in dendrites. Previously described to interfere with Akt signaling, B56 beta inhibits Akt phosphorylation and Akt-dependent dendritic branching but not Akt-independent spine formation induced by CALEB/NGC. Our results contribute to a better understanding of signaling specificity leading to neuronal process differentiation in sequential developmental events.	[Brandt, Nicola; Franke, Kristin; Johannes, Sascha; Nitsch, Robert; Schumacher, Stefan] Charite, Ctr Anat, Inst Cell Biol & Neurobiol, D-10117 Berlin, Germany; [Buck, Friedrich; Harder, Soenke] Univ Hosp Hamburg Eppendorf, Inst Clin Chem, Hamburg, Germany; [Hassel, Burkhard] Univ Hosp Hamburg Eppendorf, Inst Cell Biochem & Clin Neurobiol, Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Schumacher, S (corresponding author), Charite, Ctr Anat, Inst Cell Biol & Neurobiol, Charite Pl 1, D-10117 Berlin, Germany.	stefan.schumacher@charite.de	Nitsch, Robert/AAI-9129-2021	Harder, Sonke/0000-0002-6352-4771; Dr. Franke, Kristin/0000-0002-7402-4211; Brandt, Nicola/0000-0003-2483-9292				BANKER G, 1998, CULTURING NERVE CELL; Brandt N, 2007, EMBO J, V26, P2371, DOI 10.1038/sj.emboj.7601680; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Halpain S, 2005, PROG BRAIN RES, V147, P29, DOI 10.1016/S0079-6123(04)47003-4; Hassel B, 2003, J BIOL CHEM, V278, P40136, DOI 10.1074/jbc.M305577200; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Juttner R, 2005, NEURON, V46, P233, DOI 10.1016/j.neuron.2005.02.027; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05.2005; Leemhuis J, 2004, J BIOL CHEM, V279, P585, DOI 10.1074/jbc.M307066200; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Nakanishi K, 2006, J BIOL CHEM, V281, P24970, DOI 10.1074/jbc.M601498200; Newey SE, 2005, J NEUROBIOL, V64, P58, DOI 10.1002/neu.20153; Rocher G, 2007, J BIOL CHEM, V282, P5468, DOI 10.1074/jbc.M609712200; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Schumacher S, 2003, J NEUROCHEM, V87, P1213, DOI 10.1046/j.1471-4159.2003.02112.x; Schumacher S, 2001, J BIOL CHEM, V276, P7337, DOI 10.1074/jbc.M007234200; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Whitford KL, 2002, ANNU REV NEUROSCI, V25, P127, DOI 10.1146/annurev.neuro.25.112701.142932; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Yu X, 2003, NAT NEUROSCI, V6, P1169, DOI 10.1038/nn1132; Yuste R, 2004, NAT REV NEUROSCI, V5, P24, DOI 10.1038/nrn1300; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	32	11	11	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2521	2533		10.1096/fj.07-096115	http://dx.doi.org/10.1096/fj.07-096115			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18385213				2022-12-28	WOS:000257292500043
J	Flierl, MA; Rittirsch, D; Gao, HW; Hoesel, LM; Nadeau, BA; Day, DE; Zetoune, FS; Sarma, JV; Huber-Lang, MS; Ferrara, JLM; Ward, PA				Flierl, Michael A.; Rittirsch, Daniel; Gao, Hongwei; Hoesel, Laszlo M.; Nadeau, Brian A.; Day, Danielle E.; Zetoune, Firas S.; Sarma, J. Vidya; Huber-Lang, Markus S.; Ferrara, James L. M.; Ward, Peter A.			Adverse functions of IL-17A in experimental sepsis	FASEB JOURNAL			English	Article						gamma delta; T cells; survival; colony-forming units; cytokines; chemokines	DELTA T-LYMPHOCYTES; CENTRAL-NERVOUS-SYSTEM; VERSUS-HOST-DISEASE; GROWTH-FACTOR-BETA; EPITHELIAL-CELLS; HELPER-CELLS; INTERLEUKIN-17; INFLAMMATION; NEUTROPHILS; MORTALITY	IL-17A is a proinflammatory cytokine produced by a variety of cells. In the current study, we examined the role of IL-17A in sepsis induced in mice by cecal ligation and puncture (CLP). IL-17A levels, which rose time-dependently in plasma after CLP, were not affected in the absence of alpha beta T cells or neutrophils. In sharp contrast, gamma delta T cell-knockout or gamma delta T cell-depleted mice displayed baseline IL-17A plasma levels after CLP. Neutralization of IL-17A by two different antibodies improved sepsis (survival from similar to 10% to nearly 60%). Unexpectedly, antibody treatment was protective, even when administration of anti-IL-17A was delayed for up to 12 h after CLP. These protective effects of IL-17A blockade were associated with substantially reduced levels of bacteremia together with significant reductions of systemic proinflammatory cytokines and chemokines in plasma. In vitro incubation of mouse peritoneal macrophages with lipopolysaccharide (LPS) in the copresence of IL-17A substantially increased the production of TNF-alpha, IL-1 beta, and IL-6 by these cells. These data suggest that, during experimental sepsis, gamma delta T cell-derived IL-17A promotes high levels of proinflammatory mediators and bacteremia, resulting in enhanced lethality. IL-17A may be a potential therapeutic target in sepsis.	[Flierl, Michael A.; Rittirsch, Daniel; Hoesel, Laszlo M.; Nadeau, Brian A.; Day, Danielle E.; Zetoune, Firas S.; Sarma, J. Vidya; Ward, Peter A.] Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA; [Ferrara, James L. M.] Univ Michigan, Dept Pediat & Internal Med, Sch Med, Ann Arbor, MI 48109 USA; [Gao, Hongwei] Univ N Dakota, Sch Med, Dept Biochem & Mol Biol, Grand Forks, ND 58201 USA; [Huber-Lang, Markus S.] Univ Ulm, Sch Med, Dept Traumatol Hand & Reconstruct Surg, Ulm, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of North Dakota Grand Forks; Ulm University	Ward, PA (corresponding author), Univ Michigan, Dept Pathol, Sch Med, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Huber-Lang, Markus/AAJ-2209-2020	Rittirsch, Daniel/0000-0002-1185-2431	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656, R37GM029507, R01GM029507] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31963, P01 HL031963] Funding Source: Medline; NIGMS NIH HHS [GM29507, R01 GM029507, R01 GM061656, GM61656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Awane M, 1999, J IMMUNOL, V162, P5337; BAKER CC, 1983, SURGERY, V94, P331; Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; Benchetrit F, 2002, BLOOD, V99, P2114, DOI 10.1182/blood.V99.6.2114; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Chabaud M, 1998, J IMMUNOL, V161, P409; Chung CS, 2006, AM J PHYSIOL-REG I, V291, pR1338, DOI 10.1152/ajpregu.00283.2006; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hartupee J, 2007, J IMMUNOL, V179, P4135, DOI 10.4049/jimmunol.179.6.4135; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Hunter CA, 2007, NAT IMMUNOL, V8, P232, DOI 10.1038/ni0307-232; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kochanek Kenneth D, 2004, Natl Vital Stat Rep, V52, P1; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Linden A, 2001, INT ARCH ALLERGY IMM, V126, P179, DOI 10.1159/000049511; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Maeda Y, 2005, BLOOD, V106, P749, DOI 10.1182/blood-2004-10-4087; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Matsushima A, 2004, SHOCK, V22, P11, DOI 10.1097/01.shk.0000129203.84330.b3; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Qian YC, 2007, NAT IMMUNOL, V8, P247, DOI 10.1038/ni1439; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; SAKAI T, 1995, EUR J IMMUNOL, V25, P87, DOI 10.1002/eji.1830250117; Schwarzenberger P, 1998, J IMMUNOL, V161, P6383; Shibata K, 2007, J IMMUNOL, V178, P4466, DOI 10.4049/jimmunol.178.7.4466; Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; Van Kooten C, 1998, J AM SOC NEPHROL, V9, P1526; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wynn TA, 2005, NAT IMMUNOL, V6, P1069, DOI 10.1038/ni1105-1069; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Yokota N, 2002, TRANSPLANTATION, V74, P759, DOI 10.1097/00007890-200209270-00005; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	46	148	167	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2198	2205		10.1096/fj.07-105221	http://dx.doi.org/10.1096/fj.07-105221			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18299333	Green Submitted			2022-12-28	WOS:000257292500012
J	Shimizu, H; Nakagami, H; Osako, MK; Hanayama, R; Kunugiza, Y; Kizawa, T; Tomita, T; Yoshikawa, H; Ogihara, T; Morishita, R				Shimizu, Hideo; Nakagami, Hironori; Osako, Mariana Kiomy; Hanayama, Rie; Kunugiza, Yasuo; Kizawa, Takuji; Tomita, Tetsuya; Yoshikawa, Hideki; Ogihara, Toshio; Morishita, Ryuichi			Angiotensin II accelerates osteoporosis by activating osteoclasts	FASEB JOURNAL			English	Article						hypertension; renin-angiotensin system; RANKL; ARB; TRAP activity	HIGH EXTRACELLULAR CALCIUM; ESSENTIAL-HYPERTENSION; BONE-RESORPTION; SENSING RECEPTOR; IONIZED CALCIUM; PROTEIN-KINASE; BETA-BLOCKERS; CORTICAL BONE; CELLS; INHIBITOR	Recent clinical studies suggest that several antihypertensive drugs, especially angiotensin-converting enzyme inhibitors, reduced bone fractures. To clarify the relationship between hypertension and osteoporosis, we focused on the role of angiotensin II (Ang II) on bone metabolism. In bone marrow-derived mononuclear cells, Ang II (1 x 10(-6) M) significantly increased tartrate-resistant acid phosphatase (TRAP)-positive multinuclear osteoclasts. Of importance, Ang II significantly induced the expression of receptor activator of NF-kappa B ligand (RANKL) in osteoblasts, leading to the activation of osteoclasts, whereas these effects were completely blocked by an Ang II type 1 receptor blockade (olmesartan) and mitogen-activated protein kinase kinase inhibitors. In a rat ovariectomy model of estrogen deficiency, administration of Ang II (200 ng/kg/min) accelerated the increase in TRAP activity, accompanied by a significant decrease in bone density and an increase in urinary deoxypyridinoline. In hypertensive rats, treatment with olmesartan attenuated the ovariectomy-induced decrease in bone density and increase in TRAP activity and urinary deoxypyridinoline. Furthermore, in wild-type mice ovariectomy with five-sixths nephrectomy decreased bone volume by microcomputed tomography, whereas these change was not detect in Ang II type 1a receptor-deficient mice. Overall, Ang II accelerates osteoporosis by activating osteoclasts via RANKL induction. Blockade of Ang II might become a novel therapeutic approach to prevent osteoporosis in hypertensive patients.	[Shimizu, Hideo; Osako, Mariana Kiomy; Hanayama, Rie; Morishita, Ryuichi] Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, Osaka 5650871, Japan; [Shimizu, Hideo; Ogihara, Toshio] Osaka Univ, Grad Sch Med, Dept Geriatr Med, Osaka 5650871, Japan; [Nakagami, Hironori] Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, Osaka 5650871, Japan; [Kunugiza, Yasuo; Kizawa, Takuji; Tomita, Tetsuya; Yoshikawa, Hideki] Osaka Univ, Grad Sch Med, Dept Orthoped Surg, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University	Morishita, R (corresponding author), Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, 2-2 Yamadaoka, Osaka 5650871, Japan.	morishit@cgt.med.osaka-u.ac.jp	Osako, Mariana/G-2853-2013; Nakagami, Hironori/GLU-0570-2022; Osako, Mariana Kiomy/H-3337-2019; Osako, Mariana/B-9572-2009; Osako, Mariana Kiomy/AGX-6892-2022	Nakagami, Hironori/0000-0003-4494-3601; Osako, Mariana Kiomy/0000-0002-5021-8433				Broulik PD, 2001, PHYSIOL RES, V50, P353; Cappuccio FP, 2000, J NEPHROL, V13, P169; DUARTE CG, 1971, NEW ENGL J MED, V284, P828, DOI 10.1056/NEJM197104152841506; Hatton R, 1997, J ENDOCRINOL, V152, P5, DOI 10.1677/joe.0.1520005; Hiruma Y, 1997, BIOCHEM BIOPH RES CO, V230, P176, DOI 10.1006/bbrc.1996.5914; Ibrahim HN, 1998, J AM SOC NEPHROL, V9, P72; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; Kaji H, 1996, J BONE MINER RES, V11, P912; Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448; Kim YH, 2003, BIOCHEM BIOPH RES CO, V304, P729, DOI 10.1016/S0006-291X(03)00661-2; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Liu HW, 2002, HYPERTENSION, V40, P451, DOI 10.1161/01.HYP.0000033466.05496.89; Liu XS, 2002, J CARDIOVASC PHARM, V40, P448, DOI 10.1097/00005344-200209000-00014; Lynn H, 2006, BONE, V38, P584, DOI 10.1016/j.bone.2005.09.011; MACGREGOR GA, 1993, J HYPERTENS, V11, P781, DOI 10.1097/00004872-199308000-00003; MCCARRON DA, 1980, HYPERTENSION, V2, P162, DOI 10.1161/01.HYP.2.2.162; MCCARRON DA, 1982, NEW ENGL J MED, V307, P226, DOI 10.1056/NEJM198207223070405; Nakagami H, 2000, J HYPERTENS, V18, P1411, DOI 10.1097/00004872-200018100-00008; Nakagami H, 2003, J MOL CELL CARDIOL, V35, P851, DOI 10.1016/S0022-2828(03)00145-7; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; Reid IR, 2000, AM J MED, V109, P362, DOI 10.1016/S0002-9343(00)00510-6; Rejnmark L, 2006, J HYPERTENS, V24, P581, DOI 10.1097/01.hjh.0000203845.26690.cb; RESNICK LM, 1983, NEW ENGL J MED, V309, P888, DOI 10.1056/NEJM198310133091504; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; Schlienger RG, 2004, JAMA-J AM MED ASSOC, V292, P1326, DOI 10.1001/jama.292.11.1326; Schoofs MWCJ, 2003, ANN INTERN MED, V139, P476, DOI 10.7326/0003-4819-139-6-200309160-00010; Shimizu H, 2006, GENE THER, V13, P933, DOI 10.1038/sj.gt.3302711; SHIMIZU H, 1990, J BONE MINER RES, V5, P411, DOI 10.1002/jbmr.5650050415; Sone T, 2004, BONE, V35, P432, DOI 10.1016/j.bone.2004.05.011; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; Takeda-Matsubara Y, 2002, HYPERTENSION, V39, P41, DOI 10.1161/hy1201.097197; Taylor A, 2007, CALCIFIED TISSUE INT, V80, P132, DOI 10.1007/s00223-006-0245-6; VANDERPLUIJM G, 1991, ENDOCRINOLOGY, V129, P1596; Venken K, 2005, BONE, V36, P663, DOI 10.1016/j.bone.2005.01.003; Xiang A, 2007, BONE, V40, P1231, DOI 10.1016/j.bone.2007.01.010; Yamaguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P363, DOI 10.1006/bbrc.2000.3955; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	37	204	235	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2465	2475		10.1096/fj.07-098954	http://dx.doi.org/10.1096/fj.07-098954			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18256306				2022-12-28	WOS:000257292500038
J	Zhou, J; Werstuck, GH; Lhotak, S; Shi, YY; Tedesco, V; Trigatti, B; Dickhout, J; Majors, AK; DiBello, PM; Jacobsen, DW; Austin, RC				Zhou, Ji; Werstuck, Geoff H.; Lhotak, Sarka; Shi, Yuan Y.; Tedesco, Vivienne; Trigatti, Bernardo; Dickhout, Jeffrey; Majors, Alana K.; DiBello, Patricia M.; Jacobsen, Donald W.; Austin, Richard C.			Hyperhomocysteinemia induced by methionine supplementation does not independently cause atherosclerosis in C57BL/6J mice	FASEB JOURNAL			English	Article						homocysteine; inflammation; VLDL; atherogenesis; dietary intervention	ENDOPLASMIC-RETICULUM STRESS; LOW-DENSITY LIPOPROTEIN; CYSTATHIONINE BETA-SYNTHASE; PLASMA-LEVELS; ACCELERATES ATHEROSCLEROSIS; INDUCED ARTERIOSCLEROSIS; REDUCES ATHEROSCLEROSIS; QUANTITATIVE ASSESSMENT; CARDIOVASCULAR-DISEASE; CORONARY-ARTERY	A causal relationship between diet-induced hyperhomocysteinemia (HHcy)and accelerated atherosclerosis has been established in apolipoprotein E-deficient (apoE(-/-)) mice. However, it is not known whether the proatherogenic effect of HHcy in apoE(-/-) mice is independent of hyperlipidemia and/or deficiency of apoE. In this study, a comprehensive dietary approach using C57BL/6J mice was used to investigate whether HHcy is an independent risk factor for accelerated atherosclerosis or dependent on additional dietary factors that increase plasma lipids and/or inflammation. C57BL/6J mice at 4 wk of age were divided into 6 dietary groups: chow diet (C), chow diet + methionine (C + M), western-type diet (W), western-type diet + methionine (W + M), atherogenic diet (A), or atherogenic diet + methionine (A + M). After 2, 10, 20, or 40 wk on the diets, mice were sacrificed, and the levels of total plasma homocysteine, cysteine, and glutathione, as well as total plasma cholesterol and triglycerides were analyzed. Aortic root sections were examined for atherosclerotic lesions. HHcy was induced in all groups supplemented with methionine, compared to diet-matched control groups. Plasma total cholesterol was significantly increased in mice fed the W or A diet. However, the W diet increased LDL/IDL and HDL levels, while the A diet significantly elevated plasma VLDL and LDL/IDL levels without increasing HDL. No differences in plasma total cholesterol levels or lipid profiles were observed between methionine-supplemented groups and the diet-matched control groups. Early atherosclerotic lesions containing macrophage foam cells were only observed in mice fed the A or A + M diet. Furthermore, lesion size was significantly larger in the A + M group compared to the A group at 10 and 20 wk; however, mature lesions were never observed even after 40 wk on these diets. The presence of lymphocytes, increased hyaluronan staining, and the expression of endoplasmic reticulum (ER) stress markers were also increased in atherosclerotic lesions from the A + M group. Taken together, these results suggest that HHcy does not independently cause atherosclerosis in C57BL/6J mice even in the presence of increased total plasma lipids induced by the W diet. However, HHcy can accelerate atherosclerotic lesion development under dietary conditions that increase plasma VLDL levels and/or inflammation.	[Zhou, Ji; Werstuck, Geoff H.; Lhotak, Sarka; Shi, Yuan Y.; Dickhout, Jeffrey; Austin, Richard C.] Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; [Zhou, Ji; Werstuck, Geoff H.; Lhotak, Sarka; Shi, Yuan Y.; Dickhout, Jeffrey; Austin, Richard C.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Werstuck, Geoff H.; Tedesco, Vivienne; Trigatti, Bernardo] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada; [DiBello, Patricia M.; Jacobsen, Donald W.] Cleveland Clin, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44106 USA; [Jacobsen, Donald W.] Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA; [Austin, Richard C.] St Josephs Hosp, Div Nephrol, Hamilton, ON, Canada; [Majors, Alana K.] Cleveland Clin, Dept Pathobiol, Cleveland, OH 44106 USA	McMaster University; McMaster University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; McGill University; McMaster University; Cleveland Clinic Foundation	Austin, RC (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	raustin@thrombosis.hhscr.org	Dickhout, Jeffrey/R-2606-2019	Trigatti, Bernardo (Dino) L./0000-0002-4556-119X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052234, R37HL052234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52234, R37 HL052234-14, R01 HL052234, R37 HL052234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernstein H, 1999, TOXICOL LETT, V108, P37, DOI 10.1016/S0378-4274(99)00113-7; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Burke AP, 2002, ARTERIOSCL THROM VAS, V22, P1936, DOI 10.1161/01.ATV.0000035405.16217.86; Burleigh ME, 2005, BIOCHEM PHARMACOL, V70, P334, DOI 10.1016/j.bcp.2005.04.044; Chai S, 2005, CIRC RES, V96, P583, DOI 10.1161/01.RES.0000158963.37132.8b; Chen Zhoutao, 2002, Brain Res Gene Expr Patterns, V1, P89; Colgan SM, 2007, INT J BIOCHEM CELL B, V39, P1843, DOI 10.1016/j.biocel.2007.05.002; Dixon JL, 2002, J LIPID RES, V43, P1618, DOI 10.1194/jlr.M200134-JLR200; DONAHUE S, 1974, AM J PATHOL, V77, P167; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; Iciek M, 2004, ACTA BIOCHIM POL, V51, P815; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Ji C, 2003, GASTROENTEROLOGY, V124, P1488, DOI 10.1016/S0016-5085(03)00276-2; Kleemann R, 2003, CIRCULATION, V108, P1368, DOI 10.1161/01.CIR.0000086460.55494.AF; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Mack WJ, 1996, ARTERIOSCL THROM VAS, V16, P697, DOI 10.1161/01.ATV.16.5.697; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; MALINOW MR, 1995, CLIN CHEM, V41, P173; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; MCCULLY KS, 1969, AM J PATHOL, V56, P111; McQuillan BM, 1999, CIRCULATION, V99, P2383, DOI 10.1161/01.CIR.99.18.2383; Monetti M, 2007, PHARMACOL RES, V55, P441, DOI 10.1016/j.phrs.2007.02.001; MUDD SH, 1985, AM J HUM GENET, V37, P1; Norata GD, 2007, ATHEROSCLEROSIS, V191, P265, DOI 10.1016/j.atherosclerosis.2006.05.047; Olszanecki R, 2005, J PHYSIOL PHARMACOL, V56, P627; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; REDDY GSR, 1982, METABOLISM, V31, P778, DOI 10.1016/0026-0495(82)90075-0; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rosenblatt D. S., 2001, METABOLIC MOL BASES, V8th, P3897; Rubba P, 2000, DEV CARDIOVASC MED, V230, P117; Sampedro MC, 2001, BIOCHEM BIOPH RES CO, V285, P393, DOI 10.1006/bbrc.2001.5202; Scalia R, 2001, CIRCULATION, V103, P2598; Smilde TJ, 1998, ARTERIOSCL THROM VAS, V18, P1958, DOI 10.1161/01.ATV.18.12.1958; Srivastava RAK, 2001, INT J BIOCHEM CELL B, V33, P1215, DOI 10.1016/S1357-2725(01)00080-2; Srivastava RAK, 2000, EUR J BIOCHEM, V267, P4272, DOI 10.1046/j.1432-1327.2000.01473.x; Stollenwerk MM, 2005, BIOCHEM BIOPH RES CO, V335, P603, DOI 10.1016/j.bbrc.2005.07.123; Stollenwerk MM, 2005, ATHEROSCLEROSIS, V179, P247, DOI 10.1016/j.atherosclerosis.2004.12.002; TATAMI R, 1981, CIRCULATION, V64, P1174, DOI 10.1161/01.CIR.64.6.1174; Vergnes L, 2003, J BIOL CHEM, V278, P42774, DOI 10.1074/jbc.M306022200; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Wilcken DEL, 2000, DEV CARDIOVASC MED, V230, P5; Wilson KM, 2007, ARTERIOSCL THROM VAS, V27, P233, DOI 10.1161/01.ATV.0000251607.96118.af; Zhou J, 2005, CIRCULATION, V111, P1814, DOI 10.1161/01.CIR.0000160864.31351.C1; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97; Zhou J, 2003, ATHEROSCLEROSIS, V168, P255, DOI 10.1016/S0021-9150(03)00138-2; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582; Zulli A, 2004, ATHEROSCLEROSIS, V176, P83, DOI 10.1016/j.atherosclerosis.2004.05.013	52	37	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2569	2578		10.1096/fj.07-105353	http://dx.doi.org/10.1096/fj.07-105353			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18364397	Green Accepted			2022-12-28	WOS:000257292500048
J	Christ-Crain, M; Kola, B; Lolli, F; Fekete, C; Seboek, D; Wittmann, G; Feltrin, D; Igreja, SC; Ajodha, S; Harvey-White, J; Kunos, G; Mueller, B; Pralong, F; Aubert, G; Arnaldi, G; Giacchetti, G; Boscaro, M; Grossman, AB; Korbonits, M				Christ-Crain, Mirjam; Kola, Blerina; Lolli, Francesca; Fekete, Csaba; Seboek, Dalma; Wittmann, Gabor; Feltrin, Daniel; Igreja, Susana C.; Ajodha, Sharon; Harvey-White, Judith; Kunos, George; Mueller, Beat; Pralong, Francois; Aubert, Gregory; Arnaldi, Giorgio; Giacchetti, Gilberta; Boscaro, Marco; Grossman, Ashley B.; Korbonits, Marta			AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome	FASEB JOURNAL			English	Article						obesity; insulin resistance; lipid metabolism	HUMAN ADIPOSE-TISSUE; FATTY-ACID OXIDATION; CARDIOVASCULAR RISK; FOOD-INTAKE; ENDOCANNABINOID RELEASE; HYPOTHALAMIC NEURONS; ORAL CORTICOSTEROIDS; HUMAN ADIPOCYTES; GLUCOSE-UPTAKE; INSULIN	Chronic exposure to glucocorticoid hormones, resulting from either drug treatment or Cushing's syndrome, results in insulin resistance, central obesity, and symptoms similar to the metabolic syndrome. We hypothesized that the major metabolic effects of corticosteroids are mediated by changes in the key metabolic enzyme adenosine monophosphate-activated protein kinase (AMPK) activity. Activation of AMPK is known to stimulate appetite in the hypothalamus and stimulate catabolic processes in the periphery. We assessed AMPK activity and the expression of several metabolic enzymes in the hypothalamus, liver, adipose tissue, and heart of a rat glucocorticoid- excess model as well as in in vitro studies using primary human adipose and primary rat hypothalamic cell cultures, and a human hepatoma cell line treated with dexamethasone and metformin. Glucocorticoid treatment inhibited AMPK activity in rat adipose tissue and heart, while stimulating it in the liver and hypothalamus. Similar data were observed in vitro in the primary adipose and hypothalamic cells and in the liver cell line. Metformin, a known AMPK regulator, prevented the corticosteroid-induced effects on AMPK in human adipocytes and rat hypothalamic neurons. Our data suggest that glucocorticoid-induced changes in AMPK constitute a novel mechanism that could explain the increase in appetite, the deposition of lipids in visceral adipose and hepatic tissue, as well as the cardiac changes that are all characteristic of glucocorticoid excess. Our data suggest that metformin treatment could be effective in preventing the metabolic complications of chronic glucocorticoid excess.	[Christ-Crain, Mirjam; Kola, Blerina; Lolli, Francesca; Feltrin, Daniel; Igreja, Susana C.; Ajodha, Sharon; Grossman, Ashley B.; Korbonits, Marta] Univ London, Queen Marys Sch Med, William Harvey Res Inst, John Vane Sci Ctr,Dept Endocrinol, London EC1M 6BQ, England; [Fekete, Csaba; Wittmann, Gabor] Hungarian Acad Sci, Inst Expt Med, Dept Endocrine Neurobiol, Budapest, Hungary; [Fekete, Csaba; Wittmann, Gabor] Tufts Univ New England Med Ctr, Div Endocrinol Diabet Metab & Mol Med, Tupper Res Inst, Boston, MA USA; [Fekete, Csaba; Wittmann, Gabor] Tufts Univ New England Med Ctr, Div Endocrinol Diabet Metab & Mol Med, Dept Med, Boston, MA USA; [Seboek, Dalma] Univ Basel Hosp, Div Endocrinol Diabet & Clin Nutr, CH-4031 Basel, Switzerland; [Harvey-White, Judith; Kunos, George] NIAAA, Lab Physiol Studies, US Natl Inst Hlth, Bethesda, MD USA; [Pralong, Francois; Aubert, Gregory] CHU Vaudois, Dept Internal Med, Serv Endocrinol Diabetol & Metab, CH-1011 Lausanne, Switzerland; [Arnaldi, Giorgio; Giacchetti, Gilberta; Boscaro, Marco] Univ Ancona, Dept Internal Med, Ancona, Italy	University of London; Queen Mary University London; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Tufts Medical Center; Tufts Medical Center; University of Basel; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Marche Polytechnic University	Korbonits, M (corresponding author), Univ London, Queen Marys Sch Med, William Harvey Res Inst, John Vane Sci Ctr,Dept Endocrinol, London EC1M 6BQ, England.	m.korbonits@qmul.ac.uk	igreja, susana/M-3223-2015; Arnaldi, Giorgio/AAC-1674-2019; Aubert, Gregory/S-7075-2019; Mueller, Beat/G-2662-2012; GIACCHETTI, Gilberta/AAF-1074-2020; GIACCHETTI, Gilberta/AAF-4316-2020	igreja, susana/0000-0003-2811-4766; BOSCARO, MARCO/0000-0003-2596-1652; Korbonits, Marta/0000-0002-4101-9432; Christ-Crain, Mirjam/0000-0002-6336-0965; Arnaldi, Giorgio/0000-0002-6204-3423; Aubert, Gregory/0000-0002-5539-0224; Fekete, Csaba/0000-0002-8206-562X; Giacchetti, Gilberta/0000-0002-3942-1748	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000350, Z01AA000350] Funding Source: NIH RePORTER; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Wellcome Trust(Wellcome TrustEuropean Commission)		Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Arnaldi G, 2003, J CLIN ENDOCR METAB, V88, P5593, DOI 10.1210/jc.2003-030871; Bell ME, 2000, J NEUROENDOCRINOL, V12, P461; Boffa MB, 2003, J BIOL CHEM, V278, P9250, DOI 10.1074/jbc.M209588200; Brown PD, 2007, MOL CELL BIOCHEM, V297, P171, DOI 10.1007/s11010-006-9344-y; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; Burcelin R, 2003, ENDOCRINOLOGY, V144, P4484, DOI 10.1210/en.2003-0457; Chandola T, 2006, BMJ-BRIT MED J, V332, P521, DOI 10.1136/bmj.38693.435301.80; Chau-Van C, 2007, ENDOCRINOLOGY, V148, P507, DOI 10.1210/en.2006-1237; Colao A, 1999, J CLIN ENDOCR METAB, V84, P2664, DOI 10.1210/jc.84.8.2664; Dallman MF, 1995, ANN NY ACAD SCI, V771, P730, DOI 10.1111/j.1749-6632.1995.tb44724.x; Dallman MF, 2003, P NATL ACAD SCI USA, V100, P11696, DOI 10.1073/pnas.1934666100; DANESE RD, 1994, ENDOCRIN METAB CLIN, V23, P299, DOI 10.1016/S0889-8529(18)30099-9; Di S, 2005, ENDOCRINOLOGY, V146, P4292, DOI 10.1210/en.2005-0610; Di S, 2003, J NEUROSCI, V23, P4850; DIVERTIE GD, 1991, DIABETES, V40, P1228, DOI 10.2337/diabetes.40.10.1228; Djurhuus CB, 2002, AM J PHYSIOL-ENDOC M, V283, pE172, DOI 10.1152/ajpendo.00544.2001; Foretz M, 2005, DIABETES, V54, P1331, DOI 10.2337/diabetes.54.5.1331; GREEN PK, 1992, ENDOCRINOLOGY, V130, P269, DOI 10.1210/en.130.1.269; Gudbjornsson B, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.1.32; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hill MN, 2005, EUR J PHARMACOL, V528, P99, DOI 10.1016/j.ejphar.2005.10.058; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kola B, 2005, J BIOL CHEM, V280, P25196, DOI 10.1074/jbc.C500175200; Koricanac G, 2006, GEN PHYSIOL BIOPHYS, V25, P11; Kraegen EW, 2006, AM J PHYSIOL-ENDOC M, V290, pE471, DOI 10.1152/ajpendo.00316.2005; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; LANGLEY SC, 1990, BRAIN RES, V533, P268, DOI 10.1016/0006-8993(90)91349-L; Lindsay JR, 2006, J CLIN ENDOCR METAB, V91, P447, DOI 10.1210/jc.2005-1058; Linscheid P, 2005, ENDOCRINOLOGY, V146, P2699, DOI 10.1210/en.2004-1424; Linscheid P, 2006, AM J PHYSIOL-ENDOC M, V290, pE1068, DOI 10.1152/ajpendo.00374.2005; Lundgren M, 2004, J CLIN ENDOCR METAB, V89, P2989, DOI 10.1210/jc.2003-031157; Makimura Hideo, 2003, BMC Physiol, V3, P5, DOI 10.1186/1472-6793-3-5; Mancini T, 2004, CLIN ENDOCRINOL, V61, P768, DOI 10.1111/j.1365-2265.2004.02168.x; MAYOSMITH W, 1989, RADIOLOGY, V170, P515, DOI 10.1148/radiology.170.2.2911678; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Muiesan ML, 2003, J AM COLL CARDIOL, V41, P2275, DOI 10.1016/S0735-1097(03)00493-5; Phillips DIW, 1998, J CLIN ENDOCR METAB, V83, P757, DOI 10.1210/jc.83.3.757; Pivonello R, 2005, ENDOCRIN METAB CLIN, V34, P327, DOI 10.1016/j.ecl.2005.01.010; Rockall AG, 2003, EUR J ENDOCRINOL, V149, P543, DOI 10.1530/eje.0.1490543; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Seboek D, 2004, J CLIN ENDOCR METAB, V89, P4833, DOI 10.1210/jc.2004-0271; Seckl JR, 2004, TRENDS ENDOCRIN MET, V15, P418, DOI 10.1016/j.tem.2004.09.007; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Tataranni PA, 1996, AM J PHYSIOL-ENDOC M, V271, pE317, DOI 10.1152/ajpendo.1996.271.2.E317; van Staa TP, 2000, QJM-MON J ASSOC PHYS, V93, P105, DOI 10.1093/qjmed/93.2.105; Vander Kooi BT, 2005, MOL ENDOCRINOL, V19, P3001, DOI 10.1210/me.2004-0497; Viana AYI, 2006, DIABETES RES CLIN PR, V73, P135, DOI 10.1016/j.diabres.2005.12.011; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Walsh LJ, 1996, BRIT MED J, V313, P344, DOI 10.1136/bmj.313.7053.344; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; Wang YX, 2004, J NUTR, V134, P1032; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zakrzewska KE, 1999, DIABETES, V48, P365, DOI 10.2337/diabetes.48.2.365; Zelena D, 2006, BRAIN RES BULL, V69, P48, DOI 10.1016/j.brainresbull.2005.10.009; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	59	129	131	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1672	1683		10.1096/fj.07-094144	http://dx.doi.org/10.1096/fj.07-094144			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198220	Green Submitted			2022-12-28	WOS:000256352700008
J	Tan, WF; Palmby, TR; Gavard, J; Amornphimoltham, P; Zheng, Y; Gutkind, JS				Tan, Wenfu; Palmby, Todd R.; Gavard, Julie; Amornphimoltham, Panomwat; Zheng, Yi; Gutkind, J. Silvio			An essential role for Rac1 in endothelial cell function and vascular development	FASEB JOURNAL			English	Article						angiogenesis; S1P; VEGF; migration; cytoskeleton	IN-VIVO; TRANSGENIC MICE; ANGIOGENESIS; RHO; MIGRATION; ADHESION; GROWTH; VEGF; SPHINGOSINE-1-PHOSPHATE; VASCULOGENESIS	Numerous cell surface receptors, including tyrosine kinase and G protein-coupled receptors, play critical roles in endothelial cell function and blood vessel development. These receptors share the ability of stimulating an intricate network of intracellular signaling pathways, including the activation of members of the Ras and Rho family of small GTPases. However, the contribution of these signaling molecules to the numerous biological activities performed by endothelial cells is still not fully understood. Here, we have used a conditional Cre/ Flox approach, enabling the deletion of the Rac1 gene in endothelial cells, to examine the role of the Rho-related GTPase Rac1 in endothelial cell function and vascular development. Rac1 excision in primary endothelial cells in vitro revealed that Rac1 plays a central role in endothelial cell migration, tubulogenesis, adhesion, and permeability in response to vascular endothelial growth factor (VEGF) and sphingosine-1-phosphate (S1P), which is likely due to the inability of Rac1-deficient endothelial cells to form lamellipodial structures and focal adhesions, and to remodel their cell-cell contacts. Importantly, endothelial-specific excision of Rac1 results in embryonic lethality in midgestation (around E9.5), and defective development of major vessels and complete lack of small branched vessels was readily observed in these endothelial Rac1-deficient embryos and their yolk sacs. These findings provide direct evidence that the activity of Rac1 in endothelial cells is essential for vascular development and suggest that Rac1 and its downstream targets may represent promising therapeutic targets for the treatment of numerous human diseases that involve aberrant neovascularization.	[Tan, Wenfu; Palmby, Todd R.; Gavard, Julie; Amornphimoltham, Panomwat; Gutkind, J. Silvio] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; [Zheng, Yi] Univ Cincinnati, Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Zheng, Yi/J-7235-2015; Amornphimoltham, Walt/AAP-9654-2020; Gavard, Julie/I-5487-2012; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Gavard, Julie/I-5487-2012	Zheng, Yi/0000-0001-7089-6074; Gavard, Julie/0000-0002-7985-9007; Gutkind, J. Silvio/0000-0002-5150-4482; Gavard, Julie/0000-0003-3107-2026	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Basile JR, 2005, MOL CELL BIOL, V25, P6889, DOI 10.1128/MCB.25.16.6889-6898.2005; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Castilho RM, 2007, ONCOGENE, V26, P5078, DOI 10.1038/sj.onc.1210322; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478; Dominguez MG, 2007, P NATL ACAD SCI USA, V104, P3243, DOI 10.1073/pnas.0611510104; Drake Christopher J., 2003, Birth Defects Research, V69, P73, DOI 10.1002/bdrc.10003; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Guleng B, 2005, CANCER RES, V65, P5864, DOI 10.1158/0008-5472.CAN-04-3833; Hartwell DM, 1998, J CELL BIOL, V143, P1129, DOI 10.1083/jcb.143.4.1129; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Red-Horse K, 2007, DEV CELL, V12, P181, DOI 10.1016/j.devcel.2007.01.013; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Rosenfeldt HM, 2001, BIOCHEM SOC T, V29, P836, DOI 10.1042/0300-5127:0290836; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; van Hinsbergh VWM, 2001, ANN NY ACAD SCI, V936, P426; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Weiss-Haljiti C, 2004, J BIOL CHEM, V279, P43273, DOI 10.1074/jbc.M402924200; Williams DA, 2000, BLOOD, V96, P1646; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898	42	170	178	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1829	1838		10.1096/fj.07-096438	http://dx.doi.org/10.1096/fj.07-096438			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18245172				2022-12-28	WOS:000256352700023
J	Yu, HY; Konigshoff, M; Jayachandran, A; Handley, D; Seeger, W; Kaminski, N; Eickelberg, O				Yu, Haiying; Koenigshoff, Melanie; Jayachandran, Aparna; Handley, Dan; Seeger, Werner; Kaminski, Naftali; Eickelberg, Oliver			Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis	FASEB JOURNAL			English	Article						alveolar epithelial cell; signal transduction; bleomycin	IDIOPATHIC PULMONARY-FIBROSIS; GROWTH-FACTOR-BETA; SMOOTH-MUSCLE; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; CLINICAL-RELEVANCE; TGF-BETA; EXPRESSION; GENE; SM22-ALPHA	Enhanced transforming growth factor (TGF) -beta signaling contributes to idiopathic pulmonary fibrosis (IPF), a progressive and fatal disease characterized by alveolar epithelial type II (ATII) cell hyperplasia, (myo) fibroblast accumulation, and excessive extracellular matrix deposition. TGF-beta is a potent inducer of lung fibrosis, and it regulates the ATII cell phenotype; however, direct TGF-beta target genes controlling the ATII cell phenotype remain elusive. Here, we identified the transgelin (tagln) gene as a novel immediate target of TGF-beta/Smad3-dependent gene expression in ATII cells using a Smad3 chromatin immunoprecipitation (ChIP) screen. Direct ChIP confirmed the rapid and specific binding of Smad3 to the tagln promoter. Luciferase assays demonstrated transactivation of the tagln promoter by activin-like kinase (Alk) 5-mediated TGF-beta signaling. TGF-beta treatment resulted in rapid up-regulation of tagln, but not tagln2, mRNA and protein expression, assessed by reverse transcription-polymerase chain reaction (RT-PCR), Western blotting, and immunofluorescence. In vivo, tagln expression was significantly increased in ATII cells of mice during bleomycin-induced lung fibrosis, as well as in lung specimen obtained from IPF patients, as assessed by RT-PCR and immunohistochemistry. Knockdown of tagln using siRNA inhibited TGF-beta-induced migration of lung epithelial A549 cells, as well as primary ATII cells. We thus identified tagln as a novel target of TGF-beta/Smad3-dependent gene expression in ATII cells. Increased ATII cell expression of tagln in experimental and idiopathic pulmonary fibrosis may contribute to TGF-beta-dependent ATII cell injury, repair, and migration in lung fibrosis.	[Yu, Haiying; Koenigshoff, Melanie; Jayachandran, Aparna; Seeger, Werner; Eickelberg, Oliver] Univ Giessen, Lung Ctr, Dept Med 2, D-35392 Giessen, Germany; [Handley, Dan; Kaminski, Naftali] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Justus Liebig University Giessen; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Eickelberg, O (corresponding author), Univ Giessen, Lung Ctr, Dept Med 2, Aulweg 123,Rm 6-11, D-35392 Giessen, Germany.	oliver.eickelberg@innere.med.uni-giessen.de	Eickelberg, Oliver/A-5461-2013	Eickelberg, Oliver/0000-0001-7170-0360; Seeger, Werner/0000-0003-1946-0894; Kaminski, Naftali/0000-0001-5917-4601	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073745] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM009657] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL073745] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Thoracic Society, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/ajrccm.165.2.ats01; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; Cevallos M, 2006, DIFFERENTIATION, V74, P552, DOI 10.1111/j.1432-0436.2006.00089.x; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; Chen SY, 2003, NUCLEIC ACIDS RES, V31, P1302, DOI 10.1093/nar/gkg224; Chua F, 2005, AM J RESP CELL MOL, V33, P9, DOI 10.1165/rcmb.2005-0062TR; Frances R, 2006, MOL IMMUNOL, V43, P2124, DOI 10.1016/j.molimm.2005.12.011; Hashimoto N, 2004, J CLIN INVEST, V113, P243, DOI 10.1172/JCI200418847; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kim IY, 2005, J BIOCHEM MOL BIOL, V38, P1; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Konigshoff M, 2007, AM J RESP CELL MOL, V37, P640, DOI 10.1165/rcmb.2006-0379TR; Lee Chun Geun, 2006, Proc Am Thorac Soc, V3, P418, DOI 10.1513/pats.200602-017AW; LEESMILLER JP, 1987, J BIOL CHEM, V262, P2988; LEESMILLER JP, 1987, BIOCHEM J, V244, P705, DOI 10.1042/bj2440705; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Sheppard Dean, 2006, Proc Am Thorac Soc, V3, P413, DOI 10.1513/pats.200601-008AW; Shields JM, 2002, J BIOL CHEM, V277, P9790, DOI 10.1074/jbc.M110086200; Sinha S, 2004, AM J PHYSIOL-CELL PH, V287, pC1560, DOI 10.1152/ajpcell.00221.2004; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Strieter RM, 2005, CHEST, V128, p526S, DOI 10.1378/chest.128.5_suppl_1.526S; Strieter RM, 2007, J CLIN INVEST, V117, P549, DOI 10.1172/JCI30562; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Teng YQ, 2007, J CLIN INVEST, V117, P304, DOI 10.1172/JCI31200; Thannickal VJ, 2004, ANNU REV MED, V55, P395, DOI 10.1146/annurev.med.55.091902.103810; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Untergasser G, 2005, MECH AGEING DEV, V126, P59, DOI 10.1016/j.mad.2004.09.023; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Willis Brigham C, 2006, Proc Am Thorac Soc, V3, P377, DOI 10.1513/pats.200601-004TK; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001	37	110	115	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1778	1789		10.1096/fj.07-083857	http://dx.doi.org/10.1096/fj.07-083857			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18245174				2022-12-28	WOS:000256352700018
J	Ingram, RJ; Isaacs, JD; Kaur, G; Lowther, DE; Reynolds, CJ; Boyton, RJ; Collinge, J; Jackson, GS; Altmann, DM				Ingram, Rebecca J.; Isaacs, Jeremy D.; Kaur, Gurman; Lowther, Daniel E.; Reynolds, Catherine J.; Boyton, Rosemary J.; Collinge, John; Jackson, Graham S.; Altmann, Daniel M.			A role of cellular prion protein in programming T-cell cytokine responses in disease	FASEB JOURNAL			English	Article						T lymphocyte; knockout mouse; Th17	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LYMPHOCYTE-ACTIVATION; SIGNAL-TRANSDUCTION; PROTEOLIPID PROTEIN; DENDRITIC CELLS; PRP GENE; MICE; EXPRESSION; SCRAPIE; INDUCTION	The cellular prion protein (PrPC) is widely expressed in neural and non-neural tissues, but its function is unknown. Elucidation of the part played by PrPC in adaptive immunity has been a particular conundrum: increased expression of cell surface PrPC has been documented during T-cell activation, yet the functional significance of this activation remains unclear, with conflicting data on the effects of Prnp gene knockout on various parameters of T-cell immunity. We show here that Prnp mRNA is highly inducible within 8-24 h of T-cell activation, with surface protein levels rising from 24 h. When measured in parallel with CD69 and CD25, PrPC is a late activation antigen. Consistent with its up-regulation being a late activation event, PrP deletion did not alter T-cell-antigen presenting cell conjugate formation. Most important, activated PrP0/0 T cells demonstrated much reduced induction of several T helper (Th) 1, Th2, and Th17 cytokines, whereas others, such as TNF-alpha and IL-9, were unaffected. These changes were investigated in the context of an autoimmune model and a bacterial challenge model. In experimental autoimmune encephalomyelitis, PrP-knockout mice showed enhanced disease in the face of reduced IL-17 responses. In a streptococcal sepsis model, this constrained cytokine program was associated with poorer local control of infection, although with reduced bacteremia. The findings indicate that PrPC is a potentially important molecule influencing T-cell activation and effector function-Ingram, R. J., Isaacs, J. D., Kaur, G., Lowther, D. E., Reynolds, C. J., Boyton, R. J., Collinge, J., Jackson, G. S., Altmann, D. M. A role of cellular prion protein in programming T-cell cytokine responses in disease. FASEB J. 23, 1672-1684 (2009)	[Ingram, Rebecca J.; Isaacs, Jeremy D.; Kaur, Gurman; Lowther, Daniel E.; Altmann, Daniel M.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Infect Dis & Immun, Human Dis Immunogenet Grp, London W12 0NN, England; [Isaacs, Jeremy D.; Collinge, John; Jackson, Graham S.] UCL, Dept Neurodegenerat Dis, Inst Neurol, MRC Pr Unit, London, England; [Reynolds, Catherine J.; Boyton, Rosemary J.] Univ London Imperial Coll Sci Technol & Med, Lung Immunol Grp, Immunol & Infect NHLI, London W12 0NN, England	Imperial College London; University of London; University College London; Imperial College London	Altmann, DM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Infect Dis & Immun, Human Dis Immunogenet Grp, Du Cane Rd, London W12 0NN, England.	d.altmann@imperial.ac.uk	Ingram, Rebecca J/F-9711-2013	Ingram, Rebecca J/0000-0003-1832-2457; Kaur, Gurman/0000-0001-7722-3956; Jackson, Graham/0000-0002-3125-2011; Altmann, Daniel/0000-0002-2436-6192	UK Medical Research Council (MRC) Clinical Research Training Fellowship; Medical Research Council [G108/495, G0700153, MC_U123170362, G0400503B, MC_U123192748] Funding Source: researchfish; MRC [MC_U123192748, G108/495, MC_U123170362, G0700153] Funding Source: UKRI	UK Medical Research Council (MRC) Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a UK Medical Research Council (MRC) Clinical Research Training Fellowship awarded to J.D.I. The authors thank Professor S. Sriskandan for access to the streptococcal model and Ray Young of the MRC Prion Unit for assistance with artwork. John Collinge and Graham S. Jackson are shareholders and John Collinge is a Director of D-Gen Ltd., an MRC spinoff company that manufactures ICSM18, an anti-PrP monoclonal antibody used in this study.	Antoine N, 2000, HAEMATOLOGICA, V85, P475; Bainbridge J, 2005, IMMUNOL LETT, V96, P147, DOI 10.1016/j.imlet.2004.08.006; Ballerini C, 2006, J IMMUNOL, V176, P7254, DOI 10.4049/jimmunol.176.12.7254; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Chen Z, 2003, J IMMUNOL, V171, P3627, DOI 10.4049/jimmunol.171.7.3627; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Curtis MM, 2009, IMMUNOLOGY, V126, P177, DOI 10.1111/j.1365-2567.2008.03017.x; de Almeida CJG, 2005, J LEUKOCYTE BIOL, V77, P238, DOI 10.1189/jlb.1103531; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Durig J, 2000, BRIT J HAEMATOL, V108, P488, DOI 10.1046/j.1365-2141.2000.01881.x; Ellmerich S, 2005, J IMMUNOL, V174, P1938, DOI 10.4049/jimmunol.174.4.1938; Faulkner L, 2005, J IMMUNOL, V175, P6870, DOI 10.4049/jimmunol.175.10.6870; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; Fournier JG, 2000, MICROSC RES TECHNIQ, V50, P76, DOI 10.1002/1097-0029(20000701)50:1<76::AID-JEMT11>3.0.CO;2-#; Genoud N, 2004, P NATL ACAD SCI USA, V101, P4198, DOI 10.1073/pnas.0400131101; Hofstetter HH, 2007, J IMMUNOL, V178, P1372, DOI 10.4049/jimmunol.178.3.1372; Holada K, 1998, BRIT J HAEMATOL, V103, P276, DOI 10.1046/j.1365-2141.1998.01032.x; Hugel B, 2004, CELL MOL LIFE SCI, V61, P2998, DOI 10.1007/s00018-004-4318-2; Isaacs JD, 2006, CLIN EXP IMMUNOL, V146, P1, DOI 10.1111/j.1365-2249.2006.03194.x; Isaacs JD, 2008, IMMUNOLOGY, V125, P313, DOI 10.1111/j.1365-2567.2008.02853.x; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Kroenke MA, 2008, J EXP MED, V205, P1535, DOI 10.1084/jem.20080159; Kubosaki A, 2001, BIOCHEM BIOPH RES CO, V282, P103, DOI 10.1006/bbrc.2001.4538; Lee KS, 2003, REV MED VIROL, V13, P399, DOI 10.1002/rmv.408; Lin T, 2001, J IMMUNOL, V166, P3733; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mabbott NA, 1997, IMMUNOLOGY, V92, P161, DOI 10.1046/j.1365-2567.1997.00331.x; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Mattei V, 2004, FEBS LETT, V560, P14, DOI 10.1016/S0014-5793(04)00029-8; Mazzoni IE, 2005, BIOCHEM CELL BIOL, V83, P644, DOI 10.1139/o05-058; McBride SM, 2005, MED HYPOTHESES, V65, P570, DOI 10.1016/j.mehy.2005.02.038; O'Connor RA, 2008, J IMMUNOL, V181, P3750, DOI 10.4049/jimmunol.181.6.3750; Paar C, 2007, EUR J CELL BIOL, V86, P253, DOI 10.1016/j.ejcb.2007.03.001; Pan YL, 2006, FASEB J, V20, P1886, DOI 10.1096/fj.06-6138fje; Premzl M, 2005, GENE, V349, P121, DOI 10.1016/j.gene.2004.11.049; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; Sriskandan S, 2008, J PATHOL, V214, P211, DOI 10.1002/path.2274; Sriskandan S, 2001, J INFECT DIS, V184, P166, DOI 10.1086/322018; Steinman L, 2008, J EXP MED, V205, P1517, DOI 10.1084/jem.20072066; Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005; Stritesky GL, 2008, J IMMUNOL, V181, P5948, DOI 10.4049/jimmunol.181.9.5948; Stuermer CAO, 2004, FASEB J, V18, P1731, DOI 10.1096/fj.04-2150fje; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; Thakker P, 2007, J IMMUNOL, V178, P2589, DOI 10.4049/jimmunol.178.4.2589; TUOHY VK, 1992, J NEUROIMMUNOL, V39, P67, DOI 10.1016/0165-5728(92)90175-K; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Zhang CC, 2006, P NATL ACAD SCI USA, V103, P2184, DOI 10.1073/pnas.0510577103	53	21	23	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1672	1684		10.1096/fj.08-116087	http://dx.doi.org/10.1096/fj.08-116087			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19204074	Green Submitted			2022-12-28	WOS:000266652400007
J	Meyer, NJ; Huang, Y; Singleton, PA; Sammani, S; Moitra, J; Evenoski, CL; Husain, AN; Mitra, S; Moreno-Vinasco, L; Jacobson, JR; Lussier, YA; Garcia, JGN				Meyer, Nuala J.; Huang, Yong; Singleton, Patrick A.; Sammani, Saad; Moitra, Jaideep; Evenoski, Carrie L.; Husain, Aliya N.; Mitra, Sumegha; Moreno-Vinasco, Liliana; Jacobson, Jeffrey R.; Lussier, Yves A.; Garcia, Joe G. N.			GADD45a is a novel candidate gene in inflammatory lung injury via influences on Akt signaling	FASEB JOURNAL			English	Article						mechanical ventilation; biomarker; vascular barrier regulation; ubiquitination	RESPIRATORY-DISTRESS-SYNDROME; CELL BARRIER FUNCTION; SPHINGOSINE 1-PHOSPHATE; PHOSPHOINOSITIDE 3-KINASE; TIDAL VOLUME; GENOMIC INSTABILITY; EXPRESSION ANALYSIS; P110-DELTA ISOFORM; PULMONARY-EDEMA; RECEPTOR	We explored the mechanistic involvement of the growth arrest and DNA damage-inducible gene GADD45a in lipopolysaccharide (LPS)- and ventilator-induced inflammatory lung injury (VILI). Multiple biochemical and genomic parameters of inflammatory lung injury indicated that GADD45a(-/-) mice are modestly susceptible to intratracheal LPS-induced lung injury and profoundly susceptible to high tidal volume VILI, with increases in microvascular permeability and bronchoalveolar lavage levels of inflammatory cytokines. Expression profiling of lung tissues from VILI-challenged GADD45a(-/-) mice revealed strong dysregulation in the B-cell receptor signaling pathway compared with wild-type mice and suggested the involvement of PI3 kinase/Akt signaling components. Western blot analyses of lung homogenates confirmed similar to 50% reduction in Akt protein levels in GADD45a(-/-) mice accompanied by marked increases in Akt ubiquitination. Electrical resistance measurements across human lung endothelial cell monolayers with either reduced GADD45a or Akt expression (siRNAs) revealed significant potentiation of LPS-induced human lung endothelial barrier dysfunction, which was attenuated by overexpression of a constitutively active Akt1 transgene. These studies validate GADD45a as a novel candidate gene in inflammatory lung injury and a significant participant in vascular barrier regulation via effects on Akt-mediated endothelial signaling.-Meyer, N. J., Huang, Y., Singleton, P. A., Sammani, S., Moitra, J., Evenoski, C. L., Husain, A. N., Mitra, S., Moreno-Vinasco, L., Jacobson, J. R., Lussier, Y. A., Garcia, J. G. N. GADD45a is a novel candidate gene in inflammatory lung injury via influences on Akt signaling. FASEB J. 23, 1325-1337 (2009)	[Meyer, Nuala J.; Singleton, Patrick A.; Sammani, Saad; Moitra, Jaideep; Evenoski, Carrie L.; Mitra, Sumegha; Moreno-Vinasco, Liliana; Jacobson, Jeffrey R.; Garcia, Joe G. N.] Univ Chicago, Pritzker Sch Med, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; [Huang, Yong; Lussier, Yves A.] Univ Chicago, Pritzker Sch Med, Dept Med, Med Genet Sect, Chicago, IL 60637 USA; [Husain, Aliya N.] Univ Chicago, Pritzker Sch Med, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Garcia, JGN (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, Pulm & Crit Care Med Sect, W604,5841 S Maryland Ave, Chicago, IL 60637 USA.	jgarcia@medicine.bsd.uchicago.edu	Lussier, Yves/N-4891-2017; Garcia, Joe GN/E-8862-2010	Lussier, Yves/0000-0001-9854-1005; Mitra, Sumegha/0000-0002-5567-3347	U.S. National Institutes of Health [PPG HL-58064, F32 HL-088858-01, R01 HL-088144, K08 HL-077134-01, K22 LMV-008308]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL088858, K08HL077134, R01HL088144, P01HL058064] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K22LM008308] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We are extremely grateful to Dr. Michael O'Reilly (University of Rochester, Rochester, NY, USA) and Dr. Albert Fornace (Brigham and Women's Hospital, Boston, MA, USA) for generously providing the GADD45a<SUP>-/-</SUP> mice. We acknowledge the invaluable contributions of Dr. Shwu-Fan Ma, for her genomic expertise and other important insights. We also acknowledge Lakshmi Natarajan, Darrel Sparkman, Annette Westerberg, and Nicholas Shank, for their outstanding expertise and invaluable assistance. This work was supported by U.S. National Institutes of Health grants PPG HL-58064, F32 HL-088858-01, R01 HL-088144, K08 HL-077134-01, and K22 LMV-008308.	AGUADO MT, 1987, J IMMUNOL, V139, P1080; Altemeier WA, 2005, J IMMUNOL, V175, P3369, DOI 10.4049/jimmunol.175.5.3369; Bajwa EK, 2006, P AM THORAC SOC, V3, pA272; Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515; Befort K, 2003, EUR J NEUROSCI, V18, P911, DOI 10.1046/j.1460-9568.2003.02827.x; Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; DREYFUSS D, 1993, AM REV RESPIR DIS, V148, P1194, DOI 10.1164/ajrccm/148.5.1194; EILAT D, 1989, EUR J IMMUNOL, V19, P1241, DOI 10.1002/eji.1830190714; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Frank JA, 2006, CHEST, V130, P1906, DOI 10.1378/chest.130.6.1906; Gajic O, 2005, INTENS CARE MED, V31, P922, DOI 10.1007/s00134-005-2625-1; Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30; Garcia JGN, 1997, AM J PHYSIOL-LUNG C, V273, pL172, DOI 10.1152/ajplung.1997.273.1.L172; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gong MN, 2004, CHEST, V125, P203, DOI 10.1378/chest.125.1.203; Gong MN, 2005, EUR RESPIR J, V26, P382, DOI 10.1183/09031936.05.00000505; Grigoryev DN, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r34; Hebeis BJ, 2004, BIOCHEM SOC T, V32, P789, DOI 10.1042/BST0320789; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Hollander MC, 2005, CELL CYCLE, V4, P704, DOI 10.4161/cc.4.5.1675; Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004; Jung HJ, 2007, ONCOGENE, V26, P7517, DOI 10.1038/sj.onc.1210557; Kim N, 2007, BLOOD, V110, P3202, DOI 10.1182/blood-2007-02-075366; Kittleson MM, 2005, PHYSIOL GENOMICS, V21, P299, DOI 10.1152/physiolgenomics.00255.2004; Lionetti V, 2006, CRIT CARE MED, V34, P134, DOI 10.1097/01.CCM.0000190909.70601.2C; Liu F, 2002, FASEB J, V16, P950, DOI 10.1096/fj.01-0870com; Ma SF, 2005, AM J PHYSIOL-LUNG C, V289, pL468, DOI 10.1152/ajplung.00109.2005; Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; Meyer Nuala J, 2007, Proc Am Thorac Soc, V4, P69, DOI 10.1513/pats.200609-157JG; Miyahara T, 2007, AM J PHYSIOL-LUNG C, V293, pL11, DOI 10.1152/ajplung.00279.2005; MONESTIER M, 1986, J CLIN INVEST, V78, P753, DOI 10.1172/JCI112637; MONESTIER M, 1987, J EXP MED, V166, P1109, DOI 10.1084/jem.166.4.1109; Moss M, 2002, CRIT CARE MED, V30, P1679, DOI 10.1097/00003246-200208000-00001; Nonas SA, 2007, AM J PHYSIOL-LUNG C, V293, pL292, DOI 10.1152/ajplung.00481.2006; Nonas Stephanie A, 2005, Proc Am Thorac Soc, V2, P188, DOI 10.1513/pats.200501-005AC; O'Reilly MA, 2000, AM J PHYSIOL-LUNG C, V278, pL552, DOI 10.1152/ajplung.2000.278.3.L552; Okada T, 2000, IMMUNITY, V13, P817, DOI 10.1016/S1074-7613(00)00079-0; Okkenhaug K, 2007, TRENDS IMMUNOL, V28, P80, DOI 10.1016/j.it.2006.12.007; Okkenhaug K, 2006, J IMMUNOL, V177, P5122, DOI 10.4049/jimmunol.177.8.5122; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; Puri KD, 2005, BLOOD, V106, P150, DOI 10.1182/blood-2005-01-0023; Roper JM, 2005, AM J PHYSIOL-LUNG C, V288, pL663, DOI 10.1152/ajplung.00355.2004; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Salvador JM, 2005, NAT IMMUNOL, V6, P396, DOI 10.1038/ni1176; Salvador JM, 2005, NAT IMMUNOL, V6, P390, DOI 10.1038/ni1177; Schreibelt G, 2007, FASEB J, V21, P3666, DOI 10.1096/fj.07-8329com; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Shi S, 1998, ENDOTHELIUM-J ENDOTH, V6, P153, DOI 10.3109/10623329809072202; Singleton PA, 2006, J BIOL CHEM, V281, P34381, DOI 10.1074/jbc.M603680200; *TEAM R D C, 2006, R LANG ENV STAT COMP; Wang ZX, 2008, AM J RESP CELL MOL, V38, P724, DOI 10.1165/rcmb.2007-0354OC; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC; Young SH, 2008, J IMMUNOL METHODS, V331, P59, DOI 10.1016/j.jim.2007.11.004; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101	66	49	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1325	1337		10.1096/fj.08-119073	http://dx.doi.org/10.1096/fj.08-119073			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19124556	Green Published			2022-12-28	WOS:000266651700009
J	Song, SX; Liu, D; Peng, JL; Deng, HW; Guo, Y; Xu, LX; Miller, AD; Xu, YH				Song, Shuxian; Liu, Dan; Peng, Jinliang; Deng, Hongwei; Guo, Yan; Xu, Lisa X.; Miller, Andrew D.; Xu, Yuhong			Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo	FASEB JOURNAL			English	Article						AutoDock; epidermal growth factor; computer aided design; proteomic code; PEG; lipid	EPIDERMAL-GROWTH-FACTOR; PROLONGED CIRCULATION TIME; EFFICIENT DRUG-DELIVERY; FACTOR RECEPTOR; AUTOMATED DOCKING; TARGETED DELIVERY; COATED LIPOSOMES; TUMOR-CELLS; IMMUNOLIPOSOMES; DOXORUBICIN	Epidermal growth factor receptor (EGF-R) is an important target in anticancer therapy. Here we report how a novel EGF-R peptide ligand (D4: Leu-Ala-Arg-Leu-Leu-Thr) is identified using a computer-aided design approach from a virtual peptide library of putative EGF-R binding peptides by screening against the EGF-R X-ray crystal structure in silico and in vitro. The selected peptide is conjugated with a polyethylene glycol (PEG) lipid, and the lipid moiety of the peptide-PEG-lipid conjugate is inserted into liposome membranes by a postmodification process. D4 peptide-conjugated liposomes are found to bind to and enter cells by endocytosis specifically and efficiently in vitro in a process apparently mediated by EGF-R high-expressing cancer cells (H1299). In vivo, the D4 peptide-conjugated liposomes are found to accumulate in EGF-R-expressing xenograft tumor tissues up to 80 h after intravenous delivery, in marked contrast to controls. These results demonstrate how structure-based peptide design can be an efficient approach to identify highly novel binding ligands against important receptors. These data could have important consequences for the development of peptide-directed drug delivery systems with engineered specificities and prolonged times of action.-Song, S., Liu, D., Peng, J., Deng, H., Guo, Y., Xu, L. X., Miller, A. D., Xu, Y. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J. 23, 1396-1404 (2009)	[Miller, Andrew D.] Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, London SW7 2AZ, England; [Song, Shuxian; Liu, Dan; Guo, Yan; Xu, Lisa X.] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China; [Peng, Jinliang] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Shanghai 200240, Peoples R China; [Deng, Hongwei; Xu, Yuhong] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China; [Miller, Andrew D.] ImuThes Ltd, London, England	Imperial College London; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Miller, AD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, London SW7 2AZ, England.	a.miller@imperial.ac.uk; yhxu@sjtu.edu.cn	Miller, Andrew/G-8291-2019; Xu, Yuhong/E-4247-2012	Miller, Andrew/0000-0003-0661-249X; 	National Science Foundation of China [30472097]; Fok Ying Tong Education Foundation [91035]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fok Ying Tong Education Foundation(Fok Ying Tung Education Foundation)	Funding was provided by National Science Foundation of China grant 30472097 and Fok Ying Tong Education Foundation grant 91035.	Bhakoo A, 2004, MOL IMMUNOL, V41, P1217, DOI 10.1016/j.molimm.2004.05.011; Blessing T, 2001, BIOCONJUGATE CHEM, V12, P529, DOI 10.1021/bc0001488; Chen P, 2002, NUCL MED BIOL, V29, P693, DOI 10.1016/S0969-8051(02)00325-6; de Graaf C, 2005, J MED CHEM, V48, P2308, DOI 10.1021/jm049650u; de Menezes DEL, 1998, CANCER RES, V58, P3320; DERKSEN JTP, 1988, BIOCHIM BIOPHYS ACTA, V971, P127, DOI 10.1016/S0005-2728(88)80099-9; GABIZON A, 1994, CANCER RES, V54, P987; Gabizon A, 2003, CLIN CANCER RES, V9, P6551; Gabizon AA, 2006, J LIPOSOME RES, V16, P175, DOI 10.1080/08982100600848769; Goren D, 1996, BRIT J CANCER, V74, P1749, DOI 10.1038/bjc.1996.625; HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9; HARAN G, 1994, BBA-BIOMEMBRANES, V1190, P197; Heal JR, 2002, CHEMBIOCHEM, V3, P137, DOI 10.1002/1439-7633(20020301)3:2/3<136::AID-CBIC136>3.0.CO;2-7; Hetenyi C, 2002, PROTEIN SCI, V11, P1729, DOI 10.1110/ps.0202302; Hsu AR, 2006, MOL IMAGING BIOL, V8, P315, DOI 10.1007/s11307-006-0059-y; Huwyler J, 1997, J PHARMACOL EXP THER, V282, P1541; Ishida T, 1999, FEBS LETT, V460, P129, DOI 10.1016/S0014-5793(99)01320-4; Jinno H, 1996, CANCER CHEMOTH PHARM, V38, P303, DOI 10.1007/s002800050487; Kamaly N, 2008, BIOCONJUGATE CHEM, V19, P118, DOI 10.1021/bc7001715; Ke S, 2003, CANCER RES, V63, P7870; Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199; Koning GA, 2003, PHARMACEUT RES, V20, P1249, DOI 10.1023/A:1025009300562; Koning GA, 2001, PHARMACEUT RES, V18, P1291, DOI 10.1023/A:1013085811044; Kullberg EB, 2003, PHARMACEUT RES, V20, P229, DOI 10.1023/A:1022223204460; LEE RJ, 1995, BBA-BIOMEMBRANES, V1233, P134, DOI 10.1016/0005-2736(94)00235-H; Li ZH, 2005, FASEB J, V19, P1978, DOI 10.1096/fj.05-4058com; Liu X, 2002, CANCER GENE THER, V9, P100, DOI 10.1038/sj/cgt/7700400; Lutsenko SV, 2002, J DRUG TARGET, V10, P567, DOI 10.1080/1061186021000038058; Ma GB, 2007, APPL OPTICS, V46, P1650, DOI 10.1364/AO.46.001650; Mamot C, 2005, CANCER RES, V65, P11631, DOI 10.1158/0008-5472.CAN-05-1093; Mamot C, 2003, CANCER RES, V63, P3154; Mamot C, 2006, J DRUG TARGET, V14, P215, DOI 10.1080/10611860600691049; Maruyama K, 1997, FEBS LETT, V413, P177, DOI 10.1016/S0014-5793(97)00905-8; MARUYAMA K, 1995, BBA-BIOMEMBRANES, V1234, P74, DOI 10.1016/0005-2736(94)00263-O; Mastrobattista E, 1999, ADV DRUG DELIVER REV, V40, P103, DOI 10.1016/S0169-409X(99)00043-5; Matsumura Y, 2004, ANN ONCOL, V15, P517, DOI 10.1093/annonc/mdh092; MAYER LD, 1990, BIOCHIM BIOPHYS ACTA, V1025, P143, DOI 10.1016/0005-2736(90)90091-2; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; PARK JW, 1995, P NATL ACAD SCI USA, V92, P1327, DOI 10.1073/pnas.92.5.1327; Perez-Soler R, 2004, ONCOLOGIST, V9, P58, DOI 10.1634/theoncologist.9-1-58; Rogers JP, 2006, J MED CHEM, V49, P1658, DOI 10.1021/jm051033y; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sapra P, 2004, CLIN CANCER RES, V10, P1100, DOI 10.1158/1078-0432.CCR-03-0041; Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2; Schmidt M, 1997, BRIT J CANCER, V75, P1575, DOI 10.1038/bjc.1997.270; Song SX, 2008, INT J PHARMACEUT, V363, P155, DOI 10.1016/j.ijpharm.2008.07.012; Terada T, 2006, J DRUG TARGET, V14, P536, DOI 10.1080/10611860600849498	47	107	114	2	42	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1396	1404		10.1096/fj.08-117002	http://dx.doi.org/10.1096/fj.08-117002			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19124558				2022-12-28	WOS:000266651700016
J	Tarry-Adkins, JL; Chen, JH; Smith, NS; Jones, RH; Cherif, H; Ozanne, SE				Tarry-Adkins, J. L.; Chen, J. H.; Smith, N. S.; Jones, R. H.; Cherif, H.; Ozanne, S. E.			Poor maternal nutrition followed by accelerated postnatal growth leads to telomere shortening and increased markers of cell senescence in rat islets	FASEB JOURNAL			English	Article						cellular stress; antioxidative defense; DNA damage; DNA repair	LOW-BIRTH-WEIGHT; LOW-PROTEIN-DIET; ENZYME GENE-EXPRESSION; OXIDATIVE STRESS; GLUCOSE-TOLERANCE; INSULIN SENSITIVITY; DIABETES-MELLITUS; PANCREATIC-ISLETS; DNA-DAMAGE; FETAL	Low birth weight (LBW) followed by accelerated postnatal growth is associated with increased risk of developing age-associated diseases such as type 2 diabetes. Gestational protein restriction in rats causes LBW, beta-cell dysfunction, and reduced longevity. These effects may be mediated by accelerated cellular aging. This study tested the hypothesis that LBW followed by rapid postnatal catch-up growth leads to islet telomere shortening through alterations in antioxidant defense capacity, stress/senescence marker proteins, and DNA repair mechanisms at the gene expression level. We used our rat model of gestational protein restriction (recuperated offspring) and control offspring. Southern blotting revealed shorter (P < 0.001) islet telomeres in recuperated animals compared to controls. This was associated with increased expression of peroxiredoxin 1 (P < 0.05), peroxiredoxin 3 (P < 0.01), and heme oxygenase-1 (HO-1) (P < 0.05), which are up-regulated under stress conditions. MnSOD expression was significantly (P < 0.05) decreased in recuperated offspring, suggesting partial impairment of mitochondrial antioxidant defenses. Markers of cellular senescence p21 and p16 were also increased (P < 0.01 and P < 0.05, respectively) in the recuperated group. We conclude that maternal diet influences expression of markers of cellular stress and telomere length in pancreatic islets. This may provide a mechanistic link between early nutrition and growth and type 2 diabetes.-Tarry-Adkins, J. L., Chen, J. H., Smith, N. S., Jones, R. H., Cherif, H., Ozanne, S. E. Poor maternal nutrition followed by accelerated postnatal growth leads to telomere shortening and increased markers of cell senescence in rat islets. FASEB J. 23, 1521-1528 (2009)	[Tarry-Adkins, J. L.] Univ Cambridge, Metab Res Labs, Inst Metab Sci, Addenbrookes Treatment Ctr,Addenbrookes Hosp, Cambridge CB2 OQQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Tarry-Adkins, JL (corresponding author), Univ Cambridge, Metab Res Labs, Inst Metab Sci, Addenbrookes Treatment Ctr,Addenbrookes Hosp, Level 4,Box 289,Hills Rd, Cambridge CB2 OQQ, England.	janeadkins@googlemail.com		Ozanne, Susan/0000-0001-8753-5144; Tarry-Adkins, Jane/0000-0001-9569-6132	Biotechnology and Biological Sciences Research Council; British Heart Foundation; MRC CORD; Parthenon Trust; BBSRC [BB/E002161/1, BB/D007909/1, BB/E00797X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E002161/1, BB/E00797X/1, BB/D007909/1] Funding Source: researchfish; Medical Research Council [G0600717B] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); MRC CORD(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Parthenon Trust; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank A. Wayman and D. Hawkes for their technical expertise. This work was supported by the Biotechnology and Biological Sciences Research Council, The British Heart Foundation, MRC CORD, and the Parthenon Trust.	Bakaysa SL, 2007, AGING CELL, V6, P769, DOI 10.1111/j.1474-9726.2007.00340.x; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Bast A, 2002, DIABETOLOGIA, V45, P867, DOI 10.1007/s00125-002-0846-1; Bo S, 2000, DIABETIC MED, V17, P365, DOI 10.1046/j.1464-5491.2000.00288.x; Chen HN, 2005, DIABETES, V54, P1437, DOI 10.2337/diabetes.54.5.1437; Crowther NJ, 1998, DIABETOLOGIA, V41, P1163, DOI 10.1007/s001250051046; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; Elouil H, 2005, DIABETOLOGIA, V48, P496, DOI 10.1007/s00125-004-1664-4; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Esposito F, 2000, FEBS LETT, V470, P211, DOI 10.1016/S0014-5793(00)01318-1; Forsen T, 2000, ANN INTERN MED, V133, P176, DOI 10.7326/0003-4819-133-3-200008010-00008; Grunnet L, 2007, J INTERN MED, V262, P96, DOI 10.1111/j.1365-2796.2007.01793.x; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Haussmann MF, 2003, P ROY SOC B-BIOL SCI, V270, P1387, DOI 10.1098/rspb.2003.2385; Ishii Tetsuro, 2007, V44, P375; Jemielity S, 2007, AGING CELL, V6, P225, DOI 10.1111/j.1474-9726.2007.00279.x; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Kajimoto Y, 2004, ANN NY ACAD SCI, V1011, P168, DOI 10.1196/annals.1293.017; Kaneto H, 1999, DIABETOLOGIA, V42, P1093, DOI 10.1007/s001250051276; KARAWICZBINISKA A, 2008, MED SCI MONITOR, V8, pCR211; Kawanishi S, 2004, ANN NY ACAD SCI, V1019, P278, DOI 10.1196/annals.1297.047; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; KRISHNAMURTHY J, 2006, NATURE, V28, P404; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; McPherson JP, 2006, HUM MOL GENET, V15, P831, DOI 10.1093/hmg/ddl002; Mericq V, 2005, DIABETOLOGIA, V48, P2609, DOI 10.1007/s00125-005-0036-z; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Ong KK, 2004, DIABETOLOGIA, V47, P1064, DOI 10.1007/s00125-004-1405-8; Ozanne SE, 2005, DIABETOLOGIA, V48, P547, DOI 10.1007/s00125-005-1669-7; Ozanne SE, 2003, J ENDOCRINOL, V177, P235, DOI 10.1677/joe.0.1770235; Pastwa E, 2003, ACTA BIOCHIM POL, V50, P891; Petrik J, 1999, ENDOCRINOLOGY, V140, P4861, DOI 10.1210/en.140.10.4861; Petry C J, 2001, Int J Exp Diabetes Res, V2, P139; Poulsen P, 1997, DIABETOLOGIA, V40, P439, DOI 10.1007/s001250050698; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; Richter T, 2007, EXP GERONTOL, V42, P1039, DOI 10.1016/j.exger.2007.08.005; Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Shelley P, 2007, MECH AGEING DEV, V128, P681, DOI 10.1016/j.mad.2007.10.002; Simmons RA, 2006, FREE RADICAL BIO MED, V40, P917, DOI 10.1016/j.freeradbiomed.2005.12.018; Simmons RA, 2005, J BIOL CHEM, V280, P28785, DOI 10.1074/jbc.M505695200; Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279; Simmons RA, 2007, REV ENDOCR METAB DIS, V8, P95, DOI 10.1007/s11154-007-9045-1; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Tarry-Adkins JL, 2008, FASEB J, V22, P2037, DOI 10.1096/fj.07-099523; Tarry-Adkins JL, 2006, AM J PHYSIOL-RENAL, V290, pF509, DOI 10.1152/ajprenal.00215.2005; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Yajnik CS, 2004, J NUTR, V134, P205, DOI 10.1093/jn/134.1.205	53	140	144	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1521	1528		10.1096/fj.08-122796	http://dx.doi.org/10.1096/fj.08-122796			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19126595				2022-12-28	WOS:000266651700028
J	Pacheco-Lopez, G; Riether, C; Doenlen, R; Engler, H; Niemi, MB; Engler, A; Kavelaars, A; Heijnen, CJ; Schedlowski, M				Pacheco-Lopez, Gustavo; Riether, Carsten; Doenlen, Raphael; Engler, Harald; Niemi, Maj-Britt; Engler, Andrea; Kavelaars, Annemieke; Heijnen, Cobi J.; Schedlowski, Manfred			Calcineurin inhibition in splenocytes induced by pavlovian conditioning	FASEB JOURNAL			English	Article						cyclosporin A; immunosuppression; associative learning; placebo; taste	CYCLOSPORINE-A; SPLENIC INNERVATION; TASTE-AVERSION; IL-2 PRODUCTION; INSULAR CORTEX; IN-VIVO; IMMUNE; IMMUNOSUPPRESSION; RAT; PLACEBO	Pavlovian conditioning is one of the major neurobiological mechanisms of placebo effects, potentially influencing the course of specific diseases and the response to a pharmacological therapy, such as immunosuppression. In our study with behaviorally conditioned rats, a relevant taste (0.2% saccharin) preceded the application of the immunosuppressive drug cyclosporin A (CsA), a specific calcineurin (CaN) inhibitor. Our results demonstrate that through pavlovian conditioning the particular pharmacological properties of CsA can be transferred to a neutral taste, i.e., CaN activity was inhibited in splenocytes from conditioned rats after reexposure to the gustatory stimulus. Concomitant immune consequences were observed on ex vivo mitogenic challenge (anti-CD3). Particularly, Th1-cytokine, but not Th2-cytokine, production and cell proliferation were impeded. Appropriate pharmacological and behavioral controls certify that all these changes in T-lymphocyte reactivity are attributable to mere taste reexposure. Furthermore, the underlying sympathetic-lymphocyte interaction was revealed modeling the conditioned response in vitro. CaN activity in CD4(+) T lymphocytes is reduced by beta-adrenergic stimulation (terbutaline), with these effects antagonized by the beta-adrenoreceptor antagonist nadolol. In summary, CaN was identified as the intracellular target for inducing conditioned immunosuppression by CsA, contributing to our understanding of the intracellular mechanisms behind "learned placebo effects."-Pacheco-Lopez, G., Riether, C., Doenlen, R., Engler, H., Niemi, M.-B., Engler, A., Kavelaars, A., Heijnen, C. J., Schedlowski, M. Calcineurin inhibition in splenocytes induced by pavlovian conditioning. FASEB J. 23, 1161-1167 (2009)	[Pacheco-Lopez, Gustavo; Riether, Carsten; Doenlen, Raphael; Engler, Harald; Niemi, Maj-Britt; Engler, Andrea] ETH, Inst Behav Sci, Dept Psychol & Behav Immunobiol, Zurich, Switzerland; [Engler, Harald; Schedlowski, Manfred] Univ Duisburg Essen, Fac Med, Div Med Psychol & Behav Immunobiol, Essen, Germany; [Kavelaars, Annemieke; Heijnen, Cobi J.] Univ Med Ctr Utrecht, Lab Psychoneuroimmunol, Utrecht, Netherlands	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Duisburg Essen; Utrecht University; Utrecht University Medical Center	Pacheco-Lopez, G (corresponding author), Inst Behav Sci Psychol & Behav Immunobiol, TUR B21-1,Turnerstr 1, CH-8092 Zurich, Switzerland.	pacheco@ifv.gess.ethz.ch	Pacheco-Lopez, Gustavo/AAH-3215-2019; Riether, Carsten/ABC-7699-2021; Riether, Carsten/K-8603-2013; Engler, Harald/H-8773-2017; Pacheco-Lopez, Gustavo/E-8795-2016	Pacheco-Lopez, Gustavo/0000-0002-3458-197X; Riether, Carsten/0000-0001-7512-513X; Riether, Carsten/0000-0001-7512-513X; Engler, Harald/0000-0001-6329-1990; Pacheco-Lopez, Gustavo/0000-0002-3458-197X	ETH Fund [0-20297-05]; Dr. Donald C. Cooper Fund	ETH Fund; Dr. Donald C. Cooper Fund	This work was supported by ETH Fund grant 0-20297-05 and by the Dr. Donald C. Cooper Fund (ETH Zurich).	ADER R, 1982, SCIENCE, V215, P1534, DOI 10.1126/science.7063864; Ader R, 2001, PSYCHONEUROIMMUNOLOG, P3; Amaro S, 1996, PHYSIOL BEHAV, V60, P71, DOI 10.1016/0031-9384(95)02250-3; Barten MJ, 2006, CYTOM PART A, V69A, P155, DOI 10.1002/cyto.a.20215; Batiuk TD, 1997, TRANSPL P, V29, P1239, DOI 10.1016/S0041-1345(96)00481-2; Benedetti F, 2008, ANNU REV PHARMACOL, V48, P33, DOI 10.1146/annurev.pharmtox.48.113006.094711; BLANCK A, 1991, J STEROID BIOCHEM, V39, P33, DOI 10.1016/0960-0760(91)90009-T; Bovbjerg DH, 2003, BRAIN BEHAV IMMUN, V17, pS58; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cano G, 2001, J COMP NEUROL, V439, P1, DOI 10.1002/cne.1331; CECHETTO DF, 1990, AM J PHYSIOL, V258, pR245, DOI 10.1152/ajpregu.1990.258.1.R245; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; de la Fuente-Fernandez R, 2002, LANCET NEUROL, V1, P85, DOI 10.1016/S1474-4422(02)00038-8; Downing JEG, 2000, IMMUNOL TODAY, V21, P281, DOI 10.1016/S0167-5699(00)01635-2; Enck P, 2008, NEURON, V59, P195, DOI 10.1016/j.neuron.2008.06.030; Exton MS, 1998, PHYSIOL BEHAV, V63, P241, DOI 10.1016/S0031-9384(97)00432-0; Exton MS, 2002, J NEUROIMMUNOL, V131, P21, DOI 10.1016/S0165-5728(02)00249-7; Exton MS, 2001, IMMUNOL REV, V184, P226, DOI 10.1034/j.1600-065x.2001.1840120.x; Exton MS, 1998, J NEUROIMMUNOL, V88, P182, DOI 10.1016/S0165-5728(98)00122-2; Exton MS, 1999, AM J PHYSIOL-REG I, V276, pR1710, DOI 10.1152/ajpregu.1999.276.6.R1710; Exton MS, 2000, AM J PHYSIOL-REG I, V279, pR1310, DOI 10.1152/ajpregu.2000.279.4.R1310; Giang DW, 1996, J NEUROPSYCH CLIN N, V8, P194; Goebel MU, 2002, FASEB J, V16, P1869, DOI 10.1096/fj.02-0389com; Goehler LE, 2000, AUTON NEUROSCI-BASIC, V85, P49, DOI 10.1016/S1566-0702(00)00219-8; GROSSMAN Z, 1992, INT J NEUROSCI, V64, P275, DOI 10.3109/00207459209000555; Halloran PF, 1999, TRANSPLANTATION, V68, P1356, DOI 10.1097/00007890-199911150-00023; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Janz LJ, 1996, PHYSIOL BEHAV, V59, P1103, DOI 10.1016/0031-9384(95)02171-X; KLOSTERHALFEN S, 1990, BEHAV NEUROSCI, V104, P716, DOI 10.1037/0735-7044.104.5.716; LYSON T, 1994, HYPERTENSION, V23, P667, DOI 10.1161/01.HYP.23.5.667; MARTIN B, 1985, J BIOL CHEM, V260, P4932; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Niemi MB, 2007, J NEUROIMMUNOL, V188, P74, DOI 10.1016/j.jneuroim.2007.05.016; Niemi MB, 2006, BRAIN BEHAV IMMUN, V20, P527, DOI 10.1016/j.bbi.2006.02.004; OPPENHEIMER SM, 1992, BRAIN RES, V569, P221, DOI 10.1016/0006-8993(92)90633-K; Pacheco-Lopez G, 2005, J NEUROSCI, V25, P2330, DOI 10.1523/JNEUROSCI.4230-04.2005; Pacheco-Lopez G, 2006, BRAIN BEHAV IMMUN, V20, P430, DOI 10.1016/j.bbi.2006.05.003; Pacheco-Lopez G, 2007, PSYCHONEUROIMMUNOLOGY, VOLS I AND II, 4TH EDITION, P631; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Ramer-Quinn DS, 2000, BRAIN BEHAV IMMUN, V14, P239, DOI 10.1006/brbi.2000.0603; Riether C, 2008, REV NEUROSCIENCE, V19, P1; Sanders VM, 2002, BRAIN BEHAV IMMUN, V16, P290, DOI 10.1006/brbi.2001.0639; SCHMIDT J, 1994, IMMUNOPHARMACOLOGY, V27, P173, DOI 10.1016/0162-3109(94)90013-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Steinman L, 2004, NAT IMMUNOL, V5, P575, DOI 10.1038/ni1078; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Wrona D, 2006, J NEUROIMMUNOL, V172, P38, DOI 10.1016/j.jneuroim.2005.10.017; Xie YF, 2002, IMMUNOBIOLOGY, V206, P345, DOI 10.1078/0171-2985-00185; Zhang WG, 2000, P NATL ACAD SCI USA, V97, P9765, DOI 10.1073/pnas.170160397	51	34	34	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1161	1167		10.1096/fj.08-115683	http://dx.doi.org/10.1096/fj.08-115683			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19103649				2022-12-28	WOS:000266651600020
J	Bruneau, EG; Esteban, JA; Akaaboune, M				Bruneau, Emile G.; Esteban, Jose A.; Akaaboune, Mohammed			Receptor-associated proteins and synaptic plasticity	FASEB JOURNAL			English	Review						rapsyn; gephyrin; PSD-95; scaffold; dynamics	NICOTINIC ACETYLCHOLINE-RECEPTOR; LONG-TERM POTENTIATION; JUNCTION IN-VIVO; POSTSYNAPTIC DENSITY-95 PROTEIN; CONGENITAL MYASTHENIC SYNDROME; MAGUK SCAFFOLDING PROTEINS; GABA(A) RECEPTORS; NEUROMUSCULAR-JUNCTION; AMPA RECEPTORS; INHIBITORY SYNAPSES	Changes in synaptic strength are important for synaptic development and synaptic plasticity. Most directly responsible for these synaptic changes are alterations in synaptic receptor number and density. Although alterations in receptor density mediated by the insertion, lateral mobility, removal, and recycling of receptors have been extensively studied, the dynamics and regulators of intracellular scaffolding proteins have only recently begun to be illuminated. In particular, a closer look at the receptor-associated proteins, which bind to receptors and are necessary for their synaptic localization and clustering, has revealed broader functions than previously thought and some rather unexpected thematic similarities. More than just "placeholders" or members of a passive protein "scaffold," receptor-associated proteins in every synapse studied have been shown to provide a number of signaling roles. In addition, the most recent state-of-the-art imaging has revealed that receptor-associated proteins are highly dynamic and are involved in regulating synaptic receptor density. Together, these results challenge the view that receptor-associated proteins are members of a static and stable scaffold and argue that their dynamic mobility may be essential for regulating activity-dependent changes in synaptic strength.-Bruneau, E. G., Esteban, J. A., Akaaboune, M. Receptor-associated proteins and synaptic plasticity. FASEB J. 23, 679-688 (2009)	[Bruneau, Emile G.; Akaaboune, Mohammed] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; [Bruneau, Emile G.; Akaaboune, Mohammed] Univ Michigan, Program Neurosci, Ann Arbor, MI 48109 USA; [Esteban, Jose A.] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Akaaboune, M (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	makaabou@umich.edu	Esteban, Jose/L-4944-2014	Esteban, Jose/0000-0002-3759-3300	U.S. National Institutes of Health; National Science Foundation; Muscular Dystrophy Association	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Muscular Dystrophy Association(Muscular Dystrophy Association)	This work was supported by the U.S. National Institutes of Health (M. A.) and a National Research Service Award (G. B.), the National Science Foundation (M. A.), and the Muscular Dystrophy Association (M. A.).	Akaaboune M, 2002, NEURON, V34, P865, DOI 10.1016/S0896-6273(02)00739-0; Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; Banwell BL, 2004, NEUROMUSCULAR DISORD, V14, P202, DOI 10.1016/j.nmd.2003.11.004; Bartoli M, 2001, J BIOL CHEM, V276, P24911, DOI 10.1074/jbc.M103258200; Bats C, 2007, NEURON, V53, P719, DOI 10.1016/j.neuron.2007.01.030; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Beique JC, 2003, J PHYSIOL-LONDON, V546, P859, DOI 10.1113/jphysiol.2002.031369; Bogdanov Y, 2006, EMBO J, V25, P4381, DOI 10.1038/sj.emboj.7601309; Breese CR, 1997, J PHARMACOL EXP THER, V282, P7; Bruneau E, 2005, J NEUROSCI, V25, P9949, DOI 10.1523/JNEUROSCI.3169-05.2005; Bruneau EG, 2005, DEV BIOL, V288, P248, DOI 10.1016/j.ydbio.2005.09.041; Bruneau E, 2007, J BIOL CHEM, V282, P9932, DOI 10.1074/jbc.M608714200; Bruneau EG, 2008, CURR BIOL, V18, P109, DOI 10.1016/j.cub.2007.12.029; Bruneau EG, 2006, DEVELOPMENT, V133, P4485, DOI 10.1242/dev.02619; Cai CL, 2006, J BIOL CHEM, V281, P4267, DOI 10.1074/jbc.M505886200; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Charrier C, 2006, J NEUROSCI, V26, P8502, DOI 10.1523/JNEUROSCI.1758-06.2006; Chen F, 2007, NEURON, V55, P247, DOI 10.1016/j.neuron.2007.06.031; Chen ZW, 2007, J NEUROSCI, V27, P6655, DOI 10.1523/JNEUROSCI.0919-07.2007; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; Conroy WG, 2003, NEURON, V38, P759, DOI 10.1016/S0896-6273(03)00324-6; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; El-Hussein AE, 2000, SCIENCE, V290, P1364; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Elias GM, 2007, TRENDS CELL BIOL, V17, P343, DOI 10.1016/j.tcb.2007.07.005; Elias GM, 2006, NEURON, V52, P307, DOI 10.1016/j.neuron.2006.09.012; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gautam M, 1999, DEV BRAIN RES, V114, P171, DOI 10.1016/S0165-3806(99)00013-9; Gervasio OL, 2005, J PHYSIOL-LONDON, V562, P673, DOI 10.1113/jphysiol.2004.077685; Giesemann T, 2003, J NEUROSCI, V23, P8330; Gray NW, 2006, PLOS BIOL, V4, P2065, DOI 10.1371/journal.pbio.0040370; Greger IH, 2007, CURR OPIN NEUROBIOL, V17, P289, DOI 10.1016/j.conb.2007.04.007; Hanley JG, 2006, BIOCHEM SOC T, V34, P931, DOI 10.1042/BST0340931; Hanley JG, 2002, NEURON, V34, P53, DOI 10.1016/S0896-6273(02)00638-4; Hanus C, 2006, J NEUROSCI, V26, P4586, DOI 10.1523/JNEUROSCI.5123-05.2006; Heine M, 2008, SCIENCE, V320, P201, DOI 10.1126/science.1152089; Jacob TC, 2005, J NEUROSCI, V25, P10469, DOI 10.1523/JNEUROSCI.2267-05.2005; Kalia LV, 2006, EMBO J, V25, P4971, DOI 10.1038/sj.emboj.7601342; Kalia LV, 2003, NEUROPHARMACOLOGY, V45, P720, DOI 10.1016/S0028-3908(03)00313-7; Kanematsu T, 2002, EMBO J, V21, P1004, DOI 10.1093/emboj/21.5.1004; Kawaguchi SY, 2007, J NEUROSCI, V27, P6788, DOI 10.1523/JNEUROSCI.1981-07.2007; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kim MJ, 2007, NEURON, V56, P488, DOI 10.1016/j.neuron.2007.09.007; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Kittler JT, 2004, BIOCHEM PHARMACOL, V68, P1649, DOI 10.1016/j.bcp.2004.07.028; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kneussel M, 2001, MOL CELL NEUROSCI, V17, P973, DOI 10.1006/mcne.2001.0983; Kong XC, 2004, EMBO REP, V5, P183, DOI 10.1038/sj.embor.7400065; Kristiansen LV, 2006, MOL PSYCHIATR, V11, P737, DOI 10.1038/sj.mp.4001844; Kuriu T, 2006, J NEUROSCI, V26, P7693, DOI 10.1523/JNEUROSCI.0522-06.2006; LAROCHELLE WJ, 1987, J BIOL CHEM, V262, P8190; Leil TA, 2004, J NEUROSCI, V24, P11429, DOI 10.1523/JNEUROSCI.3355-04.2004; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Levi S, 2004, J NEUROSCI, V24, P207, DOI 10.1523/JNEUROSCI.1661-03.2004; Levi S, 2008, NEURON, V59, P261, DOI 10.1016/j.neuron.2008.05.030; Li XM, 2008, NAT NEUROSCI, V11, P262, DOI 10.1038/nn2053; Lin DT, 2007, J NEUROSCI, V27, P13903, DOI 10.1523/JNEUROSCI.1750-07.2007; Lu W, 2005, NEURON, V47, P407, DOI 10.1016/j.neuron.2005.07.006; Maimone MM, 1999, MOL CELL NEUROSCI, V14, P340, DOI 10.1006/mcne.1999.0779; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Marchand S, 2002, J NEUROSCI, V22, P8891; Marchand S, 2000, J NEUROSCI, V20, P521, DOI 10.1523/JNEUROSCI.20-02-00521.2000; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817; Maselli RA, 2003, MUSCLE NERVE, V28, P293, DOI 10.1002/mus.10433; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MUSIL LS, 1989, J CELL BIOL, V108, P1833, DOI 10.1083/jcb.108.5.1833; Nakagawa T, 2004, NEURON, V44, P453, DOI 10.1016/j.neuron.2004.10.012; O'Sullivan GA, 2005, EUR J NEUROSCI, V22, P2644, DOI 10.1111/j.1460-9568.2005.04448.x; Ohno K, 2003, HUM MOL GENET, V12, P739, DOI 10.1093/hmg/ddg089; Ohno K, 2002, AM J HUM GENET, V70, P875, DOI 10.1086/339465; Okabe S, 1999, NAT NEUROSCI, V2, P804, DOI 10.1038/12175; Ono F, 2001, J NEUROSCI, V21, P5439, DOI 10.1523/JNEUROSCI.21-15-05439.2001; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Papadopoulos T, 2007, EMBO J, V26, P3888, DOI 10.1038/sj.emboj.7601819; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; PERRY EK, 1987, J NEUROL NEUROSUR PS, V50, P806, DOI 10.1136/jnnp.50.6.806; Phillips WD, 1997, MOL CELL NEUROSCI, V10, P16, DOI 10.1006/mcne.1997.0634; Rasse TM, 2005, NAT NEUROSCI, V8, P898, DOI 10.1038/nn1484; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Romorini S, 2004, J NEUROSCI, V24, P9391, DOI 10.1523/JNEUROSCI.3314-04.2004; Rutter AR, 2000, J NEUROCHEM, V75, P2501, DOI 10.1046/j.1471-4159.2000.0752501.x; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Schluter OM, 2006, NEURON, V51, P99, DOI 10.1016/j.neuron.2006.05.016; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Sharma K, 2006, MOL CELL NEUROSCI, V31, P702, DOI 10.1016/j.mcn.2006.01.010; Shepherd JD, 2007, ANNU REV CELL DEV BI, V23, P613, DOI 10.1146/annurev.cellbio.23.090506.123516; Shin H, 2003, J BIOL CHEM, V278, P11393, DOI 10.1074/jbc.M211874200; Stein V, 2003, J NEUROSCI, V23, P5503; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thomas P, 2005, NAT NEUROSCI, V8, P889, DOI 10.1038/nn1483; Toro C, 2005, SCHIZOPHR RES, V80, P323, DOI 10.1016/j.schres.2005.07.003; Triller A, 2008, NEURON, V59, P359, DOI 10.1016/j.neuron.2008.06.022; Wang J, 2008, J BIOL CHEM, V283, P21668, DOI 10.1074/jbc.M709939200; Wang JM, 2003, NAT NEUROSCI, V6, P1017, DOI 10.1038/nn1128; Wang ZZ, 1999, J NEUROSCI, V19, P1998; Washbourne P, 2002, NAT NEUROSCI, V5, P751, DOI 10.1038/nn883; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; Xu W, 2008, NEURON, V57, P248, DOI 10.1016/j.neuron.2007.11.027; YOUNG SH, 1983, J NEUROSCI, V3, P225; Yu W, 2007, MOL CELL NEUROSCI, V36, P484, DOI 10.1016/j.mcn.2007.08.008; Zhang B, 2007, J NEUROSCI, V27, P3968, DOI 10.1523/JNEUROSCI.4691-06.2007	124	23	23	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					679	688		10.1096/fj.08-107946	http://dx.doi.org/10.1096/fj.08-107946			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18978155	Green Published, Green Submitted			2022-12-28	WOS:000265506300003
J	Jastrzebska, B; Golczak, M; Fotiadis, D; Engel, A; Palczewski, K				Jastrzebska, Beata; Golczak, Marcin; Fotiadis, Dimitrios; Engel, Andreas; Palczewski, Krzysztof			Isolation and functional characterization of a stable complex between photoactivated rhodopsin and the G protein, transducin	FASEB JOURNAL			English	Article						sucrose gradient; detergent; rhodopsin regeneration	ROD OUTER SEGMENTS; G-ALPHA-SUBUNITS; COUPLED RECEPTOR; CRYSTAL-STRUCTURE; METARHODOPSIN-II; OPSIN STABILITY; ACTIVATION; DIMERS; PHOTOTRANSDUCTION; STABILIZATION	Transitory binding between photoactivated rhodopsin (Rho* or Meta II) and the G protein transducin (Gt-GDP) is the first step in the visual signaling cascade. Light causes photoisomerization of the 11-cis-retinylidene chromophore in rhodopsin (Rho) to all-trans-retinylidene, which induces conformational changes that allow Gt-GDP to dock onto the Rho* surface. GDP then dissociates from Gt, leaving a transient nucleotide-empty Rho*-Gt(e) complex before GTP becomes bound, and Gt-GTP then dissociates from Rho*. Further biochemical advances are required before structural studies of the various Rho*-Gt complexes can be initiated. Here, we describe the isolation of n-dodecyl-beta-maltoside solubilized, stable, functionally active, Rho*-Gt(e), Rhoe*-Gt(e), and 9-cis-retinal/11-cis-retinal regenerated Rho-Gt(e) complexes by sucrose gradient centrifugation. In these complexes, Rho* spectrally remained in its Meta II state, and Gt(e) retained its ability to interact with GTP gamma S. Removal of all-trans-retinylidene from Rho*-Gt(e) had no effect on the stability of the Rho(e)*-Gt(e) complex. Moreover, opsin in the Rho(e)*-Gt(e) complex with an empty nucleotide-binding pocket in Gt and an empty retinoid-binding pocket in Rho was regenerated up to 75% without complex dissociation. These results indicate that once Rho* couples with Gt, the chromophore plays a minor role in stabilizing this complex. Moreover, in complexes regenerated with 9-cis-retinal/11-cis-retinal, Rho retains a conformation similar to Rho* that is stabilized by Gte apo-protein. - Jastrzebska, B., Golczak, M., Fotiadis, D., Engel, A., and Palczewski, K.. Isolation and functional characterization of a stable complex between photoactivated rhodopsin and the G protein, transducin. FASEB J. 23, 371-381 (2009)	[Jastrzebska, Beata; Golczak, Marcin] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Fotiadis, Dimitrios; Engel, Andreas] Univ Basel, Biozentrum, ME Muller Inst Microscopy, Basel, Switzerland; [Fotiadis, Dimitrios] Univ Bern, Inst Biochem & Mol Med, Bern, Switzerland	Case Western Reserve University; University of Basel; University of Bern	Jastrzebska, B (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, Wood Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.	bxj27@case.edu			U. S. National Institutes of Health [EY09339, GM 079191, P30 EY11373]; Swiss National Foundation (SNF) [3100A0 - 108299]; Amgen Inc.; NATIONAL EYE INSTITUTE [P30EY011373, R01EY009339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079191] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Foundation (SNF)(Swiss National Science Foundation (SNSF)); Amgen Inc.(Amgen); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs. Leslie T. Webster Jr. and Thomas Angel (Case Western Reserve University) for valuable comments on the manuscript. This research was supported by U. S. National Institutes of Health grants EY09339, GM 079191, and P30 EY11373, the Swiss National Foundation (SNF grant 3100A0 - 108299 to A.E.), and by an unrestricted grant from Amgen Inc.	Angel TE, 2006, VISION RES, V46, P4547, DOI 10.1016/j.visres.2006.08.015; Aris L, 2001, J BIOL CHEM, V276, P2333, DOI 10.1074/jbc.M002533200; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GROENENDIJK GWT, 1980, EUR J BIOCHEM, V106, P119; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200; Kisselev OG, 2003, STRUCTURE, V11, P367, DOI 10.1016/S0969-2126(03)00045-5; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Loewen MC, 2001, P NATL ACAD SCI USA, V98, P4888, DOI 10.1073/pnas.051633098; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; McKibbin C, 2007, J MOL BIOL, V374, P1319, DOI 10.1016/j.jmb.2007.10.018; McKibbin C, 2007, J MOL BIOL, V374, P1309, DOI 10.1016/j.jmb.2007.10.013; NAVON SE, 1984, J BIOL CHEM, V259, P6686; Nickell S, 2007, J CELL BIOL, V177, P917, DOI 10.1083/jcb.200612010; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Okada T, 2000, J STRUCT BIOL, V130, P73, DOI 10.1006/jsbi.1999.4209; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P240; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Salamon Z, 1996, BIOPHYS J, V71, P283, DOI 10.1016/S0006-3495(96)79224-X; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; SCHLEICHER A, 1987, J MEMBRANE BIOL, V95, P271, DOI 10.1007/BF01869489; Shichida Y, 1998, CELL MOL LIFE SCI, V54, P1299, DOI 10.1007/s000180050256; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Struthers M, 2000, BIOCHEMISTRY-US, V39, P7938, DOI 10.1021/bi000771f; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; Yan F, 2008, BIOCHEMISTRY-US, V47, P1567, DOI 10.1021/bi701476b; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	45	25	25	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					371	381		10.1096/fj.07-114835	http://dx.doi.org/10.1096/fj.07-114835			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18827025	Green Published			2022-12-28	WOS:000262892900009
J	Nordstrom, E; Fisone, G; Kristensson, K				Nordstrom, Elin; Fisone, Gilberto; Kristensson, Krister			Opposing effects of ERK and p38-JNK MAP kinase pathways on formation of prions in GT1-1 cells	FASEB JOURNAL			English	Article						scrapie; neuron; neurodegeneration; protein misfolding; PKA	CREUTZFELDT-JAKOB-DISEASE; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; CULTURED-CELLS; HISTONE H3; SCRAPIE; PROTEIN; ACTIVATION; PHOSPHORYLATION; PRPSC	Brain-derived neurotrophic factor, which activates the extracellular regulated kinase (ERK) pathway, increases formation of prions in scrapie-infected gonadotropin-releasing hormone (GT1-1) cells. This indicates that conversion of the cellular prion protein PrPC to its pathogenic isoform, PrPSc, can be regulated by physiological stimuli acting on specific signal transduction pathways. In the present study, we examined the involvement of different mitogen-activated protein (MAP) kinase cascades and the cAMP-PKA pathway in formation of proteinase K-resistant PrPSc (rPrP(Sc)). Long-term depolarization of GT1-1 cells infected with the Rocky Mountain Laboratory strain of scrapie increased the formation of rPrP(Sc). This effect was associated to ERK activation and was blocked by the MAPK/ERK kinase (MEK) inhibitor U0126. Treatment with forskolin caused a similar increase in rPrP(Sc) formation that was prevented by the protein kinase A (PKA) inhibitor H89. Both depolarization and forskolin treatment were accompanied by increased phosphorylation of the S6 ribosomal protein, while phosphorylation of histone H3 occurred only after forskolin treatment. Inhibitors of p38- and c-Jun NH2-terminal kinase (JNK) promoted the formation of rPrP(Sc), in contrast to the clearance of rPrP(Sc) produced by inhibitors of the ERK pathway. Thus, the ERK and the p38- JNK MAP kinase pathways appear to exert opposing effects on rPrP(Sc) formation, suggesting that balances between these intracellular signaling cascades may regulate replication of prions.-Nordstrom, E., Fisone, G., Kristensson, K. Opposing effects of ERK and p38- JNK MAP kinase pathways on formation of prions in GT1-1 cells. FASEB J. 23, 613-622 (2009)	[Nordstrom, Elin; Fisone, Gilberto; Kristensson, Krister] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden	Karolinska Institutet	Nordstrom, E (corresponding author), Karolinska Inst, Dept Neurosci, Retzius Vag 8, SE-17177 Stockholm, Sweden.	elin.nordstrom@ki.se		Fisone, Gilberto/0000-0002-0719-8000				Ahnert-Hilger G, 1998, EUR J NEUROSCI, V10, P1145, DOI 10.1046/j.1460-9568.1998.00129.x; Banko JL, 2004, J NEUROCHEM, V91, P462, DOI 10.1111/j.1471-4159.2004.02734.x; BASSANT MH, 1987, ELECTROEN CLIN NEURO, V66, P307, DOI 10.1016/0013-4694(87)90080-0; BASSANT MH, 1984, ELECTROEN CLIN NEURO, V57, P541, DOI 10.1016/0013-4694(84)90090-7; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Bouzamondo-Bernstein E, 2004, J NEUROPATH EXP NEUR, V63, P882, DOI 10.1093/jnen/63.8.882; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; Dhingra S, 2007, AM J PHYSIOL-HEART C, V293, pH3524, DOI 10.1152/ajpheart.00919.2007; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; Fan YM, 2007, MOL CELLS, V23, P30; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Gomez-Santos C, 2002, BRAIN RES, V935, P32, DOI 10.1016/S0006-8993(02)02422-8; Hans A, 2004, FASEB J, V18, P863, DOI 10.1096/fj.03-0764fje; Hansen TV, 2003, NEUROSCI LETT, V347, P57, DOI 10.1016/S0304-3940(03)00581-0; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Jefferys J G, 1994, Neurobiol Dis, V1, P25, DOI 10.1006/nbdi.1994.0004; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Ki MR, 2008, AM J PHYSIOL-GASTR L, V294, pG635, DOI 10.1152/ajpgi.00281.2007; Korth C, 2006, ARCH NEUROL-CHICAGO, V63, P497, DOI 10.1001/archneur.63.4.497; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; LaCasse RA, 2008, J NEUROIMMUNOL, V196, P16, DOI 10.1016/j.jneuroim.2008.02.009; Lee HP, 2005, J NEUROCHEM, V95, P584, DOI 10.1111/j.1471-4159.2005.03429.x; Leucht C, 2003, EMBO REP, V4, P290, DOI 10.1038/sj.embor.embor768; Luhr KM, 2004, J VIROL, V78, P4776, DOI 10.1128/JVI.78.9.4776-4782.2004; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Nordstrom EK, 2005, J NEUROSCI, V25, P8451, DOI 10.1523/JNEUROSCI.2349-05.2005; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Ostlund P, 2001, MOL BRAIN RES, V97, P161, DOI 10.1016/S0169-328X(01)00316-3; Pastrana MA, 2006, BIOCHEMISTRY-US, V45, P15710, DOI 10.1021/bi0615442; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; Planz O, 2001, J VIROL, V75, P4871, DOI 10.1128/JVI.75.10.4871-4877.2001; Rapoport M, 2000, J NEUROCHEM, V74, P125, DOI 10.1046/j.1471-4159.2000.0740125.x; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Sandberg MK, 2004, NEUROBIOL DIS, V15, P143, DOI 10.1016/j.nbd.2003.09.006; Schonberger O, 2003, BIOCHEM BIOPH RES CO, V312, P473, DOI 10.1016/j.bbrc.2003.10.150; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; STRAIN GM, 1986, AM J VET RES, V47, P828; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; Tzaban S, 2002, BIOCHEMISTRY-US, V41, P12868, DOI 10.1021/bi025958g; Uppington KM, 2008, J NEUROCHEM, V105, P842, DOI 10.1111/j.1471-4159.2007.05192.x; Weissmann C, 2005, ANNU REV MED, V56, P321, DOI 10.1146/annurev.med.56.062404.172936; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	53	27	27	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					613	622		10.1096/fj.08-115360	http://dx.doi.org/10.1096/fj.08-115360			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18824519				2022-12-28	WOS:000262892900032
J	Klein, J; Gonzalez, J; Duchene, J; Esposito, L; Pradere, JP; Neau, E; Delage, C; Calise, D; Ahluwalia, A; Carayon, P; Pesquero, JB; Bader, M; Schanstra, JP; Bascands, JL				Klein, J.; Gonzalez, J.; Duchene, J.; Esposito, L.; Pradere, J. P.; Neau, E.; Delage, C.; Calise, D.; Ahluwalia, A.; Carayon, P.; Pesquero, J. B.; Bader, M.; Schanstra, J. P.; Bascands, J. L.			Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy	FASEB JOURNAL			English	Article						kidney disease; bradykinin; unilateral ureteral obstruction; chemokine; reversion	NF-KAPPA-B; BRADYKININ B-1 RECEPTOR; IN-VIVO; INVOLVEMENT; PROGRESSION; ACTIVATION; MECHANISMS; MANAGEMENT; INDUCTION; RESPONSES	Renal fibrosis is the common histological feature of advanced glomerular and tubulointerstitial disease leading to end-stage renal disease (ESRD). However, specific antifibrotic therapies to slow down the evolution to ESRD are still absent. Because persistent inflammation is a key event in the development of fibrosis, we hypothesized that the proinflammatory kinin B1 receptor (B1R) could be such a new target. Here we show that, in the unilateral ureteral obstruction model of renal fibrosis, the B1R is overexpressed and that delayed treatment with an orally active non-peptide B1R antagonist blocks macrophage infiltration, leading to a reversal of the level of renal fibrosis. In vivo bone marrow transplantation studies as well as in vitro studies on renal cells show that part of this antifibrotic mechanism of B1R blockade involves a direct effect on resident renal cells by inhibiting chemokine CCL2 and CCL7 expression. These findings suggest that blocking the B1R is a promising antifibrotic therapy.-Klein, J., Gonzalez, J., Duchene, J., Esposito, L., Pradere, J. P., Neau, E., Delage, C., Calise, D., Ahluwalia, A., Carayon, P., Pesquero, J. B., Bader, M., Schanstra, J. P., Bascands, J. L. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J. 23, 134-142 (2009)	[Klein, J.; Gonzalez, J.; Duchene, J.; Pradere, J. P.; Neau, E.; Delage, C.; Schanstra, J. P.; Bascands, J. L.] INSERM, Dept Renal, F-31432 Toulouse, France; [Klein, J.; Gonzalez, J.; Duchene, J.; Pradere, J. P.; Neau, E.; Delage, C.; Schanstra, J. P.; Bascands, J. L.] INSERM, Cardiac Remodeling Team 5, F-31432 Toulouse, France; [Klein, J.; Gonzalez, J.; Pradere, J. P.; Neau, E.; Delage, C.; Schanstra, J. P.; Bascands, J. L.] Univ Toulouse 3, F-31062 Toulouse, France; [Duchene, J.; Ahluwalia, A.] Barts & London Med Sch, William Harvey Res Inst, London, England; [Esposito, L.] Toulouse Univ Hosp, Nephrol & Kidney Transplantat Dept, CHU Rangueil, Toulouse, France; [Calise, D.] INSERM, Zootechny Dept Expt Microsurg, Toulouse, France; [Carayon, P.] Sanofi Aventis R&D, Montpellier, France; [Pesquero, J. B.] Univ Fed Sao Paulo, Dept Biophys, Escola Paulista Med, Sao Paulo, Brazil; [Bader, M.] Max Delbruck Ctr Mol Med, Berlin, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of London; Queen Mary University London; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis; Sanofi France; Universidade Federal de Sao Paulo (UNIFESP); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Schanstra, JP (corresponding author), INSERM, Dept Renal, 1 Jean Poulhes, F-31432 Toulouse, France.	joost-peter.schanstra@inserm.fr; jean-loup.bascands@inserm.fr	Klein, Julie/M-7088-2017; Klein, Julie/ABE-2622-2020; Duchene, Johan/Q-9472-2019; Pesquero, Joao/C-1470-2012; Schanstra, Joost P/X-7724-2018; Bader, Michael/K-2124-2013; Bascands, Jean-loup/G-3260-2013	Klein, Julie/0000-0002-3279-0559; Klein, Julie/0000-0002-3279-0559; Duchene, Johan/0000-0002-3973-0022; Pesquero, Joao/0000-0002-4507-632X; Schanstra, Joost P/0000-0002-7471-372X; Bascands, Jean-loup/0000-0002-1667-5913; Pradere, Jean-Philippe/0000-0003-1734-1429; AHLUWALIA, Amrita/0000-0001-7626-6399; Bader, Michael/0000-0003-4780-4164	INSERM; Universite Toulouse III Paul Sabatier; Sanofi-Aventis; Basic Science Fellowship of the Barts and the London Charity	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Toulouse III Paul Sabatier; Sanofi-Aventis(Sanofi-Aventis); Basic Science Fellowship of the Barts and the London Charity	This study was mainly funded by INSERM and the Universite Toulouse III Paul Sabatier and by grants from Sanofi-Aventis. J.D. is supported by a Basic Science Fellowship of the Barts and the London Charity. P.C. is an employee of Sanofi-Aventis. We thank S. Schaak for technical advice and help.	Ahluwalia A, 1996, J IMMUNOL, V156, P269; Bascands JL, 2005, KIDNEY INT, V68, P925, DOI 10.1111/j.1523-1755.2005.00486.x; Becker GJ, 2000, CURR OPIN NEPHROL HY, V9, P133, DOI 10.1097/00041552-200003000-00006; Bockmann S, 2000, J LEUKOCYTE BIOL, V68, P587; Boor P, 2007, NEPHROL DIAL TRANSPL, V22, P3391, DOI 10.1093/ndt/gfm393; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Campos MM, 2006, TRENDS PHARMACOL SCI, V27, P646, DOI 10.1016/j.tips.2006.10.007; Chatziantoniou C, 2008, CURR OPIN NEPHROL HY, V17, P76, DOI 10.1097/MNH.0b013e3282f1bb69; Chevalier RL, 2006, NAT CLIN PRACT NEPHR, V2, P157, DOI 10.1038/ncpneph0098; Cuaz-Perolin C, 2008, ARTERIOSCL THROM VAS, V28, P272, DOI 10.1161/ATVBAHA.107.155606; de Winther Menno P J, 2003, Methods Mol Biol, V209, P281; Diez J, 2005, NAT CLIN PRACT CARD, V2, P209, DOI 10.1038/ncpcardio0158; Eddy AA, 2005, ADV CHRONIC KIDNEY D, V12, P353, DOI 10.1053/j.ackd.2005.07.011; El Nahas AM, 2005, LANCET, V365, P331, DOI 10.1016/S0140-6736(05)17789-7; Gougat J, 2004, J PHARMACOL EXP THER, V309, P661, DOI 10.1124/jpet.103.059527; Iwano M, 2004, CURR OPIN NEPHROL HY, V13, P279, DOI 10.1097/00041552-200405000-00003; Kakoki M, 2007, P NATL ACAD SCI USA, V104, P7576, DOI 10.1073/pnas.0701617104; Khwaja A, 2007, KIDNEY INT, V72, P1316, DOI 10.1038/sj.ki.5002489; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; Kluth DC, 2004, KIDNEY INT, V66, P542, DOI 10.1111/j.1523-1755.2004.00773.x; Kovescly CP, 2008, EXPERT OPIN INV DRUG, V17, P451, DOI [10.1517/13543784.17.4.451, 10.1517/13543784.17.4.451 ]; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Marin-Castano ME, 2002, CIRCULATION, V105, P627, DOI 10.1161/hc0502.102965; Marin-Castano ME, 1998, KIDNEY INT, V54, P1888, DOI 10.1046/j.1523-1755.1998.00201.x; Meltzer EB, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-8; Mori MA, 2008, DIABETES, V57, P1491, DOI 10.2337/db07-1508; NATH KA, 1992, AM J KIDNEY DIS, V20, P1; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nguyen TQ, 2008, PHARM RES-DORDR, V25, P2416, DOI 10.1007/s11095-008-9548-9; Ni AG, 2003, J BIOL CHEM, V278, P219, DOI 10.1074/jbc.M209490200; Okada H, 2005, J AM SOC NEPHROL, V16, P133, DOI 10.1681/ASN.2004040339; Okada H, 2004, J AM SOC NEPHROL, V15, P2404, DOI 10.1097/01.ASN.0000136132.20189.95; Pawluczyk IZA, 2004, KIDNEY INT, V65, P1240, DOI 10.1111/j.1523-1755.2004.00494.x; Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997; Ricupero DA, 2000, J BIOL CHEM, V275, P12475, DOI 10.1074/jbc.275.17.12475; Schanstra JP, 2002, J CLIN INVEST, V110, P371, DOI 10.1172/JCI200215493; Schanstra JP, 2000, J AM SOC NEPHROL, V11, P1208, DOI 10.1681/ASN.V1171208; Schanstra JP, 1998, J CLIN INVEST, V101, P2080, DOI 10.1172/JCI1359; Seccia TM, 2006, J HYPERTENS, V24, P1419, DOI 10.1097/01.hjh.0000234124.94013.ac; Segerer S, 2000, J AM SOC NEPHROL, V11, P152, DOI 10.1681/ASN.V111152; Seguin T, 2008, INT IMMUNOPHARMACOL, V8, P217, DOI 10.1016/j.intimp.2007.08.008; Souza DG, 2004, J IMMUNOL, V172, P2542, DOI 10.4049/jimmunol.172.4.2542; Strutz F, 2001, EXPERT OPIN INV DRUG, V10, P1989, DOI 10.1517/13543784.10.11.1989; SUNG SA, 2007, EXP NEPHROL, V105, pE1; TIFFANY CW, 1989, FEBS LETT, V247, P189, DOI 10.1016/0014-5793(89)81331-6; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Wallace K, 2008, BIOCHEM J, V411, P1, DOI 10.1042/BJ20071570; Wang PHM, 2006, INT IMMUNOPHARMACOL, V6, P1960, DOI 10.1016/j.intimp.2006.07.031; Wuyts WA, 2003, RESP MED, V97, P811, DOI 10.1016/S0954-6111(03)00036-2	49	55	57	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					134	142		10.1096/fj.08-115600	http://dx.doi.org/10.1096/fj.08-115600			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18809736	Green Submitted			2022-12-28	WOS:000262095500016
J	Pallero, MA; Elzie, CA; Chen, JP; Mosher, DF; Murphy-Ullrich, JE				Pallero, Manuel A.; Elzie, Carrie A.; Chen, Jiping; Mosher, Deane F.; Murphy-Ullrich, Joanne E.			Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis	FASEB JOURNAL			English	Article						apoptosis; fibroblasts; cell adhesion; focal adhesions; Akt	CELL-SURFACE CALRETICULIN; RECEPTOR-RELATED PROTEIN; N-TERMINAL DOMAIN; INDUCED APOPTOSIS; ENDOPLASMIC-RETICULUM; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; CATHEPSIN-G; IN-VITRO; SURVIVAL	Anoikis, apoptotic cell death due to loss of cell adhesion, is critical for regulation of tissue homeostasis in tissue remodeling. Fibrogenesis is associated with reduced fibroblast apoptosis. The matricellular protein thrombospondin 1 (TSP1) regulates cell adhesion and motility during tissue remodeling and in fibrogenesis. The N-terminal domain of TSP1 binds to the calreticulin-LRP1 receptor co-complex to signal down-regulation of cell adhesion and increased cell motility through focal adhesion disassembly. TSP1 signaling through calreticulin-LRP1 activates cell survival signals such as PI3-kinase. Therefore, we tested the hypothesis that TSP1 supports cell survival under adhesion-independent conditions to facilitate tissue remodeling. Here, we show that platelet TSP1, its N-terminal domain (NoC1) as a recombinant protein, or a peptide comprising the calreticulin-LRP1 binding site [amino acids 17-35 (hep I)] in the N-terminal domain promotes fibroblast survival under anchorage-independent conditions. TSP1 activates Akt and decreases apoptotic signaling through caspase 3 and PARP1 in suspended fibroblasts. Inhibition of PI3K/Akt activity blocks TSP1-mediated anchorage-independent survival. Fibroblasts lacking LRP1 or expressing calreticulin lacking the TSP1 binding site do not respond to TSP1 with anchorage-independent survival. These data define a novel role for TSP1 signaling through the calreticulin/LRP1 co-complex in tissue remodeling and fibrotic responses through stimulation of anoikis resistance. -Pallero, M. A., Elzie, C. A., Chen, J., Mosher, D. F., Murphy-Ullrich, J. E. Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. FASEB J. 22, 3968-3979 (2008)	[Pallero, Manuel A.; Elzie, Carrie A.; Chen, Jiping; Murphy-Ullrich, Joanne E.] Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, VH 668 1530 3rd Ave S, Birmingham, AL 35294 USA; [Pallero, Manuel A.; Elzie, Carrie A.; Chen, Jiping; Murphy-Ullrich, Joanne E.] Univ Alabama Birmingham, Ctr Metab Bone Dis, Birmingham, AL 35294 USA; [Pallero, Manuel A.; Elzie, Carrie A.; Chen, Jiping; Murphy-Ullrich, Joanne E.] Univ Alabama Birmingham, BioMatrix Engn & Regenerat Med Ctr, Birmingham, AL 35294 USA; [Mosher, Deane F.] Univ Wisconsin, Dept Med, Madison, WI USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison	Murphy-Ullrich, JE (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, VH 668 1530 3rd Ave S, Birmingham, AL 35294 USA.	murphy@uab.edu			bone biology and disease [T32AR47512-01A1]; oral biology [T32DE014300]; National Institutes of Health (NIH) [HL079644]; National Center for Research Resources, NIH [C06 RR 15490]; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR047512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE014300] Funding Source: NIH RePORTER	bone biology and disease; oral biology; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors gratefully acknowledge Marek Michalak ( University of Alberta, Edmonton, AB, Canada) for providing the CRT constructs, K41 and K42 CRT(-/-) MEFs. We also thank Doug Annis (University of Wisconsin, Madison, WI, USA) for assistance with the preparation of recombinant TSP1 proteins. We thank Silvia Goicoechea (University of North Carolina, Chapel Hill, NC, USA) for making the CRT deletion construct. We appreciate the assistance of Mariya T. Sweetwyne in preparation of the figures. This work was supported by a comprehensive training grant in bone biology and disease (T32AR47512-01A1) to C. A. E., a training grant in oral biology (T32DE014300) to J. C., and a National Institutes of Health (NIH) grant (HL079644) to J. E. M. U. This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program grant C06 RR 15490 from the National Center for Research Resources, NIH.	Aarabi S, 2007, FASEB J, V21, P3250, DOI 10.1096/fj.07-8218com; Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009; Agah A, 2002, AM J PATHOL, V161, P831, DOI 10.1016/S0002-9440(10)64243-5; Alfano D, 2006, J BIOL CHEM, V281, P17758, DOI 10.1074/jbc.M601812200; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Anilkumar N, 2002, J CELL SCI, V115, P2357; Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; Bonnefoy A, 2000, THROMB RES, V98, P323, DOI 10.1016/S0049-3848(99)00242-X; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bruel A, 2005, ANTICANCER RES, V25, P757; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chen DQ, 2005, J BIOL CHEM, V280, P22425, DOI 10.1074/jbc.M413380200; Chen JH, 2005, NAT MED, V11, P1188, DOI 10.1038/nm1307; CONWAY EM, 1995, J BIOL CHEM, V270, P17011, DOI 10.1074/jbc.270.28.17011; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DiPietro LA, 1996, AM J PATHOL, V148, P1851; do Outeiro-Bernstein MAF, 2002, MATRIX BIOL, V21, P311, DOI 10.1016/S0945-053X(02)00010-0; Duus K, 2007, SCAND J IMMUNOL, V66, P501, DOI 10.1111/j.1365-3083.2007.01999.x; Eggleton P, 1999, SCAND J IMMUNOL, V49, P466; Elzie CA, 2004, INT J BIOCHEM CELL B, V36, P1090, DOI 10.1016/j.biocel.2003.12.012; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Freyberg MA, 2001, BIOCHEM BIOPH RES CO, V286, P141, DOI 10.1006/bbrc.2001.5314; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Goicoechea S, 2002, J BIOL CHEM, V277, P37219, DOI 10.1074/jbc.M202200200; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; Gold LI, 2006, J INVEST DERM SYMP P, V11, P57, DOI 10.1038/sj.jidsymp.5650011; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Graf R, 2002, APOPTOSIS, V7, P493, DOI 10.1023/A:1020634924760; Greenwood JA, 1998, J BIOL CHEM, V273, P1755, DOI 10.1074/jbc.273.3.1755; Groenendyk J, 2004, MOL CELLS, V17, P383; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Hasanuzzaman M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-34; He B, 2006, ONCOGENE, V25, P2192, DOI 10.1038/sj.onc.1209248; Horowitz JC, 2007, CELL SIGNAL, V19, P761, DOI 10.1016/j.cellsig.2006.10.001; Hou YL, 2006, CELL SIGNAL, V18, P882, DOI 10.1016/j.cellsig.2005.07.015; Isenberg JS, 2007, J BIOL CHEM, V282, P15404, DOI 10.1074/jbc.M701638200; Jang JH, 2005, CANCER LETT, V229, P101, DOI 10.1016/j.canlet.2004.12.012; Jinnin M, 2006, J INVEST DERMATOL, V126, P551, DOI 10.1038/sj.jid.5700090; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; Koyanagi M, 2008, J NEUROSCI RES, V86, P270, DOI 10.1002/jnr.21502; Krispin A, 2006, BLOOD, V108, P3580, DOI 10.1182/blood-2006-03-013334; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee NV, 2006, EMBO J, V25, P5270, DOI 10.1038/sj.emboj.7601400; Li SS, 2005, J IMMUNOL, V174, P654, DOI 10.4049/jimmunol.174.2.654; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Liotta LA, 2004, NATURE, V430, P973, DOI 10.1038/430973a; Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097; Marchionini DM, 2003, J COMP NEUROL, V464, P172, DOI 10.1002/cne.10785; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mesaeli N, 2004, MOL BIOL CELL, V15, P1862, DOI 10.1091/mbc.E03-04-0251; Michel JB, 2003, ARTERIOSCL THROM VAS, V23, P2146, DOI 10.1161/01.ATV.0000099882.52647.E4; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; Nor Jacques E, 2005, Oral Biosci Med, V2, P153; Nunes SS, 2008, J CELL PHYSIOL, V214, P828, DOI 10.1002/jcp.21281; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Orr AW, 2004, J BIOL CHEM, V279, P48983, DOI 10.1074/jbc.M404881200; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Orr AW, 2002, J BIOL CHEM, V277, P20453, DOI 10.1074/jbc.M112091200; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; Pinkse GGM, 2004, LIVER INT, V24, P218, DOI 10.1111/j.1478-3231.2004.0914.x; RabhiSabile S, 1996, FEBS LETT, V386, P82, DOI 10.1016/0014-5793(96)00408-5; Rai Nirendra K, 2005, Int J Low Extrem Wounds, V4, P138, DOI 10.1177/1534734605280018; Rajeswari J, 2006, CELL BIOL INT, V30, P963, DOI 10.1016/j.cellbi.2006.06.022; Rath GM, 2006, INT J BIOCHEM CELL B, V38, P2219, DOI 10.1016/j.biocel.2006.07.004; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; Ring A, 2006, BBA-MOL CELL BIOL L, V1761, P416, DOI 10.1016/j.bbalip.2006.03.016; Saumet A, 2005, BLOOD, V106, P658, DOI 10.1182/blood-2004-09-3585; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; Staniszewska I, 2007, CIRC RES, V100, P1308, DOI 10.1161/01.RES.0000266662.98355.66; Szabo E, 2007, J CELL PHYSIOL, V213, P269, DOI 10.1002/jcp.21122; Takemura Y, 2007, J CLIN INVEST, V117, P375, DOI 10.1172/JCI29709; Tan K, 2006, STRUCTURE, V14, P33, DOI 10.1016/j.str.2005.09.017; Tufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Wang Y, 2006, PROTEOMICS, V6, P3862, DOI 10.1002/pmic.200500840; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Yamaki N, 2007, EXP CELL RES, V313, P2821, DOI 10.1016/j.yexcr.2007.05.010; Zahir N, 2004, CURR OPIN GENET DEV, V14, P71, DOI 10.1016/j.gde.2003.12.005; Zhang G., 2006, Experimental Oncology, V28, P36; Zvibel I, 2002, CELL TRANSPLANT, V11, P621, DOI 10.3727/000000002783985404	94	64	67	3	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3968	3979		10.1096/fj.07-104802	http://dx.doi.org/10.1096/fj.07-104802			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18653767	Green Published			2022-12-28	WOS:000260503000025
J	Roche, Y; Gerbeau-Pissot, P; Buhot, B; Thomas, D; Bonneau, L; Gresti, J; Mongrand, S; Perrier-Cornet, JM; Simon-Plas, F				Roche, Yann; Gerbeau-Pissot, Patricia; Buhot, Blandine; Thomas, Dominique; Bonneau, Laurent; Gresti, Joseph; Mongrand, Sebastien; Perrier-Cornet, Jean-Marie; Simon-Plas, Francoise			Depletion of phytosterols from the plant plasma membrane provides evidence for disruption of lipid rafts	FASEB JOURNAL			English	Article						cyclodextrin; detergent-resistant membranes; membrane lateral organization; microdomains; tobacco; spectro-fluorimetry	DETERGENT-RESISTANT MEMBRANES; LAURDAN FLUORESCENCE; CELL-MEMBRANES; GENERALIZED POLARIZATION; PHOSPHOLIPID-BILAYERS; BIOLOGICAL-MEMBRANES; STEROL BIOSYNTHESIS; SURFACE TRANSPORT; BETA-CYCLODEXTRIN; MODEL MEMBRANES	Involvement of sterols in membrane structural properties has been extensively studied in model systems but rarely assessed in natural membranes and never investigated for the plant plasma membrane (PM). Here, we address the question of the role of phytosterols in the organization of the plant PM. The sterol composition of tobacco BY-2 cell PM was determined by gas chromatography. The cyclic oligosaccharide methyl-beta-cyclodextrin, commonly used in animal cells to decrease cholesterol levels, caused a drastic reduction (50%) in the PM total free sterol content of the plant material, without modification in amounts of steryl-conjugates. Fluorescence spectroscopy experiments using DPH, TMA-DPH, Laurdan, and di-4-ANEPPDHQ indicated that such a depletion in sterol content increased lipid acyl chain disorder and reduced the overall liquid-phase heterogeneity in correlation with the disruption of phytosterol-rich domains. Methyl-beta-cyclodextrin also prevented isolation of a PM fraction resistant to solubilization by nonionic detergents, previously characterized in tobacco, and induced redistribution of the proteic marker of this fraction, NtrbohD, within the membrane. Altogether, our results support the role of phytosterols in the lateral structuring of the PM of higher plant cells and suggest that they are key compounds for the formation of plant PM microdomains.-Roche, Y., Gerbeau-Pissot, P., Buhot, B., Thomas, D., Bonneau, L., Gresti, J., Mongrand, S., Perrier-Cornet, J.-M., Simon-Plas, F. Depletion of phytosterols from the plant plasma membrane provides evidence for disruption of lipid rafts. FASEB J. 22, 3980-3991 (2008)	[Roche, Yann; Gerbeau-Pissot, Patricia; Buhot, Blandine; Thomas, Dominique; Bonneau, Laurent; Simon-Plas, Francoise] Univ Bourgogne, CNRS 5184, Lab Plantes Microbe Environm, INRA,UMR 1088, F-21065 Dijon, France; [Gresti, Joseph] Univ Bourgogne, UMR 866 Lipides, Equipe Physiopathol Dyslipidemies, F-21065 Dijon, France; [Mongrand, Sebastien] Univ Victor Segalen Bordeaux 2, CNRS, UMR 5200, Lab Biogenese Membranaire, Bordeaux, France; [Perrier-Cornet, Jean-Marie] Ensbana, Lab Genie Procedes Microbiol & Alimentaires, Dijon, France	Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Bourgogne; Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Institut Agro; AgroSup Dijon	Gerbeau-Pissot, P (corresponding author), Univ Bourgogne, CNRS 5184, Lab Plantes Microbe Environm, INRA,UMR 1088, 17 Rue Sully,BP 86510, F-21065 Dijon, France.	patricia.gerbeau-pissot@dijon.inra.fr	PERRIER-CORNET, Jean-Marie/D-2456-2014	Perrier-Cornet, Jean-Marie/0000-0002-6547-5731	French Agence Nationale de la Recherche [ANR-JC05-45555, ANR-JC05-50611]	French Agence Nationale de la Recherche(French National Research Agency (ANR))	We thank V. Gianinazzi-Pearson for kind corrections of the manuscript. This work was supported by the French Agence Nationale de la Recherche (ANR-JC05-45555, plant rafts; ANR-JC05-50611, Vegeraft). Fluorescence spectroscopy was performed at the Plateau Imagerie Spectroscopique, IFR92, Burgundy University.	Bagatolli LA, 2006, BBA-BIOMEMBRANES, V1758, P1541, DOI 10.1016/j.bbamem.2006.05.019; Baumann NA, 2005, BIOCHEMISTRY-US, V44, P5816, DOI 10.1021/bi048296z; Beck JG, 2007, FASEB J, V21, P1714, DOI 10.1096/fj.06-7809com; Benveniste P, 2004, ANNU REV PLANT BIOL, V55, P429, DOI 10.1146/annurev.arplant.55.031903.141616; Bernsdorff C, 2003, J PHYS CHEM B, V107, P10658, DOI 10.1021/jp034922a; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bohn M, 2001, ARCH BIOCHEM BIOPHYS, V387, P35, DOI 10.1006/abbi.2000.2224; Borner GHH, 2005, PLANT PHYSIOL, V137, P104, DOI 10.1104/pp.104.053041; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 2006, PHYSIOLOGY, V21, P430, DOI 10.1152/physiol.00032.2006; Bultynck L, 1997, PHYTOCHEMISTRY, V45, P1337, DOI 10.1016/S0031-9422(97)00171-4; Christian AE, 1999, J LIPID RES, V40, P1475; Danielsen EM, 2003, BBA-BIOMEMBRANES, V1617, P1, DOI 10.1016/j.bbamem.2003.09.005; dos Santos SM, 2007, BIOCHEM BIOPH RES CO, V354, P216, DOI 10.1016/j.bbrc.2006.12.202; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Gaus K, 2003, P NATL ACAD SCI USA, V100, P15554, DOI 10.1073/pnas.2534386100; GUO DA, 1995, LIPIDS, V30, P203, DOI 10.1007/BF02537823; Hac-Wydro K, 2007, CHEM PHYS LIPIDS, V150, P22, DOI 10.1016/j.chemphyslip.2007.06.211; Haines TH, 2001, PROG LIPID RES, V40, P299, DOI 10.1016/S0163-7827(01)00009-1; Halling KK, 2004, BBA-BIOMEMBRANES, V1664, P161, DOI 10.1016/j.bbamem.2004.05.006; Hancock JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Harris FM, 2002, BBA-BIOMEMBRANES, V1565, P123, DOI 10.1016/S0005-2736(02)00514-X; Hartmann MA, 1998, TRENDS PLANT SCI, V3, P170, DOI 10.1016/S1360-1385(98)01233-3; Hellgren LI, 2001, PHYSIOL PLANTARUM, V111, P165, DOI 10.1034/j.1399-3054.2001.1110206.x; Hellgren LI, 2001, PHYSIOL PLANTARUM, V113, P23, DOI 10.1034/j.1399-3054.2001.1130104.x; Hodzic A, 2008, BIOPHYS J, V94, P3935, DOI 10.1529/biophysj.107.123224; Hovenkamp E, 2007, LIPIDS, V42, P1125, DOI 10.1007/s11745-007-3119-4; Jin L, 2006, BIOPHYS J, V90, P2563, DOI 10.1529/biophysj.105.072884; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Lefebvre B, 2007, PLANT PHYSIOL, V144, P402, DOI 10.1104/pp.106.094102; LENTZ BR, 1993, CHEM PHYS LIPIDS, V64, P99, DOI 10.1016/0009-3084(93)90060-G; Lichtenberg D, 2005, TRENDS BIOCHEM SCI, V30, P430, DOI 10.1016/j.tibs.2005.06.004; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; MACALA LJ, 1983, J LIPID RES, V24, P1243; Marsan MP, 1998, BIOPHYS CHEM, V75, P45, DOI 10.1016/S0301-4622(98)00188-4; MCKEAN ML, 1977, PHYTOCHEMISTRY, V16, P683, DOI 10.1016/S0031-9422(00)89231-6; Mongrand S, 2004, J BIOL CHEM, V279, P36277, DOI 10.1074/jbc.M403440200; Mora MP, 1999, CHEM PHYS LIPIDS, V101, P255, DOI 10.1016/S0009-3084(99)00067-5; Morel J, 2006, MOL CELL PROTEOMICS, V5, P1396, DOI 10.1074/mcp.M600044-MCP200; Mouritsen OG, 2004, LIPIDS, V39, P1101, DOI 10.1007/s11745-004-1336-x; Mukherjee S, 2005, BBA-BIOMEMBRANES, V1714, P43, DOI 10.1016/j.bbamem.2005.06.010; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Palleschi S, 1996, BBA-BIOMEMBRANES, V1279, P197, DOI 10.1016/0005-2736(95)00250-2; PARASASSI T, 1993, BIOCHIM BIOPHYS ACTA, V1153, P143, DOI 10.1016/0005-2736(93)90399-K; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; Parasassi T, 1998, J FLUORESC, V8, P365, DOI 10.1023/A:1020528716621; PARASASSI T, 1994, BIOPHYS J, V66, P120, DOI 10.1016/S0006-3495(94)80763-5; Peskan T, 2000, PLANT MOL BIOL, V42, P915, DOI 10.1023/A:1006477631166; Quartacci MF, 2002, J EXP BOT, V53, P2159, DOI 10.1093/jxb/erf076; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; Reungpatthanaphong P, 2004, J BIOENERG BIOMEMBR, V36, P533, DOI 10.1007/s10863-004-9000-8; Rothblat GH, 1999, J LIPID RES, V40, P781; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schaller H, 2004, PLANT PHYSIOL BIOCH, V42, P465, DOI 10.1016/j.plaphy.2004.05.012; SCHULER I, 1991, P NATL ACAD SCI USA, V88, P6926, DOI 10.1073/pnas.88.16.6926; Shrivastava S, 2007, BIOCHEM BIOPH RES CO, V356, P705, DOI 10.1016/j.bbrc.2007.03.032; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; TRAVIS RL, 1980, PLANT PHYSIOL, V65, P871, DOI 10.1104/pp.65.5.871; Vest R, 2006, J MEMBRANE BIOL, V211, P15, DOI 10.1007/s00232-005-7008-6; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamem.2007.03.026	65	95	95	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3980	3991		10.1096/fj.08-111070	http://dx.doi.org/10.1096/fj.08-111070			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18676403				2022-12-28	WOS:000260503000026
J	Flierl, MA; Rittirsch, D; Nadeau, BA; Day, DE; Zetoune, FS; Sarma, JV; Huber-Lang, MS; Ward, PA				Flierl, Michael A.; Rittirsch, Daniel; Nadeau, Brian A.; Day, Danielle E.; Zetoune, Firas S.; Sarma, J. Vidya; Huber-Lang, Markus S.; Ward, Peter A.			Functions of the complement components C3 and C5 during sepsis	FASEB JOURNAL			English	Article						survival; cytokines; chemokines; colony-forming units; CH-50	INFLAMMATORY RESPONSE SYNDROME; WHOLE-BLOOD MODEL; THYMOCYTE APOPTOSIS; ACTIVATION PATHWAY; OXIDATIVE BURST; INNATE IMMUNITY; CECAL LIGATION; BRAIN-INJURY; MICE; MORTALITY	Activation of the complement system is a key event in the pathogenesis of sepsis. Nevertheless, the exact mechanisms remain inadequately understood. In the current study, we examined the role of complement C3 and C5 in sepsis in wild-type and C3- or C5-deficient mice induced by cecal ligation and puncture. When compared to wild-type mice, C5(-/-) showed identical survival, and C3(-/-) presented significantly reduced survival. Interestingly, this was associated with significant decreases in plasma levels of proinflammatory mediators. Moreover, although septic C3(-/-) animals displayed a 10-fold increase of blood-borne bacteria, C5(-/-) animals exhibited a 400-fold increase in bacteremia when compared to wild-type mice. These effects were linked to the inability of C5(-/-) mice to assemble the terminal membrane attack complex (MAC), as determined by complement hemolytic activity (CH-50). Surprisingly, although negative control C3(-/-) mice failed to generate the MAC, significant increases of MAC formation was found in septic C3- mice. In conclusion, our data corroborate that hemolytic complement activity is essential for control of bacteremia in septic mice. Thus, during sepsis, blockade of C5a or its receptors (rather than C5) seems a more promising strategy, because C5a-blockade still allows for MAC formation while the adverse effects of C5a are prevented.	[Flierl, Michael A.; Rittirsch, Daniel; Nadeau, Brian A.; Day, Danielle E.; Zetoune, Firas S.; Sarma, J. Vidya; Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Huber-Lang, Markus S.] Univ Ulm, Sch Med, Dept Trauma Hand & Reconstruct Surg, Ulm, Germany	University of Michigan System; University of Michigan; Ulm University	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Huber-Lang, Markus/AAJ-2209-2020	Rittirsch, Daniel/0000-0002-1185-2431	U.S. National Institutes of Health [GM29507, GM61656, HL-31963]; Deutsche Forschnngsgemeinschaft [DFG HU 823/2-1, HU 823/2-2, DFG HU 823/2-3]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029507, R01GM061656, R01GM029507] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschnngsgemeinschaft(German Research Foundation (DFG)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Beverly Schumann and Sue Scott for the preparation of this manuscript. This work was supported by U.S. National Institutes of Health grants GM29507, GM61656, and HL-31963 (to P.A.W.) and Deutsche Forschnngsgemeinschaft grants DFG HU 823/2-1, HU 823/2-2, and DFG HU 823/2-3 (to M.H.-L.).	ALPER CA, 1972, LANCET, V2, P1179; ALPER CA, 1976, J CLIN INVEST, V57, P222, DOI 10.1172/JCI108263; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; Ashare A, 2005, AM J PHYSIOL-LUNG C, V288, pL633, DOI 10.1152/ajplung.00231.2004; BAKER CC, 1983, SURGERY, V94, P331; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491; Brekke OL, 2007, J LEUKOCYTE BIOL, V81, P1404, DOI 10.1189/jlb.0806538; Buras JA, 2004, IMMUNOBIOLOGY, V209, P629, DOI 10.1016/j.imbio.2004.09.004; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9; Ebong SJ, 1999, SHOCK, V12, P118, DOI 10.1097/00024382-199908000-00005; Fischer MB, 1997, J IMMUNOL, V159, P976; Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011; Gerard C, 2003, NEW ENGL J MED, V348, P167, DOI 10.1056/NEJMcibr022995; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; Guo RF, 2000, J CLIN INVEST, V106, P1271, DOI 10.1172/JCI10793; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; HACK CE, 1989, AM J MED, V86, P20, DOI 10.1016/0002-9343(89)90224-6; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Huber-Lang MS, 2001, FASEB J, V15, P568; Kochanek Kenneth D, 2004, Natl Vital Stat Rep, V52, P1; Laudes IJ, 2002, AM J PATHOL, V160, P1867, DOI 10.1016/S0002-9440(10)61133-9; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Mollnes TE, 2002, BLOOD, V100, P1869; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NAKAE H, 1994, RES COMMUN CHEM PATH, V84, P189; Nakae H, 1996, SURG TODAY, V26, P225, DOI 10.1007/BF00311579; NEWMAN SL, 1985, J EXP MED, V161, P1414, DOI 10.1084/jem.161.6.1414; Osuchowski MF, 2007, J IMMUNOL, V179, P623, DOI 10.4049/jimmunol.179.1.623; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; REID KBM, 1981, ANNU REV BIOCHEM, V50, P433, DOI 10.1146/annurev.bi.50.070181.002245; Remick DG, 2005, SHOCK, V24, P7, DOI 10.1097/01.shk.0000191384.34066.85; Remick DG, 2000, SHOCK, V13, P110, DOI 10.1097/00024382-200013020-00004; Remick DG, 2003, CURR PHARM DESIGN, V9, P75, DOI 10.2174/1381612033392567; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Riedemann NC, 2002, FASEB J, V16, P887, DOI 10.1096/fj.02-0033fje; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Rittirsch D, 2007, J LEUKOCYTE BIOL, V81, P137, DOI 10.1189/jlb.0806542; ROSENFELD SI, 1976, J CLIN INVEST, V57, P1626, DOI 10.1172/JCI108433; Santucci L, 1996, GASTROENTEROLOGY, V111, P736, DOI 10.1053/gast.1996.v111.pm8780580; Sprong T, 2003, BLOOD, V102, P3702, DOI 10.1182/blood-2003-03-0703; Stove S, 1996, CLIN DIAGN LAB IMMUN, V3, P175; VANDIJK H, 1980, J IMMUNOL METHODS, V39, P257; Wang Q, 1998, J Gastrointest Surg, V2, P537, DOI 10.1016/S1091-255X(98)80054-1; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; Yang H, 2005, J IMMUNOL, V175, P2018, DOI 10.4049/jimmunol.175.3.2018	55	58	67	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3483	3490		10.1096/fj.08-110595	http://dx.doi.org/10.1096/fj.08-110595			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18587006	Green Submitted, Green Published			2022-12-28	WOS:000259642600010
J	Granger, A; Abdullah, I; Huebner, F; Stout, A; Wang, T; Huebner, T; Epstein, JA; Gruber, PJ				Granger, Anne; Abdullah, Ibrahim; Huebner, Faith; Stout, Andrea; Wang, Tao; Huebner, Thomas; Epstein, Jonathan A.; Gruber, Peter J.			Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice	FASEB JOURNAL			English	Article						heart; hypoxia inducible factor 1; cardiomyocytes	VESICULO-VACUOLAR ORGANELLES; VASCULAR-PERMEABILITY; ACETYLATION; APOPTOSIS; HEART; EPIGENETICS; MECHANISMS; EXPRESSION; SIGNALS; STROKE	Limitation of infarct size is a major goal of therapy for acute coronary syndromes, and research has focused on achieving rapid patency of infarct-related vessels. However, new understandings of epigenetic modifications during ischemia suggest additional targeted approaches that have not been extensively explored. Here, we show that ischemia induces histone deacetylase (HDAC) activity in the heart with deacetyladon of histones H3/4 in vitro and in vivo. We show, utilizing a standard murine model of ischemia-reperfusion, that chemical HDAC inhibitors significantly reduce infarct area, even when delivered 1 h after the ischemic insult. We demonstrate that HDAC inhibitors prevent ischemia-induced activation of gene programs that include hypoxia inducible factor-lot, cell death, and vascular permeability in vivo and in vitro, thus providing potential mechanisms to explain reduced vascular leak and myocardial injury. In vitro, siRNA knockdown experiments implicate HDAC4 as a mediator of the effects in ischemic cardiac myocytes. These results demonstrate that HDAC inhibitors alter the response to ischemic injury in the heart and reduce infarct size, suggesting novel therapeutic approaches for acute coronary syndromes.	[Granger, Anne; Abdullah, Ibrahim; Huebner, Faith; Huebner, Thomas; Gruber, Peter J.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Granger, Anne; Stout, Andrea; Wang, Tao; Epstein, Jonathan A.; Gruber, Peter J.] Penn Cardiovasc Inst, Philadelphia, PA USA; [Epstein, Jonathan A.; Gruber, Peter J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Gruber, PJ (corresponding author), Childrens Hosp Philadelphia, 34th St & Civ Ctr Blvd,Ste 8527 Main, Philadelphia, PA 19104 USA.	pgruber@mail.med.upenn.edu	GRANGER, Anne/A-9748-2010	Epstein, Jonathan/0000-0001-8637-4465	McCabe Foundation; University Research Foundation; Division of Pediatric Cardiothoracic Surgery; Children's Hospital of Philadelphia; National Institutes of Health [R01 HL071546]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071546] Funding Source: NIH RePORTER	McCabe Foundation; University Research Foundation; Division of Pediatric Cardiothoracic Surgery; Children's Hospital of Philadelphia; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Sherrie Vassallo for administrative and secretarial support and Thomas L. Spray for departmental support. This study was supported by the McCabe Foundation, University Research Foundation, and the Division of Pediatric Cardiothoracic Surgery, Children's Hospital of Philadelphia (P.J.G.), and National Institutes of Health grant R01 HL071546 (J.A.E.). P.J.G., J.A.E, and I.A. have filed U.S. Patent Application R-3701: Inhibition of histone deactylase activity as treatment, and preventive therapy for ischemic injury/inhibition of DNA methyl transferase activity its treatments and preventive therapy for ischemic injury.	Abdullah I, 2005, WOUND REPAIR REGEN, V13, P205, DOI 10.1111/j.1067-1927.2005.130212.x; Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Endres M, 2001, NEUROREPORT, V12, P3763, DOI 10.1097/00001756-200112040-00032; Endres M, 2000, J NEUROSCI, V20, P3175, DOI 10.1523/JNEUROSCI.20-09-03175.2000; Fath DM, 2006, J BIOL CHEM, V281, P13612, DOI 10.1074/jbc.M600456200; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Formisano L, 2007, P NATL ACAD SCI USA, V104, P4170, DOI 10.1073/pnas.0611704104; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; Guimaraes CL, 2002, CLIN SCI, V103, p340S, DOI 10.1042/CS103S340S; Hirao M, 2006, J BIOL CHEM, V281, P31079, DOI 10.1074/jbc.M602296200; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lee TM, 2007, AM J PHYSIOL-HEART C, V293, pH968, DOI 10.1152/ajpheart.00891.2006; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Pratt JR, 2006, TRANSPL P, V38, P3344, DOI 10.1016/j.transproceed.2006.10.112; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; ROSAMOND W, 2006, HEART DIS STROKE STA; Sanchis D, 2003, CELL DEATH DIFFER, V10, P977, DOI 10.1038/sj.cdd.4401267; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Simard B, 2002, CAN J PHYSIOL PHARM, V80, P1203, DOI 10.1139/Y02-153; Strawn W B, 2000, J Renin Angiotensin Aldosterone Syst, V1, P11, DOI 10.3317/jraas.2000.001; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Vasile E, 1999, J HISTOCHEM CYTOCHEM, V47, P159, DOI 10.1177/002215549904700205; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang Y, 2004, COLD SPRING HARB SYM, V69, P161, DOI 10.1101/sqb.2004.69.161; Webster KA, 1999, J CLIN INVEST, V104, P239; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Yamamura K, 2006, BRIT J HAEMATOL, V135, P242, DOI 10.1111/j.1365-2141.2006.06275.x; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhao TC, 2007, CARDIOVASC RES, V76, P473, DOI 10.1016/j.cardiores.2007.08.010	45	222	233	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3549	3560		10.1096/fj.08-108548	http://dx.doi.org/10.1096/fj.08-108548			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18606865	Green Published			2022-12-28	WOS:000259642600017
J	Lizarbe, TR; Garcia-Rama, C; Tarin, C; Saura, M; Calvo, E; Lopez, JA; Lopez-Otin, C; Folgueras, AR; Lamas, S; Zaragoza, C				Lizarbe, Tania R.; Garcia-Rama, Concepcion; Tarin, Carlos; Saura, Marta; Calvo, Enrique; Antonio Lopez, Juan; Lopez-Otin, Carlos; Folgueras, Alicia R.; Lamas, Santiago; Zaragoza, Carlos			Nitric oxide elicits functional MMP-13 protein-tyrosine nitration during wound repair	FASEB JOURNAL			English	Article						metalloproteinases; collagenase-3; inducible nitric oxide synthase; caveolin-1; wound healing	SMOOTH-MUSCLE-CELLS; MATRIX METALLOPROTEINASES; CAVEOLIN-1; MIGRATION; GROWTH; PROLIFERATION; EXPRESSION; PATHWAY; MICE	Nitric oxide (NO) plays a critical role in wound healing, in part by promoting angiogenesis. However, the precise repair pathways affected by NO are not well defined. We now show that NO regulates matrix metalloproteinase-13 (MMP-13) release during wound repair. We find that normally MMP-13 is kept inside endothelial cells by an association with caveolin-1. However, nitration of MMP-13 on tyrosine residue Y338 causes it to dissociate from caveolin-1 and be released from endothelial cells. We next explored the functional significance of MMP-13 nitration in vivo. Skin injury increases nitration of MMP-13 in mice. Skin wounds in inducible nitric oxide synthase knockout mice release less MMP-13 and heal more slowly than skin wounds in wild-type mice. Conversely, skin wounds in caveolin-1 knockout mice have increased NO production, increased MMP-13 nitration, and accelerated wound healing. Collectively, our data reveal a new pathway through which NO modulates wound repair: nitration of MMP-13 promotes its release from endothelial cells, where it accelerates angiogenesis and wound healing.	[Lizarbe, Tania R.; Garcia-Rama, Concepcion; Tarin, Carlos; Calvo, Enrique; Antonio Lopez, Juan; Zaragoza, Carlos] Ctr Nacl Invest Cardiovasc, Madrid, Spain; [Saura, Marta] Univ Alcala, Fac Med, Dept Fisiol, Madrid, Spain; [Lopez-Otin, Carlos; Folgueras, Alicia R.] Univ Oviedo, Inst Univ Oncol, Dept Bioquim, Oviedo, Spain; [Lamas, Santiago] Ctr Invest Biol, Inst Reina Sofia Invest Nefrol, E-28006 Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Universidad de Alcala; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Zaragoza, C (corresponding author), Fdn CNIC, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	czaragoza@cnic.es	Folgueras, Alicia/B-3281-2017; Lamas, Santiago/G-7308-2015; Lopez, Juan Antonio/G-7750-2015; Tarín, Carlos/ABE-4812-2020; Zaragoza, Carlos/AAH-9275-2019; López-Otín, Carlos/AAB-2106-2020; Zaragoza Sanchez, Carlos/G-8718-2011	Folgueras, Alicia/0000-0003-3426-9502; Lamas, Santiago/0000-0001-5166-4155; Lopez, Juan Antonio/0000-0002-9097-6060; López-Otín, Carlos/0000-0001-6964-1904; Zaragoza, Carlos/0000-0002-1706-8592	Ministerio de Educacion y Ciencia; Programa Ramon y Cajal; Plan Nacional de I + D + I [SAF 2005-06025, SAF 2006-02410]; European Union [FEDER 2FD97-1432]; Spanish Society of Nephrology; Ministerio de Sanidad y Consumo	Ministerio de Educacion y Ciencia(Spanish Government); Programa Ramon y Cajal(Spanish Government); Plan Nacional de I + D + I; European Union(European Commission); Spanish Society of Nephrology; Ministerio de Sanidad y Consumo(Instituto de Salud Carlos III)	This study was supported by the following institutions and agencies: Ministerio de Educacion y Ciencia, Programa Ramon y Cajal (to C.Z. and M.S.); Plan Nacional de I + D + I (SAF 2005-06025 to C.Z. and SAF 2006-02410 to S. L.); the European Union (FEDER 2FD97-1432, to S. L.); the Spanish Society of Nephrology (grant-in-aid 2001, to C.Z. and S.L.); and the Ministerio de Sanidad y Consumo (Red tematica de investigacion cooperativa RECAVA C03/01, to C.Z. and S.L.). We thank Dr. S. Bartlett for valuable and significant assistance with the manuscript.	Beare AHM, 2003, J INVEST DERMATOL, V120, P153, DOI 10.1046/j.1523-1747.2003.12019.x; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Ebadi M, 2005, MOL BRAIN RES, V134, P67, DOI 10.1016/j.molbrainres.2004.09.011; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Gerhardt H, 2005, EXP SUPPL, V94, P3; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hartenstein B, 2006, J INVEST DERMATOL, V126, P486, DOI 10.1038/sj.jid.5700084; Hassan GS, 2006, AM J PHYSIOL-HEART C, V290, pH2393, DOI 10.1152/ajpheart.01161.2005; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Kim HP, 2005, P NATL ACAD SCI USA, V102, P11319, DOI 10.1073/pnas.0501345102; Kuzuya Masafumi, 2003, J Atheroscler Thromb, V10, P275; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Lee PC, 1999, AM J PHYSIOL-HEART C, V277, pH1600, DOI 10.1152/ajpheart.1999.277.4.H1600; Lopez-Rivera E, 2005, P NATL ACAD SCI USA, V102, P3685, DOI 10.1073/pnas.0408217102; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Navarro A, 2004, FASEB J, V18, P1801, DOI 10.1096/fj.04-2516rev; Newby AC, 2006, CARDIOVASC RES, V69, P614, DOI 10.1016/j.cardiores.2005.08.002; Noiri E, 1998, AM J PHYSIOL-CELL PH, V274, pC236, DOI 10.1152/ajpcell.1998.274.1.C236; Pike LJ, 2005, BBA-MOL CELL RES, V1746, P260, DOI 10.1016/j.bbamcr.2005.05.005; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Ravanti L, 2000, INT J MOL MED, V6, P391; Razani B, 2001, J BIOL CHEM, V276, P38121; Stan RV, 2005, BBA-MOL CELL RES, V1746, P334, DOI 10.1016/j.bbamcr.2005.08.008; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; Weller R, 2003, CLIN EXP DERMATOL, V28, P511, DOI 10.1046/j.1365-2230.2003.01365.x; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Yamasaki K, 1998, J CLIN INVEST, V101, P967, DOI 10.1172/JCI2067; Ye YZ, 2007, J BIOL CHEM, V282, P6324, DOI 10.1074/jbc.M610800200; Yung Lai Ming, 2006, Cardiovascular & Hematological Disorders - Drug Targets, V6, P1; Zaragoza C, 2002, KIDNEY INT, V61, P804, DOI 10.1046/j.1523-1755.2002.00224.x; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	33	37	39	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3207	3215		10.1096/fj.07-103804	http://dx.doi.org/10.1096/fj.07-103804			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18495757				2022-12-28	WOS:000258761300013
J	Madonna, S; Scarponi, C; De Pita, O; Albanesi, C				Madonna, Stefania; Scarponi, Claudia; De Pita, Ornella; Albanesi, Cristina			Suppressor of cytokine signaling 1 inhibits IFN-gamma inflammatory signaling in human keratinocytes by sustaining ERK1/2 activation	FASEB JOURNAL			English	Article						skin inflammation; antiinflammatory pathways; skin immune responses; RAS; RAF-1; p120RasGAP	TRANSCRIPTIONAL ACTIVATION; CHEMOKINE EXPRESSION; PHOSPHORYLATION; KINASE; GROWTH; STAT1; PROLIFERATION; PATHWAY; PROTEINS; BLOCKADE	IFN-gamma is a pleiotropic cytokine importantly involved in the development of skin inflammatory responses. Epidermal keratinocytes are extremely susceptible to IFN-gamma action, but, once transduced with the suppressors of cytokine signaling ( SOCS) 1 molecule, they can no longer express a number of IFN-gamma inducible signal transducer and activator of transcription ( STAT) 1-dependent genes. Extracellular-signal-regulated kinase (ERK)1/2 pathway is also involved in the protection of keratinocytes from the proinflammatory effect of IFN-gamma. Here we show that, after IFN-gamma stimulation, SOCS1 inhibited IFN-gamma receptor and STAT1 phosphorylation but maintained ERK1/2 activation. SOCS1 was also necessary for the IFN-gamma-induced RAS and Raf-1 activities in keratinocytes. The enhanced ERK1/2 pathway in SOCS1-overexpressing keratinocytes was in part responsible for their inability to respond to IFN-gamma, in terms of CXCL10 and CCL2 production, and for the high production of CXCL8. Moreover, SOCS1 interacted with the RAS inhibitor p120 RasGAP and promoted its degradation after IFN-gamma stimulation. We hypothesize that SOCS1 functions as suppressor of IFN-gamma signaling, not only by inhibiting STAT1 activation but also by sustaining ERK1/2-dependent antiinflammatory pathways.	[Madonna, Stefania; Scarponi, Claudia; De Pita, Ornella; Albanesi, Cristina] IDI IRCCS, Immunol Lab, I-00167 Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Albanesi, C (corresponding author), IDI IRCCS, Immunol Lab, Via Monti Creta 104, I-00167 Rome, Italy.	c.albanesi@idi.it	Madonna, stefania/AAC-3381-2022; Albanesi, Cristina/K-4699-2016	Albanesi, Cristina/0000-0002-7537-6833	Italian Ministry of Health	Italian Ministry of Health(Ministry of Health, Italy)	This work was supported by the Italian Ministry of Health. We thank Dr. A. Cavani and Prof. G. Girolomoni for the critical reading of this manuscript.	Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Albanesi C, 2000, J IMMUNOL, V165, P1395, DOI 10.4049/jimmunol.165.3.1395; Albanesi C, 1999, J IMMUNOL, V162, P494; Albanesi Cristina, 2005, Current Drug Targets - Inflammation and Allergy, V4, P329, DOI 10.2174/1568010054022033; Ben-Zvi T, 2006, J CELL SCI, V119, P380, DOI 10.1242/jcs.02740; Bos JD, 2005, BRIT J DERMATOL, V152, P1098, DOI 10.1111/j.1365-2133.2005.06645.x; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Federici M, 2002, J IMMUNOL, V169, P434, DOI 10.4049/jimmunol.169.1.434; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gough DJ, 2007, J BIOL CHEM, V282, P938, DOI 10.1074/jbc.M607674200; Han YL, 2001, J CLIN INVEST, V108, P425, DOI 10.1172/JCI12629; He Y, 2006, J BIOL CHEM, V281, P5559, DOI 10.1074/jbc.M512338200; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Knisz J, 2007, J ALLERGY CLIN IMMUN, V119, P739, DOI 10.1016/j.jaci.2006.12.620; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299; Mascia F, 2003, AM J PATHOL, V163, P303, DOI 10.1016/S0002-9440(10)63654-1; Mujtaba MG, 2005, J IMMUNOL, V175, P5077, DOI 10.4049/jimmunol.175.8.5077; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; Pastore S, 2005, J IMMUNOL, V174, P5047, DOI 10.4049/jimmunol.174.8.5047; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; Waiboci LW, 2007, J IMMUNOL, V178, P5058, DOI 10.4049/jimmunol.178.8.5058; Wang DK, 2005, J BIOL CHEM, V280, P16393, DOI 10.1074/jbc.M413897200; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Zhang XL, 2005, EUR J IMMUNOL, V35, P3258, DOI 10.1002/eji.200526116	37	49	52	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3287	3297		10.1096/fj.08-106831	http://dx.doi.org/10.1096/fj.08-106831			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18556463				2022-12-28	WOS:000258761300021
J	Becker, R; Lenter, MC; Vollkommer, T; Boos, AM; Pfaff, D; Augustin, HG; Christian, S				Becker, Renate; Lenter, Martin C.; Vollkommer, Tobias; Boos, Anja M.; Pfaff, Dennis; Augustin, Hellmut G.; Christian, Sven			Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K	FASEB JOURNAL			English	Article						activated fibroblasts; mural cells	C-ASSOCIATED PROTEIN; CYCLOPHILIN-C; MAC-2-BINDING PROTEIN; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; CELL-ADHESION; ENDOTHELIUM; RECEPTOR; CANCER; GLYCOPROTEIN	Tumor development involves complex bidirectional interactions between tumor cells and host stromal cells. Endosialin (Tem1) has been identified as a highly O-glycosylated transmembrane glycoprotein, which is specifically expressed by tumor vessel-associated pericytes and stromal fibroblasts of a wide range of human tumors. Recent experiments in endosialin-deficient mice have unraveled a critical role of endosialin in site-specific tumor progression and metastasis. To molecularly understand the mechanisms of endosialin function, we aimed to identify extracellular endosialin ligands and identified Mac-2 BP/90K as a specific interaction partner. Detailed biochemical analyses identified a C-terminal fragment of Mac-2 BP/90K, which was shown to contain binding sites for galectin- 3, and collagens as the structures responsible for endosialin binding. Subsequent expression analysis of Mac-2 BP/90K in vivo revealed weak or no expression in most normal tissues and strong up-regulation in tumor cells of human neoplastic tissues. Intriguingly, the expression patterns of Mac-2 BP/90K and endosialin were mutually exclusive in all human tissues. Correspondingly, loss-of-function adhesion experiments of Mac-2 BP/90K-expressing tumor cells on endosialin-expressing fibroblasts revealed a repulsive outcome of the Mac-2 BP/90K interaction. Taken together, the experiments identify a novel repulsive interaction between endosialin on stromal fibroblasts and Mac-2 BP/90K on tumor cells.	[Becker, Renate; Vollkommer, Tobias; Boos, Anja M.; Pfaff, Dennis; Augustin, Hellmut G.; Christian, Sven] German Canc Res Ctr, INF 581, D-69221 Heidelberg, Germany; [Becker, Renate; Vollkommer, Tobias; Boos, Anja M.; Pfaff, Dennis; Augustin, Hellmut G.; Christian, Sven] Univ Heidelberg, Fac Med, Joint Res Div Vasc Biol, D-69221 Heidelberg, Germany; [Lenter, Martin C.] Boehringer Ingelheim Pharma GmbH & Co KG, Genom Grp Prote, Biberach, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Boehringer Ingelheim	Christian, S (corresponding author), BHC GDD TD TIV, POB 10709, D-42096 Wuppertal, Germany.	augustin@angiogenese.de; sven.christian@bayerhealthcare.com	Augustin, Hellmut/AAA-5246-2020	Augustin, Hellmut/0000-0002-7173-4242				BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; Christian S, 2001, J BIOL CHEM, V276, P48588, DOI 10.1074/jbc.M106152200; Christian S, 2001, J BIOL CHEM, V276, P7408, DOI 10.1074/jbc.M009604200; Christian S, 2008, AM J PATHOL, V172, P486, DOI 10.2353/ajpath.2008.070623; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fiedler U, 2003, J BIOL CHEM, V278, P1721, DOI 10.1074/jbc.M208550200; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; Halloran MC, 2006, CURR OPIN CELL BIOL, V18, P533, DOI 10.1016/j.ceb.2006.08.010; Hellstern S, 2002, J BIOL CHEM, V277, P15690, DOI 10.1074/jbc.M200386200; IACOBELLI S, 1994, BRIT J CANCER, V69, P172, DOI 10.1038/bjc.1994.29; INOHARA H, 1994, BIOCHEM BIOPH RES CO, V201, P1366, DOI 10.1006/bbrc.1994.1854; Inohara H, 1996, CANCER RES, V56, P4530; Kong WY, 2007, J CELL PHYSIOL, V210, P153, DOI 10.1002/jcp.20830; KOTHS K, 1993, J BIOL CHEM, V268, P14245; MacFadyen JR, 2005, FEBS LETT, V579, P2569, DOI 10.1016/j.febslet.2005.03.071; Marchetti A, 2002, CANCER RES, V62, P2535; Nanda A, 2006, P NATL ACAD SCI USA, V103, P3351, DOI 10.1073/pnas.0511306103; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pfaff D, 2006, J LEUKOCYTE BIOL, V80, P719, DOI 10.1189/jlb.1105652; RETTIG WJ, 1992, P NATL ACAD SCI USA, V89, P10832, DOI 10.1073/pnas.89.22.10832; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; Shimizu T, 2005, J CEREBR BLOOD F MET, V25, P325, DOI 10.1038/sj.jcbfm.9600029; St Croix B, 2000, SCIENCE, V289, P1197; Teicher BA, 2007, INT J ONCOL, V30, P305; Tomkowicz B, 2007, P NATL ACAD SCI USA, V104, P17965, DOI 10.1073/pnas.0705647104; Trahey M, 1999, P NATL ACAD SCI USA, V96, P3006, DOI 10.1073/pnas.96.6.3006; Ulmer TA, 2006, J CELL BIOCHEM, V98, P1351, DOI 10.1002/jcb.20784; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	28	45	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					3059	3067		10.1096/fj.07-101386	http://dx.doi.org/10.1096/fj.07-101386			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18490383				2022-12-28	WOS:000258089300045
J	Gude, DR; Alvarez, SE; Paugh, SW; Mitra, P; Yu, JD; Griffiths, R; Barbour, SE; Milstien, S; Spiegel, S				Gude, David R.; Alvarez, Sergio E.; Paugh, Steven W.; Mitra, Poulami; Yu, JiaDe; Griffiths, Rachael; Barbour, Suzanne E.; Milstien, Sheldon; Spiegel, Sarah			Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal	FASEB JOURNAL			English	Article						chemotaxis; leukemia cells; monocytes; secretion	CELL-MIGRATION; LEUKEMIA-CELLS; 1-PHOSPHATE; FTY720; RECEPTOR; N,N-DIMETHYLSPHINGOSINE; GROWTH; PHOSPHORYLATION; IMMUNOMODULATOR; INVOLVEMENT	Sphingosine-1-phosphate (S1P) is a bioactive lipid that regulates myriad important cellular processes, including growth, survival, cytoskeleton rearrangements, motility, and immunity. Here we report that treatment of Jurkat and U937 leukemia cells with the pan-sphingosine kinase (SphK) inhibitor N,N-dimethylsphingosine to block S1P formation surprisingly caused a large increase in expression of SphK1 concomitant with induction of apoptosis. Another SphK inhibitor, D, L-threo-dihydrosphingosine, also induced apoptosis and produced dramatic increases in SphK1 expression. However, up-regulation of SphK1 was not a specific effect of its inhibition but rather was a consequence of apoptotic stress. The chemotherapeutic drug doxorubicin, a potent inducer of apoptosis in these cells, also stimulated SphK1 expression and activity and promoted S1P secretion. The caspase inhibitor ZVAD reduced not only doxorubicin-induced lethality but also the increased expression of SphK1 and secretion of S1P. Apoptotic cells secrete chemotactic factors to attract phagocytic cells, and we found that S1P potently stimulated chemotaxis of monocytic THP-1 and U937 cells and primary monocytes and macrophages. Collectively, our data suggest that apoptotic cells may upregulate SphK1 to produce and secrete S1P that serves as a "come-and-get-me" signal for scavenger cells to engulf them in order to prevent necrosis.	[Gude, David R.; Alvarez, Sergio E.; Paugh, Steven W.; Mitra, Poulami; Yu, JiaDe; Griffiths, Rachael; Barbour, Suzanne E.; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Gude, David R.; Alvarez, Sergio E.; Paugh, Steven W.; Mitra, Poulami; Yu, JiaDe; Griffiths, Rachael; Barbour, Suzanne E.; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23298 USA; [Milstien, Sheldon] NIMH, NIH, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, 1101 E Marshall St,2011 Sanger Hall, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Nagarkatti-Gude, David/AAF-6996-2020; Yu, JiaDe/J-6683-2019; Paugh, Steven/A-7739-2008	Yu, JiaDe/0000-0002-0874-3170; Paugh, Steven/0000-0001-5697-9228	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA061774, R01 CA61774] Funding Source: Medline; NIGMS NIH HHS [R37 GM043880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH001039] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Baran Y, 2007, J BIOL CHEM, V282, P10922, DOI 10.1074/jbc.M610157200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; Chiba K, 2005, PHARMACOL THERAPEUT, V108, P308, DOI 10.1016/j.pharmthera.2005.05.002; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Don AS, 2007, J BIOL CHEM, V282, P15833, DOI 10.1074/jbc.M609124200; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; French KJ, 2003, CANCER RES, V63, P5962; Grimsley C, 2003, TRENDS CELL BIOL, V13, P648, DOI 10.1016/j.tcb.2003.10.004; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007; Hammad SM, 2006, PROSTAG OTH LIPID M, V79, P126, DOI 10.1016/j.prostaglandins.2005.12.004; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Huwiler A, 2006, CURR PHARM DESIGN, V12, P4625, DOI 10.2174/138161206779010422; Jin ZQ, 2006, CARDIOVASC RES, V71, P725, DOI 10.1016/j.cardiores.2006.06.010; Johann AM, 2008, J IMMUNOL, V180, P1239, DOI 10.4049/jimmunol.180.2.1239; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kinchen JM, 2007, J CELL SCI, V120, P2143, DOI 10.1242/jcs.03463; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Li QF, 2007, ONCOGENE, V26, P7904, DOI 10.1038/sj.onc.1210587; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mitra P, 2007, METHOD ENZYMOL, V434, P257, DOI 10.1016/S0076-6879(07)34014-7; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Neviani P, 2007, J CLIN INVEST, V117, P2408, DOI 10.1172/JCI31095; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Peter C, 2008, J BIOL CHEM, V283, P5296, DOI 10.1074/jbc.M706586200; Ravichandran KS, 2003, CELL, V113, P817, DOI 10.1016/S0092-8674(03)00471-9; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Singer II, 2005, J IMMUNOL, V175, P7151, DOI 10.4049/jimmunol.175.11.7151; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Taha TA, 2005, J BIOL CHEM, V280, P17196, DOI 10.1074/jbc.M413744200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Taylor RC, 2007, J BIOL CHEM, V282, P15011, DOI 10.1074/jbc.M611051200; Treede I, 2007, J BIOL CHEM, V282, P27155, DOI 10.1074/jbc.M704408200; Truman LA, 2004, IMMUNOBIOLOGY, V209, P21, DOI 10.1016/j.imbio.2004.02.001; Vessey DA, 2007, J BIOCHEM MOL TOXIC, V21, P273, DOI 10.1002/jbt.20193; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Weigert A, 2007, MOL BIOL CELL, V18, P3810, DOI 10.1091/mbc.E06-12-1096; Weigert A, 2006, BLOOD, V108, P1635, DOI 10.1182/blood-2006-04-014852; Wu CH, 2002, ONCOGENE, V21, P5160, DOI 10.1038/sj.onc.1205639	56	246	255	2	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2629	2638		10.1096/fj.08-107169	http://dx.doi.org/10.1096/fj.08-107169			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18362204	Green Published			2022-12-28	WOS:000258089300004
J	Kines, KJ; Morales, ME; Mann, VH; Gobert, GN; Brindley, PJ				Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.			Integration of reporter transgenes into Schistosoma mansoni chromosomes mediated by pseudotyped murine leukemia virus	FASEB JOURNAL			English	Article						schistosome; transgenesis; VSVG; luciferase; provirus; functional genomics	HUMAN-BLOOD FLUKE; LONG TERMINAL REPEAT; PANTROPIC RETROVIRAL VECTORS; T-CELL LEUKEMIA; PIGGYBAC TRANSPOSON; RNA INTERFERENCE; GENE-TRANSFER; GERM-LINE; IN-VITRO; GENOME	The recent release of draft genome sequences of two of the major human schistosomes has underscored the pressing need to develop functional genomics approaches for these significant pathogens. The sequence information also makes feasible genome-scale investigation of transgene integration into schistosome chromosomes. Retrovirus-mediated transduction offers a means to establish transgenic lines of schistosomes, to elucidate schistosome gene function and expression, and to advance functional genomics approaches for these parasites. We investigated the utility of the Moloney murine leukemia retrovirus (MLV) pseudotyped with vesicular stomatitis virus glycoprotein (VSVG) for the transduction of Schistosoma mansoni and delivery of reporter transgenes into schistosome chromosomes. Schistosomula were exposed to virions of VSVG-pseudotyped MLV, after which genomic DNA was extracted from the transduced schistosomes. Southern hybridization analysis indicated the presence of proviral MLV retrovirus in the transduced schistosomes. Fragments of the MLV transgene and flanking schistosome sequences recovered using an anchored PCR-based approach demonstrated definitively that somatic transgenesis of schistosome chromosomes had taken place and, moreover, revealed widespread retrovirus integration into schistosome chromosomes. More specifically, MLV transgenes had inserted in the vicinity of genes encoding immunophilin, zinc finger protein Sma-Zic, and others, as well as near the endogenous schistosome retrotransposons, the fugitive and SR1. Proviral integration of the MLV transgene appeared to exhibit primary sequence site specificity, targeting a gGATcc-like motif. Reporter luciferase transgene activity driven by the schistosome actin gene promoter was expressed in the tissues of transduced schistosomula and adult schistosomes. Luciferase activity appeared to be developmentally expressed in schistosomula with increased activity observed after 1 to 2 wk in culture. These findings indicate the utility of VSVG-pseudotyped MLV for transgenesis of S. mansoni, herald a tractable pathway forward toward germline transgenesis and functional genomics of parasitic helminths, and provide the basis for comparative molecular pathogenesis studies of chromosomal lesions arising from retroviral integration into human compared with schistosome chromosomes.	[Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.] George Washington Univ, Med Ctr, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA; [Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.] Tulane Univ, Hlth Sci Ctr, Dept Trop Med, New Orleans, LA 70118 USA; [Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.] Queensland Inst Med Res, Div Infect Dis, Brisbane, Qld 4006, Australia; [Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.] Tulane Univ, Hlth Sci Ctr, Program Biomed Sci, New Orleans, LA 70118 USA	George Washington University; Tulane University; QIMR Berghofer Medical Research Institute; Tulane University	Brindley, PJ (corresponding author), George Washington Univ, Med Ctr, Dept Microbiol Immunol & Trop Med, Ross Hall,Rm 448,2300 Eye St NW, Washington, DC 20037 USA.	mtmpjb@gwumc.edu	Gobert, Geoffrey/A-1468-2011; Gobert, Geoffrey/V-2985-2019	Brindley, Paul J./0000-0003-1765-0002; Gobert, Geoffrey/0000-0001-5884-6453	NIAID NIH HHS [R01 AI072773] Funding Source: Medline; PHS HHS [N0155270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072773] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alfa Ronald W., 2006, V129, P241; Amsterdam A, 2006, TRENDS GENET, V22, P473, DOI 10.1016/j.tig.2006.06.011; Balu B, 2005, P NATL ACAD SCI USA, V102, P16391, DOI 10.1073/pnas.0504679102; BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; Boulo V, 2000, IN VITRO CELL DEV-AN, V36, P395, DOI 10.1290/1071-2690(2000)036<0395:IOCECO>2.0.CO;2; Braschi S, 2006, MOL CELL PROTEOMICS, V5, P347, DOI 10.1074/mcp.M500287-MCP200; Brindley PJ, 2007, INT J PARASITOL, V37, P465, DOI 10.1016/j.ijpara.2006.12.012; Brindley PJ, 2003, TRENDS PARASITOL, V19, P79, DOI 10.1016/S1471-4922(02)00061-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cioli D, 2004, INT J PARASITOL, V34, P979, DOI 10.1016/j.ijpara.2004.05.001; Copeland CS, 2003, J VIROL, V77, P6153, DOI 10.1128/JVI.77.11.6153-6166.2003; Correnti JA, 2005, MOL BIOCHEM PARASIT, V143, P209, DOI 10.1016/j.molbiopara.2005.06.007; Correnti JM, 2007, INT J PARASITOL, V37, P1107, DOI 10.1016/j.ijpara.2007.02.011; DeMarco R, 2005, BIOCHEM BIOPH RES CO, V333, P230, DOI 10.1016/j.bbrc.2005.05.080; Derse D, 2007, J VIROL, V81, P6731, DOI 10.1128/JVI.02752-06; Dirks C, 2001, J VIROL, V75, P6375, DOI 10.1128/JVI.75.14.6375-6383.2001; Drew AC, 1999, MOL BIOL EVOL, V16, P1256, DOI 10.1093/oxfordjournals.molbev.a026216; Drew AC, 1997, MOL BIOL EVOL, V14, P602, DOI 10.1093/oxfordjournals.molbev.a025799; Grant WN, 2006, INT J PARASITOL, V36, P475, DOI 10.1016/j.ijpara.2005.12.002; Grevelding CG, 2006, PARASITIC FLATWORMS: MOLECULAR BIOLOGY, BIOCHEMISTRY, IMMUNOLOGY AND PHYSIOLOGY, P149, DOI 10.1079/9780851990279.0149; Haas BJ, 2007, EXP PARASITOL, V117, P225, DOI 10.1016/j.exppara.2007.06.005; Handler AM, 2002, INSECT BIOCHEM MOLEC, V32, P1211, DOI 10.1016/S0965-1748(02)00084-X; Hotez PJ, 2006, LANCET, V368, P1865, DOI 10.1016/S0140-6736(06)69765-1; Hu W, 2004, TRENDS MOL MED, V10, P217, DOI 10.1016/j.molmed.2004.03.002; Johnson C, 2005, J VIROL, V79, P57, DOI 10.1128/JVI.79.1.57-66.2005; Kalinna BH, 2007, TRENDS PARASITOL, V23, P197, DOI 10.1016/j.pt.2007.03.007; Kines KJ, 2006, EXP PARASITOL, V112, P209, DOI 10.1016/j.exppara.2006.02.003; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Krautz-Peterson G, 2007, MOL BIOCHEM PARASIT, V153, P194, DOI 10.1016/j.molbiopara.2007.03.006; Kumar A, 2004, GENOME RES, V14, P1975, DOI 10.1101/gr.2875304; Laha T, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-154; Laha T, 2004, INT J PARASITOL, V34, P1365, DOI 10.1016/j.ijpara.2004.08.007; Lampe DJ, 1998, GENETICS, V149, P179; LAZDINS JK, 1982, EXP PARASITOL, V53, P39, DOI 10.1016/0014-4894(82)90090-X; Li XS, 2006, INT J PARASITOL, V36, P671, DOI 10.1016/j.ijpara.2005.12.007; Liu F, 2006, PLOS PATHOG, V2, P268, DOI 10.1371/journal.ppat.0020029; Lu JK, 1996, P NATL ACAD SCI USA, V93, P3482, DOI 10.1073/pnas.93.8.3482; Maksakova IA, 2006, PLOS GENET, V2, P1, DOI 10.1371/journal.pgen.0020002; Marrelli MT, 2007, P NATL ACAD SCI USA, V104, P5580, DOI 10.1073/pnas.0609809104; Matsubara T, 1996, P NATL ACAD SCI USA, V93, P6181, DOI 10.1073/pnas.93.12.6181; MCLAREN DJ, 1977, NATURE, V269, P147, DOI 10.1038/269147a0; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; Miyazaki M, 2007, J VIROL, V81, P5714, DOI 10.1128/JVI.02511-06; Morales ME, 2008, MOL BIOCHEM PARASIT, V157, P160, DOI 10.1016/j.molbiopara.2007.10.009; Morales ME, 2007, FASEB J, V21, P3479, DOI 10.1096/fj.07-8726com; Nabekura T, 2006, MOL THER, V13, P301, DOI 10.1016/j.ymthe.2005.09.021; Que XC, 1999, MOL BIOCHEM PARASIT, V99, P237, DOI 10.1016/S0166-6851(99)00021-3; SHOEMAKER C, 1981, J VIROL, V40, P164, DOI 10.1128/JVI.40.1.164-172.1981; Sivasubbu S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-S1-S9; SPILIOTIS M, 2008, INT J PARASITOL, DOI DOI 10.1016/J.IJPARA.2007.4.002; SPOTILA LD, 1989, CHROMOSOMA, V97, P421, DOI 10.1007/BF00295025; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Tran MH, 2006, NAT MED, V12, P835, DOI 10.1038/nm1430; Vu HN, 2008, MOL THER, V16, P308, DOI 10.1038/sj.mt.6300350; Wang DW, 2007, P NATL ACAD SCI USA, V104, P12428, DOI 10.1073/pnas.0705502104; Wilson MH, 2007, MOL THER, V15, P139, DOI 10.1038/sj.mt.6300028; Wu P, 1998, J VIROL, V72, P5919, DOI 10.1128/JVI.72.7.5919-5926.1998	57	55	59	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2936	2948		10.1096/fj.08-108308	http://dx.doi.org/10.1096/fj.08-108308			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18403630	Green Published			2022-12-28	WOS:000258089300034
J	Palpant, NJ; D'Alecy, LG; Metzger, JM				Palpant, Nathan J.; D'Alecy, Louis G.; Metzger, Joseph M.			Single histidine button in cardiac troponin I sustains heart performance in response to severe hypercapnic respiratory acidosis in vivo	FASEB JOURNAL			English	Article						myocardial function; myofilaments; pH	POSITIVE-PRESSURE VENTILATION; THIN FILAMENT; TRANSGENIC MICE; GENE-TRANSFER; SKELETAL; PH; CALCIUM; MUSCLE; FAILURE; ADULT	Intracellular acidosis is a profound negative regulator of myocardial performance. We hypothesized that titrating myofilament calcium sensitivity by a single histidine substituted cardiac troponin I (A164H) would protect the whole animal physiological response to acidosis in vivo. To experimentally induce severe hypercapnic acidosis, mice were exposed to a 40% CO2 challenge. By echocardiography, it was found that systolic function and ventricular geometry were maintained in cTnI A164H transgenic (Tg) mice. By contrast, non-Tg (Ntg) littermates experienced rapid and marked cardiac decompensation during this same challenge. For detailed hemodymanic assessment, Millar pressure-conductance catheterization was performed while animals were treated with a beta-blocker, esmolol, during a severe hypercapnic acidosis challenge. Survival and load-independent measures of contractility were significantly greater in Tg vs. Ntg mice. This assay showed that Ntg mice had 100% mortality within 5 min of acidosis. By contrast, systolic and diastolic function were protected in Tg mice during acidosis, and they had 100% survival. This study shows that, independent of any beta-adrenergic compensation, myofilament-based molecular manipulation of inotropy by histidine-modified troponin I maintains cardiac inotropic and lusitropic performance and markedly improves survival during severe acidosis in vivo.-Palpant, N. J., D'Alecy, L. G., Metzger, J. M. Single histidine button in cardiac troponin I sustains heart performance in response to severe hypercapnic respiratory acidosis in vivo. FASEB J. 23, 1529-1540 (2009)	[Metzger, Joseph M.] Univ Minnesota, Sch Med, Dept Integrat Biol & Physiol, Minneapolis, MN 55455 USA; [Palpant, Nathan J.; D'Alecy, Louis G.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI USA	University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan	Metzger, JM (corresponding author), Univ Minnesota, Sch Med, Dept Integrat Biol & Physiol, 6-125 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	metzgerj@umn.edu	Palpant, Nathan/B-1641-2017	Palpant, Nathan/0000-0002-9334-8107	NIH; American Heart Association	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association)	We thank Dr. Robert Bartlett for generous use of his blood gas analysis machine and Dr. Terry Major for assistance with analysis of blood gas parameters. Drs. Margaret Westfall and Sharlene Day provided invaluable insight into the development of this manuscript. We also thank Steven Whitesall for his assistance with telemetered mice and Kimber Converso for her expert murine echocardiography measurements. This work was supported by grants from the NIH (J.M.) and the American Heart Association (N.P.).	ALLEN DG, 1983, J PHYSIOL-LONDON, V335, P555, DOI 10.1113/jphysiol.1983.sp014550; Arteaga GM, 2005, AM J PHYSIOL-HEART C, V289, pH2183, DOI 10.1152/ajpheart.00520.2005; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Blumenschein TMA, 2001, J BIOL CHEM, V276, P36606, DOI 10.1074/jbc.M105130200; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; Cho MC, 1999, J BIOL CHEM, V274, P22251, DOI 10.1074/jbc.274.32.22251; Crampin EJ, 2006, BIOPHYS J, V90, P3074, DOI 10.1529/biophysj.105.070557; Dargis R, 2002, J BIOL CHEM, V277, P34662, DOI 10.1074/jbc.C200419200; Davis J, 2007, CIRC RES, V100, P1494, DOI 10.1161/01.RES.0000268412.34364.50; Day SM, 2007, J MOL MED, V85, P911, DOI 10.1007/s00109-007-0181-6; Day SM, 2006, NAT MED, V12, P181, DOI 10.1038/nm1346; del Monte F, 2004, P NATL ACAD SCI USA, V101, P5622, DOI 10.1073/pnas.0305778101; Ding X L, 1996, J Card Fail, V2, P319, DOI 10.1016/S1071-9164(96)80019-4; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Fu Y, 2006, CIRC RES, V98, P659, DOI 10.1161/01.RES.0000207497.50477.60; Givertz MM, 2007, CIRCULATION, V115, P1218, DOI 10.1161/CIRCULATIONAHA.106.668640; GODT RE, 1989, J PHYSIOL-LONDON, V412, P155, DOI 10.1113/jphysiol.1989.sp017609; Harper RM, 2005, J NEUROPHYSIOL, V93, P1647, DOI 10.1152/jn.00863.2004; Jorgensen K, 2008, CIRCULATION, V117, P1075, DOI 10.1161/CIRCULATIONAHA.107.722868; KORETSUNE Y, 1989, CIRCULATION, V80, P369, DOI 10.1161/01.CIR.80.2.369; LEE JA, 1991, J CLIN INVEST, V88, P361, DOI 10.1172/JCI115311; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Linder AE, 2005, J CARDIOVASC PHARM, V46, P438, DOI 10.1097/01.fjc.0000175879.14994.63; Lindhout DA, 2003, J BIOL CHEM, V278, P27024, DOI 10.1074/jbc.M302497200; Liou YM, 2008, PFLUG ARCH EUR J PHY, V456, P787, DOI 10.1007/s00424-008-0456-y; Lutgens E, 1999, CARDIOVASC RES, V41, P586, DOI 10.1016/S0008-6363(98)00216-8; Mann DL, 2005, CIRCULATION, V111, P2837, DOI 10.1161/CIRCULATIONAHA.104.500546; Metzger JM, 2004, CIRC RES, V94, P146, DOI 10.1161/01.RES.0000110083.17024.60; Metzger JM, 2003, J BIOL CHEM, V278, P13118, DOI 10.1074/jbc.M212601200; METZGER JM, 1995, BIOPHYS J, V68, P1430, DOI 10.1016/S0006-3495(95)80316-4; Michele DE, 2002, CIRC RES, V91, P255, DOI 10.1161/01.RES.0000027530.58419.82; O'Croinin DF, 2008, CRIT CARE MED, V36, P2128, DOI 10.1097/CCM.0b013e31817d1b59; Oldner A, 2001, CRIT CARE MED, V29, P2185, DOI 10.1097/00003246-200111000-00022; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; PALPANT NJ, 2008, CARDIOVASC RES; Parsons B, 1997, J MUSCLE RES CELL M, V18, P599, DOI 10.1023/A:1018623604365; RICCIARDI L, 1994, J MOL CELL CARDIOL, V26, P601, DOI 10.1006/jmcc.1994.1072; RICCIARDI L, 1986, CARDIOVASC RES, V20, P117, DOI 10.1093/cvr/20.2.117; Rocker GM, 1999, CHEST, V115, P173, DOI 10.1378/chest.115.1.173; SOLARO RJ, 1989, MOL CELL BIOCHEM, V89, P163; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; Sorsa T, 2004, MOL CELL BIOCHEM, V266, P87, DOI 10.1023/B:MCBI.0000049141.37823.19; Steg PG, 2004, CIRCULATION, V109, P494, DOI 10.1161/01.CIR.0000109691.16944.DA; Szatkowski ML, 2001, J CLIN INVEST, V107, P191, DOI 10.1172/JCI9862; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tardiff JC, 1999, J CLIN INVEST, V104, P469, DOI 10.1172/JCI6067; Tsunezuka Y, 2000, ARTIF ORGANS, V24, P70, DOI 10.1046/j.1525-1594.2000.06339.x; Ucgun I, 2008, RESPIRATION, V76, P270, DOI 10.1159/000131707; Urboniene D, 2005, CIRC RES, V97, P70, DOI 10.1161/01.RES.0000173849.68636.1e; Westfall MV, 2007, J MOL CELL CARDIOL, V43, P107, DOI 10.1016/j.yjmcc.2007.05.017; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; Westfall MV, 2000, CIRC RES, V86, P470, DOI 10.1161/01.RES.86.4.470; Westfall MV, 2003, ADV EXP MED BIOL, V538, P169; Westfall MV, 2002, CIRC RES, V91, P525, DOI 10.1161/01.RES.0000034710.46739.C0; Westfall MV, 2001, NEWS PHYSIOL SCI, V16, P278; Westfall MV, 2001, BIOPHYS J, V80, p356A; Whitesall SE, 2004, AM J PHYSIOL-HEART C, V286, pH2408, DOI 10.1152/ajpheart.01089.2003; Windisch W, 2005, CHEST, V128, P657, DOI 10.1378/chest.128.2.657; Wolska BM, 2001, J PHYSIOL-LONDON, V536, P863, DOI 10.1111/j.1469-7793.2001.00863.x	61	12	12	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1529	1540		10.1096/fj.08-121996	http://dx.doi.org/10.1096/fj.08-121996			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19141534	Green Submitted, Green Published			2022-12-28	WOS:000266651700029
J	Henstridge, CM; Balenga, NAB; Ford, LA; Ross, RA; Waldhoer, M; Irving, AJ				Henstridge, Christopher M.; Balenga, Nariman A. B.; Ford, Lesley A.; Ross, Ruth A.; Waldhoer, Maria; Irving, Andrew J.			The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation	FASEB JOURNAL			English	Article						GPCR; cannabinoid; LPI; AM251; transcription; ROCK	CANNABINOID RECEPTOR; CONSTITUTIVE ENDOCYTOSIS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; ANANDAMIDE; CALCIUM; NEURONS	The endogenous phospholipid L-alpha-lysophosphatidylinositol (LPI) was recently identified as a novel ligand for the orphan G protein-coupled receptor 55 (GPR55). In this study we define the downstream signaling pathways activated by LPI in a human embryonic kidney (HEK) 293 cell line engineered to stably express recombinant human GPR55. We find that treatment with LPI induces marked GPR55 internalization and stimulates a sustained, oscillatory Ca2+ release pathway, which is dependent on G alpha 13 and requires RhoA activation. We then establish that this signaling cascade leads to the efficient activation of NFAT (nuclear factor of activated T cells) family transcription factors and their nuclear translocation. Analysis of cannabinoid ligand activity at GPR55 revealed no clear effect of the endocannabinoids anandamide and 2-arachidonoylglycerol; however, the classical CB1 antagonist AM251 evoked GPR55-mediated Ca2+ signaling. Thus, LPI is a potent and efficacious ligand at GPR55, which is likely to be a key plasma membrane mediator of LPI- mediated signaling events and changes in gene expression.-Henstridge, C. M., Balenga, N. A. B., Ford, L. A., Ross, R. A., Waldhoer, M., Irving, A. J. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA- dependent Ca2+ signaling and NFAT activation. FASEB J. 23, 183-193 (2009)	[Balenga, Nariman A. B.; Waldhoer, Maria] Med Univ Graz, Inst Expt & Clin Pharmacol, A-8010 Graz, Austria; [Henstridge, Christopher M.; Irving, Andrew J.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Neurosci, Dundee DD1 9SY, Scotland; [Ford, Lesley A.; Ross, Ruth A.] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland	Medical University of Graz; University of Dundee; University of Aberdeen	Waldhoer, M (corresponding author), Med Univ Graz, Inst Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.	maria.waldhoer@meduni-graz.at; a.j.irving@dundee.ac.uk	Aghaei Balenga, Nariman/A-5895-2011; Ross, R./AAG-7468-2019; Henstridge, Christopher/J-3848-2019; Waldhoer, Maria/HDO-0619-2022	Aghaei Balenga, Nariman/0000-0002-2741-9595; Henstridge, Christopher/0000-0002-0393-180X; Waldhoer, Maria/0000-0003-3534-1959	Tenovus Scotland; Royal Society; Medical Research Council; Anonymous Trust; Austrian Science Foundation; Jubilaumsfonds of the Austrian National Bank; Lanyar Stiftung Graz; Schering-Plough Corporation; Medical University of Graz, Austria	Tenovus Scotland; Royal Society(Royal Society of London); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Anonymous Trust; Austrian Science Foundation(Austrian Science Fund (FWF)); Jubilaumsfonds of the Austrian National Bank; Lanyar Stiftung Graz; Schering-Plough Corporation(Merck & CompanySchering Plough Corporation); Medical University of Graz, Austria	This work was supported by Tenovus Scotland, the Royal Society, the Medical Research Council, and the Anonymous Trust (all to A.J.I.); a grant by the Austrian Science Foundation (F.W.F.); the Jubilaumsfonds of the Austrian National Bank and the Lanyar Stiftung Graz (M.W.); Schering-Plough Corporation (R.A.R., L.F., and A.J.I.) and a fellowship within the molecular medicine Ph.D. program from the Medical University of Graz, Austria (N.B.). We thank Jennifer Whistler for critical reading of the manuscript and David Lee for assistance in generating the stable cell line.	Lacalle RA, 2007, J CELL BIOL, V179, P1539, DOI 10.1083/jcb.200705044; Brown AJ, 2007, BRIT J PHARMACOL, V152, P567, DOI 10.1038/sj.bjp.0707481; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Bushell TJ, 2006, NEUROPHARMACOLOGY, V50, P714, DOI 10.1016/j.neuropharm.2005.11.024; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Evans RM, 2004, BRIT J PHARMACOL, V141, P1223, DOI 10.1038/sj.bjp.0705723; FALASCA M, 1995, ONCOGENE, V10, P2113; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hains MD, 2006, MOL PHARMACOL, V69, P2068, DOI 10.1124/mol.105.017921; Helms WS, 2007, J LEUKOCYTE BIOL, V82, P361, DOI 10.1189/jlb.0206120; Im SH, 2004, MOL CELLS, V18, P1; Johns DG, 2007, BRIT J PHARMACOL, V152, P825, DOI 10.1038/sj.bjp.0707419; Kofalvi A, 2007, BRIT J PHARMACOL, V151, P551, DOI 10.1038/sj.bjp.0707252; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Martini L, 2007, FASEB J, V21, P802, DOI 10.1096/fj.06-7132com; McDonald NA, 2007, MOL PHARMACOL, V71, P976, DOI 10.1124/mol.106.029348; Mombouli JV, 1999, BRIT J PHARMACOL, V126, P1593, DOI 10.1038/sj.bjp.0702483; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Putney JW, 2007, CELL CALCIUM, V42, P103, DOI 10.1016/j.ceca.2007.01.011; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ryan D, 2007, EUR J NEUROSCI, V25, P2093, DOI 10.1111/j.1460-9568.2007.05448.x; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; Scragg JL, 2005, BIOCHEM BIOPH RES CO, V331, P1239, DOI 10.1016/j.bbrc.2005.04.037; STATON PC, 2008, PUTATIVE CA IN PRESS, DOI DOI 10.1016/J.PAIN.2008.04.006; Tomida T, 2003, EMBO J, V22, P3825, DOI 10.1093/emboj/cdg381; Waldeck-Weiermair M, 2008, J CELL SCI, V121, P1704, DOI 10.1242/jcs.020958; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118	31	218	227	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					183	193		10.1096/fj.08-108670	http://dx.doi.org/10.1096/fj.08-108670			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18757503				2022-12-28	WOS:000262095500021
J	Jones, HN; Woollett, LA; Barbour, N; Prasad, PD; Powell, TL; Jansson, T				Jones, Helen N.; Woollett, Laura A.; Barbour, Nicolette; Prasad, Puttur D.; Powell, Theresa L.; Jansson, Thomas			High-fat diet before and during pregnancy causes marked up-regulation of placental nutrient transport and fetal overgrowth in C57/BL6 mice	FASEB JOURNAL			English	Article; Proceedings Paper	55th Annual Meeting of the Society-for-Gynecologic-Investigation	MAR 26-29, 2008	San Diego, CA	Soc Gynecol Invest		maternal obesity; macrosomia	AMINO-ACID TRANSPORTER; INTRAUTERINE GROWTH RESTRICTION; ACTIVATED-RECEPTOR-GAMMA; MATERNAL OBESITY; GLUCOSE-TRANSPORTER; METABOLIC SYNDROME; UNITED-STATES; EXPRESSION; LEPTIN; ADIPONECTIN	Maternal overweight and obesity in pregnancy often result in fetal overgrowth, which increases the risk for the baby to develop metabolic syndrome later in life. However, the mechanisms underlying fetal overgrowth are not established. We developed a mouse model and hypothesized that a maternal high-fat (HF) diet causes up-regulation of placental nutrient transport, resulting in fetal overgrowth. C57BL/6J female mice were fed a control (11% energy from fat) or HF (32% energy from fat) diet for 8 wk before mating and throughout gestation and were studied at embryonic day 18.5. The HF diet increased maternal adiposity, as assessed by fat pad weight, and circulating maternal leptin, decreased serum adiponectin concentrations, and caused a marked increase in fetal growth (+43%). The HF diet also increased transplacental transport of glucose (5-fold) and neutral amino acids (10-fold) in vivo. In microvillous plasma membranes (MVMs) isolated from placentas of HF-fed animals, protein expression of glucose transporter 1 (GLUT1) was increased 5-fold, and protein expression of sodium-coupled neutral amino acid transporter (SNAT) 2 was elevated 9-fold. In contrast, MVM protein expression of GLUT 3 or SNAT4 was unaltered. These data suggest that up-regulation of specific placental nutrient transporter isoforms constitute a mechanism linking maternal high-fat diet and obesity to fetal overgrowth.-Jones, H. N., Woollett, L. A., Barbour, N., Prasad, P. D., Powell, T. L., Jansson, T. High-fat diet before and during pregnancy causes marked up-regulation of placental nutrient transport and fetal overgrowth in C57/BL6 mice. FASEB J. 23, 271-278 (2009)	[Jones, Helen N.] Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA; [Jones, Helen N.; Barbour, Nicolette; Powell, Theresa L.; Jansson, Thomas] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; [Prasad, Puttur D.] Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Georgia; Augusta University	Jones, HN (corresponding author), Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	helen.jones@uc.edu	Powell, Theresa/AAE-4249-2020	Powell, Theresa/0000-0001-7410-1080	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034089, R03HD058032, R56HD034089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059630] Funding Source: NIH RePORTER; NICHD NIH HHS [R03HD058032, R03 HD058032, R01 HD034089, HD34089, R56 HD034089, HD058032] Funding Source: Medline; NIDDK NIH HHS [U24 DK059630, DK59630] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ananth CV, 2002, SEMIN PERINATOL, V26, P260, DOI 10.1053/sper.2002.34772; BOILEAU P, 1995, J CLIN INVEST, V96, P309, DOI 10.1172/JCI118036; Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808; BOWERS GN, 1966, CLIN CHEM, V12, P70; Caminos JE, 2005, J CLIN ENDOCR METAB, V90, P4276, DOI 10.1210/jc.2004-0930; Catalano PM, 2006, BJOG-INT J OBSTET GY, V113, P1126, DOI 10.1111/j.1471-0528.2006.00989.x; Catalano PM, 2003, J CLIN ENDOCR METAB, V88, P3505, DOI 10.1210/jc.2003-031046; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Clifton PM, 1998, PROSTAG LEUKOTR ESS, V59, P191, DOI 10.1016/S0952-3278(98)90062-X; Cnattingius S, 1998, NEW ENGL J MED, V338, P147, DOI 10.1056/NEJM199801153380302; Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819; Desforges M, 2006, AM J PHYSIOL-CELL PH, V290, pC305, DOI 10.1152/ajpcell.00258.2005; DEVASKAR SU, 1994, AM J OBSTET GYNECOL, V171, P1316, DOI 10.1016/0002-9378(94)90154-6; Ehrenberg HM, 2004, AM J OBSTET GYNECOL, V191, P964, DOI 10.1016/j.ajog.2004.05.052; Ericsson A, 2005, AM J PHYSIOL-REG I, V288, pR656, DOI 10.1152/ajpregu.00407.2004; Ericsson A, 2005, HUM REPROD, V20, P521, DOI 10.1093/humrep/deh596; Fang X, 2005, J MOL ENDOCRINOL, V35, P465, DOI 10.1677/jme.1.01877; Gallou-Kabani C, 2007, AM J PHYSIOL-ENDOC M, V292, pE1095, DOI 10.1152/ajpendo.00390.2006; GUO F, 1995, PHYSIOL BEHAV, V57, P681, DOI 10.1016/0031-9384(94)00342-4; Han J, 2005, DIABETOLOGIA, V48, P1810, DOI 10.1007/s00125-005-1854-8; Hendler I, 2005, AM J OBSTET GYNECOL, V193, P979, DOI 10.1016/j.ajog.2005.06.041; Holemans K, 2004, AM J OBSTET GYNECOL, V190, P858, DOI 10.1016/j.ajog.2003.09.025; Jansson N, 2003, J CLIN ENDOCR METAB, V88, P1205, DOI 10.1210/jc.2002-021332; Jansson N, 2008, AM J CLIN NUTR, V87, P1743, DOI 10.1093/ajcn/87.6.1743; Jansson N, 2006, J PHYSIOL-LONDON, V576, P935, DOI 10.1113/jphysiol.2003.550004; Jansson T, 2006, PLACENTA, V27, pS91, DOI 10.1016/j.placenta.2005.11.010; Jansson T, 2002, DIABETES, V51, P2214, DOI 10.2337/diabetes.51.7.2214; Jansson T, 1999, AM J OBSTET GYNECOL, V180, P163, DOI 10.1016/S0002-9378(99)70169-9; Jansson T, 2001, AM J OBSTET GYNECOL, V184, P111, DOI 10.1067/mob.2001.108075; Jones HN, 2007, PLACENTA, V28, P763, DOI 10.1016/j.placenta.2007.05.002; KARL PI, 1992, AM J PHYSIOL, V262, pC834, DOI 10.1152/ajpcell.1992.262.4.C834; KARNIK HB, 1990, DEV PHARMACOL THERAP, V14, P135, DOI 10.1159/000480930; Khan IY, 2005, AM J PHYSIOL-REG I, V288, pR127, DOI 10.1152/ajpregu.00354.2004; KURUVILLA AG, 1994, J CLIN INVEST, V94, P689, DOI 10.1172/JCI117386; Lappas M, 2005, ENDOCRINOLOGY, V146, P3334, DOI 10.1210/en.2005-0406; Lesage J, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740037; Ling R, 2001, BBA-BIOMEMBRANES, V1512, P15, DOI 10.1016/S0005-2736(01)00310-8; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Muhlhausler BS, 2006, FASEB J, V20, P1257, DOI 10.1096/fj.05-5241fje; Muhlhausler BS, 2007, ENDOCRINOLOGY, V148, P878, DOI 10.1210/en.2006-1115; Novak D, 2006, PLACENTA, V27, P510, DOI 10.1016/j.placenta.2005.05.002; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ogura K, 1999, J ENDOCRINOL, V160, P443, DOI 10.1677/joe.0.1600443; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P958, DOI 10.1016/S0002-9378(12)80019-6; RAMSAY JE, 2006, J CLIN ENDOCR METAB, V87, P4231; Rosenbloom A, 2000, DIABETES CARE, V23, P381; Samuelsson AM, 2008, HYPERTENSION, V51, P383, DOI 10.1161/HYPERTENSIONAHA.107.101477; SARKKINEN ES, 1994, AM J CLIN NUTR, V59, P364, DOI 10.1093/ajcn/59.2.364; Sattar N, 1998, ACTA OBSTET GYN SCAN, V77, P278, DOI 10.1034/j.1600-0412.1998.770304.x; Sebire NJ, 2001, INT J OBESITY, V25, P1175, DOI 10.1038/sj.ijo.0801670; Srinivasan M, 2006, AM J PHYSIOL-ENDOC M, V291, pE792, DOI 10.1152/ajpendo.00078.2006; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Taylor PD, 2005, AM J PHYSIOL-REG I, V288, pR234; Umekawa T, 2008, ENDOCRINOLOGY, V149, P3980, DOI 10.1210/en.2007-1682; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	55	225	230	0	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					271	278		10.1096/fj.08-116889	http://dx.doi.org/10.1096/fj.08-116889			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18827021	Green Published			2022-12-28	WOS:000262095500029
J	van Waterschoot, RAB; Rooswinkel, RW; Wagenaar, E; van der Kruijssen, CMM; van Herwaarden, AE; Schinkel, AH				van Waterschoot, Robert A. B.; Rooswinkel, Rogier W.; Wagenaar, Els; van der Kruijssen, Cornelia M. M.; van Herwaarden, Antonius E.; Schinkel, Alfred H.			Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver	FASEB JOURNAL			English	Article						drug metabolism; xenobiotic metabolism; intestinal metabolism; drug-drug interactions; diet	DRUG-METABOLISM; DIETARY PHYTOCHEMICALS; PHENYTOIN INDUCTION; IN-VITRO; EXPRESSION; RECEPTOR; ENZYMES; KNOCKOUT; CYP3A4; CYP2C	CYP3A4 is an important xenobiotic metabolizing enzyme. We previously found that CYP2C55 is highly up-regulated in Cyp3a(-/-) mice. Here, we have further investigated the mechanism of regulation of CYP2C55 and other detoxifying systems in Cyp3a(-/-) mice. Induction studies with prototypical inducers demonstrated an important role for the nuclear receptors PXR and CAR in the up-regulation of CYP2C55. Subsequent diet-switch experiments revealed that food-derived xenobiotics are primarily responsible for the increased induction of CYP2C55, as well as of several other primary detoxifying systems in Cyp3a(-/-) mice. Our data suggest that CYP3A normally metabolizes food-derived activators of PXR and/or CAR, explaining the increased levels of such activators in Cyp3a(-/-) mice and subsequent up- regulation of a range of detoxifying systems. Interestingly, our studies with tissue-specific CYP3A4 transgenic Cyp3a(-/-) mice revealed that not only hepatic but also intestinal expression of CYP3A4 could reduce the hepatic expression of detoxifying systems to near wild-type levels. Apparently, intestinal CYP3A4 can limit the hepatic exposure to food-derived activators of nuclear receptors, thereby regulating the expression of a range of detoxifying systems in the liver. This broad biological effect further emphasizes the importance of intestinal CYP3A activity and could have profound implications for the prediction of drug exposure.-Van Waterschoot, R. A. B., Rooswinkel, R. W., Wagenaar, E., van der Kruijssen, C. M. M., van Herwaarden, A. E., Schinkel, A. H. Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J. 23, 224-231 (2009)	[van Waterschoot, Robert A. B.; Rooswinkel, Rogier W.; Wagenaar, Els; van der Kruijssen, Cornelia M. M.; van Herwaarden, Antonius E.; Schinkel, Alfred H.] Netherlands Canc Inst, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Schinkel, AH (corresponding author), Netherlands Canc Inst, Div Expt Therapy, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.schinkel@nki.nl	Herwaarden, A.E./L-4369-2015		Technical Sciences Foundation of the Netherlands Organization for Scientific Research (NWO/STW)	Technical Sciences Foundation of the Netherlands Organization for Scientific Research (NWO/STW)(Technologiestichting STWNetherlands Organization for Scientific Research (NWO))	We thank Drs. Conchita Vens and Christian Zimmermann ( Division of Experimental Therapy, The Netherlands Cancer Institute) for assistance with RT-PCR analysis. This work was supported by the Technical Sciences Foundation of the Netherlands Organization for Scientific Research (NWO/STW).	DeLozier TC, 2004, J PHARMACOL EXP THER, V310, P845, DOI 10.1124/jpet.104.067819; Doherty MM, 2002, CLIN PHARMACOKINET, V41, P235, DOI 10.2165/00003088-200241040-00001; Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003; Gorski JC, 2003, CLIN PHARMACOL THER, V74, P275, DOI 10.1016/S0009-9236(03)00187-5; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Ito SJ, 2007, J CLIN INVEST, V117, P1940, DOI 10.1172/JCI31647; Jackson JP, 2006, DRUG METAB DISPOS, V34, P2003, DOI 10.1124/dmd.106.012005; Jackson JP, 2004, MOL PHARMACOL, V65, P1397, DOI 10.1124/mol.65.6.1397; Lamba JK, 2002, ADV DRUG DELIVER REV, V54, P1271, DOI 10.1016/S0169-409X(02)00066-2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOWN KS, 1994, DRUG METAB DISPOS, V22, P947; Lown KS, 1997, J CLIN INVEST, V99, P2545, DOI 10.1172/JCI119439; Mandlekar S, 2006, CURR DRUG METAB, V7, P661, DOI 10.2174/138920006778017795; MCNAMARA DJ, 1982, BIOCHIM BIOPHYS ACTA, V711, P252, DOI 10.1016/0005-2760(82)90033-9; Mouly SJ, 2005, CLIN PHARMACOL THER, V78, P605, DOI 10.1016/j.clpt.2005.08.014; Ogura K, 2001, BIOCHEM BIOPH RES CO, V281, P431, DOI 10.1006/bbrc.2001.4387; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Thummel KE, 2007, J CLIN INVEST, V117, P3173, DOI 10.1172/JCI34007; Urquhart BL, 2007, J CLIN PHARMACOL, V47, P566, DOI 10.1177/0091270007299930; van de Kerkhof EG, 2007, CURR DRUG METAB, V8, P658, DOI 10.2174/138920007782109742; van Herwaarden AE, 2007, J CLIN INVEST, V117, P3583, DOI 10.1172/JCI33435; van Waterschoot RAB, 2008, MOL PHARMACOL, V73, P1029, DOI 10.1124/mol.107.043869; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85	25	37	37	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					224	231		10.1096/fj.08-114876	http://dx.doi.org/10.1096/fj.08-114876			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18794335				2022-12-28	WOS:000262095500025
J	Wu, QF; Law, PY; Wei, LN; Loh, HH				Wu, Qifang; Law, Ping-Yee; Wei, Li-Na; Loh, Horace H.			Post-transcriptional regulation of mouse mu opioid receptor (MOR1) via its 3 ' untranslated region: a role for microRNA23b	FASEB JOURNAL			English	Article						polysome-mRNA association; translation repression; K box	MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; NEURONAL CELLS; 3'-UNTRANSLATED REGION; TRANSLATIONAL CONTROL; 3'-NONCODING REGION; BINDING-PROTEIN; SEQUENCE MOTIF; K-BOX	Expression of the mu opioid receptor (MOR1) protein is regulated temporally and spatially. Although transcription of its gene has been studied extensively, regulation of MOR1 protein production at the level of translation is poorly understood. Using reporter assays, we found that the MOR1 3'-untranslated region (UTR) represses reporter expression at the post-transcriptional level. Suppression by the 3'-UTR of MOR1 is mediated through decreased mRNA association with polysomes, which requires microRNA23b (miRNA23b), a specific miRNA that is expressed in mouse brain and NS20Y mouse neuroblastoma cells. miRNA23b interacts with the MOR1 3'-UTR via a K box motif. By knocking down endogenous miRNA23b in NS20Y cells, we confirmed that miRNA23b inhibits MOR1 protein expression in vivo. This is the first study reporting a translationally repressive role for the MOR1 3'-UTR. We propose a mechanism in which miRNA23b blocks the association of MOR1 mRNA with polysomes, thereby arresting its translation and suppressing the production of MOR1 protein.	[Wu, Qifang; Law, Ping-Yee; Wei, Li-Na; Loh, Horace H.] Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wu, QF (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	wuxx0285@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	National Institutes of Health [DA00564, DA01583, DA11806, DA11190, K05-DA00153, K05-DA70554, K02-DA13926]; Minnesota Medical Foundation; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA001583, R01DA000564, R56DA000564, K02DA013926, R01DA001583, P50DA011806, K05DA070554, R01DA011190] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Minnesota Medical Foundation; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by National Institutes of Health research grants DA00564, DA01583, DA11806, DA11190, K05-DA00153, K05-DA70554, and K02-DA13926 and by the F&A Stark Fund of the Minnesota Medical Foundation. We thank Dr. Yan Zeng for his advice on miRNA and for kindly providing the psuper and pRlu-luc plasmids. Anti-MOR1 antibody was a generous gift from Dr. Lee-Yuan Liu-Chen (Temple University, Philadelphia, PA, USA). Dr. Kyu Young Song (University of Minnesota, Minneapolis, MN, USA) provided the pL1.33N plasmid. TopoUTR plasmid was constructed by Dr. Cheol Kyu Hwang (University of Minnesota, Minneapolis, MN, USA); we are grateful to him for valuable discussions and critical comments on the manuscript. We also thank Tammy Butterick and Jonathan Beckley for helpful manuscript review.	Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Behm-Ansmant I, 2006, COLD SPRING HARB SYM, V71, P523, DOI 10.1101/sqb.2006.71.013; Bi J, 2007, P NATL ACAD SCI USA, V104, P13810, DOI 10.1073/pnas.0703805104; Bi J, 2006, P NATL ACAD SCI USA, V103, P19919, DOI 10.1073/pnas.0607394104; Choe CY, 1998, J BIOL CHEM, V273, P34926, DOI 10.1074/jbc.273.52.34926; Choi HS, 2007, FASEB J, V21, P3963, DOI 10.1096/fj.07-8561com; Choi HS, 2005, MOL PHARMACOL, V67, P1674, DOI 10.1124/mol.104.008284; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Del Prete MJ, 2007, RNA, V13, P414, DOI 10.1261/rna.79407; Dostie J, 2003, RNA, V9, P180, DOI 10.1261/rna.2141503; Enright AJ, 2004, GENOME BIOL, V5; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Han WH, 2006, PHARMACOGENET GENOM, V16, P451, DOI 10.1097/01.fpc.0000215072.36965.8d; Hu XL, 2002, MOL PHARMACOL, V62, P881, DOI 10.1124/mol.62.4.881; Hwang CK, 2007, MOL CELL BIOL, V27, P4720, DOI 10.1128/MCB.00073-07; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Hwang CK, 2003, J BIOL CHEM, V278, P3742, DOI 10.1074/jbc.M208780200; Ide S, 2005, GENE, V364, P139, DOI 10.1016/j.gene.2005.05.040; Ikeda K, 2001, J NEUROSCI, V21, P1334; Kasai S, 2006, PSYCHIAT CLIN NEUROS, V60, pS11, DOI 10.1111/j.1440-1819.2006.01523.x-i1; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kim CS, 2006, NUCLEIC ACIDS RES, V34, P6392, DOI 10.1093/nar/gkl724; Kim CS, 2004, J BIOL CHEM, V279, P46464, DOI 10.1074/jbc.M403633200; Kimura Hitomi, 2004, Nucleic Acids Symp Ser (Oxf), P213; Ko JL, 2005, J NEUROCHEM, V93, P749, DOI 10.1111/j.1471-4159.2005.03089.x; Ko JL, 2003, MOL BRAIN RES, V112, P153, DOI 10.1016/S0169-328X(03)00086-X; Ko JL, 2001, J BIOL CHEM, V276, P788, DOI 10.1074/jbc.M004279200; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Lai EC, 2005, CURR BIOL, V15, pR458, DOI 10.1016/j.cub.2005.06.015; Lai EC, 1998, DEVELOPMENT, V125, P4077; Lai EC, 2005, GENE DEV, V19, P1067, DOI 10.1101/gad.1291905; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lee KJ, 2006, VIRUS GENES, V32, P171, DOI 10.1007/s11262-005-6873-5; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Palmieri A, 2007, NANOMED-NANOTECHNOL, V3, P138, DOI 10.1016/j.nano.2007.03.004; Pasternak GW, 2001, LIFE SCI, V68, P2213, DOI 10.1016/S0024-3205(01)01008-6; Qin XL, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r63; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; SACHS A, 1993, J BIOL CHEM, V268, P22955; Shabalina SA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-105; Sonenberg N, 2000, TRANSLATIONAL CONTRO; Song KY, 2007, NUCLEIC ACIDS RES, V35, P1501, DOI 10.1093/nar/gkm034; Wang TS, 2007, GENE CHROMOSOME CANC, V46, P336, DOI 10.1002/gcc.20415; Wei LN, 2004, FRONT BIOSCI-LANDMRK, V9, P1665, DOI 10.2741/1362; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10934, DOI 10.1093/nar/16.22.10934; Wu QF, 2005, MOL PHARMACOL, V68, P279, DOI 10.1124/mol.105.012567; Yang Q, 1997, J BIOL CHEM, V272, P15466, DOI 10.1074/jbc.272.24.15466; Zhang WY, 2007, AM J PATHOL, V171, P728, DOI 10.2353/ajpath.2007.070070; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006; Zhou GK, 2007, PLANT CELL PHYSIOL, V48, P391, DOI 10.1093/pcp/pcm008; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	56	44	52	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4085	4095		10.1096/fj.08-108175	http://dx.doi.org/10.1096/fj.08-108175			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18716031	Green Published			2022-12-28	WOS:000261254800008
J	Flores, M; Saavedra, R; Bautista, R; Viedma, R; Tenorio, EP; Leng, L; Sanchez, Y; Juarez, I; Satoskar, AA; Shenoy, AS; Terrazas, LI; Bucala, R; Barbi, J; Satoskar, AR; Rodriguez-Sosa, M				Flores, Marcos; Saavedra, Rafael; Bautista, Rocio; Viedma, Rubi; Tenorio, Eda P.; Leng, Lin; Sanchez, Yuriko; Juarez, Imelda; Satoskar, Anjali A.; Shenoy, Asha S.; Terrazas, Luis I.; Bucala, Richard; Barbi, Joseph; Satoskar, Abhay R.; Rodriguez-Sosa, Miriam			Macrophage migration inhibitory factor (MIF) is critical for the host resistance against Toxoplasma gondii	FASEB JOURNAL			English	Article						proinflammatory cytokines; innate immunity; cerebral toxoplasmosis	CELL-MEDIATED-IMMUNITY; DENDRITIC CELLS; PITUITARY-HORMONE; LEISHMANIA-MAJOR; IL-12 PRODUCTION; INFECTED MICE; CUTTING EDGE; TNF-ALPHA; EXPRESSION; GENE	Macrophage migration inhibitory factor (MIF) exerts either a protective or a deleterious role in the immune response to different pathogens. We analyzed herein the role of MIF in the host control of toxoplasmosis using MIF-/- mice backcrossed to either the BALB/c or the C57BL/6 genetic backgrounds. Both, wild-type (WT) BALB/c and MIF-/- BALB/c mice were susceptible to infection with highly virulent RH as well as moderately virulent ME49 strains of T. gondii. MIF-/- mice, however, showed greater liver damage and more brain cysts, produced less proinflammatory cytokines, and succumbed significantly faster than WT mice. Bone marrow-derived dendritic cells (BMDCs) from MIF-/- mice produced less interleukin-1 beta, interleukin-12, and tumor necrosis factor-alpha than WT BMDCs after stimulation with soluble Toxoplasma antigen (STAB). Similar observations were made in CD11c(+) low-density cells isolated from the spleens of MIF-/- mice challenged with STAB. MIF-/- C57BL/6 mice succumbed to ME49 infection faster than their WT counterparts. C57BL/6 mice that succumbed to infection with the ME49 strain produced less MIF than resistant BALB/c mice similarly infected. Interestingly, an analysis of brains from patients with cerebral toxoplasmosis showed low levels of MIF expression. Together, these findings demonstrate that MIF plays a critical role in mediating host resistance against T. Gondii.	[Barbi, Joseph; Satoskar, Abhay R.] Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; [Flores, Marcos; Bautista, Rocio; Viedma, Rubi; Sanchez, Yuriko; Juarez, Imelda; Terrazas, Luis I.; Rodriguez-Sosa, Miriam] Univ Nacl Autonoma Mexico, Unidad Biomed, FES Iztacala, Mexico City 04510, DF, Mexico; [Saavedra, Rafael; Tenorio, Eda P.] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City 04510, DF, Mexico; [Leng, Lin; Bucala, Richard] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; [Shenoy, Asha S.] Seth GS Med Coll, Dept Pathol, Bombay, Maharashtra, India; [Shenoy, Asha S.] King Edward Mem Hosp, Bombay, Maharashtra, India; [Satoskar, Anjali A.] Ohio State Univ, Dept Pathol, Med Ctr, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Yale University; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; University System of Ohio; Ohio State University	Rodriguez-Sosa, M (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.	satoskar.2@osu.edu; rodriguezm@campus.iztacala.unam.mx	Satoskar, Abhay/AAB-7748-2019; Terrazas, Luis I/AAV-8858-2020; Zumárraga, Dra. Eda Patricia Tenorio/ABE-8294-2020; Flores-Alamo, Marcos/A-3906-2019	Leng, Lin/0000-0002-0605-358X; Terrazas, Luis I./0000-0003-1635-9467; Tenorio, Eda/0000-0002-4725-2286; Flores-Alamo, Marcos/0000-0002-2996-7616; Sanchez Zamora, Yuriko Itzel/0000-0002-0769-8523; Rodriguez-Sosa, Miriam/0000-0003-2911-9390	Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica; UNAM (PAPIIT-UNAM) [IN208606]; Programa de Apoyo a los Profesores de Carrera para la Formacion de Grupos de Investigacion (PAPCA) FES-Iztacala; UNAM, Consejo Nacional de Ciencia y Tecnologia (CONACYT) [49812-Q]; U.S. National Institutes of Health	Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica(Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)); UNAM (PAPIIT-UNAM)(Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico); Programa de Apoyo a los Profesores de Carrera para la Formacion de Grupos de Investigacion (PAPCA) FES-Iztacala; UNAM, Consejo Nacional de Ciencia y Tecnologia (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)Universidad Nacional Autonoma de Mexico); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank L. Flores and T.Villamar for their excellent care of the animals. This work was supported by grants from Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica, UNAM (PAPIIT-UNAM) (IN208606), Programa de Apoyo a los Profesores de Carrera para la Formacion de Grupos de Investigacion (PAPCA) FES-Iztacala. UNAM, Consejo Nacional de Ciencia y Tecnologia (CONACYT) to M.R.S (49812-Q), and the U.S. National Institutes of Health to A.R.S. and R.B.	Abe R, 2001, J IMMUNOL, V166, P747, DOI 10.4049/jimmunol.166.2.747; Alexander J, 1997, PHILOS T ROY SOC B, V352, P1355, DOI 10.1098/rstb.1997.0120; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Aliberti J, 2005, NAT REV IMMUNOL, V5, P162, DOI 10.1038/nri1547; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bacher M, 1997, AM J PATHOL, V150, P235; Bacher M, 2002, VIROLOGY, V299, P32, DOI 10.1006/viro.2002.1464; Bellan C, 2002, DIAGN MOL PATHOL, V11, P2, DOI 10.1097/00019606-200203000-00002; Bernhagen J, 1995, BIOTHERAPY, V8, P123, DOI 10.1007/BF01878495; Bliss SK, 1999, J IMMUNOL, V162, P7369; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; BUCALA R, 1994, IMMUNOL LETT, V43, P23, DOI 10.1016/0165-2478(94)00152-9; Bucala R, 1996, FASEB J, V10, P1607, DOI 10.1096/fasebj.10.14.9002552; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Calandra T, 2003, J INFECT DIS, V187, pS385, DOI 10.1086/374752; CHAO CC, 1993, CLIN IMMUNOL IMMUNOP, V67, P178, DOI 10.1006/clin.1993.1062; Chen M, 2002, J PARASITOL, V88, P1017, DOI 10.1645/0022-3395(2002)088[1017:IOMIHD]2.0.CO;2; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Debierre-Grockiego F, 2007, J IMMUNOL, V179, P1129, DOI 10.4049/jimmunol.179.2.1129; Del Rio L, 2004, J IMMUNOL, V172, P6954, DOI 10.4049/jimmunol.172.11.6954; Denkers EY, 1998, CLIN MICROBIOL REV, V11, P569, DOI 10.1128/CMR.11.4.569; GAZZINELLI RT, 1994, J IMMUNOL, V153, P2533; Homan WL, 2000, INT J PARASITOL, V30, P69, DOI 10.1016/S0020-7519(99)00170-8; Juttner S, 1998, J IMMUNOL, V161, P2383; Kibiki GS, 2007, CLIN IMMUNOL, V123, P60, DOI 10.1016/j.clim.2006.12.004; Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699; Kompalic-Cristo A, 2007, PARASITOL RES, V101, P619, DOI 10.1007/s00436-007-0524-9; Leech M, 1999, ARTHRITIS RHEUM, V42, P1601, DOI 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B; Liu CH, 2006, J IMMUNOL, V177, P31, DOI 10.4049/jimmunol.177.1.31; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; Matsumoto K, 2001, AM J NEPHROL, V21, P455, DOI 10.1159/000046649; McDevitt MA, 2006, J EXP MED, V203, P1185, DOI 10.1084/jem.20052398; Mordue DG, 2001, J IMMUNOL, V167, P4574, DOI 10.4049/jimmunol.167.8.4574; Mun HS, 2003, INT IMMUNOL, V15, P1081, DOI 10.1093/intimm/dxg108; Murakami H, 2002, CLIN EXP IMMUNOL, V128, P504, DOI 10.1046/j.1365-2249.2002.01838.x; Nakano Y, 2002, MICROBES INFECT, V4, P1, DOI 10.1016/S1286-4579(01)01503-9; Nguyen TD, 2003, J MED MICROBIOL, V52, P869, DOI 10.1099/jmm.0.04860-0; Oddo M, 2005, INFECT IMMUN, V73, P3783, DOI 10.1128/IAI.73.6.3783-3786.2005; Reyes JL, 2006, INFECT IMMUN, V74, P3170, DOI 10.1128/IAI.01648-05; Rodriguez-Sosa M, 2003, INFECT IMMUN, V71, P1247, DOI 10.1128/IAI.71.3.1247-1254.2003; Roger T, 2003, J ENDOTOXIN RES, V9, P119, DOI 10.1179/096805103125001513; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Saavedra R, 2004, PARASITE IMMUNOL, V26, P67, DOI 10.1111/j.0141-9838.2004.00684.x; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; Scanga CA, 2002, J IMMUNOL, V168, P5997, DOI 10.4049/jimmunol.168.12.5997; SchartonKersten T, 1995, RES IMMUNOL, V146, P539, DOI 10.1016/0923-2494(96)83029-X; SNIDER HM, 2007, MIF MOST INTERESTING; Stavitsky AB, 2003, PARASITE IMMUNOL, V25, P369, DOI 10.1046/j.1365-3024.2003.00641.x; Suzuki T, 2000, BBA-GENE STRUCT EXPR, V1517, P100, DOI 10.1016/S0167-4781(00)00262-1; SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869; Toh ML, 2006, J IMMUNOL, V177, P4818, DOI 10.4049/jimmunol.177.7.4818; Ferro EAV, 2008, AM J PATHOL, V172, P50, DOI 10.2353/ajpath.2008.070432; Yap GS, 2006, MICROBES INFECT, V8, P1174, DOI 10.1016/j.micinf.2005.10.031; Yap GS, 1999, IMMUNOBIOLOGY, V201, P240, DOI 10.1016/S0171-2985(99)80064-3	54	53	55	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3661	3671		10.1096/fj.08-111666	http://dx.doi.org/10.1096/fj.08-111666			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18606868	Green Published			2022-12-28	WOS:000259642600027
J	Merched, AJ; Ko, K; Gotlinger, KH; Serhan, CN; Chan, L				Merched, Aksam J.; Ko, Kerry; Gotlinger, Katherine H.; Serhan, Charles N.; Chan, Lawrence			Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators	FASEB JOURNAL			English	Article						lipoxygenase; innate immunity	SCAVENGER RECEPTOR-A; ANTIINFLAMMATORY ACTIONS; PROTECTIN D1; 12/15-LIPOXYGENASE; EXPRESSION; 5-LIPOXYGENASE; CELLS; MACROPHAGES; ABSENCE; LESIONS	Atherosclerosis is now recognized as an inflammatory disease involving the vascular wall. Recent results indicate that acute inflammation does not simply passively resolve as previously assumed but is actively terminated by a homeostatic process that is governed by specific lipid-derived mediators initiated by lipoxygenases. Experiments with animals and humans support a proinflammatory role for the 5-lipoxygenase system. In contrast, results from animal experiments show a range of responses with the 12/15-lipoxygenase pathways in atherosclerosis. To date, the only two clinical epidemiology human studies both support an antiatherogenic role for 12/15-lipoxygenase downstream actions. We tested the hypothesis that atherosclerosis results from a failure in the resolution of local inflammation by analyzing apolipoprotein E-deficient mice with 1) global leukocyte 12/15-lipoxygenase deficiency, 2) normal enzyme expression, or 3) macrophage-specific 12/15-lipoxygenase overexpression. Results from these indicate that 12/15-lipoxygenase expression protects mice against atherosclerosis via its role in the local biosynthesis of lipid mediators, including lipoxin A(4), resolvin D1, and protectin D1. These mediators exert potent agonist actions on macrophages and vascular endothelial cells that can control the magnitude of the local inflammatory response. Taken together, these findings suggest that a failure of local endogenous resolution mechanisms may underlie the unremitting inflammation that fuels atherosclerosis.	[Merched, Aksam J.] Baylor Coll Med, Dept Mol & Cellular Biol, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA; [Chan, Lawrence] Baylor Coll Med, Dept Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA; [Chan, Lawrence] St Lukes Episcopal Hosp, Houston, TX 77030 USA; [Gotlinger, Katherine H.; Serhan, Charles N.] Harvard Univ, Dept Anesthesiol Perioperat & Pain Med, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury,Med Sch, Boston, MA 02115 USA	Baylor College of Medicine; Baylor College of Medicine; Saint Lukes Episcopal Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Merched, AJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Div Endocrinol Diabet & Metab, 1 Baylor Plaza,N52011, Houston, TX 77030 USA.	amerched@bcm.edu		Merched, Aksam/0000-0003-4030-4538	American Heart Association [0465093Y, 0730172N]; National Institutes of Health [P50 DE016191, HL-51386]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr. Colin Funk (University of Pcnnsylvania, Philadelphia, PA, USA) for sending 12/15-LO<SUP>-/-</SUP> mice that we used for pilot experiments before purchasing them from Jackson Laboratory for the definitive experiments. This work was supported by American Heart Association grants to A.M. (0465093Y and 0730172N) and grants from the National Institutes of Health (P50 DE016191 to C.N.S., and HL-51386 to L.C.).	Ariel A, 2006, NAT IMMUNOL, V7, P1209, DOI 10.1038/ni1392; Assimes TL, 2008, ATHEROSCLEROSIS, V198, P136, DOI 10.1016/j.atherosclerosis.2007.09.003; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; Cyrus T, 2001, CIRCULATION, V103, P2277; Duffield JS, 2006, J IMMUNOL, V177, P5902, DOI 10.4049/jimmunol.177.9.5902; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; Fadok VA, 2001, SEMIN IMMUNOL, V13, P365, DOI 10.1006/smim.2001.0333; George J, 2001, CIRCULATION, V104, P1646, DOI 10.1161/hc3901.095772; Goh J, 2003, GASTROENTEROLOGY, V124, P1043, DOI 10.1053/gast.2003.50154; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Helgadottir A, 2005, AM J HUM GENET, V76, P505, DOI 10.1086/428066; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Hong S, 2007, J AM SOC MASS SPECTR, V18, P128, DOI 10.1016/j.jasms.2006.09.002; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; Huo YQ, 2004, CIRCULATION, V110, P2024, DOI 10.1161/01.CIR.0000143628.37680.F6; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lu Y, 2006, THESCIENTIFICWORLDJO, V6, P589, DOI 10.1100/tsw.2006.118; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Merched AJ, 2004, CIRCULATION, V110, P3830, DOI 10.1161/01.CIR.0000148681.01282.89; Merched AJ, 2003, ARTERIOSCL THROM VAS, V23, P1608, DOI 10.1161/01.ATV.0000084825.88022.53; Miller KM, 2001, MOL ECOL NOTES, V1, P131, DOI 10.1046/j.1471-8278.2001.00048.x; Miller YI, 2003, MOL BIOL CELL, V14, P4196, DOI 10.1091/mbc.E03-02-0063; Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061; Munger KA, 1999, P NATL ACAD SCI USA, V96, P13375, DOI 10.1073/pnas.96.23.13375; Oka K, 2001, CIRCULATION, V103, P1274; Pouliot M, 2000, BIOCHEMISTRY-US, V39, P4761, DOI 10.1021/bi992551b; Qiu H, 2006, P NATL ACAD SCI USA, V103, P8161, DOI 10.1073/pnas.0602414103; Reardon CA, 2003, ARTERIOSCL THROM VAS, V23, P1449, DOI 10.1161/01.ATV.0000079793.58054.2E; Reilly KB, 2004, J BIOL CHEM, V279, P9440, DOI 10.1074/jbc.M303857200; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; SERHAN CN, 1990, METHOD ENZYMOL, V187, P167; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; Tang JJ, 2005, AM J PATHOL, V167, P901, DOI 10.1016/S0002-9440(10)62061-5; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wittwer J, 2007, CLIN CHEM LAB MED, V45, P487, DOI 10.1515/CCLM.2007.103	52	319	397	2	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2008	22	10					3595	3606		10.1096/fj.08-112201	http://dx.doi.org/10.1096/fj.08-112201			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18559988	Green Published			2022-12-28	WOS:000259642600021
J	Jiang, PZ; Ko, LW; Jansen, KR; Golde, TE; Yen, SH				Jiang, Peizhou; Ko, Li-wen; Jansen, Karen R.; Golde, Todd E.; Yen, Shu-Hui			Using leucine zipper to facilitate alpha-synuclein assembly	FASEB JOURNAL			English	Article						aggregation; adeno-associated virus	PROTEIN-PROTEIN INTERACTIONS; GREEN FLUORESCENT PROTEIN; PARKINSONS-DISEASE; COILED-COIL; IN-VITRO; NACP/ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; FIBRIL FORMATION; HELICAL PROTEIN	The accumulation of filamentous alpha-synuclein (alpha-S) is associated with Parkinson's disease. It remains controversial as to the mode (antiparallel or parallel) of alpha-S self-assembly and whether an exact alignment of the central hydrophobic region is essential. In the present study, we performed in vitro assembly using alpha-S with or without the attachment of artificial leucine zippers (Zips) capable of forming either parallel or antiparallel coiled coils and included a spacer in one derivative. Results showed that Zips accelerate filament assembly in both the parallel and antiparallel fashions, that a precise alignment of the central hydrophobic region is not essential, and that the antiparallel pairs displayed the highest thioflavin T signals. More importantly, cells expressing Zip-fused alpha-S, but not alpha-S alone, formed alpha-S immunopositive and thioflavin S-positive inclusions in 7 days. The results suggest that alpha-S can assemble in both parallel and antiparallel modes but have a higher tendency to assemble in the latter mode and that cells overexpressing Zip-fused alpha-S may be used to screen alpha-S assembly inhibitors due to enhanced ability to form inclusions.	[Jiang, Peizhou; Ko, Li-wen; Jansen, Karen R.; Golde, Todd E.; Yen, Shu-Hui] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA; [Jiang, Peizhou] So Med Univ, Sch Basic Med Sci, Dept Histol & Embryol, Guangzhou, Guangdong, Peoples R China	Mayo Clinic; Southern Medical University - China	Yen, SH (corresponding author), Mayo Clin, Coll Med, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	yen.shu-hui@mayo.edu			U. S. National Institutes of Health [P50-NS40256]; Mayo Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS040256] Funding Source: NIH RePORTER	U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Drs. Terrone Rosenberry and Vijayaraghavan Rangachari for assistance in CD analysis and valuable comments. We are grateful to Dr. Wen-Lang Lin for assistance in electron microscopy, to Dr. Tania Gendron for her critical reading, and to Ms. Carolina Ceballos-Diaz and Ms. Ena Causevic for technical assistance in AAV packaging and Western blot analysis. This study was supported by the U. S. National Institutes of Health (P50-NS40256) and the Mayo Foundation.	Antony T, 2003, J BIOL CHEM, V278, P3235, DOI 10.1074/jbc.M208249200; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Arndt KM, 2000, J MOL BIOL, V295, P627, DOI 10.1006/jmbi.1999.3352; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Chen M, 2007, J BIOL CHEM, V282, P24970, DOI 10.1074/jbc.M700368200; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Del Mar C, 2005, P NATL ACAD SCI USA, V102, P15477, DOI 10.1073/pnas.0507405102; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; DeVit M, 2005, GENOME RES, V15, P560, DOI 10.1101/gr.3259905; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Ghosh I, 2000, J AM CHEM SOC, V122, P5658, DOI 10.1021/ja994421w; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goers J, 2003, PROTEIN SCI, V12, P702, DOI 10.1110/ps.0230903; Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Kim BM, 2002, J AM CHEM SOC, V124, P8237, DOI 10.1021/ja020275+; Klucken J, 2006, FASEB J, V20, P2050, DOI 10.1096/fj.05-5422com; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; Kruger R, 2000, J NEURAL TRANSM, V107, P31, DOI 10.1007/s007020050002; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Levites Y, 2006, J NEUROSCI, V26, P11923, DOI 10.1523/JNEUROSCI.2795-06.2006; Lundvig D, 2005, MOL BRAIN RES, V134, P3, DOI 10.1016/j.molbrainres.2004.09.001; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Magliery TJ, 2005, J AM CHEM SOC, V127, P146, DOI 10.1021/ja046699g; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Necula M, 2003, J BIOL CHEM, V278, P46674, DOI 10.1074/jbc.M308231200; Oakley MG, 1997, BIOCHEMISTRY-US, V36, P2544, DOI 10.1021/bi962391t; Oakley MG, 1998, BIOCHEMISTRY-US, V37, P12603, DOI 10.1021/bi981269m; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pelletier JN, 1999, NAT BIOTECHNOL, V17, P683, DOI 10.1038/10897; Ramakrishnan M, 2006, BIOCHEMISTRY-US, V45, P3386, DOI 10.1021/bi052344d; Rangachari V, 2006, BIOCHEMISTRY-US, V45, P8639, DOI 10.1021/bi060323t; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharma A, 2003, MOL CELL PROTEOMICS, V2, P1217, DOI 10.1074/mcp.M300078-MCP200; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Tjernberg LO, 2002, BIOCHEM J, V366, P343, DOI 10.1042/BJ20020229; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2002, NEUROTOXICOLOGY, V23, P527, DOI 10.1016/S0161-813X(02)00067-0; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	49	9	9	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3165	3174		10.1096/fj.08-108365	http://dx.doi.org/10.1096/fj.08-108365			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18492724	Green Published			2022-12-28	WOS:000258761300009
J	Geiger, BM; Behr, GG; Frank, LE; Caldera-Siu, AD; Beinfeld, MC; Kokkotou, EG; Pothos, EN				Geiger, Brenda M.; Behr, Gerald G.; Frank, Lauren E.; Caldera-Siu, Angela D.; Beinfeld, Margery C.; Kokkotou, Efi G.; Pothos, Emmanuel N.			Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats	FASEB JOURNAL			English	Article						body weight; nucleus accumbens; striatum; prefrontal cortex; vesicular monoamine transporter 2; tyrosine hydroxylase	DECREASES EXTRACELLULAR DOPAMINE; DIET-INDUCED OBESITY; NUCLEUS-ACCUMBENS; QUANTAL SIZE; PREFRONTAL CORTEX; FOOD-DEPRIVATION; WEIGHT-LOSS; OB/OB MICE; NEURONS; REWARD	The association between dietary obesity and mesolimbic systems that regulate hedonic aspects of feeding is currently unresolved. In the present study, we examined differences in baseline and stimulated central dopamine levels in obesity-prone (OP) and obesity-resistant ( OR) rats. OP rats were hyperphagic and showed a 20% weight gain over OR rats at wk 15 of age, when fed a standard chow diet. This phenotype was associated with a 50% reduction in basal extracellular dopamine, as measured by a microdialysis probe in the nucleus accumbens, a projection site of the mesolimbic dopamine system that has been implicated in food reward. Similar defects were also observed in younger animals ( 4 wk old). In electrophysiology studies, electrically evoked dopamine release in slice preparations was significantly attenuated in OP rats, not only in the nucleus accumbens but also in additional terminal sites of dopamine neurons such as the accumbens shell, dorsal striatum, and medial prefrontal cortex, suggesting that there may be a widespread dysfunction in mechanisms regulating dopamine release in this obesity model. Moreover, dopamine impairment in OP rats was apparent at birth and associated with changes in expression of several factors regulating dopamine synthesis and release: vesicular monoamine transporter-2, tyrosine hydroxylase, dopamine transporter, and dopamine receptor-2 short-form. Taken together, these results suggest that an attenuated central dopamine system would reduce the hedonic response associated with feeding and induce compensatory hyperphagia, leading to obesity.	[Geiger, Brenda M.; Behr, Gerald G.; Frank, Lauren E.; Caldera-Siu, Angela D.; Beinfeld, Margery C.; Pothos, Emmanuel N.] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA; [Pothos, Emmanuel N.] Tufts Univ, Sch Med, Program Neurosci, Boston, MA 02111 USA; [Kokkotou, Efi G.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Tufts University; Tufts University; Harvard University; Beth Israel Deaconess Medical Center	Pothos, EN (corresponding author), Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Med & Vet Bldg,Rm 201,136 Harrison Ave, Boston, MA 02111 USA.	emmanuel.pothos@tufts.edu	behr, gerald/R-4996-2019	behr, gerald/0000-0002-2987-0005; Pothos, Emmanuel/0000-0001-8825-7852	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065872, P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA023760] Funding Source: NIH RePORTER; NIDA NIH HHS [DA023760, F31 DA023760] Funding Source: Medline; NIDDK NIH HHS [P30 DK34928, DK065872, R01 DK065872, P30 DK034928] Funding Source: Medline; NINDS NIH HHS [P30 NS047243] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 2002, J NEUROSCI, V22, P10958; Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019; Bassareo V, 1999, EUR J NEUROSCI, V11, P4389, DOI 10.1046/j.1460-9568.1999.00843.x; Berthoud HR, 2008, ANNU REV PSYCHOL, V59, P55, DOI 10.1146/annurev.psych.59.103006.093551; Berthoud HR, 2005, PHYSIOL BEHAV, V85, P1, DOI 10.1016/j.physbeh.2005.04.006; Bina KG, 2000, NEUROENDOCRINOLOGY, V71, P68, DOI 10.1159/000054522; CARROLL ME, 1985, DRUG ALCOHOL DEPEN, V16, P95, DOI 10.1016/0376-8716(85)90109-7; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032; Dijk F, 2004, BRAIN RES, V1026, P194, DOI 10.1016/j.brainres.2004.08.034; Farooqi IS, 2007, SCIENCE, V317, P1355, DOI 10.1126/science.1144599; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; Fulton S, 2006, NEURON, V51, P811, DOI 10.1016/j.neuron.2006.09.006; Harris GC, 2007, BEHAV BRAIN RES, V183, P43, DOI 10.1016/j.bbr.2007.05.025; HERNANDEZ L, 1990, BRAIN RES BULL, V25, P975, DOI 10.1016/0361-9230(90)90197-8; HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1; HERNANDEZ L, 1988, MESOCORTICOLIMBIC DO, P508; Holtje M, 2003, J BIOL CHEM, V278, P15850, DOI 10.1074/jbc.M212816200; Holtje M, 2000, J NEUROSCI, V20, P2131; Hommel JD, 2006, NEURON, V51, P801, DOI 10.1016/j.neuron.2006.08.023; Kelley AE, 2005, PHYSIOL BEHAV, V86, P773, DOI 10.1016/j.physbeh.2005.08.066; Leinninger GM, 2008, ACTA PHYSIOL, V192, P49, DOI 10.1111/j.1748-1716.2007.01784.x; Levin BE, 1997, AM J PHYSIOL-REG I, V273, pR725, DOI 10.1152/ajpregu.1997.273.2.R725; Levin BE, 2002, AM J PHYSIOL-REG I, V283, pR941, DOI 10.1152/ajpregu.00245.2002; MARK GP, 1992, J NEUROCHEM, V58, P2269, DOI 10.1111/j.1471-4159.1992.tb10973.x; Martel P, 1996, PHARMACOL BIOCHEM BE, V53, P221, DOI 10.1016/0091-3057(95)00187-5; Mutch DM, 2006, PLOS GENET, V2, P1956, DOI 10.1371/journal.pgen.0020188; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pothos EN, 1995, OBES RES, V3, pS525, DOI 10.1002/j.1550-8528.1995.tb00222.x; POTHOS EN, 1995, J NEUROSCI, V15, P6640; Pothos EN, 1998, J NEUROSCI, V18, P4106; Pothos EN, 2000, J NEUROSCI, V20, P7297; Pothos EN, 1998, APPETITE, V31, P405, DOI 10.1006/appe.1998.0210; Salamone JD, 2005, CURR OPIN PHARMACOL, V5, P34, DOI 10.1016/j.coph.2004.09.004; Scislowski PWD, 1999, INT J OBESITY, V23, P425, DOI 10.1038/sj.ijo.0800893; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; Walker QD, 2000, NEUROSCIENCE, V95, P1061; Wang GJ, 2001, LANCET, V357, P354, DOI 10.1016/S0140-6736(00)03643-6; YOSHIDA M, 1992, NEUROSCI LETT, V139, P73, DOI 10.1016/0304-3940(92)90861-Z	39	139	140	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2740	2746		10.1096/fj.08-110759	http://dx.doi.org/10.1096/fj.08-110759			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18477764	Green Published			2022-12-28	WOS:000258089300014
J	Perra, A; Simbula, G; Simbula, M; Pibiri, M; Kowalik, MA; Sulas, P; Cocco, MT; Ledda-Columbano, GM; Columbano, A				Perra, Andrea; Simbula, Gabriella; Simbula, Michela; Pibiri, Monica; Kowalik, Marta A.; Sulas, Pia; Cocco, Maria T.; Ledda-Columbano, Giovanna M.; Columbano, Amedeo			Thyroid hormone (T3) and TR beta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats	FASEB JOURNAL			English	Article						hepatic steatosis; choline deficient diet; beta-oxidation	PROLIFERATOR-ACTIVATED RECEPTOR; ACID-BINDING PROTEIN; PPAR-ALPHA; HEPATIC STEATOSIS; HEPATOCYTE PROLIFERATION; UNCOUPLING PROTEIN-3; GENE-EXPRESSION; STEATOHEPATITIS; DEFICIENT; SECRETION	Nonalcoholic fatty liver disease is the most common noninfectious liver disease in clinical practice, and there is an increasing need for new therapeutic approaches for the treatment of this liver disease. Here, we examined the effect of the thyroid hormone triiodothyronine (T3) and the agonist of the thyroid hormone receptor beta isoform (TR beta), GC-1, on fatty liver and steatohepatitis induced in rodents by a choline-methionine deficient (CMD) diet. Male Fischer 344 rats fed a CMD diet for 1 wk developed a marked fatty liver and mild hepatitis. Concurrent administration of T3 resulted in a complete prevention of the fatty change associated with increased fatty acid mitochondrial and peroxisomal beta-oxidation. To investigate whether T3 could also reverse fully established fatty liver, rats were fed a CMD diet for 10 wk and then cofed T3 for 1 wk. Coadministration of T3 resulted in a complete regression of liver steatosis associated with a decrease of lipid peroxidation, cyclooxygenase-2 expression, and activation of phospho-STAT3 and phospho-SAPK/JNK. Finally, additional experiments showed that GC-1, which has no significant side effects on heart rate, prevented and reverted CMD-induced fat accumulation, and ameliorated steatohepatitis. These results indicate that TR agonists have the potential to inhibit or reverse hepatic steatosis induced by a nutritional model.	[Perra, Andrea; Simbula, Gabriella; Simbula, Michela; Pibiri, Monica; Kowalik, Marta A.; Sulas, Pia; Cocco, Maria T.; Ledda-Columbano, Giovanna M.; Columbano, Amedeo] Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, I-09124 Cagliari, Italy	University of Cagliari	Columbano, A (corresponding author), Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, Via Porcell 4, I-09124 Cagliari, Italy.	columbano@unica.it	Simbula, Gabriella/AAN-4390-2020; Columbano, Amedeo/C-7463-2011; simbula, michela/P-6171-2018	Simbula, Gabriella/0000-0003-4946-532X; Columbano, Amedeo/0000-0002-6956-9030; simbula, michela/0000-0002-7473-5494; PIBIRI, MONICA/0000-0002-9660-9616	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; Baskin-Bey ES, 2007, WORLD J GASTROENTERO, V13, P5635, DOI 10.3748/wjg.v13.i42.5635; BASS NM, 1990, MOL CELL BIOCHEM, V98, P167; Baxter JD, 2004, TRENDS ENDOCRIN MET, V15, P154, DOI 10.1016/j.tem.2004.03.008; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; Brown SB, 1997, J BIOL CHEM, V272, P2163, DOI 10.1074/jbc.272.4.2163; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; CASTELLANI LW, 1991, BIOCHIM BIOPHYS ACTA, V1086, P197, DOI 10.1016/0005-2760(91)90008-6; Chiellini G, 1998, CHEM BIOL, V5, P299, DOI 10.1016/S1074-5521(98)90168-5; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; CRABB DW, 2003, TXB GASTROENTEROLOGY, V2, P2415; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; Grover GJ, 2004, ENDOCRINOLOGY, V145, P1656, DOI 10.1210/en.2003-0973; Han XN, 2005, GASTROENTEROLOGY, V129, P185, DOI 10.1053/j.gastro.2005.05.018; Hulbert AJ, 2000, BIOL REV, V75, P519, DOI 10.1017/S146479310000556X; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Ip E, 2004, HEPATOLOGY, V39, P1286, DOI 10.1002/hep.20170; Ip E, 2003, HEPATOLOGY, V38, P123, DOI 10.1053/jhep.2003.50307; Jansen MS, 2000, J BIOL CHEM, V275, P34989, DOI 10.1074/jbc.M001752200; Kawaguchi K, 2004, BIOCHEM BIOPH RES CO, V315, P187, DOI 10.1016/J.BBRC.2004.01.038; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; Koteish A, 2002, BEST PRACT RES CL GA, V16, P679, DOI 10.1053/bega.2002.0332; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Linden D, 2001, J LIPID RES, V42, P1831; Liu HL, 2002, AM J PHYSIOL-GASTR L, V282, pG257, DOI 10.1152/ajpgi.00304.2001; LOMBARDI B, 1968, J LIPID RES, V9, P437; Mangelsdorf David J., 1994, P319; MEIERHEUSLER SC, 1995, MOL CELL ENDOCRINOL, V107, P55, DOI 10.1016/0303-7207(94)03422-P; Mudter J, 2005, AM J GASTROENTEROL, V100, P64, DOI 10.1111/j.1572-0241.2005.40615.x; Nagasawa T, 2006, EUR J PHARMACOL, V536, P182, DOI 10.1016/j.ejphar.2006.02.028; Nagase I, 1999, FEBS LETT, V461, P319, DOI 10.1016/S0014-5793(99)01477-5; Nakatani Y, 2004, J BIOL CHEM, V279, P45803, DOI 10.1074/jbc.M406963200; Newberne P M, 1986, Adv Exp Med Biol, V206, P223; Newberry EP, 2006, HEPATOLOGY, V44, P1191, DOI 10.1002/hep.21369; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com; Rao MS, 2004, HEPATOLOGY, V40, P783, DOI 10.1002/hep.20453; Rao MS, 2002, IN VIVO, V16, P145; Reddy JK, 2006, AM J PHYSIOL-GASTR L, V290, pG852, DOI 10.1152/ajpgi.00521.2005; Reddy JK, 2001, AM J PHYSIOL-GASTR L, V281, pG1333, DOI 10.1152/ajpgi.2001.281.6.G1333; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; Schroeder-Gloeckler JM, 2007, J BIOL CHEM, V282, P15717, DOI 10.1074/jbc.M701329200; SHINOZUKA H, 1978, CANCER RES, V38, P1092; SHINOZUKA H, 1985, NUTRITIONAL PATHOLOG, P279; Spann NJ, 2006, J BIOL CHEM, V281, P33066, DOI 10.1074/jbc.M607148200; TAKEDA T, 1992, BIOCHEM BIOPH RES CO, V185, P211, DOI 10.1016/S0006-291X(05)80977-5; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; Yu J, 2006, HEPATOLOGY, V43, P826, DOI 10.1002/hep.21108; Zafrani ES, 2004, VIRCHOWS ARCH, V444, P3, DOI 10.1007/s00428-003-0943-7; ZEISEL SH, 1990, J NUTR BIOCHEM, V1, P332, DOI 10.1016/0955-2863(90)90001-2; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	55	95	102	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2981	2989		10.1096/fj.08-108464	http://dx.doi.org/10.1096/fj.08-108464			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18434432				2022-12-28	WOS:000258089300038
J	Deshpande, A; Win, KM; Busciglio, J				Deshpande, Atul; Win, Khin May; Busciglio, Jorge			Tau isoform expression and regulation in human cortical neurons	FASEB JOURNAL			English	Article						tauopathy; Alzheimer; phosphorylation; phosphatase; cytoskeleton	PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE 2A; MICROTUBULE-ASSOCIATED PROTEINS; INHERITED DEMENTIA FTDP-17; ALZHEIMERS-DISEASE; MESSENGER-RNA; PHOSPHORYLATION STATE; NEURODEGENERATIVE DISEASES; FUNCTIONAL DIFFERENCES; MONOCLONAL-ANTIBODIES	Differential expression, activity, phosphorylation, and oligomerization of tau play a critical role during neuronal development and in a number of age-related neurodegenerative diseases. An experimental system that accurately models the molecular changes involved in tauopathies, particularly changes in tau isoform activity, requires the expression at physiological levels of the full complement of tau isoforms present in the adult human brain. To this end, we analyzed tau expression in human cortical neurons (HCNs) in culture. Here, we show that the isoform profile of tau in HCNs is similar to that in the adult human brain and that isoform expression is regulated during neuronal development and by cellular substrates. Interestingly, 4R tau exhibited a distinct pattern of expression and subcellular localization, suggesting the presence of specific functional roles for tau isoforms in HCNs. Tau phosphorylation, microtubule binding, and subcellular localization were markedly altered by pharmacological manipulation of tau-directed phosphatase activities, which also induced the appearance of tau oligomeric forms associated with memory loss in animal models of tauopathy. Thus, experimentally induced changes in tau activity and function in HCNs recapitulate critical features of tauopathies that may lead to neuronal dysfunction and degeneration in the human brain.	Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Busciglio, J (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, MH 2205, Irvine, CA 92697 USA.	jbuscigl@uci.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038466] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-38466] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALONSO A, 2006, ALZHEIMERS DEMENT, V2, pS29; ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Baba Y, 2005, BIOORGAN MED CHEM, V13, P5164, DOI 10.1016/j.bmc.2005.05.013; Berger Z, 2007, J NEUROSCI, V27, P3650, DOI 10.1523/JNEUROSCI.0587-07.2007; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; COUCHIE D, 1985, J CELL BIOL, V101, P2095, DOI 10.1083/jcb.101.6.2095; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Davies P, 2000, ANN NY ACAD SCI, V924, P8, DOI 10.1111/j.1749-6632.2000.tb05553.x; de Silva R, 2003, NEUROPATH APPL NEURO, V29, P288, DOI 10.1046/j.1365-2990.2003.00463.x; Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006; DiTella MC, 1996, J CELL SCI, V109, P467; DOTTI CG, 1988, J NEUROSCI, V8, P1454; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Fujino Y, 2005, J NEUROPATH EXP NEUR, V64, P209, DOI 10.1093/jnen/64.3.209; GOEDERT M, 1995, J NEUROCHEM, V65, P2804; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; Grace EA, 2003, J NEUROSCI, V23, P493, DOI 10.1523/JNEUROSCI.23-02-00493.2003; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hall GF, 2000, J CELL SCI, V113, P1373; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ingelsson M, 2006, ACTA NEUROPATHOL, V112, P439, DOI 10.1007/s00401-006-0095-3; Iqbal K, 2006, J ALZHEIMERS DIS, V9, P219; Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558; Kampers T, 1999, FEBS LETT, V451, P39, DOI 10.1016/S0014-5793(99)00522-0; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kins S, 2001, J BIOL CHEM, V276, P38193; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; LI YM, 1993, BIOCHEM PHARMACOL, V46, P1435, DOI 10.1016/0006-2952(93)90109-A; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Makrides V, 2003, J BIOL CHEM, V278, P33298, DOI 10.1074/jbc.M305207200; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; Mills JC, 1998, J CELL SCI, V111, P625; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; Pelsman A, 2003, INT J DEV NEUROSCI, V21, P117, DOI 10.1016/S0736-5748(03)00031-5; PENG I, 1985, BRAIN RES, V361, P200, DOI 10.1016/0006-8993(85)91290-9; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Sennvik K, 2007, FASEB J, V21, P2149, DOI 10.1096/fj.06-7735com; Sergeant N, 2001, HUM MOL GENET, V10, P2143, DOI 10.1093/hmg/10.19.2143; SMITH CJ, 1995, FEBS LETT, V375, P243, DOI 10.1016/0014-5793(95)01221-Y; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017; Takanashi M, 2002, MOL BRAIN RES, V104, P210, DOI 10.1016/S0169-328X(02)00382-0; Thies E, 2007, J NEUROSCI, V27, P2896, DOI 10.1523/JNEUROSCI.4674-06.2007; Utton MA, 2001, J BIOL CHEM, V276, P34288, DOI 10.1074/jbc.M011384200; Vogelsberg-Ragaglia V, 2001, EXP NEUROL, V168, P402, DOI 10.1006/exnr.2001.7630; Wen ZX, 2004, NEURON, V43, P835, DOI 10.1016/j.neuron.2004.08.037; Yasojima K, 1999, BRAIN RES, V831, P301, DOI 10.1016/S0006-8993(99)01486-9; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010	69	31	34	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2357	2367		10.1096/fj.07-096909	http://dx.doi.org/10.1096/fj.07-096909			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263702				2022-12-28	WOS:000257292500028
J	Wagstaff, KM; Fan, JY; De Jesus, MA; Tremethick, DJ; Jans, DA				Wagstaff, Kylie M.; Fan, Jun Y.; De Jesus, Michelle A.; Tremethick, David J.; Jans, David A.			Efficient gene delivery using reconstituted chromatin enhanced for nuclear targeting	FASEB JOURNAL			English	Article						gene therapy; histone; protein transduction; NLS	CELL-PENETRATING PEPTIDES; HIV-1 TAT PROTEIN; LOCALIZATION SEQUENCES; MAMMALIAN-CELLS; PLASMID DNA; IMPORT; TRANSPORT; HISTONES; TRANSDUCTION; RECOGNITION	Nonviral gene delivery is hampered by difficulties associated with transporting negatively charged DNA through the cell membrane and, more importantly, the nuclear envelope of target cells. Here we show for the first time that chromatin reconstituted with histone H2B proteins optimized for nuclear targeting can be used as an efficient means to deliver DNA to the nucleus of intact living mammalian cells, resulting in high levels of transgene expression that were similar to 6-fold more than those achieved by commercial liposomal preparations. The high efficiency is due in part to DNA condensation and protection against degradation in the reconstituted chromatin, as well as its ability to interact with high affinity with the importin proteins of the cellular nuclear import machinery. "Chromofection," gene delivery by protein transduction using chromatin enhanced for nuclear targeting represents an efficient means to deliver DNA to a wide variety of cell types, with the potential to treat complex genetic disorders.	[Wagstaff, Kylie M.; De Jesus, Michelle A.; Jans, David A.] Monash Univ, Dept Biochem & Mol Biol, Nucl Signalling Lab, Clayton, VIC 3800, Australia; [Jans, David A.] Monash Univ, Australian Res Council, Ctr Excellence Biotechnol & Dev, Clayton, VIC 3800, Australia; [Fan, Jun Y.; Tremethick, David J.] Australian Natl Univ, John Curtin Sch Med Res, Chromatin Transcript & Regulat Lab, Canberra, ACT 2601, Australia	Monash University; Monash University; Australian National University; John Curtin School of Medical Research	Jans, DA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Nucl Signalling Lab, Clayton, VIC 3800, Australia.	david.jans@med.monash.edu.au		Jans, David/0000-0001-5115-4745; Wagstaff, Kylie/0000-0003-4791-1410; Tremethick, David/0000-0001-5274-8078				Baake M, 2001, J CELL BIOCHEM, V81, P333, DOI 10.1002/1097-4644(20010501)81:2<333::AID-JCB1048>3.3.CO;2-4; Balicki D, 1997, MOL MED, V3, P782, DOI 10.1007/BF03401715; Balicki D, 2000, P NATL ACAD SCI USA, V97, P11500, DOI 10.1073/pnas.210382997; Balicki D, 2002, P NATL ACAD SCI USA, V99, P7467, DOI 10.1073/pnas.102168299; Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200; Bao YH, 2004, EMBO J, V23, P3314, DOI 10.1038/sj.emboj.7600316; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; Chan CK, 2001, GENE THER, V8, P166, DOI 10.1038/sj.gt.3301366; Demirhan I, 1998, J Hum Virol, V1, P430; DOWTY ME, 1995, P NATL ACAD SCI USA, V92, P4572, DOI 10.1073/pnas.92.10.4572; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510; Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007; Hariton-Gazal E, 2003, J CELL SCI, V116, P4577, DOI 10.1242/jcs.00757; Hashida H, 2004, BRIT J CANCER, V90, P1252, DOI 10.1038/sj.bjc.6601680; Hubner S, 1999, J BIOL CHEM, V274, P22610, DOI 10.1074/jbc.274.32.22610; Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9; Johnson-Saliba M, 2000, FEBS LETT, V467, P169, DOI 10.1016/S0014-5793(00)01142-X; Langer T, 2000, HISTOCHEM CELL BIOL, V113, P455; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Mosammaparast N, 2002, EMBO J, V21, P6527, DOI 10.1093/emboj/cdf647; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Pollard H, 2001, J GENE MED, V3, P153, DOI 10.1002/jgm.160; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Rosenbluh J, 2004, BBA-BIOMEMBRANES, V1664, P230, DOI 10.1016/j.bbamem.2004.06.003; van der Aa MAEM, 2006, PHARM RES-DORDR, V23, P447, DOI 10.1007/s11095-005-9445-4; WAGNER E, 1991, BIOCONJUGATE CHEM, V2, P226, DOI 10.1021/bc00010a006; Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871; Wagstaff KM, 2006, ANAL BIOCHEM, V348, P49, DOI 10.1016/j.ab.2005.10.029; Wagstaff KM, 2005, J FLUORESC, V15, P469, DOI 10.1007/s10895-005-2819-5; Wagstaff KM, 2007, MOL THER, V15, P721, DOI 10.1038/sj.mt.6300093; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997	42	32	32	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2232	2242		10.1096/fj.07-099911	http://dx.doi.org/10.1096/fj.07-099911			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18356302				2022-12-28	WOS:000257292500016
J	Chang, H; Yoshimoto, M; Umeda, K; Iwasa, T; Mizuno, Y; Fukada, S; Yamamoto, H; Motohashi, N; Suzuki, YM; Takeda, S; Heike, T; Nakahata, T				Chang, Hsi; Yoshimoto, Momoko; Umeda, Katsutsugu; Iwasa, Toru; Mizuno, Yuta; Fukada, So-ichiro; Yamamoto, Hiroshi; Motohashi, Norio; Suzuki, Yuko Miyagoe; Takeda, Shin'ichi; Heike, Toshio; Nakahata, Tatsutoshi			Generation of transplantable, functional satellite-like cells from mouse embryonic stem cells	FASEB JOURNAL			English	Article						long-term engraftment; secondary transplantation; high engraftment efficiency; self-renewal	SKELETAL-MUSCLE REGENERATION; DUCHENNE MUSCULAR-DYSTROPHY; MYOGENIC CELLS; EXPRESSION; MYOBLASTS; PAX7; DIFFERENTIATION; RECONSTITUTION; HETEROGENEITY; PURIFICATION	Satellite cells are myogenic stem cells responsible for the postnatal regeneration of skeletal muscle. Here we report the successful in vitro induction of Pax7-positive satellite-like cells from mouse embryonic stem (mES) cells. Embryoid bodies were generated from mES cells and cultured on Matrigel-coated dishes with Dulbecco's modified Eagle medium containing fetal bovine serum and horse serum. Pax7-positive satellite-like cells were enriched by fluorescence-activated cell sorting using a novel anti-satellite cell antibody, SM/C-2.6. SM/C-2.6-positive cells efficiently differentiate into skeletal muscle fibers both in vitro and in vivo. Furthermore, the cells demonstrate satellite cell characteristics such as extensive self-renewal capacity in subsequent muscle injury model, long-term engraftment up to 24 wk, and the ability to be secondarily transplanted with remarkably high engraftment efficiency compared to myoblast transplantation. This is the first report of transplantable, functional satellite-like cells derived from mES cells and will provide a foundation for new therapies for degenerative muscle disorders.-Chang, H., Yoshimoto, M., Umeda, K., Iwasa, T., Mizuno, Y., Fukada, S., Yamamoto, H., Motohashi, N., Yuko-Miyagoe-Suzuki, Takeda, S., Heike, T., Nakahata, T. Generation of transplantable, functional satellite-like cells from mouse embryonic stem cells. FASEB J. 23, 1907-1919 (2009)	[Chang, Hsi; Yoshimoto, Momoko; Umeda, Katsutsugu; Iwasa, Toru; Mizuno, Yuta; Heike, Toshio; Nakahata, Tatsutoshi] Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan; [Yoshimoto, Momoko] Indiana Univ, Sch Med, Wells Ctr Pediat Res, Indianapolis, IN USA; [Fukada, So-ichiro; Yamamoto, Hiroshi] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Osaka, Japan; [Motohashi, Norio; Suzuki, Yuko Miyagoe; Takeda, Shin'ichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Therapy, Tokyo, Japan	Kyoto University; Indiana University System; Indiana University-Purdue University Indianapolis; Osaka University; National Center for Neurology & Psychiatry - Japan	Heike, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, 54 Syogoin Kawahara Cho, Kyoto 6068507, Japan.	heike@kuhp.kyoto-u.ac.jp	Motohashi, Norio/AGE-8809-2022; Yoshimoto, Momoko/N-4238-2014; Yoshimoto, Momoko/AFP-3523-2022; Fukada, So-ichiro/AAI-9151-2020	Motohashi, Norio/0000-0002-8172-4339; Yoshimoto, Momoko/0000-0002-7272-6682; Yoshimoto, Momoko/0000-0002-7272-6682; Fukada, So-ichiro/0000-0003-4051-5108	Scientific Research (S) [19109006]; Ministry of Education, Science, Technology, Sports, and Culture of Japan [18390298]; Grants-in-Aid for Scientific Research [21300149] Funding Source: KAKEN	Scientific Research (S)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Education, Science, Technology, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a Grant-in-Aid for Scientific Research (S) (19109006) and a Grant-in-Aid for Scientific Research (B) (18390298) from the Ministry of Education, Science, Technology, Sports, and Culture of Japan.	Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Darabi R, 2008, NAT MED, V14, P134, DOI 10.1038/nm1705; DEKEL I, 1992, NEW BIOL, V4, P217; Dhawan J, 2005, TRENDS CELL BIOL, V15, P666, DOI 10.1016/j.tcb.2005.10.007; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Fukada S, 2004, EXP CELL RES, V296, P245, DOI 10.1016/j.yexcr.2004.02.018; Fukada S, 2002, J CELL SCI, V115, P1285; Gross JG, 1999, MUSCLE NERVE, V22, P174, DOI 10.1002/(SICI)1097-4598(199902)22:2<174::AID-MUS5>3.0.CO;2-S; Harris JB, 2003, TOXICON, V42, P933, DOI 10.1016/j.toxicon.2003.11.011; HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526; Hashimoto N, 2004, DEVELOPMENT, V131, P5481, DOI 10.1242/dev.01395; Hirsinger E, 2001, DEVELOPMENT, V128, P107; Hollnagel A, 2002, MOL CELL BIOL, V22, P4760, DOI 10.1128/MCB.22.13.4760-4770.2002; Jejurikar SS, 2003, APOPTOSIS, V8, P573, DOI 10.1023/A:1026127307457; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Kiefer JC, 2001, DEV BIOL, V232, P77, DOI 10.1006/dbio.2000.0114; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; Michalak M, 1997, CURR OPIN NEUROL, V10, P436, DOI 10.1097/00019052-199710000-00014; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; MOSS FP, 1971, ANAT REC, V170, P421, DOI 10.1002/ar.1091700405; Nawrotzki R, 1996, TRENDS GENET, V12, P294, DOI 10.1016/0168-9525(96)10033-0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; ROSENBLATT JD, 1995, IN VITRO CELL DEV-AN, V31, P773; SCHULTZ E, 1985, MECH AGEING DEV, V30, P63, DOI 10.1016/0047-6374(85)90059-4; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; SMITH TH, 1993, DEVELOPMENT, V117, P1125; SNOW MH, 1978, CELL TISSUE RES, V186, P535; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; WEBSTER C, 1990, SOMAT CELL MOLEC GEN, V16, P557, DOI 10.1007/BF01233096; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; YAO SN, 1993, J CELL SCI, V105, P957; Yoshimoto M, 2005, STEM CELLS, V23, P610, DOI 10.1634/stemcells.2004-0220; Zammit PS, 2006, J CELL SCI, V119, P1824, DOI 10.1242/jcs.02908	46	64	69	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1907	1919		10.1096/fj.08-123661	http://dx.doi.org/10.1096/fj.08-123661			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19168704	Green Submitted			2022-12-28	WOS:000266652400030
J	Gonzalez-Periz, A; Horrillo, R; Ferre, N; Gronert, K; Dong, B; Moran-Salvador, E; Titos, E; Martinez-Clemente, M; Lopez-Parra, M; Arroyo, V; Claria, J				Gonzalez-Periz, Ana; Horrillo, Raquel; Ferre, Natalia; Gronert, Karsten; Dong, Baiyan; Moran-Salvador, Eva; Titos, Esther; Martinez-Clemente, Marcos; Lopez-Parra, Marta; Arroyo, Vicente; Claria, Joan			Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins	FASEB JOURNAL			English	Article						adiponectin; fatty liver disease; adipose tissue; lipid mediators	FATTY LIVER; DOCOSAHEXAENOIC ACID; ADIPOSE-TISSUE; LIPID MEDIATORS; PPAR-GAMMA; TNF-ALPHA; INFLAMMATION; RESOLUTION; MICE; E1	Omega-3-polyunsaturated fatty acids (omega 3-PUFAs) have well-documented protective effects that are attributed not only to eicosanoid inhibition but also to the formation of novel biologically active lipid mediators (i.e., resolvins and protectins). In this study, we examined their effects on ob/ob mice, an obesity model of insulin resistance and fatty liver disease. Dietary intake of omega-3-PUFAs had insulin-sensitizing actions in adipose tissue and liver and improved insulin tolerance in obese mice. Genes involved in insulin sensitivity (PPAR gamma), glucose transport (GLUT-2/GLUT-4), and insulin receptor signaling (IRS-1/IRS-2) were up-regulated by omega-3-PUFAs. Moreover, omega-3-PUFAs increased adiponectin, an anti-inflammatory and insulin-sensitizing adipokine, and induced AMPK phosphorylation, a fuel-sensing enzyme and a gatekeeper of the energy balance. Concomitantly, hepatic steatosis was alleviated by omega-3-PUFAs. A lipidomic analysis with liquid chromatography/mass spectrometry/mass spectrometry revealed that omega-3-PUFAs inhibited the formation of omega-6-PUFA-derived eicosanoids, while triggering the formation of omega-3-PUFA-derived resolvins and protectins. Moreover, representative members of these lipid mediators, namely resolvin E1 and protectin D1, mimicked the insulin-sensitizing and antisteatotic effects of omega-3-PUFAs and induced adiponectin expression to a similar extent that of rosiglitazone, a member of the thiazolidinedione family of antidiabetic drugs. Taken together, these findings uncover beneficial actions of omega-3-PUFAs and their bioactive lipid autacoids in preventing obesity-induced insulin resistance and hepatic steatosis.-Gonzalez-Periz, A., Horrillo, R., Ferre, N., Gronert, K., Dong, B., Moran-Salvador, E., Titos, E., Martinez-Clemente, M., Lopez-Parra, M., Arroyo, V., Claria, J. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 23, 1946-1957 (2009)	[Gonzalez-Periz, Ana; Horrillo, Raquel; Ferre, Natalia; Moran-Salvador, Eva; Titos, Esther; Martinez-Clemente, Marcos; Lopez-Parra, Marta; Claria, Joan] Univ Barcelona, Dept Biochem & Mol Genet, Inst Invest Biomed August Pi & Sunyer, Barcelona 08036, Spain; [Arroyo, Vicente] Univ Barcelona, Liver Unit, Inst Invest Biomed August Pi & Sunyer, Barcelona 08036, Spain; [Gronert, Karsten; Dong, Baiyan] Univ Calif Berkeley, Sch Optometry, Ctr Eye Dis & Dev, Berkeley, CA 94720 USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of California System; University of California Berkeley	Claria, J (corresponding author), Univ Barcelona, Dept Biochem & Mol Genet, Inst Invest Biomed August Pi & Sunyer, Villarroel 170, Barcelona 08036, Spain.	jclaria@clinic.ub.es	Ferré, Natalia/ABE-5700-2020; Arroyo, Vicente/F-9189-2015; Horrillo, Raquel/B-4348-2009; Titos, Esther/AAA-5394-2019; Claria, Joan/M-7772-2019	Ferré, Natalia/0000-0002-2838-1525; Arroyo, Vicente/0000-0002-2728-1848; Titos, Esther/0000-0002-2543-2243; Claria, Joan/0000-0003-4333-7749	Ministerio de Educacion y Ciencia [SAF 06/03191]; National Eye Institute [EY01613604]; CIBERehd is funded by the Instituto de Salud Carlos III [BES-2004-5054]; Generalitat de Catalunya-European Social Funds [2006FI-00091]	Ministerio de Educacion y Ciencia(Spanish Government); National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); CIBERehd is funded by the Instituto de Salud Carlos III(Instituto de Salud Carlos III); Generalitat de Catalunya-European Social Funds(Generalitat de Catalunya)	This work was supported by a grant from the Ministerio de Educacion y Ciencia (MEC; SAF 06/03191) to J.C. and by a grant from the National Eye Institute (EY01613604) to K.G. CIBERehd is funded by the Instituto de Salud Carlos III. A.G.-P. (BES-2004-5054) was supported by MEC. M. L.- P., E.T., and N.F. had contracts with Instituto de Salud Carlos III, CIBERehd, and MEC Juan de la Cierva, respectively. M.M.-C. (BES- 2007- 16147) and E.M.-S. (AP2007-02004) received fellowships from MEC. R. H. is supported by Generalitat de Catalunya-European Social Funds (2006FI-00091).	Alwayn IPJ, 2005, TRANSPLANTATION, V79, P606, DOI 10.1097/01.TP.0000150023.86487.44; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Arita M, 2007, J IMMUNOL, V178, P3912, DOI 10.4049/jimmunol.178.6.3912; Bozaoglu K, 2007, ENDOCRINOLOGY, V148, P4687, DOI 10.1210/en.2007-0175; Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S; Campbell EL, 2007, FASEB J, V21, P3162, DOI 10.1096/fj.07-8473com; Clark JM, 2002, GASTROENTEROLOGY, V122, P1649, DOI 10.1053/gast.2002.33573; Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; CULP BR, 1979, PROSTAG LEUKOTR ESS, V3, P269, DOI 10.1016/0161-4630(79)90068-5; El-Badry AM, 2007, HEPATOLOGY, V45, P855, DOI 10.1002/hep.21625; Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926; Ginsberg HN, 2006, CELL METAB, V4, P179, DOI 10.1016/j.cmet.2006.08.010; Glass CK, 2006, J CLIN INVEST, V116, P556, DOI 10.1172/JCI27913; Gonzalez-Periz A, 2006, FASEB J, V20, P2537, DOI 10.1096/fj.06-6250fje; Goralski KB, 2007, J BIOL CHEM, V282, P28175, DOI 10.1074/jbc.M700793200; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Gronert K, 1999, METH MOL B, V120, P119; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kamada Y, 2003, GASTROENTEROLOGY, V125, P1796, DOI 10.1053/j.gastro.2003.08.029; Kielar ML, 2003, J AM SOC NEPHROL, V14, P389, DOI 10.1097/01.ASN.0000045047.44107.0B; Levy JR, 2004, HEPATOLOGY, V39, P608, DOI 10.1002/hep.20093; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Lopez-Parra M, 2008, J LIPID RES, V49, P2513, DOI 10.1194/jlr.M800101-JLR200; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Masaki T, 2004, HEPATOLOGY, V40, P177, DOI 10.1002/hep.20282; Masoodi M, 2008, RAPID COMMUN MASS SP, V22, P75, DOI 10.1002/rcm.3331; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Murphy RC, 2005, ANAL BIOCHEM, V346, P1, DOI 10.1016/j.ab.2005.04.042; Nawrocki AR, 2006, J BIOL CHEM, V281, P2654, DOI 10.1074/jbc.M505311200; Qureshi K, 2007, WORLD J GASTROENTERO, V13, P3540, DOI 10.3748/wjg.v13.i26.3540; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Roh SG, 2007, BIOCHEM BIOPH RES CO, V362, P1013, DOI 10.1016/j.bbrc.2007.08.104; Rousseau D, 2003, AM J PHYSIOL-HEART C, V285, pH1294, DOI 10.1152/ajpheart.00651.2002; Rousseau D, 2001, MOL CELL BIOCHEM, V225, P109, DOI 10.1023/A:1012266005428; Sanyal Arun J, 2002, Gastroenterology, V123, P1705, DOI 10.1053/gast.2002.36572; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2007, METHOD ENZYMOL, V432, P275, DOI 10.1016/S0076-6879(07)32012-0; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2004, PROSTAG OTH LIPID M, V73, P155, DOI 10.1016/j.prostaglandins.2004.03.005; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Song BJ, 2008, J HEPATOL, V49, P262, DOI 10.1016/j.jhep.2008.04.023; Song XM, 2002, DIABETOLOGIA, V45, P56, DOI 10.1007/s125-002-8245-8; Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937; Todoric J, 2006, DIABETOLOGIA, V49, P2109, DOI 10.1007/s00125-006-0300-x; Trayhurn P, 2005, ACTA PHYSIOL SCAND, V184, P285, DOI 10.1111/j.1365-201X.2005.01468.x; Werner A, 2005, AM J PHYSIOL-GASTR L, V288, pG1150, DOI 10.1152/ajpgi.00456.2004; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Yamamoto K, 2005, BIOORG MED CHEM LETT, V15, P517, DOI 10.1016/j.bmcl.2004.11.053; Yu YH, 2005, CIRC RES, V96, P1042, DOI 10.1161/01.RES.0000165803.47776.38	55	431	448	3	78	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1946	1957		10.1096/fj.08-125674	http://dx.doi.org/10.1096/fj.08-125674			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19211925	Green Published			2022-12-28	WOS:000266652400033
J	Lee, J; Kannagi, M; Ferrante, RJ; Kowall, NW; Ryu, H				Lee, Junghee; Kannagi, Mari; Ferrante, Robert J.; Kowall, Neil W.; Ryu, Hoon			Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis	FASEB JOURNAL			English	Article						transcription; mitochondria; astrocytes; neurodegeneration; motor neurons	SUPEROXIDE-DISMUTASE GENE; BCL-X(L) EXPRESSION; KAPPA-B; ASTROCYTES; APOPTOSIS; DEATH; MICE; ALS; OVEREXPRESSION; NEURONS	Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterized by selective degeneration of motor neurons and glial activation. Cell-specific transcriptional regulation induced by oxidative stress may contribute to the survival and activation of astrocytes in the face of motor neuron death. In the present study, we demonstrate an age-dependent increase in Bcl-xL and Ets-2 immunoreactivity that correlates with an increase of glial fibrillary acidic protein (GFAP)-positive cells in the ventral horn of the spinal cord in both ALS transgenic mice [mutant SOD1 (G93A)] and affected humans. Chromatin immunoprecipitation (ChIP) analysis verified that Ets-2 preferentially occupies the Ets-2 binding element in the promoter of Bcl-xL in primary astrocytes under oxidative stress conditions as well as in G93A spinal cords. Ets-2 small-interfering RNA down-regulated the transcriptional activity of Bcl-xL. In primary glial cultures, Bcl-xL overexpression and mutant SOD1 (G93A) both conferred resistance to oxidative stress-induced cell death. Our findings suggest that Ets-2 transcription factor activation of Bcl-xL gene may protect glia from constitutive oxidative stress that is thought to be a key mechanism contributing to the pathogenesis of ALS. This survival pathway may contribute to the glial survival and activation seen in the spinal cord of ALS patients.-Lee, J., Kannagi, M., Ferrante, R. J., Kowall, N. W., Ryu, H. Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis. FASEB J. 23, 1739-1749 (2009)	[Lee, Junghee; Ferrante, Robert J.; Kowall, Neil W.; Ryu, Hoon] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Ferrante, Robert J.; Kowall, Neil W.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Ferrante, Robert J.] Boston Univ, Sch Med, Dept Psychol, Boston, MA 02118 USA; [Lee, Junghee; Kowall, Neil W.; Ryu, Hoon] Vet Affairs Boston Hlth Care Syst, Boston, MA USA; [Kannagi, Mari] Tokyo Med & Dent Univ, Dept Immunotherapeut, Tokyo, Japan; [Ferrante, Robert J.] Bedford Vet Affairs Med Ctr, Bedford, MA USA	Boston University; Boston University; Boston University; Tokyo Medical & Dental University (TMDU)	Lee, J (corresponding author), 150 S Huntington Ave, Boston, MA 02130 USA.	junghee@bu.edu; hoonryu@bu.edu	Kowall, Neil/M-5378-2019	Kowall, Neil/0000-0002-6624-0213; Lee, Junghee/0000-0002-9530-9806; Ryu, Hoon/0000-0001-6544-3732	National Institutes of Health (NIH) [NS-52724, P30 AG-13846, NS045242, NS045806]; Department of Veterans Affairs; World Class University; Korea Science and Engineering Foundation (KOSEF); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS045242, R01NS052724, U01NS045806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013846] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); World Class University; Korea Science and Engineering Foundation (KOSEF)(Korea Science and Engineering Foundation); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Cyd Khayter and Oh Kyu Kwon for technical assistance and the preparation of manuscript. J. L. is an awardee of a Les Turner ALS Foundation Grant. This work was supported by National Institutes of Health (NIH) NS-52724 (to H. R.), NIH P30 AG-13846 (to J. L.), NIH NS045242 and NS045806 (to R.J.F.), and a Department of Veterans Affairs (VA) merit grant (to J.L. and N.W.K.). This work was supported in part by a World Class University (WCU) grant from the Korea Science and Engineering Foundation (KOSEF)(to H.R.).	Andersen PM, 2003, AMYOTROPH LATERAL SC, V4, P62, DOI 10.1080/14660820310011700; Barbeito LH, 2004, BRAIN RES REV, V47, P263, DOI 10.1016/j.brainresrev.2004.05.003; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Grillot DAM, 1997, J IMMUNOL, V158, P4750; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Helguera P, 2005, J NEUROSCI, V25, P2295, DOI 10.1523/JNEUROSCI.5107-04.2005; Langley B, 2004, J NEUROSCI RES, V77, P621, DOI 10.1002/jnr.20210; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lee J, 2008, HUM MOL GENET, V17, P1774, DOI 10.1093/hmg/ddn067; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Niebroj-Dobosz I, 2004, FOLIA NEUROPATHOL, V42, P151; Ouyang YB, 2003, J CEREBR BLOOD F MET, V23, P275, DOI 10.1097/01.WCB.0000055774.06337.F6; Ouyang YB, 2002, FREE RADICAL BIO MED, V33, P544, DOI 10.1016/S0891-5849(02)00912-7; Phelka AD, 2006, NEUROTOXICOLOGY, V27, P192, DOI 10.1016/j.neuro.2005.09.006; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ryu H, 2005, P NATL ACAD SCI USA, V102, P13915, DOI 10.1073/pnas.0502878102; Ryu H, 2005, J NEUROCHEM, V93, P1087, DOI 10.1111/j.1471-4159.2005.03077.x; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Sanij E, 2001, BIOCHEM BIOPH RES CO, V287, P1003, DOI 10.1006/bbrc.2001.5680; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Warita H, 2001, MOL BRAIN RES, V89, P147, DOI 10.1016/S0169-328X(01)00029-8; Xu LJ, 1999, ANESTHESIOLOGY, V91, P1036, DOI 10.1097/00000542-199910000-00024; Xu LJ, 1999, NEUROSCI LETT, V277, P193, DOI 10.1016/S0304-3940(99)00882-4; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x	31	36	36	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1739	1749		10.1096/fj.08-121046	http://dx.doi.org/10.1096/fj.08-121046			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19179380	Green Published			2022-12-28	WOS:000266652400014
J	Palermo, A; Doyonnas, R; Bhutani, N; Pomerantz, J; Alkan, O; Blau, HM				Palermo, Adam; Doyonnas, Regis; Bhutani, Nidhi; Pomerantz, Jason; Alkan, Ozan; Blau, Helen M.			Nuclear reprogramming in heterokaryons is rapid, extensive, and bidirectional	FASEB JOURNAL			English	Article						gene expression; time course; microarrays; somatic fate change; balance of regulators	EMBRYONIC STEM-CELLS; GENE-EXPRESSION; SOMATIC-CELLS; DIFFERENTIATED FUNCTIONS; TRANSIENT HETEROKARYONS; ALBUMIN PRODUCTION; MUSCLE GENES; ACTIVATION; HYBRIDS; HYBRIDIZATION	An understanding of nuclear reprogramming is fundamental to the use of cells in regenerative medicine. Due to technological obstacles, the time course and extent of reprogramming of cells following fusion has not been assessed to date. Here, we show that hundreds of genes are activated or repressed within hours of fusion of human keratinocytes and mouse muscle cells in heterokaryons, and extensive changes are observed within 4 days. This study was made possible by the development of a broadly applicable approach, species-specific transcriptome amplification (SSTA), which enables global resolution of transcripts derived from the nuclei of two species, even when the proportions of species-specific transcripts are highly skewed. Remarkably, either phenotype can be dominant; an excess of primary keratinocytes leads to activation of the keratinocyte program in muscle cells and the converse is true when muscle cells are in excess. We conclude that nuclear reprogramming in heterokaryons is rapid, extensive, bidirectional, and dictated by the balance of regulators contributed by the cell types.-Adam Palermo, Regis Doyonnas, Nidhi Bhutani, Jason Pomerantz, Ozan Alkan, Helen M. Blau. Nuclear reprogramming in heterokaryons is rapid, extensive, and bidirectional. FASEB J. 23, 1431-1440 (2009)	[Palermo, Adam; Doyonnas, Regis; Bhutani, Nidhi; Pomerantz, Jason; Alkan, Ozan; Blau, Helen M.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Palermo, Adam; Doyonnas, Regis; Bhutani, Nidhi; Pomerantz, Jason; Alkan, Ozan; Blau, Helen M.] Stanford Univ, Sch Med, Stem Cell Inst, Stanford, CA 94305 USA; [Palermo, Adam] Genzyme Corp, Framingham, MA 01701 USA; [Pomerantz, Jason] Univ Calif San Francisco, Dept Surg, Div Plast & Reconstruct Surg, San Francisco, CA 94143 USA; [Alkan, Ozan] MIT, Broad Inst, Cambridge, MA 02139 USA; [Alkan, Ozan] Harvard Univ, Cambridge, MA 02138 USA	Stanford University; Stanford University; Sanofi-Aventis; Genzyme Corporation; University of California System; University of California San Francisco; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Blau, HM (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, 269 Campus Dr, Stanford, CA 94305 USA.	hblau@stanford.edu		Doyonnas, Regis/0000-0002-3818-0807	National Science Foundation; National Institutes of Health National Research Service Award [AF051678, AG009521, AG020961, AG024987, HD018179]; MDA [MDA4320]; Baxter Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024987, R37AG009521, R01AG009521, R01AG020961] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); National Institutes of Health National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MDA(Muscular Dystrophy Association); Baxter Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Sally Pennypacker and Walt Holleran (Department of Dermatology, University of California, San Francisco, CA, USA) for providing human neonatal foreskin keratinocytes. We are grateful to the members of the H. M. B laboratory for helpful discussions and critical reading of the manuscript. This work was supported by a National Science Foundation fellowship (to A. T. P.); National Institutes of Health National Research Service Award AF051678 (to J.H.P.); NIH grants AG009521, AG020961, AG024987, and HD018179; MDA grant MDA4320; and the Baxter Foundation (to H. M.B).	Adjaye J, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-83; Ambrosi DJ, 2007, STEM CELLS, V25, P1104, DOI 10.1634/stemcells.2006-0532; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CHENCHIK A, 1998, RT PCR METHODS GENE; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; DARLINGTON GJ, 1974, SCIENCE, V185, P859, DOI 10.1126/science.185.4154.859; EPHRUSSI B, 1969, NATURE, V224, P1314, DOI 10.1038/2241314a0; FOUGERE C, 1978, CELL, V15, P843, DOI 10.1016/0092-8674(78)90269-6; Grigoryev DN, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-62; Ji W, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh084; MASHAL RD, 1995, NAT GENET, V9, P177, DOI 10.1038/ng0295-177; Naef F, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni104; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; PAVLATH GK, 1986, J CELL BIOL, V102, P124, DOI 10.1083/jcb.102.1.124; PETERSEN JA, 1972, P NATL ACAD SCI USA, V69, P571, DOI 10.1073/pnas.69.3.571; Silva J, 2006, NATURE, V441, P997, DOI 10.1038/nature04914; SPEAR BT, 1990, MOL CELL BIOL, V10, P5047, DOI 10.1128/MCB.10.10.5047; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Terranova R, 2006, J CELL SCI, V119, P2065, DOI 10.1242/jcs.02945; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WRIGHT WE, 1984, EXP CELL RES, V151, P55, DOI 10.1016/0014-4827(84)90355-0; WRIGHT WE, 1984, J CELL BIOL, V98, P427, DOI 10.1083/jcb.98.2.427; Xu WY, 2001, GENE, V272, P61, DOI 10.1016/S0378-1119(01)00516-9; Zhang F, 2007, P NATL ACAD SCI USA, V104, P4395, DOI 10.1073/pnas.0700181104; Zhu YY, 2001, BIOTECHNIQUES, V30, P892, DOI 10.2144/01304pf02	30	40	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1431	1440		10.1096/fj.08-122903	http://dx.doi.org/10.1096/fj.08-122903			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19141533	Green Published			2022-12-28	WOS:000266651700019
J	Pujal, J; Huch, M; Jose, A; Abasolo, I; Rodolosse, A; Duch, A; Sanchez-Palazon, L; Smith, FJD; McLean, WHI; Fillat, C; Real, FX				Pujal, Judit; Huch, Meritxell; Jose, Anabel; Abasolo, Ibane; Rodolosse, Annie; Duch, Alba; Sanchez-Palazon, Luis; Smith, Frances J. D.; Irwin McLean, W. H.; Fillat, Cristina; Real, Francisco X.			Keratin 7 promoter selectively targets transgene expression to normal and neoplastic pancreatic ductal cells in vitro and in vivo	FASEB JOURNAL			English	Article						cytokeratins; adenovirus; cystic fibrosis; bioluminescent imaging	RECOMBINANT ADENOVIRUS; GENE-TRANSCRIPTION; CANCER; SP1; POTENT; TUMORS; ADENOCARCINOMAS; HEPATOTOXICITY; CYTOKERATINS; PROTEINS	Keratin 7 is expressed in simple epithelia but is expressed at low or undetectable levels in gastrointestinal epithelial cells. In the pancreas, it is present in ductal but not in acinar cells. K7 mRNA is overexpressed in pancreatic cancers. Here we use luciferase reporter assays to analyze the tissue-specific regulatory elements of murine keratin 7 (Krt7) promoter in vitro and in vivo. All elements required for appropriate cell and tissue specificity in reporter assays are present within the Krt7-234 bp sequence. This fragment appears more selective to pancreatic ductal cells than the Krt19 promoter. GC-rich sequences corresponding to putative Sp1, AP-2 binding sites are essential for in vitro activity. Krt7-LacZ transgenic mice were generated to analyze in vivo activity. Sequences located 1.5 or 0.25 kb upstream of the transcription initiation site drive reporter expression to ductal, but not acinar, cells in transgenic mice. LacZ mRNA was detected in the pancreas as well as in additional epithelial tissues such as the intestine and the lung-using both promoter constructs. An AdK7Luc adenovirus was generated to assess targeting selectivity in vivo by intravenous injection to immunocompetent mice and in a xenograft model of pancreatic cancer. The -0.25 kb region showed pancreatic selectivity, high activity in pancreatic cancers, and sustained transgene expression in xenografts. In conclusion, the krt7 promoter is useful to target pancreatic ductal adenocarcinoma cells in vitro and in vivo.-Pujal, J., Huch, M., Jose, A., Abasolo, I., Rodolosse, A., Duch, A., Sanchez-Palazon, L., Smith, F. J. D., McLean, W. H. I., Fillat, C., Real, F. X. Keratin 7 promoter selectively targets transgene expression to normal and neoplastic pancreatic ductal cells in vitro and in vivo. FASEB J. 23, 1366-1375 (2009)	[Huch, Meritxell; Jose, Anabel; Sanchez-Palazon, Luis; Fillat, Cristina] Univ Pompeu Fabra, Ctr Regulacio Genom, Barcelona 08003, Spain; [Pujal, Judit; Abasolo, Ibane; Rodolosse, Annie; Duch, Alba; Real, Francisco X.] Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain; [Rodolosse, Annie; Duch, Alba; Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona 08003, Spain; [Huch, Meritxell; Fillat, Cristina] Ctr Invest Biomed Red Enfermedades Raras, Barcelona, Spain; [Smith, Frances J. D.; Irwin McLean, W. H.] Univ Dundee, Coll Life Sci & Med, Div Mol Med, Epithelial Genet Grp, Dundee, Scotland; [Smith, Frances J. D.; Irwin McLean, W. H.] Univ Dundee, Coll Dent, Dundee, Scotland; [Smith, Frances J. D.; Irwin McLean, W. H.] Univ Dundee, Coll Nursing, Dundee, Scotland; [Real, Francisco X.] Ctr Nacl Invest Oncol, Programa Patol Mol, Madrid, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Dundee; University of Dundee; University of Dundee	Fillat, C (corresponding author), Univ Pompeu Fabra, Ctr Regulacio Genom, Edifici Parc Rec Biomed Barcelona,Carrer Dr Aigua, Barcelona 08003, Spain.	cristina.fillat@crg.es; freal@cnio.es	Fillat, Cristina/ABH-1674-2020; Abasolo, Ibane/H-7741-2012; Arribas, Francisco X Real/H-5275-2015; McLean, William HI/C-6352-2009; Duch, Alba/AGI-1035-2022	Abasolo, Ibane/0000-0001-5970-6276; Arribas, Francisco X Real/0000-0001-9501-498X; Duch, Alba/0000-0001-6041-1360; Fillat, Cristina/0000-0002-0801-3338; McLean, William Henry Irwin/0000-0001-5539-5757	Plan Nacional de I + D [SAF2001-0420, SAF2004-01137, SAF2007-60860]; Accion Especial de Genomica [GEN2001-4748-c05-01]; CIRIT (Generalitat de Catalunya) [SGR-00410]; Marato de TV-3; Biomed Program [QLG-CT-2002-01196]; Spanish Ministry of Education and Science [BIO2005-08682-C03-02]; Generalitat de Catalunya [SGR0500008]; CIBERER; Instituto de Salud Carlos III; Wellcome Trust Senior Research Fellowship in Basic Biomedical Science; Basque government; MRC [G0700314] Funding Source: UKRI; Medical Research Council [G0700314] Funding Source: researchfish	Plan Nacional de I + D; Accion Especial de Genomica; CIRIT (Generalitat de Catalunya)(Generalitat de Catalunya); Marato de TV-3; Biomed Program; Spanish Ministry of Education and Science(Spanish Government); Generalitat de Catalunya(Generalitat de Catalunya); CIBERER; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Wellcome Trust Senior Research Fellowship in Basic Biomedical Science(Wellcome Trust); Basque government(Basque Government); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank all investigators mentioned in the main text and Supplemental Information for providing cells and reagents; members of the Unitat de Biologia Cel.lular i Molecular, IMIM, for valuable contributions; Dr. C. Ciudad (Universitat de Barcelona, Barcelona, Spain) for valuable discussions and reagents; and Drs. M. I. Hernandez-Munoz, A. Skoudy, X. Mayol, and A. Merlos for critical reading of the manuscript. We also thank the Clinical Biochemistry Service of the Veterinary Faculty of the Autonomous University of Barcelona for the determination of serum transaminases. This work was supported, in part, by grants from Plan Nacional de I + D (SAF2001-0420, SAF2004-01137, and SAF2007-60860), Accion Especial de Genomica (GEN2001-4748-c05-01), CIRIT (Generalitat de Catalunya) (SGR-00410), Marato de TV-3, and Biomed Program (QLG-CT-2002-01196) to F.X.R., and grants BIO2005-08682-C03-02 from the Spanish Ministry of Education and Science and SGR0500008 from the Generalitat de Catalunya to C.F. The group of C.F. is also partially funded by CIBERER, Instituto de Salud Carlos III. W.H.I.M. and F.J.D.S. were supported by a Wellcome Trust Senior Research Fellowship in Basic Biomedical Science (to W.H.I.M.). M.H. was a predoctoral fellow (BEFI) at the Instituto de Salud Carlos III. A.J. was supported by a predoctoral fellowship (FPU) granted by the Spanish Ministry of Education and Science. I.A. was supported by a postdoctoral fellowship from the Basque government. The authors declare no conflict of interest.	Adell T, 2000, CELL GROWTH DIFFER, V11, P137; Alemany R, 2001, GENE THER, V8, P1347, DOI 10.1038/sj.gt.3301515; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Brembeck FH, 2003, CANCER RES, V63, P2005; Brembeck FH, 2001, GASTROENTEROLOGY, V120, P1720, DOI 10.1053/gast.2001.24846; Cascante A, 2007, GENE THER, V14, P1471, DOI 10.1038/sj.gt.3303008; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Christ M, 2000, HUM GENE THER, V11, P415, DOI 10.1089/10430340050015888; Goldstein NS, 2001, AM J CLIN PATHOL, V115, P695; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hernandez-Munoz I, 2008, PANCREATOLOGY, V8, P462, DOI 10.1159/000151537; Huch M, 2006, HUM GENE THER, V17, P1187, DOI 10.1089/hum.2006.17.1187; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Kaufman CK, 2002, MOL CELL BIOL, V22, P4293, DOI 10.1128/MCB.22.12.4293-4308.2002; Krishnan M, 2005, FASEB J, V19, P106, DOI 10.1096/fj.05-4551fje; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; Leach SD, 2004, CANCER CELL, V5, P7, DOI 10.1016/S1535-6108(03)00337-4; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Opitz OG, 2000, CANCER RES, V60, P2825; OSBORN M, 1986, LAB INVEST, V55, P497; Owens DW, 2003, BIOESSAYS, V25, P748, DOI 10.1002/bies.10316; Porter RM, 2003, TRENDS GENET, V19, P278, DOI 10.1016/S0168-9525(03)00071-4; Real FX, 2003, GASTROENTEROLOGY, V124, P1958, DOI 10.1016/S0016-5085(03)00389-5; Rodolosse A, 2004, GASTROENTEROLOGY, V127, P937, DOI 10.1053/j.gastro.2004.06.058; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUSSLER MH, 1992, AM J PATHOL, V140, P559; Smith FJD, 2003, AM J CLIN DERMATOL, V4, P347, DOI 10.2165/00128071-200304050-00005; Smith FJD, 2002, BIOCHEM BIOPH RES CO, V297, P818, DOI 10.1016/S0006-291X(02)02288-X; Steward MC, 2005, ANNU REV PHYSIOL, V67, P377, DOI 10.1146/annurev.physiol.67.031103.153247; Strelkov SV, 2003, BIOESSAYS, V25, P243, DOI 10.1002/bies.10246; Tamai Y, 2000, J CELL BIOL, V151, P563, DOI 10.1083/jcb.151.3.563; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; VILA MR, 1995, LAB INVEST, V72, P395; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Yuan P, 2007, CANCER-AM CANCER SOC, V110, P2682, DOI 10.1002/cncr.23092	39	13	13	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1366	1375		10.1096/fj.08-115576	http://dx.doi.org/10.1096/fj.08-115576			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19124560				2022-12-28	WOS:000266651700013
J	Yang, BX; Zhao, D; Verkman, AS				Yang, Baoxue; Zhao, Dan; Verkman, A. S.			Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation	FASEB JOURNAL			English	Article						AQP2; water transport; water channel; transgenic mouse; NDI; polyuria	WATER CHANNEL AQUAPORIN-2; MICE LACKING; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; TARGETING HSP90; COLLECTING DUCT; GENE; TRAFFICKING; AQP2; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN	Mutations in aquaporin-2 (AQP2) that interfere with its cellular processing can produce autosomal recessive nephrogenic diabetes insipidus (NDI). Prior gene knock-in of the human NDI-causing AQP2 mutation T126M produced mutant mice that died by age 7 days. Here, we used a novel "conditional gene knock-in" strategy to generate adult, AQP2-T126M mutant mice. Mice separately heterozygous for floxed wild-type AQP2 and AQP2-T126M were bred to produce hemizygous mice, which following excision of the wild-type AQP2 gene by tamoxifen-induced Cre-recombinase gave AQP2(T126M/-) mice. AQP2(T126M/-) mice were polyuric (9-14 ml urine/day) compared to AQP2(+/+) mice (1.6 ml/day) and had reduced urine osmolality (400 vs. 1800 mosmol). Kidneys of AQP2(T126M/-) mice expressed core-glycosylated AQP2-T126M protein in an endoplasmic reticulum pattern. Screening of candidate protein folding "correctors" in AQP2-T126M-transfected kidney cells showed increased AQP2-T126M plasma membrane expression with the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG). 17-AAG increased urine osmolality in AQP2(T126M/-) mice by > 300 mosmol but had no effect in AQP2(-/-) mice. Kidneys of 17-AAG-treated AQP2(T126M/-) mice showed partial rescue of defective AQP2-T126M cellular processing. Our results establish an adult mouse model of NDI and demonstrate partial restoration of urinary concentration function by a compound currently in clinical trials for other indications. - Yang, B., Zhao, D., Verkman, A. S. Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock- in mouse model of aquaporin-2 mutation. FASEB J. 23, 503-512 (2009)	[Yang, Baoxue] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yang, BX (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.	baoxue.yang@ucsf.edu			U.S. National Institute of Health (NIH) [DK35124, HL59198, EY13574, EB00415, DK72517, HL73856, DK66194]; Research Development Program; Cystic Fibrosis Foundation; American Heart Association [0365027Y]; Polycystic Kidney Disease Foundation [147a2r]; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072517, R01DK035124, R21DK066194, R37DK035124] Funding Source: NIH RePORTER	U.S. National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Development Program; Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); American Heart Association(American Heart Association); Polycystic Kidney Disease Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Liman Qian for mouse breeding and genotype analysis. This work was supported by U.S. National Institute of Health (NIH) grants DK35124, HL59198, EY13574, EB00415, DK72517, and HL73856, and Research Development Program and Drug Discovery grants from the Cystic Fibrosis Foundation (to A.S.V.), NIH grant DK66194, American Heart Association grant 0365027Y and Polycystic Kidney Disease Foundation grant 147a2r (to B.Y.).	Bichet DG, 2006, SEMIN NEPHROL, V26, P224, DOI 10.1016/j.semnephrol.2006.02.004; Boccalandro C, 2004, J AM SOC NEPHROL, V15, P1223, DOI 10.1097/01.ASN.0000125248.85135.43; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; Buck TM, 2004, AM J PHYSIOL-CELL PH, V287, pC1292, DOI 10.1152/ajpcell.00561.2003; Carroll P, 2006, GENET MED, V8, P443, DOI 10.1097/01.gim.0000223554.46981.7a; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Deen PMT, 1997, J AM SOC NEPHROL, V8, P1493; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; Deen PMT, 1998, CURR OPIN NEPHROL HY, V7, P37; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Drysdale MJ, 2006, CURR OPIN DRUG DISC, V9, P483; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; Fujiwara TM, 2005, J AM SOC NEPHROL, V16, P2836, DOI 10.1681/ASN.2005040371; Goji K, 1998, J CLIN ENDOCR METAB, V83, P3205, DOI 10.1210/jc.83.9.3205; Gregersen N, 2006, J INHERIT METAB DIS, V29, P456, DOI 10.1007/s10545-006-0301-4; Hasler U, 2000, J BIOL CHEM, V275, P29011, DOI 10.1074/jbc.M002867200; Jiang CW, 1998, AM J PHYSIOL-CELL PH, V275, pC171, DOI 10.1152/ajpcell.1998.275.1.C171; Kamsteeg EJ, 2000, EXP NEPHROL, V8, P326; Klein JD, 2004, J AM SOC NEPHROL, V15, P1161, DOI 10.1097/01.ASN.0000125617.19799.72; Knoers NVAM, 2001, PEDIATR NEPHROL, V16, P1146, DOI 10.1007/s004670100051; Lloyd DJ, 2005, PLOS GENET, V1, P171, DOI 10.1371/journal.pgen.0010020; Lorenz JN, 2002, J BIOL CHEM, V277, P37871, DOI 10.1074/jbc.M205627200; Lu M, 2002, J BIOL CHEM, V277, P37881, DOI 10.1074/jbc.M206644200; Luheshi LM, 2008, CURR OPIN CHEM BIOL, V12, P25, DOI 10.1016/j.cbpa.2008.02.011; Marr N, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000027355.41663.14; McDill BW, 2006, P NATL ACAD SCI USA, V103, P6952, DOI 10.1073/pnas.0602087103; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Noda Y, 2005, BIOL CELL, V97, P885; Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Rojek A, 2006, P NATL ACAD SCI USA, V103, P6037, DOI 10.1073/pnas.0511324103; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Shen HY, 2005, J BIOL CHEM, V280, P39962, DOI 10.1074/jbc.M505524200; SHI P, 2007, J PHYSL RENAL PHYSL, V292, pF1334; Sohara E, 2006, P NATL ACAD SCI USA, V103, P14217, DOI 10.1073/pnas.0602331103; Solit DB, 2007, CLIN CANCER RES, V13, P1775, DOI 10.1158/1078-0432.CCR-06-1863; Stravopodis DJ, 2007, CURR MED CHEM, V14, P3122, DOI 10.2174/092986707782793925; Sydor JR, 2006, P NATL ACAD SCI USA, V103, P17408, DOI 10.1073/pnas.0608372103; Taldone T, 2008, CURR OPIN PHARMACOL, V8, P370, DOI 10.1016/j.coph.2008.06.015; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Verkman AS, 2008, SEMIN NEPHROL, V28, P217, DOI 10.1016/j.semnephrol.2008.03.004; Yang BX, 2006, AM J PHYSIOL-RENAL, V291, pF465, DOI 10.1152/ajprenal.00494.2005; Yang BX, 2001, J BIOL CHEM, V276, P2775, DOI 10.1074/jbc.M008216200; Yun J, 2000, J CLIN INVEST, V106, P1361, DOI 10.1172/JCI9154	48	35	37	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2009	23	2					503	512		10.1096/fj.08-118422	http://dx.doi.org/10.1096/fj.08-118422			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18854434	Green Published			2022-12-28	WOS:000262892900022
J	Arya, R; Bhattacharya, A; Saini, KS				Arya, Ranjana; Bhattacharya, Alok; Saini, Kulvinder Singh			Dictyostelium discoideum-a promising expression system for the production of eukaryotic proteins	FASEB JOURNAL			English	Review						high-throughput system; recombinant; therapeutic; yield; phosphodiesterase 4D3	GREEN FLUORESCENT PROTEIN; HUMAN FAS LIGAND; GENE-EXPRESSION; RECOMBINANT GLYCOPROTEIN; HOST MODEL; CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-FALCIPARUM; REGULATED EXPRESSION; RANDOM MUTAGENESIS; ESCHERICHIA-COLI	In general, four different expression systems, namely, bacterial, yeast, baculovirus, and mammalian, are widely used for the overproduction of biochemical enzymes and therapeutic proteins. Clearly, bacterial expression systems offer ease of maneuverability with respect to large-scale production of recombinant proteins, while, a baculovirus expression system ensures proper protein modifications, processing, and refolding of complex proteins. Despite these advantages, mammalian cells remain the preferred host for many eukaryotic proteins of pharmaceutical importance, particularly, those requiring post-translational modifications. Recently, the single-celled slime mold, Dictyostelium discoideum (Dd), has emerged as a promising eukaryotic host for the expression of a variety of heterologous recombinant eukaryotic proteins. This organism possesses the complex cellular machinery required for orchestrating post-translational modifications similar to the one observed in higher eukaryotes. This review summarizes the advantages and disadvantages of Dictyostelium as an alternate system compared to other well-established expression systems. The key lessons learned from the expression of human recombinant proteins in this system are reviewed. Also, the strengths, weaknesses, and challenges associated with industrial-scale production of proteins in Dd expression system are discussed.	[Arya, Ranjana] Ranbaxy Labs Ltd, Dept Biotechnol & Bioinformat, R&D 3, Gurgaon 122015, Haryana, India; [Bhattacharya, Alok] Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India	Ranbaxy Laboratories Limited; Jawaharlal Nehru University, New Delhi	Arya, R (corresponding author), Ranbaxy Labs Ltd, Dept Biotechnol & Bioinformat, R&D 3, Sector 18,Udyog Vihar, Gurgaon 122015, Haryana, India.	ranjanaa@mail.jnu.ac.in	Saini, Kulvinder/G-4729-2013		Ranbaxy	Ranbaxy	We thank Dr. Pradip Bhatnagar for financial support and encouragement on the Dictyostelium expression system project at Ranbaxy. We thank Ms. Sudha Naithani for technical assistance on PDE4D3 work. We thank Ms. Saima Aslam, Ms. Chetali Sachdeva, and Ms. Sarada Lekshmi for literature assistance.	Alexander S, 2006, BBA-GEN SUBJECTS, V1760, P301, DOI 10.1016/j.bbagen.2005.11.015; Alibaud L, 2003, BIOTECHNIQUES, V35, P78, DOI 10.2144/03351st03; Andersen DC, 2002, CURR OPIN BIOTECH, V13, P117, DOI 10.1016/S0958-1669(02)00300-2; Arya R, 2008, PROTEIN EXPRES PURIF, V61, P149, DOI 10.1016/j.pep.2008.05.002; Arya Ranjana, 2008, Biotechnology Journal, V3, P938, DOI 10.1002/biot.200700256; Asgari S, 2001, J MOL MICROB BIOTECH, V3, P491; Baez J, 2005, APPL MICROBIOL BIOT, V69, P245, DOI 10.1007/s00253-005-0180-x; Baneyx F, 1999, CURR OPIN BIOTECH, V10, P411, DOI 10.1016/S0958-1669(99)00003-8; Beshay U, 2003, PROCESS BIOCHEM, V38, P1521, DOI 10.1016/S0032-9592(03)00042-6; Blaauw M, 2000, GENE, V252, P71, DOI 10.1016/S0378-1119(00)00227-4; BLUSCH J, 1992, NUCLEIC ACIDS RES, V20, P6235, DOI 10.1093/nar/20.23.6235; Chaumont F, 1997, P NATL ACAD SCI USA, V94, P6202, DOI 10.1073/pnas.94.12.6202; Chen J, 2007, BIOTECHNOL LETT, V29, P859, DOI 10.1007/s10529-007-9341-6; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Chou CP, 2007, APPL MICROBIOL BIOT, V76, P521, DOI 10.1007/s00253-007-1039-0; Chu L, 2001, CURR OPIN BIOTECH, V12, P180, DOI 10.1016/S0958-1669(00)00197-X; Cohen NR, 1996, BIOCHEM J, V315, P971, DOI 10.1042/bj3150971; Condreay JP, 2007, CURR DRUG TARGETS, V8, P1126, DOI 10.2174/138945007782151351; Cubeddu L, 2000, PROTEIN EXPRES PURIF, V19, P335, DOI 10.1006/prep.2000.1269; DINGERMANN T, 1991, APPL MICROBIOL BIOT, V35, P496; DINGERMANN T, 1992, MOL CELL BIOL, V12, P4038, DOI 10.1128/MCB.12.9.4038; Dingermann Theo, 2008, Biotechnology Journal, V3, P90, DOI 10.1002/biot.200700214; DITTRICH W, 1994, BIO-TECHNOL, V12, P614, DOI 10.1038/nbt0694-614; Eichinger L, 2003, CURR GENET, V44, P59, DOI 10.1007/s00294-003-0416-1; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; EMSLIE KR, 1995, J VIROL, V69, P1747, DOI 10.1128/JVI.69.3.1747-1754.1995; Emslie KR, 1995, TRENDS MICROBIOL, V3, P476, DOI 10.1016/S0966-842X(00)89015-0; Escalante R, 2000, INT J DEV BIOL, V44, P819; FASEL N, 1992, GENE, V111, P157, DOI 10.1016/0378-1119(92)90683-G; FEY P, 1995, GENE, V165, P127, DOI 10.1016/0378-1119(95)00430-E; Fischer M, 2004, FEBS LETT, V577, P227, DOI 10.1016/j.febslet.2004.09.084; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; FREEZE HH, 1995, BIOCHEM BIOPH RES CO, V208, P384, DOI 10.1006/bbrc.1995.1349; Froquet R, 2007, APPL ENVIRON MICROB, V73, P5657, DOI 10.1128/AEM.00908-07; Fuchs BB, 2006, CURR OPIN MICROBIOL, V9, P346, DOI 10.1016/j.mib.2006.06.004; Gaudet P, 2007, NAT PROTOC, V2, P1317, DOI 10.1038/nprot.2007.179; Gaudet P, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.2.e5; Geisse S, 1996, PROTEIN EXPRES PURIF, V8, P271, DOI 10.1006/prep.1996.0101; GELLISSEN G, 2005, NOVEL MICROBIAL EUKA; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.biochem.56.1.853; Gerngross TU, 2004, NAT BIOTECHNOL, V22, P1409, DOI 10.1038/nbt1028; Golstein P, 2003, NAT REV MOL CELL BIO, V4, P798, DOI 10.1038/nrm1224; Guerin NA, 2002, J MUSCLE RES CELL M, V23, P597, DOI 10.1023/A:1024494704863; Hamilton SR, 2003, SCIENCE, V301, P1244, DOI 10.1126/science.1088166; Han SI, 2004, PROCESS BIOCHEM, V39, P925, DOI 10.1016/S0032-9592(03)00215-2; Han SI, 2004, PROCESS BIOCHEM, V39, P585, DOI 10.1016/S0032-9592(03)00122-5; Hartley JL, 2006, CURR OPIN BIOTECH, V17, P359, DOI 10.1016/j.copbio.2006.06.011; Heikoop JC, 1998, EUR J BIOCHEM, V256, P359, DOI 10.1046/j.1432-1327.1998.2560359.x; Henry D H, 1995, Curr Opin Hematol, V2, P118; HITZEMAN RA, 1990, METHOD ENZYMOL, V185, P421; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; Hu YC, 2008, EXPERT REV VACCINES, V7, P363, DOI 10.1586/14760584.7.3.363; Hunt I, 2005, PROTEIN EXPRES PURIF, V40, P1, DOI 10.1016/j.pep.2004.10.018; Ikonomou L, 2003, APPL MICROBIOL BIOT, V62, P1, DOI 10.1007/s00253-003-1223-9; Jonasson P, 2002, BIOTECHNOL APPL BIOC, V35, P91, DOI 10.1042/BA20010099; Jorio H, 2006, BIOTECHNOL PROGR, V22, P319, DOI 10.1021/bp050218v; Jung E, 1998, EUR J BIOCHEM, V253, P517, DOI 10.1046/j.1432-1327.1998.2530517.x; Jung E, 1997, BIOTECHNOL APPL BIOC, V25, P3, DOI 10.1111/j.1470-8744.1997.tb00407.x; Kay RR, 2002, CURR OPIN MICROBIOL, V5, P575, DOI 10.1016/S1369-5274(02)00375-2; Kim JY, 1997, J BIOL CHEM, V272, P2060; Kliche W, 2001, EMBO J, V20, P40, DOI 10.1093/emboj/20.1.40; Knetsch MLW, 2002, J MUSCLE RES CELL M, V23, P605, DOI 10.1023/A:1024498805771; Kollmar M, 2006, INT J BIOL MACROMOL, V39, P37, DOI 10.1016/j.ijbiomac.2006.01.005; Kost TA, 2005, NAT BIOTECHNOL, V23, P567, DOI 10.1038/nbt1095; Kreppel L, 2002, NUCLEIC ACIDS RES, V30, P84, DOI 10.1093/nar/30.1.84; Kuwayama H, 2008, J BIOTECHNOL, V133, P418, DOI 10.1016/j.jbiotec.2007.11.002; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; Linskens MHK, 1999, FASEB J, V13, P639, DOI 10.1096/fasebj.13.6.639; Lu YH, 2004, J BIOTECHNOL, V108, P243, DOI 10.1016/j.jbiotec.2003.12.006; Lu YH, 2004, APPL MICROBIOL BIOT, V65, P547, DOI 10.1007/s00253-004-1620-8; Lu YH, 2004, PROCESS BIOCHEM, V39, P1859, DOI 10.1016/j.procbio.2003.09.012; Lu YH, 2008, WORLD J MICROB BIOT, V24, P491, DOI 10.1007/s11274-007-9498-0; Mahmoud K., 2007, RES J CELL MOL BIOL, V1, P9; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; Meima ME, 2007, PROTEIN EXPRES PURIF, V53, P283, DOI 10.1016/j.pep.2007.01.001; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; Pang KM, 2001, GENE, V277, P187, DOI 10.1016/S0378-1119(01)00687-4; PATTERSON RM, 1995, ENVIRON HEALTH PERSP, V103, P756, DOI 10.2307/3432869; Pijlman GP, 2006, J BIOTECHNOL, V123, P13, DOI 10.1016/j.jbiotec.2005.10.022; Pukatzki S, 2006, P NATL ACAD SCI USA, V103, P1528, DOI 10.1073/pnas.0510322103; Purnapatre K, 2008, CANCER LETT, V259, P1, DOI 10.1016/j.canlet.2007.10.024; Rai M, 2001, CURR SCI INDIA, V80, P1121; REYMOND CD, 1995, J BIOL CHEM, V270, P12941, DOI 10.1074/jbc.270.21.12941; Sa JM, 2006, MOL BIOCHEM PARASIT, V150, P219, DOI 10.1016/j.molbiopara.2006.08.006; Sahdev S, 2008, MOL CELL BIOCHEM, V307, P249, DOI 10.1007/s11010-007-9603-6; SHARKEY DJ, 1991, J BIOL CHEM, V266, P18485; Slade MB, 1997, BIOTECHNOL GENET ENG, V14, P1; Sorensen HP, 2005, MICROB CELL FACT, V4, DOI 10.1186/1475-2859-4-1; Steinert M, 2005, CELL MICROBIOL, V7, P307, DOI 10.1111/j.1462-5822.2005.00493.x; Steinert M, 2003, INT J MED MICROBIOL, V293, P321, DOI 10.1078/1438-4221-00275; Stephan M, 2003, PROCESS BIOCHEM, V39, P333, DOI 10.1016/S0032-9592(03)00085-2; Sugden CJ, 2005, BIOCHEM BIOPH RES CO, V334, P555, DOI 10.1016/j.bbrc.2005.06.117; Swartz JR, 2001, CURR OPIN BIOTECH, V12, P195, DOI 10.1016/S0958-1669(00)00199-3; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; Terpe K, 2003, APPL MICROBIOL BIOT, V60, P523, DOI 10.1007/s00253-002-1158-6; van Bemmelen MX, 2000, MOL BIOCHEM PARASIT, V111, P377, DOI 10.1016/S0166-6851(00)00330-3; Van Driessche N, 2007, P NATL ACAD SCI USA, V104, P15406, DOI 10.1073/pnas.0705996104; Varki A., 1999, ESSENTIALS GLYCOBIOL; Vats B, 2007, WORLD J MICROB BIOT, V23, P1511, DOI 10.1007/s11274-007-9395-6; Vervoort EB, 2000, NUCLEIC ACIDS RES, V28, P2069, DOI 10.1093/nar/28.10.2069; VOITH G, 1995, BIO-TECHNOL, V13, P1225, DOI 10.1038/nbt1195-1225; WARRICK HM, 1988, NUCLEIC ACIDS RES, V16, P6617, DOI 10.1093/nar/16.14.6617; Werten MWT, 1999, YEAST, V15, P1087, DOI 10.1002/(SICI)1097-0061(199908)15:11<1087::AID-YEA436>3.0.CO;2-F; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; Wildt S, 2005, NAT REV MICROBIOL, V3, P119, DOI 10.1038/nrmicro1087; WILLIAMS KL, 1995, CURR OPIN BIOTECH, V6, P538, DOI 10.1016/0958-1669(95)80089-1; Williams RSB, 2006, TRENDS MOL MED, V12, P415, DOI 10.1016/j.molmed.2006.07.003; Wurm F, 1999, CURR OPIN BIOTECH, V10, P156, DOI 10.1016/S0958-1669(99)80027-5; Zhou X, 1999, J MEMBRANE BIOL, V167, P19, DOI 10.1007/s002329900467; ZHOUCHOU T, 1995, J BIOTECHNOL, V38, P137, DOI 10.1016/0168-1656(94)00127-X	113	21	23	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4055	4066		10.1096/fj.08-110544	http://dx.doi.org/10.1096/fj.08-110544			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18714070				2022-12-28	WOS:000261254800004
J	Singh, R; Tian, BW; Kostarelos, K				Singh, Ravi; Tian, Bowen; Kostarelos, Kostas			Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo	FASEB JOURNAL			English	Article						gene therapy; liposome; cancer; nanoengineering; immunology; nanomedicine	POLYMER-COATED ADENOVIRUS; MEDIATED GENE-TRANSFER; CATIONIC LIPOSOMES; NEUTRALIZING ANTIBODY; TRANSGENE EXPRESSION; CIRCULATION TIME; SURFACE-CHARGE; VECTORS; CANCER; CELLS	Recombinant adenovirus (Ad) is a powerful tool in gene therapy. However, the ability to deliver Ad by systemic administration is limited due to rapid clearance from blood circulation, transfection of nontarget tissues, toxicity, and immunogenicity. To address these limitations, we developed an artificially enveloped Ad vector prepared by self-assembly of lipid bilayers around the Ad capsid. The physicochemical and structural features of the enveloped Ad vector can be altered according to the type of lipid used without the need for genetic modification or conjugation chemistry. Here we engineered 4 different types of artificially enveloped Ad using cationic, neutral, fusogenic, and PEGylated lipids to form the envelopes and obtained extended blood circulation times following i.v. administration and reduced vector immunogenicity. Moreover, the PEGylated lipid-enveloped Ad was capable of specifically delivering genes via the systemic circulation to solid tumors subcutaneously implanted in the absence of high levels of gene transfer to the liver and spleen. This provides the basis for the development of a novel vector platform for systemic delivery of Ad to disseminated targets. Furthermore, the artificial envelopment of Ad presented herein is an illustration of a general strategy to modulate the biological function of nonenveloped viruses and may have implications broader than gene therapy.	[Singh, Ravi; Tian, Bowen; Kostarelos, Kostas] Univ London, Sch Pharm, Ctr Drug Delivery Res, Nanomed Lab, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Kostarelos, K (corresponding author), Univ London, Sch Pharm, Ctr Drug Delivery Res, Nanomed Lab, 29-39 Brunswick Sq, London WC1N 1AX, England.	kostas.kostarelos@pharmacy.ac.uk	Kostarelos, Kostas/AAP-6879-2021; Singh, Ravi/B-1221-2010; Singh, Ravi N/A-5740-2011	Kostarelos, Kostas/0000-0002-2224-6672; Singh, Ravi N/0000-0003-0750-1804				Alemany R, 2000, J GEN VIROL, V81, P2605, DOI 10.1099/0022-1317-81-11-2605; Alemany R, 1999, EXP CELL RES, V252, P1, DOI 10.1006/excr.1999.4623; Anklesaria P, 2000, CURR OPIN MOL THER, V2, P426; Arulsudar N, 2003, J DRUG TARGET, V11, P187, DOI 10.1080/10611860310001615415; Bauerschmitz GJ, 2002, INT J ONCOL, V21, P1161; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Brandao JG, 2003, VACCINE, V21, P2268, DOI 10.1016/S0264-410X(03)00050-1; Campbell RB, 2002, CANCER RES, V62, P6831; Chen MY, 2005, J NEUROSURG, V103, P311, DOI 10.3171/jns.2005.103.2.0311; Chuah Marinee K. L., 2003, Current Gene Therapy, V3, P527, DOI 10.2174/1566523034578140; Clark PR, 1999, CANCER GENE THER, V6, P437, DOI 10.1038/sj.cgt.7700074; Croyle MA, 2002, HUM GENE THER, V13, P1887, DOI 10.1089/104303402760372972; de Chermont QL, 2007, P NATL ACAD SCI USA, V104, P9266, DOI 10.1073/pnas.0702427104; Dechecchi MC, 2001, J VIROL, V75, P8772, DOI 10.1128/JVI.75.18.8772-8780.2001; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Fang BL, 2003, CURR OPIN MOL THER, V5, P475; Fasbender A, 1997, J BIOL CHEM, V272, P6479, DOI 10.1074/jbc.272.10.6479; Fisher KD, 2001, GENE THER, V8, P341, DOI 10.1038/sj.gt.3301389; Fisher KD, 2007, J DRUG TARGET, V15, P546, DOI 10.1080/10611860701501014; Fukuhara H, 2003, ORAL ONCOL, V39, P601, DOI 10.1016/S1368-8375(03)00047-2; Gabizon AA, 2006, J LIPOSOME RES, V16, P175, DOI 10.1080/08982100600848769; Gomez-Navarro J, 2000, Lancet Oncol, V1, P148, DOI 10.1016/S1470-2045(00)00030-9; Green NK, 2004, GENE THER, V11, P1256, DOI 10.1038/sj.gt.3302295; Green NK, 2002, CANCER GENE THER, V9, P1036, DOI 10.1038/sj.cgt.7700541; Hama S, 2006, MOL THER, V13, P786, DOI 10.1016/j.ymthe.2005.10.007; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Huang YZ, 2005, BIOL PHARM BULL, V28, P387, DOI 10.1248/bpb.28.387; Jain RK, 2001, ADV DRUG DELIVER REV, V46, P149, DOI 10.1016/S0169-409X(00)00131-9; Kanerva A, 2004, INT J CANCER, V110, P475, DOI 10.1002/ijc.20129; Kim J, 2002, J VIROL, V76, P1892, DOI 10.1128/JVI.76.4.1892-1903.2002; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; KRAMP WJ, 1979, INFECT IMMUN, V25, P771, DOI 10.1128/IAI.25.2.771-773.1979; Krasnici S, 2003, INT J CANCER, V105, P561, DOI 10.1002/ijc.11108; Kunisawa J, 2005, J CONTROL RELEASE, V105, P344, DOI 10.1016/j.jconrel.2005.03.020; Lee EM, 2004, J CANCER RES CLIN, V130, P169, DOI 10.1007/s00432-003-0521-z; Lee SG, 2000, CANCER GENE THER, V7, P1329, DOI 10.1038/sj.cgt.0236; Levchenko TS, 2002, INT J PHARMACEUT, V240, P95, DOI 10.1016/S0378-5173(02)00129-1; Litzinger DC, 1996, BBA-BIOMEMBRANES, V1281, P139, DOI 10.1016/0005-2736(95)00268-5; Ma Z, 2002, GENE THER, V9, P176, DOI 10.1038/sj.gt.3301636; Martin K, 2003, MOL THER, V8, P485, DOI 10.1016/S1525-0016(03)00182-5; MeunierDurmort C, 1997, BBA-BIOMEMBRANES, V1330, P8, DOI 10.1016/S0005-2736(97)00133-8; Morral N, 2002, HUM GENE THER, V13, P143, DOI 10.1089/10430340152712692; Moura SP, 2005, LANGMUIR, V21, P10160, DOI 10.1021/la0504614; Ni SH, 2005, HUM GENE THER, V16, P664, DOI 10.1089/hum.2005.16.664; O'Riordan CR, 1999, HUM GENE THER, V10, P1349, DOI 10.1089/10430349950018021; Parker AL, 2005, J DRUG TARGET, V13, P39, DOI 10.1080/10611860400020449; Pearce OMT, 2005, ANGEW CHEM INT EDIT, V44, P1057, DOI 10.1002/anie.200461832; Qiu CB, 1998, HUM GENE THER, V9, P507, DOI 10.1089/hum.1998.9.4-507; RICHARDSON VJ, 1978, J NUCL MED, V19, P1049; Rivera AA, 2004, GENE THER, V11, P1694, DOI 10.1038/sj.gt.3302346; Roux E, 2004, J CONTROL RELEASE, V94, P447, DOI 10.1016/j.jconrel.2003.10.024; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Shayakhmetov DM, 2005, J VIROL, V79, P1053, DOI 10.1128/JVI.79.2.1053-1061.2005; Singh R, 2008, ACS NANO, V2, P1040, DOI 10.1021/nn8000565; Snoeys J, 2006, MOL THER, V13, P98, DOI 10.1016/j.ymthe.2005.06.477; Steel JC, 2007, EUR J PHARM SCI, V30, P398, DOI 10.1016/j.ejps.2006.12.004; Steel JC, 2005, J VIROL METHODS, V126, P31, DOI 10.1016/j.jviromet.2005.01.017; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Waddington SN, 2008, CELL, V132, P397, DOI 10.1016/j.cell.2008.01.016; Weissig V, 1998, PHARMACEUT RES, V15, P1552, DOI 10.1023/A:1011951016118; Wickham TJ, 2000, GENE THER, V7, P110, DOI 10.1038/sj.gt.3301115; Wolff G, 1997, J VIROL, V71, P624, DOI 10.1128/JVI.71.1.624-629.1997; Worgall S, 1997, HUM GENE THER, V8, P1675, DOI 10.1089/hum.1997.8.14-1675; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; Wu HJ, 2002, HUM GENE THER, V13, P1647, DOI 10.1089/10430340260201734; Yamashita M, 2007, INT J CANCER, V121, P1690, DOI 10.1002/ijc.22852; Yotnda P, 2002, MOL THER, V5, P233, DOI 10.1006/mthe.2002.0545; YUAN F, 1995, CANCER RES, V55, P3752	68	39	41	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3389	3402		10.1096/fj.08-103275	http://dx.doi.org/10.1096/fj.08-103275			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18556649				2022-12-28	WOS:000258761300031
J	Kirschner, KM; Hagen, P; Hussels, CS; Ballmaier, M; Scholz, H; Dame, C				Kirschner, Karin M.; Hagen, Patricia; Hussels, Christiane S.; Ballmaier, Matthias; Scholz, Holger; Dame, Christof			The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells	FASEB JOURNAL			English	Article						erythropoiesis; colony-forming; unit-erythroid; gene expression; development; oncogene	GENE WT1; SUBNUCLEAR LOCALIZATION; FUNCTIONAL INTERACTION; REGULATED EXPRESSION; EPO RECEPTOR; HUMAN FETAL; GATA-1; DIFFERENTIATION; LIVER; DISRUPTION	The Wilms' tumor protein Wt1 is required for embryonic development and has been implicated in hematologic disorders. Since Wt1 deficiency may compromise the proliferation and differentiation of erythroid progenitor cells, we analyzed the possible role of the transcriptionally active Wt1 isoform, Wt1(- KTS), in regulating the expression of the erythropoietin receptor (EpoR). Wt1 and EpoR were coexpressed in CD117(+) hematopoietic progenitor cells and in several hematopoietic cell lines. CD117(+) cells of Wt1-deficient murine embryos (Wt1(-/-)) exhibited a significantly lower proliferation response to recombinant erythropoietin than CD117(+) cells of heterozygous (Wt1(+/-)) and wild-type littermates (Wt1(+/+)). EpoR expression was significantly diminished in hematopoietic progenitors ( CD117(+)) that lacked Wt1, and the erythroid colony-forming capacity was reduced by more than 50% in fetal liver cells of Wt1-deficient embryonic mice. Wt1(- KTS) significantly increased endogenous EpoR transcripts in transfected cells. The proximal EpoR promoter of human and mouse was stimulated more than 10-fold by Wt1(- KTS) in transiently cotransfeced K562 erythroleukemia cells. A responsible cis-element, which is highly conserved in the EpoR promoter of human and mouse, was identified by mutation analysis, electrophoretic mobility shift assay, and chromatin immunoprecipitation assay. In conclusion, activation of the EpoR gene by Wt1 may represent an important mechanism in normal hematopoiesis.	[Hussels, Christiane S.; Dame, Christof] Charite, Dept Neonatol, Campus Virchow Klinikum, D-13353 Berlin, Germany; [Kirschner, Karin M.; Hagen, Patricia; Scholz, Holger] Charite, Inst Vegetat Physiol, Campus Virchow Klinikum, D-13353 Berlin, Germany; [Ballmaier, Matthias] Hannover Med Sch, Dept Pediat Hematol, D-30623 Hannover, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School	Dame, C (corresponding author), Charite, Dept Neonatol, Campus Virchow Klinikum, Augustenburger Pl 1, D-13353 Berlin, Germany.	christof.dame@charite.de	Ballmaier, Matthias/J-4175-2014	Ballmaier, Matthias/0000-0002-1352-5995; Kirschner, Karin/0000-0003-0226-8636; Krause, Patricia/0000-0001-9063-0556				Alberta JA, 2003, BLOOD, V101, P2570, DOI 10.1182/blood-2002-06-1656; Baird PN, 1997, EXP HEMATOL, V25, P312; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; Brown WM, 2007, STEM CELLS, V25, P718, DOI 10.1634/stemcells.2006-0687; Chen D, 2001, EXP HEMATOL, V29, P971, DOI 10.1016/S0301-472X(01)00670-1; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; Dame C, 1998, BLOOD, V92, P3218, DOI 10.1182/blood.V92.9.3218; Dame C, 2003, MIL DRUG TH, P35; Dame C, 2002, BRIT J HAEMATOL, V119, P510, DOI 10.1046/j.1365-2141.2002.03816.x; Dame C, 2006, BLOOD, V107, P4282, DOI 10.1182/blood-2005-07-2889; Dan YY, 2006, P NATL ACAD SCI USA, V103, P9912, DOI 10.1073/pnas.0603824103; Elliott S, 2006, BLOOD, V107, P1892, DOI 10.1182/blood-2005-10-4066; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Fandrey J, 2006, CARDIOVASC RES, V72, P1, DOI 10.1016/j.cardiores.2006.07.024; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Hosen N, 2002, BRIT J HAEMATOL, V116, P409, DOI 10.1046/j.1365-2141.2002.03261.x; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; King-Underwood L, 2005, LEUKEMIA RES, V29, P803, DOI 10.1016/j.leukres.2004.11.020; Kirkeby A, 2007, J NEUROSCI METH, V164, P50, DOI 10.1016/j.jneumeth.2007.03.026; Komatsu N, 1997, BLOOD, V89, P1182, DOI 10.1182/blood.V89.4.1182; KOMATSU N, 1993, CANCER RES, V53, P1156; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; LEONARD M, 1993, BLOOD, V82, P1071; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Loeb DM, 2003, LEUKEMIA, V17, P965, DOI 10.1038/sj.leu.2402906; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAOUCHE L, 1994, NUCLEIC ACIDS RES, V22, P338, DOI 10.1093/nar/22.3.338; Maurer U, 1997, EXP HEMATOL, V25, P945; MIGLIACCIO AR, 1993, BLOOD, V82, P3760; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; Minguet S, 2003, J CLIN INVEST, V112, P1152, DOI 10.1172/JCI200317409; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; Svedberg H, 2001, LEUKEMIA, V15, P1914, DOI 10.1038/sj.leu.2402303; Wagner KD, 2003, FASEB J, V17, P1364, DOI 10.1096/fj.02-1065fje; Wagner KD, 2001, J AM SOC NEPHROL, V12, P1188, DOI 10.1681/ASN.V1261188; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wagner N, 2005, DEVELOPMENT, V132, P1327, DOI 10.1242/dev.01682; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; Zhang XH, 1997, J BIOL CHEM, V272, P29272, DOI 10.1074/jbc.272.46.29272; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	57	19	19	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2690	2701		10.1096/fj.07-097576	http://dx.doi.org/10.1096/fj.07-097576			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18424770				2022-12-28	WOS:000258089300009
J	Edirisinghe, I; Yang, SR; Yao, H; Rajendrasozhan, S; Caito, S; Adenuga, D; Wong, C; Rahman, A; Phipps, RP; Jin, ZG; Rahman, I				Edirisinghe, Indika; Yang, Se-Ran; Yao, Hongwei; Rajendrasozhan, Saravanan; Caito, Samuel; Adenuga, David; Wong, Chelsea; Rahman, Arshad; Phipps, Richard P.; Jin, Zheng-Gen; Rahman, Irfan			VEGFR-2 inhibition augments cigarette smoke-induced oxidative stress and inflammatory responses leading to endothelial dysfunction	FASEB JOURNAL			English	Article						oxidants; eNOS; angiogenesis	NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; PROINFLAMMATORY CYTOKINE RELEASE; GROWTH-FACTOR; IN-VITRO; PULMONARY-HYPERTENSION; INDUCED EMPHYSEMA; NAD(P)H OXIDASE; RAT LUNGS; RECEPTOR	Vascular endothelial growth factor (VEGF) induces phosphorylation of VEGF receptor-2 (VEGFR-2) and activates the downstream signaling pathway resulting in endothelial cell migration, proliferation, and survival. Cigarette smoking is associated with abnormal vascular and endothelial function, leading to airspace enlargement. Herein, we investigated the mechanism of cigarette smoke (CS) -induced endothelial dysfunction by studying the VEGF-VEGFR-2 signaling in mouse lung and human endothelial cells. CS exposure caused oxidative stress, as shown by increased levels of 4-hydroxy-2-nonenal-adducts in mouse lung and reactive oxygen species generation in human lung microvascular endothelial cells (HMVEC-Ls). Inhibition of VEGFR-2 by a specific kinase inhibitor (NVP-AAD777) enhanced the CS-induced oxidative stress, causing augmented inflammatory cell influx and proinflammatory mediators release in mouse lung. The levels of endothelial nitric oxide synthase (eNOS) and phosphorylated (p) -eNOS in the lungs of mice exposed to CS and/or treated with VEGFR-2 inhibitor were decreased. CS down-regulated VEGFR-2 expression, eNOS levels, and VEGF-induced VEGFR-2 phosphorylation in HMVEC-Ls, resulting in impaired VEGF-induced endothelial cell migration and angiogenesis. Overall, these data show that inhibition of VEGFR-2 augmented CS-induced oxidative stress and inflammatory responses leading to endothelial dysfunction. This explains the mechanism of endothelial dysfunction in smokers and has implications in understanding the pathogenesis of pulmonary and cardiovascular diseases.	[Edirisinghe, Indika; Yang, Se-Ran; Yao, Hongwei; Rajendrasozhan, Saravanan; Caito, Samuel; Adenuga, David; Phipps, Richard P.; Rahman, Irfan] Univ Rochester, Dept Environm Med, Lung Biol & Dis Program, Med Ctr, Rochester, NY 14642 USA; [Wong, Chelsea; Jin, Zheng-Gen] Univ Rochester, Med Ctr, Cardiovasc Res Inst, Rochester, NY 14642 USA; [Wong, Chelsea; Jin, Zheng-Gen] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; [Rahman, Arshad] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Rahman, I (corresponding author), Univ Rochester, Dept Environm Med, Lung Biol & Dis Program, Med Ctr, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.	irfan_rahman@urmc.rochester.edu	Yao, Hongwei/G-6444-2010; Rajendrasozhan, Saravanan/ABC-5213-2020	Rajendrasozhan, Saravanan/0000-0002-4234-9417; Adenuga, David/0000-0002-8153-0235	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL080611] Funding Source: Medline; NIEHS NIH HHS [T32 ES007026, P30 ES001247, ES01247, ES07026, R01 ES007026] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; Arnal JF, 1999, CELL MOL LIFE SCI, V55, P1078, DOI 10.1007/s000180050358; CARP H, 1978, AM REV RESPIR DIS, V118, P617; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Jakkula M, 2000, AM J PHYSIOL-LUNG C, V279, pL600, DOI 10.1152/ajplung.2000.279.3.L600; Jayachandran M, 2001, BIOCHEM BIOPH RES CO, V280, P589, DOI 10.1006/bbrc.2000.4177; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117; Koyama S, 2002, AM J RESP CRIT CARE, V166, P382, DOI 10.1164/rccm.2103112; Kranenburg AR, 2005, THORAX, V60, P106, DOI 10.1136/thx.2004.023986; Lee LH, 2005, AM J RESP CRIT CARE, V172, P987, DOI 10.1164/rccm.200501-041OC; LIEBOW AA, 1959, AM REV RESPIR DIS, V80, P67; Marwick JA, 2006, AM J PHYSIOL-LUNG C, V290, pL897, DOI 10.1152/ajplung.00116.2005; Mathew Rajamma, 2007, Cardiol Rev, V15, P143, DOI 10.1097/01.crd.0000249381.49138.b9; Michaud SE, 2006, J MOL CELL CARDIOL, V41, P275, DOI 10.1016/j.yjmcc.2006.05.004; Moodie FM, 2004, FASEB J, V18, P1897, DOI 10.1096/fj.04-1506fje; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Orosz Z, 2007, AM J PHYSIOL-HEART C, V292, pH130, DOI 10.1152/ajpheart.00599.2006; Papaioannou AI, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-128; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; Puranik R, 2003, PROG CARDIOVASC DIS, V45, P443, DOI 10.1053/pcad.2003.YPCAD13; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102; Santos S, 2003, AM J RESP CRIT CARE, V167, P1250, DOI 10.1164/rccm.200210-1233OC; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091; Su YC, 2004, AM J PHYSIOL-LUNG C, V287, pL794, DOI 10.1152/ajplung.00079.2004; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tanriverdi H, 2006, CIRC J, V70, P593, DOI 10.1253/circj.70.593; Thatcher TH, 2005, AM J PHYSIOL-LUNG C, V289, pL322, DOI 10.1152/ajplung.00039.2005; Thatcher TH, 2007, AM J PATHOL, V170, P855, DOI 10.2353/ajpath.2007.060391; Thejass P, 2007, INTEGR CANCER THER, V6, P389, DOI 10.1177/1534735407309084; Thejass P, 2007, INT IMMUNOPHARMACOL, V7, P295, DOI 10.1016/j.intimp.2006.10.011; Tuder RM, 2003, AM J RESP CELL MOL, V29, P88, DOI 10.1165/rcmb.2002-0228OC; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Ucuzian AA, 2007, WORLD J SURG, V31, P654, DOI 10.1007/s00268-006-0763-4; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556; Voelkel NF, 2006, AM J PHYSIOL-LUNG C, V290, pL209, DOI 10.1152/ajplung.00185.2005; Voelkel NF, 2003, EUR RESPIR J, V22, p28S, DOI 10.1183/09031936.03.00000503; Wagner L, 2007, ENDOTHELIUM-J ENDOTH, V14, P245, DOI 10.1080/10623320701606707; Wright JL, 2006, J APPL PHYSIOL, V100, P672, DOI 10.1152/japplphysiol.00274.2005; Yamaguchi Y, 2007, J PHARMACOL SCI, V103, P275, DOI 10.1254/jphs.FP0061055; Yamato H, 1996, LAB INVEST, V75, P211; Yang SR, 2007, AM J PHYSIOL-LUNG C, V292, pL567, DOI 10.1152/ajplung.00308.2006; Yang SR, 2006, AM J PHYSIOL-LUNG C, V291, pL46, DOI 10.1152/ajplung.00241.2005; ZEIHER AM, 1995, CIRCULATION, V92, P1094, DOI 10.1161/01.CIR.92.5.1094	49	74	77	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2297	2310		10.1096/fj.07-099481	http://dx.doi.org/10.1096/fj.07-099481			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263699	Green Accepted			2022-12-28	WOS:000257292500022
J	Park, J; Will, C; Martin, B; Gullotti, L; Friedrichs, N; Buettner, R; Schneider, H; Ludwig, S; Wixler, V				Park, Jung; Will, Carola; Martin, Bernd; Gullotti, Lucia; Friedrichs, Nicolaus; Buettner, Reinhard; Schneider, Holm; Ludwig, Stephan; Wixler, Viktor			Deficiency in the LIM-only protein FHL2 impairs assembly of extracellular matrix proteins	FASEB JOURNAL			English	Article						fibronectin; integrin-mediated ERK activation; focal adhesions; cytoskeleton	SMOOTH MUSCLE ACTIN; FOCAL ADHESION KINASE; FIBRONECTIN MATRIX; MAP KINASE; TRANSCRIPTIONAL COACTIVATOR; INTEGRIN ACTIVATION; STRESS FIBERS; BETA-CATENIN; ALPHA; CELLS	We have described the scaffolding protein FHL2 as a component of focal adhesion structures, to which it is recruited via binding to both alpha- or beta-integrin subunits. Using mesenchymal stem cells from wild-type and FHL2-knockout mice, we show here that inactivation of FHL2 leads to impaired assembly of extracellular matrix proteins on the cell surface and to impaired bundling of focal adhesions. Both altered properties can be restored by reexpression of recombinant FHL2 protein in FHL2-null cells. Molecular analysis of integrin-mediated signaling revealed a higher phosphorylation of FAK at tyrosine 925 in FHL2-knockout cells compared to their wild-type counterpart. Consequently, the activation of the mitogenic kinase ERK was more pronounced in knockout cells on cell adhesion. The growth factor-induced activation of ERK, however, was not altered. The perturbed organization of extracellular matrix on FHL2-null cells was improved when the increased activation of MAPK was inhibited. Our findings point to a role of FHL2 in bundling of focal adhesion structures, in integrin-mediated ERK activation, and subsequently in proper allocation of matrix proteins on the cell surface.	[Will, Carola; Ludwig, Stephan; Wixler, Viktor] Munster Univ Hosp, Inst Mol Virol, Sch Med, D-48149 Munster, Germany; [Park, Jung] Univ Erlangen Nurnberg, Dept Expt Med 1, Erlangen, Germany; [Martin, Bernd] Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Frankfurt, Germany; [Gullotti, Lucia; Friedrichs, Nicolaus; Buettner, Reinhard] Univ Hosp, Sch Med, Inst Pathol, Bonn, Germany; [Schneider, Holm] Med Univ Innsbruck, Dept Pediat, Innsbruck, Austria	University of Munster; University of Erlangen Nuremberg; Goethe University Frankfurt; University of Bonn; Medical University of Innsbruck	Wixler, V (corresponding author), Munster Univ Hosp, Inst Mol Virol, Sch Med, Von Esmarch Str 56, D-48149 Munster, Germany.	vwixler@uni-muenster.de		Ludwig, Stephan/0000-0003-4490-3052				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Barros JC, 2005, J CELL SCI, V118, P1663, DOI 10.1242/jcs.02308; Bershadsky A, 2006, CURR OPIN CELL BIOL, V18, P472, DOI 10.1016/j.ceb.2006.08.012; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Clark K, 2005, J CELL SCI, V118, P291, DOI 10.1242/jcs.01623; Coghill ID, 2003, J BIOL CHEM, V278, P24139, DOI 10.1074/jbc.M213259200; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; deHart GW, 2004, CELL MOTIL CYTOSKEL, V57, P107, DOI 10.1002/cm.10161; Friedrichs N, 2005, MODERN PATHOL, V18, P431, DOI 10.1038/modpathol.3800292; Gabriel B, 2004, ANTICANCER RES, V24, P921; Goffin JM, 2006, J CELL BIOL, V172, P259, DOI 10.1083/jcb.200506179; GOSPODAROWICZ D, 1980, P NATL ACAD SCI-BIOL, V77, P4094, DOI 10.1073/pnas.77.7.4094; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hinz B, 2003, MOL BIOL CELL, V14, P2508, DOI 10.1091/mbc.E02-11-0729; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; ILLC D, 1995, NATURE, V377, P539; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Kong YF, 2001, CIRCULATION, V103, P2731; Lai CF, 2006, J BONE MINER RES, V21, P17, DOI 10.1359/JBMR.050915; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Park J, 2006, J GENE MED, V8, P112, DOI 10.1002/jgm.826; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Purcell NH, 2004, MOL CELL BIOL, V24, P1081, DOI 10.1128/MCB.24.3.1081-1095.2004; Samson T, 2004, J BIOL CHEM, V279, P28641, DOI 10.1074/jbc.M312894200; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1996, CELL ADHES COMMUN, V4, P413, DOI 10.3109/15419069709004458; Shemesh T, 2005, P NATL ACAD SCI USA, V102, P12383, DOI 10.1073/pnas.0500254102; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Wang JX, 2006, EXP CELL RES, V312, P205, DOI 10.1016/j.yexcr.2005.11.004; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Wixler V, 2007, J CELL BIOL, V177, P163, DOI 10.1083/jcb.200606043; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001; Yatomi Y, 2000, BLOOD, V96, P3431; Zamir E, 2001, J CELL SCI, V114, P3583	52	28	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2508	2520		10.1096/fj.07-095521	http://dx.doi.org/10.1096/fj.07-095521			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18356303				2022-12-28	WOS:000257292500042
J	Kelly, K; Brader, P; Rein, A; Shah, JP; Wong, RJ; Fong, YM; Gil, Z				Kelly, Kaitlyn; Brader, Peter; Rein, Avigail; Shah, Jatin P.; Wong, Richard J.; Fong, Yuman; Gil, Ziv			Attenuated multimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function	FASEB JOURNAL			English	Article						perineural invasion; gene therapy; prostate cancer; oncolytic therapy; erectile dysfunction	PERINEURAL INVASION; PROGNOSTIC-SIGNIFICANCE; RADICAL PROSTATECTOMY; BETA-GALACTOSIDASE; RADIATION-THERAPY; GENE DELIVERY; BRAIN-TUMORS; PHASE-I; CANCER; G207	Many cancers can cause disability and pain by invading nerves. In particular, prostate carcinoma has a high propensity for neural invasion (NI) at an early stage. Attempted surgical treatment of tumors with NI often leads to erectile dysfunction and deteriorated quality of life. Therefore, there is a need for novel modalities that will selectively target cancer cells while preserving neural function. Herpes simplex viruses (HSVs) have a natural trophism for peripheral nerves. We hypothesized that oncolytic therapy using HSV engineered to minimize neurotoxicity would be appropriate for this clinical setting. Attenuated HSV (NV1023) injected to sciatic nerves of nude mice had no toxic effect on nerve function (n = 30). NV1023 had significant oncolytic effect on prostate carcinoma cells (PC3, DU145, and LNCap) in vitro. An in vivo model of NI was established by implanting prostate carcinoma cells in the sciatic nerves of nude mice. Mice were treated with NV1023 or saline 7 days after establishment of tumors. Significant reduction in tumor size and inhibition of NI was found 6 -8 wk after treatment (P< 0.005). All animals treated with saline developed complete paralysis < 5 wk post-treatment, whereas most NV1023-treated animals had preserved nerve function > 12 wk after treatment (P< 0.0001). We conclude that oncolytic therapy effectively treats prostate carcinomas with NI in an in vivo murine model while preserving neural function. These findings may hold significant clinical implications for patients with prostate cancer or other neurotrophic tumors.	[Kelly, Kaitlyn; Rein, Avigail; Shah, Jatin P.; Wong, Richard J.; Fong, Yuman; Gil, Ziv] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Brader, Peter] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Gil, Z (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA.	gilz@mskcc.org		Shah, Jatin/0000-0002-6444-6592				AMERICAN CANCER SOCIETY, 2007, CANC FACTS FIG; Bennett JJ, 2004, FASEB J, V18, P1001, DOI 10.1096/fj.02-1080fje; Blank SV, 2002, HUM GENE THER, V13, P627, DOI 10.1089/10430340252837224; Bonin SR, 1997, CANCER-AM CANCER SOC, V79, P75, DOI 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3; Chahlavi Ali, 1999, Neoplasia (New York), V1, P162, DOI 10.1038/sj.neo.7900016; Chang S S, 1999, Curr Opin Urol, V9, P391, DOI 10.1097/00042307-199909000-00004; CHEN XW, 1995, J VIROL, V69, P7899, DOI 10.1128/JVI.69.12.7899-7908.1995; Cinatl J, 2003, CANCER RES, V63, P1508; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; Cooperberg MR, 2005, J CLIN ONCOL, V23, P8146, DOI 10.1200/JCO.2005.02.9751; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; Hu D, 1997, ANESTHESIOLOGY, V86, P957, DOI 10.1097/00000542-199704000-00026; Jarnagin WR, 2006, CANCER GENE THER, V13, P326, DOI 10.1038/sj.cgt.7700890; Jeyaretna Deva S, 2007, Neurosurg Focus, V22, pE4; Kemeny N, 2006, HUM GENE THER, V17, P1214, DOI 10.1089/hum.2006.17.1214; Kim SH, 2000, CANCER GENE THER, V7, P1279, DOI 10.1038/sj.cgt.7700231; Kooby DA, 1999, FASEB J, V13, P1325, DOI 10.1096/fasebj.13.11.1325; Kravchick S, 2003, BJU INT, V92, P28, DOI 10.1046/j.1464-410X.2003.04276.x; Maguire-Zeiss KA, 2001, CURR OPIN MOL THER, V3, P482; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Maru N, 2001, HUM PATHOL, V32, P828, DOI 10.1053/hupa.2001.26456; Mashour GA, 2001, EXP NEUROL, V169, P64, DOI 10.1006/exnr.2001.7641; MEIGNIER B, 1990, J INFECT DIS, V162, P313, DOI 10.1093/infdis/162.2.313; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Penson DF, 2003, J CLIN ONCOL, V21, P1147, DOI 10.1200/JCO.2003.07.139; Perez MCP, 2004, GENE THER, V11, P1023, DOI 10.1038/sj.gt.3302258; Quinn DI, 2003, CANCER-AM CANCER SOC, V97, P1884, DOI 10.1002/cncr.11263; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; RAMAKRISHNAN R, 1994, J VIROL, V68, P1864, DOI 10.1128/JVI.68.3.1864-1873.1994; Rigor BM, 2000, J SURG ONCOL, V75, P280, DOI 10.1002/1096-9098(200012)75:4<280::AID-JSO13>3.0.CO;2-Q; Shen Y, 2006, CANCER GENE THER, V13, P975, DOI 10.1038/sj.cgt.7700946; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; TANAKA A, 1994, CANCER-AM CANCER SOC, V73, P550, DOI 10.1002/1097-0142(19940201)73:3<550::AID-CNCR2820730309>3.0.CO;2-0; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Tobisu Kenichi, 2006, Int J Clin Oncol, V11, P351, DOI 10.1007/s10147-006-0614-1; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; VANDERWAL JE, 1990, CANCER, V66, P2031, DOI 10.1002/1097-0142(19901101)66:9<2031::AID-CNCR2820660931>3.0.CO;2-7; Wong RJ, 2001, HUM GENE THER, V12, P253, DOI 10.1089/10430340150218396; Yu ZK, 2004, INT J CANCER, V112, P525, DOI 10.1002/ijc.20421	41	14	15	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1839	1848		10.1096/fj.07-097808	http://dx.doi.org/10.1096/fj.07-097808			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18234972				2022-12-28	WOS:000256352700024
J	Lingbeck, JM; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Lingbeck, Jody M.; Trausch-Azar, Julie S.; Ciechanover, Aaron; Schwartz, Alan L.			In vivo interactions of MyoD, Id1, and E2A proteins determined by acceptor photobleaching fluorescence resonance energy transfer	FASEB JOURNAL			English	Article						ubiquitin-proteasome degradation	PROTEASOME-MEDIATED DEGRADATION; LOOP-HELIX PROTEINS; DNA-BINDING; INVIVO; DIFFERENTIATION; HETERODIMERS; HOMODIMERS; NUCLEAR; CELLS; E12	MyoD, a skeletal muscle transcription factor, is rapidly degraded by the ubiquitin-proteasome system. MyoD interacts with ubiquitously expressed E2A or inhibitor of DNA binding (Id) proteins to activate or inhibit transcription, respectively. Furthermore, MyoD has been shown to modulate the ubiquitinmediated degradation of Id1 and E2A proteins, E12 and E47. The molecular mechanisms governing these events are not clear but are hypothesized to occur via heterodimer formation. Fluorescence resonance energy transfer (FRET) is a technique for evaluation of protein-protein interactions in vivo. Using acceptor photobleaching FRET and chimeric proteins composed of MyoD, Id1, E12, E47, E12(NLS), or MyoD(NLS) and either cyan fluorescent protein or yellow fluorescent protein, we show that each of the wild-type proteins is capable of homodimerization. In addition, heterodimers form between Id1 and E2A proteins, as well as between MyoD and E2A proteins. The Id1: E2A interaction is stronger than the MyoD: E2A interaction, which is consistent with the notion that inhibition of MyoD action occurs by the sequestration of E2A proteins by Id. The stronger interaction of Id1 with E2A may also explain the decrease in the rate of ubiquitin-proteasome degradation of Id1 that is significantly greater than that of MyoD when E2A proteins are abundant. Thus, these studies extend our understanding of the molecular mechanisms of MyoD action.	[Lingbeck, Jody M.; Trausch-Azar, Julie S.; Schwartz, Alan L.] Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat & Mol Biol & Pha, St Louis, MO 63110 USA; [Lingbeck, Jody M.; Trausch-Azar, Julie S.; Schwartz, Alan L.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Ciechanover, Aaron] Technion Israel Inst Technol, Fac Med, Dept Biochem, Haifa, Israel; [Ciechanover, Aaron] Technion Israel Inst Technol, Fac Med, Rappaport Inst Res Med Sci, Haifa, Israel	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; FINKEL T, 1993, J BIOL CHEM, V268, P5; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Gu Y, 2004, J MICROSC-OXFORD, V215, P162, DOI 10.1111/j.0022-2720.2004.01365.x; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Paulmurugan R, 2002, P NATL ACAD SCI USA, V99, P15608, DOI 10.1073/pnas.242594299; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; Russo S, 1998, J CELL SCI, V111, P691; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Wendt H, 1998, J BIOL CHEM, V273, P5735, DOI 10.1074/jbc.273.10.5735; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	22	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1694	1701		10.1096/fj.07-095000	http://dx.doi.org/10.1096/fj.07-095000			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198216				2022-12-28	WOS:000256352700010
J	Mizuno, T; Zhang, GQ; Takeuchi, H; Kawanokuchi, J; Wang, JY; Sonobe, Y; Jin, SJ; Takada, N; Komatsu, Y; Suzumura, A				Mizuno, Tetsuya; Zhang, Guiqin; Takeuchi, Hideyuki; Kawanokuchi, Jun; Wang, Jinyan; Sonobe, Yoshifumi; Jin, Shijie; Takada, Naoki; Komatsu, Yukio; Suzumura, Akio			Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN gamma receptor and AMPA GluR1 receptor	FASEB JOURNAL			English	Article						proinflammatory cytokine; neuronal dysfunction	NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; UP-REGULATION; CELL-DEATH; HIPPOCAMPAL; INTERLEUKIN-6; ACTIVATION; MICROGLIA; CONNECTIONS; CYTOKINE	Interferon-gamma (IFN-gamma) is a proinflammatory cytokine that plays a pivotal role in pathology of diseases in the central nervous system (CNS), such as multiple sclerosis. However, the direct effect of IFN-gamma on neuronal cells has yet to be elucidated. We show here that IFN-gamma directly induces neuronal dysfunction, which appears as dendritic bead formation in mouse cortical neurons and enhances glutamate neurotoxicity mediated via alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) receptors but not N-methyl-D-aspartate receptors. In the CNS, IFN-gamma receptor forms a unique, neuron-specific, calcium-permeable receptor complex with AMPA receptor subunit GluR1. Through this receptor complex, IFN-gamma phosphorylates GluR1 at serine 845 position by JAK1 center dot 2/ STAT1 pathway, increases Ca2+ influx and following nitric oxide production, and subsequently decreases ATP production, leading to the dendritic bead formation. These findings provide novel mechanisms of neuronal excitotoxicity, which may occur in both inflammatory and neurodegenerative diseases in the CNS.	[Mizuno, Tetsuya; Zhang, Guiqin; Takeuchi, Hideyuki; Kawanokuchi, Jun; Wang, Jinyan; Sonobe, Yoshifumi; Jin, Shijie; Suzumura, Akio] Nagoya Univ, Environm Med Res Inst, Dept Neuroimmunol, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Takada, Naoki; Komatsu, Yukio] Nagoya Univ, Environm Med Res Inst, Dept Visual Neurosci, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Mizuno, T (corresponding author), Nagoya Univ, Environm Med Res Inst, Dept Neuroimmunol, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	tmizuno@riem.nagoya-u.ac.jp		Takeuchi, Hideyuki/0000-0001-5912-7581				Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Banno M, 2005, NEUROPHARMACOLOGY, V48, P283, DOI 10.1016/j.neuropharm.2004.10.002; BARISH ME, 1991, DEV BIOL, V144, P412, DOI 10.1016/0012-1606(91)90433-4; Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; Brask J, 2004, EUR J NEUROSCI, V19, P3193, DOI 10.1111/j.0953-816X.2004.03445.x; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHAO CC, 1995, J LEUKOCYTE BIOL, V58, P65, DOI 10.1002/jlb.58.1.65; Gomes AR, 2003, NEUROCHEM RES, V28, P1459, DOI 10.1023/A:1025610122776; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hemmer B, 2002, NAT REV NEUROSCI, V3, P291, DOI 10.1038/nrn784; Jensen MB, 2000, J NEUROSCI, V20, P3612, DOI 10.1523/JNEUROSCI.20-10-03612.2000; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Kawanokuchi J, 2006, MULT SCLER J, V12, P558, DOI 10.1177/1352458506070763; Kim IJ, 2002, J NEUROSCI, V22, P4530, DOI 10.1523/JNEUROSCI.22-11-04530.2002; Koike M, 1997, NEUROSCI RES, V29, P27, DOI 10.1016/S0168-0102(97)00067-9; Lafortune L, 1996, J NEUROPATH EXP NEUR, V55, P515, DOI 10.1097/00005072-199605000-00003; LEE AP, 1993, P 7 INT C SOL STAT S, V1, P46; Marx CE, 2001, BIOL PSYCHIAT, V50, P743, DOI 10.1016/S0006-3223(01)01209-4; Mizuno T, 2004, NEUROPHARMACOLOGY, V46, P404, DOI 10.1016/j.neuropharm.2003.09.009; Oliva AA, 2002, J NEUROSCI, V22, P8052; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Possel H, 2000, GLIA, V32, P51, DOI 10.1002/1098-1136(200010)32:1<51::AID-GLIA50>3.0.CO;2-4; Qiu ZH, 1998, J NEUROSCI, V18, P10445; Roychowdhury S, 2006, NITRIC OXIDE-BIOL CH, V14, P290, DOI 10.1016/j.niox.2005.12.001; Song JH, 2005, J BIOL CHEM, V280, P12896, DOI 10.1074/jbc.M412139200; Sonkusare SK, 2005, PHARMACOL RES, V51, P1, DOI 10.1016/j.phrs.2004.05.005; Steinman L, 2002, ANNU REV NEUROSCI, V25, P491, DOI 10.1146/annurev.neuro.25.112701.142913; Tabata T, 2004, P NATL ACAD SCI USA, V101, P16952, DOI 10.1073/pnas.0405387101; Takada N, 2005, EUR J NEUROSCI, V21, P422, DOI 10.1111/j.1460-9568.2005.03881.x; Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TSUBOKAWA H, 1995, J NEUROPHYSIOL, V74, P218, DOI 10.1152/jn.1995.74.1.218; Van Den Bosch L, 2000, J NEUROL SCI, V180, P29, DOI 10.1016/S0022-510X(00)00414-7; Vikman KS, 2001, BRAIN RES, V896, P18, DOI 10.1016/S0006-8993(00)03238-8; Viviani B, 2003, J NEUROSCI, V23, P8692; YAMAMOTO N, 1992, NEURON, V9, P217, DOI 10.1016/0896-6273(92)90161-6; YAMAMOTO N, 1989, SCIENCE, V245, P192, DOI 10.1126/science.2749258; Yu ZF, 2002, NEUROBIOL DIS, V11, P199, DOI 10.1006/nbdi.2002.0530; Zhou YP, 2006, NEUROPHARMACOLOGY, V51, P67, DOI 10.1016/j.neuropharm.2006.03.002; Zhu B, 2003, AM J PATHOL, V162, P1639, DOI 10.1016/S0002-9440(10)64298-8	45	126	133	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1797	1806		10.1096/fj.07-099499	http://dx.doi.org/10.1096/fj.07-099499			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18198214				2022-12-28	WOS:000256352700020
J	Arredondo, J; Chernyavsky, AI; Jolkovsky, DL; Pinkerton, KE; Grando, SA				Arredondo, Juan; Chernyavsky, Alexander I.; Jolkovsky, David L.; Pinkerton, Kent E.; Grando, Sergei A.			Receptor-mediated tobacco toxicity: acceleration of sequential expression of alpha 5 and alpha 7 nicotinic receptor subunits in oral keratinocytes exposed to cigarette smoke	FASEB JOURNAL			English	Article						nicotinic acetylcholine receptors; Akt; PKC; p38; JAK-2; GATA-2	ACETYLCHOLINE-RECEPTOR; EPITHELIAL-CELLS; UP-REGULATION; IN-VITRO; BINDING-SITES; DIFFERENTIAL REGULATION; HIPPOCAMPAL-NEURONS; CHOLINERGIC SYSTEM; ENDOTHELIAL-CELLS; CALCIUM INFLUX	Tobacco products and nicotine alter the cell cycle and lead to squamatization of oral keratinocytes (KCs) and squamous cell carcinoma. Activation of nicotinic acetylcholine receptors (nAChRs) elicits Ca(2+) influx that varies in magnitude between different nAChR subtypes. Normal differentiation of KCs is associated with sequential expression of the nAChR subtypes with increasing Ca(2+) permeability, such as alpha 5-containing alpha 3 nAChR and alpha 7 nAChR. Exposure to environmental tobacco smoke (ETS) or an equivalent concentration of nicotine accelerated by severalfold the alpha 5 and alpha 7 expression in KCs, which could be abolished by mecamylamine and et-bungarotoxin with different efficacies, suggesting the following sequence of autoregulation of the expression of nAChR subtypes: alpha 3(beta 2/beta 4) > alpha 3(beta 2/beta 4)alpha 5 > alpha 7 > alpha 7. This conjecture was corroborated by results of quantitative assays of subunit mRNA and protein levels, using nAChR-specific pharmacologic antagonists and small interfering RNAs. The genomic effects of ETS and nicotine involved the transcription factor GATA-2 that showed a multifold increase in quantity and activity in exposed KCs. Using protein kinase inhibitors and dominant negative and constitutively active constructs, we characterized the principal signaling cascades mediating a switch in the nAChR subtype. Cumulative results indicated that the alpha 3(beta 2/beta 4) to alpha 3(beta 2/beta 4)alpha 5 nAChR transition predominantly involved protein kinase C, alpha 3(beta 2/beta 4)alpha 5 to alpha 7 nAChR transition-Ca(2+)/calmodulin-dependent protein kinase II and p38 MAPK, and alpha 7 self-up-regulation-the p38 MAPK/Akt pathway, and JAK-2. These results provide a mechanistic insight into the genomic effects of ETS and nicotine on KCs and characterize signaling pathways mediating autoregulation of stepwise overexpression of nAChR subtypes with increasing Ca(2+) permeability in exposed cells. These observations have salient clinical implications, because a switch in the nAChR subunit composition can bring about a corresponding switch in receptor function, leading to profound pathobiologic effects observed in KCs exposed to tobacco products.	[Arredondo, Juan; Chernyavsky, Alexander I.; Grando, Sergei A.] Univ Calif Irvine, Dept Dermatol, Irvine, CA 92697 USA; [Jolkovsky, David L.] Univ Calif Los Angeles, Sch Dent, Ctr Periodont, Los Angeles, CA 90024 USA; [Pinkerton, Kent E.] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA USA	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California System; University of California Davis	Grando, SA (corresponding author), Univ Calif Irvine, Dept Dermatol, C340 Med Sci I, Irvine, CA 92697 USA.	sgrando@uci.edu			NATIONAL CANCER INSTITUTE [R03CA117327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES014384] Funding Source: NIH RePORTER; NCI NIH HHS [CA117327] Funding Source: Medline; NIDCR NIH HHS [DE14173] Funding Source: Medline; NIEHS NIH HHS [ES014384] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSSON G, 1989, J ORAL PATHOL MED, V18, P491, DOI 10.1111/j.1600-0714.1989.tb01349.x; Arredondo J, 2002, J CELL BIOL, V159, P325, DOI 10.1083/jcb.200206096; Arredondo J, 2005, J INVEST DERMATOL, V125, P1236, DOI 10.1111/j.0022-202X.2005.23973.x; Arredondo J, 2005, AM J PATHOL, V166, P597, DOI 10.1016/S0002-9440(10)62281-X; Arredondo J, 2001, LAB INVEST, V81, P1653, DOI 10.1038/labinvest.3780379; Arredondo J, 2007, LIFE SCI, V80, P2191, DOI 10.1016/j.lfs.2007.01.013; Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Arredondo J, 2006, CANCER BIOL THER, V5, P511, DOI 10.4161/cbt.5.5.2601; Bairam A, 2007, NEUROSCIENCE, V146, P1841, DOI 10.1016/j.neuroscience.2007.03.034; Campos-Caro A, 2001, DNA CELL BIOL, V20, P657, DOI 10.1089/104454901753340640; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; Charpantier E, 2005, J NEUROSCI, V25, P9836, DOI 10.1523/JNEUROSCI.3497-05.2005; Cheng YH, 2005, BIOL REPROD, V73, P500, DOI 10.1095/biolreprod.105.039941; Chernyavsky AI, 2004, J CELL SCI, V117, P5665, DOI 10.1242/jcs.01492; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; Dajas-Bailador FA, 2002, J NEUROCHEM, V81, P606, DOI 10.1046/j.1471-4159.2002.00846.x; Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x; Davila-Garcia MI, 2003, J NEUROCHEM, V85, P1237, DOI 10.1046/j.1471-4159.2003.01774.x; Delbono O, 1997, J PHARMACOL EXP THER, V280, P428; delToro ED, 1997, DEV BRAIN RES, V98, P125; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Fischer H, 2005, J NEUROSCI, V25, P3571, DOI 10.1523/JNEUROSCI.4971-04.2005; Flores CM, 1997, J NEUROCHEM, V69, P2216; Fluck CE, 2004, MOL ENDOCRINOL, V18, P1144, DOI 10.1210/me.2003-0342; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; Gerzanich V, 1998, J PHARMACOL EXP THER, V286, P311; Girod R, 1999, ANN NY ACAD SCI, V868, P578, DOI 10.1111/j.1749-6632.1999.tb11331.x; Grando SA, 2007, J INVEST DERMATOL, V127, pS31; GRANDO SA, 1995, J INVEST DERMATOL, V105, P774, DOI 10.1111/1523-1747.ep12325606; Grando SA, 2007, LIFE SCI, V80, P2181, DOI 10.1016/j.lfs.2007.03.015; Grando SA, 2006, J INVEST DERMATOL, V126, P1948, DOI 10.1038/sj.jid.5700151; Gray AC, 2001, TOXICOL IN VITRO, V15, P427, DOI 10.1016/S0887-2333(01)00047-9; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; Hellstrom-Lindahl E, 2001, NEUROSCIENCE, V105, P527, DOI 10.1016/S0306-4522(01)00209-3; HIRSCH JM, 1982, J ORAL PATHOL MED, V11, P387, DOI 10.1111/j.1600-0714.1982.tb00180.x; Huang LZ, 2006, BRAIN RES, V1113, P94, DOI 10.1016/j.brainres.2006.06.084; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; KAUGARS GE, 1989, CANCER, V64, P1527, DOI 10.1002/1097-0142(19891001)64:7<1527::AID-CNCR2820640728>3.0.CO;2-N; Kawai H, 2001, J NEUROCHEM, V78, P1367, DOI 10.1046/j.1471-4159.2001.00526.x; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; KUES WA, 1995, EUR J NEUROSCI, V7, P1376, DOI 10.1111/j.1460-9568.1995.tb01129.x; Kumar P, 2005, J BIOL CHEM, V280, P25928, DOI 10.1074/jbc.M502435200; Kurzen H, 2004, J INVEST DERMATOL, V123, P937, DOI 10.1111/j.0022-202X.2004.23425.x; Kwon OS, 1999, SKIN PHARMACOL APPL, V12, P227, DOI 10.1159/000066247; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; LECOINTE N, 1994, ONCOGENE, V9, P2623; LINDSTROM J, 1995, ADV PHAR SC, P45; Liu W, 2007, THROMB HAEMOSTASIS, V97, P839, DOI 10.1160/TH06-09-0536; LUKAS RJ, 1998, NICOTINIC ACETYLCHOL, P145; Molinari EJ, 1998, EUR J PHARMACOL, V347, P131, DOI 10.1016/S0014-2999(98)00084-3; MURRAH VA, 1993, ORAL SURG ORAL MED O, V75, P323, DOI 10.1016/0030-4220(93)90145-T; Nagavarapu U, 2001, J BIOL CHEM, V276, P16749, DOI 10.1074/jbc.M009712200; Nakayama H, 2002, J NEUROCHEM, V83, P1372, DOI 10.1046/j.1471-4159.2002.01248.x; Ndoye A, 1998, J INVEST DERMATOL, V111, P410, DOI 10.1046/j.1523-1747.1998.00299.x; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Nguyen VT, 2000, J DENT RES, V79, P939; Nguyen VT, 2001, J CELL SCI, V114, P1189; Nuutinen S, 2006, EUR J PHARMACOL, V544, P21, DOI 10.1016/j.ejphar.2006.06.038; Olale F, 1997, J PHARMACOL EXP THER, V283, P675; Orr-Urtreger A, 2005, NEUROREPORT, V16, P1123, DOI 10.1097/00001756-200507130-00018; Peng X, 1997, MOL PHARMACOL, V51, P776, DOI 10.1124/mol.51.5.776; Perry DC, 1999, J PHARMACOL EXP THER, V289, P1545; Quik M, 1997, MOL PHARMACOL, V51, P499; Ridley DL, 2001, BRIT J PHARMACOL, V133, P1286, DOI 10.1038/sj.bjp.0704207; Riganti L, 2005, BRIT J PHARMACOL, V146, P1096, DOI 10.1038/sj.bjp.0706434; Salas R, 2003, MOL PHARMACOL, V63, P1059, DOI 10.1124/mol.63.5.1059; SEGUELA P, 1993, J NEUROSCI, V13, P596; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Slotkin TA, 2004, BRAIN RES, V1030, P159, DOI 10.1016/j.brainres.2004.10.009; SUNDSTROM B, 1982, J ORAL PATHOL MED, V11, P245, DOI 10.1111/j.1600-0714.1982.tb00162.x; Taylor SC, 2000, J NEUROCHEM, V75, P1583, DOI 10.1046/j.1471-4159.2000.0751583.x; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; Teaktong T, 2004, NEUROPATH APPL NEURO, V30, P243, DOI 10.1046/j.0305-1846.2003.00528.x; THEILIG C, 1994, SKIN PHARMACOL, V7, P307; Tsuneki H, 2000, EUR J NEUROSCI, V12, P2475, DOI 10.1046/j.1460-9568.2000.00138.x; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Utsugisawa K, 2002, MOL BRAIN RES, V106, P88, DOI 10.1016/S0169-328X(02)00415-1; vanHoek ML, 1997, BIOCHEM J, V326, P271, DOI 10.1042/bj3260271; Vincler MA, 2005, PHARMACOL BIOCHEM BE, V80, P135, DOI 10.1016/j.pbb.2004.10.011; Wada T, 2007, ENDOCRINOLOGY, V148, P790, DOI 10.1210/en.2006-0907; Wang F, 1998, J BIOL CHEM, V273, P28721, DOI 10.1074/jbc.273.44.28721; Wang K, 2004, J BIOL CHEM, V279, P8779, DOI 10.1074/jbc.M309652200; Wang N, 2002, J PHYSIOL-LONDON, V542, P347, DOI 10.1113/jphysiol.2001.013456; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Winzer-Serhan UH, 2005, J COMP NEUROL, V481, P19, DOI 10.1002/cne.20357; Wityak J, 2004, BIOORG MED CHEM LETT, V14, P1483, DOI 10.1016/j.bmcl.2004.01.012; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Zia S, 1999, J INVEST DERMATOL, V112, P613; Zia S, 1997, RES COMMUN MOL PATH, V97, P243; Zia SH, 2000, J PHARMACOL EXP THER, V293, P973	92	65	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2008	22	5					1356	1368		10.1096/fj.07-9965.com	http://dx.doi.org/10.1096/fj.07-9965.com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301LW	18450646				2022-12-28	WOS:000255898700009
J	Zurier, RB; Sun, YP; George, KL; Stebulis, JA; Rossetti, RG; Skulas, A; Judge, E; Serhan, CN				Zurier, Robert B.; Sun, Yee-Ping; George, Kerri L.; Stebulis, Judith A.; Rossetti, Ronald G.; Skulas, Ann; Judge, Erica; Serhan, Charles N.			Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A(4)	FASEB JOURNAL			English	Article						lipoxygenase; resolution; arthritis; nephritis	CELLS; INFLAMMATION; SUPPRESSION; RESOLUTION; RECEPTOR	Ajulemic acid (AjA), a synthetic nonpsychoactive cannabinoid, and lipoxin A(4) (LXA(4)), an eicosanoid formed from sequential actions of 5- and 15-lipoxygenases (LOX), facilitate resolution of inflammation. The purpose of this study was to determine whether the ability of AjA to limit the progress of inflammation might relate to an increase in LXA(4), a known anti-inflammatory and proresolving mediator. Addition of AjA (0-30 mu M) in vitro to human blood and synovial cells increased production of LXA(4) (ELISA) 2- to 5-fold. Administration of AjA to mice with peritonitis resulted in a 25-75% reduction of cells invading the peritoneum, and a 7-fold increase in LXA(4) identified by mass spectrometry. Blockade of 12/15 LOX, which leads to LXA(4) synthesis via 15-HETE production, reduced (> 90%) the ability of AjA to enhance production of LXA(4) in vitro. These results suggest that AjA and other agents that increase endogenous compounds that facilitate resolution of inflammation may be useful for conditions characterized by inflammation and tissue injury.-Zurier, R. B., Sun, Y.-P., George, K. L., Stebulis, J. A., Rossetti, R. G., Skulas, A., Judge, E., Serhan, C. N. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A(4). FASEB J. 23, 1503-1509 (2009)	[Zurier, Robert B.; George, Kerri L.; Stebulis, Judith A.; Rossetti, Ronald G.; Skulas, Ann; Judge, Erica] Univ Massachusetts, Sch Med, Div Rheumatol, Worcester, MA 01655 USA; [Sun, Yee-Ping; Serhan, Charles N.] Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesia Perioperat & Pain Med, Boston, MA 02115 USA; [Sun, Yee-Ping; Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zurier, RB (corresponding author), Univ Massachusetts, Sch Med, Div Rheumatol, 55 Lake Ave, Worcester, MA 01655 USA.	robert.zurier@umassmed.edu			U.S. National Institutes of Health (NIH) [DA 3691, AI 1056362, GM38765, P50-DE016191, 5T35HL00771]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765, R29GM038765, R37GM038765] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by U.S. National Institutes of Health (NIH) grants DA 3691 and AI 1056362 (R.B.Z.) and GM38765 and P50-DE016191 (C.N.S.). E.J. was supported by NIH 5T35HL00771 (Short-Term Training for Minority Students). We thank Dr. Sumner Burstein for helpful discussion of the manuscript.	ABEL EL, 1980, MARIJUANA 1 1000 YEA; ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; BURSTEIN S, 1972, SCIENCE, V176, P422, DOI 10.1126/science.176.4033.422; Burstein S, 2005, AAPS J, V7, pE143, DOI 10.1208/aapsj070115; BURSTEIN S, 1994, BIOCHEM PHARMACOL, V48, P1253, DOI 10.1016/0006-2952(94)90163-5; Burstein SH, 2000, CURR PHARM DESIGN, V6, P1339, DOI 10.2174/1381612003399473; BURSTEIN SH, 1992, J MED CHEM, V35, P3135, DOI 10.1021/jm00095a007; Chiang N, 2005, PROSTAG LEUKOTR ESS, V73, P163, DOI 10.1016/j.plefa.2005.05.003; Clarkson MR, 1998, NEPHROL DIAL TRANSPL, V13, P3043, DOI 10.1093/ndt/13.12.3043; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; Dajani EZ, 1999, J PHARMACOL EXP THER, V291, P31; EDENIUS C, 1988, BIOCHEM BIOPH RES CO, V157, P801, DOI 10.1016/S0006-291X(88)80320-6; Fiore S, 1995, BIOCHEMISTRY-US, V34, P16678, DOI 10.1021/bi00051a016; Ghosh M, 2006, PROG LIPID RES, V45, P487, DOI 10.1016/j.plipres.2006.05.003; Johnson DR, 2007, J CELL BIOCHEM, V100, P184, DOI 10.1002/jcb.21046; Karst M, 2003, JAMA-J AM MED ASSOC, V290, P1757, DOI 10.1001/jama.290.13.1757; Lawrence T, 2007, INT J EXP PATHOL, V88, P85, DOI 10.1111/j.1365-2613.2006.00507.x; LOEV B, 1973, J MED CHEM, V16, P1200, DOI 10.1021/jm00269a002; MULLERLADNER U, 1995, ARTHRITIS RHEUM, V38, P1328, DOI 10.1002/art.1780380922; Ohse T, 2004, J AM SOC NEPHROL, V15, P919, DOI 10.1097/01.ASN.0000119962.69573.CC; Olsen NJ, 2005, NEW ENGL J MED, V352, P2578, DOI 10.1056/NEJMp058105; PAPAYIANNI A, 1995, KIDNEY INT, V47, P1295, DOI 10.1038/ki.1995.184; Parker J, 2008, RHEUMATOL INT, V28, P631, DOI 10.1007/s00296-007-0489-0; Perez-Reyes M., 1985, PHARMACOKINETICS PHA, P287; Perretti Mauro, 2003, Methods Mol Biol, V225, P139; PORTNEY LG, 1993, FDN CLIN RES APPL PR, P474; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Schwab JM, 2006, CURR OPIN PHARMACOL, V6, P414, DOI 10.1016/j.coph.2006.02.006; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; SODINSEMRL S, 2000, J EXP MED, V9, P1693; Stebulis JA, 2005, J RHEUMATOL, V32, P301; Stebulis JA, 2008, LIFE SCI, V83, P666, DOI 10.1016/j.lfs.2008.09.004; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; ZURIER RB, 1990, J RHEUMATOL, V17, P1439; Zurier RB, 2003, J CELL BIOCHEM, V88, P462, DOI 10.1002/jcb.10291; Zurier RB, 2003, BIOCHEM PHARMACOL, V65, P649, DOI 10.1016/S0006-2952(02)01604-0; Zurier RB, 1998, ARTHRITIS RHEUM-US, V41, P163, DOI 10.1002/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9	39	37	40	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1503	1509		10.1096/fj.08-118323	http://dx.doi.org/10.1096/fj.08-118323			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19124557	Green Published			2022-12-28	WOS:000266651700026
J	Kovacheva, VP; Davison, JM; Mellott, TJ; Rogers, AE; Yang, S; O'Brien, MJ; Blusztajn, JK				Kovacheva, Vesela P.; Davison, Jessica M.; Mellott, Tiffany J.; Rogers, Adrianne E.; Yang, Shi; O'Brien, Michael J.; Blusztajn, Jan Krzysztof			Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival	FASEB JOURNAL			English	Article						DNA methylation; epigenetic; diet; breast cancer; nutrition; pregnancy	BREAST-CANCER CELLS; ANTIESTROGEN RESISTANCE; EPIGENETIC REGULATION; GLAND CARCINOGENESIS; COLORECTAL-CANCER; DNA METHYLATION; MESSENGER-RNA; RATS; IDENTIFICATION; HYPERMETHYLATION	Choline is an essential nutrient that serves as a donor of metabolic methyl groups used during gestation to establish the epigenetic DNA methylation patterns that modulate tissue-specific gene expression. Because the mammary gland begins its development prenatally, we hypothesized that choline availability in utero may affect the gland's susceptibility to cancer. During gestational days 11-17, pregnant rats were fed a control, choline-supplemented, or choline-deficient diet (8, 36, and 0 mmol/kg of choline, respectively). On postnatal day 65, the female offspring received 25 mg/kg of a carcinogen 7,12-dimethylbenz[alpha]anthracene. Approximately 70% of the rats developed mammary adenocarcinomas; prenatal diet did not affect tumor latency, incidence, size, and multiplicity. Tumor growth rate was inversely related to choline content in the prenatal diet, resulting in 50% longer survival until euthanasia, determined by tumor size, of the prenatally choline-supplemented rats compared with the prenatally choline-deficient rats. This was accompanied by distinct expression patterns of similar to 70 genes in tumors derived from the three dietary groups. Tumors from the prenatally choline-supplemented rats overexpressed genes that confer favorable prognosis in human cancers (Klf6, Klf9, Nid2, Ntn4, Per1, and Txnip) and underexpressed those associated with aggressive disease (Bcar3, Cldn12, Csf1, Jag1, Lgals3, Lypd3, Nme1, Ptges2, Ptgs1, and Smarcb1). DNA methylation within the tumor suppressor gene, stratifin (Sfn, 14-3-3 sigma), was proportional to the prenatal choline supply and correlated inversely with the expression of its mRNA and protein in tumors, suggesting that an epigenetic mechanism may underlie the altered molecular phenotype and tumor growth. Our results suggest a role for adequate maternal choline nutrition during pregnancy in prevention/alleviation of breast cancer in daughters.-Kovacheva, V. P., Davison, J. M., Mellott, T. J., Rogers, A. E., Yang, S., O'Brien, M. J., Blusztajn, J. K. Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival. (2009) FASEB J. 23, 1054-1063 (2009)	[Kovacheva, Vesela P.; Davison, Jessica M.; Mellott, Tiffany J.; Rogers, Adrianne E.; Yang, Shi; O'Brien, Michael J.; Blusztajn, Jan Krzysztof] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	Boston University	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, 72 E Concord St,L804, Boston, MA 02118 USA.	jbluszta@bu.edu	O'Brien, Michael J/R-7179-2019	/0000-0001-8438-3122; Mellott, Tiffany/0000-0003-3287-9374; Yang, Shi/0000-0001-8316-6484; O'Brien, Michael J/0000-0003-1124-3537	National Institute of Health [CA120488, AG009525]; NATIONAL CANCER INSTITUTE [R21CA120488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Adam Lerner for the anti-BCAR3 antibody and Patrick Hogan and Bethany Shade for assistance. The Molecular Genetics Core Facility at Children's Hospital Boston performed the microarray analysis. These studies were supported by National Institute of Health grants CA120488 and AG009525.	Alshafie GA, 2000, ONCOL REP, V7, P1377; [Anonymous], 2000, METHODS MAMMARY GLAN; Bertagnolo V, 2006, INT J ONCOL, V28, P863; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Buendia MA, 2007, J HEPATOL, V46, P546, DOI 10.1016/j.jhep.2007.01.005; Cai DP, 2003, CANCER RES, V63, P6802; Crawford NPS, 2008, CLIN EXP METASTAS, V25, P357, DOI 10.1007/s10585-008-9146-6; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Esseghir S, 2007, CLIN CANCER RES, V13, P3164, DOI 10.1158/1078-0432.CCR-07-0224; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Food andNutrition Board Institute of Medicine, 1998, DIET REF INT THIAM R, DOI 10.17226/6015; Friess H, 2003, CELL MOL LIFE SCI, V60, P1180, DOI 10.1007/s00018-003-3036-5; Gery S, 2006, MOL CELL, V22, P375, DOI 10.1016/j.molcel.2006.03.038; Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807; Grone J, 2007, INT J COLORECTAL DIS, V22, P651, DOI 10.1007/s00384-006-0197-3; Heimann R, 2000, EUR J CANCER, V36, P1631, DOI 10.1016/S0959-8049(00)00151-9; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002; HilakiviClarke L, 1996, JNCI-J NATL CANCER I, V88, P1821, DOI 10.1093/jnci/88.24.1821; HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jeronimo C, 2008, BREAST CANCER RES TR, V109, P27, DOI 10.1007/s10549-007-9620-x; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kim SY, 2007, CELL MOL IMMUNOL, V4, P345; Korkola JE, 2003, CANCER RES, V63, P7167; Kovacheva VP, 2007, J BIOL CHEM, V282, P31777, DOI 10.1074/jbc.M705539200; Kuramoto T, 2002, CANCER RES, V62, P3592; LEONE A, 1993, ONCOGENE, V8, P855; Lewis EM, 2002, DRUG CHEM TOXICOL, V25, P437, DOI 10.1081/DCT-120014794; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lin JF, 2007, INT J CANCER, V121, P2596, DOI 10.1002/ijc.23016; Liu PCC, 2001, MOL BIOL CELL, V12, P3644, DOI 10.1091/mbc.12.11.3644; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Mayoral MA, 2008, CANCER INVEST, V26, P615, DOI 10.1080/07357900701837051; McCann JC, 2006, NEUROSCI BIOBEHAV R, V30, P696, DOI 10.1016/j.neubiorev.2005.12.003; Meck WH, 2008, FRONT INTEGR NEUROSC, V1, DOI 10.3389/neuro.07.007.2007; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Medina D, 2005, J CELL SCI, V118, P123, DOI 10.1242/jcs.01597; Mellott TJ, 2007, FASEB J, V21, P1311, DOI 10.1096/fj.06-6597com; Niculescu MD, 2006, FASEB J, V20, P43, DOI 10.1096/fj.05-4707com; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Oshiro MM, 2005, NEOPLASIA, V7, P799, DOI 10.1593/neo.05274; Ouatas T, 2003, J BIOENERG BIOMEMBR, V35, P73, DOI 10.1023/A:1023497924277; Papaconstantinou AD, 2006, INT J CANCER, V118, P17, DOI 10.1002/ijc.21247; Paret C, 2007, BRIT J CANCER, V97, P1146, DOI 10.1038/sj.bjc.6604012; Resseguie M, 2007, FASEB J, V21, P2622, DOI 10.1096/fj.07-8227com; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Russo J., 1987, The mammary gland. Development, regulation, and function., P67; RUSSO J, 1990, LAB INVEST, V62, P244; Sapi E, 2004, EXP BIOL MED, V229, P1; Shan L, 2005, TOXICOL PATHOL, V33, P768, DOI 10.1080/01926230500437027; Shan L, 2005, CARCINOGENESIS, V26, P503, DOI 10.1093/carcin/bgh330; Shan L, 2004, AM J PATHOL, V165, P191, DOI 10.1016/S0002-9440(10)63288-9; Shan L, 2002, CARCINOGENESIS, V23, P1561, DOI 10.1093/carcin/23.10.1561; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; Smalley MJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1834; Stark AH, 2003, NUTR CANCER, V46, P59, DOI 10.1207/S15327914NC4601_08; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Thorat MA, 2008, MODERN PATHOL, V21, P15, DOI 10.1038/modpathol.3800970; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ulazzi L, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-17; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; Velarde MC, 2007, MOL ENDOCRINOL, V21, P2988, DOI 10.1210/me.2007-0242; Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230; Winter SL, 2007, NEOPLASIA, V9, P797, DOI 10.1593/neo.07595; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279; Xue F, 2007, LANCET ONCOL, V8, P1088, DOI 10.1016/S1470-2045(07)70377-7; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961; ZEISEL SH, 1995, J NUTR, V125, P3049; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156	83	38	40	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1054	1063		10.1096/fj.08-122168	http://dx.doi.org/10.1096/fj.08-122168			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19047067	Green Published			2022-12-28	WOS:000266651600009
J	Chastre, E; Abdessamad, M; Kruglov, A; Bruyneel, E; Bracke, M; Di Gioia, Y; Beckerle, MC; van Roy, F; Kotelevets, L				Chastre, Eric; Abdessamad, Mahmoud; Kruglov, Alexey; Bruyneel, Erik; Bracke, Marc; Di Gioia, Yolande; Beckerle, Mary C.; van Roy, Frans; Kotelevets, Larissa			TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness	FASEB JOURNAL			English	Article						PTEN; PDZ domain; NF-kappa B; E-cadherins; PI3-kinase; Akt	NF-KAPPA-B; ZYXIN-RELATED PROTEIN; LIM-DOMAIN PROTEIN; CADHERIN EXPRESSION; UP-REGULATION; ACTIVATION; JUNCTIONS; INTERACTS; FAMILY; ZRP-1	We recently established the critical role of the PTEN/MAGI-1b signalosome in stabilization of cell-cell contacts and suppression of invasiveness. The PTEN tumor suppressor is recruited to E-cadherin junctional complexes through the binding to the second PDZ domain of the MAGI-1b scaffolding molecule, whereas beta-catenin interacts with the fifth PDZ domain. To identify additional effectors of this signalosome, we used yeast 2-hybrid screening. Among the clones identified, we focused on TRIP6, which belongs to the zyxin family of proteins. We demonstrated that TRIP6 interacted directly with MAGI-1b by binding to its fifth PDZ domain. Ectopic expression of TRIP6 induced invasiveness in the epithelial MDCK and MDCKts-src cells in a PI3-kinase-and a NF-kappa B-dependent manner and impaired cell-cell aggregation at least in part by uncoupling adherens junctional complexes from the cytoskeleton. The TRIP6Stop473 mutant, which lacks the PDZ binding motif, was still able to increase NF-kappa B and Akt activities but did not promote invasiveness or interfere with cell-cell aggregation. Intracellular delivery of competing peptides corresponding to TRIP6 or beta-catenin C terminus restored invasive properties in MDCKts-src TRIP6Stop473 cells, highlighting the requirement of PDZ scaffolds in junctional complexes activity. TRIP6 overexpression in colon tumors suggest its critical role in cancer progression.-Chastre, E., Abdessamad, M., Kruglov, A., Bruyneel, E., Bracke, M., Di Gioia, Y., Beckerle, M. C., van Roy, F., Kotelevets, L. TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness. FASEB J. 23, 916-928 (2009)	[Chastre, Eric] Univ Paris 07, INSERM, Ctr Rech Biomed Bichat Beaujon CRB3, Fac Med Bichat,U773, F-75018 Paris, France; [Kruglov, Alexey] Russian Acad Sci, Inst Theoret & Expt Biophys, Moscow, Russia; [Bruyneel, Erik; Bracke, Marc] Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; [Beckerle, Mary C.] Univ Utah, Dept Biol, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Beckerle, Mary C.] Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT USA; [van Roy, Frans] Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; [van Roy, Frans] Univ Ghent VIB, Dept Mol Biol, Ghent, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics; Ghent University; Ghent University Hospital; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Chastre, E (corresponding author), Univ Paris 07, INSERM, Ctr Rech Biomed Bichat Beaujon CRB3, Fac Med Bichat,U773, 16 Rue Henri Huchard, F-75018 Paris, France.	eric.chastre@inserm.fr; larissa.kotelevets@inserm.fr	van Roy, Frans M/C-6123-2009; CHASTRE, Eric/L-8446-2018; Kruglov, Alexey/A-6057-2014	van Roy, Frans M/0000-0003-4358-1039; CHASTRE, Eric/0000-0002-8993-1228; Kruglov, Alexey/0000-0001-9215-7387	INSERM; Association pour la Recherche contre le Cancer (ARC, France); INSERM/DGRSRT (Tunisia); Interuniversity Attraction Pools 5 of the Federal Science Policy (Belgium); European Union (BRECOSM); ARC and INSERM; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Association pour la Recherche contre le Cancer (ARC, France)(Fondation ARC pour la Recherche sur le Cancer); INSERM/DGRSRT (Tunisia)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Interuniversity Attraction Pools 5 of the Federal Science Policy (Belgium); European Union (BRECOSM)(European Commission); ARC and INSERM; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully thank Dr. I. Dobrosotskaya (University of Texas, Dallas, TX, USA) for providing the MAGI-1b expression vector. We thank S. Benadda (IFR02, Paris, France) for her assistance in confocal microscopy. This work was supported by INSERM, the Association pour la Recherche contre le Cancer (ARC, France), the partnership INSERM/DGRSRT (Tunisia), the Fund for Scientific ResearchFlanders, the Interuniversity Attraction Pools 5 of the Federal Science Policy (Belgium), Brussels, and FP6 of the European Union (BRECOSM). L. K. was a recipient of a FEBS fellowship and was supported by the ARC and INSERM.	Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Bai CY, 2007, J CELL SCI, V120, P2828, DOI 10.1242/jcs.03477; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Boterberg T, 2001, Methods Mol Med, V58, P33, DOI 10.1385/1-59259-137-X:033; Bracke M E, 2001, Methods Mol Med, V58, P81, DOI 10.1385/1-59259-137-X:081; Braga VMM, 2005, CURR OPIN CELL BIOL, V17, P466, DOI 10.1016/j.ceb.2005.08.012; Cuppen E, 2000, EUR J CELL BIOL, V79, P283, DOI 10.1078/S0171-9335(04)70031-X; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Guryanova OA, 2005, MOL BIOL+, V39, P905; Hansen MDH, 2006, J BIOL CHEM, V281, P16178, DOI 10.1074/jbc.M512771200; Hervy M, 2006, CURR OPIN CELL BIOL, V18, P524, DOI 10.1016/j.ceb.2006.08.006; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; Kato T, 2005, J CLIN INVEST, V115, P2716, DOI 10.1172/JCI24280; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kotelevets L, 2001, J CELL BIOL, V155, P1129, DOI 10.1083/jcb.200105109; Lai YJ, 2005, MOL CELL BIOL, V25, P5859, DOI 10.1128/MCB.25.14.5859-5868.2005; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2003, J BIOL CHEM, V278, P17395, DOI 10.1074/jbc.M300998200; Petit MMR, 2005, FEBS LETT, V579, P5061, DOI 10.1016/j.febslet.2005.08.012; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Shintani Y, 2006, MOL BIOL CELL, V17, P2963, DOI 10.1091/mbc.E05-12-1123; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Williams G, 1998, INDEX CENSORSHIP, V27, P186, DOI 10.1080/03064229808536405; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248	35	49	51	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					916	928		10.1096/fj.08-106344	http://dx.doi.org/10.1096/fj.08-106344			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19017743				2022-12-28	WOS:000265506300027
J	Randhawa, M; Huff, T; Valencia, JC; Younossi, Z; Chandhoke, V; Hearing, VJ; Baranova, A				Randhawa, Manpreet; Huff, Tom; Valencia, Julio C.; Younossi, Zobair; Chandhoke, Vikas; Hearing, Vincent J.; Baranova, Ancha			Evidence for the ectopic synthesis of melanin in human adipose tissue	FASEB JOURNAL			English	Article						obesity; metabolic syndrome; inflammation; alpha-MSH; pigmentation	EUMELANIN; SKIN; PATHOGENESIS; MELANOCYTES; MELANOSOMES; EXPRESSION; RADICALS	Melanin is a common pigment in animals. In humans, melanin is produced in melanocytes, in retinal pigment epithelium (RPE) cells, in the inner ear, and in the central nervous system. Previously, we noted that human adipose tissue expresses several melanogenesis-related genes. In the current study, we confirmed the expression of melanogenesis-related mRNAs and proteins in human adipose tissue using real-time polymerase chain reaction and immunohistochemical staining. TYR mRNA signals were also detected by in situ hybridization in visceral adipocytes. The presence of melanin in human adipose tissue was revealed both by Fontana-Masson staining and by permanganate degradation of melanin coupled with liquid chromatography/ultraviolet/mass spectrometry determination of the pyrrole-2,3,5-tricarboxylic acid ( PTCA) derivative of melanin. We also compared melanogenic activities in adipose tissues and in other human tissues using the L-[U-C-14] tyrosine assay. A marked heterogeneity in the melanogenic activities of individual adipose tissue extracts was noted. We hypothesize that the ectopic synthesis of melanin in obese adipose may serve as a compensatory mechanism that uses its anti-inflammatory and its oxidative damage-absorbing properties. In conclusion, our study demonstrates for the first time that the melanin biosynthesis pathway is functional in adipose tissue.-Randhawa, M., Huff, T., Valencia, J. C., Younossi, Z., Chandhoke, V., Hearing, V. J., Baranova, A. Evidence for the ectopic synthesis of melanin in human adipose tissue. FASEB J. 23, 835-843 (2009)	[Randhawa, Manpreet; Chandhoke, Vikas; Baranova, Ancha] George Mason Univ, Mol & Microbiol Dept, Manassas, VA USA; [Randhawa, Manpreet; Chandhoke, Vikas; Baranova, Ancha] George Mason Univ, Ctr Study Genom Liver Dis, Manassas, VA USA; [Huff, Tom] George Mason Univ, Coll Sci, Shared Instrumentat Res Facil, Manassas, VA USA; [Valencia, Julio C.; Hearing, Vincent J.] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; [Younossi, Zobair; Baranova, Ancha] INOVA Fairfax Hosp, Ctr Liver Dis, Fairfax, VA USA	George Mason University; George Mason University; George Mason University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Inova Fairfax Hospital	Baranova, A (corresponding author), George Mason Univ, David King Hall,MSN 3E1, Fairfax, VA 22030 USA.	abaranov@gmu.edu	, Ancha/B-4608-2012; Baranova, Anna/HGB-3721-2022	, Ancha/0000-0001-6810-5982; 	Thomas F. Jeffress and Kate Miller Jeffress Memorial Trust; U.S. National Institutes of Health; NATIONAL CANCER INSTITUTE [ZIABC010786] Funding Source: NIH RePORTER	Thomas F. Jeffress and Kate Miller Jeffress Memorial Trust; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research has been supported by a grant from the Thomas F. Jeffress and Kate Miller Jeffress Memorial Trust and by the Intramural Research Program of the National Cancer Institute at the U.S. National Institutes of Health. A. B. and M. R. are grateful to Shobha M. Gowder and Jenefir Ibister for initial technical assistance with the project, V. Espina for cryoslicing of adipose, and F. Otaizo for the help with the first round of RT-PCR experiments.	Baranova A, 2005, OBES SURG, V15, P758, DOI 10.1381/0960892054222876; BOLT A. G., 1967, LIFE SCI, V6, P1277, DOI 10.1016/0024-3205(67)90022-7; Gallone A, 2002, PIGM CELL RES, V15, P32, DOI 10.1034/j.1600-0749.2002.00052.x; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; Hoch M, 2007, OBESITY, V15, P40, DOI 10.1038/oby.2007.525; Hoggard N, 2004, CLIN ENDOCRINOL, V61, P31, DOI 10.1111/j.1365-2265.2004.02056.x; ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2; ITO S, 1989, Journal of Investigative Dermatology, V92, p261S, DOI 10.1111/1523-1747.ep13076587; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064; MAYER TC, 1973, DEV BIOL, V34, P39, DOI 10.1016/0012-1606(73)90337-0; Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x; Mohagheghpour N, 2000, CELL IMMUNOL, V199, P25, DOI 10.1006/cimm.1999.1599; Nofsinger JB, 2002, FREE RADICAL BIO MED, V32, P720, DOI 10.1016/S0891-5849(02)00763-3; Nosanchuk JD, 2003, CELL MICROBIOL, V5, P203, DOI 10.1046/j.1462-5814.2003.00268.x; Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2; Seagle BLL, 2005, J AM CHEM SOC, V127, P11220, DOI 10.1021/ja052773z; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Szekely-Klepser G, 2005, J CHROMATOGR B, V826, P31, DOI 10.1016/j.jchromb.2005.08.002; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Valencia JC, 2006, J CELL SCI, V119, P1080, DOI 10.1242/jcs.02804; Zecca L, 2006, NEUROLOGY, V67, pS8, DOI 10.1212/WNL.67.7_suppl_2.S8	22	37	38	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					835	843		10.1096/fj.08-116327	http://dx.doi.org/10.1096/fj.08-116327			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18971261	Green Published			2022-12-28	WOS:000265506300019
J	Bolego, C; Buccellati, C; Prada, A; Gaion, RM; Folco, G; Sala, A				Bolego, Chiara; Buccellati, Carola; Prada, Alberto; Gaion, Rosa Maria; Folco, Giancarlo; Sala, Angelo			Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone	FASEB JOURNAL			English	Article						selective cyclooxygenase inhibitors; prostaglandin; isoprostanes; COX-2 heterodimers; 12-HpETE	PROSTAGLANDIN-H SYNTHASE; ANTIINFLAMMATORY DRUGS; PHOSPHOLIPASE A(2); ARACHIDONIC-ACID; UP-REGULATION; SHEAR-STRESS; CYCLOOXYGENASE-2; EXPRESSION; PLATELETS; AND-2	We aimed at evaluating the relative contribution of cyclooxygenase (COX) -1 and COX-2 to the synthesis of prostacyclin in endothelial cells under static conditions in the presence or absence of exogenous arachidonic acid and/or altered intracellular redox balance. Selective inhibitors of either COX-1 (SC560 and FR122047) or COX-2 (SC236) concentration dependently (1-300 nM) reduced basal and interleukin (IL) -1 beta-induced prostacyclin production in human umbilical vein endothelial cells by 70% or more; compound selectivity was confirmed using a whole-blood assay (IC50 COX-1/COX-2: 13 nM/930 nM for SC-560; 9 mu M/457 nM for SC-236). The observed concomitant formation of isoprostane appeared to be associated with COX enzyme activity, while formation of COX-1/COX-2 heterodimers was detected by immunoprecipitation. In the presence of arachidonic acid and 12-hydroperoxy-eicosatetraenoic acid, either exogenous or provided by platelet activation, or after glutathione depletion, COX-1 inhibition but not COX-2 inhibition concentration dependently decreased prostacyclin production. Both isoforms appear to contribute to basal prostacyclin production by endothelial cells, with COX-2 providing the hydroperoxide tone required for COX-1 activity. Conversely, in the case of intracellular glutathione depletion or enhanced availability of arachidonic acid and hydroperoxides, selective COX-2 inhibition did not significantly affect the production of endothelial prostacyclin. These findings contribute to a better understanding of the effects of cyclooxygenase inhibitors on prostacyclin production.-Bolego, C., Buccellati, C., Prada, A., Gaion, R. M., Folco, G., Sala, A. Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone. FASEB J. 23, 605-612 (2009)	[Bolego, Chiara; Buccellati, Carola; Folco, Giancarlo; Sala, Angelo] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; [Gaion, Rosa Maria] Univ Padua, Dept Pharmacol & Anesthesiol, Padua, Italy; [Prada, Alberto] Rho Hosp, Rho, Italy	University of Milan; University of Padua	Sala, A (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	angelo.sala@unimi.it	Sala, Angelo/H-5478-2019	Sala, Angelo/0000-0001-9290-0257	European Community [LSHM-CT-2004-005033]; Italian Ministry of Instruction University and Research	European Community(European Commission); Italian Ministry of Instruction University and Research(Ministry of Education, Universities and Research (MIUR))	We thank Dr. A. Zanini for the assistance in collecting the umbilical cords and Dr. G. Simonutti for confocal microscopy analysis. The study was supported by grants from the European Community (LSHM-CT-2004-005033 to G. F. and A. S.) and from the Italian Ministry of Instruction, University and Research (FIRST to G. F. and A. S., and PRIN to A. S.).	Bolego C, 2006, BIOCHEM BIOPH RES CO, V339, P188, DOI 10.1016/j.bbrc.2005.11.017; Camacho M, 1998, CIRC RES, V83, P353, DOI 10.1161/01.RES.83.4.353; Camacho M, 2000, THROMB RES, V99, P155, DOI 10.1016/S0049-3848(00)00241-3; Caughey GE, 2001, J IMMUNOL, V167, P2831, DOI 10.4049/jimmunol.167.5.2831; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; Coffey MJ, 2004, CIRC RES, V94, P1598, DOI 10.1161/01.RES.0000132281.78948.65; Davidge ST, 2001, CIRC RES, V89, P650, DOI 10.1161/hh2001.098351; Flavahan NA, 2007, TRENDS PHARMACOL SCI, V28, P106, DOI 10.1016/j.tips.2007.01.003; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; HABIB A, 1993, J BIOL CHEM, V268, P23448; HABIB A, 1995, THROMB HAEMOSTASIS, V74, P770; James MJ, 2001, INFLAMM RES, V50, P249, DOI 10.1007/s000110050750; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; Kokura S, 1999, CIRC RES, V84, P516, DOI 10.1161/01.RES.84.5.516; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Mitchell JA, 2006, NAT REV DRUG DISCOV, V5, P75, DOI 10.1038/nrd1929; Mitchell JA, 2006, FASEB J, V20, P2468, DOI 10.1096/fj.06-6615com; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; Ochi T, 2000, EUR J PHARMACOL, V391, P49, DOI 10.1016/S0014-2999(00)00051-0; Okahara K, 1998, ARTERIOSCL THROM VAS, V18, P1922, DOI 10.1161/01.ATV.18.12.1922; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Pepicelli O, 2005, J NEUROCHEM, V93, P1561, DOI 10.1111/j.1471-4159.2005.03150.x; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Radi ZA, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/85091; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; Shimizu T, 2006, IUBMB LIFE, V58, P328, DOI 10.1080/15216540600702289; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; SIEGEL MI, 1980, P NATL ACAD SCI-BIOL, V77, P308, DOI 10.1073/pnas.77.1.308; Smith WL, 2002, PROSTAG OTH LIPID M, V68-9, P115, DOI 10.1016/S0090-6980(02)00025-4; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Swinney DC, 1997, J BIOL CHEM, V272, P12393, DOI 10.1074/jbc.272.19.12393; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Warner TD, 2006, FASEB J, V20, P542, DOI 10.1096/fj.05-4434fje; Yu Y, 2006, NAT MED, V12, P699, DOI 10.1038/nm1412; Zidar N, 2007, CARDIOVASC PATHOL, V16, P300, DOI 10.1016/j.carpath.2007.02.005	39	24	24	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					605	612		10.1096/fj.08-106591	http://dx.doi.org/10.1096/fj.08-106591			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18838483				2022-12-28	WOS:000262892900031
J	Yuki, K; Astrof, NS; Bracken, C; Yoo, R; Silkworth, W; Soriano, SG; Shimaoka, M				Yuki, Koichi; Astrof, Nathan S.; Bracken, Clay; Yoo, Ronnie; Silkworth, Whitney; Soriano, Sulpicio G.; Shimaoka, Motomu			The volatile anesthetic isoflurane perturbs conformational activation of integrin LFA-1 by binding to the allosteric regulatory cavity	FASEB JOURNAL			English	Article						NMR; structure; small-molecule antagonist; leukocyte; cell adhesion	FUNCTION-ASSOCIATED ANTIGEN-1; I-DOMAIN; HIGH-AFFINITY; STRUCTURAL BASIS; DISULFIDE BOND; A-DOMAIN; ADHESION; PROTEIN; NMR; INFLAMMATION	The molecular and structural basis of anesthetic interactions with conformations and functionalities of cell surface receptors remains to be elucidated. We have demonstrated that the widely used volatile anesthetic isoflurane blocks the activation-dependent conformational conversion of integrin lymphocyte function associated antigen-1 (LFA-1), the major leukocyte cell adhesion molecule, to a high-affinity configuration. Perturbation of LFA-1 activation by isoflurane at clinically relevant concentrations leads to the inhibition of T-cell interactions with target cells as well as ligand-triggered intracellular signaling. Nuclear magnetic resonance spectroscopy reveals that isoflurane binds within a cavity in the LFA-1 ligand-binding domain, which is a previously identified drug-binding site for allosteric small-molecule antagonists that stabilize LFA-1 in a low-affinity conformation. These results provide a potential mechanism for the immunomodulatory properties of isoflurane.	[Yuki, Koichi; Astrof, Nathan S.; Yoo, Ronnie; Silkworth, Whitney; Shimaoka, Motomu] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA; [Yuki, Koichi; Soriano, Sulpicio G.; Shimaoka, Motomu] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA; [Astrof, Nathan S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Yuki, Koichi; Soriano, Sulpicio G.] Childrens Hosp Boston, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA; [Astrof, Nathan S.] Cornell Med Sch, New York, NY USA; [Bracken, Clay] Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Cornell University; Cornell University	Shimaoka, M (corresponding author), Harvard Univ, Sch Med, Immune Dis Inst, 200 Longwood Ave,Rm 253, Boston, MA 02115 USA.	shimaoka@idi.harvard.edu	Bracken, Clay/A-7811-2009; Soriano, Sulpicio/K-3501-2019		National Institutes of Health [AI063421, HL048675]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063421] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank G. Song and T. A. Springer (Harvard Medical School, Boston, MA, USA) for providing reagents; T. Shimizu (University of Tokyo, Tokyo, Japan) for providing reagents and insightful comments; E. J. Park, D. Peer, and Y. Imai for technical support; S. Piva for insightful comments and stimulating our interest in integrin-isoflurane interactions; and T. Zimmerman and F. J. Blanco for sending the unpublished NMR assignments. This work was supported by grants from the National Institutes of Health, AI063421 and HL048675 (M.S.). K.Y. designed research, performed research, analyzed data, and wrote the paper; N.S.A. designed research, performed research, analyzed data, and wrote the paper; C.B. performed research and analyzed data; R.Y. performed research; W.S. performed research; S.G.S. designed research, analyzed data, and wrote the paper; M.S. designed research, performed research, analyzed data, and wrote the paper. The authors declare no conflicts of interest.	Chen X, 2007, P NATL ACAD SCI USA, V104, P6329, DOI 10.1073/pnas.0611655104; Chiang N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001879; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; Eckenhoff RG, 2001, BIOCHEMISTRY-US, V40, P10819, DOI 10.1021/bi010691r; Fang M, 2003, J BIOL CHEM, V278, P36669, DOI 10.1074/jbc.M303520200; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; Frenette PS, 2001, NEW ENGL J MED, V345, P1419, DOI 10.1056/NEJM200111083451911; Hayes JK, 2004, ANESTH ANALG, V98, P999, DOI 10.1213/01.ANE.0000104584.91385.1D; Heindl B, 1999, ANESTHESIOLOGY, V91, P521, DOI 10.1097/00000542-199908000-00027; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kriwacki RW, 2000, J BIOMOL NMR, V16, P271, DOI 10.1023/A:1008358912334; Lee HT, 2007, AM J PHYSIOL-RENAL, V293, pF713, DOI 10.1152/ajprenal.00161.2007; Lee HT, 2007, SHOCK, V27, P373, DOI 10.1097/01.shk.0000248595.17130.24; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liu RY, 2005, FASEB J, V19, P567, DOI 10.1096/fj.04-3171com; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Manderson GA, 2002, BIOCHEMISTRY-US, V41, P4080, DOI 10.1021/bi0160718; McBride WT, 1996, ANAESTHESIA, V51, P465, DOI 10.1111/j.1365-2044.1996.tb07793.x; Mobert J, 1999, ANESTHESIOLOGY, V90, P1372, DOI 10.1097/00000542-199905000-00022; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; Perez OD, 2003, NAT IMMUNOL, V4, P1083, DOI 10.1038/ni984; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Salas A, 2002, J BIOL CHEM, V277, P50255, DOI 10.1074/jbc.M209822200; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; Tang P, 1997, BIOPHYS J, V72, P1676, DOI 10.1016/S0006-3495(97)78813-1; Vemparala S, 2006, BIOPHYS J, V91, P2815, DOI 10.1529/biophysj.106.085324; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Yonkunas MJ, 2005, BIOPHYS J, V89, P2350, DOI 10.1529/biophysj.105.063396; Zimmerman T, 2007, CHEM BIOL DRUG DES, V70, P347, DOI 10.1111/j.1747-0285.2007.00566.x	36	39	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2008	22	12					4109	4116		10.1096/fj.08-113324	http://dx.doi.org/10.1096/fj.08-113324			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18708587	Green Published			2022-12-28	WOS:000261254800010
J	Nikonova, L; Koza, RA; Mendoza, T; Chao, PM; Curley, JP; Kozak, LP				Nikonova, Larissa; Koza, Robert A.; Mendoza, Tamra; Chao, Pei-Min; Curley, James P.; Kozak, Leslie P.			Mesoderm-specific transcript is associated with fat mass expansion in response to a positive energy balance	FASEB JOURNAL			English	Article						nutritional programming; epigenetics; alpha/beta fold hydrolase; imprinted genes; obesity	DIET-INDUCED OBESITY; STEAROYL-COA DESATURASE; NECROSIS-FACTOR-ALPHA; ADIPOSE-TISSUE; GENE-EXPRESSION; IMPRINTED GENE; PPAR-GAMMA; INSULIN-RESISTANCE; DIABETES-MELLITUS; COLD ENVIRONMENT	A 50-fold variation in mRNA and protein levels of the mesoderm-specific transcript gene (Mest) in white fat of C57BL/6J (B6) mice fed an obesogenic diet is positively correlated with expansion of fat mass. MEST protein was detected only in adipocytes, in which its induction occurred with both unsaturated and saturated dietary fat. To test the hypothesis that MEST modulates fat mass expansion, its expression was compared to that of stearoyl CoA desaturase (Scd1) in B6 mice exposed to diets and environmental temperatures that generated conditions separating the effects of food intake and adiposity. Under a range of conditions, Mest expression was always associated with variations in adiposity, whereas Scd1 expression was associated with the amount of saturated fat in the diet. Mest mRNA was expressed at its highest levels during early postnatal growth at the onset of the most rapid phase of fat mass expansion. MEST is localized to the endoplasmic reticulum/Golgi apparatus where its putative enzymatic properties as a lipase or acyltransferase, predicted from sequence homology with members of the alpha/beta fold hydrolase superfamily, can enable it to function in lipid accumulation under conditions of positive energy balance. Variations in adiposity and Mest expression in genetically identical mice also provides a model of epigenetic regulation. -Nikonova, L., Koza, R. A., Mendoza, T., Chao, P.-M., Curley, J. P., Kozak, L. P. Mesoderm-specific transcript is associated with fat mass expansion in response to a positive energy balance. FASEB J. 22, 3925-3937 (2008)	[Nikonova, Larissa; Koza, Robert A.; Mendoza, Tamra; Chao, Pei-Min; Kozak, Leslie P.] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; [Curley, James P.] Univ Cambridge, Darwin Coll, Madingley, England	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Cambridge	Kozak, LP (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	kozaklp@pbrc.edu	Chao, Pei-Min/L-8157-2013; Nikonova, Larissa/AAV-5151-2020; chao, P/GSD-8001-2022	Chao, Pei-Min/0000-0002-4846-3245; Curley, James/0000-0001-5546-007X	National Institutes of Health [P-30 DK072476, P20-RR021945]; Leverhulme Trust; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leverhulme Trust(Leverhulme Trust); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr. Indu Kheterpal and the Proteomic Core for analysis of MEST by mass spectroscopy and Dr. Barbara Kozak for making the photomicrographs. We thank Cody Giardino for excellent technical assistance. This research was supported by a grant from the Health Excellence Fund of the State of Louisiana and grants P-30 DK072476 and P20-RR021945 from the National Institutes of Health. J. P. C. was supported by a fellowship from the Leverhulme Trust.	Andersson L, 2006, J CELL SCI, V119, P2246, DOI 10.1242/jcs.02941; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; BARNETT SA, 1984, J PHYSIOL-LONDON, V346, P409, DOI 10.1113/jphysiol.1984.sp015031; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Bostrom P, 2005, ARTERIOSCL THROM VAS, V25, P1945, DOI 10.1161/01.ATV.0000179676.41064.d4; Burcelin M, 2002, AM J PHYSIOL-ENDOC M, V282, pE834, DOI 10.1152/ajpendo.00332.2001; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Danforth E, 2000, NAT GENET, V26, P13, DOI 10.1038/79111; de Fourmestraux V, 2004, J BIOL CHEM, V279, P50743, DOI 10.1074/jbc.M408014200; Enriori PJ, 2007, CELL METAB, V5, P181, DOI 10.1016/j.cmet.2007.02.004; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Goudriaan JR, 2001, ARTERIOSCL THROM VAS, V21, P1488, DOI 10.1161/hq0901.095147; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Holmquist M, 2000, CURR PROTEIN PEPT SC, V1, P209, DOI 10.2174/1389203003381405; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; Kobayashi S, 1997, HUM MOL GENET, V6, P781, DOI 10.1093/hmg/6.5.781; Koza RA, 2006, PLOS GENET, V2, P769, DOI 10.1371/journal.pgen.0020081; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005; Lee SH, 2004, J LIPID RES, V45, P1674, DOI 10.1194/jlr.M400039-JLR200; Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464; Lefebvre L, 1997, HUM MOL GENET, V6, P1907, DOI 10.1093/hmg/6.11.1907; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Ren Hong-shan, 2002, APPL MATH E NOTES, V2, P1; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; ROSS SR, 1993, GENE DEV, V7, P1318, DOI 10.1101/gad.7.7b.1318; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Sakai T, 2007, J BIOL CHEM, V282, P2038, DOI 10.1074/jbc.M608144200; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Soukas A, 2000, GENE DEV, V14, P963; Takahashi M, 2005, AM J PHYSIOL-ENDOC M, V288, pE117, DOI 10.1152/ajpendo.00244.2004; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X	49	72	74	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3925	3937		10.1096/fj.08-108266	http://dx.doi.org/10.1096/fj.08-108266			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18644838	Green Published			2022-12-28	WOS:000260503000021
J	Chourbaji, S; Vogt, MA; Fumagalli, F; Sohr, R; Frasca, A; Brandwein, C; Hortnagl, H; Riva, MA; Sprengel, R; Gass, P				Chourbaji, S.; Vogt, M. A.; Fumagalli, F.; Sohr, R.; Frasca, A.; Brandwein, C.; Hoertnagl, H.; Riva, M. A.; Sprengel, R.; Gass, P.			AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression	FASEB JOURNAL			English	Article						learned helplessness; serotonin; hippocampus	PERFORMANCE LIQUID-CHROMATOGRAPHY; RESISTANT MAJOR DEPRESSION; GAMMA-AMINOBUTYRIC-ACID; NMDA RECEPTOR; AFFECTIVE-DISORDERS; THERAPEUTIC TARGET; TEMPORAL CORTEX; RAT; HIPPOCAMPUS; PLASTICITY	Recent evidence indicates that glutamate homeostasis and neurotransmission are altered in major depressive disorder, but the nature of the disruption and the mechanisms by which it contributes to the syndrome are unclear. Glutamate can act via AMPA, NMDA, or metabotropic receptors. Using targeted mutagenesis, we demonstrate here that mice with deletion of the main AMPA receptor subunit GluR-A represent a depression model with good face and construct validity, showing behavioral and neurochemical features of depression also postulated for human patients. GluR-A(-/-) mice display increased learned helplessness, decreased serotonin and norepinephrine levels, and disturbed glutamate homeostasis with increased glutamate levels and increased NMDA receptor expression. These results correspond well with current concepts regarding the role of AMPA and NMDA receptors in depression, postulating that compounds that augment AMPA receptor signaling or decrease NMDA receptor functions have antidepressant effects. GluR-A(-/-) mice represent a model to investigate the pathophysiology underlying the depressive phenotype and to identify changes in neural plasticity and resilience evoked by the genetic alterations in glutamatergic function. Furthermore, GluR-A(-/-) mice may be a valuable tool to study biological mechanisms of AMPA receptor modulators and the efficacy of NMDA antagonists in reducing behavioral or biochemical changes that correlate with increased helplessness.	[Chourbaji, S.; Vogt, M. A.; Brandwein, C.; Gass, P.] Univ Heidelberg, Cent Inst Mental Hlth, D-68159 Mannheim, Germany; [Fumagalli, F.; Frasca, A.; Riva, M. A.] Univ Milan, Dept Pharmacol Sci, Milan, Italy; [Sohr, R.; Hoertnagl, H.] Charite Univ Med Berlin, Inst Pharmacol, D-13353 Berlin, Germany; [Sprengel, R.] Max Planck Inst Med Res, Heidelberg, Germany	Central Institute of Mental Health; Ruprecht Karls University Heidelberg; University of Milan; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society	Gass, P (corresponding author), Univ Heidelberg, Cent Inst Mental Hlth, J 5, D-68159 Mannheim, Germany.	peter.gass@zi-mannheim.de	Fumagalli, Fabio/E-8992-2012; Riva, Marco Andrea/N-7418-2017	Riva, Marco Andrea/0000-0002-1699-5060; Fumagalli, Fabio/0000-0002-8814-7706; Frasca, Angelisa/0000-0002-0963-9789; Vogt, Miriam Annika/0000-0002-3400-5067	Deutsche Forschungsgemeinschaft [GA427/8-1, SP602/2-1]; University of Heidelberg [GK791/2]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Heidelberg	This work was supported by grants from the Deutsche Forschungsgemeinschaft (GA427/8-1 to P. G. and SP602/2-1 to R. S.). M. A. V. holds a scholarship from the GK791/2 of the University of Heidelberg.	Amiel Jonathan M, 2007, Curr Psychiatry Rep, V9, P278, DOI 10.1007/s11920-007-0033-7; Aston C, 2005, MOL PSYCHIATR, V10, P309, DOI 10.1038/sj.mp.4001565; Bannerman DM, 2004, BEHAV NEUROSCI, V118, P643, DOI 10.1037/0735-7044.118.3.643; Bleakman D., 2007, CNS & Neurological Disorders-Drug Targets, V6, P117, DOI 10.2174/187152707780363258; Bonanno G, 2005, J NEUROSCI, V25, P3270, DOI 10.1523/JNEUROSCI.5033-04.2005; Charney DS, 1998, J CLIN PSYCHIAT, V59, P11; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; FELICE LJ, 1978, J NEUROCHEM, V31, P1461, DOI 10.1111/j.1471-4159.1978.tb06573.x; Fumagalli F, 2008, MOL PHARMACOL, V73, P1484, DOI 10.1124/mol.107.043786; Garcia LSB, 2008, PROG NEURO-PSYCHOPH, V32, P140, DOI 10.1016/j.pnpbp.2007.07.027; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Javitt DC, 2004, MOL PSYCHIATR, V9, P984, DOI 10.1038/sj.mp.4001551; Kugaya A, 2005, CNS SPECTRUMS, V10, P808, DOI 10.1017/S1092852900010403; Maeng S, 2008, BIOL PSYCHIAT, V63, P349, DOI 10.1016/j.biopsych.2007.05.028; MAIER SF, 1984, PROG NEURO-PSYCHOPH, V8, P435, DOI 10.1016/0278-5846(84)90120-9; Maltese TM, 1999, AM J PSYCHIAT, V156, P1833; MARTIN JV, 1990, J NEUROCHEM, V55, P1142, DOI 10.1111/j.1471-4159.1990.tb03117.x; McEwen BS, 2001, ANN NY ACAD SCI, V933, P265, DOI 10.1111/j.1749-6632.2001.tb05830.x; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; Newton SS, 2002, J NEUROSCI, V22, P10883; Nudmamud-Thanoi S, 2004, NEUROSCI LETT, V372, P173, DOI 10.1016/j.neulet.2004.09.035; Paul IA, 2003, ANN NY ACAD SCI, V1003, P250, DOI 10.1196/annals.1300.016; Piepponen TP, 2001, J CHROMATOGR B, V757, P277, DOI 10.1016/S0378-4347(01)00156-6; Pittenger Christopher, 2007, CNS & Neurological Disorders-Drug Targets, V6, P101, DOI 10.2174/187152707780363267; Ridder S, 2005, J NEUROSCI, V25, P6243, DOI 10.1523/JNEUROSCI.0736-05.2005; Sanacora G, 2004, ARCH GEN PSYCHIAT, V61, P705, DOI 10.1001/archpsyc.61.7.705; SCHOEPFER R, 1994, PROG NEUROBIOL, V42, P353, DOI 10.1016/0301-0082(94)90076-0; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; Skolnick P, 2002, J CLIN PSYCHIAT, V63, P19; SPERK G, 1982, J NEUROCHEM, V38, P840, DOI 10.1111/j.1471-4159.1982.tb08708.x; SPERK G, 1981, EUR J PHARMACOL, V74, P279, DOI 10.1016/0014-2999(81)90046-7; TRULLAS R, 1989, PHARMACOL BIOCHEM BE, V34, P313, DOI 10.1016/0091-3057(89)90317-1; TRULLAS R, 1990, EUR J PHARMACOL, V185, P1, DOI 10.1016/0014-2999(90)90204-J; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805; Zarate CA, 2004, AM J PSYCHIAT, V161, P171, DOI 10.1176/appi.ajp.161.1.171; Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856	36	117	124	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3129	3134		10.1096/fj.08-106450	http://dx.doi.org/10.1096/fj.08-106450			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18492725				2022-12-28	WOS:000258761300005
J	Cebe-Suarez, S; Grunewald, FS; Jaussi, R; Li, XJ; Claesson-Welsh, L; Spillmann, D; Mercer, AA; Prota, AE; Ballmer-Hofer, K				Cebe-Suarez, Stephanie; Gruenewald, Felix S.; Jaussi, Rolf; Li, Xiujuan; Claesson-Welsh, Lena; Spillmann, Dorothe; Mercer, Andrew A.; Prota, Andrea E.; Ballmer-Hofer, Kurt			Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR	FASEB JOURNAL			English	Article						neuropilin; angiogenesis; heparin sulfate; pox virus; vascular endothelial growth factor	ENDOTHELIAL-GROWTH-FACTOR; HEPARIN-BINDING DOMAIN; RECEPTOR TYROSINE KINASE; EXON 7-ENCODED DOMAIN; FLT-1 RECEPTOR; SPLICE VARIANT; TUMOR-CELLS; NEUROPILIN-1; VEGF(165); ANGIOGENESIS	Vascular endothelial growth factors (VEGFs) interact with the receptor tyrosine kinases (RTKs) VEGFR-1, -2, and -3; neuropilins (NRPs); and heparan sulfate (HS) proteoglycans. VEGF RTKs signal to downstream targets upon ligand-induced tyrosine phosphorylation, while NRPs and HS act as coreceptors that lack enzymatic activity yet modulate signal output by VEGF RTKs. VEGFs exist in various isoforms with distinct receptor specificity and biological activity. Here, a series of mammalian VEGF-A splice variants and orf virus VEGF-Es, as well as chimeric and mutant VEGF variants, were characterized to determine the motifs required for binding to NRP-1 in the absence (VEGF-E) or presence (VEGF-A165) of an HS-binding sequence. We identified the carboxyterminal peptides RPPR and DKPRR as the NRP-1 binding motifs of VEGF-E and VEGF-A, respectively. RPPR had significantly higher affinity for NRP-1 than DKPRR. VEGFs containing an RPPR motif promoted HS-independent coreceptor complex assembly between VEGFR-2 and NRP-1, independent of whether these receptors were expressed on the same or separate cells grown in cocultures. Functional studies showed that stable coreceptor assembly by VEGF correlated with its ability to promote vessel formation in an embryoid body angiogenesis assay.	[Cebe-Suarez, Stephanie; Gruenewald, Felix S.; Jaussi, Rolf; Prota, Andrea E.; Ballmer-Hofer, Kurt] Paul Scherrer Inst, Lab Biomol Res, CH-5232 Villigen, Switzerland; [Spillmann, Dorothe] Uppsala Univ, Biomed Ctr, IMBIM, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Mercer, Andrew A.] Univ Otago, Dept Microbiol & Immunol, Virus Res Unit, Christchurch, New Zealand; [Li, Xiujuan; Claesson-Welsh, Lena] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Uppsala, Sweden	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Uppsala University; University of Otago; Uppsala University	Ballmer-Hofer, K (corresponding author), Paul Scherrer Inst, Lab Biomol Res, Bldg OFLC 102, CH-5232 Villigen, Switzerland.	kurt.ballmer@psi.ch	Prota, Andrea Enrico/R-9526-2019; li, xiu/GXV-1745-2022; Mercer, Andrew A/G-6635-2015	Prota, Andrea Enrico/0000-0003-0875-5339; Grunewald, Felix Steffen/0000-0002-9390-8020; Mercer, Andrew/0000-0003-3697-1071; Ballmer-Hofer, Kurt/0000-0002-3800-9129				Bates DO, 2002, CANCER RES, V62, P4123; Errico M, 2004, J BIOL CHEM, V279, P43929, DOI 10.1074/jbc.M401418200; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; Gerhardt H, 2004, DEV DYNAM, V231, P503, DOI 10.1002/dvdy.20148; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Heil Matthias, 2003, Angiogenesis, V6, P201, DOI 10.1023/B:AGEN.0000021391.88601.92; Jakobsson L, 2006, DEV CELL, V10, P625, DOI 10.1016/j.devcel.2006.03.009; Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Keck RG, 1997, ARCH BIOCHEM BIOPHYS, V344, P103, DOI 10.1006/abbi.1997.0145; Komori Y, 1999, BIOCHEMISTRY-US, V38, P11796, DOI 10.1021/bi990562z; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Li XJ, 2007, STEM CELLS, V25, P2987, DOI 10.1634/stemcells.2007-0397; LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994; Mercer AA, 2002, J GEN VIROL, V83, P2845, DOI 10.1099/0022-1317-83-11-2845; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PAJUSOLA K, 1992, CANCER RES, V52, P5738; Pan Q, 2007, J BIOL CHEM, V282, P24049, DOI 10.1074/jbc.M703554200; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; Pieren M, 2006, J BIOL CHEM, V281, P19578, DOI 10.1074/jbc.M601842200; Savory LJ, 2000, J VIROL, V74, P10699, DOI 10.1128/JVI.74.22.10699-10706.2000; Scheidegger P, 1999, BIOL CHEM, V380, P1449, DOI 10.1515/BC.1999.187; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shraga-Heled N, 2007, FASEB J, V21, P915, DOI 10.1096/fj.06-6277com; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Starzec A, 2007, PEPTIDES, V28, P2397, DOI 10.1016/j.peptides.2007.09.013; Suarez S, 2001, J CELL SCI, V114, P1229; Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9; Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370; TERMAN BI, 1991, ONCOGENE, V6, P1677; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Tokunaga Y, 2006, BIOCHEM BIOPH RES CO, V348, P957, DOI 10.1016/j.bbrc.2006.07.117; Ueda N, 2007, VIRUS RES, V124, P50, DOI 10.1016/j.virusres.2006.09.012; Vander Kooi CW, 2007, P NATL ACAD SCI USA, V104, P6152, DOI 10.1073/pnas.0700043104; von Wronski MA, 2006, J BIOL CHEM, V281, P5702, DOI 10.1074/jbc.M511941200; Wang L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001161; Wang L, 2006, FASEB J, V20, P1513, DOI 10.1096/fj.05-5504fje; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Wise LM, 2003, J BIOL CHEM, V278, P38004, DOI 10.1074/jbc.M301194200; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; Yamazaki Y, 2005, BIOCHEMISTRY-US, V44, P8858, DOI 10.1021/bi050197d	54	46	48	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					3078	3086		10.1096/fj.08-107219	http://dx.doi.org/10.1096/fj.08-107219			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18467594				2022-12-28	WOS:000258089300047
J	Ng, AN; Toresson, H				Ng, Ai Na; Toresson, Hakan			gamma-secretase and metalloproteinase activity regulate the distribution of endoplasmic reticulum to hippocampal neuron dendritic spines	FASEB JOURNAL			English	Article						synapse; primary culture; live cell imaging	CAPACITATIVE CALCIUM-ENTRY; AMYLOID PRECURSOR PROTEIN; SERIAL ELECTRON-MICROSCOPY; CEREBELLAR PURKINJE-CELLS; PRESENILIN/GAMMA-SECRETASE; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; PLASMA-MEMBRANE; BIOPHYSICAL CHARACTERISTICS; 3-DIMENSIONAL ORGANIZATION	The neuronal endoplasmic reticulum (ER) contributes to many physiological and pathological processes in the brain. A subset of dendritic spines on hippocampal neurons contains ER that may contribute to synapse-specific intracellular signaling. Distribution of ER to spines is dynamic, but knowledge of the regulatory mechanisms is lacking. In live cell imaging experiments we now show that cultured hippocampal neurons rapidly lost ER from spines after phorbol ester treatment. ER loss was reduced by inhibiting gamma-secretase (DAPT at 2 mu M) and metalloproteinase (TAPI-0 and GM6001 at 4 mu M) activity. Inhibition of protein kinase C also diminished loss of ER by preventing exit of ER from spines. Furthermore, gamma-secretase and metalloproteinase inhibition, in the absence of phorbol ester, triggered a dramatic increase in spine ER content. Metalloproteinases and gamma-secretase cleave several transmembrane proteins. Many of these substrates are known to localize to adherens junctions, a structural specialization with which spine ER interacts. One interesting possibility is thus that ER content within spines may be regulated by proteolytic activity affecting adherens junctions. Our data demonstrate a hitherto unknown role for these two proteolytic activities in regulating dynamic aspects of cellular ultrastructure, which is potentially important for cellular calcium homeostasis and several intracellular signaling pathways.	[Ng, Ai Na; Toresson, Hakan] Lund Univ, Fac Med, Wallenberg Neurosci Ctr, Expt Brain Res Lab, S-22184 Lund, Sweden	Lund University	Toresson, H (corresponding author), Lund Univ, Fac Med, Wallenberg Neurosci Ctr, Expt Brain Res Lab, BMC A13, S-22184 Lund, Sweden.	hakan.toresson@med.lu.se		Ng, Ai Na/0000-0002-6219-5523				Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; Bardo S, 2006, TRENDS PHARMACOL SCI, V27, P78, DOI 10.1016/j.tips.2005.12.008; Begley JG, 1999, J NEUROCHEM, V72, P1030, DOI 10.1046/j.1471-4159.1999.0721030.x; Berridge Michael, 2004, Sci STKE, V2004, ppe33; Bonn S, 2007, MOL CELL BIOL, V27, P4121, DOI 10.1128/MCB.01708-06; Calabrese B, 2005, NEURON, V48, P77, DOI 10.1016/j.neuron.2005.08.027; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; Costa RM, 2003, CURR BIOL, V13, P1348, DOI 10.1016/S0960-9822(03)00492-5; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; Deller T, 2003, P NATL ACAD SCI USA, V100, P10494, DOI 10.1073/pnas.1832384100; Du YR, 2004, J CELL SCI, V117, P2871, DOI 10.1242/jcs.01286; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Hambsch B, 2005, J BIOL CHEM, V280, P15888, DOI 10.1074/jbc.M414359200; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HENKART M, 1976, J CELL BIOL, V70, P338, DOI 10.1083/jcb.70.2.338; Herms J, 2003, J BIOL CHEM, V278, P2484, DOI 10.1074/jbc.M206769200; Herz J, 2006, NAT REV NEUROSCI, V7, P850, DOI 10.1038/nrn2009; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HOLBRO N, 2007, 37 ANN M SOC NEUR; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Huschenbett J, 1998, BBA-BIOMEMBRANES, V1374, P34, DOI 10.1016/S0005-2736(98)00121-7; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kovalchuk Y, 2000, J NEUROSCI, V20, P1791; Kume H, 2003, INT J MOL MED, V12, P57; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; Lencesova L, 2004, J BIOL CHEM, V279, P2885, DOI 10.1074/jbc.M310365200; Levine T, 2006, CURR OPIN CELL BIOL, V18, P371, DOI 10.1016/j.ceb.2006.06.011; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Litterst C, 2007, J BIOL CHEM, V282, P16155, DOI 10.1074/jbc.M611449200; Mainen ZF, 1999, NATURE, V399, P151, DOI 10.1038/20187; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Mattson MP, 2007, AGING CELL, V6, P337, DOI 10.1111/j.1474-9726.2007.00275.x; Medina M, 2003, CELL SIGNAL, V15, P829, DOI 10.1016/S0898-6568(03)00041-X; Moriguchi S, 2006, P NATL ACAD SCI USA, V103, P10811, DOI 10.1073/pnas.0509863103; Ostroff LE, 2002, NEURON, V35, P535, DOI 10.1016/S0896-6273(02)00785-7; Pierce JP, 2000, NAT NEUROSCI, V3, P311, DOI 10.1038/73868; Pierce JP, 2001, CURR BIOL, V11, P351, DOI 10.1016/S0960-9822(01)00077-X; Pilpel Y, 2004, EUR J NEUROSCI, V19, P3151, DOI 10.1111/j.0953-816X.2004.03380.x; Putney JW, 2007, CELL CALCIUM, V42, P103, DOI 10.1016/j.ceca.2007.01.011; Rauch U, 2007, BIOCHEM SOC T, V35, P656, DOI 10.1042/BST0350656; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Ris L, 2003, J BIOL CHEM, V278, P44393, DOI 10.1074/jbc.M300971200; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Sala C, 2005, J NEUROSCI, V25, P4587, DOI 10.1523/JNEUROSCI.4822-04.2005; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Selkoe DJ, 2007, CELL, V131, P215, DOI 10.1016/j.cell.2007.10.012; SHARP AH, 1993, J NEUROSCI, V13, P3051; Smith IF, 2005, CELL CALCIUM, V38, P427, DOI 10.1016/j.ceca.2005.06.021; Spacek J, 1998, J COMP NEUROL, V393, P58, DOI 10.1002/(SICI)1096-9861(19980330)393:1<58::AID-CNE6>3.0.CO;2-P; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; STEWARD O, 1988, J NEUROSCI, V8, P176; Storey E, 1996, BRAIN RES, V735, P217, DOI 10.1016/0006-8993(96)00608-7; TAKEI K, 1992, J NEUROSCI, V12, P489; TERASAKI M, 1994, P NATL ACAD SCI USA, V91, P7510, DOI 10.1073/pnas.91.16.7510; Toresson H, 2005, EUR J NEUROSCI, V22, P1793, DOI 10.1111/j.1460-9568.2005.04342.x; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004; Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101; WATANABE H, 1976, J NEUROCYTOL, V5, P125, DOI 10.1007/BF01176186; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zatti G, 2006, CELL CALCIUM, V39, P539, DOI 10.1016/j.ceca.2006.03.002; Zhang KZ, 2006, NEUROLOGY, V66, pS102, DOI 10.1212/01.wnl.0000192306.98198.ec; Zhang M, 2006, FASEB J, V20, P1176, DOI 10.1096/fj.05-5531fje	74	10	10	2	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2832	2842		10.1096/fj.07-103903	http://dx.doi.org/10.1096/fj.07-103903			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18424769				2022-12-28	WOS:000258089300023
J	Winter, PM; Schmieder, AH; Caruthers, SD; Keene, JL; Zhang, HY; Wickline, SA; Lanza, GM				Winter, Patrick M.; Schmieder, Anne H.; Caruthers, Shelton D.; Keene, Jeffery L.; Zhang, Huiying; Wickline, Samuel A.; Lanza, Gregory M.			Minute dosages of alpha(nu)beta(3)-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits	FASEB JOURNAL			English	Article						MRI; cancer; drug delivery; molecular imaging	ENDOTHELIAL-CELL ANERGY; IN-VIVO; COLORECTAL-CANCER; BREAST-CANCER; INTEGRIN ALPHA(V)BETA(3); INHIBITOR TNP-470; CONTRAST AGENT; METHIONINE AMINOPEPTIDASES; VITRONECTIN RECEPTOR; SELECTIVE-INHIBITION	Fumagillin suppresses angiogenesis in cancer models and clinical trials, but it is associated with neurotoxicity at systemic doses. In this study, alpha(nu)beta(3)-targeted fumagillin nanoparticles were used to suppress the neovasculature and inhibit Vx-2 adenocarcinoma development using minute drug doses. Tumorbearing rabbits were treated on days 6, 9, and 12 postimplantation with alpha(nu)beta(3)-targeted fumagillin nanoparticles (30 mu g/kg), alpha(nu)beta(3)-targeted nanoparticles without drug, nontargeted fumagillin nanoparticles (30 mu g/kg) or saline. On day 16, MRI was performed with alpha(nu)beta(3)-targeted paramagnetic nanoparticles to quantify tumor size and assess neovascularity. Tumor volume was reduced among rabbits receiving alpha(nu)beta(3)-targeted fumagillin nanoparticles (470 +/- 120 mm(3)) compared with the three control groups: nontargeted fumagillin nanoparticles (1370 +/- 300 mm3, P<0.05), alpha(nu)beta(3)-targeted nanoparticles without drug (1080 +/- 180 mm(3), P<0.05) and saline (980 +/- 80 mm(3), P<0.05). MR molecular imaging of control rabbits ( no fumagillin) revealed a predominant peripheral distribution of neovascularity representing 7.2% of the tumor rim volume, which decreased to 2.8% (P<0.05) with alpha(nu)beta(3)-targeted fumagillin nanoparticle treatment. Microscopically, the tumor parenchyma tended to show T-cell infiltration after targeted fumagillin treatment, which was not appreciated in control animals. These results suggest that alpha(nu)beta(3)-targeted fumagillin nanoparticles could provide a safe and effective means to deliver MetAP2 inhibitors alone or in combination with cytotoxic or immunotherapy.	[Winter, Patrick M.; Schmieder, Anne H.; Caruthers, Shelton D.; Zhang, Huiying; Wickline, Samuel A.; Lanza, Gregory M.] Washington Univ, Sch Med, St Louis, MO 63108 USA; [Caruthers, Shelton D.] Philips Med Syst, Andover, MA USA; [Keene, Jeffery L.] Kereos Inc, St Louis, MO USA	Washington University (WUSTL); Philips; Philips Healthcare	Winter, PM (corresponding author), Washington Univ, Sch Med, Campus Box 8215,4320 Forest Pk Ave, St Louis, MO 63108 USA.	patrick@cvu.wustl.edu		Winter, Patrick/0000-0001-5975-5465	NATIONAL CANCER INSTITUTE [U54CA119342, U54CA136398] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073646, R01HL078631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059302] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-27031-16, U54 CA119342, N01-CO-37007, CA-119342, U54 CA136398] Funding Source: Medline; NHLBI NIH HHS [R01 HL078631, R01 HL073646, HL-78631, HL-73646] Funding Source: Medline; NIAID NIH HHS [N01CO37007] Funding Source: Medline; NIBIB NIH HHS [R01 EB001704, EB-01704] Funding Source: Medline; NINDS NIH HHS [R01 NS059302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037; ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; Baeten CIM, 2006, CLIN GASTROENTEROL H, V4, P1351, DOI 10.1016/j.cgh.2006.08.005; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bhargava P, 1999, CLIN CANCER RES, V5, P1989; Borgstrom P, 1997, J CLIN INVEST, V99, P2246, DOI 10.1172/JCI119399; Cai WB, 2006, CANCER RES, V66, P9673, DOI 10.1158/0008-5472.CAN-06-1480; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Castronovo V, 1996, EUR J CANCER, V32A, P2520, DOI 10.1016/S0959-8049(96)00388-7; Chen XY, 2004, BIOCONJUGATE CHEM, V15, P41, DOI 10.1021/bc0300403; CHERESH DA, 1991, BIOCHEM SOC T, V19, P835, DOI 10.1042/bst0190835; Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356; Coleman PJ, 2004, J MED CHEM, V47, P4829, DOI 10.1021/jm049874c; Crowder KC, 2005, ULTRASOUND MED BIOL, V31, P1693, DOI 10.1016/j.ultrasmedbio.2005.07.022; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; Dirkx AEM, 2003, CANCER RES, V63, P2322; Dirkx AEM, 2006, FASEB J, V20, P621, DOI 10.1096/fj.05-4493com; Eerola AK, 2000, CLIN CANCER RES, V6, P1875; Flacke S, 2001, CIRCULATION, V104, P1280, DOI 10.1161/hc3601.094303; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Giantonio BJ, 2006, ANN ONCOL, V17, P1399, DOI 10.1093/annonc/mdl161; Griffioen A W, 1998, Angiogenesis, V2, P235, DOI 10.1023/A:1009237324501; Griffioen AW, 1999, INT J CANCER, V80, P315, DOI 10.1002/(SICI)1097-0215(19990118)80:2<315::AID-IJC23>3.0.CO;2-L; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Harris TD, 2003, CANCER BIOTHER RADIO, V18, P627, DOI 10.1089/108497803322287727; Harris TD, 2006, BIOCONJUGATE CHEM, V17, P1294, DOI 10.1021/bc060063s; Helluin O, 2000, J BIOL CHEM, V275, P18337, DOI 10.1074/jbc.M001529200; Hess SD, 2003, J IMMUNOL, V170, P400, DOI 10.4049/jimmunol.170.1.400; Holig P, 2004, PROTEIN ENG DES SEL, V17, P433, DOI 10.1093/protein/gzh055; Hu G, 2007, INT J CANCER, V120, P1951, DOI 10.1002/ijc.22581; Imagawa Y, 2004, AURIS NASUS LARYNX, V31, P239, DOI 10.1016/j.anl.2004.03.008; Itoh H, 1997, J VASC SURG, V25, P1061, DOI 10.1016/S0741-5214(97)70130-7; Jackaman C, 2003, J IMMUNOL, V171, P5051, DOI 10.4049/jimmunol.171.10.5051; Janssen ML, 2002, CANCER RES, V62, P6146; Kageshita T, 2000, INT J CANCER, V89, P153, DOI 10.1002/(SICI)1097-0215(20000320)89:2<153::AID-IJC9>3.0.CO;2-1; Konno H, 1996, CANCER-AM CANCER SOC, V77, P1736; Kudelka AP, 1998, NEW ENGL J MED, V338, P991, DOI 10.1056/NEJM199804023381412; Lanza GM, 2002, CIRCULATION, V106, P2842, DOI 10.1161/01.CIR.0000044020.27990.32; Li LY, 2004, INT J RADIAT ONCOL, V58, P1215, DOI 10.1016/j.ijrobp.2003.10.057; LIS LJ, 1982, BIOPHYS J, V37, P657; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Logothetis CJ, 2001, CLIN CANCER RES, V7, P1198; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; McQuade P, 2004, BIOCONJUGATE CHEM, V15, P988, DOI 10.1021/bc049961j; Meoli DF, 2004, J CLIN INVEST, V113, P1684, DOI 10.1172/JCI200420352; Mizutani N, 2004, Breast Dis, V20, P81; Mulder WJM, 2007, FASEB J, V21, P378, DOI 10.1096/fj.06-6791com; Offodile R, 1999, TUMORI, V85, P51, DOI 10.1177/030089169908500111; Okaji Y, 2006, EJSO, V32, P363, DOI 10.1016/j.ejso.2006.01.016; Onthank DC, 2004, BIOCONJUGATE CHEM, V15, P235, DOI 10.1021/bc034108q; Plum Stacy M, 2004, Curr Opin Investig Drugs, V5, P1243; Posey JA, 2001, CANCER BIOTHER RADIO, V16, P125, DOI 10.1089/108497801300189218; Preda A, 2004, J MAGN RESON IMAGING, V20, P865, DOI 10.1002/jmri.20184; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Roberts TPL, 2002, ACAD RADIOL, V9, pS261, DOI 10.1016/S1076-6332(03)80452-X; Rosen MA, 2007, CLIN CANCER RES, V13, p770S, DOI 10.1158/1078-0432.CCR-06-1921; Sadeghi MM, 2004, CIRCULATION, V110, P84, DOI 10.1161/01.CIR.0000133319.84326.70; Schmieder AH, 2005, MAGN RESON MED, V53, P621, DOI 10.1002/mrm.20391; Shukla R, 2005, CHEM COMMUN, P5739, DOI 10.1039/b507350b; Shusterman S, 2001, CLIN CANCER RES, V7, P977; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; SOMAN NR, 2008, NANO LETT; Tran HT, 2004, CANCER CHEMOTH PHARM, V54, P308, DOI 10.1007/s00280-004-0816-z; Tromp SC, 2000, INT IMMUNOL, V12, P671, DOI 10.1093/intimm/12.5.671; Turetschek K, 2003, EUR J NUCL MED MOL I, V30, P448, DOI 10.1007/s00259-002-1000-5; Turk BE, 1999, CHEM BIOL, V6, P823, DOI 10.1016/S1074-5521(99)80129-X; Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D; Weissleder R, 2001, BIOCONJUGATE CHEM, V12, P213, DOI 10.1021/bc000091p; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; Winter PM, 2003, CANCER RES, V63, P5838; Ye YP, 2006, J MED CHEM, V49, P2268, DOI 10.1021/jm050947h; Zhang CF, 2007, CANCER RES, V67, P1555, DOI 10.1158/0008-5472.CAN-06-1668; Zhang XZ, 2006, J NUCL MED, V47, P113	75	86	89	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2758	2767		10.1096/fj.07-103929	http://dx.doi.org/10.1096/fj.07-103929			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18362202	Green Published			2022-12-28	WOS:000258089300016
J	Koehl, M; Meerlo, P; Gonzales, D; Rontal, A; Turek, FW; Abrous, DN				Koehl, M.; Meerlo, P.; Gonzales, D.; Rontal, A.; Turek, F. W.; Abrous, D. N.			Exercise-induced promotion of hippocampal cell proliferation requires beta-endorphin	FASEB JOURNAL			English	Article						running; opioids; cell survival; adult neurogenesis; homeostatic balance	MU-OPIOID RECEPTORS; SPONTANEOUSLY HYPERTENSIVE-RAT; SPRAGUE-DAWLEY RATS; MOUSE DENTATE GYRUS; VOLUNTARY EXERCISE; ADULT HIPPOCAMPUS; PHYSICAL-ACTIVITY; ENVIRONMENTAL ENRICHMENT; INCREASE NEUROGENESIS; ENHANCES NEUROGENESIS	variety of stimuli, including exercise, but the mechanisms by which running affects neurogenesis are not yet fully understood. Because beta-endorphin, which is released in response to exercise, increases cell proliferation in vitro, we hypothesized that it could exert a similar effect in vivo and mediate the stimulatory effects of running on neurogenesis. We thus analyzed the effects of voluntary wheel-running on adult neurogenesis (proliferation, differentiation, survival/death) in wild-type and beta-endorphin-deficient mice. In wild-type mice, exercise promoted cell proliferation evaluated by sacrificing animals 24 h after the last 5-bromo-2'-deoxyuridine (BrdU) pulse and by using endogenous cell cycle markers (Ki67 and pH(3)). This was accompanied by an increased survival of 4-wk-old BrdU-labeled cells, leading to a net increase of neurogenesis. beta-Endorphin deficiency had no effect in sedentary mice, but it completely blocked the running-induced increase in cell proliferation; this blockade was accompanied by an increased survival of 4-wk-old cells and a decreased cell death. Altogether, adult neurogenesis was increased in response to exercise in knockout mice. We conclude that beta-endorphin released during running is a key factor for exercise-induced cell proliferation and that a homeostatic balance may regulate the final number of new neurons.	[Koehl, M.] INSERM, Ctr Rech, U862, F-33077 Bordeaux, France; [Koehl, M.; Gonzales, D.; Abrous, D. N.] Univ Bordeaux, Bordeaux, France; [Meerlo, P.] Univ Groningen, Dept Mol Neurobiol, Haren, Netherlands; [Rontal, A.; Turek, F. W.] Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; University of Groningen; Northwestern University	Koehl, M (corresponding author), INSERM, Ctr Rech, U862, 146 Rue Leo Saignat, F-33077 Bordeaux, France.	koehl@bordeaux.inserm.fr	Abrous, Nora-Djoher/N-6977-2017; Koehl, Muriel/C-3698-2011; Koehl, Muriel/ABI-2043-2020	Koehl, Muriel/0000-0002-7601-1422; Koehl, Muriel/0000-0002-7601-1422; abrous, nora/0000-0002-8589-305X; Meerlo, Peter/0000-0002-8330-6050				ABLEITNER A, 1992, J PHARMACOL EXP THER, V262, P415; Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; AKANA SF, 1983, ENDOCRINOLOGY, V113, P2226, DOI 10.1210/endo-113-6-2226; AKANA SF, 1983, ENDOCRINOLOGY, V113, P2232, DOI 10.1210/endo-113-6-2232; Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Belvindrah R, 2002, J NEUROSCI, V22, P3594; Bjornebekk A, 2005, INT J NEUROPSYCHOPH, V8, P357, DOI 10.1017/S1461145705005122; Brown J, 2003, EUR J NEUROSCI, V17, P2042, DOI 10.1046/j.1460-9568.2003.02647.x; Ciaroni S, 2002, MECH AGEING DEV, V123, P1341, DOI 10.1016/S0047-6374(02)00070-2; COLT EWD, 1981, LIFE SCI, V28, P1637, DOI 10.1016/0024-3205(81)90319-2; Cooper-Kuhn CM, 2004, J NEUROSCI RES, V77, P155, DOI 10.1002/jnr.20116; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Drake CT, 2002, HIPPOCAMPUS, V12, P119, DOI 10.1002/hipo.1107; Drake CT, 1999, BRAIN RES, V849, P203, DOI 10.1016/S0006-8993(99)01910-1; Drapeau E, 2007, J NEUROSCI, V27, P6037, DOI 10.1523/JNEUROSCI.1031-07.2007; Droste SK, 2003, ENDOCRINOLOGY, V144, P3012, DOI 10.1210/en.2003-0097; Dupret D, 2007, PLOS BIOL, V5, P1683, DOI 10.1371/journal.pbio.0050214; Eisch AJ, 2006, HIPPOCAMPUS, V16, P271, DOI 10.1002/hipo.20161; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Ferreira A, 2006, EUR PSYCHIAT, V21, P580, DOI 10.1016/j.eurpsy.2005.02.003; Goldfarb AH, 1997, SPORTS MED, V24, P8, DOI 10.2165/00007256-199724010-00002; Gomez F, 1996, NEUROENDOCRINOLOGY, V63, P327, DOI 10.1159/000126973; Greenwood BN, 2003, J NEUROSCI, V23, P2889; Harburg GC, 2007, NEUROSCIENCE, V144, P77, DOI 10.1016/j.neuroscience.2006.09.018; Hayward MD, 2002, J NEUROSCI, V22, P8251; HOFFMANN P, 1990, REGUL PEPTIDES, V28, P233, DOI 10.1016/0167-0115(90)90021-N; Holmes MM, 2004, J NEUROSCI RES, V76, P216, DOI 10.1002/jnr.20039; Holmes MM, 2002, BEHAV NEUROSCI, V116, P160, DOI 10.1037//0735-7044.116.1.160; JANAL MN, 1984, PAIN, V19, P13, DOI 10.1016/0304-3959(84)90061-7; Jonsdottir IH, 2000, LIFE SCI, V66, P1231, DOI 10.1016/S0024-3205(00)00428-8; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849; Kim SH, 2002, LIFE SCI, V71, P1331, DOI 10.1016/S0024-3205(02)01849-0; Kitamura T, 2003, NEUROSCI RES, V47, P55, DOI 10.1016/S0168-0102(03)00171-8; Knubben K, 2007, BRIT J SPORT MED, V41, P29, DOI 10.1136/bjsm.2006.030130; Kronenberg G, 2003, J COMP NEUROL, V467, P455, DOI 10.1002/cne.10945; Kronenberg G, 2006, NEUROBIOL AGING, V27, P1505, DOI 10.1016/j.neurobiolaging.2005.09.016; LAPCHAK PA, 1989, NEUROSCIENCE, V31, P313, DOI 10.1016/0306-4522(89)90376-X; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; Lemaire V, 1999, EUR J NEUROSCI, V11, P4006, DOI 10.1046/j.1460-9568.1999.00833.x; Li G, 2004, PHYSIOL BEHAV, V83, P515, DOI 10.1016/j.physbeh.2004.09.003; MANSOUR A, 1994, J COMP NEUROL, V350, P412, DOI 10.1002/cne.903500307; MARTINSEN EW, 1990, SPORTS MED, V9, P380, DOI 10.2165/00007256-199009060-00006; MATSUMOTO M, 1994, BRAIN RES, V636, P1, DOI 10.1016/0006-8993(94)90169-4; Mayo W, 2005, NEUROBIOL AGING, V26, P103, DOI 10.1016/j.neurobiolaging.2004.03.013; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Naylor AS, 2005, J NEUROPHYSIOL, V93, P2406, DOI 10.1152/jn.01085.2004; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Persson AI, 2003, EUR J NEUROSCI, V17, P1159, DOI 10.1046/j.1460-9568.2003.02538.x; Persson AI, 2003, MOL CELL NEUROSCI, V23, P360, DOI 10.1016/S1044-7431(03)00061-7; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rhodes JS, 2003, BEHAV NEUROSCI, V117, P1006, DOI 10.1037/0735-7044.117.5.1006; Rizk P, 2006, NEUROPSYCHOPHARMACOL, V31, P1146, DOI 10.1038/sj.npp.1300954; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Stranahan AM, 2006, NAT NEUROSCI, V9, P526, DOI 10.1038/nn1668; Svoboda KR, 1999, J NEUROSCI, V19, P85, DOI 10.1523/JNEUROSCI.19-01-00085.1999; Svoboda KR, 1998, J NEUROSCI, V18, P7084; van der Borght K, 2006, BEHAV BRAIN RES, V167, P36, DOI 10.1016/j.bbr.2005.08.012; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vreugdenhil E, 2007, EUR J NEUROSCI, V25, P635, DOI 10.1111/j.1460-9568.2007.05318.x; Walker TL, 2007, J NEUROSCI, V27, P3734, DOI 10.1523/JNEUROSCI.5060-06.2007; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	69	69	74	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2253	2262		10.1096/fj.07-099101	http://dx.doi.org/10.1096/fj.07-099101			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263701				2022-12-28	WOS:000257292500018
J	Meyer-Hoffert, U; Hornef, M; Henriques-Normark, B; Normark, S; Andersson, M; Putsep, K				Meyer-Hoffert, Ulf; Hornef, Mathias; Henriques-Normark, Birgitta; Normark, Staffan; Andersson, Mats; Putsep, Katrin			Identification of heparin/heparan sulfate interacting protein as a major broad-spectrum antimicrobial protein in lung and small intestine	FASEB JOURNAL			English	Article						epithelial defense; innate immunity; HIP/RPL29; ribosomal protein; mucosa	UTERINE EPITHELIAL-CELLS; HEPARIN-BINDING PROTEIN; HIGH-AFFINITY BINDING; HOST-DEFENSE; CDNA CLONING; RIBOSOMAL-PROTEINS; SURFACE EXPRESSION; HISTONE H2A; PEPTIDE; ANTIBACTERIAL	The lungs are continuously exposed to a broad array of microbes through inhalation, and microorganisms that escape clearance by the upper airway mucociliary motion will deposit in the alveolar compartment of the lower airways. The pulmonary epithelium in the alveolar compartment is covered by a thin aqueous layer that contains surfactant proteins but also microbicidal components. We have here identified the epithelial cell surface-expressed heparin/heparan sulfate interacting protein (HIP/RPL29) by high-performance liquid chromatography-fractionation, N-terminal sequencing, and mass spectrometry analysis as a major antimicrobial component in extracts of mouse lung tissue. HIP/RPL29 was also detected in extracts of mouse small intestinal tissue. HIP/RPL29 exhibited broad antibacterial activity, notably against Pseudomonas aeruginosa strains. Human recombinant HIP/RPL29 exhibited killing activity in the same order of magnitude. The HIP/RPL29 protein was demonstrated to be localized to the epithelial cells and cell surface of the lungs and intestines by immunohistochemistry. We suggest that HIP/RPL29 fulfills a function as an abundant antibacterial factor of the epithelial innate defense shield against invading bacteria in both the lungs and the small intestine.	[Meyer-Hoffert, Ulf; Henriques-Normark, Birgitta; Normark, Staffan; Andersson, Mats; Putsep, Katrin] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Hornef, Mathias; Henriques-Normark, Birgitta] Swedish Inst Infect Dis Control, Stockholm, Sweden; [Hornef, Mathias] Hannover Med Sch, Inst Med Microbiol, D-3000 Hannover, Germany; [Hornef, Mathias] Hannover Med Sch, Hosp Epidemiol, D-3000 Hannover, Germany; [Meyer-Hoffert, Ulf] Univ Clin Schleswig Holstein, Dept Dermatol, Kiel, Germany	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Hannover Medical School; Hannover Medical School; University of Kiel; Schleswig Holstein University Hospital	Meyer-Hoffert, U (corresponding author), Univ Hosp Schleswig Holstein, Dept Dermatol, Campus Kiel,Schittenhelmstr 7D, D-24105 Kiel, Germany.	umeyerhoffert@dermatology.uni-kiel.de	Meyer-Hoffert, Ulf/F-4623-2012; Andersson, Mats L/M-9124-2014	Meyer-Hoffert, Ulf/0000-0003-2305-1428; Andersson, Mats L/0000-0001-7582-8791; Hornef, Mathias/0000-0001-6096-9110				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bergsson G, 2005, FEBS J, V272, P4960, DOI 10.1111/j.1742-4658.2005.04906.x; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; FUJITA Y, 1994, BIOCHEM BIOPH RES CO, V199, P706, DOI 10.1006/bbrc.1994.1286; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; HIEMSTRA PS, 1993, INFECT IMMUN, V61, P3038, DOI 10.1128/IAI.61.7.3038-3046.1993; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Hoke DE, 2000, BIOCHEMISTRY-US, V39, P15686, DOI 10.1021/bi0009688; Hoke DE, 1998, J BIOL CHEM, V273, P25148, DOI 10.1074/jbc.273.39.25148; Hornef MW, 2004, NAT IMMUNOL, V5, P836, DOI 10.1038/ni1094; Howell SJ, 2003, PEPTIDES, V24, P1763, DOI 10.1016/j.peptides.2003.07.028; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; Julian J, 2001, BIOL REPROD, V64, P1165, DOI 10.1095/biolreprod64.4.1165; Kim HS, 1996, BIOCHEM BIOPH RES CO, V229, P381, DOI 10.1006/bbrc.1996.1814; Kirn-Safran CB, 2007, DEV DYNAM, V236, P447, DOI 10.1002/dvdy.21046; Kirn-Safran CB, 2002, DEV DYNAM, V223, P70, DOI 10.1002/dvdy.1226; Kirn-Safran CB, 2000, GENOMICS, V68, P210, DOI 10.1006/geno.2000.6283; LANDOWSKI TH, 1995, CLIN EXP METASTAS, V13, P357; Law PTW, 1996, BBA-GENE STRUCT EXPR, V1305, P105, DOI 10.1016/0167-4781(95)00224-3; Liu SC, 1996, J BIOL CHEM, V271, P11817, DOI 10.1074/jbc.271.20.11817; Liu SC, 1998, J BIOL CHEM, V273, P9718, DOI 10.1074/jbc.273.16.9718; Liu SC, 1997, J BIOL CHEM, V272, P25856, DOI 10.1074/jbc.272.41.25856; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Nuding S, 2007, GUT, V56, P1240, DOI 10.1136/gut.2006.118646; Oppenheim JJ, 2007, ADV EXP MED BIOL, V601, P185; Park IY, 1998, FEBS LETT, V437, P258, DOI 10.1016/S0014-5793(98)01238-1; Patat SA, 2004, EUR J BIOCHEM, V271, P4825, DOI 10.1111/j.1432-1033.2004.04448.x; Putsep K, 1999, NATURE, V398, P671, DOI 10.1038/19439; Putsep K, 2000, J BIOL CHEM, V275, P40478, DOI 10.1074/jbc.M007816200; Putsep K, 2002, LANCET, V360, P1144, DOI 10.1016/S0140-6736(02)11201-3; Rogan MP, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-29; Rohde LH, 1996, J BIOL CHEM, V271, P11824, DOI 10.1074/jbc.271.20.11824; Rose FRAJ, 1998, INFECT IMMUN, V66, P3255, DOI 10.1128/IAI.66.7.3255-3263.1998; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Swidsinski A, 2005, WORLD J GASTROENTERO, V11, P1131, DOI 10.3748/wjg.v11.i8.1131; Tollin M, 2003, PEPTIDES, V24, P523, DOI 10.1016/S0196-9781(03)00114-1; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Yang D, 2004, ANNU REV IMMUNOL, V22, P181, DOI 10.1146/annurev.immunol.22.012703.104603; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zimmermann RA, 2003, CELL, V115, P130, DOI 10.1016/S0092-8674(03)00804-3	47	6	6	2	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2427	2434		10.1096/fj.07-103440	http://dx.doi.org/10.1096/fj.07-103440			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18299334				2022-12-28	WOS:000257292500034
J	Peng, Z; Fernandez, P; Wilder, T; Yee, H; Chiriboga, L; Chan, ESL; Cronstein, BN				Peng, Zhongsheng; Fernandez, Patricia; Wilder, Tuere; Yee, Herman; Chiriboga, Luis; Chan, Edwin S. L.; Cronstein, Bruce N.			Ecto-5 '-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis	FASEB JOURNAL			English	Article						stellate cell; carbon tetrachloride; thioacetamide	INDUCED MOTOR INCOORDINATION; LIVER FIBROSIS; STELLATE CELLS; ALKALINE-PHOSPHATASE; MOLECULAR-MECHANISMS; RECEPTOR BLOCKADE; TISSUE FIBROSIS; NG108-15 CELLS; RAT-LIVER; TGF-BETA	Adenosine is a potent endogenous regulator of tissue repair that is released from injured cells and tissues. Hepatic fibrosis results from chronic hepatic injury, and we have previously reported that endogenously generated adenosine, acting at A(2A) receptors, plays a role in toxin-induced hepatic fibrosis. Adenosine may form intracellularly and then be transported to the extracellular space or it may form extracellularly from adenine nucleotides released from injured cells. Because ecto-5'-nucleotidase (CD73) catalyzes the terminal step in extracellular adenosine formation from AMP, we determined whether CD73 plays a role in the development of hepatic fibrosis. Mice were treated overnight with PBS, CCl4, ethanol, or thioacetamide (TAA); their livers were harvested, and slices were incubated in medium for 20 h before adenosine concentration in the supernatant was measured by HPLC. Hepatic fibrosis was induced by CCl4 or TAA treatment in CD73 knockout (CD73KO and C57BL/6 background) and C57BL/6 control mice [wild-type (WT)] mice and quantified by digital analysis of picrosirius red stained slides and hydroxyproline content. mRNA expression was quantified by real-time polymerase chain reaction, and protein was quantified by Western blot or enzyme-linked immunosorbent assay. Livers from WT mice treated with CCl4, ethanol, and TAA released 2- to 3-fold higher levels of adenosine than livers from comparably treated CD73KO mice. CD73KO mice were protected from fibrosis with significantly less collagen content in the livers of CD73KO than WT mice after treatment with either CCl4 or TAA. There were far fewer alpha-smooth muscle actin positive hepatic stellate cells in CCl4-treated KO mice than that in WT mice. After CCl4 treatment, the mRNA level of A(1), A(2A), A(2B), and A(3) adenosine receptors, tumor necrosis factor-alpha, interleukin (IL) -1 beta, IL-13r alpha 1, matrix metalloproteinase (MMP)-2, MMP-14, tissue inhibitor of metalloproteinase (TIMP) -1, and TIMP-2, and IL-13 level increased markedly in both CD73KO and WT mice, but Co11 alpha 1, Co13 alpha 1, and transforming growth factor-beta 1 mRNA increased much more in WT mice than that in KO mice. Moreover, IL-13r alpha 1, MMP-13 mRNA, and MMP-13 protein were higher in KO mice than that in WT mice. These results indicate that adenosine, formed extracellularly from adenine nucleotides, plays a major role in the pathogenesis of hepatic fibrosis and that inhibition of adenosine production or blockade of adenosine receptors may help prevent hepatic fibrosis.	[Peng, Zhongsheng; Fernandez, Patricia; Wilder, Tuere; Chan, Edwin S. L.; Cronstein, Bruce N.] New York Univ, Div Clin Pharmacol & Rheumatol, Dept Med, Sch Med, New York, NY 10016 USA; [Yee, Herman; Chiriboga, Luis] New York Univ, Sch Med, Dept Pathol, New York, NY 10016 USA	New York University; New York University	Cronstein, BN (corresponding author), New York Univ, Div Clin Pharmacol, Dept Med, Sch Med, 550 1st Ave, New York, NY 10016 USA.	cronsb01@med.nyu.edu		Cronstein, Bruce/0000-0002-4295-7383; Chiriboga, Luis/0000-0002-2028-6873	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056672, R01AR041911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013336] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00096] Funding Source: Medline; NIAAA NIH HHS [AA13336] Funding Source: Medline; NIAMS NIH HHS [AR41911, R01 AR056672] Funding Source: Medline; NIGMS NIH HHS [GM56268] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews AL, 2006, J ALLERGY CLIN IMMUN, V118, P858, DOI 10.1016/j.jaci.2006.06.041; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Arvilommi AM, 1997, EUR J IMMUNOL, V27, P248, DOI 10.1002/eji.1830270137; Bachmann S, 1997, KIDNEY INT, V51, P479, DOI 10.1038/ki.1997.66; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; BRUNDEGE JM, 1995, NEUROSCI LETT, V186, P214, DOI 10.1016/0304-3940(95)11320-V; Carmichael F J, 1993, Alcohol Alcohol Suppl, V2, P411; Castrop H, 2004, J CLIN INVEST, V114, P634, DOI 10.1172/JCI200421851; Chan ESL, 2006, ARTHRITIS RHEUM-US, V54, P2632, DOI 10.1002/art.21974; Chan ESL, 2006, BRIT J PHARMACOL, V148, P1144, DOI 10.1038/sj.bjp.0706812; Che J, 2007, MOL PHARMACOL, V72, P1626, DOI 10.1124/mol.107.038760; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; Connole L, 2004, BASIC CLIN PHARMACOL, V95, P299, DOI 10.1111/j.1742-7843.2004.pto950509.x; Corrao G, 2001, ANN EPIDEMIOL, V11, P458, DOI 10.1016/S1047-2797(01)00223-X; CRONSTEIN BN, 1991, P NATL ACAD SCI USA, V88, P2441, DOI 10.1073/pnas.88.6.2441; Dar M S, 1993, Alcohol Alcohol Suppl, V2, P425; Dar MS, 2006, BRAIN RES BULL, V71, P287, DOI 10.1016/j.brainresbull.2006.09.016; Dar MS, 2002, BRAIN RES, V957, P53, DOI 10.1016/S0006-8993(02)03599-0; DIAMOND I, 1994, EXS, V71, P175; El Yacoubi M, 2003, NEUROPHARMACOLOGY, V45, P977, DOI 10.1016/S0028-3908(03)00254-5; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Faller J, 1984, Adv Exp Med Biol, V165 Pt A, P457; Fallowfield JA, 2007, J IMMUNOL, V178, P5288, DOI 10.4049/jimmunol.178.8.5288; FORTUNA R, 1980, CALCIFIED TISSUE INT, V30, P217, DOI 10.1007/BF02408631; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gallus S, 2002, ANN EPIDEMIOL, V12, P202, DOI 10.1016/S1047-2797(01)00304-0; Gordon A S, 1990, Biochem Soc Symp, V56, P117; GORDON AS, 1991, ADV EXP MED BIOL, V309, P387; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Hashmi AZ, 2007, AM J PHYSIOL-GASTR L, V292, pG395, DOI 10.1152/ajpgi.00208.2006; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; JAMES J, 1990, LIVER, V10, P1; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kaviratne M, 2004, J IMMUNOL, V173, P4020, DOI 10.4049/jimmunol.173.6.4020; KELLY E, 1995, BRIT J PHARMACOL, V114, P1433, DOI 10.1111/j.1476-5381.1995.tb13366.x; Klatsky A L, 1993, Ann Epidemiol, V3, P375, DOI 10.1016/1047-2797(93)90064-B; KLATSKY AL, 1992, AM J EPIDEMIOL, V136, P1248, DOI 10.1093/oxfordjournals.aje.a116433; Klatsky AL, 2006, ARCH INTERN MED, V166, P1190, DOI 10.1001/archinte.166.11.1190; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Koszalka P, 2004, CIRC RES, V95, P814, DOI 10.1161/01.RES.0000144796.82787.6f; Lappas CM, 2005, EXPERT OPIN INV DRUG, V14, P797, DOI 10.1517/13543784.14.7.797; Ledoux S, 2003, CIRC RES, V92, P848, DOI 10.1161/01.RES.0000069022.95401.FE; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Linden J, 2005, MOL PHARMACOL, V67, P1385, DOI 10.1124/mol.105.011783; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MENG ZH, 1995, ALCOHOL CLIN EXP RES, V19, P892, DOI 10.1111/j.1530-0277.1995.tb00964.x; Mentink-Kane MM, 2004, IMMUNOL REV, V202, P191, DOI 10.1111/j.0105-2896.2004.00210.x; Morabito L, 1998, J CLIN INVEST, V101, P295, DOI 10.1172/JCI1554; Nagy L E, 1993, Alcohol Alcohol Suppl, V2, P419; NAGY LE, 1989, MOL PHARMACOL, V36, P744; NAGY LE, 1991, MOL PHARMACOL, V40, P812; NAGY LE, 1990, J BIOL CHEM, V265, P1946; NAITO Y, 1981, BIOCHEMISTRY-US, V20, P5188, DOI 10.1021/bi00521a014; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; PUIG JG, 1984, J CLIN INVEST, V74, P936, DOI 10.1172/JCI111512; Rivkees SA, 2001, MOL GENET METAB, V74, P160, DOI 10.1006/mgme.2001.3217; Ruhl CE, 2005, GASTROENTEROLOGY, V129, P1928, DOI 10.1053/j.gastro.2005.08.056; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SCHMID TC, 1994, HISTOCHEMISTRY, V101, P439, DOI 10.1007/BF00269494; Sharp DS, 1999, ANN EPIDEMIOL, V9, P391; Siegmund SV, 2005, DIGEST DIS, V23, P264, DOI 10.1159/000090174; Song ZY, 2007, BIOCHEM PHARMACOL, V74, P521, DOI 10.1016/j.bcp.2007.05.005; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Sugimoto R, 2005, LIVER INT, V25, P420, DOI 10.1111/j.1478-3231.2005.01087.x; Sun CX, 2006, J CLIN INVEST, V116, P2173, DOI 10.1172/JCI27303; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Tverdal A, 2003, ANN EPIDEMIOL, V13, P419, DOI 10.1016/S1047-2797(02)00462-3; Volmer JB, 2006, J IMMUNOL, V176, P4449, DOI 10.4049/jimmunol.176.7.4449; Zhou XY, 2004, LIVER INT, V24, P492, DOI 10.1111/j.1478-3231.2004.0946.x; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	76	91	93	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2263	2272		10.1096/fj.07-100685	http://dx.doi.org/10.1096/fj.07-100685			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18263696				2022-12-28	WOS:000257292500019
J	Rashid, ST; Fuller, B; Hamilton, G; Seifalian, AM				Rashid, S. T.; Fuller, B.; Hamilton, G.; Seifalian, A. M.			Tissue engineering of a hybrid bypass graft for coronary and lower limb bypass surgery	FASEB JOURNAL			English	Article						compliance; polyurethanes; shear stress; smooth muscle cell; endothelial	ENDOTHELIAL-CELL RETENTION; PULSATILE SHEAR-STRESS; VASCULAR GRAFTS; IN-VITRO; BLOOD-VESSEL; POLYTETRAFLUOROETHYLENE GRAFTS; SAPHENOUS-VEIN; PROSTHESES; COLLAGEN; VIVO	Tissue-engineered blood vessels have largely relied on inelastic scaffolds or biological solutions with uncertain long-term in vivo durability. In this report we present for the first time a hybrid tissue-engineered bypass graft consisting of an elastic scaffold of compliant poly(carbonate-urea) urethane (CPU), incorporated with human smooth muscle cells (SMCs) and endothelial cells (ECs) from the same human source. Human vascular SMCs and ECs were extracted from umbilical cord vessels. The effect of shear stress preconditioning on cell retention on the hybrid bypass graft was investigated under pulsatile arterial flow conditions. Retention of ECs seeded onto CPU precoated with SMCs was significantly improved by a period of shear stress preconditioning, especially when the stress incrementally increased. This is probably because the mechanical stimuli orient cells and increase the release of matrix proteins and attachment factors. The stage is now set for developing a hybrid graft for in vivo studies.	[Rashid, S. T.; Fuller, B.; Seifalian, A. M.] UCL, Royal Free & Univ Coll Med Sch, Div Surg & Intervent Sci, Biomat & Tissue Engn Ctr, London NW3 2PF, England; [Hamilton, G.] Royal Free Hampstead Natl Hlth Serv, Vasc Unit, London, England	University of London; University College London	Seifalian, AM (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Div Surg & Intervent Sci, Biomat & Tissue Engn Ctr, Rowland Hill St, London NW3 2PF, England.	a.seifalian@ucl.ac.uk	Seifalian, Alexander M/I-6028-2013; hamilton, george/K-4764-2013; Rashid, T/B-9474-2008	Seifalian, Alexander M/0000-0002-1180-3322; RASHID, TAWQEER/0000-0002-5377-8671; seifalian, Alexander/0000-0002-8334-9376				ABBOTT WM, 1993, J VASC SURG, V17, P746, DOI 10.1016/0741-5214(93)90120-B; BENNION RS, 1985, SURG GYNECOL OBSTET, V160, P239; BUTTON M, 2002, CARDIOVASC PATHOL, V11, P39; Dardik A, 1999, J VASC SURG, V29, P157, DOI 10.1016/S0741-5214(99)70357-5; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Edwards A, 1995, J BIOMATER APPL, V10, P171, DOI 10.1177/088532829501000207; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V281, pL529, DOI 10.1152/ajplung.2001.281.3.L529; Giudiceandrea A, 1998, EUR J VASC ENDOVASC, V15, P147, DOI 10.1016/S1078-5884(98)80136-6; Giudiceandrea A, 2000, J ARTIF ORGANS, V3, P16; Greenwald SE, 2000, J PATHOL, V190, P292, DOI 10.1002/(SICI)1096-9896(200002)190:3<292::AID-PATH528>3.0.CO;2-S; Hirai J, 1996, CELL TRANSPLANT, V5, P93, DOI 10.1016/0963-6897(95)02002-0; Hoerstrup SP, 2001, EUR J CARDIO-THORAC, V20, P164, DOI 10.1016/S1010-7940(01)00706-0; Ishibashi K, 1994, ASAIO J, V40, pM284, DOI 10.1097/00002480-199407000-00009; KANDA K, 1994, CELL TRANSPLANT, V3, P481, DOI 10.1177/096368979400300605; Kannan RY, 2005, J BIOMED MATER RES B, V74B, P570, DOI 10.1002/jbm.b.30247; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kobashi T, 1999, TISSUE ENG, V5, P515, DOI 10.1089/ten.1999.5.515; Kobashi T, 1999, CELL TRANSPLANT, V8, P477, DOI 10.1177/096368979900800503; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lebaron RG, 2000, TISSUE ENG, V6, P85, DOI 10.1089/107632700320720; MILLS I, 1999, TISSUE ENG PROSTHETI, P425; Nerem RM, 2000, YONSEI MED J, V41, P735, DOI 10.3349/ymj.2000.41.6.735; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Niklason LE, 2001, J VASC SURG, V33, P628, DOI 10.1067/mva.2001.111747; Parikh SA, 2000, ADV DRUG DELIVER REV, V42, P139, DOI 10.1016/S0169-409X(00)00058-2; Rashid ST, 2004, EUR J VASC ENDOVASC, V27, P608, DOI 10.1016/j.ejvs.2004.01.020; Salacinski HJ, 2001, ARTIF ORGANS, V25, P974, DOI 10.1046/j.1525-1594.2001.06716.x; Salacinski HJ, 2002, J BIOMED MATER RES, V59, P207; Salacinski HJ, 2001, J BIOMATER APPL, V15, P241, DOI 10.1106/NA5T-J57A-JTDD-FD04; Seifalian AM, 2003, BIOMATERIALS, V24, P2549, DOI 10.1016/S0142-9612(02)00608-7; Seliktar D, 2000, ANN BIOMED ENG, V28, P351, DOI 10.1114/1.275; Shigematsu K, 2000, INT ANGIOL, V19, P39; Solan A, 2003, TISSUE ENG, V9, P579, DOI 10.1089/107632703768247287; STANSBY G, 1994, BRIT J SURG, V81, P1286, DOI 10.1002/bjs.1800810908; Stock UA, 2001, TISSUE ENG, V7, P1, DOI 10.1089/107632701300003241; Tai NR, 2000, BRIT J SURG, V87, P1516, DOI 10.1046/j.1365-2168.2000.01566.x; Thakrar RR, 2006, FASEB J, V20, P874, DOI 10.1096/fj.05-5304com; Tiwari A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0826com; Tiwari A, 2002, CARDIOVASC SURG, V10, P191, DOI 10.1016/S0967-2109(02)00004-2; WATKINS MT, 1984, J SURG RES, V36, P588, DOI 10.1016/0022-4804(84)90145-8; World Health Organization, 1999, WHO WORLD HLTH REP 1; WU MHD, 1995, J VASC SURG, V22, P382, DOI 10.1016/S0741-5214(95)70005-6; Yu H, 2003, J VASC SURG, V38, P557, DOI 10.1016/S0741-5214(03)00334-3; Yu H, 2001, J VASC SURG, V34, P337, DOI 10.1067/mva.2001.114817	44	46	50	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					2084	2089		10.1096/fj.07-096586	http://dx.doi.org/10.1096/fj.07-096586			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18203957				2022-12-28	WOS:000256352700047
J	Yang, S; Liu, X; Yin, YQ; Fukuda, MN; Zhou, JW				Yang, Shuo; Liu, Xuan; Yin, Yanqing; Fukuda, Michiko N.; Zhou, Jiawei			Tastin is required for bipolar spindle assembly and centrosome integrity during mitosis	FASEB JOURNAL			English	Article						microtubules; mitotic block	ENDOMETRIAL EPITHELIAL-CELLS; MITOTIC SPINDLE; CYTOPLASMIC DYNEIN; LIGHT-CHAIN; PROTEIN; COMPLEX; ORGANIZATION; MECHANISMS; TROPHININ; INTERACTS	Tastin was previously characterized as an accessory protein for cell adhesion that participates in early embryo implantation. Here, we report that tastin is also required for spindle assembly during mitosis. Tastin protein levels peaked in the G(2)/M phase and abruptly declined after cell division. Microscopy showed that tastin is primarily localized on the microtubules, centrosomes, and the mitotic spindle during the cell cycle. Tastin interacted with the dynein intermediate chain, p150(Glued), and gamma-tubulin in addition to Tctex-1 ( the light chain of dynein). Overexpression of tastin led to monopolar spindle formation, whereas loss of tastin expression caused profound mitotic block and preferentially induced multipolar spindles. These multipolar spindles were generated through a loss of cohesion in mitotic centrosomes; specifically, tastin depletion caused the fragmentation of pericentrosomal material and the splitting of the centrioles at the spindle poles. Tastin depletion induced centrosome abnormalities exclusively during mitosis and required both microtubule integrity and Eg5 activity. However, tastin depletion did not disrupt the organization of spindle poles, as revealed by localization of nuclear mitotic apparatus protein (NuMA) and the p150(Glued) component of dynactin. These data indicate that the major function of tastin during mitosis is to maintain the structural and dynamic features of centrosomes, thereby contributing to spindle bipolarity.	[Yang, Shuo; Liu, Xuan; Yin, Yanqing; Zhou, Jiawei] Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,Lab Mol Cell Biol, Shanghai 200031, Peoples R China; [Fukuda, Michiko N.] Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Sanford Burnham Prebys Medical Discovery Institute	Zhou, JW (corresponding author), Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol,Lab Mol Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	jwzhou@ion.ac.cn		Zhou, Jiawei/0000-0002-1844-9178				Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; COMPTON DA, 1995, J CELL SCI, V108, P621; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Fukuda MN, 1999, SEMIN REPROD ENDOCR, V17, P229, DOI 10.1055/s-2007-1016230; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Huang SC, 2005, MOL BIOL CELL, V16, P117, DOI 10.1091/mbc.E04-05-0426; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Maxwell CA, 2005, CANCER RES, V65, P850; Maxwell CA, 2003, MOL BIOL CELL, V14, P2262, DOI 10.1091/mbc.E02-07-0377; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Mitchison TJ, 1989, CURR OPIN CELL BIOL, V1, P67, DOI 10.1016/S0955-0674(89)80039-0; Nadano D, 2002, BIOCHEM J, V364, P669, DOI 10.1042/BJ20011836; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 2001, CANCER RES, V61, P2212; Rieder CL, 1991, CURR OPIN CELL BIOL, V3, P59, DOI 10.1016/0955-0674(91)90166-V; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P5027, DOI 10.1073/pnas.95.9.5027; Suzuki N, 1999, BIOL REPROD, V60, P621, DOI 10.1095/biolreprod60.3.621; Tai AW, 1998, J BIOL CHEM, V273, P19639, DOI 10.1074/jbc.273.31.19639; Uto K, 2000, EMBO J, V19, P1816, DOI 10.1093/emboj/19.8.1816; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Yang J, 2006, MOL BIOL CELL, V17, P1033, DOI 10.1091/mbc.E05-10-0943; Zimmerman W, 2000, TRAFFIC, V1, P927, DOI 10.1034/j.1600-0854.2000.011202.x	38	31	31	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2008	22	6					1960	1972		10.1096/fj.07-081463	http://dx.doi.org/10.1096/fj.07-081463			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18218922				2022-12-28	WOS:000256352700035
J	Almulki, L; Noda, K; Amini, R; Schering, A; Garland, RC; Nakao, S; Nakazawa, T; Hisatomi, T; Thomas, KL; Masli, S; Hafezi-Moghadam, A				Almulki, Lama; Noda, Kousuke; Amini, Reza; Schering, Alexander; Garland, Rebecca C.; Nakao, Shintaro; Nakazawa, Toru; Hisatomi, Toshio; Thomas, Kennard L.; Masli, Sharmila; Hafezi-Moghadam, Ali			Surprising up-regulation of P-selectin glycoprotein ligand-1 (PSGL-1) in endotoxin-induced uveitis	FASEB JOURNAL			English	Article						leukocyte rolling velocity; autoperfused micro-flow chamber; lipopolysaccharides; adhesion molecules; acute immune response	IN-VIVO; ISCHEMIA/REPERFUSION INJURY; ENDOTHELIAL INTERACTIONS; MONOCLONAL-ANTIBODIES; OCULAR INFLAMMATION; ADHESION MOLECULES; RAT-KIDNEY; LEUKOCYTE; INHIBITION; NEUTROPHILS	P-selectin glycoprotein ligand-1 (PSGL-1) is constitutively expressed on leukocytes and was thought to be down-regulated with cell activation. However, this work shows the surprising finding of functional PSGL-1 up-regulation during acute inflammation. PSGL-1 function was studied in our autoperfusion assay, in which blood from a mouse carotid flows through a microchamber coated with a fixed density of P-selectin. Under the inflammatory conditions-uveitis induced by systemic lipopolysaccharide injection-we recorded significantly reduced leukocyte rolling velocity, which suggests PSGL-1 up-regulation; however, flow cytometry showed reduced PSGL-1. When bound leukocytes were released from the vasculature by PSGL-1 blockade, a large peripheral blood leukocyte (PBL) population showed elevated PSGL-1, which could account for the reduced PSGL-1 in the remaining unbound population. In the eye, systemic blockade of PSGL-1 with a monoclonal antibody or recombinant soluble PSGL-1 drastically reduced the severe manifestations of uveitis. Furthermore, PSGL-1 blockade was significantly more effective in reducing retinal leukostasis than was P-selectin blockade. Our results provide surprising evidence for functional PSGL-1 up-regulation in PBLs during acute inflammation. The temporal overlap between PSGL-1 and P-selectin up-regulation reveals an as yet unrecognized collaboration between this receptor-ligand pair, increasing efficiency of the first steps of the leukocyte recruitment cascade.-Almulki, L., Noda, K., Amini, R., Schering, A., Garland, R. C., Nakao, S., Nakazawa, T., Hisatomi, T., Thomas, K. L., Masli, S., Hafezi-Moghadam, A. Surprising up-regulation of P-selectin glycoprotein ligand-1 (PSGL-1) in endotoxin-induced uveitis. FASEB J. 23, 929-939 (2009)	[Almulki, Lama; Noda, Kousuke; Amini, Reza; Schering, Alexander; Garland, Rebecca C.; Nakao, Shintaro; Nakazawa, Toru; Hisatomi, Toshio; Thomas, Kennard L.; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA; [Almulki, Lama; Noda, Kousuke; Amini, Reza; Schering, Alexander; Garland, Rebecca C.; Nakao, Shintaro; Nakazawa, Toru; Hisatomi, Toshio; Thomas, Kennard L.; Masli, Sharmila; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; [Masli, Sharmila] Schepens Eye Res Inst, Boston, MA USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Harvard University; Schepens Eye Research Institute	Hafezi-Moghadam, A (corresponding author), Massachusetts Eye & Ear Infirm, Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.	ali_hafezi-moghadam@meei.harvard.edu		Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam, Ali/0000-0002-5336-0697	U. S. National Institue of Health [HL086933, AI050775]; National Eye Institute [EY14104]; NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER	U. S. National Institue of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are grateful to Dr. P. Cheung, Director of Preclinical Research and Discovery at Y's Therapeutics for graciously providing research- grade YSPSL (recombinant soluble Pselectin glycoprotein ligand IgG fusion protein, rPSGL-Ig). The authors thank Dr. S. E. Leeman for a critical review of the manuscript and R. Huang for his assistance with flow cytometry. This work was supported by U. S. National Institue of Health grants (HL086933, AI050775) and a National Eye Institute core grant (EY14104). We are indebted to the Massachusetts Lions Foundation for generous funds provided for laboratory equipment used in this project. We thank Research to Prevent Blindness for unrestricted funds awarded to the Department of Ophthalmology at Harvard Medical School. We are grateful to the Marion W. and Edward F. Knight Fund for support of A. H.-M.'s research.	BAATZ H, 1995, INVEST OPHTH VIS SCI, V36, P1960; Becker MD, 2001, INVEST OPHTH VIS SCI, V42, P2563; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Davenpeck KL, 2000, J IMMUNOL, V165, P2764, DOI 10.4049/jimmunol.165.5.2764; Dulkanchainun TS, 1998, ANN SURG, V227, P832, DOI 10.1097/00000658-199806000-00006; Frenette PS, 2000, J EXP MED, V191, P1413, DOI 10.1084/jem.191.8.1413; Fuller TF, 2001, TRANSPLANTATION, V72, P216, DOI 10.1097/00007890-200107270-00008; GABER AO, 2007, AM TRANSPL C; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Hafezi-Moghadam A, 2007, FASEB J, V21, P464, DOI 10.1096/fj.06-6390com; Hafezi-Moghadam A, 2004, AM J PHYSIOL-CELL PH, V286, pC876, DOI 10.1152/ajpcell.00500.2003; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Hicks AER, 2003, BLOOD, V101, P3249, DOI 10.1182/blood-2002-07-2329; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; Khor SP, 2000, J PHARMACOL EXP THER, V293, P618; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Marie O, 1999, INVEST OPHTH VIS SCI, V40, P2275; Marsik C, 2004, J CLIN IMMUNOL, V24, P62, DOI 10.1023/B:JOCI.0000018064.13793.83; Mertens P, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.04.020; Miyamoto K, 1996, INVEST OPHTH VIS SCI, V37, P2708; Miyamoto K, 1998, MICROVASC RES, V55, P230, DOI 10.1006/mvre.1998.2084; Moore KL, 1998, LEUKEMIA LYMPHOMA, V29, P1, DOI 10.3109/10428199809058377; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P2925, DOI 10.1167/iovs.04-1476; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; Planck SR, 1998, CURR EYE RES, V17, P941, DOI 10.1076/ceyr.17.9.941.5139; ROSENBAUM JT, 1993, CURR EYE RES, V12, P827, DOI 10.3109/02713689309020387; ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Smith JR, 1998, IMMUNOL CELL BIOL, V76, P497, DOI 10.1046/j.1440-1711.1998.00783.x; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; Strauss EC, 1999, INVEST OPHTH VIS SCI, V40, P1336; Suzuma K, 1997, INVEST OPHTH VIS SCI, V38, P1610; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Tamesis RR, 1996, OPHTHALMOLOGY, V103, P768; Thadani Sunil M, 2004, Paediatr Drugs, V6, P289, DOI 10.2165/00148581-200406050-00003; Tsuchihashi S, 2006, J IMMUNOL, V176, P616, DOI 10.4049/jimmunol.176.1.616; WHITCUP SM, 1993, CLIN IMMUNOL IMMUNOP, V67, P143, DOI 10.1006/clin.1993.1057; WHITCUP SM, 1995, EXP EYE RES, V60, P597, DOI 10.1016/S0014-4835(05)80001-6; Whitcup SM, 1997, CLIN IMMUNOL IMMUNOP, V83, P45, DOI 10.1006/clin.1996.4324; Yang Y, 2003, AM J RESP CELL MOL, V29, P583, DOI 10.1165/rcmb.2002-0315OC	43	17	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					929	939		10.1096/fj.08-118760	http://dx.doi.org/10.1096/fj.08-118760			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19050046	Green Published			2022-12-28	WOS:000265506300028
J	Mukhopadhyay, A; Saddoughi, SA; Song, PF; Sultan, I; Ponnusamy, S; Senkal, CE; Snook, CF; Arnold, HK; Sears, RC; Hannun, YA; Ogretmen, B				Mukhopadhyay, Archana; Saddoughi, Sahar A.; Song, Pengfei; Sultan, Iyad; Ponnusamy, Suriyan; Senkal, Can E.; Snook, Christopher F.; Arnold, Hugh K.; Sears, Rosalie C.; Hannun, Yusuf A.; Ogretmen, Besim			Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling	FASEB JOURNAL			English	Article						bioactive lipids; c-Myc degradation	LONGEVITY ASSURANCE GENE-1; SQUAMOUS-CELL CARCINOMAS; REVERSE-TRANSCRIPTASE PROMOTER; HUMAN HEAD; C-MYC; NONVESICULAR TRAFFICKING; SET; ACTIVATION; MECHANISMS; GROWTH	In this study, the inhibitor 2 of protein phosphatase 2A (I2PP2A) was identified in vitro and in situ as a ceramide-binding protein, which exhibits stereoisomer specificity and fatty acid chain length preference. Site-directed mutagenesis coupled with structural details of I2PP2A suggested that VIK 207-209 residues localized on helix 7 are important for ceramide binding and single mutation of K209D altered this interaction. Notably, I2PP2A-ceramide binding decreased the association between PP2A and the inhibitor, preventing the inhibition of PP2A activity in vitro. In addition, studies in A549 human lung cancer cells revealed that ceramide mediates c-Myc degradation via its PP2A-dependent dephosphorylation at S62, and treatment with okadaic acid and expression of c-Myc mutants with S62A or S62D conversions resulted in resistance to ceramide-mediated degradation. Importantly, whereas down-regulation of I2PP2A enhanced PP2A-mediated c-Myc degradation in response to ceramide, ectopic expression of wild-type I2PP2A but not of its K209D mutant protected this degradation in A549 cells. Moreover, expression of wild-type I2PP2A prevented the growth-inhibitory effects of ceramide both against A549 cells and xenograft-driven tumors in situ and in vivo compared with that in controls. Thus, these results suggest that direct interaction of I2PP2A with ceramide plays important biological roles via the regulation of PP2A activity and signaling, which in turn control ceramide-mediated degradation of c-Myc and antiproliferation.-Mukhopadhyay, A., Saddoughi, S. A., Song, P., Sultan, I., Ponnusamy, S., Senkal, C. E., Snook, C. F., Arnold, H. K., Sears, R. C., Hannun, Y. A., Ogretmen, B. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 23, 751-763 (2009)	[Mukhopadhyay, Archana; Saddoughi, Sahar A.; Song, Pengfei; Sultan, Iyad; Ponnusamy, Suriyan; Senkal, Can E.; Hannun, Yusuf A.; Ogretmen, Besim] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Mukhopadhyay, Archana; Saddoughi, Sahar A.; Song, Pengfei; Sultan, Iyad; Ponnusamy, Suriyan; Senkal, Can E.; Snook, Christopher F.; Hannun, Yusuf A.; Ogretmen, Besim] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Arnold, Hugh K.; Sears, Rosalie C.] Oregon Hlth & Sci Univ, Dept Mol Med Genet, Portland, OR 97201 USA	Medical University of South Carolina; Medical University of South Carolina; Oregon Health & Science University	Ogretmen, B (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	ogretmen@musc.edu			U.S. National Institutes of Health [CA-088932, CA-097132]; Abney and Wachovia Foundations; NATIONAL CANCER INSTITUTE [P01CA097132, R01CA088932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016572] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Abney and Wachovia Foundations; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr. J.G. Schnellmann for critically reviewing the manuscript. This work was supported by research grants from the U.S. National Institutes of Health (CA-088932 and CA-097132). S.A.S. was supported by scholarships obtained from they Abney and Wachovia Foundations.	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2008, CANCER METAST REV, V27, P147, DOI 10.1007/s10555-008-9128-9; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chalfant CE, 2004, J LIPID RES, V45, P496, DOI 10.1194/jlr.M300347-JLR200; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Faustino RS, 2008, J LIPID RES, V49, P654, DOI 10.1194/jlr.M700464-JLR200; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; Guo HB, 2007, P NATL ACAD SCI USA, V104, P8797, DOI 10.1073/pnas.0702981104; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Kawano M, 2006, J BIOL CHEM, V281, P30279, DOI 10.1074/jbc.M605032200; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Kudo N, 2008, P NATL ACAD SCI USA, V105, P488, DOI 10.1073/pnas.0709191105; Ledeen RW, 2008, J LIPID RES, V49, P1176, DOI 10.1194/jlr.R800009-JLR200; Ledeen RW, 2006, BBA-MOL CELL BIOL L, V1761, P588, DOI 10.1016/j.bbalip.2006.04.010; Li M, 1998, METH MOL B, V93, P59; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lin CF, 2007, J CELL SCI, V120, P2935, DOI 10.1242/jcs.03473; Muto S, 2007, P NATL ACAD SCI USA, V104, P4285, DOI 10.1073/pnas.0603762104; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Senkal CE, 2006, J PHARMACOL EXP THER, V317, P1188, DOI 10.1124/jpet.106.101949; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Snook CF, 2006, BBA-MOL CELL BIOL L, V1761, P927, DOI 10.1016/j.bbalip.2006.06.004; Sundararaj KP, 2004, J BIOL CHEM, V279, P6152, DOI 10.1074/jbc.M310549200; Szulc ZM, 2006, BIOORGAN MED CHEM, V14, P7083, DOI 10.1016/j.bmc.2006.07.016; ten Klooster JP, 2007, EMBO J, V26, P336, DOI 10.1038/sj.emboj.7601518; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Wang GH, 2005, J BIOL CHEM, V280, P26415, DOI 10.1074/jbc.M501492200; Wooten LG, 2005, J BIOL CHEM, V280, P28867, DOI 10.1074/jbc.M413444200; Wooten-Blanks LG, 2007, FASEB J, V21, P3386, DOI 10.1096/fj.07-8621com; Yan L, 2008, J BIOL CHEM, V283, P7411, DOI 10.1074/jbc.M708083200; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	43	160	161	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					751	763		10.1096/fj.08-120550	http://dx.doi.org/10.1096/fj.08-120550			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	19028839	Green Published			2022-12-28	WOS:000265506300011
J	Varalakshmi, P; Panneerselvam, C; Sakthisekaran, D				Varalakshmi, Palaninathan; Panneerselvam, Chinnakannu; Sakthisekaran, Dhanapal			A "simple" method for spurious biostatistics: response to the manuscript submitted to The FASEB Journal by Hudes, et al.	FASEB JOURNAL			English	Editorial Material						lipoic acid; oxidative stress; antioxidants; aging; data variability; data manipulation			[Varalakshmi, Palaninathan; Panneerselvam, Chinnakannu; Sakthisekaran, Dhanapal] Univ Madras, ALM Post Grad Inst Basic Med Sci, Dept Med Biochem, Madras 600113, Tamil Nadu, India	University of Madras	Varalakshmi, P (corresponding author), Univ Madras, ALM Post Grad Inst Basic Med Sci, Dept Med Biochem, Taramani Campus, Madras 600113, Tamil Nadu, India.	drvlakshmi@yahoo.com							0	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2009	23	3					704	705		10.1096/fj.08-118265	http://dx.doi.org/10.1096/fj.08-118265			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	437SD	18940891				2022-12-28	WOS:000265506300005
J	Kawamori, T; Kaneshiro, T; Okumura, M; Maalouf, S; Uflacker, A; Bielawski, J; Hannun, YA; Obeid, LM				Kawamori, Toshihiko; Kaneshiro, Tatsuya; Okumura, Masae; Maalouf, Samer; Uflacker, Andre; Bielawski, Jacek; Hannun, Yusuf A.; Obeid, Lina M.			Role for sphingosine kinase 1 in colon carcinogenesis	FASEB JOURNAL			English	Article						inflammation; azoxymethane; dextran sodium sulfate; cell proliferation; apoptosis	CYCLOOXYGENASE-2 INHIBITOR; TNF-ALPHA; MICE; SPHINGOSINE-1-PHOSPHATE; INDUCTION; CELECOXIB; TISSUES; FTY720; CELLS	Sphingosine kinase 1 (SphK1) phosphorylates sphingosine to form sphingosine-1-phosphate (S1P) and is a critical regulator of sphingolipid-mediated functions. Cell-based studies suggest a tumor-promoting function for the SphK1/S1P pathway. Also, our previous studies implicated the SphK1/S1P pathway in the induction of the arachidonic acid cascade, a major inflammatory pathway involved in colon carcinogenesis. Therefore, we investigated whether the SphK1/S1P pathway is necessary for mediating carcinogenesis in vivo. Here, we report that 89% (42/47) of human colon cancer samples stained positively for SphK1, whereas normal colon mucosa had negative or weak staining. Adenomas had higher expression of SphK1 vs. normal mucosa, and colon cancers with metastasis had higher expression of SphK1 than those without metastasis. In the azoxymethane (AOM) murine model of colon cancer, SphK1 and S1P were significantly elevated in colon cancer tissues compared to normal mucosa. Moreover, blood levels of S1P were higher in mice with colon cancers than in those without cancers. Notably, SphK1(-/-) mice subjected to AOM had significantly less aberrant crypt foci (ACF) formation and significantly reduced colon cancer development. These results are the first in vivo evidence that the SphK1/S1P pathway contributes to colon carcinogenesis and that inhibition of this pathway is a potential target for chemoprevention. - Kawamori, T., Kaneshiro, T., Okumura, M., Maalouf, S., Uflacker, A., Bielawski, J., Hannun, Y. A., Obeid, L. M. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J. 23, 405-414 (2009)	[Kawamori, Toshihiko; Kaneshiro, Tatsuya; Okumura, Masae; Maalouf, Samer; Uflacker, Andre] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Bielawski, Jacek; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Kawamori, T (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 165 Ashley Ave,Ste 309, Charleston, SC 29425 USA.	kawamori@musc.edu	Kawamori, Toshihiko/G-7636-2012	obeid, lina/0000-0002-0734-0847	NIH [P20RR17677, P01CA097132, R01GM62887]; NIH Extramural Research Facilities Program of the National Center for Research Resources [C06RR015455]; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Extramural Research Facilities Program of the National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Margaret Romano and the Tumor Bank for technical assistance and Dr. Takuji Tanaka (Kanazawa Medical University, Kanazawa, Japan) for his diagnostic review of colon tumors. Also, we thank the Lipidomics Core Facility and Animal Carcinogenesis Core, the Hollings Cancer Center, MUSC. This work was supported by NIH grants (P20RR17677 to T. K.; P01CA097132 to Y.A.H. and L.M.O.; R01GM62887 to L.M.O.) and a seed grant to T. K. from the Hollings Cancer Center, MUSC. This work was conducted in a facility constructed with support from the NIH Extramural Research Facilities Program of the National Center for Research Resources (C06RR015455).	Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Billich A, 2005, CELL SIGNAL, V17, P1203, DOI 10.1016/j.cellsig.2004.12.005; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; French KJ, 2003, CANCER RES, V63, P5962; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; Hansen-Petrik MB, 2002, CANCER RES, V62, P403; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kawamori T, 2003, CARCINOGENESIS, V24, P985, DOI 10.1093/carcin/bgg033; Kawamori T, 1998, CANCER RES, V58, P409; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05; Krutovskikh V A, 1994, IARC Sci Publ, P195; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Murate T, 2001, J HISTOCHEM CYTOCHEM, V49, P845, DOI 10.1177/002215540104900705; Nakatsugi S, 1997, JPN J CANCER RES, V88, P1117, DOI 10.1111/j.1349-7006.1997.tb00337.x; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pettus BJ, 2005, MOL PHARMACOL, V68, P330, DOI 10.1124/mol.104.008722; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Zemann B, 2006, BLOOD, V107, P1454, DOI 10.1182/blood-2005-07-2628	27	194	207	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2009	23	2					405	414		10.1096/fj.08-117572	http://dx.doi.org/10.1096/fj.08-117572			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18824518	Green Published			2022-12-28	WOS:000262892900012
J	Sun, W; Hu, W; Xu, RJ; Jin, JF; Szulc, ZM; Zhang, GF; Galadari, SH; Obeid, LM; Mao, CG				Sun, Wei; Hu, Wei; Xu, Ruijuan; Jin, Junfei; Szulc, Zdzislaw M.; Zhang, Guofeng; Galadari, Sehamuddin H.; Obeid, Lina M.; Mao, Cungui			Alkaline ceramidase 2 regulates beta 1 integrin maturation and cell adhesion	FASEB JOURNAL			English	Article						retinoic acid; protein kinase C; Golgi; sphingolipid	INTEGRIN RECEPTORS; MOLECULAR-CLONING; SPHINGOID BASES; DOWN-REGULATION; RETINOIC ACID; GLYCOSYLATION; EXPRESSION; APOPTOSIS; DIFFERENTIATION; TRANSPORT	The polypeptide core of the integrin beta 1 subunit (beta 1) is glycosylated sequentially in the endoplasmic reticulum and the Golgi complex to form beta 1 precursor and mature beta 1, respectively. The beta 1 precursor to mature beta 1 conversion, termed beta 1 maturation, regulates the cell surface levels and function of beta 1-containing integrins, beta 1 integrins. Here we demonstrate that the human alkaline ceramidase 2 (ACER2), a Golgi enzyme, regulates beta 1 maturation by controlling the generation of sphingosine. ACER2 overexpression inhibited beta 1 maturation, thus leading to a decrease in the levels of mature beta-1 in T-REx HeLa cells, whereas RNA interference-mediated knockdown of ACER2 enhanced beta 1 maturation in MCF-7 cells. ACER2 overexpression decreased the cell surface levels of beta 1 integrins, thus inhibiting cell adhesion to fibronectin or collagen, whereas ACER2 knockdown has the opposite effects. Treatment with all-trans retinoic acid (ATRA) increased both the expression of ACER2 and the generation of sphingosine in HeLa cells and inhibited beta 1 maturation. ACER2 knockdown attenuated the inhibitory effects of ATRA on both beta 1 maturation and cell adhesion. In contrast, treatment with phorbol myristate acetate (PMA), a protein kinase C activator, decreased the expression of ACER2 and sphingosine in T-REx HeLa cells, thus enhancing beta 1 maturation. ACER2 overexpression inhibited the stimulatory effects of PMA on both beta 1 maturation and cell adhesion. These results suggest that the ACER2/sphingosine pathway plays an important role in regulating beta 1 maturation and cell adhesion mediated by beta 1 integrins. Sun, W., Hu, W., Xu, R., Jin, J., Szulc, Z. M., Zhang, G., Galadari, S. H., Obeid, L. M, Mao, C. Alkaline ceramidase 2 regulates beta 1 integrin maturation and cell adhesion. FASEB J. 23, 656-666 (2009)	[Sun, Wei; Xu, Ruijuan; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Hu, Wei; Jin, Junfei; Szulc, Zdzislaw M.; Obeid, Lina M.; Mao, Cungui] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Zhang, Guofeng] NIH, Div Bioengn & Phys Sci, Bethesda, MD 20892 USA; [Galadari, Sehamuddin H.] United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates; [Obeid, Lina M.] Ralph H Johnson Vet Adm Hosp, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; National Institutes of Health (NIH) - USA; United Arab Emirates University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Mao, CG (corresponding author), Div Gen Internal Med, 114 Doughty St,Rm 605 STB,POB 250779, Charleston, SC 29425 USA.	maoc@musc.edu	xu, rui/GRX-5734-2022; Galadari, Sehamuddin/AAK-6039-2020	obeid, lina/0000-0002-0734-0847	National Institutes of Health [R01CA104834]; Veterans Affairs Merit award; NATIONAL CANCER INSTITUTE [R01CA104834] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit award(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by the National Institutes of Health grant R01CA104834 (to C.M.) and a Veterans Affairs Merit award (to L.M.O.).	AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; Bellis SL, 2004, BBA-BIOMEMBRANES, V1663, P52, DOI 10.1016/j.bbamem.2004.03.012; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boles BK, 2000, AM J PHYSIOL-LUNG C, V278, pL703, DOI 10.1152/ajplung.2000.278.4.L703; Chattopadhyay N, 1999, GYNECOL ONCOL, V75, P215, DOI 10.1006/gyno.1999.5574; Chen XN, 2006, BIOCHEM BIOPH RES CO, V343, P910, DOI 10.1016/j.bbrc.2006.03.046; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; el Bawab Samer, 2002, Subcell Biochem, V36, P187; Gilcrease MZ, 2007, CANCER LETT, V247, P1, DOI 10.1016/j.canlet.2006.03.031; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Hu W, 2005, MOL BIOL CELL, V16, P1555, DOI 10.1091/mbc.E04-07-0594; Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Jee BK, 2007, BIOCHEM BIOPH RES CO, V359, P703, DOI 10.1016/j.bbrc.2007.05.159; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; KIM LT, 1992, J CELL SCI, V103, P743; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Menaldino DS, 2003, PHARMACOL RES, V47, P373, DOI 10.1016/S1043-6618(03)00054-9; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Morini M, 1997, EXP CELL RES, V232, P304, DOI 10.1006/excr.1997.3528; Nikolova-Karakashian M, 2000, METHOD ENZYMOL, V311, P194; Obeid L.M., 2001, J BIOL CHEM, V16, P16; Pruett ST, 2008, J LIPID RES, V49, P1621, DOI 10.1194/jlr.R800012-JLR200; Rozzo C, 1997, INT J CANCER, V70, P688, DOI 10.1002/(SICI)1097-0215(19970317)70:6<688::AID-IJC11>3.3.CO;2-V; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; Sengupta S, 2000, J EXP CLIN CANC RES, V19, P81; Shen X, 2007, P NATL ACAD SCI USA, V104, P1230, DOI 10.1073/pnas.0610535104; Sun W, 2008, J INVEST DERMATOL, V128, P389, DOI 10.1038/sj.jid.5701025; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; Tani M, 2005, J BIOL CHEM, V280, P36592, DOI 10.1074/jbc.M506827200; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; Woodcock J, 2006, IUBMB LIFE, V58, P462, DOI 10.1080/15216540600871118; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; Xu RJ, 2006, FASEB J, V20, P1813, DOI 10.1096/fj.05-5689com; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; Zou K, 2008, BIOCHEMISTRY-US, V47, P3370, DOI 10.1021/bi7014508	40	30	33	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					656	666		10.1096/fj.08-115634	http://dx.doi.org/10.1096/fj.08-115634			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18945876	Green Published			2022-12-28	WOS:000262892900036
J	Callewaert, F; Venken, K; Ophoff, J; De Gendt, K; Torcasio, A; van Lenthe, GH; Van Oosterwyck, H; Boonen, S; Bouillon, R; Verhoeven, G; Vanderschueren, D				Callewaert, Filip; Venken, Katrien; Ophoff, Jill; De Gendt, Karel; Torcasio, Antonia; van Lenthe, G. Harry; Van Oosterwyck, Hans; Boonen, Steven; Bouillon, Roger; Verhoeven, Guido; Vanderschueren, Dirk			Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha	FASEB JOURNAL			English	Article						sex steroid action; trabecular bone; cortical bone; bone strength; muscle and fat mass	ADULT MALE-MICE; MINERAL METABOLISM; TRABECULAR BONE; GROWTH-HORMONE; KNOCKOUT MICE; CORTICAL BONE; ER-ALPHA; IN-VIVO; RATS; TESTOSTERONE	Osteoporosis and muscle frailty are important health problems in elderly men and may be partly related to biological androgen activity. This androgen action can be mediated directly through stimulation of the androgen receptor (AR) or indirectly through stimulation of estrogen receptor-alpha (ER alpha) following aromatization of androgens into estrogens. To assess the differential action of AR and ER alpha pathways on bone and body composition, AR-ER alpha double-knockout mice were generated and characterized. AR disruption decreased trabecular bone mass, whereas ER alpha disruption had no additional effect on the AR-dependent trabecular bone loss. In contrast, combined AR and ER alpha inactivation additionally reduced cortical bone and muscle mass compared with either AR or ER alpha disruption alone. ER alpha inactivation-in the presence or absence of AR-increased fat mass. We demonstrate that AR activation is solely responsible for the development and maintenance of male trabecular bone mass. Both AR and ER alpha activation, however, are needed to optimize the acquisition of cortical bone and muscle mass. ER alpha activation alone is sufficient for the regulation of fat mass. Our findings clearly define the relative importance of AR and ER alpha signaling on trabecular and cortical bone mass as well as body composition in male mice.-Callewaert, F., Venken, K., Ophoff, J., De Gendt, K., Torcasio, A., van Lenthe, G. H., Van Oosterwyck, H., Boonen, S., Bouillon, R., Verhoeven, G., Vanderschueren, D. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. FASEB J. 23, 232-240 (2009)	[Callewaert, Filip; Venken, Katrien; Ophoff, Jill; De Gendt, Karel; Boonen, Steven; Bouillon, Roger; Verhoeven, Guido; Vanderschueren, Dirk] Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Dept Expt Med, B-3000 Leuven, Belgium; [Torcasio, Antonia; van Lenthe, G. Harry; Van Oosterwyck, Hans] Katholieke Univ Leuven, Div Biomech & Engn Design, Dept Mech Engn, B-3000 Leuven, Belgium	KU Leuven; KU Leuven	Verhoeven, G (corresponding author), Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Dept Expt Med, Herestr 49, B-3000 Leuven, Belgium.	vanderschueren@uz.kuleuven.be	van Lenthe, Harry (GH)/C-1030-2008; Van Oosterwyck, Hans/C-2528-2016; De Gendt, Karel/A-6332-2009	van Lenthe, Harry (GH)/0000-0001-8303-4959; Van Oosterwyck, Hans/0000-0002-2142-9717; vanderschueren, dirk/0000-0003-1395-0104	Katholieke Universiteit Leuven [OT/05/53, OT/04/26]; Fund for Scientific Research Flanders; Roche; GlaxoSmithKline	Katholieke Universiteit Leuven(KU Leuven); Fund for Scientific Research Flanders(FWO); Roche(Roche Holding); GlaxoSmithKline(GlaxoSmithKline)	The authors thank E. Van Herck, W. Coopmans, and L. Deboel for excellent technical assistance. This study was supported by grants OT/05/53 and OT/04/26 from the Katholieke Universiteit Leuven. K. V. and K. D. are postdoctoral fellows of the Fund for Scientific Research Flanders ( F. W. O.-Vlaanderen). S. B. and D. V. are senior clinical researchers of the Fund for Scientific Research Flanders. S. B. is holder of the Leuven University Chair in Metabolic Bone Diseases, supported by Roche and GlaxoSmithKline.	Akingbemi BT, 2003, ENDOCRINOLOGY, V144, P84, DOI 10.1210/en.2002-220292; Bhasin S, 2001, AM J PHYSIOL-ENDOC M, V281, pE1172, DOI 10.1152/ajpendo.2001.281.6.E1172; Boonen S, 2007, EUR J INTERN MED, V18, P6, DOI 10.1016/j.ejim.2006.09.005; Bouillon R, 2004, J CLIN ENDOCR METAB, V89, P6025, DOI 10.1210/jc.2004-0602; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; De Gendt K, 2005, ENDOCRINOLOGY, V146, P4117, DOI 10.1210/en.2005-0300; Dupont S, 2000, DEVELOPMENT, V127, P4277; FELDKAMP LA, 1984, J OPT SOC AM A, V1, P612, DOI 10.1364/JOSAA.1.000612; Frost HM, 2003, ANAT REC PART A, V275A, P1081, DOI 10.1002/ar.a.10119; Gao WQ, 2005, ENDOCRINOLOGY, V146, P4887, DOI 10.1210/en.2005-0572; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Hildebrand T, 1997, J MICROSC-OXFORD, V185, P67, DOI 10.1046/j.1365-2818.1997.1340694.x; Jones MEE, 2000, P NATL ACAD SCI USA, V97, P12735, DOI 10.1073/pnas.97.23.12735; Juul A, 2001, HUM REPROD UPDATE, V7, P303, DOI 10.1093/humupd/7.3.303; Katznelson L, 1996, J CLIN ENDOCR METAB, V81, P4358, DOI 10.1210/jc.81.12.4358; Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100; Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008-0002; Kos M, 2002, J MOL ENDOCRINOL, V29, P281, DOI 10.1677/jme.0.0290281; Lindberg MK, 2002, J BONE MINER RES, V17, P555, DOI 10.1359/jbmr.2002.17.4.555; Lindberg MK, 2001, J ENDOCRINOL, V171, P229, DOI 10.1677/joe.0.1710229; Marcus R, 2000, J CLIN ENDOCR METAB, V85, P1032, DOI 10.1210/jc.85.3.1032; Marin P, 1996, J CLIN ENDOCR METAB, V81, P1018, DOI 10.1210/jc.81.3.1018; Moverare S, 2003, P NATL ACAD SCI USA, V100, P13573, DOI 10.1073/pnas.2233084100; Moverare-Skrtic S, 2006, OBESITY, V14, P662, DOI 10.1038/oby.2006.75; Muller ME, 2003, OSTEOPOROSIS INT, V14, P345, DOI 10.1007/s00198-003-1380-9; Pendaries C, 2002, P NATL ACAD SCI USA, V99, P2205, DOI 10.1073/pnas.042688499; Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279; Salmon PL, 2003, J BONE MINER RES, V18, pS256; Sato T, 2003, BIOCHEM BIOPH RES CO, V300, P167, DOI 10.1016/S0006-291X(02)02774-2; Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756-3282(01)00643-3; Sims NA, 2003, J CLIN INVEST, V111, P1319, DOI 10.1172/JCI200317246; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; Smith EP, 2008, J CLIN ENDOCR METAB, V93, P3088, DOI 10.1210/jc.2007-2397; TURNER RT, 1990, J ORTHOPAED RES, V8, P612, DOI 10.1002/jor.1100080418; Vandenput L, 2001, BIOCHEM BIOPH RES CO, V285, P70, DOI 10.1006/bbrc.2001.5101; VANDERSCHUEREN D, 1993, J BONE MINER RES, V8, P801; Vanderschueren D, 1997, ENDOCRINOLOGY, V138, P2301, DOI 10.1210/en.138.6.2301; Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003-0003; Venken K, 2006, J BONE MINER RES, V21, P576, DOI 10.1359/JBMR.060103; Venken K, 2005, J BONE MINER RES, V20, P2138, DOI 10.1359/JBMR.050811; VERHAEGHE J, 1989, J ENDOCRINOL, V120, P143, DOI 10.1677/joe.0.1200143; VERHAEGHE J, 1990, DIABETES, V39, P477, DOI 10.2337/diabetes.39.4.477; Vidal O, 2000, P NATL ACAD SCI USA, V97, P5474, DOI 10.1073/pnas.97.10.5474	44	100	106	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					232	240		10.1096/fj.08-113456	http://dx.doi.org/10.1096/fj.08-113456			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18809737				2022-12-28	WOS:000262095500026
J	Moos, MPW; Mewburn, JD; Kan, FWK; Ishii, S; Abe, M; Sakimura, K; Noguchi, K; Shimizu, T; Funk, CD				Moos, Michael P. W.; Mewburn, Jeffrey D.; Kan, Frederick W. K.; Ishii, Satoshi; Abe, Manabu; Sakimura, Kenji; Noguchi, Kyoko; Shimizu, Takao; Funk, Colin D.			Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport	FASEB JOURNAL			English	Article						inflammation; intravital microscopy; transgenic mice; caveolae	ENDOTHELIAL PERMEABILITY; PROTEIN-KINASES; CALCIUM; CELLS; EXOCYTOSIS; EXPRESSION; ATHEROSCLEROSIS; TRANSCYTOSIS; MECHANISMS; RESPONSES	Cysteinyl leukotrienes (CysLTs) are potent mediators of inflammation synthesized by the concerted actions of 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), leukotriene C4 synthase, and additional downstream enzymes, starting with arachidonic acid substrate. CysLTs produced by macrophages, eosinophils, mast cells, and other inflammatory cells activate 3 different high-affinity CysLT receptors: CysLT1R, CysLT2R, and GPR 17. We sought to investigate vascular sites of CysLT2R expression and the role and mechanism of this receptor in mediating vascular permeability events. Vascular expression of CysLT2R was investigated by reporter gene expression in a novel CysLT2R deficient-LacZ mouse model. CysLT2R was expressed in small, but not large, vessels in mouse brain, bladder, skin, and cremaster muscle. Intravital, in addition to confocal and electron, microscopy investigations using FITC-labeled albumin in cremaster postcapillary venule preparations indicated rapid CysLT-mediated permeability, which was blocked by application of BAY-u9773, a dual CysLT(1)R/CysLT(2)R antagonist or by CysLT2R deficiency. Endothelial human CysLT2R overexpression in mice exacerbated vascular leakage even in the absence of exogenous ligand. The enhanced vascular permeability mediated by CysLT2R takes place via a transendothelial vesicle transport mechanism as opposed to a paracellular route and is controlled via Ca2+ signaling. Our results reveal that CysLT2R can mediate inflammatory reactions in a vascular bed-specific manner by altering transendothelial vesicle transport-based vascular permeability. Moos, M. P. W., Mewburn, J. D., Kan, F. W. K., Ishii, S., Abe, M., Sakimura, K., Noguchi, K., Shimizu, T., Funk, C. D. Cysteinyl leukotriene 2 receptor-mediated vascular permeability via transendothelial vesicle transport. FASEB J. 22, 4352-4362 (2009)	[Moos, Michael P. W.; Funk, Colin D.] Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; [Funk, Colin D.] Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; [Mewburn, Jeffrey D.] Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; [Kan, Frederick W. K.] Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; [Ishii, Satoshi; Noguchi, Kyoko; Shimizu, Takao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan; [Ishii, Satoshi] Japan Sci & Technol Agcy, PRESTO, Tokyo, Japan; [Abe, Manabu; Sakimura, Kenji] Niigata Univ, Brain Res Inst, Dept Cellular Neurobiol, Niigata, Japan	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; University of Tokyo; Japan Science & Technology Agency (JST); Niigata University	Funk, CD (corresponding author), Queens Univ, Dept Physiol, 433 Botterell Hall,Stuart St, Kingston, ON K7L 3N6, Canada.	funkc@queensu.ca	Abe, Manabu/A-9221-2008; Shimizu, Takao/AAV-7052-2021; Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	German Academy of Sciences Leopoldina with the German Federal Ministry of Education and Research [BMBF-LPD9901/8-132]	German Academy of Sciences Leopoldina with the German Federal Ministry of Education and Research	We thank Dr. Yves St. Pierre ( University of Quebec) for kindly supplying the murine b-end. 3 cells. This work was supported by Canadian Institutes of Health Research grant MOP-68930 and the Canadian Foundation for Innovation. C. D. F. holds a Tier I Canada Research Chair in Molecular, Cellular, and Physiological Medicine and is recipient of a Career Investigator Award from the Heart and Stroke Foundation of Ontario. M. P. W. M. was supported by the German Academy of Sciences Leopoldina with the German Federal Ministry of Education and Research, BMBF-LPD9901/8-132.	Aller MA, 2006, MED SCI MONITOR, V12, pRA225; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Bates DO, 2002, J ANAT, V200, P581, DOI 10.1046/j.1469-7580.2002.00066.x; Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; Casillan AJ, 2003, J APPL PHYSIOL, V94, P2313, DOI 10.1152/japplphysiol.00047.2002; Chen XK, 2006, NEUROSCIENTIST, V12, P375, DOI 10.1177/1073858406291588; Choileain NN, 2006, ARCH SURG-CHICAGO, V141, P1132, DOI 10.1001/archsurg.141.11.1132; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079; El-Mestrah M, 1999, ANAT REC, V255, P227, DOI 10.1002/(SICI)1097-0185(19990601)255:2<227::AID-AR12>3.0.CO;2-E; Ferri LE, 2002, CRIT CARE MED, V30, P1842, DOI 10.1097/00003246-200208000-00028; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; Fredholm BB, 2007, ACTA PHYSIOL, V190, P3, DOI 10.1111/j.1365-201X.2007.01689.x; Funk CD, 2005, NAT REV DRUG DISCOV, V4, P664, DOI 10.1038/nrd1796; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Garcia AG, 2006, PHYSIOL REV, V86, P1093, DOI 10.1152/physrev.00039.2005; GERICKE M, 1993, PFLUG ARCH EUR J PHY, V422, P552, DOI 10.1007/BF00374001; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; Hashizume K, 2002, J NEUROPATH EXP NEUR, V61, P725, DOI 10.1093/jnen/61.8.725; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Huang QB, 2003, SHOCK, V20, P363, DOI 10.1097/01.shk.0000079425.0000.db; Hui YQ, 2004, CIRCULATION, V110, P3360, DOI 10.1161/01.CIR.0000147775.50954.AA; Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200; Jiang W, 2008, AM J PATHOL, V172, P592, DOI 10.2353/ajpath.2008.070834; Koopman WJH, 2001, PFLUG ARCH EUR J PHY, V443, P250, DOI 10.1007/s004240100680; Laemmel E, 2004, J VASC RES, V41, P400, DOI 10.1159/000081209; Lominadze D, 2006, AM J PHYSIOL-HEART C, V290, pH1206, DOI 10.1152/ajpheart.00376.2005; Lotzer K, 2005, BBA-MOL CELL BIOL L, V1736, P30, DOI 10.1016/j.bbalip.2005.07.001; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; McCafferty DM, 2002, J IMMUNOL, V168, P4930, DOI 10.4049/jimmunol.168.10.4930; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Ogasawara H, 2002, J BIOL CHEM, V277, P18763, DOI 10.1074/jbc.M109447200; Oheim M, 2006, CELL CALCIUM, V40, P423, DOI 10.1016/j.ceca.2006.08.007; Predescu D, 2004, AM J PHYSIOL-LUNG C, V287, pL895, DOI 10.1152/ajplung.00075.2004; Rusakov DA, 2006, NEUROSCIENTIST, V12, P317, DOI 10.1177/1073858405284672; Shiels IA, 2000, MED HYPOTHESES, V54, P193, DOI 10.1054/mehy.1999.0017; Warren M, 2007, CIRC RES, V101, pE90, DOI 10.1161/CIRCRESAHA.107.162735	39	43	44	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2008	22	12					4352	4362		10.1096/fj.08-113274	http://dx.doi.org/10.1096/fj.08-113274			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18779380				2022-12-28	WOS:000261254800033
J	Khetani, SR; Chen, AA; Ranscht, B; Bhatia, SN				Khetani, Salman R.; Chen, Alice A.; Ranscht, Barbara; Bhatia, Sangeeta N.			T-cadherin modulates hepatocyte functions in vitro	FASEB JOURNAL			English	Article						CHO; fibroblasts; coculture; cytochrome P450	JUNCTIONAL COMMUNICATION; ENDOTHELIAL-CELLS; DRUG-METABOLISM; SMOOTH-MUSCLE; LIVER; COCULTURE; CONTACT; DIFFERENTIATION; IDENTIFICATION; EXPRESSION	Primary hepatocytes from several different species rapidly lose viability and phenotypic functions on isolation from their native microenvironment of the liver. Stromal cells derived from both within and outside the liver can induce phenotypic functions in primary hepatocytes in vitro; however, the molecular mediators underlying this "coculture effect" have not been fully elucidated. We have previously developed a functional genomic screen utilizing cocultures of hepatocytes and 3T3 fibroblasts to identify such candidate hepatocyte-function-inducing molecules. In particular, truncated-cadherin (T-cadherin) was identified as a potential molecule of interest in induction of hepatic functions. Here we demonstrate that liver-specific functions of primary rat hepatocytes are induced on cocultivation with Chinese hamster ovary cells engineered to express T-cadherin on their surface as compared with wild-type controls. Additionally, culture of cells on substrata presenting recombinant T-cadherin protein (acellular presentation) enhanced hepatic functions in both pure hepatocyte cultures and in hepatocyte-stromal cocultures lacking endogenous T-cadherin expression. Collectively, these data indicate that both cellular and acellular presentation of T-cadherin can be used to modulate the hepatocyte phenotype in vitro for tissue engineering applications. Our work suggests potential avenues for investigating the role of T-cadherin on hepatocellular function in vivo in settings such as embryogenesis and liver pathology.-Khetani, S. R., Chen, A. A., Ranscht, B., Bhatia, S. N. T-cadherin modulates hepatocyte functions in vitro. FASEB J. 22, 3768-3775 (2008)	[Bhatia, Sangeeta N.] MIT, Lab Multiscale Regenerat Technol, Div Hlth Sci & Technol Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Chen, Alice A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Ranscht, Barbara] Burnham Inst Med Res, La Jolla, CA USA; [Bhatia, Sangeeta N.] Brigham & Womens Hosp, Div Med, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Sanford Burnham Prebys Medical Discovery Institute; Harvard University; Brigham & Women's Hospital	Bhatia, SN (corresponding author), MIT, Lab Multiscale Regenerat Technol, Div Hlth Sci & Technol Elect Engn & Comp Sci, 77 Massachusetts Ave,E19-502D, Cambridge, MA 02139 USA.	sbhatia@mit.edu	Yu, weiting/I-7417-2013		National Science Foundation (NSF); National Institutes of Health (NIH) [HD 25938]; NSF CAREER; NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); David and Lucile Packard Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065152] Funding Source: NIH RePORTER	National Science Foundation (NSF)(National Science Foundation (NSF)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF CAREER(National Science Foundation (NSF)NSF - Office of the Director (OD)); NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); David and Lucile Packard Foundation(The David & Lucile Packard Foundation); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Jennifer Felix and Kathryn Hudson for rat hepatocyte isolation, Craig Sharp for assistance with cell culture and biochemical assays, Sandra March for critical review of the manuscript, and James Thomson for providing mouse embryonic fibroblasts. Funding was provided by National Science Foundation (NSF) Graduate Fellowships (S.R.K, A.A.C.), National Institutes of Health (NIH) grant HD 25938 (B.R), NSF CAREER, NIH-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the David and Lucile Packard Foundation.	Adachi Y, 2006, VIRCHOWS ARCH, V448, P311, DOI 10.1007/s00428-005-0098-9; Allen JW, 2002, TISSUE ENG, V8, P725, DOI 10.1089/10763270260424097; Bhatia SN, 1999, FASEB J, V13, P1883, DOI 10.1096/fasebj.13.14.1883; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; Brieva TA, 2004, TISSUE ENG, V10, P553, DOI 10.1089/107632704323061915; Brieva TA, 2001, BIOTECHNOL BIOENG, V76, P295, DOI 10.1002/bit.10041; Chia SM, 2005, BIOTECHNOL BIOENG, V89, P565, DOI 10.1002/bit.20372; Corlu A, 1997, CELL BIOL TOXICOL, V13, P235, DOI 10.1023/A:1007475122321; CORLU A, 1991, J CELL BIOL, V115, P505, DOI 10.1083/jcb.115.2.505; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; Eschbach E, 2005, J CELL BIOCHEM, V95, P243, DOI 10.1002/jcb.20360; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Gebhardt R, 2003, DRUG METAB REV, V35, P145, DOI 10.1081/DMR-120023684; GOULET F, 1988, HEPATOLOGY, V8, P1010, DOI 10.1002/hep.1840080506; GUGUENGUILLOUZO C, 1983, MOL CELL BIOCHEM, V53-4, P35; Guillouzo A, 1998, ENVIRON HEALTH PERSP, V106, P511, DOI 10.2307/3433803; Hamilton GA, 2001, CELL TISSUE RES, V306, P85; Hewitt NJ, 2007, DRUG METAB REV, V39, P159, DOI 10.1080/03602530601093489; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Hui EE, 2007, P NATL ACAD SCI USA, V104, P5722, DOI 10.1073/pnas.0608660104; Joshi MB, 2005, FASEB J, V19, P1737, DOI 10.1096/fj.05-3834fje; Khetani SR, 2008, NAT BIOTECHNOL, V26, P120, DOI 10.1038/nbt1361; Khetani SR, 2004, HEPATOLOGY, V40, P545, DOI 10.1002/hep.20351; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MESNIL M, 1987, EXP CELL RES, V173, P524, DOI 10.1016/0014-4827(87)90292-8; Omelchenko T, 2001, P NATL ACAD SCI USA, V98, P8632, DOI 10.1073/pnas.151247698; Philippova M, 2008, MOL CELL BIOL, V28, P4004, DOI 10.1128/MCB.00157-08; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; REID LM, 1986, ISOLATED CULTURED HE, P226; ROJKIND M, 1995, AM J PATHOL, V146, P1508; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sivaraman A, 2005, CURR DRUG METAB, V6, P569, DOI 10.2174/138920005774832632; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Takeuchi T, 2001, HISTOL HISTOPATHOL, V16, P1287, DOI 10.14670/HH-16.1287; Tkachuk VA, 1998, FEBS LETT, V421, P208, DOI 10.1016/S0014-5793(97)01562-7; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451	37	42	46	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2008	22	11					3768	3775		10.1096/fj.07-105155	http://dx.doi.org/10.1096/fj.07-105155			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	366SF	18635739	Green Published			2022-12-28	WOS:000260503000005
J	Franks, PW; Scheele, C; Loos, RJF; Nielsen, AR; Finucane, FM; Wahlestedt, C; Pedersen, BK; Wareham, NJ; Timmons, JA				Franks, P. W.; Scheele, C.; Loos, R. J. F.; Nielsen, A. R.; Finucane, F. M.; Wahlestedt, C.; Pedersen, B. K.; Wareham, N. J.; Timmons, J. A.			Genomic variants at the PINK1 locus are associated with transcript abundance and plasma nonesterified fatty acid concentrations in European whites	FASEB JOURNAL			English	Article						oxidative metabolism; mitochondria; diabetes; single nucleotide polymorphism; gene-environment interaction	ONSET PARKINSONS-DISEASE; MITOCHONDRIAL DYSFUNCTION; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; GENE-EXPRESSION; BINDING PROTEIN; METABOLISM; MUSCLE; MICE; MUTATIONS	The purpose of this study was to characterize associations between PINK1 genotypes, PINK1 transcript levels, and metabolic phenotypes in healthy adults and those with type 2 diabetes (T2D). We measured PINK1 skeletal muscle transcript levels and 8 independent PINK1 single nucleotide polymorphisms (SNPs) in a cohort of 208 Danish whites and in a cohort of 1701 British whites (SNPs and metabolic phenotypes only). Furthermore, we assessed the effects of PINK1 transcript ablation in primary adipocytes using RNA interference (RNAi). Six PINK1 SNPs were associated with PINK1 transcript levels (P < 0.04 to P < 0.0001). Obesity modified the association between PINK1 transcript levels and T2D risk (interaction P=0.005); transcript levels were inversely related with T2D in obese (n=105) [odds ratio (OR) per SD increase in expression levels=0.44; 95% confidence interval (CI): 0.23, 0.84; P=0.013] but not in nonobese (n=103) (OR=1.20; 95% CI: 0.82, 1.76; P=0.34) individuals. In the British cohort, several PINK1 SNPs were associated with plasma nonesterified fatty acid concentrations. Nominal genotype associations were also observed for fasting glucose, 2-h glucose, and maximal oxygen consumption, although these were not statistically significant after correcting for multiple testing. In primary adipocytes, Pink1 knockdown affected fatty acid binding protein 4 (Fabp4) expression, indicating that PINK1 may influence substrate metabolism. We demonstrate that PINK1 polymorphisms are associated with PINK1 transcript levels and measures of fatty acid metabolism in a concordant manner, whereas our RNAi data imply that PINK1 may indirectly influence lipid metabolism.	[Franks, P. W.] Umea Univ Hosp, Div Med, Dept Publ Hlth & Clin Med, Genet Epidemiol & Clin Res Grp, S-90187 Umea, Sweden; [Franks, P. W.; Loos, R. J. F.; Finucane, F. M.; Wareham, N. J.] Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England; [Scheele, C.; Timmons, J. A.] Stockholm Univ, Arrhenius Labs, Wenner Gren Inst, S-10691 Stockholm, Sweden; [Scheele, C.; Timmons, J. A.] Heriot Watt Univ, Sch Life Sci, Edinburgh, Midlothian, Scotland; [Scheele, C.; Nielsen, A. R.; Pedersen, B. K.] Univ Copenhagen, Rigshosp, Ctr Inflammat & Metab, DK-2100 Copenhagen, Denmark; [Wahlestedt, C.] Scripps Res Inst, Dept Biochem, Jupiter, FL USA	Umea University; University of Cambridge; Stockholm University; Heriot Watt University; Rigshospitalet; University of Copenhagen; Scripps Research Institute	Franks, PW (corresponding author), Umea Univ Hosp, Div Med, Dept Publ Hlth & Clin Med, Genet Epidemiol & Clin Res Grp, S-90187 Umea, Sweden.	paul.franks@medicin.umu.se	Loos, Ruth/GON-5877-2022; Pedersen, Bente Klarlund/AGR-3217-2022; Finucane, Francis/G-6031-2012; Loos, Ruth J F/Q-2862-2016; Wahlestedt, Claes/A-7039-2009; Timmons, James A/J-4698-2014; Scheele, Camilla/S-6401-2017; Timmons, James A/M-6350-2019; Franks, Paul/AAA-3300-2020; Scheele, Camilla/AAA-3599-2020	Pedersen, Bente Klarlund/0000-0001-6508-6288; Finucane, Francis/0000-0002-5374-7090; Loos, Ruth J F/0000-0002-8532-5087; Timmons, James A/0000-0002-2255-1220; Scheele, Camilla/0000-0002-6055-9709; Timmons, James A/0000-0002-2255-1220; Scheele, Camilla/0000-0002-6055-9709; Rinnov, Anders Rasmussen/0000-0003-3859-3289; Franks, Paul/0000-0002-0520-7604	UK Medical Research Council; Wellcome Trust; Commission of the European Communities [LSHM-CT-2004-005272]; Danish National Research Foundation [DG 02-512-555]; Swedish Diabetes Association; Swedish Heart-Lung Foundation; Vasterbottens Health Authority; Swedish Parkinson's Society; SSF Genome Canada; MRC [MC_U106188470] Funding Source: UKRI; Medical Research Council [MC_U106188470] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Commission of the European Communities(European Commission); Danish National Research Foundation(Danmarks Grundforskningsfond); Swedish Diabetes Association; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Vasterbottens Health Authority; Swedish Parkinson's Society; SSF Genome Canada; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful to the individuals who took part in the studies described herein. We thank Tomas Walden for his technical support with DNA isolation from the Danish cohort and for the brown adipose dissections. We also thank Matt Sims, Stewart Laing, and Cathy Elks for expert genotyping assistance. The MRC Ely study was supported by the UK Medical Research Council and the Wellcome Trust (N.J.W.). The Danish cohort was supported by the Commission of the European Communities (contract LSHM-CT-2004-005272 EXGENESIS and Danish National Research Foundation grant DG 02-512-555. P. W. F. was supported by grants from the Swedish Diabetes Association, Novo Nordisk, the Swedish Heart-Lung Foundation, and Vasterbottens Health Authority. J.A.T. was supported by the Swedish Diabetes Association, the Swedish Parkinson's Society, and SSF Genome Canada. The funding agencies did not influence study design, data collection, data analysis, the decision to publish, or the preparation of the manuscript.	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; [Anonymous], 2000, TECHN REP SER WHO; Barroso I, 2003, PLOS BIOL, V1, P41, DOI 10.1371/journal.pbio.0000020; BERGSTROM J, 1966, NATURE, V210, P309, DOI 10.1038/210309a0; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; Brambor T, 2006, POLIT ANAL, V14, P63, DOI 10.1093/pan/mpi014; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; Ekelund U, 2007, DIABETES CARE, V30, P2101, DOI 10.2337/dc07-0719; Fischer H, 2006, BIOCHEM BIOPH RES CO, V346, P125, DOI 10.1016/j.bbrc.2006.05.083; Franks PW, 2007, DIABETOLOGIA, V50, P569, DOI 10.1007/s00125-006-0580-1; Franks PW, 2004, DIABETES CARE, V27, P1187, DOI 10.2337/diacare.27.5.1187; Gandhi S, 2006, BRAIN, V129, P1720, DOI 10.1093/brain/awl114; Grunewald A, 2007, NEUROGENETICS, V8, P103, DOI 10.1007/s10048-006-0072-y; Haque ME, 2008, P NATL ACAD SCI USA, V105, P1716, DOI 10.1073/pnas.0705363105; Haunerland NH, 2004, PROG LIPID RES, V43, P328, DOI 10.1016/j.plipres.2004.05.001; Hoepken HH, 2007, NEUROBIOL DIS, V25, P401, DOI 10.1016/j.nbd.2006.10.007; HOLM S, 1979, SCAND J STAT, V6, P5; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Kitada T, 2007, P NATL ACAD SCI USA, V104, P11441, DOI 10.1073/pnas.0702717104; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Muqit MMK, 2006, ARCH NEUROL-CHICAGO, V63, P649, DOI 10.1001/archneur.63.5.649; NECHAD M, 1987, AM J PHYSIOL, V253, pC889, DOI 10.1152/ajpcell.1987.253.6.C889; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200; Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Schapira AHV, 2007, CELL DEATH DIFFER, V14, P1261, DOI 10.1038/sj.cdd.4402160; Scheele C, 2007, FASEB J, V21, P3653, DOI 10.1096/fj.07-8520com; Shaughnessy S, 2000, DIABETES, V49, P904, DOI 10.2337/diabetes.49.6.904; Sim CH, 2006, HUM MOL GENET, V15, P3251, DOI 10.1093/hmg/ddl398; Steinberg GR, 2007, CELL CYCLE, V6, P888, DOI 10.4161/cc.6.8.4135; Takatori S, 2008, NEUROSCI LETT, V430, P13, DOI 10.1016/j.neulet.2007.10.019; Timmons JA, 2005, FASEB J, V19, P750, DOI 10.1096/fj.04-1980com; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Wang DL, 2006, P NATL ACAD SCI USA, V103, P13520, DOI 10.1073/pnas.0604661103; Wang F, 2006, NEUROSCI LETT, V410, P121, DOI 10.1016/j.neulet.2006.09.080; Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103; Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120; Zhou HX, 2007, INT J BIOL SCI, V3, P242	41	13	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3135	3145		10.1096/fj.08-107086	http://dx.doi.org/10.1096/fj.08-107086			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18495756	Green Published			2022-12-28	WOS:000258761300006
J	Mavroidis, M; Panagopoulou, P; Kostavasili, I; Weisleder, N; Capetanaki, Y				Mavroidis, Manolis; Panagopoulou, Panagiota; Kostavasili, Ioanna; Weisleder, Noah; Capetanaki, Yassemi			A missense mutation in desmin tail domain linked to human dilated cardiomyopathy promotes cleavage of the head domain and abolishes its Z-disc localization	FASEB JOURNAL			English	Article						intercalated discs; IF proteolysis; transgenic mice	MICE LACKING DESMIN; INTERMEDIATE-FILAMENTS; SKELETAL MYOPATHY; MEMBRANE INTERACTIONS; NULL CARDIOMYOPATHY; SITE-SPECIFICITY; PLASMA-MEMBRANE; GENE; CARDIOMYOCYTES; CYTOSKELETON	A missense mutation (Ile 451 to Met) at the tail domain of the muscle-specific intermediate filament protein desmin has been suggested to be a genetic cause of dilated cardiomyopathy. The Ile451Met mutation is located inside a conserved motif in the desmin tail domain, believed to have a potential role in the lateral packing of type III intermediate filaments. Nevertheless, the role of the type III intermediate filament tail domain remains elusive. To further study the role of this domain in the function of cardiomyocytes and in the development of cardiomyopathy, we generated transgenic mice expressing the mutant desmin(I451M) in the cardiac tissue. Analysis of hearts from transgenic animals revealed that mutant desmin loses its Z-disc localization but it can still associate with the intercalated discs, which, however, have an altered architecture, resembling other examples of dilated cardiomyoplathy. This is the first report demonstrating a critical role of the desmin head and tail domains in the formation of the IF scaffold around Z discs. It is further suggested that in cardiomyocytes, an interplay between desmin tail and head domains is taking place, which potentially protects the amino terminus of desmin from specific proteases. The fact that the association with intercalated discs seems unchanged suggests that this association must take place through the desmin tail, in contrast to the head domain that is most possibly involved in the Z-disc binding.	[Mavroidis, Manolis; Panagopoulou, Panagiota; Kostavasili, Ioanna; Weisleder, Noah; Capetanaki, Yassemi] Acad Athens, Biomed Res Fdn, Ctr Basic Res, Div Cell Biol, Athens, Greece	Academy of Athens	Capetanaki, Y (corresponding author), Soranou Efesiou 4, Athens 11527, Greece.	ycapetanaki@bioacademy.gr	Weisleder, Noah L/A-7098-2013	Weisleder, Noah L/0000-0002-2619-8022; Mavroidis, Manolis/0000-0002-3870-3954; Weisleder, Noah/0000-0003-2710-3088	SCOR NIH [HL-98]; Greek Secretariat of Research and Development [EPAN-YB22, PEP-ATT-39, PENED-01ED371]	SCOR NIH; Greek Secretariat of Research and Development	The authors thank Dr. M. Samiotaki (Fleming Research Center, Athens, Greece) and Drs. K. Vougas and A. Vlachou (Biomedical Research Foundation, Academy of Athens, Athens, Greece) for mass spectroscopy analysis; Dr. M. Fountoulakis (Hoffmann-La Roche, Basel, Switzerland) for automated Edman degradation; and Dr. N. Kostomitsopoulos (Biomedical Research Foundation, Academy of Athens) for rabbit immunization. This work was supported by grant SCOR NIH SCOR NIH HL-98, and grants EPAN-YB22, PEP-ATT-39, and PENED-01ED371 from the Greek Secretariat of Research and Development to Y.C. This work is dedicated to the memory of K. Karagiaouris.	Arbustini E, 2006, EUR J HEART FAIL, V8, P477, DOI 10.1016/j.ejheart.2005.11.003; Bar H, 2006, EXP CELL RES, V312, P1554, DOI 10.1016/j.yexcr.2006.01.021; Bar H, 2004, J STRUCT BIOL, V148, P137, DOI 10.1016/j.jsb.2004.04.003; Bar H, 2005, P NATL ACAD SCI USA, V102, P15099, DOI 10.1073/pnas.0504568102; Bar H, 2007, HUM MUTAT, V28, P374, DOI 10.1002/humu.20459; BIRKENBERGER L, 1990, J CELL BIOL, V111, P2063, DOI 10.1083/jcb.111.5.2063; Cameron BM, 1996, ST HEAL T, V29, P447; Capetanaki Y, 1998, Subcell Biochem, V31, P463; Capetanaki Y, 2002, TRENDS CARDIOVAS MED, V12, P339, DOI 10.1016/S1050-1738(02)00184-6; Capetanaki Y, 2007, EXP CELL RES, V313, P2063, DOI 10.1016/j.yexcr.2007.03.033; CARY RB, 1994, J CELL SCI, V107, P1609; Dagvadorj A, 2004, J NEUROL, V251, P143, DOI 10.1007/s00415-004-0289-3; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; Dalakas MC, 2003, NEUROMUSCULAR DISORD, V13, P252, DOI 10.1016/S0960-8966(02)00271-7; Fountoulakis M, 2005, J MOL CELL CARDIOL, V38, P461, DOI 10.1016/j.yjmcc.2004.12.008; Franke WW, 2006, EUR J CELL BIOL, V85, P69, DOI 10.1016/j.ejcb.2005.11.003; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GEORGATOS SD, 1985, J CELL BIOL, V100, P1962, DOI 10.1083/jcb.100.6.1962; Goldfarb LG, 2004, BRAIN, V127, P723, DOI 10.1093/brain/awh033; Goudeau B, 2006, HUM MUTAT, V27, P906, DOI 10.1002/humu.20351; Haubold K, 2003, CELL MOTIL CYTOSKEL, V54, P105, DOI 10.1002/cm.10090; HERRMANN H, 1992, J MOL BIOL, V223, P637, DOI 10.1016/0022-2836(92)90980-X; Hofner M, 2007, DIFFERENTIATION, V75, P605, DOI 10.1111/j.1432-0436.2007.00162.x; Hollrigl A, 2002, FEBS LETT, V523, P229, DOI 10.1016/S0014-5793(02)02995-2; Kaplan SR, 2004, CARDIOVASC PATHOL, V13, P26, DOI 10.1016/S1054-8807(03)00107-8; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; KOUKLIS PD, 1991, J CELL BIOL, V114, P773, DOI 10.1083/jcb.114.4.773; Kouloumenta A, 2007, J BIOL CHEM, V282, P35211, DOI 10.1074/jbc.M704733200; Lapouge K, 2006, J CELL SCI, V119, P4974, DOI 10.1242/jcs.03255; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Liu JB, 2006, J MOL CELL CARDIOL, V40, P451, DOI 10.1016/j.yjmcc.2005.12.011; Mavroidis M, 2002, AM J PATHOL, V160, P943, DOI 10.1016/S0002-9440(10)64916-4; Milner DJ, 1999, J MOL CELL CARDIOL, V31, P2063, DOI 10.1006/jmcc.1999.1037; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; NELSON WJ, 1982, J BIOL CHEM, V257, P5544; Olive M, 2004, J NEUROL SCI, V219, P125, DOI 10.1016/j.jns.2004.01.007; Parry DAD, 1999, Q REV BIOPHYS, V32, P99, DOI 10.1017/S0033583500003516; Perriard JC, 2003, TRENDS CARDIOVAS MED, V13, P30, DOI 10.1016/S1050-1738(02)00209-8; Selcen D, 2004, BRAIN, V127, P439, DOI 10.1093/brain/awh052; SHOEMAN RL, 1993, BIOESSAYS, V15, P605, DOI 10.1002/bies.950150906; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Taylor MRG, 2007, CIRCULATION, V115, P1244, DOI 10.1161/CIRCULATIONAHA.106.646778; Thornell LE, 1997, J MOL CELL CARDIOL, V29, P2107, DOI 10.1006/jmcc.1997.0446; Weisleder N, 2004, J MOL CELL CARDIOL, V36, P121, DOI 10.1016/j.yjmcc.2003.10.010; Weisleder N, 2004, P NATL ACAD SCI USA, V101, P769, DOI 10.1073/pnas.0303202101; Zerefos PG, 2006, PROTEOMICS, V6, P4346, DOI 10.1002/pmic.200500671	49	30	30	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3318	3327		10.1096/fj.07-088724	http://dx.doi.org/10.1096/fj.07-088724			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18539904	Green Published			2022-12-28	WOS:000258761300024
J	Hu, XY; He, WX; Diaconu, CD; Tang, XY; Kidd, GJ; Macklin, WB; Trapp, BD; Yan, RQ				Hu, Xiangyou; He, Wanxia; Diaconu, Claudiu; Tang, Xiaoying; Kidd, Grahame J.; Macklin, Wendy B.; Trapp, Bruce D.; Yan, Riqiang			Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves	FASEB JOURNAL			English	Article						neuregulin; myelin; nerve crush; alpha-secretase; gamma-secretase	AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE ACTIVITY; MYELIN SHEATH THICKNESS; PERIPHERAL-NERVE; ALZHEIMERS-DISEASE; A-BETA; WALLERIAN DEGENERATION; EXPRESSION; NEUREGULIN-1; AXONS	BACE1 is a promising therapeutic and preventive target for Alzheimer's disease because it is essential for amyloid deposition. However, the recent demonstration of BACE1 in modulating developmental myelination in both peripheral and central nervous systems raises a concern of its effect on myelin maintenance or remyelination, and inhibition of these processes will potentially be detrimental to the BACE1 inhibitor users who are susceptible to myelination diseases such as adult peripheral nerve injury or multiple sclerosis. In this report, we investigated the role of BACE1 during peripheral nerve remyelination in wildtype (WT) and BACE1-null mice. We show here that genetic deletion of BACE1 affects sciatic nerve remyelination. The impaired remyelination appears to stem from the loss of neuregulin-1 cleavage by BACE1. To demonstrate a direct cleavage of neuregulin-1 by BACE1, we have identified a BACE1 cleavage site that turns out be highly conserved among neuregulin-1 paralogues. Moreover, we show that neuregulin-1 family member neuregulin-3 is also cleavable by BACE1. We hypothesize that the BACE1-cleaved extracellular domain of axonal neuregulin-1, perhaps neuregulin-3 as well, binds to Schwann cell ErbB receptors, which in turn regulate remyelination. Pharmacological inhibition of BACE1 should be carefully monitored to avoid alteration of signaling pathway that regulates remyelination.	[Hu, Xiangyou; He, Wanxia; Diaconu, Claudiu; Tang, Xiaoying; Kidd, Grahame J.; Macklin, Wendy B.; Trapp, Bruce D.; Yan, Riqiang] Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Yan, RQ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.	yanr@ccf.org	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Yan, Riqiang/0000-0001-7195-7617; Kidd, Grahame/0000-0003-3956-2206	NATIONAL INSTITUTE ON AGING [R01AG025493] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG025493, AG025493] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akassoglou K, 2003, NEUROSCI LETT, V338, P185, DOI 10.1016/S0304-3940(02)01387-3; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Brady SF, 2004, BIOORG MED CHEM LETT, V14, P601, DOI 10.1016/j.bmcl.2003.11.061; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Carroll SL, 1997, J NEUROSCI, V17, P1642; Carteron C, 2006, J CELL SCI, V119, P898, DOI 10.1242/jcs.02799; Chang WP, 2004, J NEUROCHEM, V89, P1409, DOI 10.1111/j.1471-4159.2004.02452.x; Chen S, 2006, J NEUROSCI, V26, P3079, DOI 10.1523/JNEUROSCI.3785-05.2006; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Funakoshi H, 1998, P NATL ACAD SCI USA, V95, P5269, DOI 10.1073/pnas.95.9.5269; Haney CA, 1999, J CELL BIOL, V146, P1173, DOI 10.1083/jcb.146.5.1173; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; LEBLANC AC, 1990, J NEUROSCI RES, V26, P317, DOI 10.1002/jnr.490260308; Lemke G., 2006, SCI STKE, V2006, pe11; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; MARTINI R, 1995, J NEUROSCI, V15, P4488; McConlogue L, 2007, J BIOL CHEM, V282, P26326, DOI 10.1074/jbc.M611687200; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; MORGANHUGHES JA, 1968, ARCH NEUROL-CHICAGO, V19, P598, DOI 10.1001/archneur.1968.00480060068009; Navel KA, 2006, CURR OPIN NEUROBIOL, V16, P492, DOI 10.1016/j.conb.2006.08.008; Ozaki M, 2004, J NEUROCHEM, V91, P176, DOI 10.1111/j.1471-4159.2004.02719.x; Pietrak BL, 2005, ANAL BIOCHEM, V342, P144, DOI 10.1016/j.ab.2005.04.019; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; ROSENBLUTH J, 1980, J COMP NEUROL, V193, P729, DOI 10.1002/cne.901930310; SCHRODER JM, 1972, BRAIN RES, V45, P49, DOI 10.1016/0006-8993(72)90215-6; Selkoe DJ, 2005, ARCH NEUROL-CHICAGO, V62, P192, DOI 10.1001/archneur.62.2.192; Singer O, 2005, NAT NEUROSCI, V8, P1343, DOI 10.1038/nn1531; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; SMITH GM, 1993, EXP NEUROL, V121, P239, DOI 10.1006/exnr.1993.1091; Takebayashi H, 2002, CURR BIOL, V12, P1157, DOI 10.1016/S0960-9822(02)00926-0; Taveggia C, 2005, NEURON, V47, P681, DOI 10.1016/j.neuron.2005.08.017; Tomasselli AG, 2003, J NEUROCHEM, V84, P1006, DOI 10.1046/j.1471-4159.2003.01597.x; Turner RT, 2002, BIOCHEMISTRY-US, V41, P8742, DOI 10.1021/bi025926t; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEBSTER HDF, 1962, J CELL BIOL, V12, P361; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; WONG E, 1992, J NEUROCHEM, V58, P2212, DOI 10.1111/j.1471-4159.1992.tb10966.x; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Yin XH, 2006, J CELL BIOL, V172, P469, DOI 10.1083/jcb.200509174; Yue T, 2006, J NEUROSCI, V26, P1275, DOI 10.1523/JNEUROSCI.4717-05.2006; Zanazzi G, 2001, J CELL BIOL, V152, P1289, DOI 10.1083/jcb.152.6.1289; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	51	145	151	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2970	2980		10.1096/fj.08-106666	http://dx.doi.org/10.1096/fj.08-106666			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18413858	Green Published			2022-12-28	WOS:000258089300037
J	Kleinau, G; Jaeschke, H; Mueller, S; Raaka, BM; Neumann, S; Paschke, R; Krause, G				Kleinau, Gunnar; Jaeschke, Holger; Mueller, Sandra; Raaka, Bruce M.; Neumann, Susanne; Paschke, Ralf; Krause, Gerd			Evidence for cooperative signal triggering at the extracellular loops of the TSH receptor	FASEB JOURNAL			English	Article						glycoprotein hormone receptors; activation mechanism; signal transduction; endocrinology	THYROID-STIMULATING HORMONE; LEUCINE-RICH REPEATS; SITE-DIRECTED MUTAGENESIS; THYROTROPIN RECEPTOR; CRYSTAL-STRUCTURE; GONADOTROPIN RECEPTORS; CONSTITUTIVE ACTIVITY; CHORIONIC-GONADOTROPIN; TRANSMEMBRANE DOMAIN; SOMATIC MUTATIONS	The mechanisms governing transition of the thyroid stimulating hormone (TSH) receptor (TSHR) from basal to active conformations are poorly understood. Considering that constitutively activating mutations (CAMs) and inactivating mutations in each of the extracellular loops (ECLs) trigger only partial TSHR activation or inactivation, respectively, we hypothesized that full signaling occurs via multiple extracellular signal propagation events. Therefore, individual CAMs in the extracellular region were combined to create double and triple mutants. In support of our hypothesis, combinations of mutants in the ECLs are in some cases additive, while in others they are even synergistic, with triple mutant I486A/I568V/V656F exhibiting a 70-fold increase in TSH-independent signaling. The proximity but likely different spatial orientation of the residues of activating and inactivating mutations in each ECL supports a dual functionality to facilitate signal induction and conduction, respectively. This is the first report for G-protein coupled receptors, suggesting that multiple and cooperative signal propagating events at all three ECLs are required for full receptor activation. Our findings provide new insights concerning molecular signal transmission from extracellular domains toward the transmembrane helix bundle of the glycoprotein hormone receptors.	[Kleinau, Gunnar; Krause, Gerd] Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; [Jaeschke, Holger; Mueller, Sandra; Paschke, Ralf] Univ Klinikum Leipzig, Dept Med, Leipzig, Germany; [Raaka, Bruce M.; Neumann, Susanne] NIDDK, NIH, Clin Endocrinol Branch, Bethesda, MD USA	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Leipzig University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Krause, G (corresponding author), Leibniz Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.	gkrause@fmp-berlin.de	Kleinau, Gunnar/GPX-6330-2022; Horstmann, Britta/C-2154-2008		Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aarons EJ, 2001, VIROLOGY, V287, P382, DOI 10.1006/viro.2001.1046; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; Bogerd J, 2007, MOL CELL ENDOCRINOL, V260, P144, DOI 10.1016/j.mce.2006.01.019; Bonomi M, 2006, MOL ENDOCRINOL, V20, P3351, DOI 10.1210/me.2005-0521; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Case D. A., 2002, AMBER 7; Chen CR, 2003, ENDOCRINOLOGY, V144, P3821, DOI 10.1210/en.2003-0430; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Claeysen S, 2002, FEBS LETT, V517, P195, DOI 10.1016/S0014-5793(02)02620-0; Claus M, 2005, ENDOCRINOLOGY, V146, P5197, DOI 10.1210/en.2005-0713; Claus M, 2005, THYROID, V15, P1089, DOI 10.1089/thy.2005.15.1089; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Fan QR, 2007, MOL CELL ENDOCRINOL, V260, P73, DOI 10.1016/j.mce.2005.12.055; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Galet C, 2005, MOL ENDOCRINOL, V19, P1263, DOI 10.1210/me.2004-0410; Gromoll J, 2000, J CLIN ENDOCR METAB, V85, P2281, DOI 10.1210/jc.85.6.2281; Gudermann T, 2005, EXP CLIN ENDOCR DIAB, V113, P245, DOI 10.1055/s-2005-865679; Ho SC, 2005, MOL CELL ENDOCRINOL, V245, P158, DOI 10.1016/j.mce.2005.11.008; Ho SC, 2001, ENDOCRINOLOGY, V142, P2760, DOI 10.1210/en.142.7.2760; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Jaeschke H, 2006, ENDOCRINOLOGY, V147, P1753, DOI 10.1210/en.2005-1138; Karges B, 2005, MOL ENDOCRINOL, V19, P2086, DOI 10.1210/me.2004-0378; Kleinau G, 2004, J BIOL CHEM, V279, P51590, DOI 10.1074/jbc.M404748200; Kleinau G, 2007, MOL ENDOCRINOL, V21, P574, DOI 10.1210/me.2006-0309; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; KOSUGI S, 1991, J BIOL CHEM, V266, P19413; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lawson Z, 2004, BIOCHEM SOC T, V32, P1048, DOI 10.1042/BST0321048; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Leitolf H, 2000, J BIOL CHEM, V275, P27457; Lin W, 2007, MOL CELL ENDOCRINOL, V260, P83, DOI 10.1016/j.mce.2006.06.012; Morgenthaler NG, 2007, J CLIN ENDOCR METAB, V92, P1058, DOI 10.1210/jc.2006-2213; MUELLER S, 2007, EXP CLIN ENDOCR S1, V115, P33; Mueller S, 2006, J BIOL CHEM, V281, P31638, DOI 10.1074/jbc.M604770200; Muller T, 2003, J CLIN ENDOCR METAB, V88, P2242, DOI 10.1210/jc.2002-021946; Nakabayashi K, 2003, MOL CELL ENDOCRINOL, V202, P139, DOI 10.1016/S0303-7207(03)00075-3; Neumann S, 2005, EUR J ENDOCRINOL, V152, P625, DOI 10.1530/eje.1.01891; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Nurwakagari P, 2007, J MOL ENDOCRINOL, V38, P259, DOI 10.1677/jme.1.02160; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; Rapoport B, 2007, THYROID, V17, P911, DOI 10.1089/thy.2007.0170; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Sanders J, 2007, THYROID, V17, P699, DOI 10.1089/thy.2007.0041; Sanders J, 2007, THYROID, V17, P395, DOI 10.1089/thy.2007.0034; Sanders J, 2006, THYROID, V16, P1195, DOI 10.1089/thy.2006.16.1195; Sangkuhl K, 2002, J BIOL CHEM, V277, P47748, DOI 10.1074/jbc.M203491200; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; Srinivasan S, 2004, J CLIN INVEST, V114, P1158, DOI 10.1172/JCI200421927; Standfuss J, 2007, J MOL BIOL, V372, P1179, DOI 10.1016/j.jmb.2007.03.007; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Vischer HF, 2003, J BIOL CHEM, V278, P15505, DOI 10.1074/jbc.M300634200; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; Zhang M, 2000, ENDOCRINOLOGY, V141, P3514, DOI 10.1210/en.141.9.3514; ZHANG ML, 1995, BIOCHEM BIOPH RES CO, V211, P205, DOI 10.1006/bbrc.1995.1797	65	39	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2798	2808		10.1096/fj.07-104711	http://dx.doi.org/10.1096/fj.07-104711			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18381815	Green Published			2022-12-28	WOS:000258089300020
J	Hruz, PW; Yan, QY; Struthers, H; Jay, PY				Hruz, Paul W.; Yan, Qingyun; Struthers, Heidi; Jay, Patrick Y.			HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy	FASEB JOURNAL			English	Article						insulin resistance; glucose transport; diastolic dysfunction; ritonavir; atazanavir; pulmonary edema	IMMUNODEFICIENCY-VIRUS-INFECTION; INSULIN-RESISTANCE; DIABETIC CARDIOMYOPATHY; GLUCOSE DISPOSAL; RITONAVIR; INDINAVIR; RATS; METABOLISM; MORTALITY; QUANTIFICATION	The clinical use of HIV protease inhibitors is associated with insulin resistance and other metabolic changes that increase long-term cardiovascular risk. Since the failing heart has increased reliance on glucose, the influence of drug exposure on glucose homeostasis, myocardial glucose uptake, cardiac function, and survival was determined in TG9 mice, an established transgenic model of dilated cardiomyopathy generated by cardiac-specific overexpression of Cre-recombinase, as these animals progressed to overt heart failure. Beginning on day of life 75, TG9 mice and nontransgenic littermate controls were given a daily 10 mg/kg intraperitoneal injection of HIV protease inhibitors (ritonavir, lopinavir/ritonavir 4: 1, atazanavir, atazanavir/ritonavir 4: 1) or vehicle. Glucose tolerance testing, measurement of in vivo myocardial 2-deoxyglucose uptake, and echocardiography were performed before and 30 min following drug administration. The progression of dilated cardiomyopathy in TG9 animals was accompanied by impaired glucose tolerance, which was acutely exacerbated by exposure to ritonavir. Ritonavir and lopinavir precipitated acute, decompensated heart failure and death from pulmonary edema in TG9 mice. However, atazanavir, which does not inhibit glucose transport, had no effect. These studies demonstrate that, in the presence of dilated cardiomyopathy, HIV protease inhibitors that impair glucose transport induce acute, decompensated heart failure. The potential for HIV protease inhibitors to contribute to or exacerbate cardiomyopathy in human patients warrants further investigation.	[Hruz, Paul W.; Yan, Qingyun; Struthers, Heidi; Jay, Patrick Y.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Hruz, Paul W.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Jay, Patrick Y.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Hruz, PW (corresponding author), 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.	hruz_p@kids.wustl.edu		Hruz, Paul/0000-0002-1478-3355	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD001487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064572, P30DK056341, P30DK052574] Funding Source: NIH RePORTER; NICHD NIH HHS [K12-HD001487] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-08, P30 DK056341-07, P30DK056341, DK64572, P30DK052574] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2004, FRONT BIOSCI-LANDMRK, V9, P201, DOI 10.2741/1216; An D, 2006, AM J PHYSIOL-HEART C, V291, pH1489, DOI 10.1152/ajpheart.00278.2006; Boudina S, 2007, CIRCULATION, V115, P3213, DOI 10.1161/CIRCULATIONAHA.106.679597; Buerger A, 2006, J CARD FAIL, V12, P392, DOI 10.1016/j.cardfail.2006.03.002; CURRIE PF, 1994, BRIT MED J, V309, P1605, DOI 10.1136/bmj.309.6969.1605; *DADSG, 2007, NEW ENGL J MED, V356, P1723; Denissen JF, 1997, DRUG METAB DISPOS, V25, P489; Foisy ML, 1999, J CHROMATOGR B, V721, P239, DOI 10.1016/S0378-4347(98)00451-4; Gandhi SK, 2001, NEW ENGL J MED, V344, P17, DOI 10.1056/NEJM200101043440103; Guery BP, 1998, J APPL PHYSIOL, V85, P842, DOI 10.1152/jappl.1998.85.3.842; Hadigan C, 2001, CLIN INFECT DIS, V32, P130, DOI 10.1086/317541; HOM FG, 1984, DIABETES, V33, P141, DOI 10.2337/diabetes.33.2.141; Hruz PW, 2002, DIABETES, V51, P937, DOI 10.2337/diabetes.51.4.937; Kim J, 2006, HYPERTENS RES, V29, P775, DOI 10.1291/hypres.29.775; Lee GA, 2004, ANTIVIR THER, V9, pL6; Lee GA, 2007, AIDS, V21, P2183, DOI 10.1097/QAD.0b013e32826fbc54; Lee GA, 2006, CLIN INFECT DIS, V43, P658, DOI 10.1086/505974; Lewis W, 2006, AIDS, V20, P675, DOI 10.1097/01.aids.0000216367.23325.58; Liao YL, 2002, AM J PHYSIOL-HEART C, V282, pH1703, DOI 10.1152/ajpheart.00238.2001; Lipshultz SE, 2000, CIRCULATION, V102, P1542, DOI 10.1161/01.CIR.102.13.1542; McMullen JR, 2007, P NATL ACAD SCI USA, V104, P612, DOI 10.1073/pnas.0606663104; Mulder P, 2006, ADV CARDIOL, V43, P97, DOI 10.1159/000095431; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Murata H, 2002, AIDS, V16, P859, DOI 10.1097/00002030-200204120-00005; Nanavati Kinjal A, 2004, Am J Cardiovasc Drugs, V4, P315, DOI 10.2165/00129784-200404050-00004; Noor MA, 2002, AIDS, V16, pF1, DOI 10.1097/00002030-200203290-00002; Noor MA, 2006, AIDS, V20, P1813, DOI 10.1097/01.aids.0000244200.11006.55; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; Silva-Cardoso J, 1998, J Card Fail, V4, P19, DOI 10.1016/S1071-9164(98)90504-8; SMITH SA, 1986, BIOCHEM J, V237, P789, DOI 10.1042/bj2370789; Tan QY, 2005, JAIDS-J ACQ IMM DEF, V40, P398, DOI 10.1097/01.qai.0000176654.97392.c7; Van Bilsen M, 2004, ANN NY ACAD SCI, V1015, P238, DOI 10.1196/annals.1302.020; Zile MR, 2004, NEW ENGL J MED, V350, P1953, DOI 10.1056/NEJMoa032566	34	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2161	2167		10.1096/fj.07-102269	http://dx.doi.org/10.1096/fj.07-102269			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18256305				2022-12-28	WOS:000257292500008
J	Huellner, MW; Schrepfer, S; Weyand, M; Weiner, H; Wimplinger, I; Eschenhagen, T; Rau, T				Huellner, Martin W.; Schrepfer, Sonja; Weyand, Michael; Weiner, Henry; Wimplinger, Isabella; Eschenhagen, Thomas; Rau, Thomas			Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins	FASEB JOURNAL			English	Article						nitric oxide; organic nitrates; pharmacodynamics; biotransformation; capacitance vessels	TRINITRATE-INDUCED VASODILATION; SOLUBLE GUANYLATE-CYCLASE; NITRIC-OXIDE; NITRATE TOLERANCE; GLYCERYL TRINITRATE; ORGANIC NITRATES; OXIDATIVE STRESS; SMOOTH-MUSCLE; RELAXING FACTOR; BIOTRANSFORMATION	Recent studies suggest that the mitochondrial aldehyde dehydrogenase (ALDH) 2 is involved in vascular bioactivation of nitroglycerin (GTN). However, neither expression of ALDH2 nor its functional role in GTN bioactivation has been reported for the main drug target in humans, namely capacitance vessels. We investigated whether ALDH2 is expressed in human veins and whether inhibition of the enzyme attenuates nitroglycerin effects in these vessels. We determined expression of ALDH2 and dehydrogenase activity in human veins by reverse transcriptase-polymerase chain reaction, Western blotting, and immunofluorescence microscopy. In vitro contraction experiments were performed in the presence or absence of the ALDH inhibitors chloral hydrate, cyanamide, and ethoxycyclopropanol. Concentration response curves were determined for the alpha-agonist phenylephrine, nitroglycerin, and the direct NO donor diethylamine NONOate (DEA-NONOate). ALDH2 expression was largely confined to smooth muscle cells as determined by confocal immunofluorescence microscopy. Contractile responses to phenylephrine were unaffected by all ALDH inhibitors tested. In clear contrast, the ALDH inhibitors significantly reduced the potency of nitroglycerin by approximately 1 order of magnitude (P <= 0.01). Neither of the inhibitors affected the potency of the direct NO donor DEA-NONOate, which ruled out nonspecific effects on the NO signaling cascade. In human capacitance vessels, ALDH2 is a key enzyme in the biotransformation of the frequently used antianginal drug nitroglycerin.	[Huellner, Martin W.; Eschenhagen, Thomas; Rau, Thomas] Univ Med Ctr Hamburg Eppendorf, Inst Expt & Clin Pharmacol, D-20246 Hamburg, Germany; [Wimplinger, Isabella] Univ Med Ctr Hamburg Eppendorf, Inst Human Genet, Hamburg, Germany; [Weyand, Michael] Univ Erlangen Nurnberg, Dept Cardiovasc Surg, Erlangen, Germany; [Weiner, Henry] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Erlangen Nuremberg; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Rau, T (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Expt & Clin Pharmacol, Martinistr 52, D-20246 Hamburg, Germany.	t.rau@uke.uni-hamburg.de						ABRAMS J, 1985, AM HEART J, V110, P216, DOI 10.1016/0002-8703(85)90490-9; Artz JD, 2002, J BIOL CHEM, V277, P18253, DOI 10.1074/jbc.C200170200; BRESLOW R, 1967, J AM CHEM SOC, V89, P3073, DOI 10.1021/ja00988a063; BRIEN JF, 1988, J PHARMACOL EXP THER, V244, P322; Chen ZQ, 2006, TRENDS CARDIOVAS MED, V16, P259, DOI 10.1016/j.tcm.2006.05.001; Chen ZQ, 2005, P NATL ACAD SCI USA, V102, P12159, DOI 10.1073/pnas.0503723102; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; Daiber A, 2005, MOL PHARMACOL, V68, P579, DOI 10.1124/mol.105.011585; Daiber A, 2004, MOL PHARMACOL, V66, P1372, DOI 10.1124/mol.104.002600; de la Lande IS, 2004, EUR J PHARMACOL, V496, P141, DOI 10.1016/j.ejphar.2004.06.010; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KAWAMOTO JH, 1990, J CARDIOVASC PHARM, V15, P714, DOI 10.1097/00005344-199005000-00005; Kleschyov AL, 2003, CIRC RES, V93, pE104, DOI 10.1161/01.RES.0000100067.62876.50; Kollau A, 2005, BIOCHEM J, V385, P769, DOI 10.1042/BJ20041354; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YF, 2006, J CLIN INVEST, V116, P506, DOI 10.1172/JCI26564; Mackenzie IS, 2005, ARTERIOSCL THROM VAS, V25, P1891, DOI 10.1161/01.ATV.0000179599.71086.89; MCDONALD BJ, 1993, BIOCHEM PHARMACOL, V45, P268, DOI 10.1016/0006-2952(93)90403-J; MCDONALD BJ, 1990, CAN J PHYSIOL PHARM, V68, P1552, DOI 10.1139/y90-236; McGuire JJ, 1998, BIOCHEM PHARMACOL, V56, P881, DOI 10.1016/S0006-2952(98)00216-0; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; MUKERJEE N, 1994, J BIOL CHEM, V269, P21664; Munzel T, 2005, CIRC RES, V97, P618, DOI 10.1161/01.RES.0000184694.03262.6d; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; Nunez C, 2005, CIRC RES, V97, P1063, DOI 10.1161/01.RES.0000190588.84680.34; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PIETRUSZKO R, 1995, ADV EXP MED BIOL, V372, P25; SAMBROOK J, 1989, MOL CLONING, V1, P7; Schulz E, 2002, CIRCULATION, V105, P1170, DOI 10.1161/hc1002.105186; SETH P, 1993, BIOCHEM PHARMACOL, V46, P1481, DOI 10.1016/0006-2952(93)90115-D; Sydow K, 2004, J CLIN INVEST, V113, P482, DOI 10.1172/JCI200419267; THIEMANN T, 2000, J CHEM SOC P1, V17, P2968; TSUCHIDA S, 1990, J BIOL CHEM, V265, P7150; Wenzel P, 2007, BRIT J PHARMACOL, V150, P526, DOI 10.1038/sj.bjp.0707116; Wenzel P, 2007, J BIOL CHEM, V282, P792, DOI 10.1074/jbc.M606477200; YEATES RA, 1989, BIOCHEM PHARMACOL, V38, P1749, DOI 10.1016/0006-2952(89)90408-5; Zhang J, 2004, CIRCULATION, V110, P750, DOI 10.1161/01.CIR.0000138105.17864.6B; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	40	22	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2561	2568		10.1096/fj.07-098830	http://dx.doi.org/10.1096/fj.07-098830			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18272654				2022-12-28	WOS:000257292500047
J	Liu, G; Park, YJ; Abraham, E				Liu, Gang; Park, Young-Jun; Abraham, Edward			Interleukin-1 receptor-associated kinase (IRAK)-1-mediated NF-kappa B activation requires cytosolic and nuclear activity	FASEB JOURNAL			English	Article						transcription; histone H3; nuclear translocation; Toll-like receptor	TOLL-LIKE RECEPTORS; IL-1 RECEPTOR; ADAPTER PROTEIN; GENE-EXPRESSION; INNATE IMMUNITY; HISTONE H3; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAYS; IRAK FAMILY; PHOSPHORYLATION	Interleukin-1 receptor-associated kinase (IRAK) -1 plays an essential role in Toll-like receptor/interleukin-1 receptor (TLR/IL-1R) -associated NF-kappa B activation through its involvement in IKK activation, which then leads to subsequent I kappa B degradation and NF-kappa B nuclear translocation. In the present studies, we demonstrate a novel pathway in which IRAK-1 present in the nucleus participates in NF-kappa B-dependent gene expression. Nuclear localization of IRAK-1 is increased on cellular stimulation with IL-1 and LPS, or CRM-1-dependent nuclear export blockade. Induction of IRAK-1 produces enhanced NF-kappa B transcriptional activity that precedes I kappa B-alpha degradation and nuclear translocation of NF-kappa B. IRAK-1 binds to the promoter of NF-kappa B-regulated gene, I kappa B-alpha, and enhances binding of the NF-kappa B p65 subunit to NF-kappa B responsive elements within the I kappa B-alpha promoter. IRAK-1 phosphorylates histone H3 in vitro and is required for IL-1-induced phosphorylation of histone H3 at serine 10 in vivo. These data indicate that both cytosolic and nuclear actions of IRAK-1 participate in the activation of NF kappa B-dependent transcriptional events.	[Abraham, Edward] Univ Alabama, Dept Med, Sch Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Abraham, E (corresponding author), Univ Alabama, Dept Med, Sch Med, 420 Boshell Bldg,1808 7th Ave S, Birmingham, AL 35294 USA.	eabraham@uab.edu		, Gang/0000-0002-6999-7633; Liu, Gang/0000-0003-2615-131X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068743, R01HL062221] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-62221, HL-068743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Arcaroli J, 2006, AM J RESP CRIT CARE, V173, P1335, DOI 10.1164/rccm.200603-341OC; Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522; Bol GF, 2000, FEBS LETT, V477, P73, DOI 10.1016/S0014-5793(00)01759-2; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Dong ZG, 2006, MOL CARCINOGEN, V45, P416, DOI 10.1002/mc.20220; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; Gan L, 2006, IMMUNOL RES, V35, P295, DOI 10.1385/IR:35:3:295; Geetha T, 2005, EMBO J, V24, P3859, DOI 10.1038/sj.emboj.7600845; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Huang YS, 2004, J BIOL CHEM, V279, P51697, DOI 10.1074/jbc.M410369200; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kadam S, 2002, CURR OPIN CELL BIOL, V14, P262, DOI 10.1016/S0955-0674(02)00330-7; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Knop J, 1998, EUR J IMMUNOL, V28, P3100, DOI 10.1002/(SICI)1521-4141(199810)28:10<3100::AID-IMMU3100>3.0.CO;2-7; Kollewe C, 2004, J BIOL CHEM, V279, P5227, DOI 10.1074/jbc.M309251200; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Ordureau A, 2008, BIOCHEM J, V409, P43, DOI 10.1042/BJ20071365; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Quivy V, 2004, BIOCHEM PHARMACOL, V68, P1221, DOI 10.1016/j.bcp.2004.05.039; Sanjabi S, 2005, GENE DEV, V19, P2138, DOI 10.1101/gad.1329805; Su JM, 2007, MOL IMMUNOL, V44, P900, DOI 10.1016/j.molimm.2006.03.021; Suzuki N, 2002, TRENDS IMMUNOL, V23, P503, DOI 10.1016/S1471-4906(02)02298-6; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Thomas JA, 1999, J IMMUNOL, V163, P978; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540	59	52	54	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2008	22	7					2285	2296		10.1096/fj.07-101816	http://dx.doi.org/10.1096/fj.07-101816			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18276832				2022-12-28	WOS:000257292500021
J	Yan, HHN; Mruk, DD; Lee, WM; Cheng, CY				Yan, Helen H. N.; Mruk, Dolores D.; Lee, Will M.; Cheng, C. Yan			Blood-testis barrier dynamics are regulated by testosterone and cytokines via their differential effects on the kinetics of protein endocytosis and recycling in Sertoli cells	FASEB JOURNAL			English	Article						preleptotene spermatocyte migration; seminiferous epithelial cycle; spermatogenesis; tight junction; basal ectoplasmic specialization	NECROSIS-FACTOR-ALPHA; TIGHT JUNCTION PROTEINS; ADULT-RAT TESTES; ANDROGEN RECEPTOR; SEMINIFEROUS EPITHELIUM; MICE LACKING; IN-VITRO; ECTOPLASMIC SPECIALIZATION; ADHERENS JUNCTIONS; SELECTIVE KNOCKOUT	During spermatogenesis in the mammalian testis, preleptotene/leptotene spermatocytes differentiate from type B spermatogonia and traverse the blood-testis barrier (BTB) at stage VIII of the seminiferous epithelial cycle for further development. This timely movement of germ cells involves extensive junction restructuring at the BTB. Previous studies have shown that these events are regulated by testosterone (T) and cytokines [e.g., the transforming growth factor (TGF) -beta s], which promote and disrupt the BTB assembly, respectively. However, the mechanisms underlying the "opening" of the BTB above a migrating preleptotene/leptotene spermatocyte and the "resealing" of the barrier underneath this cell remain obscure. We now report findings on a novel mechanism utilized by the testes to regulate these events. Using cell surface protein biotinylation coupled with immunoblotting and immunofluorescent microscopy, we assessed the kinetics of endocytosis and recycling of BTB-associated integral membrane proteins: occludin, JAM-A, and N-cadherin. It was shown that these proteins were continuously endocytosed and recycled back to the Sertoli cell surface via the clathrin-mediated but not the caveolin-mediated pathway. When T or TGF-beta 2 was added to Sertoli cell cultures with established functional BTB, both factors accelerated the kinetics of internalization of BTB proteins from the cell surface, perhaps above the migrating preleptotene spermatocyte, thereby opening the BTB. Likewise, T also enhanced the kinetics of recycling of internalized biotinylated proteins back to the cell surface, plausibly relocating these proteins beneath the migrating spermatocyte to reassemble the BTB. In contrast, TGF-beta 2 targeted internalized biotinylated proteins to late endosomes for degradation, destabilizing the BTB. In summary, the transient opening of the BTB that facilitates germ cell movement is mediated via the differential effects of T and cytokines on the kinetics of endocytosis and recycling of integral membrane proteins at the BTB. The net result of these interactions, in turn, determines the steady-state protein levels at the Sertoli-Sertoli cell interface at the BTB.	[Yan, Helen H. N.; Mruk, Dolores D.; Cheng, C. Yan] Populat Council, Mary M Wohlford Lab Male Contracept Res, Ctr Biomed Res, New York, NY 10065 USA; [Lee, Will M.] Univ Hong Kong, Sch Biol Sci, Pokfulam, Hong Kong, Peoples R China	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, Mary M Wohlford Lab Male Contracept Res, Ctr Biomed Res, 1230 York Ave, New York, NY 10065 USA.	y-cheng@popcbr.rockefeller.edu	Lee, Will M/D-2357-2009	Yan, Hoi Ning Helen/0000-0001-5693-8231; Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [U54 HD029990-110007, U01 HD045908-04, U01 HD045908-01, U01 HD045908-03, R03 HD051512-01A2, U01 HD045908, R03 HD051512, U01 HD045908-05, U01 HD045908-02, U54 HD029990] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045908, R03HD051512] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMNER WJ, 1994, ENDOCRINOLOGY, V135, P1227, DOI 10.1210/en.135.3.1227; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; Bruewer M, 2005, FASEB J, V19, P923, DOI 10.1096/fj.04-3260com; BYERS SW, 1986, J ANDROL, V7, P59; CAVICCHIA JC, 1988, TISSUE CELL, V20, P577, DOI 10.1016/0040-8166(88)90059-6; Chang CS, 2004, P NATL ACAD SCI USA, V101, P6876, DOI 10.1073/pnas.0307306101; Chung NPY, 2001, ENDOCRINOLOGY, V142, P1878, DOI 10.1210/en.142.5.1878; CLERMONT Y, 1987, ANN NY ACAD SCI, V513, P1, DOI 10.1111/j.1749-6632.1987.tb24994.x; CYR DG, 1992, ENDOCRINOLOGY, V131, P139, DOI 10.1210/en.131.1.139; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; DEKRETSER DM, 1988, CYTOLOGY TESTIS, V1; Denolet E, 2006, MOL ENDOCRINOL, V20, P321, DOI 10.1210/me.2005-0113; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; DYM M, 1994, ENDOCR REV, V15, P102, DOI 10.1210/er.15.1.102; Florin A, 2005, ENDOCRINOLOGY, V146, P1532, DOI 10.1210/en.2004-0834; GALDIERI M, 1981, J ANDROL, V2, P249; Guttman JA, 2004, BIOL REPROD, V71, P548, DOI 10.1095/biolreprod.104.028803; Gye MC, 2003, INT J ANDROL, V26, P271, DOI 10.1046/j.1365-2605.2003.00423.x; Ivanov AI, 2005, BIOESSAYS, V27, P356, DOI 10.1002/bies.20203; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; JANECKI A, 1986, J ANDROL, V7, P69; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Li MWM, 2006, J ENDOCRINOL, V190, P313, DOI 10.1677/joe.1.06781; Lui WY, 2003, ENDOCRINOLOGY, V144, P1139, DOI 10.1210/en.2002-0211; Lui WY, 2001, ENDOCRINOLOGY, V142, P1865, DOI 10.1210/en.142.5.1865; Lui WY, 2003, BIOL REPROD, V68, P1597, DOI 10.1095/biolreprod.102.011387; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; Meng J, 2005, P NATL ACAD SCI USA, V102, P16696, DOI 10.1073/pnas.0506084102; Morimoto S, 2005, J BIOL CHEM, V280, P2220, DOI 10.1074/jbc.M406906200; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 2006, NAT MED, V12, P1323, DOI 10.1038/nm1420; ODonnell L, 1996, BIOL REPROD, V55, P895, DOI 10.1095/biolreprod55.4.895; Payne CK, 2007, TRAFFIC, V8, P389, DOI 10.1111/j.1600-0854.2007.00540.x; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Pierini LM, 2000, BLOOD, V95, P2471; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; Russell L. D., 1993, SERTOLI CELL, P1; RUSSELL LD, 1985, INT REV CYTOL, V94, P177, DOI 10.1016/S0074-7696(08)60397-6; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Sasaki N, 2007, GENES CELLS, V12, P89, DOI 10.1111/j.1365-2443.2007.01037.x; Schmitz H, 1999, J CELL SCI, V112, P137; Shan LX, 1997, ENDOCRINOLOGY, V138, P1259, DOI 10.1210/en.138.3.1259; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Siu MKY, 2003, ENDOCRINOLOGY, V144, P371, DOI 10.1210/en.2002-220786; Sluka P, 2006, J ENDOCRINOL, V189, P381, DOI 10.1677/joe.1.06634; Smith MW, 2006, J DRUG TARGET, V14, P191, DOI 10.1080/10611860600650086; Spencer BJ, 2007, P NATL ACAD SCI USA, V104, P7594, DOI 10.1073/pnas.0702170104; TCHOLAKIAN RK, 1979, STEROIDS, V33, P495, DOI 10.1016/0039-128X(79)90032-1; Tsai MY, 2006, P NATL ACAD SCI USA, V103, P18975, DOI 10.1073/pnas.0608565103; Ueno M, 2007, CURR MED CHEM, V14, P1199, DOI 10.2174/092986707780597943; Utech M, 2005, MOL BIOL CELL, V16, P5040, DOI 10.1091/mbc.E05-03-0193; Vaid KS, 2007, J CELL PHYSIOL, V210, P644, DOI 10.1002/jcp.20855; Wang RS, 2006, ENDOCRINOLOGY, V147, P5624, DOI 10.1210/en.2006-0138; WELSH MJ, 1978, ENDOCRINOLOGY, V103, P838, DOI 10.1210/endo-103-3-838; Wong CH, 2005, CURR TOP DEV BIOL, V71, P263, DOI 10.1016/S0070-2153(05)71008-5; Wong CH, 2007, FASEB J, V21, P438, DOI 10.1096/fj.05-4144com; Xia WL, 2006, J BIOL CHEM, V281, P16799, DOI 10.1074/jbc.M601618200; Yan HHN, 2007, BIOESSAYS, V29, P36, DOI 10.1002/bies.20513; Yan HHN, 2006, J BIOL CHEM, V281, P17286, DOI 10.1074/jbc.M513218200; Yan HHN, 2005, P NATL ACAD SCI USA, V102, P11722, DOI 10.1073/pnas.0503855102; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399	66	182	194	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					1945	1959		10.1096/fj.06-070342	http://dx.doi.org/10.1096/fj.06-070342			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18192323	Green Accepted			2022-12-28	WOS:000256352700034
J	Desmard, M; Davidge, KS; Bouvet, O; Morin, D; Roux, D; Foresti, R; Ricard, JD; Denamur, E; Poole, RK; Montravers, P; Motterlini, R; Boczkowski, J				Desmard, Mathieu; Davidge, Kelly S.; Bouvet, Odile; Morin, Didier; Roux, Damien; Foresti, Roberta; Ricard, Jean D.; Denamur, Erick; Poole, Robert K.; Montravers, Philippe; Motterlini, Roberto; Boczkowski, Jorge			A carbon monoxide-releasing molecule (CORM-3) exerts bactericidal activity against Pseudomonas aeruginosa and improves survival in an animal model of bacteraemia	FASEB JOURNAL			English	Article						pharmacology; anti-infective agents; sepsis; microbiology	THERAPEUTIC APPLICATIONS; MITOCHONDRIAL; CO; SENSITIVITY; INFECTIONS; OXIDASE; TARGETS	The search for new molecules to fight Pseudomonas aeruginosa is of paramount importance. Carbon monoxide (CO) is known to act as an effective inhibitor of the respiratory chain in P. aeruginosa, but the practical use of this gas as an antibacterial molecule is hampered by its toxicity and difficulty to manipulate. Here, we show that a water-soluble CO releaser (CORM-3) possesses bactericidal properties against laboratory and antibiotic-resistant P. aeruginosa. CORM-3 reduced the bacterial count by 4 logs 180 min after in vitro treatment. CORM-3-treated bacteria had a lower O-2 consumption than vehicle-treated bacteria, and the decrease in O-2 consumption temporally preceded the bactericidal action of CORM-3. These results support the hypothesis that the antimicrobial effect of CORM-3 is mediated by an interaction of CO liberated by the carrier with the bacterial respiratory chain. The antibacterial effect occurred at concentrations of CORM-3 that are 50-fold lower than toxic concentrations for eukaryotic cells. CORM-3 treatment compared to vehicle treatment decreased bacterial counts in the spleen and increased survival in immunocompetent and immunosuppressed mice following P. aeruginosa bacteremia. Our results suggest that CORMs could form the basis for developing a new therapeutic strategy against P. aeruginosa-induced infection.-Desmard, M., Davidge, K. S., Bouvet, O., Morin, D., Roux, D., Foresti, R., Ricard, J. D., Denamur, E., Poole, R. K., Montravers, P., Motterlini, R., Boczkowski, J. A carbon monoxide-releasing molecule (CORM-3) exerts bactericidal activity against Pseudomonas aeruginosa and improves survival in an animal model of bacteraemia. FASEB J. 23, 1023-1031 (2009)	[Desmard, Mathieu; Boczkowski, Jorge] Univ Paris 07, Fac Med, INSERM, U700, Paris, France; [Desmard, Mathieu; Boczkowski, Jorge] Univ Paris 07, Fac Med, INSERM, U722, Paris, France; [Davidge, Kelly S.; Poole, Robert K.] Univ Sheffield, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England; [Morin, Didier] Univ Paris 12, Fac Med, INSERM, U841 Equipe 3, Creteil, France; [Ricard, Jean D.] Hop Louis Mourier, AP HP, F-92701 Colombes, France; [Desmard, Mathieu; Montravers, Philippe] Hop Bichat Claude Bernard, AP HP, Dept Anesthesie Reanimat Chirurg, F-75877 Paris 18, France; [Boczkowski, Jorge] Hop Bichat Claude Bernard, AP HP, Ctr Invest Clin 07, F-75877 Paris 18, France; [Foresti, Roberta; Motterlini, Roberto] Northwick Pk Inst Med Res, Dept Surg Res, Harrow, Middx, England; [Foresti, Roberta; Motterlini, Roberto] Italian Inst Technol, Dept Drug Discovery & Dev, Genoa, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Sheffield; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Istituto Italiano di Tecnologia - IIT	Desmard, M (corresponding author), Fac Med Paris 7, INSERM, U700, Site X Bichat,BP416, F-75870 Paris 18, France.	desmardmathieu@yahoo.fr	Roux, Damien/C-5618-2014; Motterlini, Roberto/Q-1890-2019; Boczkowski, Jorge/S-7474-2018; Motterlini, Roberto/G-2489-2013; Roux, Damien/L-3671-2014	Roux, Damien/0000-0002-6103-6416; Motterlini, Roberto/0000-0003-2684-2612; Boczkowski, Jorge/0000-0001-6619-5785; Motterlini, Roberto/0000-0003-2684-2612; Roux, Damien/0000-0002-6103-6416; foresti, roberta/0000-0002-0836-7937; didier, MORIN/0000-0002-0967-1850; Davidge, Sandra/0000-0002-5559-4905	Assistance Publique-Hopitaux de Paris, France; French Cystic Fibrosis Association Vaincre La Mucoviscidose; BBSRC [BB/E015883/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E015883/1] Funding Source: researchfish	Assistance Publique-Hopitaux de Paris, France; French Cystic Fibrosis Association Vaincre La Mucoviscidose; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The study was performed under grants from Assistance Publique-Hopitaux de Paris, France (as a Contrat d'Interface to J. B.) and the French Cystic Fibrosis Association Vaincre La Mucoviscidose.	Alcaraz MJ, 2008, CURR PHARM DESIGN, V14, P465, DOI 10.2174/138161208783597362; Bedos JP, 2003, ANN FR ANESTH, V22, P534, DOI 10.1016/S0750-7658(03)00167-9; Boczkowski J, 2006, TRENDS BIOCHEM SCI, V31, P614, DOI 10.1016/j.tibs.2006.09.001; Chung SW, 2008, J CLIN INVEST, V118, P239, DOI 10.1172/JCI32730; Clark JE, 2003, CIRC RES, V93, pE2, DOI 10.1161/01.RES.0000084381.86567.08; Desmard M, 2007, ANTIOXID REDOX SIGN, V9, P2139, DOI 10.1089/ars.2007.1803; Ferrandiz ML, 2008, ANN RHEUM DIS, V67, P1211, DOI 10.1136/ard.2007.082412; Flamm RK, 2004, ANTIMICROB AGENTS CH, V48, P2431, DOI 10.1128/AAC.48.7.2431-2436.2004; Foresti R, 2004, BRIT J PHARMACOL, V142, P453, DOI 10.1038/sj.bjp.0705825; GIBSON JF, 1982, J GEN MICROBIOL, V128, P2211; Gorman D, 2003, TOXICOLOGY, V187, P25, DOI 10.1016/S0300-483X(03)00005-2; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Hou SW, 2008, P NATL ACAD SCI USA, V105, P4039, DOI 10.1073/pnas.0800304105; Kaneko Y, 2007, J CLIN INVEST, V117, P877, DOI 10.1172/JCI30783; Motterlini R, 2004, FASEB J, V18, P284, DOI 10.1096/fj.04-2169fje; Motterlini R, 2005, EXPERT OPIN INV DRUG, V14, P1305, DOI 10.1517/13543784.14.11.1305; Motterlini R, 2002, CIRC RES, V90, pE17, DOI 10.1161/hh0202.104530; Nobre LS, 2007, ANTIMICROB AGENTS CH, V51, P4303, DOI 10.1128/AAC.00802-07; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Otterbein LE, 2002, ANTIOXID REDOX SIGN, V4, P309, DOI 10.1089/152308602753666361; PARR SR, 1975, BIOCHEM J, V151, P51, DOI 10.1042/bj1510051; Ryter SW, 2006, CURR OPIN PHARMACOL, V6, P257, DOI 10.1016/j.coph.2006.03.002; Suliman HB, 2007, J CELL SCI, V120, P299, DOI 10.1242/jcs.03318; Taille C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200; Vera T, 2005, J AM SOC NEPHROL, V16, P950, DOI 10.1681/ASN.2004090736; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Vincent JL, 2003, LANCET, V361, P2068, DOI 10.1016/S0140-6736(03)13644-6; Williams SE, 2008, PFLUG ARCH EUR J PHY, V456, P561, DOI 10.1007/s00424-007-0439-4; ZHANG J, 1992, J CLIN INVEST, V90, P1193, DOI 10.1172/JCI115980; Zuckerbraun BS, 2007, FASEB J, V21, P1099, DOI 10.1096/fj.06-6644com	30	122	131	2	48	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1023	1031		10.1096/fj.08-122804	http://dx.doi.org/10.1096/fj.08-122804			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19095732				2022-12-28	WOS:000266651600006
J	Bebas, P; Goodall, CP; Majewska, M; Neumann, A; Giebultowicz, JM; Chappell, PE				Bebas, Piotr; Goodall, Cheri P.; Majewska, Magda; Neumann, Adam; Giebultowicz, Jadwiga M.; Chappell, Patrick E.			Circadian clock and output genes are rhythmically expressed in extratesticular ducts and accessory organs of mice	FASEB JOURNAL			English	Article						V-ATPase; carbonic anhydrase; prostate; sperm maturation; testis	MALE REPRODUCTIVE-TRACT; CARBONIC-ANHYDRASE-II; ADULT-RAT EPIDIDYMIS; PERIPHERAL-TISSUES; V-ATPASE; SPODOPTERA-LITTORALIS; ANDROGEN REGULATION; COTTON LEAFWORM; CONSTANT LIGHT; SPERM RELEASE	Circadian clocks regulate multiple rhythms in mammalian tissues. In most organs core clock gene expression is oscillatory, with negative components Per and Cry peaking in antiphase to Bmal1. A notable exception is the testis, where clock genes seem non-rhythmic. Earlier mammalian studies, however, did not examine clock expression patterns in accessory ductal tissue required for sperm maturation and transport. Previous studies in insects demonstrated control of sperm maturation in vas deferens by a local circadian system. Sperm ducts express clock genes and display circadian pH changes controlled by vacuolar-type H+-ATPase and carbonic anhydrase (CA-II). It is unknown whether sperm-processing rhythms are conserved beyond insects. To address this question in mice housed in a light-dark environment, we examined temporal patterns of mPer1 and Bmal1 gene expression and protein abundance in epididymis, vas deferens, seminal vesicles, and prostate. Results demonstrate variable tissue-specific patterns of expression of the two genes, with variations in levels of clock proteins and their nucleo-cytoplasmic cycling observed among examined tissues. Strikingly, mPer1 and Bmal1 mRNA and proteins oscillate in antiphase in the prostate, with similar peak-trough patterns as observed in the suprachiasmatic nuclei, the brain's central clock. Genes encoding CA and a V-ATPase subunit, which are rhythmically expressed in sperm ducts of moths, are also rhythmic in some segments of murine sperm ducts. Our data suggest that some sperm duct segments may contain peripheral circadian systems whereas others may express clock genes in a pleiotropic manner. - Bebas, P., Goodall, C. P., Majewska, M., Neumann, A., Giebultowicz, J. M., Chappell, P. E. Circadian clock and output genes are rhythmically expressed in extratesticular ducts and accessory organs of mice. FASEB J. 23, 523-533 (2009)	[Bebas, Piotr; Goodall, Cheri P.; Majewska, Magda; Giebultowicz, Jadwiga M.; Chappell, Patrick E.] Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; [Bebas, Piotr; Neumann, Adam] Univ Warsaw, Dept Anim Physiol, Fac Biol, Warsaw, Poland	Oregon State University; University of Warsaw	Chappell, PE (corresponding author), Oregon State Univ, Dept Zool, Cordley Hall 3029, Corvallis, OR 97331 USA.	patrick.chappell@science.oregonstate.edu		Bebas, Piotr/0000-0003-2956-5892	National Institutes of Health-National Institute of General Medical Studies (NIH-NIGMS) [GM073792]; Polish Science Foundation (MNiSzW) [NN303342235]; NIH [R01 DK075357, K01 DK064919]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK064919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073792] Funding Source: NIH RePORTER	National Institutes of Health-National Institute of General Medical Studies (NIH-NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Polish Science Foundation (MNiSzW)(Foundation for Polish Science); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. David Weaver (University of Massachusetts Medical School, Worcester, MA, USA) for the gift of anti-mPER1 antibody, antigen, and tissues of mPER1 K/O mice. This research was supported by National Institutes of Health-National Institute of General Medical Studies (NIH-NIGMS) grant GM073792 to J.M.G., Polish Science Foundation (MNiSzW) grant NN303342235 to P.B., and NIH grants R01 DK075357 and K01 DK064919 to P.E.C.	Alvarez JD, 2008, J BIOL RHYTHM, V23, P26, DOI 10.1177/0748730407311254; Alvarez JD, 2003, BIOL REPROD, V69, P81, DOI 10.1095/biolreprod.102.011833; Beaver LM, 2002, P NATL ACAD SCI USA, V99, P2134, DOI 10.1073/pnas.032426699; Bebas P, 1999, PHYSIOL ENTOMOL, V24, P165, DOI 10.1046/j.1365-3032.1999.00127.x; Bebas P, 2002, J EXP BIOL, V205, P37; Bebas P, 2002, BMC Physiol, V2, P15, DOI 10.1186/1472-6793-2-15; Bebas P, 2001, J INSECT PHYSIOL, V47, P859, DOI 10.1016/S0022-1910(01)00058-0; Bebas P, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-64; Bittman EL, 2003, AM J PHYSIOL-REG I, V285, pR561, DOI 10.1152/ajpregu.00783.2002; Boden MJ, 2006, REPRODUCTION, V132, P379, DOI 10.1530/rep.1.00614; Breton S, 2001, JOP, V2, P159; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; Breton S, 1998, AM J PHYSIOL-CELL PH, V275, pC1134, DOI 10.1152/ajpcell.1998.275.4.C1134; Brown D, 1997, J EXP BIOL, V200, P257; Chappell PE, 2003, J NEUROSCI, V23, P11202; Davidson Alec J, 2003, Novartis Found Symp, V253, P110; Fahrenkrug J, 2006, ENDOCRINOLOGY, V147, P3769, DOI 10.1210/en.2006-0305; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Gery S, 2006, MOL CELL, V22, P375, DOI 10.1016/j.molcel.2006.03.038; Giebultowicz JM, 1996, J COMP PHYSIOL A, V178, P629, DOI 10.1007/BF00227376; GIEBULTOWICZ JM, 1990, PHYSIOL ENTOMOL, V15, P149, DOI 10.1111/j.1365-3032.1990.tb00502.x; GIEBULTOWICZ JM, 1989, SCIENCE, V245, P1098, DOI 10.1126/science.245.4922.1098; HARKONEN PL, 1988, BIOL REPROD, V38, P377, DOI 10.1095/biolreprod38.2.377; He PJ, 2007, J ENDOCRINOL, V194, P511, DOI 10.1677/JOE-07-0172; Herak-Kramberger CM, 2001, BIOL REPROD, V64, P1699, DOI 10.1095/biolreprod64.6.1699; Hermo L, 2005, J HISTOCHEM CYTOCHEM, V53, P699, DOI 10.1369/jhc.4A6575.2005; HOFFMANN K, 1977, ACTA ENDOCRINOL-COP, V86, P193, DOI 10.1530/acta.0.0860193; Karman BN, 2006, BIOL REPROD, V75, P624, DOI 10.1095/biolreprod.106.050732; Kaunisto K, 1999, BIOL REPROD, V61, P1521, DOI 10.1095/biolreprod61.6.1521; Ko GYP, 2004, BRAIN RES, V1021, P277, DOI 10.1016/j.brainres.2004.05.072; Kotwica J, 2006, J PHYSIOL PHARMACOL, V57, P107; Lambert CM, 2006, J BIOL RHYTHM, V21, P77, DOI 10.1177/0748730405281843; Liu S, 2007, CHRONOBIOL INT, V24, P793, DOI 10.1080/07420520701672556; Mewe M, 2006, ENDOCRINOLOGY, V147, P2051, DOI 10.1210/en.2005-1324; Miller BH, 2004, CURR BIOL, V14, P1367, DOI 10.1016/j.cub.2004.07.055; Miyamoto Y, 1999, MOL BRAIN RES, V71, P238, DOI 10.1016/S0169-328X(99)00192-8; Morse D, 2003, MOL ENDOCRINOL, V17, P141, DOI 10.1210/me.2002-0184; Nakao N, 2007, ENDOCRINOLOGY, V148, P3031, DOI 10.1210/en.2007-0044; Oishi K, 1998, BIOCHEM BIOPH RES CO, V253, P199, DOI 10.1006/bbrc.1998.9779; Oster H, 2006, J BIOL RHYTHM, V21, P350, DOI 10.1177/0748730406293053; Pastor-Soler N, 2005, PHYSIOLOGY, V20, P417, DOI 10.1152/physiol.00036.2005; Pastor-Soler NM, 2008, AM J PHYSIOL-CELL PH, V294, pC488, DOI 10.1152/ajpcell.00537.2007; Pyza E, 2004, J INSECT PHYSIOL, V50, P985, DOI 10.1016/j.jinsphys.2004.08.003; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Simanainen U, 2008, ENDOCRINOLOGY, V149, P3330, DOI 10.1210/en.2007-1805; Tong YH, 2004, J BIOL RHYTHM, V19, P113, DOI 10.1177/0748730403262871; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WINTERS SJ, 1991, ENDOCRINOLOGY, V129, P1755, DOI 10.1210/endo-129-4-1755; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	52	39	41	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					523	533		10.1096/fj.08-113191	http://dx.doi.org/10.1096/fj.08-113191			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18945877	Green Published			2022-12-28	WOS:000262892900024
J	Porter, JC; Hall, A				Porter, Joanna C.; Hall, Alan			Epithelial ICAM-1 and ICAM-2 regulate the egression of human T cells across the bronchial epithelium	FASEB JOURNAL			English	Article						transepithelial migration; lymphocytes; LFA-1; lung; Neuronal Wiskott-Aldrich syndrome protein; coxsackie-adenovirus receptor	INTERCELLULAR-ADHESION MOLECULE-1; OBSTRUCTIVE PULMONARY-DISEASE; LYMPHOCYTE MIGRATION; ENDOTHELIAL ICAM-1; PERIPHERAL-TISSUES; TIGHT JUNCTIONS; CC CHEMOKINES; LUNG; NEUTROPHILS; RECEPTOR	Egression of inflammatory cells from the lung interstitium into the airway lumen is critical for the resolution of inflammation, but the underlying mechanisms of this egression are unclear. Here, we use an in vitro system, in which human T cells migrate across a bronchial epithelial monolayer, to investigate the molecules involved. We show that although inhibition of T-cell LFA-1 blocks egression by 75 +/- 5.6% (P < 0.0001), inhibition of the FA-1-ligand ICAM-1 on the epithelium only inhibits by 52.7 +/- 0.06% (P = 0.0001). We, therefore, looked for other epithelial ligands for LFA-1 and demonstrate that ICAM-2, but not ICAM-3, is expressed on the bronchial epithelium. Blocking ICAM-2 inhibits egression by 50.95 +/- 10.79% (P = 0.04), and blocking both ICAM-1 and ICAM-2 inhibits egression by 69.6 +/- 5.2% (P < 0.0001). Inhibition of LFA-1/ICAM-1 and ICAM-2 interactions on the basolateral epithelium does not prevent egressing T cells from adhering, polarizing, or moving over the basal epithelium, but it does prevent their recognition of the interepithelial junctions. In conclusion, we show that egression of T cells involves three distinct sequential steps: adhesion, junctional recognition, and diapedesis; we further demonstrate that ICAM-2 is expressed on the bronchial epithelium and, together with ICAM-1, has an essential function in the clearance of T cells from the lung. - Porter, J.C., Hall, A. Epithelial ICAM-1 and ICAM-2 regulate the egression of human T cells across the bronchial epithelium. FASEB J. 23, 492-502 (2009)	[Porter, Joanna C.] Univ Coll London Hosp, Univ Coll London Hosp NHS Trust, Dept Resp Med, London NW1 2BU, England; [Porter, Joanna C.] UCL, MRC, Mol Cell Biol Lab, London, England; [Hall, Alan] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; Memorial Sloan Kettering Cancer Center	Porter, JC (corresponding author), Univ Coll London Hosp, Univ Coll London Hosp NHS Trust, Dept Resp Med, Euston Rd, London NW1 2BU, England.	joanna.porter@ucl.ac.uk	Porter, Joanna/C-7162-2009	Porter, Joanna/0000-0002-7307-169X	CRUK; Wellcome Trust Advanced Clinical Fellowship	CRUK(Cancer Research UK); Wellcome Trust Advanced Clinical Fellowship(Wellcome Trust)	We thank Nancy Hogg (Cancer Research UK, London, UK) and Dieter Gruenert (California Pacific Medical Center, San Francisco, CA, USA) for generously providing reagents and Martin Raff for careful reading of the manuscript. This work was supported by CRUK and a Wellcome Trust Advanced Clinical Fellowship to J.C.P.	Adamson P, 1999, J IMMUNOL, V162, P2964; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240; BURNS AR, 1994, J IMMUNOL, V153, P3189; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Corry DB, 2004, FASEB J, V18, P995, DOI 10.1096/fj.03-1412fje; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; Coyne CB, 2006, CELL, V124, P119, DOI 10.1016/j.cell.2005.10.035; Coyne CB, 2005, ADV DRUG DELIVER REV, V57, P869, DOI 10.1016/j.addr.2005.01.007; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Ely KH, 2006, J IMMUNOL, V176, P537, DOI 10.4049/jimmunol.176.1.537; Etienne S, 1998, J IMMUNOL, V161, P5755; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gerwin N, 1999, IMMUNITY, V10, P9, DOI 10.1016/S1074-7613(00)80002-3; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Hikono H, 2006, IMMUNOL REV, V211, P119, DOI 10.1111/j.0105-2896.2006.00385.x; Li ZW, 2005, ENVIRON HEALTH PERSP, V113, P1747, DOI 10.1289/ehp.7947; Medoff BD, 2008, ANNU REV IMMUNOL, V26, P205, DOI 10.1146/annurev.immunol.26.021607.090312; Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356; Miller LA, 1998, AM J RESP CELL MOL, V19, P892, DOI 10.1165/ajrcmb.19.6.3245mrev; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; Peterson JR, 2004, NAT STRUCT MOL BIOL, V11, P747, DOI 10.1038/nsmb796; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; PORTER JCM, 1998, IMMUNOLOGY, P246; Porter JC, 2008, J IMMUNOL, V180, P1866, DOI 10.4049/jimmunol.180.3.1866; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Taguchi M, 1998, J EXP MED, V187, P1927, DOI 10.1084/jem.187.12.1927; Takenawa T, 2001, J CELL SCI, V114, P1801; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; Zen K, 2003, CURR OPIN CELL BIOL, V15, P557, DOI 10.1016/S0955-0674(03)00103-0; Zen K, 2005, MOL BIOL CELL, V16, P2694, DOI 10.1091/mbc.E05-01-0036; Zhu J, 1999, EUR RESPIR J, V13, P1318, DOI 10.1183/09031936.99.13613299	37	38	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2009	23	2					492	502		10.1096/fj.08-115899	http://dx.doi.org/10.1096/fj.08-115899			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18842965	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000262892900021
J	Song, GJ; Li, Y; Cheng, CY; Zhao, Y; Gao, A; Zhang, RG; Joachimiak, A; Shaw, N; Liu, ZJ				Song, Gaojie; Li, Yang; Cheng, Chongyun; Zhao, Yu; Gao, Ang; Zhang, Rongguang; Joachimiak, Andrzej; Shaw, Neil; Liu, Zhi-Jie			Structural insight into acute intermittent porphyria	FASEB JOURNAL			English	Article						human porphobilinogen deaminase; X-ray structure; heme biosynthesis; porphobilinogen hinge	HUMAN PHENYLALANINE-HYDROXYLASE; UROPORPHYRINOGEN-I SYNTHETASE; PORPHOBILINOGEN DEAMINASE; ESCHERICHIA-COLI; HEME-BIOSYNTHESIS; PURIFICATION; PHENYLKETONURIA; GENE; SITE; REVEALS	Acute intermittent porphyria (AIP), an inherited disease of heme biosynthesis, is one of the most common types of porphyria. Reduced activity of the enzyme porphobilinogen deaminase (PBGD), which catalyzes the sequential condensation of 4 molecules of porphobilinogen to yield preuroporphyrinogen, has been linked to the symptoms of AIP. We have determined the 3-dimensional structure of human PBGD at 2.2 angstrom resolution. Analysis of the structure revealed a dipyrromethane cofactor molecule covalently linked to C261, sitting in a positively charged cleft region. In addition to the critical catalytic D99, a number of other residues are seen hydrogen bonded to the cofactor and play a role in catalysis. Sequential entry of 4 pyrrole molecules into the active site is accomplished by movement of the domains around the hinges. H120P mutation resulted in an inactive enzyme, supporting the role of H120 as a hinge residue. Interestingly, some of the mutations of the human PBGD documented in patients suffering from AIP are located far away from the active site. The structure provides insights into the mechanism of action of PBGD at the molecular level and could aid the development of potential drugs for the up-regulation of PBGD activity in AIP. - Song, G., Li, Y., Cheng, C., Zhao, Y., Gao, A., Zhang, R., Joachimiak, A., Shaw, N., Liu, Z.-J. Structural insight into acute intermittent porphyria. FASEB J. 23, 396-404 (2009)	[Song, Gaojie; Li, Yang; Cheng, Chongyun; Zhao, Yu; Gao, Ang; Shaw, Neil; Liu, Zhi-Jie] Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, 15 Datun Lu, Beijing 100101, Peoples R China; [Zhang, Rongguang; Joachimiak, Andrzej] Argonne Natl Lab, Adv Photon Source, Struct Biol Ctr, Argonne, IL 60439 USA	Chinese Academy of Sciences; Institute of Biophysics, CAS; United States Department of Energy (DOE); Argonne National Laboratory	Shaw, N (corresponding author), Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, 15 Datun Lu, Beijing 100101, Peoples R China.	neilshaw@moon.ibp.ac.cn; zjliu@ibp.ac.cn	Li, Yang/G-3685-2011; Li, Yang/M-1246-2013; Liu, Zhi-Jie/A-3946-2012	Liu, Zhi-Jie/0000-0001-7279-2893; Shaw, Neil/0000-0003-2722-9967	National Natural Science Foundation of China [20572063, 30670427]; Ministry of Science and Technology of China [2006AA02A316, 2006CB910901]; CAS-KIST [07CF09]; U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences [W-31-109-Eng-38]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); CAS-KIST; U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE))	This work was funded by the National Natural Science Foundation of China (grants 20572063 and 30670427), the Ministry of Science and Technology of China (grants 2006AA02A316 and 2006CB910901), a CAS-KIST collaboration grant, and a CAS research grant (07CF09). Crystallographic data were collected at the Structural Biology Center's 19-ID beamline at the Advanced Photon Source, Argonne National Laboratory. The use of the Advanced Photon Source was supported by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract W-31-109-Eng-38. Atomic coordinates for the structure of human PBGD have been deposited in the Protein Data Bank (PDB code 3ECR).	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON KE, 2001, METABOLIC MOL BASES, P2991; ANDERSON PM, 1980, J BIOL CHEM, V255, P1993; Brons-Poulsen J, 2005, SCAND J CLIN LAB INV, V65, P93, DOI 10.1080/00365510410003075; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; Emekli U, 2008, PROTEINS, V70, P1219, DOI 10.1002/prot.21613; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Furuyama K, 2007, TOHOKU J EXP MED, V213, P1, DOI 10.1620/tjem.213.1; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; Gamez A, 2007, MOL GENET METAB, V91, P325, DOI 10.1016/j.ymgme.2007.04.015; GARCIA SRC, 1991, Z NATURFORSCH C, V46, P1017; Grandchamp B, 1998, SEMIN LIVER DIS, V18, P17, DOI 10.1055/s-2007-1007136; GRANDCHAMP B, 1987, EUR J BIOCHEM, V162, P105, DOI 10.1111/j.1432-1033.1987.tb10548.x; Granick S, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P33; Hrdinka M, 2006, PHYSIOL RES, V55, pS119, DOI 10.33549/physiolres.930000.55.S2.119; JONES RM, 1994, BIOCHEM J, V299, P895, DOI 10.1042/bj2990895; JORDAN PM, 1988, BIOCHEM J, V254, P427, DOI 10.1042/bj2540427; JORDAN PM, 1973, J BIOL CHEM, V248, P1019; JORDAN PM, 2003, BIOCHEM SOC T, V31, P731; JORDAN PM, 1996, NEW COMPREHENSIVE BI, P1; JORDAN PMS, 1996, BIOCHEM J, V316, P373; KAPPAS A, 1995, METABOLIC MOL BASES, P2116; Kauppinen R, 2005, LANCET, V365, P241; KAUPPINEN R, 1992, MEDICINE, V71, P1; Long F, 2008, ACTA CRYSTALLOGR D, V64, P125, DOI 10.1107/S0907444907050172; LOUIE GV, 1992, NATURE, V359, P33, DOI 10.1038/359033a0; Matalon R, 2005, MOL GENET METAB, V86, pS17, DOI 10.1016/j.ymgme.2005.06.024; MAZZETTI MB, 1988, BIOCHIM BIOPHYS ACTA, V957, P97, DOI 10.1016/0167-4838(88)90161-6; MEYER UA, 1978, METABOLIC BASIS INHE, P1166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Puy H, 1997, AM J HUM GENET, V60, P1373, DOI 10.1086/515455; Stols L, 2002, PROTEIN EXPRES PURIF, V25, P8, DOI 10.1006/prep.2001.1603; STRAND LJ, 1972, J CLIN INVEST, V51, P2530, DOI 10.1172/JCI107068; WARREN MJ, 1988, BIOCHEMISTRY-US, V27, P9020, DOI 10.1021/bi00425a021; Woodard SI, 2000, ARCH BIOCHEM BIOPHYS, V384, P375, DOI 10.1006/abbi.2000.2069; WOODARD SI, 1995, ARCH BIOCHEM BIOPHYS, V316, P110, DOI 10.1006/abbi.1995.1016; WOODCOCK SC, 1994, BIOCHEMISTRY-US, V33, P2688, DOI 10.1021/bi00175a043	39	42	43	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2009	23	2					396	404		10.1096/fj.08-115469	http://dx.doi.org/10.1096/fj.08-115469			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400TZ	18936296				2022-12-28	WOS:000262892900011
J	Cristofanon, S; Morceau, F; Scovassi, AI; Dicato, M; Ghibelli, L; Diederich, M				Cristofanon, Silvia; Morceau, Franck; Scovassi, A. Ivana; Dicato, Mario; Ghibelli, Lina; Diederich, Marc			Oxidative, multistep activation of the noncanonical NF-kappa B pathway via disulfide Bcl-3/p50 complex	FASEB JOURNAL			English	Article						glutathione; Bcl-2; ROS; p38	GLUTATHIONE DEPLETION; MAP KINASE; NUCLEAR TRANSLOCATION; BCL-2 EXPRESSION; P50 HOMODIMERS; CELLS; APOPTOSIS; TRANSCRIPTION; BINDING; MODULATION	Buthionine sulfoximine ( BSO) is a well-known inhibitor of glutathione synthesis, producing slow glutathione ( GSH) depletion and oxidative stress; some "responder" cells avoid BSO-induced death by trans-activating the prosurvival protein Bcl-2. Here we show that BSO activates a noncanonical, inhibitory NF-kappa B- and p65-independent NF-kappa B pathway via a multistep process leading to the up-regulation of Bcl-2. The slow BSO-induced GSH depletion allows separation of two redox-related phases, namely, early thiol disequilibrium and late frank oxidative stress; each phase contributes to the progressive activation of a p50-p50 homodimer. The early phase, coinciding with substantial thiol depletion, produces a cytosolic preparative complex, consisting of p50 and its interactor Bcl-3 linked by interprotein disulfide bridges. The late phase, coinciding with reactive oxygen species production, is responsible, probably via p38 activation, for nuclear targeting of the complex and trans-activation of Bcl-2. Cristofanon, S., Morceau, F., Scovassi, A. I., Dicato, M., Ghibelli, L., Diederich, M. Oxidative, multistep activation of the noncanonical NF-kappa B pathway via disulfide Bcl-3/p50 complex. FASEB J. 23, 45-57 ( 2009)	[Cristofanon, Silvia; Ghibelli, Lina] Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; [Cristofanon, Silvia; Morceau, Franck; Dicato, Mario; Diederich, Marc] Hop Kirchberg, Lab Biol Mol & Ecllulaire Canc, Fdn Rech Canc & Maladies Sang, L-2540 Luxembourg, Luxembourg; [Scovassi, A. Ivana] Ist Genet Mol Consiglio Nazl Ric, Pavia, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR)	Diederich, M (corresponding author), Hop Kirchberg, Lab Biol Mol & Ecllulaire Canc, Fdn Rech Canc & Maladies Sang, 9 Rue Edward Steichen, L-2540 Luxembourg, Luxembourg.	ghibelli@uniroma2.it; marc.diederich@lbmcc.lu	Diederich, Marc/O-7335-2015; Scovassi, Anna Ivana/F-2458-2010	Diederich, Marc/0000-0003-0115-4725; Scovassi, Anna Ivana/0000-0003-3484-9881	Bourse de Formation-Recherche of the Ministere de la Culture; de l'Enseignement superieur et de la Recherche of Luxembourg; Televie; Fondation de Recherche Cancer et Sang; Recherches Scientifiques Luxembourg association; Een Haerz fir Kriibskrank Kanner association; Action Lions Vaincre le Cancer; Fonds National de la Recherche-Luxembourg	Bourse de Formation-Recherche of the Ministere de la Culture; de l'Enseignement superieur et de la Recherche of Luxembourg; Televie; Fondation de Recherche Cancer et Sang; Recherches Scientifiques Luxembourg association; Een Haerz fir Kriibskrank Kanner association; Action Lions Vaincre le Cancer; Fonds National de la Recherche-Luxembourg(Luxembourg National Research Fund)	C.S. was supported by a Bourse de Formation-Recherche of the Ministere de la Culture, de l'Enseignement superieur et de la Recherche of Luxembourg. Research was supported in part by Televie, the Fondation de Recherche Cancer et Sang and Recherches Scientifiques Luxembourg association. The authors thank Een Haerz fir Kriibskrank Kanner association and the Action Lions Vaincre le Cancer for additional support. Printing costs were covered by Fonds National de la Recherche-Luxembourg.	Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Byun MS, 2002, EXP MOL MED, V34, P332, DOI 10.1038/emm.2002.47; Casini A F, 1984, Toxicol Pathol, V12, P295; Celli A, 1998, AM J PHYSIOL-GASTR L, V275, pG749, DOI 10.1152/ajpgi.1998.275.4.G749; D'Alessio M, 2005, FASEB J, V19, P1504, DOI 10.1096/fj.04-3329fje; D'Alessio M, 2004, FASEB J, V18, P1609, DOI 10.1096/fj.04-1813fje; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Duvoix A, 2004, CANCER LETT, V216, P207, DOI 10.1016/j.canlet.2004.05.004; Escarcega RO, 2007, CLIN ONCOL-UK, V19, P154, DOI 10.1016/j.clon.2006.11.013; Frouin I, 2003, J BIOL CHEM, V278, P39265, DOI 10.1074/jbc.C300098200; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Keutgens A, 2006, BIOCHEM PHARMACOL, V72, P1069, DOI 10.1016/j.bcp.2006.06.011; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Michel F, 2001, EMBO J, V20, P6180, DOI 10.1093/emboj/20.22.6180; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Nishikori M, 2003, BLOOD, V101, P2789, DOI 10.1182/blood-2002-08-2464; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pineda-Molina E, 2001, BIOCHEMISTRY-US, V40, P14134, DOI 10.1021/bi011459o; Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004; Ramos AM, 2006, J CELL PHYSIOL, V209, P1006, DOI 10.1002/jcp.20806; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Xiao WH, 2004, CELL MOL IMMUNOL, V1, P425; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234	43	26	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					45	57		10.1096/fj.07-104109	http://dx.doi.org/10.1096/fj.07-104109			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18796561				2022-12-28	WOS:000262095500007
J	Hirosawa-Takamori, M; Ossipov, D; Novoselov, SV; Turanov, AA; Zhang, Y; Gladyshev, VN; Krol, A; Vorbruggen, G; Jackle, H				Hirosawa-Takamori, Mitsuko; Ossipov, Dmitri; Novoselov, Sergey V.; Turanov, Anton A.; Zhang, Yan; Gladyshev, Vadim N.; Krol, Alain; Vorbrueggen, Gerd; Jaeckle, Herbert			A novel stem loop control element-dependent UGA read-through system without translational selenocysteine incorporation in Drosophila	FASEB JOURNAL			English	Article						conserved; GAP factor; eEFsec; GAPsec mutant; selenoprotein; biosynthesis	SELENOPROTEIN SYNTHESIS; STRUCTURAL-ANALYSIS; PROTEIN-SYNTHESIS; MECHANISMS; STOP; INSERTION; INSIGHTS; DOMAIN; YEAST; GENE	Translational read-through of the UGA stop codon is an evolutionarily conserved feature that most prominently represents the basis of selenoprotein biosynthesis. It requires a specific cis-acting stem loop control element, termed SECIS, which is located in the 3'-untranslated region of eukaryotic selenoprotein mRNAs. In a search for novel factors underlying the SECIS-directed UGA read-through process, we identified an evolutionary conserved GTPase-activating protein, termed GAPsec. We show that the activity of the Drosophila GAPsec (dGAPsec) is necessary to support SECIS-dependent UGA read-through activity in flies and the mouse homolog mGAPsec in mice tissue culture cells. However, selenoprotein biosynthesis is not impaired in flies that lack dGAPsec activity. The results indicate that GAPsec is part of a novel SECIS-dependent translational read-through system that does not involve selenocysteine incorporation.-Hirosawa- Takamori, M., Ossipov, D., Novoselov, S.V., Turanov, A.A., Zhang, Y., Gladyshev, V.N., Krol, A., Vorbruggen, G., Jackle, H. A novel stem loop control element-dependent UGA readthrough system without translational selenocysteine incorporation in Drosophila. FASEB J. 23, 107-113 (2009)	[Hirosawa-Takamori, Mitsuko; Ossipov, Dmitri; Vorbrueggen, Gerd; Jaeckle, Herbert] Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, D-37077 Gottingen, Germany; [Novoselov, Sergey V.; Turanov, Anton A.; Zhang, Yan; Gladyshev, Vadim N.] Univ Nebraska, Dept Biochem, Lincoln, NE 68583 USA; [Krol, Alain] Univ Strasbourg, CNRS, Inst Biol Mol & Cellulaire, Architecture & React ARN, Strasbourg, France	Max Planck Society; University of Nebraska System; University of Nebraska Lincoln; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Jackle, H (corresponding author), Max Planck Inst Biophys Chem, Abt Mol Entwicklungsbiol, Fassberg 11, D-37077 Gottingen, Germany.	vp-bms@gv.mpg.de	Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Novoselov, Sergey/0000-0003-0104-6492; Gladyshev, Vadim/0000-0002-0372-7016	Max-Planck-Society; Deutsche Forschungsgemeinschaft; U.S. National Institutes of Health [GM061603]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER	Max-Planck-Society(Max Planck Society); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank our colleagues in the laboratory for various contributions and critical discussions, G. Dowe for sequencing, and U. Jahns-Meyer for generating fly transformants. This work was supported by the Max-Planck-Society, the SP "Selenoproteine" of the Deutsche Forschungsgemeinschaft (G.V. and H.J.), and U.S. National Institutes of Health grant GM061603 (V.N.G.).	Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Atkins JF, 2000, NATURE, V407, P463, DOI 10.1038/35035189; Blanke S, 2006, FASEB J, V20, P683, DOI 10.1096/fj.05-5376com; Bock A, 2000, Biofactors, V11, P77; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; Hirosawa-Takamori M, 2000, EMBO REP, V1, P441, DOI 10.1093/embo-reports/kvd087; Hirosawa-Takamori M, 2004, EMBO REP, V5, P317, DOI 10.1038/sj.embor.7400097; Kollmus H, 1996, NUCLEIC ACIDS RES, V24, P1195, DOI 10.1093/nar/24.7.1195; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Novoselov SV, 2002, EMBO J, V21, P3681, DOI 10.1093/emboj/cdf372; Persson BC, 1997, J MOL BIOL, V274, P174, DOI 10.1006/jmbi.1997.1371; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rodnina MV, 2000, BIOL CHEM, V381, P377, DOI 10.1515/BC.2000.050; Scheffzek K, 1998, EMBO J, V17, P4313, DOI 10.1093/emboj/17.15.4313; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stark A, 2007, NATURE, V450, P219, DOI 10.1038/nature06340; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; VALLE RPC, 1988, FEBS LETT, V235, P1, DOI 10.1016/0014-5793(88)81225-0; von der Haar T, 2007, TRENDS MICROBIOL, V15, P78, DOI 10.1016/j.tim.2006.12.002; Wahl MC, 2002, CURR PROTEIN PEPT SC, V3, P93, DOI 10.2174/1389203023380756; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3	27	11	11	2	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2009	23	1					107	113		10.1096/fj.08-116640	http://dx.doi.org/10.1096/fj.08-116640			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	389LZ	18772345	Green Published			2022-12-28	WOS:000262095500013
J	van Roermund, CWT; Visser, WF; Ijlst, L; van Cruchten, A; Boek, M; Kulik, W; Waterham, HR; Wanders, RJA				van Roermund, Carlo W. T.; Visser, Wouter F.; Ijlst, Lodewijk; van Cruchten, Arno; Boek, Maxim; Kulik, Wim; Waterham, Hans R.; Wanders, Ronald J. A.			The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters	FASEB JOURNAL			English	Article						beta-oxidation; ATP-binding-cassette transporter; FA transport; carrier	X-LINKED ADRENOLEUKODYSTROPHY; ACID BETA-OXIDATION; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; FATTY-ACIDS; GENE; IDENTIFICATION; MITOCHONDRIA; METABOLISM	Peroxisomes play a major role in human cellular lipid metabolism, including the beta-oxidation of fatty acids. The most frequent peroxisomal disorder is X-linked adrenoleukodystrophy (X-ALD), which is caused by mutations in the ABCD1 gene. The protein involved, called ABCD1, or alternatively ALDP, is a member of the ATP-binding-cassette (ABC) transporter family and is located in the peroxisomal membrane. The biochemical hallmark of X-ALD is the accumulation of very long-chain fatty acids (VLCFAs), due to an impaired peroxisomal beta-oxidation. Although this suggests a role of ALDP in VLCFA import, no experimental evidence is available to substantiate this. In the yeast Saccharomyces cerevisiae, peroxisomes are the exclusive site of fatty acid beta-oxidation. Earlier work has shown that uptake of fatty acids into peroxisomes may occur via two routes, either as free fatty acids thus requiring intraperoxisomal activation into acyl-CoA esters or as long-chain acyl-CoA esters. The latter route involves the two peroxisomal half ABC transporters Pxa1p and Pxa2p that form a heterodimeric complex in the peroxisomal membrane. Using different strategies, including the analysis of intracellular acyl-CoA esters by tandem-MS, we show that the Pxa1p/Pxa2p heterodimer is involved in the transport of a spectrum of acyl-CoA esters. Interestingly, we found that the mutant phenotype of the pxa1/pxa2 Delta mutant can be rescued, at least partially, by the sole expression of the human ABCD1 cDNA coding for ALDP, the protein that is defective in the human disease X-linked adrenoleukodystrophy. Our data indicate that ALDP can function as a homodimer and is involved in the transport of acyl-CoA esters across the peroxisomal membrane.	Univ Amsterdam, Lab Genet Metab Dis, Acad Med Ctr, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Lab Genet Metab Dis, Acad Med Ctr, Dept Clin Chem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van Roermund, CWT (corresponding author), Univ Amsterdam, Lab Genet Metab Dis, Acad Med Ctr, Dept Pediat, Rm F0-226,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	c.vanroermund@amc.uva.nl			EU X-ALD [LSHM-CT2004-502987X-ALD, LSHG-CT2004-512018]	EU X-ALD	This work was supported by the EU X-ALD project (Project No. LSHM-CT2004-502987X-ALD) and the EU peroxisome project (Project No. LSHG-CT2004-512018).	Berger J, 2006, BBA-MOL CELL RES, V1763, P1721, DOI 10.1016/j.bbamcr.2006.07.010; CONTRERAS M, 1994, FEBS LETT, V344, P211, DOI 10.1016/0014-5793(94)00400-5; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V237, P152, DOI 10.1006/bbrc.1997.7102; Jia ZZ, 2007, J BIOL CHEM, V282, P20573, DOI 10.1074/jbc.M700568200; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; Pohl A, 2005, BBA-MOL CELL BIOL L, V1733, P29, DOI 10.1016/j.bbalip.2004.12.007; Rottensteiner H, 2006, BBA-MOL CELL RES, V1763, P1527, DOI 10.1016/j.bbamcr.2006.08.012; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Takahashi N, 2007, J NEUROCHEM, V101, P1632, DOI 10.1111/j.1471-4159.2007.04457.x; Theodoulou FL, 2006, FEBS LETT, V580, P1139, DOI 10.1016/j.febslet.2005.12.095; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; van Roermund CWT, 2003, CELL MOL LIFE SCI, V60, P1838, DOI 10.1007/s00018-003-3076-x; van Roermund CWT, 2001, MOL CELL BIOL, V21, P4321, DOI 10.1128/MCB.21.13.4321-4329.2001; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; Verleur N, 1997, EUR J BIOCHEM, V249, P657, DOI 10.1111/j.1432-1033.1997.00657.x; Visser WF, 2007, BIOCHEM BIOPH RES CO, V357, P335, DOI 10.1016/j.bbrc.2007.03.083; Visser WF, 2007, BIOCHEM J, V401, P365, DOI 10.1042/BJ20061352; WANDERS RJA, 1992, BIOCHEM BIOPH RES CO, V188, P1139, DOI 10.1016/0006-291X(92)91350-Y; Wanders RJA, 2007, PFLUG ARCH EUR J PHY, V453, P719, DOI 10.1007/s00424-006-0142-x; Wanders RJA, 2006, ANNU REV BIOCHEM, V75, P295, DOI 10.1146/annurev.biochem.74.082803.133329; Weller S, 2003, ANNU REV GENOM HUM G, V4, P165, DOI 10.1146/annurev.genom.4.070802.110424	26	169	172	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2008	22	12					4201	4208		10.1096/fj.08-110866	http://dx.doi.org/10.1096/fj.08-110866			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	377MH	18757502				2022-12-28	WOS:000261254800019
J	Einstein, FH; Fishman, S; Bauman, J; Thompson, RF; Huffman, DM; Atzmon, G; Barzilai, N; Muzumdar, RH				Einstein, Francine H.; Fishman, Sigal; Bauman, Jeffery; Thompson, Reid F.; Huffman, Derek M.; Atzmon, Gil; Barzilai, Nir; Muzumdar, Radhika H.			Enhanced activation of a "nutrient-sensing" pathway with age contributes to insulin resistance	FASEB JOURNAL			English	Article						hexosamine biosynthetic pathway; calorie restriction	HEPATIC GLUCOSE-PRODUCTION; CALORIC RESTRICTION; DIABETIC RATS; GENE-EXPRESSION; IN-VIVO; LEPTIN; TISSUE; HYPERGLYCEMIA; ACCUMULATION; SECRETION	Calorie restriction improves life span whereas nutrient excess leads to obesity and unfavorable metabolic consequences, supporting the role for a cellular "nutrient sensor" in aging. Hexosamine biosynthetic pathway (HBP) is a candidate nutrient-sensing pathway. We hypothesized that altered nutrient sensing (by HBP) with age may provide a link among aging, nutrient flux, and insulin resistance. Using a hyperinsulinemic clamp in young rats, we show that experimental activation of HBP, through the systemic infusion of glucosamine, induced severe insulin resistance (36% decline in peripheral insulin action; P < 0.05), increased adipose tissue gene expression of fat-derived peptides (PAI-1 by 4-fold, angiotensinogen 3-fold, leptin 2-fold, resistin 4-fold, and adiponectin 4-fold; P < 0.01 compared with young saline-infused), and enhanced glycosylation of transcription factors, thus mimicking a physiological and biological phenotype of aging. We further demonstrate a greater activation of nutrient-sensing HBP with age in both old ad libitum-fed and calorie-restricted rats. Interestingly, old calorie-restricted animals rapidly develop insulin resistance when exposed to glucosamine, despite their "young" phenotype. These results suggest that altered nutrient sensing by HBP with age may be the link among nutrients, insulin resistance, and age-related diabetes.	[Einstein, Francine H.; Fishman, Sigal; Bauman, Jeffery; Thompson, Reid F.; Huffman, Derek M.; Atzmon, Gil; Barzilai, Nir; Muzumdar, Radhika H.] Albert Einstein Coll Med, Inst Aging Res, Dept Med, Bronx, NY 10461 USA; [Einstein, Francine H.] Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10461 USA; [Barzilai, Nir] Albert Einstein Coll Med, Inst Aging Res, Dept Mol Biol, Bronx, NY 10461 USA; [Muzumdar, Radhika H.] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; [Muzumdar, Radhika H.] Montefiore Med Ctr, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Barzilai, N (corresponding author), Albert Einstein Coll Med, Inst Aging Res, Dept Med, Belfer Bldg,Suite 701,1300 Morris Pk Ave, Bronx, NY 10461 USA.	barzilai@aecom.yu.edu	Muzumdar, Radhika/D-9860-2014	Thompson, Reid/0000-0003-3661-5296	U.S. National Institutes of Health [P01-AG021654, R01-AG18381]; American Association of Obstetricians anti-Gynecologists Foundation/Society of Maternal-Fetal Medicine [K08-AG027462]; Albert Einstein Diabetes Research and Training Center [DK 20541]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021654, K08AG027462, R01AG018381] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Association of Obstetricians anti-Gynecologists Foundation/Society of Maternal-Fetal Medicine; Albert Einstein Diabetes Research and Training Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grants from the U.S. National Institutes of Health to N.B. (P01-AG021654 and R01-AG18381) and to R.H.M. (K08-AG027462), from the American Association of Obstetricians anti Gynecologists Foundation/Society of Maternal-Fetal Medicine to F.H.E., and by the Core Laboratories of the Albert Einstein Diabetes Research and Training Center (DK 20541).	Anderson RM, 2006, EXP GERONTOL, V41, P1247, DOI 10.1016/j.exger.2006.10.019; ANUMULA KR, 1991, ANAL BIOCHEM, V197, P113, DOI 10.1016/0003-2697(91)90365-Z; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Barzilai N, 1999, DIABETES, V48, P94, DOI 10.2337/diabetes.48.1.94; Corton JC, 2005, J GERONTOL A-BIOL, V60, P1494, DOI 10.1093/gerona/60.12.1494; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Einstein FH, 2005, DIABETES, V54, P672, DOI 10.2337/diabetes.54.3.672; Fishman S, 2007, FASEB J, V21, P53, DOI 10.1096/fj.06-6557com; Gabriely I, 2002, DIABETES, V51, P1016, DOI 10.2337/diabetes.51.4.1016; Gabriely I, 2002, ATHEROSCLEROSIS, V160, P115, DOI 10.1016/S0021-9150(01)00574-3; Gazdag AC, 2000, AM J PHYSIOL-REG I, V278, pR504, DOI 10.1152/ajpregu.2000.278.2.R504; GIACCARI A, 1989, J CHROMATOGR-BIOMED, V497, P69, DOI 10.1016/0378-4347(89)80006-4; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; Goldberg HJ, 2006, ENDOCRINOLOGY, V147, P222, DOI 10.1210/en.2005-0523; Goldberg HJ, 2002, J BIOL CHEM, V277, P33833, DOI 10.1074/jbc.M112331200; Gupta G, 2000, AM J PHYSIOL-ENDOC M, V278, pE985, DOI 10.1152/ajpendo.2000.278.6.E985; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; IWASAKI K, 1988, J GERONTOL, V43, pB13, DOI 10.1093/geronj/43.1.B13; KAPAHI P, 2004, SCI AGING KNOWLEDGE, pPE34; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Muzumdar R, 2003, FASEB J, V17, P1130, DOI 10.1096/fj.02-0991fje; Muzumdar RH, 2006, DIABETES, V55, P2788, DOI 10.2337/db06-0318; Obici S, 2002, J CLIN INVEST, V109, P1599, DOI 10.1172/JCI0215258; ROSSETTI L, 1993, J CLIN INVEST, V92, P2963, DOI 10.1172/JCI116919; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407	32	43	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2008	22	10					3450	3457		10.1096/fj.08-109041	http://dx.doi.org/10.1096/fj.08-109041			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	354MB	18566293	Green Published			2022-12-28	WOS:000259642600007
J	Li, HW; Gao, YX; Qi, YF; Katovich, MJ; Jiang, N; Braseth, LN; Scheuer, DA; Shi, P; Sumners, C				Li, Hongwei; Gao, Yongxin; Qi, Yanfei; Katovich, Michael J.; Jiang, Nan; Braseth, Leah N.; Scheuer, Deborah A.; Shi, Peng; Sumners, Colin			Macrophage migration inhibitory factor in hypothalamic paraventricular nucleus neurons decreases blood pressure in spontaneously hypertensive rats	FASEB JOURNAL			English	Article						angiotensin II; thiol-protein oxidoreductase; hypertension	ROSTRAL VENTROLATERAL MEDULLA; ANGIOTENSIN-II; CARDIOVASCULAR-DISEASE; NEUROGENIC HYPERTENSION; BRAIN NUCLEI; PVN; PROJECTIONS; RECEPTORS; INCREASES; SALT	Macrophage migration inhibitory factor (MIF) expression is increased by angiotensin II (Ang II) within paraventricular nucleus (PVN) neurons of normotensive rats and acts via its intrinsic thiol protein oxidoreductase (TPOR) to counterregulate the central nervous system-mediated pressor action of Ang II. Considering that the PVN-mediated actions of Ang II are enhanced in spontaneously hypertensive rats (SHRs) and contribute to the development of hypertension in these animals, we investigated this MIF regulatory mechanism in SHRs. Here, we have demonstrated that Ang II failed to increase MIF protein expression in the PVN of SHRs. Furthermore, although basal levels of MIF protein and mRNA were similar in the PVN of SHRs and normotensive rats, immunostaining revealed that MIF was either absent from or diminished in PVN neurons of SHRs. AAV2-mediated increases in MIF expression within PVN neurons of young (8 wk old) SHRs produced a chronic attenuation of hypertension and cardiac hypertrophy. However, similar AAV2-mediated transduction of [C60S]-MIF, which lacks TPOR activity, did not alter the development of hypertension or cardiac hypertrophy in SHRs. Collectively, these findings suggest that a lack of MIF expression within PVN neurons contributes to the development of hypertension and cardiac hypertrophy in SHRs.	[Sumners, Colin] Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA; [Li, Hongwei; Gao, Yongxin; Jiang, Nan; Braseth, Leah N.; Scheuer, Deborah A.; Shi, Peng; Sumners, Colin] Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; [Qi, Yanfei; Katovich, Michael J.] Univ Florida, Dept Pharmacodynam, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Sumners, C (corresponding author), Univ Florida, Coll Med, Dept Physiol & Funct Genom, Box 100274,1600 SW Archer Rd, Gainesville, FL 32610 USA.	csumners@ufl.edu	JIANG, NAN/AHB-1945-2022	Sumners, Colin/0000-0002-9689-2255	National Institutes of Health [HL-076803]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076803] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by National Institutes of Health grant HL-076803 (C.S.). We thank Arseniy Shabashvili for technical assistance.	Akine A, 2003, AUTON NEUROSCI-BASIC, V108, P17, DOI 10.1016/j.autneu.2003.08.009; Allen AM, 2002, HYPERTENSION, V39, P275, DOI 10.1161/hy0202.104272; [Anonymous], [No title captured]; Auricchio A, 2001, HUM GENE THER, V12, P71, DOI 10.1089/104303401450988; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; Benarroch EE, 2005, CLIN AUTON RES, V15, P254, DOI 10.1007/s10286-005-0290-7; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Chen QH, 2001, AM J PHYSIOL-REG I, V281, pR1844, DOI 10.1152/ajpregu.2001.281.6.R1844; Ferguson AV, 2001, EXP BIOL MED, V226, P85, DOI 10.1177/153537020122600205; Gong Y, 2004, BRAIN RES PROTOC, V14, P18, DOI 10.1016/j.brainresprot.2004.08.001; Grassi G, 2004, HYPERTENSION, V43, P154, DOI 10.1161/01.HYP.0000109870.99110.7e; GUTKIND JS, 1988, AM J PHYSIOL, V255, pH646, DOI 10.1152/ajpheart.1988.255.3.H646; HARDING JW, 1987, BRAIN RES, V410, P130, DOI 10.1016/S0006-8993(87)80033-1; Ito S, 2003, HYPERTENSION, V41, P744, DOI 10.1161/01.HYP.0000052944.54349.7B; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; Kudrin A, 2008, IMMUNOL CELL BIOL, V86, P232, DOI 10.1038/sj.icb.7100133; Li HW, 2006, FASEB J, V20, P1748, DOI 10.1096/fj.06-5836fje; Li YF, 2006, AM J PHYSIOL-REG I, V290, pR1035, DOI 10.1152/ajpregu.00338.2004; Matsuura T, 2006, J NEUROPHYSIOL, V95, P1042, DOI 10.1152/jn.00499.2005; McKinley MJ, 2001, CLIN EXP PHARMACOL P, V28, P990, DOI 10.1046/j.1440-1681.2001.03592.x; MEYER JM, 1990, EXP NEUROL, V107, P164, DOI 10.1016/0014-4886(90)90154-K; Miller EJ, 2008, NATURE, V451, P578, DOI 10.1038/nature06504; Osborn JW, 2007, CURR HYPERTENS REP, V9, P228, DOI 10.1007/s11906-007-0041-3; Perez DM, 2005, PHARMACOL REV, V57, P147, DOI 10.1124/pr.57.2.2; Reja V, 2006, CLIN EXP PHARMACOL P, V33, P690, DOI 10.1111/j.1440-1681.2006.04420.x; Reyes BAS, 2005, EUR J NEUROSCI, V22, P93, DOI 10.1111/j.1460-9568.2005.04197.x; Rohr UP, 2002, J VIROL METHODS, V106, P81, DOI 10.1016/S0166-0934(02)00138-6; SAWCHENKO PE, 1987, BRAIN RES, V437, P253, DOI 10.1016/0006-8993(87)91641-6; Schlaich MP, 2004, HYPERTENSION, V43, P169, DOI 10.1161/01.HYP.0000103160.35395.9E; Stocker SD, 2006, J COMP NEUROL, V494, P673, DOI 10.1002/cne.20835; Stocker SD, 2004, AM J PHYSIOL-REG I, V287, pR1172, DOI 10.1152/ajpregu.00394.2004; Sun CW, 2007, HYPERTENSION, V49, P528, DOI 10.1161/01.HYP.0000257877.11495.cb; Sun CW, 2004, J NEUROSCI, V24, P9944, DOI 10.1523/JNEUROSCI.2856-04.2004; SWANSON LW, 1983, ANNU REV NEUROSCI, V6, P269, DOI 10.1146/annurev.ne.06.030183.001413; Thiele M, 2005, ANTIOXID REDOX SIGN, V7, P1234, DOI 10.1089/ars.2005.7.1234; Walker BR, 2007, EUR J ENDOCRINOL, V157, P545, DOI 10.1530/EJE-07-0455; Yu Y, 2007, CIRC RES, V101, P304, DOI 10.1161/CIRCRESAHA.107.148940; Zernecke A, 2008, CIRCULATION, V117, P1594, DOI 10.1161/CIRCULATIONAHA.107.729125; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	39	29	30	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3175	3185		10.1096/fj.08-108662	http://dx.doi.org/10.1096/fj.08-108662			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18535252	Green Published			2022-12-28	WOS:000258761300010
J	Navaratna, D; Menicucci, G; Maestas, J; Srinivasan, R; McGuire, P; Das, A				Navaratna, Deepti; Menicucci, Gina; Maestas, Joann; Srinivasan, Ramprasad; McGuire, Paul; Das, Arup			A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes	FASEB JOURNAL			English	Article						VE-cadherin; extracellular proteinases; vascular permeability	UROKINASE PLASMINOGEN-ACTIVATOR; GLYCATION END-PRODUCTS; MATRIX METALLOPROTEINASES; ENDOTHELIAL PERMEABILITY; GENE-EXPRESSION; OXIDANT STRESS; CELL-SURFACE; PROTEOLYSIS; RETINOPATHY; REPERFUSION	One of the major complications of diabetes is the alteration of the blood-retinal barrier, leading to retinal edema and consequent vision loss. The aim of this study was to evaluate the role of the urokinase plasminogen activator (uPA)/uPA receptor ( uPAR) system in the regulation of retinal vascular permeability. Biochemical, molecular, and histological techniques were used to examine the role of uPA and uPAR in the regulation of retinal vascular permeability in diabetic rats and cultured retinal endothelial cells. The increased retinal vascular permeability in diabetic rats was associated with a decrease in vascular endothelial (VE)-cadherin expression in retinal vessels. Treatment with the uPA/uPAR-inhibiting peptide (angstrom 6) was shown to reduce diabetes-induced permeability and the loss of VE-cadherin. The increased permeability of cultured cells in response to advanced glycation end products (AGEs) was significantly inhibited with angstrom 6. Treatment of endothelial cells with specific matrix metalloproteinases or AGEs resulted in loss of VE-cadherin from the cell surface, which could be inhibited by angstrom 6. uPA/uPAR physically interacts with AGEs/receptor for advanced glycation end products on the cell surface and regulates its activity. uPA and its receptor uPAR play important roles in the alteration of the blood-retinal barrier through proteolytic degradation of VE-cadherin. The ability of angstrom 6 to block retinal vascular permeability in diabetes suggests a potential therapeutic approach for the treatment of diabetic macular edema.	[McGuire, Paul; Das, Arup] Univ New Mexico, Dept Surg, Hlth Sci Ctr, Div Ophthalmol, Albuquerque, NM 87131 USA; [Navaratna, Deepti; Menicucci, Gina; Maestas, Joann; Srinivasan, Ramprasad; McGuire, Paul; Das, Arup] Univ New Mexico, Dept Cell Biol & Physiol, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Das, Arup] New Mexico VA Hlth Care Syst, Albuquerque, NM USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Das, A (corresponding author), Univ New Mexico, Dept Surg, Hlth Sci Ctr, Div Ophthalmol, MSC 5610-10,1, Albuquerque, NM 87131 USA.	adas@unm.edu			Juvenile Diabetes Research Foundation International [1-2006-36]; National Institutes of Health [RO1 EY12604]; NATIONAL EYE INSTITUTE [R01EY012604] Funding Source: NIH RePORTER	Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The authors thank Angstrom Pharmaceuticals for the kind gift of the angstrom 6 peptide used for these studies. This work was supported by Juvenile Diabetes Research Foundation International 1-2006-36 and National Institutes of Health grant RO1 EY12604.	Alexander JS, 2002, J ANAT, V200, P561, DOI 10.1046/j.1469-7580.2002.00057.x; Alfano D, 2005, THROMB HAEMOSTASIS, V93, P205, DOI 10.1160/TH04-09-0592; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561; Binder BR, 2007, THROMB HAEMOSTASIS, V97, P336, DOI 10.1160/TH06-11-0669; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; Carden D, 1998, AM J PHYSIOL-HEART C, V275, pH385, DOI 10.1152/ajpheart.1998.275.2.H385; Cauwe B, 2007, CRIT REV BIOCHEM MOL, V42, P113, DOI 10.1080/10409230701340019; Dagher Z, 2004, DIABETES, V53, P2404, DOI 10.2337/diabetes.53.9.2404; Danielsen CC, 1998, J MOL CELL CARDIOL, V30, P1431; Ehringer WD, 2000, INFLAMMATION, V24, P175, DOI 10.1023/A:1007037711339; El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Etoh T, 2001, AM J PHYSIOL-HEART C, V281, pH987, DOI 10.1152/ajpheart.2001.281.3.H987; Franco P, 2006, J CELL SCI, V119, P3424, DOI 10.1242/jcs.03067; Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251; Harhaj NS, 2006, INVEST OPHTH VIS SCI, V47, P5106, DOI 10.1167/iovs.06-0322; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Makowski GS, 1998, INFLAMMATION, V22, P287, DOI 10.1023/A:1022300216202; McGuire PG, 2003, INVEST OPHTH VIS SCI, V44, P2736, DOI 10.1167/iovs.02-1160; NAVARATNA D, 2007, DIABETES, V56, P1; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Salzmann J, 2000, BRIT J OPHTHALMOL, V84, P1091, DOI 10.1136/bjo.84.10.1091; SMITH JR, 1994, INFLAMMATION, V18, P193, DOI 10.1007/BF01534560; SMITH JR, 1994, P W PHARMACOL SOC, V37, P3; TADA H, 1994, DIABETES RES CLIN PR, V24, P33, DOI 10.1016/0168-8227(94)90083-3; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Wachtel M, 1999, J CELL SCI, V112, P4347; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; YAN SD, 1994, J BIOL CHEM, V269, P9889	37	38	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2008	22	9					3310	3317		10.1096/fj.08-110155	http://dx.doi.org/10.1096/fj.08-110155			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18559877	Green Published			2022-12-28	WOS:000258761300023
J	Wong, SLA; Chan, WM; Chan, HYE				Wong, S. L. Alan; Chan, Wing Man; Chan, H. Y. Edwin			Sodium dodecyl sulfate-insoluble oligomers are involved in polyglutamine degeneration	FASEB JOURNAL			English	Article						aggregate; Drosophila; neurodegeneration; solubility	HISTONE DEACETYLASE INHIBITORS; N-TERMINAL HUNTINGTIN; PROTEIN AGGREGATION; EXPANSION PROTEINS; GENE-EXPRESSION; PRONE PROTEINS; DISEASE; DROSOPHILA; NEURODEGENERATION; SUPPRESSION	In polyglutamine (polyQ) degeneration, disease protein that carries an expanded polyQ tract is neurotoxic. Expanded polyQ protein exists in different conformations that display distinct solubility properties. In this study, an inducible transgenic Drosophila model is established to define the pathogenic form of polyQ protein at an early stage of degeneration in vivo. We show that microscopic polyQ aggregates are neither pathogenic nor protective. Further, no toxic effect of sodium dodecyl sulfate (SDS)-soluble polyQ protein is observed in our model. By means of filtration, 2 forms of SDS-insoluble protein species are identified according to their size. Coexpression of an ATPase-defective form of the molecular chaperone Hsc70 (Hsc70-K71S) selectively reduces the abundance of the large SDS-insoluble polyQ species, but such modulation has no modifying effects on degeneration. Notably, we detect a distinct Hsc70-K71S-resistant, small, SDS-insoluble polyQ oligomeric species that is closely correlated with degeneration. Our data highlight the toxic role of SDS-insoluble oligomers in polyQ degeneration in vivo.	[Chan, H. Y. Edwin] Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China; [Wong, S. L. Alan; Chan, Wing Man; Chan, H. Y. Edwin] Chinese Univ Hong Kong, Lab Drosophila Res, Shatin, Hong Kong, Peoples R China; [Wong, S. L. Alan; Chan, Wing Man; Chan, H. Y. Edwin] Chinese Univ Hong Kong, Mol Biotechnol Programme, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Chan, HYE (corresponding author), Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China.	hyechan@cuhk.edu.hk	Chan, Edwin/A-9478-2011	Chan, Edwin/0000-0003-4307-474X; Wong, Alan S.L./0000-0003-1790-3233	Hong Kong Research Grants Council [CUHK4314/03M]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	We thank E. Chen for making the pUAST-EGFP-polyQ76-FLAG construct, J. Lam for performing initial characterization on EGFP-polyQ76-FLAG transgenic lines, A. Li for the excellent technical assistance on the AFM analysis, M. Feder for antibodies, and C. O'Kane and members of the Laboratory of Drosophila Research for critical comments on the manuscript. This work was supported by the Hong Kong Research Grants Council (CUHK4314/03M).	Agrawal N, 2005, P NATL ACAD SCI USA, V102, P3777, DOI 10.1073/pnas.0500055102; Apostol BL, 2003, P NATL ACAD SCI USA, V100, P5950, DOI 10.1073/pnas.2628045100; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Behrends C, 2006, MOL CELL, V23, P887, DOI 10.1016/j.molcel.2006.08.017; Berger Z, 2005, HUM MOL GENET, V14, P3003, DOI 10.1093/hmg/ddi331; Bilen J, 2005, ANNU REV GENET, V39, P153, DOI 10.1146/annurev.genet.39.110304.095804; Boeddrich A, 2006, EMBO J, V25, P1547, DOI 10.1038/sj.emboj.7601043; Brignull HR, 2007, ADV EXP MED BIOL, V594, P167; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Butler R, 2006, NAT REV NEUROSCI, V7, P784, DOI 10.1038/nrn1989; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chan HYE, 2002, HUM MOL GENET, V11, P2895, DOI 10.1093/hmg/11.23.2895; Diaz-Hernandez M, 2004, J NEUROSCI, V24, P9361, DOI 10.1523/JNEUROSCI.2365-04.2004; Ehrnhoefer DE, 2006, HUM MOL GENET, V15, P2743, DOI 10.1093/hmg/ddl210; Ellisdon AM, 2006, J BIOL CHEM, V281, P16888, DOI 10.1074/jbc.M601470200; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Hazeki N, 2000, BIOCHEM BIOPH RES CO, V277, P386, DOI 10.1006/bbrc.2000.3682; Hoffner G, 2005, J NEUROCHEM, V95, P125, DOI 10.1111/j.1471-4159.2005.03348.x; Huen NYM, 2007, CEREBELLUM, V6, P111, DOI 10.1080/14734220600996480; Huen NYM, 2005, BIOCHEM BIOPH RES CO, V334, P1074, DOI 10.1016/j.bbrc.2005.07.008; Iuchi S, 2003, P NATL ACAD SCI USA, V100, P2409, DOI 10.1073/pnas.0437660100; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Klucken J, 2004, BIOCHEM BIOPH RES CO, V325, P367, DOI 10.1016/j.bbrc.2004.10.037; Li M, 2007, J BIOL CHEM, V282, P3157, DOI 10.1074/jbc.M609972200; MCGUIRE SE, 2004, SCI STKE, P16; Michalik A, 2003, HUM MOL GENET, V12, pR173, DOI 10.1093/hmg/ddg295; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Mukai H, 2005, P NATL ACAD SCI USA, V102, P10887, DOI 10.1073/pnas.0409283102; Nagai Y, 2007, NAT STRUCT MOL BIOL, V14, P332, DOI 10.1038/nsmb1215; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Riley BE, 2006, GENE DEV, V20, P2183, DOI 10.1101/gad.1436506; Ross CA, 2005, NAT REV MOL CELL BIO, V6, P891, DOI 10.1038/nrm1742; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Rub U, 2006, BRAIN PATHOL, V16, P218, DOI 10.1111/j.1750-3639.2006.00022.x; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Slepko N, 2006, P NATL ACAD SCI USA, V103, P14367, DOI 10.1073/pnas.0602348103; Slow EJ, 2006, TRENDS GENET, V22, P408, DOI 10.1016/j.tig.2006.05.008; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; VELAZQUEZ JM, 1983, J CELL BIOL, V96, P286, DOI 10.1083/jcb.96.1.286; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Warrick JM, 2005, MOL CELL, V18, P37, DOI 10.1016/j.molcel.2005.02.030; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Weydt P, 2006, EXPERT OPIN THER TAR, V10, P505, DOI 10.1517/14728222.10.4.505; Wolfgang WJ, 2005, P NATL ACAD SCI USA, V102, P11563, DOI 10.1073/pnas.0505321102; Wong SLA, 2005, BIOCHEM BIOPH RES CO, V337, P720, DOI 10.1016/j.bbrc.2005.09.098; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	54	26	26	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2008	22	9					3348	3357		10.1096/fj.07-103887	http://dx.doi.org/10.1096/fj.07-103887			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CD	18559990				2022-12-28	WOS:000258761300027
J	Metzner, C; Mostegl, MM; Gunzburg, WH; Salmons, B; Dangerfield, JA				Metzner, Christoph; Mostegl, Meike M.; Guenzburg, Walter H.; Salmons, Brian; Dangerfield, John A.			Association of glycosylphosphatidylinositol-anchored protein with retroviral particles	FASEB JOURNAL			English	Article						GPI; retrovirus; lentivirus; gene therapy; vaccine development	SIMIAN IMMUNODEFICIENCY VIRUS; MAGNETIC NANOPARTICLES; CELLS; INSERTION; ENZYME	We describe for the first time the association of glycosylphosphatidylinositol (GPI)-anchored proteins with retroviral and lentiviral particles, similar to a process well established for cells, termed "painting." The aim of the study was to assess the feasibility of modification of retroviral vectors by exogenous addition of recombinant protein, removing the need for genetic engineering of virus producer cell lines. The recombinant GPI protein CD59his was purified via fast protein liquid chromatography and associated with concentrated virus stock in a controlled incubation procedure. Reaction mixtures were purified in order to remove nonassociated GPI protein and endogenous protein. Analysis of samples by immunoblotting revealed that CD59his was only detectable in the presence of viral particles. From this, we conclude that CD59his could be stably associated with retroviral particles. In addition, we demonstrated by flow cytometry that virus particles remain infectious after these procedures. As well as suggesting a novel possibility for interaction between enveloped virus and host, we believe that the stable association of recombinant GPI proteins to retroviral particles can be developed into an important tool for both research and clinical applications, especially in the fields of gene therapy and vaccine development.	[Metzner, Christoph; Mostegl, Meike M.; Guenzburg, Walter H.; Dangerfield, John A.] Univ Vet Med, Inst Virol, A-1210 Vienna, Austria; [Metzner, Christoph; Guenzburg, Walter H.] Christian Doppler Lab Gene Therapeut Vector Dev, Vienna, Austria; [Mostegl, Meike M.; Guenzburg, Walter H.; Dangerfield, John A.] Foreign Module Retroviral Nanotechnol, Christian Doppler Lab Gene Therapeut Vector Dev, Singapore, Singapore; [Salmons, Brian; Dangerfield, John A.] Austrianova, Vienna, Austria; [Salmons, Brian] Austrianova Biomfg, Vienna, Austria	University of Veterinary Medicine Vienna	Metzner, C (corresponding author), Univ Vet Med, Inst Virol, Vet Pl 1, A-1210 Vienna, Austria.	christoph.metzner@vu-wien.ac.at	Gunzburg, Walter/ABI-6076-2020; Salmons, Brian/E-3001-2010	Gunzburg, Walter/0000-0001-8907-1021; Salmons, Brian/0000-0002-9490-9447; Metzner, Christoph/0000-0001-6036-4138				Breun S, 1999, BIOCHEM BIOPH RES CO, V264, P1, DOI 10.1006/bbrc.1999.1474; Chan L, 2005, J VIROL, V79, P13190, DOI 10.1128/JVI.79.20.13190-13194.2005; Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; Hlavaty J, 2004, J VIROL, V78, P1384, DOI 10.1128/JVI.78.3.1384-1392.2004; Ikeda Y, 2003, NAT BIOTECHNOL, V21, P569, DOI 10.1038/nbt815; Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1; Jordan A, 2006, J NEURO-ONCOL, V78, P7, DOI 10.1007/s11060-005-9059-z; Klein D, 1997, GENE THER, V4, P1256, DOI 10.1038/sj.gt.3300519; Kueng HJ, 2007, J VIROL, V81, P8666, DOI 10.1128/JVI.00682-07; Lauc G, 2006, BBA-GEN SUBJECTS, V1760, P584, DOI 10.1016/j.bbagen.2005.11.014; Legler DF, 2004, FASEB J, V18, P73, DOI 10.1096/fj.03-1338fje; MCHUGH RS, 1995, P NATL ACAD SCI USA, V92, P8059, DOI 10.1073/pnas.92.17.8059; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Morandat S, 2002, BBA-BIOMEMBRANES, V1564, P473, DOI 10.1016/S0005-2736(02)00497-2; Pambalk K, 2002, BIOCHEM BIOPH RES CO, V293, P239, DOI 10.1016/S0006-291X(02)00207-3; Premkumar DRD, 2001, J CELL BIOCHEM, V82, P234, DOI 10.1002/jcb.1154; Ronzon F, 2004, J MEMBRANE BIOL, V197, P169, DOI 10.1007/s00232-004-0651-5; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Skountzou I, 2007, J VIROL, V81, P1083, DOI 10.1128/JVI.01692-06; Sloand EM, 2004, BLOOD, V104, P3782, DOI 10.1182/blood-2004-02-0645; Steinrigl A, 2007, VIROLOGY, V362, P50, DOI 10.1016/j.virol.2006.11.037; Taraboletti G, 2006, NEOPLASIA, V8, P96, DOI 10.1593/neo.05583; Wilhelm C, 2007, J NANOSCI NANOTECHNO, V7, P2933, DOI 10.1166/jnn.2007.668; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817	25	22	26	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2734	2739		10.1096/fj.08-108217	http://dx.doi.org/10.1096/fj.08-108217			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18477763				2022-12-28	WOS:000258089300013
J	Tarry-Adkins, JL; Martin-Gronert, MS; Chen, JH; Cripps, RL; Ozanne, SE				Tarry-Adkins, J. L.; Martin-Gronert, M. S.; Chen, J. -H.; Cripps, R. L.; Ozanne, S. E.			Maternal diet influences DNA damage, aortic telomere length, oxidative stress, and antioxidant defense capacity in rats	FASEB JOURNAL			English	Article						developmental programming; aging; aorta	SINGLE-STRAND BREAKS; FOR-GESTATIONAL-AGE; LOW-PROTEIN-DIET; SUPEROXIDE-DISMUTASE; CARDIOVASCULAR-DISEASE; ENDOTHELIAL FUNCTION; ADHESION MOLECULE-1; ADULT LIFE; RESTRICTION; GROWTH	Low birth weight is associated with increased cardiovascular disease (CVD) in humans. Detrimental effects of low birth weight are amplified by rapid catch-up growth. Conversely, slow growth during lactation reduces CVD risk. Gestational protein restriction causes low birth weight, vascular dysfunction, and accelerated aging in rats. Atherosclerotic aortic tissue has shortened telomeres, and oxidative stress accelerates telomere shortening through generation of DNA single-strand breaks (ssbs). This study tested the hypothesis that maternal diet influences aortic telomere length through changes in DNA ssbs, antioxidant capacity, and oxidative stress. We used our models of gestational protein restriction followed by rapid catch-up growth (the recuperated group) and protein restriction during lactation (the postnatal low-protein [PLP] group). Southern blotting revealed fewer aortic DNA ssbs and subsequently fewer short telomeres (P < 0.05) in the PLP group. This result was associated with reduced ( P < 0.01) 8-hydroxy-2-deoxyguanosine, a marker of oxidative stress. PLP animals expressed increased (P < 0.01) manganese superoxide-dismutase, copper-zinc superoxide-dismutase, catalase, and glutathione-reductase. Age-dependent changes in antioxidant defense enzymes indicated more protection to oxidative stress in the PLP animals; conversely, recuperated animals demonstrated age-associated impairment of antioxidant defenses. We conclude that maternal diet has a major influence on aortic telomere length. This finding may provide a mechanistic link between early growth patterns and CVD.	[Tarry-Adkins, J. L.; Martin-Gronert, M. S.; Chen, J. -H.; Cripps, R. L.; Ozanne, S. E.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Tarry-Adkins, JL (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Box 232,Hills Rd, Cambridge CB2 2QR, England.	janeadkins@googlemail.com		Ozanne, Susan/0000-0001-8753-5144	Biotechnology and Biological Sciences Research Council [BB/E002161/1, BB/D007909/1, BB/E00797X/1] Funding Source: Medline; British Heart Foundation Funding Source: Medline; BBSRC [BB/D007909/1, BB/E002161/1, BB/E00797X/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aviv H, 2001, ATHEROSCLEROSIS, V159, P281, DOI 10.1016/S0021-9150(01)00506-8; Baird DM, 2004, ANN NY ACAD SCI, V1019, P265, DOI 10.1196/annals.1297.044; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Bennett MR, 2002, ARTERIOSCL THROM VAS, V22, P713, DOI 10.1161/01.ATV.0000019008.18226.C3; Brawley L., 2003, Archives of Physiology and Biochemistry, V111, P23, DOI 10.1076/apab.111.1.23.15138; Cambonie G, 2007, AM J PHYSIOL-REG I, V292, pR1236, DOI 10.1152/ajpregu.00227.2006; Castello L, 2005, FASEB J, V19, P1863, DOI 10.1096/fj.04-2864fje; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chen JH, 2007, NUCLEIC ACIDS RES, V35, P7417, DOI 10.1093/nar/gkm681; Cooke CLM, 2003, CARDIOVASC RES, V60, P635, DOI 10.1016/j.cardiores.2003.08.011; Corstius HB, 2005, PEDIATR RES, V57, P796, DOI 10.1203/01.PDR.0000157726.65492.CD; Cutler RG, 2005, REJUV RES, V8, P138, DOI 10.1089/rej.2005.8.138; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Didion SP, 2006, HYPERTENSION, V48, P1072, DOI 10.1161/01.HYP.0000247302.20559.3a; Dwivedi VK, 2006, J ENZYM INHIB MED CH, V21, P43, DOI 10.1080/14756360500286070; Eriksson JG, 2002, ANN MED, V34, P157, DOI 10.1080/713782141; Forgione MA, 2002, CIRCULATION, V106, P1154, DOI 10.1161/01.CIR.0000026820.87824.6A; Franco MDP, 2003, CARDIOVASC RES, V59, P767, DOI 10.1016/S0008-6363(03)00461-9; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; Harder T, 2005, AM J EPIDEMIOL, V162, P397, DOI 10.1093/aje/kwi222; Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2139; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Ju YJ, 2006, EXP MOL MED, V38, P686, DOI 10.1038/emm.2006.81; Kajstura J, 2000, AM J PATHOL, V156, P813, DOI 10.1016/S0002-9440(10)64949-8; Lee HC, 2007, EXP BIOL MED, V232, P592; Leeson CPM, 2001, CIRCULATION, V103, P1264; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lim KJ, 2006, PEDIATR RES, V60, P83, DOI 10.1203/01.pdr.0000220361.08181.c3; Lin SJ, 2005, ARTERIOSCL THROM VAS, V25, P334, DOI 10.1161/01.ATV.0000152114.00114.d8; Mohn A, 2007, J CLIN ENDOCR METAB, V92, P1372, DOI 10.1210/jc.2006-1344; Okuda K, 2000, ATHEROSCLEROSIS, V152, P391, DOI 10.1016/S0021-9150(99)00482-7; Rich-Edwards JW, 2004, EPIDEMIOLOGY, V15, P550, DOI 10.1097/01.ede.0000129513.69321.ba; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Sambrook J, 1989, MOL CLONING LAB MANU, pE3; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Shen X, 2006, DIABETES, V55, P798, DOI 10.2337/diabetes.55.03.06.db05-1039; Singhal A, 2004, CIRCULATION, V109, P1108, DOI 10.1161/01.CIR.0000118500.23649.DF; Singhal A, 2004, LANCET, V363, P1571, DOI 10.1016/S0140-6736(04)16198-9; Singhal A, 2007, CIRCULATION, V115, P213, DOI 10.1161/CIRCULATIONAHA.106.617811; Skilton MR, 2006, CLIN SCI, V111, P281, DOI 10.1042/CS20060036; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; STARR JM, EXP GERONTOL, V6, P571; Tarry-Adkins JL, 2007, AM J PHYSIOL-REG I, V293, pR1259, DOI 10.1152/ajpregu.00231.2007; Tarry-Adkins JL, 2006, AM J PHYSIOL-RENAL, V290, pF509, DOI 10.1152/ajprenal.00215.2005; Tsukahara H, 2007, CURR MED CHEM, V14, P339, DOI 10.2174/092986707779941177; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Zou Y, 2003, FASEB J, V17, P320, DOI 10.1096/fj.03-0849fje	51	114	116	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2008	22	6					2037	2044		10.1096/fj.07-099523	http://dx.doi.org/10.1096/fj.07-099523			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	307XK	18230683				2022-12-28	WOS:000256352700042
